[
  {
    "title": "Paludisme",
    "text": "Principaux faits En 2023, on estime à 263 millions le nombre de cas de paludisme et à 597 000 le nombre de décès dus au paludisme dans 83 pays. La Région africaine de l'OMS supporte une part importante et disproportionnée de la charge mondiale du paludisme. En 2023, 94 des cas de paludisme (246 millions) et 95 des décès dus à la maladie (569 000) ont été enregistrés dans la Région africaine. Les enfants de moins de cinq ans représentaient quelque 76 des décès dus au paludisme dans la Région. Vue d'ensemble Le paludisme est une maladie potentiellement mortelle qui est transmise à l'être humain par les piqûres de certains types de moustiques. Il sévit principalement dans les pays tropicaux. Il s'agit d'une maladie évitable dont on peut guérir. L'infection est causée par un parasite et ne se transmet pas d'une personne à l'autre. Les symptômes peuvent être bénins ou engager le pronostic vital. Les symptômes bénins sont la fièvre, les frissons et les maux de tête. Les symptômes graves sont la fatigue, la confusion, les convulsions et des difficultés à respirer. Les nourrissons, les enfants de moins de cinq ans, les femmes et filles enceintes, les voyageurs et les personnes vivant avec le VIH ou atteintes de sida courent un risque plus élevé d'infection grave. Il est possible de prévenir le paludisme en évitant les piqûres de moustiques et en prenant des médicaments. Les traitements peuvent empêcher les cas bénins de s'aggraver. Le paludisme se propage à l'être humain essentiellement par la piqûre de certains moustiques anophèles femelles infectés. Le paludisme peut également se transmettre par transfusion sanguine et par des aiguilles contaminées. Les premiers symptômes peuvent être bénins, semblables à ceux de nombreuses maladies fébriles, et difficiles à reconnaître. En l'absence de traitement, le paludisme à P. falciparum peut évoluer vers une affection grave, voire mortelle, dans les 24 heures. Sur les cinq espèces de parasites du genre Plasmodium responsables du paludisme chez l'être humain, P. falciparum et P. vivax sont les plus dangereux. P. falciparum est le parasite provoquant le plus de décès et aussi le plus répandu sur le continent africain, tandis que P. vivax est l'espèce dominante dans la plupart des pays en dehors de l'Afrique subsaharienne. Les autres espèces qui peuvent infecter l'être humain sont P. malariae , P. ovale et P. knowlesi . Symptômes Les premiers symptômes les plus courants du paludisme sont la fièvre, les maux de tête et les frissons. Les symptômes apparaissent généralement dans les 10 à 15 jours suivant la piqûre d'un moustique infecté. Ils peuvent être bénins pour certaines personnes, en particulier pour celles qui ont déjà eu une infection palustre. Étant donné que certains symptômes du paludisme ne sont pas spécifiques, il est important de se faire tester rapidement. Certains types de paludisme peuvent causer des manifestations graves et la mort. Les nourrissons, les enfants de moins de cinq ans, les femmes enceintes, les voyageurs et les personnes vivant avec le VIH ou atteintes de sida courent un risque plus élevé. Les symptômes graves comprennent : une fatigue extrême et un épuisement des troubles de la conscience des convulsions répétées une difficulté à respirer des urines foncées ou du sang dans les urines un ictère (coloration jaune des yeux et de la peau) des saignements anormaux. Les personnes présentant des symptômes graves doivent être prises en charge immédiatement. Un traitement précoce en cas de paludisme léger peut empêcher l'infection de s'aggraver. Une infestation palustre pendant la grossesse peut en outre provoquer un accouchement prématuré ou une insuffisance pondérale à la naissance. Charge de morbidité Selon le dernier Rapport sur le paludisme dans le monde, on comptait 263 millions de cas de paludisme en 2023 contre 252 millions en 2022. Le nombre estimé de décès imputables au paludisme s'est quant à lui élevé à 597 000 en 2023 contre 600 000 en 2022. La Région africaine de l'OMS continue de supporter une part importante et disproportionnée de la charge mondiale du paludisme. En 2023, environ 94 des cas de paludisme et 95 des décès dus à la maladie ont été enregistrés dans cette Région. Les enfants de moins de cinq ans représentaient quelque 76 des décès dus au paludisme dans la Région. Plus de la moitié de ces décès sont survenus dans quatre pays : le Nigéria (30,9 ), la République démocratique du Congo (11,3 ), le Niger (5,9 ) et la République-Unie de Tanzanie (4,3 ). Prévention Il est possible de prévenir le paludisme en évitant les piqûres de moustiques et en prenant des médicaments. Consultez un médecin pour savoir si vous pouvez prendre des médicaments tels qu'une chimioprophylaxie avant de vous rendre dans des régions où le paludisme est fréquent. Limitez le risque de contracter le paludisme en évitant les piqûres de moustiques : Utilisez des moustiquaires lorsque vous dormez dans des endroits où le paludisme est présent. Utilisez des répulsifs contre les moustiques (contenant du DEET, de l'IR3535 ou de l'icaridine) après le crépuscule Utilisez des serpentins et des vaporisateurs. Portez des vêtements protecteurs. Placez des moustiquaires sur les fenêtres. Lutte contre les vecteurs La lutte antivectorielle est une composante essentielle des stratégies visant à combattre et éliminer le paludisme, car elle s'avère extrêmement efficace pour prévenir l'infection et réduire la transmission. Les deux interventions principales sont l'utilisation de moustiquaires imprégnées d'insecticide et la pulvérisation intradomiciliaire à effet rémanent. Les progrès dans la lutte mondiale contre la maladie sont pourtant menacés par l'émergence d'une résistance de l'anophèle aux insecticides. Cependant, les moustiquaires de nouvelle génération, qui apportent une meilleure protection contre le paludisme que les moustiquaires imprégnées uniquement d'un pyréthrinoïde, sont de plus en plus accessibles et constituent un outil important dans les efforts mondiaux de lutte contre le paludisme. Anopheles stephensi constitue un problème supplémentaire pour la lutte contre le paludisme en Afrique. Originaire de certaines parties de l'Asie du Sud et de la péninsule arabique, cette espèce de moustique invasive a étendu son aire de répartition au cours de la dernière décennie elle a ainsi été détectée dans huit pays africains à ce jour. An. stephensi prospère en milieu urbain, supporte des températures élevées et résiste à de nombreux insecticides employés en santé publique. Chimioprophylaxie Les voyageuses et les voyageurs se rendant dans des zones d'endémie palustre doivent consulter leur médecin plusieurs semaines avant leur départ. Celui-ci déterminera quels médicaments prophylactiques sont appropriés pour le pays de destination. Dans certains cas, la prise de médicaments prophylactiques doit commencer deux à trois semaines avant le départ. Tous les médicaments prophylactiques doivent être pris en temps voulu pendant toute la durée du séjour dans la zone à risque et leur prise doit être poursuivie pendant quatre semaines après la dernière exposition possible à l'infection, car les parasites peuvent encore apparaître dans le foie au cours de cette période. Chimiothérapie préventive La chimiothérapie préventive (ou chimioprévention) est l'utilisation de médicaments ou d'associations médicamenteuses visant à prévenir l'infection palustre et ses conséquences. Il s'agit d'administrer un traitement complet d'un médicament antipaludique aux populations vulnérables à des moments précis de la période où le risque de paludisme est le plus élevé, que la ou le bénéficiaire soit ou non infecté(e) par le paludisme. La chimiothérapie préventive recouvre la chimioprévention du paludisme pérenne, la chimioprévention du paludisme saisonnier, le traitement préventif intermittent des femmes enceintes et des enfants d'âge scolaire, la chimioprévention du paludisme post-hospitalisation et l'administration de masse de médicaments. Ces stratégies sûres et économiques visent à compléter les activités de lutte antipaludique en cours, y compris les mesures de lutte antivectorielle, le diagnostic rapide des cas suspects et le traitement des cas confirmés au moyen d'antipaludiques. Vaccin Depuis octobre 2021, l'OMS recommande une large utilisation du vaccin antipaludique RTS,SAS01 chez l'enfant dans les zones où la transmission du paludisme à P. falciparum est modérée à forte. Il est démontré que le vaccin réduit considérablement la morbidité et la mortalité palustres chez le jeune enfant. En octobre 2023, l'OMS a recommandé un deuxième vaccin antipaludique sûr et efficace, le R21Matrix-M. Ces vaccins sont actuellement déployés dans le cadre des programmes de vaccination systématique des enfants en Afrique. Sur ce continent, les vaccins devraient sauver des dizaines de milliers d'enfants chaque année. Cependant, l'impact sera maximal lorsque les vaccins seront introduits en même temps que plusieurs autres interventions recommandées par l'OMS, telles que l'usage de moustiquaires et la chimioprophylaxie. Questions et réponses sur les vaccins antipaludiques Traitement Le diagnostic et le traitement précoces du paludisme réduisent la morbidité et préviennent la mortalité palustre et ils contribuent aussi à réduire la transmission. L'OMS recommande que, dans tous les cas présumés, le paludisme soit confirmé par un diagnostic basé sur la recherche des plasmodies (par microscopie ou test diagnostique rapide). Le paludisme est une infection grave qui nécessite toujours un traitement médicamenteux. Plusieurs médicaments sont utilisés pour prévenir et traiter le paludisme. Les médecins en choisiront un ou plusieurs en fonction : du type de paludisme de la résistance d'un parasite du paludisme à un médicament du poids ou de l'âge de la personne infectée par le paludisme du fait que la personne est enceinte ou non. Voici les médicaments les plus courants contre le paludisme : Les combinaisons thérapeutiques à base d'artémisinine sont le traitement le plus efficace contre le paludisme à P. falciparum . La chloroquine est recommandée pour le traitement de l'infection à P. vivax uniquement dans les endroits où ce parasite est encore sensible à ce médicament. La primaquine doit être ajoutée au traitement principal pour prévenir les rechutes de l'infection à P. vivax et à P. ovale . La plupart des médicaments utilisés se présentent sous forme de pilules. Certaines personnes devront se rendre dans un centre de santé ou un hôpital pour obtenir des médicaments injectables. Résistance aux antipaludiques Suivant l'apparition d'une résistance partielle à l'artémisinine dans le bassin du Mékong, l'OMS est très préoccupée par le fait qu'une résistance partielle à l'artémisinine a été confirmée en Érythrée, en Ouganda, en République-Unie de Tanzanie et au Rwanda. Les données disponibles semblent indiquer que cette résistance est également présente en Éthiopie, en Namibie, au Soudan et en Zambie. En 2022, l'OMS a élaboré une stratégie de riposte face à la résistance aux antipaludiques en Afrique . Un suivi régulier de l'efficacité des antipaludiques est nécessaire pour orienter les politiques thérapeutiques dans les pays d'endémie et assurer une détection précoce de la résistance aux antipaludiques et une intervention rapide. Pour davantage de précisions sur les travaux de l'OMS concernant la résistance aux antipaludiques dans le bassin du Mékong, consulter la page Web du Programme d'élimination du paludisme dans le Mékong (en anglais). Mutations génétiques La plupart des tests de diagnostic rapide (TDR) du paludisme ciblent une ou deux protéines spécifiques produites par le parasite du paludisme P. falciparum : HRP2 et HRP3. Cependant, ils ne détectent pas les parasites présentant des mutations génétiques, qui empêchent l'expression de ces protéines. Il s'ensuit que des patients atteints de paludisme risquent de ne pas être diagnostiqués, permettant ainsi à ces parasites mutants de se propager. En 2023, ces parasites mutants ont été signalés dans 41 pays d'endémie palustre, dont le Burkina Faso, le Tchad, le Togo et, pour la première fois, l'Indonésie. Bien que leur prévalence soit encore faible dans la plupart des pays, elle dépasse 15 au Brésil, à Djibouti, en Érythrée, au Nicaragua et au Pérou. Élimination L'élimination du paludisme est définie comme l'interruption de la transmission locale d'une espèce déterminée du parasite, dans une zone géographique définie, à la suite d'activités spécifiquement menées à cette fin. Les mesures doivent être poursuivies pour empêcher une reprise de la transmission. En 2023, 35 pays ont signalé moins de 1000 cas autochtones, alors qu'ils étaient à peine 13 en 2000. Les pays n'ayant déclaré aucun cas autochtone pendant trois années consécutives peuvent soumettre à l'OMS une demande de certification de l'élimination du paludisme . Depuis 2015, 14 pays ont été certifiés exempts de paludisme par le Directeur général de l'OMS : les Maldives (2015), Sri Lanka (2016), le Kirghizistan (2016), le Paraguay (2018), l'Ouzbékistan (2018), l'Argentine (2019), l'Algérie (2019), la Chine (2021), El Salvador (2021), l'Azerbaïdjan (2023), le Tadjikistan (2023), Belize (2023), Cabo Verde (2024) et l'Égypte (2024). Pays et territoires certifiés exempts de paludisme par l'OMS. Surveillance Par surveillance du paludisme , on entend la collecte, l'analyse et l'interprétation continues et systématiques de données relatives au paludisme, et l'utilisation de ces données pour la planification, la mise en œuvre et l'évaluation des pratiques de santé publique. L'amélioration de la surveillance des cas et des décès palustres aide les ministères de la santé à déterminer les zones ou les groupes les plus touchés et permet aux pays de suivre l'évolution épidémiologique. Des systèmes bien établis de surveillance du paludisme aident également les pays à mettre au point des interventions sanitaires efficaces et à évaluer l'impact de leur programme de lutte. Action de l'OMS La Stratégie technique mondiale de lutte contre le paludisme 2016-2030 mise à jour en 2021, constitue un cadre technique pour tous les pays d'endémie. Elle est censée orienter et soutenir les programmes régionaux et nationaux qui s'efforcent de combattre et d'éliminer la maladie. La Stratégie fixe des buts ambitieux, mais réalistes à l'échelle mondiale : réduire d'au moins 90 l'incidence du paludisme d'ici à 2030 réduire d'au moins 90 la mortalité palustre d'ici à 2030 éliminer le paludisme dans 35 pays au moins d'ici à 2030 empêcher une résurgence du paludisme dans tous les pays exempts. Le Programme mondial de lutte contre le paludisme coordonne les activités menées par l'OMS au niveau mondial pour lutter contre le paludisme et l'éliminer. À cet égard : il joue un rôle de premier plan dans la lutte contre le paludisme, en soutenant efficacement les États Membres et en ralliant les partenaires afin de parvenir à la couverture sanitaire universelle et d'atteindre les buts et les cibles de la Stratégie technique mondiale de lutte contre le paludisme ; il oriente le programme de recherche et promeut la production de données probantes afin d'étayer les orientations mondiales concernant les nouveaux outils et les nouvelles stratégies permettant d'obtenir un impact ; il élabore des orientations mondiales conformes à l'éthique et fondées sur des données probantes concernant le paludisme et les diffuse efficacement afin de favoriser leur adoption et leur mise en œuvre par les programmes nationaux de lutte contre le paludisme et d'autres parties prenantes concernées ; et il surveille les tendances et les menaces mondiales en matière de paludisme et y réagit.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/malaria",
    "length": 15701,
    "type": "html",
    "id": 0,
    "source": "WHO"
  },
  {
    "title": "Dengue et dengue sévère",
    "text": "L'essentiel La dengue est une infection virale causée par le virus de la dengue (DENV), qui est transmis à l'être humain par piqûre de moustiques infectés. Environ la moitié de la population mondiale est aujourd'hui exposée au risque de dengue, quelque 100 à 400 millions d'infections survenant chaque année. La dengue sévit dans les régions tropicales et subtropicales du monde entier, principalement dans les zones urbaines et semi-urbaines. Si de nombreuses infections à DENV sont asymptomatiques ou ne s'accompagnent que de manifestations bénignes, il existe des formes plus sévères, qui peuvent entraîner la mort. Pour prévenir et combattre la dengue, il est indispensable d'appliquer des mesures de lutte antivectorielle. Il n'existe pas de traitement spécifique contre la denguedengue sévère. La détection précoce et l'accès à des soins médicaux appropriés réduisent considérablement les taux de mortalité de la dengue sévère. Généralités La dengue est une infection virale qui se transmet des moustiques aux humains. Elle est plus courante sous les climats tropicaux et subtropicaux que sous les climats tempérés. La plupart des personnes qui contractent la dengue n'ont pas de symptômes. Chez les cas symptomatiques, les manifestations les plus courantes sont une forte fièvre, des maux de tête, des courbatures, des nausées et des éruptions cutanées. La plupart des malades se rétablissent en 1 à 2 semaines. Certains développent une dengue sévère et sont hospitalisés. Dans les cas graves, la dengue peut être mortelle. On peut réduire le risque de maladie en évitant les piqûres de moustiques, surtout pendant la journée. La dengue se traite par analgésiques, car il n'existe pas de traitement. Symptômes La plupart des malades ont des symptômes légers ou n'ont aucun symptôme et se rétablissent en 1 à 2 semaines. Dans de rares cas, la dengue peut être grave et entraîner la mort. Si des symptômes apparaissent, ils commencent habituellement 4 à 10 jours après l'infection et durent de 2 à 7 jours. Les symptômes sont notamment les suivants : forte fièvre (40 C104 F) céphalées intenses douleurs rétro-orbitaires douleurs musculaires et articulaires nausées vomissements adénopathies éruption cutanée. Les personnes infectées pour la deuxième fois courent un risque accru de dengue sévère. Les symptômes de la dengue sévère surviennent souvent après la disparition de la fièvre et peuvent inclure : douleurs abdominales sévères vomissements persistants respiration rapide saignement des gencives ou du nez fatigue intense agitation sang dans les vomissures ou les selles forte sensation de soif peau pâle et froide sensation de faiblesse Les personnes présentant ces symptômes graves doivent se faire soigner immédiatement. Après leur guérison, les personnes qui ont eu la dengue peuvent se sentir fatiguées pendant plusieurs semaines. Diagnostic et traitement Le diagnostic en laboratoire et sur le lieu des soins est essentiel pour combattre et prendre en charge la dengue, mais les disparités mondiales en matière de capacités de laboratoire sont très problématiques. Les algorithmes de diagnostic et les stratégies et méthodes de test varient en fonction des capacités des systèmes de laboratoire nationaux. La qualité et l'efficacité des nombreux tests disponibles tests d'amplification des acides nucléiques (TAAN), tests d'immunoadsorption enzymatique (ELISA) et tests de diagnostic rapide (TDR) sont extrêmement variables. Les tests de laboratoire pour les arbovirus reposent sur des méthodes de détection directe, comme l'isolement du virus, la détection moléculaire des acides nucléiques ou la détection de l'antigène, y compris pour les tests de diagnostic rapide (TDR) au cours de la première semaine de la maladie Il n'existe pas de traitement spécifique de la dengue, mais il est possible de soulager la douleur grâce au paracétamol (acétaminophène). Les anti-inflammatoires non stéroïdiens, comme l'ibuprofène et l'aspirine, sont à éviter, car ils peuvent augmenter le risque d'hémorragie. Pour les personnes atteintes de dengue sévère, une hospitalisation est souvent nécessaire. Charge mondiale Au cours des dernières décennies, l'incidence de la dengue a progressé de manière spectaculaire partout dans le monde : le nombre de cas notifiés à l'OMS est passé de 505 430 en 2000 à 14,6 millions en 2024. L'immense majorité des cas sont asymptomatiques ou bénins et les malades se soignent eux-mêmes, d'où la sous-notification du nombre réel de cas de dengue. La maladie est aujourd'hui endémique dans plus de 100 pays. (2). En 2024, un nombre historique de cas de dengue a été enregistré sur une période de 12 mois, dans plus de 100 pays sur tous les continents. En raison de la transmission active et d'un pic inattendu des cas de dengue, un record historique a été atteint plus de 14,6 millions de cas de dengue, dont plus de 12 000 mortels ont été notifiés. La Région des Amériques a supporté une part importante de la charge mondiale, avec plus de 13 millions de cas notifiés à l'OMS. Plusieurs facteurs sont associés au risque croissant de propagation de l'épidémie de dengue, parmi lesquels l'évolution de la répartition des vecteurs en cause (principalement Aedes aegypti et Aedes albopictus ), en particulier dans des pays qui n'avaient jamais été atteints par la dengue ; les changements climatiques, qui entraînent une élévation des températures, des précipitations abondantes et de l'humidité ; les systèmes de santé fragiles et surchargés ; les limites de la surveillance et de la notification ; et l'instabilité politique et financière dans les pays confrontés à des crises humanitaires complexes, ainsi que d'importants mouvements de population. Selon des estimations issues d'une modélisation, 390 millions d'infections par le virus de la dengue se produisent chaque année, dont 96 millions se manifestent cliniquement (1) . Selon une étude récente sur la prévalence de la dengue, 5,6 milliards de personnes sont exposées à un risque d'infection par le virus de la dengue et d'autres arbovirus (2) . De janvier à juillet 2025, plus de 4 millions de cas, dont plus de 3000 mortels, ont été notifiés à l'OMS par 97 pays. La dengue se propage à de nouvelles Régions, notamment la Région européenne et la Région de la Méditerranée orientale. En 2024, 308 cas ont été notifiés à l'OMS par trois pays européens (l'Espagne, la France et l'Italie) et 1291 cas supplémentaires, dont quatre mortels, ont été enregistrés dans les départements français d'outre-mer de Mayotte et de la Réunion. Transmission Transmission par piqûre de moustique Le virus se transmet à l'être humain par piqûre de moustiques femelles infectés, principalement de l'espèce Aedes aegypti . D'autres espèces du genre Aedes peuvent également être des vecteurs, mais leur contribution est généralement secondaire par rapport à celle d' Aedes aegypti . Lorsqu'un moustique s'est nourri du sang d'une personne infectée par le virus de la dengue, le virus se réplique dans son intestin moyen avant de se propager aux tissus secondaires, y compris les glandes salivaires. Le délai qui s'écoule entre l'ingestion du virus et la transmission à un nouvel hôte est appelé période d'incubation extrinsèque (PEI). La PEI dure environ 8 à 12 jours lorsque la température ambiante est comprise entre 25 C et 28 C. Les variations de la PEI ne dépendent pas seulement de la température ambiante, mais aussi de plusieurs facteurs, tels que l'ampleur des fluctuations quotidiennes de température, le génotype du virus et la concentration virale initiale, qui peuvent également modifier le délai nécessaire pour qu'un moustique transmette le virus. Une fois qu'il est infectieux, un moustique peut transmettre le virus jusqu'à sa mort. Transmission de l'être humain au moustique Les moustiques peuvent être infectés par des personnes virémiques. Il peut s'agir de sujets chez lesquels la dengue est symptomatique, de sujets qui ne présentent pas encore de symptômes (présymptomatiques), voire de sujets qui ne présentent aucun signe de la maladie (asymptomatiques). La transmission de l'être humain au moustique peut survenir jusqu'à deux jours avant l'apparition des symptômes de la maladie et jusqu'à deux jours après la disparition de la fièvre. Il existe une corrélation positive entre le risque d'infection des moustiques et la présence d'une virémie élevée et d'une forte fièvre chez le patient ou la patiente ; inversement, des niveaux élevés d'anticorps anti-DENV sont associés à une diminution du risque d'infection des moustiques. La plupart des sujets sont virémiques pendant 4 à 5 jours, mais la virémie peut durer jusqu'à 12 jours. Transmission maternelle Entre êtres humains, le DENV se transmet principalement par l'intermédiaire de moustiques vecteurs. Cependant, certaines données indiquent qu'une transmission maternelle (d'une femme enceinte à son enfant) est possible. Il semble toutefois que cette transmission verticale soit peu fréquente et que le risque dépende du moment où l'infection par la dengue est contractée au cours de la grossesse. Lorsqu'une femme est infectée par le DENV pendant la grossesse, il est possible que l'enfant naisse prématuré et présente une insuffisance pondérale à la naissance ou une détresse fœtale. Autres modes de transmission De rares cas de transmission par des produits sanguins, des dons d'organes et des transfusions ont été constatés. De même, une transmission transovarienne du virus chez les moustiques a également été observée. Facteurs de risque Une infection antérieure par le virus de la dengue augmente le risque de contracter une dengue sévère. L'urbanisation (en particulier lorsqu'elle est rapide et anarchique) joue un rôle dans la transmission de la dengue, en fonction de plusieurs facteurs sociaux et environnementaux : densité de population, mobilité humaine, accès à des sources d'eau fiables, pratiques de stockage de l'eau, etc. Le risque de dengue dans une communauté dépend également des connaissances, des attitudes et des pratiques de la population vis-à-vis de la dengue, l'exposition étant étroitement liée aux comportements adoptés en matière de stockage de l'eau, d'entretien des plantes et de protection contre les piqûres de moustiques, notamment. Les activités systématiques de surveillance des vecteurs et de lutte antivectorielle et la participation ciblée des communautés contribuent grandement à améliorer la résilience. Les vecteurs peuvent s'adapter à de nouveaux environnements et à de nouveaux climats. L'interaction entre le virus de la dengue, l'hôte et l'environnement est dynamique. Par conséquent, les risques de dengue peuvent évoluer avec les changements climatiques dans les zones tropicales et subtropicales, ainsi qu'avec l'urbanisation et les mouvements de populations accrus. Prévention et lutte Les moustiques qui propagent la dengue sont actifs pendant la journée. Pour réduire le risque de contracter la dengue, protégez-vous des piqûres de moustiques à l'aide : de vêtements qui couvrent autant que possible votre corps ; de moustiquaires de lit, idéalement imprégnées d'insecticide, si vous dormez pendant la journée ; de moustiquaires aux fenêtres ; de répulsifs contre les moustiques (contenant du DEET, de l'icaridine ou de l'IR3535) ; et de serpentins fumigènes et de vaporisateurs. Pour empêcher les moustiques de se reproduire : mettre en œuvre des pratiques de gestion et de modification de l'environnement pour empêcher les moustiques d'accéder aux gîtes larvaires ; éliminer correctement les déchets solides et en enlevant les habitats artificiels susceptibles de retenir l'eau ; couvrir, vider et nettoyer toutes les semaines les conteneurs pour la conservation de l'eau domestique ; et épandre des insecticides adaptés sur les conteneurs pour la conservation de l'eau à l'extérieur. Si vous contractez la dengue, il est important : de vous reposer ; de boire beaucoup de liquides ; de prendre du paracétamol (de l'acétaminophène) pour soulager la douleur ; d'éviter les anti-inflammatoires non stéroïdiens, comme l'ibuprofène et l'aspirine ; d'être attentif aux symptômes graves et de contacter votre médecin dès que possible si vous en remarquez. À ce jour, un vaccin (QDenga) est disponible et homologué dans certains pays. Cependant, son utilisation n'est recommandée que chez les personnes de 6 à 16 ans, dans les zones de forte transmission. Plusieurs autres vaccins sont en cours d'évaluation. Action de l'OMS L'action de l'OMS face à la dengue consiste à : aider les pays à confirmer les flambées par l'intermédiaire de son réseau de laboratoires collaborateurs ; fournir un avis technique et des orientations aux pays pour une gestion efficace des flambées épidémiques de dengue ; aider les pays à améliorer leurs systèmes de notification et à déterminer la véritable charge de la maladie ; assurer des formations sur la prise en charge clinique, le diagnostic et la lutte antivectorielle au niveau national et régional, avec certains de ses centres collaborateurs ; élaborer des stratégies et des politiques fondées sur des bases factuelles ; aider les pays à élaborer des stratégies de lutte contre la dengue et à adopter l'Action mondiale pour lutter contre les vecteurs (2017-2030) et l'Initiative mondiale de lutte contre les arbovirus (2022-2025) ; examiner les activités de mise au point de nouveaux outils, dont des produits insecticides et des techniques d'application, et faire des recommandations à cet égard ; rassembler les notifications officielles des cas de dengue et de dengue sévère en provenance de plus d'une centaine d'États Membres ; et publier régulièrement, à l'intention des États Membres, des orientations et des manuels pour la surveillance, la prise en charge des cas, le diagnostic, la prévention et la lutte contre la dengue. Références bibliographiques Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al. The global distribution and burden of dengue. Nature. 2013; 496(7446):504507. doi: 10.1038nature12060. Lim A, Shearer FM, Sewalk K, Pigott DM, Clarke J, Ghouse A, et al. The overlapping global distribution of dengue, chikungunya, Zika and yellow fever. Nat Commun. 2025;16(1):3418. doi: 10.1038s41467-025-58609-5.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/dengue-and-severe-dengue",
    "length": 14192,
    "type": "html",
    "id": 1,
    "source": "WHO"
  },
  {
    "title": "Principaux repères sur la fièvre jaune",
    "text": "Principaux faits La fièvre jaune est une maladie infectieuse transmise par des moustiques qui piquent principalement pendant la journée. En 2023, la fièvre jaune est endémique sur tout le territoire ou dans certaines régions de 34 pays d'Afrique et 13 pays d'Amérique centrale et d'Amérique du Sud. Il existe un vaccin efficace, sûr et abordable contre la fièvre jaune (le vaccin antiamaril). Une seule dose de vaccin antiamaril suffit à conférer une protection à vie. Une modélisation basée sur des sources de données africaines a permis d'estimer la charge de morbidité imputable à cette maladie en 2013 : il y a eu 84 000 à 170 000 cas graves et 29 000 à 60 000 décès (1). Vue d'ensemble La fièvre jaune est une maladie à tendance épidémique transmise à l'être humain par la piqûre de moustiques infectés et qui peut être évitée par la vaccination. Elle est due à un arbovirus (un virus transmis par des vecteurs tels que les moustiques, les tiques ou d'autres arthropodes) transmis à l'être humain par les piqûres de moustiques Aedes et Haemagogus infectés. Ces moustiques, qui piquent pendant la journée, se reproduisent autour des habitations (moustiques domestiques), dans les forêts ou les jungles (moustiques sylvatiques), ou dans les deux habitats (moustiques semi-domestiques). La fièvre jaune est une maladie qui constitue une lourde menace, qui a de graves conséquences et dont le risque de propagation internationale représente une menace potentielle pour la sécurité sanitaire mondiale. Symptômes La période d'incubation de la fièvre jaune est de trois à six jours. L'infection reste asymptomatique chez de nombreuses personnes. La maladie se manifeste habituellement par de la fièvre, des myalgies, des céphalées, une perte d'appétit, des nausées ou des vomissements. Dans la plupart des cas, les symptômes disparaissent au bout de 3 à 4 jours. Dans une petite proportion des cas, les patients entrent dans une deuxième phase, plus toxique, dans les 24 heures suivant la disparition des premiers symptômes. Une fièvre élevée se réinstalle et plusieurs organes sont touchés, en général le foie et les reins. Au cours de cette phase, un ictère apparaît souvent (jaunissement de la peau et des yeux, d'où le nom de fièvre jaune ), accompagné d'urines sombres et des douleurs abdominales avec vomissements. On peut observer des saignements au niveau de la bouche, du nez, des yeux ou de l'estomac. La moitié des malades entrant dans cette phase toxique meurent dans les 7 à 10 jours. Traitement Il n'existe aucun médicament antiviral spécifique contre la fièvre jaune. Les patients doivent se reposer, s'hydrater et consulter un médecin. En fonction de leur tableau clinique et d'autres facteurs, les patients peuvent être invités à rentrer chez eux, être orientés pour une prise en charge hospitalière ou nécessiter un traitement d'urgence et une orientation vers des services d'urgence. Le traitement de la déshydratation, de l'insuffisance hépatique, de l'insuffisance rénale et de la fièvre améliore l'issue de la maladie. Des antibiotiques permettent de traiter les surinfections bactériennes. Diagnostic La fièvre jaune est difficile à diagnostiquer, surtout aux stades précoces. Dans sa forme plus sévère, on peut la confondre avec le paludisme, la leptospirose, l'hépatite virale, d'autres fièvres hémorragiques, d'autres maladies à flavivirus (comme la dengue) ou une intoxication. Les tests PCR (amplification en chaîne par polymérase) à partir d'un échantillon de sang permettent parfois de détecter le virus aux premiers stades de la maladie. Aux stades plus tardifs, il faut procéder à des tests de recherche des anticorps (ELISA et PRNT). Prévention 1. Vaccination La vaccination est le moyen de prévention le plus important pour éviter la fièvre jaune. Le vaccin antiamaril est sûr et peu coûteux ; une seule dose confère une protection à vie contre la maladie. Une dose de rappel du vaccin n'est pas nécessaire. Le vaccin confère une immunité efficace chez 80 à 100 des personnes vaccinées dans les 10 jours, et à plus de 99 des personnes vaccinées dans les 30 jours. Le vaccin antiamaril a rarement des effets secondaires. Les personnes généralement exclues de la vaccination sont les suivantes : les nourrissons âgés de moins de 9 mois ; les femmes enceintes, sauf au cours d'une flambée quand le risque d'infection est élevé ; les personnes présentant des allergies sévères aux protéines de l'œuf ; et les personnes présentant une immunodéficience grave due à une infection à VIHun sida symptomatique ou à d'autres causes, ou des troubles du thymus. Conformément au Règlement sanitaire international (RSI), les pays ont le droit d'exiger des voyageurs qu'ils présentent un certificat de vaccination antiamarile. S'il existe des motifs médicaux pour qu'ils ne soient pas vaccinés, cela doit également être certifié par les autorités compétentes. 2. Lutte antivectorielle On peut réduire le risque de transmission de la fièvre jaune dans les zones urbaines en éliminant les gîtes larvaires potentiels, notamment en appliquant des produits larvicides dans les conteneurs pour conserver l'eau et dans tous les endroits où l'eau peut s'accumuler. Il est recommandé d'appliquer des mesures préventives, telles que le port de vêtements pour réduire autant que possible l'exposition de la peau et l'utilisation de répulsifs, pour éviter les piqûres de moustiques. L'utilité des moustiquaires de lit imprégnées d'insecticide est limitée car les moustiques Aedes piquent pendant la journée. La surveillance des vecteurs et la lutte antivectorielle s'inscrivent dans la lutte contre les maladies à transmission vectorielle, notamment contre la transmission en cas d'épidémie. Pour ce qui est de la fièvre jaune, la surveillance ciblant les moustiques Aedes aegypti ainsi que d'autres espèces d' Aedes permettra de connaître les zones urbaines susceptibles d'être touchées par une flambée. 3. Préparation et riposte aux épidémies Pour lutter contre les flambées, il est essentiel de détecter précocement la fièvre jaune et d'y riposter rapidement en organisant campagnes de vaccination d'urgence. Cependant, la sous-déclaration reste un problème. L'OMS estime que le nombre réel de cas est 10 à 250 fois supérieur à ce qui est actuellement signalé. L'OMS recommande à chaque pays à risque de disposer au moins d'un laboratoire national pouvant pratiquer les analyses de sang de base pour le diagnostic de la fièvre jaune. On considère qu'un cas confirmé au sein d'une population non vaccinée constitue à lui seul une flambée. Un cas confirmé, quel que soit le contexte, doit faire l'objet d'une enquête approfondie. Les équipes d'enquête doivent évaluer la flambée et riposter à la fois en prenant des mesures d'urgence et en établissant des plans de vaccination à plus long terme. Action de l'OMS La Stratégie mondiale pour l'élimination des épidémies de fièvre jaune (EYE) a été établie à la suite deux flambées urbaines de fièvre jaune liées à Luanda (Angola) et à Kinshasa (République démocratique du Congo), avec une exportation internationale plus large de la maladie de l'Angola vers d'autres pays, y compris la Chine montrant que la fièvre jaune représente une grave menace à l'échelle mondiale, qui exige d'entamer une nouvelle réflexion stratégique. La stratégie EYE est exhaustive et pluripartite, et comporte plusieurs éléments. Certes, elle recommande la vaccination, mais elle préconise également la construction de centres urbains résilients, la planification de la préparation urbaine et le renforcement de l'application du Règlement sanitaire international (2005). Pour en savoir plus sur la stratégie EYE, cliquez ici : Stratégie d'élimination des épidémies de fièvre jaune (EYE) 2017-2026 (en anglais) D'ici à la fin de 2026, près de 1 milliard de personnes devraient être protégées contre la fièvre jaune grâce à la vaccination. (1) Garske T. et al. Yellow fever in Africa: Estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. 2014;11(5):e1001638 - https:pubmed.ncbi.nlm.nih.gov24800812 (en anglais)",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/yellow-fever",
    "length": 8095,
    "type": "html",
    "id": 2,
    "source": "WHO"
  },
  {
    "title": "Principaux repères sur la leishmaniose",
    "text": "Principaux faits Il existe trois formes principales de leishmaniose : viscérale (la plus grave dans la mesure où elle est presque toujours fatale), cutanée (la plus fréquente, qui cause habituellement des ulcères cutanés) et cutanéomuqueuse (qui touche la bouche, le nez et la gorge). La leishmaniose est due à un parasite protozoaire du genre Leishmania , transmis par la piqûre de phlébotomes femelles infectées. La maladie, qui touche des populations parmi les plus pauvres du monde, est associée à certains facteurs tels que la malnutrition, les déplacements de population, l'insalubrité des logements, un système immunitaire affaibli et le manque de ressources financières. On estime que 700 000 à 1 million de nouveaux cas se déclarent chaque année. L'infestation par les parasites Leishmania n'évolue jusqu'au stade de la maladie que chez une faible proportion de sujets infectés. Vue d'ensemble La leishmaniose est due à des parasites protozoaires appartenant à plus de 20 espèces différentes de Leishmania . On sait que plus de 90 espèces de phlébotomes transmettent ces parasites. Il existe trois formes principales de la maladie : La leishmaniose viscérale (LV), également appelée kala-azar, est mortelle dans plus de 95 des cas si elle n'est pas traitée. Elle se caractérise par des poussées irrégulières de fièvre, une perte de poids, une hépatosplénomégalie (augmentation du volume du foie et de la rate) et une anémie. La plupart des cas sont observés au Brésil, en Afrique de l'Est et en Inde. On estime que 50 000 à 90 000 nouveaux cas de LV surviennent chaque année dans le monde et que seuls 25 à 45 de ces cas sont notifiés à l'OMS. Cette maladie présente un fort potentiel épidémique et un fort taux de mortalité. La leishmaniose cutanée (LC) est la forme la plus fréquente de la maladie. Elle provoque des lésions cutanées, principalement des ulcères, sur les parties exposées du corps. Ces ulcères peuvent entraîner des cicatrices permanentes sources de stigmatisation et entraînant des handicaps graves. Environ 95 des cas de LC surviennent dans les Amériques, dans le bassin méditerranéen, au Moyen-Orient et en Asie centrale. On estime qu'il y a entre 600 000 et 1 million de nouveaux cas chaque année dans le monde, mais seuls 200 000 d'entre eux sont notifiés à l'OMS. La leishmaniose cutanéomuqueuse détruit partiellement ou totalement les muqueuses du nez, de la bouche et de la gorge. Plus de 90 des cas de leishmaniose cutanéomuqueuse se concentrent au Brésil, dans l'État plurinational de Bolivie, en Éthiopie et au Pérou. Transmission Les parasites Leishmania se transmettent par la piqûre de phlébotomes femelles infectées, qui se nourrissent de sang pour produire des œufs. Soixante-dix espèces animales, dont l'être humain, peuvent être des réservoirs naturels des parasites Leishmania . Spécificités selon les Régions de l'OMS Région africaine de l'OMS La leishmaniose cutanée est fortement endémique en Algérie. On ne dispose que de peu d'informations épidémiologiques pour Afrique de l'Ouest, en revanche toutes les formes de leishmaniose sont endémiques en l'Afrique de l'Est, où des épidémies de leishmaniose viscérale sévissent fréquemment. Région OMS des Amériques La leishmaniose cutanée est la forme la plus présente de la maladie dans la Région. Son épidémiologie est complexe, dans la mesure où plusieurs animaux sont des réservoirs du parasite et où de nombreux types de phlébotomes et plusieurs espèces de Leishmania cohabitent dans la même zone géographique. Le Brésil est le principal pays d'endémie de la LV dans cette région. Région OMS de la Méditerranée orientale Cette Région concentre 80 des cas de leishmaniose cutanée signalés dans le monde. La leishmaniose viscérale est fortement endémique en Iraq, en Somalie, au Soudan et au Yémen. Région européenne de l'OMS La leishmaniose cutanée et la leishmaniose viscérale sont endémiques dans cette Région. Les cas importés sont nombreux, principalement en provenance d'Afrique et des Amériques. Région OMS de l'Asie du Sud-Est La leishmaniose viscérale est la forme principale de la maladie dans cette Région, mais la leishmaniose cutanée y est également endémique. Leishmaniose dermique post-kala-azar (LDPKA) La leishmaniose dermique post-kala-azar (LDPKA) est en général une séquelle de la leishmaniose viscérale qui se manifeste par une éruption maculaire, papuleuse ou nodulaire, habituellement localisée sur le visage, le haut des bras et le tronc. Elle touche principalement l'Afrique de l'Est (en particulier le Soudan) et le sous-continent indien, où l'on observe l'apparition d'une LDPKA chez 5 à 10 des patients atteints de kala-azar. Bien que rares, des cas ont également été notifiés au Brésil ainsi que chez des personnes présentant une co-infection LV-VIH causée par L . infantum . La LDPKA survient généralement entre 6 mois et 1 an ou plus après la guérison apparente du kala-azar, mais elle peut également se déclarer plus tôt. Les personnes atteintes de LDPKA sont considérées comme une source potentielle d'infection par Leishmania . Co-infection Leishmania -VIH Les personnes vivant avec le VIH et infectées par la leishmaniose ont de fortes chances de développer une forme complète de la maladie, avec des taux élevés de rechute et de mortalité. Un traitement antirétroviral permet de réduire le risque d'évolution vers la maladie, de retarder les rechutes et d'améliorer la survie. En 2021, des cas de co-infection Leishmania -VIH avaient été signalés dans 45 pays. On observe des taux élevés de co-infection au Brésil, en Éthiopie et dans l'État du Bihar en Inde. En 2022, l'OMS a publié de nouvelles recommandations thérapeutiques (en anglais) pour les patients présentant une co-infection Leishmania -VIH en Afrique de l'Est et en Asie du Sud-Est. Principaux facteurs de risque Conditions socioéconomiques La pauvreté accroît le risque de leishmaniose. L'insalubrité des logements et des infrastructures d'assainissement domestique insuffisantes (absence de système de gestion des déchets ou égouts à ciel ouvert) peuvent favoriser le développement des sites de reproduction et de repos des phlébotomes et augmenter les contacts de ces derniers avec l'humain. Les phlébotomes sont attirés par les logements surpeuplés, où ils ont la possibilité de mordre davantage de personnes et de se nourrir de leur sang. Certains comportements humains, notamment le fait de dormir dehors ou à même le sol, sont également susceptibles d'accroître le risque. Malnutrition Les carences alimentaires en protéines, en fer, en vitamine A et en zinc augmentent le risque de progression de l'infection jusqu'à une forme complète de la maladie. Mobilité de la population Les épidémies de leishmaniose surviennent souvent lorsque de nombreuses personnes non immunisées se déplacent vers des zones où la transmission est élevée. Changements climatiques et environnementaux Les changements induits par l'urbanisation, la déforestation et l'incursion des humains dans les zones forestières peuvent avoir un impact sur l'incidence de la leishmaniose. Les changements climatiques jouent sur la propagation de la leishmaniose en raison de l'évolution des températures et des précipitations, qui ont des conséquences sur la taille et la répartition géographique des populations de phlébotomes. La sécheresse, la famine et les inondations provoquent également la migration des populations vers des zones où la transmission du parasite est élevée. Diagnostic et traitement Les personnes qui pourraient être atteintes de leishmaniose viscérale doivent consulter immédiatement un médecin. Le diagnostic de leishmaniose viscérale est posé sur la base d'un examen clinique associé à des tests parasitologiques ou sérologiques (tests diagnostiques rapides notamment). Pour les formes cutanée et cutanéomuqueuse de la maladie, les tests sérologiques sont d'un intérêt limité et le diagnostic repose sur l'observation des manifestations cliniques et la confirmation par des tests parasitologiques. Le traitement de la leishmaniose dépend de plusieurs facteurs, parmi lesquels la forme de la maladie, les affections concomitantes, l'espèce parasitaire et la situation géographique. La leishmaniose est une maladie qui peut être traitée et guérie, mais qui requiert un système immunitaire compétent, car les médicaments n'éliminent pas entièrement le parasite de l'organisme, ce qui induit un risque de rechute en cas d'immunosuppression. Un traitement complet doit être administré rapidement à tous les patients chez lesquels une leishmaniose viscérale a été diagnostiquée. Des informations détaillées sur le traitement sont fournies dans le numéro 949 de la série de rapports techniques de l'OMS consacré à la lutte contre la leishmaniose (en anglais), dans les dernières lignes directrices publiées sur les co-infections VIH-VL en Afrique de l'Est et en Asie du Sud-Est, ainsi que dans les lignes directrices pour le traitement de la leishmaniose dans les Amériques. Prévention et lutte La prévention de la leishmaniose et la lutte contre sa propagation sont complexes et nécessitent de nombreux outils. Les stratégies essentielles sont les suivantes : Un diagnostic précoce et un traitement rapide et efficace permettent de réduire la prévalence de la maladie et de prévenir les situations de handicap et les décès, de faire reculer la transmission et de surveiller la charge de morbidité et la propagation de la maladie. Il existe des médicaments très efficaces et sûrs contre la leishmaniose, en particulier contre sa forme viscérale, mais leur emploi peut s'avérer difficile. L'accès aux médicaments s'est sensiblement amélioré grâce au système de prix négociés de l'OMS et à un programme de dons de médicaments coordonné par l'OMS. La lutte antivectorielle permet d'atténuer ou d'interrompre la transmission de la maladie en réduisant le nombre de phlébotomes. Parmi les méthodes utilisées figurent la pulvérisation d'insecticides, l'utilisation de moustiquaires imprégnées d'insecticides, la gestion de l'environnement et la protection individuelle. Une surveillance efficace de la maladie est importante pour assurer un suivi et une intervention rapides en cas d'épidémies ou en présence de taux élevés de létalité sous traitement. La lutte contre les réservoirs animaux est complexe et doit être adaptée à la situation locale. Mobilisation sociale et renforcement des partenariats : les activités de mobilisation et d'éducation des communautés, visant à modifier les comportements au moyen d'interventions efficaces, doivent toujours être adaptées à la situation locale. L'établissement de partenariats et la collaboration avec diverses parties prenantes, ainsi qu'avec d'autres programmes de lutte contre les maladies à transmission vectorielle, revêtent une importance essentielle. Action de l'OMS En vue de lutter contre la leishmaniose, l'OMS : apporte un appui financier et technique aux programmes nationaux de lutte contre la leishmaniose pour mettre à jour les lignes directrices, garantir l'accès à des médicaments de qualité garantie, et mettre sur pied des plans de lutte contre la maladie, des systèmes de surveillance, ainsi que des systèmes de préparation et de riposte aux épidémies ; surveille les tendances épidémiologiques et évalue l'impact des activités de lutte au moyen du système mondial de surveillance sur le Web, ce qui permet d'appuyer les efforts de plaidoyer et de sensibilisation à la charge mondiale de la leishmaniose et de promouvoir un accès équitable aux services de santé ; élabore des politiques, des stratégies et des normes fondées sur des données factuelles pour la prévention et la lutte contre la leishmaniose, ce qui comprend le renforcement des capacités, notamment par l'intermédiaire de cours en ligne sur les maladies tropicales négligées (openwho.org) (en anglais) ; renforce la collaboration et la coordination entre les partenaires et les autres parties prenantes ; encourage la recherche portant notamment sur des médicaments sûrs, efficaces et abordables, des outils de diagnostic et des vaccins ; et apporte son soutien à la Région de l'Asie du Sud-Est, la seule dotée d'une initiative pour l'élimination de la leishmaniose viscérale en tant que problème de santé publique, qui court de 2022 à 2026 ; l'élimination y est définie comme moins d'un cas pour 10 000 habitants au niveau des districts au Népal et au niveau des sous-districts au Bangladesh et en Inde. Les pays prévoient de demander à l'OMS de valider l'élimination d'ici à fin 2023. Un cadre stratégique régional a été lancé pour accélérer et pérenniser l'élimination du kala-azar dans la Région de l'Asie du Sud-Est sur la période 2022-2026 (en anglais).",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/leishmaniasis",
    "length": 12672,
    "type": "html",
    "id": 3,
    "source": "WHO"
  },
  {
    "title": "Schistosomiase",
    "text": "Principaux faits La schistosomiase est une maladie aiguë et chronique provoquée par des vers parasites. Les personnes contractent l'infection dans le cadre de leurs activités agricoles, domestiques, professionnelles ou récréatives habituelles, qui les exposent à une eau contaminée. Le manque d'hygiène et certaines habitudes de jeu, telles que la natation ou la pêche dans des eaux infestées, rendent les enfants d'âge scolaire particulièrement vulnérables à l'infection. La lutte contre la schistosomiase vise à réduire le nombre de malades moyennant le traitement périodique à grande échelle des populations par le praziquantel ; une démarche plus globale, incluant l'accès à l'eau potable et à des moyens d'assainissement appropriés, ainsi que la lutte contre les gastéropodes, devrait aussi faire régresser la transmission. On estimait en 2021 qu'au moins 251,4 millions de personnes avaient besoin d'un traitement préventif contre la schistosomiase, alors que le nombre des personnes traitées était de 75,3 millions. En 2021, la pandémie de COVID-19 et les efforts visant à en atténuer les conséquences ont fait baisser le nombre d'interventions contre les maladies tropicales négligées (MTN) et la couverture du traitement de la schistosomiase. Vue d'ensemble La schistosomiase est une parasitose aiguë et chronique provoquée par des vers (trématodes) du genre Schistosoma . Selon les estimations, au moins 251,4 millions de personnes avaient besoin d'un traitement préventif en 2021. Le traitement préventif, qui devrait être renouvelé pendant un certain nombre d'années, permettra de réduire et de prévenir la morbidité. La transmission de la schistosomiase est avérée dans 78 pays. Cependant, la chimioprophylaxie de la maladie, dont le but est de traiter à grande échelle les populations et les communautés, n'est nécessaire que dans 51 pays d'endémie où la transmission est de modérée à forte. Infection et transmission L'infection chez l'être humain se produit quand les larves du parasite, libérées par des gastéropodes d'eau douce, pénètrent dans la peau lors d'un contact avec de l'eau infestée. La transmission a lieu quand les personnes atteintes de schistosomiase contaminent les sources d'eau douce avec leurs selles ou leurs urines contenant les œufs du parasite, qui vont y éclore. Dans l'organisme, les larves se développent et passent au stade du schistosome adulte. Les vers adultes vivent dans les vaisseaux sanguins, où les femelles pondent leurs œufs. Certains des œufs sont évacués dans les selles ou l'urine, ce qui permet au parasite de poursuivre son cycle de vie. D'autres sont piégés dans les tissus, causant des réactions immunitaires et des lésions organiques progressives. Épidémiologie Les zones de prévalence de la schistosomiase se situent dans les régions tropicales et subtropicales, notamment dans les communautés les plus pauvres qui n'ont pas accès à l'eau potable ni à des moyens d'assainissement satisfaisants. On estime qu'au moins 90 des personnes qui ont besoin d'un traitement contre la schistosomiase vivent en Afrique. Il existe 2 formes principales de schistosomiase : intestinale et urogénitale, provoquées principalement par 5 espèces de vers nématodes. Tableau : Espèces parasitaires et répartition géographique de la schistosomiase Espèces Répartition géographique Espèces Répartition géographique Schistosomiase intestinale Schistosoma mansoni Afrique, Moyen-Orient, Caraïbes, Brésil, Venezuela et Suriname Schistosoma japonicum Chine, Indonésie, Philippines Schistosoma mekongi Plusieurs districts du Cambodge et de la République démocratique populaire lao Schistosoma guineansis et S. intercalatum espèce voisine Zones des forêts tropicales humides en Afrique centrale Schistosomiase urogénitale Schistosoma haematobium Afrique, Moyen-Orient, Corse (France) La schistosomiase touche essentiellement les communautés pauvres et rurales, en particulier les populations d'agriculteurs et de pêcheurs. Les femmes qui accomplissent leurs tâches domestiques, comme le lavage du linge, dans de l'eau infestée sont également exposées au risque, et peuvent être atteintes de schistosomiase (ou bilharziose) génitale féminine. Le manque d'hygiène et le contact avec de l'eau contaminée rendent les enfants particulièrement vulnérables à l'infection. L'exode rural et les déplacements de population introduisent la maladie dans de nouvelles régions. La croissance démographique, allant de pair avec une augmentation des besoins en énergie et en eau, est souvent à l'origine de programmes d'aménagement, et de modifications de l'environnement qui facilitent la transmission. Avec l'essor de l'écotourisme et des voyages dans des régions reculées, un nombre croissant de touristes contractent la schistosomiase. On peut parfois observer des infections aiguës sévères et des problèmes inhabituels pouvant aller jusqu'à une paralysie. La schistosomiase urogénitale est considérée comme un facteur de risque de l'infection à VIH, en particulier chez la femme. Symptômes Les symptômes de la schistosomiase sont principalement causés par la réaction de l'organisme aux œufs du parasite. La schistosomiase intestinale peut se manifester par des douleurs abdominales, de la diarrhée et l'apparition de sang dans les selles. L'hépatomégalie est courante à un stade avancé et est fréquemment associée à une accumulation de liquide dans la cavité péritonéale et à une hypertension dans les vaisseaux sanguins de l'abdomen. Dans ce cas, il arrive d'observer aussi une splénomégalie. L'hématurie (sang dans les urines) est le signe classique de la schistosomiase urogénitale. Les lésions rénales et la fibrose de la vessie et de l'uretère sont parfois diagnostiquées à un stade avancé. Le cancer de la vessie est aussi une complication possible à un stade tardif. La femme peut présenter des lésions génitales, des saignements vaginaux, des douleurs pendant les rapports sexuels et des nodules dans la vulve. Chez l'homme, la schistosomiase urogénitale peut provoquer une pathologie des vésicules séminales, de la prostate et d'autres organes. La maladie peut avoir d'autres conséquences irréversibles à long terme, comme la stérilité. Les conséquences économiques et sanitaires de la schistosomiase sont considérables et cette maladie handicape plus qu'elle ne tue. Chez l'enfant, elle peut causer une anémie, un retard de croissance, une diminution des capacités d'apprentissage mais, avec le traitement, ces effets sont en général réversibles. Dans sa forme chronique, la schistosomiase peut avoir une incidence sur la capacité d'un adulte à travailler et, dans certains cas, entraîner le décès. Le nombre de décès qui lui sont imputables est difficile à estimer en raison des pathologies cachées telles que les insuffisances hépatique et rénale, le cancer de la vessie et les grossesses ectopiques provoquées par la schistosomiase génitale féminine. On estime que la schistosomiase est responsable actuellement de 11 792 décès par an dans le monde. Cependant, ces chiffres sont probablement sous-estimés et doivent être réévalués. Diagnostic Le diagnostic de la schistosomiase repose sur la détection des œufs du parasite dans les selles ou les urines. La présence d'anticorps etou d'antigènes dans les échantillons de sang ou d'urine signe également l'infection. Pour diagnostiquer la schistosomiase urogénitale, on a normalement recours à une technique de filtration avec des filtres en nylon, en papier ou en polycarbonate. Les enfants porteurs de S. haematobium présentent presque toujours une hématurie microscopique détectable au moyen de bandelettes réactives. En cas de schistosomiase intestinale, on met en évidence les œufs dans les échantillons de matières fécales au moyen de feuilles de cellophane enduites de glycérine colorée au bleu de méthylène ou de lames de verre (technique de Kato-Katz). Dans les zones de transmission de S. mansoni , le test de détection de l'antigène cathodique circulant (CCA) peut également être utilisé. Pour les personnes vivant dans des zones exemptes de l'endémie ou ou dans lesquelles la transmission est faible, les techniques sérologiques et immunologiques peuvent s'avérer utiles pour mettre en évidence une exposition à l'infection et la nécessité de procéder à des analyses plus poussées, de traiter et d'assurer un suivi. Prévention et lutte La lutte contre la schistosomiase repose sur le traitement à grande échelle des groupes de population à risque, l'accès à l'eau potable, l'amélioration de l'assainissement, l'éducation en matière d'hygiène, le changement de comportements, la lutte contre les gastéropodes et l'aménagement de l'environnement. La nouvelle Feuille de route pour les maladies tropicales négligées 2021-2030, adoptée par l'Assemblée mondiale de la Santé, a fixé comme objectifs mondiaux l'élimination de la schistosomiase en tant que problème de santé publique dans tous les pays d'endémie et l'interruption de la transmission (absence d'infection chez l'être humain) dans certains pays. L'OMS axe sa stratégie de lutte sur la réduction de la morbidité au moyen de traitements réguliers et ciblés au praziquantel, dans le cadre du traitement à grande échelle (chimioprophylaxie) des populations touchées. Tous les groupes à risque bénéficient régulièrement du traitement. Dans quelques pays où la transmission est faible, l'objectif doit être l'interruption de la transmission. Les groupes ciblés en vue d'un traitement sont les suivants : les enfants d'âge préscolaire ; les enfants d'âge scolaire ; les adultes exposés au risque dans les zones d'endémie, et les personnes dont les activités impliquent un contact avec des eaux infestées, comme les pêcheurs, les agriculteurs, les personnes qui font des travaux d'irrigation et les femmes amenées à être en contact avec des eaux infestées en raison de leurs tâches domestiques ; et l'ensemble de la population des communautés des zones de forte endémie. L'OMS recommande de traiter les enfants d'âge préscolaire infectés à l'issue d'une décision diagnostique et clinique et de les faire bénéficier du traitement à grande échelle en utilisant la formulation pédiatrique du praziquantel. La fréquence du traitement est déterminée par la prévalence de l'infection chez les enfants d'âge scolaire. Dans les zones de forte transmission, les traitements devront avoir lieu tous les ans pendant plusieurs années. Le suivi est indispensable pour déterminer l'impact des mesures de lutte. Le but est de réduire la morbidité et d'enrayer la transmission pour parvenir à l'élimination de la maladie en tant que problème de santé publique : les traitements réguliers des populations à risque guérissent les symptômes bénins et évitent l'aggravation et la chronicisation de la maladie. La lutte contre la schistosomiase s'est néanmoins heurtée à un obstacle majeur : la disponibilité limitée du praziquantel, en particulier pour le traitement des adultes. Les données pour 2021 montrent que 29,9 des personnes ayant besoin du traitement ont pu en bénéficier à l'échelle mondiale, la proportion d'enfants d'âge scolaire ayant besoin de la chimiothérapie préventive pour la schistosomiase qui ont été traités n'étant que de 43,3 . Ceci représente une baisse de 38 par rapport à 2019, en raison de la pandémie de COVID-19 qui a entraîné la suspension des campagnes de traitement dans de nombreuses zones d'endémie. Le praziquantel est le médicament recommandé contre toutes les formes de schistosomiase. Il est efficace, sûr et peu coûteux. Même si des réinfections sont possibles après le traitement, le risque de contracter une forme grave diminue, voire disparaît lorsque le traitement est instauré et répété dans l'enfance. Ces 40 dernières années, le praziquantel a été utilisé avec succès pour lutter contre la schistosomiase dans plusieurs pays, dont l'Arabie saoudite, le Brésil, le Cambodge, la Chine, l'Égypte, la Jordanie, le Maroc, Maurice, Oman, la République islamique d'Iran et la Tunisie, entre autres. Dans de nombreux pays, il a été possible d'étendre le traitement de la schistosomiase au niveau national et d'avoir un impact sur la maladie en quelques années. Une évaluation de l'état de la transmission est nécessaire dans plusieurs pays. Depuis 10 ans, les campagnes de traitement ont pris de l'ampleur dans plusieurs pays d'Afrique subsaharienne où vivent la majorité des populations à risque. Ces campagnes de traitement ont entraîné une diminution de près de 60 de la prévalence de la schistosomiase chez les enfants d'âge scolaire (1) . Action de l'OMS L'action de l'OMS contre la schistosomiase entre dans le cadre de l'approche intégrée pour lutter contre les maladies tropicales négligées. Malgré leur diversité clinique, ces maladies ont des caractéristiques communes qui leur permettent de persister dans des situations de pauvreté où elles se regroupent et se superposent fréquemment. L'OMS coordonne la stratégie de chimioprophylaxie en consultation avec ses centres collaborateurs et ses partenaires, qu'il s'agisse des établissements universitaires et instituts de recherche, du secteur privé, des organisations non gouvernementales, des organisations internationales ou des autres institutions des Nations Unies. Elle met également au point des lignes directrices et des outils techniques destinés aux programmes nationaux de lutte. En collaboration avec ses partenaires et le secteur privé, l'OMS a entrepris d'améliorer l'accès au praziquantel et d'obtenir des ressources pour la mise en œuvre des campagnes de traitement. Le secteur privé et les partenaires du développement ont ainsi promis des quantités importantes de praziquantel permettant de traiter plus de 100 millions d'enfants d'âge scolaire par an. Kokaliaris C, Garba A, Matuska M, Bronzan RN, Colley DG, et al. Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study. Lancet Infect Dis. 2022 Jan;22(1):136-149. doi: 10.1016S1473-3099(21)00090-6. Epub 2021 Dec 2. Erratum in: Lancet Infect Dis. 2022 Jan;22(1):e1.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/schistosomiasis",
    "length": 14060,
    "type": "html",
    "id": 4,
    "source": "WHO"
  },
  {
    "title": "Filariose lymphatique",
    "text": "Principaux faits La filariose lymphatique altère le système lymphatique et peut entraîner une augmentation anormale du volume de certaines parties du corps, donnant lieu à des douleurs, un handicap sévère et une stigmatisation sociale. À l'échelle mondiale, plus de 657 millions de personnes dans 39 pays sont exposées à un risque de filariose lymphatique et nécessitent une chimioprévention pour endiguer la propagation de cette parasitose. Il est possible d'éliminer la filariose lymphatique en mettant fin à la propagation de l'infection grâce à une chimioprévention répétée tous les ans, reposant sur l'administration d'une association de médicaments sûrs. Depuis 2000, plus de 9,7 milliards de traitements ont été administrés pour enrayer la propagation de l'infection. En 2018, 51 millions de personnes avaient été infectées, ce qui représente une baisse de 74 depuis le début du Programme mondial pour l'élimination de la filariose lymphatique en 2000. Grâce aux stratégies mises en œuvre avec succès par l'OMS, 871 millions de personnes n'ont désormais plus besoin de chimioprévention. Un ensemble essentiel de soins recommandés permet de soulager la souffrance des personnes atteintes de filariose lymphatique et d'éviter une aggravation de leur handicap. Vue d'ensemble La filariose lymphatique, communément appelée éléphantiasis, est une maladie tropicale négligée. L'infection se produit lorsque les parasites filaires responsables de la maladie sont transmis à l'être humain par des moustiques. Généralement contractée dans l'enfance, cette infection provoque des lésions non apparentes du système lymphatique. Les manifestations visibles, douloureuses et gravement défigurantes de la maladie à savoir le lymphœdème, l'éléphantiasis et la tuméfaction du scrotum n'apparaissent que plus tard et peuvent entraîner un handicap permanent. Outre ce handicap physique, la maladie a des répercussions négatives sur la santé mentale, la vie sociale et la situation financière des malades, ce qui contribue à leur stigmatisation et à leur pauvreté. En 2023, 657 millions de personnes dans 39 pays vivaient dans des zones où une chimioprévention était nécessaire pour mettre un terme à la propagation de l'infection. Selon les estimations initialement établies sur la filariose lymphatique dans le monde, 25 millions d'hommes étaient atteints d'hydrocèle et plus de 15 millions de personnes souffraient de lymphœdème. Ces manifestations chroniques de la maladie persistent chez au moins 36 millions de personnes. L'élimination de la filariose lymphatique permet d'éviter des souffrances inutiles et contribue à faire reculer la pauvreté. Cause et transmission La filariose lymphatique résulte de l'infestation par des nématodes (vers) parasites appartenant à la famille des Filaridés. Ces vers filaires, d'apparence filiforme, sont de trois types : Wuchereria bancrofti , qui est responsable de 90 des cas ; Brugia malayi , qui est à l'origine de la plupart des autres cas ; Brugia timori , qui provoque aussi la maladie dans certains cas. Les vers adultes se logent dans les vaisseaux lymphatiques et altèrent les fonctions du système lymphatique. Ils ont une longévité d'environ six à huit ans et, au cours de leur vie, produisent des millions de microfilaires (larves immatures) qui circulent dans le sang. Les moustiques sont infestés par les microfilaires lorsqu'ils piquent un hôte infecté et ingèrent son sang. Les microfilaires se développent à l'intérieur du moustique jusqu'à devenir des larves infestantes. Lorsqu'une nouvelle personne est piquée par le moustique infecté, les larves matures du parasite sont déposées sur sa peau et peuvent alors pénétrer dans l'organisme. Les larves migrent ensuite vers les vaisseaux lymphatiques où elles parviennent à maturité, perpétuant ainsi le cycle de transmission. La filariose lymphatique est transmise par différents types de moustiques, notamment les moustiques Culex , largement répandus dans les zones urbaines et semi-urbaines, les moustiques Anopheles , essentiellement présents dans les zones rurales, et les moustiques Aedes , que l'on trouve principalement dans les îles du Pacifique où la maladie est endémique. Symptômes La filariose lymphatique peut être asymptomatique, aiguë ou chronique. La plupart des infections sont asymptomatiques : elles ne se manifestent par aucun signe extérieur, mais contribuent à la transmission du parasite. Bien qu'asymptomatiques, ces infections entraînent toutefois une atteinte du système lymphatique et des reins et altèrent le système immunitaire de l'organisme. Lorsque la filariose lymphatique devient chronique, elle conduit à un lymphœdème (tuméfaction des tissus), à un éléphantiasis des membres (épaississement de la peau et des tissus) ou à une hydrocèle (tuméfaction scrotale). Les seins et les organes génitaux sont fréquemment atteints. Souvent, ces difformités physiques donnent lieu à une stigmatisation sociale, ont des répercussions négatives sur la santé mentale des malades, compromettent leurs possibilités de revenu et entraînent des dépenses médicales qui représentent une charge financière accrue pour les personnes atteintes et pour celles qui les aident. Le fardeau socioéconomique associé à l'isolement et à la pauvreté des malades est énorme. Le lymphœdème et l'éléphantiasis chroniques s'accompagnent souvent d'épisodes aigus d'inflammation localisée de la peau, des ganglions lymphatiques et des vaisseaux lymphatiques. Certains de ces épisodes sont imputables à la réponse immunitaire de l'organisme au parasite. Dans la plupart des cas, ces inflammations sont dues à une surinfection bactérienne cutanée résultant d'une perte partielle des défenses normales de l'organisme provoquée par l'atteinte du système lymphatique. Ces crises aiguës sont débilitantes, peuvent durer plusieurs semaines et sont la cause principale de la perte de revenus parmi les personnes atteintes. Traitement Il est possible d'éliminer la filariose lymphatique en mettant fin à la propagation de l'infection grâce à la chimioprévention. L'administration de masse de médicaments (AMM) est la stratégie de chimioprévention recommandée par l'OMS pour éliminer la maladie. Elle consiste à administrer une dose annuelle de médicaments à l'ensemble de la population à risque. Les médicaments employés n'ont qu'un effet limité sur les parasites adultes, mais ils réduisent efficacement la densité des microfilaires dans le sang et préviennent ainsi la transmission des parasites aux moustiques. Le schéma thérapeutique recommandé pour les AMM dépend de la coendémicité éventuelle de la filariose lymphatique avec d'autres maladies filariennes. L'OMS recommande les schémas d'AMM suivants : albendazole seul (400 mg) deux fois par an dans les zones de coendémicité de la loase ; ivermectine (200 μgkg) en association avec l'albendazole (400 mg) dans les pays touchés par l'onchocercose ; citrate de diéthylcarbamazine (DEC) (6 mgkg) en association avec l'albendazole (400 mg) dans les pays exempts d'onchocercose ; et ivermectine (200 μkg) en association avec le citrate de diéthylcarbamazine (DEC) (6 mgkg) et l'albendazole (400 mg) dans les pays exempts d'onchocercose et où d'autres conditions programmatiques sont remplies. L'impact des AMM dépend de l'efficacité du schéma thérapeutique employé, ainsi que du taux de couverture obtenu (proportion de la population totale ayant pris les médicaments). Il a été observé que les AMM réalisées avec une association de deux médicaments parvenaient à interrompre le cycle de transmission lorsqu'elles étaient menées chaque année pendant au moins quatre à six ans, avec une couverture efficace de toute la population à risque. Du sel enrichi en DEC a également été employé exceptionnellement dans quelques contextes pour interrompre le cycle de transmission. Au début du Programme mondial pour l'élimination de la filariose lymphatique, la filariose lymphatique était considérée comme endémique dans 81 pays. Depuis, de nouvelles données épidémiologiques ont montré que la chimioprévention était devenue inutile dans 10 pays. Entre 2000 et 2023, 9,7 milliards de traitements ont été distribués, permettant à plus de 943 millions de personnes d'être traitées au moins une fois dans 71 pays, d'où une forte baisse de la transmission dans de nombreuses parties du monde. Le nombre de personnes nécessitant une AMM a régressé de 58,6 (871 millions) dans les endroits où la prévalence de l'infection a été ramenée au-dessous des seuils d'élimination. Selon des estimations prudentes, le bénéfice économique global de ce programme s'élève à 24 milliards de dollars des États-Unis (USD) pour la période 2000-2007. On estime que les traitements administrés jusqu'en 2015 ont permis d'éviter des pertes économiques d'au moins 100,5 milliards USD sur toute la durée de vie des cohortes traitées. On considère désormais que la filariose lymphatique est éliminée en tant que problème de santé publique dans 21 pays et territoires (Bangladesh, Brésil, Cambodge, Égypte, Îles Cook, Îles Marshall, Kiribati, Maldives, Malawi, Nioué, Palaos, République démocratique populaire lao, Sri Lanka, Thaïlande, Timor-Leste, Tonga, Togo, Vanuatu, Viet Nam, Wallis et Futuna, et Yémen). En 2023, 14 pays avaient appliqué avec succès les stratégies recommandées et mis un terme aux traitements de masse, et faisaient l'objet d'une surveillance visant à démontrer que la maladie avait bien été éliminée. Une chimioprévention est encore nécessaire dans 39 pays. Dans six d'entre eux, les zones d'endémie n'avaient pas toutes fait l'objet d'une AMM à la fin 2023. Prise en charge de la morbidité La prise en charge de la morbidité et la prévention des handicaps revêtent une importance vitale pour la santé publique et constituent des services essentiels devant être assurés par le système de santé pour en garantir la pérennité. La chirurgie permet de soulager la plupart des cas d'hydrocèle. La gravité clinique et la progression de la maladie, y compris les épisodes inflammatoires aigus, peuvent être atténuées et prévenues grâce à de simples mesures d'hygiène, des soins de la peau, des exercices et l'élévation des membres affectés. Les personnes atteintes de lymphœdème doivent pouvoir bénéficier de soins continus tout au long de leur vie, tant pour prendre en charge la maladie que pour prévenir son aggravation. Le Programme mondial pour l'élimination de la filariose lymphatique vise à garantir l'accès à un ensemble essentiel d'interventions à toutes les personnes atteintes d'affections chroniques liées à la filariose lymphatique dans toutes les zones d'endémie afin de soulager leurs souffrances et d'améliorer leur qualité de vie. Les objectifs d'élimination de la filariose lymphatique seront atteints si les personnes touchées ont accès à l'ensemble de soins essentiels suivant : traitement des épisodes d'adénolymphangite ; conseils sur l'application de mesures simples de prise en charge du lymphœdème afin de prévenir l'évolution de la maladie et la survenue d'épisodes débilitants et inflammatoires d'adénolymphangite ; traitement chirurgical de l'hydrocèle ; et traitement de l'infection. Lutte contre les vecteurs La lutte contre les moustiques est une stratégie complémentaire soutenue par l'OMS. Elle permet de réduire la transmission de la filariose lymphatique et d'autres infections transmises par les moustiques. Selon l'espèce du vecteur porteur du parasite, l'utilisation de moustiquaires imprégnées d'insecticide, la pulvérisation d'insecticides à effet rémanent à l'intérieur des habitations ou l'application de mesures de protection individuelle peuvent contribuer à protéger la population. Dans les zones où les moustiques Anopheles sont le principal vecteur de la filariose, le recours aux moustiquaires imprégnées d'insecticide renforce l'impact des traitements sur la transmission pendant et après les AMM. Il a déjà été constaté que, dans certains endroits, la lutte antivectorielle avait contribué à l'élimination de la filariose lymphatique en l'absence d'une chimioprévention de masse. Action de l'OMS Dans sa résolution WHA50.29, l'Assemblée mondiale de la Santé encourageait les États Membres à éliminer le problème de santé publique que constitue la filariose lymphatique. En 2000, pour donner suite à cette résolution, l'OMS a lancé le Programme mondial pour l'élimination de la filariose lymphatique. Cette stratégie de l'OMS se fonde sur deux éléments essentiels : enrayer la propagation de l'infection grâce à un traitement de masse annuel ciblant toutes les personnes concernées dans les zones ou régions touchées par l'infection ; et soulager les souffrances liées à la filariose lymphatique grâce à un ensemble essentiel de soins recommandés. En 2020, le Programme mondial a fixé les objectifs suivants pour la nouvelle feuille de route pour les maladies tropicales négligées (2021-2030) : 58 pays d'endémie (80 ) satisfont aux critères de validation de l'élimination de la filariose lymphatique en tant que problème de santé publique, avec à la fois des taux d'infection soutenus sous les seuils visés pendant au moins quatre ans après l'arrêt de l'administration de masse de médicaments et la mise à disposition de l'ensemble essentiel de soins dans toutes les zones où l'on sait qu'il y a des patients ; 72 pays d'endémie (100 ) mettent en place une surveillance faisant suite à l'administration de masse de médicaments ou à la validation ; et le nombre de personnes dans la population nécessitant une administration de masse de médicaments est ramené à 0.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/lymphatic-filariasis",
    "length": 13533,
    "type": "html",
    "id": 5,
    "source": "WHO"
  },
  {
    "title": "Onchocercose",
    "text": "Principaux faits L'onchocercose, plus connue sous le nom de cécité des rivières , est due au ver parasite Onchocerca volvulus . Le parasite se propage et est transmis à l'être humain par les piqûres répétées de simulies infectées qui se reproduisent dans les cours d'eau à débit rapide. L'onchocercose se manifeste par de très fortes démangeaisons, une atteinte cutanée qui provoque un défigurement, et une déficience visuelle pouvant aller jusqu'à la cécité Elle touche surtout les populations rurales d'Afrique subsaharienne et du Yémen, même si des foyers d'endémie plus réduits sont également présents en Amérique latine. Le traitement de la population par l'ivermectine (également connu sous le nom d'administration de masse de médicaments (AMM)) est actuellement la principale stratégie mise en œuvre pour éliminer l'onchocercose, la couverture thérapeutique minimale à atteindre étant de 80 . Le laboratoire Merck fait des dons d'ivermectine sous le nom de marque Mectizan. Généralités L'onchocercose se transmet à l'être humain par la piqûre d'une simulie infectée (du genre Simulium ), qui se reproduit dans les cours d'eau à débit rapide. La simulie ingère des microfilaires (vers immatures) lorsqu'elle pique une personne infectée. À l'intérieur de la mouche, les microfilaires évoluent en larves infectieuses qui sont ensuite transmises à un autre être humain lors des piqûres ultérieures. Une fois à l'intérieur de l'hôte humain, les larves deviennent des vers adultes, formant des nodules sous la peau. Tandis que les simulies continuent de s'accoupler et de produire des microfilaires, les populations doivent être traitées pendant au moins 10 à 15 ans pour éliminer la transmission, ce qui correspond à la durée de vie de l' O. volvulus adulte. Ampleur du problème Plus de 99 des personnes infectées vivent en Afrique et au Yémen et 1 vivent à la frontière entre le Brésil et le Venezuela (République bolivarienne du). En 2023, au moins 249,5 millions de personnes avaient besoin d'un traitement préventif contre l'onchocercose. Selon l'étude sur la charge mondiale de morbidité réalisée en 2017, 14,6 millions de personnes infectées souffraient déjà d'une atteinte dermique et 1,15 million d'une perte de la vision. L'OMS a vérifié que cinq pays étaient exempts d'onchocercose après avoir appliqué avec succès des activités d'élimination pendant des décennies. Quatre de ces pays se trouvent dans la Région des Amériques (la Colombie (en 2013), l'Équateur (en 2014), le Mexique (en 2015) et le Guatemala (en 2016)) et un se trouve dans la Région africaine (le Niger (en 2025)). En 2022, le traitement a été interrompu au Sénégal et le pays est désormais sous surveillance. L'Éthiopie, la Guinée équatoriale, le Mali, le Nigéria, l'Ouganda, la République-Unie de Tanzanie, le Soudan, le Togo et le Venezuela (République bolivarienne du) ont arrêté l'AMM dans au moins un foyer. Au niveau mondial, 1,8 million de personnes vivent dans des zones où il n'est plus nécessaire d'administrer les traitements de masse contre l'onchocercose. Ceci prouve qu'il est possible de progresser dans la lutte contre les maladies tropicales négligées (MTN) sur l'ensemble du continent africain. Des informations détaillées concernant les statistiques annuelles pour l'année 2023 figurent dans le Relevé épidémiologique du 11 octobre 2024 . Signes et symptômes cliniques L'onchocercose est une maladie des yeux et de la peau. Les symptômes sont dus aux microfilaires qui se déplacent dans les tissus sous-cutanés et provoquent de violentes réactions inflammatoires lorsqu'ils meurent. Les personnes infectées ressentent de fortes démangeaisons et présentent des lésions cutanées. Elles présentent aussi parfois des lésions oculaires qui peuvent entraîner une déficience visuelle et une cécité irréversible. Dans la plupart des cas, des nodules apparaissent sous la peau autour des vers adultes. L'exposition précoce à O. volvulus est associée à l'épilepsie chez l'enfant. Programmes de prévention, de lutte et d'élimination Les efforts déployés par le Programme de lutte contre l'onchocercose entre 1974 et 2002 ont permis de maîtriser la maladie en Afrique de l'Ouest. Le Programme a principalement eu recours à la pulvérisation d'insecticides contre les larves de simulies (lutte antivectorielle) par hélicoptère et par avion, puis à la distribution d'ivermectine à grande échelle à partir de 1989. Le Programme africain de lutte contre l'onchocercose (APOC) a été créé en 1995 afin de lutter contre la maladie dans les derniers pays africains d'endémie. Il a été clôturé fin 2015 après le commencement de la transition vers l'élimination de l'onchocercose. La principale stratégie a été la mise en place du traitement par l'ivermectine sous directives communautaires (TIDC) et, le cas échéant, de la lutte antivectorielle au moyen de méthodes sans risque pour l'environnement. Fort du succès du Programme de lutte contre l'onchocercose et du Programme africain de lutte contre l'onchocercose, le Projet spécial élargi pour l'élimination des maladies tropicales négligées (ESPEN) a été lancé en 2016 par le Bureau régional de l'OMS pour l'Afrique afin de fournir aux programmes nationaux de lutte contre les MTN un soutien technique et pour la collecte de fonds afin d'éliminer plus vite l'onchocercose dans les pays africains. Des comités nationaux pour l'élimination de l'onchocercose ont été mis en place dans 25 pays d'Afrique afin d'élaborer et de mettre en œuvre de nouvelles stratégies. Le Réseau mondial pour l'élimination de l'onchocercose (GONE) a été lancé en janvier 2023 par l'OMS, ses États Membres et ses partenaires en vue d'aider les pays à progresser plus vite vers la réalisation des objectifs inscrits dans la feuille de route pour l'élimination de l'onchocercose. Le Programme pour l'élimination de l'onchocercose dans les Amériques (OEPA) a été lancé en 1992 dans le but d'éliminer la morbidité et d'interrompre la transmission dans six pays des Amériques où la maladie était endémique : le Brésil, la Colombie, l'Équateur, le Guatemala, le Mexique et le Venezuela. L'OEPA est un partenariat composé des six pays d'endémie, de l'Organisation panaméricaine de la Santé (OPS), du secteur privé (MSD), des pays donateurs et d'organisations non gouvernementales de développement (ONGD). Traitement L'OMS recommande de traiter l'onchocercose par l'ivermectine au moins une fois par an pendant 10 à 15 ans. Lorsque O. volvulus coexiste avec Loa loa , les stratégies thérapeutiques doivent parfois être adaptées. Loa loa est une autre filaire parasitaire endémique en Angola, au Cameroun, au Congo, au Gabon, en Guinée équatoriale, au Nigéria, en République centrafricaine, en République démocratique du Congo, au Soudan du Sud et au Tchad. Le traitement des personnes présentant des taux élevés de L. loa dans le sang peut parfois entraîner des effets indésirables graves. Dans les pays touchés, il faut suivre les recommandations conjointes du Comité d'experts du Mectizan et de l'APOC sur la prévention et la prise en charge des éventuels effets indésirables graves. Priorités de la recherche Pour parvenir à éliminer l'onchocercose, il faudra établir un programme de recherche ambitieux permettant aux programmes de progresser. À cet égard, il faut : optimiser les stratégies destinées à atteindre les populations marginalisées et migrantes ; valider des stratégies de cartographie et d'intervention sûre dans les endroits où l'onchocercose et la loase sont toutes deux endémiques ; définir plus précisément des seuils à partir desquels commencer et arrêter l'AMM ; mettre au point des outils de diagnostic fiables pour faciliter la prise de décisions dans le cadre des programmes ; démontrer l'utilité des mesures de lutte antivectorielle pour les programmes ; tester de nouveaux schémas thérapeutiques ; optimiser la conception des études en utilisant de nouveaux outils géostatistiques ; optimiser l'utilisation de l'imagerie satellitaire et des outils géospatiaux pour détecter les gîtes larvaires ; réagir correctement aux indices de la présence d' Onchocerca volvulus détectés au cours de la surveillance ; élaborer des stratégies pour la période postérieure à la vérification ; envisager des possibilités d'intégrer la surveillance. Action de l'OMS L'OMS apporte un appui administratif, technique et opérationnel à la recherche dans les trois Régions où l'onchocercose se transmet. Selon la feuille de route de l'OMS pour les maladies tropicales négligées (MTN) 2021-2030 , l'onchocercose est l'une des maladies à éliminer. La feuille de route fixe des cibles ambitieuses à atteindre d'ici à 2030 : éliminer la nécessité d'une administration de masse d'ivermectine dans au moins 1 foyer dans 34 pays, pour plus de 50 de la population dans au moins 16 pays et pour l'ensemble de la population vivant en zone d'endémie dans au moins 12 pays. Le sous-groupe consultatif technique sur l'onchocercose, créé par l'OMS en 2017, fournit des orientations pour les travaux de recherche opérationnelle visant à recenser les zones d'endémie où l'AMM est nécessaire et assure une supervision à cet égard. Le Groupe consultatif technique pour le diagnostic des MTN considère que la mise au point de nouveaux outils de diagnostic de l'onchocercose est une priorité. Avec le passage de la lutte à l'élimination, il faut cartographier de grandes zones d'Afrique pour déterminer si la transmission est active et si un traitement est nécessaire. Une stratégie d'échantillonnage pour cartographier l'élimination de l'onchocercose a été mise au point afin d'aider les pays à mener ces évaluations et à débuter un traitement si nécessaire.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/onchocerciasis",
    "length": 9643,
    "type": "html",
    "id": 6,
    "source": "WHO"
  },
  {
    "title": "Géohelminthiases",
    "text": "Principaux faits Les géohelminthiases sont dues à différentes espèces de vers parasites. Elles se transmettent par des œufs présents dans les excréments humains, qui contaminent les sols là où les conditions d'assainissement sont insuffisantes. Les enfants infestés présentent des troubles nutritionnels et physiques. Dans le cas des filles et des femmes infestées en âge de procréer, les pertes de sang exacerbent l'anémie ferriprive et augmentent le risque de mortalité maternelle et infantile et d'insuffisance pondérale à la naissance. La lutte contre la maladie repose sur l'administration périodique d'un traitement vermifuge pour éliminer les vers infestants, l'éducation sanitaire pour prévenir les réinfections et l'amélioration des moyens d'assainissement pour réduire la contamination des sols par les œufs. Il existe des médicaments sûrs et efficaces contre les géohelminthiases. Vue d'ensemble Les géohelminthiases comptent parmi les infections les plus courantes dans le monde, plus de 1,5 milliard de personnes, soit près de 24 de la population mondiale, étant infestées à l'échelle mondiale. Ces infections touchent les communautés les plus pauvres et les plus défavorisées ayant un accès limité à l'eau potable, à l'assainissement et à l'hygiène dans les régions tropicales et subtropicales, la plus forte prévalence étant recensée en Afrique subsaharienne, en Chine, en Amérique du Sud et en Asie. Elles se transmettent par des œufs présents dans les excréments humains, qui contaminent les sols là où les conditions d'assainissement sont insuffisantes. Plus de 260 millions d'enfants d'âge préscolaire, 654 millions d'enfants d'âge scolaire, 108 millions d'adolescentes et 138,8 millions de femmes enceintes ou allaitantes vivent dans des zones où il existe une transmission à grande échelle de ces parasites et nécessitent un traitement et la mise en place de mesures préventives. On estime que plus de 600 millions de personnes dans le monde sont infestées par S. stercoralis . Toutefois, étant donné que ce parasite se transmet lui aussi dans des zones où l'assainissement est insuffisant, sa distribution géographique coïncide en grande partie avec celle des autres géohelminthiases. Types d'espèces Les principales espèces responsables de la maladie chez l'homme sont le ver rond ( Ascaris lumbricoides ), le trichocéphale ( Trichuris trichiura ) et les ankylostomes ( Necator americanus et Ancylostoma duodenale ). Les géohelminthiases dues à ces différentes espèces sont généralement regroupées dans une même catégorie car elles sont diagnostiquées de manière similaire et répondent aux mêmes médicaments. Strongyloides stercoralis est un helminthe intestinal présentant des caractéristiques particulières : son diagnostic nécessite des méthodes différentes de celles utilisées pour les autres géohelminthiases et il échappe de ce fait souvent à la détection. En outre, ce parasite n'est pas sensible à l'albendazole et au mébendazole et ne peut donc pas être combattu dans le cadre de campagnes préventives de masse ciblant les autres géohelminthiases. Transmission Les géohelminthes sont transmis par des œufs excrétés dans les selles des personnes infestées. Les vers adultes vivent dans les intestins, où ils pondent des milliers d'œufs chaque jour. Dans les endroits où les moyens d'assainissement sont insuffisants, ces œufs contaminent les sols. La transmission peut avoir lieu selon différents scénarios : des œufs présents sur les légumes sont ingérés lorsque ces légumes sont consommés sans avoir été convenablement cuits, lavés ou épluchés ; des œufs sont ingérés lors de la consommation d'eau contaminée ; et des œufs sont ingérés par des enfants qui jouent sur un sol contaminé et mettent leurs mains à la bouche sans les avoir lavées. En outre, les œufs d'ankylostomes éclosent dans le sol, libérant des larves qui poursuivent leur développement jusqu'à atteindre un stade où elles sont capables de traverser activement la peau. La plupart des cas d'infestation par les ankylostomes se produisent lorsqu'une personne marche pieds nus sur un sol contaminé. Il n'existe pas de transmission interhumaine directe, ni d'infestation à partir de selles fraîches, car les œufs excrétés dans les selles doivent subir une maturation d'environ 3 semaines dans le sol avant d'acquérir un pouvoir infectieux. Étant donné que les vers A. lumbricoides , T. trichiura et les ankylostomes ne se multiplient pas à l'intérieur de l'organisme humain, une réinfection ne peut avoir lieu qu'à l'issue d'un contact avec des larves se trouvant à un stade infestant dans l'environnement. S. stercoralis peut se reproduire chez l'hôte et chez les sujets immunodéprimés ; si cette multiplication n'est pas contrôlée, elle peut être mortelle. Effets sur l'état nutritionnel Les géohelminthes altèrent de plusieurs manières l'état nutritionnel des personnes infestées. Les vers s'alimentent à partir des tissus de l'hôte, y compris le sang, ce qui entraîne une perte de fer et de protéines. Les ankylostomes provoquent en outre une perte chronique de sang intestinal pouvant conduire à l'anémie, en particulier chez les adolescentes et les femmes en âge de procréer. Les vers amplifient la malabsorption des nutriments. Les ascaris sont en outre susceptibles de capturer une partie de la vitamine A dans l'intestin. Certains géohelminthes provoquent également une perte d'appétit et donc une réduction de l'apport nutritionnel et une baisse de la forme physique. T. trichiura , en particulier, peut entraîner une diarrhée et une dysenterie. Morbidité et symptômes La morbidité dépend du nombre de vers dont le sujet est porteur. Les personnes dont l'infestation est de faible intensité (vers peu nombreux) ne présentent généralement pas de souffrance particulière. Les infestations de plus forte intensité peuvent provoquer divers symptômes, dont des manifestations intestinales (diarrhées et douleurs abdominales), une malnutrition, un état général de malaise et de faiblesse et des troubles de la croissance et du développement physique. Les infestations de très forte intensité peuvent être à l'origine d'obstructions intestinales nécessitant une intervention chirurgicale. L'infestation par S. stercoralis peut induire une morbidité dermatologique et gastro-intestinale et est associée à une malnutrition chronique chez l'enfant. Chez les hôtes dont le système immunitaire est affaibli, elle peut conduire à un syndrome d'hyperinfestationdissémination qui est invariablement mortel en l'absence d'un traitement adapté et rapide, et même souvent mortel en dépit d'un traitement. Stratégie de l'OMS pour lutter contre les géohelminthiases En 2001, les délégués à l'Assemblée mondiale de la Santé ont approuvé à l'unanimité une résolution (WHA54.19) qui invitait instamment les pays d'endémie à intensifier leurs efforts pour combattre les vers parasites, plus particulièrement les schistosomes et les géohelminthes. La stratégie de lutte contre les géohelminthiases consiste à maîtriser la morbidité par l'administration d'un traitement périodique aux personnes à risque qui vivent dans des zones d'endémie. Les personnes à risque sont : les enfants d'âge préscolaire ; les enfants d'âge scolaire ; les femmes en âge de procréer (y compris les femmes enceintes au deuxième et au troisième trimestre de la grossesse et les femmes allaitantes) ; et les adultes exerçant certains métiers à haut risque (cueilleurs de thé ou travailleurs miniers, par exemple). L'OMS recommande d'administrer périodiquement un traitement médicamenteux (vermifuge ou chimioprévention) à l'ensemble des personnes à risque habitant dans les zones d'endémie, sans diagnostic individuel préalable. Cette intervention permet de faire régresser la morbidité en réduisant la charge parasitaire. En outre : les initiatives d'éducation en matière de santé et d'hygiène réduisent le risque de transmission et de réinfection en favorisant des comportements sains ; et la mise en place de services d'assainissement adéquats revêt également une grande importance, mais n'est pas toujours possible dans les milieux pauvres en ressources. Le traitement périodique vise à réduire durablement l'intensité des infestations et à prévenir la morbidité chez les personnes à risque qui sont infestées. Le déparasitage peut être facilement organisé à l'occasion des journées de la santé de l'enfant ou des activités de supplémentation en vitamine A destinées aux enfants d'âge préscolaire ainsi que des campagnes de vaccination contre le papillomavirus humain destinées aux adolescentes, ou intégré aux programmes de santé scolaire. La lutte contre la morbidité liée à S. stercoralis a été ajoutée aux objectifs fixés par l'OMS à l'horizon 2030. Cet objectif est réalisable dans la mesure où l'ivermectine préqualifiée est actuellement disponible à un coût abordable. La distribution de l'ivermectine peut être assurée au moyen des plateformes utilisées dans la lutte contre les autres géohelminthiases. Des interventions pilotes sont en cours pour affiner cette stratégie et en évaluer l'impact. En 2021, plus de 500 millions d'enfants ont été traités au moyen de médicaments anthelminthiques dans les pays d'endémie, ce qui représente 62 de tous les enfants à risque. En outre, plus de 99 millions de femmes en âge de procréer ont été bénéficié d'un traitement par l'albendazole dans le cadre des programmes d'élimination de la filariose lymphatique. Entre 2010 et 2019, le nombre d'années de vie ajustées sur l'incapacité (DALY) perdues chaque année en raison des géohelminthiases a diminué de plus de 50 , ce qui correspond à la période d'intensification de la chimioprévention contre ces infections dans les pays d'endémie. L'OMS recommande aux pays d'endémie de mesurer le succès de leurs programmes en procédant à des évaluations épidémiologiques après 5 à 6 ans de mise en œuvre de la chimioprévention associée à une couverture thérapeutique efficace de 75 et d'ajuster la fréquence des traitements administrés. Les indicateurs permettant de contrôler l'impact sont le taux de prévalence des géohelminthiases ainsi que le taux de prévalence d'intensité modérée ou forte. Traitement Les médicaments recommandés par l'OMS l'albendazole (400 mg) et le mébendazole (500 mg) sont efficaces et peu coûteux et peuvent aisément être administrés par du personnel non médical (enseignants, par exemple). Leur innocuité a été rigoureusement testée et ils ont été administrés à des millions de personnes, avec des effets secondaires peu nombreux et mineurs. L'albendazole et le mébendazole sont fournis, sous forme de dons gérés par l'OMS, aux ministères de la santé de l'ensemble des pays d'endémie en vue de traiter tous les enfants d'âge scolaire. Depuis 2021, l'ivermectine générique est disponible à un prix abordable pour lutter contre S. stercoralis . Action de l'OMS Six cibles ont été fixées par l'OMS à l'horizon 2030 dans la lutte contre les géohelminthiases : atteindre et pérenniser l'élimination de la morbidité liée aux géohelminthiases chez les enfants d'âge préscolaire et scolaire ; réduire le nombre de comprimés nécessaires à la chimioprévention contre les géohelminthiases ; accroître les ressources financières nationales allouées à la chimioprévention contre les géohelminthiases ; mettre en place un programme efficace de lutte contre les géohelminthiases chez les adolescentes et les femmes enceintes ou allaitantes ; mettre en place un programme efficace de lutte contre l'anguillulose chez les enfants d'âge scolaire ; et garantir l'accès universel à des services d'assainissement et d'hygiène au moins élémentaires d'ici 2030 dans les zones d'endémie des géohelminthiases. Afin de réaliser la feuille de route 2030 pour les maladies tropicales négligées, l'OMS collabore avec ses États Membres et ses partenaires de sorte à atteindre et à maintenir une couverture efficace de la chimioprévention contre les géohelminthiases dans tous les groupes à risque, à mesurer l'impact des interventions dans les pays qui mettent en œuvre le programme depuis plus de 5 ans et à œuvrer en faveur de l'intégration de la lutte contre les géohelminthiases dans les soins de santé primaires (SSP) pour garantir la durabilité du programme.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/soil-transmitted-helminth-infections",
    "length": 12214,
    "type": "html",
    "id": 7,
    "source": "WHO"
  },
  {
    "title": "Maladie de Chagas (ou trypanosomiase américaine)",
    "text": "Principaux faits D'après les estimations, plus de 7 millions de personnes dans le monde sont infectées par Trypanosoma cruzi ( T. cruzi ), le parasite responsable de la maladie de Chagas. La plupart de ces personnes vivent en Amérique latine. La maladie peut se transmettre par un insecte appelé triatome (transmission vectorielle), ainsi que par voie orale (transmission alimentaire), pendant la grossesse ou l'accouchement (transmission congénitale), par le sangles produits sanguins, au cours de la transplantation d'organes et lors d'accidents de laboratoire. La maladie de Chagas est curable si un traitement antiparasitaire est instauré rapidement, durant la phase aiguë. Chez les personnes infectées de façon chronique, le traitement et le suivi peuvent éventuellement prévenir ou enrayer la progression de la maladie et éviter sa transmission, notamment pendant la grossesse et l'accouchement. En l'absence de diagnostic et de traitement précoces, jusqu'à un tiers des personnes infectées de façon chronique présentent des troubles cardiaques et une personne sur dix souffre de troubles digestifs etou neurologiques, ce qui peut imposer un traitement spécifique. Les principales stratégies de prévention de la maladie de Chagas sont notamment la lutte antivectorielle (en Amérique latine) ; le dépistage de la maladie dans le sang avant la transfusion et la transplantation ; le dépistage et le traitement de la maladie chez les filles, les femmes en âge de procréer et les nouveau-nés et autres enfants de mères infectées ; un diagnostic, un suivi et des soins complets le plus rapidement possible ; et l'information, la sensibilisation et la communication à l'intention des communautés et des professionnels de santé. Vue d'ensemble La maladie de Chagas est causée par l'infection d'un parasite protozoaire ( Trypanosoma cruzi ). Elle constitue un problème de santé complexe, caractéristique des maladies tropicales négligées et des maladies socialement déterminées. À cause d'un mauvais diagnostic ou d'un diagnostic tardif, et en l'absence d'un traitement et d'un suivi complets, l'infection peut rapidement se transformer en maladie potentiellement mortelle. D'après les estimations, plus de 7 millions de personnes dans le monde sont infectées par T. cruzi , et on dénombre plus de 10 000 décès chaque année. Bien qu'elle soit de plus en plus répandue partout dans le monde, la maladie de Chagas se rencontre principalement dans les zones endémiques de 21 pays continentaux d'Amérique latine (1) , où la transmission est largement liée à la présence de l'insecte vecteur. Aujourd'hui, on estime que plus de 100 millions de personnes sont exposées à un risque d'infection. La maladie de Chagas doit son nom à Carlos Chagas, médecin et chercheur brésilien qui, le 14 avril 1909, a diagnostiqué pour la première fois la maladie chez l'humain. Le 14 avril est désormais la Journée mondiale de la maladie de Chagas. Distribution La maladie de Chagas ne touchait autrefois que des zones rurales continentales des Amériques, mais, en raison de changements socio-environnementaux et d'une mobilité accrue de la population, la plupart des personnes infectées vivent aujourd'hui en milieu urbain et l'infection a été détectée dans 44 pays (dont le Canada, les États-Unis d'Amérique, de nombreux pays d'Europe et certains pays du Pacifique occidental, d'Afrique et de la Méditerranée orientale). Transmission En Amérique latine, T. cruzi se transmet principalement lors de contacts avec des selles ou de l'urine de triatomes hématophages infectés. Ces insectes vivent habituellement dans les fissures des murs ou des toitures d'habitations ou de structures avoisinantes, comme des poulaillers, des enclos et des entrepôts, en milieu rural ou suburbain. Généralement, ils se cachent pendant la journée et sortent la nuit pour se nourrir de sang animal et humain. Ils piquent souvent une zone cutanée exposée comme le visage et défèquent ou urinent à proximité de la piqûre. Si, instinctivement, la personne piquée se frotte, les selles ou l'urine pénètrent dans l'organisme en passant par la lésion cutanée créée par la piqûre, une autre lésion cutanée, les yeux ou la bouche. T. cruzi peut également infecter les animaux ; les opossums communs sont considérés comme l'un des plus importants réservoirs sauvages d'infection. T. cruzi peut aussi se transmettre : par la consommation d'aliments ou de boissons contaminés par T. cruzi , par exemple du fait de contacts avec des selles ou de l'urine de triatomes ou d'opossums communs infectés. Ce type de transmission tend à provoquer des flambées épidémiques ; pendant la grossesse ou l'accouchement ; par la transfusion de sang ou de produits sanguins ; par la transplantation de certains organes (comme le cœur ou les reins) ; et lors d'accidents de laboratoire. Signes et symptômes La maladie de Chagas comporte deux phases. La première phase, aiguë, dure environ deux mois à compter de l'infection. Bien que de très nombreux parasites puissent circuler dans le sang, la personne infectée, dans la plupart des cas, est asymptomatique ou présente seulement des symptômes bénins et aspécifiques (fièvre, céphalées, adénopathies, pâleur, myalgies, difficultés respiratoires, œdèmes et douleurs abdominales ou thoraciques). Il arrive plus rarement que les personnes piquées par un triatome présentent les premiers signes caractéristiques visibles de la maladie, à savoir une lésion cutanée (chagome) ou un œdème violacé au niveau d'une paupière (signe de Romaña). Pendant la phase chronique de la maladie, les parasites sont présents principalement dans le myocarde et les muscles du système digestif. Dix à trente ans après l'infection, jusqu'à un tiers des patients présentent des troubles cardiaques et une personne sur dix souffre de troubles digestifs (généralement un mégaœsophage ou mégacôlon) etou neurologiques. Plus tard, l'infection peut provoquer chez ces patients des lésions du système nerveux et des muscles du cœur et de l'appareil digestif, entraînant des arythmies, une insuffisance cardiaque progressive et la mort subite, entre autres manifestations et complications cliniques. Traitement La maladie de Chagas peut être traitée avec du benznidazole ou du nifurtimox. Ces deux médicaments tuent le parasite et, s'ils sont administrés rapidement durant la phase aiguë, sont totalement efficaces dans le traitement de la maladie, y compris en cas de transmission congénitale. Toutefois, plus l'infection est ancienne, plus leur efficacité diminue. Des effets indésirables plus fréquents et potentiellement graves peuvent survenir chez les personnes âgées. Le traitement est aussi indiqué pour les personnes chez qui l'infection a été réactivée (par exemple en raison d'une immunodépression) et pour les personnes qui entament la phase chronique de la maladie, et il peut notamment être prescrit aux femmes et aux filles en âge de procréer (avant ou après la grossesse) afin de prévenir toute transmission congénitale. Il convient de proposer un traitement aux adultes infectés, en particulier à ceux qui ne présentent pas de symptômes, car un traitement antiparasitaire peut prévenir ou enrayer la progression de la maladie. Dans d'autres cas, il convient de peser, d'une part, les avantages que peut offrir un traitement dans la prévention ou le retardement du développement de la maladie de Chagas et, d'autre part, la durée du traitement (jusqu'à deux mois) ainsi que les effets indésirables possibles (observés chez un pourcentage de patients adultes s'élevant jusqu'à 40 ). Le benznidazole et le nifurtimox ne doivent pas être administrés aux femmes enceintes ni aux personnes souffrant d'insuffisance rénale ou hépatique. Le nifurtimox est également contre-indiqué chez les personnes qui présentent des antécédents en matière de troubles neurologiques ou psychiatriques. Enfin, un suivi et un traitement particulier à vie sont généralement nécessaires en cas d'apparition de troubles cardiaques, digestifs ou neurologiques. Prévention et lutte En raison du grand nombre d'espèces de triatomes et d'animaux sauvages (réservoirs) infectés par T. cruzi dans les Amériques, l'infection ne peut pas être éradiquée. Les priorités en matière de santé publique consistent plutôt à éliminer la transmission à l'humain, à permettre l'accès rapide aux soins et à assurer le suivi à vie des personnes infectées. Il n'existe pas de vaccin permettant de prévenir la maladie de Chagas. La lutte antivectorielle, qui réduit les interactions entre les humains et les insectes vecteurs, est la méthode la plus efficace pour prévenir la maladie de Chagas en Amérique latine. Dans le monde entier, le dépistage sanguin est nécessaire pour prévenir l'infection par transfusion, transplantation d'organes et transmission congénitale, ainsi que pour accroître la détection de la maladie et l'accès aux soins chez les personnes touchées. En fonction de la zone géographique, l'OMS recommande les stratégies de prévention et de lutte suivantes : la mise au point de supports et d'activités d'information, de sensibilisation et de communication adaptés à divers acteurs et différents scénarios, reposant sur l'approche Une seule santé ; l'accès rapide au diagnostic, au traitement et au suivi ; le dépistage de la maladie chez les nouveau-nés et autres enfants de mères infectées ; le dépistage de la maladie chez les donneurs de sang ; le dépistage de la maladie chez les donneurs et receveurs d'organes, de tissus et de cellules ; la pulvérisation d'insecticides à effet rémanent dans les habitations et leurs environs ; l'amélioration des logements et le maintien de la propreté, afin de prévenir les infestations par les vecteurs ; et des mesures de prévention individuelle, comme l'utilisation de moustiquaires de lit et l'application de bonnes pratiques d'hygiène lors de la préparation, du transport, du stockage et de la consommation d'aliments. Le coût des soins médicaux prodigués aux patients atteints de troubles cardiaques, digestifs etou neurologiques dus à la maladie est supérieur de plus de 80 au coût de la pulvérisation d'insecticides à effet rémanent visant à lutter contre les vecteurs et à prévenir les infections. Tous les professionnels et professionnelles de santé, depuis le premier niveau de soins (soins de santé primaires), ayant reçu une formation de base et continue ont un rôle clé à jouer dans le renforcement de la détection, du traitement, du suivi et du signalement des cas. Pour mieux détecter les cas, il est primordial d'évaluer les diagnostics disponibles (y compris les tests sérologiques ou par chimiluminescence rapides et les tests de biologie moléculaire) et les algorithmes les plus rentables. L'innovation, la recherche-développement et l'évaluation de nouveaux produits de diagnostic et médicaments peuvent accélérer le processus d'élimination de la maladie en tant que problème de santé publique. Si l'on veut trouver de nouvelles approches pour prévenir et combattre la maladie de Chagas, il est essentiel de promouvoir des études biomédicales, psychosociales et environnementales qui soient axées sur les déterminants et les facteurs de risque. Il est essentiel que les pays aient un système d'information national permettant de surveiller le nombre de cas aigus et chroniques et les voies de transmission actives. Mais il n'en existe que dans 6 des 44 pays qui ont signalé des cas jusqu'à présent. Action de l'OMS Depuis les années 1990, des initiatives intergouvernementales sont menées avec succès dans les Amériques, ce qui a permis de réduire considérablement la transmission et d'élargir l'accès au diagnostic et au traitement antiparasitaire de la maladie de Chagas. Le risque de transmission de T. cruzi par transfusion a fortement diminué grâce au dépistage universel qui a été assuré dans toutes les banques de sang d'Amérique latine continentale et qui est mis en place progressivement dans d'autres pays et continents. En 2005, l'OMS a classé la maladie de Chagas parmi les maladies tropicales négligées. Ce statut a permis de mieux faire reconnaître la maladie comme problème de santé publique mondial et a contribué à renforcer la prévention, le diagnostic rapide, le traitement antiparasitaire, les soins complets, le suivi psychosocial, ainsi que les activités d'information, de sensibilisation et de communication. Il a aussi favorisé la lutte contre la mésinformation tout en renforçant les attentes de la société et en stimulant un engagement politique jusqu'alors faible pour faire face à la charge de morbidité de la maladie. En mai 2019, la Soixante-Douzième Assemblée mondiale de la Santé a institué la Journée mondiale de la maladie de Chagas, qui est célébrée le 14 avril. La feuille de route pour les MTN 2021-2030 énumère la maladie de Chagas parmi les maladies à éliminer en tant que problème de santé publique, avec cinq cibles proposées : vérification de l'interruption de la transmission vectorielle à domicile ; vérification de l'interruption de la transmission par transfusion ; vérification de l'interruption de la transmission par transplantation d'organes ; vérification de l'interruption de la transmission congénitale ; couverture à 75 de la population éligible par un traitement antiparasitaire. Pour parvenir à éliminer la transmission de la maladie de Chagas à l'humain et dispenser les soins de santé nécessaires aux personnes touchées par la maladie partout dans le monde, l'OMS entend renforcer les réseaux au niveau mondial et consolider les capacités régionales et nationales. Argentine, Belize, Bolivie (État plurinational de), Brésil, Chili, Colombie, Costa Rica, El Salvador, Équateur, Guatemala, Guyana, Guyane française, Honduras, Mexique, Nicaragua, Panama, Paraguay, Pérou, Suriname, Uruguay et Venezuela (République bolivarienne du).",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis)",
    "length": 13784,
    "type": "html",
    "id": 8,
    "source": "WHO"
  },
  {
    "title": "Trypanosomiasis, human African (sleeping sickness)",
    "text": "Overview Human African trypanosomiasis, also known as sleeping sickness, is a vector-borne parasitic disease. It is caused by protozoans of the genus Trypanosoma , transmitted to humans by bites of tsetse flies (glossina) which have acquired the parasites from infected humans or animals. Tsetse flies inhabit sub-Saharan Africa and only certain species transmit the disease. Rural populations which depend on agriculture, fishing, animal husbandry or hunting are the most exposed. In many regions where tsetse flies are found, HAT is not. The disease has a focal distribution ranging from single villages to entire regions, and the incidence can vary from one village to the next. Forms of human African trypanosomiasis HAT takes 2 forms, depending on the parasite subspecies: Trypanosoma brucei gambiense, found in 24 countries of west and central Africa, currently accounts for 92 of reported cases and causes a chronic illness. A person can be infected for months or even years without major signs or symptoms. When evident symptoms emerge, often the disease is advanced with the central nervous system already affected. Trypanosoma brucei rhodesiense , found in 13 countries of eastern and southern Africa accounts for 8 of reported cases and causes an acute disease. First signs and symptoms emerge a few weeks or months after infection. The disease develops rapidly with multi-organ invasion, including the brain. American trypanosomiasis, or Chagas disease , occurs mainly in Latin America. It is caused by a different Trypanosoma subgenus, transmitted by another vector and the disease characteristics are very different from HAT. Animal trypanosomiasis Other trypanosomes cause disease in wild and domestic animals. In African cattle, it is called Nagana . Trypanosomiasis in domestic animals is a major obstacle to rural economic development. Domestic and wild animals are the main reservoir of human-pathogenic T. b. rhodesiense . Animals can also be infected with T. b. gambiense and possibly act as a reservoir to a lesser extent not precisely known. Disease burden and distribution HAT threatens mainly populations of remote rural areas with limited health services, which complicates its diagnosis and treatment. These populations are also affected by war, displacement and poverty, factors favoring transmission. Several epidemics occurred over the last century: between 1896 and 1906, mostly in Uganda and the Congo Basin in the 1920's in several countries between 1970 and the late 1990s. The 1920 epidemic was controlled via mobile teams that screened millions of people. By the mid-1960s HAT was under control with below 5000 annual cases continent-wide. As surveillance relaxed, a resurgence ensued, reaching epidemic proportions in several regions by 1970. In 1998 almost 40 000 cases were reported, amidst an estimated 300 000 undetected and untreated cases. The prevalence reached 50 in several villages in Angola, the Democratic Republic of the Congo (DRC), and South Sudan. HAT was the first or second greatest cause of mortality in those communities. The efforts of WHO, national control programmes, bilateral cooperation and nongovernmental organizations during the 1990s and early 2000s reversed the curve, and the WHO Neglected Tropical Diseases Roadmap targeted for 2020 its elimination as a public health problem, and for 2030 the interruption of transmission (zero case). After continued control efforts, HAT occurrence reached a historic low under 2000 cases in 2017 and under 1000 cases in 2018, remaining below that threshold as of 2022. The population at risk estimated for the period 20162020 was 55 million people, with only 3 million at moderate-high risk. HAT incidence strongly differs by country and by region. Taking the last 5 years: The DRC reported 61 of the cases (mean 522 casesyear). Angola, Central African Republic, Chad, Congo, Gabon, Guinea, Malawi and South Sudan declared 10100 cases, while Cameroon, Côte d'Ivoire, Equatorial Guinea, Uganda, Tanzania, Ethiopia and Zambia declared 110 cases. Burkina Faso, Ghana, Kenya, Nigeria and Zimbabwe, reported sporadic cases in the last decade. Benin, Botswana, Burundi, Eswatini, Gambia, Guinea Bissau, Liberia, Mali, Mozambique, Namibia, Niger, Rwanda, Senegal, Sierra Leone and Togo have not reported cases for over a decade. HAT transmission seems to have stopped in some of these countries but this was not fully assessed yet. Infection and symptoms HAT is mostly transmitted through tsetse flies. Other possible transmission ways are: mother-to-child: trypanosomes can cross the placenta and infect the fetus; mechanical transmission by other blood-sucking insects is possible, although its epidemiological impact is likely marginal; accidental infection in laboratories via pricks with contaminated needles; and transmission through sexual contact has been reported once. Initially the trypanosomes multiply in subcutaneous tissue, blood and lymph. This is called haemo-lymphatic or first stage, which entails bouts of fever, headache, enlarged lymph nodes, joint pains and itching. Later the parasites cross the blood-brain barrier into the central nervous system causing the meningo-encephalitic or second stage. Generally this is when more obvious signs and symptoms of HAT appear: behaviour changes, confusion, sensory disturbances and poor coordination. Sleep cycle disturbance, which gives the disease its name, is a prominent feature. Without treatment, HAT is usually fatal although rare cases of self-cure have been reported. Diagnosis Diagnosis involves 3 steps: screening for potential infection using serological tests (only available for T. b.gambiense ) and clinical examination; confirmation by observing microscopically the parasite in body fluids; and staging the disease progression via clinical examination and analysis of cerebrospinal fluid obtained by lumbar puncture, if needed. Early diagnosis is important to avoid progressing to the neurological stage with more complex and risky treatment. The long, relatively asymptomatic first stage of gambiense -HAT is one of the reasons why active screening of exposed populations is done, to detect cases at an early stage and remove them as reservoir. Exhaustive screening requires a major investment in human and material resources. In Africa such resources are often scarce, particularly in remote areas. Hence, some infected individuals may die before they can ever be diagnosed and treated. Treatment The treatment choice depends on the disease form and the disease stage. The earlier the disease is treated, the better the prospect of cure. The assessment of treatment outcome requires follow up for up to 24 months with clinical assessment and laboratory exams including sometimes of cerebrospinal fluid, because parasites may remain viable and reproduce the disease many months after treatment. Treatment in the second stage requires drugs that cross the bloodbrain barrier. All anti-trypanosomals are donated to WHO by the manufacturers and distributed for free to endemic countries. New WHO treatment guidelines for gambiense-HAT were issued in 2019. Six drugs are used: In gambiense-HAT Pentamidine, intramuscular: in first stage, generally well tolerated by patients. Eflornithine, intravenous: much safer than melarsoprol, only effective in gambiense-HAT. It is generally co-administered with nifurtimox (Nifurtimox-eflornithine combination therapy, NECT) but can be used also as monotherapy. The administration is complex. Nifurtimox, oral: in second stage, only as a component of NECT, which is a shorter treatment with four-times fewer eflornithine infusions, safer and more effective than eflornithine alone. WHO supplies NECT free of charge to endemic countries in a kit containing all the material needed for its administration. Fexinidazole, oral: in first stage and non-severe second stage. To ensure efficacy, intake after a solid meal and under supervision of trained medical staff is required. In rhodesiense-HAT Suramin, intravenous: in first stage. May provoke adverse effects including nephrotoxicity and allergic reactions. Melarsoprol, intravenous: in second stage. An arsenic derivate, it has many adverse effects, the most dramatic being the reactive encephalopathy which is 310 fatal. WHO response A range of activities of the WHO HAT surveillance and control program are enabled since 2001 by publicprivate partnerships with the Sanofi Foundation and Bayer HealthCare. WHO supplies all anti-trypanosome medicines worldwide gratis thanks to donations from Sanofi and Bayer, and collaboration with MSF-Logistics for conditioning and shipment. A WHO biobank is available to researchers for the development of new and affordable diagnostic tools. Hosted in the Institut Pasteur of Paris, it contains samples from gambiense-HAT and rhodesiense-HAT patients and from uninfected controls. The WHO Atlas of HAT, jointly implemented with FAO, compiles epidemiological data geolocated at village level. The WHO Network for HAT Elimination coordinates efforts from all stakeholders including national HAT programmes, international and non-governmental organizations, academia and donors. Network subgroups deal with the diagnostic, therapeutic, antivectorial, sociocultural, programatic and scientific aspects of HAT. WHO collaborates with FAO, IAEA and the African Union within the Program Against African Trypanosomiasis (PAAT). WHO provides support to national programs in order to: strengthen, coordinate and sustain HAT control activities ensure access to diagnosis and the best treatment available train staff at different levels ensure appropriate HAT surveillance and response.",
    "url": "https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness)",
    "length": 9680,
    "type": "html",
    "id": 9,
    "source": "WHO"
  },
  {
    "title": "Neglected tropical diseases -- GLOBAL",
    "text": "C. Carnemark Young children queuing to get treated against intestinal worms during MDA. Credits Neglected tropical diseases Overview Neglected tropical diseases (NTDs) are a diverse group of conditions 1 caused by a variety of pathogens (including viruses, bacteria, parasites, fungi and toxins) and associated with devastating health, social and economic consequences. NTDs are mainly prevalent among impoverished communities in tropical areas, although some have a much larger geographical distribution. It is estimated that NTDs affect more than 1 billion people, while the number of people requiring NTD interventions (both preventive and curative) is 1.495 billion. The epidemiology of NTDs is complex and often related to environmental conditions. Many of them are vector-borne, have animal reservoirs and are associated with complex life cycles. All these factors make their public-health control challenging. ------------------------------------- 1. NTDs include: Buruli ulcer; Chagas disease; dengue and chikungunya; dracunculiasis; echinococcosis; foodborne trematodiases; human African trypanosomiasis; leishmaniasis; leprosy; lymphatic filariasis; mycetoma, chromoblastomycosis and other deep mycoses; noma; onchocerciasis; rabies; scabies and other ectoparasitoses; schistosomiasis; soil-transmitted helminthiases; snakebite envenoming; taeniasiscysticercosis; trachoma; and yaws. Impact WHO estimates that over 1.495 billion of the world's population should be targeted by prevention and treatment activities for at least one of these diseases, every year. In addition to significant mortality and morbidity - approximately 120,000 deaths and 14.1 million disability adjusted life years (DALYs) lost annually, NTDs cost developing communities the equivalent of billions of United States dollars each year in direct health costs, loss of productivity and reduced socioeconomic and educational attainment. They are also responsible for other consequences such as disability, stigmatization, social exclusion and discrimination and place considerable financial strain on patients and their families. In spite of this, NTDs have historically ranked very low and almost absent from the global health policy agenda only to gain recognition in 2015 with the Sustainable Development Goals (SDG target 3.3). SDG3 can therefore be achieved only if the NTD goals are met but, because interventions to tackle NTDs are widely cross-sectoral, increasing their global prioritization can in fact catalyze progress to achieve all SDGs. WHO response WHO's action to control, prevent, eliminate and eradicate NTDs is guided by the NTD road map for 2021-2030 , that moves away from vertical disease programmes to integrated cross-cutting approaches. The aim is to facilitate the coordinated scale-up of key interventions through public health approaches such as preventive chemotherapy, individual case management, vector control, veterinary public health and water, sanitation and hygiene (WASH). The overarching 2030 global targets include a 90 reduction in the number of people requiring treatment for NTDs; a 75 reduction in DALYs related to NTDs; at least 100 countries eliminating at least one NTD; and the eradication of two diseases (dracunculiasis and yaws). Additional cross-cutting targets focus on integrated approaches, multisectoral coordination, universal health coverage and country ownership, while a further set of targets has been devised to measure progress against each disease. Fact sheets Buruli ulcer (Mycobacterium ulcerans infection) Chagas disease (also known as American trypanosomiasis) Chromoblastomycosis Dengue Dracunculiasis (Guinea-worm disease) Echinococcosis Foodborne trematode infections Trypanosomiasis, human African (sleeping sickness) Leishmaniasis Leprosy Lymphatic filariasis Mycetoma Noma Onchocerciasis Podoconiosis (non-filarial lymphoedema) Rabies Scabies Schistosomiasis Snakebite envenoming Soil-transmitted helminth infections Sporotrichosis Taeniasiscysticercosis Trachoma Tungiasis Yaws Questions and answers Frequently asked questions on Neglected tropical diseases Road map for neglected tropical diseases Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 20212030 WHA Resolutions and Decisions Resolutions and Decisions on Neglected Tropical Diseases since 1948 Initiatives and groups Skin NTDs Laboratory Network (Skin NTDs LABNET) Global Initiative on Artificial Intelligence for Skin Conditions Global Buruli Ulcer Initiative (GBUI) Global Onchocerciasis Network for Elimination (GONE) United Against Rabies WHO teams Control of Neglected Tropical Diseases",
    "url": "https://www.who.int/health-topics/neglected-tropical-diseases",
    "length": 4666,
    "type": "html",
    "id": 10,
    "source": "WHO"
  },
  {
    "title": "Principaux repères",
    "text": "Coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV) Enregistrement des faits d'état civil et statistiques d'état civil Nouveau-nés : améliorer leur survie et leur bien-être Produits médicaux de qualité inférieure et falsifiés Sécurité transfusionnelle et approvisionnement en sang Trypanosomiase humaine africaine (maladie du sommeil) Ulcère de Buruli (infection à Mycobacterium ulcerans)",
    "url": "https://www.who.int/fr/news-room/fact-sheets",
    "length": 400,
    "type": "html",
    "id": 11,
    "source": "WHO"
  },
  {
    "title": "Fact sheets - PAHOWHO Pan American Health Organization",
    "text": "Home Communication Materials Fact sheets Fact sheets Topic - Any - Substance Use Intersectoral Action Health in All Policies Trans-fatty Acids Physical Activity Adolescent Health Advanced HIV Disease Age-friendly Cities and Communities Agenda for Sustainable Development Water and Sanitation Air Quality Alcohol Breastfeeding and complementary feeding Healthy Diet Antimicrobial Resistance Antiretroviral Therapy and HIV Drug Resistance Arboviral Encephalitis Primary Health Care Avian Influenza Blood Breast cancer Brucelosis Climate Change and Health Cancer Cervical cancer Childhood and Adolescence Cancer Cardiovascular diseases Poison control center Chagas disease Chemical Safety Chemicals Chikungunya Child Health Chlamydia infection Cholera Chronic kidney disease Combination HIV Prevention Communicable Diseases Risk and Outbreak Communication Quality Control of Medicines Tobacco control Coronavirus infections Health Accounts Palliative Care Cultural Diversity and Health Healthy Life Course Disability Dementia Dengue Depression Human Rights and Health HIV Testing Services Environmental Determinants of Health Social Determinants of Health Diabetes Diphtheria Disaster Risk Reduction in Health Medical Devices Organ Donation and Transplants Evidence and information in human resources for health Drowning Prevention Earthquakes Ebola Virus Disease Economics of NCDs Ectoparasitosis Education of human resources for health Pharmaceutical Education Elimination of Mother-to-Child Transmission of HIV, Syphilis,Hepatitis B, and Chagas Nursing and Midwifery Oropouche virus disease Neglected, Tropical and Vector Borne Diseases Noncommunicable Diseases Enfermedades transmitidas por alimentos Healthy Aging Envenoming from venomous animal bites Epidemic Intelligence Epidemiología Epilepsy Health Equity Gender Equality in Health Volcanic Eruptions Schistosomiasis Essential Public Health Functions Front-of-package labeling Health Technology Assessment HIV Drug Resistance Pharmacovigilance Fascioliasis Foot-and-mouth disease Yellow Fever Lymphatic Filariasis Health Financing Food Safety Genital Herpes Soil Transmitted Helminthiasis Gestión del Conocimiento y acceso a la información en salud Gonorrhea Haemophilus influenzae Leprosy (Hansen disease) Health Care Models Health Emergencies and Disaster Response Health Emergency and Disaster Preparedness Health Information Systems Health Promotion Health Services Health Taxes Health Technicians Hearing Health Hepatitis Hydatidosis Echinococcosis Highly hazardous pesticides Hypertension HIVAIDS Human resources for health Human T lymphotropic virus (HTLV) Immunization Wildfires Sexually Transmitted Infections Infection Prevention and Control Influenza, SARS-CoV-2, RSV and other respiratory viruses Integrated Health Services Networks International Health Regulations Interprofessional health teams Research Laboratórios de Inovação em Saúde Laboratory Systems Lead Leishmaniasis Leptospirosis Malaria Marketing of Ultra-processed and Processed Food and Non-alcoholic Drink Products Maternal Health Measles Medicines and Health Technologies Medicinas tradicionais, complementares e integrativas Meningitis Meningococcus Mental Health Mental Health and Psychosocial Support in Emergencies (MHPSS) Mental Health in Primary Care Mercury Miasis por larvas de Cochliomyia hominivorax Microcephaly Micronutrients Mpox Pneumococcus Newborn Health Nutrition Obesity Prevention Sustainable Development Goals Onchocerciasis - \"River Blindness\" Oral Health Pertussis Pharmaceutical Policies Poliomyelitis Post-Exposure Prophylaxis (PEP) PrEP, PEP, and Key Populations Violence Prevention Suicide Prevention Substandard, falsified and unregistered medical products Protection and promotion of human rights in mental health Rabies Radiological Health Rational Use of Medicines and Other Health Technologies Salt reduction Regulación de medicamentos y otras tecnologías sanitarias Rehabilitation Solid Waste Road Safety Rotavirus Rubella Workers' Health Sexual and Reproductive Health Universal Health Urban health Visual Health Saúde mental dos adolescentes Vaccine Safety Sepsis Syphilis Storms Surveillance and Monitoring of NCDs and Mental Health Taenia solium Taeniasiscysticercosis Tetanus Trachoma Transtorno do espectro autista Transtornos mentais Trichomoniasis Tuberculosis Vectors: Integrated management and public health entomology Violence against children Violence against women Youth Violence Zika Zoonosis Fecha Min Max Apply 25 Sep 2025 Best Buys to Accelerate Disease Elimination in the Americas: Yaws 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas - Package 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: HIVAIDS 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Tuberculosis 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Trachoma 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Maternal and neonatal tetanus elimination 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Measles and rubella 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Congenital rubella 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Human rabies 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Poliomyelitis 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Plague 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Onchocerciasis 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Bacterial meningitis 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Malaria 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Leprosy 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas:Sexually transmitted infections 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Hepatitis B and C 14 Jul 2025 Best Buys to Accelerate Disease Elimination in the Americas: Soil transmitted helminthiasis Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Next page Last page",
    "url": "https://www.paho.org/en/fact-sheets",
    "length": 6201,
    "type": "html",
    "id": 12,
    "source": "WHO"
  },
  {
    "title": "Vector-borne diseases",
    "text": "Key facts Vector-borne diseases account for more than 17 of all infectious diseases, causing more than 700 000 deaths annually. They can be caused by either parasites, bacteria or viruses. Malaria is a parasitic infection transmitted by Anopheline mosquitoes. It causes an estimated 249 million cases globally, and results in more than 608 000 deaths every year. Most of the deaths occur in children under the age of 5 years. Dengue is the most prevalent viral infection transmitted by Aedes mosquitoes. More than 3.9 billion people in over 132 countries are at risk of contracting dengue, with an estimated 96 million symptomatic cases and an estimated 40 000 deaths every year. Other viral diseases transmitted by vectors include chikungunya fever, Zika virus fever, yellow fever, West Nile fever, Japanese encephalitis (all transmitted by mosquitoes), tick-borne encephalitis (transmitted by ticks) and Oropouche fever (transmitted by Culicoides flies) Many of vector-borne diseases are preventable through protective measures and community mobilization. Overview Vectors are living organisms that can transmit infectious pathogens between humans, or from animals to humans. Many of these vectors are bloodsucking insects which ingest disease-producing microorganisms during a blood meal from an infected host (human or animal) and later transmit it into a new host, after the pathogen has replicated. Often, once a vector becomes infectious, they are capable of transmitting the pathogen for the rest of their life during each subsequent biteblood meal. Vector-borne diseases Vector-borne diseases are human illnesses caused by parasites, viruses and bacteria that are transmitted by vectors. Every year there are more than 700 000 deaths from diseases such as malaria, dengue, schistosomiasis, human African trypanosomiasis, leishmaniasis, Chagas disease, yellow fever, Japanese encephalitis and onchocerciasis. The burden of these diseases is highest in tropical and subtropical areas, and they disproportionately affect the poorest populations. Since 2014, major outbreaks of dengue, malaria, chikungunya, yellow fever and Zika have afflicted populations, claimed lives, and overwhelmed health systems in many countries. Other diseases such as chikungunya, leishmaniasis and lymphatic filariasis cause chronic suffering, life-long morbidity, disability and occasional stigmatization. Distribution of vector-borne diseases is determined by a complex set of demographic, environmental and social factors. Global travel and trade, unplanned urbanization, climate change and silent spread and adaptation of the vectors have all contributed to the spread of vector-borne diseases. Climate change substantially affects pathogens (parasites, viruses and bacteria), vectors, and reservoir hosts, with implications for the transmission of many vector-borne diseases. Several vectors have expanded their latitude and altitude ranges, and the length of the season during which they are active is increasing. These trends are expected to continue as the climate continues to get warmer. List of vector-borne diseases, according to their vector The following table is a non-exhaustive list of vector-borne disease, ordered according to the vector by which it is transmitted. The list also illustrates the type of pathogen that causes the disease in humans. Vector Disease caused Type of pathogen Mosquito Aedes Chikungunya Dengue Lymphatic filariasis Rift Valley fever Yellow Fever Zika Virus Virus Parasite Virus Virus Virus Anopheles Lymphatic filariasis Malaria O'nyong'nyong virus Parasite Parasite Virus Culex Japanese encephalitis Lymphatic filariasis West Nile fever Virus Parasite Virus Aquatic snails Schistosomiasis ( bilharziasis ) Parasite Culicoides flies Oropouche fever Virus Blackflies Onchocerciasis (river blindness) Parasite Fleas Plague (transmitted from rats to humans) Tungiasis Bacteria Ecto parasite Lice Typhus Louse-borne relapsing fever Bacteria Bacteria Sandflies Leishmaniasis Sandfly fever ( phlebotomus fever) Parasite Virus Ticks Crimean-Congo haemorrhagic fever Lyme disease Relapsing fever (borreliosis) Rickettsial diseases ( eg : spotted fever and Q fever) Tick-borne encephalitis Tularaemia Virus Bacteria Bacteria Bacteria Virus Bacteria Triatome bugs Chagas disease (American trypanosomiasis) Parasite Tsetse flies Sleeping sickness (African trypanosomiasis) Parasite WHO response The Global Vector Control Response (GVCR) 20172030 was approved by the World Health Assembly in 2017. It provides strategic guidance to countries and development partners for urgently strengthening vector control as a fundamental approach to preventing disease and responding to outbreaks. To achieve this, a re-alignment of vector control programmes is required, supported by increased technical capacity, improved infrastructure, strengthened monitoring and surveillance systems, and greater community mobilization. Ultimately, this will support the implementation of a comprehensive approach to vector control that will enable the achievement of disease-specific national and global goals and contribute to the achievement of the Sustainable Development Goals and universal health coverage. WHO Secretariat provides strategic, normative, and technical guidance to countries and development partners to strengthen vector control as a fundamental approach based on GVCR to prevent disease and respond to outbreaks. Specifically, WHO responds to vector-borne diseases by: providing evidence-based guidance for controlling vectors and protecting people against infection; providing technical support to countries so that they can effectively manage cases and outbreaks; supporting countries to improve their reporting systems and capture the true burden of the disease; providing training (capacity building) on clinical management, diagnosis and vector control with support from some of its collaborating centres; and supporting the development and evaluation of new tools, technologies and approaches for vector-borne diseases, including vector control and disease management technologies. A crucial element in reducing the burden of vector-borne diseases is behavioural change. WHO works with partners to provide education and improve public awareness, so that people know how to protect themselves and their communities from mosquitoes, ticks, bugs, flies and other vectors. Access to water and sanitation is a very important factor in disease control and elimination. WHO works together with many different government sectors to improve water storage, sanitation, thereby helping to control these diseases at the community level.",
    "url": "https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases",
    "length": 6647,
    "type": "html",
    "id": 13,
    "source": "WHO"
  },
  {
    "title": "Principaux repères de l'OMS sur la rage",
    "text": "Principaux faits La rage est un grave problème de santé publique dans plus de 150 pays et territoires, principalement en Asie et en Afrique. Il s'agit d'une maladie tropicale virale, zoonotique et négligée qui entraîne des dizaines de milliers de décès chaque année, dont 40 parmi les enfants de moins de 15 ans. Les morsures et les griffures de chien, à l'origine de 99 des cas de rage humaine, peuvent être évitées grâce à la vaccination des chiens et à la prévention des morsures. Dès lors que le virus atteint le système nerveux central et les symptômes cliniques apparaissent, l'issue est toujours fatale. Cependant, il est possible d'éviter le décès en instaurant rapidement une prophylaxie post-exposition (PPE) pour empêcher le virus d'atteindre le système nerveux central. La PPE consiste à laver soigneusement des plaies et à administrer un vaccin antirabique et, le cas échéant, des immunoglobulines antirabiques. En cas de morsure ou de griffure par un animal potentiellement enragé, une PPE doit systématiquement être instaurée. L'OMS et ses partenaires mondiaux visent à mettre fin aux décès humains dus à la rage transmise par les chiens grâce à une approche globale Une seule santé qui repose sur la vaccination de masse des chiens, l'accès à la PPE, la formation des soignants, l'amélioration de la surveillance et la prévention des morsures en sensibilisant les communautés. Vue d'ensemble Rage d'origine canine La rage est une zoonose virale à prévention vaccinale qui touche le système nerveux central. Les chiens sont responsables de la transmission du virus dans 99 des cas de rage humaine. Les enfants âgés de 5 à 14 ans sont des victimes fréquentes. Le virus de la rage infecte les mammifères, y compris les chiens, les chats, le bétail et les animaux sauvages. La rage se transmet à l'être humain et à l'animal par la salive, généralement en cas de morsures , d'égratignures ou de contact direct avec les muqueuses (par exemple, avec les yeux, avec la bouche ou avec une plaie ouverte). Dès lors que les symptômes cliniques apparaissent, la rage est mortelle dans pratiquement 100 des cas. Le coût mondial de la rage est estimé à environ 8,6 milliards de dollars des États-Unis (USD) par an, compte tenu des décès et de la perte de moyens de subsistance, du coût des soins médicaux et des dépenses associées, auquel s'ajoutent des traumatismes psychologiques dont il est impossible d'estimer le coût. La rage est présente sur tous les continents, sauf l'Antarctique. On estime à 59 000 le nombre de décès dus à la rage chaque année dans le monde ; cependant, les cas étant sous-notifiés, il y a souvent un écart entre le nombre de cas avérés et les estimations. La rage est une maladie tropicale négligée (MTN) qui touche principalement les populations marginalisées. Bien qu'il existe des vaccins et des immunoglobulines à usage humain efficaces, ces produits sont souvent inaccessibles ou inabordables pour les personnes qui en ont besoin. En 2018, le coût moyen estimé de la prophylaxie post-exposition (PPE) contre la rage était de 108 USD (auxquels il faut ajouter les frais de déplacement et la perte de revenus), ce qui peut représenter une lourde charge financière pour les personnes qui gagnent à peine 1 à 2 USD par jour. Plus de 29 millions de personnes dans le monde sont vaccinées contre la rage humaine chaque année. Rage transmise par d'autres animaux que les chiens Dans les Amériques, où la rage transmise par les chiens est pratiquement maîtrisée, les chauves-souris hématophages sont maintenant la principale source de rage humaine. La transmission par les chauves-souris est aussi une nouvelle menace pour la santé publique en Australie et dans certaines régions d'Europe de l'Ouest. Les décès humains consécutifs à une exposition à des renards, des ratons laveurs, des mouffettes et d'autres mammifères sauvages sont très rares et l'on ne connaît pas de cas de transmission par des morsures de rongeurs. Dans certains cas qui ont été décrits, mais sont extrêmement rares, la rage peut être contractée par inhalation d'aérosols contenant le virus, à la suite de la consommation de viande crue ou de lait d'animaux infectés ou après une transplantation d'organes. La transmission interhumaine par morsure ou par la salive est théoriquement possible, mais n'a jamais été confirmée. Symptômes La période d'incubation de la rage est habituellement de deux à trois mois, mais peut aller de moins d'une semaine à un an, en fonction de facteurs tels que le site de pénétration du virus et la charge virale. Les premiers symptômes sont aspécifiques (fièvre accompagnée de douleurs ou de fourmillements, démangeaisons ou sensations de brûlure inexpliqués à l'endroit de la blessure). La propagation du virus dans le système nerveux central entraîne une inflammation progressive et mortelle de l'encéphale et de la moelle épinière. Chez l'être humain, la phase clinique de la maladie peut être prise en charge, mais très rarement guérie, et non sans séquelles neurologiques graves. Il existe deux formes de rage : La forme furieuse , caractérisée par une hyperactivité, une excitabilité, des hallucinations, des troubles de la coordination, une hydrophobie (peur de l'eau) et une aérophobie (peur des courants d'air ou de l'air frais). Le décès survient en quelques jours par arrêt cardiorespiratoire. La forme paralytique , qui représente environ 20 du nombre de cas humains. Cette forme de rage est moins spectaculaire que la forme furieuse et son évolution est généralement plus longue. Les muscles se paralysent progressivement, à partir de l'endroit de la blessure. Le coma s'installe lentement et le décès finit par survenir. Les cas de rage paralytique sont souvent mal diagnostiqués, ce qui contribue à la sous-notification de la maladie. Diagnostic Il n'existe actuellement aucun outil de diagnostic approuvé par l'OMS pour détecter la rage avant le début de la phase clinique. Le diagnostic clinique de la rage est difficile à poser si on ne sait pas si la personne a été en contact avec un animal enragé ou s'il n'y a pas de symptômes spécifiques d'hydrophobie ou d'aérophobie. Une évaluation précise des risques est cruciale pour décider de l'administration d'une prophylaxie postexposition. Une fois que les symptômes apparaissent et que la mort est inéluctable, il est recommandé de prodiguer des soins palliatifs complets et de faire preuve de compassion. La rage humaine est confirmée post mortem au moyen de diverses techniques pour détecter le virus entier, les antigènes viraux ou les acides nucléiques dans les tissus infectés (encéphale, peau ou salive). Dans la mesure du possible, l'animal à l'origine de la morsure doit être testé. Prévention Vaccination des chiens La vaccination des chiens, y compris les chiots, dans le cadre de programmes de vaccination de masse, est la stratégie la plus rentable pour prévenir la rage chez les humains, car elle permet d'interrompre la transmission à la source. L'abattage des chiens errants ne permet pas de lutter efficacement contre la rage. Sensibilisation En complément des programmes de vaccination antirabique, il est essentiel d'apprendre aux enfants et aux adultes comment les chiens se comportent et comment éviter les morsures, ce qu'il faut faire en cas de morsure ou de griffure par un animal potentiellement enragé et quelles sont les responsabilités d'un propriétaire d'animal de compagnie. Vaccination des personnes Il existe des vaccins efficaces permettant d'acquérir une immunité avant et après une exposition potentielle. Comme indiqué sur la liste des produits médicaux préqualifiés par l'OMS , en 2024, seuls trois vaccins antirabiques à usage humain préqualifiés par l'OMS sont disponibles dans le monde : RABIVAX-S , du laboratoire Serum Institute of India Pvt. Ltd., VaxiRab N , du laboratoire Zydus Lifesciences Limited, et VERORAB , du laboratoire Sanofi Pasteur. La prophylaxie préexposition (PPrE) est recommandée pour les personnes exerçant un métier à risque (le personnel de laboratoire qui manipule des virus rabiques ou apparentés) et les personnes dont les activités professionnelles ou personnelles peuvent les amener à être directement en contact avec des animaux infectés (le personnel chargé de la lutte contre les zoonoses ou les gardes forestiers). La PPrE pourrait également être indiquée avant la pratique de loisirs ou avant un voyage dans certaines régions et pour les personnes qui vivent dans des régions éloignées où le risque d'exposition à la rage est élevé et où l'accès aux produits biologiques en lien avec la maladie est limité. Attention, la PrEP ne dispense pas de la PPE. Il faut instaurer une prophylaxie postexposition pour toute personne exposée à un animal chez lequel la rage est suspectée. La prophylaxie post-exposition (PPE) est l'intervention d'urgence indispensable en cas d'exposition à la rage. Elle empêche le virus de pénétrer dans le système nerveux central. La PPE comporte les éléments suivants : nettoyage soigneux des plaies à l'eau et au savon pendant au moins 15 minutes peu après la morsure ; vaccination antirabique complète ; et administration d'immunoglobulines ou d'anticorps monoclonaux antirabiques, si indiqué. Risque d'exposition et indications de la PPE En fonction de la gravité de l'exposition, l'administration d'une PPE complète est recommandée, comme suit : Catégories de contact avec un animal chez lequel la rage est suspectée Mesures de prophylaxie post-exposition Catégorie I animal touché ou nourri, léchage de la peau saine (pas d'exposition) Lavage des surfaces cutanées exposées, pas de PPE Catégorie II mordillage de la peau nue, griffures ou égratignures superficielles sans saignement (exposition) Nettoyage de la plaie et vaccination immédiate Catégorie III morsures ou griffures uniques ou multiples ayant traversé le derme, contamination des muqueuses ou d'une peau érodée par la salive après léchage par un animal, exposition par contact direct avec des chauves-souris (exposition grave). Nettoyage de la plaie, vaccination immédiate et administration d'immunoglobulinesd'anticorps monoclonaux antirabiques N. B. : Les expositions de catégorie II et III nécessitent l'administration d'un vaccin antirabique. Qualité des vaccins L'OMS recommande que tous les vaccins antirabiques à usage humain soient conformes aux normes de l'OMS . L'utilisation de vaccins antirabiques de mauvaise qualité a entraîné des échecs en santé publique dans plusieurs pays. Administration intradermique (ID) ou intramusculaire (IM) du vaccin Comme indiqué dans les orientations sur l'administration de la PPE , l'OMS recommande de passer de l'administration intramusculaire (IM) à l'administration intradermique (ID) des vaccins antirabiques à usage humain. L'administration intradermique réduit la quantité de vaccin nécessaire et le nombre de doses et permet donc de faire baisser les coûts de 60 à 80 , sans compromettre l'innocuité ni l'efficacité. S'il y a moins de doses, il est plus probable que les patients suivront le schéma vaccinal recommandé. Action de l'OMS La rage figure sur la Feuille de route pour les maladies tropicales négligées 2021-2030 , qui fixe des cibles régionales et progressives pour mettre en œuvre le plan stratégique mondial fixant comme objectif de mettre fin aux décès humains dus à la rage transmise par les chiens à l'horizon 2030 (voir également la stratégie Zero by 30 ). Cela suppose : d'améliorer l'accès aux vaccins antirabiques à usage humain grâce aux efforts de l'OMS, en partenariat avec Gavi, l'Alliance du vaccin qui a inclus les vaccins antirabiques à usage humain dans sa stratégie d'investissement en faveur des vaccins pour la période 2021-2025 (1) . Malgré les retards liés à la pandémie de COVID-19, l'OMS collabore désormais avec Gavi pour mettre en œuvre le programme en 2024 ; de fournir des conseils techniques aux pays pour l'élaboration et la mise en œuvre de leurs plans nationaux destinés à éliminer la rage, en mettant l'accent sur le renforcement de la surveillance et de la notification des cas ; d'encourager les pays à renforcer les capacités de leur personnel relevant de l'approche Une seule santé en utilisant les programmes d'élimination de la rage pour favoriser la collaboration multisectorielle ; et de promouvoir l'utilisation du forum multipartite United Against Rabies (UAR) (2) , qui a été lancé en collaboration avec l'OMS, l'Organisation des Nations Unies pour l'alimentation et l'agriculture (FAO) et l'Organisation mondiale de la santé animale (OMSA, anciennement OIE), pour plaider en faveur d'une action et d'investissements dans la lutte contre la rage.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/rabies",
    "length": 12622,
    "type": "html",
    "id": 14,
    "source": "WHO"
  },
  {
    "title": "Principaux repères sur la dracunculose ou maladie du ver de Guinée.",
    "text": "Principaux faits La dracunculose est une maladie parasitaire invalidante qui est sur le point d'être éradiquée, avec 14 et 13 cas notifiés chez l'humain en 2023 et 2022, respectivement. Après l'infestation, il faut entre 10 et 14 mois pour que le cycle de transmission s'achève. C'est à peu près à ce moment-là qu'un ver femelle parvenu à maturité émerge de la peau. Dans la plupart des cas, le parasite se transmet lorsqu'une personne boit de l'eau stagnante contaminée par des copépodes (puces d'eau) infestés. La dracunculose était endémique dans 20 pays (1) au milieu des années 1980. Vue d'ensemble La dracunculose, également appelée maladie du ver de Guinée, est une maladie causée par le parasite Dracunculus medinensis . Elle est rarement mortelle, mais les personnes touchées peuvent souffrir d'invalidité pendant plusieurs semaines, voire plusieurs mois. La maladie sévit dans des communautés rurales défavorisées et isolées qui sont essentiellement tributaires de points d'eau stagnante superficiels non aménagés, comme des étangs, pour s'approvisionner en eau de boisson. Ampleur du problème Au milieu des années 1980, on estimait à 3,5 millions le nombre de cas de dracunculose dans le monde, répartis dans 20 pays, dont 17 en Afrique et les 3 autres en Asie. Le nombre de cas signalés a ensuite chuté, passant en dessous du seuil de 10 000 cas pour la première fois en 2007, puis à 542 cas en 2012 et 126 cas en 2014. Depuis 2015, le nombre de cas humains est resté de l'ordre des dizaines (passant de 22 en 2015 à 14 en 2023). En 2023, des cas humains ont été signalés dans seulement 11 villages de 5 pays : le Tchad (9), le Mali (1), le Soudan du Sud (2) ainsi que le Cameroun (1) et la République centrafricaine (1), deux pays certifiés (dans les deux cas, il s'agissait de cas importés du Tchad). Actuellement, 5 pays (Angola, Éthiopie, Mali, Soudan du Sud et Tchad) sont considérés comme des pays d'endémie, tandis que le Soudan est en phase de précertification. Transmission, cycle évolutif et période d'incubation Environ un an après l'infestation, une vésicule douloureuse se forme sur la partie inférieure de la jambe dans 90 des cas et un ou plusieurs vers émergent de la peau, accompagnés d'une sensation de brûlure. Pour apaiser cette douleur, les patients plongent souvent le membre infesté dans l'eau. Les vers libèrent alors des milliers de larves dans l'eau. Ces dernières parviennent au stade infestant après avoir été ingérées par de petits crustacés ou copépodes, également appelés puces d'eau. Lorsque des personnes boivent cette eau contaminée, elles ingèrent les puces d'eau parasitées. Les puces d'eau meurent dans l'estomac, mais les larves infestantes y sont libérées. Elles traversent alors la paroi intestinale et migrent à travers l'organisme. Le ver femelle fécondé (qui mesure entre 60 et 100 cm de long) se déplace sous les tissus cutanés jusqu'à atteindre son point de sortie, généralement au niveau des membres inférieurs, formant une vésicule ou une tuméfaction d'où il finit par émerger. L'émergence du ver a lieu 10 à 14 mois après l'infestation. Prévention Il n'existe pas de vaccin contre la dracunculose, ni de médicaments pour traiter les patients. La prévention est toutefois possible et la maladie est désormais sur le point d'être éradiquée grâce à la mise en œuvre de diverses stratégies de prévention, consistant notamment à : renforcer la surveillance pour détecter tous les cas humains et tous les animaux infestés dans les 24 heures suivant l'émergence du ver ; prévenir les complications (infection des lésions et septicémie) en traitant chaque lésion d'où un ver a émergé et en assurant le nettoyage régulier et le bandage des lésions cutanées jusqu'à ce que le ver ait été totalement expulsé de l'organisme ; prévenir la contamination de l'eau de boisson en veillant à ce que les personnes et les animaux infestés (chiens et chats) présentant des vers émergents ne s'immergent pas dans les sources d'eau ; garantir un accès plus large à des sources améliorées d'eau potable ; filtrer l'eau provenant de points d'eau non aménagés et stagnants avant toute consommation ; mener des interventions de lutte antivectorielle à l'aide du téméphos (larvicide) ; et promouvoir l'éducation sanitaire et les changements de comportement. Chemin parcouru vers l'éradication L'organe décisionnel de l'OMS, l'Assemblée mondiale de la Santé, a adopté plusieurs résolutions sur l'élimination, puis l'éradication, de la dracunculose : WHA39.21 (1986), WHA42.29 (1989), WHA44.5 (1991), WHA57.9 (2004), WHA64.16 (2011). En mai 1981, le Comité directeur interinstitutions pour la coopération dans le cadre de la Décennie internationale de l'eau potable et de l'assainissement (1981-1990) a proposé que l'élimination de la dracunculose soit utilisée comme indicateur du succès des activités menées au titre de cette Décennie. La même année, l'Assemblée mondiale de la Santé a adopté la résolution WHA34.25, dans laquelle elle reconnaissait que la Décennie constituait une occasion d'éliminer la dracunculose. Cela a conduit l'OMS et les Centers for Disease Control and Prevention des États-Unis d'Amérique à formuler une stratégie et des lignes directrices techniques pour une campagne d'éradication. En 1986, le Carter Center s'est également engagé dans la lutte contre cette maladie et, depuis, il est en première ligne pour les activités d'éradication, en partenariat avec l'OMS et l'UNICEF. En 2011, pour imprimer un dernier élan aux efforts d'éradication, l'Assemblée mondiale de la Santé, par sa résolution WHA64.16, a appelé tous les États Membres où la dracunculose était endémique à accélérer l'interruption de la transmission et à mettre en œuvre une surveillance à l'échelle nationale afin de veiller à l'éradication de la maladie. Certification des pays Pour être déclaré exempt de dracunculose, un pays ne doit avoir enregistré aucun cas humain ni aucune infestation animale pendant au moins 3 années consécutives, au cours desquelles une surveillance active doit avoir été maintenue. Une fois cette période écoulée, une équipe internationale de certification se rend dans le pays pour déterminer si le système de surveillance est suffisamment efficace, pour étudier les données relatives aux enquêtes menées en présence de rumeurs faisant état de cas potentiels ou d'animaux infestés, et pour examiner les mesures prises en conséquence. Certains indicateurs, comme l'accès à des points d'eau potable améliorés dans les zones infestées, sont examinés et des évaluations sont menées dans les villages pour confirmer l'absence de transmission. Le risque de réintroduction de la maladie est également évalué. Enfin, un rapport est soumis pour examen à la Commission internationale pour la certification de l'éradication de la dracunculose (CICED). Depuis 1995, la CICED s'est réunie 16 fois et, sur la base de ses recommandations, l'OMS a certifié 199 pays, zones et territoires (appartenant à 187 États membres) comme étant exempts de dracunculose. La République démocratique du Congo, où la maladie était autrefois endémique, est le dernier pays en date à avoir obtenu ce statut, en décembre 2022. La dernière mise à jour des critères de certification de l'éradication de la dracunculose a été publiée par l'OMS en 2023. Poursuite de la surveillance L'OMS recommande le maintien d'une surveillance active de la dracunculose pendant au moins 3 années consécutives dans les pays etou zones ayant récemment interrompu la transmission. Ce point est essentiel pour vérifier qu'aucun cas humain ou aucun animal infesté n'est passé inaperçu et éviter la réapparition de la maladie. La période d'incubation du ver étant de 10 à 14 mois, l'émergence d'un vers passée inaperçue suffit pour que l'éradication soit retardée d'un an ou plus. Des signes de réémergence ont été constatés en Éthiopie (2008) alors que le programme national d'éradication avait indiqué que la transmission était interrompue, et plus récemment au Tchad (2010), où la transmission a repris alors que le pays n'avait notifié aucun cas depuis près de 10 ans. La transmission est supposée interrompue dans un pays lorsque ce dernier n'a notifié aucun cas pendant 14 mois consécutifs. Le pays entre alors dans la phase de précertification pour une période d'au moins 3 ans à compter de la détection du dernier cas autochtone, au cours de laquelle une surveillance intensive doit se poursuivre. Même après la certification, la surveillance doit être maintenue jusqu'à ce que l'éradication mondiale soit déclarée. Défis à relever La détection et le confinement des derniers cas humains et des derniers animaux infestés constituent l'étape la plus difficile et la plus coûteuse du processus d'éradication, car ces infestations surviennent généralement dans des zones rurales isolées, souvent inaccessibles. L'insécurité, qui entrave l'accès aux zones d'endémie, représente un obstacle majeur. De plus, des infestations chez l'humain ou l'animal (principalement chez le chien) sont de plus en plus souvent signalées dans des pays ayant des frontières communes avec des pays où la transmission se poursuit. Cela souligne le risque que présente la réintroduction de la transmission et la nécessité de mettre en place une surveillance post-certification soutenue et adaptée, y compris une surveillance transfrontalière, jusqu'à ce que l'éradication mondiale soit déclarée. L'infestation des chiens par Dracunculus medinensis reste un obstacle pour la campagne mondiale d'éradication, en particulier au Tchad, en Éthiopie et au Mali. Ce phénomène a été observé au Tchad en 2012, et, depuis lors, plusieurs chiens porteurs de vers émergents, génétiquement identiques à ceux qui infestent l'humain, continuent d'être détectés dans la même zone à risque. En 2023, le Tchad a notifié 406 cas d'infestation chez le chien et 88 cas chez le chat ; l'Éthiopie, 1 cas chez le chien ; le Mali, 41 cas chez le chien, 5 cas chez le chat et 1 cas chez l'âne. La transmission chez l'animal peut être interrompue moyennant les mesures suivantes : surveillance renforcée pour identifier tous les animaux infestés et procéder au confinement (mise en laisse des animaux, tant à titre proactif qu'en présence d'un animal infesté), éducation sanitaire des membres de la communauté et des propriétaires d'animaux, et mesures énergiques et exhaustives de lutte antivectorielle. Action de l'OMS Pour endiguer la dracunculose, en collaboration avec les États Membres et les principaux partenaires, l'OMS mène une action de plaidoyer en faveur de l'éradication, fournit des orientations techniques, coordonne les activités d'éradication, veille à la mise en œuvre de la surveillance dans les zones exemptes de dracunculose, assure un suivi de la situation et rend compte des progrès accomplis. L'OMS est la seule organisation habilitée à certifier qu'un pays est exempt de transmission de la dracunculose, sur recommandation de la CICED. La CICED se réunit selon les besoins pour évaluer la transmission dans les pays ayant déposé une demande de certification de l'éradication de la dracunculose et formuler des recommandations sur l'opportunité de certifier un pays comme étant exempt de transmission. (1) Avant d'obtenir son indépendance le 9 juillet 2011, le Soudan du Sud faisait partie du Soudan et les cas de dracunculose survenus au Soudan du Sud étaient notifiés avec ceux du Soudan ; ainsi, entre les années 1980 et 2011, les pays d'endémie étaient au nombre de 20.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/dracunculiasis-(guinea-worm-disease)",
    "length": 11455,
    "type": "html",
    "id": 15,
    "source": "WHO"
  },
  {
    "title": "Lèpre (maladie de Hansen)",
    "text": "Principaux faits La lèpre est une maladie infectieuse chronique causée par le bacille Mycobacterium leprae, un type de bactérie Elle touche principalement la peau et les nerfs périphériques. En l'absence de traitement, elle peut entraîner des incapacités progressives et permanentes. Le bacille se transmet par des gouttelettes provenant du nez et de la bouche lors de contacts étroits et fréquents avec des cas non traités. Une polychimiothérapie permet de guérir la lèpre. Des cas de lèpre sont notifiés dans les six Régions de l'OMS ; la majorité des nouveaux cas détectés chaque année surviennent dans la Région de l'Asie du Sud-Est. Vue d'ensemble La lèpre, également connue sous le nom de maladie de Hansen, est une maladie infectieuse chronique causée principalement par le bacille Mycobacterium leprae , un type de bactérie. Elle se manifeste par des lésions de la peau, des nerfs périphériques, de la muqueuse des voies respiratoires supérieures ainsi que des yeux. Les personnes touchées par la lèpre sont atteintes de difformités physiques et sont également confrontées à la stigmatisation et à la discrimination. Cependant, la lèpre est curable et le traitement à un stade précoce permet d'éviter les incapacités. Ampleur du problème La lèpre est une maladie tropicale négligée (MTN) encore présente dans plus de 120 pays, et dont environ 200 000 nouveaux cas sont notifiés chaque année. L'élimination de la lèpre en tant que problème de santé publique (c'est-à-dire l'obtention d'une prévalence inférieure à 1 cas pour 10 000 habitants, conformément à la résolution WHA44.9 de l'Assemblée mondiale de la Santé) a été accomplie à l'échelle mondiale en 2000, puis au niveau national dans la plupart des pays en 2010. La régression du nombre de nouveaux cas a été progressive. Selon des données de 2023, le nombre de nouveaux cas signalés est resté supérieur à 10 000 au Brésil, en Inde et en Indonésie, tandis qu'il était compris entre 1000 et 10 000 dans 12 autres pays (Bangladesh, Éthiopie, Madagascar, Mozambique, Myanmar, Népal, Nigéria, Philippines, République démocratique du Congo, République-Unie de Tanzanie, Somalie et Sri Lanka). Cinquante-six pays ont notifié 0 cas et 112 pays ont signalé moins de 1000 nouveaux cas. Des informations détaillées concernant les statistiques annuelles pour l'année 2023 figurent dans le Relevé épidémiologique du 13 septembre 2024, volume 99 . Transmission On pense que la maladie se transmet par des gouttelettes provenant du nez et de la bouche d'un cas non traité, qui contiennent l'agent étiologique, à la suite d'un contact étroit et prolongé. Le fait d'être occasionnellement en contact avec une personne atteinte de la lèpre (par exemple de lui serrer la main, de la serrer dans les bras, de partager un repas avec elle ou de s'asseoir à côté d'elle) ne suffit pas pour contracter la maladie. Le malade cesse d'être contagieux lorsqu'il commence le traitement. Diagnostic Le diagnostic de la lèpre est clinique. Des examens de laboratoire peuvent être nécessaires dans les cas difficiles à diagnostiquer. La maladie se manifeste généralement par une lésion cutanée et une atteinte des nerfs périphériques. Le diagnostic de la lèpre repose sur la présence d'au moins l'un des signes pathognomoniques suivants : i) perte manifeste de sensibilité sur une zone de la peau pâle (hypopigmentée) ou rougeâtre ; ii) épaississement ou hypertrophie d'un nerf périphérique, accompagné d'une perte de sensibilité etou d'une faiblesse des muscles innervés ; iii) détection au microscope de bacilles dans un frottis cutané. Ces signes permettent de distinguer deux types de cas en vue de l'instauration d'un traitement : les cas paucibacillaires et les cas multibacillaires. Cas paucibacillaire : cas de lèpre où l'on retrouve 1 à 5 lésions cutanées, sans présence avérée de bacilles dans le frottis cutané. Cas multibacillaire : cas de lèpre où l'on retrouve plus de cinq lésions cutanées ou une atteinte nerveuse (névrite seule ou névrite accompagnée de plusieurs lésions cutanées) ou bien la présence avérée de bacilles dans le frottis cutané, quel que soit le nombre de lésions cutanées. Traitement La lèpre est une maladie curable. Le schéma thérapeutique actuellement recommandé est une polychimiothérapie qui comprend trois médicaments : la dapsone, la rifampicine et la clofazimine. L'OMS recommande le même schéma pour les cas paucibacillaires et multibacillaires, en suivant respectivement une durée de six mois et de 12 mois. La polychimiothérapie permet d'éliminer l'agent pathogène et de guérir le malade. Un diagnostic précoce et l'instauration rapide du traitement peuvent aider à prévenir les incapacités. L'OMS assure la distribution gratuite de la polychimiothérapie. Le traitement était initialement financé par The Nippon Foundation (TNP) ; depuis 2000, il et fait l'objet de dons de Novartis. Prévention On a constaté que la détection des cas et le traitement par polychimiothérapie ne permettaient pas à eux seuls d'interrompre la transmission. L'OMS recommande de rechercher les contacts (au sein du ménage, parmi les voisins et dans l'entourage ), puis d'administrer une dose unique de rifampicine à titre de prophylaxie post-exposition. Action de l'OMS L'OMS fournit un appui technique aux pays et aux territoires en matière de prévention et de lutte contre la lèpre. Chaque année, l'OMS rassemble des données épidémiologiques sur la lèpre provenant des pays et territoires et publie un rapport de synthèse en anglais et en français dans le Relevé épidémiologique hebdomadaire. Après des consultations approfondies avec les pays, des experts, les partenaires et des personnes atteintes de la lèpre, l'OMS a publié la Stratégie mondiale de lutte contre la lèpre (maladie de Hansen) 2021-2030 Vers zéro lèpre , qui est conforme à la Feuille de route pour les maladies tropicales négligées 2021-2030 . La Stratégie défend une vision zéro lèpre : zéro infection, zéro maladie, zéro incapacité, zéro stigmatisation et zéro discrimination. Les quatre piliers stratégiques de la Stratégie sont les suivants : mise en œuvre des feuilles de route nationales intégrées pour zéro lèpre dans tous les pays d'endémie ; renforcement de la prévention de la lèpre parallèlement à un effort intégré de dépistage actif de cas ; prise en charge de la lèpre et de ses complications et prévention de nouvelles incapacités ; et lutte contre la stigmatisation et assurance du respect des droits humains. La Stratégie reconnaît également qu'il faut investir dans la recherche et propose un ensemble de priorités de recherche clés. L'OMS a mis au point des modules de formation en ligne pour étendre les connaissances et améliorer les compétences des agents de santé à tous les niveaux dans des domaines liés au diagnostic et au traitement de la lèpre et à la prise en charge des incapacités. Ces modules peuvent être consultés sur la plateforme de l'Académie de l'OMS (en anglais).",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/leprosy",
    "length": 6931,
    "type": "html",
    "id": 16,
    "source": "WHO"
  },
  {
    "title": "Principaux repères de l'OMS sur le trachome",
    "text": "L'essentiel Le trachome est une maladie infectieuse de l'œil due à une bactérie, Chlamydia trachomatis . Cette maladie constitue un problème de santé publique dans 32 pays et est responsable de cécité ou de déficiences visuelles chez environ 1,9 million de personnes. La cécité due au trachome est souvent irréversible. Selon les données d'avril 2025, 103 millions de personnes vivent dans des zones où le trachome est endémique et sont donc exposées au risque de cécité lié à cette maladie. L'infection se transmet par contact personnel avec les sécrétions oculaires ou nasales d'une personne infectée (via les mains, les vêtements, les draps ou des surfaces dures) ou par l'intermédiaire de mouches ayant été en contact avec ces sécrétions. En cas d'infections répétées pendant plusieurs années, les cils peuvent se recourber vers l'intérieur et frotter contre le globe oculaire, ce qui provoque des douleurs et peut endommager la cornée de manière irréversible. En 2024, 87 349 personnes ont reçu un traitement chirurgical pour un stade avancé de la maladie et 44,4 millions de personnes ont été traitées par des antibiotiques. La couverture antibiotique au niveau mondial était de 39 en 2024. Vue d'ensemble Le trachome est la principale cause de cécité d'origine infectieuse dans le monde. Il est dû à une bactérie à multiplication intracellulaire obligatoire connue sous le nom de Chlamydia trachomatis . L'infection se transmet par contact direct ou indirect avec les sécrétions oculaires ou nasales de personnes infectées, en particulier les jeunes enfants qui forment le principal réservoir de l'infection. Certaines espèces de mouches peuvent également être vectrices de la maladie après avoir été en contact avec les yeux ou le nez d'une personne infectée. Symptômes et transmission Dans les zones où le trachome est endémique, le trachome évolutif (inflammatoire) est fréquent chez les enfants d'âge préscolaire, avec des taux de prévalence qui peuvent atteindre 60 à 90 . L'infection est moins fréquente et de plus courte durée à mesure que l'âge augmente. L'infection s'acquiert généralement lorsque l'on vit en proximité étroite avec des personnes atteintes de trachome évolutif ; la famille est donc le principal lieu de transmission. Le système immunitaire d'une personne peut vaincre un épisode infectieux isolé, mais dans les communautés d'endémie, les réinfections sont fréquentes. Après des années d'infections répétées, l'intérieur de la paupière peut se couvrir de tissus cicatriciels (cicatrices conjonctivales trachomateuses) au point que le bord de la paupière se retourne vers l'intérieur et que les cils frottent contre le globe oculaire (trichiasis trachomateux), ce qui entraîne une douleur constante et une intolérance à la lumière. Cette altération de l'œil, parmi d'autres, peut provoquer l'apparition de cicatrices sur la cornée. En l'absence de traitement, cette affection conduit à la formation d'opacités irréversibles, menant à des déficiences visuelles ou à une cécité. L'âge auquel ces problèmes surviennent dépend de plusieurs facteurs, dont l'intensité de la transmission locale. Dans les communautés de forte endémie, ils peuvent apparaître dès l'enfance, mais la déficience visuelle survient le plus souvent entre 30 et 40 ans. Les déficiences visuelles ou la cécité aboutissent à une détérioration des conditions de vie des personnes touchées et de leur famille, qui figurent généralement déjà parmi les plus pauvres. La cécité est quatre fois plus fréquente chez les femmes que chez les hommes, probablement parce que les femmes sont davantage en contact avec des enfants infectés et subissent donc des épisodes infectieux plus fréquents. Certains facteurs environnementaux sont associés à une transmission plus intense de C. trachomatis, notamment : une hygiène insuffisante ; des logements surpeuplés ; un accès insuffisant à l'eau ; et un manque d'accessibilité et une utilisation inadéquate des moyens d'assainissement. Répartition géographique Le trachome est hyperendémique dans un grand nombre des zones parmi les plus pauvres et les plus rurales d'Afrique, d'Amérique centrale, d'Amérique du Sud, d'Asie, d'Australie et du Moyen-Orient. Il est à l'origine de déficiences visuelles et de cécité chez environ 1,9 million de personnes et est responsable d'environ 1,4 des cas de cécité dans le monde. Dans l'ensemble, l'Afrique reste le continent le plus touché et celui où les efforts de lutte sont les plus intensifs. Au 18 juillet 2025, l'élimination du trachome en tant que problème de santé publique avait été validée dans 25 pays : Arabie saoudite, Bénin, Burundi, Cambodge, Chine, Gambie, Ghana, Inde, Iraq, Malawi, Mali, Maroc, Mauritanie, Mexique, Myanmar, Népal, Oman, Pakistan, Papouasie-Nouvelle-Guinée, République démocratique populaire lao, République islamique d'Iran, Sénégal, Togo, Vanuatu et Viet Nam. Impact économique Le trachome fait peser une charge énorme sur les personnes et les communautés touchées. On estime que son coût, en termes de perte de productivité due aux déficiences visuelles et à la cécité, se situe entre 2,9 et 5,3 milliards de dollars des États-Unis (USD) par an, voire 8 milliards USD si l'on inclut le trichiasis. Prévention et lutte Dans les pays d'endémie, les programmes d'élimination du trachome reposent sur la stratégie CHANCE, recommandée par l'OMS, dont les composantes sont les suivantes : la CH irurgie pour traiter le stade cécitant de la maladie (trichiasis trachomateux) ; les A ntibiotiques pour traiter l'infection, en particulier dans le cadre de campagnes d'administration de masse de l'azithromycine, un antibiotique donné par le fabricant aux programmes d'élimination par l'intermédiaire de l'Initiative internationale contre le trachome ; le N ettoyage du visage ; et le C hangement de l' E nvironnement, en particulier en améliorant l'accès à l'eau potable et à l'assainissement. La plupart des pays d'endémie s'emploient à accélérer la mise en œuvre de cette stratégie afin d'atteindre les objectifs d'élimination. Les données communiquées à l'OMS par les États Membres indiquent qu'en 2024, 87 349 personnes atteintes de trichiasis trachomateux ont bénéficié d'une chirurgie correctrice et 44,4 millions de personnes vivant dans les communautés d'endémie ont reçu un traitement antibiotique en vue d'éliminer le trachome. Les efforts d'élimination doivent se poursuivre si l'on veut atteindre la cible fixée dans la résolution de l'Assemblée mondiale de la Santé (WHA51.11), à savoir l'élimination du trachome en tant que problème de santé publique (1) . À cette fin, il est particulièrement important de mobiliser les différents acteurs intervenant dans les secteurs de l'eau, de l'assainissement et du développement socioéconomique. Action de l'OMS L'OMS, qui a adopté la stratégie CHANCE en 1993, a pour mandat de diriger et de coordonner les efforts internationaux visant à éliminer le trachome en tant que problème de santé publique et de rendre compte des progrès accomplis dans la réalisation de cet objectif. En 1996, l'OMS a lancé l'Alliance pour l'élimination mondiale du trachome à l'horizon 2020. Il s'agit d'un partenariat qui soutient la mise en œuvre de la stratégie CHANCE par les États Membres et le renforcement des capacités nationales au moyen d'enquêtes épidémiologiques et d'activités de suivi, de surveillance, d'évaluation des projets et de mobilisation des ressources. La résolution WHA51.11 adoptée par l'Assemblée mondiale de la Santé en 1998 visait l'élimination mondiale du trachome en tant que problème de santé publique, avec pour date cible l'année 2020. La feuille de route pour les maladies tropicales négligées 2021-2030 , approuvée par l'Assemblée mondiale de la Santé en 2020 par sa décision WHA73(33), fixe l'année 2030 comme nouvelle échéance pour l'élimination mondiale de cette maladie. Notes (1) L'élimination du trachome en tant que problème de santé publique se définit comme suit : i) prévalence des cas de trichiasis trachomateux inconnus du système de santé 0,2 chez les adultes de 15 ans (soit environ 1 cas pour 1000 habitants) ; et ii) prévalence de l'inflammation trachomateuse folliculaire chez les enfants âgés de 1-9 ans 5 , maintenue pendant au moins 2 ans en l'absence d'une administration de masse d'antibiotique en cours, dans chaque ancien district d'endémie ; plus iii) existence d'un système capable d'identifier et de gérer les cas incidents de trichiasis trachomateux à l'aide de stratégies définies, avec des ressources financières suffisantes pour mettre en œuvre ces stratégies.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/trachoma",
    "length": 8563,
    "type": "html",
    "id": 17,
    "source": "WHO"
  },
  {
    "title": "Principaux repères sur le mycétome",
    "text": "Le mycétome est une maladie chronique du pied en général, mais il peut affecter n'importe quelle partie du corps. L'infection se contracte le plus probablement par inoculation de champignons ou de bactéries dans le tissu sous-cutané à la suite d'un traumatisme. À ce jour, plus de 70 bactéries et champignons ont été identifiés comme agents étiologiques. Il affecte couramment les jeunes adultes, plutôt des hommes âgés de 15 à 30 ans, pour la plupart dans les pays en développement. Les plus couramment touchés sont ceux qui sont défavorisés sur le plan socioéconomique, ainsi que les travailleurs manuels, comme les agriculteurs, les manœuvres et les gardiens de troupeaux. Le mycétome a de nombreuses conséquences médicales, sanitaires et socioéconomiques négatives pour les patients, les communautés et les autorités sanitaires. On a signalé le mycétome pour la première fois au milieu du XIX e siècle à Madurai (Inde), ce qui l'a fait appeler au départ le pied de Madura. On ne dispose pas actuellement de données précises sur son incidence et sa prévalence. La détection précoce et le traitement sont néanmoins importants pour réduire la morbidité et améliorer l'issue thérapeutique. Répartition géographique On trouve les différents agents étiologiques du mycétome dans le monde entier, mais ils sont endémiques dans les zones tropicales et subtropicales de la ceinture du mycétome , qui comprend notamment l'Éthiopie, l'Inde, la Mauritanie, le Mexique, la République bolivarienne du Venezuela, le Sénégal, la Somalie, le Soudan, le Tchad, la Thaïlande et le Yémen. Le nombre de cas notifiés diffère d'un pays à l'autre mais, actuellement, c'est au Mexique et au Soudan que la plupart des cas ont été signalés. Transmission La transmission survient très probablement lorsque l'agent étiologique pénètre dans l'organisme à la faveur de petits traumatismes ou de plaies par perforation, souvent dus à des piqûres d'épines. On peut clairement associer le mycétome et les personnes qui marchent pieds nus et les travailleurs manuels. Tableau clinique Le mycétome se caractérise par l'association d'une masse sous-cutanée indolore, de multiples fistules et des écoulements avec la présence de grains. C'est dans ces grains que se trouve l'agent étiologique. Il se propage en général à la peau, aux structures profondes et aux os, entraînant des destructions, des déformations et une perte de la fonction pouvant être mortelle. Le mycétome touche souvent les extrémités, la région dorsale et le fessier, mais toutes les autres parties du corps peuvent être affectées. Du fait de sa lente évolution, de son caractère indolore, du manque important d'information et de la rareté des établissements médicaux et des structures de santé dans les zones d'endémie, de nombreux patients se présentent à un stade tardif et avancé de l'infection, lorsque le seul traitement possible est l'amputation. Les surinfections bactériennes sont courantes et peuvent provoquer des douleurs, une incapacité et une septicémie fatale (infection sévère touchant l'ensemble de l'organisme) en l'absence de traitement. L'infection ne se transmet pas d'une personne à l'autre. Diagnostic Le diagnostic du mycétome repose sur le tableau clinique et sur l'identification des organismes pathogènes, qui peuvent être détectés grâce à une biopsie à l'aiguille fine ou à une biopsie chirurgicale. Bien que l'examen des grains au microscope puisse être utile pour cette détection, il est important de poursuivre l'identification par la culture, mais même alors, des erreurs de classification sont possibles. L'identification par amplification en chaîne par polymérase (PCR) est la méthode la plus fiable mais elle a un coût élevé et il n'y a pas de techniques standardisées. Il n'existe pas de test de diagnostic rapide sur le lieu des soins utilisable sur le terrain. Les techniques d'imagerie (radiographie, échographie, imagerie par résonance magnétique ou scanner) permettent d'évaluer l'étendue des lésions et de planifier la prise en charge clinique. Traitement Le traitement dépend de l'agent étiologique. Pour le mycétome bactérien, le traitement consiste en une association d'antibiotiques, tandis que pour mycétome fongique, on associe des médicaments antifongiques et la chirurgie. Le traitement est long, a de nombreux effets secondaires, est cher, n'est pas disponible dans les régions d'endémie et, surtout, il est rarement satisfaisant. Dans le cas du mycétome fongique, les amputations et les rechutes sont courantes. Prévention et lutte Le mycétome n'est pas une maladie à déclaration obligatoire (dont la notification est exigée par la loi) et un système de surveillance mondial est toujours en cours d'élaboration. Il n'existe pas encore de programmes de lutte, sauf au Soudan. La prévention est difficile, mais il faut conseiller aux personnes qui vivent ou voyagent dans les zones d'endémie de ne pas marcher pieds nus. Action de l'OMS et mesures prises au niveau mondial Afin de renforcer les capacités nationales de lutte contre le mycétome, le Gouvernement du Soudan et l'OMS ont organisé le premier atelier international de formation sur le mycétome, qui s'est tenu à Khartoum du 10 au 14 février 2019. S'appuyant sur l'expertise du Centre de recherche de Khartoum sur le mycétome, cet atelier, auquel ont participé environ 70 agents de santé venant de pays d'endémie du mycétome, a fourni une occasion unique de partager des expériences et de standardiser les pratiques de diagnostic, de traitement et de surveillance. Cet atelier a été suivi de la Sixième conférence internationale sur le mycétome (Khartoum, 15-17 février 2019). Les participants à cette conférence ont adopté l'Appel à l'action de Khartoum sur le mycétome, qui prie un large éventail d'acteurs de prendre des mesures de santé publique spécifiques, afin de réduire la charge de cette maladie. Perspectives L'élaboration d'une stratégie de santé publique de lutte et de prévention nécessite de collecter des données épidémiologiques sur la charge de morbidité, d'investir dans la recherche et le développement de produits de façon à pouvoir instaurer à faible coût la prévention, le diagnostic, le traitement précoce et la prise en charge des cas dans les milieux ayant peu de ressources. Actuellement, le dépistage actif des cas avec un diagnostic et un traitement précoces à l'aide des outils disponibles est l'approche la plus adaptée pour faire baisser la charge du mycétome. L'approche la plus appropriée pour réduire la morbidité et les incapacités dues au mycétome est à ce jour la détection active des cas grâce à un diagnostic précoce et un traitement recourant aux outils actuellement disponibles. Toutefois, des mesures de santé publique de grande envergure sont nécessaires pour faire face à la charge du mycétome, notamment : intégration de la maladie dans les services de santé nationaux, et mise en place d'un registre dans les pays touchés ; intégration de la détection du mycétome dans l'approche relative aux MTN (maladies tropicales négligées) de la peau pour améliorer la détection précoce ; amélioration de l'accès aux produits de diagnostic et aux médicaments ainsi que des protocoles de prise en charge des cas ; renforcement des mesures préventives (par exemple le port de chaussures) pour réduire l'incidence ; intensification de la sensibilisation des communautés affectées et des capacités des agents de santé. Des études sur l'innocuité et l'efficacité du fosravuconazole dans le traitement du mycétome fongique au Soudan sont en cours, sous l'égide de l'Initiative sur les médicaments pour les maladies négligées (DNDi) et d'autres partenaires. Outre une augmentation du taux de guérison, le recours à ce traitement permettrait d'écourter le protocole thérapeutique, ce qui renforcerait l'observance du traitement et économiserait des ressources financières.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/mycetoma",
    "length": 7847,
    "type": "html",
    "id": 18,
    "source": "WHO"
  },
  {
    "title": "Pian",
    "text": "Principaux faits Le pian est une maladie infectieuse chronique de l'enfance, défigurante et débilitante. Le pian affecte la peau, les os et les cartilages. Les êtres humains sont actuellement le seul réservoir connu de cette infection. La transmission se fait de personne à personne. Une dose unique par voie orale d'azithromycine, un antibiotique peu onéreux, permet de guérir le pian. La maladie est actuellement endémique dans 15 pays. Aperçu général Le pian fait partie d'un groupe d'infections bactériennes chroniques que l'on désigne couramment par le terme tréponématoses endémiques . Ces maladies sont dues à des bactéries spiralées appartenant au genre Treponema , qui comprend aussi la syphilis endémique (béjel) et la pinta. Le pian est la plus courante de ces trois infections. Le micro-organisme qui cause le pian, Treponema pallidum sous-espèce pertenue , est proche génétiquement de Treponema pallidum sous-espèce pallidum , responsable de la syphilis, du béjel et de la pinta. La maladie est présente principalement dans les communautés défavorisées des régions forestières tropicales chaudes et humides d'Afrique, d'Asie, d'Amérique latine et du Pacifique. Les populations les plus touchées vivent dans des zones rurales éloignées des services de santé. La pauvreté, la précarité socioéconomique et le manque d'hygiène personnelle facilitent la propagation du pian. Ampleur du problème Environ 75 à 80 des personnes touchées par le pian sont des enfants de moins de 15 ans. L'incidence de la maladie est maximale chez les enfants de 6 à 10 ans, et il n'y a pas de différence d'incidence selon le genre. Le pian se transmet de personne à personne, par contact avec une blessure sans gravité. La lésion qui résulte de ce contact initial est remplie de bactéries. La plupart des lésions touchent les bras et les jambes. La période d'incubation dure de 9 à 90 jours, et 21 jours en moyenne. En l'absence de traitement, l'infection peut conduire à des déformations ou à des mutilations chroniques et à une invalidité. L'OMS classe les pays en trois groupes épidémiologiques. Groupe A : pays dont le statut d'endémicité est actuellement connu Groupe B : pays qui étaient auparavant des pays d'endémicité, mais dont le statut actuel est inconnu Groupe C : pays sans antécédents de pian En 2013, le pian était endémique dans 13 pays. Depuis lors, dans le cadre d'activités de surveillance intensive, deux autres pays ont signalé des cas confirmés de pian (le Libéria et les Philippines) (1) et trois pays ont signalé des cas suspects (la Colombie, l'Équateur et Haïti). En 2021, un seul cas de pian a été signalé chez un enfant de 5 ans en Malaisie, répertoriée par l'OMS comme faisant partie des pays qui étaient auparavant des pays d'endémicité, mais dont le statut actuel est inconnu (2) . Des recherches plus approfondies sont nécessaires. Sur l'ensemble des pays et territoires d'endémicité connus dans les années 1950, au moins 76 appartiennent au groupe B et doivent faire l'objet d'une évaluation pour déterminer si la maladie y est toujours présente. Cela peut se faire au moyen de la surveillance intégrée du pian et d'autres maladies, en particulier les maladies tropicales négligées à manifestation cutanée. En 2020, 87 877 cas suspects de pian ont été signalés à l'OMS dans 11 pays, mais seulement 346 cas ont été confirmés dans 7 pays, la majorité des cas se trouvant dans la Région du Pacifique occidental (Îles Salomon, Papouasie-Nouvelle-Guinée et Vanuatu). En 2021, 123 866 cas ont été signalés dans 13 pays et 1102 cas ont été confirmés dans 9 pays. Plus de 80 des cas ont été signalés dans la Région du Pacifique occidental, surtout en Papouasie-Nouvelle-Guinée, mais la plupart des cas dans cette Région ne sont pas confirmés en laboratoire. Manifestations cliniques Au départ, le pian se manifeste par un papillome (une tumeur semblable à une verrue) rempli de bactéries, ce qui rend le diagnostic clinique simple. En l'absence de traitement, le papillome va s'ulcérer. Le diagnostic de la forme ulcéreuse est plus difficile et nécessite une confirmation sérologique. Le papillome et les ulcères sont très contagieux et ils peuvent contaminer rapidement d'autres personnes en l'absence de traitement. Il existe d'autres formes cliniques, mais elles ne sont pas aussi contagieuses. Le pian secondaire survient des semaines ou des mois après l'infection primaire et se manifeste habituellement par de multiples lésions surélevées jaunâtres ou des douleurs et le gonflement des os longs et des doigts (dactylite). Diagnostic On utilise couramment les tests sérologiques en laboratoire, tels que le test d'agglutination passive de Treponema pallidum (TPPA) et le test rapide de mise en évidence de la réagine plasmatique (RPR), pour diagnostiquer les tréponématoses (par exemple la syphilis et le pian), mais ils ne permettent pas de faire la distinction entre le pian et la syphilis. En outre, leur interprétation chez l'adulte vivant en zone d'endémicité du pian nécessite une évaluation clinique minutieuse. Environ 40 des ulcères diagnostiqués à tort comme étant causés par le pian sont dus à Haemophilus ducreyi , une bactérie sans rapport avec la maladie. Les tests rapides de diagnostic des tréponématoses sont largement disponibles et bon marché ; en revanche, ils ne permettent pas pour la plupart de faire la distinction entre une infection actuelle et passée, et sont donc d'une utilité limitée pour le suivi de l'interruption de la transmission. Les tests Dual Path Platform Syphilis Screen and Confirm (DPP, Chembio Diagnostics, États-Unis) permettent de diagnostiquer les infections passées et présentes. En raison du coût élevé des tests DPP, le dépistage initial des cas suspects de pian peut être effectué par des tests de diagnostic des tréponématoses en confirmant les cas positifs par DPP. Cependant, les pays peuvent choisir d'utiliser uniquement les tests DPP s'ils ont les moyens financiers de ce faire. La technique de la PCR (amplification en chaîne par polymérase) est utilisée pour confirmer sans ambiguïté le pian en détectant l'ADN dans les lésions cutanées. Elle peut également être utilisée pour surveiller la résistance à l'azithromycine. Elle sera utile après les traitements de masse et dans le cadre de la surveillance post-éradication. Traitement et soins Deux antibiotiques, l'azithromycine ou la benzathine pénicilline, peuvent être utilisés pour traiter le pian : L'azithromycine (en dose unique par voie orale), selon une posologie de 30 mgkg (2 g au maximum), constitue le traitement privilégié. La benzathine pénicilline (en dose unique par voie intramusculaire), selon une posologie de 0,6 million d'unités (chez l'enfant de moins de 10 ans) et de 1,2 million d'unités (chez les sujets de plus de 10 ans) dans les cas où l'on suppose un échec clinique du traitement à l'azithromycine ou chez les patients ne pouvant bénéficier de ce traitement. Les patients doivent être réexaminés quatre semaines après avoir reçu le traitement antibiotique. Dans plus de 95 des cas, une guérison complète est observée. Tout patient chez lequel on suppose un échec thérapeutique doit être soumis à un test de résistance aux macrolides et recevoir un traitement de benzathine pénicilline. Prévention et lutte Il n'existe pas de vaccin contre le pian. L'éducation sanitaire et l'amélioration de l'hygiène personnelle sont des mesures essentielles pour réduire la transmission. Les personnes ayant été en contact avec des patients atteints de pian doivent recevoir un traitement empirique. La stratégie d'éradication de la maladie repose sur le traitement de masse (ou traitement de toute la communauté) consistant à administrer une dose orale d'azithromycine (30 mgkg, 2 g au maximum) à l'ensemble de la population (couverture de 90 au minimum) dans les régions touchées par le pian. Trois critères ont été définis pour l'éradication du pian : l'absence de nouveaux cas autochtones confirmés par sérologie pendant trois années consécutives ; l'absence de cas confirmés par PCR ; et l'absence de signe de transmission pendant trois années consécutives, mesurée par enquête sérologique chez les enfants âgés de 1 à 5 ans. Progrès sur la voie de l'éradication En 2020, dans le cadre de l'accord conclu entre l'OMS et le groupe pharmaceutique EMS (Brésil), 1,4 million de comprimés d'azithromycine ont été envoyés au Cameroun en vue d'un traitement à grande échelle (administration massive de médicaments ou AMM). Entre 2021 et 2023, le groupe EMS a fourni 9 millions de comprimés afin de faciliter l'AMM dans plusieurs pays, notamment le Cameroun, le Congo, les Îles Salomon, la Papouasie-Nouvelle-Guinée, la République centrafricaine et Vanuatu. D'autres pays d'endémicité ont reçu de l'azithromycine pour la surveillance active. Une étude effectuée récemment en Papouasie-Nouvelle-Guinée (3) confirme que l'administration de trois cycles d'azithromycine dans le cadre de l'AMM à six mois d'intervalle réduit de façon significative la prévalence des formes active et latente du pian par rapport à l'administration d'un seul cycle du médicament. Ces résultats suscitent l'espoir que ce mode d'administration, combiné à une surveillance active visant à détecter et à traiter les cas entre les cycles de traitement de masse, pourra entraîner une interruption précoce de la transmission. L'émergence de souches résistantes à l'azithromycine est très rare, mais constitue une menace potentielle. Une surveillance clinique étroite des cas ainsi qu'une surveillance biologique sont nécessaires. Le linézolide, une oxazolidinone peu coûteuse, possède une activité in vitro et in vivo contre T. pallidum . Des recherches cliniques visant à évaluer l'efficacité du linézolide comme traitement alternatif du pian en cas de résistance aux macrolides sont en cours. Le Partenariat des pays européens et en développement sur les essais cliniques (programme EDCTP) soutient l'évaluation d'une nouvelle méthode d'amplification isotherme induite par boucle (LAMP) au Cameroun, en Côte d'Ivoire et au Ghana permettant de détecter le tréponème et la résistance à l'azithromycine. Les résultats de cette étude aideront à intensifier les efforts déployés en vue d'éradiquer le pian. Action de l'OMS En vue d'éradiquer le pian, l'OMS : élabore des stratégies visant à guider les pays dans la planification et la mise en œuvre d'activités d'éradication du pian ; crée des matériels pédagogiques pour aider les agents de santé et les bénévoles communautaires à reconnaître la maladie ; apporte son soutien aux pays moyennant le don garanti par l'Organisation de 153 millions de comprimés d'azithromycine ; met au point des outils normalisés pour la collecte et la communication des données ; renforce la collaboration et la coordination entre les partenaires et les autres parties prenantes ; et mène des activités de sensibilisation et établit des partenariats. L'OMS recommande d'intégrer les activités d'éradication du pian aux programmes de lutte contre les maladies tropicales négligées (pour ce qui est de l'administration de masse de médicaments) et concernant les maladies tropicales négligées à manifestation cutanée (pour la surveillance active). À cet égard, afin de guider les pays, l'OMS a publié en juin 2022 un cadre stratégique pour la lutte intégrée contre les maladies tropicales négligées à manifestation cutanée (en anglais). (1) Yaws in the Philippines: first reported cases since the 1970s ( https:www.ncbi.nlm.nih.govpmcarticlesPMC6990502 , en anglais) (2) Yaws: The forgotten tropical skin disease ( https:www.ncbi.nlm.nih.govpmcarticlesPMC8680937 , en anglais) (3) Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication ( https:pubmed.ncbi.nlm.nih.gov34986286 , en anglais)",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/yaws",
    "length": 11748,
    "type": "html",
    "id": 19,
    "source": "WHO"
  },
  {
    "title": "Échinococcose",
    "text": "L'échinococcose humaine est une zoonose (maladie transmise à l'homme par l'animal) causée par des parasites, à savoir des ténias du genre Echinococcus . L'échinococcose se présente sous 4 formes : l'échinococcose kystique, également connue sous le nom de maladie hydatique ou hydatidose, due à l'infestation par un complexe d'espèces centrée sur Echinococcus granulosus ; l'échinococcose alvéolaire, due à l'infestation par E. multilocularis ; deux formes d'échinococcose néotropicale : l'échinococcose polykystique causée par E. vogeli ; et l'échinococcose unikystique causée par E. oligarthrus . Les deux formes principales, qui présentent un intérêt médical et de santé publique chez l'homme, sont l'échinococcose kystique et l'échinococcose alvéolaire. Transmission Un certain nombre d'animaux herbivores et omnivores agissent comme des hôtes intermédiaires pour Echinococcus . Ils s'infectent en ingérant les œufs du parasite présents dans des aliments et de l'eau contaminés qui se développent ensuite en stades larvaires dans les viscères. Les carnivores agissent comme des hôtes définitifs pour le parasite et hébergent le ténia mature dans leurs intestins. Ces hôtes définitifs s'infectent en ingérant les viscères d'hôtes intermédiaires contenant les larves du parasite. Les humains agissent comme des hôtes intermédiaires dits accidentels en ce sens qu'ils contractent l'infection de la même manière que d'autres hôtes intermédiaires, mais ne participent pas à la transmission de l'infection à l'hôte définitif. On connaît plusieurs génotypes différents d' E. granulosus , dont certains ont des préférences distinctes en matière d'hôtes intermédiaires. Certains génotypes sont considérés comme des espèces distinctes d' E. granulosus . Tous les génotypes n'entraînent pas des infections chez l'homme. Le génotype responsable de la grande majorité des cas humains d'échinococcose kystique se maintient principalement dans un cycle chien-mouton-chien, mais plusieurs autres animaux domestiques peuvent également être impliqués, notamment les chèvres, les porcs, les bovins, les chameaux et les yaks. L'échinococcose alvéolaire est généralement issue d'un cycle faisant intervenir des animaux sauvages comme des renards ou d'autres carnivores, dont les hôtes intermédiaires sont de petits mammifères (principalement des rongeurs). Les chiens et les chats domestiques peuvent également servir d'hôtes définitifs. Signes et symptômes Échinococcose kystique hydatidose L'infestation humaine par E. granulosus entraîne le développement d'un ou plusieurs kystes hydatiques situés le plus souvent dans le foie et les poumons, et moins fréquemment dans les os, les reins, la rate, les muscles et le système nerveux central. La période d'incubation asymptomatique de la maladie peut durer de nombreuses années avant que les kystes hydatiques soient suffisamment développés pour déclencher des signes cliniques. Cependant, environ la moitié des patients reçoivent un traitement médical quelques années après l'infestation initiale par le parasite. Les hydatides hépatiques entraînent souvent des douleurs abdominales, des nausées et des vomissements. En cas d'atteinte pulmonaire, les signes cliniques sont une toux chronique, des douleurs thoraciques et un essoufflement. Les autres signes dépendent de l'emplacement des kystes hydatiques et de la pression exercée sur les tissus environnants. Les signes non spécifiques comprennent l'anorexie, la perte de poids et l'asthénie. Échinococcose alvéolaire L'échinococcose alvéolaire se caractérise par une période d'incubation asymptomatique de 5 à 15 ans et le développement lent d'une lésion primaire d'aspect tumoral généralement localisée dans le foie. Les signes cliniques sont une perte de poids, des douleurs abdominales, un malaise général et des signes d'insuffisance hépatique. Les métastases larvaires peuvent se propager vers des organes adjacents au foie (par exemple, la rate) ou vers des sites plus éloignés (comme les poumons ou le cerveau) par voie sanguine ou lymphatique. En l'absence de traitement, l'échinococcose alvéolaire progresse et conduit au décès. Répartition géographique L'échinococcose kystique existe sur tous les continents sauf l'Antarctique. L'échinococcose alvéolaire est confinée à l'hémisphère Nord, en particulier à certaines régions de la Chine, de la Fédération de Russie et de pays d'Europe continentale et d'Amérique du Nord. Dans les régions d'endémie, les taux d'incidence de l'échinococcose kystique chez l'homme peuvent dépasser 50 pour 100 000 personnes-années, et la prévalence peut atteindre 5 à 10 dans certaines régions d'Argentine, du Pérou, d'Afrique de l'Est, d'Asie centrale et de Chine. Chez les animaux d'élevage, la prévalence de l'échinococcose kystique observée dans les abattoirs des zones d'hyperendémie en Amérique du Sud varie de 20 à 95 parmi les animaux abattus. C'est dans les zones rurales où les animaux abattus sont plus âgés que la prévalence est la plus élevée. Selon l'espèce infectée, les pertes en termes de production animale imputables à l'échinococcose kystique découlent de l'impossibilité d'utiliser le foie et éventuellement d'une réduction du poids de la carcasse, d'une diminution de la valeur de la peau, d'une diminution de la production de lait et d'une réduction de la fertilité. Diagnostic L'échographie est la technique d'imagerie à privilégier pour le diagnostic de l'échinococcose kystique et de l'échinococcose alvéolaire chez l'homme. Elle est généralement complétée ou validée par la tomodensitométrie (TDM) etou l'imagerie par résonance magnétique (IRM). Les kystes peuvent être découverts fortuitement lors d'une radiographie. Différents tests sérologiques détectent des anticorps spécifiques et peuvent étayer le diagnostic. La détection précoce des infections à E. granulosus et à E. multilocularis , en particulier dans les milieux à faibles ressources, demeure nécessaire pour faciliter le choix des options de traitement clinique. Traitement L'échinococcose kystique et l'échinococcose alvéolaire sont toutes deux souvent coûteuses et compliquées à traiter, nécessitant parfois une intervention chirurgicale lourde etou un traitement médicamenteux prolongé. Il existe 4 options thérapeutiques pour traiter l'échinococcose kystique : le traitement percutané des kystes hydatiques par la technique PAIR (ponction, aspiration, injection, réaspiration) ; la chirurgie ; le traitement médicamenteux anti-infectieux ; l'observation vigilante. Le choix doit se fonder principalement sur les images échographiques du kyste, selon son stade de développement, ainsi que sur l'infrastructure médicale et les ressources humaines disponibles. Concernant l'échinococcose alvéolaire, les principes généraux demeurent un diagnostic précoce et une chirurgie radicale (telle que celle pratiquée pour les tumeurs) suivie d'une prophylaxie anti-infectieuse par l'albendazole. Quand la lésion est confinée, la chirurgie radicale permet la guérison. Malheureusement, chez de nombreux patients, la maladie est diagnostiquée à un stade avancé. Par conséquent, si la chirurgie palliative n'est pas accompagnée d'un traitement anti-infectieux complet et efficace, les rechutes seront fréquentes. Charge de morbidité et fardeau économique L'échinococcose kystique et l'échinococcose alvéolaire représentent toutes deux une charge de morbidité importante. À l'échelle mondiale, plus d'un million de personnes vivraient avec l'une ou l'autre de ces maladies. Nombre d'entre elles connaîtront des syndromes cliniques sévères qui engagent le pronostic vital en l'absence de traitement. Même lorsqu'elles sont traitées, leur qualité de vie est souvent diminuée. Pour l'échinococcose kystique, le taux de mortalité post-opératoire est de 2,2 en moyenne et environ 6,5 des cas rechutent après l'intervention, ce qui prolonge la convalescence. En 2015, le groupe de référence de l'OMS sur l'épidémiologie des maladies d'origine alimentaire a estimé que l'échinococcose était à l'origine de 19 300 décès et d'environ 871 000 années de vie ajustées sur l'incapacité (DALY)( 1 ) par an dans le monde. Les coûts annuels associés au traitement des cas et aux pertes pour le secteur de l'élevage imputables à l'échinococcose kystique sont estimés à 3 milliards de dollars des Etats-Unis. Surveillance et lutte Il est fondamental de disposer de données de surveillance solides pour déterminer la charge de morbidité et évaluer les progrès et le succès des programmes de lutte. Toutefois, comme pour d'autres maladies négligées qui touchent des populations mal desservies et des zones reculées, les données sont particulièrement peu nombreuses et devront faire l'objet d'une plus grande attention si l'on veut mettre en œuvre et évaluer les programmes de lutte. Échinococcose kystique hydatidose La surveillance de l'échinococcose kystique chez l'animal est difficile car l'infection est asymptomatique chez le bétail et les chiens. Le besoin de surveillance n'est pas non plus reconnu par les communautés ou les services vétérinaires locaux qui n'en font pas une priorité. L'échinococcose kystique est une maladie évitable car les hôtes définitifs et intermédiaires sont des espèces animales domestiques. La vermifugation périodique des chiens avec du praziquantel (au moins 4 fois par an), l'amélioration de l'hygiène lors de l'abattage du bétail (y compris la destruction appropriée des abats infectés) et les campagnes d'éducation du public se sont révélées efficaces pour réduire et, dans les pays à revenu élevé, prévenir la transmission et diminuer la charge de morbidité chez l'homme. La vaccination des moutons avec un antigène recombinant d' E. granulosus (EG95) offre des perspectives encourageantes en matière de lutte. Le vaccin est actuellement fabriqué pour être disponible sur le marché et il est homologué en Chine et en Argentine. En Argentine, des essais ont démontré la valeur ajoutée de la vaccination des moutons et en Chine, le vaccin est utilisé à grande échelle. Un programme combinant la vaccination des agneaux, la vermifugation des chiens et l'abattage des moutons âgés pourrait permettre d'éliminer l'échinococcose kystique chez l'homme en moins de 10 ans. Échinococcose alvéolaire La lutte contre l'échinococcose alvéolaire est plus complexe car son cycle implique des espèces animales sauvages comme hôtes définitifs et intermédiaires. La vermifugation régulière des animaux domestiques carnivores qui entrent en contact avec des rongeurs sauvages devrait contribuer à réduire le risque d'infection chez l'homme. Dans des études européennes et japonaises, la vermifugation des hôtes définitifs sauvages et errants au moyen d'appâts contenant des anthelminthiques a entraîné une réduction notable de la prévalence de l'échinococcose alvéolaire. En revanche, l'abattage des renards et des chiens errants semble être inefficace. La pérennité et l'efficacité de telles campagnes par rapport à leur coût sont controversées. Réponse de l'OMS et des pays Renforcement de la lutte contre l'échinococcose Des groupes de travail informels sur l'échinococcose ont été créés en 1985 sous les auspices de l'OMS. Pendant 10 ans, sous la direction du professeur J. Eckert de l'Université de Zurich (Suisse), ces groupes ont organisé des réunions de spécialistes et ont encouragé les échanges et la coopération scientifiques internationaux dans le domaine de la recherche sur l'échinococcose. En 1995, l'OMS a modifié la structure des groupes et les a transformés en un seul groupe, le groupe de travail informel de l'OMS sur l'échinococcose. La mission de ce groupe est de renforcer la lutte contre l'échinococcose grâce à une collaboration efficace avec des partenaires stratégiques et les secteurs concernés. Le président actuel groupe est le Professeur Thomas Junghanss de l'Université de Heidelberg (Allemagne), et le co-président, le Professeur Okan Akhan de l'Université Hacettepe (Turquie). En 1995, le groupe a élaboré une classification standardisée de l'échinococcose kystique qui peut être appliquée dans tous les contextes. En 2009, le groupe est parvenu à un consensus sur le diagnostic et le traitement de l'échinococcose kystique et de l'échinococcose alvéolaire qui a donné lieu à la publication de lignes directrices actualisées pour le diagnostic et le traitement de ces maladies (Brunetti et al, 2010). Le groupe est en train de revoir le diagnostic et la prise en charge clinique associée de l'échinococcose et d'élaborer des manuels techniques destinés à un usage pratique. Plusieurs groupes de travail ont été créés pour couvrir les différents aspects de ces maladies et travaillent à l'élaboration de ces documents. Le groupe s'attache également à promouvoir la collecte et la cartographie des données épidémiologiques. Renforcement des capacités pour améliorer le diagnostic précoce et la prise en charge clinique de l'échinococcose kystique Les pays d'endémie ont demandé à l'OMS de leur apporter un soutien en matière de diagnostic précoce et de prise en charge clinique de l'échinococcose kystique. L'OMS appuie le renforcement des capacités au moyen de formations destinées aux personnels médical et paramédical, axés sur la prise en charge clinique de l'échinococcose kystique dans les zones rurales des pays touchés. Cela fait partie intégrante des efforts visant à parvenir à la couverture sanitaire universelle. Le Maroc a entrepris un projet de décentralisation des techniques diagnostiques et thérapeutiques et de promotion de la stratégie PAIR (ponction, aspiration, injection, réaspiration) dans les zones rurales et d'hyperendémie. La Mongolie a reconnu l'importance de l'échinococcose en tant que problème de santé publique et, à la demande du Ministère de la santé, l'OMS a procédé en 2013 à une première analyse de la situation. Cette analyse portait principalement sur la mise en œuvre du diagnostic précoce et sur la création d'un système de surveillance de base couvrant les êtres humains et les animaux en vue de comprendre la charge de morbidité actuelle de cette maladie. Une étude transversale menée en Bulgarie, en Roumanie et en Turquie en 2014-2015 a révélé que la véritable charge de l'échinococcose kystique était mal comprise et que de nombreux cas demeuraient asymptomatiques, sans diagnostic ni traitement médical appropriés. Cette étude a évalué la prévalence de la maladie dans les populations rurales des trois pays. Dans les Amériques, un manuel de lutte contre l'échinococcose kystique a été élaboré en 2017 par l'Organisation panaméricaine de la Santé, le Bureau régional OMS des Amériques (OPS), et le Centre panaméricain de la fièvre aphteuse. Il a été publié en espagnol. Collaboration avec les autorités vétérinaires et de sécurité sanitaire des aliments pour soutenir l'élaboration de programmes de lutte contre l'échinococcose Le cycle de transmission de l'échinococcose kystique implique des chiens et des hôtes intermédiaires, généralement des moutons. Afin de rompre le cycle de transmission, les mesures de lutte doivent tenir compte de ces animaux. Dans le cadre d'une approche Un monde, une santé (One Health), ces mesures comprennent la vermifugation des chiens avec du praziquantel au moins 4 fois par an et la vaccination des agneaux avec le vaccin EG95. Sous l'égide des principes Un monde, une santé , l'OMS et son partenaire, l'Organisation mondiale de la Santé animale (OIE), soutiennent l'élaboration de programmes de lutte contre l'échinococcose, y compris les interventions sur les animaux. Des réunions conjointes sont organisées régulièrement et un appui technique est fourni pour promouvoir la lutte, par exemple dans les pays d'Asie centrale et dans le sud du Caucase. L'OMS aide les pays à élaborer et à mettre en œuvre des projets pilotes qui permettront de valider des stratégies efficaces de lutte contre l'échinococcose kystique. La collaboration avec les autorités vétérinaires et de sécurité sanitaire des aliments, ainsi qu'avec d'autres secteurs, est essentielle pour parvenir à des résultats à long terme en matière de réduction de la charge de morbidité et de préservation de la chaîne de valeur alimentaire. L'OMS aide pays individuellement à développer leur programme de lutte contre l'échinococcose kystique. Par exemple, en Mongolie, une réunion multidisciplinaire des parties prenantes a été organisée à Oulan-Bator en 2018 pour commencer à élaborer le Plan d'action national de lutte contre l'échinococcose. Aucun investissement significatif n'ayant été réalisé pour l'échinococcose, les étapes du programme ont progressé lentement, mais l'OMS continue de réunir les parties prenantes et de nouvelles actions ont été convenues en 2019. L'OMS a également facilité la validation des tests de diagnostic utilisés pour dépister l'échinococcose chez le chien, ce qui est important pour la surveillance, et elle a créé une base de référence dans la province de Bayankhongor en Mongolie. La Chine intègre la lutte et le traitement de l'échinococcose dans ses plans économiques et de développement afin d'attirer l'attention sur le vaste problème qui se pose dans le pays, en particulier sur le plateau tibétain, ainsi que dans les républiques d'Asie centrale. L'OMS encourage les approches Un monde, une santé , comme celle développée par le D r Larrieu en Patagonie argentine, qui fait intervenir des agents de santé communautaires et comprend la vermifugation des chiens et la vaccination des moutons. Amélioration des données sur l'échinococcose kystique Les données de surveillance sont essentielles pour comprendre la situation épidémiologique de la maladie et prendre des mesures dans les zones à risque, ainsi que pour établir des priorités. Les données sont également nécessaires pour suivre la progression des interventions et évaluer les résultats des mesures de lutte. Les indicateurs sont des variables spécifiques qui aident à l'analyse des données et fournissent des outils aux autorités sanitaires et aux personnes impliquées dans la lutte contre la maladie. L'OMS a défini un nouvel ensemble d'indicateurs aux niveaux national et mondial pour l'échinococcose kystique et développe des systèmes de notification pour guider et aider les pays dans la collecte et la communication des données. Au niveau mondial, les indicateurs sont 1) le nombre de pays où l'échinococcose kystique est endémique et 2) le nombre de pays dotés d'un programme de lutte renforcée dans les zones d'hyperendémie. Une zone d'hyperendémie a été définie comme une zone où l'incidence annuelle atteint 5 cas humains100 000 personnes. Au niveau des pays, il existe des indicateurs épidémiologiques et des indicateurs de progression de la lutte. Les indicateurs épidémiologiques sont une combinaison de données de surveillance passive et active. Les indicateurs de lutte sont des indicateurs d'impact et de résultat. ( 1 ) Une DALY (année de vie ajustée sur l'incapacité) peut être considérée comme une année de vie saine perdue. La somme de ces DALY dans la population, ou la charge de morbidité, peut être considérée comme une mesure de l'écart entre l'état de santé actuel et une situation sanitaire idéale où toute la population vit jusqu'à un âge avancé sans maladie ni handicap.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/echinococcosis",
    "length": 19189,
    "type": "html",
    "id": 20,
    "source": "WHO"
  },
  {
    "title": "Trématodoses d'origine alimentaire",
    "text": "Principaux faits Les infections à trématodes (ou trématodoses) d'origine alimentaire entraînent chaque année dans le monde plus de deux millions d'années de vie perdues ou vécues avec une incapacité. Les personnes sont infestées lorsqu'elles consomment du poisson, des crustacés ou des légumes crus qui hébergent les larves de parasites. Les trématodoses d'origine alimentaire sont plus courantes en Asie du Sud-Est et en Amérique du Sud. Les infections à trématodes d'origine alimentaire provoquent des pathologies hépatiques et pulmonaires graves. Il existe des médicaments sûrs et efficaces pour prévenir et traiter les trématodoses d'origine alimentaire. La prévention et la prise en charge des trématodoses d'origine alimentaire nécessitent une collaboration intersectorielle à l'interface entre l'homme et l'animal et les écosystèmes. Transmission et charge de la maladie Les trématodoses d'origine alimentaire sont des zoonoses et ne deviennent infectieuses qu'à l'issue d'un cycle biologique complexe comprenant différents stades chez des hôtes intermédiaires non humains. Chez toutes les espèces, le premier hôte intermédiaire est un mollusque d'eau douce, tandis que le second hôte diffère en fonction de l'espèce concernée : il s'agit d'un poisson d'eau douce pour Clonorchis et Opisthorchis et d'un crustacé pour Paragonimus . L'infection par Paragonimus spp peut également être provoquée par la consommation d'animaux qui se nourrissent de crustacés, par exemple de viande de sanglier crue. Fasciola spp ne nécessite pas de deuxième hôte intermédiaire et les personnes sont infectées lorsqu'elles consomment des plantes d'eau douce. L'hôte final est toujours un mammifère (Tableau 1). Les personnes sont infestées lorsqu'elles ingèrent le second hôte intermédiaire, ou dans le cas de la fasciolase, en ingérant des larves avec les végétaux aquatiques auxquels elles sont attachées. La clonorchiase et l'opisthorchiase sont essentiellement présentes en Asie, et on dénombre de nombreux pays d'endémie. Dans certains villages en état d'hyperendémie de la République démocratique populaire lao, on a enregistré une prévalence de plus de 80 pour O. viverrini . La paragonimose est présente en Afrique, en Asie et en Amérique latine et peut être associée à une co-endémicité avec la tuberculose, ce qui entraîne souvent des erreurs de diagnostic et de traitement et contribue à une sous notification de la maladie. La fasciolase est une maladie mondiale, qui touche un grand nombre de pays dans le monde entier, avec de fortes charges signalées en Amérique latine et au Moyen-Orient. Bien que des cas de trématodoses d'origine alimentaire aient été notifiés dans plus de 70 pays du monde, on dispose de peu de données sur la prévalence et la charge réelles, et on manque largement d'informations sur la situation épidémiologique en Afrique. À l'intérieur des pays, la transmission n'a souvent lieu que dans des zones limitées et selon des schémas comportementaux et écologiques. L'insuffisance de l'assainissement et de l'hygiène alimentaire, l'accès limité à l'eau potable et les habitudes alimentaires sont associés à un risque accru d'infection. Les habitudes culturelles concernant le partage de la nourriture peuvent également contribuer à l'apparition de foyers d'infection au sein des familles et des communautés. On ne connaît pas la charge réelle associée à ces infections, car la sensibilisation aux questions de santé auprès du grand public ainsi que la disponibilité des établissements de santé sont souvent limitées au sein des populations touchées. Le groupe de référence de l'OMS (2015) sur l'épidémiologie des maladies d'origine alimentaire (FERG) selon son acronyme anglais a identifié les quatre espèces de trématodoses d'origine alimentaire comme causes importantes de handicap, responsables selon les estimations d'un total annuel de 200 000 maladies et de plus de 7000 décès, soit plus de deux millions d'années de vie ajustées sur l'incapacité (DALY) à l'échelle mondiale. On observe un impact économique majeur causé par les trématodoses d'origine alimentaire et celui-ci est lié aux pertes enregistrées dans les industries de l'élevage et de l'aquaculture du fait d'une moindre productivité animale, ainsi qu'aux restrictions imposées aux exportations et à la baisse de la demande des consommateurs. Tableau 1 : Caractéristiques épidémiologiques des trématodoses d'origine alimentaire Maladie Agent infectieux Contracté par la consommation de Hôte final naturel de l'infection Clonorchiase Clonorchis sinensis Poisson d'eau douce Chiens et autres carnivores mangeurs de poisson Opisthorchiase Opisthorchis viverrini Poisson d'eau douce Chats et autres carnivores mangeurs de poisson Fasciolase Fasciola hepatica , F. gigantica Végétaux aquatiques Ovins, bovins et autres herbivores Paragonimose Paragonimus spp. Crustacés d'eau douce (crabes et écrevisses) Chats, chiens et autres carnivores mangeurs de crustacés Symptômes La charge pour la santé publique attribuable aux trématodoses d'origine alimentaire est principalement due à la morbidité plutôt qu'à la mortalité, en effet les infestations précoces et légères passent souvent inaperçues. Les infestations chroniques sont associées à une morbidité sévère, les symptômes étant principalement organiques et fonction de la localisation finale des vers adultes dans l'organisme. Les infestations aiguës à Opisthorchis spp et Clonorchis sinensis peuvent être asymptomatiques dans le cas d'infestations légères, mais des symptômes cliniques tels que fièvre, douleurs dans la région abdominale peuvent être observés si la charge parasitaire est élevée du fait de l'obstruction de la vésicule biliaire par le ver. L'infection chronique à O. viverrini et à C. sinensis résultant d'épisodes prolongés de réinfection dans le temps peut être la plus grave, l'inflammation chronique entraînant une fibrose des canaux et la destruction du parenchyme hépatique adjacent. Ces changements peuvent entraîner un carcinome cholangiolaire, un grave cancer des canaux biliaires qui est souvent mortel. Pour cette raison, O. viverrini et C. sinensis sont tous deux classés comme agents cancérigènes. Les données sur les infestations chroniques à O. felineus sont rares, et ce parasite n'est pas classé comme agent cancérigène. La fasciolase se caractérise par une période d'incubation asymptomatique après l'ingestion du parasite, suivie d'une phase clinique aiguë et chronique. La phase aiguë de la fasciolase commence lorsque les vers immatures pénètrent dans la paroi intestinale et le péritoine, puis perforent la surface du foie et se dirigent vers les canaux biliaires. Ce processus entraîne la destruction des cellules hépatiques et provoque des hémorragies internes. Parmi les symptômes figurent notamment la fièvre, les nausées, le gonflement du foie, les éruptions cutanées et de fortes douleurs abdominales. La phase chronique débute lorsque les vers atteignent les canaux biliaires, mûrissent et commencent à produire des œufs. Ces œufs sont libérés dans la bile puis atteignent l'intestin avant d'être évacués dans les fèces. Au nombre des symptômes figurent des douleurs intermittentes, la jaunisse, l'anémie, la pancréatite et les calculs biliaires. Les infections chroniques entraînent une cirrhose du foie due à une inflammation de longue durée. Les stades précoces de la paragonimose peuvent être asymptomatiques. Une fois que les vers atteignent les poumons, les symptômes peuvent être importants et comprennent toux chronique et crachats avec traces de sang, douleurs thoraciques, dyspnée et fièvre, et peuvent entraîner des complications notamment un épanchement pleural ou un pneumothorax. Les symptômes et les signes peuvent être confondus avec ceux de la tuberculose et doivent être pris en compte chez les cas suspects de tuberculose ne répondant pas au traitement. La paragonimose ectopique est également fréquente, la paragonimose cérébrale étant la forme la plus courante. Les symptômes qui y sont associés comprennent des maux de tête, des troubles de la vue, des crises d'épilepsie et des hémorragies cérébrales. Diagnostic Les trématodoses d'origine alimentaire sont suspectées sur la base du tableau clinique, des antécédents de facteurs de risque appropriés (consommation de poisson cru, de crustacés, de plantes d'eau douce non cuites), de la détection de l'éosinophilie et des résultats typiques des échographies, de la tomographie assistée par ordinateur ou de l'imagerie par résonance magnétique (IRM). La confirmation du diagnostic repose sur différentes techniques de diagnostic. Techniques parasitologiques pour détecter les œufs dans les échantillons de selles en vue de déterminer la clonorchiase, l'opisthorchiase et la fasciolase, et microscopie directe des frottis d'expectoration pour la paragonimose. Ces techniques sont les plus couramment utilisées et ont une faible sensibilité dans les infections à charge légère, en revanche elles sont précises si les microscopistes sont bien formés, bien que la différenciation morphologique des œufs puisse être difficile. Il est recommandé de préparer 2 frottis Kato-Katz. Techniques immunologiques pour détecter des anticorps spécifiques de parasites dans des échantillons de sérum ou des antigènes spécifiques de parasites dans des échantillons de sérum ou de selles. Ces techniques peuvent être plus sensibles mais la détection des anticorps ne permet pas de faire la distinction entre les infections actuelles, récentes ou passées. Il peut y avoir des réactions croisées avec d'autres antigènes de trématodes. Des techniques moléculaires telles que l'amplification en chaîne par polymérase peuvent également être utiles et sont actuellement en phase d'expérimentation. Traitement, prévention et lutte La lutte contre les trématodoses d'origine alimentaire vise à réduire les risques d'infestation et à maîtriser la morbidité associée. Il convient d'utiliser une approche intégrée Un monde, une santé reliant les aspects relatifs à l'animal, à l'homme et à l'environnement. Des interventions en matière d'information, d'éducation et de communication sur les pratiques alimentaires sûres, l'amélioration de l'assainissement et les mesures de santé publique vétérinaire devraient être mises en œuvre pour réduire les taux de transmission et le risque d'infection. Pour maîtriser la morbidité, l'OMS recommande un meilleur accès au traitement au moyen d'anthelmintiques sûrs et efficaces. Le traitement de la clonorchiase et de l'opisthorchiase repose sur une administration de praziquantel, à raison de 25mgkg, 3 fois par jour, pendant 2 à 3 jours consécutifs ou sur une administration unique à 40mgkg. La fasciolase doit être traitée avec du triclabendazole à 10mgkg, administré en une seule dose. En cas d'échec du traitement, la dose peut être portée à 20mgkg, en deux doses fractionnées, à 12-24 heures d'intervalle. La paragonimose peut être traitée avec du triclabendazole à 20mgkg, en deux doses de 10mgkg à administrer le même jour, ou du praziquantel à 25mgkg, 3 fois par jour pendant 3 jours. Le traitement au triclabendazole est préférable en raison de la simplicité de son schéma thérapeutique et donc d'une observance accrue du traitement. Dans le cadre de l'action de santé publique, l'OMS recommande d'effectuer un diagnostic communautaire au niveau du district et de mettre en œuvre une chimiothérapie préventive au niveau de la population dans les zones où un grand nombre de personnes sont infectées. La prise en charge individuelle avec traitement des personnes dont l'infection est confirmée ou suspectée est appropriée lorsque les cas sont moins regroupés et que des établissements de santé sont disponibles. La chimiothérapie préventive seule ne suffit pas à réduire la prévalence. Des facteurs tels que les mauvaises conditions d'assainissement et d'hygiène alimentaire, les réservoirs animaux et les habitudes alimentaires culturelles contribuent à des taux de réinfection élevés après le traitement. Ainsi, les programmes d'administration massive de médicaments devraient s'inscrire dans le cadre d'une approche Une seule santé plus large, intégrant l'éducation à la santé communautaire, les interventions au niveau vétérinaire et agricole, la sécurité sanitaire des aliments et l'amélioration des systèmes d'approvisionnement en eau, d'assainissement et d'hygiène. Le tableau 2 présente un résumé des traitements et des stratégies recommandés. Tableau 2 : Traitements et stratégies recommandés Maladie Médicaments recommandés et posologie Stratégie recommandée Clonorchiase et opisthorchiase Prise en charge individuelle des cas Praziquantel : 25 mgkg trois fois par jour pendant 2-3 jours consécutifs Traiter tous les cas confirmés Dans les zones d'endémie : traiter tous les cas suspects Chimiothérapie préventive Praziquantel : 40 mgkg en une seule prise Dans les sous-districts, les villages ou les communautés où les cas semblent groupés, traiter tous les habitants pendant 12 mois Fasciolase Prise en charge individuelle des cas Triclabendazole : 10 mgkg en une seule prise (une double dose de 20mgkg, à 1224 heures d'intervalle, peut être administrée en cas d'échec du traitement) Traiter tous les cas confirmés Dans les zones d'endémie : traiter tous les cas suspects Chimiothérapie préventive Triclabendazole : 10 mgkg en une seule prise Dans les sous-districts, les villages ou les communautés où les cas de fasciolase semblent groupés : traiter tous les enfants d'âge scolaire (514 ans) ou tous les habitants, tous les 12 mois Paragonimose Prise en charge individuelle des cas Triclabendazole : 2 x 10 mgkg le même jour Praziquantel : 25 mgkg trois fois par jour pendant 3 jours Traiter tous les cas confirmés Dans les zones d'endémie : traiter tous les cas suspects Chimiothérapie préventive Triclabendazole : 20 mgkg en une seule prise Dans les sous-districts, les villages ou les communautés où les cas de paragonimose semblent groupés: traiter tous les habitants tous les 12 mois Notre travail Soutenir les pays dans leurs efforts de lutte contre les trématodoses d'origine alimentaire L'OMS encourage l'introduction des trématodoses d'origine alimentaire parmi les objectifs des interventions de chimiothérapie préventive. Dans le but de fournir un accès à des médicaments de qualité, l'OMS a négocié avec les entreprises pharmaceutiques des dons de triclabendazole pour traiter la fasciolase et la paragonimose dans les pays d'endémie, ainsi que du praziquantel pour traiter la clonorchiase et l'opisthorchiase. L'OMS rassemble les demandes auprès des ministères de la santé et les médicaments sont expédiés gratuitement. Promouvoir la prévention et la lutte contre les trématodoses d'origine alimentaire moyennant l'approche Une seule santé Les cycles de vie des zoonoses que sont les trématodoses d'origine alimentaire sont complexes et sont étroitement liés à des conditions d'assainissement et d'hygiène des aliments insuffisantes, et à la présence de réservoirs animaux à proximité étroite des communautés. L'approche Une seule santé qui intègre des interventions dans les secteurs vétérinaire et agricole, l'amélioration de l'assainissement et de l'accès à l'eau potable, ainsi que la communication sur l'amélioration de la sécurité sanitaire et de l'hygiène alimentaire, est vitale pour lutter contre les infections à trématodes d'origine alimentaire. L'OMS travaille étroitement avec les organisations partenaires telles que l'Organisation mondiale de la santé animale (OIE) et l'Organisation des Nations Unies pour l'alimentation et l'agriculture (FAO) pour promouvoir une collaboration interdisciplinaire. Des réunions tripartites conjointes ont été organisées pour encourager les actions intersectorielles et aider collectivement les pays à renforcer leurs capacités pour lutter efficacement contre les parasitoses d'origine alimentaire, notamment la réunion visant à accélérer la prévention et la lutte contre les zoonoses parasitaires négligées d'origine alimentaire dans les pays d'Asie qui s'est tenue en République démocratique populaire lao en 2018. En outre, une série de communications et des publications d'orientations visant différents secteurs, notamment les praticiens de santé publique, les autorités de sécurité sanitaire des aliments et les praticiens vétérinaires ont été produites conjointement par les trois organisations en Asie. Promouvoir la mise en œuvre des interventions relatives aux trématodoses conjointement aux interventions relatives aux autres maladies tropicales négligées (MTN) Une collaboration intersectorielle efficace au sein du réseau des MTN permet d'améliorer la qualité et le rapport coût-efficacité des interventions et de réduire au minimum les activités faisant double emploi. Les infections à trématodes d'origine alimentaire sont souvent co-endémiques avec de nombreuses autres maladies, en particulier celles touchant les populations vulnérables. L'OMS préconise l'intégration de la surveillance et des interventions relatives aux trématodoses d'origine alimentaire aux programmes dans le domaine de l'eau, de l'assainissement et de l'hygiène (WASH), et aux activités relatives à d'autres MTN en rapport avec ce domaine, ainsi que l'administration de la chimiothérapie préventive aux populations touchées parallèlement à des programmes adaptés d'approvisionnement en aliments ou de vaccination. La détection conjointe de la paragonimose et de la tuberculose peut améliorer la surveillance et permettre un diagnostic exact et le traitement des cas.",
    "url": "https://www.who.int/fr/news-room/fact-sheets/detail/foodborne-trematodiases",
    "length": 17505,
    "type": "html",
    "id": 21,
    "source": "WHO"
  },
  {
    "title": "Neglected, Tropical and Vector Borne Diseases - PAHOWHO Pan American Health Organization",
    "text": "SUBMENU HIGHLIGHTS FACT SHEET ELIMINATION RESOURCES Neglected ('forgotten') diseases and vector-borne diseases are a set of infectious diseases, that primarily affect the most vulnerable populations. These populations include those with the least access to health services, especially impoverished people living in remote rural areas and urban shantytowns, although some of these diseases, such as dengue , zika and chikungunya , also affect large urban areas. Dealing with these poverty-related diseases requires a more integrated and multi-disease approach that includes multisectoral action, piggy-backed initiatives, and cost-effective interventions to reduce the negative impacts that these diseases have on the health, social, and economic well-being of all people in the Americas. Fact sheet Mission Strengthen national capabilities to implement effective preventive, therapeutic and control programs that are technically feasible, economically viable, and socially acceptable. Promote the development of the infrastructure of clinical and laboratory field operations, including epidemiological analysis, surveillance systems, vector biology, control activities, and operational research to reduce the burden caused by communicable diseases in the Region. Strengthen national capacities for managing information; human and material resources to prevent, control and eliminate tropical diseases, infectious diseases, emerging and re-emerging diseases; and foster operational research for the control of communicable diseases. Objectives Strengthen national and local capabilities to detect and analyze changes in the frequency and distribution of common, new emerging and reemerging infectious diseases. Implement proper prevention and control activities. Support member countries in the process of elimination of leprosy, onchocerciasis, and trypanosomiasis or Chagas disease. Collaborate with the Regional efforts to control blood transfusion-transmitted infectious agents. Implement the Global Malaria Control Strategy based on administrative and programmatic integration of specialized services into the local level. Foster the development of applied research in support of prevention and control activities. Strategies and Lines of Action Resource Mobilization Develop strategies and lines of action to mobilize resources. Promote and support collaboration between the public and non-governmental sectors with national, international and other development agencies to mobilize resources for the prevention and control of communicable diseases. Cooperate with different partners to strengthen a national infrastructure for disease control. Training Promote and support training activities for the development of human resources at national and local levels, for the establishment of a regional network aimed at disease prevention and control. Emphasize epidemiological analysis and development of political and technical interventions for the prevention and control of communicable diseases. Carry out training on clinical case management, program management at the local level and use of standard guidelines for prevention and control activities. Dissemination of Information Support data production, collection, and analysis of the determinants and control of communicable diseases. Develop basic guidelines relevant to distributing this information. Promotion of Research Promote and coordinate research directed at obtaining information on the status and trends of relevant diseases and their determinants throughout the Region. Assign priority to support operational research to evaluate products, strategies, and procedures for the prevention, diagnosis, treatment, and control of communicable diseases. Policies, Plans, and Guidelines: Aim technical cooperation at meeting international guidelines for the formulation, implementation, and evaluation of national and regional policies and planning programs for the prevention, control and elimination of communicable diseases. Direct Technical Cooperation: Collaborate with national counterparts in the development, implementation, and management of controlelimination programs at different levels. Areas of work Vector Borne Diseases Chikungunya Dengue Malaria Oropouche virus disease Yellow Fever Zika Vectors: Integrated management and public health entomology Neglected tropical diseases Chagas disease Congenital Chagas Envenoming from venomous animal bites Fascioliasis HydatidosisEchinococcosis Lymphatic filariasis Leishmaniasis Leprosy Mycetoma Onchocerciasis Rabies Scabies and other ectoparasites Schistosomiasis Soil-transmitted helminthiasis Taenia solium taeniasiscysticercosis Trachoma Yaws PAHO Response The Neglected, Tropical and Vector Borne Diseases Unit, part of the Department of Communicable Diseases and Environmental Determinants of Health (ADCDE), is the group inside PAHO assigned to the area of infectious disease, surveillance, prevention, and control. This is one of the 30 conditions that the Elimination Initiative has proposed to eliminate in the Region of the Americas by the year 2030 .",
    "url": "https://www.paho.org/en/topics/neglected-tropical-and-vector-borne-diseases",
    "length": 5087,
    "type": "html",
    "id": 22,
    "source": "WHO"
  },
  {
    "title": "PubMed_41184765",
    "text": "Superior vena cava (SVC) syndrome is primarily associated with malignancy, with infectious etiologies being less common. Tuberculosis is the most common infectious cause of SVC syndrome (SVCS). There has been no report of SVCS caused by nontuberculous mycobacteria (NTM). Here, we present a case of SVCS caused by disseminated Mycobacterium intracellulare in a patient who was previously healthy and subsequently tested positive for anti-interferon gamma autoantibodies. A 38-year-old woman with no significant past medical history presented with a 3-month history of fever, progressive dyspnea, productive cough, and weight loss. She also reported a one-year history of ulcerative wounds on her right ankle and chest wall. On examination, she exhibited fever, tachycardia, tachypnea, facial and bilateral upper extremity edema, and cervical lymphadenopathy. Chest computed tomography revealed a 4-cm right paratracheal mass, causing SVC obstruction, and suspicious lytic lesions in the thoracic bones. Radiologic imaging of the right ankle showed an osteolytic lesion. Tissue specimens from lymph node biopsy and ankle wound demonstrated positive staining for acid-fast bacilli. While awaiting culture results, an anti-interferon gamma autoantibody assay was performed and returned positive. Mycobacterial culture subsequently identified M. intracellulare. Empiric therapy for NTM infection was initiated with imipenem and azithromycin. Following species identification, treatment was switched to a combination of azithromycin, rifampin, ethambutol, and levofloxacin. Clinical symptoms and imaging findings gradually resolved following the treatment. Nontuberculous mycobacterial (NTM) disease is a rare cause of superior vena cava syndrome. In cases of disseminated NTM infection, a thorough evaluation for associated underlying conditions, particularly adult-onset immunodeficiency (AOID), linked to anti-IFN-γ autoantibodies, is essential.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41184765/",
    "length": 1943,
    "id": 1000,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41184623",
    "text": "Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is characterized by limited treatment options and a therapeutic ceiling. Failure to resolve inflammation is the key driver of disease progression. Formyl peptide receptor 2 (FPR2/ALX), a pivotal mediator of inflammation resolution, has emerged as a promising therapeutic target. In this study, we investigated the expression patterns of FPR2 and clinical relevance in myeloid and lymphoid cells of active IBD patients. By analyzing transcriptomic and single-cell RNA-sequencing data from the GEO database, we revealed aberrant expression of FPR2 and its associated genes in colonic mucosa of IBD patients. We found that FPR2/ALX was highly expressed in the colonic mucosa of UC and CD patients compared to non-IBD controls, strongly correlating with alterations in the MAPK pathway and myeloid cell composition. Notably, high mucosal FPR2/ALX levels were associated with poor response to anti-tumor necrosis factor-α (TNF-α) agent infliximab, and were predictive of disease status (AUC = 0.9143). To assess therapeutic potential, we established a dextran sulfate sodium (DSS)-induced colitis model in wild-type and Fpr2-silenced mice. The mice were orally treated with FPR2/ALX modulators Quin-C1 (QC1) and Quin-C7 (QC7) for 7 days. We showed that oral administration of QC1 or QC7 significantly reduced disease active index (DAI) in wild-type mice, whereas the therapeutic effects were markedly impaired in Fpr2-silenced mice. We conclude that FPR2/ALX may serve as a potential biomarker and therapeutic target for IBD.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41184623/",
    "length": 1614,
    "id": 1001,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41184039",
    "text": "The increase in global mobility has led to a higher prevalence of imported diseases in immunocompromised patients, often asymptomatic but with the potential for reactivation or severe progression. This executive summary presents the key recommendations of the consensus document developed by the Imported Pathology Study Group (GEPI-SEIMC) in collaboration with GeSIDA, GESITRA and GEIRAS (SEIMC), targeting healthcare professionals who manage immunocompromised individuals. Based on a structured narrative review, the document proposes systematic screening strategies to detect imported infections during their asymptomatic phase, clearly distinguishing them from the clinical approach in symptomatic patients. Major infections of concern are summarized. Specific guidance is provided for people living with HIV, donors and transplant recipients, oncohematologic patients, and those receiving immunosuppressive therapy. Differences in reactivation risk, preferred diagnostic methods, and therapeutic decisions in cases of latent infection are highlighted. The document underscores the need to incorporate screening into pre-treatment and pre-transplant assessments, promoting standardized protocols.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41184039/",
    "length": 1200,
    "id": 1002,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41183475",
    "text": "Chromoblastomycosis, subcutaneous phaeohyphomycosis, and mycetoma are implantation mycoses that cause substantial morbidity and decreased quality of life. Limited data on the global epidemiology of these diseases are available in addition to a lack of robust diagnostic and clinical options. The skin is the key starting point for the diagnosis and management of these infections, the steps for which are outlined in this article.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41183475/",
    "length": 430,
    "id": 1003,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41183110",
    "text": "People living in economically disadvantaged circumstances experience higher risks of infections and death from arboviruses. However, more evidence is needed to better understand the socioeconomic factors influencing dengue mortality. We investigated if people of lower socioeconomic conditions in Brazil are more likely to die following dengue infection. Linking nationwide socioeconomic data from the 100 Million Brazilian Cohort with dengue disease and death records registered in Brazil between 1st January 2007 and 31st December 2018, we used multivariable hierarchical analysis to investigate the socioeconomic determinants of dengue-specific and all-cause mortality within 15 days of dengue symptom onset. Among the 3,018,131 individuals from the 100 Million Brazilian Cohort diagnosed with dengue, 1810 died from dengue (Case Fatality Rate (CFR)=0.06%, 95%CI = 0.06-0.06%) and 3076 (CFR = 0.10%, 95%CI = 0.10-0.11%) died from any cause within 15 days of dengue symptom onset. People residing in the Northeast (OR=2.32; 95%CI = 1.74-3.10) and Midwest (OR=1.68; 95%CI = 1.25-2.27) regions, self-identifying as black race/ethnicity (OR=1.58; 95%CI = 1.31-1.90), having lower level of education (OR=2.35, 95%CI = 1.17-4.73), being retired/receiving pension (OR=2.24; 95%CI = 1.76-2.86), living in a household with rudimentary sewage (OR=1.19; 95%CI = 1.04-1.37) and having >2 inhabitants per room (OR=1.31; 95%CI = 1.11-1.55) had at higher odds of dengue-specific mortality. Similar characteristics were also associated with higher all-cause mortality after dengue infection, but also included residing in North region (OR=1.60; 95%CI = 1.24-2.06) and rural areas (OR=1.12; 95%CI = 1.01-1.24), self-identifying as Asian (OR=1.65; 95%CI = 1.07-2.54) and mixed race/brown (OR=1.20; 95%CI = 1.10-1.31) and living in households with poorer quality building and sanitary conditions. Our findings provide evidence that individuals in Brazil with lower socioeconomic condition experience increased odds of dengue-specific and all-cause mortality within 15 days of dengue symptom onset. These findings underscore the importance of ensuring equitable access to high-quality treatment for severe dengue and suggest that reducing poverty and social inequality, including through improvement of sanitation and housing, may help mitigate dengue-related mortality.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41183110/",
    "length": 2353,
    "id": 1004,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41183019",
    "text": "Globally, tuberculosis incidence and mortality is driven by syndemic interactions of tuberculosis with other chronic conditions including HIV, diabetes and undernutrition in a deleterious social and structural context, often characterised by poverty. Systematic screening for tuberculosis among household contacts is a core element of the WHO tuberculosis strategy but is hampered in high-tuberculosis incidence settings by health system constraints and low participation by household members of people with tuberculosis. Reframing screening as a health check, informed by the syndemic framework, could improve uptake and address proximate determinants of tuberculosis. Within a larger research study aimed at evaluating new tuberculosis diagnostic tests we developed and, using mixed methods, evaluated an integrated health check in a prospective cohort of tuberculosis household contacts in Zimbabwe. This included screening for a range of health conditions, health education and counselling, and on-site treatment or referral. Of 836 identified household contacts, 700 (84%) participated in tuberculosis screening. Of those, 467 people (67% women, median age 28 years) were invited to the health check; all participated in the intervention. One percent (n = 5/459) were diagnosed with tuberculosis. Almost two thirds (n = 288) had at least one unmet health need (either undiagnosed or uncontrolled diabetes, hypertension, HIV, anaemia, undernutrition, common mental health disorders, vision impairment, or tuberculosis). Of those referred following the health check, 66% accessed care for at least one condition, with variation across conditions. In-depth interviews with participants (n = 28), informed development of a refined explanatory theory, illustrating the benefits of a syndemic theory-based approach to tuberculosis screening for household contacts. Members of tuberculosis affected households have multiple, intersecting and unmet health needs. A holistic approach to systematic screening of household contacts guided by the syndemic framework could improve the health of these vulnerable people, advancing progress towards both tuberculosis and sustainable development goals.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41183019/",
    "length": 2191,
    "id": 1005,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41182632",
    "text": "Amastigotes are the replicative intracellular life cycle stage of the protozoan parasite Trypanosoma cruzi, the causative agent of Chagas disease. They have the ability to proliferate in any nucleated mammalian cell. A greater understanding of amastigote biology would greatly aid drug development since this life cycle stage is the principal target of chemotherapy. Reports have linked recrudescence following drug treatment with the possible existence of a quiescent amastigote phenotype. However, the lack of a rapid and straightforward method for isolating amastigotes from infected host cells has limited research progress in this area. This is particularly the case with omics technology, where the current complex fractionation and purification procedures can act to perturb RNA and protein expression. Here, we outline a methodology that largely overcomes these problems. Our protocol exploits MP Bio-Lysing Matrix M tubes to promote the differential lysis of host cells and the release of intact amastigotes in a 1-min time frame. Immediate treatment of the lysate with CellCover reagent then maintains RNA and protein in their native states. Amastigotes stabilized in this way can undergo further manipulations, such as cell sorting, without modification of their proteome or transcriptome profiles. This methodology, which is flexible and widely applicable, should greatly benefit research into the intracellular life cycle of T. cruzi.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41182632/",
    "length": 1447,
    "id": 1006,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41182622",
    "text": "The adaptive immune response is integral to controlling infections. Both T-cell receptors (TCRs) and immunoglobulin G (IgG) recognize antigens via hypervariable regions in their binding sites, referred to as complementarity determining regions (CDRs), of which CDR3 is one of the best characterized. CDR3 sequence diversity is generated by rearrangement of the respective TCR and IgG variable (V), joining (J), and diversity (D) gene segments during cell maturation, which can produce a highly diverse repertoire of TCR or IgG clonotypes. The diversity of clonotypes produced, as well as the expansion of some and/or their replacement by others, illustrates host responses to infection and its efficacy. It may also reflect changes induced by vaccination or treatment, guiding their optimization. Here, we present a method for the analysis of the TCR and IgG immune repertoire from bulk RNA-sequencing data of peripheral blood mononuclear cells (PBMCs) from Rhesus macaques, with a focus on CDR3 sequences in the context of Trypanosoma cruzi infection, a protozoan parasite causing chronic disease.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41182622/",
    "length": 1098,
    "id": 1007,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41181881",
    "text": "Nutritional status has been compromised by ongoing war and restrictions on food deliveries in the Gaza Strip. We developed a mathematical model that outputs retrospective estimates and scenario-based projections of acute malnutrition prevalence among children given caloric intake and other factors. We present here the model and its application to the crisis in Gaza.We extended an existing mechanistic model for weight change as a function of energy balance, calibrating it to represent variability in growth curves observed in pre-war Gaza. We simulated open cohorts of children exposed to time-varying caloric intake, infant exclusive breastfeeding prevalence, incidence of infectious disease and coverage of malnutrition treatment, while allowing for adult caloric sacrifice to supplement child intake in times of food scarcity.The model accurately replicates growth standards, pre-war growth patterns and expected parameter dependencies. It suggests that a considerable increase in acute malnutrition occurred in northern Gaza during early 2024. Projections for late 2024 include a serious nutritional emergency if relatively pessimistic assumptions are made about food availability. The model may hold considerable promise for informing decisions in humanitarian response but requires further validation and development.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41181881/",
    "length": 1327,
    "id": 1008,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41181113",
    "text": "EchinococcosisEchinococcusE. granulosusIn vitro",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41181113/",
    "length": 47,
    "id": 1009,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41178124",
    "text": "Myrothamnus flabellifolia is a dioecious resurrection plant endemic to southern Africa that has become an important model for understanding desiccation tolerance. Despite its ecological and medicinal significance, genomic and transcriptomic resources for the species are limited. We generated a chromosome-level, haplotype-resolved reference genome assembly and annotation for M. flabellifolia and conducted transcriptomic profiling across a natural dehydration-rehydration time course in the field. Genome architecture and sex determination were characterized, and co-expression network and cis-regulatory element (CRE) enrichment analyses were used to investigate dynamic responses to desiccation. The 1.28-Gb genome exhibits unusually consistent chromatin architecture with unique chromosome organization across highly divergent haplotypes. We identified an XY sexual system with a small sex-determining region on Chromosome 8. Transcriptomic responses varied with dehydration severity, pointing to early suppression of growth, progressive activation of protective mechanisms, and subsequent return to homeostasis upon rehydration. Late embryogenesis abundant and early light-induced protein transcripts were dynamically regulated and showed enrichment of abscisic acid and stress-responsive CREs pointing toward conserved responses. Together, this study provides foundational resources for understanding the genomic architecture and reproductive biology of M. flabellifolia and offers new insights into the mechanisms of desiccation tolerance.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41178124/",
    "length": 1547,
    "id": 1010,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41171764",
    "text": "The use of certain medicinal plants during childbirth has been linked to negative outcomes such as uterine rupture and foetal distress, both globally and in Sub-Saharan Africa including Tanzania. Despite this, little is known about the factors influencing women's use of medicinal plants during labour or delivery in Tanzania. This study sought to assess the prevalence and determinants of medicinal plants use during labour and/or delivery in the Butiama district. This community-based quantitative study used a cross-sectional design with 398 participants, selected through multistage sampling. Data were collected via a structured questionnaire in Swahili language using the Kobo Toolbox from June to July 2024. Analysis was performed with SPSS version 27.0, including checks for completeness before data entry. Descriptive statistics were computed for univariate analysis, while bivariate analysis, conducted through cross-tabulation, determined relationships between variables. Multivariate logistic regression identified significant predictors at p < 0.05. In a study of 398 participants, 233(58.5%) reported using medicinal plants during labour and/or delivery. Peasants and homemakers had 2.6 times higher odds of using medicinal plants than those in formal employment (AOR = 2.584, 95% CI: 1.249-5.349, p = 0.011). Women with one child were 1.8 times more likely to use medicinal plants than those with two or more children (AOR = 1.823, 95% CI: 1.136-2.926, p = 0.013). Women within five kilometres of a health facility had 47.7% lower odds of using medicinal plants compared to their counterparts (AOR = 0.523, 95% CI: 0.334-0.819, p = 0.005). Married and cohabiting women were 42.1% less likely to use medicinal plants than divorced/separated/widowed women (AOR = 0.579, 95% CI: 0.338-0.990, p = 0.046). Women with fewer than four antenatal visits were 55.6% more likely to use medicinal plants compared to those with four or more visits. (AOR = 0.556, 95% CI: 0.365-0.848, p = 0.006). Over fifty percent of participants reported using medicinal plants during childbirth, with socio-economic status and healthcare access factors suggesting that targeted education and interventions around medicinal plant use would be beneficial.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41171764/",
    "length": 2241,
    "id": 1011,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41162860",
    "text": "Identifying pathogenic fungi from vegetable is a critical first step in disease management and development of effective plant-based antifungal agent, aligning with environmentally friendly and sustainable agricultural practices. This study aimed to isolate, identify, and characterize the major fungal pathogens of vegetables and to evaluate the antifungal efficacy of selected plant extracts against vegetable pathogenic fungi. Therefore clear identification is crucial for designing effective management protocols against these persistent fungal threats in Western Hararghe, Ethiopia. Diseased onion samples (leaves, bulbs, and roots) and pepper samples (leaves and fruits) were collected from Gemechis and Boke district, Western Hararghe, Ethiopia, respectively, from July 2023 to January 2025. Data were analyzed using a Completely Randomized Design (CRD) and ANOVA. Three medicinal plants (Allium sativum, Azadirachta indica, and Acokanthera schimperi) were selected based on traditional usage and literature evidence. Crude extracts were prepared using maceration method, while essential oils were obtained through hydro distillation, using Clevenger apparatus. The chemical composition of the crude extracts was assessed using standard phytochemical screening and essential oils was analyzed by using gas chromatography-mass spectrometry (GC-MS). Antifungal activity of both extract was evaluated using the agar well diffusion method and detached leaf assay for obligate biotroph. A total of six major fungal pathogens (Peronospora destructor, Rhizoctonia solani, and Fusarium oxysporum from onions; and Erysiphe species, Sclerotinia sclerotiorum, and Aspergillus niger from pepper) were identified. Phytochemical screening of these selected plants confirmed the presence of alkaloids, flavonoids, phenolics, tannins, and sulfur compounds in the crude extracts. Antifungal assays results demonstrated that the plant extracts significantly inhibited fungal growth, particularly at higher concentrations (200 µl/ml). Acokanthera schimperi showed the highest antifungal activity, followed by Azadirachta indica, while Allium sativum exhibited moderate effects. The findings underscored the potential of botanical extracts as environmentally friendly alternatives for managing fungal diseases in vegetable crops.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41162860/",
    "length": 2315,
    "id": 1012,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41162617",
    "text": "In the hyper-arid deserts of Egypt, where extreme environmental conditions prevail, understanding the symbiotic relationship between the sparse vegetation cover and the underlying soil is crucial for unraveling the mechanisms of plant survival and ecosystem functioning. This study investigates vegetation composition, environmental drivers, and their interactions in an unprotected area of Egypt's northern Eastern Desert, which has recently experienced substantial anthropogenic disturbances. Primary threats to vegetation include road construction, unregulated quarrying, and overexploitation of natural resources. To represent the habitats present in the study area, 20 stands were selected. In each stand, the existing plant species were recorded, soil samples were taken from each stand, and multivariate statistics (DCA) were conducted to show the relationship between the distinctive plant indicators for each stand, as well as the most influential soil factors in each stand. Then, the state of the vegetation cover in previous years (2014) was compared with the state in the study year (2024). A total of 75 plant species were documented, with Asteraceae (15 species) and Fabaceae (6 species) representing the most diverse families. Perennials (73%), chamaephytes (44%), and Saharo-Arabian species (71%) dominated the flora. Detrended Correspondence Analysis (DCA) revealed that the studied stands were divided into four groups (A, B, C, and D). Each group was ecologically similar to the other. Each group of stands had distinctive plant indicators and the soil factors most closely associated with them. Based on the IUCN Red List, conservation status assessments were provided for each species (65 species were unevaluated, while only 11% of the total species are classified as Least Concern, with no taxa appearing in the threatened category). The presence of invasive non-native taxa, such as Beta vulgaris and Centaurea calcitrapa, which threaten native biodiversity, was noted. Analysis of the Soil Adjusted Vegetation Index (SAVI) revealed a reduction in vegetation cover between 2014 (SAVI range: -0.523911 to 0.860437) and 2024 (SAVI range: -0.574714 to 1.08698). The recorded plant species include 16 medicinal plants. Escalating habitat destruction and anthropogenic pressures underscore the urgent need for targeted conservation strategies to safeguard biodiversity in this vulnerable region.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41162617/",
    "length": 2415,
    "id": 1013,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41155263",
    "text": "According to the World Health Organization, cancer is still the leading cause of death for humans worldwide. Although over 100 chemotherapeutic agents are currently available for the treatment of cancer patients, the overall long term clinical benefit is disappointing due to the lack of effectiveness or severe side effects from these drugs. The use of complementary and alternative medicinal products from plants has continued to increase in past decades, due to fewer side effects of bioactive compounds from medicinal plants of which pentacyclic triterpenoids have been identified as one class of secondary metabolites that could play an important role in the treatment and management of a number of non-communicable diseases. The main aim of this study is to extract, isolate, identify, and elucidate pentacyclic triterpenoid (ursolic acid, UA (",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41155263/",
    "length": 850,
    "id": 1014,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41152361",
    "text": "In areas with limited access to modern healthcare, local communities often depend on plant-based traditional medicine for livestock care. However, these practices and the plants themselves are declining owing to sociocultural and environmental changes. This study aimed to document the plants used in ethnoveterinary medicine with associated indigenous knowledge in the Metema and Quara districts. To collect ethnobotanical data, a total of 396 informants from 21 kebeles (the smallest administrative units) were selected. The ages of interviewees ranged from 20 to 81 years, with 267 males and 129 females. The ethnobotanical data collection was carried out using semi-structured interviews, use reports, direct matrix ranking, guided field walks, and focus group discussion. The ethnobotanical data were analyzed and verified using descriptive statistics (frequency and percentage), comparison, use reports, and direct matrix ranking. Nonparametric tests Kruskal-Wallis H and Mann-Whitney U were used to compare indigenous and local knowledge across different socio-demographic factors. This study documented 64 medicinal plants from 32 families, mainly Fabaceae, addressing 37 livestock health issues. The animal species reported to be treated by the medicinal plants were cattle, sheep, goat, poultry, equines, and dogs. Common ailments include wounds and febrile illnesses. Trees were the predominant form (39.1%), with leaves most used (28%), typically prepared fresh. Crushing and drenching were common preparation methods (21.05%), with oral administration being most frequent (45.8%). Piliostigma thonningii and Ximenia americana were the most cited, with 74 and 59 use reports, respectively. DMR highlighted Ziziphus spina-christi and Piliostigma thonningii as important multipurpose species needing conservation. Most informants recognized that abundance of some species decreased in the last years as a result of human activities and climatic changes. Ethnoveterinary knowledge varied significantly (P < 0.05) among informant groups, age classes, education levels, and ethnic backgrounds. Communities in Metema and Quara possess valuable ethnoveterinary knowledge of diverse medicinal plants. Conservation efforts are therefore required to protect these resources. Engaging local communities in conservation initiatives is therefore essential. Future research should focus on the validation of plant bioactivity and the investigation of the antimicrobial properties of the most cited plants.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41152361/",
    "length": 2503,
    "id": 1015,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41148658",
    "text": "Background/ObjectivesMethodsnResultsRhoicissus tridentataRosmarinus officinalisXimenia caffraR. officinalisRhoicissus tridentataMycobacterium smegmatisConclusionsMycobacterium tuberculosis",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41148658/",
    "length": 188,
    "id": 1016,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41119316",
    "text": "Rhode zaccarensis sp. nov. is described based on male and female specimens collected from Djebel Zaccar, Miliana (An Defla, Algeria). A detailed morphological description and a comparative diagnosis with related species are provided, along with an identification key for males of the Rhode species in the Maghreb. Furthermore, comments on their distribution ranges are presented.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41119316/",
    "length": 379,
    "id": 1017,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41116149",
    "text": "Universal Health Coverage (UHC) aims to guarantee access to health services without financial risk for the entire population. Despite the efforts made in Cameroon, particularly in Souza, the enrolment rate remains low. This study aims to identify the socio-demographic factors, knowledge, and perceptions that influence the enrolment of residents in the UHC, in order to adapt health policies and strengthen equitable access to care. The study was carried out in the city of Souza over a six-month period, from March to August 2024, with data collected between May and July. A sample of 400 participants was selected, including residents aged 21 and over. A structured questionnaire, pre-tested for clarity, was administered during face-to-face interviews. The data were analysed using R Studio, conducting descriptive, bivariate, and multivariate analyses to identify factors associated with enrolment in the UHC. The results show that out of 400 inhabitants, only 7% (28 inhabitants) were enrolled at the UHC. The most common gender was male (51.25%), 34.5% were aged between 21 and 30, and 55.25% had a secondary education. The results of the multivariate analyses showed that having a university education [AOR = 2.01; 95% CI: 1.12-4.91; p = 0.04], having heard of universal health coverage [AOR = 18.99; 95% CI: 4.25-84.88; p = 0.04], and perceiving the cost of enrolment as low [AOR = 2.12; 95% CI: 1.45-6.19; p = 0.03] significantly increased the probability of enrolment in universal health coverage. This study highlights significant barriers to UHC enrolment, including a lack of awareness and negative perceptions of costs. The results suggest that targeted communication efforts and awareness-raising initiatives are essential to improve enrolment. Strengthening education and information about the UHC could contribute to better access to healthcare and increased participation by residents. Not applicable.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41116149/",
    "length": 1920,
    "id": 1018,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41106792",
    "text": "Anethole, a naturally-occurring aromatic phenylpropene compound, is commonly present in the essential oils derived from botanically diverse plants, including anise, star anise, fennel and basil. It is highly regarded for its therapeutic properties, imparting various health benefits spanning many different conditions. This comprehensive and critical review unites the knowledge on anethole up to the year 2024, available from the scientific platforms Scopus, PubMed and Web of Science, retrieved using the search term \"Anethole\". A bibliometrics overview is also provided which outlines the trend in the publication output over time, the major contributing authors, collaborative networks and popular research topics on this molecule. The collected data suggests that, in addition to its significance in the flavour and fragrance sectors, anethole exhibits a host of diverse medicinal activities. In-depth research highlights its contributing potential in addressing cancer, infections, wounds, and conditions related to the liver, lungs and skin. However, the research on anethole lacks comprehensive investigations into its mechanisms of action and synergistic effects with other compounds, hindering the understanding of its full therapeutic potential. While it holds promise beyond culinary uses, further research is needed to address this knowledge void and develop targeted therapeutic interventions.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41106792/",
    "length": 1407,
    "id": 1019,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41162496",
    "text": "Dermatophytosis is a common superficial fungal infection that affects many people worldwide. Although various species of dermatophytes respond to common antifungal drugs, the recently identified Trichophyton indotineae isolates have exhibited significant terbinafine resistance due to mutations in the Squalene Epoxidase (SQLE) gene. Piperlongumine (PL), a natural alkaloid that stimulates ROS production and inhibits some crucial enzymes, has a good capacity to treat these fungal infections. As part of nanotechnology, niosomes can increase the success of the drug by targeting the affected areas. This study investigates the effectiveness of PL niosomal gel 1% in an infected animal model with T. indotineae, providing important insights for infection treatment. Thirty guinea pigs empirically infected with T. indotineae were divided into five groups (e.g., untreated control, treated groups with terbinafine 1%, niosome, PL gel 1%, and PL niosomal gel 1%) and subsequently scored both clinically and mycologically until the 38th day of inoculation. On the 38th day of the study, histological evaluation was performed. In contrast to the terbinafine group, which demonstrated no efficacy (P < 0.05), the 1% PL niosomal gel significantly decreased mycological and clinical lesion scores, leading to complete mycological cure (negative fungal cultures) by day 28. Moreover, histopathological analysis confirmed that this compound reduced epidermal thickness, fungal burden, and inflammation. However, it should be noted that the difference in recovery rate of pigs with PL gel 1% and PL niosomal gel 1% was not statistically significant (p = 0.6). Treatment of T. indotineae dermatophytosis using PL niosomal gel is a safer and more effective alternative to conventional topical and oral antifungal therapies. However, further studies are warranted to correlate these findings with clinical outcomes.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41162496/",
    "length": 1902,
    "id": 1020,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41155688",
    "text": "Parasitic infections remain a major global health challenge, particularly in resource-limited settings where they are closely tied to poverty and inadequate sanitation. The increasing emergence of drug resistance and the limited accessibility of current therapies highlight the urgent need for novel, safe, and affordable alternatives.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41155688/",
    "length": 335,
    "id": 1021,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41136979",
    "text": "The Mbabaram Aboriginal community lives in Atherton Tableland of Far North Queensland, Australia. While most of the knowledge had been lost due to colonial influences, this community still has remnants of traditional biocultural knowledge, which is critically endangered. They have been closely working with the Tropical Indigenous Ethnobotany Centre (Queensland Herbarium, James Cook University) in the areas of documenting traditional biocultural knowledge and biodiscovery projects. The current study investigated five medicinal plants used by the Mbabaram Aboriginal community for treating wounds, and inflammation-associated diseases. In this study, crude extracts of five medicinal plants from the Mbabaram community (Breynia oblongifolia, Cajanus reticulatus, Dodonaea lanceolata, Exocarpos latifolius, and Coleus amoenus) were assessed for their phytochemical contents. The antioxidant activity was determined using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay. Furthermore, crude extracts were evaluated for their effect on cell viability and anti-inflammatory activities using the human peripheral blood mononuclear cells (PBMC) assay. While some plants tested positive for flavonoids and saponins, B. oblongifolia and C. amoenus did not test positive for saponins. Only C. reticulatus and E. latifolius tested positive for alkaloids. The water extract of C. amoenus and the ethanol extract of B. oblongifolia exhibited the highest TPC with 99.88 ± 4.47 GAE/g extract and 128.36 ± 14.09 GAE/g extract, respectively. While the crude water extract of E. latifolius stems showed the best antioxidant activity with EC Of the five aqueous crude extracts studied here, E. latifolius stems showed the best antioxidant activity and B. oblongifolia leaf showed the best anti-inflammatory activity. This result validated the traditional uses of medicinal plants, which is used for treating inflammation-related conditions including wounds and sores. B. oblongifolia has potential to yield drug lead molecules for developing treatment for inflammation and sores/ulcers related diseases such as IBD.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41136979/",
    "length": 2118,
    "id": 1022,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41135560",
    "text": "The global burden of sepsis, a life-threatening dysregulated host response to infection leading to organ dysfunction, remains challenging to quantify. We aimed to comprehensively estimate the global, regional, and national burden of sepsis, including the impact of the COVID-19 pandemic and underlying causes of sepsis-related deaths with co-occurring infectious syndromes. We used multiple cause-of-death, hospital, minimally invasive tissue sampling, and linked death certificate and hospital record data representing 149 million deaths, covering 4290 location-years with mortality estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 to capture explicit and implicit sepsis cases and deaths. We estimated age-location-sex-specific fractions of sepsis-related deaths from 195 underlying causes of death and 22 infectious syndromes from 1990 to 2021 using binomial logistic regression models, and estimated sepsis-related deaths using GBD cause-specific mortality estimates. Using 250 million hospital admissions and 7·82 million deaths from hospital data, representing 1310 location-years, we modelled case fatality rates by use of binomial logistic regression, applied to sepsis death estimates to estimate sepsis incidence by age, location, and year. In 2021, we estimated 166 million (95% uncertainty interval 135-201) sepsis cases and 21·4 million (20·3-22·5) all-cause sepsis-related deaths globally, representing 31·5% of total global deaths. Sepsis-related deaths decreased between 1990 and 2019, followed by a surge in 2020 and 2021. As of 2021, individuals aged 15 years and older experienced increases across incidence (230%) and mortality (26·3%) since 1990. Those aged 70 years and older had the highest sepsis-related mortality in 2021 (9·28 million [8·74-9·86] deaths). Sepsis-related deaths from infectious underlying causes decreased from 11·8 million (11·1-12·5) in 1990 to 8·34 million (7·72-9·01) in 2019, then increased by 86·4% to 15·5 million (14·7-16·4) in 2021. Sepsis-related mortality due to non-infectious underlying causes of death increased from 4·69 million (4·35-5·05) in 1990 to 5·81 million (5·40-6·25) in 2021; the leading non-infectious underlying causes of death with sepsis were stroke, chronic obstructive pulmonary disease, and cirrhosis. In 2021, bloodstream infections inclusive of HIV and malaria (3·08 million [2·83-3·35]) and lower respiratory infections inclusive of COVID-19 (11·33 million [1·20-1·47]) were the most prominent infectious syndromes complicating sepsis-related deaths from non-infectious underlying causes, representing a consistent trend since 1990. The global burden of sepsis increased in 2020 and 2021, reversing progress from 1990. Sepsis incidence and mortality increased in people aged 15 years and older, especially those aged 70 years and older, and as a complication of non-infectious underlying causes of death such as stroke, primarily through bloodstream infections and lower respiratory infections. The global burden of sepsis is substantial, and sepsis is increasingly a complication of non-infectious causes of death. Gates Foundation, Wellcome Trust, and Department of Health and Social Care using UK aid funding managed by the Fleming Fund.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41135560/",
    "length": 3258,
    "id": 1023,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41132222",
    "text": "Candidiasis is one of the most common fungal infections caused by Fifty clinical isolates of The minimum inhibitory concentrations 50 and geometric mean of fluconazole and dry extract of We found that the antifungal activity of the dry extract of",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41132222/",
    "length": 246,
    "id": 1024,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41120673",
    "text": "Ziziphus mauritiana Lam., a tropical tree from the Rhamnaceae family, is valued for its nutritional benefits and traditional medicinal uses. This study assessed the antimicrobial activity of different plant parts which are leaves, roots, bark, stems, and fruits, against Escherichia coli and Fusarium solani using methanolic extracts at 1.0 mg/mL. Streptomycin (1.0 mg/mL) and 0.8% methanol served as positive and negative controls, respectively. Plant-derived antimicrobial agents are gaining attention for their bioavailability, safety, and low resistance potential. The methanolic extracts exhibited potent antimicrobial effects, with minimum bactericidal and fungicidal concentrations (MBC/MFC) of 0.8 mg/mL for E. coli and 1.0 mg/mL for F. solani. Leaf extracts showed the strongest inhibition, with zones of 101.47 mm² for E. coli and 88.11 mm² for F. solani, followed by root extracts (86.48 mm² against F. solani). The study supports Z. mauritiana's potential in treating human diseases and underscores the need for sustainable conservation. The results also emphasize the need to conserve this underutilized species for future pharmacological applications.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41120673/",
    "length": 1165,
    "id": 1025,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41115483",
    "text": "Excoecaria agallocha L., popularly known as 'Blind-your-eye mangrove' or 'Milky-mangrove', is a substantial mangrove species abundantly distributed around the coastal areas of the tropical and temperate zones of Asia, East Africa, Australia, and the Pacific regions. Several preparations from this plant have been used to treat numerous health disorders, both in preventive and curative measures, from ancient times, including epilepsy, ulcer, toothache, wound, leprosy, conjunctivitis, paralysis, dermatitis, mosquito-borne disease etc., which makes this plant a great candidate for further extensive research. The key objective of this review is to assemble a comprehensive index of global distribution, morphological characteristics, ethnopharmacology, pharmacological activities of different solvent extracts and bioactive constituents of E. agallocha with the evaluation of remaining and the latest published literatures, which may guide in prospective research studies for the effective implementation of this plant extract and its isolated constituents in medical aspects. Thus, this compilation will be very helpful to the researchers for further botanical and phytochemical studies leading to future novel drug discovery and in the validation and implementation of the already established bioactivities. Bibliographic resources, including Google Scholar, Web of Science, PubMed, SCOPUS, and others, were thoroughly searched in order to get relevant material for this review on Excoecaria agallocha. Synonyms, taxonomy, and worldwide distribution data were obtained from websites such as GBIF and the India Biodiversity Portal. Furthermore, chemical structures were produced using ChemBio Draw Ultra 14.0, and the IUPAC names of the secondary metabolites that were found were verified using PubChem. Comprehensive phytochemical studies on various parts of E. agallocha have identified at least 235 phytoconstituents across diverse structural classes, including alkaloid, diterpenoids, flavonoids, organic fatty acids, phenolic acids, sterols, tannins, triterpenoids, and other miscellaneous compounds. Excoecaria agallocha L. also exhibits various prominent pharmacological and bioactivities like antimicrobial, antioxidant, anti-inflammatory, analgesic, anticancer, anti-diabetic, anti-convulsant, anti-ulcer, anti-collagenase, non-specific immunity, sedative, anti-histamine release, anti-elastase, and hedgehog signaling inhibiting properties evident from several in vitro and in vivo research. Excoecaria agallocha L. exhibits a broad spectrum of pharmacological activities, as inferred from thorough in vitro and in vivo studies. Its phytochemical diversity mirrors its enormous utility as a rich source of bioactive entities. With its multi-spectrum therapeutic activity, E. agallocha holds high potential for the discovery of new drugs. But for its complete exploitation as a drug, more bioassay-guided investigation, complemented by extensive clinical and toxicological studies, is needed. The present findings demand further research aimed at the development of safe and effective therapeutic drugs from this mangrove species.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41115483/",
    "length": 3143,
    "id": 1026,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41112670",
    "text": "By the end of 2020, several vaccines aimed at combating COVID-19 were authorized for widespread immunization. The aim of this study was to assess the factors that were associated with COVID-19 Vaccine refusal in Bamenda I. This was a retrospective study carried out in the subdivision of Bamenda I, from March to June 2024, through interviews and questionnaires in which participants were asked to recall important events during the COVID-19 pandemic. A questionnaire-based survey was conducted to ensure diverse representation in the community study. The questionnaire comprised four sections: socio-demographic characteristics, knowledge about COVID-19 and vaccines, attitudes toward COVID-19, and beliefs about the vaccine. Data were collected during community gatherings, such as focus group discussions and training sessions, and also through Google Forms via the Kobo tool for participants with Android phones. Data were then transferred to SPSS for analysis, using the Pearson chi-square test to examine associations, with Our results show that 42.40% participants had high knowledge about COVID-19, 39.40% had moderate knowledge while 18.20% had low knowledge. Their vaccination status, showed that, just 12.10% were vaccinated, and 87.90% were unvaccinated. Socio-demographic factors like age, gender, and education recorded significant associations with respect to vaccine refusal The study highlights significant knowledge gaps and widespread concerns about vaccine safety among the population in Bamenda I, indicating a need for targeted educational interventions to improve vaccination rates.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41112670/",
    "length": 1605,
    "id": 1027,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092928",
    "text": "Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46·8 years (95% UI 46·6-47·0) in 1990 to 63·4 years (63·1-63·7) in 2023. For males, mean age increased from 45·4 years (45·1-45·7) to 61·2 years (60·7-61·6), and for females it increased from 48·5 years (48·1-48·8) to 65·9 years (65·5-66·3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80·9 years (80·9-81·0) and for males 74·8 years (74·8-74·9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38·0 years (37·5-38·4) for females and 35·6 years (35·2-35·9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. We examined global mortality patterns over the past three decades, highlighting-with enhanced estimation methods-the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092928/",
    "length": 7205,
    "id": 1028,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092927",
    "text": "Comprehensive, comparable, and timely estimates of demographic metrics-including life expectancy and age-specific mortality-are essential for evaluating, understanding, and addressing trends in population health. The COVID-19 pandemic highlighted the importance of timely and all-cause mortality estimates for being able to respond to changing trends in health outcomes, showing a strong need for demographic analysis tools that can produce all-cause mortality estimates more rapidly with more readily available all-age vital registration (VR) data. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is an ongoing research effort that quantifies human health by estimating a range of epidemiological quantities of interest across time, age, sex, location, cause, and risk. This study-part of the latest GBD release, GBD 2023-aims to provide new and updated estimates of all-cause mortality and life expectancy for 1950 to 2023 using a novel statistical model that accounts for complex correlation structures in demographic data across age and time. We used 24 025 data sources from VR, sample registration, surveys, censuses, and other sources to estimate all-cause mortality for males, females, and all sexes combined across 25 age groups in 204 countries and territories as well as 660 subnational units in 20 countries and territories, for the years 1950-2023. For the first time, we used complete birth history data for ages 5-14 years, age-specific sibling history data for ages 15-49 years, and age-specific mortality data from Health and Demographic Surveillance Systems. We developed a single statistical model that incorporates both parametric and non-parametric methods, referred to as OneMod, to produce estimates of all-cause mortality for each age-sex-location group. OneMod includes two main steps: a detailed regression analysis with a generalised linear modelling tool that accounts for age-specific covariate effects such as the Socio-demographic Index (SDI) and a population attributable fraction (PAF) for all risk factors combined; and a non-parametric analysis of residuals using a multivariate kernel regression model that smooths across age and time to adaptably follow trends in the data without overfitting. We calibrated asymptotic uncertainty estimates using Pearson residuals to produce 95% uncertainty intervals (UIs) and corresponding 1000 draws. Life expectancy was calculated from age-specific mortality rates with standard demographic methods. For each measure, 95% UIs were calculated with the 25th and 975th ordered values from a 1000-draw posterior distribution. In 2023, 60·1 million (95% UI 59·0-61·1) deaths occurred globally, of which 4·67 million (4·59-4·75) were in children younger than 5 years. Due to considerable population growth and ageing since 1950, the number of annual deaths globally increased by 35·2% (32·2-38·4) over the 1950-2023 study period, during which the global age-standardised all-cause mortality rate declined by 66·6% (65·8-67·3). Trends in age-specific mortality rates between 2011 and 2023 varied by age group and location, with the largest decline in under-5 mortality occurring in east Asia (67·7% decrease); the largest increases in mortality for those aged 5-14 years, 25-29 years, and 30-39 years occurring in high-income North America (11·5%, 31·7%, and 49·9%, respectively); and the largest increases in mortality for those aged 15-19 years and 20-24 years occurring in Eastern Europe (53·9% and 40·1%, respectively). We also identified higher than previously estimated mortality rates in sub-Saharan Africa for all sexes combined aged 5-14 years (87·3% higher in GBD 2023 than GBD 2021 on average across countries and territories over the 1950-2021 period) and for females aged 15-29 years (61·2% higher), as well as lower than previously estimated mortality rates in sub-Saharan Africa for all sexes combined aged 50 years and older (13·2% lower), reflecting advances in our modelling approach. Global life expectancy followed three distinct trends over the study period. First, between 1950 and 2019, there were considerable improvements, from 51·2 (50·6-51·7) years for females and 47·9 (47·4-48·4) years for males in 1950 to 76·3 (76·2-76·4) years for females and 71·4 (71·3-71·5) years for males in 2019. Second, this period was followed by a decrease in life expectancy during the COVID-19 pandemic, to 74·7 (74·6-74·8) years for females and 69·3 (69·2-69·4) years for males in 2021. Finally, the world experienced a period of post-pandemic recovery in 2022 and 2023, wherein life expectancy generally returned to pre-pandemic (2019) levels in 2023 (76·3 [76·0-76·6] years for females and 71·5 [71·2-71·8] years for males). 194 (95·1%) of 204 countries and territories experienced at least partial post-pandemic recovery in age-standardised mortality rates by 2023, with 61·8% (126 of 204) recovering to or falling below pre-pandemic levels. There were several mortality trajectories during and following the pandemic across countries and territories. Long-term mortality trends also varied considerably between age groups and locations, demonstrating the diverse landscape of health outcomes globally. This analysis identified several key differences in mortality trends from previous estimates, including higher rates of adolescent mortality, higher rates of young adult mortality in females, and lower rates of mortality in older age groups in much of sub-Saharan Africa. The findings also highlight stark differences across countries and territories in the timing and scale of changes in all-cause mortality trends during and following the COVID-19 pandemic (2020-23). Our estimates of evolving trends in mortality and life expectancy across locations, ages, sexes, and SDI levels in recent years as well as over the entire 1950-2023 study period provide crucial information for governments, policy makers, and the public to ensure that health-care systems, economies, and societies are prepared to address the world's health needs, particularly in populations with higher rates of mortality than previously known. The estimates from this study provide a robust framework for GBD and a valuable foundation for policy development, implementation, and evaluation around the world. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092927/",
    "length": 6303,
    "id": 1029,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41168903",
    "text": "The study by Nikièma et al. demonstrates the absence of Wuchereria bancrofti infection in Anopheles mosquitoes a decade after cessation of mass drug administration (MDA) in Burkina Faso. This rare longitudinal evidence underscores the utility of molecular xenomonitoring (MX) as a sensitive early-warning tool that complements traditional transmission assessment surveys (TAS). MX enables detection of recrudescence earlier than human-based diagnostics, particularly in low-prevalence settings, and offers opportunities for integration with malaria vector surveillance. Ethical and operational challenges associated with human landing catches highlight the need for alternative trapping methods to maintain MX sensitivity safely. Sustaining lymphatic filariasis elimination globally will depend on institutionalizing MX alongside TAS, ensuring robust surveillance, and safeguarding long-term programmatic gains.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41168903/",
    "length": 911,
    "id": 1030,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41164411",
    "text": "Post-stroke depression (PSD), a common neuropsychiatric complication, significantly hinders stroke recovery and quality of life. Given the established role of inflammation in the pathogenesis of PSD, this study aimed to identify key inflammation-related genes and pathways using bioinformatics and machine learning and further evaluate the protective effects of traditional Chinese medicine (TCM) monomer compounds. PSD-related datasets (GSE16561, GSE98793) were obtained from the Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) were identified using the limma package, followed by functional enrichment analysis with Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Three machine learning algorithms-random forest, support vector machine-recursive feature elimination (SVM-RFE), and least absolute shrinkage and selection operator (LASSO)-were applied to screen inflammation-related hub genes. Immune cell infiltration was analyzed using single-sample gene set enrichment analysis (ssGSEA). Candidate TCM compounds were explored via the Coremine Medical database. A PSD rat model was established to validate hub gene expression and to assess the efficacy of berberine (BBR). Analysis identified 35 inflammation-related DEGs (IDEGs) significantly enriched in immunological processes, including malaria pathogenesis, NETosis, innate immune deficiencies, Rap1 signaling, and IL-17 cascades. The integration of machine learning pinpointed TLR2 and CYP1B1 as core hub genes, demonstrating robust diagnostic performance in external validation. Molecular docking suggested a strong binding affinity between the TCM compound BBR and TLR2/CYP1B1 proteins. PSD rats exhibited prolonged immobility in forced swim/tail suspension tests and decreased sucrose preference versus controls, alongside neuronal damage, edema, and inflammatory infiltration (HE staining). BBR treatment reversed these behavioral deficits and pathological changes. Western blot analysis confirmed elevated TLR2 and CYP1B1 expression in PSD rats, significantly downregulated by BBR. Enzyme-linked immunosorbent assay (ELISA) showed increased serum IL-1β, IL-6, and TNF- This study identifies TLR2 and CYP1B1 as core inflammation-related genes in PSD. BBR demonstrates therapeutic efficacy as an active monomer compound against PSD, likely mediated through downregulating TLR2 and CYP1B1 expression, consequently diminishing the concentrations of pro-inflammatory mediators (IL-1β, IL-6, TNF-",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41164411/",
    "length": 2497,
    "id": 1031,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41160559",
    "text": "Mpox, a zoonotic viral disease endemic in Central and West Africa, has posed major public health challenges, particularly following the 2022 outbreak. The World Health Organization declared it a public health emergency of international concern in July 2022. In Africa, the ongoing outbreak has exacerbated existing healthcare system weaknesses, further strained by civil conflict, poverty, and recurring diseases like Marburg, Lassa fever, and Ebola. Between January 1, 2022, and September 28, 2025, a total of 54,906 Mpox cases and 239 deaths were recorded from 30 WHO member states in Africa. Traditional healers, often the first contact for approximately 58% of the African population for treatment and management of illness, play a crucial role in the treatment of febrile illnesses like malaria, measles, and Mpox. Without effective engagement and regulation of informal health providers, their activities can contribute to delayed access to biomedical care, spread of misinformation, and non-adherence to infection prevention and control measures. By following medical pluralism/healthcare seeking behaviour framework to guide our argument, this viewpoint investigated the role of traditional healers in Mpox outbreaks and proposes strategies for effective collaboration in future outbreaks. Despite challenges like delayed case detection and misinformation, integrating traditional healers into public health responses offers opportunities to strengthen outbreak management. Strategies include training traditional healers in early symptom identification and referral protocols, engaging them in public health campaigns, and establishing clear referral systems to formal healthcare facilities. Providing infection prevention and control tools and training can minimize transmission risks. By fostering collaboration between traditional and formal healthcare systems, stakeholders can enhance disease prevention and control efforts, ultimately contributing to more resilient healthcare systems in Africa. This approach acknowledges the cultural significance of traditional healers and promotes a unified and culturally sensitive strategy to tackle the ongoing Mpox outbreak and other future public health outbreaks.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41160559/",
    "length": 2221,
    "id": 1032,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41160271",
    "text": "As a type of skin cancer, melanoma is characterized by a high rate of recurrence and metastasis, making it one of the leading causes of mortality associated with skin cancer. With the continuous advancement in technology, current treatment options for melanoma and metastatic melanoma have significantly improved; however, the threat posed by melanoma still warrants attention from the broader population. Artemisinin, derived from the plant Artemisia annua, is recognized as a promising drug molecule that demonstrates effective activity against both malaria and cancer. In this study, artemisinin and its derivatives (such as artemisinic acid, artesunate, and dihydroartemisinin) were shown to possess inhibitory effects on melanoma and ocular melanoma Further investigations revealed that the efficacy of these compounds is primarily linked to their ability to reduce melanin content, inhibit melanogenesis and cellular proliferation, suppress tumor growth in murine models, counteract tumor metastasis and angiogenesis, as well as promote apoptosis. The core mechanisms underlying these effects may be associated with signaling pathways such as PI3K/AKT/mTOR, MALAT918/YAP, along with those related to angiogenesis. In this study, we reviewed the inhibition of melanoma angiogenesis by natural products and its potential mechanisms using literature from PubMed, EMBASE, Web of Science, Ovid, ScienceDirect, Geenmedica, Cochrane Library and China National Knowledge Infrastructure databases. The search timeframe spans from the inception of the database to September 2025. Inclusion criteria encompass original English-language research articles, clinical trials, case reports, and relevant reviews focusing on the mechanisms, efficacy, or clinical applications of artemisinin derivatives in melanoma and ocular melanoma. Exclusion criteria include non-English literature, studies not directly related to melanoma, ocular melanoma, or the antitumour effects of artemisinin, and inaccessible Chinese-language literature. We additionally identified supplementary eligible studies through manual screening of reference lists from relevant literature.This study emphasizes the critical role of artemisinin and its derivatives in combating melanoma and ocular melanoma. The aim is to facilitate further development and utilization of these compounds while providing relevant insights for clinical research endeavors.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41160271/",
    "length": 2414,
    "id": 1033,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41155688",
    "text": "Parasitic infections remain a major global health challenge, particularly in resource-limited settings where they are closely tied to poverty and inadequate sanitation. The increasing emergence of drug resistance and the limited accessibility of current therapies highlight the urgent need for novel, safe, and affordable alternatives.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41155688/",
    "length": 335,
    "id": 1034,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41153059",
    "text": "Malaria remains a significant global health burden, necessitating the development of effective vaccines. Traditional vaccine development is challenged by the complexity of the Plasmodium parasite and lengthy empirical processes. Machine learning (ML) offers a promising avenue to accelerate and enhance vaccine research. This review synthesizes recent advances in the application of ML to malaria vaccine research, focusing on immunological signature identification, antigen discovery, and predictive modeling of vaccine efficacy, to highlight its transformative potential. A targeted literature search was conducted for peer-reviewed articles, reviews, and systematic analyses published between 2017 and 2025. Studies directly addressing ML or AI in malaria vaccine development were included. Data extraction covered ML methodologies, data types, applications, validation strategies, challenges, and limitations. Thematic analysis categorized findings, and a quality assessment ensured methodological rigor. Thematic analysis identified five key areas: (1) antigen discovery and prioritization using supervised and semi-supervised learning; (2) immune signature identification and efficacy prediction via diverse ML algorithms; (3) computational tool and framework development for data integration; (4) broad reviews of AI/ML applications; and (5) epidemiological modeling for policy support. Most studies were conducted in Europe and North America, often with collaborations in Africa. ML is transforming malaria vaccine research by accelerating antigen discovery, enabling precise immune profiling, and predicting vaccine efficacy. Addressing data quality, model interpretability, and validation challenges is crucial for realizing the full potential of ML in developing next-generation malaria vaccines.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41153059/",
    "length": 1807,
    "id": 1035,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41138269",
    "text": "Vernonia amygdalina Del. (VA) is an Asteraceae family plant locally grown in Western Africa and has been cultivated in South China for a short time. VA is regarded as a medicinal plant for the treatment of breast cancer, nasopharyngeal cancer, prostate cancer, lung cancer, and malaria in folk Africa and Southeast Asia. This review aims to make a comprehensive analysis of the botanical characterization and distribution, traditional Chinese medicinal property, phytochemistry, pharmacology, safety, and industrial application of VA. The literatures about VA were searched from SciFinder, PubMed, Web of Science, Elsevier, CNKI, VIP, and patent databases published before April 2025. A total of 348 chemical components from VA, including 128 steroids, 14 sesquiterpene enolactones, 43 flavonoids, 62 terpenoids, 11 alkaloids, and 90 other constituents. The pharmacological activities of VA, such as antitumor, anti-inflammatory, antioxidant, and hypoglycemic effects, were also summarized. As a new exotic traditional Chinese medicine, the TCM property was assigned according to TCM theory. The safety and industrial applications of VA were also summed up. Future research on VA should focus on the pharmacological studies on single ingredients from VA and elucidations of their mechanisms. These efforts will facilitate the development and comprehensive utilization of VA application in food, TCM drug, and other supplements.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41138269/",
    "length": 1427,
    "id": 1036,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41137017",
    "text": "Severe anaemia poses a significant threat to children under five in sub-Saharan Africa, serving as one of the leading causes of hospitalisation and mortality in Malawi. In endemic regions, malaria complicates recovery in children admitted with severe anaemia and increases relapse risk. The World Health Organization (WHO) recommends post-discharge malaria chemoprevention (PDMC) in moderate to high malaria transmission areas to reduce post-discharge mortality and readmissions. Still, it offers limited guidance on its implementation. This formative research study aimed to assess stakeholders’ perceptions of the WHO recommendation on PDMC and considerations for its practical implementation in Malawi. This exploratory qualitative study, conducted in May 2024, employed in-depth and key informant interviews across various stakeholder levels in Malawi. We purposively sampled 31 participants. Interviews were audio-recorded, transcribed verbatim, and thematically analysed using inductive coding in NVivo 14. Stakeholders revealed a continued high burden of malaria and anaemia, with significant gaps in knowledge among Health Surveillance Assistants and follow-up care. Caregivers faced numerous barriers to timely healthcare access, including traditional beliefs, financial constraints, and logistical challenges. Four broad themes emerged from the data: (i) understanding the dual challenge of malaria and anaemia in Malawian children, (ii) barriers to timely healthcare access, (iii) stakeholder perspectives on strategies to improve caregiver adherence to the PDMC regimen, and (iv) PDMC implementation considerations. Findings underscore operational challenges such as logistical constraints, medication supply issues, and targeted health worker training. It emphasises the importance of community engagement, strengthening supply chains, and integrating PDMC into health systems. Effective implementation will require collaboration among government agencies, health organisations, and local communities to foster sustainable practices, improve caregiver support, and ensure equitable access. These insights advance implementation science by illustrating how interventions like PDMC can be adapted and scaled in low-resource, high-burden settings to reduce childhood malaria and anaemia-related morbidity and mortality. The online version contains supplementary material available at 10.1186/s12913-025-13577-w.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41137017/",
    "length": 2421,
    "id": 1037,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41121359",
    "text": "Despite significant progress in global malaria reduction since 2000, driven primarily by supply-side interventions including improvements in bed nets and medication availability, recent years have seen a stagnation in this decline. In certain regions, cases have even increased ([World Health Organization], [World Malaria Report], [2023]). This trend is particularly concerning in high-burden areas such as Suba South Sub-county in Homa Bay County, Kenya, where malaria remains a persistent public health challenge. However, demand-side barriers-such as lack of knowledge of the disease and perceived costs of prevention and treatment among residents-have been relatively overlooked in control efforts. To address this gap, we conducted a cluster-randomized controlled trial (cRCT) to investigate the impact of an educational intervention and financial incentives on malaria-related behaviors (Trials 25:165, 2024). This second-round cRCT aims to build upon the first-round findings, with modifications to the experimental design and educational content to further explore the potential of demand-side interventions and inform future malaria control strategies. This second-round cRCT will re-randomize the original 92 clusters to either conditional cash transfer (CCT), lottery incentive scheme (LIS), or control arms. Each intervention arm will include updated malaria education and financial incentives linked to negative malaria test results, with reward amounts adjusted to reflect local inflation. We will re-assess malaria prevalence using RDT, microscopy, and PCR at 3 and 6 months post-intervention. The primary outcomes are changes in malaria prevalence, LLIN usage, and knowledge/perception of malaria. The analysis will combine data from both the first and second rounds to improve statistical power and provide a more comprehensive assessment of the intervention's impact. This study addresses the limitations of the first-round trial by increasing statistical power and refining the educational component. By evaluating the effectiveness of demand-side interventions, we aim to inform policy and program design for malaria control in high-burden settings. The resulting evidence on the role of demand-side factors will complement traditional supply-side approaches, ultimately refining future malaria control policies and programs. This research, thereby, has the potential to contribute to the development of sustainable, community-based strategies for malaria elimination. Trial registration UMIN000053284. Registered on January 6, 2024.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41121359/",
    "length": 2554,
    "id": 1038,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41108693",
    "text": "Malaria is a global public health concern, where Plasmodium knowlesi contributes to most human malaria cases in Malaysia. The leaves of Vernonia amygdalina (Delile) were found to exhibit significant anti-plasmodial properties and are commonly used in sub-Saharan Africa countries for malaria treatment. Nonetheless, studies are lacking in the effect of this plant against P. knowlesi specifically. This study aimed to investigate the in vitro anti-plasmodial activity of crude extracts from V. amygdalina (Delile) against P. knowlesi. The fresh leaves of V. amygdalina were sequentially extracted in three solvents, dichloromethane (DCM), methanol (MeOH) and water (H",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41108693/",
    "length": 667,
    "id": 1039,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41147465",
    "text": "Artemisinin, an antimalarial sesquiterpene lactone, is biosynthesized in glandular trichomes of Artemisia annua. Although numerous transcription factors have been demonstrated to regulate artemisinin biosynthesis, the molecular mechanisms underlying the high expression of artemisinin-associated biosynthetic enzyme and transcription factor genes in young leaves and their marked decline during leaf maturation remain elusive. Here, we identify a trichome-enriched bHLH transcription factor, AabHLH93, through yeast two-hybrid screening using AaWRKY9 as bait. Yeast one-hybrid and electrophoretic mobility shift assays demonstrate that AabHLH93 directly binds to the AaCYP71AV1 promoter. Furthermore, overexpressing AabHLH93 elevates artemisinin levels, while its RNAi suppresses artemisinin biosynthesis. In young leaves, elevated JA represses AaMYB7 expression and triggers 26S proteasome-mediated degradation of AaJAZ9. AabHLH93 physically interacts with AaWRKY9 through its C-terminal domain to form the AaWRKY9-AabHLH93 complex, enhancing the activation of artemisinin biosynthetic genes. Conversely, age-dependent accumulation of the R2R3-MYB repressor AaMYB7 in mature trichomes disrupts this synergy. In mature leaves, age-dependent JA depletion permits AaMYB7 upregulation and AaJAZ9 accumulation. AaMYB7 directly binds to AabHLH93's C-terminal domain, displacing AaWRKY9 and hindering the formation of the AaWRKY9-AabHLH93 activation complex. These findings elucidate how antagonistic AabHLH93-AaWRKY9 and AabHLH93-AaMYB7 modules, coupled with JA and developmental cues, dynamically control artemisinin biosynthesis.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41147465/",
    "length": 1626,
    "id": 1040,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41076144",
    "text": "Artemisinin and hydroxychloroquine, derived respectively from Artemisia annua L. (Qinghao) and Cinchona calisaya Wedd., have been widely used for centuries to treat malaria and inflammatory disorders. In addition to their antimalarial activity, these compounds exhibit multifunctionality, including anti-inflammatory, antifibrotic, and immunomodulatory effects. Although preliminary studies suggested that the artemisinin-hydroxychloroquine (AH) combination may attenuate idiopathic pulmonary fibrosis (IPF), its underlying mechanisms remain poorly understood. This study aimed to systematically investigate the antifibrotic efficacy of AH and its underlying molecular mechanisms through in vivo and in vitro experiments. IPF was induced in Sprague-Dawley rats via intratracheal bleomycin (BLM) instillation. Beginning on day 7 post-modeling, animals received oral AH or nintedanib. Lung structure and fibrosis severity were assessed by small animal energy spectrum CT imaging, pulmonary function tests, hematoxylin-eosin (HE) and Masson's trichrome staining, and lung tissue hydroxyproline (HYP) quantification. The mechanism of AH was examined by Western blot, immunohistochemistry, and transcriptomic analysis. An in vitro epithelial-mesenchymal transition (EMT) model was established in A549 cells via TGF-β1 induction to validate AH's effects. AH treatment produced multidimensional improvements in BLM-induced pulmonary fibrosis, effectively alleviating pathological tissue damage and respiratory dysfunction, reducing and mitigating pulmonary inflammation and collagen deposition. Mechanistically, our integrated transcriptomic analysis and experimental validation revealed that AH undefined anti-pulmonary fibrosis effects modulate the PI3K/AKT/GSK3β signaling pathway to inhibit epithelial-mesenchymal transition, thereby slowing the progression of idiopathic pulmonary fibrosis. Our study provides the first evidence that the traditional antimalarial combination AH alleviates IPF by specifically modulating the PI3K/AKT/GSK3β signaling axis to inhibit EMT. These findings reveal a novel drug repurposing opportunity and underscore the potential of AH as a promising therapeutic candidate for IPF.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41076144/",
    "length": 2207,
    "id": 1041,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41068871",
    "text": "Chrysosplenetin (CHR), a polymethoxy flavonol co-occurring with artemisinin (ART) in Artemisia annua L., reverses ART resistance in Plasmodium berghei K173 potentially by downregulating intestinal P-glycoprotein (P-gp, encoded by Mdr1a) expression. In the present study, we further elaborated on the mechanism by comparing differences in antimalarial activity and resistance-associated molecular expression profiles between ART alone and combination therapy in blood and tissues of Mdr1a wild-type (WT) and knockout (KO) mice infected with either sensitive or resistant malarial parasites. We evaluated the effects of monotherapy and combination therapy in WT and KO mice infected with sensitive and resistant P. berghei K173 strains. The mRNA expressions of multi-resistance proteins (Mrp1, 2, 4, 5) and breast cancer resistance proteins (Bcrp) were detected. Hemoglobin levels, mRNA expressions of cytokines including tumor necrosis factor-α (IFN-α), interferon-α (IFN-α), and interleukin (IL-1β) in blood and tissues, and redox balance (ROS/GSH levels), as well as gene or protein expression of signaling pathway (PI3K/AKT-mTOR and MAPK) were investigated. In drug-resistant mice, combination therapy maintained the highest survival (100%) and inhibition (30%) rates and the lowest parasitaemia percentage (approximately 20.0%), irrespective of Mdr1a gene status. Furthermore, combination reshaped the spatial and ART resistance-phenotypic disparities in Mrps and Bcrp mRNA expressions (with a fold change ranging from 1.35 to 38.03), ROS/GSH balance (ranging from 1.02-fold to 10.18-fold), hemoglobin levels (ranging from 1.04-fold to 1.20-fold), and cytokine profiles (ranging from 1.14-fold to 37.79-fold) induced by ART alone, which were partially dysregulated by Mdr1a deficiency. Monotherapy and combination exert oppositely regulatory effects on the PI3K/AKT-mTOR pathway in a tissue-, Mdr1a genotype-, and parasite sensitivity/resistance-dependent manner (ranging from 1.52-fold to 84.00-fold). Specifically, CHR reversed ART-induced changes via PI3K/AKT protein inhibition (ranging from 1.20-fold to 63.00-fold), which was contingent on P-gp functionality. Finally, mitogen-activated protein kinase (MAPK) pathway was involved in the antagonistic regulation between ART alone and combination therapy in a P-gp-independent manner (ranging from 1.39-fold to 16.69-fold). The efflux pump function of P-gp is probably not a critical factor in the mechanism by which CHR reverses ART resistance. Instead, CHR acts as a homeostasis stabilizer with dual functions: it disrupts Plasmodium berghei K173 resistance to ART driven by both ABC transporters and the heme-ROS/GSH axis, in which the non-transport function of P-gp on ART is involved.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41068871/",
    "length": 2746,
    "id": 1042,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41028755",
    "text": "Artemisinin, the key antimalarial drug, is synthesized in Artemisia annua glandular secretory trichomes (GSTs), yet their development and artemisinin's precise cellular origins are unclear. Utilizing single-nucleus RNA sequencing and spatial transcriptomics, we construct a high-resolution cellular atlas mapping metabolic dynamics across GST development. We define three developmental states: the initiation phase, transcriptional activation of core metabolic pathways establishes fundamental cellular machinery; the intermediate phase, marked lipid metabolism activation with coordinated fatty acid and wax biosynthesis, accompanied by active photosynthetic activity; the terminal differentiation phase, metabolite specialized through spatial compartmentalization of terpenoid and lipid biosynthetic pathways. Notably, we discover that six specific secretory cells within the 10-cell GSTs constitute the primary site for artemisinin production. We identify hundreds of hub genes potentially contributing to trichome development or artemisinin biosynthesis. Overall, this study systematically elucidates GST development and artemisinin biosynthesis, revealing its spatial production mechanism and providing essential cellular and genetic foundations for metabolic engineering and fundamental trichome biology.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41028755/",
    "length": 1310,
    "id": 1043,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40901832",
    "text": "Artemisia annua L. (A. annua) is a medicinal herb that has been used for the last two millennia to treat various diseases. In African countries, teas prepared from cultivated A. annua have been used to treat malaria for the past three decades. In another work, our team investigated the antiplasmodial efficacy of these traditional preparations using a Liquid-Chromatography-Mass Spectrometry metabolomic approach on various teas prepared from different batches of A. annua collected in Benin and in France and highlighted an original nitrogenous compound. The present work aimed to isolate and characterize its structure. Therefore we describe the fractionation of an alkaloid extract from a Beninese sample of the plant's aerial parts led to the isolation of two previously undescribed alkaloids, annuanine A (1) and annuanine B (2) along with the known fabianine (3), all possessing a very unusual skeleton. Their structures were determined through NMR and MS data analyses. The structure of 1 was further confirmed by single-crystal X-ray structural analysis. Compounds 1 and 2 were evaluated for cell-growth inhibition on Caco-2, VERO, and Thp1 cells, as well as on the Plasmodium falciparum FcB1 strain. Unfortunately, the two compounds 1 and 2 were inactive in these in vitro models. Comparison of LC-HRMS data between annuanine B and A. annua tea allowed us to identify it as the nitrogenous compound highlighted by our previous study. These results enhance the chemical knowledge of this well-known ethnopharmacological herb and highlight a very rare alkaloid skeleton that may have formed from the degradation of artemisinin during plant storage.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40901832/",
    "length": 1656,
    "id": 1044,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40867523",
    "text": "Systemic lupus erythematosus (SLE) is characterized by autoimmune dysregulation, elevated autoantibody production, and persistent inflammation, predisposing patients to atherosclerosis (AS). Atherogenesis is dependent on lipid homeostasis and inflammatory processes, with the formation of lipid-laden, macrophage-derived foam cells (MDFC) essential for atherosclerotic lesion progression. Elevated cholesterol levels within lipid rafts trigger heightened pro-inflammatory responses in macrophages via Toll-like receptor 9 (TLR9). Artesunate (ART), an artemisinin derivative sourced from",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40867523/",
    "length": 586,
    "id": 1045,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40862548",
    "text": "The medicinal herb Artemisia annua L. has traditionally been used to promote human and animal health. One of the most important bioactive metabolites is dihydroartemisinin; however, its impact on intestinal health in broilers has not been sufficiently researched. The aim of this study was to investigate the effects of dihydroartemisinin on growth performance, slaughter performance, serum biochemistry, and intestinal health of AA broiler chickens. Four hundred broilers were randomly divided into five treatment groups, with eight replicates and ten chickens per replicate. The birds were fed a basal diet supplemented with 0, 5, 10, 20, or 40 mg/kg dihydroartemisinin for 42 consecutive days. The data were analyzed by one-way ANOVA and orthogonal polynomial contrast. Results showed that dihydroartemisinin supplementation at 10 mg/kg quadratically increased the average body weight, and supplementation at 10 to 20 mg/k quadratically increased the average daily gain from days 1 to 21. Dihydroartemisinin supplementation at 20 mg/kg quadratically increased the breast muscle rate and relative length of the jejunum (P < 0.05). Dihydroartemisinin supplementation at 5 to 40 mg/kg also quadratically increased the serum total protein, albumin, and IgG concentrations at d 42 (P < 0.05). Dihydroartemisinin supplementation at 5 to 10 mg/kg also quadratically increased the serum globulin concentrations (P < 0.05). Furthermore, dihydroartemisinin supplementation at 10 to 20 mg/kg quadratically improved villus length and the villus length to crypt depth ratio in both the jejunum and ileum, while reducing crypt depth and increasing the thickness of jejunal tunica muscularis (P < 0.05). Dihydroartemisinin supplementation at 10 to 20 mg/kg caused a linear and quadratic increase in the mRNA expression of claudin-1 in the jejunum (P < 0.05), an indicator of positive effects on intestinal tight junctions. Dihydroartemisinin supplementation at 10 to 20 mg/kg also linearly and quadratically increased the mRNA expression of mucin2 (MUC2) and toll-like receptor 4 in the jejunum (P < 0.05). Compared to the control group, dihydroartemisinin supplementation at 5, 20, and 40 mg/kg quadratically increased the mRNA expression of kruppel-like factor 4 (KLF4) in the jejunum (P < 0.05). In conclusion, dihydroartemisinin promoted slaughter performance, serum biochemistry, and intestinal health, including improvements to intestinal morphology and the mucus barrier through the induction of MUC2 and KLF4 genes expression. Artemisia annua L., an annual herb of the Asteraceae family, is renowned for its ability to treat malaria and other various diseases. Its medicinal properties are due to the presence of the sesquiterpene lactone artemisinin. Both artemisinin and its major in vivo metabolite dihydroartemisinin, have been identified as the bioactive components of A. annua extracts and have diverse biological activities. However, previous research has focused predominantly on crude A. annua extracts and artemisinin, with limited exploration of dihydroartemisinin. The aim of this study was to investigate the effects of dihydroartemisinin on growth performance, slaughter performance, serum biochemistry, and intestinal health in broilers. Our results showed that 5 to 20 mg/kg dihydroartemisinin had no adverse effects on growth performance, but improved the breast muscle rate and the relative length of the jejunum and small intestine. Dietary 5 to 40 mg/kg dihydroartemisinin also had a beneficial effect on serum immunoglobulin concentrations, intestinal morphology, and the intestinal mucosal barrier function during the 42-d experiment. Overall, 10 to 20 mg/kg dihydroartemisinin was optimal for poultry production and efficiently improved intestinal health.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40862548/",
    "length": 3774,
    "id": 1046,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40844983",
    "text": "The use of teas made from locally cultivated Artemisia annua to fight malaria in remote areas where access to care is difficult is a matter of debate. This study aimed at document differences in the composition of A. annua teas cultivated in Benin to be sold as antimalarial teas, and in France, and their impact on antiplasmodial activity. A. annua teas were prepared with plants from one location in south France and from ten different plantations in Benin. Artemisinin was quantified in herbal teas with a liquid chromatography system coupled to mass spectrometry and multiple reaction monitoring detection methods. The herbal teas were tested against chloroquine-sensitive 3D7 strain of Plasmodium falciparum using isotopic microtest to determine IC50 values and calculate the concentration of artemisinin corresponding to the IC50 of the teas [ART(tea)_IC50]. Chemical profiles were determined by liquid chromatography coupled to high resolution mass spectrometry and a metabolomic analysis was performed to annotate compounds statistically linked to the antiplasmodial properties of the teas. Artemisinin content varied between 0.3 mg/L for tea with plants from France to 15.7 mg/L for teas made with plants from Benin with differences between locations. Artemisinin content was decreasing after a one-year storage of the plant for 3 localities in Benin with loss of 33%, 48% and 24% (P < 0.05). Artemisinin concentrations and antiplasmodial activity of teas were positively correlated although the comparison of ART(tea)_IC50s to IC50 of pure artemisinin suggested that other compounds present in the tea were involved in the activity, either enhancing or limiting it. Unknown alkaloids in A. annua teas correlated to antiplasmodial activity were also detected. These findings suggest that A. annua teas deserve further studies to identify other metabolites of interest and determine their role in antiplasmodial activity in relation to other molecules, particularly artemisinin.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40844983/",
    "length": 1986,
    "id": 1047,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40812518",
    "text": "Malaria is a significant cause of morbidity and mortality, with 263 million cases and 597,000 deaths estimated in 2023. While effective drug combinations are available to prevent and treat malaria, Plasmodium parasite drug resistance is compromising all current options. This situation means that new drugs that act on novel Plasmodium drug targets are needed. Natural products, including artemisinin, derived from Artemisia annua, and its derivatives, have been an important source of antimalarials. In this study we investigated a panel of 43 compounds from the NatureBank natural product library for in vitro activity against asexual stage P. falciparum parasites. Four compounds isolated from Australian plant and marine samples were identified with novel antiplasmodial activity - tambjamine F (IC",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40812518/",
    "length": 802,
    "id": 1048,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40756346",
    "text": "Modern medical approaches to cancer treatment face significant obstacles, including limited therapeutic options, narrow drug applicability, and rapid development of drug resistance. Consequently, re-evaluating traditional medicinal plants and natural compounds has emerged as a promising strategy to address this public health issue, particularly amid challenges in developing novel pharmaceuticals. Artemisiae Annuae Herba, a versatile natural drug renowned for its established efficacy against malaria and for other diverse pharmacological activities, is gaining recognition for its anti-cancer potential due to the unique structures and biological effects of its constituents. This review comprehensively outlines the major components of Artemisiae Annuae Herba and their reported anti-cancer activities, beginning with an examination of the molecular structures of the foundational components and an exploration of derivatives of these compounds. Furthermore, through an analysis of observed pharmacological effects, we systematically elucidate the multifaceted influence of Artemisiae Annuae Herba on cancerous tissues, including cell cycle arrest, apoptosis induction, non-apoptotic cell death induction, angiogenesis inhibition, tumor microenvironment remodeling, and immune modulation. Finally, we discuss the feasibility of Artemisiae Annuae Herba in cancer therapy as well as the challenges and unresolved issues that require further investigation. We also consider ways that new drug formulations and routes of administration might overcome these translational hurdles. By synthesizing existing research on applications of Artemisiae Annuae Herba to cancer therapy, this review underscores potentially innovative clinical approaches, ultimately paving the way for the discovery of effective anti-cancer drugs with far-reaching benefits.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40756346/",
    "length": 1847,
    "id": 1049,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40901661",
    "text": "The neem tree (",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40901661/",
    "length": 15,
    "id": 1050,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40881566",
    "text": "This report explores the potential role of neem (",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40881566/",
    "length": 49,
    "id": 1051,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40821711",
    "text": "Orexinergic system dysfunction is the fundamental basis for several neurological illnesses like narcolepsy, insomnia, and drug dependency, yet none of the existing medications are subtype receptor specific. This study examines 124 chemicals from neem to determine if they can be utilised as specific orexinergic receptor modulators using advanced computational methods. The methodology includes detailed clustering, pharmacophoric interaction, pharmacokinetic, statistical, and clustering analyses. Molecular property profiling indicated the majority of the compounds exhibit excellent drug-like qualities (MW 350-450 Da, LogP 0-2), while principal component analysis captured 100 % structural variability between two components (92.5 % and 7.5 %, respectively). Molecular docking simulations indicated selective binding to the 6V9S receptor (-11.3 to -4 kcal/mol) over 4S0V (-9.7 to -4 kcal/mol). Lead compounds Neem_PDB_10257 (Tirucallol) (-11.3 kcal/mol) and Neem_PDB_12072821 ([(5 R,7 R,8 R,9 R,10 R,13S,17 R) -17-(2-methoxy-5-oxo-4,4,8,10,13-pentamethyl-3-oxo-5,6,7,9,11,12,16,17-octahydrocyclopenta[",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40821711/",
    "length": 1105,
    "id": 1052,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40532617",
    "text": "Copper Oxide Nanoparticles (CuONPs) contain medicinal properties and are an essential component of the next generation due to their unique properties. CuONPs have a vital role in therapeutics, especially for cancer treatment. This study's main focus was synthesizing the CuONPs and assessing the anti-cancer activity, including the in vitro anti-angiogenesis and cytotoxicity analyses. CuONPs are synthesized using the enzymatic suspension of endophytic fungal strains FCSRL3 and FCPRS11 isolated from the Azadirachta indica grown in a minimal medium at optimum pH 7.2. About 14 different endophytic fungi confined from the neem tree, and the antagonistic and antioxidant properties were evaluated. The efficient FCSRL3 and FCPRS11 were identified as Aspergillus sydowi and Aspergillus versicolor at a molecular level. The synthesized CuONPs from two fungi were confirmed through characterization determination using SEM, EDAX, FT-IR, and XRD analyses. CuONPs revealed maximum antibacterial, antimycotic, and antioxidant activities at minimum concentration, exerting the highest bioactive properties. The anti-angiogenic activity of the CuONPs from two different fungal strains exhibited maximum inhibition of blood vessels in chick embryos, and the assessment was performed using HET-CAM. The outcomes of this research demonstrate the notable role of CuONPs in cancer remedies.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40532617/",
    "length": 1378,
    "id": 1053,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40472397",
    "text": "Neophytadiene (NPT) [C An overview of the function of neophytadiene is given in this article, along with information on its biological application, pharmacological significance, clinical uses, and its safety concerns. A systematic literature review has been conducted using the PRISMA flow technique. Data for the literature survey was gathered online from various journals, computational databases, and search engines like Scopus, PubMed, Science Direct, and Google Scholar until March 2025. The biological efficiency of neophytadiene was affirmed using several in vitro and animal model approaches. The efficacy, therapeutic utility and mechanism of neophytadiene against a range of disorders have all been attempted to be assessed. Neophytadiene plays an important role in the anti-inflammation pathway by TLR4 activation and neuroprotective role by PI3K/Akt signaling pathway. Notably, neophytadiene has shown efficacy against a wide range of organisms, including the malaria parasites. This molecule has multiple uses that can help reduce the severity of certain diseases. It also has the potential to be used as a pharmaceutical ingredient. To maximize its advantages, future research will examine the combined effects of neophytadiene with those of other medications and naturally occurring substances. The acceptance of these phytocompounds as potential medications is clarified by elaborating on their pharmacological safety dosages and various stages of clinical testing. According to the reviewed studies, neophytadiene can be used as a medication candidate for treating diseases. However, these agents are used in therapeutic settings, so more clinical and experimental research is required in the future.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40472397/",
    "length": 1717,
    "id": 1054,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40365176",
    "text": "Azadirachta indica Valency-based indices, including Zagreb and atom bond connectivity indices, were used to characterize boiling point, vaporization, enthalpy, mass, and refractivity. Regression analysis and multi-criteria decision-making methods were employed for predictive modeling and compound ranking. Statistical metrics demonstrated the predictive power of the models. Ranking methods provided a hierarchical ordering of compounds based on therapeutic potential. This study contributes to analogous prediction, optimization, and virtual screening of neem compounds using a cost-effective approach. The findings offer insight into neem compound properties, potentially accelerating drug discovery and development.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40365176/",
    "length": 719,
    "id": 1055,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40242687",
    "text": "Dandruff is a widespread scalp issue that affects many people worldwide, often causing itching and discomfort. It is linked to the presence of certain microorganisms on the scalp, especially A quasi-experimental pre-test post-test control group study was conducted on female students aged 18-24 with minimal, moderate, and severe dandruff levels. The modified Van Abbe's scale was used to assess the dandruff level. A total of 100 female students were selected using non-probability purposive sampling with no history of allergy to neem leaf formulations. The primary objective was to reduce the dandruff score. The dandruff levels were assessed before and after the application of neem leaf paste at baseline, Week 1, and Week 2. Statistical analysis was performed using frequency and percentage for demographic variables, and a t-test was used to compare dandruff levels between the control and experimental groups. A p-value of 0.05 was considered statistically significant. The study included 50 female students in the experimental group and 50 in the control group. Before applying neem leaf paste, 66% (n=33) in the experimental group and 60% (n=30) in the control group had a moderate level of dandruff, while 10% (n=5) and 14% (n=7) in the respective groups had severe dandruff. After the intervention, 44% (n=22) in the experimental group had no dandruff, compared to just 4% (n=2) in the control group. Additionally, 42% (n=21) in the experimental group had a minimal level of dandruff, whereas 28% (14 participants) in the control group had the same. Only 14% (n=7) in the experimental group still had moderate dandruff, compared to 60% (n=30) in the control group. The control group also had 8% (n=4) with severe dandruff, while none remained at this level in the experimental group. After one week, the mean dandruff score significantly dropped to 0.7 in the experimental group, compared to 1.72 in the control group (p-value = 0.00001), indicating a statistically significant reduction in dandruff severity due to neem leaf paste application. The application of neem leaf paste was effective in managing dandruff among the participants. Neem leaf paste, known for its antimicrobial and anti-inflammatory properties, offers a cost-effective and natural alternative for managing dandruff. Its effectiveness in reducing dandruff levels among study participants highlights its potential as a safe and accessible treatment option.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40242687/",
    "length": 2439,
    "id": 1056,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40230792",
    "text": "Tick-borne diseases represent a major threat to both animal and human health globally. This study explores the prevalence of tick infestation and associated piroplasm infections specifically Among 130 cattle examined, 61 were infested with ticks and subsequently screened for piroplasm infections. Molecular analysis identified infections caused by A strong association was found between tick infestation and These findings highlight the potential of",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40230792/",
    "length": 450,
    "id": 1057,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40156810",
    "text": "Neem (Azadirachta indica A. Juss, Meliaceae) is a popular medicinal plant widely sought for its antipyretic, antimalarial, anti-inflammatory, antidiabetic, and antibacterial properties, among others. Cold-pressed oil from neem seed (NOil) and its cyclohexane-methanol extract (NOHM) were evaluated for their effects on α-amylase and α-glucosidase activities in vitro. Also, NOil (75, 150, and 200 mg/kg) and NOHM (200, 400, and 800 mg/kg) were orally administered to normal experimental rats for 30 days, following which the lipid profile, antioxidant status, and serum and tissue indices of hepatic, renal, and cardiac damage were evaluated. NOHM caused significantly higher (p<0.05) α-glucosidase inhibition than NOil. Respectively, the α-amylase and α-glucosidase inhibitory effects of NOil (IC50 = 4.88 ± 0.38 µg/mL and 74.54 ± 25.26 µg/mL) and NOHM (5.00 ± 0.22 µg/mL and 14.17 ± 5.14 µg/mL) were superior to that of acarbose (9.67 ± 0.09 µg/mL and >150 µg/mL). NOHM produced a stronger hypoglycemic effect than NOil. However, no biochemical alteration of toxicological importance was caused by either following subacute administration to animals as the organ-body weight ratio and serum and tissue indicators of organ damage were not adversely altered. The present findings support the safety of NOil and NOHM at the evaluated dosages. The effect of both oil and extract on key carbohydrate-metabolizing enzymes could partly explain the biochemical rationale underlying the popular ethnomedicinal application of the seed in diabetic management.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40156810/",
    "length": 1550,
    "id": 1058,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40154100",
    "text": "Inflammation is a universal response of mammalian tissue to harm, comprising reactions to injuries, pathogens, and foreign particles. Chronic inflammation, often present in allergies and autoimmune disorders, poses significant risks, potentially leading to conditions such as rheumatoid arthritis, Alzheimer's disease, asthma, and inflammatory bowel disease. It can also be a common precursor to cancer. However, Contemporary therapies like NSAIDs and corticosteroids often provide incomplete relief from chronic inflammation and carry significant side effects, underscoring the need for exploring traditional and plant-based medicines for new, effective treatments. As such, there is a growing demand for natural bioactive substances for health maintenance and disease risk reduction. Traditional and plant-based medicines, long-used in managing inflammation and other disorders, hold promise for the discovery of bioactive lead compounds and subsequent drug development for treating inflammatory disorders. This review encompasses an extensive study of the anti-inflammatory potential of selected traditional Indian herbal medicines and the associated pharmacological mechanisms of action. The inflammatory process often entails the activation of transcription factors, induction of various signaling cascades, gene expression, activation of inflammatory enzymes, and release of pro-inflammatory cytokines in inflammatory or immune cells. Detailed exploration of active components in traditional herbal medicines such as the Neem (Azadirachta indica), Salai guggul (Boswellia serrata), Green tea (Camellia sinensis), Saffron (Crocus sativus), Turmeric (Curcuma longa), Mangosteen (Garcinia mangostana), Indian mulberry (Morinda citrifolia), Black cumin (Nigella sativa), Ashwagandha (Withania somnifera), and Ginger (Zingiber officinale) reveals their potential anti-inflammatory properties. The in-depth study of these plants provides insight into their potential applications in managing inflammatory disorders. Further research and development are necessary to substantiate these findings and translate them into clinically effective therapeutics.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40154100/",
    "length": 2152,
    "id": 1059,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41177169",
    "text": "Climate change is likely to exacerbate a range of determinants that drive tuberculosis, the world's leading cause of death from a single infectious agent. However, tuberculosis is often neglected in wider climate health discussions. Commissioned by WHO, we developed an analytical framework outlining potential causal relationships between climate change and tuberculosis. We drew on existing knowledge of tuberculosis determinants, identified determinants likely to be sensitive to the effects of climate change, and conceptualised the mechanistic pathways through which these effects might occur. We collated evidence for these pathways, but found no studies directly linking climate change and tuberculosis, warranting research to build evidence for action. Nevertheless, the available indirect evidence supports the existence of plausible causal links between climate change and tuberculosis. This evidence highlights the need to consider tuberculosis as a climate-sensitive disease, and include tuberculosis in climate risk adaptation and mitigation programmes, and climate-resilient funding and response mechanisms. Only through urgent research and comprehensive action can we address this overlooked intersection and ensure that climate change does not become a barrier to ending the global tuberculosis epidemic.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41177169/",
    "length": 1320,
    "id": 1060,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41174302",
    "text": "Neglected tropical diseases (NTDs) remain a major public health concern in sub-Saharan Africa, where inadequate sanitation and unsafe water contribute to ongoing transmission. This study examined the prevalence and associated risk factors of Schistosoma haematobium among school-aged children in 20 WASH-focused communities across four Local Government Areas in Ogun Central, Nigeria, between March 2021 and March 2023. Urine and stool samples were collected from 1019 pupils and analyzed using standard parasitological techniques, while structured questionnaires captured demographic information, WASH indicators, and attitudes toward anthelmintic treatment. The overall prevalence of S. haematobium was 2%. Significant associations were observed between infection and water sources (p < 0.05), toilet facilities (p = 0.045), and hematuria (p < 0.001). Age was also identified as a significant demographic factor influencing infection. These findings highlight the persistent vulnerability of children in WASH-dependent communities to urinary schistosomiasis and emphasize the need for integrated control strategies that combine improved sanitation, safe water supply, health education, and regular mass drug administration.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41174302/",
    "length": 1225,
    "id": 1061,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41173066",
    "text": "Cutaneous leishmaniasis (CL) is one of the most widespread neglected tropical diseases, transmitted by Phlebotomus sandflies and caused by protozoan parasites of the genus Leishmania. It poses a major global public health concern, particularly in arid and semi-arid regions where ecological and socio-environmental factors favor vector proliferation. In Algeria, CL is endemic across several regions, yet few studies have explored its long-term epidemiological dynamics in the Sahara Desert, where the disease continues to expand. This study aimed to investigate the spatio-temporal evolution and epidemiological characteristics of CL in the Sahara Desert of Algeria, specifically within the Djamaa province which represents an active and historically persistent focus of infection. Using a Bayesian analytical framework, we sought to identify demographic, temporal, and clinical determinants influencing disease occurrence and distribution, thereby providing insights for more effective control and prevention strategies. Data were obtained from the official public health records of the Djamaa province covering a 12-year period (2012-2023). Epidemiological variables included gender, age, number and anatomical site of lesions, and spatio-temporal case distribution across municipalities. Descriptive statistics and chi-square tests were applied to assess differences between groups. To account for uncertainty and the hierarchical structure of the data, a Bayesian Markov chain Monte Carlo Sampler for Multivariate Generalized Linear Mixed Model (MCMCglmm) was employed to evaluate the effects of temporal and clinical predictors on CL incidence. A total of 4436 confirmed CL cases were recorded during the study period, with a mean annual incidence of 369.7 cases. The highest peak was observed in 2012 (23.91%), followed by a gradual decline in subsequent years. Monthly distribution indicated pronounced seasonality, with maximum case occurrence in November (22.9%) and January (13.8%), reflecting the transmission dynamics of Phlebotomus vectors. CL affected both sexes and all age groups, but males (65.2%) and teenagers aged 10-20 years (33.7%) were the most affected, likely due to greater outdoor exposure. Lesions were mainly located on the lower extremities (64.9%), and multiple lesions were observed in 54% of patients. The Bayesian MCMCglmm analysis identified significant temporal effects (annual and monthly) and clinical variables (number and site of lesions) as major determinants shaping CL occurrence, confirming the strong seasonal and ecological dependence of the disease. The findings confirm that CL remains a major endemic health issue in the Sahara Desert of Algeria, particularly in Djamaa province. The disease exhibited clear temporal and demographic patterns linked to vector ecology and host exposure. To our knowledge, this is the first application of a Bayesian spatial model to characterize CL risk in the Northern Sahara of Algeria, this approach provided a robust framework for integrating uncertainty and multiple covariates, offering valuable evidence for risk-based vector control. Future research should combine epidemiological, entomological, molecular, and environmental analyses to develop an integrated strategy for CL management in hot arid lands.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41173066/",
    "length": 3295,
    "id": 1062,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41169530",
    "text": "Accurate and timely differential diagnoses are a challenge for health care, particularly in infrastructure-poor settings. To investigate fevers of unknown origin in Africa, a mobile suitcase laboratory was deployed to DRC and Southwest Nigeria to support the control of the 2018-2020 Ebola virus disease outbreak in North-Kivu and Ituri provinces (DRC) and to provide a point-of-need solution for malaria confirmation during the dry season, respectively. In DRC, the samples were tested for Ebola virus and the differentials The etiological agents circulating in febrile patients in Sub-Saharan Africa and the true incidence of neglected tropical diseases are still underestimated.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41169530/",
    "length": 681,
    "id": 1063,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41168821",
    "text": "Schistosomiasis japonica, caused by Schistosoma japonicum, remains a significant public health concern in the Philippines, where 12.4 million people are at risk due to persistent transmission in endemic regions. The distribution of schistosomiasis is closely linked to the distribution of its snail intermediate host. This study aims to assess the potential of using soil samples to detect the environmental presence of Oncomelania hupensis quadrasi and Schistosoma japonicum. This cross-sectional observational study utilized a soil-based environmental DNA (eDNA) detection system for simultaneous detection of O. h. quadrasi, and S. japonicum mitochondrially encoded cytochrome c oxidase subunit 1 gene in multiplex quantitative real-time PCR and digital PCR platforms. A two-phase sample collection and testing were carried out in December 2023 (Phase 1) and March 2024 (Phase 2) across 30 selected sampling sites in Ekiran village, Leyte, Philippines. Wilcoxon two-sample/Mann-Whitney U test was used to determine whether there was a significant difference in eDNA presence and edaphic factors, while percent agreement was used to assess the concordance among methods. This study reveals that S. japonicum eDNA can be detected in soil samples and confirms the strong applicability of soil-based eDNA for detecting O. h. quadrasi snails and even in sites without visible snail presence. Furthermore, it demonstrates the superiority of soil-eDNA system compared to classical malacological surveys in detecting O. h. quadrasi and S. japonicum microhabitats: in Phase 1, eDNA detected O. h. quadrasi and S. japonicum in 50% (3/6) and 66.67% (4/6) of sites, respectively, while malacological surveys detected them in only 50% and 16.67% (1/6) of sites. In Phase 2, eDNA detected O. h. quadrasi in 20% (6/30) of sites compared to only 10% (3/30) by malacological survey, and S. japonicum was detected only by eDNA in 10% (3/30) of sites. Among the measured soil parameters, only pH showed a statistically significant difference between eDNA-positive and eDNA-negative sites (P = 0.04). Soil-based eDNA sensitively detected O. h. quadrasi and S. japonicum, enabling scalable, non-invasive transmission site identification and outperforming traditional surveys without visible snails. Its ability to detect S. japonicum highlights its value for comprehensive schistosomiasis monitoring.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41168821/",
    "length": 2382,
    "id": 1064,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41166344",
    "text": "Neglected tropical diseases (NTDs), notably leprosy and Buruli ulcer (BU), often lead to visible impairments and disabilities. Consequently, individuals affected by these conditions face stigmatization, discrimination, and mental health disorders. Stigma is particularly prevalent in leprosy, affecting self-esteem, social participation, self-efficacy, and overall quality of life. Various interventions have been developed to mitigate leprosy-related stigma, including individual and group counseling, peer support, economic empowerment initiatives, and establishment of self-help groups. However, rigorous evaluation of the various interventions through randomized controlled trials is lacking, especially within the Nigerian context, and none has included persons affected by BU. To address this gap, effectiveness of combined leprosy and BU self-help groups (SHGs) on stigma reduction was assessed as part of a larger randomized controlled study. A cluster randomized study was conducted in Southern Nigeria from 2021 to 2023. Five local government areas (LGAs) were selected for each of the intervention and control arms. People affected by leprosy or BU were organized into SHGs in the intervention LGAs. Control LGAs were maintained on the existing standard of care, which did not include SHGs. Monthly peer-support meetings were held for 24 months following standardized guidelines after appropriate training of SHG members. The intervention targeted perceived and experienced stigma. Pre- and post-intervention stigma assessments were conducted using the stigma assessment and reduction of impact (SARI) scale in both intervention and control LGAs. A total of 635 persons affected by leprosy or BU were recruited-362 in the intervention group and 273 in the control group. At baseline, respondents in the intervention group had a significantly higher adjusted mean total score on the SARI Stigma Scale compared to the control group, with an adjusted mean difference of 10.75 (95% CI: 8.05-13.46, p < 0.000). However, post-intervention, the adjusted mean SARI Stigma Score significantly decreased in the intervention group compared to the control group, with an adjusted mean difference of 37.72 (95% CI: 36.01-39.43, p < 0.000). Peer-support and psychosocial support through SHGs significantly contributed to stigma reduction among persons affected by Leprosy/BU. SHGs can play a key role in stigma reduction interventions within NTD programs, contributing to the global leprosy target of achieving zero stigma and discrimination. Trial Registration: ISRCTN Registry: ISRCTN 83649248. https://trialsearch.who.int/Trial2.aspx? TrialID = ISRCTN83649248.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41166344/",
    "length": 2660,
    "id": 1065,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41161395",
    "text": "Visceral leishmaniasis (VL) is a neglected tropical disease whose transmission is shaped by environmental and social conditions. In the Brazilian Amazon, extensive landscape change has raised concerns about how deforestation may influence disease dynamics. This study investigated the spatiotemporal association between VL incidence and deforestation from 2001 to 2023 across all health regions of the Brazilian Amazon. Data on confirmed cases of VL and annual deforested areas were aggregated by health region and analyzed via temporal and spatial statistical models. We observed a statistical association between deforestation and VL incidence, with increases in reported cases between 2001 and 2010 and from 2015 onward. Spatial analysis revealed an association between areas of increased deforestation and increased disease incidence, particularly along the arc of deforestation. While this ecological design does not allow causal inference, the findings highlight correlations that can guide future studies on the ecological mechanisms linking land-use change, vectors, and reservoirs. Integrating environmental indicators into surveillance systems may enhance early detection, inform more effective control strategies, and support intersectoral public policies. These approaches, which are consistent with the One Health framework of the World Health Organization, are especially relevant in socially vulnerable Amazonian territories undergoing rapid landscape transformation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41161395/",
    "length": 1482,
    "id": 1066,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41160647",
    "text": "Scabies is one of the most common neglected tropical diseases predominantly affecting children from low socio-economic background. This study was conducted to determine the prevalence and associated factors of scabies among the children living in the orphanages of Bangladesh. This was a cross-sectional study among children in selected orphanages in Dhaka city of Bangladesh from May to December 2023. The participants were screened for scabies according to the diagnosis criteria of the International Alliance for the Control of Scabies guideline (IACS, 2020). A logistic regression model was used to determine the factors associated with scabies among the children. A total of 471 children living in five selected orphanages of Dhaka city of Bangladesh were screened for scabies. Majority of the children living in orphanages were female with a mean age of 11.9 (SD 3.24) years. The overall prevalence of scabies among the children was 31.6% (mild 60.4%, moderate 28.2% and severe 11.4%). Male gender (aOR 2.76, 95% CI 1.14, 7.45, p-value 0.032), increased number of children per room (aOR 1.07, 95% CI 1.03, 1.12, p-value 0.001), and history of pruritus in the close contacts or peers (aOR 1.89, 95% CI 1.04, 3.46, p-value 0.038) were associated with a higher odds of being infected by scabies. One-third of the children living in the orphanages were suffering from scabies. Male children and those who live in crowded facilities and had close contact with infected peers were at higher risk of scabies.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41160647/",
    "length": 1507,
    "id": 1067,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41157188",
    "text": "A shift in the public health goal for onchocerciasis from control to elimination implies that the treatment of onchocerciasis must be extended to communities that are hypoendemic for the disease. However, in such communities, the majority of the population may not manifest the symptoms of onchocerciasis. As a result, they may be reluctant to take part in epidemiological surveys aimed at monitoring parasite transmission, particularly due to the invasive nature of the currently approved diagnostic tests. This reluctance is compounded by the absence of visible, severe manifestations of the disease in these areas. On the other hand, diagnostic methods that utilize samples collected by a non-invasive procedure, such as urine, are generally painless and not risky. In this context, we evaluated the diagnostic performances of OvMANE1 and OvMCBL02 multiepitope antigens using urine samples. The evaluation of total IgG and IgG subclass responses revealed IgG3 as the most effective IgG for the OvMANE1 test (sensitivity = 87.5%, specificity = 100.0%), total IgG for the OvMCBL02 test (sensitivity = 92.5%, specificity = 100.0%), and IgG3 for the OvMANE1_OvMCBL02 cocktail test (sensitivity = 92.5%, specificity = 100.0%). These tests have the potential to meet the criteria of a diagnostic test's target product profile to map onchocerciasis in low-prevalence areas, where a sensitivity of ≥60.0% and specificity of ≥99.8% are recommended. Furthermore, the OvMCBL02 and OvMANE1_OvMCBL02 cocktail tests may have the features of a diagnostic test's target product profile to determine treatment endpoints (recommended sensitivity ≥ 89.0%, specificity ≥ 99.8%) as reported by the Diagnostics Technical Advisory Group for Neglected Tropical Diseases of the World Health Organization. Consequently, further characterization of these multiepitope antigens may enable urine, which can be collected non-invasively, to be used in the OvMANE1 and OvMCBL02 tests for the field evaluation of onchocerciasis.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41157188/",
    "length": 1998,
    "id": 1068,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41150375",
    "text": "Background:Anopheles arabiensisMethods:Anopheles gambiaeResults:Anopheles gambiaeAnophelesAn. gambiaeAn. arabiensisAn. arabiensisAn. arabiensisAnophelesConclusions:Anopheles arabiensisAn. arabiensis",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41150375/",
    "length": 198,
    "id": 1069,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41184832",
    "text": "Paediatric cerebral malaria (CM) kills thousands of children globally each year. Despite multiple interventional trials, no adjunctive therapy has demonstrated a survival benefit. As CM is known to cause multiple organ dysfunction syndrome (MODS), failure to consider the immediate cause of death or cause-specific mortality may partially explain these negative findings, particularly for targeted, organ specific therapies. A retrospective review of data from children with CM enrolled in interventional clinical trials at the Blantyre Malaria Project/Queen Elizabeth Central Hospital between 2018 and 2025 was performed. For participants who died during their hospitalization, the immediate cause of death was categorized into one of seven groups using a priori definitions. A total of 393 children were enrolled in the study period, and 52 (13%) died. Cerebral herniation was the most common immediate cause of death (46%) followed by status epilepticus with apnea (17%). Non-neurologic immediate causes of death occurred in 37% and included: cardiac failure/shock (13%), respiratory failure (12%), renal failure (6%), hepatic failure (4%), and other/indeterminant (2%). Admission coma score was significantly lower in children who died of cerebral herniation or hepatic failure (p = 0.001). Admission oxygen saturation was lowest in patients who died of respiratory failure (p = 0.04) and admission lactate was highest in those that died of cardiac failure/shock, hepatic failure, or other/indeterminant causes (p = 0.01). MODS was prevalent across the cohort regardless of the immediate cause of death. Multiple different immediate causes of death were identified in children with CM. This may dilute the measured impact of brain-focused therapies aimed at reducing central nervous system injury. Modifications in sample size estimates may need to be made in future clinical trials.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41184832/",
    "length": 1887,
    "id": 1070,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41184373",
    "text": "Recent reports from East African countries indicate the emergence and spread of artemisinin partial resistance (ART-R), posing a significant threat to malaria control efforts in the region. The presence of critical Plasmodium falciparum kelch13 (k13) resistance markers, including C469Y, P553L and A675V, have been detected in Kenya, although their clinical significance remains unclear. This highlights an urgent need to closely monitor the prevalence of these mutations. A total of 24,227 dried blood spot (DBS) samples were collected from 82 primary schools across eight counties in Western Kenya during repeated cross-sectional surveys conducted in 2019 (n = 8,111), 2022 (n = 8,086), and 2023 (n = 8,200). Initial screening was performed using a rapid diagnostic test (RDT), and DNA extraction was conducted on RDT-positive samples. These samples were further analyzed using a Pf18s qPCR assay to quantify the Plasmodium falciparum DNA. Amplicons from malaria-positive samples were sequenced using a previously established amplicon deep sequencing pipeline to analyze mutations in Pfk13. A total of 500, 920 and 1058 samples from 2019, 2022, and 2023, respectively were successfully processed, enabling a temporal assessment of the changes in k13 mutations in the region. Four mutations that have previously been associated with artemisinin resistance were found. The A675V mutation was the most prevalent, being found in all 8 counties. It was absent in 2019 and increased from 0.9% in 2022 to 5% in 2023. In contrast, the C469Y mutation declined from 4% in 2022 to 1% in 2023, maintaining a presence in 3 counties. The P553L mutation was only detected in 2022 in 1.2% of the samples across 5 counties. The R561H mutation was not detected in 2019 and 2022 but emerged at a low frequency (0.5%) in 2023 in 2 counties. Siaya and Kisumu were the only counties with all 4 validated mutations between 2022 and 2023. The rising prevalence and geographical presence of the A675V mutation and the new detection of R561H in 2023 highlights the critical need for robust molecular surveillance systems to track the frequency and geographic spread of resistance markers. School-based sampling presents a practical and scalable approach for molecular surveillance, providing early warning signals for potential resistance hotspots. Additionally, the detection of the four WHO validatedPfk13 artemisinin resistance mutations in Western Kenya underscores the urgency of conducting regular Therapeutic Efficacy Studies (TES) to assess the continued efficacy of frontline antimalarial treatments. Integrating molecular surveillance with TES will generate important data to inform national treatment policies and support the long-term effectiveness of malaria control strategies in Kenya.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41184373/",
    "length": 2776,
    "id": 1071,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41184277",
    "text": "The sterile insect technique (SIT) reduces population numbers by releasing sterile males that produce non-viable progeny. Specifically, CRISPR/Cas9-based precision-guided SIT (pgSIT) generates sterile males through genetic crosses of two transgenic lines: a Cas9 strain and a guide RNA (gRNA) strain targeting male sterility and female viability or infertility. However, pgSIT requires separate maintenance of the two lines and sorting to obtain sterile males, creating possible challenges for scaling. To overcome this, we propose using Cas12a nuclease, which is inoperative at lower temperatures but active at higher temperatures. Here, we develop a Cas12a-based pgSIT system involving a single strain containing both the Cas12a nuclease and gRNAs to induce male sterility and female lethality. This strain can be maintained as a mixed stock of both sexes and only activated by increasing temperature, producing sterile males after just one generation. By reducing the challenges that arise with maintaining two separate lines, this system could offer a scalable alternative for vector control in combating vector-borne diseases.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41184277/",
    "length": 1131,
    "id": 1072,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41183110",
    "text": "People living in economically disadvantaged circumstances experience higher risks of infections and death from arboviruses. However, more evidence is needed to better understand the socioeconomic factors influencing dengue mortality. We investigated if people of lower socioeconomic conditions in Brazil are more likely to die following dengue infection. Linking nationwide socioeconomic data from the 100 Million Brazilian Cohort with dengue disease and death records registered in Brazil between 1st January 2007 and 31st December 2018, we used multivariable hierarchical analysis to investigate the socioeconomic determinants of dengue-specific and all-cause mortality within 15 days of dengue symptom onset. Among the 3,018,131 individuals from the 100 Million Brazilian Cohort diagnosed with dengue, 1810 died from dengue (Case Fatality Rate (CFR)=0.06%, 95%CI = 0.06-0.06%) and 3076 (CFR = 0.10%, 95%CI = 0.10-0.11%) died from any cause within 15 days of dengue symptom onset. People residing in the Northeast (OR=2.32; 95%CI = 1.74-3.10) and Midwest (OR=1.68; 95%CI = 1.25-2.27) regions, self-identifying as black race/ethnicity (OR=1.58; 95%CI = 1.31-1.90), having lower level of education (OR=2.35, 95%CI = 1.17-4.73), being retired/receiving pension (OR=2.24; 95%CI = 1.76-2.86), living in a household with rudimentary sewage (OR=1.19; 95%CI = 1.04-1.37) and having >2 inhabitants per room (OR=1.31; 95%CI = 1.11-1.55) had at higher odds of dengue-specific mortality. Similar characteristics were also associated with higher all-cause mortality after dengue infection, but also included residing in North region (OR=1.60; 95%CI = 1.24-2.06) and rural areas (OR=1.12; 95%CI = 1.01-1.24), self-identifying as Asian (OR=1.65; 95%CI = 1.07-2.54) and mixed race/brown (OR=1.20; 95%CI = 1.10-1.31) and living in households with poorer quality building and sanitary conditions. Our findings provide evidence that individuals in Brazil with lower socioeconomic condition experience increased odds of dengue-specific and all-cause mortality within 15 days of dengue symptom onset. These findings underscore the importance of ensuring equitable access to high-quality treatment for severe dengue and suggest that reducing poverty and social inequality, including through improvement of sanitation and housing, may help mitigate dengue-related mortality.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41183110/",
    "length": 2353,
    "id": 1073,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41182618",
    "text": "This chapter outlines the standardization of serodiagnostic protocols for Trypanosoma cruzi, with an emphasis on optimizing enzyme-linked immunosorbent assays (ELISAs). The standardization process aims to enhance the reliability and reproducibility of diagnostic outcomes across diverse epidemiological settings. The methodology includes detailed descriptions of materials, buffers, and reagents, as well as protocols for antigen coating, assay optimization, and troubleshooting. Performance parameters such as sensitivity, specificity, and predictive values are evaluated using robust statistical analyses to ensure diagnostic accuracy. This comprehensive approach facilitates the validation of diagnostic tools critical for effective disease management and public health strategies.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41182618/",
    "length": 784,
    "id": 1074,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41182615",
    "text": "Chagas disease (ChD), caused by Trypanosoma cruzi, remains a significant public health concern in Latin America, despite advances in control measures. While traditionally associated with vector-borne transmission, oral transmission has emerged as the predominant route for acute infections, particularly through contaminated food and beverages. Outbreaks have been reported across Latin America, with Brazil accounting for a significant number of cases, especially in the Amazon region. Consumption of açai pulp and sugarcane juice has been frequently implicated in outbreaks of acute Chagas disease orally transmitted in Brazil. The açai palm-tree fruit is one of the most widely marketed Amazonian fruits, both in Brazil and internationally. Thus, it is essential to incorporate procedures into the production process of açaí juice and pulp that ensure effective hygiene and quality control. Hence, the molecular diagnostic based on qPCR and RT-qPCR assays can be powerful tools for surveillance and control of orally-transmitted ChD. In this chapter, we describe a real-time PCR methodology to the detection and quantification of T. cruzi DNA and RNA, capable of differentiating viable parasites in the food samples.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41182615/",
    "length": 1219,
    "id": 1075,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41182614",
    "text": "Trypanosoma cruzi isolates are classified into six discrete typing units (DTUs), TcI to TcVI, and TcBat. An accurate identification of T. cruzi genotype is critical for understanding its epidemiology, pathogenesis, and response to treatment. Several typing methodologies have been developed with variable levels of complexity, selectivity, and analytical sensitivity. This chapter describes a standardized multiplex real-time polymerase chain reaction (PCR) protocol using TaqMan probes to identify parasite DTUs based on the analysis of T. cruzi SL-IR, 18S rDNA, COII, and 24Sα rDNA targets. This methodology can identify the six main DTUs directly from clinical and biological specimens in a single or two sequential qPCR reactions with high sensitivity and specificity, minimizing contamination risks and reducing the number of steps required. It offers a simplified approach to genotyping that is adaptable for field studies and clinical diagnostics.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41182614/",
    "length": 954,
    "id": 1076,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41182613",
    "text": "Trypanosoma cruzi exhibits remarkable genetic diversity, with six main evolutionary lineages or discrete typing units (DTUs), namely TcI to TcVI. Identifying these DTUs is essential for understanding the role of genetics in the biology, epidemiology, and clinical implications of Chagas disease. However, molecular methods proposed to identify T. cruzi lineages in clinical samples exhibit sensitivity limitations due to the low parasitemia in blood or tissue samples. The high diversity and copy number of the minicircle hypervariable regions (mHVRs) in kinetoplast DNA (kDNA) makes it a viable target for typing. This chapter presents a high-sensitivity and high-resolution typing protocol based on deep sequencing of the mHVRs using Illumina technology. This protocol includes two consecutive PCRs for amplification and indexing, followed by sequencing. The resulting reads are processed by a user-friendly pipeline on Google Colab. This pipeline compares the reads against reference mHVRs in our database in order to determine infecting DTUs in each sample.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41182613/",
    "length": 1061,
    "id": 1077,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41181193",
    "text": "Cytauxzoonosis is a tick borne hemoprotozoal disease of wild and domestic felids. Its epidemiology and clinical importance is less appreciated in India. The aim of this study was to diagnose the disease in domestic cats and identify the associated clinico-haemato-biochemical changes. Three hundred ninety domestic cats, presented at Veterinary Clinical Complex, Bihar Veterinary College and three private clinics in Bihar, India were screened, out of which 90 cats showing symptoms of cytauxzoonosis were included in microscopic and molecular examination. The clinical, haematological and biochemical findings of the positive cats were recorded. The microscopic and molecular prevalence was 26.66% (24/90) and 37.77% (34/90) respectively. Lethargy, fever, anorexia, tachypnea and tachycardia were the most common clinical findings. The significant haematological changes recorded were decreased haemoglobin, haematocrit, TEC and thrombocytopenia. The significant biochemical changes were increased ALT and AST activities, hyperbilirubinemia, hypoproteinaemia with hypoalbuminemia and increased BUN concentration. The infection of",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41181193/",
    "length": 1130,
    "id": 1078,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41180547",
    "text": "BartonellaBartonella henselaeB. henselaeB. henselaeB. henselae",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41180547/",
    "length": 62,
    "id": 1079,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41163016",
    "text": "Mycetoma is a neglected tropical disease with significant physical, social, and economic consequences. In Sudan, biomedical services dominate health policy and funding, often marginalising coexisting traditional healing systems. Understanding the interplay between these parallel systems is essential for improving patient outcomes. To explore the role of traditional healers in mycetoma management in Sudan, examine patients' health-seeking behaviours, and analyse the power dynamics shaping healthcare pathways. We conducted a qualitative study using a critical medical anthropology framework. Data were collected through in-depth interviews, focus group discussions, and environmental observations, including analysis of health promotion materials. Participants included individuals with mycetoma, their families, carers, biomedical practitioners, and traditional healers. Data were thematically analysed to identify patterns in help-seeking, treatment experiences, and inter-system relationships. Traditional healers were found to be the first point of contact for most people with mycetoma. Reliance on healers was influenced not only by economic barriers but also by cultural trust, social support, and systemic inequities. Biomedical practitioners frequently perceived healers as a cause of treatment delays, reflecting entrenched power asymmetries between health systems. Health promotion materials reinforced biomedical dominance and contributed to the marginalisation of traditional healing. Patients' experiences were shaped by both interpersonal and institutional power relations. Traditional healers play a crucial role in sustaining access to care for people with mycetoma in Sudan. Effective collaboration between health systems will require addressing the structural and relational power imbalances that currently hinder integration. Recognising traditional healers as healthcare stakeholders is essential for culturally appropriate and equitable health interventions.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41163016/",
    "length": 1984,
    "id": 1080,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41162699",
    "text": "Each year, snakebite envenoming claims thousands of lives and causes severe injury to victims across sub-Saharan Africa, many of whom depend on antivenoms derived from animal plasma as their sole treatment option",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41162699/",
    "length": 212,
    "id": 1081,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41128977",
    "text": "This review synthesises current evidence on the cardiovascular disease (CVD) burden among young people living with HIV. It explores myocardial and vascular pathology, evaluates the role of advanced imaging, and highlights critical gaps in understanding the mechanisms driving HIV-associated CVD in this population. Emerging data suggest that HIV-associated CVD in youth may be predominantly driven by non-atherosclerotic mechanisms, including direct myocardial injury, fibrosis, and remodelling, rather than traditional coronary atherosclerosis. Imaging studies have revealed subclinical myocardial changes such as increased left ventricular mass and reduced strain. Vascular studies show inconsistent findings. However, longitudinal data and multimodal imaging approaches remain scarce, particularly in high-burden regions like Africa. Young adults with HIV face a significant burden of cardiovascular pathology, often subclinical and poorly understood. The prevailing paradigm focused on atherosclerosis may not fully apply to this group, especially in African settings. There is an urgent need for longitudinal, mechanistic research to inform tailored clinical strategies and policy interventions aimed at reducing long-term cardiovascular morbidity in young people with HIV.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41128977/",
    "length": 1278,
    "id": 1082,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41121359",
    "text": "Despite significant progress in global malaria reduction since 2000, driven primarily by supply-side interventions including improvements in bed nets and medication availability, recent years have seen a stagnation in this decline. In certain regions, cases have even increased ([World Health Organization], [World Malaria Report], [2023]). This trend is particularly concerning in high-burden areas such as Suba South Sub-county in Homa Bay County, Kenya, where malaria remains a persistent public health challenge. However, demand-side barriers-such as lack of knowledge of the disease and perceived costs of prevention and treatment among residents-have been relatively overlooked in control efforts. To address this gap, we conducted a cluster-randomized controlled trial (cRCT) to investigate the impact of an educational intervention and financial incentives on malaria-related behaviors (Trials 25:165, 2024). This second-round cRCT aims to build upon the first-round findings, with modifications to the experimental design and educational content to further explore the potential of demand-side interventions and inform future malaria control strategies. This second-round cRCT will re-randomize the original 92 clusters to either conditional cash transfer (CCT), lottery incentive scheme (LIS), or control arms. Each intervention arm will include updated malaria education and financial incentives linked to negative malaria test results, with reward amounts adjusted to reflect local inflation. We will re-assess malaria prevalence using RDT, microscopy, and PCR at 3 and 6 months post-intervention. The primary outcomes are changes in malaria prevalence, LLIN usage, and knowledge/perception of malaria. The analysis will combine data from both the first and second rounds to improve statistical power and provide a more comprehensive assessment of the intervention's impact. This study addresses the limitations of the first-round trial by increasing statistical power and refining the educational component. By evaluating the effectiveness of demand-side interventions, we aim to inform policy and program design for malaria control in high-burden settings. The resulting evidence on the role of demand-side factors will complement traditional supply-side approaches, ultimately refining future malaria control policies and programs. This research, thereby, has the potential to contribute to the development of sustainable, community-based strategies for malaria elimination. Trial registration UMIN000053284. Registered on January 6, 2024.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41121359/",
    "length": 2554,
    "id": 1083,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41121351",
    "text": "Buruli ulcer (BU) is a skin-related neglected tropical disease (skin NTD) considered to be a disease of the poor. This study explored BU wound management in a traditional therapeutic setting in the Atwima Mponua District of Ghana and described the social interactions observed. Ethnographic data about the practices of a herbalist renowned for his experience in treating BU wounds were obtained using direct observations, photography, and informal conversations. At this therapeutic setting, we observed wounds cleaned and dressed using gloves, gauze, antiseptic solutions, non-sterile scissors, and a petrol and bark preparation supported with prayers. Most clients of the traditional healer indicated that they experienced their BU as a stubborn wound that needed powerful medicine to cure it, and believed the wounds might have supernatural origins. Key reasons clients provided for seeking care at the traditional therapeutic setting included trust in the traditional healer, his practices, respectful care, a friendly and non-stigmatising environment, low-cost and flexible payment options, and people's opinions about the potency of traditional plant medicines. Our findings suggest that the traditional healer enjoyed substantial public legitimacy from his clients due to his perceived interest in helping affected individuals achieve cures using culturally and financially appropriate ways to manage wounds. However, we also observed the use of non-sterile procedures and unregulated preparations, which may be potentially deleterious. The willingness of the traditional healer to collaborate with the formal healthcare system to meet the health needs of people with wounds could form the basis for future collaborative approaches between the two healthcare systems to address inequities regarding clients' access to care.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41121351/",
    "length": 1830,
    "id": 1084,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41112670",
    "text": "By the end of 2020, several vaccines aimed at combating COVID-19 were authorized for widespread immunization. The aim of this study was to assess the factors that were associated with COVID-19 Vaccine refusal in Bamenda I. This was a retrospective study carried out in the subdivision of Bamenda I, from March to June 2024, through interviews and questionnaires in which participants were asked to recall important events during the COVID-19 pandemic. A questionnaire-based survey was conducted to ensure diverse representation in the community study. The questionnaire comprised four sections: socio-demographic characteristics, knowledge about COVID-19 and vaccines, attitudes toward COVID-19, and beliefs about the vaccine. Data were collected during community gatherings, such as focus group discussions and training sessions, and also through Google Forms via the Kobo tool for participants with Android phones. Data were then transferred to SPSS for analysis, using the Pearson chi-square test to examine associations, with Our results show that 42.40% participants had high knowledge about COVID-19, 39.40% had moderate knowledge while 18.20% had low knowledge. Their vaccination status, showed that, just 12.10% were vaccinated, and 87.90% were unvaccinated. Socio-demographic factors like age, gender, and education recorded significant associations with respect to vaccine refusal The study highlights significant knowledge gaps and widespread concerns about vaccine safety among the population in Bamenda I, indicating a need for targeted educational interventions to improve vaccination rates.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41112670/",
    "length": 1605,
    "id": 1085,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41096832",
    "text": "Biomphalaria pfeifferiB. pfeifferiCOI16S16S rRNAB. pfeifferiSchistosoma mansoniF/RCOI16SCOI16SCOI16SB. pfeifferi16SCOIS. mansoniF/RS. mansoni",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41096832/",
    "length": 141,
    "id": 1086,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092928",
    "text": "Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46·8 years (95% UI 46·6-47·0) in 1990 to 63·4 years (63·1-63·7) in 2023. For males, mean age increased from 45·4 years (45·1-45·7) to 61·2 years (60·7-61·6), and for females it increased from 48·5 years (48·1-48·8) to 65·9 years (65·5-66·3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80·9 years (80·9-81·0) and for males 74·8 years (74·8-74·9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38·0 years (37·5-38·4) for females and 35·6 years (35·2-35·9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. We examined global mortality patterns over the past three decades, highlighting-with enhanced estimation methods-the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092928/",
    "length": 7205,
    "id": 1087,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092927",
    "text": "Comprehensive, comparable, and timely estimates of demographic metrics-including life expectancy and age-specific mortality-are essential for evaluating, understanding, and addressing trends in population health. The COVID-19 pandemic highlighted the importance of timely and all-cause mortality estimates for being able to respond to changing trends in health outcomes, showing a strong need for demographic analysis tools that can produce all-cause mortality estimates more rapidly with more readily available all-age vital registration (VR) data. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is an ongoing research effort that quantifies human health by estimating a range of epidemiological quantities of interest across time, age, sex, location, cause, and risk. This study-part of the latest GBD release, GBD 2023-aims to provide new and updated estimates of all-cause mortality and life expectancy for 1950 to 2023 using a novel statistical model that accounts for complex correlation structures in demographic data across age and time. We used 24 025 data sources from VR, sample registration, surveys, censuses, and other sources to estimate all-cause mortality for males, females, and all sexes combined across 25 age groups in 204 countries and territories as well as 660 subnational units in 20 countries and territories, for the years 1950-2023. For the first time, we used complete birth history data for ages 5-14 years, age-specific sibling history data for ages 15-49 years, and age-specific mortality data from Health and Demographic Surveillance Systems. We developed a single statistical model that incorporates both parametric and non-parametric methods, referred to as OneMod, to produce estimates of all-cause mortality for each age-sex-location group. OneMod includes two main steps: a detailed regression analysis with a generalised linear modelling tool that accounts for age-specific covariate effects such as the Socio-demographic Index (SDI) and a population attributable fraction (PAF) for all risk factors combined; and a non-parametric analysis of residuals using a multivariate kernel regression model that smooths across age and time to adaptably follow trends in the data without overfitting. We calibrated asymptotic uncertainty estimates using Pearson residuals to produce 95% uncertainty intervals (UIs) and corresponding 1000 draws. Life expectancy was calculated from age-specific mortality rates with standard demographic methods. For each measure, 95% UIs were calculated with the 25th and 975th ordered values from a 1000-draw posterior distribution. In 2023, 60·1 million (95% UI 59·0-61·1) deaths occurred globally, of which 4·67 million (4·59-4·75) were in children younger than 5 years. Due to considerable population growth and ageing since 1950, the number of annual deaths globally increased by 35·2% (32·2-38·4) over the 1950-2023 study period, during which the global age-standardised all-cause mortality rate declined by 66·6% (65·8-67·3). Trends in age-specific mortality rates between 2011 and 2023 varied by age group and location, with the largest decline in under-5 mortality occurring in east Asia (67·7% decrease); the largest increases in mortality for those aged 5-14 years, 25-29 years, and 30-39 years occurring in high-income North America (11·5%, 31·7%, and 49·9%, respectively); and the largest increases in mortality for those aged 15-19 years and 20-24 years occurring in Eastern Europe (53·9% and 40·1%, respectively). We also identified higher than previously estimated mortality rates in sub-Saharan Africa for all sexes combined aged 5-14 years (87·3% higher in GBD 2023 than GBD 2021 on average across countries and territories over the 1950-2021 period) and for females aged 15-29 years (61·2% higher), as well as lower than previously estimated mortality rates in sub-Saharan Africa for all sexes combined aged 50 years and older (13·2% lower), reflecting advances in our modelling approach. Global life expectancy followed three distinct trends over the study period. First, between 1950 and 2019, there were considerable improvements, from 51·2 (50·6-51·7) years for females and 47·9 (47·4-48·4) years for males in 1950 to 76·3 (76·2-76·4) years for females and 71·4 (71·3-71·5) years for males in 2019. Second, this period was followed by a decrease in life expectancy during the COVID-19 pandemic, to 74·7 (74·6-74·8) years for females and 69·3 (69·2-69·4) years for males in 2021. Finally, the world experienced a period of post-pandemic recovery in 2022 and 2023, wherein life expectancy generally returned to pre-pandemic (2019) levels in 2023 (76·3 [76·0-76·6] years for females and 71·5 [71·2-71·8] years for males). 194 (95·1%) of 204 countries and territories experienced at least partial post-pandemic recovery in age-standardised mortality rates by 2023, with 61·8% (126 of 204) recovering to or falling below pre-pandemic levels. There were several mortality trajectories during and following the pandemic across countries and territories. Long-term mortality trends also varied considerably between age groups and locations, demonstrating the diverse landscape of health outcomes globally. This analysis identified several key differences in mortality trends from previous estimates, including higher rates of adolescent mortality, higher rates of young adult mortality in females, and lower rates of mortality in older age groups in much of sub-Saharan Africa. The findings also highlight stark differences across countries and territories in the timing and scale of changes in all-cause mortality trends during and following the COVID-19 pandemic (2020-23). Our estimates of evolving trends in mortality and life expectancy across locations, ages, sexes, and SDI levels in recent years as well as over the entire 1950-2023 study period provide crucial information for governments, policy makers, and the public to ensure that health-care systems, economies, and societies are prepared to address the world's health needs, particularly in populations with higher rates of mortality than previously known. The estimates from this study provide a robust framework for GBD and a valuable foundation for policy development, implementation, and evaluation around the world. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092927/",
    "length": 6303,
    "id": 1088,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092926",
    "text": "For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associated risk factors. This paper presents GBD 2023 findings on disease and injury burden and risk-attributable health loss, offering a global audit of the state of world health to inform public health priorities. This work captures the evolving landscape of health metrics across age groups, sexes, and locations, while reflecting on the remaining post-COVID-19 challenges to achieving our collective global health ambitions. The GBD 2023 combined analysis estimated years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 375 diseases and injuries, and risk-attributable burden associated with 88 modifiable risk factors. Of the more than 310 000 total data sources used for all GBD 2023 (about 30% of which were new to this estimation round), more than 120 000 sources were used for estimation of disease and injury burden and 59 000 for risk factor estimation, and included vital registration systems, surveys, disease registries, and published scientific literature. Data were analysed using previously established modelling approaches, such as disease modelling meta-regression version 2.1 (DisMod-MR 2.1) and comparative risk assessment methods. Diseases and injuries were categorised into four levels on the basis of the established GBD cause hierarchy, as were risk factors using the GBD risk hierarchy. Estimates stratified by age, sex, location, and year from 1990 to 2023 were focused on disease-specific time trends over the 2010-23 period and presented as counts (to three significant figures) and age-standardised rates per 100 000 person-years (to one decimal place). For each measure, 95% uncertainty intervals [UIs] were calculated with the 2·5th and 97·5th percentile ordered values from a 250-draw distribution. Total numbers of global DALYs grew 6·1% (95% UI 4·0-8·1), from 2·64 billion (2·46-2·86) in 2010 to 2·80 billion (2·57-3·08) in 2023, but age-standardised DALY rates, which account for population growth and ageing, decreased by 12·6% (11·0-14·1), revealing large long-term health improvements. Non-communicable diseases (NCDs) contributed 1·45 billion (1·31-1·61) global DALYs in 2010, increasing to 1·80 billion (1·63-2·03) in 2023, alongside a concurrent 4·1% (1·9-6·3) reduction in age-standardised rates. Based on DALY counts, the leading level 3 NCDs in 2023 were ischaemic heart disease (193 million [176-209] DALYs), stroke (157 million [141-172]), and diabetes (90·2 million [75·2-107]), with the largest increases in age-standardised rates since 2010 occurring for anxiety disorders (62·8% [34·0-107·5]), depressive disorders (26·3% [11·6-42·9]), and diabetes (14·9% [7·5-25·6]). Remarkable health gains were made for communicable, maternal, neonatal, and nutritional (CMNN) diseases, with DALYs falling from 874 million (837-917) in 2010 to 681 million (642-736) in 2023, and a 25·8% (22·6-28·7) reduction in age-standardised DALY rates. During the COVID-19 pandemic, DALYs due to CMNN diseases rose but returned to pre-pandemic levels by 2023. From 2010 to 2023, decreases in age-standardised rates for CMNN diseases were led by rate decreases of 49·1% (32·7-61·0) for diarrhoeal diseases, 42·9% (38·0-48·0) for HIV/AIDS, and 42·2% (23·6-56·6) for tuberculosis. Neonatal disorders and lower respiratory infections remained the leading level 3 CMNN causes globally in 2023, although both showed notable rate decreases from 2010, declining by 16·5% (10·6-22·0) and 24·8% (7·4-36·7), respectively. Injury-related age-standardised DALY rates decreased by 15·6% (10·7-19·8) over the same period. Differences in burden due to NCDs, CMNN diseases, and injuries persisted across age, sex, time, and location. Based on our risk analysis, nearly 50% (1·27 billion [1·18-1·38]) of the roughly 2·80 billion total global DALYs in 2023 were attributable to the 88 risk factors analysed in GBD. Globally, the five level 3 risk factors contributing the highest proportion of risk-attributable DALYs were high systolic blood pressure (SBP), particulate matter pollution, high fasting plasma glucose (FPG), smoking, and low birthweight and short gestation-with high SBP accounting for 8·4% (6·9-10·0) of total DALYs. Of the three overarching level 1 GBD risk factor categories-behavioural, metabolic, and environmental and occupational-risk-attributable DALYs rose between 2010 and 2023 only for metabolic risks, increasing by 30·7% (24·8-37·3); however, age-standardised DALY rates attributable to metabolic risks decreased by 6·7% (2·0-11·0) over the same period. For all but three of the 25 leading level 3 risk factors, age-standardised rates dropped between 2010 and 2023-eg, declining by 54·4% (38·7-65·3) for unsafe sanitation, 50·5% (33·3-63·1) for unsafe water source, and 45·2% (25·6-72·0) for no access to handwashing facility, and by 44·9% (37·3-53·5) for child growth failure. The three leading level 3 risk factors for which age-standardised attributable DALY rates rose were high BMI (10·5% [0·1 to 20·9]), drug use (8·4% [2·6 to 15·3]), and high FPG (6·2% [-2·7 to 15·6]; non-significant). Our findings underscore the complex and dynamic nature of global health challenges. Since 2010, there have been large decreases in burden due to CMNN diseases and many environmental and behavioural risk factors, juxtaposed with sizeable increases in DALYs attributable to metabolic risk factors and NCDs in growing and ageing populations. This long-observed consequence of the global epidemiological transition was only temporarily interrupted by the COVID-19 pandemic. The substantially decreasing CMNN disease burden, despite the 2008 global financial crisis and pandemic-related disruptions, is one of the greatest collective public health successes known. However, these achievements are at risk of being reversed due to major cuts to development assistance for health globally, the effects of which will hit low-income countries with high burden the hardest. Without sustained investment in evidence-based interventions and policies, progress could stall or reverse, leading to widespread human costs and geopolitical instability. Moreover, the rising NCD burden necessitates intensified efforts to mitigate exposure to leading risk factors-eg, air pollution, smoking, and metabolic risks, such as high SBP, BMI, and FPG-including policies that promote food security, healthier diets, physical activity, and equitable and expanded access to potential treatments, such as GLP-1 receptor agonists. Decisive, coordinated action is needed to address long-standing yet growing health challenges, including depressive and anxiety disorders. Yet this can be only part of the solution. Our response to the NCD syndemic-the complex interaction of multiple health risks, social determinants, and systemic challenges-will define the future landscape of global health. To ensure human wellbeing, economic stability, and social equity, global action to sustain and advance health gains must prioritise reducing disparities by addressing socioeconomic and demographic determinants, ensuring equitable health-care access, tackling malnutrition, strengthening health systems, and improving vaccination coverage. We live in times of great opportunity. Gates Foundation and Bloomberg Philanthropies.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092926/",
    "length": 7451,
    "id": 1089,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41179637",
    "text": "There is a paucity of consensus regarding the occurrence of reproductive disorders after the utilization of antimalarial. The objective of this study was to conduct a comparative analysis of an established pharmaceutical agent (Amatem) and a traditional herbal remedy (Mangifera indica), which is commonly utilized for the treatment of malaria, with respect to their impact on male reproductive hormones. The primary research question guiding this study was to ascertain which of these agents would offer protection against adverse effects on reproductive parameters. The present study utilized a sample of twenty-five male rats, with a mean weight of 250-300 grams, to investigate the effects of caffeine on the cardiovascular system. The animals were divided into five groups, namely: The following groups were utilized in the study: control, low-dose M. indica (Mag (LD)), middle-dose M. indica (Mag (MD)), high-dose M. indica (Mag (HD)), and the Amatem group. During the course of the experiment, all animals were provided with access to a standard rodent diet and water ad libitum. Subsequent to the oral toxicity study, Mag (LD), Mag (MD), and Mag (HD) were administered ethanolic extracts of M. indica leaf at 400 mg/kg, 800 mg/kg, and 1600 mg/kg body weight, respectively. Amatem was dissolved in normal saline and administered following the recommended dose of 8 mg/kg body weight. The duration of the administration was one week, and the sacrifice was conducted on the eighth day. Blood was obtained via cardiac puncture and subjected to centrifugation to obtain the serum, which was then utilized for the testosterone, FSH, and LH assays through the enzyme-linked immunoassay (ELISA) method. The testis was excised and subjected to histological analysis using hematoxylin and eosin (H&E) staining. A one-way analysis of variance (ANOVA) was employed to ascertain the statistical significance of the results obtained among the experimental groups. Serum testosterone levels were elevated in the Amatem, Mag (MD), and Mag (HD) groups compared to the control group at a significance level of p < 0.05. A significant increase in testosterone was observed in the Amatem group compared to the Mag (MD) and Mag (HD) groups at a p < 0.05 level of statistical significance. The analysis revealed that the follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels of the Amatem Mag (LD), Mag (MD), and Mag (HD) groups did not exhibit a statistically significant difference when compared with the control group. Distortions ranging from mild to severe were observed in the histology of the testis in both the extract and drug-administered groups. Although Amatem and M. indica have been observed to elevate testosterone levels, it is imperative to exercise caution, as there is a potential for detrimental effects on testicular health in the long term. Gas chromatography mass spectrometry (GC-MS) analysis yielded a total of 43 compounds, with heptadecane exhibiting the highest peak area percentage at 8.00%.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41179637/",
    "length": 3023,
    "id": 1090,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092926",
    "text": "For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associated risk factors. This paper presents GBD 2023 findings on disease and injury burden and risk-attributable health loss, offering a global audit of the state of world health to inform public health priorities. This work captures the evolving landscape of health metrics across age groups, sexes, and locations, while reflecting on the remaining post-COVID-19 challenges to achieving our collective global health ambitions. The GBD 2023 combined analysis estimated years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 375 diseases and injuries, and risk-attributable burden associated with 88 modifiable risk factors. Of the more than 310 000 total data sources used for all GBD 2023 (about 30% of which were new to this estimation round), more than 120 000 sources were used for estimation of disease and injury burden and 59 000 for risk factor estimation, and included vital registration systems, surveys, disease registries, and published scientific literature. Data were analysed using previously established modelling approaches, such as disease modelling meta-regression version 2.1 (DisMod-MR 2.1) and comparative risk assessment methods. Diseases and injuries were categorised into four levels on the basis of the established GBD cause hierarchy, as were risk factors using the GBD risk hierarchy. Estimates stratified by age, sex, location, and year from 1990 to 2023 were focused on disease-specific time trends over the 2010-23 period and presented as counts (to three significant figures) and age-standardised rates per 100 000 person-years (to one decimal place). For each measure, 95% uncertainty intervals [UIs] were calculated with the 2·5th and 97·5th percentile ordered values from a 250-draw distribution. Total numbers of global DALYs grew 6·1% (95% UI 4·0-8·1), from 2·64 billion (2·46-2·86) in 2010 to 2·80 billion (2·57-3·08) in 2023, but age-standardised DALY rates, which account for population growth and ageing, decreased by 12·6% (11·0-14·1), revealing large long-term health improvements. Non-communicable diseases (NCDs) contributed 1·45 billion (1·31-1·61) global DALYs in 2010, increasing to 1·80 billion (1·63-2·03) in 2023, alongside a concurrent 4·1% (1·9-6·3) reduction in age-standardised rates. Based on DALY counts, the leading level 3 NCDs in 2023 were ischaemic heart disease (193 million [176-209] DALYs), stroke (157 million [141-172]), and diabetes (90·2 million [75·2-107]), with the largest increases in age-standardised rates since 2010 occurring for anxiety disorders (62·8% [34·0-107·5]), depressive disorders (26·3% [11·6-42·9]), and diabetes (14·9% [7·5-25·6]). Remarkable health gains were made for communicable, maternal, neonatal, and nutritional (CMNN) diseases, with DALYs falling from 874 million (837-917) in 2010 to 681 million (642-736) in 2023, and a 25·8% (22·6-28·7) reduction in age-standardised DALY rates. During the COVID-19 pandemic, DALYs due to CMNN diseases rose but returned to pre-pandemic levels by 2023. From 2010 to 2023, decreases in age-standardised rates for CMNN diseases were led by rate decreases of 49·1% (32·7-61·0) for diarrhoeal diseases, 42·9% (38·0-48·0) for HIV/AIDS, and 42·2% (23·6-56·6) for tuberculosis. Neonatal disorders and lower respiratory infections remained the leading level 3 CMNN causes globally in 2023, although both showed notable rate decreases from 2010, declining by 16·5% (10·6-22·0) and 24·8% (7·4-36·7), respectively. Injury-related age-standardised DALY rates decreased by 15·6% (10·7-19·8) over the same period. Differences in burden due to NCDs, CMNN diseases, and injuries persisted across age, sex, time, and location. Based on our risk analysis, nearly 50% (1·27 billion [1·18-1·38]) of the roughly 2·80 billion total global DALYs in 2023 were attributable to the 88 risk factors analysed in GBD. Globally, the five level 3 risk factors contributing the highest proportion of risk-attributable DALYs were high systolic blood pressure (SBP), particulate matter pollution, high fasting plasma glucose (FPG), smoking, and low birthweight and short gestation-with high SBP accounting for 8·4% (6·9-10·0) of total DALYs. Of the three overarching level 1 GBD risk factor categories-behavioural, metabolic, and environmental and occupational-risk-attributable DALYs rose between 2010 and 2023 only for metabolic risks, increasing by 30·7% (24·8-37·3); however, age-standardised DALY rates attributable to metabolic risks decreased by 6·7% (2·0-11·0) over the same period. For all but three of the 25 leading level 3 risk factors, age-standardised rates dropped between 2010 and 2023-eg, declining by 54·4% (38·7-65·3) for unsafe sanitation, 50·5% (33·3-63·1) for unsafe water source, and 45·2% (25·6-72·0) for no access to handwashing facility, and by 44·9% (37·3-53·5) for child growth failure. The three leading level 3 risk factors for which age-standardised attributable DALY rates rose were high BMI (10·5% [0·1 to 20·9]), drug use (8·4% [2·6 to 15·3]), and high FPG (6·2% [-2·7 to 15·6]; non-significant). Our findings underscore the complex and dynamic nature of global health challenges. Since 2010, there have been large decreases in burden due to CMNN diseases and many environmental and behavioural risk factors, juxtaposed with sizeable increases in DALYs attributable to metabolic risk factors and NCDs in growing and ageing populations. This long-observed consequence of the global epidemiological transition was only temporarily interrupted by the COVID-19 pandemic. The substantially decreasing CMNN disease burden, despite the 2008 global financial crisis and pandemic-related disruptions, is one of the greatest collective public health successes known. However, these achievements are at risk of being reversed due to major cuts to development assistance for health globally, the effects of which will hit low-income countries with high burden the hardest. Without sustained investment in evidence-based interventions and policies, progress could stall or reverse, leading to widespread human costs and geopolitical instability. Moreover, the rising NCD burden necessitates intensified efforts to mitigate exposure to leading risk factors-eg, air pollution, smoking, and metabolic risks, such as high SBP, BMI, and FPG-including policies that promote food security, healthier diets, physical activity, and equitable and expanded access to potential treatments, such as GLP-1 receptor agonists. Decisive, coordinated action is needed to address long-standing yet growing health challenges, including depressive and anxiety disorders. Yet this can be only part of the solution. Our response to the NCD syndemic-the complex interaction of multiple health risks, social determinants, and systemic challenges-will define the future landscape of global health. To ensure human wellbeing, economic stability, and social equity, global action to sustain and advance health gains must prioritise reducing disparities by addressing socioeconomic and demographic determinants, ensuring equitable health-care access, tackling malnutrition, strengthening health systems, and improving vaccination coverage. We live in times of great opportunity. Gates Foundation and Bloomberg Philanthropies.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092926/",
    "length": 7451,
    "id": 1091,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41028792",
    "text": "Somalia's healthcare system is marked by a reliance on traditional medicine and under-resourced modern facilities. This study explores how communities navigate treatment choices for infectious diseases, such as malaria and cholera, amid competing trust in herbal remedies and biomedical care. We conducted in-depth interviews with 30 participants, including 15 patients, 10 traditional healers, and 5 healthcare providers, alongside 3 focus group discussions (FGDs). Data were analyzed using thematic analysis. Three key themes emerged: (1) the cultural legitimacy of traditional medicine, (2) the perceived efficacy and safety of herbs versus antibiotics, and (3) structural barriers to accessing hospitals. Participants expressed divergent perspectives, with some preferring hospitals for severe infections due to perceived reliability, while others relied on herbal medicine due to financial constraints and cultural alignment. Somalia's healthcare challenges require integrating traditional and modern medicine while addressing structural barriers. Key solutions include training traditional healers, implementing health subsidies, and launching community education on proper medication use. By combining these approaches, Somalia can build a culturally sensitive, accessible healthcare system that improves public health outcomes.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41028792/",
    "length": 1335,
    "id": 1092,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40892845",
    "text": "Cerebral malaria (CM), a life-threatening consequence of Plasmodium falciparum infection, is associated with a high fatality rate and long-term brain impairment in survivors. Despite advances in malaria treatment, effective therapies to mitigate the severe neurological consequences of CM remain limited. Consequently, novel antimalarial drugs with different mechanisms or neuroprotective advantages are urgently required. This study aimed to explore the potential antimalarial and neuroprotective properties of the five-flower remedy (FFR), a traditional herbal formulation, in experimental cerebral malaria (ECM). Male C57BL/6 mice were induced with Plasmodium berghei ANKA to establish the ECM model. The ethanolic extract of FFR (600 mg/kg) was assessed both as a monotherapy and in combination with artesunate and administered for seven consecutive days starting at the onset of CM symptoms. Parasitemia levels, clinical progression, behavioral changes, and histopathological analysis of brain tissue were analyzed. The results revealed that the ethanolic extract of FFR alone improved outcomes in ECM, while its combination with artesunate significantly reduced parasitemia levels (80%), increased survival rates, reduced neurological deficits, and mitigated brain inflammation and behavioral changes. Histological analysis revealed decreased brain hemorrhage, leukocyte infiltration, and neuronal apoptosis. These promising results suggest that combining artesunate with FFR extract could be a valuable additional treatment for CM. This combination not only improves survival rates but also helps protect the brain by reducing inflammation, neurological damage, and behavioral changes. Further studies are needed to elucidate its drug interaction, mechanisms of action and potential clinical applications.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40892845/",
    "length": 1812,
    "id": 1093,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40721828",
    "text": "Although considered safe and widely used, some natural remedies are responsible for health ailments to their users that deserve to be investigated. SAYE PLUS is one of the most widely used traditional recipes as antimalaria for decades and recently against Covid-19 in Burkina Faso and beyond, and is commonly regarded as safe to use. In the present study, sub-chronic toxicity tests were performed orally in Wistar rats at daily doses of 250, 500, and 1000 mg/kg for 90 days, following the guidelines of the Organization for Economic Cooperation and Development (OECD). The results revealed neither symptoms of toxicity nor mortality. Depending on the dose, time frame, or animal sex, compared with the control, SAYE PLUS powder caused a statistically significant reduction in the water and food consumption of the treated rats. Significantly increases in serum creatinine, total protein, hydrogen phosphate ion (PO",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40721828/",
    "length": 916,
    "id": 1094,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40689214",
    "text": "Since time immemorial, Tanzanians, particularly the Luguru tribe, have utilised medicinal herbs (MHs) to manage various ailments. However, few ethnobotanical studies have been conducted to document and quantitatively analyze them. This study documents and quantitatively analyzes MHs used by the Luguru people of Morogoro Rural District to address various ailments. The research was conducted between September 2022 and October 2023. Ethnobotanical data on MH were collected from 100 informants identified through the snowball method, employing semistructured interviews, focus group discussions, and field walks. A one-way analysis of variance (ANOVA) and an independent samples",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40689214/",
    "length": 679,
    "id": 1095,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40665320",
    "text": "Traditional medicine (TM) has been a cornerstone of healthcare across various cultures, especially in Africa, where it has played an integral role in the management of diseases such as malaria. Despite the popularity and historical significance of TM, scientific validation remains a key challenge, hindering its widespread acceptance in modern healthcare systems. This study explores the potential of traditional African medicine, particularly in the context of Nigeria, as a vital resource in the fight against malaria. Drawing on the success of plants like Artemisia annua in the development of modern anti-malarial drugs, the research emphasizes the need for comprehensive investment in TM research. With Nigeria facing the highest malaria burden globally, the research advocates for increased funding, scientific investigations into the efficacy of traditional remedies, and enhanced regulation of herbal medicine. The paper also highlights the growing trust and reliance on herbal remedies in rural areas of Nigeria and the importance of ensuring their safety through pharmacological testing. This study examines these issues through an analysis of existing literature, historical applications, and documented successes of herbal treatments. By integrating traditional medicine into national health systems, Nigeria could unlock new strategies for combating malaria and other infectious diseases, advancing toward sustainable health outcomes.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40665320/",
    "length": 1448,
    "id": 1096,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40658735",
    "text": "Yellow fever (YF), a mosquito-borne viral hemorrhagic fever, is endemic to Uganda and has caused numerous outbreaks in recent years. This study explored local perceptions of YF outbreaks among vulnerable groups in Uganda to inform future public health campaigns. A qualitative study examined community perceptions of YF and its treatment practices. Data were collected in six districts where YF outbreaks were reported in 2010 and 2016. A total of 76 individuals participated, comprising 43 semi-structured interviews, 10 expert interviews, and 4 focus group discussions, including vulnerable groups of older adults ≥ 65 years and pregnant women. Data were analyzed using grounded theory. Participants often recognized jaundice but did not distinguish YF from other causes of jaundice, such as newborn jaundice, severe malaria or hepatitis. Nevertheless, participants still considered YF a deadly disease. It was perceived to be transmitted through multiple pathways, including mosquito bites, airborne transmission, close contact with sick individuals, sexual intercourse, vertical transmission during pregnancy, poor hygiene, and certain foods. Treatments ranged from herbal remedies to visiting health centers. Several YF survivors shared first-hand experience, often relying on traditional medicine due to limited access to health facilities, diagnostic options, and no specific treatment for YF. In remote areas, participants often did not know the cause of the outbreak, as awareness campaigns focused on symptoms, prevention, and mass vaccination. If YF is not seen as a distinct disease entity, implementing diagnostic and preventive measures may be impeded. Moreover, failure to diagnose YF in clinical settings can hamper timely outbreak response. We recommend strengthening health literacy through health education and public participation in vulnerable communities with programs tailored to local needs, given that other infectious diseases are prevalent in the region. Furthermore, we propose that access to diagnostic testing for YF may be enhanced.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40658735/",
    "length": 2063,
    "id": 1097,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40532803",
    "text": "Ilex umbellulata (Wall.) Loes. (Family: Aquifoliaceae), is widely used by different tribes of Southeast Asia as a herbal remedy. The Mizo tribe in India used the stem bark to treat malaria, gland inflammation, inflammation in pregnant women, tonsillitis, dysentery, and for veterinary purposes to treat pig sickness and mange. In Meghalaya, India, the decocted bark is used for digestion. In Thailand, the raw fruit was consumed to relieve stomach aches. The study aims to evaluate the in vitro antimalarial efficacy of I. umbellulata bark by screening against chloroquine-sensitive (Pf3D7) and chloroquine-resistant (PfRKL-9) strains of Plasmodium falciparum. Also, the study aims to identify the phytocompounds present in the most active extract and explore the molecular mechanisms against P. falciparum and malaria through in silico approaches. I. umbellulata bark, collected from Mizoram, India, was taxonomically authenticated by the Botanical Survey of India. Twelve extracts obtained using Soxhlet extraction, decoction, and cold maceration techniques were evaluated for in vitro antimalarial activity against the Pf3D7 and PfRKL-9. Fractions obtained from the active extract were screened for in vitro antimalarial activity. The active extract and fraction were tested for their cytotoxicity using the human embryonic kidney (HEK)-293 cell line and also for their hemolytic activity. The selected extract underwent gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-time of flight (LC-ToF)-MS analyses. Molecular docking, dynamic simulations, and binding free energy calculations were also employed to identify potential targets in P. falciparum. Network pharmacology revealed the malaria pathway genes affected by the phytocompounds of I. umbellulata. The 80 % MeOH extract (IC The study identifies 25 phytocompounds in the active extract of I. umbellulata, elucidating their key molecular mechanisms and validating the plant's traditional use, thereby signifying its efficacy and safety for malaria treatment on a global scale.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40532803/",
    "length": 2058,
    "id": 1098,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40468310",
    "text": "Malaria remains a major cause of morbidity and mortality especially in sub-Saharan Africa. Whereas herbal medicines have long been used for disease remedy in many African communities, there is limited evidence on the extent of use, their safety, and efficacy. This study, sought to identify herbal medicinal plants used by communities in low and high malaria transmission settings in Uganda for managing of malaria. An Ethnobotanical survey was conducted across four geographical regions purposively selected to represent moderate-to-high (Apac, Arua and Tororo districts) and low (Kabale district) malaria transmission settings. One-hundred and two (102) traditional medicine practitioners (TMPs) in Ugandan local communities were included in the study. A checklist was used to collect data and covered the following areas; knowledge on malaria transmission, malaria symptoms, diagnosis, medicinal plants used, preparations, preservation methods and doses. Data was analyzed in MS Excel Ninety-seven plant species distributed across 45 families were mentioned by TMPs in management of malaria in Ugandan communities. Plant family Asteraceae, 15.5% (15/97) had the highest distribution of plants reported by TMPs. Vernonia amygdalina Delile, Aloe vera Burm. F., Artemisia annua L., Vernonia grantii Oliv. and Justicia betonica L. were the most mentioned, with use values of 0.4, 0.3, 0.2, 0.15 and 0.14 respectively. Leaves 64% and root barks 18% were the most harvested plant parts while decoctions (54%) and infusions 26% were the most common methods of preparing herbal products for individuals with malaria. Medicines were stored as dry powders for extended periods although some were prepared as fresh plants. Nearly all medicinal preparations were administered orally with varying dosage (5 ml-500 ml*3times a day) recommendations. Treatment duration varied between 3 and 7 days among practitioners. TMPs mentioned that malaria is transmitted by mosquitoes while others, said poor hygiene, stagnant water and body contact. A diverse number of plant species, use and preparation methods are documented in this study as a way of preserving traditional knowledge in Uganda. Vernonia amygdalina Del., Aloe vera (L) Burm. f, Vernonia grantii Oliv. and Justicia betonica L. were identified as important plant species that can be further studied to validate their safety, antiplasmodial and active bioactive phytochemicals that can provide novel lead compounds for malaria treatment. These plant species can also be conserved through cultivation for sustainable use.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40468310/",
    "length": 2565,
    "id": 1099,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41152272",
    "text": "The Mexican Social Security Institute registered a significant number of suspected Zika virus (ZIKV) cases during the 2016-2018 outbreak. This study aims to describe the distribution of confirmed ZIKV cases, their correlation with rainfall and temperature, and associated factors with infection or hospitalization, considering pregnancy. A retrospective analysis was performed on 13,259 suspected ZIKV cases. Binary logistic regression was performed to determine potentially associated factors with infection or hospitalization. Correlations between positive cases and environmental factors were analyzed using the Pearson correlation and an autoregressive integrated moving average (ARIMA) test. Female sex and age > 30 were associated with ZIKV infection when excluding pregnant women. In pregnant women, a higher infection rate in the first and second trimesters compared to third trimester was observed. In Veracruz, rainfall correlated with positive cases in 2016 (n = 5; r = 0.9977, p < 0.001) and 2017 (n = 12; r = 0.7467, p = 0.005) correlated with rainfall only in 2017 (r = 0.7975, p = 0.002); this was not significant with the ARIMA analysis. Further research is suggested to elucidate factors involved in the transmission, pathogenicity and epidemiology of this and other vector-borne disease viruse.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41152272/",
    "length": 1312,
    "id": 1100,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41147565",
    "text": "Zika virus ( A narrative synthesis of studies reporting ZIKV infection in Nigeria was conducted using targeted searches of PubMed, Scopus, Web of Science, and African Journals Online. Eligible studies included peer-reviewed articles in English reporting serological or molecular data from human or vector populations. Evidence from eleven studies across ten states shows seroprevalence of ZIKV ranging from 1.4% to over 50%, particularly among pregnant women and febrile patients. Diagnostic gaps, including symptom overlap and serological cross-reactivity, contribute to underreporting. Co-endemicity with other arboviruses and limited surveillance further obscure ZIKV's public health impact. ZIKV likely circulates silently in Nigeria, sustained by ecological and infrastructural factors. Fragmented vector control, inadequate diagnostics, and lack of integrated arboviral surveillance hinder timely recognition. Lessons from other Aedes-borne viruses should inform a more unified and proactive national strategy. Предпосылки. Передаваемый комарами вирус Зика (",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41147565/",
    "length": 1064,
    "id": 1101,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41133059",
    "text": "Tropical infections often present with characteristic dermatologic manifestations, which can serve as early indicators for diagnosis. However, these signs are frequently misidentified or underreported in emerging and outbreak settings. This narrative review critically evaluates the diagnostic utility of dermatologic findings across over 25 tropical infections, spanning viral (e.g., dengue, Zika, chikungunya, Mayaro virus, O'nyong-nyong virus), bacterial (e.g.,",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41133059/",
    "length": 464,
    "id": 1102,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41121690",
    "text": "Mosquito-borne viruses, including dengue virus (DENV), chikungunya virus (CHIKV), and Zika virus (ZIKV), pose major threats to public health in tropical and subtropical regions worldwide. Neonates are particularly vulnerable, and the associated disease burden has drawn increasing attention. Routes of neonatal infection include vertical mother-to-child transmission (transplacental and peripartum) and postnatal mosquito bites. Clinical manifestations are often nonspecific; a proportion of cases may progress to central nervous system infection, hemorrhagic disease, or long-term neurodevelopmental impairment, with serious consequences for survival and quality of life. Although China has issued prevention and control guidelines for adults and pregnant women, systematic clinical guidance tailored to neonates remains lacking. In response, the Perinatal Group of the Pediatric Branch of the Chinese Medical Doctor Association convened a multidisciplinary panel to develop this expert consensus, integrating the latest international evidence with China's practical prevention and control experience. The consensus addresses epidemiology; the effects of maternal infection on fetuses and neonates; clinical manifestations; diagnosis and differential diagnosis; early warning indicators of severe disease; therapeutic strategies and supportive care; and prevention and maternal-infant management. It aims to provide evidence-based, standardized, and practical guidance for frontline clinicians managing neonatal mosquito-borne viral infections. 登革病毒（dengue virus）、基孔肯雅病毒（chikungunya virus）和寨卡病毒（Zika virus, ZIKV）等蚊媒病毒感染已成为全球热带及亚热带地区人群健康的重大威胁，特别是在新生儿中，蚊媒病毒感染的易感性和疾病负担引起了广泛关注。新生儿蚊媒病毒感染的传播途径包括母婴垂直传播（胎盘传播、分娩期暴露等）和蚊虫叮咬。其临床表现常不具特异性，部分病例可进展为中枢神经系统感染、出血性疾病或引发远期神经发育障碍，严重影响患儿的生命安全与生活质量。我国已发布成人和孕产妇相关防控方案，但尚缺乏新生儿蚊媒病毒感染的系统性临床诊疗与防控指导。中国医师协会儿科医师分会围产医学学组牵头组织专家，结合国内外最新循证医学证据和我国实际防控经验，针对新生儿蚊媒病毒感染的流行病学、孕母感染对胎儿和新生儿的影响、新生儿感染的临床表现、诊断与鉴别诊断、重症病例预警、治疗策略与支持治疗、防控与母婴管理等方面制定了该共识，旨在为临床一线提供科学、规范的诊疗指导。.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41121690/",
    "length": 1978,
    "id": 1103,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41120442",
    "text": "In 2015, the Orthoflavivirus zikaense (ZIKV) outbreak in Brazil caught the attention of the global community as a public health emergency. ZIKV, an Orthoflavivirus transmitted by Aedes mosquitoes, initially identified in 1947, has evolved from a historically inconspicuous pathogen to a significant public health concern. Beyond mild symptoms resembling Dengue fever, severe conditions such as microcephaly and Guillain-Barré syndrome have been linked to the infection caused by ZIKV. In regions already burdened by arboviruses such as Orthoflavivirus denguei (DENV), the co-circulation of these pathogens has created challenges for diagnosis and clinical management. Studies highlighted the simultaneous circulation of DENV and ZIKV, often following one another in time and space. The Asian genotype of ZIKV have shown evidence of codon usage adaptations enhancing replication efficiency in human hosts, contributing to the virus's rapid global spread. Furthermore, the arbovirus outbreaks in Brazil were characterized by a wave-like pattern, where viral transmission appears to follow a coordinated sequence. Despite the critical public health implications of ZIKV, studies focusing on the detailed epitope mapping of ZIKV proteins remain scarce. This study aims to investigate the epitope mapping patterns of ZIKV polyprotein in IgG ZIKV-positive individuals, correlating with newborns' maternal immune interaction by SPOT-synthesis. Notably, protein C, E, NS1, and NS5 regions exhibited high membrane reactivity and epitope recognition patterns. Additionally, C, E, NS1, and NS5 proteins displayed immunogenic potential with differential responses in newborns. The study enhances the understanding of ZIKV humoral immune response and suggests further investigations for epitope validation and potential vaccine development.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41120442/",
    "length": 1827,
    "id": 1104,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41097095",
    "text": "Viral metagenomic next-generation sequencing (vmNGS) has transformed our capacity for the untargeted detection and characterisation of (re)emerging zoonotic viruses, surpassing the limitations of traditional targeted diagnostics. In this review, we critically evaluate the current landscape of vmNGS, highlighting its integration within the One Health paradigm and its application to the surveillance and discovery of (re)emerging viruses at the human-animal-environment interface. We provide a detailed overview of vmNGS workflows including sample selection, nucleic acid extraction, host depletion, virus enrichment, sequencing platforms, and bioinformatic pipelines, all tailored to maximise sensitivity and specificity for diverse sample types. Through selected case studies, including SARS-CoV-2, mpox, Zika virus, and a novel henipavirus, we illustrate the impact of vmNGS in outbreak detection, genomic surveillance, molecular epidemiology, and the development of diagnostics and vaccines. The review further examines the relative strengths and limitations of vmNGS in both passive and active surveillance, addressing barriers such as cost, infrastructure requirements, and the need for interdisciplinary collaboration. By integrating molecular, ecological, and public health perspectives, vmNGS stands as a central tool for early warning, comprehensive monitoring, and informed intervention against (re)emerging viral threats, underscoring its critical role in global pandemic preparedness and zoonotic disease control.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41097095/",
    "length": 1527,
    "id": 1105,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41084061",
    "text": "Bangladesh is a nation highly vulnerable to the detrimental effects of climate change on infectious diseases. Research on general population's awareness and knowledge of this issue remains limited, making the One Health approach challenging due to factors such as low socioeconomic status, limited public health infrastructure, and gaps in climate-health literacy. To prevent and control climate-sensitive infectious diseases in Bangladesh, this study aimed to (i) assess knowledge and beliefs concerning climate change and infectious diseases and (ii) recommend One Health policies to reduce the burden of diseases. A cross-sectional descriptive study was conducted among 1,905 participants in the northern region of Bangladesh from February to April 2024. Survey data were collected using a pretested and structured questionnaire. To assess climate change knowledge, respondents were asked to accurately identify infectious diseases from a list of climate-sensitive infectious diseases, risk factors that increase the likelihood of infectious diseases, methods of transmission, signs and symptoms, and management and treatment. To assess identification of infectious diseases, respondents were asked about malaria, dengue, zika, chikungunya, tuberculosis, Lyme disease, influenza, SARS (severe acute respiratory syndrome), and HIV (human immunodeficiency virus). Participants' knowledge was classified as high (scores above 75%), moderate (50% to 75%), and low (below 50%), and beliefs were categorized as sound (scores of 80% or more) and poor (scores of less than 80%). Descriptive statistics and ordinal logistic regression were used to analyze the data. Of 1,905 valid responses, 70.9% of the respondents knew that climate change and infectious disease outbreaks are related. Only about a third of the respondents (27.9%) reported receiving information about climate change updates and methods to mitigate infectious disease risks. More than half of study respondents had good knowledge about climate change (57.7%). However, fewer were knowledgeable about emerging infectious diseases (21.2%) and about the effects of climate change on infectious diseases (30.3%). Place of residence (OR: 1.3, 95% CI: 1.1-1.6), gender (OR: 1.5, 95% CI: 1.2-1.8), income (OR: 1.5, 95% CI: 0.9-1.8), and education (OR: 11.4, 95% CI: 8.1-16.4) were significantly associated with respondents' level of knowledge (P < 0.05) about climate change and how it affects infectious diseases. This study offers an overview of public perception in Bangladesh to help prevent and control climate-sensitive infectious diseases. The results can be incorporated into the One Health approach to develop integrated and dynamic that promote education, strengthen surveillance, and address socioeconomic disparities.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41084061/",
    "length": 2785,
    "id": 1106,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41073070",
    "text": "The global expansion of mosquito-borne diseases such as dengue, chikungunya, Zika, and West Nile virus is a major public health concern, intensified by climate change and environmental alterations.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41073070/",
    "length": 197,
    "id": 1107,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41061233",
    "text": "Targeted indoor residual spraying focuses insecticide applications on common resting surfaces of We conducted a two-group, parallel, unblinded, cluster-randomized trial in Merida, Mexico, to quantify the efficacy of targeted indoor residual spraying for preventing aedes-borne diseases (chikungunya, dengue, or Zika). Children 2 to 15 years of age were enrolled from households in 50 clusters of five-by-five city blocks. Households in 25 clusters received an annual application of targeted indoor residual spraying (intervention) before each season of aedes-borne disease (July through December). All clusters received routine Ministry of Health vector control. The primary end point was laboratory-confirmed, symptomatic aedes-borne disease. Community effects were assessed with the use of geolocated national surveillance data. A total of 4461 children were monitored for up to three seasons (2021, 2022, and 2023). The indoor density of Despite lower entomologic indexes with targeted indoor residual spraying than with routine vector control, the cumulative incidence of aedes-borne diseases was not significantly lower with targeted indoor residual spraying. (Funded by the National Institutes of Health and the Innovative Vector Control Consortium; ClinicalTrials.gov number, NCT04343521.).",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41061233/",
    "length": 1297,
    "id": 1108,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41044315",
    "text": "Dengue and Chikungunya are caused by the same vectors, Aedes aegypti and Aedes albopictus. Both mosquitoes are endemic in Pakistan, and various parts of the country experienced outbreaks of Dengue virus over the past decades. However, Chikungunya infection remained either unidentified or misdiagnosed before its outbreak in Karachi during 2018-19. This study aimed to determine the seroprevalence of Dengue virus (DENV) (a flavivirus) and Chikungunya virus (CHIKV) (an alphavirus) in suspected samples of the Pakistani population collected during 2014-2015. Immunological and molecular methods were used for the diagnosis of DENV and CHIKV. The serum samples of both healthy and febrile participants were tested for prior exposure to CHIKV and DENV using indirect IgG ELISA. The current infection of DENV was diagnosed by the presence of NS1 antigen (ELISA) and IgM (ELISA), whereas the active infection of CHIKV was identified by the presence of viral RNA (RT-PCR) and IgM. The seroprevalence of DENV and CHIKV as a single infection was 70% and 17%, respectively. However, 6% of febrile patients tested positive for both DENV and CHIKV, representing co-existence and co-infection of DENV and CHIKV during 2014-2015 in Pakistan. The presence of DENV and CHIKV co-infection evidently proved that CHIKV also caused infection during 2014-15 before its known outbreak of 2018-19. This study addressed gap analysis and highlighted the need for a comprehensive diagnostic approach and facilities in Pakistan for other arboviruses like Zika virus the virus shares the same vectors. In conclusion, developing countries like Pakistan must gain competence in response and preparedness to face future probable co-infection outbreaks of DENV, CHIKV, and other arboviruses in Pakistan. Further surveillance and epidemiological studies are required to determine the true burden of these infections and the spectrum of diseases associated with these exposures.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41044315/",
    "length": 1946,
    "id": 1109,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41173489",
    "text": "Mycetoma is a chronic, granulomatous infection typically affecting the lower limbs. We report a rare case of eumycetoma involving the upper back in a young man with a 10-year history of painless swelling that became symptomatic only recently. After initially diagnosed as an abscess, intraoperative discovery of black granules prompted further investigation. Histopathology confirmed",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41173489/",
    "length": 383,
    "id": 1110,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092928",
    "text": "Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46·8 years (95% UI 46·6-47·0) in 1990 to 63·4 years (63·1-63·7) in 2023. For males, mean age increased from 45·4 years (45·1-45·7) to 61·2 years (60·7-61·6), and for females it increased from 48·5 years (48·1-48·8) to 65·9 years (65·5-66·3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80·9 years (80·9-81·0) and for males 74·8 years (74·8-74·9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38·0 years (37·5-38·4) for females and 35·6 years (35·2-35·9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. We examined global mortality patterns over the past three decades, highlighting-with enhanced estimation methods-the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092928/",
    "length": 7205,
    "id": 1111,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40908438",
    "text": "Intravenous dosing of L- and D-eflornithine in a racemic mixture is a currently recommended late-stage gambiense human African trypanosomiasis (g-HAT) treatment, either as 14-day monotherapy or in combination with oral nifurtimox for seven days. However, an oral eflornithine treatment against late-stage g-HAT would be preferable. Pharmacokinetics of eflornithine are enantioselective with different oral absorption of the enantiomers. L-eflornithine has a greater in vitro antitrypanosomal potency than D-eflornithine. This study aimed to integrate knowledge about in vitro potency and literature data from the only clinical study with enantiospecific pharmacokinetic oral data to predict L-eflornithine concentrations in plasma and cerebrospinal fluid to estimate the probability of target attainment. L- and D-eflornithine concentrations in cerebrospinal fluid from the clinical study with enantiospecific data were described with a compartment model that was validated using external data with total eflornithine concentrations. Simulations were performed with oral L-eflornithine doses ranging between 125 to 1000 mg/kg/day administered twice to twelve times daily. The probability of target attainment analysis showed that oral L-eflornithine doses of 750 mg/kg/day administered four or twelve times daily (i.e., drinking a solution every 2nd hour) as monotherapy would be needed to acquire efficacious exposures. In combination with nifurtimox, L-eflornithine dosed at 375 mg/kg/day four or twelve times daily would give exposures over the threshold concentration in cerebrospinal fluid. The presented simulation framework may serve as a starting point to find a suitable oral dose regimen to assess the clinical potential for an oral L-eflornithine-based combination treatments against late-stage g-HAT.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40908438/",
    "length": 1812,
    "id": 1112,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40876562",
    "text": "Schistosomiasis currently relies on the long-term use of a single drug, praziquantel (PZQ). Artesunic acid (AcART) has emerged as a promising alternative, as it is efficient against juvenile worms. However, like PZQ, it has low aqueous solubility. Self-Emulsifying Drug Delivery Systems (SEDDS) and Lyotropic Liquid Crystal Nanoparticles (NPs-LLC) present advantages for oral administration, including enhanced solubility and protection of the drug from first-pass metabolism. This study compared the in vitro and in vivo efficacy of AcART incorporated into SEDDS and NPs-LLC against juvenile and adult worms of two different Schistosoma mansoni strains. In vitro phenotypic assays with AcART incorporated into both SEDDS and NPs-LLC demonstrated a progressive decrease in parasite viability, significant tegumental changes, inhibition of oviposition, and 100 % mortality at a concentration 6.25 µg/mL. In vivo treatments performed at 21- and 60-days post-infection with AcART formulated in SEDDS and NPs-LLC led to a significant reduction in worms' burden and eggs eliminated in feces compared to the control group. The SEDDS nanosystems (drug-free) influenced the in vitro results, whereas the NPs-LLC (drug- free) did not influence any of the assays. Our findings demonstrate that these nanosystems enhance the efficacy of AcART against both BH and SE strains of S. mansoni, even at substantially lower concentrations than conventional formulations. This represents an innovative approach for the treatment of schistosomiasis, with potential applications to other neglected diseases.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40876562/",
    "length": 1586,
    "id": 1113,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40861388",
    "text": "Melioidosis is a significant yet neglected cause of sepsis in tropical regions, particularly in southeast Asia, with poor clinical outcomes. It is a growing threat with an expanding global footprint. The causative organism, A 60-year-old farmer presented in septic shock to a hospital in Laos, and Mutations in Melioidosis is a bacterial infection that is common in tropical and sub-tropical countries. It usually causes pneumonia, but can spread through the bloodstream to various organs. Infections often have very poor outcomes, partly because few antibiotics can be used to treat these infections. In this case, treatment failed likely because a mutation in the genome of the bacteria caused resistance to antibiotics. Compared to other bacteria, little is known about drug resistance in melioidosis, so studying resistant strains by whole genome sequencing provides important information. Deletion of a large part of the genome, including a regulator that controls the number of efflux pumps that move antibiotics out of the cell, was the cause of resistance in this case.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40861388/",
    "length": 1077,
    "id": 1114,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40754226",
    "text": "Scabies is a highly contagious parasitic dermatosis caused by the mite Sarcoptes scabiei var. hominis, affecting over 200 million individuals globally and imposing a significant health burden. Traditionally linked to low socioeconomic status and overcrowding, its prevalence is rising globally, especially among urban and institutional settings. Beyond its cutaneous manifestations, secondary bacterial complications contribute to significant morbidity, particularly in endemic areas. Advances in non-invasive imaging techniques including ultraviolet dermoscopy, reflectance confocal microscopy and line-field confocal optical coherence tomography, have improved diagnostic accuracy, while molecular assays show promise for enhanced sensitivity. Conventional diagnostics remain dependent on clinical evaluation and microscopic identification of mites, eggs, or scybala. First-line treatment involves topical and systemic therapies, and topical permethrin, benzyl benzoate, and oral ivermectin are commonly recommended in international guidelines. Emerging drug resistance has prompted research toward optimizing drug regimens and novel therapies, including moxidectin and combination treatments. Outbreaks of scabies in institutional settings, as well as endemic disease in those with limited resources, demonstrate the importance of coordinated public health efforts in the form of early case detection, simultaneous treatment of contacts and other environmental control measures. In this review, we present an updated and thorough description of scabies, covering the relevant epidemiology, clinical picture and the new diagnostic methods. In summary, by combining new updates and essential unanswered questions, this review describes the current dilemma and covers the latest data in the field.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40754226/",
    "length": 1797,
    "id": 1115,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40737275",
    "text": "Diarrheal pathogens, such as Cryptosporidium, impose a heavy burden of disease in resource-limited regions. Cryptosporidiosis often causes chronic infection in immunocompromised people and gastrointestinal injury in malnourished children, leading to wasting, stunting, and cognitive impairment. Current treatment for cryptosporidiosis fails in these vulnerable populations, highlighting the need for new medicines. Here we describe the anti-Cryptosporidium efficacy, pharmacokinetics, and safety of a bumped kinase inhibitor BKI-1708. BKI-1708 inhibits the essential molecular target, calcium-dependent protein kinase 1 (CDPK1), which is highly expressed in the major proliferative stages of the parasite life cycle. Efficacy was demonstrated in the Cryptosporidium parvum IFNγ-KO mouse infection and calf diarrhea models. Dose response in the mouse model demonstrated oral doses as low as 15 mg/kg administered daily for 3 days completely suppressed oocyst shedding. Metabolite profiling in pre-clinical species and human hepatocytes identified an active metabolite, M2, which retains sub-micromolar activity against C. parvum. Pharmacokinetic analysis of BKI-1708 and M2 in mice demonstrates good systemic exposure, important for treating biliary and upper respiratory infections in some cases of cryptosporidiosis. In mice, M2 reaches 7-fold and >3-fold higher levels over BKI-1708 in plasma and the gastrointestinal tract, respectively. Oral administration of M2 completely suppressed oocyst shedding in the mouse model at doses as low as 8 mg/kg for 3 days. Wide safety margins are demonstrated in mice, rats, and dogs. BKI-1708 has characteristics of a safe and effective drug for treating Cryptosporidium infections in animal models and shows promise for use in humans. Moreover, BKI-1708 and M2 formed in vivo, offer an attractive prospect of a dually active preclinical candidate for the treatment of cryptosporidiosis.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40737275/",
    "length": 1928,
    "id": 1116,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40610818",
    "text": "High-throughput screening (HTS) is one of the critical strategies that can accelerate the process of drug discovery by exploring small drug-like molecule libraries. HTS noticeably contributes to the identification of potential hits using various automation tools and biological assays. Leishmaniasis, a neglected tropical disease, is one of the most deadly protozoan parasitic infections causing significant global burden in certain poverty-stricken countries. Given the paucity of effective chemotherapeutic agents available for the treatment of this life-threatening infection, the discovery of novel leishmanicidal scaffolds through innovative strategies is pivotal to combating this parasitic disease. In the present study, we have employed the HTS strategy to scrutinize 10,000 drug-like molecules from the in-house ChemDiv library to identify potent hits against Leishmania donovani. Noticeably, 99 molecules showed > 80% inhibitory effect against the L. donovani parasites at 50 µM concentration, and among them, four molecules displayed a 50% inhibitory concentration (IC",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40610818/",
    "length": 1079,
    "id": 1117,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40476513",
    "text": "Rabies, a fatal zoonotic infectious diseases caused by rabies virus (RABV) infection, still has a high incidence with no effective cure in many Asian countries, even though numerous commercial vaccines have been administered for decades. One of the most important reasons is the neglected that main reservoirs of RABV, such as many stray and wild animals, are inaccessible for effective vaccination, especially in natural wilderness environments. In this study, we developed a highly effective gut-targeted oral rabies vaccine (ORV), which containing the immunoadjuvant LTB by targeted administration of microparticles with local release in the intestine. Based on the virus like particles (RVLPs) were assembled by RABV glycoprotein (RVGP) and matrix protein (RVMP), the enterically released microparticles ELPGA MPs loaded with RVLPs and djuvant LTB (RVLPs + LTB/EPLGA MPs) were prepared and demonstrated the ability of intestinal targeting which released in a pH-dependent manner. Subsequently,",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40476513/",
    "length": 997,
    "id": 1118,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40433693",
    "text": "The first clinical trial on eumycetoma was recently conducted in Sudan, comparing oral fosravuconazole, prodrug of active ravuconazole, with the standard-of-care oral itraconazole. Building on this trial, the present study aimed to characterize the pharmacokinetics-pharmacodynamics (PK-PD) of ravuconazole, itraconazole, and hydroxyitraconazole in patients with eumycetoma and guide selection of either a 200-mg or 300-mg dose of fosravuconazole. Nonlinear mixed-effects modeling was used to develop population PK models in 52 patients receiving 3 daily loading doses followed by weekly fosravuconazole (200 mg or 300 mg) or twice-daily itraconazole (total 400 mg), both over 12 months. Attainment of the in vitro 90% minimum inhibitory concentration (MIC90) for Madurella mycetomatis was assessed, and the relationships between drug exposure, lesion size reduction, and complete cure were evaluated. Ravuconazole PK followed a 2-compartment model with Michaelis-Menten elimination and a 63% (95% confidence interval, 38%-90%) bioavailability increase during the loading phase, leading to 75% higher exposure for a 50% dose increase. Itraconazole and hydroxyitraconazole were modeled jointly, with autoinhibition of itraconazole metabolism. Free ravuconazole remained above the MIC90 throughout the entire 12-month treatment period, while free itraconazole never reached the MIC90. Despite a large range in antifungal exposure, no significant relationships were found between drug exposure and lesion size reduction or complete cure, indicating no additional benefit of 300 mg over 200 mg fosravuconazole. Ravuconazole and itraconazole showed nonlinear clearance with no clear exposure-response relationship. The 200 mg fosravuconazole dose is preferred for future use over 300 mg, as it lowers pill burden and enhances cost-effectiveness. Clinical Trials Registration. NCT03086226.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40433693/",
    "length": 1883,
    "id": 1119,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41179551",
    "text": "Like many other countries, Mali, a West African country, has encountered various obstacles in the fight against the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite resource constraints, however, the country implemented containment strategies. Therefore, in early 2021, Mali initiated a vaccination campaign as a tangible defense against COVID-19, prioritizing the administration of the first vaccine doses to healthcare personnel. Consequently, we found assessing anti-SARS-CoV-2 IgG antibody levels important to gauge the efficacy of vaccines administered to frontline healthcare workers in Bamako, Mali. The study enrolled 172 vaccinated front-line healthcare workers from referral hospitals in Bamako, Mali, between March and June 2022. Serum samples were subjected to enzyme-linked immunosorbent assay (ELISA) to assess the levels of anti-SARS-CoV-2 IgG antibodies. Prevaccination serum samples served as controls. Chi-square and Mann-Whitney tests were used to compare proportions and means. Among the 172 participants, 98.2% had high levels of anti-SARS-CoV-2 spike protein antibodies; only 1.6% (n=2) were seronegative. The majority, 62.2% (n=107), received a two-dose vaccination schedule, and the Astra Zeneca® vaccine was the most widely used (52.3%). The average level of postvaccine antibodies was significantly greater in participants who received two doses of vaccine than in those who received one dose (33.7 index vs. 29.1 index; p=0.02). Most healthcare workers exhibited favorable vaccine responses, as indicated by their positive reactivity to anti-SARS-CoV-2 IgG spike proteins. The nature and dosage of the vaccines influenced the antibody response, with a notable advantage observed for individuals who received a two-dose regimen. These findings underscore the importance of continuous research and evaluation to understand and enhance vaccine effectiveness.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41179551/",
    "length": 1919,
    "id": 1120,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41171871",
    "text": "Discovery of novel bioactive natural products from",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41171871/",
    "length": 50,
    "id": 1121,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41162599",
    "text": "SARS-CoV-2 transmission in Malawi remains unclear due to high proportions of mild/asymptomatic infections and limited diagnostics. Existing seroprevalence studies in Malawi have primarily used convenience samples and enzyme-linked immunosorbent assays (ELISAs). We assessed SARS-CoV-2 neutralisation in a longitudinal Malawian population-based cohort, assessing protective immunity post-infection and vaccination. Sera were obtained from rural (Karonga, n = 958) and urban (Lilongwe, n = 918) based participants at three-monthly intervals (February 2021-April 2022). Neutralising antibodies against SARS-CoV-2 were measured using human immunodeficiency (HIV)-based pseudotype assays in HIV-uninfected participants, and vesicular stomatitis virus-based assays in HIV-infected participants and an HIV-uninfected subset. Nucleocapsid ELISAs identified vaccinated participants also infected. SARS-CoV-2 neutralisation profiles increased in complexity over time from rising vaccination coverage and emerging variants. Neutralising antibody prevalence was higher in Lilongwe than Karonga (68.1% (CI 63.5-72.4) vs. 45.4% (CI 41.6-49.3), Survey 4). Hybrid immune and solely vaccinated participants exhibited higher titres than those solely infected. Children < 15 years had the lowest neutralising antibody titres among infected (not vaccinated) participants. People living with HIV had lower neutralising responses than those HIV-uninfected, particularly post vaccination. We therefore recommend surveillance of children and people living with HIV as low neutralisation responses increase reinfection risk. COVID-19 vaccination should be prioritised for HIV-infected individuals.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41162599/",
    "length": 1672,
    "id": 1122,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41159345",
    "text": "Diseases resulting from animal bites have been a public health concern globally, including in Iran, and continue to show annual growth. Therefore, this study aimed to investigate the epidemiological patterns of animal bites in Babol city over 8 years. This cross-sectional study was conducted on all individuals injured by animal bites from March 2015 to February 2022. The data for these cases were recorded by trained professionals at the Central Rabies Center in the county. A total of 13,550 cases with a mean age of 36.18±35.86 years were examined. Three-quarters of the cases (76.0%) were male, and 48.7% were urban residents. Additionally, 11,504 individuals (84.9%) received three doses of the rabies vaccine. The trend of animal bites showed an increase from 199.07 cases per 100,000 population in 2015 to 547.98 cases per 100,000 population in the final year of the study (2022) ( The occurrence of animal bites showed an increasing trend during the study years, indicating growing concern and the need for effective preventive measures. Furthermore, the results can assist in developing strategies, policies, and public health interventions in Babol.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41159345/",
    "length": 1161,
    "id": 1123,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41133501",
    "text": "Background.Burkholderia pseudomalleiMethods.Results.I2I2Conclusions.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41133501/",
    "length": 68,
    "id": 1124,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41131587",
    "text": "The Expanded Programme on Immunization (EPI) is the most successful global childhood programme in reducing mortality and morbidity from vaccine-preventable diseases. Introducing the RTS, S/AS01 malaria vaccine into the routine health system added additional vaccination visits at 24 months. This study determined the factors contributing to compliance with EPI, including RTS, S/AS01 malaria vaccine schedules in the Central Tongu District of Ghana. A matched case-control study (1:1) was undertaken between December 2021 and February 2022 among caregivers of children aged 24 to 40 months. Mantel-Haenzel odds ratio and conditional logistic regression analysis were used to determine the strength of association between the level of compliance and independent variables. Of the 220 caregivers,110 were cases, and 110 were controls. Good knowledge about vaccines and vaccination schedules among caregivers was 62% (n = 139). Caregivers who earned income 46% (OR Non-compliance with recommended EPI vaccinations, including RTS,S/AS01, was largely due to socio-economic factors, having information and knowledge about vaccines, immunization schedules, and access to immunization services. Healthcare providers can improve immunization coverage by emphasizing education on vaccines and vaccine schedules, using technologies and making services accessible in Ghana.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41131587/",
    "length": 1361,
    "id": 1125,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41112670",
    "text": "By the end of 2020, several vaccines aimed at combating COVID-19 were authorized for widespread immunization. The aim of this study was to assess the factors that were associated with COVID-19 Vaccine refusal in Bamenda I. This was a retrospective study carried out in the subdivision of Bamenda I, from March to June 2024, through interviews and questionnaires in which participants were asked to recall important events during the COVID-19 pandemic. A questionnaire-based survey was conducted to ensure diverse representation in the community study. The questionnaire comprised four sections: socio-demographic characteristics, knowledge about COVID-19 and vaccines, attitudes toward COVID-19, and beliefs about the vaccine. Data were collected during community gatherings, such as focus group discussions and training sessions, and also through Google Forms via the Kobo tool for participants with Android phones. Data were then transferred to SPSS for analysis, using the Pearson chi-square test to examine associations, with Our results show that 42.40% participants had high knowledge about COVID-19, 39.40% had moderate knowledge while 18.20% had low knowledge. Their vaccination status, showed that, just 12.10% were vaccinated, and 87.90% were unvaccinated. Socio-demographic factors like age, gender, and education recorded significant associations with respect to vaccine refusal The study highlights significant knowledge gaps and widespread concerns about vaccine safety among the population in Bamenda I, indicating a need for targeted educational interventions to improve vaccination rates.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41112670/",
    "length": 1605,
    "id": 1126,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41107776",
    "text": "The malaria parasite, caused by Plasmodium falciparum, continues to pose serious public health threats in tropical and sub-tropical regions of the world, despite the availability of malaria vaccine. Since October 2021 when WHO recommended the first malaria vaccine, RTS, S/AS01, Nigeria, like many other sub-Saharan African countries is yet to commence immunization of children with the malaria vaccines. We carried out a national evaluation of physicians' knowledge of and willingness to encourage caregivers to partake in the RTS S/AS01 and R21 Matrix M malaria vaccinations in Nigeria. The study was a cross-sectional online survey among physicians across the six geopolitical zones of Nigeria. The questionnaire we employed generated information on participants' demographics, their knowledge of the two approved malaria vaccines, how they source information related to the malaria vaccine, and the factors and barriers physicians consider in recommending any malaria vaccine. Bivariate analysis was conducted to determine the factors associated with knowledge of malaria vaccines and recommendations for vaccination. More than half (68.9%) of the respondents knew about the malaria vaccine, while a substantial proportion, 152 (29.9%) of the participants responded that they did not know the malaria vaccine. The majority of the physicians (64%) were able to correctly state five years as the appropriate age that either vaccine is administered while the others (13.8%) either provided a higher age (5-10 years) or did not respond to this question (22.2%). The majority of the physicians were very willing to recommend the malaria vaccines to caregivers and a good proportion stated that caregivers are very likely to accept vaccination of their children. This study shows that many physicians in Nigeria still lack knowledge about malaria vaccination. There is an urgent need for educational interventions to demystify physicians' concerns about the malaria vaccine such as its efficacy, safety, number of doses, affordability, and availability, to achieve a successful malaria vaccination implementation strategy.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41107776/",
    "length": 2120,
    "id": 1127,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41099205",
    "text": "As local vaccine manufacturing becomes a strategic goal for future pandemic preparedness, investigating public trust in domestic vaccine production is essential for ensuring equitable uptake and long-term success. A cross-sectional web-based survey was conducted to assess confidence in the local scientific community, manufacturers, regulatory authorities, and locally-produced mRNA vaccines. A vaccine confidence index (VCI) captured attitudes toward mRNA vaccine safety, efficacy, and acceptability. In multivariable logistic regression analysis, confidence in the competency of the local scientific community (aOR = 1.55, 95% CI: 1.14-2.10,",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41099205/",
    "length": 644,
    "id": 1128,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092928",
    "text": "Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46·8 years (95% UI 46·6-47·0) in 1990 to 63·4 years (63·1-63·7) in 2023. For males, mean age increased from 45·4 years (45·1-45·7) to 61·2 years (60·7-61·6), and for females it increased from 48·5 years (48·1-48·8) to 65·9 years (65·5-66·3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80·9 years (80·9-81·0) and for males 74·8 years (74·8-74·9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38·0 years (37·5-38·4) for females and 35·6 years (35·2-35·9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. We examined global mortality patterns over the past three decades, highlighting-with enhanced estimation methods-the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092928/",
    "length": 7205,
    "id": 1129,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41174302",
    "text": "Neglected tropical diseases (NTDs) remain a major public health concern in sub-Saharan Africa, where inadequate sanitation and unsafe water contribute to ongoing transmission. This study examined the prevalence and associated risk factors of Schistosoma haematobium among school-aged children in 20 WASH-focused communities across four Local Government Areas in Ogun Central, Nigeria, between March 2021 and March 2023. Urine and stool samples were collected from 1019 pupils and analyzed using standard parasitological techniques, while structured questionnaires captured demographic information, WASH indicators, and attitudes toward anthelmintic treatment. The overall prevalence of S. haematobium was 2%. Significant associations were observed between infection and water sources (p < 0.05), toilet facilities (p = 0.045), and hematuria (p < 0.001). Age was also identified as a significant demographic factor influencing infection. These findings highlight the persistent vulnerability of children in WASH-dependent communities to urinary schistosomiasis and emphasize the need for integrated control strategies that combine improved sanitation, safe water supply, health education, and regular mass drug administration.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41174302/",
    "length": 1225,
    "id": 1130,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41071831",
    "text": "Mass drug administration (MDA) is the main intervention strategy for the elimination of several neglected tropical diseases (NTDs). In many endemic settings, monitoring and collation of MDA treatment data are conducted through paper-based forms and Excel-based spreadsheets. These methods are often slow, prone to errors and do not facilitate timely evidence-based decision making during and after MDA campaigns. The Nigerian National NTD programme and Sightsavers, developed a DHIS2 based platform for real-time collection, monitoring, and reporting of MDA treatment data. We piloted and scaled this DHIS2-based platform, monitoring the data quality, access, government ownership and utility of data for programmatic action at all levels. Three study areas (Jigawa, Enugu and Kwara States), with upcoming MDA campaigns were selected based on geographic spread and model of non-governmental development organisation (NGDO) implementing partner support. Following a pilot in Jigawa State, the DHIS2 platform was scaled-up across all three study areas, alongside the existing Excel-based systems. Programmatic data routinely collected via the two platforms were compared. Instances of data entry and access were monitored via the platform's metadata and a monitored helpline. Data was collected from participants through a self-administered questionnaire, field diaries and focus group discussions/key informant interviews. Quantitative data was analysed using Stata analytical software, while qualitative data was thematically analysed. There was increased access and use of data at all levels within the DHIS2 system along with improved perceptions of government ownership of the data. Participants reported the ability to address errors and improve decision-making during campaigns as significant benefits of the platform. Scaling up DHIS2 was feasible, and similar benefits were observed in all the models of NGDO partner assistance. The DHIS2 platform enhanced all components of ownership, as well as demonstrated ability to be replicated in different settings. However, operating models, cultural contexts, and technical capacities across the diverse locations need to be considered when scaling up the platform.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41071831/",
    "length": 2216,
    "id": 1131,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41068673",
    "text": "The global program to eliminate lymphatic filariasis (GPELF) was started in 2003 with two strategies: mass drug administration (MDA) to interrupt disease transmission and the morbidity management and disability prevention (MMDP) to provide basic hygienic care to filariasis lymphoedema patients. We conducted a mixed methods study with pre-intervention, intervention and post-intervention phases without control groups among 106 participants from two lymphatic filariasis-endemic wards of Lunga Lunga sub-county, Kwale county on the coastal Kenya between 2019 and 2021. During the intervention phase, a lymphoedema management care package was developed using participatory approaches. In the post-intervention phase, qualitative data was collected to assess perceptions of the impact of the intervention on patients' knowledge of and access to lymphoedema management services. In the pre-intervention phase, 86.8% of patients reported experiencing pain, swelling, or redness in their limbs, and 44.3% felt negatively about their condition. More than half (52.8%) did not know the cause of their limb swelling, and 73.6% did not use appropriate footwear. Additionally, 57.5% did not know how to care for their wounds to prevent acute attacks. Key challenges included financial constraints (39.6% spent up to 200 Ksh per visit), long distances to health facilities (24.5% lived > 5 km away), and stigma. In the post-intervention phase, participants reported improved knowledge and self-care practices, including washing, elevating, and exercising affected limbs. Community health volunteers (CHVs) were reported to play a critical role in raising awareness, identifying and referring patients, and improving health-seeking behavior, which contributed to increased service utilization and perceived improvements in quality of life. Training of health care providers, caregivers and patients using the developed intervention care package contributed to improved knowledge on cause and management of lymphoedema. The CHVs played a critical role in the identification and referral of patients, which contributed to improved health-care seeking behaviour and increased service utilization. Collaboration with the county health authorities contributed to improved quality of health care services provided for lymphoedema management.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41068673/",
    "length": 2324,
    "id": 1132,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41059693",
    "text": "Chlamydia trachomatisC. trachomatisC. trachomatis,C. trachomatisC. trachomatisC. trachomatis",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41059693/",
    "length": 92,
    "id": 1133,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41057763",
    "text": "Neglected tropical diseases (NTDs) affect over a billion people globally. From 2020 to 2021, when this study was conducted, Mali remained endemic for multiple NTDs, including schistosomiasis and trachoma. At the time, significant efforts were underway to scale up control and elimination programs, although challenges persisted, particularly in reaching mobile populations such as nomads, migrants, and internally displaced persons (IDPs), with mass drug administration (MDA). These groups were often missed during campaigns, contributing to gaps in coverage and sustained transmission in certain areas. This study was designed to investigate the factors contributing to non-participation in schistosomiasis MDA among mobile populations in Mali, to inform strategies for more equitable and effective delivery. A cross-sectional study was conducted among adults (18 + years) in two Malian health districts targeting nomads, migrants, and IDPs from March to July 2020. A multi-stage cluster sampling approach was used to select participants. Mobility was defined as temporary or permanent movement for livelihood (e.g., herding, mining) or due to displacement. Structured, interviewer-administered questionnaires were used, after development by the study team and pre-tested in a similar population. Questions focused on barriers to MDA access, mobility patterns, awareness about MDA, and logistical challenges. The main outcome was self-reported participation in the last MDA (i.e., taking praziquantel). Data were analyzed using descriptive statistics and multivariable mixed-effects logistic regression models. A total of 1067 participants were included in the study. All groups had MDA coverage rates below the recomended 75% threshold for schistosomiasis elimination. Only 40.8% of IDPs and 3.62% of migrants participated in the last MDA. The most reported reason for non-participation was a lack of information (64.5%). Lower income and occupations such as mining were significantly associated with non-participation (p < 0.001). Mixed-effects logistic regression showed that males were nearly three times more likely to miss MDA than females (aOR = 2.89, 95% CI = 1.65-5.06). Participants facing accessibility barriers (e.g., long distances, physical limitations) were also more likely to miss MDA (aOR = 2.60, 95% CI = 1.45-4.66). Nomads and transhumants were more likely to miss MDA compared to IDPs (aOR = 3.16, 95% CI = 1.05-9.47). These findings reveal notable disparities in MDA participation, influenced by mobility patterns, information access, and trust in health programs. Addressing these barriers requires context-specific approaches, such as improved communication, tailored MDA delivery, and greater community engagement. Strengthening these efforts is essential for equitable NTDs control and ensuring mobile populations are not left behind in schistosomiasis elimination efforts.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41057763/",
    "length": 2900,
    "id": 1134,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40999519",
    "text": "The Lymphatic Filariasis Elimination Programme was launched in Burkina Faso in 2001 aiming to eliminate the disease as a public health concern through mass drug administration (MDA). After eight years of MDA, the Hauts-Bassins region successfully passed the Transmission Assessment Survey (TAS), which led to the MDA being stopped. This study aims to assess whether parasite transmission has resurfaced in areas where MDA was stopped more than ten years ago. A cross-sectional entomological survey was conducted in the villages of Tiebalogo and Tondogosso, in the Hauts-Bassins region. From August to December 2022, adult mosquitoes were collected using Human Landing Collection (HLC) indoor and outdoor, Window Exit Trap (WET) and Pyrethrum Spray Collection (PSC). Mosquitoes were identified morphologically. Genomic DNAs extracted from An. gambiae s.l., An. funestus, An. nili were amplified by PCR for Wuchereria bancrofti parasite detection. A total of 2688 mosquitoes were collected in both study sites, with 630 being collected in Tondogosso and 2058 in Tiebalogo. The An. gambiae s.l. was the predominant mosquitoes, with high numbers being collected in both sites. Of those collected in Tiebalogo, 1786 (86.78%) were identified as An. gambiae s.l., while 373 (59.21%) were identified in Tondogosso. The HLC method collected the greatest number of mosquitoes, followed by the PSC and WET methods. No Wuchereria bancrofti DNA was detected in any of the mosquito pools analyzed in both sites. These findings provide further evidence that there is no Lymphatic Filariasis transmission occurring in Hauts-Bassin's post-TAS area. Molecular xenomonitoring of the filarial parasite which is a sensitive tool, could also serve as a complementary tool for monitoring transmission in post-MDA area and help national neglected tropical disease control program with surveillance in these areas.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40999519/",
    "length": 1889,
    "id": 1135,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40966246",
    "text": "Lymphatic filariasis (LF) is a parasitic disease-causing severe pain, disfiguring, and disabling clinical conditions such as lymphoedema and hydrocoele that are associated with morbidity and stigma. The disease has been targeted for global elimination with the annual mass drug administration (MDA) strategy. We have evaluated the need to implement mass drug administration against W. bancrofti infection in urban zones of Monrovia using both serology and molecular Xenomonitoring (XM). Confirmatory mapping protocols recommended by WHO were carried out in the four health districts of Monrovia. Schools were selected using probability proportionate to size (PPS) and eligible children aged 9-14 years were tested for circulating filarial antigen (CFA) using an Alere Filariasis Test Strip (FTS). Health Districts were assessed as requiring MDA if they exceeded the critical cut off of 3 positive tests corresponding to CFA ≥ 2%. Two health districts were selected for entomological investigations based on pre-disposing risk factors for mosquitoes. Mosquito collection was carried out using exit traps (ETs) and gravid trap (GTs) for 6 months. Mosquitos were tested for W. bancrofti DNA using qPCR. Ninety-six children in the sample had a positive serology test result, with a mean CFA prevalence of 5.3% (95% CI: 4.4 - 6.5%). All four health districts exceeded the critical cut off of 3 cases and in Somalia Drive there were 59 positive tests. In Central Monrovia which had 4 cases, 2 of them are likely locally imported from Somalia Drive where the children reported living. A total of 19,355 potential vector mosquitoes were collected, of which 84.4% (16,335) were Culex and 16.6% (3,020) An. gambiae. All mosquitoes were analyzed, and none were found to be infected with W. bancrofti. MDA is required in three health districts of Monrovia. Confirmatory mapping protocols require adaptation for urban settings. The sampling strategy for the XM was unable to identify transmission in this case and requires further research to optimise it for informing MDA implementation decisions.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40966246/",
    "length": 2085,
    "id": 1136,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40953116",
    "text": "Ivermectin (IVM) is widely used in mass drug administration (MDA) programs for the control of neglected tropical diseases (NTDs). Current regimens rely on weight- or height-based dosing, which lead to operative challenges. This study evaluates an age-based fixed-dose regimen for IVM. This is an individual participant data (IPD) meta-analysis including anthropometric data from over 700,000 individuals, across 53 NTD-endemic countries. Fixed-dose regimens were developed based on weight distribution by age. The proportion of individuals achieving the target range dose (200-400 µg/kg) was assessed and compared to traditional dosing regimens. Fixed-doses of 3 mg for pre-school children (PSAC), 9 mg for school-aged children (SAC), and 18 mg for women of reproductive age (WRA) resulted in a higher proportion of participants receiving the target dose compared to weight- and height-based regimens (79.9% vs. 32.7% and 37.3%, respectively, p < 0.001). Underdosed individuals were fewer with fixed-dose (8.7%) compared to weight-based (32.6%) and height-based (46.3%) regimens. Although doses above the target range increased slightly, most remained within 600 µg/kg. An age-based fixed-dose regimen for IVM could improve treatment coverage and simplify MDA activities. Simplified logistics could lead to cost savings in drug distribution and administration, improving the overall efficiency of MDA programs. These findings support the inclusion of currently excluded PSAC in IVM-based MDA interventions. More broadly, this paper provides evidence for considering the potential policy and programmatic implications of fixed-dose IVM. This Individual Participant Data Meta-analysis (IPD-MA) is registered in PROSPERO (CRD42024521610).",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40953116/",
    "length": 1735,
    "id": 1137,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40920825",
    "text": "A high onchocerciasis disease burden and a low coverage of community-directed treatment with ivermectin (CDTI) have been observed in many parts of South Sudan. In the Maridi County, CDTI was re-introduced in 2017 and various interventions implemented to improve coverage. Through successive community-based surveys, we investigated whether an onchocerciasis awareness campaign and a switch from annual to bi-annual distribution of ivermectin in Maridi County increased CDTI coverage. We also reviewed the evolution of ivermectin distribution in Maridi since 2017 and identified the determinants for ivermectin uptake. For past years in Maridi, CDTI programme performance has been highly variable due to security concerns, limited funding, misconceptions about ivermectin, and poor organisation of mass treatment campaigns. Community-based surveys conducted between 2018 and 2024 in Maridi found that upon switching from annual CDTI (2017-2019) to bi-annual CDTI (2021 onward), therapeutic coverage significantly increased from 40.8% in 2017 to 70.3% in 2023. Lower age, male gender, more CDTI information sources, and awareness of a link between onchocerciasis and epilepsy were all associated with increased uptake of ivermectin. This study showed that with reinforced awareness raising accompanying biannual CDTI, a higher ivermectin treatment coverage is achievable. The findings present an opportunity for the health system to advance its onchocerciasis elimination scheme in remote, conflict-stricken communities in South Sudan.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40920825/",
    "length": 1533,
    "id": 1138,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40901843",
    "text": "Direct morbidity assessments are rarely included in monitoring and evaluation of Schistosoma mansoni mass drug administration programmes. This is despite morbidity reduction being the leading objective of control and elimination as a public health problem in the World Health Organization (WHO) targets. Instead, the number of eggs-per-gram (EPG) of faeces are used as a morbidity proxy. Furthermore, current WHO guidelines use infection intensity thresholds to determine where and when MDA is to be implemented. However, recent work has begun to question this assumption of a direct association between infection intensity in intestinal schistosomiasis and host morbidity. Here we aimed to examine the potential association between S. mansoni infection intensity and morbidity from pre-school-aged children (PSAC) through to elderly individuals, living in Bugoto, Uganda. Prevalence and intensities of S. mansoni infection were diagnosed by Kato-Katz and point-of-care circulating cathodic antigen tests (POC-CCAs) in 287 individuals aged 3-74 years, from Bugoto, Uganda. In addition to data on anaemia and self-reported symptoms, abdominal ultrasound examinations were conducted to identify liver parenchyma image pattern (IP), portal vein dilation (PVD) and left parasternal line (PSL) enlargement. Malaria status was determined using rapid diagnostic testing. Generalised additive models estimated associations between morbidity outcomes and infection intensity/presence, diagnostic method, co-infections, age and sex. The prevalence of positive IP scores, dilated PVD, enlarged PSL and anaemia were 9%, 34%, 33% and 13% respectively. Neither S. mansoni infection intensity or status were significantly associated with PVD, PSL, or anaemia. Age was the most consistent predictor of morbidity, with the highest burden of PVD, PSL and anaemia in PSAC. Malaria infection was also positively associated with PVD and anaemia. A positive POC-CCA predicted only self-reported blood in stool. Our findings add to growing evidence that current infection intensity is an inappropriate proxy for schistosomiasis morbidity, urging a revaluation of tools and targets. The observed prevalence of morbidities in PSAC evidence a need to elucidate the impact of less-specific morbidities, past S. mansoni and other parasitic infections on host health, and adds urgency to the on-going roll out of treatment to this age group.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40901843/",
    "length": 2412,
    "id": 1139,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41133153",
    "text": "Brucellosis remains one of the most impactful zoonotic diseases worldwide, posing major socioeconomic and public health challenges, particularly in low- and middle-income countries. This review presents recent progress in understanding the pathogenesis of",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41133153/",
    "length": 255,
    "id": 1140,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41107814",
    "text": "Rebounding to a higher malaria endemicity level or remaining at the same level despite implementation of malaria control interventions has been reported in high-endemic areas of many sub-Saharan Africa (SSA) countries. Based on current trends, the 2030 targets of the World Health Organization, which aim for at least a 90% reduction in malaria mortality and morbidity, are out of reach. Moreover, the experiences of many countries in SSA show that the implementation of various packages of malaria control interventions in areas of low to moderate transmission can achieve a significant reduction in the disease burden but ultimately fail to interrupt malaria transmission. Multiple factors may contribute to the stagnation or even reversal of the declining trend of malaria endemicity intensity in endemic countries across SSA. Notably, high levels of receptivity and vulnerability can hinder the sustainability of achieved reductions in malaria transmission. To address these challenges, based on evidence from the literature focusing on Uganda, this article presents a novel approach- the Integrated Vector and Parasite Management (IVPM)- for endemicity reduction and maintaining hard-earned gains following reduction of malaria endemicity intensity in high-endemic areas. In line with IVPM, the article also proposes the \"Pummel and Pin\" strategy, outlining an implementation framework for IVPM. The IVPM Pummel-and-Pin model emphasizes the need to reduce both the parasite reservoir and vectorial capacity, highlighting the often-neglected Pin strategy as essential to sustaining achieved reductions in endemicity without any lag. It may offer a practical solution to prevent setbacks and accelerate progress towards achieving the national malaria targets on burden reduction in Uganda and other SSA countries. However, assessing its feasibility and cost-effectiveness across different endemicity levels remains a priority for operational research, particularly since IVPM is resource-driven and malaria control programmes worldwide have faced growing financial deficits. Operational research aimed at reducing malaria endemicity in high-transmission areas of sub-Saharan African countries needs to cover two key questions: how to reduce transmission intensity and how to sustain those reductions.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41107814/",
    "length": 2303,
    "id": 1141,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41083302",
    "text": "Vector control is imperative for eliminating leishmaniasis as a public health problem in Kenya. As elimination efforts expand in East Africa, it is crucial to understand the current research landscape. To address that need and identify gaps, a scoping review was conducted to characterise the landscape of leishmaniasis vector research in Kenya. Building on a previously published scoping review by this team, we updated database searches in PubMed, Embase via Embase.com, Web of Science Core Collection, the Cochrane Library, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP) and the Pan African Clinical Trials Registry to incorporate literature up to 4 January 2024 and focused on vector-related papers. Studies classified as 'prevention' in the original scoping review were included due to overlapping definitions. A total of 95 studies were included in the analysis. Although a wide range of sandfly species have been documented, most of the research is outdated, having taken place 20-40 years ago. Existing studies are mostly epidemiological with little focus on basic and clinical research. There are also no studies on post-kala-azar dermal leishmaniasis despite its potential contribution to the disease transmission cycle. The geographical scope of the research is largely limited to traditional transmission foci with little attention to new disease hotspots such as North Eastern Kenya. These research gaps need to be addressed to better inform the country's leishmaniasis prevention and vector control strategy.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41083302/",
    "length": 1555,
    "id": 1142,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41082582",
    "text": "Schistosomiasis is a major neglected tropical disease that lacks an effective vaccine and faces increasing challenges from praziquantel resistance, underscoring the urgent need for novel therapeutics. Target-based drug discovery (TBDD) is a powerful strategy for drug development. In this study, we utilized AlphaFold to predict the structures of target proteins from Schistosoma mansoni and S. japonicum, followed by virtual molecular screening to identify potential inhibitors. Among 202 potential therapeutic targets, we identified 37 proteins with high-accuracy structural predictions suitable for molecular docking with 14,600 compounds. This screening yielded 268 candidate compounds, which were further evaluated ex vivo for activity against both adult and juvenile S. mansoni and S. japonicum. Seven compounds exhibited strong anti-schistosomal activity, with HY-B2171A (Carubicin hydrochloride, CH) emerging as the most potent. CH was predicted to target the splicing factor U2AF65, and knockdown of its coding gene Smp_019690 resulted in a phenotype similar to CH treatment. RNA sequencing revealed that both CH treatment and Smp_019690 RNA interference (RNAi) disrupted splicing events in the parasites. Further studies demonstrated that CH impairs parasite viability by inhibiting U2AF65 function in mRNA splicing regulation. By integrating RNAi-based target identification with structure-based virtual screening, alongside ex vivo phenotypic and molecular analyses of compound-treated schistosomes, our study provides a comprehensive framework for anti-schistosomal drug discovery and identifies promising candidates for further preclinical development.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41082582/",
    "length": 1666,
    "id": 1143,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41071751",
    "text": "BACKGROUND Oral diseases, though largely preventable, continue to affect billions of people worldwide and impose a significant economic burden. Global estimates from 2015 are over $350 billion in direct costs and nearly $190 billion in indirect costs to dental diseases, which disproportionately impact low-income and marginalized populations. Despite effective preventive measures such as fluoride application and minimally invasive dentistry, untreated dental caries remains the most common oral pathology. Left unmanaged, these conditions can lead to severe complications, including infective endocarditis and deep neck infections (DNIs), with systemic implications ranging from sepsis to cardiovascular events. CASE REPORT A 65-year-old man was admitted with malaise and neck stiffness. Laboratory analyses revealed leukocytosis, elevated procalcitonin, and D-dimer levels, although pulmonary embolism was excluded. The differential diagnosis included meningitis, severe osteoarthritis, and acute cervical spine inflammation. Empiric treatment with vancomycin and levofloxacin was initiated, while further evaluation with CT and contrast-enhanced MRI revealed extensive inflammation: a retropharyngeal abscess extending into the epidural space and compressing the spinal cord at the craniospinal junction. Initially, urosepsis was suspected due to catheterization challenges; however, urinary cultures were negative. A preoperative airway assessment led to a dental consultation, revealing extensive caries and poor oral hygiene. Multiple extractions confirmed an odontogenic source, but the patient ultimately developed sepsis from the abscess, leading to heart failure and death. CONCLUSIONS This case underscores the critical impact of neglected oral health and the necessity for timely dental intervention. It reinforces that early recognition and integrated oral-systemic healthcare are essential in preventing the progression of odontogenic infections into life-threatening complications.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41071751/",
    "length": 1998,
    "id": 1144,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41027996",
    "text": "Chagas disease (CD) is an emerging public health concern in Europe. In non-endemic countries, congenital transmission is the main route of new infections. Italy is the second-largest host country in Europe for Latin American migrants and the prevalence of the disease is estimated around 3.5%. The aim is to evaluate the cost-effectiveness of a congenital CD screening program in pregnant women at risk of infection living in Italy and their newborns. We conducted a cost-effectiveness analysis from the perspective of the Italian National Health Service, comparing a screening scenario with a no-screening scenario. A Bayesian decision tree model with a lifetime horizon was developed. In the base-case analysis, the screening strategy yielded an incremental cost-effectiveness ratio of €15,193 per quality-adjusted life year gained (95% CI: €14,885-€15,552), falling well within the accepted cost-effectiveness threshold (€30,000-€50,000) in Italy. Probabilistic sensitivity analysis confirmed the robustness of these findings. Here we show that screening for congenital CD is a cost-effective strategy that improves health outcomes and aligns with international public health priorities. Our findings support the implementation of a national screening program integrated within existing maternal care pathways, contributing to the prevention of neglected tropical diseases and the promotion of migrant health.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41027996/",
    "length": 1412,
    "id": 1145,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41022740",
    "text": "The WHO recently issued guidelines for public health control of Strongyloides stercoralis in endemic areas. We aimed to evaluate the feasibility of implementing the WHO recommendations in Rwanda, and our secondary objective was to estimate S. stercoralis prevalence. We conducted a community-based cross-sectional study in two Rwandan districts (Gisagara and Rubavu) including a training session focused on diagnostics for S. stercoralis: parasitological assays (Baermann and agar plate culture, APC) and a novel rapid diagnostic test (RDT). Technicians' perceptions of each assay were evaluated via a questionnaire; 1,415 individuals were screened. A critical aspect of the parasitological assays was the length of training, but there was no issues with RDT implementation. Based on the combination of Baermann and APC diagnostics, prevalence was 1.1% (95% CI 0.5-2.3) in Gisagara, and 3.9% (95% CI 2.6-5.7) in Rubavu, which was similar for the RDT. Overall, we found the implementation of S. stercoralis-specific tests was feasible, though intense training was crucial.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41022740/",
    "length": 1071,
    "id": 1146,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41014009",
    "text": "This paper explores the application of the One Health framework to atopic dermatitis (AD), a complex, chronic skin disease, emphasizing interdisciplinary approaches to prevention and management. One Health integrates human, animal, environmental, and plant health, addressing challenges such as antimicrobial resistance, infectious diseases, and neglected tropical diseases (NTDs). In the context of AD, One Health principles are applied to explore etiological factors like urbanization, climate change, biodiversity loss, and environmental pollution. Key findings include the interplay between lifestyle and environmental exposures, as evidenced by studies on human-dog microbiota sharing, which reveal that rural environments confer protective effects against allergic conditions for both species. Historical observations of the \"old farm effect\" highlight the protective role of traditional rural living, including raw milk consumption, in preventing atopic diseases. However, modern urbanization and industrial farming have eroded these benefits. Climate change intensifies AD symptoms through extreme weather, proliferation of more and higher allergenic pollen, likely also of house dust mites, allergen proliferation, and pollution. Rising CO",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41014009/",
    "length": 1248,
    "id": 1147,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40997058",
    "text": "Skin-related neglected tropical diseases (sNTDs) remain a significant public health challenge in Cameroon, where limited resources, training, and infrastructure hinder early diagnosis and management. The World Health Organization (WHO) has developed the SkinNTDs app version 3.0 as a digital solution to assist frontline healthcare workers (FHWs) in recognizing and managing sNTDs. As utilization will rely on a high degree of awareness among FHWs, a dedicated and effective marketing plan is required. This study describes the design, implementation, and evaluation of a structured marketing plan to promote the app among FHWs in Cameroon. We conducted a pilot quasi‑experimental before‑and‑after study comparing three 6‑month phases-pre‑campaign, campaign, and post‑campaign. The multi‑channel marketing campaign combined communications via WhatsApp, in‑person training sessions, video presentations, and email outreach. Google Play Console Analytics provided monthly metrics on store listing visits, downloads, installations, uninstalls, and retention. During the campaign (1 April 2024-30 September 2024), store page visits totaled 961, yielding 616 downloads (conversion rate = 64.1%) and the app was installed 751 times; new-user acquisition exceeded 81.6%. Net installs surged by 227.3% in April and 140.4% in May, with retention above 88%. ANOVA revealed significant period effects on growth rate (p = 0.007, ε² = 0.591), loss rate (p = 0.011, η² = 0.452), churn rate (p = 0.003, η² = 0.532), and retention rate (p = 0.003, η² = 0.532), with campaign performance superior to pre‑ and post‑campaign phases. Interrupted time series analyses found gradual adoption and sustained retention following intervention start, but significant decrease at campaign end. A context‑adapted, multi‑channel marketing strategy markedly improved adoption and retention of the WHO SkinNTDs app among Cameroonian FHWs. Digital (WhatsApp, videos) and face‑to‑face (training) channels were complementary. Sustained integration into routine health activities and automated re‑engagement tools are recommended to maintain long‑term use and inform scale‑up in other endemic settings.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40997058/",
    "length": 2166,
    "id": 1148,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40994285",
    "text": "Pain is a major health problem among musicians. However, data concerning pain in a nationwide perspective are scarce, particularly among Portuguese musicians. Therefore, we aim to evaluate performance-related pain among professional orchestra musicians throughout a nationwide characterisation of all Portuguese orchestras. We performed a multicenter cross-sectional study involving all Portuguese professional orchestras, which included 432 musicians (response rate of 72.1%). The main outcome was performance-related pain (evaluated by the Performance-related Pain among Musicians Questionnaire-PPAM). The secondary outcomes were: pain approach, physical activity levels, fatigue, distress, perfectionism, and health-related quality of life. We calculated the prevalence of PRP and performed a descriptive analysis of the main characteristics of our sample (distinguishing musicians with and without PRP) and of PRP, fatigue, distress, perfectionism, and health-related quality of life among musicians with pain, comparing full-time and partial-time musicians. The lifetime and point prevalence of performance-related pain were 71.8% and 33.3%, respectively. Pain intensity score was 14.9 (out of 40), pain interference in general activities was 21.8 (out of 70) and pain interference in performance was even higher (28.3 out of 50). Pain intensity and interference, fatigue, and perfectionism were higher, and quality of life was lower among full-time musicians. Pain was significantly more prevalent among full-time musicians, string instrumentalists, older and more sedentary musicians, with longer careers, and those who play more hours per week. Multivariate logistic regression defined a model containing five factors significantly associated with higher probability of performance-related pain. We highlight the high prevalence of pain and the significant negative impact of pain on performance and quality of life. This first Portuguese nationwide study demonstrated that pain is a highly disabling condition among professional orchestra musicians, particularly among full-time musicians, supporting the integration of healthcare professionals in the professional orchestra framework for a closed follow-up, early assessment and treatment, and implementation of preventive programs. The proper evaluation and management of pain seems to still be neglected, contributing to significant impairments and reduced quality of life.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40994285/",
    "length": 2435,
    "id": 1149,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41168716",
    "text": "The experiences of patients and healthcare providers are fundamental in understanding the patient journey, particularly in the context of neglected diseases affecting rural populations. These insights are crucially important for advancing people-centred, high-quality healthcare and achieving improved health outcomes. Cutaneous leishmaniasis (CL) causes chronic, disfiguring skin lesions leading to a significant burden on the affected communities and the health systems. Our study aims to examine the experiences of people with CL after entering the biomedical healthcare system. We also integrate these findings with our previous work to map the entire CL patient journey in a disease-endemic district in Sri Lanka. We conducted a qualitative study in three rural communities with high disease prevalence in the Anuradhapura district, Sri Lanka. We collected data through (1) a participant experience reflection journal (PERJ), (2) post-PERJ interviews and (3) an interview study with healthcare professionals. We analysed data through thematic analysis. Thirty PERJs were completed by individuals with CL, with 25 participating in post-PERJ interviews and 16 healthcare professionals participated in the key informant interviews. Upon entering a biomedical healthcare facility, a person with CL navigated through the stages of clinical suspicion and laboratory diagnosis, receiving treatment and achieving a cure (as clinically confirmed by the treating dermatologist). Although many physicians accurately suspected cases upon initial presentation, some failed to clinically diagnose CL promptly. Some patients experienced prolonged waiting times for their initial consultations with the dermatologist and to receive diagnostic test results. Accessibility issues, travel and meal costs, and competing responsibilities like household work, education, and employment further added to the burden of attending frequent clinic visits for CL. Despite the long and painful nature of the treatment, compliance among people with CL remained satisfactory, with rare reports of treatment failure. For some people, the CL patient journey extends beyond the clinically defined cure, as they continue to live with constant fears, perceived physical impacts associated with the disease, and effects of treatment. We found that, despite certain positive aspects, the CL patient journey is complex, with substantial and pervasive delays and barriers along with psychosocial impacts that persist beyond clinical cure. Our study findings can inform evidence-based, context-specific interventions to reduce the public health burden of CL in resource-limited settings.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41168716/",
    "length": 2651,
    "id": 1150,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41151093",
    "text": "Skin-related neglected tropical diseases (NTDs) represent an emerging public health and economic challenge in India. In the present prospective observational study, out-of-pocket expenditure and catastrophic health expenditure among patients diagnosed with mycetoma, subcutaneous mycoses, leishmaniasis, and cutaneous tuberculosis and nontuberculous mycobacterial (TB-NTM) infections were assessed. Using structured questionnaires, direct and indirect costs were recorded over a 6-month period. Of the 21 patients enrolled (median age 42 years), 42.9% were household heads and 61.9% lived below the international poverty line. The mean direct and indirect medical costs were $171 ± $113 and $315 ± $338, respectively, with treatment costs being the major driver of expenditure. Catastrophic health expenditure was observed in 95.2% of patients, and in nearly one-quarter of cases, health expenses exceeded the total family income. Notably, patients with TB-NTM incurred the highest individual expenses (mean $642 ± $323). The economic fallout was profound: 33.3% of patients lost employment because of disease-related disability. The study findings highlight the urgent need for enhanced public healthcare access, expanded insurance coverage-including outpatient services and essential medications-and targeted social support to reduce the crippling financial burden of skin-related NTDs in vulnerable populations. In addition, the development of standardized, country-specific diagnostic and treatment guidelines is critical for facilitating early diagnosis, timely intervention, and the prevention of disability and impoverishment in affected populations.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41151093/",
    "length": 1657,
    "id": 1151,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40975392",
    "text": "Blastomycosis, coccidioidomycosis, histoplasmosis, paracoccidioidomycosis, emergomycosis, and talaromycosis are sapronoses restricted to specific geographical areas associated with particular environmental niches that can lead to high morbidity and mortality if diagnosed or treated late. Challenges in clinical awareness arise from their nonspecific clinical presentations and the limited availability of sensitive diagnostic tools. Although advances in molecular diagnosis and antigen detection-based tests are promising, they are not available for all systemic endemic mycoses (SEM). Treatment guidelines emphasize the importance of early antifungal treatment, although only a few limited therapeutic options have remained available over the years. Most SEM are not notifiable diseases, resulting in underreporting and a poor understanding of their true burden. The inclusion of several SEM-causing dimorphic fungi in the WHO Fungal Priority Pathogens List highlights their growing public health impact, the lack of prevention methods, and unmet research needs. Recognizing SEM as neglected diseases, improving surveillance, expanding diagnostic access, and developing affordable vaccines and therapeutics are essential steps toward addressing this evolving global health challenge. Coordinated international efforts are urgently needed.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40975392/",
    "length": 1340,
    "id": 1152,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40961107",
    "text": "Female genital schistosomiasis (FGS) is a neglected gynaecological condition that is a manifestation of chronic urogenital schistosomiasis. This disease has significant implications for the reproductive health and overall well-being of women and girls, especially in areas with limited access to water, sanitation, and hygiene (WASH). In Kenya, where urogenital schistosomiasis is endemic, the burden of FGS and how to best address it within existing sexual and reproductive health (SRH) services has not been fully explored. This mixed-methods study applied an implementation research approach to assess the feasibility and acceptability of integrating FGS services into routine SRH interventions across public health facilities in three high schistosomiasis endemic counties in Kenya. The intervention included implementing a minimum service package, between December 2023 and December 2024, encompassing health literacy, screening, diagnosis, and treatment. A total of 8,856 women were screened for FGS, with an overall estimated positivity rate of 27.7% (95% CI [26.7, 28.7]). A quantitative survey with a subset of 1,041 clients revealed high acceptability of integration 98.8% (95% CI [98, 99.3]). Integration enabled diagnosis and highlighted a hidden burden of FGS. Qualitative findings revealed significant gaps in knowledge and awareness, stigma-related barriers, and the absence of standardised indicators in the Kenya Health Information System (KHIS), which hampers effective data collection, reporting, and resource planning, including procurement of praziquantel. These findings show the urgent need for health system improvements, including the integration of standardised FGS indicators into the KHIS, to support surveillance, preparedness, and equitable resource distribution, the need for inclusion of FGS within medical training curricula, and for normative clinical guidance on FGS. The evidence supports scaling up FGS-SRH integration and positions MCH clinics and outreach programs as critical entry points.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40961107/",
    "length": 2029,
    "id": 1153,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40642251",
    "text": "Neglected tropical diseases (NTDs) remain major public health challenge in low- and middle-income countries (LMICs), especially in rural and underserved regions. Although telemedicine has expanded globally, evidence on its implementation for individual clinical care of NTDs remains scarce. This pilot implementation study aimed to assess the feasibility and acceptability of synchronous telemedicine consultations for patients with Chagas disease (CD) and American Cutaneous Leishmaniasis (ACL) in a national reference hospital in Brazil. We conducted a mixed-methods implementation study using the Design Science Research Methodology (DSRM). The context analysis involved structured surveys with 31 health professionals and semi-structured interviews with two local managers. Patients diagnosed with CD or ACL were recruited from August to October 2024. Teleconsultations were performed via WhatsApp video calls by four specialists. Patient satisfaction was evaluated using structured questionnaires. Of the 46 patients recruited, 38 (82.6%) completed teleconsultations. Most were older adults and had no prior telehealth experience. Despite low digital literacy and education levels, 63.2% (24/38) completed the teleconsultation without assistance. High levels of satisfaction were reported: 97.4% (37/38) were satisfied and would attend future virtual visits. Participants reported the reduced travel burden and improved access to care. No major technical issues were observed. Synchronous telemedicine via a low-cost, widely available platform was feasible and well-accepted for clinical follow-up of CD and ACL in a Brazilian public hospital. This approach may help reduce access barriers to specialized care for NTDs. Further research should evaluate clinical outcomes and cost-effectiveness in LMIC settings.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40642251/",
    "length": 1816,
    "id": 1154,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40588088",
    "text": "Tinea capitis is a common fungal infection of the skin and hair follicles of the scalp, primarily affecting the pediatric population. It is caused by dermatophytes, mainly from the Trichophyton and Microsporum genera, and clinical diagnosis can be confirmed through microscopic examination, culture, or molecular techniques. Adequate treatment should involve systemic antifungal drugs. Ethiopia, the second most populous country in Africa, also reports the second-highest prevalence of tinea capitis on the continent. However, fungal diseases remain largely neglected in public health initiatives. This narrative review aims to synthesize current epidemiological data, risk factors, and diagnostic and therapeutic approaches, to estimate the disease burden, guide clinical practice, and inform future public health strategies. A systematic literature search was conducted in open-access databases. Data on study populations, prevalence, risk factors, diagnosis, and treatment were extracted and analyzed. A total of 14 studies were included, encompassing 7077 patients with tinea capitis in Ethiopia. The condition was found to be highly prevalent among Ethiopian children, mirroring trends seen in other African regions. The predominance of urban-based studies reveals a critical gap in data from rural areas, limiting a full understanding of the national disease burden. Clinical diagnosis alone may overestimate prevalence, potentially leading to inappropriate treatments and increased antifungal resistance. Transmission is strongly influenced by socioeconomic and hygiene-related factors. Trichophyton species are the main etiological agents. While national efforts have improved hygiene and sanitation, significant challenges persist. Moreover, despite the existence of diagnostic and treatment guidelines, their uneven application, often due to economic and logistical constraints, continues to hinder effective disease management.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40588088/",
    "length": 1938,
    "id": 1155,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40587583",
    "text": "Epilepsy is a major health concern in onchocerciasis-endemic regions with intense transmission, where the infection is associated with a high epilepsy burden. This study investigated epilepsy prevalence and mortality in five onchocerciasis-endemic counties of South Sudan, and the association between onchocerciasis transmission and epilepsy, including probable nodding syndrome (pNS). House-to-house cross-sectional surveys (2021-2024) identified persons with suspected epilepsy (sPWE) and retrospectively documented deaths among sPWE and individuals without epilepsy (IWE). Epilepsy diagnoses, including pNS, were confirmed by trained clinicians. Ongoing transmission was assessed using anti-Ov16 seroprevalence in children aged 3‒9 years. Age- and sex-standardised epilepsy, pNS and anti-Ov16 prevalence were calculated, along with age- and sex-standardised mortality rates and standardised mortality ratios (SMRs) with 95% confidence intervals (95%CIs), using IWE as the reference population. Weighted arcsin-transformed linear regression was used to explore the association between epilepsy and anti-Ov16 prevalence. Among 34,019 individuals screened, 166 deaths occurred in 3,101 person-years for sPWE versus 466 deaths in 63,420 person-years for IWE. Epilepsy prevalence was 4.1% (range: 2.3-7.1%), and pNS prevalence was 1.5% (range: 0.6-2.2%). Anti-Ov16 seroprevalence among children was 23.3% (range: 1.4-44.1%). Each 1.0 percentage point increase in standardised anti-Ov16 seroprevalence was statistically significantly associated with an average rise of 0.10 percentage points in standardised epilepsy prevalence and 0.04 percentage points in standardised pNS prevalence. Median age at death was lower for sPWE (20 years) than IWE (38 years; Mann-Whitney U-test p-value < 0.0001). Standardised mortality rates per 1,000 person-years were statistically significantly higher in sPWE (67.6, 95%CI: 52.6-87.1) than in IWE (9.0, 95%CI: 7.8-10.3). The overall SMR was 6.9 (95%CI: 5.9-8.0), indicating sPWE were seven times more likely to die than IWE. The high epilepsy burden in onchocerciasis-endemic areas is driven by elevated epilepsy prevalence and mortality. Integrated onchocerciasis and epilepsy programmes must be strengthened to decrease epilepsy incidence and ensure uninterrupted access to antiseizure medication.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40587583/",
    "length": 2332,
    "id": 1156,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40423365",
    "text": "Visceral leishmaniasis (VL) is a severe parasitic disease caused by",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40423365/",
    "length": 67,
    "id": 1157,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40339984",
    "text": "Sporotrichosis is a neglected zoonotic infection caused by pathogenic Sporothrix species, primarily affecting the skin and lymphatic system but occasionally leading to life-threatening systemic disease in some cases. Brazil bears the highest global burden of cat and human sporotrichosis. Transmission mainly occurs through traumatic inoculation of the fungus via cat bites, scratches, thorns, or wooden splinters. To date, nosocomial transmission of Sporothrix spp. has not been reported. This report describes two cases of healthcare-associated sporotrichosis in cats in Belo Horizonte (Minas Gerais, Brazil). Both animals (cases 1 and 2) underwent trichotomy at two different veterinary clinics, with both undergoing abdominal ultrasound examination and one (case 2) receiving further venous access. Small skin lesions caused by the trichotomy presented with purulent content approximately six days after the procedure. Samples from the cutaneous lesions were collected and subjected to cytological examination and mycological culture. S. brasiliensis was confirmed through species-specific PCR and calmodulin (CAL) gene sequencing. Phylogenetic analysis revealed that both isolates clustered with clinical S. brasiliensis isolates extracted from infected cats, dogs, and humans in Brazil. These findings highlight the potential for S. brasiliensis transmission through contaminated fur clippers in veterinary hospitals, underscoring the risk of nosocomial infection in animals.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40339984/",
    "length": 1481,
    "id": 1158,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_34424645",
    "text": "Pythium insidiosumPythiaceaeP. insidiosumPythiumP. insidiosumPythiumPythium PythiumPythiumPythiumin vitroPythium PythiumP. insidiosum PythiumPythiumPythiumPythiumPythium",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34424645/",
    "length": 169,
    "id": 1159,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41177169",
    "text": "Climate change is likely to exacerbate a range of determinants that drive tuberculosis, the world's leading cause of death from a single infectious agent. However, tuberculosis is often neglected in wider climate health discussions. Commissioned by WHO, we developed an analytical framework outlining potential causal relationships between climate change and tuberculosis. We drew on existing knowledge of tuberculosis determinants, identified determinants likely to be sensitive to the effects of climate change, and conceptualised the mechanistic pathways through which these effects might occur. We collated evidence for these pathways, but found no studies directly linking climate change and tuberculosis, warranting research to build evidence for action. Nevertheless, the available indirect evidence supports the existence of plausible causal links between climate change and tuberculosis. This evidence highlights the need to consider tuberculosis as a climate-sensitive disease, and include tuberculosis in climate risk adaptation and mitigation programmes, and climate-resilient funding and response mechanisms. Only through urgent research and comprehensive action can we address this overlooked intersection and ensure that climate change does not become a barrier to ending the global tuberculosis epidemic.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41177169/",
    "length": 1320,
    "id": 1160,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41168821",
    "text": "Schistosomiasis japonica, caused by Schistosoma japonicum, remains a significant public health concern in the Philippines, where 12.4 million people are at risk due to persistent transmission in endemic regions. The distribution of schistosomiasis is closely linked to the distribution of its snail intermediate host. This study aims to assess the potential of using soil samples to detect the environmental presence of Oncomelania hupensis quadrasi and Schistosoma japonicum. This cross-sectional observational study utilized a soil-based environmental DNA (eDNA) detection system for simultaneous detection of O. h. quadrasi, and S. japonicum mitochondrially encoded cytochrome c oxidase subunit 1 gene in multiplex quantitative real-time PCR and digital PCR platforms. A two-phase sample collection and testing were carried out in December 2023 (Phase 1) and March 2024 (Phase 2) across 30 selected sampling sites in Ekiran village, Leyte, Philippines. Wilcoxon two-sample/Mann-Whitney U test was used to determine whether there was a significant difference in eDNA presence and edaphic factors, while percent agreement was used to assess the concordance among methods. This study reveals that S. japonicum eDNA can be detected in soil samples and confirms the strong applicability of soil-based eDNA for detecting O. h. quadrasi snails and even in sites without visible snail presence. Furthermore, it demonstrates the superiority of soil-eDNA system compared to classical malacological surveys in detecting O. h. quadrasi and S. japonicum microhabitats: in Phase 1, eDNA detected O. h. quadrasi and S. japonicum in 50% (3/6) and 66.67% (4/6) of sites, respectively, while malacological surveys detected them in only 50% and 16.67% (1/6) of sites. In Phase 2, eDNA detected O. h. quadrasi in 20% (6/30) of sites compared to only 10% (3/30) by malacological survey, and S. japonicum was detected only by eDNA in 10% (3/30) of sites. Among the measured soil parameters, only pH showed a statistically significant difference between eDNA-positive and eDNA-negative sites (P = 0.04). Soil-based eDNA sensitively detected O. h. quadrasi and S. japonicum, enabling scalable, non-invasive transmission site identification and outperforming traditional surveys without visible snails. Its ability to detect S. japonicum highlights its value for comprehensive schistosomiasis monitoring.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41168821/",
    "length": 2382,
    "id": 1161,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41132010",
    "text": "Brucellosis is one of the neglected zoonotic diseases (NZD) in the world that causes disease globally. Brucella melitensis, one of the organisms responsible for causing the disease in sheep and goat, is responsible for the disease in humans. The disease is transmitted mainly from sheep and goat to humans via ingestion (typically through milk), inhalation, abrasion and so on. Despite the zoonotic importance of the disease, there is lack of comprehensive data such as overall prevalence around the world is yet to be measured. The aim of this study is to review all the available articles on the prevalence of the infection in sheep and goats systematically and determine the overall prevalence around the world. Therefore, a literature search was conducted in PubMed for articles published from January 2010 to December 2023 on the relevant topic. The inclusion criteria were set to extract relevant data from the selected articles. A random effect meta-analysis model was used in analysing the data. The derived prevalence was presented in percentage along with 95% confidence interval (CI). The pooled prevalence of B. melitensis infection globally in goat was 2.46% (95% CI: 1.70%-3.21%) and in sheep was 8.07% (95% CI: 6.36%-9.78%); the combined pooled prevalence in both sheep and goat was 5.54% (95% CI: 4.63%-6.45%). Overall, on the basis of regions, the pooled prevalence in goat ranged from 0.07% (95% CI: -0.08% to 0.22%) to 16.82% (95% CI: 12.69%-20.95%). In sheep, the regional pooled prevalence ranged from 0.03% (95% CI: -0.03% to 0.08%) to 60.39% (95% CI: 58.50%-62.27%). This systematic review and meta-analysis demonstrated the global burden of B. melitensis infection in sheep and goat that would help better understanding the global distribution of the infection and the potential areas of zoonotic transmission. The data have been retrieved from various types of journals with different types of study designs and were analysed to highlight the variation of prevalence across the countries, among different species, diagnostic methods and sample sources. This knowledge would help in planning effective control measures targeting high risk species, areas and so on.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41132010/",
    "length": 2188,
    "id": 1162,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092928",
    "text": "Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46·8 years (95% UI 46·6-47·0) in 1990 to 63·4 years (63·1-63·7) in 2023. For males, mean age increased from 45·4 years (45·1-45·7) to 61·2 years (60·7-61·6), and for females it increased from 48·5 years (48·1-48·8) to 65·9 years (65·5-66·3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80·9 years (80·9-81·0) and for males 74·8 years (74·8-74·9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38·0 years (37·5-38·4) for females and 35·6 years (35·2-35·9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. We examined global mortality patterns over the past three decades, highlighting-with enhanced estimation methods-the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092928/",
    "length": 7205,
    "id": 1163,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41084847",
    "text": "Schistosomiasis is the most impactful Neglected Tropical Diseases (NTDs) affecting over 240 million people in impoverished tropical and subtropical regions across 78 countries. Despite significant advances in research, praziquantel (PZQ) remains the only available treatment, raising concerns about the emergence of tolerant or resistant",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41084847/",
    "length": 337,
    "id": 1164,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41083299",
    "text": "Leishmaniasis poses a significant public health problem in Kenya, where effective case management and treatment rely on accurate diagnosis. This review aims to summarise the research landscape on leishmaniasis diagnostics in Kenya and identify gaps. This scoping review expands a previously published scoping review on leishmaniasis in Kenya to further analyse studies focusing on diagnostics. The field of diagnostics was chosen because of recent pushes for novel tools and because of the role timely diagnosis plays in disease elimination. A comprehensive search of PubMed, Embase via Embase.com, Web of Science Core Collection, the Cochrane Library, ClinicalTrials.gov, WHO ICTRP and the Pan African Clinical Trials Registry was conducted, covering studies up to 5 January 2024. After dual, blind screening with conflict resolution by a third reviewer, 41 studies were included in the review. These studies examined a range of diagnostic tools; however most were assessed in one or few studies, and none evaluated real-time PCR. Additional gaps in the research landscape include a lack of diagnostics for cutaneous leishmaniasis and post-kala-azar dermal leishmaniasis in Kenya, outdated literature surrounding the Direct Agglutination Test and randomised trials for any diagnostic tool. Future research should focus on solidifying the validity and reliability of diagnostic tools in the Kenyan context and updating previous work.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41083299/",
    "length": 1433,
    "id": 1165,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41049789",
    "text": "The triazole scaffold has garnered considerable attention over the preceding decade as a privileged pharmacophore in the rational design of chemotherapeutic agents targeting neglected tropical diseases (NTDs). This review provides a comprehensive elucidation of the multifaceted research dedicated to the structural optimization of the triazole nucleus and its consequential outcomes on biological efficacy. Emphasis is placed on the methodical investigation of diverse substituents appended to the triazole core, underscoring the profound influence of seemingly marginal modifications on critical pharmacological parameters. Through a comprehensive deconstruction of structure-activity relationships (SAR), this exposition identifies the essential functional moieties underpinning biological efficacy that potentiate anti-parasitic, anti-fungal, and anti-viral activities across a spectrum of NTD-relevant biological targets. These insights deepen the knowledge of triazole based hybrid molecules and guide future rational design of novel compounds. By synthesizing and analyzing findings from a wide array of studies, this review aims to serve as a valuable resource for researchers interested in the continued development of triazole derivatives to manage neglected tropical diseases effectively.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41049789/",
    "length": 1299,
    "id": 1166,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41037978",
    "text": "Kinetoplastids are parasites which cause various neglected tropical diseases. A hallmark feature of their genomic composition is the presence of polycistronic transcription, a phenomenon that involves the transcription of multiple genes into a single mRNA molecule, along with unconventional modes of gene regulation. In these organisms, histone variants and post-translational modifications play pivotal roles in modulating chromatin structure and transcriptional activity. This review provides a comprehensive overview of histone variants and post-translational modifications identified across Leishmania spp., Trypanosoma cruzi, and Trypanosoma brucei, detailing both the diversity of modifications and their known functional roles. This review also focuses on the writers, erasers, and readers proteins, including available three-dimensional structural data, to better understand their contribution to chromatin regulation, cell cycle progression, and parasite adaptation. Concurrently, this review offers a synopsis of therapeutic endeavors that have targeted these pathways, emphasizing the outcomes of in silico, in vitro and in vivo studies. This comprehensive review underscores the potential of unraveling kinetoplastid epigenetic mechanisms as a promising avenue for developing innovative treatments against these major human pathogens.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41037978/",
    "length": 1347,
    "id": 1167,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41035901",
    "text": "Leishmaniasis represents a significant threat to global health as a neglected tropical disease. While therapeutic options exist, their high cost, safety concerns, and significant adverse effects necessitate the discovery of safer and more efficacious alternatives. Natural products, possessing diverse biological activities including inherent anti-leishmanial properties, constitute a vital resource for drug development. However, the intrinsic activity of these compounds is frequently suboptimal. Structural modification offers a potent strategy to significantly enhance their efficacy. This comprehensive review summarizes advances from 2010 to 2024 in the structural modification of natural products to improve anti-leishmanial activity, with particular emphasis on phenylpropanoid derivatives and other natural product classes, and provides detailed synthetic routes for each derivative. The findings demonstrate that strategic structural modifications can substantially increase potency, achieving IC",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41035901/",
    "length": 1006,
    "id": 1168,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41027231",
    "text": "Leishmaniasis, a neglected tropical disease, poses a significant global health challenge mainly in tropical and subtropical areas. The limited treatment alternatives, coupled with significant associated toxicity, necessitate the requirement to identify new chemical scaffolds with reduced toxicity and improved efficacy. The two essential enzymes of the sterol biosynthetic pathway, Sterol C-24 methyl transferase (SMT) and Sterol 14α-demethylase (SDM), hold great promise as plausible drug targets due to their essentiality for parasite survival and virulence, along with exhibiting minimal homology with human counterparts. The present review discusses the importance of targeting leishmanial SDM and SMT proteins in the perquisite for anti-leishmanial drug discovery. We have performed a comprehensive search using various databases and created a small-molecule sterol inhibitor library, and by utilizing computational biology approaches, we tried to meticulously understand enzyme-inhibitor interactions of the library molecules with the leishmanial SMT and SDM proteins. Information pertaining to the chemical structure of the inhibitors, binding affinities, and interacting residues with both the proteins that drive their mode of action towards them has been elucidated. Thus, this review addresses inclusive information on Leishmanial SMT and SDM proteins, which can aid in unraveling new molecules to fight against the deadly parasitic infection by leveraging computational tools.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41027231/",
    "length": 1489,
    "id": 1169,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41107973",
    "text": "The number of reports of arboviral outbreaks is increasing and, consequently, the need for effective surveillance and vector control plans for Aedes-borne diseases is becoming more urgent. To explore the current state of knowledge of Aedes arbovirus vectors in Africa, we reviewed studies published between 1980 and 2023 that involved Aedes vector surveillance, vector control or insecticide resistance, with the aim to synthesize information and identify knowledge gaps to guide future Aedes research and control in Africa. Studies conducted in Africa and published between 1980 and 2023 were retrieved from twelve electronic databases using search strings designed to capture relevant concepts. Articles that did not meet the eligibility criteria were excluded during relevance screening. Out of 17,337 publications identified, 877 full-text articles were reviewed, of which seven included information on vector surveillance, 56 on vector control and 57 on insecticide resistance. Publications reporting longitudinal data from sustained Aedes vector surveillance systems were only available for Senegal and La Réunion. Aedes vector control studies were principally controlled bioassays or small-scale studies conducted before and after entomological studies which lacked epidemiological outcomes. The most studied methods were larval control (n = 21 publications), integrated control combining different interventions (n = 7), topical repellents (n = 6), environmental management (n = 5) and spatial repellents (n = 3). Four publications described typical vector control responses during arbovirus epidemics in Africa: these often combined larviciding, ultra-low volume (ULV) space spraying and community engagement to reduce larval sites, alongside active source reduction. There was a lack of high-quality evidence generated through rigorous study design on the effectiveness of control measures in reducing arbovirus transmission in the African context. As a consequence, the scientific basis for evidence-informed decisions in Africa, both for routine Aedes vector control or for outbreak response, remains weak. Insecticide resistance studies focused on adulticides using WHO tube tests (n = 43 publications), with larval bioassays relatively less common (n = 13). Aedes aegypti (n = 53) and Aedes albopictus (n = 12) were the only Aedes species tested. The most commonly tested adulticides were permethrin and deltamethrin (pyrethroids); bendiocarb (carbamate); and dichlorodiphenyltrichloroethane (DDT; organochlorine), although the results were rarely reported in connection with decision-making about Aedes control. Results of the most relevant adulticides indicated that Ae. aegypti populations were generally susceptible to malathion (organophosphate), but resistance to permethrin and deltamethrin was detected in West and Central Africa. Most studies pre-dated the revised WHO guidance, and insecticide concentrations were mostly those recommended for Anopheles susceptibility testing that use relatively higher discriminating doses, and thus likely underestimate true Aedes resistance levels. Larval susceptibility bioassays were conducted with temephos (n = 12) and Bacillus thuringiensis israelensis (n = 6). Temephos resistance was only detected in Cabo Verde following several decades of use. Given the increasing frequency of arbovirus epidemics in Africa, countries urgently need to develop plans for emergency response and robust control strategies that make use of evidence from good-quality studies to strengthen resilience.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41107973/",
    "length": 3549,
    "id": 1170,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092928",
    "text": "Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46·8 years (95% UI 46·6-47·0) in 1990 to 63·4 years (63·1-63·7) in 2023. For males, mean age increased from 45·4 years (45·1-45·7) to 61·2 years (60·7-61·6), and for females it increased from 48·5 years (48·1-48·8) to 65·9 years (65·5-66·3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80·9 years (80·9-81·0) and for males 74·8 years (74·8-74·9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38·0 years (37·5-38·4) for females and 35·6 years (35·2-35·9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. We examined global mortality patterns over the past three decades, highlighting-with enhanced estimation methods-the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092928/",
    "length": 7205,
    "id": 1171,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092927",
    "text": "Comprehensive, comparable, and timely estimates of demographic metrics-including life expectancy and age-specific mortality-are essential for evaluating, understanding, and addressing trends in population health. The COVID-19 pandemic highlighted the importance of timely and all-cause mortality estimates for being able to respond to changing trends in health outcomes, showing a strong need for demographic analysis tools that can produce all-cause mortality estimates more rapidly with more readily available all-age vital registration (VR) data. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is an ongoing research effort that quantifies human health by estimating a range of epidemiological quantities of interest across time, age, sex, location, cause, and risk. This study-part of the latest GBD release, GBD 2023-aims to provide new and updated estimates of all-cause mortality and life expectancy for 1950 to 2023 using a novel statistical model that accounts for complex correlation structures in demographic data across age and time. We used 24 025 data sources from VR, sample registration, surveys, censuses, and other sources to estimate all-cause mortality for males, females, and all sexes combined across 25 age groups in 204 countries and territories as well as 660 subnational units in 20 countries and territories, for the years 1950-2023. For the first time, we used complete birth history data for ages 5-14 years, age-specific sibling history data for ages 15-49 years, and age-specific mortality data from Health and Demographic Surveillance Systems. We developed a single statistical model that incorporates both parametric and non-parametric methods, referred to as OneMod, to produce estimates of all-cause mortality for each age-sex-location group. OneMod includes two main steps: a detailed regression analysis with a generalised linear modelling tool that accounts for age-specific covariate effects such as the Socio-demographic Index (SDI) and a population attributable fraction (PAF) for all risk factors combined; and a non-parametric analysis of residuals using a multivariate kernel regression model that smooths across age and time to adaptably follow trends in the data without overfitting. We calibrated asymptotic uncertainty estimates using Pearson residuals to produce 95% uncertainty intervals (UIs) and corresponding 1000 draws. Life expectancy was calculated from age-specific mortality rates with standard demographic methods. For each measure, 95% UIs were calculated with the 25th and 975th ordered values from a 1000-draw posterior distribution. In 2023, 60·1 million (95% UI 59·0-61·1) deaths occurred globally, of which 4·67 million (4·59-4·75) were in children younger than 5 years. Due to considerable population growth and ageing since 1950, the number of annual deaths globally increased by 35·2% (32·2-38·4) over the 1950-2023 study period, during which the global age-standardised all-cause mortality rate declined by 66·6% (65·8-67·3). Trends in age-specific mortality rates between 2011 and 2023 varied by age group and location, with the largest decline in under-5 mortality occurring in east Asia (67·7% decrease); the largest increases in mortality for those aged 5-14 years, 25-29 years, and 30-39 years occurring in high-income North America (11·5%, 31·7%, and 49·9%, respectively); and the largest increases in mortality for those aged 15-19 years and 20-24 years occurring in Eastern Europe (53·9% and 40·1%, respectively). We also identified higher than previously estimated mortality rates in sub-Saharan Africa for all sexes combined aged 5-14 years (87·3% higher in GBD 2023 than GBD 2021 on average across countries and territories over the 1950-2021 period) and for females aged 15-29 years (61·2% higher), as well as lower than previously estimated mortality rates in sub-Saharan Africa for all sexes combined aged 50 years and older (13·2% lower), reflecting advances in our modelling approach. Global life expectancy followed three distinct trends over the study period. First, between 1950 and 2019, there were considerable improvements, from 51·2 (50·6-51·7) years for females and 47·9 (47·4-48·4) years for males in 1950 to 76·3 (76·2-76·4) years for females and 71·4 (71·3-71·5) years for males in 2019. Second, this period was followed by a decrease in life expectancy during the COVID-19 pandemic, to 74·7 (74·6-74·8) years for females and 69·3 (69·2-69·4) years for males in 2021. Finally, the world experienced a period of post-pandemic recovery in 2022 and 2023, wherein life expectancy generally returned to pre-pandemic (2019) levels in 2023 (76·3 [76·0-76·6] years for females and 71·5 [71·2-71·8] years for males). 194 (95·1%) of 204 countries and territories experienced at least partial post-pandemic recovery in age-standardised mortality rates by 2023, with 61·8% (126 of 204) recovering to or falling below pre-pandemic levels. There were several mortality trajectories during and following the pandemic across countries and territories. Long-term mortality trends also varied considerably between age groups and locations, demonstrating the diverse landscape of health outcomes globally. This analysis identified several key differences in mortality trends from previous estimates, including higher rates of adolescent mortality, higher rates of young adult mortality in females, and lower rates of mortality in older age groups in much of sub-Saharan Africa. The findings also highlight stark differences across countries and territories in the timing and scale of changes in all-cause mortality trends during and following the COVID-19 pandemic (2020-23). Our estimates of evolving trends in mortality and life expectancy across locations, ages, sexes, and SDI levels in recent years as well as over the entire 1950-2023 study period provide crucial information for governments, policy makers, and the public to ensure that health-care systems, economies, and societies are prepared to address the world's health needs, particularly in populations with higher rates of mortality than previously known. The estimates from this study provide a robust framework for GBD and a valuable foundation for policy development, implementation, and evaluation around the world. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092927/",
    "length": 6303,
    "id": 1172,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092926",
    "text": "For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associated risk factors. This paper presents GBD 2023 findings on disease and injury burden and risk-attributable health loss, offering a global audit of the state of world health to inform public health priorities. This work captures the evolving landscape of health metrics across age groups, sexes, and locations, while reflecting on the remaining post-COVID-19 challenges to achieving our collective global health ambitions. The GBD 2023 combined analysis estimated years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 375 diseases and injuries, and risk-attributable burden associated with 88 modifiable risk factors. Of the more than 310 000 total data sources used for all GBD 2023 (about 30% of which were new to this estimation round), more than 120 000 sources were used for estimation of disease and injury burden and 59 000 for risk factor estimation, and included vital registration systems, surveys, disease registries, and published scientific literature. Data were analysed using previously established modelling approaches, such as disease modelling meta-regression version 2.1 (DisMod-MR 2.1) and comparative risk assessment methods. Diseases and injuries were categorised into four levels on the basis of the established GBD cause hierarchy, as were risk factors using the GBD risk hierarchy. Estimates stratified by age, sex, location, and year from 1990 to 2023 were focused on disease-specific time trends over the 2010-23 period and presented as counts (to three significant figures) and age-standardised rates per 100 000 person-years (to one decimal place). For each measure, 95% uncertainty intervals [UIs] were calculated with the 2·5th and 97·5th percentile ordered values from a 250-draw distribution. Total numbers of global DALYs grew 6·1% (95% UI 4·0-8·1), from 2·64 billion (2·46-2·86) in 2010 to 2·80 billion (2·57-3·08) in 2023, but age-standardised DALY rates, which account for population growth and ageing, decreased by 12·6% (11·0-14·1), revealing large long-term health improvements. Non-communicable diseases (NCDs) contributed 1·45 billion (1·31-1·61) global DALYs in 2010, increasing to 1·80 billion (1·63-2·03) in 2023, alongside a concurrent 4·1% (1·9-6·3) reduction in age-standardised rates. Based on DALY counts, the leading level 3 NCDs in 2023 were ischaemic heart disease (193 million [176-209] DALYs), stroke (157 million [141-172]), and diabetes (90·2 million [75·2-107]), with the largest increases in age-standardised rates since 2010 occurring for anxiety disorders (62·8% [34·0-107·5]), depressive disorders (26·3% [11·6-42·9]), and diabetes (14·9% [7·5-25·6]). Remarkable health gains were made for communicable, maternal, neonatal, and nutritional (CMNN) diseases, with DALYs falling from 874 million (837-917) in 2010 to 681 million (642-736) in 2023, and a 25·8% (22·6-28·7) reduction in age-standardised DALY rates. During the COVID-19 pandemic, DALYs due to CMNN diseases rose but returned to pre-pandemic levels by 2023. From 2010 to 2023, decreases in age-standardised rates for CMNN diseases were led by rate decreases of 49·1% (32·7-61·0) for diarrhoeal diseases, 42·9% (38·0-48·0) for HIV/AIDS, and 42·2% (23·6-56·6) for tuberculosis. Neonatal disorders and lower respiratory infections remained the leading level 3 CMNN causes globally in 2023, although both showed notable rate decreases from 2010, declining by 16·5% (10·6-22·0) and 24·8% (7·4-36·7), respectively. Injury-related age-standardised DALY rates decreased by 15·6% (10·7-19·8) over the same period. Differences in burden due to NCDs, CMNN diseases, and injuries persisted across age, sex, time, and location. Based on our risk analysis, nearly 50% (1·27 billion [1·18-1·38]) of the roughly 2·80 billion total global DALYs in 2023 were attributable to the 88 risk factors analysed in GBD. Globally, the five level 3 risk factors contributing the highest proportion of risk-attributable DALYs were high systolic blood pressure (SBP), particulate matter pollution, high fasting plasma glucose (FPG), smoking, and low birthweight and short gestation-with high SBP accounting for 8·4% (6·9-10·0) of total DALYs. Of the three overarching level 1 GBD risk factor categories-behavioural, metabolic, and environmental and occupational-risk-attributable DALYs rose between 2010 and 2023 only for metabolic risks, increasing by 30·7% (24·8-37·3); however, age-standardised DALY rates attributable to metabolic risks decreased by 6·7% (2·0-11·0) over the same period. For all but three of the 25 leading level 3 risk factors, age-standardised rates dropped between 2010 and 2023-eg, declining by 54·4% (38·7-65·3) for unsafe sanitation, 50·5% (33·3-63·1) for unsafe water source, and 45·2% (25·6-72·0) for no access to handwashing facility, and by 44·9% (37·3-53·5) for child growth failure. The three leading level 3 risk factors for which age-standardised attributable DALY rates rose were high BMI (10·5% [0·1 to 20·9]), drug use (8·4% [2·6 to 15·3]), and high FPG (6·2% [-2·7 to 15·6]; non-significant). Our findings underscore the complex and dynamic nature of global health challenges. Since 2010, there have been large decreases in burden due to CMNN diseases and many environmental and behavioural risk factors, juxtaposed with sizeable increases in DALYs attributable to metabolic risk factors and NCDs in growing and ageing populations. This long-observed consequence of the global epidemiological transition was only temporarily interrupted by the COVID-19 pandemic. The substantially decreasing CMNN disease burden, despite the 2008 global financial crisis and pandemic-related disruptions, is one of the greatest collective public health successes known. However, these achievements are at risk of being reversed due to major cuts to development assistance for health globally, the effects of which will hit low-income countries with high burden the hardest. Without sustained investment in evidence-based interventions and policies, progress could stall or reverse, leading to widespread human costs and geopolitical instability. Moreover, the rising NCD burden necessitates intensified efforts to mitigate exposure to leading risk factors-eg, air pollution, smoking, and metabolic risks, such as high SBP, BMI, and FPG-including policies that promote food security, healthier diets, physical activity, and equitable and expanded access to potential treatments, such as GLP-1 receptor agonists. Decisive, coordinated action is needed to address long-standing yet growing health challenges, including depressive and anxiety disorders. Yet this can be only part of the solution. Our response to the NCD syndemic-the complex interaction of multiple health risks, social determinants, and systemic challenges-will define the future landscape of global health. To ensure human wellbeing, economic stability, and social equity, global action to sustain and advance health gains must prioritise reducing disparities by addressing socioeconomic and demographic determinants, ensuring equitable health-care access, tackling malnutrition, strengthening health systems, and improving vaccination coverage. We live in times of great opportunity. Gates Foundation and Bloomberg Philanthropies.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092926/",
    "length": 7451,
    "id": 1173,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40972625",
    "text": "Fractures related to osteoporosis and low bone mineral density lead to substantial morbidity, mortality, and cost to individuals and health systems. Here we present the most up-to-date global, regional, and national estimates of the contribution of low bone mineral density to the burden of fractures from falls and additional categories of injuries from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. The burden of low bone mineral density was estimated from 1990 to 2020 in terms of years lived with disability (YLDs), disability-adjusted life years (DALYs), and deaths, for individuals aged 40 years and older, using data from population-based studies from 48 countries or territories (169 unique sources). Mean standardised femoral neck bone mineral density values were estimated by GBD location, age, and sex by meta-regression. Based on a separate meta-analysis of population-based studies from nine countries (12 unique sources), we also estimated the pooled relative risk of fractures per unit decrease in bone mineral density (g/cm In 2020, 8·32 million (95% UI 5·58-10·84) YLDs, 17·2 million (14·1-20·2) DALYs, and 477 000 (411 000-536 000) deaths were attributable to low bone mineral density globally in individuals aged 40 years and older. Between 1990 and 2020, global YLDs, DALYs, and deaths attributable to low bone mineral density increased by 91·8% (88·5-95·1), 89·8% (81·5-99·0), and 127·1% (108·5-144·5), respectively. Over this period, the age-standardised global rates of YLDs, DALYs, and deaths attributable to low bone mineral density showed modest decreases. In 2020, falls accounted for 76·2% (95% UI 74·2-78·3) of YLDs, 65·2% (62·9-67·6) of DALYs, and 71·0% (67·4-72·8) of deaths attributable to low bone mineral density, and road injuries largely accounted for the remaining amount: 12·4% (11·1-13·6) of YLDs, 24·6% (22·5-27·1) of DALYs, and 23·1% (21·6-26·2) of deaths. As a proportion of all fall-related burden, low bone mineral density accounted for 26·6% (23·2-28·7) of YLDs, 25·6% (22·1-27·4) of DALYs, and 40·6% (35·4-44·0) of deaths in 2020. Of all road injury-related burden, 12·6% (10·8-13·5) of YLDs, 6·3% (5·4-6·9) of DALYs, and 8·9% (7·6-9·6) of deaths were attributable to low bone mineral density. In men, road injuries accounted for the largest proportion of DALYs attributable to low bone mineral density in those aged 40-59 years and the largest proportion of deaths in those aged 40-64 years. In women, road injuries were the leading cause of DALYs attributable to low bone mineral density in those aged 40-44 years and the leading cause of deaths attributable to low bone mineral density in those aged 40-54 years. In older age groups among both men and women, falls were the leading cause of the burden attributable to low bone mineral density. Low bone mineral density is a crucial modifiable risk factor for fractures, which are an important cause of morbidity and mortality particularly in ageing populations. This analysis highlights low bone mineral density as a cause of health loss not just from falls, but also from road injuries. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40972625/",
    "length": 3134,
    "id": 1174,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40502558",
    "text": "Tuberculosis (TB) remains a global health crisis, disproportionately affecting low- and middle-income countries. Strategic resource allocation is essential to achieving the WHO End TB targets. Existing TB costing tools have limitations in conducting global analyses, prompting the development of a novel model tailored to address these gaps. We developed a new, open-source TB costing model that simulates detailed TB care cascades comprising steps of screening, diagnosis, treatment, and prevention for those eligible - according to WHO guidelines for 20 distinct population groups. These include 10 groups each from patient-initiated and provider-initiated pathways, capturing variations in pulmonary status, age, HIV/ART status, and drug sensitivity. The model captures the cost of a large-scale vaccine. We demonstrate the model's functionality through a case study that informed the Global Fund's Investment Case for its 8th replenishment (2027-2029). In the case study, the model was first used to estimate the cost of implementing the TB Global Plan 2023 - 2030. This scenario incorporated intervention targets, normative standards of care, and the availability of new TB tools. An optimization routine applied to 29 high-burden countries estimated maximal TB impact under constrained funding scenarios. The results were also used to assess the potential impact and contribution of innovation within the Global Fund's 8th replenishment. This new TB costing model offers improved representation of TB care complexity across diverse populations, with enhanced transparency, flexibility, and policy relevance. Its application in global TB strategy analysis highlights its value in informing investment cases and prioritizing interventions for maximal impact under resource constraints.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40502558/",
    "length": 1789,
    "id": 1175,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40365032",
    "text": "Treatment outcomes may be compromised among individuals with multidrug/rifampicin-resistant TB (MDR/RR-TB) with fluoroquinolone (FQ) resistance. Among people in whom an FQ was unlikely to be effective, we compared the effectiveness of longer individualised regimens comprised of bedaquiline (Bdq) for 5-8 months, linezolid, and clofazimine to those reinforced with at least 1 Group C drug and/or longer Bdq duration. We emulated a target trial to compare the effectiveness of initiating and remaining on the core regimen to a regimen reinforced with 1) Bdq for ≥9 months, 2) Bdq for ≥9 months, and delamanid (Dlm), 3) imipenem (Imp), 4) a second-line injectable, or 5) Bdq for ≥9 months, Dlm and Imp. We used cloning, censoring, and inverse-probability weighting to estimate the probabilities of successful treatment. Adjusted probabilities of successful treatment ranged from 0.75 (95% CI 0.61-0.89) to 0.84 (95% CI 0.76-0.91). Ratios of treatment success ranged from 1.01 for regimens reinforced with Bdq ≥9 months (95% CI 0.79-1.28) and Bdq ≥9 months plus Dlm (95% CI 0.81-1.31) to 1.11 for regimens reinforced with an injectable (95% CI 0.92-1.39) and Bdq ≥9 months, Dlm and Imp (95% CI 0.90-1.41). Some reinforced regimens had modestly higher treatment success rates, but estimates were imprecise. Additional studies of strategies for maximising treatment success among individuals with FQ resistance are needed.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40365032/",
    "length": 1417,
    "id": 1176,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_39915825",
    "text": "Larval source management (LSM) has a long history of advocacy and successes but is rarely adopted where funds are limited. The World Health Organization (WHO) guidelines on malaria prevention recommend the use of LSM as a supplementary intervention to the core vector control methods (insecticide-treated nets and indoor residual spraying), arguing that its feasibility in many settings can be limited by larval habitats being numerous, transient, and difficult to find or treat. Another key argument is that there is insufficient high-quality evidence for its effectiveness to support wide-scale implementation. However, the stagnation of progress towards malaria elimination demands that we consider additional options to the current emphasis on insecticidal commodities targeting adult mosquitoes inside homes. This letter is the result of a global, crossdisciplinary collaboration comprising: (a) detailed online expert discussions, (b) a narrative review of countries that have eliminated local malaria transmission, and (c) a mathematical modeling exercise using two different approaches. Together, these efforts culminated in seven key recommendations for elevating larval source management as a strategy for controlling malaria and other mosquito-borne diseases in Africa (Box 1). LSM encompasses the use of larvicide (a commodity) as well as various environmental sanitation measures. Together, these efforts lead to the long-term reduction of mosquito populations, which benefits the entire community by controlling both disease vector and nuisance mosquitoes. In this paper, we argue that the heavy reliance on large-scale cluster-randomized controlled trials (CRTs) to generate evidence on epidemiological endpoints restricts the recommendation of approaches to only those interventions that can be measured by functional units and deliver relatively uniform impact and, therefore, are more likely to receive financial support for conducting these trials. The explicit impacts of LSM may be better captured by using alternative evaluation approaches, especially high-quality operational data and a recognition of locally distinct outcomes and tailored strategies. LSM contributions are also evidenced by the widespread use of LSM strategies in nearly all countries that have successfully achieved malaria elimination. Two modelling approaches demonstrate that a multifaceted strategy, which incorporates LSM as a central intervention alongside other vector control methods, can effectively mitigate key biological threats such as insecticide resistance and outdoor biting, leading to substantial reductions in malaria cases in representative African settings. This argument is extended to show that the available evidence is sufficient to establish the link between LSM approaches and reduced disease transmission of mosquito-borne illnesses. What is needed now is a significant boost in the financial resources and public health administration structures necessary to train, employ and deploy local-level workforces tasked with suppressing mosquito populations in scientifically driven and ecologically sensitive ways. In conclusion, having WHO guidelines that recognize LSM as a key intervention to be delivered in multiple contextualized forms would open the door to increased flexibility for funding and aid countries in implementing the strategies that they deem appropriate. Financially supporting the scale-up of LSM with high-quality operations monitoring for vector control in combination with other core tools can facilitate better health. The global health community should reconsider how evidence and funding are used to support LSM initiatives.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39915825/",
    "length": 3669,
    "id": 1177,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_39856664",
    "text": "Africa's involvement in clinical trials remains very low. Although the crucial role of training initiatives in building clinical trial capacity in Africa has been documented, current efforts fall short as they lack alignment with local contexts. This study aimed to design, develop, implement, and evaluate an innovative clinical trial operations training program for Africa. We developed ClinOps, a novel 10-week clinical trial operations training program for study coordinators in Africa to enhance their expertise in four fundamental areas: designing, conducting, managing, and reporting clinical trials. To streamline the learning process, we used cloud-based applications that minimize the need for software installations while maximizing student engagement. VoiceThread facilitated interactive content that could be accessed offline. Moodle, an open-source learning management system, offered a platform for sharing learning tools, mentorship, and rubric-driven competency assessments, including quizzes, forums, tutorials, and group assignments. We utilized Zoom for live tutorials and mentoring as required. Effectiveness of the program was evaluated through quantitative pre- and post-surveys, qualitative end-course evaluations, and a comprehensive monitoring and evaluation framework. The pre- and post-surveys measured changes in trainees' confidence in clinical trial domains and leadership and coordination skills. End-course evaluations gathered feedback on the course content, organization, technology, and instructional methods. We used Wilcoxon rank test to analyze pre- and post-survey scores and thematic analysis to analyze the qualitative data. In the initial cohort, 88 study coordinators from 19 countries participated, including 56 (64%) females, with 57 (65%) actively employed as study coordinators during the training, and 85 (97%) possessing prior experience in clinical trial roles. Among these, 71 (81%) successfully completed the course, with 69 (97%) also completing the post-course assessment. Post-training scores demonstrated substantial improvement compared to pre-training scores in each competency area, including in designing (pre-post training median score = 3.6 vs. 4.6, median difference = 1.0, 95% CI 0.8-1.1, p < 0.001), managing (pre-posttest median score = 3.4 vs. 4.2, median difference = 0.6, 95% CI 0.4-0.8, p < 0.001), conducting (pre-post training median score = 3.9 vs. 4.7, median difference = 0.9, 95% CI 0.6-1.0, p < 0.001), and reporting (pre-posttest median score = 3.0 vs. 4.5, median difference = 1.0, 95% CI 0.9-1.5, p < 0.001) clinical trials. The monitoring and evaluation data confirm the program's adherence to training best practices, including alignment with local priorities, country ownership, pedagogic innovation, institutional capacity building, sustainability, and ongoing partnerships. The end-course evaluation reflects participants' positive feedback on the program's structure, content, relevance to their current roles, and overall delivery methods. The ClinOps program, designed by experts from academia and product development partners, enhanced participants' clinical trial competencies. To effectively build clinical trials capacity on the continent, training programs should provide thorough competency development in designing, conducting, managing, and reporting trials.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39856664/",
    "length": 3355,
    "id": 1178,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_39675710",
    "text": "Trypanosoma cruzi is a flagellated protozoan and the etiological agent of Chagas disease, a neglected tropical disease described by Carlos Chagas in 1909 that remains without appropriate diagnostics and treatment. Throughout its life cycle, T. cruzi undergoes through many different environments, requiring adaptation of its metabolism to different nutrition sources. Recent studies have confirmed the adaptability of T. cruzi metabolism to different carbon sources and encouraged a deeper investigation of related metabolic pathways. In the present study, we investigated the catabolism of threonine in T. cruzi epimastigotes cultivated in LIT medium and following 24h of starvation in PBS. In LIT medium, threonine, serine, and histidine were rapidly consumed concomitantly with carbohydrates during parasite exponential growth. When threonine was provided as the only carbon source to starved parasites, they excreted acetate and glycine, corroborating the activity of a mitochondrial threonine degradation pathway. Subsequently, we used a recombinant T. cruzi L-threonine dehydrogrenase (TcTDH) to screen the Chagas Box, an open-source collection of phenotypic hits, and identified compound TCMDC-143160 as a low micromolar TcTDH inhibitor (IC50 = 3.5 μM). When TCMDC-143160 was administrated to starved parasites, it inhibited the threonine degradation pathway. Finally, we report the crystal structure of TcTDH and characterize its allosteric activation by potassium. Collectively, these data demonstrate the relevance of threonine catabolism in T. cruzi metabolism and provide a set of tools to further investigate TcTDH as a potential drug target for Chagas disease.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39675710/",
    "length": 1674,
    "id": 1179,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41129649",
    "text": "Understanding how life is adapting to urban environments represents an important challenge in evolutionary biology. In this work, we investigate a widely cited example of urban adaptation,",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41129649/",
    "length": 188,
    "id": 1180,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40781311",
    "text": "Malaria continues to exert a severe toll on public health in East Africa, accounting for a large share of global morbidity and mortality. Despite national strategies and donor-funded efforts, the disease persists due to complex, intersecting biological, environmental, and socioeconomic drivers. This review aims to analyse malaria burden, identify risk factors, and assess the effectiveness of control strategies across twelve East African countries to inform tailored and evidence-based interventions. A systematic review was conducted using peer-reviewed literature, national reports, and World Health Organization surveillance data from 2015-2024. Data were synthesized from Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Rwanda, Somalia, South Sudan, Tanzania, and Uganda. Analysis focused on incidence, mortality, resistance trends, intervention coverage, and climate-related impacts. Uganda, South Sudan, and Burundi report the highest malaria incidence (250 + per 1000), while Eritrea and Comoros maintain the lowest. Artemisinin partial resistance has reached > 20% in multiple areas, and pyrethroid resistance in Anopheles vectors is undermining control efforts. Climate change is expanding malaria transmission into highland zones. Funding gaps persist, with only 48% of required resources secured. Nonetheless, integrated strategies involving LLINs, indoor residual spraying, vaccination, and community engagement reduce severe malaria by up to 47%. To combat malaria in East Africa, urgent investments in sustainable financing, climate-adaptive interventions, resistance monitoring, and community-driven strategies are essential to avert projected excess mortality and achieve regional malaria elimination goals.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40781311/",
    "length": 1744,
    "id": 1181,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40764911",
    "text": "Madagascar faces unique challenges in tropical disease management due to its diverse geography, tropical climate, and socioeconomic factors. This review examines current challenges in tropical medicine in Madagascar and explores opportunities for improving public health outcomes, with a focus on six priority diseases. We conducted a comprehensive scoping review of literature published between January 2000 and December 2024, searching PubMed, Google Scholar, ScienceDirect, and Web of Science. Studies were included if they reported on tropical disease burden, interventions, health outcomes, or health system capacity in Madagascar. Studies were excluded if they were not available in English or French, lacked Madagascar-specific focus, did not discuss health systems or population-level disease control, focused solely on laboratory techniques without public health relevance, were conference abstracts or reports without full-text availability, or came from non-credible sources. Peer-reviewed literature was supplemented with grey literature. Data were extracted using a standardized form by two independent reviewers and analyzed thematically. Madagascar shows divergent disease patterns compared to regional averages. Malaria represents the biggest concern, with cases up 132% and deaths up 278% by 2023, now exceeding regional rates. Conversely, lymphatic filariasis represented a remarkable public health success, achieving 93% prevalence reduction and slightly outperforming regional outcomes. Dengue control remained exemplary throughout the study period, with Madagascar maintaining rates approximately three times lower than regional averages. Leprosy burden persistently exceeded regional averages by threefold despite achieving 54% reduction, while tuberculosis and schistosomiasis follow continental reduction trends. Control strategies included integrated vector management, mass drug administration achieving 76.3% national coverage for lymphatic filariasis, seasonal malaria chemoprevention, and targeted treatment approaches. Disease spread is driven by poor infrastructure, poverty, water access issues, and favorable climate. Research gaps exist in disease interactions, economic impact, and intervention acceptance. Addressing tropical disease burden in Madagascar requires strengthened public health infrastructure, increased domestic health financing, improved health workforce retention, and targeted interventions for remote communities. Building local research capacity, investing in innovative technologies, and implementing integrated disease control approaches are essential for improving population health outcomes.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40764911/",
    "length": 2650,
    "id": 1182,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40521702",
    "text": "In Africa, female genital schistosomiasis (FGS) damages women's health. In Cameroon, diagnosis is rare and healthcare workers lack knowledge. Clinicians can be trained to identify FGS lesions, but the accuracy is uncertain. We assessed the acceptability and feasibility of FGS screening in Cameroon's East Province by comparing static HIV clinics and mobile pop-up clinics through consultations and acceptance rates, guided by precise disease mapping. A clinician was remotely trained to diagnose FGS lesions, with success measured by expert comparison using cervix images. The proportion of FGS was compared between settings. A total of 1242 women were approached, 624 in the HIV clinics and 618 in the mobile clinics, respectively. Women at HIV clinics were significantly older [37.0 years (interquartile range, IQR: 31-43)] than those at mobile clinics [28.5 years (IQR: 23-36)]. Refusal of the screening procedures was significantly higher in the HIV clinics (50%) than in the mobile clinics (31%). FGS lesions were present in over half of women examined, 51% in the HIV clinic and 56% in the community. The diagnostic concordance between clinicians was more than 90%. It is both feasible and acceptable to identify and treat FGS lesions in areas without specialized care. Mobile pop-up clinics' acceptability is better, with younger women participating which helps to better rectify age-inequities in FGS surveillance, and remote telemedicine training is effective. Prevalence of FGS suspect lesions was very high in both settings.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40521702/",
    "length": 1536,
    "id": 1183,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40481567",
    "text": "In December 2024, L'Initiative-Expertise France organized a workshop in Musanze, Rwanda, for National Malaria Control and Elimination Programmes (NMC/EPs) representatives from 19 sub-Saharan African countries. The workshop focused on surveillance, modeling, climate forecasting, and innovative control methods to mitigate climate change impacts on malaria. Participants shared challenges, experiences and best practices. Key challenges highlighted include shifts in malaria transmission seasons, disease spread to mid-altitude regions, and infrastructure damage from extreme weather. Additional factors, such as drug and insecticide resistance, the spread of Anopheles stephensi, and changes in vector behaviour, are exacerbating malaria transmission in African cities. Participants stressed the need for collaborative efforts to tackle these evolving threats. This comment reflects the expertise and insights of 19 NMCPs actively managing malaria control and aims at raising awareness, inform policy discussions, and strengthen global partnerships to address the intersection of malaria and climate change.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40481567/",
    "length": 1107,
    "id": 1184,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40379274",
    "text": "The Global Approach to Biology Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) network is an international scientific network of 21 centres coordinated by the Merieux Foundation (Lyon, France). Mapping and characterising the similarities and differences in expertise and activities across four major infectious diseases (tuberculosis, antimicrobial-resistant infections, acute respiratory infections and emerging pathogens) among these centres would help to provide a better understanding of the network's capacity. It will also highlight how the applied methodology can enhance information sharing within research networks. Each centre responded to a questionnaire on their core activities and research themes. An advanced multivariate analysis was performed to relate all items together and highlight new synergies among members of the GABRIEL network. Similarities were found using a clustering algorithm and data were visualised using alluvial plots. This strategy enabled to find new patterns in the GABRIEL network for the implementation of new projects on global health, regardless of geographical proximity or historical connections. Five clusters based on core activities, consisting of 6, 1, 3, 9 and 2 research units, respectively, have been identified, with clusters 1 and 4, including the majority of the units. Four clusters have been defined based on the four major infectious diseases, comprising 7, 3, 5 and 6 research units, respectively. The same methodology could also be applied to identify proximities on other networks of experts or between members of different networks for more efficient research or surveillance global programmes.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40379274/",
    "length": 1686,
    "id": 1185,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40245080",
    "text": "Mass drug administration (MDA) programs involving praziquantel are used in public health programs to control diseases such as schistosomiasis, taeniasis caused by Taenia solium, opisthorchiasis and clonorchiasis. Praziquantel is a systemically distributed anthelmintic drug also used to treat neurocysticercosis (NCC) caused by the larval stages of T. solium in the central nervous system. The doses of praziquantel used in MDA are low compared to those used for the treatment of NCC, but in people with latent NCC (without symptoms or signs), there is a potential risk of neurological adverse events (AE) due to the development of inflammation around the cysts following administration. In Madagascar two large MDA campaigns aimed at T. solium were conducted using praziquantel in the Vakinankaratra region. Prior to the first MDA campaign, we implemented a program designed to minimize the occurrence of neurological AE and improve their management, which included training of health agents and community workers as well as health centres staff, population awareness, post-MDA active and passive surveillance and the supply of basic medicines to health centres. This program was repeated for the second MDA campaign. A total of 117,216 and 163,089 people were treated during the first and second MDA campaign respectively, with 10 participants experiencing serious AE, which were successfully managed. The beneficial results from our program in Madagascar can help other programs and countries using MDA with praziquantel in T. solium endemic areas to improve the safety of these campaigns.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40245080/",
    "length": 1592,
    "id": 1186,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_39975080",
    "text": "Understanding how life is adapting to urban environments represents an important challenge in evolutionary biology. Here we investigate a widely cited example of urban adaptation,",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39975080/",
    "length": 179,
    "id": 1187,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_39890226",
    "text": "In mid-November, 2021, the SARS-CoV-2 omicron variant (B.1.1.529; BA.1 sublineage) was detected in southern Africa, prompting international travel restrictions. We aimed to investigate the spread of omicron BA.1 in Africa. In this observational study, samples from patients infected with SARS-CoV-2 from 27 laboratories in 24 African countries, collected between June 1, 2021 and April 14, 2022, were tested for omicron BA.1 and delta (B.1.617.2) variants using real-time RT-PCR. Samples that tested positive for BA.1 by RT-PCR and were collected before estimated BA.1 emergence according to epidemiological properties were excluded from downstream analyses. The diagnostic precision of the assays was evaluated by high-throughput sequencing of samples from four countries. The observed spread of BA.1 was compared with mobility-based mathematical simulations and entries for SARS-CoV-2 in the Global Initiative on Sharing All Influenza Data (GISAID) genomic database. We estimated the effective reproduction number (R Through testing of 13 294 samples from patients infected with SARS-CoV-2, we established that, by November-December, 2021, omicron BA.1 had replaced the delta variant of SARS-CoV-2 in all African subregions, following a south-north gradient, with a median R Omicron BA.1 was widespread in Africa when travel bans were implemented, limiting their effectiveness. Combined with genomic surveillance and mobility-based mathematical modelling, PCR-based strategies can inform R Bill & Melinda Gates Foundation. For the French, Portugese and Spanish translations of the abstract see Supplementary Materials section.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39890226/",
    "length": 1628,
    "id": 1188,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092928",
    "text": "Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46·8 years (95% UI 46·6-47·0) in 1990 to 63·4 years (63·1-63·7) in 2023. For males, mean age increased from 45·4 years (45·1-45·7) to 61·2 years (60·7-61·6), and for females it increased from 48·5 years (48·1-48·8) to 65·9 years (65·5-66·3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80·9 years (80·9-81·0) and for males 74·8 years (74·8-74·9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38·0 years (37·5-38·4) for females and 35·6 years (35·2-35·9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. We examined global mortality patterns over the past three decades, highlighting-with enhanced estimation methods-the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092928/",
    "length": 7205,
    "id": 1189,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41065132",
    "text": "Inflammatory bowel disease triggers extraintestinal manifestations, including in the central nervous system (CNS). However, the direct impact of peripheral inflammation on the CNS is largely unknown. Using a mouse model of colitis with pain and anxiety-like behavior, we investigated the intricate pathogenic link between colonic inflammation, disruptions in circadian rhythmicity and impaired glymphatic circulation. By in vivo magnetic resonance imaging, we observed a derangement of brain fluid dynamics, with a significant enlargement of the cerebral lateral ventricles and waste deposition within the brain parenchyma. Proteomics revealed changes in cerebrospinal fluid (CSF) composition, enriched in proteins related to inflammation, immune response, complement, neuronal, and lipid metabolic pathways. Alterations in brain metabolite concentrations and in inhibitory control mechanisms and excitatory transmission were detected. Colonic inflammation induces remodeling in CSF volume distribution, clearance, and metabolism, with derangement of the crosstalk between neurons and astrocytes, priming synaptopathy. An acute peripheral inflammatory trigger affects the central level by remodeling central nervous system (CNS) fluid distribution and priming early signals of synaptopathy. A single dextran sulfate sodium (DSS) challenge disrupts the circadian clock machinery and alters CNS fluid distribution, a so far neglected system, thereby impairing glymphatic clearance of waste products and indirectly altering neurotransmitter release dynamics. These combined effects ultimately impact brain function, extending to the regulation of behavior. Understanding how an intestinal inflammatory insult may derange the daily rhythm of the mechanisms controlling brain waste disposal may help identify specific groups of subjects at high risk of developing neurological disorders.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41065132/",
    "length": 1882,
    "id": 1190,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41039076",
    "text": "Remote-living Aboriginal children in Australia contend with higher rates of skin infections than non-Indigenous children. This work was embedded within a stepped-wedge, cluster randomised controlled trial aiming to halve the rate of skin infections in remote Kimberley communities. It outlines and reflects upon the co-development of a health promotion resource in partnership with the East Kimberley community of Warmun, whilst understanding community perceptions of its impact. Through a community participatory action research methodology over several years, relationship building and consultation identified there was a community preference for health promotion resources that documented both traditional and Western ways of supporting skin health. Two-way learning was prioritised throughout the development process. Yarning methodology informed evaluation activities, with data analysed thematically. The resulting resource Berrembi Jarragboo-boorroo Wajawoorroo Men'gawoom Gijam (Gija Healthy Skin Story) was launched in March 2023. To date, over 500 hard copies of this and the subsequent Kriol version-Dijan Wen Wi Tokin Bela Propa Good Wan Skin Gota Gija-have been distributed. Eight Warmun community members and service providers participated in the evaluation yarns with themes specific to the development of the book, an assessment of impact and community-identified strengths. Berrembi Jarragboo-boorroo Wajawoorroo Men'gawoom Gijam (Gija Healthy Skin Story) exemplifies the elements of co-design emphasized across the Kimberley and Australia; opportunities for two-way learning, preference for community priorities and highlighting culture above all else. SO WHAT?: Health promotion activities completed within remote Aboriginal communities should prioritize two-way understanding, authentic relationships, Aboriginal-led, local language inclusion, equitable resourcing and ongoing evaluation to ensure that the results and outcomes are impactful for the communities involved.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41039076/",
    "length": 1991,
    "id": 1191,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41027996",
    "text": "Chagas disease (CD) is an emerging public health concern in Europe. In non-endemic countries, congenital transmission is the main route of new infections. Italy is the second-largest host country in Europe for Latin American migrants and the prevalence of the disease is estimated around 3.5%. The aim is to evaluate the cost-effectiveness of a congenital CD screening program in pregnant women at risk of infection living in Italy and their newborns. We conducted a cost-effectiveness analysis from the perspective of the Italian National Health Service, comparing a screening scenario with a no-screening scenario. A Bayesian decision tree model with a lifetime horizon was developed. In the base-case analysis, the screening strategy yielded an incremental cost-effectiveness ratio of €15,193 per quality-adjusted life year gained (95% CI: €14,885-€15,552), falling well within the accepted cost-effectiveness threshold (€30,000-€50,000) in Italy. Probabilistic sensitivity analysis confirmed the robustness of these findings. Here we show that screening for congenital CD is a cost-effective strategy that improves health outcomes and aligns with international public health priorities. Our findings support the implementation of a national screening program integrated within existing maternal care pathways, contributing to the prevention of neglected tropical diseases and the promotion of migrant health.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41027996/",
    "length": 1412,
    "id": 1192,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40999519",
    "text": "The Lymphatic Filariasis Elimination Programme was launched in Burkina Faso in 2001 aiming to eliminate the disease as a public health concern through mass drug administration (MDA). After eight years of MDA, the Hauts-Bassins region successfully passed the Transmission Assessment Survey (TAS), which led to the MDA being stopped. This study aims to assess whether parasite transmission has resurfaced in areas where MDA was stopped more than ten years ago. A cross-sectional entomological survey was conducted in the villages of Tiebalogo and Tondogosso, in the Hauts-Bassins region. From August to December 2022, adult mosquitoes were collected using Human Landing Collection (HLC) indoor and outdoor, Window Exit Trap (WET) and Pyrethrum Spray Collection (PSC). Mosquitoes were identified morphologically. Genomic DNAs extracted from An. gambiae s.l., An. funestus, An. nili were amplified by PCR for Wuchereria bancrofti parasite detection. A total of 2688 mosquitoes were collected in both study sites, with 630 being collected in Tondogosso and 2058 in Tiebalogo. The An. gambiae s.l. was the predominant mosquitoes, with high numbers being collected in both sites. Of those collected in Tiebalogo, 1786 (86.78%) were identified as An. gambiae s.l., while 373 (59.21%) were identified in Tondogosso. The HLC method collected the greatest number of mosquitoes, followed by the PSC and WET methods. No Wuchereria bancrofti DNA was detected in any of the mosquito pools analyzed in both sites. These findings provide further evidence that there is no Lymphatic Filariasis transmission occurring in Hauts-Bassin's post-TAS area. Molecular xenomonitoring of the filarial parasite which is a sensitive tool, could also serve as a complementary tool for monitoring transmission in post-MDA area and help national neglected tropical disease control program with surveillance in these areas.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40999519/",
    "length": 1889,
    "id": 1193,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40940648",
    "text": "The recognition of the unintended impact of COVID-19 mitigation measures to the availability of sexual and reproductive health (SRH) services led to the initiation of mitigation and health systems support mechanisms within public health facilities by the Ministry of Health (MoH) in Kenya to maintain pre-Covid-19 levels of SRH service provision. These recovery mechanisms however concentrated on policy and infrastructural elements of service provision with limited attention given to the psychosocial impacts of COVID-19 on health care workers (HCWs). This paper examines the psychosocial impact of COVID-19 on front line family planning (FP) and sexually transmitted infections (STI) management HCWs and their coping mechanisms with a view to suggesting ways in which HCWs can be supported during future pandemics. This paper employs a mixed methods approach with quantitative methodology analyzing data on the preparedness of the health sector to maintain service provision levels and qualitative data examining the mental and psychosocial states of HCWs who provide FP and STI health care services within Kenyan public health facilities. Our main finding was that the psychosocial wellbeing of HCWs was majorly neglected in the government response mechanisms for the pandemic leading to burnout and depression, as well as HCWs absconding their duties in the initial stages of the pandemic, and avoidance of testing and disclosure of status as the pandemic progressed. Some of these mechanisms undermined the mitigation measures by the government and put patients and colleagues at risk of infection by HCWs whose COVID-19 status remained unknown. We recommend that future responses include mechanisms that address the psychosocial wellbeing of HCWs as a core element of the response for effective management of pandemics. In the case of new and unprecedented pandemics such as COVID-19, it is important that HCWs are provided with accurate and timely information about the pandemic as well as to what is expected of their conduct in service delivery and in the promotion of a culture of risk reduction.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40940648/",
    "length": 2107,
    "id": 1194,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40768534",
    "text": "Schistosomiasis remains a critical public health challenge in endemic regions, particularly among school-aged children. Despite global efforts, conventional health education approaches show limited success in translating knowledge into sustained practices change. This study evaluates the efficacy of two innovative educational approaches-curriculum-integrated infiltration and stepwise progressive approaches-compared to traditional methods in enhancing schistosomiasis-related knowledge, attitudes, and practices (KAP) among students. A school-based intervention was conducted in Duchang County's Zhouxi township, with is an area afferted by schistosomiasis in China. Sixth-grade students (n ≈ 300) were divided into three groups: a traditional intervention group receiving standard WHO-aligned lectures, an infiltration group with cross-disciplinary curriculum integration, and a stepwise group with modular, tiered content. KAP outcomes were assessed via validated questionnaires at baseline and post-intervention. Both intervention groups demonstrated significant knowledge gains compared to traditional intervention (post-intervention accuracy: infiltration 89.67%, stepwise 91.10%, traditional intervention 86.50%; P < 0.001). Practices knowledge showed the most significant improvement (41.47% increase in the infiltration group vs. 22.38% in traditional intervention). The stepwise approaches achieved the highest overall accuracy (91.10%) but showed no statistically significant advantage over the infiltration approach (P > 0.05). Attitudinal improvements were consistent across groups, with high baseline rates limiting further gains (post-intervention: 95.60-96.68%). Curriculum-integrated and stepwise approaches effectively address the knowledge-practices gap in schistosomiasis education. The infiltration strategy, requiring minimal resources, is ideal for practices reinforcement in low-resource settings, while the stepwise approach suits rapid knowledge dissemination in well-resourced areas. These findings advocate for context-adaptive, multisectoral frameworks to optimize school-based interventions, aligning with WHO goals for neglected tropical disease elimination.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40768534/",
    "length": 2191,
    "id": 1195,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40720496",
    "text": "Non-communicable diseases (NCDs) represent the largest burden of disease, even in low-and middle-income countries (LMICs). The long latency period, chronicity, and common environmental, behavioral and genetic etiologies of NCDs-as shown through the example of Type 2 diabetes mellitus (T2DM)-expose health system failures to undertake multi-sectoral public health actions, address early detection, and provide integrated care. Development assistance for health (DAH), with its focus on donor priorities, often exacerbates such health system challenges. DAH has mainly focused on infectious diseases along with conditions related to reproductive health. Some programs show how DAH could help LMICs reorient health systems by focusing on neglected areas like economic and social policies, along with environmental and behavioral drivers of diseases like T2DM. Furthermore, in an era of declining resources for DAH, external support needs to be catalytic, supporting reforms more than financing services. Orienting limited DAH to address NCDs could support the necessary transformation of service organization, financial allocation criteria, data generation and use, health promotion, and training of care providers. DAH could also strengthen the public institutions and policies that prevent NCDs like T2DM through economic policies, environmental regulation, and health promotion interventions that address social and behavioral risk factors. Four broad categories of actions can guide DAH to better orient health systems to address NCDs: \"First, do no harm,\" help transform health systems, think outside the box, and match tools to needs. Several existing assistance modalities are also presented to show specific ways that this reorientation can be implemented.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40720496/",
    "length": 1762,
    "id": 1196,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40704221",
    "text": "The One Health (OH) approach is essential for preventing and managing zoonotic diseases through the promotion of intersectoral collaboration. Integrated surveillance systems enhance resource efficiency, support targeted interventions, and provide a comprehensive understanding of disease dynamics. However, operationalizing OH in resource-limited contexts encounters various obstacles due to systemic limitations. This study explores intersectoral collaboration across sectors engaged in zoonotic disease surveillance and response (ZDSR) in Ghana at the district level, identifying key operational gaps. We performed 46 key informant interviews with actors in the human, animal and wildlife health sectors directly involved in ZDSR. We developed an interview guide informed by WHO's",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40704221/",
    "length": 782,
    "id": 1197,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40654248",
    "text": "Diabetes is a fast-growing health issue in low- and middle-income countries, with ~80% of diabetics living in the tropics and sub-tropics. It is a deadly condition claiming the lives of millions of individuals annually, with no therapeutic treatment available to date. The management of diabetes is thus limited to symptomatic relief by glycemic control. Furthermore, the geographical overlap of diabetes and neglected tropical diseases (NTDs) is of concern, as diabetes is known to increase infection susceptibility and severity. In contrast, diabetes-infection comorbidity can negatively affect treatment responses. Leishmaniasis ranks among the top 10 NTDs. Its current therapeutic treatment relies on a handful of drugs that are marred with two main shortcomings: toxicity and reduced efficacy due to pathogenic resistance. Hence, there is a pressing need for new, effective antileishmanial therapeutics. There is evidence of rising cases of leishmaniasis-diabetes co-infection, which may require the use of dual-active therapeutics to curb them. In search of new effective antileishmanial agents with potential for dual use, we evaluated in vitro the antileishmanial and antidiabetic activities of a series of arylidenes derived from hydantoin, glitazone, and rhodanine scaffolds using phenotypic assays, some of which had previously been investigated for antidiabetic potential. Additionally, the antitrypanosomal potential of these compounds was also considered due to the taxonomic relation between Leishmania and Trypanosoma spp. and reported concerns of Chagas disease and human African trypanosomiasis-diabetes comorbidities. Three leishmanicidal early leads with submicromolar activity were uncovered, but no antitrypanosomal or dual leishmaniasis-diabetes active hits were identified.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40654248/",
    "length": 1797,
    "id": 1198,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41176393",
    "text": "The interconnectedness of the global HIV and sexually transmitted infection (STI) epidemics necessitates integrated strategies to address both. This Series paper highlights the biological link between HIV and STIs, and describes the successful progress in HIV response versus STI response over the past decades. The concept of undetectable=untransmissible (U=U) in HIV treatment has revolutionised HIV prevention by reducing stigma and promoting early treatment. In line with this approach, we discuss the role of chronic suppressive therapy for herpes simplex virus type 2 and the importance of the accurate diagnosis and treatment of curable STIs to prevent transmission between sexual partners. This Series paper explores the potential of pre-exposure prophylaxis (PrEP) for HIV in different forms (eg, daily oral PrEP, event-driven PrEP, and long-acting injectable PrEP), and highlights the challenges of adherence to daily regimens and the promise of longer-acting agents, such as cabotegravir and lenacapavir. The potential of doxycycline post-exposure prophylaxis for the prevention of bacterial STIs is also discussed, with concerns about antimicrobial resistance. Although vaccine development for HIV and STIs is a key biomedical advance, we discuss the challenges and possibilities of developing effective vaccines, including lessons learnt from previous HIV vaccine trials, the potential of mRNA-based vaccines for herpes simplex virus, ongoing trials for gonorrhoea and chlamydia vaccines, and the impact of existing human papillomavirus and mpox vaccines. Diagnostic innovations emphasise the importance of point-of-care tests for HIV and STIs. This Series paper discusses the benefits, landscape, and pipeline of rapid diagnostic tests (eg, lateral flow tests and molecular assays) and the challenges of implementing these tests in low-resource settings, particularly the need for rapid results to inform clinical decisions, promote convenience, and reduce cost. This Series paper also addresses innovations in service delivery and advocates for integrated and person-centred approaches (eg, differentiated services) that combine HIV and STI services, and highlights the potential of community-based and home-based models to improve access and reduce stigma.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41176393/",
    "length": 2272,
    "id": 1199,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41143074",
    "text": "SalmonellaSalmonella We report the first documented case of SVO with bilateral psoas myositis in a 56-year-old Vietnamese woman with newly diagnosed type 2 diabetes mellitus (HbA1c 9.2%). The patient presented with high fever (39 °C), visual analogue scale (8/10), and absence of gastrointestinal symptoms. Multiple antibiotic-susceptible In summary, this exceptional case represents the first reported SVO with bilateral psoas myositis, emphasizing the importance of advanced imaging and aggressive antibiotic therapy in diabetic patients presenting with fever and back pain, even without gastrointestinal symptoms.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41143074/",
    "length": 616,
    "id": 1200,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41126298",
    "text": "Screening and surveillance of HIV-positive pregnant women remain major public health challenges in the Democratic Republic of the Congo (DRC). This study aimed to describe the epidemiological, clinical, and biological characteristics of HIV-positive pregnant women in South Kivu. A retrospective cohort study was conducted at Panzi Hospital from July 2015 to July 2020. Multivariate logistic regression analyses were performed to identify factors associated with HIV status. Among the 9,143 women enrolled in PMTCT, 6,318 were tested, of whom 256 (4.1%) were HIV-positive, including 112 pregnant women (1.8%). Compared with their HIV-negative counterparts, HIV-positive pregnant women had lower antenatal care attendance compared with HIV-negative counterparts. The main opportunistic infections were candidiasis and genital herpes (2.7% each). Only 58% had available CD4 counts, all above 500 cells/ml. An undetectable viral load (< 30copies/l) was recorded in 60.7% of cases. Liver and renal dysfunctions were observed in 6.2% and 30.3% of patients, respectively, wereas d anemia (< 12 g/dl) affected 61.6%. In multivariable analysis, HIV infection was associated with age < 20 years (aOR = 7.20), primary education (aOR = 5.30), household income of $50-100/month (aOR = 56.4), primiparity (aOR = 10.68), and poverty (aOR = 18). Conversely, multigravidity (aOR = 0.19) and residence in the Ibanda and Kadutu health zones were protective factors CONCLUSION: Epidemiological and biological profiles strongly influence PMTCT outcomes. Strengthening HIV testing, expanding ART access, and routine viral load monitoring particularly among young and primiparous women are essential to improve maternal and neonatal health outcomes in the DRC.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41126298/",
    "length": 1738,
    "id": 1201,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41087950",
    "text": "Talaromycosis is an invasive fungal infection with high mortality in patients with advanced human immunodeficiency virus (HIV) disease in the tropical and subtropical regions of Asia. The lungs are the most commonly involved organ, and chest computed tomographic (CT) typically reveals diffuse pulmonary reticular and ground-glass changes. However, cavitary nodules are rare in HIV-positive patients, often leading to delay diagnosis. A 46-year-old female with a 3-year history of untreated HIV infection was referred to our hospital due to recurrent fever lasting for 4 months. The chest CT showed a large nodular lesion with cavitary in the right lung, which was initially considered a neoplastic lesion at the referring hospital. A CT-guided percutaneous lung biopsy was performed, and fungal spores were found in lung pathology. Talaromyces marneffei was cultured from lung tissue and bone marrow at 4-day and 10-day post-sampling, respectively. The patient was diagnosed with disseminated talaromycosis. The patient received a two-week induction therapy with amphotericin B, resulting in a remarkable clinical response with substantial resolution of the cavitary pulmonary nodules. Following discharge, the patient continued antifungal therapy with itraconazole, and showed no evidence of disease recurrence during the 1-year follow-up period. This case highlights that pulmonary talaromycosis may present as cavitary nodular lesions, and further microbiological examination is indispensable for definitive diagnosis.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41087950/",
    "length": 1522,
    "id": 1202,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41025254",
    "text": "This study investigates the innovative application of nanomaterial-based micro-devices aimed at enhancing the diagnosis and management of acyclovir (ACV) for herpes virus infections, specifically those caused by HSV-1, HSV-2, CMV, and VZV. Herpes viruses are associated with various clinical diseases, highlighting the urgent need for effective antiviral therapies. Acyclovir remains a primary treatment option; however, its potential for kidney toxicity and allergic reactions necessitates careful dosage monitoring, particularly in immunocompromised patients. Recent advancements in drug monitoring systems have been developed to optimize dosing regimens and reduce the risk of misuse. This study focuses on the integration of biological and electrochemical nanosensors utilizing nanomaterials, which have shown significant improvements in detection capabilities and diagnostic sensitivity for ACV. We delineate the novel features and applications of these micro-devices, emphasizing their unique configurations and unprecedented limits of detection. This research illustrates how these advanced technologies can enhance existing methodologies in herpes virus management, ultimately leading to improved treatment outcomes.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41025254/",
    "length": 1224,
    "id": 1203,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41017776",
    "text": "People who inject drugs (PWID) are highly affected by hepatitis C (HCV) worldwide, particularly in low- and middle-income countries (LMICs), where access to addiction services is often limited. Reducing the burden of HCV, as promoted by WHO, requires effective interventions in this high-risk population. Here, we report the safety and efficacy of a pangenotypic generic HCV treatment among PWID in Vietnam, using a sofosbuvir/daclatasvir regimen. PWID were screened for HCV at two community-based organisations (CBO) premises in Haiphong during both a respondent-driven sampling survey and cohort follow-up visits. PWID with detectable HCV RNA were referred to three public hospitals for a 12-week regimen of generic sofosbuvir/daclatasvir, with ribavirin if cirrhosis, and with CBO support for referral and adherence. Treatment safety was assessed over the course of treatment and success was measured by sustained virologic response 12 weeks after the end of treatment (SVR12). Of the 1201 PWID screened with detectable HCV RNA, 1021 were enrolled: 96% male, median age 42 years, 45% HIV-infected, 16% with advanced liver fibrosis, 55% currently injecting, and 71.5% on methadone maintenance therapy (MMT). In total, 979 participants started HCV treatment, and 901 of the 924 participants tested at SVR12 (98%) were cured. Genotype 3, current drug use, lack of MMT, and HIV infection were independently associated with treatment failure. High HCV cure rates can be achieved among PWID in LMICs such as Vietnam using a simple model of care, including a pangenotypic generic direct-acting antiviral combination and CBO support. Trial Registration: ClinicalTrials.gov identifier: NCT03537196.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41017776/",
    "length": 1692,
    "id": 1204,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41015051",
    "text": "Cancer is a leading cause of death globally. Accurate cancer burden information is crucial for policy planning, but many countries do not have up-to-date cancer surveillance data. To inform global cancer-control efforts, we used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 framework to generate and analyse estimates of cancer burden for 47 cancer types or groupings by age, sex, and 204 countries and territories from 1990 to 2023, cancer burden attributable to selected risk factors from 1990 to 2023, and forecasted cancer burden up to 2050. Cancer estimation in GBD 2023 used data from population-based cancer registration systems, vital registration systems, and verbal autopsies. Cancer mortality was estimated using ensemble models, with incidence informed by mortality estimates and mortality-to-incidence ratios (MIRs). Prevalence estimates were generated from modelled survival estimates, then multiplied by disability weights to estimate years lived with disability (YLDs). Years of life lost (YLLs) were estimated by multiplying age-specific cancer deaths by the GBD standard life expectancy at the age of death. Disability-adjusted life-years (DALYs) were calculated as the sum of YLLs and YLDs. We used the GBD 2023 comparative risk assessment framework to estimate cancer burden attributable to 44 behavioural, environmental and occupational, and metabolic risk factors. To forecast cancer burden from 2024 to 2050, we used the GBD 2023 forecasting framework, which included forecasts of relevant risk factor exposures and used Socio-demographic Index as a covariate for forecasting the proportion of each cancer not affected by these risk factors. Progress towards the UN Sustainable Development Goal (SDG) target 3.4 aim to reduce non-communicable disease mortality by a third between 2015 and 2030 was estimated for cancer. In 2023, excluding non-melanoma skin cancers, there were 18·5 million (95% uncertainty interval 16·4 to 20·7) incident cases of cancer and 10·4 million (9·65 to 10·9) deaths, contributing to 271 million (255 to 285) DALYs globally. Of these, 57·9% (56·1 to 59·8) of incident cases and 65·8% (64·3 to 67·6) of cancer deaths occurred in low-income to upper-middle-income countries based on World Bank income group classifications. Cancer was the second leading cause of deaths globally in 2023 after cardiovascular diseases. There were 4·33 million (3·85 to 4·78) risk-attributable cancer deaths globally in 2023, comprising 41·7% (37·8 to 45·4) of all cancer deaths. Risk-attributable cancer deaths increased by 72·3% (57·1 to 86·8) from 1990 to 2023, whereas overall global cancer deaths increased by 74·3% (62·2 to 86·2) over the same period. The reference forecasts (the most likely future) estimate that in 2050 there will be 30·5 million (22·9 to 38·9) cases and 18·6 million (15·6 to 21·5) deaths from cancer globally, 60·7% (41·9 to 80·6) and 74·5% (50·1 to 104·2) increases from 2024, respectively. These forecasted increases in deaths are greater in low-income and middle-income countries (90·6% [61·0 to 127·0]) compared with high-income countries (42·8% [28·3 to 58·6]). Most of these increases are likely due to demographic changes, as age-standardised death rates are forecast to change by -5·6% (-12·8 to 4·6) between 2024 and 2050 globally. Between 2015 and 2030, the probability of dying due to cancer between the ages of 30 years and 70 years was forecasted to have a relative decrease of 6·5% (3·2 to 10·3). Cancer is a major contributor to global disease burden, with increasing numbers of cases and deaths forecasted up to 2050 and a disproportionate growth in burden in countries with scarce resources. The decline in age-standardised mortality rates from cancer is encouraging but insufficient to meet the SDG target set for 2030. Effectively and sustainably addressing cancer burden globally will require comprehensive national and international efforts that consider health systems and context in the development and implementation of cancer-control strategies across the continuum of prevention, diagnosis, and treatment. Gates Foundation, St Jude Children's Research Hospital, and St Baldrick's Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41015051/",
    "length": 4204,
    "id": 1205,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41013685",
    "text": "Eumycetoma is an endemic chronic granulomatous infection in tropical and subtropical regions, including Sudan. This case series presents three Sudanese patients with intracranial mycetoma (27-year-old female from Central Sudan, 20-year-old male from Central Sudan, and 23-year-old male from West Sudan), highlighting different clinical presentations, diagnostic challenges, and management strategies. All cases involved young individuals with painless swellings, discharging sinuses, and other central nervous system manifestations. The diagnosis was confirmed by different histopathological and imaging modalities. Surgical management was performed for the localized lesion case but, unfortunately, the other two cases were difficult to operate on owing to the large extension of the disease and were followed with medical management. This series highlights the difficulties in diagnosing and managing cases of intracranial mycetoma. It emphasizes the importance of early diagnosis, multidisciplinary management, and public health efforts to reduce the burden of mycetoma in endemic regions.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41013685/",
    "length": 1092,
    "id": 1206,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41009833",
    "text": "Veillonella We report the case of an 80-year-old patient diagnosed with discitis caused by In our case, antimicrobial susceptibility testing was performed using the Kirby-Bauer disc diffusion method. Based on the results, the patient was treated with amoxicillin/clavulanate, which led to a favourable clinical outcome. A review of the literature revealed that, to date, only 14 cases of spondylodiscitis or discitis caused by Spondylodiscitis due to",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41009833/",
    "length": 450,
    "id": 1207,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40972751",
    "text": "Recurrent cystic echinococcosis (RCE) occurs by the spillage of live protoscoleces during unsuccessful surgery or spontaneous rupturing of fertile hydatid cyst. Currently, RCE presents a significant concern within surgical community. Managing RCE cases is challenging due to limitations in diagnostic follow-up, therapeutic pitfalls, emerging drug resistance, and innate immunological responses between host-parasite cross-talk. Recent advances suggest that parasite-derived microRNAs hold promise as biomarkers for early detection and monitoring of RCE. Additionally, combining benzimidazoles (parasito-static) with praziquantel (parasiticidal) in nano-formulation derivatives has demonstrated potential pharmacokinetic synergism, highlighting the need for personalized treatment plans. Optimizing surgical methods and ensuring regular chemotherapy following both conservative and radical surgeries are crucial for minimizing RCE. Furthermore, identifying β-tubulin codons in albendazole-resistant hydatid cyst and the role of toll-like receptor polymorphisms are critical for developing targeted therapies. The insights presented here aim to support specialists in developing effective interventions and preventive measures to reduce and improve patient outcomes in.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40972751/",
    "length": 1268,
    "id": 1208,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40658735",
    "text": "Yellow fever (YF), a mosquito-borne viral hemorrhagic fever, is endemic to Uganda and has caused numerous outbreaks in recent years. This study explored local perceptions of YF outbreaks among vulnerable groups in Uganda to inform future public health campaigns. A qualitative study examined community perceptions of YF and its treatment practices. Data were collected in six districts where YF outbreaks were reported in 2010 and 2016. A total of 76 individuals participated, comprising 43 semi-structured interviews, 10 expert interviews, and 4 focus group discussions, including vulnerable groups of older adults ≥ 65 years and pregnant women. Data were analyzed using grounded theory. Participants often recognized jaundice but did not distinguish YF from other causes of jaundice, such as newborn jaundice, severe malaria or hepatitis. Nevertheless, participants still considered YF a deadly disease. It was perceived to be transmitted through multiple pathways, including mosquito bites, airborne transmission, close contact with sick individuals, sexual intercourse, vertical transmission during pregnancy, poor hygiene, and certain foods. Treatments ranged from herbal remedies to visiting health centers. Several YF survivors shared first-hand experience, often relying on traditional medicine due to limited access to health facilities, diagnostic options, and no specific treatment for YF. In remote areas, participants often did not know the cause of the outbreak, as awareness campaigns focused on symptoms, prevention, and mass vaccination. If YF is not seen as a distinct disease entity, implementing diagnostic and preventive measures may be impeded. Moreover, failure to diagnose YF in clinical settings can hamper timely outbreak response. We recommend strengthening health literacy through health education and public participation in vulnerable communities with programs tailored to local needs, given that other infectious diseases are prevalent in the region. Furthermore, we propose that access to diagnostic testing for YF may be enhanced.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40658735/",
    "length": 2063,
    "id": 1209,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_40352114",
    "text": "The use of herbal medicines to treat ailments is a common practice in several regions in Africa, relying on knowledge systems that have evolved over several generations. These herbal remedies are often based on anecdotal claims, many of which lack scientific validation. This study investigates the mode of action of two bioactive fractions, F1 (IC",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40352114/",
    "length": 348,
    "id": 1210,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_37719535",
    "text": "Andrographis paniculataA. paniculataA. paniculataA. paniculataA. paniculata",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37719535/",
    "length": 75,
    "id": 1211,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_37143036",
    "text": "Kheaw Hom remedy is a traditional Thai medicine used to treat fever. Some plants used in the Kheaw Hom remedy show promising in vitro antimalarial activity. This study prepared novel formulations of plants from the Kheaw Hom remedy and evaluated their antimalarial and toxicological activities. Seven new formulations were prepared by combining at least three herbs of six selected plants from the Kheaw Hom remedy, namely Mammea siamensis Kosterm., Mesua ferrea L., Dracaena loureiroi Gagnep., Pogostemon cablin (Blanco) Benth., Kaempferia galanga L, and Eupatorium stoechadosmum Hance. In vitro antimalarial activities of each formulation's aqueous and ethanolic extracts were evaluated using the parasite lactate dehydrogenase (pLDH) assay. Cytotoxicity in Vero and HepG2 cells was assessed using the MTT assay. An extract with good antimalarial potency and selectivity index (SI) was selected for in vivo antimalarial activity using Peter's 4-day suppressive test and acute oral toxicity test in mice. In addition, bioactive compounds were identified using Gas chromatography-mass spectrometry (GC-MS) analysis. Among the seven new formulations, ethanolic extracts of CPF-1 (Formulation 1) showed the highest activity with an IC The ethanolic extract of CPF-1 showed promising in vitro and in vivo antimalarial efficacy, with no toxic effects at a dose of 2000 mg/kg, suggesting that the ethanolic extract of CPF-1 may serves as a new herbal formulation for the treatment of malaria. Additional research is required for safety and clinical pharmacology studies.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37143036/",
    "length": 1565,
    "id": 1212,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_36617576",
    "text": "The people in Ethiopia have developed their own specific knowledge to use, manage and conserve plant resources, giving traditional medicine its diverse nature. Documenting and investigating the traditional and cultural use of remedial plants is vital to extract bioactive chemicals and preserve plant species. This research was conducted with the aim of documenting ethnobotanical and associated knowledge on medicinal plants in Asagirt District, northeastern Ethiopia. The study was conducted from September 27, 2018, to April 9, 2019. A total of 367 informants (244 males and 123 females) were involved in the interviews. General informants (n = 349) were randomly selected, whereas key informants (n = 18) were selected purposively. Data were collected by using semistructured interviews, group discussions and guided field walks. We performed direct matrix ranking and preference ranking, and calculated the fidelity level and informant consensus factor (ICF). Descriptive statistics, including analysis of variance (ANOVA) and independent sample t-test were used to analyse the data. Overall, 103 medicinal plant species belonging to 96 genera under 45 plant families were recorded to be used by Asagirt people to alleviate different health problems. The species used to heal human diseases only were (64%, 66 species) followed by both livestock and human ailments (31%, 32 species) and livestock diseases only (5%, 5 species). Asteraceae and Fabaceae were best-represented (10.7%, 11 species each). The most frequently used plant parts were leaves (28%, 29 species), followed by seeds (16%, 17 species). The most important method of herbal remedy preparation was crushing (20.4%, 21 species). The common route of administration was oral (46.6%, 48 species), followed by dermal (22.3%, 23 species). Febrile illness, fever, headache, amoebiasis, typhoid and diarrhoea ailment categories had the highest ICF value (0.99). Ocimum lamiifolium Hochst. ex Benth. scored the maximum fidelity level value (98%). Asagirt District is comparatively rich in medicinal plants and their associated knowledge. However, firewood collection, construction, the expansion of agricultural activities and timber production are the major challenges to medicinal plants. Hence, joint management with the people in Asagirt District in overall medicinal plant conservation would save medicinal plant resources.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36617576/",
    "length": 2390,
    "id": 1213,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_12639738",
    "text": "The ethnographic study was conducted in two communities in Oyo State in Southwestern Nigeria. The study sites consisted of a rural and an urban local government area located in the tropical rain forest zone of Nigeria. The study was designed to obtain information on febrile illnesses and herbal remedies for treatment with the aim of identifying potential antimalarial drugs. The study revealed that fever is a general term for describing illnesses associated with elevated body temperature. The indigenous Yoruba ethnic population has categorized fever based on symptoms and causes. The present communication is the result of focus group discussion and semi-structured questionnaire administered to traditional healers, herb sellers, elders and mothers. This was on types of fevers, symptoms and causes of febrile illnesses. The investigation also included use of traditional herbs in the prevention and treatment of the illnesses in the two communities.A total of 514 respondents were interviewed. This was made up of 266 (51.8%) from Atiba local government area (LGA), an urban centre while 248 (48.2%) respondents were interviewed from Itesiwaju LGA, a rural community. The LGAs are located in Oyo State of Nigeria. The respondents proffered 12 types of febrile illnesses in a multiple response answering system in Yoruba language. The most common ones (direct translation into English) were: yellow fever (39.1%), typhoid (34.8%), ordinary (28.8%), rainy season (20.8%) and headache (10.5%) fevers, respectively. Perceived causes of each of the febrile illnesses included stress, mosquito bites, unclean water, rains and over exposure to the sun. Methods of fever prevention were mainly with the use of herbal decoctions, powdered herbs, orthodox medications and maintenance of proper hygiene. Of a total of 112 different herbal remedies used in the treatment of the febrile illnesses compiled from the study, 25 recipes are presented. Recipes consisted of 2-7 ingredients. Oral decoctions (84%), oral powders (63%), use as soaps and creams (40%) in a multiple response system, were the most prevalent routes of administration of prepared herbs used in the treatment of the fevers. Boiling in water or alcohol was the most common method used in the preparation of the remedies. The four most frequently mentioned (multiple response system) plants in the Southwest ethnobotany for fevers were Azadirachta indica (87.5%), Mangifera indica (75.0%), Morinda lucida (68.8%) and Citrus medica (68.8%).",
    "url": "https://pubmed.ncbi.nlm.nih.gov/12639738/",
    "length": 2501,
    "id": 1214,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41101186",
    "text": "The Western honey bee (Apis mellifera L.) plays a crucial role in global ecosystems and agriculture, yet the ectoparasitic mite Varroa destructor remains a primary cause of severe varroosis and significant colony morbidity and mortality. Current reliance on synthetic acaricides often leads to the development of mite resistance and raises concerns regarding chemical residues in hive products. This has created an urgent need for innovative and effective veterinary strategies for parasite control. This study investigated the efficacy of traditional plant-based remedies as an alternative treatment for V. destructor infestations in honey bee colonies. Herbal decoctions from medicinal plants (e.g., nettle, clove, linden, peppermint, lavender, sage, dandelion), known for their anti-parasitic properties, were applied to bee colonies via aerosol. V. destructor infestation levels were monitored monthly using a non-destructive CO₂-induced narcosis method. Statistical analysis, specifically a Linear Mixed Model (LMM), revealed a significant decrease in mean Varroa infestation from 1.8 % in 2021-1.1 % in 2023 across the experimental colonies (p < 0.000001 for year effect). Furthermore, the LMM confirmed significant differences in efficacy among the tested decoctions (p < 0.000001 for Decoction label effect), with specific extracts (DIII and DV) demonstrating superior performance. These findings highlight a validated, ecologically derived phytotherapeutic approach for Varroa management, demonstrating its potential to significantly reduce mite populations over multiple years without adverse effects on honey bee health. This research provides valuable insights into natural alternatives for parasitic mite control in domesticated animals like honey bees.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41101186/",
    "length": 1766,
    "id": 1215,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41095247",
    "text": "In Africa, the folkloric practices involving plant-based remedies play a crucial role in livestock farming, often attributed to the limited access to modern veterinary services. The use of",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41095247/",
    "length": 188,
    "id": 1216,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_39196821",
    "text": "Anogeissus latifolia, commonly known as Axlewood, Indian Gum Tree, or Gum Ghatti, belongs to the Combretaceae family and is native to India, Nepal, Myanmar, and Sri Lanka. It thrives in most tropical and subtropical regions of India. Different parts of the plant contain various proteins, carbohydrates, sugars (arabinose, galactose, mannose, xylose, rhamnose, and glucuronic acid), minerals (magnesium and calcium salts of ghattic acid), and a wide range of phytochemicals such as alkaloids, flavonoids, phenols, terpenoids, sterols, saponins, tannins, coumarins, quinine, and ellagic acid. Studies have indicated the potential of Anogeissus latifolia in managing various health conditions, including antimicrobial, anti-inflammatory, anti-diabetic, anti-parasitic, antioxidant, hepatoprotective, wound healing, and hypolipidemic effects. However, like many medicinal plants, Anogeissus latifolia demonstrates a dose-dependent toxicity profile, particularly when administered intraperitoneally. Research efforts have been directed towards elucidating its safety profile, and findings suggest that it can be considered safe when administered within prescribed dosages. This paper aims to provide a comprehensive review encompassing the ethnobotanical significance, morphological characteristics, phytochemistry, pharmacological actions, and toxicological aspects of Anogeissus latifolia. Additionally, it explores future research perspectives in the field of Anogeissus latifolia pharmacology and therapeutics.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/39196821/",
    "length": 1510,
    "id": 1217,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_38515660",
    "text": "Due to the health benefits that medicinal plants present, they are applied in traditional healthcare in developing and developed countries alike.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38515660/",
    "length": 145,
    "id": 1218,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_37705864",
    "text": "The Qinghai-Tibet Plateau, known as the \"Third Pole of the World,\" has a rich variety of medicinal plants that play an important role in the field of medicine due to its unique geographical environment. However, due to the limited resources of Tibetan medicinal plants and the fragility of the ecological environment of the Qinghai-Tibet Plateau, more and more Tibetan medicinal plants are on the verge of extinction. As a reservoir of biologically active metabolites, endophytes of medicinal plants produce a large number of compounds with potential applications in modern medicine (including antibacterial, immunosuppressive, antiviral, and anticancer) and are expected to be substitutes for Tibetan medicinal plants. This paper reviews 12 Tibetan medicinal plants from the Qinghai-Tibet Plateau, highlighting the diversity of their endophytes, the diversity of their metabolites and their applications. The results show that the endophytes of Tibetan medicinal plants are remarkably diverse, and the efficacy of their metabolites involves various aspects, such as antioxidant, anti-disease and anti-parasitic. In addition, conservation measures for the resources of Tibetan medicinal plants are summarised to provide a reference for an in-depth understanding of the endophytes of Tibetan medicinal plants and to stimulate the scientific community to bioprospect for the endophytes of Tibetan medicinal plants, as well as to provide ideas for their rational exploitation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37705864/",
    "length": 1473,
    "id": 1219,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_36577457",
    "text": "The genus Piper, a member of the Piperaceae family, comprises >2000 species, of which many are well known to possess considerable economic and medicinal values. Lignans are essential ingredients and are rich in Piper plants. Although many phytochemical studies have reported many lignans identified from Piper plants, comprehensive research has not reviewed these compounds. Hence, the present review reports on natural lignans from the genus Piper and their pharmacological activities. At least 275 lignans have been discovered from the Piper genus until October 2022, including traditional lignans, neolignans, oxyneolignans, norlignans, secolignans, and polyneolignans, especially some neolignans and norlignans with novel and complex scaffolds. In addition, these lignans have been reported to show various pharmacological activities, such as antimicrobial, anti-inflammatory, neuroprotective, antioxidative, anti-platelet aggregation, cytotoxic, anti-parasitic, CYP3A4 inhibitory activities, and so on. The current work presents an up-to-date critical review and a systematic summary of publications on lignans from the genus Piper to lay the groundwork and show better insights for further investigations.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36577457/",
    "length": 1211,
    "id": 1220,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_36399185",
    "text": "Medicinal plants have a long track record of use in history, and one of them is Commiphora myrrh which is commonly found in the southern part of Arabia, the northeastern part of Africa, in Somalia, and Kenya. Relevant literatures were accessed via Google Scholar, PubMed, Scopus, and Web of Science to give updated information on the phytochemical constituents and pharmacological action of Commiphora myrrh. It has been used traditionally for treating wounds, mouth ulcers, aches, fractures, stomach disorders, microbial infections, and inflammatory diseases. It is used as an antiseptic, astringent, anthelmintic, carminative, emmenagogue, and as an expectorant. Phytochemical studies have shown that it contains terpenoids (monoterpenoids, sesquiterpenoids, and volatile/essential oil), diterpenoids, triterpenoids, and steroids. Its essential oil has applications in cosmetics, aromatherapy, and perfumery. Research has shown that it exerts various biological activities such as anti-inflammatory, antioxidant, anti-microbial, neuroprotective, anti-diabetic, anti-cancer, analgesic, anti-parasitic, and recently, it was found to work against respiratory infections like COVID-19. With the advancement in drug development, hopefully, its rich phytochemical components can be explored for drug development as an insecticide due to its great anti-parasitic activity. Also, its interactions with drugs can be fully elucidated.This review highlights an updated information on the history, distribution, traditional uses, phytochemical components, pharmacology, and various biological activities of Commiphora myrrh. Graphical summary of the phytochemical and pharmacological update of Commiphora myrrh.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36399185/",
    "length": 1701,
    "id": 1221,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_36089201",
    "text": "Researchers are exploring natural resources in search of a new and effective anti-malarial compound to address the challenges in malarial treatment due to emerging incidences of drug-resistant strains. Following background knowledge of traditional medicine, we evaluated the in-vitro and in-vivo anti-malarial efficacy of Putranjiva P. roxburghii (Putranjivaceae) twigs ethanol extracts and fraction (PRT). In-vitro parasite-specific lactate dehydrogenase (pLDH) assay was performed using a chloroquine-sensitive Plasmodium falciparum strain. The results of the in-vitro study were further validated by in-vivo anti-malarial studies on P. berghei Keyberg 173 (K173) infected mice. The crude ethanol extract of the PRT showed the most moderate antiparasitic activity (IC",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36089201/",
    "length": 769,
    "id": 1222,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_35721148",
    "text": "Tetradenia ripariaLamiaceaeT. ripariaT. ripariaT. riparia.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35721148/",
    "length": 58,
    "id": 1223,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_35405253",
    "text": "Duranta erecta Linn. belonging to the Verbenaceae family is widely used in the traditional systems of medicines practiced in Bangladesh, India, Nigeria, the Philippines, and Brazil. The ethnomedicinal application as vermifuge, febrifuge, diuretic, anti-parasitic, and anti-malarial are well documented. D. erecta is also a significant source of phenylethanoid glycoside known as acteoside-a drug in clinical trials for IgA nephropathy patients. This review aims to critically highlight the existing studies on D. erecta, including its botanical authentication, geographical distribution, ethnomedicinal uses, phytochemistry, and pharmacological properties. Critical discussion is focused on the overview and gap in knowledge for future research. Additionally, the clinical significance of its major secondary metabolite, i.e., acteoside, has also been discussed with emphasis on biosynthesis, distribution, pre-clinical, and clinical outcomes. Professional research data from 1963 to 2021 appeared in scholarly journals, and books were retrieved from scientific database platforms viz. Sci-Finder, PubMed, CNKI, Science Direct, Web of Science, Wiley, Google Scholar, Taylor and Francis, Springer, and Scopus. The chemical structures for all the phytomolecules were validated using Sci-finder and first-hand references. While plant name and synonyms were corroborated by \"The Plant List\" (www.theplantlist.org). D. erecta and its key metabolite acteoside display various biological actions like antimalarial, antimicrobial, antioxidant, anticancer, antinephritic, hepatoprotective, neuroprotective, and antiviral properties. Acteoside literature analysis shows its presence in different stages of clinical trials for anti-nephritic, hepatoprotective, and osteoarthritic activity. The phytochemical review of D. erecta exhibited 64 compounds that have been isolated and identified from D. erecta, such as iridoid glycosides, phenylethanoid glycosides, flavonoids, steroids, phenolics, terpenoids, and saponins. The other significant secondary metabolites responsible for its medicinal properties are acteoside, durantol, pectolinaringenin, repenins, scutellarein, and repennoside. Duranta erecta is one of the Verbenaceae plants, widely used in ethnomedicines having various phytochemicals with understandable pharmacological actions mainly confined at the crude extract level. However, further bioactivity-guided or fingerprint-assisted studies are required to validate the ethnomedicinal uses, concerning cellular and molecular mechanisms, quality standardization, and safety with respect to its bioactive constituent(s). Therefore, the present review identified the gap in the research on scientific validation of Duranta based ethnomedicines and may provide critical information for the development of phytopharmaceuticals/Phyto-cosmeceuticals.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35405253/",
    "length": 2846,
    "id": 1224,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41148138",
    "text": "There is limited direct evidence of the effects of policies regarding ambient particulate matter with an aerodynamic diameter of 2.5 µm or less (PM2.5) on the risk of hospitalization for cardiovascular diseases (CVD). This evidence is essential for estimating the benefits of meeting specific PM2.5 standards in the regulatory impact analysis. To estimate the association of strengthening ambient PM2.5 standards with the risk of hospitalization for major CVD outcomes. This population-based study used data from the UK Biobank cohort and followed up the participants from January 1, 2015, to December 31, 2019. All participants were 60 years or older and had no history of hospitalization with a primary diagnosis of a specific CVD at baseline. Data were analyzed from August 1, 2022, to August 25, 2025. Annual mean PM2.5 exposure was assigned based on a 1 × 1-km2 resolution PM2.5 model linked to participants' residential locations. The main outcomes were the first hospitalization with a primary diagnosis of stroke, myocardial infarction, heart failure, or arrhythmia. Longitudinal targeted maximum likelihood estimation was used to estimate 5-year hospitalization risks under hypothetical PM2.5 interventions. Among the 502 133 UK Biobank participants recruited from 2006 to 2010 (273 158 [54.4%] female), 307 202 participants met the eligibility criteria for stroke, 304 212 for myocardial infarction, 310 100 for heart failure, and 302 255 for arrhythmia. The median age was 68.0 (IQR, 64.6-71.5) years for stroke, myocardial infarction, and arrhythmia, 68.0 (IQR, 64.7-71.5) years for heart failure, with female participants ranging from 54.4% to 55.0% across cohorts. Compared with no intervention on PM2.5, implementing a stricter ambient PM2.5 standard would reduce the absolute risk of hospitalization for major CVD. It was estimated that for the hypothetical PM2.5 intervention of reducing PM2.5 exposure by 5% if it is above the threshold of 9 µg/m3, the estimated 5-year risk difference of hospitalization for stroke was -2.26 per mille (95% CI, -8.97 to -20.64 per mille); for myocardial infarction, -8.64 per mille (95% CI, -9.16 to -6.38 per mille); for heart failure, -3.20 per mille (95% CI, -4.16 to -1.25 per mille); and for arrythmia, -4.16 per mille (95% CI, -12.70 to 12.93 per mille). For the hypothetical PM2.5 intervention of reducing PM2.5 exposure by 5% if it is above the threshold of 12 µg/m3, the estimated 5-year risk difference of hospitalization for stroke was -1.54 per mille (95% CI, -2.21 to 0.73 per mille). However, the reduction in risk for arrhythmia was not statistically significant (-2.06 per mille [95% CI, -4.79 to 3.12 per mille]). In this cohort study using data from the UK Biobank, the absolute risk reduction of hospitalization for stroke, myocardial infarction, heart failure, and arrhythmia due to hypothetical ambient PM2.5 interventions was quantified. The findings suggest the beneficial cardiovascular health impacts of further strengthening the current PM2.5 regulations in the United Kingdom.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41148138/",
    "length": 3055,
    "id": 1225,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41118354",
    "text": "This paper introduces GeneDrive.jl, the first software package to optimize operational planning for the biological control of mosquito disease vectors (access: https://github.com/vnvasquez/GeneDrive.jl). Mosquitoes are responsible for transmitting a significant percentage of the global infectious disease burden, a problem being exacerbated as climate change shifts the range and alters the abundance of these temperature-sensitive arthropods. The efficacy and cost of vector control varies according to species, region, and intervention type. Meanwhile, existing computational tools lack the ability to explicitly tailor interventions for local health objectives and resource limitations. GeneDrive.jl addresses this equity and efficiency gap, which is of particular concern for the tropical regions that both bear the highest mosquito-borne disease burden and are subject to disproportionate climate impacts. The software customizes vector population reduction strategies that employ genetic biocontrol, a broad suite of technologies that alter the genotype or phenotype of mosquito disease vectors, according to specific health goals and financial constraints. It can also be used to characterize risk by analyzing the temperature-responsive dynamics of wildtype vectors. GeneDrive.jl is designed to accommodate two important realities shaping the future of vector-borne disease: first, the genetic-based tools that are defining a new era in control, and second, the uncertainty that increasingly variable and extreme temperatures bring for the climate-sensitive pathogens transmitted by mosquitoes. Written in the Julia programming language, the software provides a 'build once, solve twice' feature wherein users may define a problem, optimize it, and subsequently subject outcomes to scenario-based testing within a single coherent platform. We demonstrate the policy relevance of this scalable open-source framework via case studies featuring the use of Release of Insects with Dominant Lethality (RIDL) to suppress Aedes aegypti populations in the dengue-endemic region of Nha Trang, Vietnam. This work is intended for an interdisciplinary audience and includes a Glossary to facilitate understanding (see S1 Text).",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41118354/",
    "length": 2224,
    "id": 1226,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092928",
    "text": "Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46·8 years (95% UI 46·6-47·0) in 1990 to 63·4 years (63·1-63·7) in 2023. For males, mean age increased from 45·4 years (45·1-45·7) to 61·2 years (60·7-61·6), and for females it increased from 48·5 years (48·1-48·8) to 65·9 years (65·5-66·3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80·9 years (80·9-81·0) and for males 74·8 years (74·8-74·9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38·0 years (37·5-38·4) for females and 35·6 years (35·2-35·9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. We examined global mortality patterns over the past three decades, highlighting-with enhanced estimation methods-the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092928/",
    "length": 7205,
    "id": 1227,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41092926",
    "text": "For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associated risk factors. This paper presents GBD 2023 findings on disease and injury burden and risk-attributable health loss, offering a global audit of the state of world health to inform public health priorities. This work captures the evolving landscape of health metrics across age groups, sexes, and locations, while reflecting on the remaining post-COVID-19 challenges to achieving our collective global health ambitions. The GBD 2023 combined analysis estimated years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 375 diseases and injuries, and risk-attributable burden associated with 88 modifiable risk factors. Of the more than 310 000 total data sources used for all GBD 2023 (about 30% of which were new to this estimation round), more than 120 000 sources were used for estimation of disease and injury burden and 59 000 for risk factor estimation, and included vital registration systems, surveys, disease registries, and published scientific literature. Data were analysed using previously established modelling approaches, such as disease modelling meta-regression version 2.1 (DisMod-MR 2.1) and comparative risk assessment methods. Diseases and injuries were categorised into four levels on the basis of the established GBD cause hierarchy, as were risk factors using the GBD risk hierarchy. Estimates stratified by age, sex, location, and year from 1990 to 2023 were focused on disease-specific time trends over the 2010-23 period and presented as counts (to three significant figures) and age-standardised rates per 100 000 person-years (to one decimal place). For each measure, 95% uncertainty intervals [UIs] were calculated with the 2·5th and 97·5th percentile ordered values from a 250-draw distribution. Total numbers of global DALYs grew 6·1% (95% UI 4·0-8·1), from 2·64 billion (2·46-2·86) in 2010 to 2·80 billion (2·57-3·08) in 2023, but age-standardised DALY rates, which account for population growth and ageing, decreased by 12·6% (11·0-14·1), revealing large long-term health improvements. Non-communicable diseases (NCDs) contributed 1·45 billion (1·31-1·61) global DALYs in 2010, increasing to 1·80 billion (1·63-2·03) in 2023, alongside a concurrent 4·1% (1·9-6·3) reduction in age-standardised rates. Based on DALY counts, the leading level 3 NCDs in 2023 were ischaemic heart disease (193 million [176-209] DALYs), stroke (157 million [141-172]), and diabetes (90·2 million [75·2-107]), with the largest increases in age-standardised rates since 2010 occurring for anxiety disorders (62·8% [34·0-107·5]), depressive disorders (26·3% [11·6-42·9]), and diabetes (14·9% [7·5-25·6]). Remarkable health gains were made for communicable, maternal, neonatal, and nutritional (CMNN) diseases, with DALYs falling from 874 million (837-917) in 2010 to 681 million (642-736) in 2023, and a 25·8% (22·6-28·7) reduction in age-standardised DALY rates. During the COVID-19 pandemic, DALYs due to CMNN diseases rose but returned to pre-pandemic levels by 2023. From 2010 to 2023, decreases in age-standardised rates for CMNN diseases were led by rate decreases of 49·1% (32·7-61·0) for diarrhoeal diseases, 42·9% (38·0-48·0) for HIV/AIDS, and 42·2% (23·6-56·6) for tuberculosis. Neonatal disorders and lower respiratory infections remained the leading level 3 CMNN causes globally in 2023, although both showed notable rate decreases from 2010, declining by 16·5% (10·6-22·0) and 24·8% (7·4-36·7), respectively. Injury-related age-standardised DALY rates decreased by 15·6% (10·7-19·8) over the same period. Differences in burden due to NCDs, CMNN diseases, and injuries persisted across age, sex, time, and location. Based on our risk analysis, nearly 50% (1·27 billion [1·18-1·38]) of the roughly 2·80 billion total global DALYs in 2023 were attributable to the 88 risk factors analysed in GBD. Globally, the five level 3 risk factors contributing the highest proportion of risk-attributable DALYs were high systolic blood pressure (SBP), particulate matter pollution, high fasting plasma glucose (FPG), smoking, and low birthweight and short gestation-with high SBP accounting for 8·4% (6·9-10·0) of total DALYs. Of the three overarching level 1 GBD risk factor categories-behavioural, metabolic, and environmental and occupational-risk-attributable DALYs rose between 2010 and 2023 only for metabolic risks, increasing by 30·7% (24·8-37·3); however, age-standardised DALY rates attributable to metabolic risks decreased by 6·7% (2·0-11·0) over the same period. For all but three of the 25 leading level 3 risk factors, age-standardised rates dropped between 2010 and 2023-eg, declining by 54·4% (38·7-65·3) for unsafe sanitation, 50·5% (33·3-63·1) for unsafe water source, and 45·2% (25·6-72·0) for no access to handwashing facility, and by 44·9% (37·3-53·5) for child growth failure. The three leading level 3 risk factors for which age-standardised attributable DALY rates rose were high BMI (10·5% [0·1 to 20·9]), drug use (8·4% [2·6 to 15·3]), and high FPG (6·2% [-2·7 to 15·6]; non-significant). Our findings underscore the complex and dynamic nature of global health challenges. Since 2010, there have been large decreases in burden due to CMNN diseases and many environmental and behavioural risk factors, juxtaposed with sizeable increases in DALYs attributable to metabolic risk factors and NCDs in growing and ageing populations. This long-observed consequence of the global epidemiological transition was only temporarily interrupted by the COVID-19 pandemic. The substantially decreasing CMNN disease burden, despite the 2008 global financial crisis and pandemic-related disruptions, is one of the greatest collective public health successes known. However, these achievements are at risk of being reversed due to major cuts to development assistance for health globally, the effects of which will hit low-income countries with high burden the hardest. Without sustained investment in evidence-based interventions and policies, progress could stall or reverse, leading to widespread human costs and geopolitical instability. Moreover, the rising NCD burden necessitates intensified efforts to mitigate exposure to leading risk factors-eg, air pollution, smoking, and metabolic risks, such as high SBP, BMI, and FPG-including policies that promote food security, healthier diets, physical activity, and equitable and expanded access to potential treatments, such as GLP-1 receptor agonists. Decisive, coordinated action is needed to address long-standing yet growing health challenges, including depressive and anxiety disorders. Yet this can be only part of the solution. Our response to the NCD syndemic-the complex interaction of multiple health risks, social determinants, and systemic challenges-will define the future landscape of global health. To ensure human wellbeing, economic stability, and social equity, global action to sustain and advance health gains must prioritise reducing disparities by addressing socioeconomic and demographic determinants, ensuring equitable health-care access, tackling malnutrition, strengthening health systems, and improving vaccination coverage. We live in times of great opportunity. Gates Foundation and Bloomberg Philanthropies.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41092926/",
    "length": 7451,
    "id": 1228,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41088037",
    "text": "Visceral leishmaniasis (VL), also known as kala-azar, has posed significant challenges to elimination efforts due to increased reporting of new cases from high mountain and previously considered non-endemic areas in Nepal. Understanding the potential distribution of disease risk and its changing patterns in the context of climate change is vital to inform policies and target available resources effectively. In this study we modelled and mapped climatically (environmentally) areas suitable for VL transmission based on the ecological niche principle and machine learning modelling techniques. The results revealed that about 34% of the land area in the lowland Tarai region and river valleys in the hill and mountain regions of Nepal are currently suitable for VL transmission. Climate change is expected to increase the suitable area to 43% in the pessimistic scenario (SSP 585) for both time periods (2050s and 2070s), while the area at risk of transmission will remain static stagnant or slightly decrease in the optimistic scenario (SSP245) for both periods. Environmental suitability for VL transmission will decrease in the eastern lowland but increase in the West. The assessment of the proportion of the population at risk of VL transmission is about 81% which is expected to decrease in future, as VL risk decreases in some more densely populated areas. However, the predicted spatial shift of the population at risk will expose new populations at risk of transmission of VL. Our findings may contribute to design evidence-based health polices and to optimally target limited resources in the National VL Elimination programme.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41088037/",
    "length": 1640,
    "id": 1229,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41084606",
    "text": "An unprecedented heatwave swept the globe in 2023, marking it one of the hottest years on record and raising concerns about its health impacts. However, a comprehensive assessment of the heatwave-related mortality and its attribution to human-induced climate change remains lacking. We aim to address this gap by analyzing high-resolution climate and mortality data from 2,013 locations across 67 countries/territories using a three-stage modeling approach. First, we estimated historical heatwave-mortality associations using a quasi-Poisson regression model with distributed lag structures, considering lag effects, seasonality, and within-week variations. Second, we pooled the estimates in meta-regression, accounting for spatial heterogeneity and potential changes in heatwave-mortality associations over time. Third, we predicted grid-specific (0.5 0.5) association in 2023 and calculated the heatwave-related excess deaths, death ratio, and death rate per million people. Attribution analysis was conducted by comparing heatwave-related mortality under factual and counterfactual climate scenarios. We estimated 178,486 excess deaths (95% empirical confidence interval [eCI], 159,892≥204,147) related to the 2023 heatwave, accounting for 0.73% of global deaths, corresponding to 23 deaths per million people. The highest mortality rates occurred in Southern (120, 95% eCI, 116≥126), Eastern (107, 95% eCI, 100≥114), and Western Europe (66, 95% eCI, 62≥70), where the excess death ratio was also higher. Notably, 54.29% (95% eCI, 45.71%≥61.36%) of the global heatwave-related deaths were attributable to human-induced climate change. These results underscore the urgent need for adaptive public health interventions and climate mitigation strategies to reduce future mortality burdens in the context of increasing global warming.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41084606/",
    "length": 1835,
    "id": 1230,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41082884",
    "text": "Antimicrobial resistance (AMR) is an urgent global crisis and one of the world's most complex challenges. Although there is increasing evidence of its impact on human mortality and morbidity, precise burden estimation has many challenges, and thus far has been elusive for the Eastern Mediterranean Region. Here, we present a comprehensive time-trend analysis of regional and country-level AMR burden estimates in the WHO Eastern Mediterranean Region (EMR), between 1990 and 2021, with forecasts up to 2050. We estimated deaths and disability-adjusted life-years (DALYs) attributable to and associated with AMR for 11 infectious syndromes, 22 bacterial pathogens, and 84 pathogen-drug combinations for the WHO EMR and each of its countries from 1990 to 2021. Data were obtained from mortality registries, surveillance systems, hospital records, systematic literature reviews, and other sources. We based our modelling approach on five broad components: the number of deaths in which infection had a role, the proportion of infectious deaths attributable to a given infectious syndrome, the proportion of infectious syndrome deaths attributable to a given pathogen, the percentage of a given pathogen resistant to an antimicrobial drug of interest, and the excess risk of mortality (or duration of an infection) associated with this resistance. These components were then used to estimate the disease burden by using two counterfactual scenarios: deaths and DALYs attributable to AMR (considering an alternative scenario where drug-resistant infections are replaced with susceptible infections), and deaths and DALYs associated with AMR (considering an alternative scenario where infections would not occur at all). Predictive statistical modelling was applied to generate estimates of AMR burden for each country. We also generated AMR burden forecasts up to 2050. We generated 95% uncertainty intervals (UIs) for the final estimates by taking the 2·5th and 97·5th percentiles across 500 draws through the multistage computational pipeline, and models were cross-validated for out-of-sample predictive validity. We estimated 380 000 deaths (95% UI 332 000-426 000) associated with bacterial AMR and 92 800 deaths (78 300-111 000) attributable to bacterial AMR in the EMR in 2021. In the past 31 years, there was considerable variation in AMR mortality trends across countries of the region and different age groups. Between 1990 and 2021, associated deaths among children younger than 5 years decreased by 50·0% (38·2-62·0), while those among adults aged 70 and older rose by over 85·7% (95% UI 57·0-115·7). Six pathogens were identified as the primary generators of burden: Streptococcus pneumoniae, Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus, Acinetobacter baumannii, and Pseudomonas aeruginosa. A substantial increase in the AMR burden due to S aureus was observed between 1990 (28 200 deaths [21 600-34 000]) and 2021 (49 500 deaths [43 100-56 200]); consequently, in 2021, methicillin-resistant S aureus was a leading pathogen-drug combination for most countries in the region for deaths and DALYs attributable to, and associated with AMR. Somalia had the highest age-standardised mortality rates in the region: for deaths attributable to and associated with AMR per 100 000 population in both 1990 and 2021; conversely, the country with the lowest burden in the EMR was Qatar. By 2050, the number of deaths attributable to AMR in region is forecasted to reach 187 000 (157 000-223 000) and deaths associated with AMR were projected to reach 752 000 (629 000-879 000). Our study shows that bacterial AMR has been a serious public health threat in the EMR for more than 30 years, with a substantial fatal and non-fatal burden for priority bacterial pathogens and pathogen-drug combinations. The magnitude of this issue, future projects, and the inadequate response capacity in many countries underscore the need for more stringent regional leadership in this field. The insights gained from this study can direct targeted mitigation strategies for individual countries within the region, aiding in resource allocation and funding decisions, and emphasising the need for collaborative multisectoral endeavours among nations to address this issue. Wellcome Trust, and the UK Department of Health and Social Care using aid funding managed by the Fleming Fund.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41082884/",
    "length": 4380,
    "id": 1231,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41080465",
    "text": "Substantial shifts in contemporary diets are needed to halt the growing burden of chronic diseases and the accelerating climate crisis. Achieving this will require strong action and the use of policy instruments that can aid consumers in making the right dietary choices. Real-life evidence on changing dietary behaviors within complex food systems at scale demands resources and research that might not be realistic to acquire or realize. This project applied innovative models to predict the dietary and environmental effects of broad-scale strategies designed to transform dietary behaviors among consumers. Scenarios were numerically simulated using agent-based opinion-dynamics models to evaluate the impact of governmental influence on people's consumption of meat, vegetables, pulses, and meat alternatives. We considered the problem of influencing the opinions of a group of agents (representing the UK population) connected in a social network over a sequence of campaigns to achieve convergence to 2 different targets: achieving the UK Climate Change Committee's goal of 35% and 50% average reduction in meat consumption by 2030 and 2050, respectively. The opinion dynamics comprised consumers (i.e., agents), with empirically derived baseline food intake patterns (i.e., initial opinions) and sociodemographic attributes. Changes in environmental impacts following changes in consumption were quantified. In a scenario of high governmental influence, uniform in the population, achievement of the 35% and 50% meat reduction goals corresponded to ∼5.2 and ∼8.1 y, respectively. As meat consumption reduced, intake of vegetables, pulses, and meat alternatives increased by 84.7%, 108.5%, and 30.8%, respectively (-35% scenario). Greenhouse gas emissions, land use, water use, and scarcity-weighted water were reduced by -23.8%, -20.2%, -0.5%, and -14.5%, respectively (-35% scenario). The findings of this project provide valuable insights for policymakers and governmental authorities to develop effective influence strategies aimed at promoting healthy and sustainable dietary habits.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41080465/",
    "length": 2095,
    "id": 1232,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41071808",
    "text": "In the Brazilian Amazon, approximately 900,000 people live along riverbanks, relying on the biome for survival and livelihoods. Severe droughts and flooding events, intensified by the El Niño phenomenon and human-driven actions such as deforestation and fires, exacerbate the isolation of traditional communities. This isolation limits access to essential healthcare services and worsens existing health inequalities among vulnerable populations. This study investigates how extreme climatic events impact health and healthcare access in traditional riverine communities, focusing on their perceptions and lived experiences. A qualitative study was conducted in a riverine community in Tabatinga, Western Brazilian Amazon. Thirty-two purposively selected participants (farmers, fishermen, and students) took part in in-depth interviews and focus-group discussions. Thematic analysis was conducted using MAXQDA software. After the analysis two main themes emerged: (1) the impacts of Amazonian seasonality on healthcare access, and (2) the dynamics of arrivals and departures along riverbanks. Participants highlighted health challenges tied to seasonal extremes, including water and food insecurity, financial vulnerability, spikes in gastrointestinal diseases, increased accidents with aquatic or wild animals, river pollution, and higher drowning rates. They also noted births and deaths occurring along riverbanks during extreme events. Most respondents perceived that extreme weather events, especially severe droughts, have intensified over the past decade, worsening health and food/water security and further restricting healthcare access. In this scenario, riverine communities are highly vulnerable to climate change, as existing health challenges are compounded by escalating climatic crises. Tailored healthcare solutions, including telemedicine platforms, mobile clinics, and resilient transportation networks, are urgently needed. Investments in communication infrastructure and emergency air transportation are critical as riverine navigation becomes increasingly unreliable.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41071808/",
    "length": 2089,
    "id": 1233,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41181113",
    "text": "EchinococcosisEchinococcusE. granulosusIn vitro",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41181113/",
    "length": 47,
    "id": 1234,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41178789",
    "text": "A residual focus of bancroftian filariasis was found in Fuchuan County, Guangxi Zhuang Autonomous Region, China in 2007, and the response measures were implemented with participation and guidance from the National Institute of Parasitic Diseases at the Chinese Center for Disease Control and Prevention (China CDC). This study aims to assess the infection sources and summarize the management processes of the residual focus to fill the gap of the re-emergence of focus after elimination as a public health problem. The assessment of the infection sources in the residual filariasis focus was conducted by on-site investigation and review of the database that was created and maintained by the China CDC. Historical records that were created by the China/Fuchuan CDC and maintained by the China CDC were retrospectively reviewed to summarize the experience of the handling process for filariasis. Statistical tests and logistic regression were performed to analyse the epidemic characteristics of the residual filariasis focus. A total of 7308 test records were reviewed, of which 919 were from the focus's natural village while 6389 were from other affected populations. Age and sex significantly affect filariasis infection, and the high-risk population was the 50-69 y age group and males in this focus. The on-site evaluation result and database monitoring showed that the focus did not spread locally or to neighbouring places and thus did not pose a public health threat. The emergency response process (ERP) for residual filariasis focus was developed and the rapid report and survey of the first case serves as the pre-trigger signal for ERP. Implementation of the ERP should account for local technical resource availability, representing the optimal approach under capacity-constrained conditions. Maintenance of a sensitive and effective surveillance system and stockpiling of technologies and medicines are key to consolidating the elimination of filariasis and preventing its re-emergence. The disposal process is a systematic and scientific action that must follow epidemiological and medical principles according to local conditions.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41178789/",
    "length": 2148,
    "id": 1235,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41173066",
    "text": "Cutaneous leishmaniasis (CL) is one of the most widespread neglected tropical diseases, transmitted by Phlebotomus sandflies and caused by protozoan parasites of the genus Leishmania. It poses a major global public health concern, particularly in arid and semi-arid regions where ecological and socio-environmental factors favor vector proliferation. In Algeria, CL is endemic across several regions, yet few studies have explored its long-term epidemiological dynamics in the Sahara Desert, where the disease continues to expand. This study aimed to investigate the spatio-temporal evolution and epidemiological characteristics of CL in the Sahara Desert of Algeria, specifically within the Djamaa province which represents an active and historically persistent focus of infection. Using a Bayesian analytical framework, we sought to identify demographic, temporal, and clinical determinants influencing disease occurrence and distribution, thereby providing insights for more effective control and prevention strategies. Data were obtained from the official public health records of the Djamaa province covering a 12-year period (2012-2023). Epidemiological variables included gender, age, number and anatomical site of lesions, and spatio-temporal case distribution across municipalities. Descriptive statistics and chi-square tests were applied to assess differences between groups. To account for uncertainty and the hierarchical structure of the data, a Bayesian Markov chain Monte Carlo Sampler for Multivariate Generalized Linear Mixed Model (MCMCglmm) was employed to evaluate the effects of temporal and clinical predictors on CL incidence. A total of 4436 confirmed CL cases were recorded during the study period, with a mean annual incidence of 369.7 cases. The highest peak was observed in 2012 (23.91%), followed by a gradual decline in subsequent years. Monthly distribution indicated pronounced seasonality, with maximum case occurrence in November (22.9%) and January (13.8%), reflecting the transmission dynamics of Phlebotomus vectors. CL affected both sexes and all age groups, but males (65.2%) and teenagers aged 10-20 years (33.7%) were the most affected, likely due to greater outdoor exposure. Lesions were mainly located on the lower extremities (64.9%), and multiple lesions were observed in 54% of patients. The Bayesian MCMCglmm analysis identified significant temporal effects (annual and monthly) and clinical variables (number and site of lesions) as major determinants shaping CL occurrence, confirming the strong seasonal and ecological dependence of the disease. The findings confirm that CL remains a major endemic health issue in the Sahara Desert of Algeria, particularly in Djamaa province. The disease exhibited clear temporal and demographic patterns linked to vector ecology and host exposure. To our knowledge, this is the first application of a Bayesian spatial model to characterize CL risk in the Northern Sahara of Algeria, this approach provided a robust framework for integrating uncertainty and multiple covariates, offering valuable evidence for risk-based vector control. Future research should combine epidemiological, entomological, molecular, and environmental analyses to develop an integrated strategy for CL management in hot arid lands.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41173066/",
    "length": 3295,
    "id": 1236,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41170573",
    "text": "An outbreak of an ertapenem-resistant",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41170573/",
    "length": 37,
    "id": 1237,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41167952",
    "text": "As an emerging interdisciplinary field bridging ecology and immunology, eco-immunology focuses on the co-evolutionary dynamics between hosts and parasites within natural environments, and aims to unravel the ecological mechanisms underlying the formation of host immune strategies, so as to provide new insights into parasitology and parasitic diseases research. Based on case studies of diverse host-parasite systems, including insects-protozoans, fish-cestodes, amphibians-nematodes, reptiles-arthropods, birds-ectoparasites, and mammals-helminths, this review summarizes critical eco-immunological principles, including host tolerance trade-offs under resource constraints, transgenerational epigenetic adaptation, nutrition-immunity interactions, and immune conflicts triggered by multiparasite co-infections. In addition, the article discusses the feasibility and practical pathways of ecological management and interventions to achieve biodiversity conservation and disease control based on the eco-immunological theory, so as to provide innovative insights into responses to address ecological conservation and public health challenges in the context of global changes. ［摘要］",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41167952/",
    "length": 1181,
    "id": 1238,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41167945",
    "text": "To investigate the tick species, and tick-derived Rickettsiales bacteria and recently emerging tick-derived viruses in hilly and costal mudflat wetland settings in northern Jiangsu Province, so as to provide insights into management of tick-borne tropical diseases in northern Jiangsu Province. Ticks were sampled from hilly settings in Yuyi County, Huai'an City and coastal mudflat wetland settings in Jiangsu Yancheng Wetlands & Rare Birds National Nature Reserve in Tinghu District, Yancheng City on April, 2025. Following characterization of tick species, nucleic acid was isolated from ticks under a sterile condition, and tick-derived pathogens were detected using nested and semi-nested real-time PCR assays, including A total of 154 ticks were captured, including 114 from Huai'an City and 40 from Yancheng City, and 153 ticks were characterized as Ticks are widely distributed in hilly and costal mudflat wetland settings in northern Jiangsu Province, and tick-derived pathogens have a genetic diversity. Tick-borne ［摘要］目的方法结果结论",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41167945/",
    "length": 1037,
    "id": 1239,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41167941",
    "text": "To evaluate the value of inquiry examinations for diagnosis of taeniasis in field investigations, so as to provide insights into improving the efficiency and accuracy of taeniasis control programmes. Four taeniasis-endemic villages were sampled in Dali Bai Autonomous Prefecture, Yunnan Province in October 2023 as survey sites, and at least 305 permanent residents at ages of over 3 years were randomly sampled from each site. Face-to-face inquiries were performed with structured questionnaires to investigate participants' history and frequency of proglottids release during the past year, consumption of raw or undercooked meat products or pork liver during the past six months, history and time of deworming. Participants' stool samples were collected, and A total of 1 842 participants were included, and 1 842 valid questionnaires were recovered. A total of 1 533 stool samples were collected, among which 25 egg-positives were identified. Questionnaire surveys showed that 1 305 respondents had consumed raw or undercooked meat products during the past six months, and 42 respondents had a history of proglottids release during the past year. Diagnostic deworming was given to the aforementioned 25 egg-positive individuals and 42 participants who self-reported a history of proglottids release during the past year, and 33 participants had a release of complete worms. Following exclusion of records of individuals receiving deworming during the past 3 months, during the past year, and all participants with a history of deworming, the AUCs were 0.767 ( A history of ［摘要］目的方法结果ZPZPZPDPZPZPZPDPP结论",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41167941/",
    "length": 1606,
    "id": 1240,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41167939",
    "text": "Currently, echinococcosis is highly prevalent in both China and Mongolia, and the risk of cross-border echinococcosis transmission raises growing concerns. This article describes the epidemiology of echinococcosis in China and Mongolia, compares echinococcosis control measures between the countries, and discusses the potential risk of cross-border echinococcosis transmission due to human and animal mobility, transboundary movement of animal hosts, and disparities in control capacity between the two countries. In addition, the article proposes the promising cooperation areas for joint prevention and control of echinococcosis between the two countries, including the joint development of guidelines and standards, technical and financial assistance, and cross-border pathogen monitoring and tracing, so as to provide insights into cross-boundary health cooperation between China and Mongolia, effective management of echinococcosis transmission, and improvements in the regional public health security. ［摘要］",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41167939/",
    "length": 1013,
    "id": 1241,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41165304",
    "text": "The transmission of tick-borne viruses is associated with the biological functions of tick tissues. This study investigated the viromes in salivary glands, ovaries, and midguts collected from nine tick species of six genera and identified 49 viruses from at least 14 families. A variety of viral abundance and diversity across the three tissues was demonstrated. Ovaries of Tick tissues (salivary glands, ovaries, and midguts) are critical for the development of ticks and virus transmission. This study analyzed viromes in these tissues across six tick genera, thereby revealing the viral heterogeneity in tick tissues and suggesting differential transmission advantages among the examined genera. The results provide a novel insight into the understanding of the competence for virus transmission by ticks, based on viral populations, and into the mechanisms underlying virus dissemination within tick bodies, as well as those of vertical or horizontal transmission of viruses linked to the biological functions of tick tissues. The findings also suggest the importance of a more in-depth investigation into viral transmission, with a particular focus on the viromes of tick eggs, saliva, and hemolymph. All these would serve as a crucial foundational framework, establishing a robust foundation for the future development of strategies aimed at the control of viral transmission by ticks.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41165304/",
    "length": 1391,
    "id": 1242,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41164979",
    "text": "The rhizosphere microbial community serves as a protective barrier against soil-borne diseases. However, it is unclear how Trichoderma influences the rhizosphere microbial community to control cucumber Fusarium wilt (CFW). This study demonstrated that Trichoderma asperellum FJ035 effectively suppresses CFW under continuous cropping by altering the rhizosphere microbiome, as confirmed through microbiome transfer experiments. Amplicon sequencing combined with cultivation-based methods showed that T. asperellum FJ035 modifies the composition and abundance of cucumber rhizosphere microbial communities. Based on these findings, a synthetic consortium, TB11, was constructed containing T. asperellum FJ035 and 30 bacterial strains that effectively controlled CFW and promoted cucumber growth. We simplified this consortium to TB5, comprising six strains closely related to T. asperellum FJ035, with a 71.43% reduction in CFW and 54.69% increase in plant weight. Further investigation revealed that T. asperellum FJ035 promotes the colonisation of B5 in cucumber roots and forms a protective microbiota to resist Fusarium oxysporum infection. This study reported a novel mechanism by which T. asperellum FJ035 prevents and controls CFW by regulating native bacterial communities in the rhizosphere. Moreover, the construction of synthetic consortia is described as a sustainable strategy for healthy cucumber cultivation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41164979/",
    "length": 1422,
    "id": 1243,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41181113",
    "text": "EchinococcosisEchinococcusE. granulosusIn vitro",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41181113/",
    "length": 47,
    "id": 1244,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41135800",
    "text": "Understanding the red blood cell (RBC) invasion mechanism by Plasmodium falciparum, the causative agent of human malaria, is critical for developing blood-stage vaccines. Most research on the roles of parasite molecules during invasion into the RBC has focused on the pre-invasion and invasion phases, particularly on merozoite proteins in these early steps. Consequently, well-established blood-stage vaccine candidates, such as MSP1, AMA1, EBA175, Rh5, CyRPA, and Ripr, have been discovered by research targeting the early invasion phases. Recently, we identified that Liver Stage Antigen 3 (LSA3) is a merozoite dense granule protein and a novel blood-stage vaccine candidate, given that antigen-specific antibodies inhibit parasite growth by 24%. However, the precise role of LSA3 in RBC invasion remains unclear. In this study, we investigated the function of LSA3 during merozoite invasion of RBCs. In the late-invasion phase, LSA3 localized to the posterior end of invading wild-type merozoites accessible to anti-LSA3 antibodies in the culture medium. In vitro cultured lsa3 knockout parasites (ΔLSA3) exhibited slowed parasite growth. Time-lapse imaging revealed that knockout of lsa3 resulted in a 65% reduction in normal invasion completion relative to the wild-type. Furthermore, ΔLSA3 parasites displayed a high frequency of accolé-form: aberrant morphology, with a protruding convex-shaped ring-stage just beneath the RBC membrane, following successful internalization into RBCs. This study provides the first evidence that a merozoite dense granule protein potentially plays an important role in the late-invasion phase of the P. falciparum erythrocytic cycle.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41135800/",
    "length": 1675,
    "id": 1245,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41071742",
    "text": "Since its establishment in 1962, the Vaccine and Treatment Evaluation Units (VTEUs) have employed cutting-edge technologies to develop novel vaccines and therapeutics to mitigate emerging public health threats in the United States and globally. Clinical trial innovation has been the hallmark of these efforts as novel approaches to testing countermeasures are investigated in pace with advances in technology and evolving public health needs. The spectrum of trials conducted by the VTEUs ranges from proof-of-concept or first-in-human phase 1 to late-phase trials that establish efficacy and inform licensure decisions or \"real world\" vaccine usage such as with the coronavirus disease 2019 (COVID-19) and rotavirus mix-and-match trials aimed to inform standard of care. The VTEUs have also been instrumental in developing experimental wild-type challenge studies to preliminarily assess vaccine immunogenicity against influenza, shigellosis, cholera, enterotoxigenic Escherichia coli, enteropathogenic E. coli, and malaria to help select promising vaccine candidates for further development. During the COVID-19 pandemic, novel strategies for recruitment and improved accessibility of vaccine clinical trials emerged. However, the pandemic also highlighted the need for improved representation in clinical trials and underscored the importance of community engagement. As we consider what challenges to address in the upcoming years, engagement of the population in clinical trials is critical to establishing safety and efficacy and community acceptance of vaccines and therapeutics. It is imperative to develop skills that engender community advocacy while staying on the cutting edge of science, henceforth serving as the guideposts for new frontiers in clinical trial innovation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41071742/",
    "length": 1786,
    "id": 1246,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41063982",
    "text": "Sex, race and geographic location may affect vaccine-induced immune responses, yet few preventive HIV vaccine trials have systematically evaluated such effects. The main objective of this study was therefore to examine the role of these factors on vaccine-induced HIV-specific immune responses within the HVTN 204 trial. This randomized, double-blinded, placebo-controlled phase 2 trial enrolled 480 Black and Caucasian adults from Africa and the Americas, who received a trivalent DNA-HIV-1 vaccine prime followed by a rAd5 vector HIV-1 vaccine boost. Available serum samples from baseline and four weeks after the final vaccination boost from Black (n=85, 59% female) and Caucasian (n=49, 51% female) HVTN 204 vaccine recipients from South Africa and the United States of America were studied using an Enzyme-Linked Immunosorbent Assay to determine titers of Envelope-specific IgG1, IgG3 and IgA antibodies. Recognition of linear Envelope peptide-specific IgG responses was mapped in a randomly selected subgroup analysis using a custom-designed peptide microarray (n = 41, 49% female). Associations between vaccine-induced Envelope-specific antibody responses and sex assigned at birth (female or male), race and geographic location were then analyzed by the Mann-Whitney U test, Fisher's exact test and multivariate logistic regression. Four weeks post-final vaccination boost, we observed that Envelope-specific antibody titers were significantly increased for IgG1 but reduced for IgA in females (female vs. male median titer: 900 vs. 300, p=0.030 and <100 vs. 100, p=0.007, respectively). Multivariate logistic regression confirmed that female sex increased the odds for higher Envelope-specific IgG1 and low IgA titers compared to males. In terms of antibody epitopes, the V2 region was more frequently recognized in females than males (p=0.008). Race and geographic location had no apparent influence on antibody isotype titers investigated. Female sex was associated with higher vaccine-induced IgG Envelope-specific binding antibody titers and recognition of V2 region of HIV Envelope in HVTN 204 volunteers. No such associations were detected for race or geographic location. Understanding biological factors driving these sex-based differences may improve the design of a new generation of HIV vaccine candidates.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41063982/",
    "length": 2326,
    "id": 1247,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41063484",
    "text": "Dengue fever poses a grave threat to public health worldwide, claiming numerous fatalities each year with tropical regions being particularly hard hit by dengue outbreaks. The multiple-epitope construct is tailored to the dengue virus's geographical prevalence and the genetics of the Pakistani population. 14 experimentally validated MHC-I and MHC-II epitope sequences, were employed to generate the variants by taking into account the conservancy in all serotypes. Subsequently, the binding affinities of each derived variant against the human leukocyte antigen alleles most common among the Pakistani population were analyzed. A total of three epitopes, two Class-I (GTSGSPIINR and RSWNTGFDW), and one Class-II (ILAPTRVVAAEMEEA), with a combined Pakistani population coverage of more than 73%, together with five linear B cell epitopes were used to create six possible multi-epitope fusion constructs. The molecular docking analysis indicated that two constructs demonstrated notable binding affinities for the most abundant HLA-A*11:01 in Pakistan. Additionally, molecular dynamics (MD) simulations identified one of the constructs as a promising therapeutic candidate. The vaccine construct selected from this analysis could aid in future vaccine design for the dengue virus following further in vitro test validation and in vivo studies to investigate its immune protection capacity.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41063484/",
    "length": 1389,
    "id": 1248,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41053546",
    "text": "The SARS-CoV-2 spike protein is the primary antigen used in most COVID-19 vaccines. To improve protection, especially at mucosal surfaces, a robust and safe delivery system capable of inducing both systemic and mucosal immunity is needed. Bacillus subtilis spores offer a promising platform due to their stability, safety, and capacity for protein display. A study to evaluate the potential acute oral toxicity of recombinant B. subtilis spores expressing SARS-CoV-2 spike proteins was undertaken. B. subtilis spore was used to express the SARS-CoV-2 S1 domain spike proteins during the bacterial sporulation. No in vitro cytotoxicity was observed when the spores were used to treat cells. BALB/c mice were given a single oral dose (5 × 10 These findings suggest that the SARS-CoV-2 S1 domain spike proteins expressed on B. subtilis spores is well tolerated in mice when administered orally at a high dose. Findings from this study, hence, support further investigation of the recombinant bacterial spores expressing SARS-CoV-2 S1 domain spike proteins as an oral vaccine candidate against SARS-CoV-2 infection.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41053546/",
    "length": 1111,
    "id": 1249,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41051941",
    "text": "A multivalent vaccine targeting high-consequence infectious diseases in Sub-Saharan Africa (SSA), which are linked to high mortality, morbidity and overlapping clinical manifestations, would significantly improve health security and economic stability in this region. Trivalent vector vaccines were devised to deliver digitally optimized versions of Orthoebolavirus, Orthomarburgvirus glycoproteins (GPs) and a Lassa mammarenavirus (LASV) nucleoprotein (NP) by a single Modified Vaccinia Ankara (MVA) known to protect against mpox virus (MPXV) along with a matched DNA vaccine. Three immunizations in mice and Hartley guinea pigs with MVA only or a DNA prime followed by two MVA administrations induced comparable levels of binding antibodies and LASV-specific T-cells, respectively. While DNA priming mitigated MVA-specific antibody responses, GP- and NP-specific antibodies developed already after a single MVA vaccination. Although a post-outbreak Ebola virus vaccine is available, outbreaks by other filoviruses, annual LASV epidemics and increased incidence of MPXV infections support the rationale for an MVA-based trivalent haemorrhagic fever vaccine for endemic and high-risk human populations in SSA.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41051941/",
    "length": 1209,
    "id": 1250,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41037401",
    "text": "The ongoing outbreak and emergence of monkeypox virus (MPXV) clade Ib and IIb lineage have heightened its transmissibility, morbidity, and mortality, underscoring the urgent need for safe and effective vaccines against MPXV infection. In this study, we developed a \"two-in-one\" nanoparticle vaccine, DAM-NP, which incorporates bivalently fused M1 and A35 antigens conjugated to a self-assembled 24-meric ferritin nanoparticle. Preclinical evaluations demonstrated that DAM-NP elicits robust humoral and cellular immune responses, providing complete protection against lethal vaccinia virus challenge. Importantly, pre-existing antibodies resulting from prior infection with the VACV Tiantan strain utilized for smallpox prevention did not diminish vaccine efficacy. A single dose was sufficient to prevent both morbidity and mortality following a lethal MPXV challenge. These findings establish DAM-NP as a highly immunogenic and promising single-dose vaccine candidate for prevention of MPXV and other orthopoxvirus infections.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41037401/",
    "length": 1028,
    "id": 1251,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41005346",
    "text": "Malaria remains a leading cause of mortality among children in Africa, and recent advances in control have stagnated. Although new vaccines are available, protective efficacy is not optimum. Monoclonal antibodies targeting the Plasmodium falciparum circumsporozoite protein have potential to simplify prevention. We assessed the safety, pharmacokinetics, and protective efficacy of MAM01, a monoclonal antibody preferentially directed against the conserved Asn-Ala-Asn-Pro (NANP) central repeat region of circumsporozoite protein. This phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial was done at the Center for Vaccine Development and Global Health, University of Maryland, Baltimore, MD, USA. Adults aged 18-50 years, with no previous malaria vaccinations or infections, and BMI of 18-30 kg/m Between Aug 14, 2023, and Dec 13, 2024, 63 participants were assessed for eligibility, 38 were enrolled, and 37 were randomly assigned. After review of sentinel group safety data (1·5 mg/kg [n=1] and placebo [n=1]), 29 participants were assigned to receive MAM01 at doses of 1·5 mg/kg (n=5), 5 mg/kg (n=6), 10 mg/kg (n=6), or 40 mg/kg (n=6) intravenously or 5 mg/kg subcutaneously (n=6) and six were assigned to the placebo group. One participant was included as an untreated infectivity control. MAM01 administration was well tolerated. No treatment-related serious adverse events occurred after one or two doses. After controlled human malaria infection, six of six participants in the control group and 18 of 22 participants in the MAM01 group developed parasitaemia. None of three participants in the 40 mg/kg intravenous dose group developed parasitaemia. Pharmacokinetic analysis showed that serum MAM01 concentrations greater than 88 μg/mL protected against malaria challenge. MAM01 was well tolerated, met safety targets, and showed clinical proof-of-principle by eliciting protection in malaria-naive adults using the controlled human malaria infection model. Progress driving down the cost of goods coupled with dose selection within target populations will dictate the feasibility of malaria monoclonal antibody deployment. Gates Foundation.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41005346/",
    "length": 2173,
    "id": 1252,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "PubMed_41000379",
    "text": "The four serotypes of dengue virus (DENV1-4) are the leading cause of arboviral diseases in humans. Currently, developing a safe and effective DENV vaccine remains a challenge. Previously we reported potently neutralizing human monoclonal antibodies (mAbs) preferentially recognize mature DENV particles, on which there is limited access to the fusion loop (FL) epitope and no premembrane (prM) protein. As FL and prM antibodies are weakly- or non-neutralizing and contribute to antibody-dependent enhancement, mature DENV particles represent an ideal DENV vaccine candidate. Several inactivated flavivirus vaccines, generated using formalin, ultraviolet or other inactivation methods, have progressed through preclinical and clinical studies. Little is known about how different inactivation methods affect viral epitopes and the quality of antibodies induced. We investigated epitopes on Tween 20-inactivated mature DENV1 particles by testing a panel of well-characterized human mAbs and membrane integrity by sucrose-gradient ultracentrifugation and protein K digestion. We examined the mechanisms of Tween 20 inactivation by measuring RNA copy numbers, virus binding to cells and acid exposure, and antibody responses induced by Tween 20-inactivated mature DENV1 particles in mice. Tween 20 inactivation better preserved the epitopes recognized by potently neutralizing mAbs compared with other methods. Sucrose-gradient ultracentrifugation and protein K digestion revealed no disruption of membrane integrity by Tween 20. Mechanistically, Tween 20 treatment caused reduced virus binding to cells and RNA degradation, which was reverted by pre-treatment with RNAseOUT, suggesting the involvement of extracellular RNase, and prevented the envelope protein conformational changes induced by acid exposure. Moreover, Tween 20-inactivated mature DENV1 particles induced a neutralizing antibody response to all four DENV serotypes characterized by competition with several potently neutralizing mAbs and limited recognition of FL. Our results suggest that Tween 20-inactivated mature particles are a promising strategy for DENV vaccine development.",
    "url": "https://pubmed.ncbi.nlm.nih.gov/41000379/",
    "length": 2147,
    "id": 1253,
    "source": "PubMed",
    "has_abstract": true
  },
  {
    "title": "La part oubliée de l'étude des pharmacopées traditionnelles africaines",
    "text": "Home All issues 21 Ethnosciences (ethnobotanique, et... La part oubliée de l'étude des ph... En Afrique francophone, les pionniers de l'étude des pharmacopées traditionnelles furent essentiellement des pharmaciens militaires, tels Joseph Kerharo au Sénégal, Pierre Boiteau à Madagascar, Armand Bouquet en Côte d'Ivoire ou au Congo, en lien avec le laboratoire fondé par Portères. Ils entendaient explicitement poser les bases d'une ethno-pharmacologie, et non de la seule part d'ethno-botanique, car il s'agit de la préparation et de l'administration du pharmakon pour le traitement de troubles, de maladies et non de la seule matière première végétale. Mais c'est l'orientation biologique ( étique ) qui a prévalu. Ces travaux disent très peu du point de vue des praticiens et des malades ( emic ), ce que l'anthropologie de la santé étudie. Un retournement de perspective tel que celui réalisé par Marc Augé (1986) à propos de l'anthropologie de la maladie a été tenté proposant une anthropologie du remède. Il s'agit de dépasser les apories bien discutées par Tim Ingold (1992-2013) entre écologie culturelle et anthropologie écologique, pour tenter l'anthropologie écologique alternative, en travaillant sur les propriétés médicinales (pharmacologiques) d'item comme autant d'affordances sélectionnées dans un environnement donné par une communauté d'humains ou d'animaux. Cet article suit ainsi mon propre parcours de la pharmacie à l'anthropologie, situant les impasses rencontrées. In French-speaking Africa, the pioneers of the study of traditional pharmacopoeias were essentially military pharmacists, such as Joseph Kerharo in Senegal, Pierre Boiteau in Madagascar, Armand Bouquet in the Côte d'Ivoire or in the Congo, in connection with the laboratory founded by Portères. They explicitly intended to lay the foundations of an ethno-pharmacology rather than only the ethnobotanical part, because it focused on the preparation and administration of the pharmakon to treat disorders, diseases , and note solely on the plant raw materials . But the biological ( etic ) orientation has prevailed. These works say very little from the point of view of practitioners and patients ( emic ), which is the purpose of the study of health anthropology. A reversal of perspective such as the one operated by Marc Augé (1986) concerning the anthropology of illness has been attempted, proposing an anthropology of the remedy. It is a matter of going beyond the thoroughly discussed aporias by Tim Ingold (1992-2013) between cultural ecology and ecological anthropology, to attempt the alternative ecological anthropology he proposes, and working on the medicinal (pharmacological) properties of items as so many affordances selected in a given environment by a community of humans beings or animals. This article thus follows my own path from pharmacy to anthropology, and points out the deadlocks I have encountered. 1 Roland Portères, fondateur du laboratoire d'Ethnobotanique en 1963, qui classa l'ethnobotanique dans les sciences humaines (Portères 1961), avait réorienté en ce sens le laboratoire d'Agronomie tropicale du Muséum où il succédait à Auguste Chevalier (Bahuchet Lizet 2003). Sa revue devenue Journal d'Agronomie Tropicale et de Botanique Appliquée (JATBA) avait, dès le premier numéro sous cet intitulé (1954), introduit ce terme ethnobotanique , actant le tournant scientifique pris par les membres de ce laboratoire que André-Georges Haudricourt avait rejoint en 1941 (Hoare 2012). Ingénieur en agronomie tropicale, en lien avec ce laboratoire au début de sa carrière (1928-29), Portères fut nommé professeur au Muséum national d'Histoire naturelle en 1947 et la même année ingénieur en chef des services de l'agriculture d'Outre-mer. C'est à ce titre que, dès 1955, il avait mis en place, en collaboration avec la faculté de pharmacie de Paris, une organisation ... de la prospection, de l'inventaire et d e l 'étude des plantes médicinales ... vivant dans la zone ... tropicale, en priorité dans les territoires soumis directement ou indirectement au contrôle ou à l'influence française (Portères 1957). 2 Elle était dotée d'une Commission des plantes médicinales d'Outre-mer qui comportait différents directeurs d'instituts, de centres comme l'ORSTOM, l'IFAN, de laboratoires de recherches et de laboratoires pharmaceutiques. Le programme était centré sur l'Afrique francophone dont Madagascar. Il intégrait tant des agronomes, des forestiers et des géographes que des ethnologues. Il était prévu la mise en place de jardins botaniques, d'essais de culture de plantes médicinales ainsi que des études environnementales visant à préserver les sites. Il était donc requis à plusieurs titres des investigations d'ordre ethnographique ..., l'ethnobotanique étant une branche scientifique s'occupant des relations entre l'homme et la plante . Joseph Kerharo alors pharmacien du service de Santé militaire Outre-mer en faisait partie. Devenu plus tard professeur de matière médicale à la faculté de Pharmacie de Dakar, il fut l'auteur, en collaboration avec le botaniste Jacques Georges Adam, d'un ouvrage longtemps présenté comme modèle La pharmacopée sénégalaise traditionnelle (1974). 3 Il nous importera dans cet article de nous attacher aux objectifs que Kerharo assignait à ces études. Dans l'idéal, elles auraient dû prendre une double direction tenant compte simultanément de ce qu'il qualifie en 1950 de binôme botanique et ethnique . Il dit n'avoir pu, dans l'urgence, travailler le second. A fortiori , du fait de l'étendue pluriethnique des enquêtes alimentant cet ouvrage, il ne contribua pas à donner des éléments de compréhension de ce qu'est la maladie et ses remèdes pour une communauté donnée, comme il l'avait envisagé lors de sa collaboration avec l'ethnologue Louis Vincent Thomas (Kerharo Thomas 1963) chez les Diola. Depuis, l'ethnopharmacologie n'en finit pas de se heurter aux mêmes apories, elle est approchée soit par la botanique ou la pharmacologie soit par l'ethnologie, ne pouvant dépasser l'opposition natureculture introduite par le découpage des sciences occidentales ni en appréhender la complémentarité voire la non-pertinence du point de vue des communautés enquêtées (Descola 2005). Je présenterai les propositions qui affrontent actuellement ces questions et, m'en tenant à l'Afrique francophone, nous verrons comment s'en sont saisi les héritiers de Portères. Ce faisant, je donnerai à suivre mon propre parcours de pharmacienne et botaniste se voulant ethnopharmacognosiste selon le modèle de Kerharo ; puis, devenue anthropologue de la santé et du remède après m'être heurtée à ces mêmes obstacles, je présenterai mes tentatives successives pour les surmonter. La sélection de références sera donc subjective et leur analyse rétroactive. 4 Les hommes de terrain qu'étaient les premiers ethnobotanistes-ethnopharmacologues n'étaient pas sans ressentir quelque insatisfaction dans cette incapacité à restituer les enseignements de leurs hôtes, piégés qu'ils étaient par leur cadre conceptuel. Je le fus moi-même quand, au cours d'une enquête d'ethnopharmacologie chez les Gbaya (Haxaire 1979, 1982, 1983), dans le cadre d'une équipe pluridisciplinaire d'ethno- et de sociolinguistes, travail qui adoptait le point de vue de mes interlocuteurs, je fus bien embarrassée à établir le lien entre leurs pratiques et la pharmacologie, il me fallait travailler leur médecine . Cela me conduisit, à mon retour en France en 1984, à me former à l'anthropologie à l'EHESS avec Marc Augé et à réaliser qu'à l'instar de l'ethnomédecine (Augé 1986) la discipline ethnopharmacologie devait opérer une clarification épistémologique. Tout comme il fut pertinent d'envisager l'étude des maladies et plus encore de la santé dans une perspective anthropologique, il devait être fécond d'étudier les recettes de médecine populaire telles que Françoise Loux et Francine Saillant (1991) avaient tenté d'en dégager les principes organisateurs, pour envisager une anthropologie du remède (Haxaire 1994, 2017) ou du pharmakon (Guttierez Choquevilca 2017), ce que la Revue d'ethnoécologie a permis d'accueillir (Haxaire 2012). Le remède s'entend au sens étymologique dans la perspective d'une restauration globale d'équilibres de la personne et de son monde tels qu'envisagés par le collectif auquel elle appartient. Nous suivrons Tim Ingold (2013 : 133) dans sa tentative de dépasser l'opposition entre écologie culturelle et anthropologie écologique, pour tenter l'anthropologie écologique alternative qu'il propose, mobilisant la psychologie écologique élaborée par J. Gibson (1979 et 1982), et en travaillant sur les propriétés médicinales (pharmacologiques) d'items comme autant d'affordances sélectionnées dans un environnement donné par une communauté d'humains (ou d'animaux, Krief et al. 2005). C'est ainsi que le recueil des pharmacopées traditionnelles prises comme systèmes en évolution (Dagognet 1964) pourrait informer tant les sciences biologiques que les sciences humaines de la santé. 5 Dans l'introduction de La pharmacopée sénégalaise traditionnelle (Kerharo Adam 1974), Kerharo définit ce qu'il entend par pharmacopées ( l'art de préparer les médicaments ), précise pourquoi il les qualifie de traditionnelles (elles sont à transmission orale) avant d'exposer son point de vue sur la façon dont elles doivent être étudiées. 6 Cette enquête, initiée en 1959, s'inscrit pour son auteur dans la suite d'un travail du même type entrepris dès 1945, en collaboration avec le pharmacien militaire Armand Bouquet, portant sur les plantes médicinales de Côte-d'Ivoire et de Haute-Volta. Kerharo et Bouquet (1950) travaillaient alors dans le cadre de l'ORSTOM. Ces recherches anticipaient la résolution WHA 22-54 de la 22 e Assemblée mondiale de la santé à laquelle œuvra le professeur Michel Attisso (1969). Déjà, était fixé le programme d'une discipline, l'ethnopharmacognosie, que les colloques et congrès de la fin du xx e siècle n'en finirent pas de redécouvrir, la baptisant souvent indûment ethnopharmacologie (Middelkoop 1985 cité par De Smet et River 1989). 7 Si Kerharo, pharmacien et professeur de pharmacognosie lui-même, emploie le terme de pharmacopée , il n'en ignore pas pour autant la signification orthodoxe : un recueil écrit de drogues identifiées avec les formules et recettes pour préparer les médicaments 1 . C'est ainsi que fut établie autrefois la pharmacopée française, que remplace petit à petit son homologue européenne et c'est dans ce but que se constitue la liste des plantes médicinales destinées à figurer dans La Pharmacopée africaine dont la première version fut publiée en 1985 (CSTROUA) 2 . Si Kerharo prend soin, en 1950, de mettre ce terme entre guillemets, dans le sens large qu'il avait quand il fut employé pour la première fois par Diogène de Laerte, au iii e siècle de notre ère , c'est peut-être pour donner ses lettres de noblesse au savoir traditionnel africain, et aussi parce qu'il a dans l'esprit d'établir les bases de cette véritable pharmacopée africaine qu'il appelait de ses vœux. C'est l'ampleur de cette tâche et son urgence à l'heure où, comme le dit Amadou Hampaté Ba qu'il cite En Afrique, chaque fois qu'un vieillard meurt c'est une bibliothèque qui brûle , qui lui a fait privilégier l'inventaire des usages de ces plantes et leur analyse, bien qu'il n'ignorât pas, dès 1950, que l'étude des pharmacopées africaines traditionnelles ... dominées par ce que nous avons appelé un binôme ethnique et botanique dût être abordée impérativement dans ces deux directions à la fois . 8 Lorsque plusieurs dizaines de millions d'individus dépendaient journellement de plantes pour assurer leur survie, il lui semblait difficilement concevable d'ignorer jusqu'à l'identification des drogues 3 entrant dans les préparations. Il assignait un double but à son travail. Il se proposait d'une part et avant tout d'établir pour les drogues botaniquement bien définies, mais dont nous ignorons encore trop souvent les principes actifs, une échelle de valeur, empirique certes, mais susceptible de donner un ordre de priorité aux travaux de chimie et de pharmacologie , ce qui était dans la ligne de toutes les études entreprises en particulier dans le cadre de l'ORSTOM (Bouquet 1969, 1972 ; Bouquet Debray 1974). D'autre part, il préconisait pour parer au plus pressé, de faire un tri parmi les drogues des pharmacopées locales afin de proscrire, en application du vieil adage primum non nocere celles qui sont dangereuses et de recommander, dans des conditions de préparation et d'administration modifiées, celles qui sont les plus actives. 9 Cette œuvre de vulgarisation fut entreprise par l'un de ses successeurs à la chaire de pharmacognosie de l'Université de Dakar (Pousset 1989). 10 Comme tout pharmacien, Kerharo inclut dans son étude les usages alimentaires mais se limite à ceux des plantes dont certaines parties sont par ailleurs médicinales ; il traite en particulier de diverses feuilles consommées en brèdes considérées comme des aliments de disette (par exemple Amaranthus spinosus ). 11 Pour nous aider à atteindre les objectifs exposés plus haut, cet auteur nous donne de précieux conseils sur la façon de mener une enquête auprès des guérisseurs, de gagner leur confiance au point de les voir préparer devant nous le remède, ou nous guider dans la région environnante. Ces règles, ainsi que les judicieuses remarques qu'il fait à propos de l'échange de confidences qui peut s'établir entre deux spécialistes de cultures différentes, sont peut-être le seul moyen d'aborder ces difficiles enquêtes d'ethnosciences en général comme le soulignait par ailleurs Claude Lévi-Strauss (1962). Kerharo entend d'ailleurs contribuer à l'ethnobotanique, entendue selon Portères (1969-1970) qu'il cite, comme la discipline scientifique qui s'attache à connaître et à interpréter les faits d'interrelation entre les sociétés humaines et les plantes en vue de comprendre et d'expliquer en partie la naissance et le progrès des civilisations, depuis leurs débuts végétaliens jusqu'à l'utilisation et la transformation des végétaux eux-mêmes dans les sociétés primitives ou évoluées . Le travail d'enquête sur les plantes médicinales était alors considéré comme un travail d'ethnobotanique dans le sens que lui donnait la botanique économique américaine. Cette tradition scientifique avait déjà restreint le champ de l'ethnobotanique médicale telle que les premiers utilisateurs de ce dernier terme l'avaient défini (Wyman Harris 1941), eux qui décrivaient les rituels Navajos dans lesquels ces plantes étaient incluses. C'est ainsi au sens de la botanique économique que Bouquet (1969) qui se proposait de faire une étude ethnobotanique des plantes médicinales entendait ce terme. Mais Kerharo ayant collaboré avec l'ethnologue Louis-Vincent Thomas sur une enquête portant sur la médecine traditionnelle des Dioula (1963) notait page 675, que l'examen des thérapeutiques constitue un moyen efficace pour comprendre le sens exact que le Diola confère à la maladie et sa manière de concevoir la médecine . Par la suite Kheraro ne put malheureusement pas explorer ce qu'il entendait par la part ethnique du binôme, ni prendre l'orientation vers les sciences humaines que Portères (1961) avait voulu donner à la discipline dont il tentait de définir les bases. 12 Nombre d'enquêteurs à cette époque pressentaient cette nécessité. Pierre Louis Boiteau, quoique diplômé de l'école d'horticulture de Versailles donc non pharmacien, mais à qui la connaissance de la langue malgache avait permis de travailler avec les tradipraticiens dès 1936, avait tenté, en collaboration avec le docteur Ratsimamanga, de mettre au point des médicaments (Boiteau Ratsimamanga 1956). Menant une enquête sur les plantes médicinales de Madagascar, publiée à titre posthume (Boiteau 1979), Boiteau s'était suffisamment intéressé au projet de Portères pour le présenter dans la revue La pensée (Boiteau 1971). Il mentionne dans cet article l'importance qu'eut pour lui, lors du huitième Congrès international de botanique de 1954 (Paris), l'exposé de J. Belin-Milleron sur les plantes sacrées dans le psychisme et les institutions des anciennes civilisations , exposé qui montrait nettement le rôle de l'ethnie prise en tant qu'entité particulière, dans ces rapports entre le monde végétal et l'homme (Belin-Milleron 1954). Il comprit, écrit-il, pourquoi l'ancienne conception utilitaire de Botanique appliquée ou de Botanique économique comme l'on disait encore, était trop étroite pour servir de cadre à des travaux qui se préoccupaient d'embrasser les divers aspects des rapports entre la végétation et l'homme . C'est peut-être pourquoi il envisage, pour étudier la matière médicale d'un pays, la méthode ethnopharmacologique dérivée de l'ethnobotanique au sens où il l'entendait (Boiteau 1972), et qui, dit-il, nécessite un corpus de connaissance d'un caractère beaucoup plus vaste que la méthode chimiotaxonomique et, tout d'abord, la connaissance de la langue. Il est souhaitable que le chercheur qui veut la mettre en œuvre ait une compréhension approfondie du groupe qu'il étudie et soit capable de s'y intégrer dans une certaine mesure... Le principal inconvénient de cette méthode est la lenteur... . Il s'agit de pénétrer la nature profonde des mobiles des traditions populaires . Pour forger son outil d'enquête, il s'inspira d'abord des travaux de B. Koechlin, J. Matras, L. Bernot et des chercheurs de la VI e section de l'École Pratique des Hautes Études (Koechlin 1971) en y apportant les modifications dues, pour lui, à la part plus importante d'idéologie que doit parvenir à interpréter l'enquêteur ethnopharmacologue . 13 Boiteau recommande pour l'enquête de constituer deux dossiers, l'un pour la matière médicale et l'autre pour les méthodes de prévention, de diagnostic ou de traitement. Mais si l'on peut se référer à la grille documentaire de Boiteau comme à un véritable document d'ethno-pharmacologie 4 , Kerharo et Adam n'en auraient utilisé que la partie utile à leur propos : l'ethno-pharmacognosie. En effet, les deux hommes ne peuvent avoir oublié que dans le premier cas on étudie le médicament tandis que dans le second, c'est de la seule matière médicale qu'il s'agit. Cette grille, qui circulait déjà comme littérature grise , était publiée dès 1976 dans Enquête et description des langues à tradition orale de L. Bouquiaux et J.M.C. Thomas. 14 Pour réaliser les objectifs plus limités fixés par le professeur Kerharo, l'ethno-pharmacognosie, entendue comme recueil des usages traditionnels de la matière médicale , la formation de pharmacien spécialisé en pharmacognosie, complétée de celle de botaniste (celle de Adam) semble suffisante. En effet, leur ouvrage est bâti sur le plan des traités de matière médicale 5 . Il en est tout autrement des objectifs fixés par Boiteau. Mais l'insurrection malgache de 1947 obligea ce dernier à rentrer en France où il fut accueilli dans le Laboratoire de physiologie nutritionnelle, des hormones et des vitamines dirigé à Paris par le Dr Ratsimamanga, tout en collaborant avec le Muséum national d'Histoire naturelle. L'histoire cette fois nous priva de l'application au travail de terrain de l'approche souhaitée, autant dire du développement possible de la partie ethnique de notre binôme , car Boiteau dut se résoudre à ne publier par la suite qu'un Précis de matière médicale malgache (1979). 15 Tous ces pionniers de l'ethnopharmacologie, agronomes ou pharmaciens mais hommes de terrain, ressentaient la nécessité d'un apport ethnologique, en ayant une idée confuse de ce qu'il pouvait être ( idéologie , nature profonde des mobiles populaires ), mais ils ne le réduisaient certainement pas à documenter précisément les indications et le mode des préparations comme nous le verrons plus bas. 16 Au milieu des années 1970, jeune pharmacienne ayant vécu au Sénégal où enseignait Kerharo, j'entamai une formation de botanique tropicale pour mener selon son modèle une enquête d'ethnobotanique , sur les pharmacopées traditionnelles . Lors de cette formation, bien que menant un DEA sur la régénération de la forêt dans les abattis amérindiens de Guyane, je fus familiarisée avec les herborisations et le recueil de données en compagnie de Pierre Grenand (Grenand et al. 1987) et des équipes de l'ORSTOM de Cayenne. Je fus ensuite accueillie au Laboratoire des langues et Civilisations à tradition orale, le LACITO, pour collaborer en tant que botaniste aux enquêtes d'ethnobotaniques gbaya projetées par une linguiste convertie à l'ethnolinguistique, Paulette Roulon, tout en approfondissant ce qui concernait la pharmacopée familiale qui allait donner matière à ma thèse (Haxaire 1979). Mes présupposés alors fort naïfs sur la nécessité d'étudier la maladie et sa symptomatologie en lien avec les représentations locales du corps rencontraient les débats en cours dans le monde des socio- et anthropo-linguistes de l'équipe. Les informations recueillies au cours de mes herborisations ainsi qu'en compagnie de quelques guérisseurs étaient complétées de retour au village avec les informateurs de l'ethnolinguiste, selon la pratique classique en linguistique, pour établir le corpus ethnobotanique, les fiches étant remplies sur le modèle présenté plus haut. Mes tournées biquotidiennes à travers le village pour noter les remèdes préparés ne me permettaient, elles aussi, que de noter le déclaratif, plus rarement de voir préparer les recettes, et moins encore de me les voir commenter ; c'étaient essentiellement les modes opératoires qui étaient repris après coup lors de l'écriture (de la retranscription) dans la langue (les commentaires qu'aurait pu émettre le guérisseur n'avaient pas été enregistrés). J'avais bien conscience de travailler sur la seule médecine familiale et qu'une autre dimension accessible à ceux qui voyaient les choses restait à documenter. Néanmoins il était apparu qu'une classification des maladies fondée sur la symptomatologie organisait les thérapeutiques, et qu'ainsi pouvaient se dégager des recettes communes à la classe en question, outre des recettes plus spécifiques. Il a pu être mis en évidence dans un nombre non négligeable de cas, que des étiologies locales (des ethno-étiologies) étaient proposées et que souvent les thérapeutiques avaient un fondement explicité (ou déductible). Des agents pathogènes étaient envisagés. Ou alors un mécanisme physiopathologique était proposé, la douleur par exemple résultant d'une stase sanguine (Haxaire 1991), il convenait de rétablir de diverses manières la circulation, les plantes odorantes faisant merveille en ce cas. Les critères d'efficacité pour la communauté devaient être étudiés, comme Nina Etkin (1988a), que je ne connaissais pas encore, le préconisera. Je réalisai qu'il y avait une logique à dégager, comme William Rivers (1924), que je ne connaissais pas davantage, l'avait depuis longtemps noté et que parfois les caractères organoleptiques étaient retenus dans ces logiques. Ainsi, prendre en compte le volet ethnique du binôme dans cette enquête dont le point de départ, ethnobotanique au sens restreint de la botanique voire la pharmacologie des autres , induisait une clôture autour de l'aspect empirique des remèdes et symptomatique des maladies (Nicolaï 1986). J'avais moi aussi qualifié de magiques les pratiques qui sortaient de ce cadre, je ne percevais pas encore la difficulté à mettre en relation ces usages empiriques avec les effets pharmacologiques des préparations en question. Mais il m'était apparu qu'une certaine cohérence guidait les choix. Il me fallait néanmoins davantage travailler en anthropologue pour donner tout son sens à l'étude du volet ethnique du binôme . 17 C'est à l'UFR de Sciences pharmaceutiques de l'université Félix Houphouët-Boigny d'Abidjan que mon parcours me conduisit ensuite. L'ethnobotanique n'y ayant pas sa place, sinon pour développer le volet botanique au sens de la pharmacognosie présenté plus haut, j'y entamai une seconde thèse, de pharmacognosie, dans les difficiles conditions d'un laboratoire en cours de montage. Je l'ai vite abandonnée, au profit d'un terrain en pays gouro sur lequel je reviendrai plus bas. 18 Parmi les orientations de recherches définies par Kerharo, la recension des ressources médicinales et leur analyse, la restitution aux populations, et le développement de médicaments traditionnels améliorés, la première, c'est-à-dire l'alimentation en matière première des laboratoires de pharmacognosie, qui à cette époque s'appelaient encore matière médicale, fut longtemps privilégiée. L'inventaire fut développé par les équipes de l'ACCT 6 (Adjanohoun 1989), avec des bonheurs divers (Peeters 1982) au niveau de différents pays d'Afrique. Adjanohoun qualifie le résultat de ces enquêtes d'ethnopharmacopées, qu'il différencie des travaux de Kerharo, nommés pharmacopée traditionnelle originale et dont il dénonce le caractère hétérogène (résultats scientifiques connus diversement plus que codification de recettes traditionnelles). Les équipes de nombreuses universités d'Afrique de l'Ouest et de Madagascar menèrent des travaux d'analyse des plantes et collaborèrent à l'établissement de la pharmacopée africaine officielle, puis des diverses pharmacopées locales 7 . Elles publient dans la revue du CAMES ou dans les revues spécialisées, y compris dans le Journal of ethnopharmacology qui donne une place prééminente aux travaux de chimie (Etkin Elisabetsky 2005) et Ethnopharmacologia , revue de l'association française d'ethnopharmacologie sise à Metz. L'équivalent du projet TRAMIL sur les Caraïbes (Weniger 1991) destiné à restituer aux populations les résultats d'analyse des remèdes courants fut porté par des ONG telle Jardins du monde 8 ou AVERTEM 9 à Madagascar (Razafindravao Sattler 2017), tandis qu'en Afrique de l'Ouest francophone s'est développée, tant au Burkina Faso (équipe du professeur Pierre Guissou) (Nikiema et al. 2010, Ouédraogo et al . 2018) qu'au Mali (équipe du professeur Rokia Sanogo) (Sanogo 2014), la mise au point de médicaments traditionnels améliorés (MTA), aux devenirs contrastés (Sambaré et al . 2018). À la suite des pays anglophones, Ghana et Nigeria essentiellement, des spécialités industrielles à base de plantes locales sont commercialisées : on en trouve au Sénégal (Desclaux 2015) et parfois, comme en Côte d'Ivoire et au Sénégal, sous le régime de complément alimentaire. Ces MTA, ou médicaments néotraditionnels, font l'objet d'études en soi, par exemple au Bénin (Simon Egrot 2012). Quant aux Programmes nationaux de Promotion de la Médecine traditionnelle, ils peuvent, comme en Côte d'Ivoire sous la coordination du docteur Ehoulé Kroa, élargir leurs objets de la coordination des études sur la pharmacopée ivoirienne ( op.cit .), à l'organisation des tradipraticiens, aux travaux sur les spiritualistes , les accoucheuses traditionnelles et des komian, prêtresses traditionnelles agni, participant à l'éducation pour la santé. 19 En Europe, l'ethnopharmacologie s'est renouvelée entre temps avec diverses sociétés d'ethnopharmacologie ( européenne et française ) qui organisèrent leurs congrès respectifs. Notons simplement ici comment les deux congrès initiateurs du renouvellement ont traité le volet ethnique . 20 Les organisateurs du premier colloque européen d'Ethnopharmacologie exprimaient la volonté d'œuvrer, au niveau de chaque discipline impliquée, à l'élaboration de méthodes spécifiques d'étude des pharmacopées traditionnelles dans un contexte pluridisciplinaire, cette approche pluridisciplinaire étant d'ailleurs définie d'entrée (Dos Santos Fleurentin 1991). Ces deux chercheurs, l'un sociologue, José Dos Santos, et l'autre pharmacognosiste Jacques Fleurentin, disent avoir fait le choix de proposer une vue de synthèse sur la discipline, de façon à permettre de poursuivre une réflexion sur ... le programme de cette jeune science , on s'étonne que ces deux Français datent les premières tentatives pour définir l'ethnopharmacologie, en tant que discipline autonome sic , au début des années 1980. Ils s'en tiennent en effet à la définition de Bruhn Holmstedt (1982) 10 : L'exploration interdisciplinaire des agents biologiquement actifs traditionnellement employés ou observés par l'homme , en intentant un mauvais procès à ses auteurs à propos des termes. Ils proposent de remplacer agents par ensemble des matières d'origine végétale, animales ou minérales, et des savoirs ou pratiques s'y rattachant . 21 Ils s'insurgent surtout contre le terme traditionnel qui pour eux a des connotations péjoratives et réfère à des cultures autrefois dites traditionnelles parce qu'on ne savait y voir que transmission à l'identique , ce que les ethnologues ne pensaient plus depuis un certain temps (Balandier 1974), et proposaient de le remplacer par vernaculaire ! Ils oubliaient tout simplement que traditionnel vient du latin tradere remettre transmettre et qu'en employant ce terme on insiste sur l'héritage transmis de siècle en siècle originellement par la parole et par l'usage d'après le Petit Robert , ce qui est précisément la raison pour laquelle cette approche serait plus rentable en termes de découverte pharmacologique, ce qu'ils démontrent à la page suivante reprenant Farnsworth et Kaas (1981). La dernière critique porte sur le fait que l'accent serait mis sur agent et non sur usage . Bref, tout cela nous mène à une nouvelle définition : l'ethnopharmacologie devient l'étude scientifique interdisciplinaire de l'ensemble des matières d'origine végétale, animale ou minérale, et des savoirs ou des pratiques s'y rattachant, que les cultures vernaculaires mettent en œuvre pour modifier les états des organismes vivants, à des fins thérapeutiques, curatives, préventives, ou diagnostiques . Définition qui renvoie à celle du médicament. Cette nouvelle discipline ne se constituant donc non par spécialisation mais par agrégation des compétences, il s'agit alors de reformuler en profondeur ses objectifs et ses méthodes et de définir le rôle de chacune des disciplines agrégées . 22 L'ethnologie est définie pour l'occasion comme une approche scientifique de la culture . Dans son aspect ethnographique, elle a pour rôle de recueillir les données utiles de façon aussi précise que possible, mais les auteurs abordent un aspect plus intéressant : au niveau ethnologique, elle l'ethnopharmacologie contribue à la mise en relation des usages entre eux, afin de restituer les principes d'organisation des pharmacopées, et, plus largement, des systèmes thérapeutiques étudiés . Nous en venons donc aux critiques portées par Brown (1987) aux travaux de Etkin (1986) dont nous exposerons les thèses plus bas. Brown (1987) estimait que l'ethnobotanique médicale était idéalement placée pour contribute to the study of such critical issues as the structure of cognitive processes, the coevolution of cultural and biological systems, and the links between symbolism and cultural adaptation . 23 Les auteurs ne citent cependant pas ces travaux américains, mais se réfèrent aux propositions du philosophe Dagognet (1964) pour qui la pharmacopée doit être étudiée comme un système. 24 Dans sa communication, José dos Santos (1991) tente d'étudier ses matériaux ethnographiques cévenols en termes d'espaces d'attributs, reprenant en cela l'analyse de Francis Zimermann (1989) qui, à la suite d'Alan Young (1981), retrouve dans les catégories nosologiques kéralaises les définitions polythétiques des syndromes un peu flous des médecines traditionnelles. L'on sait en effet que depuis l'article de Rodney Needham (1975) auquel se réfère Young, les ethnologues tentent de faire appel à des logiques non aristotéliciennes pour rendre compte de l'organisation des matériaux qu'ils ont à analyser. Bien qu'il néglige les critiques déjà portées par les ethnologues eux-mêmes sur le fait de soutenir sans nuance l'hypothèse de l'homogénéité culturelle du groupe (Gardner 1976), le rappel que fait dos Santos de la nécessité de travailler sur la variabilité des savoirs et des pratiques, ce sur quoi avait déjà insisté Alan Young (1978, 1981) qu'il ne cite pas, nous semble salutaire. À travers l'exemple de certains dépuratifs et de certains calmants de la pharmacopée cévenole, il propose d'analyser le spectre d'activité de chaque remède, puis la répartition de ces remèdes selon des domaines d'utilisation, enfin la mise en relation de ces deux angles d'analyse selon un troisième point de vue, celui des visées thérapeutiques. Cet article qui reste cependant un modèle d'approche du volet ethnique du binôme n'a pas été suivi d'effet dans le champ de l'ethnopharmacologie. Peut-être parce que pesait sur ce champ de recherche le poids de la tradition anglosaxonne, dont le premier congrès international qui eut lieu à Strasbourg le mois suivant, donnait un aperçu. 25 Holmstedt (1991), dans son allocution d'ouverture, reprenant un de ses articles (Homsedt Bruhn 1983), différencie la nouvelle discipline de la partie historique des traités de matière médicale d'antan par le fait que ces auteurs did not carry out field studies among different ethnic groups, nor did they in all cases realize the utmost importance of authenticating plant and drug material . The observation, identification, description and experimental investigation of the ingredients and the effects of indigenous drugs is a truly interdisciplinary field of research. The term ethnopharmacology has been used to describe this field. Ethnopharmacological research is based on botany, pharmacology, toxicology and chemistry, but other disciplines make vital contributions, not least anthropology . 27 Les disciplines concernées, si l'on excepte la part faite à l'anthropologie (pas la moindre mais de quelle part s'agit-il ?) semblent correspondre à celles auxquelles tout doctorant en matière médicale devait faire appel pour mener sa thèse à terme, avant que cette discipline ne devienne pharmacognosie et relève de plus en plus exclusivement de la chimie. Le préfixe ethno- redonnerait-il une légitimité à des travaux dépassés par l'évolution rapide et la spécialisation de plus en plus pointue de la recherche sur la chimie des plantes ? Serait-ce un moyen de mettre au goût du jour une vieille spécialité à l'instar de la phytothérapie ? Mais l'auteur nous rassure, la spécificité de cette nouvelle discipline est bien dans l'inventaire (l'archivage en quelque sorte) des connaissances avant qu'elles ne disparaissent The study of traditional drugs is not meant to advocate a return to the use of these remedies in their aboriginal form, nor to exploit traditional medecine. The objectives of ethnopharmacology are to rescue and document an important cultural heritage before it is lost, and to investigate and evaluate the agents employed (Alger 1976, Bruhn Holmstedt 1982, Holmstedt Bruhn 1983, De Smet et Rivers 1989, Phillipson Anderson 1989). Pour ce qui est du recueil de données, nous en restons donc au modèle de l'ethnobotanique telle que l'avait définie en 1895 Harshberger (1896) et avant que Portères (1969-1970) n'en fasse, une discipline qui doit s'étendre au-delà des usages des plantes par les primitifs parce qu'elle doit toucher à la pensée et à la vie des Peuples , qui nous donne la vision de l'intérieur . Le modèle adopté par les ethnopharmacologues cités précédemment relève donc de la botanique économique enseignée à Harvard par Ames et qui traitait entre autres des poisons de flèche. Dans l'équipe pluridisciplinaire, l'anthropologue voit son rôle défini par lui de la manière suivante to gather data about the uses of the plants, the way in which they are prepared and served and the folklore surrounding them... (sic). 28 La perspective adoptée est donc résolument étique, ce qu'atteste le programme du Congrès qui aborde l'évaluation des informations issues du terrain, l'intégration des données pharmacologiques, chimiques et toxicologiques, la validation clinique et la mise au point de futurs médicaments. Il s'agit au mieux d'évaluer l'efficacité de drogues traditionnelles, voire de toute une pharmacopée comme Weniger (1991), présentant le projet TRAMIL, s'inscrivant plus dans la perspective tracée par l'OMS, qui se propose de faire l'inventaire des remèdes populaires de la Caraïbe, de sélectionner les remèdes les plus employés, d'en évaluer les propriétés, la toxicité, de les classer en fonctions des critères précédents et de retourner ces informations à la population. C'est beaucoup plus récemment, dans une perspective décoloniale, que ce projet s'attache à prendre en compte les remèdes des entités culturellement définies localement. (Emmanuel Nossin 2022 11 ). 29 Seuls Etkin et Ross (1991) suggèrent d'étudier le contexte d'utilisation de ces drogues et d'en évaluer les effets : Should we set a place for diet in ethnopharmacology? . Fidèles à l'approche bio-comportementale d'Etkin (1988b), ils cherchent à attirer l'attention des ethnopharmacologues sur l'aspect alimentaire des plantes qu'ils étudient par ailleurs. L'approche conventionnelle étant en effet de se focaliser sur les propriétés médicinales des plantes sans explorer de façon adéquate les autres usages, disent-ils. Parmi ceux-ci, ils choisissent d'étudier les usages alimentaires, influencés par les catégories des Haussa parmi lesquels Etkin a travaillé : We draw inspiration from the Haussa term for medecine magani', a concept so inclusive that it signifies plants administred to cure fever' as well as foods used to remedy hunger' . Ils soulignent la non-pertinence (au regard des pratiques observées) des catégories étudiées par les ethnopharmacologues et suggèrent un modèle multicontextuel pour établir la signification physiologique de l'utilisation des plantes..., c'est-à-dire permettant l'évaluation de leurs usages interdépendants par des populations réelles dans des contextes culturels spécifiques. Pour évaluer correctement les effets biologiques d'un remède, il convient de relever les régimes ou les interdits alimentaires qui lui sont associés, et bien sûr d'en tenir compte dans l'expérimentation. Réciproquement, on manque d'informations sur les propriétés médicinales de plantes alimentaires et particulièrement des plantes dites de disette qui interviennent dans la ration alimentaire pour une part que l'on est loin d'estimer à sa juste valeur, et on ignore tout de la fréquence de leur consommation. Cela n'est sans doute pas sans incidence sur le régime et donc sur la résistance éventuelle à certaines maladies, comme l'ont montré les auteurs à propos du paludisme (Etkin Ross 1983). Diverses cultures et en particulier la culture chinoise (Ho 1985) ont en effet élaboré un système très précis de régimes alimentaires en rapport avec le traitement des maladies et la préservation de la santé. Cette approche demande bien entendu d'accorder beaucoup plus d'attention qu'il ne l'est fait d'ordinaire aux doses, modes de préparation, antagonismes ou synergie entre constituants de préparations complexes et entre médicaments et aliments. Bien que l'approche des auteurs ne soit pas véritablement anthropologique comme le souligne Brown (1987) déjà cité, mais bio-comportementale comme s'en réclame l'auteur qui l'inscrit dans une perspective d'écologie humaine, il s'agit ici d'une tentative d'évaluer l'efficacité de la phytothérapie dans les conditions où elle est pratiquée. 30 Rien dans ce congrès de 1990 (aux améliorations techniques près) ne me semblait remettre en cause les directives des ethnopharmacognosistes français des années 70 précédemment exposées, bien au contraire, puisque Etkin elle-même, redécouvre les préoccupations qui devraient être celles d'un pharmacien attentif aux doses, aux associations, à la fréquence d'emploi des remèdes, aux régimes, à la durée des traitements. Sa recherche démontre la valeur heuristique d'une telle approche lorsqu'elle s'attache de plus à tenir compte des catégories vernaculaires. 31 D'une façon générale, les différentes contributions de ce congrès reflètent bien les orientations prises principalement par les auteurs des articles d'un petit nombre de revues comme Economic Botany ou plus spécifiquement Journal of Ethnopharmacology. Le terme ethnopharmacologie lui-même serait apparu en 1967 d'après De Smet (1991), dans une communication sur les plantes psychoactives lors d'un symposium (Efron et al. 1967) ; Bruhn et Holmsted (1980) en auraient par la suite donné la définition citée plus haut. La différence avec la pharmacognosie tiendrait d'une part, au fait que l'ethnopharmacologie n'étudierait que les drogues employées dans un contexte traditionnel et essaierait d'en replacer l'usage dans ce contexte : ethnopharmacology strives to provide a more comprehensive view of the traditional use of naturally occurring crude drugs than does pharmacognosy . Cependant, dans les communications de ce colloque et des suivants, si la compétence de l'ethnologue est requise, c'est pour fournir les informations les plus fiables. Aussi, devant cette orientation très étique serions-nous justifiés de revenir sur les méthodes de l'ethnologie et spécifiquement des ethnosciences telles que les membres du Muséum national d'histoire naturelle le développaient à cette époque en France (Friedberg 1991). 32 D'autres chercheurs cependant, comme Elisabetsky (1986), appellent de leurs vœux une collaboration entre ethnologie et ethnopharmacologie qui, non seulement recueillerait le savoir populaire sur les plantes et les animaux, mais surtout en resituerait l'usage dans leur contexte religieux, cérémoniel tout comme dans le système médical local où les représentations de la maladie seraient étudiées. Ceci non seulement pour aider à déterminer les drogues utiles, mais encore pour pouvoir ensuite restituer ce savoir à la population. En effet, tout un courant de recherche s'est développé dans ce sens, en particulier à la suite du Premier congrès international d'Ethnobiologie à Belém (1988). Nombre d'exemples de ce type de travaux dont ceux qui ont abouti à l'ouvrage Medical ethnobiology of the Highland Maya of Chiapas, Mexico (Berlin Berlin 1996) nous sont donnés tout au long des divers congrès d'ethnobiologie. Dans celui-ci, l'ethnopharmacologie entendue au sens d'analyse de la composition chimique et de la pharmacodynamie des plantes médicinales, n'est qu'une petite partie de ce que les auteurs nomment ethnobiologie médicale, laquelle comprend entre autres une ethnobotanique médicale, une ethnoanatomie, etc. 33 Beaucoup de ceux qui, comme Nina Etkin, entreprennent de resituer les conditions d'utilisation des drogues, le font dans la perspective d'une meilleure évaluation biologique. Cet auteur (Etkin 1988b), recherche le bon niveau d'analyse qui lui permette de retrouver les traces de l'expérience empirique des propriétés thérapeutiques des plantes qu'elle suppose à juste titre aux pharmacopées populaires. Aborder cette question au niveau de l'ensemble de la pharmacopée par l'étude des classifications ne lui semble pertinent qu'à adopter le point de vue de Eugène Hunn (1982) ou Brian Morris (1984) pour lesquels l'utilité est le critère-clef de la classification. Elle élimine comme étant trop intellectuelles et donc non pragmatiques les logiques symboliques mises au jour par les structuralistes tout comme les classifications des ethnosciences à la recherche d'universaux de l'école de Berlin (Berlin et al . 1974). Néanmoins, aucun exemple ne nous est donné de la façon dont ces classifications nous permettent de comprendre how different biological and behavioral variables, including efficacy, influence the content and character of herbal pharmacopoeias . 34 Comme préalable nécessaire, Etkin (1988a) souligne l'importance d'étudier les conceptions de l'efficacité propres à chaque culture étudiée, soulignant que le traitement doit être envisagé comme un processus constitué de plusieurs étapes, et qu'à chacune de ces étapes un certain type de résultat est attendu. Parmi les exemples les plus dramatiques du point de vue de la biomédecine, elle cite l'administration de purgatifs pour éliminer l'agent pathogène à l'origine d'une diarrhée avant de donner des émollients et des tanins pour la soigner. Certains anthropologues médicaux comme Young (1983) familiers de la distinction établie par cette discipline entre soigner ( healing illness pour Kleinman) et guérir ( curing the disease ) avaient déjà attiré l'attention sur le fait que du point de vue de la population étudiée, l'efficacité pouvait ne pas être la même que pour la biomédecine. Mais toute à la défense de la rationalité (bio-comportementale) des pratiques de ses hôtes, Etkin intente un faux procès à Young, lui attribuant des stéréotypes que tous ses travaux démentent. While this distinction helps to clarify some of the differences, it also implies that Western biomedical and ethnomedical understandings of efficacy cannot be the same. But of course they can, and to ignore that advances the western stereotyped view that other medical systems are fundamentally irrational' and based on the precepts of magic and religion rather than on empirical observation of the biological universe . 35 De même écarte-t-elle les travaux de Kleinman (Kleinman Sung 1979) pour qui la médecine traditionnelle traite illness , qui selon elle, serait les réactions secondaires, affectives et subjectives à disease secondary, affective and subjective reaction to disease 12 . Or Young prend bien soin de décrire plusieurs cas de figure dont celui où healing est analogue à curing tout en spécifiant que The three forms frequently interpenetrate in real life: healing which is analogous to curing also reduces the sick person's anxiety . Analyser la logique symbolique à l'œuvre dans les soins n'implique pas que ces soins n'ont pas d'efficacité biologique. 36 La littérature existante, remarque-t-elle, nous indique très rarement l'effet attendu par la population. Lorsque c'est le cas, par exemple dans les travaux de Bastien sur les Quallawaya (Bastien 1981, 1983 et 1985), qui décrit avec précision les aspects humoraux de cette médecine et les manipulations d'oppositions binaires qu'opère la thérapeutique. Il n'est, se désole-t-elle, ni possible ni signifiant de rapprocher ces critères d'efficacité de ceux de la biomédecine. Elle partage par ailleurs avec Delaveau (1981) l'idée que les exemples de la théorie des signatures qui abondent dans la littérature ne sont que des repères mnémotechniques et pour elle, on ne leur accorde tant d'importance qu'à défaut d'avoir mis au jour d'autres critères de sélection. 37 L'erreur que commettent trop souvent les ethnopharmacologues (ou les pharmacologues), lorsqu'ils n'ignorent pas souverainement les logiques du système médical local, serait de rabattre globalement l'un sur l'autre les modèles biomédicaux ou locaux. Il s'agit alors de déterminer précisément quel effet est attendu par la population locale, à quelle étape du traitement, pour orienter de façon plus précise l'expérimentation (cela n'excluant pas qu'un effet peut en cacher un autre !). De très rares travaux comme ceux de Elwin-Lewis (1986) contiennent à la fois une partie clinique et à la fois l'exposé des attentes indigènes ainsi que les modes de préparation et d'administration. Ce vers quoi tend l'auteur est de tenir compte à la fois des aspects étics et émics . Dans un article ultérieur où elle nous expose les Anthropological methods in ethnopharmacology (Etkin 1993), il s'avère que, pour elle, les anthropologues, acquis aux méthodes quantitatives au même titre que leurs collègues biologistes regard as a necessary analytic step the transformation of at least a subset of the qualitative data for quantitative analysis. From this vantage we seek data that are meaningful to local correspondents and also amenable to analysis through such extrinsic paradigms as phytochemistry, pharmacology and physiology . De ce point de vue, elle n'est pas loin de partager avec les équipes du laboratoire américain Shaman Pharmaceutical (Carlson King 1996) qui ont mis au point une méthodologie très précise d'évaluation rapide des ressources l'idée que seuls doivent être étudiés les remèdes pour les indications desquels guérisseurs et cliniciens occidentaux se rejoignent, ce qui élimine tous les syndromes culturellement construits qui bien entendu posent problème. 38 L'étude de ces syndromes, ainsi que le contexte social, le rituel des soins, dans la mesure où ils n'apportent pas de données pragmatiques utilisables et donc sortent d'une analyse bio-comportementale, semblent ne pas concerner l'auteur. Inversant les critiques qu'elle formule à l'encontre des anthropologues de l'école de Kleinman, nous pourrions dire qu'une thérapeutique n'est pour elle étudiée que du point de vue où elle cure the disease . Et toute thérapeutique, fondée sur des données empiriques accumulées au cours des siècles par une population donnée, à condition de l'analyser correctement, a pour elle cette visée. Aussi l'aspect symbolique laissé de côté se voit-il réservé à l'ethnologue (Moerman 1979 et 1983), du moins est-ce ainsi que se répartissent les compétences dans les ouvrages ou coexistent ces deux spécialités (Romanucci-Ross et al. 1983), l'efficacité symbolique relevant de l'ethnomédecine. Mais ce sont toujours des critères de sélection des plantes médicinales dans les cultures traditionnelles et leur relation avec les propriétés biologiques avérées que traite Moerman. 39 L'on sait la réalité de l'effet placebo, mais de la richesse de ce phénomène, Moerman, dans l'enthousiasme de sa découverte, n'a retenu que la conception réductrice selon laquelle la forme de la thérapeutique soigne, ce qui le conduit à chercher l'efficacité physiologique de la métaphore, passant sous silence les conséquences de l'attente sociale dans l'effet placebo, et les aspects relationnels qu'il est difficile d'ignorer. 40 Dans la perspective bio-comportementale, cette recherche de sens n'est requise que lorsqu'elle informe l'analyse biologique ; dans l'exemple cité, il s'agit de mettre au jour les représentations locales de l'efficacité à chaque étape du processus thérapeutique. Mais est-ce dire pour autant que la tâche de l'ethnologue se résume à déterminer les ressorts culturels de l'effet placebo ? 41 Sa recherche plus spécifiquement anthropologique devrait plutôt s'attacher à définir ce qu'est le remède dans une culture donnée, et comment s'organise le savoir thérapeutique. 42 Force est de constater que les ethnologues, à l'instar d'Evans-Prichard (1972), furent plus attirés par les aspects symboliques ou rituels des pratiques de soin que de leur fondement empirique. Imprégnés du dualisme inhérent à notre culture occidentale moderne, ils eurent du mal, dans les formulations mêmes (magique, magico-religieux) à prendre en compte la globalité des pratiques. Beaucoup ne s'intéressèrent pas aux remèdes empiriques ou à ceux de la médecine familiale et lorsque ce fut le cas pour les meilleurs, ils produisirent deux publications juxtaposées. Louis-Vincent Thomas (1972) lui-même, publie dans le Bulletin de l'IFAN une note distincte : De l'ethnobotanique à la médecine, l'exemple diola , où il expose les traitements empiriques d'un certain nombre de maux sans faire de liens avec la première partie de sa note qui décrit avec finesse la vision du monde diola. Constatant que le savoir du Diola est plutôt implicite qu'explicite, plutôt vécu que réfléchi, plus apte à vérifier qu'à émettre une hypothèse, entièrement du côté de l'action, capable d'observations minutieuses, voire stupéfiantes, mais aussi tissé d'inexplicables ignorances , il n'explore pas cet implicite, ce savoir qu'il souligne d'action ou issu de la pratique, ce que nous aborderons plus loin. 43 Il faut dire que les monographies antérieures traitaient de la médecine avec la religion, et au mieux citaient une classification étiologique des maladies et infortunes. Les interlocuteurs gbaya de Tessmann (1937) par exemple semblaient avoir organisé ainsi leur savoir à propos de la maladie (maladies envoyées par les sorciers, par les esprits, nées d'elles-mêmes). Concernant le pays gouro, Tauxier (1924) cite les phytothérapeutes en deux phrases dans sa liste des sacerdotes (devins, prêtres, etc.) des divinités (cultes ou masques). 44 Il faut également souligner qu'alors même que Rivers (1924), un autre père de l'anthropologie médicale, insistait à écrire que : les pratiques médicales de ces peuples ne sont pas une macédoine décousue et insensée, mais elles sont inspirées par des conceptions précises concernant les causes de la maladie. Leur mode de traitement découle directement de ces conceptions étiologiques et pathologiques. D'un point de vue moderne, nous pouvons voir que ces conceptions sont fausses. Mais l'important ici est que, aussi fausses que soient les croyances des Papou concernant les causes de la maladie, leurs pratiques sont des conséquences logiques de ces croyances (trad. française in Massé 1995) . 45 Ses successeurs en ethnomédecine sur l'Afrique se préoccupèrent plus de l'étiologie des troubles que de leurs manifestations (Pool 1994) et moins encore de la logique des traitements. 46 Néanmoins, parmi les premiers ethnologues africanistes français de l'école de Griaule, bien que sous l'intitulé Classification des végétaux chez les Dogon , Germaine Dieterlen (1952) nous eût restitué en fait les séries d'analogies qui auraient pu sous-tendre l'organisation de la pharmacopée, on n'alla alors pas plus loin faute d'études sur la médecine, lesquelles seront menées plus tard par le programme italo-malien sur la médecine traditionnelle (Coppo Keita 1990, Keita Coppo 1993). Cette classification a ensuite été critiquée par Friedberg (1974) citée par l'historienne Dominique Juhé-Beaulaton (2020) qui, à partir des herbiers et des notes de Dieterlen, nous donne le contexte de cette enquête. 47 Pour nous en tenir au JATBA nouvelle mouture ethnobotanique (de 1954 à la fin des années 90), les publications dans ce domaine relèvent plus du catalogue, de la recension (la pharmacopée de tel ou tel groupe, ou les plantes médicinales dans la liste des plantes utiles de tel groupe ou pays), de l'étude approfondie de plantes médicinales utiles à l'industrie, par exemple les Rauwolfia (Pham-Hoang Ho 1958, Kerharo 1970), voire d'articles de pharmacognosie écrits par des chimistes bien connus (Paris Moyse 1957). Sont également étudiées les plantes magiques des haies (Portères 1965), ce à quoi fera pendant la place des plantes protectrices dans l'espace du jardin (Benoit 1999), ou les plantes utilisées dans les rituels (Friedberg 1965). Mais l'ouverture vers une appréhension autre du monde végétal présentée par Dournes (1954), Le monde végétal du montagnard est-il animé ? , ne fit pas d'émule parmi les africanistes. Il décrivait pourtant ce que plus tard Descola (2005) catégorisera comme ontologie animiste. Mais il ne développera pas les usages médicinaux donnés plus tard (Dournes 1973), faute sans doute de lien avec un travail d'ethnomédecine. Il faudra attendre 1983 pour que soit présentée une étude sur les plantes ayant un pouvoir chez les Shipibo (Tournon Reategui 1983) et que soient décrites les catégories locales. La revue est le lieu de publication de résultats partiels de ce qui donnera des ouvrages plus importants, ainsi Kerharo et Adam proposent dès 1964 Plantes médicinales et toxiques des Peuhl et des Toucouleur du Sénégal . Si le volet botanique du binôme est rigoureusement étudié, les identifications et les descriptions étant précises, cette précision étendue au diagnostic médical interdit l'accès à la compréhension de ce que sont la maladie et les remèdes pour la population en question, les indications de la plante s'apparentant à un inventaire à la Prévert : par exemple Gardenia ternifolia Schum. et Thonn. : les mêmes écorces de racine contre ascite, caries dentaires, hémorroïdes et défatiguant . Tout au plus Kerharo (1970 : 354) notera-t-il à propos du Rauvolfia le caractère fétiche propre à cette drogue employée pour cette raison dans de nombreux traitements médico-magiques rappelant en note la théorie des signatures. 48 C'est à un ethnologue amateur rapportant ses observations au folklore , Antonin Marius Vergiat, officier naviguant de l'aviation coloniale et photographe participant à des missions en Oubangui, et publiant à son retour Les rites secrets des primitifs de l'Oubangui (1936), que nous devrons, au-delà des préjugés et des formulations de l'époque, une prise en compte globale des troubles et de leurs remèdes, publiée dans plusieurs livraisons successives du JATBA (Vergiat 1969 et 1970). Son âge (il est né en 1900, mort en 1983) et le sujet sans doute, font qu'il n'échappe pas au comparatisme tout azimut du Rameau d'or (Frazer, paru en français en 1925-1935) lorsqu'il traite des Loranthacées d'Afrique centrale, Le gui dans le folklore des Noirs de l'Oubangui (1975) tout de même, dans le JATBA . Affranchi des cadres théoriques de la pharmacologie tout comme de l'ethnologie, il nous restitue, sous couvert de folklore, et intégrant la magie , un compte rendu des pratiques de guérisseurs-féticheurs dont il avait gagné la confiance, sans analyse des implicites mentionnés plus haut, mais sans les filtres que nous retrouverons plus tard. 49 Il faut en effet d'anciens missionnaires, ce qu'était Dournes, mais en Afrique cette fois, comme l'abbé André Walker (1934), pour inclure dès avant ce tournant ethnobotanique , les plantes fétiches dans leurs recensions ( Plantes aromatiques offertes par les Gabonais aux mânes de leurs ancêtres ) en prenant en compte leurs qualités sensibles. Il faut encore un missionnaire, Lluis Mallart-Guimerà, pour s'intéresser aux pratiques de soin de ceux qu'il cherche à comprendre sans toujours les convertir. Ce dernier avoue dans ses premières publications sur ces sujets (1977a, 1981), être embarrassé d'utiliser les termes de religion, de magie et de sorcellerie alors qu'il entend traduire d'une certaine manière quelques catégories de la pensée symbolique du peuple evuzok (1981 : 12). 50 Le JATBA dans ces années-là, rend compte des controverses autour des classifications, autour des logiques des humeurs, du chaud et du froid dans les médecines de Mésoamérique ou aux Antilles, qui permettent un peu de comprendre l'organisation des soins sinon des pharmacopées (Bougerol 1975) alors que l'anthropologie médicale interprétative américaine (Kleinman 1980) avait rendu évidente la distinction étiqueémique et le non-recouvrement de la maladie du médecin ( disease ) de la maladie du malade ( illness ) et du rôle social de malade ( sickness ). Mais un travail équivalent à propos du remède, travail de déconstruction de l'efficacité biologique du médicament à l'efficacité du point de vue du malade, n'avait pas eu lieu, du moins en Afrique. Les médecines écrites d'Inde (Zimmermann 1989) ou de Chine (Needham 1973), et même certains pans des médecines populaires européennes (Lieutaghi 1986, Loux Saillant 1991), ou de Mésoamérique (Bastien 1981 et 1985, Nicolas 1999), avaient fait l'objet d'études permettant de comprendre les fondements de la thérapeutique du point de vue de ces cultures respectives. Mais dans les territoires francophones d'Afrique et de Madagascar, peu de chercheurs ont suivi les traces amorcées par les premiers ethnologues. 51 Il se confirmait, à travers cette bibliographie, que comprendre les fondements de la thérapeutique pour la communauté étudiée, nécessitait un travail sur la maladie dans toutes ses dimensions. Les enquêtes que j'avais débutées en Côte d'Ivoire m'ont confortée dans cette nécessité, je le reprendrai plus bas. 52 C'est lors de la rédaction de ma thèse sur la médecine familiale gbaya que j'ai découvert l'anthropologie médicale. Les sociolinguistes de l'équipe m'avaient introduite auprès de deux spécialistes de ce domaine à l'université de Nanterre. András Zempleni d'une part, qui me fit lire Victor Turner (1972), incontournable à l'époque comme référence d'anthropologie symbolique, et Lluis Mallart-Guimerà de l'autre, travaillant sur la religion et la sorcellerie autant que sur la médecine, qui abordait quant à lui la pharmacopée des guérisseurs, en tenant compte des propriétés de cette matière médicale retenues par ses interlocuteurs, ce qu'il ne publiera que bien plus tard, en 2003, quand il présentera la somme de ses analyses en deux tomes ( Le système médical des Evuzok du Cameroun et Le savoir botanique des Evuzok , composant La forêt de nos ancêtres (2003) qui met les deux champs en rapport). Qualifié d'ethnobotanique exemplaire par Laburthe-Tolra (2005), cet ouvrage laisse néanmoins dans l'ombre leur chevauchement dans la pratique, faute d'implication de l'auteur dans le soin relevant du système descriptif, alors qu'il participa aux rituels et en gagna une connaissance fine des initiations. L'identification des maladies qu'il fit avec un médecin, et qui pêche par trop de précision médicale, ne permet pas de dégager l'ethno-sémiologie éventuelle des troubles et son éventuel lien avec la thérapeutique. Cette difficulté est récurrente. Pour y échapper, il est nécessaire de donner des tableaux symptomatiques, supports de tentatives d'assimilations, telles que, pour la médecine du Kerala, Francis Zimmermann (1989) le fit en usant abondamment des termes d'ancienne médecine encore mentionnés par Littré . Un médecin enquêtant chez les Peulh, Alain Epelboin (1983), bien que plus vague dans ses identifications, n'y avait pas complètement renoncé adoptant quant à lui la convention de les inclure dans des listes ouvertes : par exemple page 357, daneyel Affection spécifique (diverses affections avec œdèmes etou ascites, insuffisance hépatique, rénale, etc.) . Convenons avec Zimmermann que ces gloses ne sont pas faciles à utiliser dans le texte. De magnifiques travaux sur la sémiologie et l'organisation des noms de maladies tels celui de Bibeau (1978), auraient pu servir de base à une véritable anthropologie du remède, si cet auteur ne s'en était tenu aux seules maladies. L'anthropologie médicale n'était pas développée en France, il fallut le colloque inaugural organisé par Anne Retel-Laurentin en 1983, pour regrouper la communauté dispersée qui travaillait d'une façon ou d'une autre sur la maladie, l'alimentation et les systèmes de santé en lien avec les sciences sociales. Deux ouvrages en furent tirés : les actes du colloque édités par Anne Retel Laurentin (1987) et un numéro spécial de la revue L'ethnographie : La maladie et ses causes dont András Zempleni (1985) était directeur. C'est lors de ce colloque que Dournes (1987) exposa sa méthode, l'implication dans la pratique de soin, la communication dans la langue lui permettant de comprendre la conception du mal, de la maladie, de la guérison dans l'univers de représentations de populations autochtones traditionnelles en Indochine . Il insista sur l'implicite accessible par exemple dans les métaphores, sur la nécessité de tenir compte de l'évolution de la société donc de l'enquête en diachronie, ainsi que d'envisager la personne globale appelant à se débarrasser de la dichotomie occidentale corpsâme . Il se référa au complexe shamanique (Lévi-Strauss 1958) mais conclut sur un appel à la psychosomatique, ne faisant pas, malheureusement pour notre propos, retour sur les simples. 53 Ce qui me préoccupait, c'est-à-dire le lien entre l'ethnopathogénèse et les soins, empiriques ou rituels, me restait à explorer. À mon retour en France, je m'inscrivis donc à l'EHESS, seule possibilité universitaire pour passer de la biologie à l'anthropologie. Je suivis alors les enseignements de Marc Augé (1984) et sur ses conseils les cours de Françoise Héritier, réunis en 1995 dans l'ouvrage Masculin, féminin . 54 Les critiques du terme ethnomédecine et même anthropologie médicale au profit d' anthropologie de la maladie , portées en particulier par Marc Augé (1986) furent salutaires, permettant un déplacement épistémologique. Adopter la perspective d'anthropologie de la maladie, et plus tard d' anthropologie de la santé (Fassin 2000), a grandement libéré la réflexion du dualisme induit par notre culture. En termes de santé publique même, ceci rejoint la nécessité de prendre en considération le point de vue des populations visées (Massé 1995) . Reste à appliquer cette analyse à l'ethnopharmacologie dans le sens d'un basculement sur une anthropologie du remède. Zimmermann (1989) n'intitulait-il pas son ouvrage Le remède au pays des épices ? Le terme remède , nous rappellent Reynaud et Coudert (1987), dérive du bas latin remedium , désignant l'écart entre le titre d'une pièce d'argenterie et son taux réel, la masse de métal fin dans l'alliage. Plus tard, appliqué à une thérapeutique, il désigne ce qui comble l'écart entre l'état de bien-être tel qu'envisagé et l'état de mal-être ressenti par la personne, ce qui, dans d'autres ontologies que naturaliste, implique d'autres instances ou d'autres existants que le corps. 55 Dans cette approche, les analyses de Marc Augé sont précieuses. Cet auteur montre bien que la démarche typologique (présentée plus haut) néglige les dimensions sociales de la maladie autres que la dimension étiologique et s'interdit par là-même de penser le schéma d'ensemble qui donne leur cohérence et leur efficacité à la nosologie et aux pratiques thérapeutiques . Il faut selon E. Gillies citée par Augé (1984), s'intéresser au how et pas seulement au who et si l'ouvrage de Turner est le meilleur qui soit sur la médecine africaine, c'est parce qu'il s'est intéressé principalement aux world views symbols and underlying patterns of thought écrit-elle. Mettre en évidence les idéo-logiques qui permettent de penser le monde, le corps et la société, comme le font les auteurs de l'ouvrage Le sens du mal qu'Augé a codirigé, et en particulier Françoise Héritier à propos des questions de fécondité et de stérilité chez les Samo, ouvre la possibilité de comprendre le mal et les remèdes qui le traitent, dans toutes leurs dimensions. Marc Augé, à propos de consultation de l'oracle du fa au Togo, et des plantes données en traitement, met en évidence la cohérence virtuelle entre ces domaines qui ouvre la possibilité exclusive, alternative ou cumulative de deux cheminements, l'un privilégiant la détermination de la cause, l'autre l'analyse du symptôme . 56 Ainsi, juger de l'efficacité à l'aune des effets considérés comme désirables produits par les plantes, within the user's own system of medical knowledge (Brown 1987), demande d'adopter une perspective inverse à celle utilisée jusqu'alors par les ethnopharmacologues : soit dégager les effets de sens pour y situer le savoir empirique. En effet Augé (1986) s'interrogeant sur les rapports entre sens et savoir, reprend Lévi-Strauss (1950) qui rappelle que dès que sont apparus conscience et langage, il a fallu que l'univers signifiât . Cette nécessité immédiate de sens est incompatible avec la lente constitution du savoir, mais est œuvre de la même raison humaine. Dès lors la coupure (entre l'empirico rationnel et le rationnel pur) naît de l'observation scientifique occidentale ; mais elle n'est pas le fait des cultures païennes ; celles-ci ne distinguent pas un domaine qui serait accessible au savoir et un domaine qui ne serait accessible qu'à la foi. On peut dire au contraire simultanément à leur propos que les acquis de l'expérience s'insèrent dans la logique symbolique et que la logique symbolique ne contredit jamais l'expérience et même se fonde partiellement sur elle... . 57 La rencontre cette approche me fut féconde au moment où le terrain que j'ouvrais seule cette fois chez les Gouro de la région de Zuénoula (Côte d'ivoire) m'apportait de nouveaux problèmes, car je prenais cette enquête à rebours de celle que j'avais menée précédemment. 58 Arrivée en pays gouro et présentée comme pharmacienne enseignante à l'université donc en lien avec le monde médical, mais seule et sans l'introduction d'une équipe, il n'était pas question de débuter d'emblée une enquête sur les plantes médicinales, car les recettes avaient de la valeur pour mes interlocuteurs, ni question de ne pas envisager un contre-don de valeur équivalente pour mes hôtes aux informations qui me seraient communiquées 13 . Il fut convenu que j'aiderais les malades dans leurs parcours de soin. Cette proposition fut immédiatement saisie au vol par les femmes du village qui me demandèrent de trouver remède à une maladie qu'elles disaient sans recours et qui résultait de la transgression d'un interdit des ancêtres, celui pour les femmes en aménorrhées d'avoir des rapports sexuels. Ce premier problème à résoudre me projetait d'emblée dans leur monde et dans une implication pratique dans le soin. Il me fallut avoir pris connaissance des travaux de Françoise Héritier (1984) pour comprendre ce qui pouvait se lire dans les données de terrain. Comprendre que dans cette société, comme chez les Samo que cet auteur avait étudiés, le cumul de qualités semblables était délétère : l'humeur masculine chaude sur une femme ayant perdu sa jouvence provoquait une consomption (Haxaire 1987) que pouvait aggraver la perte de la protection des ancêtres, le danger étant pensé chaud. La même idéo-logique régissait tant la société, le cosmos, que le corps, et les remèdes agissaient aux différents niveaux, des humeurs du corps aux instances invisibles de la personne en lien avec les ancêtres (Haxaire 1987, 1999). Plus ou autant que l'anthropologie de la maladie, c'était l'anthropologie sociale et culturelle, en particulier les travaux sur la notion de personne en Afrique (Bastide Dieterlen 1973) qu'il me fallait aborder. Lors de l'enquête, je m'en tenais aux catégories gouro, ne me préoccupant plus de savoir ce qui relevait de l'empirique, du magique ou du religieux, recueillant in extenso dans la langue les descriptions d'évènements maladie tout comme celles de préparations de remèdes, avec les commentaires de mes interlocuteurs laissant transparaître ce qui était implicite pour eux. Parallèlement à l'accueil des malades et à un début d'herborisation, je menais des entretiens sur le corps et la personne avec de vieux sages, ce qui me permettait de comprendre de quel dysfonctionnement du corps ou de quelles instances invisibles il était question. Il s'est avéré qu'un remède agissant en apparence par sa matérialité (par exemple sa qualité organoleptique) pouvait agir sur l'invisible et réciproquement (Haxaire 1998). Il s'est avéré également que l'analyse des recettes enregistrées (un millier à ce jour) permettait de voir se dessiner une organisation fondée sur ce que la maladie, le trouble ou le symptôme, révélait d'une altération du fonctionnement du corps etou des instances invisibles : il se dégageait une ethno-sémiologie. À la lumière de cette ethno-sémiologie, les usages de drogues (partie de la matière médicale utilisée) composant ces recettes apparaissaient avoir des airs de famille (Wittgenstein 1961) qui laissaient comprendre les points communs de maladies (très diverses pour la biomédecine) ou de leurs aggravations dans l'invisible. Je retrouvais les classes polythétiques décrites au Kerala par Zimmermann (Haxaire 1996) ainsi que l'analyse en termes d'espaces d'attribut proposée par José Dos Santos pour les calmants et les dépuratifs (Dos Santos 1991), mais ce dernier s'est ensuite orienté vers l'anthropologie cognitive, s'éloignant de la société d'ethnopharmacologie. C'est également ce que Jean-Pierre Olivier de Sardan (1999) constate en Afrique pour les maladies populaires, avec cependant des solutions de continuité que je ne retrouve ni au niveau des maladies ni au niveau des remèdes (Haxaire 2011). 59 L'organisation possible des pharmacopées traditionnelles comme système, déjà décrite par un philosophe des sciences (Dagognet 1964) pour notre pharmacologie occidentale se retrouvait donc, mais comment appréhender théoriquement ce qui était apparu : la fluidité entre les remèdes du corps dans sa matérialité et ceux des instances invisibles dont il est le support, de leurs liens avec leur environnement climatique et sociétal ? Comment par ailleurs rendre compte dans tout cela de l'efficacité biologique de ces remèdes ? 60 En 1986, le laboratoire d'ethnobotanique change de nom pour devenir le Laboratoire d'ethnobiologie-biogéographie. En 1994, le JATBA s'intitule JATBA-revue d'ethnobiologie , pour disparaître en 2005 (Hoare 2012). En 2012, la Revue d'ethnoécologie qui lui succède adopte donc un point de vue plus large, plus systémique. Dans son introduction au numéro inaugural, Serge Bahuchet (2012) trace l'historique dans le JATBA , des articles qui en sont les prémisses. Il cite l'écologue mexicain Toledo (1992) pour qui l'ethnoécologie étudie : ... the connections between corpus (the whole repertory of symbols, concepts and perceptions on nature) and praxis (the set of practical operations through which take place the material appropriation of nature) in the concrete process of production should be the starting point of any ethnoecological research. ( Bahuchet 2012 ) 61 Je souligne à nouveau praxis : l'importance de travailler sur les pratiques en contexte (j'y reviendrai plus bas). 62 Dans la Revue d'ethnoécologie , si quelques rares articles traitent directement de questions ethnopharmacologiques soit de plantes antilithiasiques (Khitri et al. 2016), ces usages apparaissent plutôt à propos de leur place dans une problématique écologique. Nous trouvons mention d'usages médicinaux de poisson dans un article portant sur leur écologie (Oishi 2016), les plantes médicinales préservées dans les cacaoyères comme plantes compagnes sont également citées dans un article (Yao Adou et al. 2016). 63 Ce seront des articles réflexifs, historiques, qui aborderont les questions fondamentales de l'ethnopharmacologie comme celui que Juhé-Beaulaton (2020) consacre à Germaine Dieterlen. Il y est fait mention des recherches de cette dernière menées en Côte d'Ivoire où elle a pu observer les pratiques de soins du prophète Abert Atcho. Ces recherches dans les archives mettent en évidence que G. Dieterlen attendait de ces collectes de plantes et des savoirs associés des informations sur l'interprétation des connaissances physiologiques et des maladies des personnes interrogées, connaissances reflétées dans la terminologie utilisée pour décrire les maladies et les symptômes . Il en était de même du travail sur les classifications déjà cité plus haut qu'elle n'a eu de cesse de compléter par des enquêtes sur les plantes médicinales, ni les unes ni les autres n'étant publiées. Ceci conforte mon opinion sur les objectifs non réalisés et les difficultés des premiers ethnologues présentées plus haut. 64 L'article de Carole Brousse (2015) sur les spécialisations réciproques du séminaire de Salagon, du Muséum national d'histoire naturelle et du séminaire d'ethnopharmacologie de Metz, entre plus directement encore au cœur de la question. Il nous est expliqué pourquoi, bien que Lieutaghi (1986) ait pu être cité plus haut comme modèle en anthropologie du remède, Salagon ne développe pas cet aspect de l'ethnobotanique , le renvoyant à l'ethnopharmacologie telle que définie par le colloque de Metz, cela bien qu'une proportion notable des participants s'intéressât à l'herboristerie. Lieutaghi dans un entretien du 11 juillet 2013 cité dans l'article constatait qu'en France : L'ethnobotanique était quasiment synonyme de connaissance populaire du végétal. Et cette connaissance concernait à 90 les plantes médicinales. Après il y avait des histoires de ressources alimentaires sauvages et éventuellement les usages artisanaux. Mais il y avait donc confusion confusion qui persiste à mon sens aujourd'hui entre ethnobotanique et médecine populaire par les plantes. On a donc voulu se démarquer de cela pour ne pas valider, même implicitement, cette confusion. (Brousse 2015) 65 Bien que ne traitant pas de plantes médicinales, un article aborde la problématique qui se pose à nous, celui de l'efficacité des tabous en matière de conservation de la nature (Artaud 2014) et donc de la nécessité de dépasser les analyses en termes de magie . 66 J'avais pour ma part proposé une tentative d'analyse des remèdes de la folie causée par les ancêtres tutélaires (des zù ) (Haxaire 2012). 67 Mais il s'agissait bien de passer de l'anthropologie du remède à une anthropologie plus générale incluant les liens entre ce que la société en question considère comme actants (dirait Bruno Latour, in Akrich et al. 2006) induisant la maladie ou la traitant, il fallait une ethnoécologie au-delà des concepts de nature et culture qui nous ont enfermés, nous l'avons vu, dans une dichotomie qui n'était pas celle de nos interlocuteurs. La publication du livre de Philippe Descola (2005), qui marque le tournant ontologique au xxi e siècle de l'anthropologie en France, fut une ouverture et une légitimation de cette orientation de recherche. 68 Ce sont bien en effet des ethnologues, qui se sont heurtés aux apories entre écologie culturelle et anthropologie écologique et qui les ont dépassées, que viendra un nouvel éclairage sur le remède. Deux d'entre eux, se retrouvant dans ce dépassement du dualisme natureculture, Philippe Descola et Tim Ingold, récemment traduit en français, (2011-2013), se sont retrouvés pour débattre de ce qui les oppose, débat publié en 2014 sous le titre Être au monde . 69 Philippe Descola se réclame de l'analyse structurale et en cela il n'opère pas de rupture avec les ethnologues africanistes cités précédemment comme référents, Marc Augé et Françoise Héritier. Son cours, cité dans l'introduction au débat, vise à proposer un cadre général d'analyse permettant de rendre compte des différentes configurations ontologiques et cosmologiques au sein desquelles s'organisent et prennent corps les interactions entre les hommes et les objets de leur environnement. (Descola Ingold 2014). 70 Une fois libérée du manque d'ajustement de la configuration étudiée à l'ontologie naturaliste occidentale, la méthodologie antérieure était applicable. Je comprenais alors pourquoi le médecin ayant eu à juger ma thèse sur les Gbaya avait qualifié d'hippocratique ce système : il s'agissait de médecine s'inscrivant dans une ontologie analogique, ce qui valait également pour le pays gouro. Néanmoins, en matière de remède empirique, aucune voie n'apparaissait pour établir un lien avec les propriétés pharmacologiques. 71 Tim Ingold (2011) quant à lui se propose d'étudier ce qui fait être vivant, Being alive , comme processus, comme activité ; il parle d'ontogénèse plutôt que d'ontologie. Se développe alors une anthropologie de la vie à laquelle en France s'attache Perig Pitrou (2014). Tim Ingold insiste sur le processus d'apprentissage auprès de nos Autres, qu'est l'observation participante, observation en action donc, praxis tenant compte du contexte relationnel. En matière d'anthropologie du remède, ceci implique la posture d'apprentissage, de transmission de pratique dans la relation confraternelle, que tant Kerharo que Lévi-Strauss donnaient comme nécessaire. Ne serait-ce que les underlying patterns of thought (Gillies 1976) ne sont accessibles que dans la pratique. Une recette n'est jamais explicitée au malade s'il n'y a pas intention de la transmettre. Elle sera commentée au guérisseur à qui elle est confiée tout en la lui montrant, et dans ces propos sera rappelé ce qui est non-dit, ce qui est donné par prétérition. Ce fut le cas des équilibres chaudfrais ou sechumide dans les recettes de l'ictère-anémie détaillées dans Haxaire (2017). Les interactions autour du soin, le partage d'expérience dans l'accompagnement de malades ou dans la pratique du soin donnent accès à tout ceci au détour des échanges. Peu d'ethnologues se sont mis dans cette posture de guérisseurs alors qu'ils soignaient pour beaucoup, ils étaient plus enclins à participer aux rituels. 72 Mais un autre dépassement de la dualité natureculture proposé par Tim Ingold nous importe, celui d'une ethnologie écologique alternative qui envisage : une conception directement inspirée par l'idée de réciprocité entre personne et environnement. Pour y parvenir, nous avons besoin d'une nouvelle théorie de la perception montrant comment les personnes peuvent acquérir une connaissance directe de leur environnement au cours de leurs activités quotidiennes (Ingold 2013 : 133), 73 rendant alors caduque la nécessité de passer par les représentations culturelles , ce qui était la problématique présentée précédemment. 74 Cette nouvelle théorie de la perception , il la trouve dans la psychologie écologique élaborée par James J. Gibson (1979, 1982). Ce dernier soutient que les animaux perçoivent les objets de l'environnement en fonction du rôle, positif ou négatif, qu'ils jouent dans leur comportement ... Les affordances d'un environnement sont ce qu'il l'environnement offre à l'animal, ce qu'il lui procure ou lui fournit, en bien ou en mal (Gibson 1979 : 127). 75 Pour Gibson, poursuit Ingold différents animaux peuvent vivre dans un environnement partagé, et peuvent qui plus est partager leurs perceptions à propos de ce qu'il offre . Sans développer plus avant, notons dès lors pour notre propos qu'il est pertinent de prendre en compte la double valence remèdepoison et donc qu'il est judicieux de développer une anthropologie du pharmakon , telle que Andréa Luz Gutierrez-Choquevilca (2017) le propose, ce qui formalise l'intérêt des premiers ethnopharmacologues incluant les poisons, substances actives, dans leurs enquêtes. Mais surtout, une autre dimension qu'induit le pharmakon et que l'anthropologie apporte, est que cette notion nous place d'emblée au cœur des interactions sociales incluant l'invisible (Haxaire 2021). Notons également, comme nous le montrent le terrain et les enquêtes d'ethnosciences qui, a minima , enregistraient le rapport entre plantes et animaux (selon les grilles présentées plus haut), que les humains ne sont pas sans s'inspirer du comportement animal observé. Les primatologues comme Sabrina Krief ont sur ce plan mené des études précises (Krief et al. 2005) et la collaboration de cette dernière avec une ethnologue, Florence Brunois-Pasina, nous conduit à l'exposé de leurs interrogations épistémologiques (Krief Brunois-Pasina 2017). Il s'agit de travailler sur les propriétés pharmacologiques d'items comme autant d'affordances sélectionnées dans un environnement donné par une communauté d'humains (ou d'animaux) et, en ce cas précis, dans le système d'interactions complexes humains-animaux-esprits (Brunois et al. 2008) nous dirions dans les interactions entre tous les actants. 76 Une revue bibliographique des drogues trouvées dans les traitements curatifs et préventifs de l'ictère-anémie (Haxaire 2017) atteste que des propriétés hépatoprotectrices sont bien identifiées pour certaines. Mais dans la classe polythétique que constituent les usages de chacune de ces drogues, comment savoir a priori de quel usage dérivent les autres ? comment traiter le bricolage (Lévi-Strauss 1962) qui les associe et dont le sens peut être déduit de l'ethnosémiologie ? La pragmatique du pharmakon rejoindrait-elle sa poétique ? (Gutierrez-Choquevilca 2017) 77 Des cent ans de la Revue de Botanique Appliquée (1921-2021), ce parcours n'a tenu compte que des années suivant sa métamorphose en Journal d'Agriculture Tropicale et de Botanique Appliquée , à partir de 1954, lorsque la revue s'est orientée vers l'ethnobotanique sous l'impulsion de Portères. Nous avons vu ce qu'il en a été de l'ethnobotanique des plantes médicinales, depuis de simples recensions à des études plus poussées auxquelles manquait une appréhension plus développée du rapport des communautés étudiées à ces remèdes. Il manquait selon Kerharo un volet ethnique au volet botanique qui demandait toute son attention devant l'urgence à recueillir un savoir en voie de disparition. Nous avons vu que ces premiers ethnopharmacognosistes ou ethnopharmacologues, qui n'étaient pas ethnologues, mais hommes de terrain familiarisés avec la langue de leurs interlocuteurs comme Boiteau, avec le contact avec les guérisseurs comme Kerharo, ou avec les deux comme les missionnaires, pressentaient la nécessité de partir de ces pratiques pour comprendre le sens que prenaient la maladie et les soins ; ils notaient la part plus importante de l'idéologie mais ne purent atteindre leurs objectifs faute de collaboration avec des ethnologues, ou de véritable enquête d'ethnomédecine. Ils notaient également la part implicite à dévoiler, les guérisseurs étant entièrement du côté de l'action . 78 L'ethnopharmacologie qui vit son renouveau dans les années 90 se définit alors comme agrégeant la collaboration de plusieurs disciplines scientifiques mais entend le préfixe ethno comme pharmacologie des autres, et n'interroge pas les postures qu'induisent les sciences instituées en Occident. 79 Au contact du terrain en effet, adopter le point de vue de nos interlocuteurs en travaillant dans leur langue, rend évident le fait que maladie et remèdes s'organisent de façon spécifique, au niveau le plus empirique qu'est la médecine familiale même. Un autre cadre de référence tel que Mallart-Guimerà l'avait noté donnait accès aux étiologies, sorcellaires par exemple, qu'il fallait prendre en compte pour une approche holiste de la maladie et du soin. 80 L'ethnopharmacologie doit, tout comme l'ethnomédecine, se déconstruire en déplaçant sa posture épistémologique. C'est par abus de langage qu'il peut être question de science du médicament des autres, car il s'agit bien de remèdes dont la composition et les effets sont pensés selon les idéo-logiques mises en évidence par Augé. Ils traitent la maladie et l'infortune dans toutes leurs dimensions, dépassant les catégories occidentales. Cependant la difficulté demeurait d'ajuster ces pratiques, sous tendues par des ontologies autres, à nos visions dualistes, ce à quoi nous aident les anthropologues ayant dépassé l'opposition natureculture, Descola puis Ingold. Ce dernier ouvre à une anthropologie de la vie, axée sur les processus, sur l'expérience pratique, qui réconcilie en partie les données biologiques et les effets de sens grâce à l'approche d'ethnologie écologique alternative qu'il adopte. Il devient plus juste alors de reconnaître toute l'ambivalence du pharmakon . 81 Ainsi, suivre le devenir du volet ethnique dans le binôme ethnique et botanique envisagé par Kerharo nous a mené, d'impasses surmontées en impasses nouvelles, à suivre les évolutions de l'anthropologie puis de l'ethnoécologie, ce qui, depuis 2012, est bien l'intitulé du nouvel avatar de la Revue de Botanique Appliquée . Adjanohoun E. 1989 Le processus de rénovation de la pharmacopée africaine. Bull. Soc. Bot. Fr. 136 Actual Bot. (3-4) : 35-39. Akrich M., Callon M. Latour B. (Ed.) 2006 Sociologie de la traduction : textes fondateurs . Paris, Presses des Mines, 401 p. (Sciences sociales). Alger N. 1976 Pharmacology, ethnopharmacology, and the use of drugs in curanderismo. Actas del XLI Congresso International de Americanistas, Mexico, 2-7 Sept 1974) III : 262-268. Artaud H. 2014 De l' efficacité symbolique des interdits à leur fonctionnalité écologique. Revue d'ethnoécologie , 6. https:doi.org10.4000ethnoecologie.2055 Attisso M.A. 1969 Approche scientifique rationnelle des médications traditionnelles des pays en voie de développement en vue d'une phytothérapie rénovée . Organisation Mondiale de la Santé. Augé M. 1986 L'anthropologie de la maladie. L'Homme XXVI (1-2) : 81-90. Bahuchet S. 2012 Du JATBA-revue d'ethnobiologie à la revue d'ethnoecologie, Revue d'ethnoécologie , 1. https:doi.org10.4000ethnoecologie.689 Bahuchet S. Lizet B. 2003 L'ethnobotanique au Muséum national d'histoire naturelle. Les hommes, les idées, les structures. In : Lieutaghi P. Musset D. (Ed.), Plantes, sociétés, savoirs, symboles. Matériaux pour une ethnobotanique européenne , Actes du séminaire d'Ethnobotanique de Salagon . Premier volume, année 2001 . Mane, les Alpes de lumière : 15-32. (Les cahiers de Salagon 8). Balandier G. 1974 Anthropo-logiques . Paris, Presses universitaires de France. Bastide R. Dieterlen G. (Ed.) 1973 La notion de Personne en Afrique Noire . Paris CNRS. Bastien J.W. 1981 Metaphorical relations between sickness, society and land in a qollahuaya ritual. In : Bastien J.W. Donahue J. (Ed.) Health in the Andes . Washington DC, American Anthropological Association : 19-37. Bastien J.W. 1983 Pharmacopoeia of qollahuaya andeans. Journal of ethnopharmacology 8 (1) : 97-11. Bastien J.W. 1985 Qollahuaya-andeans body concepts: a topographical-hydraulic model of physiology. American Anthropologist 87 : 595-611. Belin-Milleron J. 1954 Huitième Congrès international de botanique . Paris, Section 15 : 37-39. Benoit C. 1999 Les jardins de la Caraïbe : lieu d'histoire et de territoire ? L'exemple de la Guadeloupe. JATBA 41-2 : 221-249. Berlin B., Breedlove D. Raven P. 1974 The principles of Tzeltal plant classification . New York London, Academic Press. Berlin E.A. Berlin B 1996 Medical ethnobiology of the Highland Maya of Chiapas, Mexico : the gastrointestinal diseases . Princeton, N.J., Princeton University Press. Bibeau G. 1978 L'organisation ngandi des noms de maladies. Anthropologie et société 23 : 83-116. Boiteau P. 1971 L'ethnobotanique : vues nouvelles sur l'origine de l'agriculture. La Pensée 157 : 74-85. Boiteau P. 1972 Qu'est-ce que l'ethnopharmacologie. La Pensée 164 : 65-78. Boiteau P. 1976 Grille documentaire d'ethnopharmacologie. In : Bouquiaux L. Thomas J. (Ed.) Enquête et description des Langues à tradition orale III : 835-839. Boiteau P. 1979 Précis de matière médicale Malgache . Antananarivo, La librairie de Madagascar. Boiteau P. Ratsimamanga A.R. 1956 L'asiaticoside extrait de Centella asiatica et ses emplois thérapeutiques dans la cicatrisation des plaies expérimentales et rebelles (lèpre, tuberculose cutanée et lupus). Thérapie II (1) : 125-151. Bougerol C. 1975 Phytotherapie et perception du corps en Guadeloupe. JATBA 23 (7-12) : 221-228. Bouquet A. 1969 Féticheurs et médecines traditionnelles du Congo-Brazza . Paris, ORSTOM. Bouquet A. 1972 Plantes médicinales du Congo-Brazzaville . Paris, ORSTOM. (Travaux et Documents 13). Bouquet A. Debray M. 1974 Plantes médicinales de la Côte-d'Ivoire . Paris, ORSTOM. (Travaux et documents 32). Bouquiaux L. Thomas J.M.C. 1976 Enquête et description des langues à tradition orale . Paris, Selaf. Brousse C. 2015 L'ethnobotanique au carrefour du Muséum national d'Histoire naturelle et du Musée ethnologique de Salagon (Alpes-de-Haute-Provence). Revue d'ethnoécologie , 7. https:doi.org10.4000ethnoecologie.2157 Brown M.F. 1987 Toward a human ecology: medical ethnobotany and the search for dynamic models of plant use. Rev. Anthropol. 14 : 5-11. Bruhn J.G. Holmstedt B. 1980 Ethnopharmacology: Objectives, principles and perspectives. In : Reinhard E. Beal J.L. (Ed.) Natural products as Medicinal Agents. Stuttgart, Hippokrates-Verlag : 405-430. Brunois F., Lestel D. Gaunet F. 2008 Le jardin du casoar, la forêt des Kasua. Savoir être et savoir faire écologiques . Paris, CNRS éditions, Éditions de la maison des Sciences de l'Homme. (Chemin de l'ethnologie). Carlson T. King St. R. 1996 Ethnobiomedical approach to understanding indigenous science of rainforest botanical healers. 5th International Congress of Ethnobiology : Ethnobiology and conservation of cultural an biological diversity , September 2-6 1996, Nairobi, Kenya. Coppo P. Keita A. 1990 Médecine traditionnelle : Acteurs, Itinéraires Thérapeutiques . Trieste, Edizioni. CSTROUA 1985 Pharmacopée Africaine , 1. Lagos (Nigeria), 264 p. Dagognet F. 1964 La raison, le remède . Paris, PUF. De Smet P.A.G.M. River L. 1989 A general oulook on ethnopharmacology. Journal of Ethnopharmacology 25 : 127-138. Delaveau P. 1981 Evaluation of traditional pharmacopoeia. In : Beal J.L. Reinhard E. (Ed.) Natural Products as Medicinal Agents . Stuttgart, Hippokrates Verlag : 395-404. Desclaux A. 2015 Un médicament qui n'est pas un médicament : la pharmaceuticalisation par les plantes médicinales. Étude de cas au Sénégal. In : Anthropologie du médicament au Sud. La pharmaceuticalisation à ses marges . Paris, L'Harmattan : 235-250. Descola P. 2005 Par-delà nature et culture . Paris, Gallimard. Descola P. Ingold T., débat présenté par Lussault M. 2014 Être au monde, quelle expérience commune ? Grands débats mode d'emploi. Lyon, PUL. Dieterlen G. 1952 La classification des végétaux chez les Dogon. Journal des Africanistes 22 : 115-158. Dos Santos J.R. 1991 Espace des maux, espace des remèdes : étude d'une pharmacopée locale en termes d'espaces d'attributs. In : Fleurentin J., Cabalion P., Mazars G., Dos Santos J. Younos C. (Ed.) Ethnopharmacologie , Sources, Méthodes, Objectifs . ORSTOM, Société française d'Ethnopharmacologie : 100-114. Dos Santos J.R. Fleurentin J. 1991 L'ethnopharmacologie : une approche pluridisciplinaire. In : Fleurentin J., Cabalion P., Mazars G., Dos Santos J. Younos C. (Ed.) Ethnopharmacologie , Sources, Méthodes, Objectifs . ORSTOM, Société française d'Ethnopharmacologie : 26-39. Dournes J. 1954 Le monde végétal du montagnard est-il animé ? Observations en pays Srê. JATBA 1 (5-6) : 214-219. Dournes J. 1973 Chi-Che la botanique des Srê. JATBA 20 (1-2) : 1-189. Dournes J. 1987 Conception du mal, de la maladie, de la guérison dans l'univers de représentations de populations autochtones traditionnelles en Indochine. In : Retel-Laurentin A. (Ed.), Étiologie et perception de la maladie dans les sociétés modernes et traditionnelles . Paris, L'Harmattan : 65-72. Efron D.H., Holmstedt B. Kline N.S. 1967 Ethnopharmacologic Search for Psychoactive Drugs . Washington D.C., Govt. Printing Office. Elisabetsky E. 1986 New directions in ethnopharmacology. J. Ethnobiol. 6 : 121-28. Elwin-Lewis M. 1986 Therapeutic rationale of plants used to treat dental infections. In : Etkin N.L. (Ed.) Plants in indigenous medicine and diet: bio-behavioral approches. Bedford Hills, New-York, Redgrave Publishers : 48-69. Epelboin A. 1983 Savoirs médicaux et phytopharmacopées des Fulbe Bande et des Nyokholonke, Sénégal oriental . Thèse de 3e cycle, E.H.E.S.S. Etkin N.L. 1986 Multidisciplinary perspectives in the interpretation of plants used in indigenous medicine and Diet. In : Etkin N.L. (Ed.) Plants in Indigenous Medicine and Diet . Bedford Hills, New York, Redgrave publishers. Etkin N.L. 1988a Cultural construction of efficacy. In : Van der Geest S. Whyte S.R. (Ed.) The context of Medicines in developing Countries . Dordrecht, Holland, Reidel Publishers : 299-326. Etkin N.L. 1988b Ethnopharmacology : biobehavioral approches in the anthropological study of indigenous medecines. Ann. Rev. Anthropol. 17 : 23-42. Etkin N.L. 1993 Anthropological methods in ethnopharmacology. Journal of Ethnopharmacology 38 : 93-104. Etkin N.L. Elisabetsky E. 2005 Seeking a transdisciplinary and culturally germane science : the future of ethnopharmacology. Ethnopharmacology , 100 (1-2) : 23-27. Etkin N.L. Ross P.J. 1983 Malaria, Medicine, and Meals ; Plant use among the Haussa and its impact on disease. In : Romanucci-Ross L., Moerman D.E. Tancredi L.R. (Ed.), The Anthropology of Medicine , From Culture to Method . New York, Praeger : 231-259. Etkin N.L. Ross P.J. 1991 Should we set a place for diet in ethnopharmacology? Journal of Ethnopharmacology 32 : 25-36. Evans-Prichard E.E. 1972 Sorcellerie, oracles et magie chez les Azande . Paris Gallimard. Fassin D. 2000 Entre politiques de la vie et politiques du vivant. Pour une anthropologie de la santé. Anthropologie et Sociétés 24 (1) : 95-116. Frazer J.G. 2010 Le Rameau d'or . Introduction de N. Belmont et M. Izard . Paris, Robert Laffont. (Bouquins). Farnsworth N.R. Kaas C.J. 1981 An approach utilizing information from traditional medicine to identify tumor-inhibiting plants. J. Ethnopharmacology 3 : 92. Friedberg C. 1965 Des Banisteropsis utilisés comme drogue en Amérique du Sud. Essai d'étude critique. JATBA 12 (9-10) : 403-437 ; 12 (12) : 729-780. Friedberg C. 1974 Les processus classificatoires appliqués aux objets naturels et leur mise en évidence. Quelques principes méthodologiques. JATBA XXI (10-11-12) : 313-334. Friedberg C. 1991 Méthodologie d'enquête sur les plantes médicinales dans le cadre de l'ethnoscience : Exemples indonésiens. In : Fleurentin J., Cabalion P., Mazars G., Dos Santos J. Younos C. (Ed.), Ethnopharmacologie, Sources, Méthodes, Objectifs . Paris, ORSTOM : 77-86. Gardner P. 1976 Birds, words, and a requiem for the omniscient informant. American ethnologist 3 (3) : 446-468. Gibson J.J. 1979 The ecological approach to visual perception . Boston, Houghton Mifflin. Gibson J.J. 1982 Reason for realism: selected essays of James J. Gibson . In : Reed E. Jones R (Ed.). Hillsdale (New Jersey), Laurence Herlbaum. Gillies E. 1976 Causal criteria in African classification of disease. In : Loudon J.R. (Ed.) Social Anthropology and medicine. Londres, Academic Press : 358-395. Grenand P., Moretti C. Jacquemin H. 1987 Pharmacopées traditionnelles en Guyane . Paris, ORSTOM. Guttierez Choquevilca A.L. 2017 Introduction. Transformer la nature, anthropologie du Pharmakon. In : Guttierez-Choquevila A.L. (Ed.) Guérir-Tuer . L'Herne : 9-24. (Cahiers d'Anthropologie sociale 14). Harshberger J.W. 1896 The purpose of ethnobotany. American Antiquarian 17-2 : 73-81. Haxaire C. 1979 Phytothérapie et médecine familiale chez les Gbaya-kara (R.C.A.) . Thèse 3e cycle : Ecologie terrestre option Botanique Tropicale, Université des Sciences et Techniques du Languedoc. Montpellier. Haxaire C. 1982 Comment les Gbaya soignent la toux, ou l'ethnopharmacologie à l'articulation de l'ethnomédecine et de l'ethnobotanique. Revue du CAMES n spécial Ve Colloque du C.A.M.E.S. Brazzaville. Haxaire C. 1983 Itinéraires de guérisseurs en pays Gbaya. Bulletin d'ethnomédecine 25 : 51-68. Haxaire C . 1987 Les maux qui le cachent. Étiologie et perception de troubles gynécologiques chez les femmes gouro. In : Retel-Laurentin A. (Ed.) Étiologie et perception de la maladie. Paris, L'Harmattan : 73-89. Haxaire C. 1991 L'efficacité propre du mode d'administration dans les remèdes de la douleur et les soins du nouveau-né (chez les Gouro de R.C.I. et les Gbaya de R.C.A.). In : Ethnopharmacologie, sources, méthodes, objectifs , (Actes du Premier Colloque Européen d'Ethnopharmacologie. Metz, 22-23-24 Mars1990). Paris, ORSTOM : 189-190. Haxaire C . 1994 La femme adultère et le palmier. Esquisse pour une anthropologie du remède. Revue d'Écologie Humaine n spécial la plante et le corps 12 (2) : 3-28. Haxaire C . 1996 Thérapeutique préventive de l'amaigrissement des nouveau-nés chez les Gouro de Côte-d'Ivoire : variabilité et dérives. In : Schröder E., Balansard G., Cabalion P., Fleuretin J. Mazars G., Médicaments et aliments, approche ethnopharmacologique , Medecines and foods, the Ethnopharmacological Approach . orstom, Sté Française d'Ethnopharmacologie : 68-86. Haxaire C. 1998 Si l'arbre ne respirait pas, comment grandirait-il ? Conception du vivant pour les Gouro de Côte d'Ivoire, exemple de l'arbre. Anthropologica 40 (1) : 83-98. Haxaire C. 1999 Remèdes de jouvence, remèdes de femme. In : Guerci A. (Ed.), Incontri tra medicine , meeting between medicines. Genova, Erga : 199-216. Haxaire C. 2011 Paroles de malades, recettes de guérisseurs : actualisations de la polysémie de djekwasô du 'palu' au sida en pays gouro (RCI). In : Bordes R. (Ed.) Dire les maux. Anthropologie de la parole dans les médecines du monde . Paris, L'Harmattan : chap. 7 : 211-246. Haxaire C. 2012 La folie de l'arc-en-ciel ou la longue errance de Bwila, et les éléments organisateurs des remèdes de la folie des zu chez les Gouro de Côte d'Ivoire . Revue d'ethnoecologie , 1. https:doi.org10.4000ethnoecologie.797 Haxaire C. 2017 Quand la semence se fait poison : organisation de la pharmacopée gouro autour des troubles de la fécondité. In : Guttierez-Choquevila A.L. (Ed.) Guérir-Tuer , L'Herne : 87 -111. (Cahiers d'Anthropologie sociale, 14). Haxaire C. 2021 Yu duun fétiches lancés ou poisons de contact ? Vivre sous le regard des ancêtres et la menace du poison en pays Gouro (RCI). Corps 19 : 283-293. Héritier F. 1984 Stérilité, aridité, sècheresse : quelques invariants de la pensée symbolique. In : Augé M. Herzlich C. (Ed.), Le sens du mal . Paris, Archives contemporaines : 123-154. Héritier F. 1995 Masculin Féminin, la pensée de la différence . Paris, Odile Jacob. Ho S. 1985 Dietary beliefs in health and illness among a Hong Kong community. Social sciences and Medicine 20 : 223-230. Hoare C. 2012 Le JATBA et ses ancêtres, essais d'histoire de la revue d'un laboratoire du Muséum National d'Histoire Naturelle Revue d'ethnoécologie , 1. https:doi.org10.4000ethnoecologie.673 Holmstedt B. 1991 Historical perspective and future of ethnopharmacology. Journal of ethnopharmacology 32 : 7-24. Holmstedt B. Bruhn J.G. 1983 Ethnopharmacology a challenge. Journal of Ethnopharmacology 8 : 251-256. Hunn E.S. 1982 The utilitarian factor in folk biological classification. American anthropologist 84 : 830-847. Ingold T. 2011 Being alive: Essays on Movement, knowledge and description . London, Routledge. Ingold T. 2013 Marcher avec les dragons . Zones sensibles, Diff. Les Belles Lettres. Juhé-Beaulaton D. 2020 Les enquêtes ethnobotaniques de Germaine Dieterlen (1903-1999), nouveau regard sur une ethnologue. Revue d'ethnoécologie , 17. https:doi.org10.4000ethnoecologie.5989 Keita A. Coppo P. 1993 Plantes et remèdes du plateau Dogon . CRMT, PSMTM. Kerharo J. 1970 Pharmacognosie du Rauvolfia vomitoria Afz., grand médicament africain. JATBA 17 (10-11) : 353-460. Kerharo J. Adam J.G. 1964 Plantes médicinales et toxiques des Peuhl et des Toucouleur du Sénégal. JATBA 11 (12) : 543-599. Kerharo J. Adam J.G. 1974 La pharmacopée Sénégalaise traditionnelle . Paris, Vigot. Kerharo J. Bouquet A. 1950 Plantes médicinales et toxiques de la Côte-d'Ivoire-Haute-Volta . Paris, Vigot Frères. Kerharo J. Thomas L.V. 1963 La médecine traditionnelle des Diola de Basse-Casamance. Afrique-Documents 70-71 : 167-179. Khitri W., Lachgueur N., Tasfaout A., Lardjam A. Ali Khalfa A. 2016 Plantes antilithiasiques utilisées en médecine traditionnelle dans la ville d'Oran, Algérie . Revue d'ethnoécologie , 9. https:doi.org10.4000ethnoecologie.2511 Kleinman A. 1980 Patients and healers in the context of culture . Berkeley, University of California Press. Kleinman A. Sung L.H. 1979 Why do indigenous practitioners successfully heal? Soc. Sci. Med. 13B : 7-26. Koechlin B. 1971 Pour une ethno-technologie. Elément d'un manuel de technologie culturelle (un prototype de grille documentaire). École Pratique des Hautes Études (VIe section) et CNRS (RCP 61), II, 3. Krief S., Hladick M. Haxaire C. 2005 Ethnomedicinal and bioactive properties of plants ingested by wild chimpanzees in Uganda. Journal of ethnopharmacology 101 : 1-15. Krief S. Brunois-Pasina F. 2017 L'interspécificité du pharmakon dans le parc Kibale (Ouganda). In : Guttierez-Choquevila A.L. (Ed.) Guérir-Tuer . L'Herne : 112-134. (Cahiers d'Anthropologie sociale 14). L aburthe -T olra P. Mallart-Guimera L. 2005 La Forêt de nos Ancêtres. I. Le Système Médical des Evuzok du Cameroun. II. Le Savoir botanique des Evuzok. Journal des africanistes 75 (2) : 156-157. Lévi-Strauss C. 1950 Introduction à l'œuvre de Marcel Mauss. In : Mauss M., Sociologie et anthropologie . Paris, P.U.F. Lévi-Strauss C. 1958 Anthropologie structurale . Paris, Plon. Lévi-Strauss C. 1962 La pensée sauvage . Paris, Plon. (Agora). Lieutaghi P. 1986 L'Herbe qui renouvelle : un aspect de la médecine traditionnelle en Haute-Provence . Paris, Maison des sciences de l'homme. (Ethnologie de la France, 6). Loux F. Saillant F. 1991 Saigner comme un bœuf ; le sang dans les recettes de médecine populaire québécoises et françaises. Une analyse comparative ? Culture 11 (1-2) : 151-163. Mallart-Guimera L. 1977a La classification evuzok des maladies. J. des africanistes 47 (2) : 9-47. Mallart-Guimera L. 1977b Médecine et Pharmacopée Evu zok. Nanterre, Laboratoire d'ethnologie et de sociologie comparative. Mallart-Guimera L. 1981 Ni dos ni ventre . Paris, Société d'ethnographie. Mallart-Guimera L. 2003 La forêt de nos ancêtres . Tervuren, Musée Royal de l'Afrique Centrale, 2 vol. Massé R. 1995 Culture et santé publique. Les contributions de l'anthropologie à la prévention et à la promotion de la santé . Montréal, Éditions Gaëtan Morin. Moerman D.E. 1979 Symbols and selectivity. J. Ethnopharmacol. 1 : 111-119. Moerman D.E. 1983 Physiology and symbols: the anthropological implications of placebo effect. In : Romanucci-Ross L. (Ed.) The anthropology of medecine: From culture to method . Praeger Publishers : 156-167. Morris B. 1984 The pragmatics of folk classification. Journal of Ethnobiology 4 (1) : 45-60. Needham J. 1973 La Science chinoise et l'Occident . Paris, Seuil. Needham R. 1975 Polythetic classification: convergence and consequences. Man 10 (3) : 349-369. Nicolaï R. 1986 Catégorisation pratique et dynamique linguistico-langagière. Langage et société 35 : 33-66. Nicolas J.P. 1999 Plantes médicinales des Mayas K'iché du Guatemala. Paris, Ibis press. Nikiema J.B., Compaore M., Djierro K., Guissou I.-P., Kasilo O.-M., Ouattara B. Semde S. 2010 Promotion de la médecine traditionnelle au Burkina Faso : Essai de développement d'un médicament antidrépanocytaire, le FACA. The African Health Monitor (WHO Publication) . Oishi T. 2016 Ethnoécologie et utilisation ethnomédicinale des poissons chez les Bakwele de Sud-Est Cameroun. Revue d'ethnoécologie , 10. https:doi.org10.4000ethnoecologie.2893 Olivier de Sardan J.-P. 1999 Les représentations des maladies : des modules ? In : Jaffré Y. Olivier de Sardan J.-P. (Ed.). La construction sociale des maladies : les entités nosologiques populaires en Afrique de l'Ouest . Paris, Presses Universitaires de France : 15-40. (Les Champs de la Santé). Ouédraogo S., Traoré S., Koala M., Ouédraogo J.C.W., Belemnaba L., Kini F., Ouédraogo S. Guissou I.P. 2018 Essai de production de sirop FACA , phytomédicament antidrépanocytaire à base de poudres d'écorce standardisées. In : Baxerres C. Marquis C. Régulations, Marchés, Santé : interroger les enjeux actuels du médicament en Afrique . Actes. Régulations, Marchés, Santé : interroger les enjeux actuels du médicament en Afrique Regulations, Markets, Health : questioning current stakes of pharmaceuticals in Africa , Ouidah, Bénin. Paris R. Moyse H. 1957 Les pervenches indigènes et exotiques. JATBA 4 (11-12) : 481-489 et 645-656. Paris R. Moyse H. 1958 Les pervenches indigènes et exotiques. JATBA 5 (1-3) : 35-43. Peeters A. 1982 Pharmacopées et médecines traditionnelles : un exemple d'abus de langage. JATBA 29 : 97-100. Pham-Hoang Ho 1958 À propos des Rauwolfia d'Indochine. JATBA 5 (1-3) : 177-178. Phillipson J.D. Anderson L.A. 1989 Ethnopharmacology and western medicine. Journal of Ethnopharmacology 25 : 61-72. Pitrou P. 2014 La vie, un objet pour l'anthropologie ? L'Homme 212 : 159-189. Pool R. 1994 On the creation and dissolution of ethnomedical system in the medical ethnography of Africa. Africa 64 (1) : 1-19. Portères R. 1957 Vers une Organisation française de Recherche Scientifique et Technique sur de nouvelles drogues pharmaceutiques d'origine végétale. JATBA 4 (12) : 94-105. Portères R. 1961 L'ethnobotanique : place-objet-méthode-philosophie. JATBA 7 (4-5) : 102-109. Portères R. 1965 Le caractère magique originel des haies vives et de leurs constituants (Europe et Afrique occidentale). JATBA 12 (4-5) : 133-152. Portères R. 1969-1970 Cours d'ethno-botanique générale . Institut d'EthnologieLaboratoire d'Ethno-botanique et d'Ethno-zoologie. Pousset J.L. 1989 Plantes médicinales africaines, utilisation pratique . Poitiers, Aubin. (Ellipse). Razafindravao M. Sattler C 2017 Les outils novateurs de protection et de valorisation des patrimoines culturels et natures liés aux plantes médicinales : Jardins pédagogiques, recueils ethnobotaniques et éducation populaire. Ethnopharmacologia 58 : 1-16. Retel-Laurentin A. (Ed.) 1987 Étiologie et perception de la maladie dans les sociétés modernes et traditionnelles . Paris, L'Harmattan. (Connaissance des Hommes). Reynaud M. Coudert A.J. 1987 Essai sur l'art thérapeutique . Paris, Synapse-Frison-Roche. Rivers William H.R. 1924 Medicine, Magic and Religion . London, Kegan Paul. Romanucci-Ross L., Moerman D.E. Tancredi L.R. 1983 The anthropology of medicine . New-York, Praeger. Sambaré A.P., d'Alessandro E., Soubeiga A.K. 2018 Les pratiques de prescription des médicaments traditionnels améliorés (MTA) dans les structures sanitaires publiques de la ville de Ouagadougou. In : Baxerres C., Marquis C. Régulations, Marchés, Santé : interroger les enjeux actuels du médicament en Afrique. Actes . Régulations, Marchés, Santé : interroger les enjeux actuels du médicament en Afrique Regulations, Markets, Health : questioning current stakes of pharmaceuticals in Africa , Ouidah, Bénin. Sanogo R. 2014 Development of phytodrugs from indigenous plants of Mali. The Mali experience. In : Gurib-Fakim A. (Ed.) Novel Plant Bioresources: Applications in Food, Medicine and Cosmetics (the Work ). John Wiley Sons. Simon E. Egrot M. 2012 Médicaments néotraditionnels : une catégorie pertinente ? À propos d'une recherche anthropologique au Bénin. Sciences Sociales et Santé 2 (30) : 67-91. Tauxier L. 1924 Nègres Gouro et Gagou . Paris, Geuthner. Tessmann G. 1937 Die Baja, ein Negerstamm in Mittleren Sudan . Stuttgart, Strecker und Schröder, 2 vol. Thomas L.V. 1972 De l'ethnobotanique à la médecine, l'exemple diola. Notes Africaines 134 : 48-51. Toledo V.M. 1992 What is ethnoecology? Origins, scope and implications of a rising discipline. Etnoecologica 1 : 5-21. Tournon J Reategui U. 1983 Aspects de la médecine traditionnelle et des plantes médicinales des Shipibo-Conibo de l'Ucayali. JATBA 30 (3-4) : 249-265. Turner V.W. 1972 Les tambours d'affliction . Paris, Gallimard. Vergiat A.M. 1936 Les rites secrets des primitifs de l'Oubangui. Pris, Payot. Vergiat A.M. 1969 - Plantes magiques et médicinales des féticheurs de l'Oubangui (Région de Bangui). JATBA 16 (2-5) : 84-111 ; JATBA 16 (6-8) : 335-367 ; JATBA 16 (9-10) : 418-456. Vergiat A.M. 1970 - Plantes magiques et médicinales des féticheurs de l'Oubangui (Région de Bangui). JATBA 17 (1-4) : 60-91 ; JATBA 17 (5-6) : 171-199 ; JATBA 17 (7-9) : 295-339. Vergiat A.-M. 1975 - Le Gui dans le folklore des Noirs de l'Oubangui. Journal d'agriculture tropicale et de botanique appliquée 22 (4-6) : 159-165. Walker abbé A. 1934 Plantes aromatiques offertes par les Gabonais aux mânes de leurs ancêtres. JATBA 15 :102-106. Weniger B. 1991 Interest and limitation of a global ethnopharmacological survey. Journal of ethnopharmacology 32 : 37-41. Wittgenstein L. 1961 Tractatus logico-philosophicus , suivi d' Investigations Philosophiques . Paris, Gallimard. (Tel, 109). Wyman LC Harris SK 1941 Navajo Indian Medical Ethnobotany. The University of New Mexico Bulletin . Anthropological series 3 (5) : 3-76. Yao Adou C.Y., Kpangui K.B., Bi Tra A.V. Ouattara D. 2016 Pratiques culturales, valeurs d'usage et perception des paysans des espèces compagnes du cacaoyer dans des agroforêts traditionnelles au centre de la Côte d'Ivoire. Revue d'ethnoecologie 9. https:doi.org10.4000ethnoecologie.2474 Young A. 1978 Mode of production of medical knowledge. Medical anthropology 2 (2) : 97-122. Young A. 1981 When rational men fall sick : an inquiry into some assumptions made by medical anthropologists. Culture, Medicine and Psychiatry V : 317-335. Young A. 1983 The relevance of traditional medical cultures to modern primary health care. Soc. Sci. Med. 17 (16) : 1205-1211. Zempleni A. (Ed.) 1985 Causes, origines et agents de la maladie chez les peuples sans écriture. L'Ethnographie n spécial : 96-87. Zimmermann F. 1989 Le discours des remèdes au pays des épices . Paris, Payot. 1 La pharmacopée officielle ou Code des médicaments est un recueil écrit sous l'égide d'un gouvernement ou d'une institution juridique intergouvernementale. Elle traite des drogues entrant dans la composition des médicaments, des formes médicamenteuses, ainsi que de leurs modes d'obtention et de leurs méthodes de contrôle. 2 Publication du Comité Interafricain sur les plantes médicinales et la médecine traditionnelle et de l'Organisation de l'Unité Africaine. Le second volume de 263 pages parut en 1988. 3 J'emploie le terme drogue dans son sens pharmaceutique, c'est-à-dire la matière première entrant dans la composition d'une forme médicamenteuse (partie utile de la plante par exemple). 4 Définition de la pharmacologie dans l' Encyclopedia universalis : Dans son sens le plus restreint et selon l'étymologie, la pharmacologie est la science des médicaments. Définition proposée par T. Sollmann : la pharmacologie est la science qui étudie les effets du milieu chimique environnant sur la matière vivante. De ce milieu chimique sont exclus les corps qui participent au métabolisme cellulaire et qui, de ce fait, sont l'objet de la biochimie. Toute substance capable de perturber les mécanismes physiologiques est une drogue ; les médicaments sont des drogues employées à des fins thérapeutiques . La pharmacognosie étudie les sources des drogues naturelles et leurs principes actifs. Elle aide à reconnaître ces dernières selon des critères botaniques ou physicochimiques. Anciennement appelée matière médicale , la pharmacognosie joue le rôle d'intermédiaire entre la chimie, la botanique et la pharmacodynamie... ; S.H.. 5 Renseignements botaniques : nom latin (nom d'auteur), synonymes, différents noms vernaculaires, caractères remarquables, description botanique de la plante, habitat. Emplois : différents usages médicinaux des drogues selon une séméiologie occidentale sommaire, leur préparation, leur mode d'administration et éventuellement leur posologie, ces données étant parfois partielles. Chimie : revue bibliographique des données connues. 6 ACCT, Agence de Coopération Culturelle et Technique, entre pays francophones, créée en 1970 à la conférence de Niamey, devenue en 1996 l'Agence Intergouvernementale de la Francophonie. 7 Par exemple , coordonnée par le Programme National de Promotion de la Médecine Traditionnelle, la Pharmacopée Ivoirienne , 1ère édition, 2018 (coordination : Dr KROA Ehoulé), République de Côte d'Ivoire Ministère de la Santé et de l'Hygiène Publique éd. : Centre National de Documentation Juridique, Abidjan. 8 Jardins du Monde, Solidarité, Santé et Plantes médicinales, http:www.jardindumonde.org 9 Association pour la Valorisation de l'Ethnopharmacologie en Régions Tropicales Et Méditerranéenne ( http:www.avertem.fr ) 10 Holmstedt précise sa définition ainsi : The observation, identification, description and experimental investigation of the ingredients and the effects of indigenous drugs is a truly interdisciplinary field of research. The term ethnopharmacology has been used to describe this field. Ethnopharmacological research is based on botany, pharmacology, toxicology and chemistry, but other disciplines make vital contributions, not least anthropology . 11 Emmanuel Nossin, pharmacien, ethnopharmacologue, Pluralisme thérapeutique dans la pharmacopée traditionnelle Martiniquaise , séminaire Rond-Kozé, Décoloniser les savoirs sur les plantes , organisé le 18 mars 2022, Observatoire Terre-Monde. 12 Or tout étudiant en anthropologie médicale apprend au premier cours qu'il peut y avoir disease sans illness (certaines hypertensions atypiques pour reprendre l'exemple de Kleinman) ou illness sans disease (les hyponcondries) (Kleinman 1980). 13 Je ne voulais pas entrer dans un système marchand qui en l'occurrence ne me garantissait ni la validité de la recette, ni à l'inverse qu'une recette active pour mon interlocuteur de bonne foi n'ait été recueillie déjà dix fois. Pensons à Euphorbia hirta très commune et très efficace contre les dysenteries par exemple. Claudie Haxaire , La part oubliée de l'étude des pharmacopées traditionnelles africaines , Revue d'ethnoécologie Online, 21 2022, Online since 30 June 2022 , connection on 04 November 2025 . URL : http:journals.openedition.orgethnoecologie8925; DOI : https:doi.org10.4000ethnoecologie.8925 The text only may be used under licence CC BY-NC-ND 4.0 . All other elements (illustrations, imported files) may be subject to specific use terms. TCU of OpenEdition Journals Privacy Policy About Cookies Report a problem OpenEdition Journals member Published with Lodel Administration only",
    "url": "https://journals.openedition.org/ethnoecologie/8925?lang=en",
    "length": 116618,
    "type": "html",
    "id": 3000,
    "source": "MedicinalPlants"
  },
  {
    "title": "African Herbal Medicines: Adverse Effects and Cytotoxic Potentials with Different Therapeutic Applications - PMC",
    "text": "Int J Environ Res Public Health . 2021 Jun 2;18(11):5988. doi: 10.3390ijerph18115988 Search in PMC Search in PubMed View in NLM Catalog Add to search African Herbal Medicines: Adverse Effects and Cytotoxic Potentials with Different Therapeutic Applications Kunle Okaiyeto Kunle Okaiyeto 1 Phytomedicine and Phytochemistry Group, Oxidative Stress Research Centre, Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville 7535, South Africa; okaiyetokcput.ac.za Find articles by Kunle Okaiyeto 1 , Oluwafemi O Oguntibeju Oluwafemi O Oguntibeju 1 Phytomedicine and Phytochemistry Group, Oxidative Stress Research Centre, Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville 7535, South Africa; okaiyetokcput.ac.za Find articles by Oluwafemi O Oguntibeju 1, Editor: Oliver Grundmann 1 Author information Article notes Copyright and License information 1 Phytomedicine and Phytochemistry Group, Oxidative Stress Research Centre, Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville 7535, South Africa; okaiyetokcput.ac.za Correspondence: Oguntibejuocput.ac.za Roles Oliver Grundmann : Academic Editor Received 2021 May 7; Accepted 2021 May 25; Collection date 2021 Jun. 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https:creativecommons.orglicensesby4.0 ). PMC Copyright notice PMCID: PMC8199769 PMID: 34199632 Abstract The African continent is naturally endowed with various plant species with nutritional and medicinal benefits. About 80 of the people in developing countries rely on folk medicines to treat different diseases because of indigenous knowledge, availability, and cost-effectiveness. Extensive research studies have been conducted on the medicinal uses of African plants, however, the therapeutic potentials of some of these plants has remained unexploited. Over the years, several studies have revealed that some of these African floras are promising candidates for the development of novel drugs. Despite the plethora of studies on medicinal plant research in Africa, there is still little scientific data supporting the folkloric claims of these plants. Besides, safety in the use of folk medicines has been a major public health concern over the year. Therefore, it has become mandatory that relevant authority should take measures in safeguarding the populace on the use of herbal mixtures. Thus, the present review extracted relevant information from different scientific databases and highlighted some problems associated with folk medicines, adverse effects on reproductive systems, issue about safety due to the toxicity of some plants and their toxicity effects with potential therapeutic benefits are discussed. Keywords: African herbal medicines, adverse effects, toxicity, therapeutic values 1. Introduction The African continent is magnificently endowed with different plant diversity, mainly due of the prevailing climatic conditions and this advantage has supported the richness of secondary metabolites in the plants for surviving under harsh environmental conditions 1 , 2 . Besides, the ultraviolet rays in this region are stronger than those observed in other parts of the world, and this also enables the plants to accumulate some important bioactive substances of economic importance 1 . These reasons justify the exploitation of these plants for their therapeutic values that have been in continual use in this region for the past several decades 3 , 4 . According to a report by the WHO 5 , about 80 of the people in developing countries rely on traditional herbal mixtures to treat different diseases. Most villages in Africa still depend solely on traditional herbal mixtures as a source of health treatments because of their beliefs and culturally acceptable indigenous knowledge, accessibility, and affordability. Many herbal mixtures are indubitably expedient for maintaining good health or treating diverse diseases 6 , 7 . Besides, numerous African rural dwellers believe that since their ancestors used herbal mixturesconcoctions for their wellbeing in the past and with no side effect, they habitually assume that because the herbal mixtures are natural, therefore their safety is guaranteed. Unfortunately, this assumption has led to several instances of organ damage and death of the users 8 , 9 . In addition, traditional healers are very secretive about their indigenous practices handed down from their ancestors to the new generation and this makes their treatment prescriptions vague, often resulting in overdoses of the mixtures by their patients since no regulatory body controls the usage of herbal medicines. Perhaps nothing indicates to the patients that too much of a good thing could be dangerous. Sadly, some people ignorantly combine herbal mixtures with orthodox medicines without a doctor's prescription and perhaps, not considering their adverse interactions. It is important to note that uncontrolled consumption of herbal mixtures could lead to liver damage, kidney failure and stomach upsets, diarrhoea, etc. 10 . Herbal mixtures contain some bioactive compounds that are potentially toxic. The reports documented in the literature have shown that despite the crucial role of herbal medicine for man, some plant species are reported to cytotoxic at high dosage. This simply means that a very safe compound can be toxic at a high dose and vice versa. The toxicity-related issues about herbal medicines such as carcinogenicity, hepatotoxicity, mutagenicity, genotoxicity have been highlighted by Fanell et al. 11 . Therefore, safety relating to herbal mixtures or products cannot be disregarded, as knowledge is key in preventing overdoses or abuse. On the other hand, deforestation of the natural habitat due to anthropogenic activities has mounted pressure on the African ecosystem 1 . Nevertheless, it is worth noting that Africa represents about 25 of the world trade in biodiversity and it is still surprising that despite the contribution, only a few drugs from African plants have been commercialized compared to other continents. 2. Factors Influencing the Use of Herbal Medicines According to the WHO 5 , traditional medicine is the total of knowledge, skills, and experiences based on the theories, beliefs, and practices indigenous to different cultures, whether explicable, that are used to maintain health, and to prevent, diagnose, improve, or treat physical and mental illnesses. Hence, these practices have been explored by people since time immemorial to treat various diseases before the arrival of orthodox medicines. These herbal medicines may include herbs, herbal materials, herbal concoctions and finished herbal products 3 . Over the years, the patronage of people towards herbal medicine has been increasing tremendously because of several reasons that include but are not limited to the following: (a) The belief of rural dwellers and their indigenous cultures: Numerous rural dwellers have strong convictions that their beliefs and cultural practices for treating diseases are far better than modern medicine. Some even have a strong phobia towards orthodox medicines. As a result, nothing can make them opt for orthodox medicine even if the government is willing to pay their medical bills. They prefer consulting their gods and searching for a practical solution by sacrificing animals to please their gods. Different African traditional healers have their unique ways of consulting their oracles and communicating their findings to clients on their health-related issues and the possible solutions. In addition, these patients are more comfortable in expressing their health problems to the traditional healers in their local dialects than to a professional medical doctor 12 . (b) A perception that herbal medicines are natural and safe: Most herbal medicine users believe that herbal medicines are safe because they are products of plant naturally found in the environment and thus, they assume that being natural implies safety with no adverse effect compared to those reported from the use of orthodox medicine 13 . (c) Accessibility and cost-effectiveness: Herbal medicines have been the only option source of treatment in some African communities because they are cheap and the raw materials for preparing the mixtures are easily available. Besides, their cost-effectiveness cannot be compared with orthodox medicines, as most people living in these areas are poor and unable to afford the cost of modern treatments. These salient reasons have mitigated the rural dwellers towards the use of herbal medicines 14 . (d) Superior efficacy of herbal medicines: Many people believe that herbal medicines are more potent than orthodox medicines and the failure of orthodox medicines to treat some complicated health problems has diverted people's attention in seeking herbal mixtures as an alternative source. Herbal mixtures contain several bioactive compounds that are believed to work together in synergy and thus enhancing their potency over orthodox medicines 15 , 16 . (e) Confidentiality of health problem information: Most people are not comfortable when information regarding their health problem is revealed to many people other than their doctor 13 . All patients have files containing their health information and the medical record clerks are responsible for handling these files. However, local people who use herbal medicines feel safer and prefer to discuss their health problem with the traditional healers to a modern health system where their files will be handle by different people on duty. (f) Self-medication: This habit is common among the people living in the rural and semi-urban communities in African countries since the plant materials are easily accessible coupled with the little knowledge they acquired from generation about herbal concoctions, they tend to prescribe herbs preparations for people around them with similar kind of illnesses. The assumption is that since the concoctions have worked for other people, they would also serve the same purpose for any sick person with related symptoms 6 . (g) Fear of erroneous diagnosis: Most people prefer to opt for traditional medicines because of the fear of the wrong diagnosis from the modern health system. There are several reasons why a patient can be wrongly diagnosed in the hospital and such factors include unskilled medical operators (lack of advanced training of medical operators on the usage of new medical equipment), failure of old medical equipment, over the labour of medical staff, underpayment of medical staff, the inexperience of medical staff, mismanagement of patient's file, inconsistencychanging of the medical doctor in charge of a patient 13 . (h) Long waiting period and queue involved to see a medical doctor: The queue involved, and time spent in seeing a medical doctor at the hospital is unbearable for most people in Africa, most especially, people without medical aid that patronize the government hospitals. Most hospitals in Africa are understaffed, so the population of patients overwhelms the capacity of these hospitals, and consequently, patients often seek an immediate alternative to solve their health problems. In some cases, sick people in the village might need urgent attention, with no ambulance available in the villages to convey them to the modern hospital in the town or city. In addition, a bad road network in the villages has been a huge challenge for the rural dwellers to get proper medical treatment. Besides, even the so-called mobile clinics are always frustrated or unwilling to go to the villages to attend to the poor people because of the poor road network, consequently, the villagers tend to opt for the most available alternative treatment 17 . (i) Advertisement of herbal products: Over the years, the market strategies of herbal mixtures or products in different ways have captured people's attention in testing the efficacy of these products. Some traditional healers go on the street advertising their products by sharing handbills, pasting their posters everywhere in the town, or even employing marketing agents that will help them display their products on the television, different social media platforms. Marketing promotes business because of the awareness it creates for people and the visibility of a product is usually enhanced with an advertisement 18 . 3. WHO Views on African Herbal Medicine WHO has a substantial contribution to the acknowledgement and acceptance of traditional herbal medicine in African countries. Between 20022005, WHO provided a framework to promote traditional medicine to reduce the high death rate occurring in developing countries. WHO inspires African member states to endorse and incorporate folk medicine in their health system 19 . Therefore, four strategic objectives to incorporate folk medicine into the national healthcare systems include 20 , 21 : i. To ensure that traditional medicines are easily accessible, available, and affordable for the poor populace. ii. To ensure that traditional medicines are of high quality and effective without compromising on their safety for the populace. iii. To promote the therapeutic use of traditional medicines for consumers. iv. To ensure that traditional healersspecialists get the appropriate training and education required to improve on the preparation and prescription of their herbal products. 4. Justifications for Research on African Medicinal Plants A plethora of supporting documents in the literature have validated the efficacy of African medicinal plants for the treatment of different human illnesses, however, there are still several gaps that are needed to be addressed, especially concerning the safety of these herbal mixtures or products to public health on the African continent. Thus far, the extensive research on African plants is geared towards drug discovery and development; there is a dire need to compile a list of promising African flora with significant therapeutic values, as most of these plants are not well documented. Likewise, there is a need to introduce African traditional healers to modern scientific practices. For the acceptance of folk medicines, the issue relating to active principles in the plant extracts, identification of secondary metabolites, mechanism of actions, and their toxicology need to be addressed. For that reason, WHO instigates further rigorous research on traditional medicines to substantiate their potency and establish safety for their usage 19 . Acceptance of Traditional Medicines by Developed Countries Folkloric medicine has been embraced by other people beyond their original indigenous culture, and this is referred to as complementary or alternative medicine 11 , 19 . The utilization of traditional medicines has been accepted in several advanced nations of the world, and complementary or alternative medicine has gained huge popularity in Europe, North America, and Australia 22 , 23 . The people living in these regions use medicinal herbal products to promote healthier living, as a blood cleanser, diet supplements, or for reducing body size. This therapeutic option drastically reduces the amount of money spent to purchase expensive drugs at the pharmacy and justifies the growth in the marketability of herbal products in these regions 6 , 24 . 5. Safety of Traditional Herbal Medicines Despite the numerous advantages associated with folkloric medicines, the big question is always about their safety to public health. The primitive techniques used by traditional healers are not modern or either scientific, hence, there are high chances of microbes and heavy metals contamination in the herbal products that could affect the health of the populace 16 . Therefore, the relevant authority needs to give a directive on how to protect the public from the negative effects (including death) that could result from the use or abuse of herbal products 25 , 26 , 27 . Microbial contamination is often common in herbal medicines, and it is always difficult for traditional healers to prevent or control this contamination. Thus, there is a need to recommend some quality control guidelines in their practices and perhaps awareness regarding the potential health risks associated with the use or abuse of herbal mixtures 25 , 27 . 5.1. Adverse Effects of African Medicinal Plants and Role in Humans' Reproductive System In African communities, the introduction of herbal mixtures to the market is a norm even without scientific evaluation to ascertain their safety. There is also a belief that herbal products are safe. Besides, traditional healers lack regulatory control to guide their products, all these factors have worked together to misinform millions of people, resulting in the death of people 16 . Apart from microbial contamination, heavy metals have been reported to be contributors to the toxicity of herbal products that have led to life-threatening situations or death 6 . Several plants contain toxic bioactive compounds that can disturb normal physiological activities by chelating with cellular macromolecules such as DNA and proteins, leading to cellular toxicity and mutation 28 . The problem of herbal toxicity could result from production factors such as incorrect use of plants, species or plant parts, the quality of herbal products, high level of impurities, contaminants, and adulterants. Other possible factors could be resulting from the patient, such as co-morbidity, co-medication, and self-medication 29 . Several studies in the literature have highlighted the adverse effect of medicinal plants on the liver 30 , 31 . Liver enzymes are key biomarkers that indicate the level of liver damage and their presence in the blood is used to monitor liver disease in patients in the developing countries of the world 32 . In addition, the clinical symptoms of liver damage include asymptomatic mild biochemical irregularities to severe hepatitis with jaundice 33 . In agriculture, organophosphate pesticides are usually used to control pest in developing countries 33 . For instance, dichlorvos acts by irreversibly inhibiting acetylcholinesterase enzyme (AChE) at the cholinergic junctions of the nervous system and produces hepatotoxicity in rats 34 . Furthermore, aflatoxin, a potent hepatocarcinogen and hepatotoxin, is another potential microbial contaminant that has been identified in herbal products 35 . There is a general notion that traditional healing is dominated by men, as the percentage of male traditional healers is far greater than that of females. Notwithstanding this, the rich knowledge of indigenous women about folk medicines cannot be underrated 36 . Besides, female patients are always comfortable discussing women's problems with the female traditional healers. Medicinal plant intake has contributed substantially to treating women-related health problems such as irregular menstruation, birth control, fertility, abdominal pain, pregnancy, waist pain, vomiting during pregnancy, child delivery, and postpartum care, lactation, infant care, etc. 37 , 38 , 39 . Examples of the medicinal plants commonly used by pregnant women includes Zingiber officinale , Allium sativum , Ocimuml amiifolium , Eucalyptus and Rutachalepensis , etc. 40 . For example, the usage of Clivia miniata has been reported to be associated with some side effects such as salivation and diarrhoea while Callilepis laureola causes confusion, convulsion, hepatic, and renal failures. Also, Scadoxus puniceus has been reported to be associated with visual disturbances and dizziness 41 . Medicinal plants have been folklorically used for the treatment of different types of reproductive diseases. However, contaminants such as heavy metals and persistent organic pollutants picked up by medicinal plants from the environment, especially when their concentrations are above the permissible limits, disrupt the normal physiological function of the human reproductive system 42 , 43 . Contaminant toxicity in plant extracts has been reported to be associated with a decrease in sex organs, sex performance, implantation rate, fertility, chromosome aberration, and mitotic inhibition in some in vivo studies 44 , 45 , 46 . These contaminants in plant extracts could trigger the production of free radicals and higher accumulation may lead to oxidative damage of the organ or tissues and macromolecules followed by oxidative stress thereby resulting in impaired reproductive systems 47 , 48 , 49 . For example, the report of a study conducted in Nigeria by Nwangwa 50 on ethanolic extract of Xylopia aethiopica showed a decrease in sperm viability, motility, and counts in rats. Another study by Akbarsha et al. 51 with Andrograpis paniculata in rats caused a decrease in spermatogenesis and degenerative changes in seminiferous tubules. It is quite unfortunate that folk medicines are the only source of treatment for pregnant women in some Africa countries 52 , 53 . Normally, conventional antimalarial drugs are encouraged for pregnant women 4 , however, the cost implication of these drugs in the developing countries by low-income earners has impelled this category of people to seek folk medicines, without considering the side effects on their foetus 54 . In addition, the use of medicinal plants for child delivery is a normal practice in some rural areas in African countries 55 . 5.2. Hurdles to Safeguarding the QualitySafety of Herbal Products With the drastic upsurge in the number of people interested in herbal products, adverse effects associated with the use of these herbal products have posed a serious threat to public health. Hence, there is a dire need to monitor the production of these products, enlighten the populace about their toxicity and give adequate advice on their consumption and use 56 , 57 . Several challenges affect the quality of herbal products, which could result from the following: i. Insufficient knowledge or information about the plant species: Most people that practice traditional medicine in Africa do not have good knowledge about the plants used in the treatment of different ailments since they strongly believe in the information passed to them from one generation to another. They do not know the scientific information about the toxicity of one plant to another when used in combination. Besides, the collection or harvest time for medicinal plants is one of the significant factors that affect the potency of the plant for their therapeutic usages and when the traditional healers lack the basic information about the plant, there is a high possibility of misidentification or the use wrong plant species that could result in the toxicity of the herbal mixtures or products 13 . ii. Lack of quality control on the herbal products: The preparation of most herbal products in the market or those used by the people in the villages are devoid of quality control assessment and the chances of their toxicity or adverse effect on human are very high, though some have been proven to be promising. There is no regulatory or standard set aside for the preparation of herbal products in the villages in Africa, hence, microbial contamination from the harvesting stage, production, and packaging is common in these products. Hence, the quality of materials used for the preparation of the herbal products determines the level of their safety 58 . iii. Lack of standard preparation methods: Different communities in Africa have their ways of preparing herbal mixtures and the method used in the preparation influences the extraction of the bioactive compounds in these plants, which are significant to their therapeutic values. Lack of standard methods may indirectly affect the difference in the efficacy of plants from various communities 59 . iv. Complex nature of the plant extracts: Several researchers have reported that the plant extracts contain many bioactive compounds and the complex nature of the method used in isolating and purifying individual bioactive compounds is critical and such analysis might not be possible in a local setting 60 . v. Overdose prescription: The prescription of herbal mixturesproducts by traditional healers in the African communities is one of the factors that have resulted in many deaths in this region 61 . Most herbal mixtures contain several bioactive ingredients and adequate knowledge about the pharmacokinetics and the mechanism of actions of these products is lacking, hence, the prescription about the dosage used by the patients is not evidenced-based, which consequently leads to liver or kidney damage 8 . vi. Lack of scientific proof: Most herbal products in African countries lack any scientific validation 62 . 6. Cytotoxic Effects of African Medicinal Preparations with Different Therapeutic Uses From ancient times, the plant kingdom has been a reliable source of therapeutic agents for the treatment of different human illnesses because of the secondary plant metabolites 63 . Usually, plants produce numerous secondary metabolites as a defense mechanism against an array of pathogens 64 . The abundance and concentration of these secondary metabolites differ from plant to plant, geographical locations as well as abiotic factors that trigger their production 65 . A report by Samuelsson 66 has revealed that about 2528 of orthodox drugs originated from plants. As a result, it has been predicted that the plant-based drug market could grow up to US 39.2 billion in 2022 67 . Thus, continual screening of African biodiversity to search for cost-effective, novel, and effective plant secondary metabolites could play an important role in the biopharmaceutical industries 68 , 69 , 70 . However, it is worth noting that from a biological perceptive, the cytotoxicity of a plant does not only mean adverse effects, as this also has some therapeutic uses, and these have been well documented in the literature 71 . Unlike some protective roles such as antioxidant, antidiabetic, hepatoprotective, neuroprotective activities demonstrated by African plants, their cytotoxic effects have been reported to be beneficial to humans 72 , 73 . 6.1. Antibacterial Activity Bacterial infections represent a high percentage of the global causes of ill health and mortality because of the high prevalence of multidrug-resistant bacteria leading to antibiotic treatment failure thereby exposing the public to risk therefore, immediate intervention is highly imperative 74 , 75 , 76 . On the other hand, plants represent a significant source of novel antimicrobial agents. Plants are always exposed to different stresses from abiotic and microorganisms' assault, and this prompts them to produce some defensive substances with antimicrobial activity 77 . Remarkably, these secondary metabolites produced by various plants have been recognized to have some therapeutic uses, including antibacterial activity 78 , 79 . A perusal of the literature indicated that several antibacterial studies on African plants have been documented 63 , 80 , 81 . However, poor toxicological documentation of plants used in folk medicines is the major limitation facing Africa traditional medicine, and this research gap has been the subject of active research lately 82 . Table 1 presents some African plants that have been reported to have antibacterial activity. Table 1. Antibacterial activity of some African flora. Family Genus Part Used Solvent Tested Bacterial Strians Country Reference Anacardiaceae Mangifera indica Linn Stem Methanol Pseudomonas aeruginosa (isolate); Escherichia coli (ATCC 8739); Staphylococcus aureus (ATCC 25922); Proteus mirabilis (isolate); Enterococcus faecalis (ATCC 10541) Cameroon 83 Cactaceae Opuntia streptacantha Fruit skin Ethanol and water Bacillus subtilis , Staphylococcus aureus , Micrococcus luteus , Salmonella enteritidis , Bacillus cereus , Klebsiella pneumonia Tunisia 84 Celastraceae Lauridia tetragona Leaves Acetone and methanol Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (OK), Bacillus subtilis KZN, Bacillus cereus , and Streptococcus pyogenes , Vibrio cholera , Klebsiella pneumonia (ATCC 4352), Pseudomonas aeruginosa (ATCC 19582), Salmonella typhi (OK), and Escherichia coli (ATCC 8739) South Africa 85 Fabales Elephantorrhiza elephantina Rhizome Methanol Bacillus cereus , Shigella flexneri South Africa 86 Zingiberaceae Zingiber officinale Rhizome Methanol Pseudomonas aeruginosa , Salmonella typhi , Klebsiella pneumonia , Staphylococcus aureus and Escherichia coli Nigeria 70 Vitaceae Cissus quadrangularis Aerial Methanol Staphylococcus aureus , Pseudomonas aeruginosa , Escherichia coli , Klebsiella pneumonia Ethiopia 87 Araceae Colocasia esculenta Whole plant Methanol Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter aerogenes, Escherichia coli and Providencia stuartii Cameroon 88 Asphodelaceae Bulbine frutescens Whole plant Methanol Escherichia coli Kenya 89 Salvadoraceae Salvadora persica L. Bark Aqueous and methanol Staphylococcus aureus ATCC33862 and Escherichia coli ATCC25922 Zimbabwe 69 Hypericaceae Hypericum roeperianum Leaves Acetone Staphylococcus aureus, Enterococcus faecalis and Bacillus cereus, Escherichia coli, Salmonella typhimurium and Pseudomonas aeruginosa Nigeria 68 Phyllanthaceae Bridelia ferruginea Root Ethanol Escherichia coli and Staphylococcus aureus Nigeria 90 Verbenaceae Lippia javanica Leaves Dichloromethane:methanol (1:1) Clostridium perfringens South Africa 91 Agavaceae Agave americana Leaves Dichloromethane and methanol (1:1) Neisseria gonorrhoeae South Africa 92 Myrtaceae Myrtus nivellei Aerial Butanol Bacillus cereus , Escherichia coli , Listeria monocytogenes Algeria 93 Open in a new tab ATCCAmerican Type Culture Collection. 6.2. Antiplasmodial Activity Malaria remains one of the most prevalent public health issues in the African countries of the world 94 , 95 . The high resistance of malaria parasites to the existing antimalarial drugs poses a serious threat to public health globally 96 . Hence, there is a pressing need to strategize on how to identify effective, inexpensive, and innocuous novel antimalarial agents. As part of this perpetual quest, African researchers and foreign collaborators have explored African biodiversity in the exploration of secondary metabolites from extracts of African plants for new antimalarial agents 94 . Traditionally, herbs have been the major treatment of malaria in most developing countries, especially in African countries 97 . These plants have been reported to be promising and could serve as a good alternative source for the isolation of lead compounds that could be used in the development of new antimalarial agents from this continent, and this could solve the problem of resistance of the malarial parasites 98 . Nevertheless, further studies on their toxicities such as carcinogenicity, teratogenicity, mutagenicity, toxicity should be the subject of active research to ensure their safety. Table 2 summarizes a few African florae with proven antiplasmodial activity. Table 2. Antiplasmodial activity of selected African flora. Family Species Part Used Solvent Assay Type Tested Organisms Country Reference Phyllanthaceae Phyllanthus amarus Whole plant Aqueous and Ethanol In vivo Plasmodium yoelii Nigeria 99 Asclepiadaceae Periploca linearifolia Stem bark Hexane, chloroform, ethyl acetate and methanol In vitro D-6 Plasmodium falciparum Kenya 100 Anacardiaceae Haematostaphis barteri Stem bark Dichloromethanemethanol In vivo Plasmodium berghei Ghana 101 Solanaceae Withania frutescens Leaves and roots n-hexane In vitro Plasmodium falciparum Morocco 102 Neobegua mahafaliensis Leaves Methanol In vitro Plasmodium falciparum FcM29-Cameroon Congo 103 Ebenaceae Diospyros species stem bark Methanol In vitro Plasmodium falciparum 3D7 Tanzania 104 Euphorbiaceae Sebastiania chamaelea Whole plant Methanol In vitro Plasmodium falciparum FcM29, FcB1, F32 and W2 Niger 105 Fabaceae Baphia pubescens Stem Hydroethanolic In vivo Plasmodium berghei Nigeria 106 Burseraceae Commiphora africana Stem Dichloromethane and methanol in a 1:1 ratio ( vv ) In vitro and in vivo Plasmodium falciparum (D6 and Dd2) Tanzania 107 Zingiberaceae Aframomum giganteum Stem bark Dichloromethane and methanol In vitro Plasmodium falciparum (FCB and W2) Gabon 108 Combretaceae Terminalia avicennioides leaves CH 2 Cl 2 , MeOHandMeOHH 2 O (11) In vitro Plasmodium falciparum strain K1 Burkina Faso 109 Meliaceae Melia azedarach leaves Cyclohexane, ethyl acetate, dichloromethane, and methanol In vitro Plasmodium falciparum (3D7 and W2) Senegal 110 Asteraceae Bidens pilosa leaves Methanolic and Ethyl Acetate In vitro Plasmodium falciparum (Pf3D7 and PfINDO) Cameroon 111 Labiatae Ajuga remota leaves Hydroethanolic In vivo Plasmodium berghei (ANKA strain) Ethiopia 112 Euphorbiaceae Alchornea laxiflora leaves Ethanol In vivo Plasmodium falciparum (Pf 3D7) and (Pf INDO) Nigeria 113 Compositae Vernonia adoensis Leaves Aqueous, methanol and chloroform In vivo Plasmodium berghei Ethiopia 114 Lamiaceae Clerodendrum rotundifolium Leaves ethyl acetate In vitro Plasmodium falciparum (NF54 and FCR3) Uganda 115 Apocynaceae Tabernaemontana elegans Stem bark Dichloromethane: 50 methanol (1:1) In vitro Plasmodium falciparum (NF54) South Africa 96 Zygophyllaceae Balanites aegyptiaca aerial Methanol In vitro Plasmodium falciparum Togo 116 Caesalpiniaceae Cassia occidentalis Leaves Ethanol In vitro Plasmodium falciparum Congo 117 Fabaceae Pericopsis laxiflora Bark Ethanol In vitro Plasmodium falciparum (NF54) and K1) Côte d'Ivoire 118 Canellaceae Warburgia salutaris stem bark Dichloromethane In vitro and in vivo NF54 Plasmodium falciparum South Africa 119 Asterales Oedera genistifolia leaves Chloroform, ethyl acetate, and ethanol In vitro Plasmodium falciparum strain 3D South Africa 120 Open in a new tab 6.3. Antifungal Activity Fungal infections have been recognized as one of the deadly diseases that are difficult to treat in humans, animals, and plants because of the multidrug-resistant of the fungal pathogens to the existing antifungal agents. Besides, the current antifungal drugs have adverse effects both on the patients and the environment 121 , 122 . Thus, the need to search for alternative cost-effective and effective alternatives is indispensable. On the other hand, rural dwellers are highly knowledgeable about the culture and traditional practices used by their ancestors for treating fungal infections 123 , 124 . Herbs have been the only source for the treatment of fungal diseases and as a result, the antifungal activity of these plants has been validated by some African researchers to establish the therapeutic claims of these plants. Hence, continual ethnobotanical survey and screening of African plants in search of novel bioactive compounds that could be used in the development of effective antifungal drugs have been the focus of research in this field 125 , 126 . Table 3 summarises a few African florae with proven antifungal activity. Table 3. Antifungal activity of some African flora. Family Genus Part Used Solvent Tested Organisms Country Reference Asteraceae Scolymus hispanicus Leaves and stem Ethanol and dichloromethane Candida neoformans and Candida albicans Morocco 127 Fabaceae Prosopis juliflora Whole plant Methanol or water Colletotrichum musae Ethiopia 128 Asphodelaceae Aloe barbadensis leaves Ethanol Candida albicans and Tessaracoccus flavus Ghana 129 Lythraceae Punica granatum Fruits Ethanol Fusarium oxysporum, Fusarium culmorum, Fusarium graminearum, Aspergillus niger and Alternaria alternata Tunisia 130 Celastraceae Mystroxylon aethiopicum Leave, stems and roots Dichloromethane and ethyl acetate Candida albicans and Candida neoformans Tanzania 131 Canellaceae Warburgia ugandensis Leaves Water, acetone, ethanol, and hexane Candida albicans SC5314, Candida glabrata BG2, Candida glabrata ATCC 2001 Kenya 132 Lamiaceae Gmelina arborea seeds Water Athelia rolfsii and Sclerotium rolfsii Nigeria 133 Ranunculaceae Clematis flammula leaves and bark Ethanol Candida albicans Algeria 134 Lamiaceae Marrubium vulgare aerial Methanol and acetone Botrytis cinerea, Pythium ultimum Tunisia 135 Asteraceae Artemisia herba alba aerial Water Usarium graminearum (ITEM-6477) and Fusarium sporotrichioides (ITEM-692) Algeria 136 Euphorbiaceae Ricinus communis Leaves Aqueous, methanol and ethanol Candida albicans Ghana 137 Lecythidaceae Barringtonia asiatica Leaves Methanol Aspergillus niger, Aspergillus flavin, Candida tropicalis and Fusarium oxysporium Nigeria 138 Asparagaceae Agave sisalana Roots Acetone, n-hexane, dichloromethane and methanol Candida albicans , Candida glabrata , Candida krusei , Candida parapsilosis , Candida tropicalis and Cryptococcus neoformans South Africa 139 Open in a new tab 6.4. Anticancer Activity Cancer is one of the topmost killer diseases globally, and it is predicted to be a major cause of death in the future 140 . It is a global public health issue affecting both developed and developing countries of the world, despite the innovation in the different therapy treatments 141 . This disease is a distressing issue, especially when not detected at the early stage, and the treatment costs are too high for the poor to afford 142 . However, radiotherapy and surgery have been acknowledged to be some of the most successful treatments, but the side effects and high treatment cost cannot be neglected 143 . Thus, this necessitates the urgent need to search for alternatives. Over the years, the use of herbal products for the treatment of different human diseases such as cancer has gained wide attention 144 , 145 . This means that plants or herbs may provide the main active principles for the development of new anticancer agents 146 , 147 . As a result, extensive studies on the anticancer activity of African plants have been well reported in the literature 148 , 149 , 150 . It has been established that bioactive compounds produced for plants' defense have the potential to inhibit cancer cell growth. In addition, the report of Kawashima et al. 151 has highlighted that some of these bioactive compounds are toxic to humans. Regrettably, the toxicity of these plants has been documented in many cases to originate from various contaminants, such as pesticides, heavy metals, and other pollutants in the environment 29 . Evidence to validate the therapeutic values of these plants is still scarce, hence, there is a need for further research to confirm the traditional anticancer claims of these plants 152 , 153 , 154 . Several researchers have been investigating how the antioxidant potential of a plant can be related to its anticancer effects 155 . The bioactive compounds responsible for the antioxidant properties could however be different from those accounting for the antiproliferative effect. Nevertheless, the most important approach should be directed towards producing anticancer agents that could completely inhibit the growth of cancerous cells with no effect on normal cells. However, the findings of Lobo et al. 156 have highlighted that oxidative stress caused by the excessive reactive oxygen species such as superoxide anion (O 2 ), nitric oxide (NO), hydroxyl radical ( OH) and peroxy radicals (ROO ) are involved in the pathogenesis of several pathologies, including cancer. The reactive species tend to cause DNA mutations, which could play a significant role in cancer 140 . Therefore, using plant-based antioxidant agents such as flavonoids, alkaloids and polyphenols could reduce the uncontrollable cell division caused by oxidative stress imposed by free radicals 157 . Thus, the use of natural antioxidants could play a lead role in the development of effective anticancer agents 158 , 159 . It is also worth noting that natural compounds have multi-target cellular effects 72 , 160 , 161 . Hence, this significant attribute could be more effective in the treatment of cancer than drugs that are target specific in their mode of action 72 . In Table 4 , we have highlighted a few African plants that have been shown to possess anticancer activity. Table 4. Anticancer activity of some African flora. Family Genus Part Used Solvent Tested Organisms Country Reference Curtisiaceae Curtisia dentata Leaves Acetone MCF-7, colorectal carcinoma cells (Caco-2), A549 and HeLa South Africa 73 Lamiaceae Origanum compactum leaves n-hexane L20B, RD and Vero Morocco 162 Liliaceae Allium ascalonicum Tuber Methanol MCF-7, MDA-MB-231 and fibroblast cells Nigeria 163 Asparagales Boophone disticha Bulb Chloroform, acetone, and ethanol HeLa South Africa 164 Annonaceae Uvariodendron anisatum Root Methanol and water 4T1 breast cancer cell line Kenya 165 Lauraceae Beilschmiedia acuta Kosterm, roots, leaves, bark Methanol Leukemia CCRF-CEM Cameroon 72 Aristolochiaceae Aristolochia ringens Vahl. Root Ethanol and water A549 (lung), HCT-116 (colon), PC3 (prostate), A431 (skin), HeLa (cervix), and THP-1 (leukemia) Nigeria 166 Fabaceae Acacia nilotica (L.) Delile Fruit Dichloromethane or hexane with chloroform or ethyl acetate or ethanol or methanol 80 Human leukemic CCRF-CEM and the ABCB1 (P-gp) Sudan 167 Euphorbiaceae Jatropha zeyheri roots Ethyl acetate Human dermal fibroblast (HDF), colon adenocarcinoma (Caco-2), lung cancer (A547) and breast cancer (MCF-7) South Africa 168 Poaceae Cymbopogon schoenanthus L. Spreng Aerial Ethanol MCF-7 Tunisia 169 Malvaceae Hibiscus sabdariffa Whole plant Methanol PC3 (prostate cancer cell line) Sudan 170 Anacardiaceae Rhus tripartita Aerial Methanol 70 and acetone 70 CaCo-2 (colon carcinoma) and K-562 (myelogenous leukemia) Tunisia 171 Myrtales Syzygium jambos Leaves Ethanol HeLa, Vero and HEK-293 South Africa 172 Bignoniaceae Jacaranda copaia leaves, bark, flower, root, Ethanol MDA-MB231 (breast) and PANC-1 (pancreas) Venezuela 173 Asteraceae Ageratum conyzoides whole plant and parts - stem, leaves and flower 50 hydroethanolic Jurkat, LNCap, MCF7 Ghana 174 Clusiaceae Pentadesma butyracea Fruits Methanol Skin cancer: A431 Cameroon 175 Sapotaceae Sideroxylon oxyacanthum Leaves 80 methanol (MeOH) in H 2 O MT-1, MCF-7 and MCF-10A Ethiopia 176 Chrysobalanaceae Parinari curatellifolia (Planch ex Benth) leaves, roots stem and bark Methanol Wil 2 and Jurkat T Zimbabwe 177 Open in a new tab 6.5. Antiviral Activity Apart from bacterial and fungal infections, the world, and Africa in particular, has to deal with the ruthless devastation of viral diseases, which in most cases are the most difficult to deal with 178 . Unlike bacterial and fungal cells, which exist as free-living entities, viruses are small infectious intracellular parasites, which contain little more than wads of genetic material in the form of either RNA or DNA, surrounded by a lipid-carbohydrate-containing envelope 179 . Viruses can infect all types of organisms, humans, animals, and plants alike. Several antiviral drugs are currently available 180 , nonetheless, the high incidence of viral resistance to the existing antiviral drugs has called for an urgent need to search for effective alternative agents 181 . Hence, great attention has been shifted towards screening African plants for novel antiviral agents 182 , 183 . Antiviral chemotherapy is a standard practice in the management of viral infections in humans 184 . Further research to authenticate the safety of these plants, both in vivo studies and human clinical trials, is necessary. Table 5 lists a few African plants that have been proven to demonstrate antiviral activity. Table 5. Antiviral activity of some African flora. Family Genus Part Used Solvent Tested Organisms Country Reference Myrtaceae Syzygium jambos Leaves Ethanol HSV-1 South Africa 172 Euphorbiaceae Macaranga barteri Leaves Methanol Echoviruses (E7 and and E19) Nigeria 185 Meliaceae Trichilia dregeana Roots Methanol hepatitis C virus (HCV) Cameroon 186 Celastraceae Cassine transvaalensis Bark Methanol HIV South Africa 187 Fabaceae Caesalpinia decapetala Root Water HSV-1 Kenya 188 Apocynaceae Carissa edulis Root Water HSV-1 and HSV-2 Kenya 189 Fabaceae Cajanus cajan Leaves, stem, roots Hot water HSV-1 Nigeria 190 Poaceae Bambusa vulgaris Leaf Ethanol Measles and yellow fever virus Nigeria 191 Combretaceae Combretum molle Roots Methanol HIV-1 South Africa 192 Amaryllidaceae Zephyranthes candida Stem bark and root bark methanol Poliovirus Type-PV1 Nigeria 185 Apocynaceae Tabernaemontana ventricosa Leaves Methanol influenza A virus (IAV) South Africa 183 Amaryllidaceae Crinum macowani Leaves Aqueous and ethanol HIV South Africa 193 Malvaceae Hibiscus sabdariffa Leaves Ethanol Measles Virus Nigeria 194 Open in a new tab 7. Conclusions Folk medicines are the oldest and most widely utilized out of the different therapeutic systems in African countries and other developing countries. In these countries, the native doctors prescribe easily available herbs to sick people in the rural and semi-urban communities to solve their immediate health problems, and as such, they have utilized several folkloric herbs for different therapeutic purposes. The big question about the safety of the folk medicines will continue to be a major public health issue as their preparation is not hygienic and scientific procedures are not followed. Despite the extensive efforts by researchers, there is still a paucity of information regarding the compilation of plants that can be used in the treatment of several human diseases and their adverse effects. The issues concerning the toxicity of herbal mixtures, appropriate doses to be used, identification of active ingredients, mode(s) of action, quality control measures in herbal preparation and labelling, integration of folkloric and orthodox medicines should be addressed by the relevant authorities to safeguard the life of the populace that explore folk medicines for therapeutic purposes. Awareness about the potential adverse effect, mode of action, and integration of herbal products with orthodox medicines should be encouraged. Acknowledgments The authors duly acknowledgement Cape Peninsula University of Technology for their financial support. Author Contributions Conceptualization, K.O.; and O.O.O.; methodology, K.O.; investigation, K.O.; resources, O.O.O.; K.O.; writingoriginal draft preparation, K.O.; and O.O.O.; writingreview and editing, supervision, K.O.; funding acquisition, O.O.O. Both authors have read and agreed to the published version of the manuscript. Funding This research was funded by Cape Peninsula University of Technology, grant number CPUT-RJ23 and The APC was funded by Cape Peninsula University of Technology. Institutional Review Board Statement Not applicable. Informed Consent Statement Not applicable. Data Availability Statement Not applicable. Conflicts of Interest The authors declare no conflict of interest. Footnotes Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. References 1. Mahomoodally F.M. Traditional medicines in Africa: An appraisal of ten potent African medicinal plants. Evid. Based Complement. Altern. Med. 2013;2013:617459. doi: 10.11552013617459. DOI PMC free article PubMed Google Scholar 2. Manach C., Scalbert A., Morand C., R'em esy C., Jim enez L. Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr. 2004;79:727747. doi: 10.1093ajcn79.5.727. DOI PubMed Google Scholar 3. World Health Organisation Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems. (accessed on 6 December 2020);2004 Available online: httpapps.who.intmedicinedocsdocumentss14215e . 4. World Health Organisation A Global Brief on Hypertension: World Health Day. (accessed on 5 December 2020);2013 Available online: http:www.who.int . 5. World Health Organization Traditional Medicines. (accessed on 8 October 2020);2008 Available online: http:www.who.intmediacentrefactsheetsfs134en 6. Bandaranayake W.M. Modern Phytomedicine: Turning Medicinal Plants into Drugs. Wiley; Hoboken, NJ, USA: 2006. Quality Control, Screening, Toxicity, and Regulation of Herbal Drugs; pp. 2557. Google Scholar 7. Bodeker C., Bodeker G., Ong C.K., Grundy C.K., Burford G., Shein K. WHO Global Atlas of Traditional, Complementary and Alternative Medicine. World Health Organization; Geneva, Switzerland: 2005. Google Scholar 8. Frenzel C., Teschke R. Herbal hepatotoxicity: Clinical characteristics and listing compilation. Int. J. Mol. Sci. 2016;17:588. doi: 10.3390ijms17050588. DOI PMC free article PubMed Google Scholar 9. Fokunang C.N., Ndikum V., Tabi O.Y., Jiofack R.B., Ngameni B., Guedje N.M., Tembe-Fokunang E.A., Tomkins P., Barkwan S., Kechia F., et al. Traditional medicine: Past, present and future research and development prospects and integration in the National Health System of Cameroon. Afr. J. Tradit. Complement. Altern. Med. 2011;8:284295. doi: 10.4314ajtcam.v8i3.65276. DOI PMC free article PubMed Google Scholar 10. Gurib-Fakim A. Medicinal plants: Traditions of yesterday and drugs of tomorrow. Mol. Asp. Med. 2006;27:193. doi: 10.1016j.mam.2005.07.008. DOI PubMed Google Scholar 11. Fennell C.W., Light M.E., Sparg S.G., Stafford G.I., van Staden J. Assessing African medicinal plants for efficacy and safety: Agricultural and storage practices. J. Ethnopharmacol. 2004;95:113121. doi: 10.1016j.jep.2004.05.025. DOI PubMed Google Scholar 12. Mphasha L.E., Lebese R.T. The importance of indigenous languages in health-care services: Some observations from Limpopo Province, South Africa. Stud. Ethno Med. 2015;9:8995. doi: 10.108009735070.2015.11905425. DOI Google Scholar 13. Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol. 2014;4:177. doi: 10.3389fphar.2013.00177. DOI PMC free article PubMed Google Scholar 14. Yuan H., Ma Q., Ye L., Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016;21:559. doi: 10.3390molecules21050559. DOI PMC free article PubMed Google Scholar 15. Mothibe M.E., Sibanda M. Traditional and Complementary Medicine. IntechOpen; London, UK: 2019. African traditional medicine: South African perspective. DOI Google Scholar 16. Ozioma E.O.J., Chinwe O.A.N. Herbal medicines in African traditional medicine. Herb. Med. 2019;10:191214. Google Scholar 17. Agyemang-Duah W., Peprah C., Peprah P. Barriers to formal healthcare utilisation among poor older people under the livelihood empowerment against poverty programme in the Atwima Nwabiagya District of Ghana. BMC Public Health. 2019;19:112. doi: 10.1186s12889-019-7437-2. DOI PMC free article PubMed Google Scholar 18. Parle M., Bansal N. Herbal medicines: Are they safe? Nat. Prod. Radiance. 2006;5:614. Google Scholar 19. World Health Organization Traditional Medicine, Highlights of the 56th World Health Assembly. (accessed on 5 November 2020);2003 Available online: www.who.intfeatures200305ben . 20. World Health Organisation Regional Office for Africa, Progress Report on Decade of Traditional Medicine in the African Region. (accessed on 2 October 2020);2011 Available online: www.afro.who.int 21. World Health Organisation The WHO Traditional Medicine Strategy 20142023. (accessed on 3 November 2020);2012 Available online: https:www.who.intmedicinespublicationstraditionaltrm_strategy14_23en 22. Calapai G. European legislation on herbal medicines: A look into the future. Drug Saf. 2008;31:428431. doi: 10.216500002018-200831050-00009. DOI PubMed Google Scholar 23. Anquez-Traxler C. The legal and regulatory framework of herbal medicinal products in the European Union: A focus on the traditional herbal medicines category. Drug Inf. J. 2011;45:1523. doi: 10.1177009286151104500102. DOI Google Scholar 24. Kong J.M., Goh N.K., Chia L.S., Chia T.F. Recent advances in traditional plant drugs and orchids. Acta Pharmacol. Sin. 2003;24:721. PubMed Google Scholar 25. Govender S., Du Plessis-Stoman D., Downing T.G., van de Venter M. Traditional herbal medicines: Microbial contamination, consumer safety and the need for standards. S. Afr. J. Sci. 2006;102:253255. Google Scholar 26. Kosalec I., Cvek J., Tomić S. Contaminants of medicinal herbs and herbal products. Arch. Ind. Hyg. Toxicol. 2009;60:485501. doi: 10.247810004-1254-60-2009-2005. DOI PubMed Google Scholar 27. van Vuuren S., Williams V.L., Sooka A., Burger A., van der Haar L. Microbial contamination of traditional medicinal plants sold at the faraday muthi market, Johannesburg, South Africa. S. Afr. J. Bot. 2014;94:95100. doi: 10.1016j.sajb.2014.06.002. DOI Google Scholar 28. Rietjens I.M., Martena M.J., Boersma M.G., Spiegelenberg W., Alink G.M. Molecular mechanisms of toxicity of important food-borne phytotoxins. Mol. Nutr. Food Res. 2005;49:131158. doi: 10.1002mnfr.200400078. DOI PubMed Google Scholar 29. Teschke R., Wolff A., Frenzel C., Schulze J., Eickhoff A. Herbal hepatotoxicity A tabular compilation of reported cases. Liver Int. 2012;32:15431556. doi: 10.1111j.1478-3231.2012.02864.x. DOI PubMed Google Scholar 30. Seeff L.B., Bonkovsky H.L., Navarro V.J., Wang G. Herbal products and the liver: A review of adverse effects and mechanisms. Gastroenterology. 2015;148:517532. doi: 10.1053j.gastro.2014.12.004. DOI PubMed Google Scholar 31. Omage K., Azeke M.A., Orhue J.N., Iseghohi S.O. Toxicological implications of the therapeutic use of Acalypha wilkesiana leaves in traditional medicine. Clin. Phytosci. 2017;3:15. doi: 10.1186s40816-017-0053-8. DOI Google Scholar 32. Iroezindu M.O., Agbaji O.O., Daniyam C.A., Isiguzo G.C., Isichei C., Akanbi M.O. Liver function test abnormalities in Nigerian patients with human immunodeficiency virus and hepatitis B virus co-infection. Int. J. STD AIDS. 2013;24:461467. doi: 10.11770956462412473889. DOI PubMed Google Scholar 33. Amadi C.N., Orisakwe O.E. Herb-induced liver injuries in developing nations: An update. Toxics. 2018;6:24. doi: 10.3390toxics6020024. DOI PMC free article PubMed Google Scholar 34. Ogutcu A., Suludere Z., Kalendar Y. Dichlorvos-induced hepatotoxicity in rats and the protective effects of vitamins C and E. Environ. Toxicol. Pharmacol. 2008;26:355361. doi: 10.1016j.etap.2008.07.005. DOI PubMed Google Scholar 35. Chang S.Y., Voellinger J.L., van Ness K.P., Chapron B., Shaffer R.M., Neumann T., White C.C., Kavanagh T.J., Kelly E.J., Eaton D.L. Characterization of rat or human hepatocytes cultured in microphysiological systems (MPS) to identify hepatotoxicity. Toxicol. In Vitro. 2017;40:170183. doi: 10.1016j.tiv.2017.01.007. DOI PubMed Google Scholar 36. Pfeiffer J.M., Butz R.J. Assessing cultural and ecological variation in ethnobiological research: The importance of gender. J. Ethnobiol. 2005;25:240278. doi: 10.29930278-0771(2005)25240:ACAEVI2.0.CO;2. DOI Google Scholar 37. Lamxay V., de Boer H.J., Björk L. Traditions and plant use during pregnancy, childbirth and postpartum recovery by the Kry ethnic group in Lao PDR. J. Ethnobiol. Ethnomed. 2011;7:14. doi: 10.11861746-4269-7-14. DOI PMC free article PubMed Google Scholar 38. Titilayo O.K., Rasaq A., Ismail E.M. Attitude and use of herbal medicines among pregnant women in Nigeria. BMC Complement. Altern. Med. 2009;9:53. doi: 10.11861472-6882-9-53. DOI PMC free article PubMed Google Scholar 39. Zumsteg I.S., Weckerle C.S. Bakera, a herbal steam bath for postnatal care in Minahasa (Indonesia): Documentation of the plants used and assessment of the method. J. Ethnopharmacol. 2007;111:641650. doi: 10.1016j.jep.2007.01.016. DOI PubMed Google Scholar 40. Adane F., Seyoum G., Alamneh Y.M., Abie W., Desta M., Sisay B. Herbal medicine use and predictors among pregnant women attending antenatal care in Ethiopia: A systematic review and meta-analysis. BMC Pregnancy Childbirth. 2020;20:111. doi: 10.1186s12884-020-2856-8. DOI PMC free article PubMed Google Scholar 41. Veale D.J.H., Furman K.I., Oliver D.W. South African traditional herbal medicines used during pregnancy and childbirth. J. Ethnopharmacol. 1992;36:185191. doi: 10.10160378-8741(92)90043-Q. DOI PubMed Google Scholar 42. Sarkar M., Chaudhuri G.R., Chattopadhayay A., Biswas N.M. Effect of sodium arsenita on spermatogenesis, plasma gonadotrophins and testosterone in rats. Asian J. Androl. 2003;1:2731. PubMed Google Scholar 43. Yakubu T.M., Ajiboye O.T., Adewunmi A.M. Toxicological Survey of African Medicinal Plants. Elsevier; New York, NY, USA: 2014. Toxicity and beneficial effects of some african plants on the reproductive system; pp. 445492. Google Scholar 44. Ait H.N., Slimani M., Aous A.E.K. Reproductive toxicity of lead acetate in albinos' rat. Am. J. Sci. Res. 2009;3:3850. Google Scholar 45. Cinar O., Simez O., Can A. Carbofuran alters centrosome and spindle organization, and delays cell division in oocytes and mitotic cells. Toxicol. Sci. 2015;28:437444. doi: 10.1093toxscikfu317. DOI PubMed Google Scholar 46. Sorelle D.N., Ferdinand N., Vemo Bertin Narcisse T. Medicinal plants and female reproduction disorders due to oxidative stress. Arch. Vet. Sci. 2019;2:5873. Google Scholar 47. Heikal T.M., Mossa T.H., Marei G.I.K.H., Abdel Rasoul M.A. Cyromazine and chlorpyrifos induced renal toxicity in rats: The ameliorating effects of green tea extract. J. Anal. Toxicol. 2012;2:146152. doi: 10.41722161-0525.1000146. DOI Google Scholar 48. Doltade S., Lonare M., Raut S., Telang A. Evaluation of acetamiprid mediated oxidative stress and pathological changes in male rats: Ameliorative effect of curcumin. Proc. Natl. Acad. Sci. USA India Sect. B Biol. Sci. 2019;89:191199. doi: 10.1007s40011-017-0934-0. DOI Google Scholar 49. Sangha G.K., Kaur K., Khera K.S. Cypermethrin induced pathological and biochemical changes in reproductive organs of female rats. J. Environ. Biol. 2013;34:99105. PubMed Google Scholar 50. Nwangwa E.K. Antifertility effects of ethanolic extract of Xylopia aethiopica on male reproductive organ of wistar rats. Am. J. Med. Sci. 2012;2:1215. Google Scholar 51. Akbarsha M.A., Mavivannan B., Hamid K.S., Vijayan B. Antifertility effect of Andrographis paniculata (Nees) in albino rats. Indian J. Exp. Biol. 1990;28:421426. PubMed Google Scholar 52. Nergard C.S., Ho T.P.T., Diallo D., Ballo N., Paulsen B.S., Nordeng H. Attitudes and use of medicinal plants during pregnancy among women at health care centers in three regions of Mali, West-Africa. J. Ethnobiol. Ethnomed. 2015;11:73. doi: 10.1186s13002-015-0057-8. DOI PMC free article PubMed Google Scholar 53. Nyeko R., Tumwesigye N.M., Halage A.A. Prevalence and factors associated with use of herbal medicines during pregnancy among women attending postnatal clinics in Gulu district, Northern Uganda. BMC Pregnancy Childbirth. 2016;16:296. doi: 10.1186s12884-016-1095-5. DOI PMC free article PubMed Google Scholar 54. Hill J., Kayentao K., Achieng F., Diarra S., Dellicoour S., Diawara S.I., Hamel M.J., Ouma P., Desai M., Doumbo O.K., et al. Access and use of interventions to prevent and treat malaria among pregnant women in Kenya and Mali: A qualitative study. PLoS One. 2015;10:e119848. doi: 10.1371journal.pone.0119848. DOI PMC free article PubMed Google Scholar 55. Shewamene Z., Dune T., Smith C.A. The use of traditional medicine in maternity care among African women in Africa and the diaspora: A systematic review. BMC Complement. Altern. Med. 2017;17:382. doi: 10.1186s12906-017-1886-x. DOI PMC free article PubMed Google Scholar 56. Moreira D.D.L., Teixeira S.S., Monteiro M.H.D., de-Oliveira A.C.A., Paumgartten F.J. Traditional use and safety of herbal medicines. Rev. Bras. Farmacogn. 2014;24:248257. doi: 10.1016j.bjp.2014.03.006. DOI Google Scholar 57. Zhou J., Ouedraogo M., Qu F., Duez P. Potential genotoxicity of traditional Chinese medicinal plants and phytochemicals: An overview. Phytother. Res. 2013;27:17451755. doi: 10.1002ptr.4942. DOI PubMed Google Scholar 58. de Sousa Lima C.M., Fujishima M.A.T., de Paula Lima B., Mastroianni P.C., de Sousa F.F.O., da Silva J.O. Microbial contamination in herbal medicines: A serious health hazard to elderly consumers. BMC Complement. Altern. Med. 2020;20:17. doi: 10.1186s12906-019-2723-1. DOI PMC free article PubMed Google Scholar 59. Tugume P., Nyakoojo C. Ethno-pharmacological survey of herbal remedies used in the treatment of paediatric diseases in Buhunga parish, Rukungiri District, Uganda. BMC Complement. Altern. Med. 2019;19:353. doi: 10.1186s12906-019-2763-6. DOI PMC free article PubMed Google Scholar 60. Sasidharan S., Saravanan D., Chen Y., Sundram K.M., Latha L.Y. Extraction, isolation and characterization of bioactive compounds from plants' extracts. Afr. J. Tradit. Complement. Altern. Med. 2011;8:110. doi: 10.4314ajtcam.v8i1.60483. DOI PMC free article PubMed Google Scholar 61. Mensah M.L., Komlaga G., Forkuo A.D., Firempong C., Anning A.K., Dickson R.A. Toxicity and safety implications of herbal medicines used in Africa. Herb. Med. 2019;63 doi: 10.5772intechopen.72437. DOI Google Scholar 62. Muhammad B.Y., Awaisu A. The need for enhancement of research, development, and commercialization of natural medicinal products in Nigeria: Lessons from the Malaysian experience. Afr. J. Tradit. Complement. Altern. Med. 2008;5:120. PMC free article PubMed Google Scholar 63. Manilal A., Sabu K.R., Shewangiza M., Aklilu A., Seid M., Merdekios B., Tsegaye B. In vitro antibacterial activity of medicinal plants against biofilm-forming methicillin-resistant Staphylococcus aureus: Efficacy of Moringa stenopetala and Rosmarinus officinalis extracts. Heliyon. 2020;6:e03303. doi: 10.1016j.heliyon.2020.e03303. DOI PMC free article PubMed Google Scholar 64. Berdy J. Bioactive microbial metabolites. J. Antibiot. 2005;58:126. doi: 10.1038ja.2005.1. DOI PubMed Google Scholar 65. Manilal A., Sujith S., Sabarathnam B., Selvin J., Shakir C., Lipton A.P. Biological activity of the red alga, Laurencia brandenii. Acta Bot. Croat. 2011;70:8190. doi: 10.2478v10184-010-0001-x. DOI Google Scholar 66. Samuelsson G. Drugs of Natural Origin: A Textbook of Pharmacognosy. 5th ed. Swedish Pharmaceutical Press; Stockholm, Sweden: 2004. Google Scholar 67. Stefanovic O.D. Bacterial Pathogenesis and Antibacterial Control. IntechOpen; London, UK: 2018. Synergistic Activity of Antibiotics and Bioactive Plant Extracts: A Study Against Gram-Positive and Gram-Negative Bacteria; pp. 2348. Google Scholar 68. Elisha L.L., Botha F.S., McGaw L.J., Eloff J.N. The antibacterial activity of extracts of nine plant species with good activity against Escherichia coli against five other bacteria and cytotoxicity of extracts. BMC Complement. Altern. Med. 2017;17:133. doi: 10.1186s12906-017-1645-z. DOI PMC free article PubMed Google Scholar 69. Mudzengia C.P., Murwiraa A., Tivapasic M.T., Murungwenid C., Joan V., Burumue V.B., Halimanif T. Antibacterial activity of aqueous and methanol extracts of selected species used in livestock health management. Pharm. Biol. 2017;55:10541060. doi: 10.108013880209.2017.1287744. DOI PMC free article PubMed Google Scholar 70. Yusuf A.A., Lawal B., Abubakar A.N., Berinyuy E.B., Omonije Y.O., Umar S.I., Shebe M.N., Alhaji Y.M. In-vitro antioxidants, antimicrobial and toxicological evaluation of Nigerian Zingiber officinale. Clin. Phytosci. 2018;4:12. doi: 10.1186s40816-018-0070-2. DOI Google Scholar 71. Leonti M., Dal Cero M., Weckerle C.S., Laura C. Reverse Etnopharmacology and drug discovery; Proceedings of the 15th International Congress of the International Society for Ethnopharmacology; Petra, Jordan. 58 May 2015. Google Scholar 72. Kuete V., Tankeo S.B., Saeed M.E., Wienc B., Tane P., Efferth T. Cytotoxicity and modes of action of five Cameroonian medicinal plants against multi-factorial drug resistance of tumor cells. J. Ethnopharmacol. 2014;153:207219. doi: 10.1016j.jep.2014.02.025. DOI PubMed Google Scholar 73. Soyingbe O.S., Mongalo N.I., Makhafola T.J. In vitro antibacterial and cytotoxic activity of leaf extracts of Centella asiatica (L.) Urb, Warburgia salutaris (Bertol. F.) Chiov and Curtisia dentata (Burm. F.) CA Sm-medicinal plants used in South Africa. BMC Complement. Altern. Med. 2018;18:110. doi: 10.1186s12906-018-2378-3. DOI PMC free article PubMed Google Scholar 74. Idris O.A., Wintola O.A., Afolayan A.J. Evaluation of the bioactivities of Rumex crispus L. leaves and root extracts using toxicity, antimicrobial, and antiparasitic assays. Evid. Based Complement. Altern. Med. 2019;2019 doi: 10.115520196825297. DOI PMC free article PubMed Google Scholar 75. Kuete V. Medicinal plant research in Africa. In: Kuete V., editor. Pharmacology and Chemistry. Elsevier; Oxford, UK: 2013. Google Scholar 76. Okach D., Nyunja A., Opande G. Phytochemical screening of some wild plants from Lamiaceae and their role in traditional medicine in Uriri district-Kenya. Int. J. Herb. Med. 2013;1:135143. Google Scholar 77. Ortíz-Castro R., Contreras-Cornejo H.A., Macías-Rodríguez L., López-Bucio J. The role of microbial signals in plant growth and development. Plant. Signal. Behav. 2009;4:701712. doi: 10.4161psb.4.8.9047. DOI PMC free article PubMed Google Scholar 78. Ayaz M., Ullah F., Sadiq A., Ulla F., Ovais M., Ahmed J., Devkota H.P. Synergistic interactions of phytochemicals with antimicrobial agents: Potential strategy to counteract drug resistance. Chem. Biol. Interact. 2019;308:294303. doi: 10.1016j.cbi.2019.05.050. DOI PubMed Google Scholar 79. Nguta J.M., Kiraithe M.N. In vitro antimicrobial activity of aqueous extracts of Ocimum suave Willd., Plectranthus barbatus andrews and Zanthoxylum chalybeum Engl. against selected pathogenic bacteria. Biomed. Biotechnol. Res. J. 2019;3:30. doi: 10.4103bbrj.bbrj_128_18. DOI Google Scholar 80. Ali S.S., Ayub A., Ali S.N., Begum S., Siddiqui B.S., Mahmood M., Khan K.L. Antibacterial activity of methanolic extracts from some selected medicinal plants FUUAST. J. Biol. 2017;7:123125. Google Scholar 81. Deshpande B., Varsha C., Bhawana P. Antibacterial activity of plant extract of Amaranthus spinosus. Indian J. Scientometr. Res. 2017;12:041044. Google Scholar 82. Ogbunugafor H.A., Ugochukwu C.G., Kyrian-Ogbonna A.E. The role of spices in nutrition and health: A review of three popular spices used in southern Nigeria. Food Qual. Saf. 2017;1:171185. doi: 10.1093fqsafefyx020. DOI Google Scholar 83. Tchoumi L.T., Nchouwet M.L., Kaman S.P., Nana W.Y., Djimeli R.D., Kamanyi A., Ngnokam S.W. Antimicrobial and antidiarrhoeal activities of aqueous and methanolic extracts of Mangifera indica Linn stem bark (Anarcadiaceae) in Wistar rats. Adv. Tradit. Med. 2020:114. doi: 10.1007s13596-020-00470-6. DOI Google Scholar 84. Zourgui M.N., Hfaiedh M., Brahmi D., Affi W., Gharsallah N., Zourgui L., Amri M. Phytochemical screening, antioxidant and antimicrobial activities of Opuntia streptacantha fruit skin. J. Food Meas. Charact. 2020;14:27212733. doi: 10.1007s11694-020-00518-w. DOI Google Scholar 85. Wintola O.A., Afolayan A.J. Phytochemical and antimicrobial evaluation of Lauridia tetragona (LF) RH Archer A medicinal plant used for the management of dysentery in the Eastern Cape Province of South Africa. Pharmacogn. Res. 2019;11:134. doi: 10.4103pr.pr_41_18. DOI Google Scholar 86. Asong J.A., Amoo S.O., McGaw L.J., Nkadimeng S.M., Arem A.O., Otang-Mbeng W. Antimicrobial activity, antioxidant potential, cytotoxicity and phytochemical profiling of four plants locally used against skin diseases. Plants. 2019;8:350. doi: 10.3390plants8090350. DOI PMC free article PubMed Google Scholar 87. Mummed B., Abraha A., Feyera T., Nigusse A., Assefa S. In vitro antibacterial activity of selected medicinal plants in the traditional treatment of skin and wound infections in Eastern Ethiopia. BioMed Res. Int. 2018 doi: 10.115520181862401. DOI PMC free article PubMed Google Scholar 88. Dzotam J.K., Touani F.K., Kuete V. Antibacterial activities of the methanol extracts of Canarium schweinfurthii and four other Cameroonian dietary plants against multi-drug resistant Gram-negative bacteria. Saudi J. Biol. Sci. 2016;23:565570. doi: 10.1016j.sjbs.2015.06.006. DOI PMC free article PubMed Google Scholar 89. Opinde H.R., Gatheri G.W., Nyamache A.K. Antimicrobial evaluation of crude methanolic leaf extracts from selected medicinal plants against Escherichia coli. J. Bacteriol. Parasitol. 2016;7:272. doi: 10.41722155-9597.1000272. DOI Google Scholar 90. Yunana B.T., Guiyi J.C., Bukar B.B. In vitro and in vivo evaluation of antibacterial activity of Bridelia ferrugine extracts on some clinical isolates. J. Phytopharmacol. 2018;7:392398. Google Scholar 91. Shirinda H., Leonard C., Candy G., van Vuuren S. Antimicrobial activity and toxicity profile of selected southern African medicinal plants against neglected gut pathogens. S. Afr. J. Sci. 2019;115:110. doi: 10.17159sajs.20196199. DOI Google Scholar 92. Seleteng-Kose L., Moteetee A., van Vuuren S. Medicinal plants used for the treatment of sexually transmitted infections in the Maseru District, Lesotho: Antimicrobial validation, phytochemical and cytotoxicity studies. S. Afr. J. Bot. 2019;122:457466. doi: 10.1016j.sajb.2019.01.035. DOI Google Scholar 93. Ramdane F., Essid R., Fares N., El Ouassis D., Aziz S., Mahammed M.H., Hadj M.D.O., Limam F. Antioxidant antileishmanial cytotoxic and antimicrobial activities of a local plant Myrtus nivellei from Algeria Sahara. Asian Pac. J. Trop. Biomed. 2017;7:702707. doi: 10.1016j.apjtb.2017.07.011. DOI Google Scholar 94. Kigondu E.V.M., Rukunga G.M., Gathirwa J.W., Irungu B.N., Mwikwabe N.M., Amalemba G.M., Omar S.A., Kirira P.G. Antiplasmodial and cytotoxicity activities of some selected plants used by the Maasai community, Kenya. S. Afr. J. Bot. 2011;77:725729. doi: 10.1016j.sajb.2011.03.008. DOI Google Scholar 95. Bekono B.D., Ntie-Kang F., Onguéné P.A., Lifong L.L., Sippl W., Fester K., Owono L.C. The potential of anti-malarial compounds derived from African medicinal plants: A review of pharmacological evaluations from 2013 to 2019. Malar. J. 2020;19:135. doi: 10.1186s12936-020-03231-7. DOI PMC free article PubMed Google Scholar 96. Bapela M.J., Meyer J.M., Kaiser M. In vitro antiplasmodial screening of ethnopharmacologically selected South African plant species used for the treatment of malaria. J. Ethnopharmacol. 2014;156:370373. doi: 10.1016j.jep.2014.09.017. DOI PubMed Google Scholar 97. Ahmed E.H.M., Nour B.Y., Mohammed Y.G., Khalid H.S. Antiplasmodial activity of some medicinal plants used in Sudanese folk-medicine. Environ. Health Insights. 2010;4:EHI-S4108. doi: 10.4137EHI.S4108. DOI PMC free article PubMed Google Scholar 98. Onguéné P.A., Ntie-Kang F., Lifongo L.L., Ndom J.C., Sippl W., Mbaze L.M.A. The potential of anti-malarial compounds derived from African medicinal plants. Part I: A pharmacological evaluation of alkaloids and terpenoids. Malar. J. 2013;12:449. doi: 10.11861475-2875-12-449. DOI PMC free article PubMed Google Scholar 99. Ajala T.O., Igwilo C.I., Oreagba I.A., Odeku O.A. The antiplasmodial effect of the extracts and formulated capsules of Phyllanthus amarus on Plasmodium yoelii infection in mice. Asian Pac. J. Trop. Med. 2011;4:283287. doi: 10.1016S1995-7645(11)60087-4. DOI PubMed Google Scholar 100. Ayuko T.A., Njau R.N., Cornelius W., Leah N., Ndiege I.O. In vitro antiplasmodial activity and toxicity assessment of plant extracts used in traditional malaria therapy in the Lake Victoria Region. Memórias Inst. Oswaldo Cruz. 2009;104:689694. doi: 10.1590S0074-02762009000500004. DOI PubMed Google Scholar 101. Boampong J.N., Karikari A.A., Ameyaw E.O. In vivo antiplasmodial and in vitro antioxidant properties of stem bark extracts of Haematostaphis barteri. Asian Pac. J. Trop. Biomed. 2015;5:446450. doi: 10.1016j.apjtb.2015.02.002. DOI Google Scholar 102. El Bouzidi L., Bakrim W.B., Mahiou V., Azas N., Larhsini M., Markouk M., Ollivier E., Bekkouche K. In vitro antiplasmodial activity of Withania frutescensSolanaceae. Eur. J. Integr. Med. 2017;14:2831. doi: 10.1016j.eujim.2017.08.009. DOI Google Scholar 103. Ngbolua K.N., Rafatro H., Rakotoarimanana H., Ratsimamanga U.S., Mudogo V., Mpiana P.T., Tshibangu D.S.T. Pharmacological screening of some traditionally used antimalarial plants from the Democratic Republic of Congo compared to their ecological taxonomic equivalence in Madagascar. Int. J. Biol. Chem. 2011;5:17971804. doi: 10.4314ijbcs.v5i5.3. DOI Google Scholar 104. Christopher R., Mgani Q.A., Nyandoro S.S., Rousseau A.L., van Vuuren S.F., Isaacs M., Hoppe H.C. Antitrypanosomal, antiplasmodial, and antibacterial activities of extracts from selected Diospyros and Annonaceae species. J. Complement. Med. Res. 2018;7:161170. doi: 10.5455jcmr.20171205011734. DOI Google Scholar 105. Garcia-Alvarez M.C., Moussa I., Soh P.N., Nongonierma R., Abdoulaye A., Nicolau-Travers M.L., Fabre A., Wdzieczak-Bakala J., Ahond A., Poupat C., et al. Both plants Sebastiania chamaelea from Niger and Chrozophora senegalensis from Senegal used in African traditional medicine in malaria treatment share a same active principle. J. Ethnopharmacol. 2013;149:676684. doi: 10.1016j.jep.2013.07.024. DOI PubMed Google Scholar 106. Ihekwereme C.P., Agbata C.A., Chukwueze K.O., Agu S.C. In vivo evaluation of antiplasmodial activity of hydroethanolic stem extract of Baphia pubescens in Plasmodium berghei infected albino mice. J. HerbMed Pharmacol. 2016;5:149152. Google Scholar 107. Kweyamba P.A., Zofou D., Efange N., Assob J.C.N., Kitau J., Nyindo M. In vitro and in vivo studies on anti-malarial activity of Commiphora africana and Dichrostachys cinerea used by the Maasai in Arusha region, Tanzania. Malar. J. 2019;18:119. doi: 10.1186s12936-019-2752-8. DOI PMC free article PubMed Google Scholar 108. Lekana-Douki J.B., Bongui J.B., Liabagui S.L.O., Edou S.E.Z., Zatra R., Bisvigou U., Druilhe P., Lebibi J., Ndouo F.S.T., Kombila M. In vitro antiplasmodial activity and cytotoxicity of nine plants traditionally used in Gabon. J. Ethnopharmacol. 2011;133:11031108. doi: 10.1016j.jep.2010.11.056. DOI PubMed Google Scholar 109. Ouattara L.P., Sanon S., Mahiou-Leddet V., Gansané A., Baghdikian B., Traoré A., Nébié I., Traoré A.S., Azas N., Ollivier E., et al. In vitro antiplasmodial activity of some medicinal plants of Burkina Faso. Parasitol. Res. 2014;113:405416. doi: 10.1007s00436-013-3669-8. DOI PubMed Google Scholar 110. Manga A., Gassama A., Diatta K., Bassène E., Cojean S., Cavé C. Antiplasmodial activity of extracts OF Khaya senegalensis (DERS.) A. Jus (Meliaceae) and Melia azedarach L.; Plants of Senegalese Traditional Medicine. Int. J. Pharm. Sci. Res. 2018;9:46594665. Google Scholar 111. Zofou D., Tene M., Ngemenya M.N., Tane P., Titanji V.P. In vitro antiplasmodial activity and cytotoxicity of extracts of selected medicinal plants used by traditional healers of Western Cameroon. Malar. Res. Treat. 2011;2011 doi: 10.40612011561342. DOI PMC free article PubMed Google Scholar 112. Nardos A., Makonnen E. In vivo antiplasmodial activity and toxicological assessment of hydroethanolic crude extract of Ajuga remota. Malar. J. 2017;16:25. doi: 10.1186s12936-017-1677-3. DOI PMC free article PubMed Google Scholar 113. Okokon J.E., Obot A.U., Mohanakrishnan D., Mittal G., Sahal D. Antimalarial and antiplasmodial activity of leaf extract of Alchornea laxiflora. J. Herbs Spices Med. Plants. 2017;23:128141. doi: 10.108010496475.2016.1275072. DOI Google Scholar 114. Zemicheal G., Mekonnen Y. Antiplasmodial activity of Vernonia adoensis aqueous, methanol and chloroform leaf extracts against chloroquine sensitive strain of Plasmodium berghei in vivo in mice. BMC Res. Notes. 2018;11:736. doi: 10.1186s13104-018-3835-2. DOI PMC free article PubMed Google Scholar 115. Adia M.M., Emami S.N., Byamukama R., Faye I., Borg-Karlson A.K. Antiplasmodial activity and phytochemical analysis of extracts from selected Ugandan medicinal plants. J. Ethnopharmacol. 2016;186:1419. doi: 10.1016j.jep.2016.03.047. DOI PubMed Google Scholar 116. Karou S.D., Tchacondo T., Ouattara L., Anani K., Savadogo A., Agbonon A., Attaia M.B., de Souza C., Sakly M., Simpore J. Antimicrobial, antiplasmodial, haemolytic and antioxidant activities of crude extracts from three selected Togolese medicinal plants. Asian Pac. J. Trop. Dis. 2011;4:808813. doi: 10.1016S1995-7645(11)60199-5. DOI PubMed Google Scholar 117. Tona L., Cimanga R.K., Mesia K., Musuamba C.T., de Bruyne T., Apers S., Hernans N., van Miert S., Pieters L., Totté J., et al. In vitro antiplasmodial activity of extracts and fractions from seven medicinal plants used in the Democratic Republic of Congo. J. Ethnopharmacol. 2004;93:2732. doi: 10.1016j.jep.2004.02.022. DOI PubMed Google Scholar 118. Koffi J.A., Silué K.D., Tano D.K., Dable T.M., Yavo W. Evaluation of antiplasmodial activity of extracts from endemic medicinal plants used to treat malaria in Côte d'Ivoire. BioImpacts BI. 2020;10:151. doi: 10.34172bi.2020.19. DOI PMC free article PubMed Google Scholar 119. Nyaba Z.N., Murambiwa P., Opoku A.R., Mukaratirwa S., Shode F.O., Simelane M.B. Isolation, characterization, and biological evaluation of a potent anti-malarial drimane sesquiterpene from Warburgia salutaris stem bark. Malar. J. 2018;17:296. doi: 10.1186s12936-018-2439-6. DOI PMC free article PubMed Google Scholar 120. Okaiyeto K., Okoh A.I. In vitro assessment of antiplasmodial and antitrypanosomal activities of chloroform, ethyl acetate and ethanol leaf extracts of Oedera genistifolia. Appl. Sci. 2020;10:6987. doi: 10.3390app10196987. DOI Google Scholar 121. Sales M.D.C., Costa H.B., Fernandes P.M.B., Ventura J.A., Meira D.D. Antifungal activity of plant extracts with potential to control plant pathogens in pineapple. Asian Pac. J. Trop. Biomed. 2016;6:2631. doi: 10.1016j.apjtb.2015.09.026. DOI Google Scholar 122. Samie A., Mashau F. Antifungal activities of fifteen Southern African medicinal plants against five Fusarium species. J. Med. Plants Res. 2013;7:18391848. Google Scholar 123. Lall N., Kishore N. Are plants used for skin care in South Africa fully explored? J. Ethnopharmacol. 2014;153:6184. doi: 10.1016j.jep.2014.02.021. DOI PubMed Google Scholar 124. Lewu F.B., Afolayan A.J. Ethnomedicine in South Africa: The role of weedy species. Afr. J. Biotechnol. 2009;8:929934. Google Scholar 125. Arif T., Bhosale J.D., Kumar N., Mandal T.K., Bendre R.S., Lavekar G.S., Dabur R. Natural products-antifungal agents derived from plants. J. Asian Nat. Prod. Res. 2009;11:621638. doi: 10.108010286020902942350. DOI PubMed Google Scholar 126. Mahlo S.M., McGaw L.J., Eloff J.N. Antifungal activity of leaf extracts from South African trees against plant pathogens. Crop. Prot. 2010;29:15291533. doi: 10.1016j.cropro.2010.08.015. DOI Google Scholar 127. Aboukhalaf A., El Amraoui B., Tabatou M., da Rocha J.M.F., Belahsen R. Screening of the antimicrobial activity of some extracts of edible wild plants in Morocco. Funct. Food Health Dis. 2020;10:265273. doi: 10.31989ffhd.v10i6.718. DOI Google Scholar 128. Bazie S., Ayalew A., Woldetsadik K. Antifungal activity of some plant extracts against (Colletotrichum musae) the cause of postharvest banana anthracnose. J. Plant Pathol. Microbiol. 2014;5:14. Google Scholar 129. Donkor A.M., Donkor M.N., Kuubabongnaa N. Evaluation of anti-infective potencies of formulated aloin A ointment and aloin A isolated from Aloe barbadensis Miller. BMC Chem. 2020;14:18. doi: 10.1186s13065-020-0659-7. DOI PMC free article PubMed Google Scholar 130. Hlima H.B., Bohli T., Kraiem M., Ouederni A., Mellouli L., Michaud P., Abdelkafi S., Smaoui S. Combined effect of Spirulina platensis and Punica granatum peel extracts: Phytochemical content and antiphytophatogenic activity. Appl. Sci. 2019;9:5475. doi: 10.3390app9245475. DOI Google Scholar 131. Kilonzo M., Ndakidemi P.A., Chacha M. In vitro antifungal and cytotoxicity activities of selected Tanzanian medicinal plants. Trop. J. Pharm. Res. 2016;15:21212130. doi: 10.4314tjpr.v15i10.10. DOI Google Scholar 132. Kipanga P.N., Liu M., Panda S.K., Mai A.H., Veryser C., van Puyvelde L., de Borggraeve W.M., van Dijck P., Matasyoh J., Luyten W. Biofilm inhibiting properties of compounds from the leaves of Warburgia ugandensis Sprague subsp ugandensis against Candida and staphylococcal biofilms. J. Ethnopharmacol. 2020;248:112352. doi: 10.1016j.jep.2019.112352. DOI PubMed Google Scholar 133. Nwogwugwu J.O., Batcho A.A. Antifungal potentials of some botanicals on Sclerotium rolfsii schum., the causal pathogen of damping-off of Gmelina arborea Roxb. in Ibadan, Southwestern Nigeria. J. Plant. Dis. Prot. 2019;126:543551. doi: 10.1007s41348-019-00267-z. DOI Google Scholar 134. Ourabah A., Atmani-Kilani D., Debbache-Benaida N., Kolesova O., Azib L., Yous F., Benloukil M., Botta B., Atmani D., Simonetti G. Anti-Candida albicans biofilm activity of extracts from two selected indigenous Algerian plants: Clematis flammula and Fraxinus angustifolia. J. Herb. Med. 2020;20:100319. doi: 10.1016j.hermed.2019.100319. DOI Google Scholar 135. Rezgui M., Majdoub N., Mabrouk B., Baldisserotto A., Bino A., Kaab L.B., Manfredini S. Antioxidant and antifungal activities of marrubiin, extracts and essential oil from Marrubium vulgare L. against pathogenic dermatophyte strains. J. Mycol. Med. 2020:100927. doi: 10.1016j.mycmed.2020.100927. DOI PubMed Google Scholar 136. Salhi N., Mohammed Saghir S.A., Terzi V., Brahmi I., Ghedairi N., Bissati S. Antifungal activity of aqueous extracts of some dominant Algerian medicinal plants. BioMed Res. Int. 2017 doi: 10.115520177526291. DOI PMC free article PubMed Google Scholar 137. Suurbaar J., Mosobil R., Donkor A.M. Antibacterial and antifungal activities and phytochemical profile of leaf extract from different extractants of Ricinus communis against selected pathogens. BMC Res. Notes. 2017;10:660. doi: 10.1186s13104-017-3001-2. DOI PMC free article PubMed Google Scholar 138. Umaru I.J., Badruddin F.A., Ha U. Antifungal potential of some medicinal plants on selected pathogenic fungi. MOJ Proteom. Bioinform. 2018;7:271276. doi: 10.15406mojpb.2018.07.00246. DOI Google Scholar 139. Maema L.P., Potgieter M., Masevhe N.A., Samie A. Antimicrobial activity of selected plants against fungal species isolated from South African AIDS patients and their antigonococcal activity. J. Complement. Integr. Med. 2020;17 doi: 10.1515jcim-2019-0087. DOI PubMed Google Scholar 140. Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2015;65:529. doi: 10.3322caac.21254. DOI PubMed Google Scholar 141. Bollyky T.J., Andridge C. Cancer Prevention and Treatment in Developing Countries: Recommendations for Action Cancer Control. Global Health Dynamics; Suffolk, UK: 2015. Google Scholar 142. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394424. doi: 10.3322caac.21492. DOI PubMed Google Scholar 143. Mans D.R., da Rocha A.B., Schwartsmann G. Anti-cancer drug discovery and development in Brazil: Targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncolgist. 2000;5:185198. doi: 10.1634theoncologist.5-3-185. DOI PubMed Google Scholar 144. Newman D.J. Natural products as leads to potential drugs: An old process or the new hope for drug discovery? J. Med. Chem. 2008;51:25892599. doi: 10.1021jm0704090. DOI PubMed Google Scholar 145. Shamim G., Ranjan S.K., Pandey D.M., Sharma K.K., Ramani R. Lac dye as a potential anti-neoplastic agent. J. Cancer Res. Ther. 2016;12:1033. doi: 10.41030973-1482.155975. DOI PubMed Google Scholar 146. Tiwari R., Latheef S.K., Ahmed I., Iqbal H., Bule M.H., Dhama K., Samad H.A., Karthik K., Alagawany M., El-Hack M.E., et al. Herbal immunomodulators-a remedial panacea for designing and developing effective drugs and medicines: Current scenario and prospects. Curr. Drug Metab. 2018;19:264301. doi: 10.21741389200219666180129125436. DOI PubMed Google Scholar 147. Fridlender M., Kapulnik Y., Koltai H. Plant derived substances with anti-cancer activity: From folklore to practice. Front. Plant Sci. 2015;6:799. doi: 10.3389fpls.2015.00799. DOI PMC free article PubMed Google Scholar 148. Catalano E., Maestri P., Cochis A., Azzimonti B., Varoni E., Fraschini F., Rimondini L., Megna S., Iriti M. Cytotoxic activity of plant extract on cancer cells. Ital. J. Anat. Embryol. 2014;118:50. Google Scholar 149. Kumar R., Sharma M. Herbal nanomedicine interactions to enhance pharmacokinetics, pharmaco-dynamics, and therapeutic index for better bioavailability and biocompatibility of herbal formulations. J. Mater. NanoSci. 2018;5:3558. Google Scholar 150. Kumar G., Gupta R., Sharan S., Roy P., Pandey D.M. Anticancer activity of plant leaves extract collected from a tribal region of India. 3 Biotech. 2019;9:399. doi: 10.1007s13205-019-1927-x. DOI PMC free article PubMed Google Scholar 151. Kawashima K., Misawa H., Moriwaki Y. Ubiquitous expression of acetylcholine and its biological functions in life forms without nervous systems. Life Sci. 2007;80:22062209. doi: 10.1016j.lfs.2007.01.059. DOI PubMed Google Scholar 152. Balasubramanian K., Padma P.R. Anticancer activity of Zea mays leaf extracts on oxidative stress-induced Hep2 Cells. J. Acupunct. Meridian Stud. 2013;6:149158. doi: 10.1016j.jams.2013.01.015. DOI PubMed Google Scholar 153. Bauml J.M., Chokshi S., Schapira M.M. Do attitudes and beliefs regarding complementary and alternative medicine impact its use among patients with cancer? A cross-sectional survey. Cancer. 2015;121:24312438. doi: 10.1002cncr.29173. DOI PMC free article PubMed Google Scholar 154. Kondhare D., Lade H. Phytochemical profile, aldose reductase inhibitory, and antioxidant activities of Indian traditional medicinal Coccinia grandis (L.) fruit extract. 3 Biotech. 2017;7:378. doi: 10.1007s13205-017-1013-1. DOI PMC free article PubMed Google Scholar 155. Hawk M.A., McCallister C., Schafer Z.T. Antioxidant activity during tumour progression: A necessity for the survival of cancer cells? Cancers. 2016;8:92. doi: 10.3390cancers8100092. DOI PMC free article PubMed Google Scholar 156. Lobo V., Patil A., Phatak A., Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn. Rev. 2010;4:118126. doi: 10.41030973-7847.70902. DOI PMC free article PubMed Google Scholar 157. Kaurinovic B., Vastag D. Antioxidants. IntechOpen; London, UK: 2019. Flavonoids and phenolic acids as potential natural antioxidants. Google Scholar 158. Adebiyi O.E., Olayemi F.O., Ning-Hua T., Guang-Zhi Z. In vitro antioxidant activity, total phenolic and flavonoid contents of ethanol extract of stem and leaf of Grewia carpinifolia. Beni-Seuf Univ. J. Basic Appl. Sci. 2017;6:1014. doi: 10.1016j.bjbas.2016.12.003. DOI Google Scholar 159. Rahman M.A., Bjada S., Akhtar J. Evaluation of anticancer activity of Cordia dichotoma leaves against a human prostate carcinoma cell line, PC3. J. Tradit. Complement. Med. 2016;7:315321. doi: 10.1016j.jtcme.2016.11.002. DOI PMC free article PubMed Google Scholar 160. Efferth T., Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug Targets. 2011;12:122132. doi: 10.2174138945011793591626. DOI PubMed Google Scholar 161. Wöll S., Kim S., Efferth T. Animal plant warfare and secondary metabolite evolution. Nat. Prod. Bioprospect. 2013;3:17. doi: 10.1007s13659-013-0004-0. DOI Google Scholar 162. Bouyahya A., Bakri Y., Et-Touys A., Assemian I.C.C., Abrini J., Dakka N. In vitro antiproliferative activity of selected medicinal plants from the North-West of Morocco on several cancer cell lines. Eur. J. Integr. Med. 2018;18:2329. doi: 10.1016j.eujim.2018.01.001. DOI Google Scholar 163. Alabi M.A., Muthusamy A., Kabekkodu S.P., Adebawo O.O., Satyamoorthy K. Anticancer properties of recipes derived from Nigeria and African medicinal plants on breast cancer cells in vitro. Sci. Afr. 2020;8:e00446. doi: 10.1016j.sciaf.2020.e00446. DOI Google Scholar 164. Tonisi S., Okaiyeto K., Mabinya L.V., Okoh A.I. Evaluation of bioactive compounds, free radical scavenging, and anticancer activities of bulb extracts of Boophone disticha from Eastern Cape Province, South Africa. Saudi J. Biol. Sci. 2020;27:35593569. doi: 10.1016j.sjbs.2020.07.028. DOI PMC free article PubMed Google Scholar 165. Onyancha J.M., Gikonyo N.K., Wachira S.W., Mwitari P.G., Gicheru M.M. Anticancer activities and safety evaluation of selected Kenyan plant extracts against breast cancer cell lines. J. Pharmacogn. Phytother. 2018;10:2126. doi: 10.5897JPP2017.0465. DOI Google Scholar 166. Akindele A.J., Wani Z., Mahajan G., Sharma S., Aigbe F.R., Satti N., Adeyemi O.O., Mondhe D.M. Anticancer activity of Aristolochia ringens Vahl. (Aristolochiaceae) J. Tradit. Complement. Med. 2015;5:3541. doi: 10.1016j.jtcme.2014.05.001. DOI PMC free article PubMed Google Scholar 167. Saeed M.E., Abdelgadir H., Sugimoto Y., Khalid H.E., Efferth T. Cytotoxicity of 35 medicinal plants from Sudan towards sensitive and multidrug-resistant cancer cells. J. Ethnopharmacol. 2015;174:644658. doi: 10.1016j.jep.2015.07.005. DOI PubMed Google Scholar 168. Mongalo N.I., Soyingbe O.S., Makhafola T.J. Antimicrobial, cytotoxicity, anticancer and antioxidant activities of Jatropha zeyheri Sond. roots (Euphorbiaceae) Asian Pac. J. Trop. Biomed. 2019;9:307. doi: 10.41032221-1691.261822. DOI Google Scholar 169. Najjaa H., Abdelkarim B.A., Doria E., Boubakri A., Trabelsi N., Falleh H., Tlili H., Neffati M. Phenolic composition of some Tunisian medicinal plants associated with anti-proliferative effect on human breast cancer MCF-7 cells. EuroBiotech. J. 2020;4:104112. doi: 10.2478ebtj-2020-0012. DOI Google Scholar 170. Elnour M.A., Penech F., Mesaik M. Four selected Sudanese medicinal plants induce anticancer and cytotoxic effects in prostate cancer cell line. Clin. Med. Biochem. 2017;3:24712663. Google Scholar 171. Tlili H., Hanen N., Ben A.A., Neffati M., Boubakri A., Buonocore D., Dossena M., Verri M., Doria E. Biochemical profile and in vitro biological activities of extracts from seven folk medicinal plants growing wild in southern Tunisia. PLoS ONE. 2019;14:e0213049. doi: 10.1371journal.pone.0213049. DOI PMC free article PubMed Google Scholar 172. Twilley D., Langhansová L., Palaniswamy D., Lall N. Evaluation of traditionally used medicinal plants for anticancer, antioxidant, anti-inflammatory and anti-viral (HPV-1) activity. S. Afr. J. Bot. 2017;112:494500. doi: 10.1016j.sajb.2017.05.021. DOI Google Scholar 173. Taylor P.G., Cesari I.M., Arsenak M., Ballen D., Abad M.J., Fernández A., Milano B., Ruiz M.C., Williams B., Michelangeli F. Evaluation of Venezuelan medicinal plant extracts for antitumor and antiprotease activities. Pharm. Biol. 2006;44:349362. doi: 10.108013880200600748119. DOI Google Scholar 174. Acheampong F., Larbie C., Appiah-Opong R., Arthur F.K., Tuffour I. In vitro antioxidant and anticancer properties of hydroethanolic extracts and fractions of Ageratum conyzoides. Eur. J. Med. Plants. 2015;7:205214. doi: 10.9734EJMP201517088. DOI Google Scholar 175. Tamokou de Dieu Chouna J., Fischer-Fodor J.R., Chereches G., Barbos O., Damian G., Benedec D., Duma M., Efouet A.P.N., Wabo H.K., Kuiate J.R. Anticancer and antimicrobial activities of some antioxidant-rich Cameroonian medicinal plants. PLoS ONE. 2013;8:e55880. doi: 10.1371journal.pone.0055880. DOI PMC free article PubMed Google Scholar 176. Tuasha N., Seifu D., Gadisa E., Petros B., Oredsson S. Cytotoxicity of selected Ethiopian medicinal plants used in traditional breast cancer treatment against breast-derived cell lines. J. Med. Plants Res. 2019;13:188198. doi: 10.1186s12906-020-03154-5. DOI PMC free article PubMed Google Scholar 177. Mukanganyama S., Dumbura S.C., Mampuru L. Anti-proliferative effects of plant extracts from Zimbabwean medicinal plants against human leukaemic cell lines. Afr. J. Plant. Sci. Biotechnol. 2012;6:1420. Google Scholar 178. Ndhlala A.R., Amoo S.O., Ncube B., Moyo M., Nair J.J., van Staden J. Antibacterial, antifungal, and antiviral activities of african medicinal plants. In: Kuete V., editor. Medicinal Plant Research in Africa. Elsevier; Oxford, UK: 2013. pp. 621659. Google Scholar 179. Wagner E.K., Hewlett M.J. Basic Virology. Blackwell Science; Oxford, UK: 1999. Google Scholar 180. de Clercq E., Field H.J. Antiviral prodrugsthe development of successful prodrug strategies for antiviral chemotherapy. Br. J. Pharmacol. 2006;10:111. doi: 10.1038sj.bjp.0706446. DOI PMC free article PubMed Google Scholar 181. Jaime M.F.V., Redko F., Muschietti L.V., Campos R.H., Martino V.S., Cavallaro L.V. In vitro antiviral activity of plant extracts from Asteraceae medicinal plants. Virol. J. 2013;10:245. doi: 10.11861743-422X-10-245. DOI PMC free article PubMed Google Scholar 182. Henkin J.M., Sydara K., Xayvue M., Souliya O., Kinghorn A.D., Burdette J.E., Chen W.L., Elkington B.G., Soejarto D.D. Revisiting the linkage between ethnomedical use and development of new medicines: A novel plant collection strategy towards the discovery of anticancer agents. J. Med. Plant Res. 2017;11:621. doi: 10.5897jmpr2017.6485. DOI PMC free article PubMed Google Scholar 183. Mehrbod P., Abdalla M.A., Njoya E.M., Ahmed A.S., Fotouhi F., Farahmand B., Gado D.A., Tabatabaian M., Fasanmi O.G., Eloff J.N., et al. South African medicinal plant extracts active against influenza A virus. BMC Complement. Altern. Med. 2018;18:112. doi: 10.1186s12906-018-2184-y. DOI PMC free article PubMed Google Scholar 184. Todorov D., Shishkova K., Dragolova D., Hinkov A., Kapchina-Toteva V., Shishkov S. Antiviral activity of medicinal plant Nepeta nuda. Biotechnol. Biotechnol. Equip. 2015;29(Suppl. 1):S39S43. doi: 10.108013102818.2015.1047215. DOI Google Scholar 185. Ogbole O.O., Akinleye T.E., Segun P.A., Faleye T.C., Adeniji A.J. In vitro antiviral activity of twenty-seven medicinal plant extracts from Southwest Nigeria against three serotypes of echoviruses. Virol. J. 2018;15:110. doi: 10.1186s12985-018-1022-7. DOI PMC free article PubMed Google Scholar 186. Galani B.R., Sahuc M.E., Njayou F.N., Deloison G., Mkounga P., Feudjou W.F., Brodin P., Rouillé Y., Nkengfack A.E., Moundipa P.F., et al. Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. Front. Microbiol. 2015;6:488. doi: 10.3389fmicb.2015.00488. DOI PMC free article PubMed Google Scholar 187. Mthethwa N.S., Oyedeji B.A., Obi L.C., Aiyegoro O.A. Anti-staphylococcal, anti-HIV and cytotoxicity studies of four South African medicinal plants and isolation of bioactive compounds from Cassine transvaalensis (Burtt. Davy) codd. BMC Complement. Altern. Med. 2014;14:512. doi: 10.11861472-6882-14-512. DOI PMC free article PubMed Google Scholar 188. Radol A.O., Kiptoo M., Makokha A.O., Tolo F.M. Determination of antioxidant value and chemical groups in selected medicinal plants used for conditions associated with herpes simplex and herpes Zoster Infections in Kakamega County, Kenya. Asian J. Biol. 2019;8:110. doi: 10.9734ajob2019v8i430068. DOI Google Scholar 189. Tolo F.M., Rukunga G.M., Muli F.W., Njagi E.N., Njue W., Kumon K., Mungai G.M., Muthaura C.N., Muli J.M., Keter L.K., et al. Anti-viral activity of the extracts of a Kenyan medicinal plant Carissa edulis against herpes simplex virus. J. Ethnopharmacol. 2006;104:9299. doi: 10.1016j.jep.2005.08.053. DOI PubMed Google Scholar 190. Nwodo U.U., Ngene A.A., Iroegbu C.U., Onyedikachi O.A.L., Chigor V.N., Okoh A.I. In vivo evaluation of the antiviral activity of Cajanus cajan on measles virus. Arch. Virol. 2011;156:15511557. doi: 10.1007s00705-011-1032-x. DOI PMC free article PubMed Google Scholar 191. Ojo O.O., Oluyege J.O., Famurewa O. Antiviral properties of two Nigerian plants. Afr. J. Plant Sci. 2009;3:157159. Google Scholar 192. Bessong P.O., Obi C.L., Andre ola M.L., Rojas L.B., Pouyse gu L., Igumbor E., Meyer J.M., Quideau S., Litvak S. Evaluation of selected South African medicinal plants for inhibitory properties against immunodeficiency virus type 1 reverse transcriptase and integrase. J. Ethnopharmacol. 2005;99:8391. doi: 10.1016j.jep.2005.01.056. DOI PubMed Google Scholar 193. Klos M., van de Venter M., Milne P.J., Traore H.N., Meyer D., Oosthuizen V. In vitro anti-HIV activity of five selected South African medicinal plant extracts. J. Ethnopharmacol. 2009;124:182188. doi: 10.1016j.jep.2009.04.043. DOI PubMed Google Scholar 194. Sunday O.A., Munir A.B., Akeeb O.O., Bolanle A.A., Badaru S.O. Antiviral effect of Hibiscus sabdariffa and Celosia argentea on measles virus. Afr. J. Microbiol. Res. 2010;4:293296. Google Scholar Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article. Data Availability Statement Not applicable. Articles from International Journal of Environmental Research and Public Health are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8199769/",
    "length": 97318,
    "type": "html",
    "id": 3001,
    "source": "MedicinalPlants"
  },
  {
    "title": "PHARMEL: African Medicinal Plants Database PDF Wellness Medical",
    "text": "ABSTMCT :The ethnobotmic database PHARMEL on African medicinalplants This data bank was created in 1986with the help of the \"Agencede Coopération Culturelle et Technique\" (ACCT), an international Agency covering 40 french speaking countries and working for the development of cultural and technical relationships between them. PHARMEL (PAR forpharmacopoea, ME formedicinalplant and L for traditional) hasthe two main following aims : i) to gather together the data concerning the usesof medicinal plants in folk Medicine (mainlyin Mica)and synthesis this information. ii)topromote a networkwithlocalornationaldatabankshavingfacilities to exchange their data between them and so increase the total volume of treated and thus available data. In order to standardize the collection d captureof the complex data included in the traditional prescriptions, a booklet was published in 1989 by the ACCT with al1 the codificationconcerningthecharacteristics ofused plants, the different methods of drug preparation and administration and finally therapeutic indications (disease type or physiological effects). Futhermore, a user friendly software for data capture has been developed.Now, PHARMEL contains the data issuedfrom the traditional prescriptions. This is included in books or papers published by ACCT and other authors concerning ethnobotanical knowledge of the 21 following countries : Benin, Central Africa Rep., Comores, Congo, Gabon, Mali, Maurice, Niger, Seychelles, Togo, Canaries Islands, Burkina Faso,IvoryCoast,Senegal,Burundi,Rwanda,Zaïre,Kenya, Zimbabwe, Madagascar and Dominique. La valorisation des plantes médicinales est me préoccupation majeure de nombreux chercheurs et responsables des pays du Sud car une grande partie de la population recourt largement -A la mdecinetraditionnelle. Souvent, les gens n'ont pas d'autre choix compte t a u du prix ledes mtklicaments ou de I'impossibilith de 11sut.erun mcidecin. De plus, dans le cas de certaines maladies pour l e s q u e k la mticiee moderne ne propose pas de th6rapeertique efficace il'heure actuelle bar ex. les hkatites virales), le recours A des recettes traditionnelles est trhs randu et pratiquk aussi par les clients habituelsde la mkcine moderne. Patte (1989) et Adjmohoun (1989) ont montrk le r6le des udes ethnobotmiques systématiques pour l'approche d'me politique rationnelle de valorisation de la phamacopk traditionnelle. La base de d o m k s L-P est le fruit du travail d'un groupe de chercheurs prbccupés par la valorisation des pharmacopk et m6decine traditionnelles. Depuis son origine, les forces de cshksion du goupe ont l'utilisation d'une langue c o m m e , le franqais, et une focalisation g6ographique concentréeessentiellement sur 1'Afrique tropicale et malgache. De 1970 A 1986, les premGres r6alisations ont abouti, sous la direction du Prof. Adjmohoun, B l'acceunulation de donn6e.s via l'organisation et la publication d'mques ethobhques dms 12 pays surtout zfricains. Depuis 1986, les piorit du goupe ont kvoluk et l'accent a kt6 mis sur la circulation la plus large possible de l'Somation phgrtolh6rapedque traditionnelle entre les chercheurs et entre les pays. Cet objectif a é concrsk, avec le soutien de l'Agence de Coopération Culturelle et Technique (ACCT), par l'tion d'un bulletin de liaison ' - cine traditionnelle et PhamacopS' et surtout par la mise au point d'un de banques de domkes permettant une meilleureconcertation des chercheurs. Le premier objectif de cette banque consiste i rassembler les domées concernantl'utilisation des plantesm6dicinales en mkcine traditionnelle (surtout africaine) pour en faire une sgmthkse afin de mieuxrondre, terme, aux besoins locaux prioritaires de santé. Ensuite, la conception même de PHARMEL est prévue pour promouvoir unréseaudebanquesdedonnéeslocalespouvantéchanger leurs données entre elleset accroître ainsi le volume global des données gérées. La base même de la valorisation des recettes traditionnelles est l'analyse des convergences d'emploi à un niveau le plus large possible afin de repérer les recettes similaires dans les différents pays et par conséquent celles qui sont susceptiblesd'être les plus fiables. Plus le pays est petit, plus le décloisonnement du chercheurest nécessaire pour lui permettre de relativiser les résultatsde ses enquêtes avec les données issues despays voisins utilisant lesmêmes plantes. Système de codification PHARMEL propose une méthodologie standardpour la collecte complae et homogèned'informationsquiconcernentl'utilisationtraditionnelledes plantes médicinales (Adjanohounet al. 1989). Lesdiverses rubriques codifiéessont au nombrede 54 et ont été rassemblées en trois groupes correspondant chacunà une fichede saisie : - la fiche enquête qui concerne les données récoltées au moment d'une enquête ou qui résultent directement de celle-ci ; - la fiche nomenclaturale qui traite de la mise au point des noms latins de plantes admis dans les travaux récents, de leurs synonymes, du système de référence pour désignerlesfamilles et del'extensiongéographiquedes espèces ; - la fiche bibliographique qui permet l'encodage des données définissant,pour chaque plante médicinale, les références des publications et les aspects qui y sont traités. Le système de codification permet d'utiliser les données accumulées dans lespublicationsethnobotaniquesmais un deuxièmerôle apparaît qui est d'améliorer la récoltedesdonnéesdanslesenquêtes futures en attirant l'attention sur les aspects quantitatifs des modes de préparation et d'administration (posologie) qui restent souvent très vagues dans beaucoup de recettes récoltéesjusqu'à présent. Logiciel de saisie des données Il a été élaboré pour faciliter la mise en mémoire des données récoltées selon la méthodologiestandarddécriteci-dessus. Le logiciel proposé est convivial et permet la mise a jour automatique des index correspondant aux nombreuses rubriques envisagées. Il fonctionne sur TBM-PC ou sur du matériel compatible muni d'un disque dur d'au moins 20 Mo de capacité. En 3 85 plus de la saisie, le logiciel prhvoit la correction des fiches, le transfert des fichiers, la recherche d'une infornation et l'examen des fiches B l'krm. Le logiciel de saisie P m L peut Ztre obtenu sur demmde adressk auprhs de I'ACCT ou directement. i l'auteur ; il est livré avec me notice explicative (Adjanohun et al. 1992) et est destiné h faciliter la Gche des nombreuses pipes codrontkes avec le traitement de données ehobatmiques. La difision de ce logkiel vise A favoriser la wnstit.ution de banques Iseales, irmdentesentre elles, mais pouvant nmoins changer leurs donns car ellesutilisent les m6mes systkmes de codification des donnks et le m6me logiciel de saisie. Ainsi un véritable seau a pu are m i s en place o i les divers partenaires conjuguent leurs efforts a we d'accrotre le plus vite possible le volume global des dombs gbrbs. Les inkmnations stocls dans la banque ont d'abord téextraites des enqu6tes nobotaniques orgmisbs par I'ACCT. Quelques 21 autres travaux ont é analysés et au total, les 21 pays suivants sont concem6s : B h i n (Adjanohoun et al., 1989), Comores (Adjanohoun et al., 1982), Congo (Adjanohon et al., 19881,Dominique(Adjanohoun et al., 1985) (Adjmohoun et a2., 1984), Mali (Adjanohoun et a2.? 1980), (Adjmohoun et al., 19831, Niger (Adjanohoun et al., 1981), 19.C.A. ( k é Assi et d o1980), Seychelles (Adjanohoun et a2., 1983), Togo (Adjanohoun , et ale,1986), Iles Canaries (Darias et al., 1990), Burkina Faso (Femmdez, 1981, 19821 et 1982b), C6te d'Ivoire (Adjanohoun et k é k s i , 1979 ; fié k s i , 1983 ; Al Assi, 1990), S h p l o u s s e t ,1989), B u m (IBaerts et L e h m , 1989), Rwanda (Hdcizamungu et. Wéri, 1988 ; Van Puyelde et al., 1977), Zaïre (Bokdam et Drsogers, 1975 ; Breyne et al., 1978 ; Delaude et al., 1971 ; Dhetchuvi et Lejoly, 1990 ; Lubinî, 1990 ; hdkndmgo et Bandole, 1988 ; ?vhndango et al., 1990 ; Nyakabwa et Dibaluh, 1990), Kenya (Lindsay et Hqper, 1978),Zimbabwe (Gelfmd et al., 1985) et Bhadagascar (Boitau, 1986). Au total, 12091 recettes ont Ce introduites faisant intervenir 2734 espkes de plantes diff6rentes en citant pour chacune d'elles le pays, l'organe de la plante utilise, le mode de praration, le mode d'administrationet la maladie soi ou l'effet physiologique obtenu. Le volume des donnks gérs est encore relativement faible au w des centaines .de publications contenant des recettes de phytothérapie et non encore informatis6es jusqu'i présent. De plus, comme le montre le tableau 1, certains pays ont fait l'objet d'enques plus comples ce qui dsuilibre l'échantillon étudié. Néanmoins,desinformations intéressantes quoique partiellespeuventdéjà être fournies en interrogeantlabanque ; elles concernent surtout les convergencesd'emploithérapeutiques.Ainsi Senna occidentalis (syn. : Cmsia occidentalis) est utilisé pour soigner les ictères dans les 7 pays suivants : Niger (1 recette), Bénin (9), Togo (l), Burkina Faso (l), Côte d'Ivoire (3), Congo (2), Dominique (2), soit au total 19 recettes. L'interrogation de PHARMEL permetaussi, dès à prkent, d'obtenir l'inventaire des plantes pouvant être utilisées pour traiter une maladie ou symptôme déterminé. Avantages du réseau - Éviter les doubles emplois Le système prévoit la distribution aux membres du réseau d'éléments de base communs. Il n'est pas nécessaire que chaque chercheur constitue lui- même la liste des espèces de plantes médicinales avec leurs caractéristiques phytogéographiques ; celles-ci ont été analysées par un seul groupe qui en a assuré la difision. De même, les analyses de toxicité et d'innocuité si nécessaires avant la diffusion d'une recette peuvent aussifaire l'objet de mise au point collectiveet concertée sans obligation de refaire au niveau de chaque chercheur toute la bibliographie pour chaque plante médicinale intervenant dans les recettes. - Miser sur la complémentarité Ainsichaquechercheur peut concentrersesefforts sur desactivités originales : engranger les recettes médicinales traditionnelles nouvelles de sa régjon ou de son pays et les interpréter à la lueur d'un système général de donnéesréférentielles au niveauafricain. Il peutaussicontribuer,s'il le souhaite, à enrichir le volumeglobaldesinformationscirculantesen permettant aux autres chercheurs d'utiliser ses propres données. Tableau 1 : Statistiques globales des nombres d'espkces mdicinales, des nombres de recettes et des nombres d'indiations. eis dans les travaux inclus d m s la banque PL -. Pays wbre de plantes Nbre de recettes re d'indications Canaries 23 23 43 Mali 107 176 330 Niger 159 277 439 Bn 530 1976 3468 Togo 410 972 1663 Burkina Faso 134 347 554 C6te d'Ivoire 311 533 745 Sénbgl 51 71 1 06 RCA 341 209 46 1 Gabon 131 149 222 Congo 288 647 973 Bum 2717 510 5073 Rwanda 177 177 460 Zaïre 29 1 49 1 754 KaP 174 26 1 3 16 Zimbabwe 1320 423 1670 mudee 106 148 259 Seyc11elles 77 91 13 1 Comores 202 123 305 Madagascar 515 75 1 1348 Dominique 169 42 1 620 TOT 2734 12091 19940 ADJANOHOUNE., 1989, La voie desenquêtes ethnobotaniques pour les pharmacopées africaines, Bull. hféd. Trad. Pharm. 3( l), pp. 47-5 1. ADJANOHOUN E., ABELA., AK.E ASSI L.,BROWND.,CHETTY K.S., CHONG-SENG L., EYMÉ FRIEDMAN J., GASSITA F., J.N., GOUDOTÉ E.N.,GOVINDEN P., KEITAA.,KOUDOGBOB.,LAI- . L A M G.,LANDREAUD.,LIONNETG.,SOOPRAMANIENA., 1983, Contribution aux études ethnobotaniques et jloristiques aux Seychelles, Paris : ACCT, 170 p. ADJANOHOUNE., ADJAKTDJE V., AHYI M.R.A., AKE ASSI L., AKOEGNTNOU A., D'ALMEIDA APOVO J., F., BOUKEF K., CHADARE M., CUSSET G., DRAMANE K., EYME J., GASSITA J.-N., GBAGUIDI N., GOUDOTE E., GUINKO S., HOUNGNON P., ,ISSA LO, 'KEITA A., KINIFFO H.V., KONE-BAMBA D., MUSAMPA NSEYYA A., SAADOU M., SODOGANDJI, Th., DE SOUZA S., TCHABI A., ZINSOUDOSSA C., ZOHOUN Th., 1989, Contribution aux études ethnobotaniques etjloristiques au Bénin, Paris : ACCT, 895 p. ADJANOHOUNE., AHYI A., AKE ASSI L., BANIAKINAJ.,CHlBON P., CUSSETG.,DOULOUV.,ENZANZAA., EYMÉ J.,GOUDOTEE., 'KEITA A., MBEMBA C., MOLLET, J., MOUTSAMBOTE J.-M., MPATI J.B., SITA P., 1988, Contribution aux études ethnobotaniques et Jloristiques au Congo, Paris : ACCT, 605 p. ADJANOHOUNE., AHYI A.M.R., AKE ASSI L.,DAN DICKO L., DAOUDA H., DELMAS M., DE SOUZA S., GARJ3A M., G T J \" 0 S., KAYONGA A.,N'GLOD., RAYNAL, J.-L.,SAADOU M., 1981, Contribution aux études ethnobotaniques etfloristiques au Niger, Paris :-ACCT, 250 p. ADJANOHOUN E., AHYI M.R.A., AKE ASSI L., AKPAGANA K., CHlBON P., EL-ADJI,A.,EYMÉ J., GARBAM.,GASSITAJ.-N.,GBEASSORM., GOUDOTE E., GUINKO S., HODOUTO K.-K., HOUNGNON P., KEITA A., KEOULA Y., KLUGA-OCLOO W.P., LO I., SIAMEVI K.M., TAFFAME K.K., 1986, Contribution aux études ethnobotaniques et jloristiques au Togo, Paris : A\"T, 671 p. ADJANOHOUNE., AKE ASSI L., AHMED A., EYMÉ J., GUINKO S., KAYONGAA.,KEITAA.,LEBRASM., 1982, Contribution aux études ethnobotaniques etjloristiques aux Comores, Paris : ACCT, 216 p. ADJANOHOUN E., AKE ASSIL.,CHIBON P., CUFFY S., DARNAULT J.-J., EDWARDS M.-J., ETIENNE C., EYMÉ J., GOUDOTE E., JEREMIE J., KEITA A., LONGUEFOSSE J.-L., PORTECOP J., SOOPRAMANlEN A., TROIAN J., 1985, Contribution aux études ethnobotaniques et Jloristiques à la Dominique (Commonwealth ofDominica), Paris : ACCT, 400 p. 389 ADJANOHOUN E., AKX ASSI L.,CHIBON P.,DE VECCHY H.,DUBOZE E., E J., GASSITA J.N., GOUDOTE E., GUINKO S., KEITA A., K6uE)OGBO B., LE B U S M., M OU I., I3wlE-MENG61vIEE., NG M.-G.?OELBME J.-B., POSS6 P.,SITA P., 1984, Contribzdion w x étr4des ethnobstaniques etJloristique.9au Gabon, Paris : ACCT, 294 p. ADJANOHBUNE., MCE ASSI L., E J., GASSITA J.N., GOUDOT8 E., GUÉHO J., II9 F.S.L., JACKANA D., IL4LACHAND S.K.K., KEITA A., MOTJDBGBO B., LMVDREAU D., OW_AD3_ALLY A.W., S O O P W A - M E N A., 1983, Contribution a m ktudes ethnobotaniques et goristiques Pr blfazrrice leshIauriceet Rodrigues), Paris : ACCT, 214 p. ADJANOHOUN E., ASSI L.,FLORET J.J., GUIMKO S., K O m M., _\"YI A.M.R., RAYNAL J., 1980, Csntribzation uux ktz4des ethmbotaniqzfes etgoristiques au Mali, Paris : ACCT, 249 p. _ADJANOHOUNE., ASSI E., 1979, Contribution au recensement des plantes wlkdicides de Côte d'lvoire. Centre National de Floristique, UniversitB d'Abidjan, 358 p. ADJANOHBUN E.,CUSSET G.,ISSA LO, KEITA A., LEBMS M., LEJOLY J., WAECJDER P.,1989, Banque de donnkes de nzkdecine traditionnelle et pharnzacope(\"EL). Notice pour la rkcolie et l'entrke des donnSes, Paris : ACCT, 124 p. ADJANOHBUN E.,CUSSE .,E W J., LE BRAS M., LEJBLY J., RICHELT., W C H T E RP., 1992, Banque de dsnrzdes de tnkdecine traditionnelle et gharmaeopke (pdt4NEL). Notice d'emploi du logiciel de saisie des donnkes. ACCT, Paris. AKE ASSI L., ABEX J.,GUINKO S., GIGTJET R., BANGAVOU X., 1980, ontribution azw kfzndes ethnobstaniques et goristiques en Rkpublique CentrnjFicaine,Paris : ACCT, 139 p. -\"E ASSI L., 1983, \"Qvdques vertus médicinales de C m i a sccidelztalis E. (Caesalpiniae6es) en basse Cate d'lvoire\", Bothalia, 14, pp. 617-628. MCE ASSI L., 1990, \"Utilisatiom de diverses espices de Ficus (Moraceae) dans la pharmacopée traditionmelle africaine en Ce d'Ivoire\", 12e Congks de l'AELTFAT,Mitt. Inst. Allg. Bof., Hmburg, 23, pp. 1039-1046. BAEWTS M., LE- J., 1989, Gudrissetfrs et plantes nzkdicinales de la rkgion des crtesZak4Vil au Burzmdj9Mus6e Roy. M . Centr. Temlren, Belgique ;h m . Se. Ecoa 18,214 p. BOITEAU P.,1986, Prbcjs de wmfi8rewkdicale nzalgache, ris : ACCT, 141 p. B O I C I \" J., DROOGERS A.F., 1975, \"ContributionA 1'6tude ethobotmique des Wagenia de Kisangani, Zaïre\", Mededelingen Landbsz4alhogeschsol Wageningen,75-19, pp. 1-74. BMYNE H., DELAUDE C., DELAUDE J., 1978, \"Plantes médicinales et ingrédients magiques du Grand Marehé de Kisangani (Zaïre)\", Eejezmin, nouv. sér., 9, pp. 1-7. DARIASV.,BRAVOL.,RABANALR.,ABDALLAH S., MARTIN-CONDE J.A.,HERNANDEZ-PEREZM.,1991,\"Espècesde la floredesIles Canaries employées dans les affections hépatiques\",Actes du ler Colloque Européen d'Ethnopharmacologie (Metz, 22-25 mars 1990), Paris : ORSTOM, pp. 164-165. DELAUDEC.,DELAUDE J., BREYNE H., 1971, \"Plantesmédicinaleset ingrédientsmagiques du GrandMarchédeKinshasa\", AjFicu-Tervuren, 17(4). DHETCHUVIM.-M.,LEJOLY J., 1990,\"Contribution à la connaissancedes plantesmédicinalesduNord-EstduZaïre\",12eCongrès de l'AETFAT, Mitt. Inst. Allg. Bot., Hamburg, 23, pp. 991-1006. FERNANDEZ C., 1981, Des plantes qui nous ont'guéris (l), Jeunesse d'Mique, Ouagadougou, 208 p. FERNANDEZ C., 1982a., Des plantes qui nous ont guéris (2), Pabre, Ouagadougou, 101 p. FERNANDEZC.,1982b., Plantes médicinalesvenduessur les marchés de Ouagadougo, Pabre, 46 p. GELFAND M., MAVI S., DRUMMONDR.B.,NDEMERAB.,1985, 17ze traditionalmedicinal practitioner inZimbabwe, MamboPress,Gweru, Zimbabwe, 411 p. HAKIZAMUNGU E., WERI M., 1988, \"L'usage de plantes médicinales dans le traitement du paludisme en médecine traditionnelle rwandaise\", Bull. Méd. Trad. Pharm. 2, Paris : ACCT, pp. 11-17. LEJOLY J., 1988, Liste de 1124 espèces médicinales utilisées dans 11 pays avec indication de la maladie soignée et du nombre derecettes par pays (Projet PHAMEL, ACCT), Labo. Bot. Syst. et Phytosoc., Univ. Libre Bruxelles, 122p. LEJOLY J., 1990, \"La pharmaFopéetraditionnelleenréseau\",Communication présentée au Congrès PRELUDE, Réseaux, mode d'emploi, environnement, communication, recherche, Namur, 21-23 novembre 1990. LEJOLY J., 1991, \"Valorisationdes plantes médicinales africaines\",Morale laïque 91, Bruxelles, pp. 9-11. LINDSAY R.S., HEPPER F.N.,1978, hiedicinul plants of AdarakWet, Kenyu, Royal Botanic Gardens Kew. LUBINI A., 1990, \"Les plantes utilisées en médecine traditionnelle par les Yansi de l'entre Kwilu-Kamtsha (Zaïre)\", Comptes-rendus de la 12e réunion de I'AETFAT, Mitt. Inst. Allg. Bot., Hamburg, 23b, pp. 1007-1020. MANDANGO M.A., BANDOLE M.B., 1988, \"Contributionà la connaissance des plantes médicinales des Turumbu de la zone de Basoko (Zaïre)\", Monogr. Syst. Bot. Missouri Bot. Gard.25, pp. 373-383. MANDANGO 'M.A., BOEMU L., BONGOMBOLA M., 1990, \"Plantes antidiabétiques de Kinshasa (Zaïre)\", Comptes-rendus de la 12e réunion de l'AETFAT,Mtt. Inst. Allg. Bot., Hamburg, 23b, pp. 1021-1031. NMMLU3WA M., DBALW M. 1990, \"Plantes m6dicinaks cultivks dans la zone de Kabondo à Kisangani (Zaire)\". Aj?. Stzrdy Monographs, 11, pp. 87- 99. PATTE F.,1989, \"Valorisation de la pharmacopie traditiomelle : Approche d'une plitique ratiomelle\", Bull. h44d. Trad. Pham., 3(2), pp. 159-164. POUSSET J.-L., 1989, Plantes mdicinnles-iicaines9Paris : ACCT, 156 p. VAN PWVELDE L., NGAl3OYTSONGA M., RWMWABO P.C., S., IUYONGA A., R-A-B obotaniqws sur la nzhclecine tradition Tome 1 : Prkfecture de Kibuye, Univ. Nat. et Inst. Nat. Rech. Sc. du Rwmda, Butare (inhdit), 147 WAE?CHTER P., LEJOLY J., 1991, L : Banque de domies de m6decine traditionnelle et de pharmacop6e\", Actes du ler C'ollogue europken d'eSlnsaharmacoloie (Metz, 22-25 mars 1990), Paris : ORSTOM, pp. 152- 154. WEMGER B., ROBINEAU L., 1989, Élmenbpour m e pharrnacopke caraibe, Séminaire TRAMIL 3. enda-caribe, Santo Domingo, République Dominicaine, 3 18 p.",
    "url": "https://www.scribd.com/document/516515095/La-banque-de-donnees-ethnobotaniques-PHARMEL-sur-les-plantes-medicinales-africaines",
    "length": 18999,
    "type": "html",
    "id": 3002,
    "source": "MedicinalPlants"
  },
  {
    "title": "Traditional African medicine Research Starters EBSCO Research",
    "text": "Research Starters Home EBSCO Knowledge Advantage TM Traditional African medicine Traditional African medicine is a holistic healing system that has been practiced for thousands of years and encompasses a rich tapestry of cultural and spiritual beliefs. It integrates the use of locally sourced herbs, animal products, and spiritual rituals to address not only physical ailments but also emotional and spiritual well-being. Traditional practitioners, often without formal education, acquire their knowledge through generations of oral tradition, apprenticing, and personal spiritual experiences. The diagnosis of illness typically involves understanding spiritual imbalances, with practitioners employing methods like divination and incantations alongside herbal treatments. In Africa, over 80 of the population relies on traditional medicine as their primary healthcare resource, particularly in rural areas where access to Western medical facilities is limited or unaffordable. Despite the influence of Western medicine, traditional practices remain deeply embedded in community life and continue to adapt to modern challenges, including urban migration and changing perceptions among younger generations. The World Health Organization recognizes the significance of traditional medicine, advocating for its integration into formal health systems to enhance healthcare accessibility and efficacy. As interest in herbal remedies grows globally, traditional African medicine increasingly attracts attention for its potential contributions to modern health care and the ongoing research into its herbal practices. Published in: 2022 By: Hutchinson, Jocelyn Go to EBSCOhost and sign in to access more content about this topic. Traditional African medicine Traditional African medicine is one of the oldest types of folk medicine that uses local traditions developed over generations to provide medical care to patients. It involves the use of herbs, spirituality, and divination to provide cures for many ailments. The health practices are based on various ethnic and religious beliefs and customs passed down in a particular area, usually a village or other community. Remedies generally also have a spiritual or symbolic reference because illness is thought to occur from a spiritual imbalance, and herbs or medicinal plants from the local area are often also part of the treatment. Traditional medicine seeks to treat not only the body but also the patient's mind and spirituality. Traditional African medicine is an important aspect of life for the people of Africa. It is estimated that in Africa, more than 80 percent of the people rely on traditional medicine as their primary means of health care. Research shows that many only have access to traditional practitioners, especially in rural areas. Cost is also a factor since Western pharmaceuticals may be too expensive for most people to consider. Traditional medicine has for thousands of years been an integral part of African life, and it continues, even with Western influence, to remain a part of most Africans' lives. Background Evidence of the use of traditional African medicine can be traced back to the Stone Age . The use of magic and spirituality in healing in Africa is even older than other traditional medical practices. Before the arrival of Europeans to colonize the African continent, traditional medicine was the only means of health care available. Tribes used herbs and other implements found in their area to provide cures that had been passed down orally from previous generations for common ailments. Traditional African religions relied on animism , veneration of dead ancestors, and other spiritual practices, and these practices were woven into medical treatment as well. There was not much demarcation, if any, between curing an illness and practicing religion. In the nineteenth century when Europe began its conquest of Africa, some aspects of traditional medicine were made illegal, and controls on herbal medicine attempted to be implemented. Along with the arrival of colonists, Christianity was also introduced. The beliefs and practices of Christianity were often in stark contrast to the spirituality-based diagnoses and healings of traditional medicine, which further put it at odds with Western medicine. However, it was very difficult, if not impossible, to enforce the abolishment of traditional medical practices offensive to Christianity and science-based medicine, especially in rural villages. Colonists and Christian missionaries brought hospitals to many areas in Africa. Prior to this, sick people were cared for at home by family or other village members. The Europeans were concerned about the diseases they found in Africa, which could be treated or controlled with conventional medical care. Although having the knowledge and cures to fight preventable illnesses, acceptance by African communities was often slow due to mistrust and the Westerners' vastly different approach to medical care. Western medicine practitioners often did not involve any aspects of traditional medicine, including herbal remedies, in their practice. Even when some of these had been used effectively by generations of Africans, they also did not accept the contribution that traditional practitioners played in village life and the basic health needs they served in the community, such as childbirth. Missionaries and government officials discouraged or penalized Africans for using traditional practices, and this further promoted distrust and widened the gap between the two types of health care. After some countries gained independence from colonization in the twentieth century, efforts were made to regulate traditional medicine, and this process continues in the twenty-first century. Although regulation could increase the possibility of sharing effective cures and reducing risks and dangers, it is difficult to implement on a broad scale. Many countries struggle with creating the necessary framework for such a massive undertaking, and research and development into a comprehensive plan to integrate traditional therapies into conventional medicine are slow. As some Africans migrated throughout the world, they brought with them the practices of traditional medicine. Although how Africans' medical practices and thinking change when migrating to other countries has not been well researched, many traditional cures can be found in various forms throughout any country with a sizable African immigrant population. As a result, traditional African medical practices are being used in many other places in the world and even by non-Africans for their beneficial effects. Modern Western-style scientifically based medicine is simply not an option for everyone in Africa, even in the twenty-first century, especially in inaccessible rural areas or countries with poor infrastructure. It also remains much more costly, especially for uneducated individuals or women and children. Also, the technology used is often not the best quality available, and maintenance and obtainment of resources can be difficult due to supply chain issues. This lack of consistency and efficacy also erodes trust in Western-style medicine, especially in older people or rural communities. For some serious illnesses, such as HIVAIDS or malaria , that are very common in Africa, there is a significant lack of modern medical treatment available. Hence, traditional medicine continues to be a staple in the life of many Africans, and in some cases, it is the only access to medical care Africans may have. However, there is a noticeable decline in the use of traditional medicine in some places in Africa. Although relied on by many as a basic need in rural areas, many younger generations are moving to more urban areas for education or employment where conventional medical care is available. The use of traditional practices is looked down upon by some as being ignorant of science or old-fashioned. Therefore, interest has waned in learning practices as traditional healers grow old and die, taking their wealth of knowledge with them. To help prevent the decay of traditional medical practices, bridge the gap between medical practice styles, and promote more comprehensive and patient-focused care, some conventional and Western-style practitioners have integrated traditional healing medicines and methodology. The pharmaceutical industry has taken an interest in traditional African herbalism to find more bioactive agents to treat conditions, and the herbal trading market in Africa is extensive. Although African herbalism is not generally well-researched or regulated, many promising plants and compounds may provide cures for illness. Safety and effectiveness need to be demonstrated, but research on many common traditional African herbal remedies is underway. On August 31 of each year, the World Health Organization (WHO) celebrates African Traditional Medicine Day. It pays tribute to the role that traditional medicine has had and continues to have in the lives of African people. Through this and similar initiatives, WHO seeks to educate the world about the benefits of traditional medicine and promote its role in health systems. Through funding, education, regulation, and research, WHO feels that traditional medicine has a valuable place when integrated into conventional medical practice. Overview Traditional African medicine is as diverse as the cultural and ethnic variety in Africa, and differences in belief and practice can also vary from village to village. A practitioner provides care to those in the community and uses locally sourced plants and animal products along with spiritually based incantations and other practices that relate to the local people's culture and beliefs. Although there may be many differences, some similarities exist. Practitioners Traditional practitioners usually do not have a formal education but have received an education through information passed on to them by others. A traditional practitioner may take on an apprentice or pass down knowledge to children or other relatives. However, some traditional practitioners view their knowledge as a secret entrusted to them by a spiritual source and are not willing to share it, at least as long as they are able to continue their work. Other practitioners may find their calling to medicine after being healed through traditional practices, and these individuals rely heavily on their spiritual connection for their knowledge. Most traditional practitioners view their ability to diagnose and heal as a gift from the spirit world and highly prize their abilities. Practitioners may also specialize in a particular area of medicine, much like Western-style practitioners. Some may be expert herbalists, diviners, seers, or spiritual guides, heal specific injuries and ailments, or attend to women giving birth as midwives. Religion, spirituality, and custom play a role almost universally in methods used by traditional practitioners. Most villages or communities have at least one practitioner that provides different services or methods of treatment. Like other professionals, practitioners usually expect some form of payment for their services, as it is their livelihood. While they may not require a monetary sum, especially in rural or economically depressed areas, they may ask for useful goods or services in exchange for cures or services rendered. One difference from Western-style medicine is that in African societies payment may be directly linked to the efficacy of the treatment. The better the cure, the higher the price paid for it. For this reason, traditional medicine makes much more sense to many Africans. However, in the twenty-first century, there is an increase in traditional healers, especially in urban areas, that require monetary payment, even sometimes prior to treatment. Diagnosis Traditional practitioners usually rely on spiritual or supernatural means for diagnosis but also use observation and experience. Practitioners usually address the spiritual aspects of a patient prior to the medical need, since the belief is that the gift of healing is from a spiritual source along with the ailment and remedy. Practitioners try to first determine what may be causing a patient's illness, and illness is often tied closely to any type of misfortune. Since any ailment is believed to stem from an imbalance in the spiritual world or environment around the patient, the practitioner seeks to find the proper way to restore this balance. An incantation, or spell, may be used for the practitioner to understand what the imbalance is and how to restore it. Divination using spiritual omens and rituals may also be used to identify the illness. In some cases, a practitioner may have the patient consult a specialized diviner who can provide a diagnosis and recommended treatment. This may even require the patient to perform certain rituals or possibly provide an offering or sacrifice to a spirit. Dreams, trances, and hallucinations from a god or another spiritual source may also offer insight into a patient's condition or cure. Also, certain rituals, such as dances or chants, may be required to encourage the spirit realm to make contact to provide information to the practitioner. Treatments Various treatments are prescribed for their spiritual and symbolic significance as well as their medicinal effect on a patient. Treatments may range from medical-based practices, such as setting a bone or delivering a baby, to an action to provide a spiritual benefit or a combination of both. Herbal remedies may also be prescribed as medicines. Herbal and medicinal plant remedies are a mainstay of traditional medicine in Africa because they are an inexpensive and easily obtained resource that has a long history of medical use in most communities. These may include delivery in the form of ointments, steam baths, emetics to induce vomiting, and teas, powders, pills, or tinctures to be consumed. The tropical regions of Africa are rich with diverse plant life that has known healing properties even in Western medicine. The plants commonly used contain phytochemicals that work together to produce a beneficial effect to treat or prevent an illness. However, in traditional medicine, plants are also valued for their spiritual and symbolic significance. The color, shape, or other properties of the plant can be symbolic and ascertained to have special properties. Although herbal and plant remedies vary by regional area, popular ones include Acacia Senegal (gum Arabic), Artemisia herba-alba (wormwood), Aspalathus linerairs (rooibos), Centella asiatica (centella), Catharanthus roseus (Madagascar periwinkle), Cyclopia genistoides (honeybush), Harpagophytum procumbens (devil's claw), Momordica charantia (bitter melon), and Pelargonium sidoides (umckaloabo). These are used to treat a range of symptoms or ailments from relatively minor to serious medical conditions, such as infection, bleeding, gastric upset, leprosy , cancer, diabetes, heart problems, and neuralgia . Interestingly, some of these, such as rooibos, have become popular herbal products in Western countries as people outside Africa become acquainted with the unique therapeutic properties of plants. A plant known as Sutherlandia microphylla (cancer bush) from South Africa is also being researched as an inexpensive and widely available way to help improve the quality of life of HIV patients. Animal products can also be used in traditional forms of treatment, which is known as zootherapy . Animal products such as blood, skin, urine, fat, or bone can be used directly or provide an ingredient for a remedy to be consumed or applied topically. They may also be used in the form of an amulet, a charm, or a ceremonial implement. Local markets or shops supply communities with animal products that provide common cures for ailments. This is heavily influenced by cultural and religious beliefs and represents the close connection between human and animal life. This practice has met with some resistance from Western cultures because animals are generally sourced from the wild, and this may include the use of endangered species. Incantations involving the use of spells, charms, amulets, or rituals are also usually included in treatments. Another practitioner may also be required to perform part of the spiritually directed actions. Sympathetic, or imitative, magic may also be employed using a model of the patient or another person thought to be responsible for a malady. Actions done to the model are thought to be magically transferred to the person in a manner similar to the use of a voodoo doll. These may also be used in relation to people who are deceased since traditional beliefs include the involvement of dead friends, relatives, and ancestors in living people. Rituals may also be required for not only diagnosis, but also treatment. For example, a tribal dance may need to be performed either by the practitioner, the patient, or family and friends. This is done to mediate a spiritual or social imbalance and may be combined with medicinal herbal or animal products and incantations to complete treatment. Rituals can take a variety of forms, from a simple ceremony being done by a single person to an elaborate performance by a large group of people to achieve the desired effect. Bibliography Baily, Deborah. Traditional Healing vs. Western Medicine in the African Continent. Afro News , 19 Mar. 2021, afro.comtraditional-healing-vs-western-medicine-in-the-african-continent. Accessed 6 Oct. 2022. Chakamba, Rumbi. Africa's Attempt to Regulate Traditional Medicine Fails to Gain Traction. Devex , 28 Jan. 2021, www.devex.comnewsafrica-s-attempt-to-regulate-traditional-medicine-fails-to-gain-traction-98999. Accessed 6 Oct. 2022. Moeti, Matshidiso. African Traditional Medicine Day 2022. World Health Organization: Africa , 31 Aug. 2022, www.afro.who.intregional-directorspeeches-messagesafrican-traditional-medicine-day-2022. Accessed 6 Oct. 2022. Onyalo Odhiambo, Martin The Place of African Traditional Medicine in Response to COVID-19 and Beyond. UNESCO , 12 Mar. 2020, en.unesco.orgnewsplace-african-traditional-medicine-response-covid-19-and-beyond. Accessed 6 Oct. 2022. Ozioma, Ezekwesili-Ofili Josephine and Okaka Antoinette Nwamaka Chinwe. Herbal Medicines in African Traditional Medicine. Herbal Medicine , 30 Jan. 2019, www.intechopen.comchapters64851. Accessed 6 Oct. 2022. Rasamiravaka, Tsiry et al. Traditional African medicine: From ancestral knowledge to a modern integrated future. Science , Jan. 2015, www.researchgate.netpublication306401100 Traditional African medicine From ancestral knowledge to a modern integrated future. Accessed 6 Oct. 2022. Shewamene, Z., Dune, T. and C.A. Smith. Use of Traditional and Complementary Medicine for Maternal Health and Wellbeing by African Migrant Women in Australia: A Mixed Method Study. BMC Complementary Medical Therapy , 18 Feb. 2020, bmccomplementmedtherapies.biomedcentral.comarticles10.1186s12906-020-2852-6. Accessed 6 Oct. 2022. Traditional African Medicine and Its Role in Healing in a Modern World. Ancient Origins, 9 Apr. 2019, www.ancient-origins.nethistory-ancient-traditionstraditional-african-medicine-and-its-role-healing-modern-world-004522. Accessed 6 Oct. 2022. Traditional Medicine. World Health Organization: Africa , 2021, www.afro.who.inthealth-topicstraditional-medicine. Accessed 6 Oct. 2022. WHO Calls on Taking Advantage of Traditional Medicine in Africa. teleSUR , 1 Sept. 2022, www.telesurenglish.netnewsWHO-Calls-on-Taking-Advantage-of-Traditional-Medicine-in-Africa-20220901-0011.html. Accessed 6 Oct. 2022. Wild, Sarah. Bringing Traditional Healing Under the Microscope in South Africa. Undark , 20 Dec. 2020, undark.org20201230covid-19-south-africa-traditional-medicine. Accessed 6 Oct. 2022. On This Page Overview Full Article Background Practitioners Diagnosis Treatments Bibliography Related Topics Stone Age Christianity Acquired immunodeficiency syndrome (AIDS) Malaria Phytochemicals Leprosy Neuralgia, neuritis, and neuropathy Related Topics Stone Age Christianity Acquired immunodeficiency syndrome (AIDS) Malaria Phytochemicals Leprosy Neuralgia, neuritis, and neuropathy",
    "url": "https://www.ebsco.com/research-starters/health-and-medicine/traditional-african-medicine",
    "length": 20284,
    "type": "html",
    "id": 3003,
    "source": "MedicinalPlants"
  },
  {
    "title": "PROTA, Introduction aux Plantes médicinales PlntUse",
    "text": "PROTA 11 (1), 2008. Ressources végétales de l'Afrique tropicale . vol. 11 (1). Plantes médicinales , tome 1. éd. par G.H. Schmelzer A. Gurib-Fakim. Wageningen, Fondation PROTA - Backhuys - CTA. 869 p. PROTA 11 (2), 2013. Ressources végétales de l'Afrique tropicale . vol. 11 (2). Plantes médicinales , tome 2. éd. par G.H. Schmelzer A. Gurib-Fakim. Wageningen, Fondation PROTA - CTA. 417 p. PROTA 11(1) : Plantes médicinales 1 est le premier de 4 tomes décrivant les espèces de plantes sauvages, ou parfois cultivées, d'Afrique tropicale, qui sont traditionnellement utilisées en médecine locale. Certaines d'entre elles ne sont pas exclusivement utilisées pour les soins médicaux humains, mais également appliquées en médecine vétérinaire, comme plantes toxiques utilisées comme pesticide, poison de flèche ou de pêche, ou encore comme narcotiques. La plupart des espèces ont en outre plusieurs autres usages secondaires. PROTA affecte normalement un seul usage primaire et, si cela est pertinent, un ou plusieurs usages secondaires à toutes les espèces de plantes utilisées en Afrique. L'usage primaire de Voacanga africana Stapf étant celui d'une plante médicinale, il est donc traité dans PROTA 11, mais il a de nombreux usages secondaires, par exemple les branches sont utilisées en construction et pour fabriquer des instruments de musique, le bois sert de bois de feu, l'écorce donne des fibres pour de la corde et du fil, et les fruits sont réputés comestibles. En Tanzanie, Voacanga africana est planté à des fins ornementales grâce à ses fleurs blanches odorantes. Les industries pharmaceutiques en Europe extraient de la tabersonine de ses graines, qui se transforme facilement en vincamine, composé largement utilisé en médicaments en gériatrie. Des extraits de graines s'appliquent aussi en médicaments pour traiter les maladies cardiaques, l'hypertension et le cancer. Carissa spinarum L. (synonyme : Carissa edulis (Forssk.) Vahl) est également assez important comme plante médicinale, mais son usage primaire est celui d'un fruit ; par conséquent, il est décrit dans PROTA 6 : Fruits. Les autres plantes dont l'usage comme médicament est l'usage primaire seront traitées dans les tomes 11(2) à 11(4). Dans le dernier tome 11(4), les plantes médicinales dont c'est l'usage secondaire seront listées comme Plantes médicinales ayant un autre usage primaire et seront renvoyées à d'autres volumes de l'encyclopédie. Dans PROTA 11(1), une espèce est décrite qui, à part son usage primaire comme plante médicinale, a un autre usage considéré comme primaire et par conséquent sera incluse dans 2 groupes d'usage. Il s'agit de Jatropha curcas L. (inclus aussi dans PROTA 14 : Oléagineux). Ce tome traite particulièrement de plusieurs familles botaniques qui comprennent un grand nombre d'espèces de plantes médicinales, les plus nombreuses étant les Apocynaceae , Asphodelaceae , Caesalpiniaceae , Euphorbiaceae , Loganiaceae , Menispermaceae et Solanaceae . On y trouvera aussi 19 autres familles qui comprennent des plantes médicinales importantes, mais moins nombreuses. Dans PROTA 11(1) : Plantes médicinales 1, 134 espèces importantes de plantes médicinales font l'objet de description complète. La plupart sont des espèces sauvages, mais certaines sont cultivées ou semi-domestiquées. Les articles de synthèse sont présentés dans un format détaillé et illustrés d'un dessin au trait et d'une carte de répartition. En outre, 272 plantes médicinales secondaires font l'objet d'articles au format simplifié, et ne comportent habituellement ni dessin ni carte car les informations sur ces espèces sont souvent succintes. Pour 488 autres espèces, l'information était tellement limitée que des articles séparés n'étaient pas justifiés ; ces espèces sont seulement mentionnées dans les articles sur les espèces apparentées. Chaque article décrit les usages traditionnels et modernes et les propriétés phytochimiques et pharmacologiques. Il rend plus facile et plus fiable l'identification des espèces utiles, décrit les méthodes de collecte (récolte), de culture et d'application les plus convenables, et indique le statut de recherche et de conservation de ces plantes. Environ deux tiers des espèces de plantes utilisées en Afrique tropicale ont un usage médicinal documenté, mais le nombre actuel est probablement plus élevé. Pour PROTA 11, on n'a retenu que les espèces pour lesquelles la littérature fait preuve qu'elles sont actuellement ou ont été jadis utilisées comme plante médicinale. De telles références sont toutefois rares, souvent datées et généralement pauvres en détails sur leur usage. Seules les espèces dont on connaît au moins une application pratique ont été retenues. Cela signifie que l'on a exclu les espèces mentionnées dans la littérature avec des remarques laconiques comme la plante est utilisée médicinalement ou les racines s'utilisent en médecine. Dans l'Afrique sub-saharienne, la médecine traditionnelle est restée depuis des siècles le système de santé le plus accessible et le moins cher. Les plantes médicinales contribuent de façon significative à la vie des populations rurales et à l'équilibre social en Afrique. La demande des marchés locaux et internationaux ne cesse d'augmenter, ainsi que les activités de bioprospection à la recherche de nouvelles substances actives. Les ressources de plantes médicinales diminuent à un rythme alarmant, sous l'effet de leur utilisation large et non durable, de leur importance économique croissante et de l'évolution des milieux. De plus, la perte des savoirs autochtones sur les plantes médicinales et la médecine traditionnelle s'accélère, surtout en Afrique, du fait de la disparition des personnes âgées qui ont traditionnellement été les gardiens de ces savoirs, et des transformations socio-culturelles des sociétés. Cette situation rend nécessaires des politiques et des programmes de recherche, tant au niveau national qu'international, sur la conservation et l'utilisation durable des plantes médicinales, ainsi que sur la protection des droits des communautés autochtones sur l'usage de leurs savoirs traditionnels. PROTA 11(2) : Plantes médicinales 2 est le deuxième de 4 tomes décrivant les espèces de plantes sauvages, ou parfois cultivées, d'Afrique tropicale, qui sont traditionnellement utilisées en médecine locale. Certaines d'entre elles ne sont pas exclusivement utilisées pour les soins médicaux humains, mais également appliquées en médecine vétérinaire, comme plantes toxiques utilisées comme pesticide, poison de flèche ou de pêche, ou encore comme narcotiques. La plupart des espèces ont en outre plusieurs autres usages secondaires. PROTA affecte normalement un seul usage primaire et, si cela est pertinent, un ou plusieurs usages secondaires à toutes les espèces de plantes utilisées en Afrique. L'usage primaire de Terminalia avicennioides Guill. Perr. étant celui d'une plante médicinale, il est donc traité dans PROTA 11(2), mais il a de nombreux usages secondaires, par exemple son bois est utilisé en construction, pour fabriquer des outils, comme bois de feu et pour la production de charbon de bois, et son feuillage sert de fourrage et pour colorer des tissus. L'écorce et les feuilles de Terminalia ivorensis A.Chev. s'utilisent également en médecine traditionnelle, mais l'usage primaire de cette espèce est celui d'un bois d'œuvre ; par conséquent il est décrit dans PROTA 7(2) : Bois d'œuvre 2. Les autres plantes dont l'usage comme médicament est l'usage primaire seront traitées dans les tomes 11(3) et 11(4). Dans le dernier tome 11(4), les plantes médicinales dont c'est l'usage secondaire seront listées comme Plantes médicinales ayant un autre usage primaire et seront renvoyées à d'autres volumes de l'encyclopédie. Ce tome PROTA 11(2) traite les espèces de plantes médicinales des familles botaniques suivantes : Asclepiadaceae, Balanophoraceae, Capparaceae, Combretaceae, Convolvulaceae, Physenaceae et Rutaceae ; on a ajouté aussi l'article déjà disponible sur Dichrostachys cinerea (L.) Wight Arn. ( Mimosaceae ) bien que les autres Mimosaceae ayant un usage comme médicament seront traités dans le tome 11(3). Dans PROTA 11(2) : Plantes médicinales 2, les 146 espèces les plus importantes de plantes médicinales font l'objet de description complète. La plupart sont des espèces sauvages, mais certaines sont cultivées ou semi-domestiquées. Les articles de synthèse sont illustrés d'une carte de répartition et régulièrement aussi d'un dessin au trait. Pour 263 autres espèces, l'information était tellement limitée que des articles séparés n'étaient pas justifiés ; ces espèces sont seulement mentionnées dans les articles sur les espèces apparentées. Chaque article décrit les usages traditionnels et modernes et les propriétés phytochimiques et pharmacologiques. Il rend plus facile et plus fiable l'identification des espèces utiles, décrit les méthodes de collecte (récolte), de culture et d'application les plus convenables, et indique le statut de recherche et de conservation de ces plantes. Environ deux tiers des espèces de plantes utilisées en Afrique tropicale ont un usage médicinal documenté, mais le nombre actuel est probablement plus élevé. Pour PROTA 11, on n'a retenu que les espèces pour lesquelles la littérature fait preuve qu'elles sont actuellement ou ont été jadis utilisées comme plante médicinale. De telles références sont toutefois rares, souvent datées et généralement pauvres en détails sur leur usage. Seules les espèces dont on connaît au moins une application pratique ont été retenues. Cela signifie que l'on a exclu les espèces mentionnées dans la littérature avec des remarques laconiques comme la plante est utilisée médicinalement ou les racines s'utilisent en médecine. Dans l'Afrique sub-saharienne, la médecine traditionnelle est restée depuis des siècles le système de santé le plus accessible et le moins cher. Les plantes médicinales contribuent de façon significative à la vie des populations rurales et à l'équilibre social en Afrique. La demande des marchés locaux et internationaux ne cesse d'augmenter, ainsi que les activités de bioprospection à la recherche de nouvelles substances actives. Les ressources de plantes médicinales diminuent à un rythme alarmant, sous l'effet de leur utilisation large et non durable, de leur importance économique croissante et de l'évolution des milieux. De plus, la perte des savoirs autochtones sur les plantes médicinales et la médecine traditionnelle s'accélère, surtout en Afrique, du fait de la disparition des personnes âgées qui ont traditionnellement été les gardiens de ces savoirs, et des transformations socio-culturelles des sociétés. Cette situation rend nécessaires des politiques et des programmes de recherche, tant au niveau national qu'international, sur la conservation et l'utilisation durable des plantes médicinales, ainsi que sur la protection des droits des communautés autochtones sur l'usage de leurs savoirs traditionnels. Famille : à part les noms de famille classiques, le nom correspondant à la classification APG ( Angiosperm Phylogeny Group ) est également noté lorsqu'il diffère du nom classique. Synonymes : seuls sont mentionnés les synonymes le plus communément utilisés et ceux qui risquent de prêter à confusion. Noms vernaculaires : seuls sont inclus les noms utilisés dans les langues officielles d'importance régionale en Afrique, à savoir l'anglais, le français, le portugais et le swahili. Fournir des données approfondies sur les noms d'une espèce dans toutes les langues parlées dans sa zone de répartition dépasserait la portée de PROTA, car la simple vérification des noms demanderait aux spécialistes de longues recherches sur le terrain. Bien que certaines formes régionales d'arabe soient parlées dans plusieurs pays d'Afrique, le nombre d'espèces de plantes africaines possédant un nom en arabe classique écrit est limité. C'est pourquoi les noms arabes ont été omis. Quant aux noms des produits végétaux, ils sont mentionnés dans la section Usages. Pour éviter de longues listes de pays dans le texte, une carte de répartition a été ajoutée pour les principales espèces. Cette carte indique les pays dans lesquels une espèce a été répertoriée, soit à l'état sauvage, soit en culture. Toutefois, pour bon nombre d'espèces, ces cartes sont incomplètes parce qu'elles sont réalisées sur la base d'informations publiées dont la quantité et la qualité varient énormément d'une espèce à l'autre. Ceci est tout particulièrement vrai pour les espèces sauvages que ne couvrent pas, ou pas complètement, les flores régionales africaines, et pour les espèces cultivées uniquement à petite échelle (par ex. dans les jardins familiaux). Pour certains pays (comme la Centrafrique, le Tchad, le Soudan et l'Angola), il existe relativement peu d'informations dans la littérature. Parfois, ces pays ne sont pas consignés dans des flores régionales ou nationales récentes, et, même si certaines espèces y sont présentes, il est impossible de le prouver ou de le confirmer. La phytochimie des différentes parties de la plante est indiquée, avec une attention spéciale pour les composés bio-actifs. Autant que possible, la connection est faite entre les usages traditionnels d'une partie de la plante, les composés actifs isolés de cette partie et les essais pharmacologiques confirmant ou non l'activité de ces composés ou des extraits végétaux contenant ces composés actifs. Une caractérisation morphologique des espèces est donnée. Cette description, rédigée en style télégraphique, fait usage des termes botaniques. Il n'est pas facile de fournir une description destinée au grand public, car les termes de la langue commune manquent souvent de la précision requise pour une description botanique. Un dessin au trait est ajouté pour un certain nombre d'espèces, pour servir de complément à la description et l'illustrer. La description des méthodes culturales, comprenant l'application d'engrais, l'irrigation et les mesures de lutte contre les ravageurs et les maladies, est donnée dans les sections Gestion et Maladies et ravageurs. Elle reflète les pratiques actuelles ou des recommandations généralisées, et optent pour une vue d'ensemble, mais sans recommandations détaillées adaptées aux conditions locales extrêmement diversifiées que rencontrent les agriculteurs. Les recommandations concernant la lutte chimique contre les ravageurs et les maladies sont purement indicatives et les règlements locaux doivent avoir la priorité. PROTA participera à la réalisation de produits dérivés pour la vulgarisation et l'enseignement, basés sur les textes de ce volume, mais auxquels des informations locales spécifiques seront ajoutées. La diversité génétique de nombreuses espèces de plantes d'Afrique est en train de se réduire, parfois à une vitesse alarmante, à la suite de la destruction des milieux et de la surexploitation. Le remplacement des variétés locales d'espèces cultivées par des cultivars modernes commercialisés représente une autre cause d'érosion génétique. Un bilan est fait de la diversité intraspécifique et des menaces probables au niveau de l'espèce, et lorsqu'il y a lieu il est fait référence à la Liste rouge des espèces menacées de l'UICN. Les informations sur les collections ex situ de ressources génétiques sont extraites pour la plupart des publications de Bioversity International (l'ancien Institut international des ressources phytogénétiques - IPGRI). L'objectif principal de la liste de références donnée est de guider le lecteur vers des informations complémentaires, et elle ne prétend pas être exhaustive. Les auteurs et éditeurs ont sélectionné deux catégories de références. Le nombre de références principales est limité à 10, et celui des autres références à 20. Les références figurant sur la liste incluent celles qui ont été utilisées lors de la rédaction de l'article de synthèse. Lorsque Internet a été utilisé, le site web et la date de consultation sont mentionnés.",
    "url": "https://plantuse.plantnet.org/fr/PROTA,_Introduction_aux_Plantes_m%C3%A9dicinales",
    "length": 15976,
    "type": "html",
    "id": 3004,
    "source": "MedicinalPlants"
  },
  {
    "title": "Pharmacopée africaine -",
    "text": "retour à la recherche Pharmacopée africaine 1985 - 264 pages - 1 Volumes Edition : Lagos (Nigeria), CSTROUA, Langues : Français Mot-clés : Afrique , Chimie analytique , Pharmacopée traditionnelle , Pharmacopées nationales Description : L'Afrique, et avec elle ses archipels de l'Océan Indien, est réputée pour la richesse de sa flore qui comprend plusieurs dizaines de milliers d'espèces végétales. Un nombre relativement restreint contient des principes actifs remarquables, d'usages courants, mentionnés dans les pharmacopées modernes. La grande majorité des autres plantes renferme d'immenses potentialités thérapeutiques soupçonnées ou non et est utilisée avant tout en médecine traditionnelle pratiquée par plus de 80 des populations africaines. La première édition de la Pharmacopée africaine présente un recueil de 96 plantes et drogues identifiées, disposant d'une monographie complète avec les formules et recettes pour préparer les médicaments à base de plantes. Dans chaque monographie sont indiqués les noms d'espèces et de famille, les synonymes, les noms vulgaires en français et en anglais et dans les principales langues africaines, une brève description botanique et la répartition géographique pour permettre l'identification La médecine indienne L'Afrique, et avec elle ses archipels de l'Océan Indien, est réputée pour la richesse de sa flore qui comprend plusieurs dizaines de milliers d'espèces végétales. Un nombre relativement restreint contient des principes actifs remarquables, d'usages courants, mentionnés dans les pharmacopées modernes. La grande majorité des autres plantes renferme d'immenses potentialités thérapeutiques soupçonnées ou non et est utilisée avant tout en médecine traditionnelle pratiquée par plus de 80 des populations africaines. La première édition de la Pharmacopée africaine présente un recueil de 96 plantes et drogues identifiées, disposant d'une monographie complète avec les formules et recettes pour préparer les médicaments à base de plantes. Dans chaque monographie sont indiqués les noms d'espèces et de famille, les synonymes, les noms vulgaires en français et en anglais et dans les principales langues africaines, une brève description botanique et la répartition géographique pour permettre l'identification",
    "url": "https://www.ethnopharmacologia.org/bibliotheque-ethnopharmacologie/pharmacopee-africaine/",
    "length": 2272,
    "type": "html",
    "id": 3005,
    "source": "MedicinalPlants"
  },
  {
    "title": "TRADITIONAL MEDICINE AUC Library",
    "text": "\"Books are a Capital Resource. The more they are used, the more they add value into the lives of the readers....\" Deputy Chairperson of the AUC, Feb. 2019 Library Hours Monday-Friday ( Mornings ): 8am-1pm Monday-Friday ( Afternoons ): 2pm-5pm Closed on Weekends and AU Officials Holidays Links Contact us Ask a Librarian FAQ Sitemap Help AU Home AU Offices Webmail",
    "url": "https://library.au.int/traditional-medicine",
    "length": 364,
    "type": "html",
    "id": 3006,
    "source": "MedicinalPlants"
  },
  {
    "title": "w7261e",
    "text": "PDF Document: https://www.fao.org/4/w7261e/w7261e.pdf",
    "url": "https://www.fao.org/4/w7261e/w7261e.pdf",
    "length": 0,
    "type": "pdf",
    "id": 3007,
    "source": "MedicinalPlants"
  },
  {
    "title": "HARVESTING OF NON-WOOD FOREST PRODUCTS",
    "text": "Wild plants have been an important component of healthcare throughout human history. Medicinal plants continue to make important contributions to healthcare and livelihoods, and were recently identified by FAO as being among the most valuable non-wood forest products (FAO, 1999). Unfortunately, harvests to meet the demand for a growing number of medicinal species are in many cases exceeding sustainable levels. Wild medicinal plant populations and the benefits derived therefrom are coming under threat as a result. More effective co-operation among the variety of institutions concerned with the use and trade of medicinal plants, including those from the healthcare, conservation, development and commercial sectors, is required to ensure the conservation of biodiversity and continued availability of medicinal resources. Medicinal plants underpin healthcare practices across the globe. Much of the world's population depends on traditional medicine to meet daily health requirements, especially within developing countries. Traditional medicine in turn relies heavily on medicinal plants. Reliance on natural medicinal resources can be attributed to cultural preferences as well as to the high cost and inaccessibility of western medicine. Use of plant-based remedies is also widespread in many industrialised countries. Herbal remedies are made directly from plant materials, and numerous pharmaceutical products are based on or derived from plant compounds. Similarly, cosmetics and other household products may contain plants of medicinal or therapeutic value. The use of medicinal plants for healthcare is believed to be increasing throughout much of the world, e.g. in Africa (Cunningham, 1993; Marshall, 1998), China (He and Sheng, 1997), Europe (Lange, 1998) and North America (Brevoort, 1998). The large and growing demand for plant-based medicines and changing population patterns have prompted a growing domestic and international trade in medicinal plants. The following information from Lange (1997, 1998) gives an indication of the scale of the trade. According to Customs data, approximately 440 000 t of medicinal and aromatic plants were traded internationally in 1996, with a reported value of USD1.3 billion. Hong Kong, Japan and Germany were the largest importers during 1994 and 1995, the United States being the third largest importer overall during the period 1992 to 1996. Approximately 60 of imports into Germany in 1996 originated from non-European countries, with exports from Asia dominating the trade, followed by exports from Africa. China was also by far the largest exporter of medicinal and aromatic plants to world markets during the mid-1990s, with average exports topping 140 000 t from 1992 to 1996. The second largest exporter was India, with export volumes averaging approximately 36 000 t during this period. A wide diversity of medicinal plant species are used and traded for medicinal purposes. A recent TRAFFIC 1 study of the European medicinal plant trade (Lange, 1998) estimates that over 2000 medicinal and aromatic plant species are used commercially in Europe, of which 1200 to 1300 are native. Approximately 90 of the European species are collected from the wild, with eastern Europe and the Mediterranean regions being the main suppliers (Lange, 1998). In India it has been estimated that approximately 7500 species are used for medicinal and veterinary purposes (Uniyal et al. , 2000). Over 10,000 species are used medicinally in China (He and Cheng, 1991), with 1,000 species commonly used in medicinal preparations, of which 80 are wild-collected (He and Sheng, 1997). Harvest of medicinal plants to supply domestic and foreign markets provides an important source of cash income in many countries. In Nepal, for example, Olsen (1998, cited in Olsen, 1999) has estimated that 470 000 households are engaged in commercial collection of medicinal plants. Several publications in the FAO Non-Wood Forest Product Series have drawn attention to the current and potential role of medicinal plants in economic development (e.g. see FAO, 1995; FAO, 1997). There is growing evidence that the populations of many medicinal plant species are declining in the wild. These declines are the result of several factors, key among them being habitat degradation and expanding harvests. TRAFFIC's study of the European medicinal plant trade identified approximately 150 European species reported to be threatened in at least one European country (Lange, 1998); a TRAFFIC study in EastSouthern Africa identified approximately 100 species of conservation concern in one or more countries (Marshall, 1998). Reviews of the status of medicinal plant species according to the Red List' (threat) criteria of IUCN-The World Conservation Union in three regions of India identified approximately 70 species considered at risk (Anon., 1998). Fourteen species have been included in the Appendices of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) owing to concern that they might be threatened unless international trade is subject to specific controls. Sustainable Use of Medicinal Plants: A Multi-Sectoral Challenge and Opportunity A variety of individuals and institutions have an interest in securing the future of medicinal plant species both because of the direct benefits they provide and in the wider context of biodiversity conservation. These range from local collectors, healers and communities to national governments, multi-national corporations, non-governmental organisations and international treaty bodies. Areas of concern include the role of medicinal plants in healthcare (both local and national) and development, biodiversity conservation, the use of traditional knowledge, intellectual property rights and benefit sharing, marketing and trade. Individuals acting within different sectors are frequently unaware of the shared andor conflicting interests and motivations of other sectors. In some cases, this can lead to different sectors unnecessarily working at cross-purposes. For example, government agencies charged with species conservation may be unaware of the importance accorded medicinal plants by health agencies. Similarly, health agencies may be unaware of the status of certain species in the wild. The former may seek to restrict use and trade of specific species, while the latter seeks to expand it. In many cases, the long-term interests sought by different sectors might be better served through increased information sharing, dialogue and cooperation. For example, efforts to promote commercial trade of medicinal plants as a basis for economic development would benefit from greater knowledge of species biology and market dynamics. Efforts to ensure the conservation of medicinal plant species and their availability for healthcare would similarly benefit from such knowledge. Policies intended to support these andor other objectives similarly seem more likely to succeed if the full range of stakeholder perspectives and interests are understood and taken into account. The need for more effective cross-sector collaboration to address medicinal plant conservation issues was first brought to world attention by the International Consultation on the Conservation of Medicinal Plants , convened by the World Wide Fund for Nature (WWF), IUCN and the World Health Organisation in Chiang Mai, Thailand, in 1988. This message was reiterated a decade later during the international conference Medicinal Plants for Survival , hosted by the Foundation for Revitalization of Local Health Traditions in Bangalore, India in 1998. More recently, 20 participants at the symposium Medicinal Utilisation of Wild Species signed a Joint Declaration for the Health of People and Nature', which emphasises the need to address conservation concerns in a multi-disciplinary and collaborative manner. Signatories include representatives of the phytopharmaceutical industry, practitioners' associations and conservation organisations. The depository for the Joint Declaration is WWF Germany, who organised the symposium with TRAFFIC Europe - Germany, and, who, with TRAFFIC, is working to encourage and monitor the Declaration's transformation from words into actions. These and other initiatives indicate the potential for more and more effective cooperation among individuals and institutions concerned with the use, trade and conservation of medicinal plants. Additional effort needs to be invested in putting these good intentions into practice in order to secure the future of medicinal plant populations and the benefits they provide. Anon. (1998). Report of BCPP, Conservation Assessment and management Plant (CAMP) Workshop on selected medicinal plants of northern, northeastern and central India. Brevoort, P. (1998). The booming U.S. botanical market: A new overview. HerbalGram 44: 3345. Cunningham, A.B. (1993). African Medicinal Plants: Setting Priorities at the Interface Between Conservation and Primary Healthcare . UNESCO, Paris, France. Cunningham, A.B. (1993). African Medicinal Plants: Setting Priorities at the Interface Between Conservation and Primary Healthcare . UNESCO, Paris, France. FAO. (1995). Non-wood Forest Products for Rural Income and Sustainable Forestry . FAO, Rome, Italy. FAO. (1997). Medicinal Plants for Forest Conservation and Healthcare . FAO, Rome, Italy. FAO. (1999). State of the World's Forests 1999 . FAO, Rome, Italy. He, S.A. and Sheng, N. (1997). Utilization and conservation of medicinal plants in China with special reference to Atractylodes lancea . In: FAO. (1997). Medicinal Plants for Forest Conservation and Healthcare . FAO, Rome, Italy. He, S.A. and Cheng, Z.M. (1991). The role of Chinese botanical gardens in conservation of medicinal plants. In: Akerele, Ol, Heywood, V. and Synge, H. (eds.) (1991). The Conservation of Medicinal Plants . WHO, IUCN-The World Conservation Union and WWF, Geneva and Gland, Switzerland. He, S.A. and Sheng, H. (1997). Utilization and conservation of medicinal plants in China with special reference to Atractylodes lancea . In: FAO. (1997). Medicinal Plants for Forest Conservation and Healthcare . FAO, Rome, Italy. Lange, D., (1997). Trade in plant material for medicinal and other purposes: A German case study. TRAFFIC Bulletin 17(1): 2032. Lange, D. (1998). Europe's Medicinal and Aromatic Plants: Their Use, Trade and Conservation . TRAFFIC International, Cambridge, United Kingdom. Marshall, N.T. (1998). Searching for a Cure: Conservation of Medicinal Wildlife Resources in East and Southern Africa . TRAFFIC International, Cambridge, United Kingdom. Olsen, C.S. (1998). The trade in medicinal plants from Nepal. THeme paper presented at the International Conference on Medicinal Plants, Bangalore, India, 1619 February 1998. Olsen, C.S. (1999). CITES Appendix II re-visited: Is the listing of Nardostachys grandiflora and Picrorhiza kurrooa appropriate? Medicinal Plant Conservation 5: 810. Uniyal, R.C., Uniyal, M.R. and Jain, P. (2000). Cultivation of Medicinal Plants in India: A Reference Book . TRAFFIC India, Delhi, India. 1 TRAFFIC is the joint wildlife trade monitoring programme of WWF - World Wide Fund for Nature and IUCN-The World Conservation Union. TRAFFIC has grown from a single office when it was first formed in 1976 to a worldwide network with staff based in 22 countries and a coordinating office in Cambridge, UK. TRAFFIC's aim is to ensure that trade in wild plants and animals is not a threat to the conservation of nature. Additional information regarding TRAFFIC's work can be found on TRAFFIC's website ( www.traffic.org ) or by sending a request to TRAFFIC (219c Huntingdon Road, Cambridge CB3 0DL, United Kingdom; email: email protected ).",
    "url": "https://www.fao.org/4/y4496e/Y4496E42.htm",
    "length": 11767,
    "type": "html",
    "id": 3008,
    "source": "MedicinalPlants"
  },
  {
    "title": "Monographies de l'OMS sur certaines plantes médicinales ECHOcommunity.org",
    "text": "ECHO reçoit souvent des demandes d'informations sur les plantes médicinales. Bien que ECHO ne se concentre pas sur la recherche ou l'expérimentation des caractéristiques médicinales des plantes tropicales, de nombreuses cultures tropicales promues par ECHO à d'autres fins ont également une valeur médicinale. Par le passé, ECHO a orienté les membres du réseau intéressés vers les travaux d' ANAMED , une organisation internationale à but non lucratif ayant plus de 30 ans d'expérience dans le domaine des plantes médicinales. Il a récemment été porté à notre attention que l'Organisation mondiale de la santé dispose également de ressources sur les plantes médicinales dans un ensemble de quatre volumes. Les volumes sont organisés par nom scientifique de la plante et comprennent une grande quantité d'informations. Bien que certaines informations ne correspondent pas à ce que la plupart des membres du réseau de ECHO recherchent, comme la composition chimique et la description détaillée de l'apparence de la plante, certaines sections sous chaque description de plante peuvent être très utiles. Pour chaque plante, les sujets d'intérêt potentiel suivants sont présentés en détail s'ils sont disponibles : Matière végétale d'intérêt médicinal Attributs médicinaux testés cliniquement Rapports anecdotiques d'attributs médicinaux Avertissementseffets indésirablesprécautions Parcours ou explication de l'activité médicinale Les volumes contiennent des informations sur les plantes suivantes, familières à ECHO, dont beaucoup sont proposées par notre banque mondiale de semences : Oignons (volume 1) Séné (volume 1) Calendula (volume 2) Fruit de la passion (volume 3) Neem (volume 3) Jujube (volume 3) Cucurbita (volume 4) Goyave (volume 4) Les volumes 3 et 4 ont des index cumulatifs. Vous pouvez donc les utiliser pour voir ce que contient le volume que vous êtes en train de lire, ainsi que le contenu des volumes précédents. Il existe également un index cumulatif pour les parties de plantes (au lieu du nom de la plante) telles que les fruits (fructus) et les racines (radix). Malheureusement, les monographies ne comportent pas d'index par affection. Vous trouverez ces monographies de l'OMS sur certaines plantes médicinales et d'autres informations sur les plantes médicinales sur le site http:edn.linkqettfp .",
    "url": "https://www.echocommunity.org/fr/resources/f4cbe972-a04a-4bb7-9c14-641b823b5fe8",
    "length": 2320,
    "type": "html",
    "id": 3009,
    "source": "MedicinalPlants"
  },
  {
    "title": "Medicinal Plants of Aromatic Potential from Burkina Faso: a Review: Revue des Plantes Médicinales à Potentiel Aromatique du Burkina Faso HEALTH RESEARCH IN AFRICA",
    "text": "Medicinal Plants of Aromatic Potential from Burkina Faso: a Review Revue des Plantes Médicinales à Potentiel Aromatique du Burkina Faso Authors W. Jedida Ouedraogo 1. Université Nazi Boni, Ecole Doctorale Sciences Naturelles et Parasitologie, Bobo-Dioulasso, Burkina Faso R. Serge Yerbanga 2. Techniques, 226 20970811, Bobo-Dioulasso, Burkina Faso Roland Meda 1. Université Nazi Boni, Ecole Doctorale Sciences Naturelles et Parasitologie, Bobo-Dioulasso, Burkina Faso Jean Bosco Ouedraogo 3. Institut de Recherche en Sciences de la Santé, 226 71484866, Bobo-Dioulasso, Burkina Faso Georges A. Ouedraogo 1. Université Nazi Boni, Ecole Doctorale Sciences Naturelles et Parasitologie, Bobo-Dioulasso, Burkina Faso DOI: https:doi.org10.5281hra.v2i8.5940 Keywords: medicinal plants, essential, oil, aromatic plants, Burkina Faso Abstract RÉSUMÉ Introduction. Au Burkina Faso la production et l'utilisation des huiles essentielles ne sont pas encore bien développées. En 2002 on dénombrait environ 90 espèces aromatiques, et seulement 30 étudiées. Une étude approfondie et une exploitation des huiles essentielles provenant de plantes médicinales pourraient valoriser la médecine traditionnelle. L'objectif de cette revue était donc d'identifier et de répertorier les plantes médicinales à potentiel aromatique du Burkina Faso. Méthodologie. Une revue bibliographique et des moteurs de recherche à base de données scientifiques ont servi de méthodologie. Résultats. Dans cette étude, 84 plantes médicinales à potentiel aromatique ont été répertoriées. Ces plantes étaient issues de 44 familles dont celle des Césalpiniaceae la plus représentée. Les feuilles étaient les parties les plus utilisées pour l'extraction des huiles essentielles. Les composés actifs tels que les caryophyllènes, pinènes, phytols, linalols, acide hexadécanoïque, cinéole et phellandrène étaient les plus dominants. Les propriétés biologiques associées étaient anti-inflammatoire, antibactérienne, antioxydante et antimicrobienne. Conclusion. Cette revue indique le potentiel qu'ont certaines plantes médicinales du Burkina Faso pour l'exploitation de leurs huiles essentielles. Ainsi, les 85 plantes aromatiques répertoriées par cette étude pourrait être utilisée pour initier une investigation en produits cosmétologiques naturels, biologiques ou en pétrochimie. ABSTRACT Introduction. In Burkina Faso, the production and use of essential oils are not yet well developed. In 2002, there were approximately 90 aromatic species, with only 30 studied. A thorough study and exploitation of essential oils from medicinal plants could enhance traditional medicine. The objective of this review was therefore to identify and list medicinal plants with aromatic potential in Burkina Faso. Methodology. A literature review and search engines based on scientific databases were used as methodology. Results. In this study, 84 medicinal plants with aromatic potential were listed. These plants came from 44 families, with the Césalpiniaceae family being the most represented. Leaves were the most commonly used parts for essential oil extraction. Active compounds such as caryophyllenes, pinenes, phytols, linalols, hexadecanoic acid, cineole, and phellandrene were the most dominant. The associated biological properties were anti-inflammatory, antibacterial, antioxidant, and antimicrobial. Conclusion. This review indicates the potential of certain medicinal plants in Burkina Faso for the exploitation of their essential oils. Thus, the 85 aromatic plants listed in this study could be used to initiate an investigation into natural, organic, or petrochemical cosmetic products. References Petitjean A. Plantes Aromatiques et médicinales communes aux iles de l'océan Indien. Dans CIRAD-CITE-GRET, éditeurs. Plantes aromatiques et médicinales à Madagascar. Madagascar, Juin 1996, p.19. https:docplayer.fr28680190-Plantes-a-romatiques-medicinales-madagascar-c-1-t-e-gre-t-seminaire-tenu-au-cite-du-17-au-22-juin-1996-j.html Adossides A. La filière Plantes Aromatiques Médicinales. Dans République Libanaise Ministère de l'Agriculture. Stratégie et Politique agricole. Octobre 2003. p.1-70. http:www.agriculture.gov.lbgetattachmentStatistics-and-StudiesStudies-and-Publicationsagri-production-chainsD8A7D984D8A7D986D8AAD8A7D8AC-D8A7D984D8B2D8B1D8A7D8B9D98APlante-Aromatique-et-Medicinale.pdf?langar-LB 15 janvier 2024 Cortadellas D, Andriantsiferana M, Laboute P, Razanamparany L. Les substances naturelles d'intérêt pharmacologique. Dans Feller C, Sandron F, éditeurs. Parcours de Recherche à Madagascar. Marseille (France) : IRD ; 2010. p.391-405. https:doi.org10.1051978-2-7598-2349-9.c015 Antonelli A, Fry C, Smith RJ, Eden J, Govaerts RHA, Kersey P, et al. State of the World's Plants and Fungi, 2023. Internet. Royal Botanic Gardens, Kew; 2023 cité 1 juin 2024. Disponible sur: https:kew.iro.bl.ukconcernreportsfccd9838-42a9-401f-a518-e76142164193 Van Wyk BE. A Review of African Medicinal and Aromatic Plants. Dans : Neffati M, Najjaa H, Máthé Á, éditeurs. Medicinal and Aromatic Plants of the World - Africa Volume 3 Internet. Dordrecht: Springer Netherlands; 2017 cité 1 juin 2024. p. 1960. http:link.springer.com10.1007978-94-024-1120-1_2 Zerbo P, Millogo-Rasolodimby J, Nacoulma-Ouedraogo OG, Van Damme P. Plantes médicinales et pratiques médicales au Burkina Faso : cas des Sanan. Bois et Forêts des Tropiques. 2011 ; 307(1) :41-53. Bakkali F, Averbeck S, Averbeck D, Idaomar M. Biological effects of essential oils A review. Food Chem Toxicol. févr 2008;46(2):44675. Sangwan N, Farooqi AHA, Fatima S, Sangwan R. Regulation of essential oil production in plants. Plant Growth Regul. mai 2001;34:321. Baser KHC, Buchbauer G. Ch1: Introduction. Dans: Handbook of essential oil: science, technology, and applications. Florida, USA: Taylor and Francis Group-CRC Press; 2010. Burt S. Essential oils: their antibacterial properties and potential applications in foodsa review. Int J Food Microbiol. août 2004;94(3):22353. Fanny B. Effet larvicide des huiles essentielles sur Stomoxys calcitrans a la Réunion Doctorat Veterinaire. Toulouse (France): Université Paul-Sabatier de Toulouse; 2008. Feral C. La place des plantes médicinales dans l'industrie pharmaceutique et la réglementation européenne Doctorat Pharmacie. Toulouse (France) : Université Paul-Sabatier de Toulouse; 2020. Essential Oils Market Size, Share Growth Report, 2030 Internet. cité 29 mai 2024. Disponible sur: https:www.grandviewresearch.comindustry-analysisessential-oils-market Dabiré CM, Palé E, Nébié RHC, Samaté AD. L'huile essentielle de Grangea maderaspatana (L.) poir. du Burkina Faso : rendement d'extraction et composition chimique. J Soc Ouest-Afr Chim. 2009;28:816. Eklu-Natey RD, Balet A, Ahyi AMR, Adjanohoun E, Aké Assi L, Borst F, et al. Pharmacopée africaine: dictionnaire et monographies multilingues du potentiel médicinal des plantes africaines: Afrique de l'Ouest. Lausanne : Génève: Éditions d'en bas ; Traditions médecine T M; 2012. Arbonnier M. Arbres, arbustes et lianes des zones sèches d'Afrique de l'Ouest. 2e éd. Montpellier (Paris): CIRAD; 2002. Sofowora A. Plantes médicinales et médecine traditionnelle d'Afrique. Paris : Berne: Karthala ; Académie suisse des sciences naturelles; 2010. 378 p. Pousset JL. Plantes médicinales d'Afrique: comment les reconnaître et les utiliser. Aix-en-Provence (France): SECUM Édisud; 2004. Ogunbinu AO, Okeniyi S, Flamini G, Cioni PL, Ogunwande IA, Babalola IT. Essential Oil Composition of Acacia nilotica Linn., and Acacia albida Delile (Leguminosae) from Nigeria. J Essent Oil Res. nov 2010;22(6):5402. Vivekanandhan P, Venkatesan R, Ramkumar G, Karthi S, Senthil-Nathan S, Shivakumar MS. Comparative Analysis of Major Mosquito Vectors Response to Seed-Derived Essential Oil and Seed Pod-Derived Extract from Acacia nilotica. Int J Environ Res Public Health. févr 2018;15(2):388. Alva M, Popich S, Borkosky S, Cartagena E, Bardón A. Bioactivity of the Essential Oil of an Argentine Collection of Acanthospermum hispidum (Asteraceae). Nat Prod Commun. févr 2012;7(2):2458. Menut C, Molangui T, Lamaty G, Ouamba JM, Silou T, Bessière JM. Aromatic Plants of Tropical Central Africa. XXIV. Volatile Constituents of Acanthospermum hispidum DC from the Congo. J Essent Oil Res. nov 1995;7(6):58992. Kayode RM, Azubuike CU, Laba SA, Dauda AO, Balogun MA, Ajala SA. Chemical composition and anti-microbial activities of the essential oil of Adansonia digitata stem-bark and leaf on post-harvest control of tomato spoilage. LWT. juill 2018;93:5863. Ajaiyeoba EO, Ekundayo O. Essential oil constituents of Aframomum melegueta (Roscoe) K. Schum. seeds (alligator pepper) from Nigeria. Flavour Fragr J. 1999;14(2):10911. Kamte SLN, Ranjbarian F, Campagnaro GD, Nya PCB, Mbuntcha H, Woguem V, et al. Trypanosoma brucei Inhibition by Essential Oils from Medicinal and Aromatic Plants Traditionally Used in Cameroon (Azadirachta indica, Aframomum melegueta, Aframomum daniellii, Clausena anisata, Dichrostachys cinerea and Echinops giganteus). Int J Environ Res Public Health. 6 juill 2017;14(7):737. Menut C, Lamaty G, Zollo PHA, Atogho BM, Abondo R, Bessière JM. Aromatic plants of tropical central Africa. V. volatile components of three zingiberaceae from Cameroon:Aframomum melegueta (roscoe) K. Schum.,A. Daniellii (hook. f.) K. Schum. andA. Sulcatum (oliv. and hanb.) K. Schum. Flavour Fragr J. sept 1991;6(3):1836. Owokotomo I, Ekundayo O, Oguntuase BJ. Chemical Constituents of the Leaf, Stem, Root and Seed Essential Oils of Aframomum melegueta (K. Schum) from South West Nigeria. Int Res J Pure Appl Chem. 10 janv 2014;4(4):395401. Essien E, Newby J, Walker T, Setzer W, Ekundayo O. Characterization and Antimicrobial Activity of Volatile Constituents from Fresh Fruits of Alchornea cordifolia and Canthium subcordatum. Medicines. 29 déc 2015;3(1):1. Okoye F, Osadebe P, Okoye N, Ukwueze N, David E. The GCMS characterization of the volatile oil from fresh leaves of Alchornea cordifolia leaves. Planta Med Internet. juill 2009 cité 22 sept 2020;75(09). Disponible sur: http:www.thieme-connect.deDOIDOI?10.1055s-0029-1234799 Benkeblia N. Antimicrobial activity of essential oil extracts of various onions (Allium cepa) and garlic (Allium sativum). LWT - Food Sci Technol. mars 2004;37(2):2638. Ye CL, Dai DH, Hu WL. Antimicrobial and antioxidant activities of the essential oil from onion (Allium cepa L.). Food Control. mars 2013;30(1):4853. Ndoye Foe FMC, Tchinang TFK, Nyegue AM, Abdou JP, Yaya AJG, Tchinda AT, et al. Chemical composition, in vitro antioxidant and anti-inflammatory properties of essential oils of four dietary and medicinal plants from Cameroon. BMC Complement Altern Med. déc 2016;16:117. Ahmed A, Bassem SEM, Mohamed Y, Gamila M. Cytotoxic essential oil from Annona sengalensis Pers. Leaves. Phcog Res. Juillet-aout 2010;2(4), 211-214. doi: 10.41030974-8490.69105 Ekundayo O, Oguntimein B. Composition of the Essential Oils of Annona senegalensis var. senegalensis. Planta Med. juin 1986;52(03):2024. Moronkola D, Kunle O. Constituents of leaf, stem bark and root volatile oils of Anogeissus leiocarpus DC. Guill. Perr. Int J Biol Chem Sci. 2014;8(4):180818. Aromdee C, Sriubolmas N. Essential oil of the flowers of Azadirachta indica (Meliaceae). Songklanakarin J Sci Technol. 2006;28(1):1159. El-hawary SS, El-Tantawy ME, Rabeh MA, Badr WK. Chemical composition and biological activities of essential oils of Azadirachta indica A. Juss. Int J Appl Res Nat Prod. 2013;6(4):3342. Akinpelu OE, Moronkola DO, Dawodu FA, Sichilongo K. Chemical compositions of seven essential oils from Blighia sapida (K. Koenig), (Sapindaceae). Int J Biol Chem Sci. oct 2016;10(5):235167. Bouare S, Traore N, Somboro A, Tembély L. Chemical compositions of the essential oils and absolutes of the flowers of bombax costatum pellgr et vuillet bombacaceae from mal. Asian J Plant Sci Res. 2017;7(2):17. Kohoude MJ, Gbaguidi F, Agbani P, Ayedoun MA, Cazaux S, Bouajila J. Chemical composition and biological activities of extracts and essential oil of Boswellia dalzielii leaves. Pharm Biol. 1 janv 2017;55(1):3342. Kubmarawa D, Ogunwande IA, Okorie DA, Olawore NO, Kasali AA. Constituents of the Essential Oils of Boswellia dalzielii Hutch. from Nigeria. J Essent Oil Res. mars 2006;18(2):11920. Kubmarawa D, Ogunwande IA. Composition of the Leaves Essential Oil of Calotropis procera (R. Br.) from Nigeria. J Essent Oil Bear Plants. 1 janv 2008;11(1):758. Okiei W, Ogunlesi M, Ofor E, Osibote AE. Analysis of essential oil constituents in hydro-distillates of Calotropis procera (Ait.) R. Br.pdf. Res J Phytochem Internet. cité 18 nov 2020;(2009). Disponible sur: https:ir.unilag.edu.ngbitstreamhandle1234567896029Analysis20of20essential20oil20constituents20in20hydro-distillates20of20Calotropis20procera2028Ait.2920R.20Br.pdf?sequence1isAllowedy He X, Ma Y, Yi G, Wu J, Zhou L, Guo H. Chemical composition and antifungal activity of Carica papaya Linn. seed essential oil against Candida spp. Lett Appl Microbiol. mai 2017;64(5):3504. Ogunwande IA, Avoseh NO, Flamini G, Hassan ASO, Ogunmoye AO, Ogunsanwo AO, et al. Essential Oils from the Leaves of Six Medicinal Plants of Nigeria. Nat Prod Commun. févr 2013;8(2):2438. Adedoyin B, Muhammad A, Dangoggo SM, Rabah A, Sharples G, Nahar L, Sarker S. Chemical Composition and Bioactivity of the Essential Oil of Cassia singueana Flowers Growing in Nigeria. Pharmaceutical and Biomedical Research. 25 décembre 2019;5(3):1-7. Satyal P, Mallik S, Gautam T, Vogler B, Setzer WN. Composition and Bioactivities of Leaf Essential Oil of Cassia tora. Chem Nat Compd. juill 2013;49(3):5534. Ouattara ZA, Sangaré N, Mamyrbekova-Bekro AJ, Békro YA, Tomi P, Paoli M, et al. Composition and Chemical Variability of Essential Oils Isolated from Aerial Parts of Cassytha filiformis from Côte d'Ivoire. Nat Prod Commun. févr 2018;13(2):2178. Mevy JP, Bessiere JM, Dherbomez M. Composition, Antimicrobial and Antioxidant Activities of the Volatile Oil of Chrysanthellum americanum (Linn.) Vatke. J Essent Oil Bear Plants. janv 2012;15(3):48996. de Santana Campos RN, Nascimento Lima CB, Passos Oliveira A, Albano Araújo AP, Fitzgerald Blank A, Barreto Alves P, et al. Acaricidal properties of vetiver essential oil from Chrysopogon zizanioides (Poaceae) against the tick species Amblyomma cajennense and Rhipicephalus (Boophilus ) microplus (Acari: Ixodidae). Vet Parasitol. sept 2015;212(34):32430. doi: 10.1016j.vetpar.2015.08.022 Khogli, SKA. Analysis of the Volatile oil of Vetiveria Nigritana Roots by Gas Chromatography Mass Spectrometry master. Soudan: University of Gezira;2018. Ogundajo AL, Owoyele OA, Ogunwande IA, Owolabi MS. Chemical Composition of Essential Oil from the Leaves of Clerodendrum polycephalum Baker growing in Nigeria. J Essent Oil Bear Plants. 2 janv 2016;19(1):11924. Ouattara L, Koudou J, Obame LCE, Karou DS,Traore A, Bessiere JM. Chemical Composition and Antibacterial Activity of Cochlospermum planchoni Hook.f. Ex Planch Essential Oil from Burkina Faso. Pakistan Journal of Biological Sciences. 2007;10(22): 41774179. Benoit-Vical F, Valentin A, Mallié M, Bessière JM. Antiplasmodial Activity of Cochlospermum planchonii and C. tinctorium Tubercle Essential Oils. J Essent Oil Res. janv 2001;13(1):657. Bossou AD, Mangelinckx S, Yedomonhan H, Boko PM, Akogbeto MC, De Kimpe N, et al. Chemical composition and insecticidal activity of plant essential oils from Benin against Anopheles gambiae (Giles). Parasit Vectors. 2013;6(1):337. Da Fonseca AM, Bizerra AMC, De Souza JSN, Monte FJQ, De Oliveira M da CF, De Mattos MC, et al. Constituents and antioxidant activity of two varieties of coconut water (Cocos nucifera L.). Rev Bras Farmacogn. mars 2009;19(1b):1938. Fit IN, Rapuntean G, Rapuntean S, Chirila F, Nadas GC. Antibacterial Effect of Essential Vegetal Extracts on Staphylococcus aureus. Not Bot Horti Agrobot Cluj-Napoca. 2009;37(2):11723. Avlessi F, Alitonou GA, Sohounhloue DK, Bessiere JM, Menut C. Aromatic Plants of Tropical West Africa. Part XV. Chemical and Biological Evaluation of Leaf Essential Oil of Commiphora africana from Benin. J Essent Oil Res. sept 2005;17(5):56971. Gadir SA, Ahmed IM. Commiphora myrrha and commiphora Africana essential oils. J Chem Pharm Res. 2014;6(7):1516. Driss D, Kaoubaa M, Mansour RB, Kallel F, Abdelmalek B eddine, Chaabouni SE. Antioxidant, Antimutagenic and Cytotoxic Properties of Essential Oil from Corchorus olitorius L. Flowers and Leaf. Free Radic Antioxid.10 janv 2016;6(1):3443. Kanko C, Sawaliho BEH, Kone S, Koukoua G, N'Guessan YT. Étude des propriétés physico-chimiques des huiles essentielles de Lippia multiflora, Cymbopogon citratus, Cymbopogon nardus, Cymbopogon giganteus. Comptes Rendus Chim. oct 2004;7(1011):103942. De Toledo L, Ramos M, Spósito L, Castilho E, Pavan F, Lopes É, et al. Essential Oil of Cymbopogon nardus (L.) Rendle: A Strategy to Combat Fungal Infections Caused by Candida Species. Int J Mol Sci. 9 août 2016;17(8):1252. Bokobana EM, Koba K, Poutouli WP, Akantetou PK, Nadio NA, Laba B, et al. Evaluation du potentiel insecticide et repulsif de l'huile essentielle de Cymbopogon schoenanthus (l.) Spreng. sur Aphis gossypii glover (homoptera : aphididae), ravageur du cotonnier au Togo. Rev CAMES. 2014;2(2):4855. Khadri A, Serralheiro MLM, Nogueira JMF, Neffati M, Smiti S, Araújo MEM. Antioxidant and antiacetylcholinesterase activities of essential oils from Cymbopogon schoenanthus L. Spreng. Determination of chemical composition by GCmass spectrometry and 13C NMR. Food Chem. août 2008;109(3):6307. Menut C, Lamaty G, Bessière JM, Ayedoun MA, Setondji J, Samaté D, et al. Aromatic Plants from Tropical West Africa. II. Volatile Constituents of Daniellia oliveri (Rolfe) Hutch Dalz. from Benin and Burkina Faso. J Essent Oil Res. nov 1994;6(6):6479. Schwob I, Viano J, Bessière JM, Haddad C. Comparison of Essential Oil Composition of Daniellia oliveri (Rolfe) Hutch et Dalz. (Caesalpiniaceae) leaves from Senegal and Ivory Coast. J Essent Oil Res. mars 2008;20(2):1557. Essien EE, Walker TM, Ogunwande IA, Bansal A, Setzer WN, Ekundayo O. Essential oil composition, cytotoxicity and antimicrobial activities of Datura metel L. from Nigeria. Int J Essent Oil Ther. 2010;4:6972. Xue J, Sun Y, Wei Q, Wang C, Yang B, Kuang H, et al. Chemical composition and cytotoxicity of the essential oil from different parts of Datura metel L. Nat Prod Res. 1 sept 2016;30(17):193840. Samaté AD, Nacro M, Menut C, Lamaty G, Bessière JM. Aromatic Plants of Tropical West Africa. VII. Chemical Composition of the Essential Oils of two Eucalyptus Species (Myrtaceae) from Burkina Faso: Eucalyptus alba Muell. and Eucalyptus camaldulensis Dehnardt. J Essent Oil Res. 1 mai 1998;10(3):3214. Ogunlesi M, Okiei W, Ofor E, Osibote AE. Analysis of the essential oil from the dried leaves of Euphorbia hirta Linn (Euphorbiaceae), a potential medication for asthma. Afr J Biotechnol. 2009;8(24):704250. Kashima Y, Miyazawa M. Chemical Composition and Aroma Evaluation of Essential Oils from Evolvulus alsinoides L. Chem Biodivers. mars 2014;11(3):396407. Essien EE, Aboaba SO, Ogunwande IA. Constituents and antimicrobial properties of the leaf essential oil of Gossypium barbadense (Linn.). J Med Plants Res. 2011;5(5):7025. Ajayi IA, Jonathan SG, Adewuyi A, Oderinde RA. Antimicrobial Screening of the Essential Oil of Some Herbal Plants from Western Nigeria. World Appl Sci J. 2008;3(1):7981. Dabiré CM, Palé E, Nébié RHC, Samaté AD. L'huile essentielle de Grangea maderaspatana (L.) poir. du Burkina Faso : rendement d'extraction et composition chimique. 2009;6. Gbolade AA, Tira-Picos V, Nogueira JMF, Oladele AT. Comparative analysis of essential oils from the leaf, fruit and stem bark of Harungana madagascariensis. Int J Green Pharm. 2009;3(4):2902. Machan T, Korth J, Liawruangrath B, Liawruangrath S, Pyne SG. Composition and antituberculosis activity of the volatile oil of Heliotropium indicum Linn. growing in Phitsanulok, Thailand. Flavour Fragr J. 2006;21(2):2657. Ogunbinu AO, Flamini G, Cioni PL, Adebayo MA, Ogunwande IA. Constituents of Cajanus Cajan (L.) Millsp., Moringa Oleifera Lam., Heliotropium Indicum L. and Bidens Pilosa L. from Nigeria. Nat Prod Commun. avr 2009;4(4):5738. Inikpi E, Lawal OA, Ogunmoye AO, Ogunwande A. Volatile composition of the floral essential oil of Hibiscus sabdariffa L. from Nigeria. Am J Essent Oils Nat Prod. 2014;2(2):47. Shen CY, Zhang TT, Zhang WL, Jiang JG. Anti-inflammatory activities of essential oil isolated from the calyx of Hibiscus sabdariffa L. Food Funct. 2016;7(10):44519. Aboaba SA, Fasimoye GF.Volatile Constituents and Toxicity Profile of the Leaves, Stem Bark and Root Bark Essential Oils of Holarrhena Floribunda and Crescentia Cujete. International Journal of Sciences. 2018;7(2), 3135. https:doi.org10.18483 Gundidza GM, Deans SG, Svoboda KP, Mavi S. Antimicrobial activity of essential oil from Hoslundia opposita. Cent Afr J Med. juill 1992;38(7):2903. Usman LA, Zubai MF, Adebayo SA, Oladosu IA, Muhammad NO, Akolade JO. Chemical Composition of Leaf and Fruit Essential Oils of Hoslundia opposita Vahl Grown in Nigeria. Am Eurasian J Agric Environ Sci. 2010;8(1):403. Kini F, Kam B, Aycard JP, Gaydou EM, Bombarda I. Chemical Composition of the Essential Oil of Hyptis spicigera Lam. from Burkina Faso. J Essent Oil Res. 1 mars 1993;5(2):21921. Onayade OA, Looman A, Scheffer JJC, Svendsen AB. Composition of the herb essential oil of Hyptis spicigera Lam. Flavour Fragr J. 1990;5(2):1015. Takayama C, de-Faria FM, de Almeida ACA, Valim-Araújo D de A e O, Rehen CS, Dunder RJ, et al. Gastroprotective and ulcer healing effects of essential oil from Hyptis spicigera Lam. (Lamiaceae). J Ethnopharmacol. avr 2011;135(1):14755. Uraku A, Okaka A, Ibiam U, Agbafor K, Obasi N, Ajah P, et al. Antiplasmodial Activity of Ethanolic Leaf Extracts of Spilanthes uliginosa, Ocimum basilicum (Sweet Basil), Hyptis spicigera and Cymbopogon citratus on Mice Exposed to Plasmodium berghei Nk 65. Int J Biochem Res Rev. 10 janv 2015;6(1):2836. Ogunmoye A, Adebayo M, Inikpi E, Ogunwande I. Chemical Constituents of Essential Oil from the Leaves of Ipomoea batatas L. (Lam.). Int Res J Pure Appl Chem. 10 janv 2015;7(1):428. Ait Babahmad R, Aghraz A, Boutafda A, Papazoglou EG, Tarantilis PA, Kanakis C, et al. Chemical composition of essential oil of Jatropha curcas L. leaves and its antioxidant and antimicrobial activities. Industrial Crops and Products. 2018;121:405410. Asekun OT, Olusegun E, Adebola O. The volatile constituents of the leaves and flowers of Kigelia africana Benth. Flavour Fragr J. 2007;22(1):213. Oyedeji AO, Ekundayo O, Koenig WA. Essential Oil Composition of Lawsonia inermis L. leaves from Nigeria. J Essent Oil Res. juill 2005;17(4):4034. Folashade KO, Omoregie EH. Essential oil of Lippia multiflora Moldenke: A review. J Appl Pharm Sci. 2012;2(1):1523. Gebara SS, de Oliveira Ferreira W, Ré-Poppi N, Simionatto E, Carasek E. Volatile compounds of leaves and fruits of Mangifera indica var. coquinho (Anacardiaceae) obtained using solid phase microextraction and hydrodistillation. Food Chem. juill 2011;127(2):68993. Wang HW, Liu YQ, Wei SL, Yan ZJ, Lu K. Comparison of Microwave-Assisted and Conventional Hydrodistillation in the Extraction of Essential Oils from Mango (Mangifera indica L.) flowers. Molecules. 29 oct 2010;15(11):771523. Braca A, Siciliano T, D'Arrigo M, Germanò MP. Chemical composition and antimicrobial activity of Momordica charantia seed essential oil. Fitoterapia. févr 2008;79(2):1235. Moronkola DO, Ogunwande IA, Oyewole IO, Başer KHC, Ozek T, Ozek G. Studies on the Volatile Oils of Momordica charantia L. (Cucurbitaceae) and Phyllanthus amarus Sch. et Thonn (Euphorbiaceae). J Essent Oil Res. sept 2009;21(5):3939. Okoh SO, Asekun OT, Familoni OB, Afolayan AJ. Composition and Antioxidant Activities of Leaf and Root Volatile Oils of Morinda lucida. Nat Prod Commun. oct 2011;6(10):153741. Owolabi MS, Padilla-Camberos E, Ogundajo AL, Ogunwande IA, Flamini G, Yusuff OK, et al. Insecticidal Activity and Chemical Composition of the Morinda lucida Essential Oil against Pulse Beetle Callosobruchus maculatus. Sci World J. 2014;8. Marrufo T, Nazzaro F, Mancini E, Fratianni F, Coppola R, De Martino L, et al. Chemical Composition and Biological Activity of the Essential Oil from Leaves of Moringa oleifera Lam. Cultivated in Mozambique. Molecules. 9 sept 2013;18(9):109891000. Popova V, Ivanova T, Prokopov T, Nikolova M, Stoyanova A, Zheljazkov VD. Carotenoid-Related Volatile Compounds of Tobacco (Nicotiana tabacum L.) Essential Oils. Molecules. 23 sept 2019;24(19):3446. Thaweboon S, Thaweboon B. In vitro antimicrobial activity of Ocimum americanum L. essential oil against oral microorganisms. Southeast Asian J Trop Med Public Health. 2009;40(5):102533. Chimnoi N, Reuk-Ngam N, Chuysinuan P, Khlaychan P, Khunnawutmanotham N, Chokchaichamnankit D, et al. Characterization of essential oil from Ocimum gratissimum leaves: Antibacterial and mode of action against selected gastroenteritis pathogens. Microb Pathog. mai 2018;118:290300. Asekun OT, Okoh SO, Familoni OB, Afolayan AJ. Chemical Profiles and Antioxidant Activity of Essential Oils Extracted from the Leaf and Stem of Parkia biglobosa (Jacq) Benth. Res J Med Plant. 1 févr 2013;7(2):8291. Ogunwande IA, Osunsam AA, Sotubo SE, Lawal OA. Chemical constituents and insecticidal activity of essential oil of Paullinia pinnata L (Sapindaceae). Bol Latinoam Caribe Plantas Med Aromáticas. 2017;16(5):45562. Gbolade A, Tira-Picos V, Nogueira JosephMF. Comparative analysis of leaf essential oil constituents of Piliostigma thonningii and Piliostigma reticulatum. Int J Green Pharm. 2010;4(2):6770. Boyom FF, Fotio D, Zollo PHA, Agnaniet H, Menut C, Bessière JM. Aromatic plants of tropical central Africa. Part XLIV. Volatile components from Pseudocedrela kotschyi (Schweinf.) harms growing in Cameroon. Flavour Fragr J. janv 2004;19(1):911. Kpoviessi DSS, Gbaguidi FA, Kossouoh C, Agbani P, Yayi-Ladekan E, Sinsin B, et al. Chemical composition and seasonal variation of essential oil of Sclerocarya birrea (A. Rich.) Hochst subsp birrea leaves from Benin. J Med Plants Res. 2011;5(18):46406. Ordaz G, D'Armas H, Yáñez D, Moreno S. Chemical composition of essential oils from leaves of Helicteres guazumifolia (Sterculiaceae), Piper tuberculatum (Piperaceae), Scoparia dulcis (Arecaceae) and Solanum subinerme (Solanaceae) from Sucre, Venezuela. Rev Biol Trop. juin 2011;59(2):58595. Adebayo MA, Karioti A, Skaltsa H, Ogunwande IA. Essential Oils of Nigeria II : Analysis of the leaf Oil of Securidaca longependuculata Fers. Journal of Essential Oil Research. 2007;19(5), 452454. Alitonou GA, Koudoro AY, Dangou JS, Yehouenou B, Avlessi F, Adeoti S, et al. Volatile constituents and biological activity of Securidaca longepedunculata Fers. growing in Benin. Sci Study Res Chem Chem Eng Biotechnol Food Ind. 2012;13(1):3342. Bahta TL. Essential oil and biodiversity study of Securidaca longipedunculata Master. Norwegian University of Science and Technology; 2017. Essien EE, Walker TM., Newby JS, Setzer WN, Ekundayo O. Characterization and Antimicrobial Activity of Essential Oils of Stachytarpheta indica (Linn.) Vahl and Mariscus alternifolius Vahl. J Med Act Plants. 2016;5(2):4752. Hoet S, Stévigny C, Hérent MF, Quetin-Leclercq J. Antitrypanosomal Compounds from the Leaf Essential Oil of Strychnos spinosa. Planta Med. févr 2006;72(05):4802. El-Siddig K, Gunasena HPM, Prasad BA, Pushpakumara DKNG, Ramana KVR, Vijayanand P, et al. Tamarind: Tamarindus indica L. Rev. ed. Southampton UK: Internat. Centre for Underutilised Crops, Univ. of Southampton; 2006. 188 p. Zhang Y, Ho CT, Khurana AL. Volatile Flavor Components of Tamarind (Tamarindus indica L.). J Essent Oil Res. juill 1990;2(4):1978. Atewolara-Odule OC, Oladosu IA. Comparison of chemical compositions of essential oils from the fresh and dried leaves of Tapinanthus bangwensis (Engl. and K. Krause) Danser Loranthaceae. Am J Essent Oils Nat Prod. 2016;4(3):313. Noudogbessi J, Philippe S, Wotto V, Figueredo G, Chalard P, Chalchat JC, et al. Chemical Compositions and Preventive Activity of Essential Oils Extracted from the Leaves of two varieties of Tephrosia (Leguminosae-papilionoideae) collected in Benin on Callosobruchus maculatus (Fabricius). Asian J Res Chem. 28 déc 2012;5(12):14316. Moronkola DO, Ekundayo O. Chemical constituents in the fruit essential oil of Terminalia catappa Linn (almond fruits). J Trop For Resour. 2000;16(1):729. Owolabi MS, Lawal OA, Ogunwande IA, Hauser RM, Setzer WN. Chemical composition of the leaf essential pil of Terminalia catappa L. growing in southwestern Nigeria. Am J Essent Oils Nat Prod. 2013;1(1):514. Aboaba SA, Ogunwande IA, Walker TM, Setzer WN, Oladosu IA, Ekundayo O. Essential Oil Composition, Antibacterial Activity and Toxicity of the Leaves of Tetrapleura Tetraptera (Schum. Thonn.) Taubert from Nigeria. Natural Product Communications. 2009;4(2):287-290. Aboaba SA, Choudhary IM. Chemical Composition and Biological Activities of the Volatile Oils of Palisota hirsuta (Thunb) K. Schum and Trema orientalis (L) Blume. International Journal of Chemistry. 2015;7(2): 21. Senatore F, Formisano C, Sanogo R. Essential oil from aerial parts of Vernonia colorata Drake and Vernonia nigritiana Oliver et Hiern. (Asteraceae) growing wild in Mali. J Essent Oil Bear Plants. janv 2004;7(3):26774. Aboaba S, Akande A, Flamini G. Chemical Composition and Toxicity of Essential Oil of Vitellaria paradoxa (C.F. Gaertn.) from Nigeria. J Essent Oil Bear Plants. 2014;17(1), 126130. Sonibare OO, Effiong I, Oladosu IA, Ekundayo O. Chemical Constituents and Antimicrobial activity of the Essential Oil of Vitex doniana Sweet (Verbernaceae). J Essent Oil Bear Plants. janv 2009;12(2):1858. Moke LE, Ngbolua K te N, Bongo GN, Messi M, Noté OP, Mbing JN, et al. Vitex madiensis Oliv. (Lamiaceae): phytochemistry, pharmacology and future directions, a mini-review. J Pharmacogn Phytochem. 2018;7(2):24451. Liu X, Yang D, Liu J, Ren N. Analysis of essential oils from Voacanga africana seeds at different hydrodistillation extraction stages: chemical composition, antioxidant activity and antimicrobial activity. Nat Prod Res. 18 oct 2015;29(20):19503. Avoseh ON, Ogunwande IA, Lawal OA, Atabo J, Ascrizzi R, Flamini G. Anti-inflammatory and anti-nociceptive activities of essential oil of Waltheria indica. Boletin Latinoam Caribe Plantas Med Aromat. nov 2019;18(6):56676. Mevy JP, Bessiere JM, Greff S, Zombre G, Viano J. Composition of the volatile oil from the leaves of Ximenia americana L. Biochem Syst Ecol. juill 2006;34(7):54953. Ngassoum MB, Essia-Ngang JJ, Tatsadjieu LN, Jirovetz L, Buchbauer G, Adjoudji O. Antimicrobial study of essential oils of Ocimum gratissimum leaves and Zanthoxylum xanthoxyloides fruits from Cameroon. Fitoterapia. avr 2003;74(3):2847. Savadogo S, Lykke AM, Traore L, Sereme A, Thiombiano A. Bio-insecticide potential of three aromatic plants of Burkina Faso (Ocimum americanum L., Cymbopogon schoenanthus L. and Hyptis suaveolens Poit.) and their importance in cowpea seed conservation. Int J Biol Chem Sci. 17 août 2020;14(4):116776. Wangrawa DW, Badolo A, Ilboudo Z, Guelbéogo WM, Kiendrébeogo M, Nébié RCH, et al. Insecticidal Activity of Local Plants Essential Oils Against Laboratory and Field Strains of Anopheles gambiae s. l. (Diptera: Culicidae) From Burkina Faso. J Econ Entomol. 3 oct 2018;111(6):284453. Wangrawa D, Badolo A, Guelbéogo W, Kiendrébeogo M, Nébié R, Sagnon N, et al. Biological activities of four essential oils against Anopheles gambiae in Burkina Faso and their in vitro inhibition of acetylcholinesterase. Int J Biol Chem Sci. 2015;9(2):793802. Bayala B, Bassole IHN, Gnoula C, Nebie R, Yonli A, Morel L, et al. Chemical Composition, Antioxidant, Anti-Inflammatory and Anti-Proliferative Activities of Essential Oils of Plants from Burkina Faso. Vanacker JM, éditeur. PLoS ONE. 24 mars 2014;9(3):e92122. Cooke B, Ernst E. Aromatherapy: a systematic review. Br J Gen Pract J R Coll Gen Pract. juin 2000;50(455):4936. Farrar AJ, Farrar FC. Clinical Aromatherapy. Nurs Clin North Am. déc 2020;55(4):489504. Downloads PDF (Français (Canada)) Published 25-07-2024 Updated on 30-07-2024 How to Cite W. Jedida Ouedraogo, R. Serge Yerbanga, Roland Meda, Jean Bosco Ouedraogo, Georges A. Ouedraogo. (2024). Medicinal Plants of Aromatic Potential from Burkina Faso: a Review: Revue des Plantes Médicinales à Potentiel Aromatique du Burkina Faso. HEALTH RESEARCH IN AFRICA , 2 (8). https:doi.org10.5281hra.v2i8.5940 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Download Citation EndnoteZoteroMendeley (RIS) BibTeX Issue Vol. 2 No. 8 (2024): Health Research in Africa Section Research Articles License Copyright (c) 2024 W. Jedida Ouedraogo, R. Serge Yerbanga, Roland Meda, Jean Bosco Ouedraogo, Georges A. Ouedraogo This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License . Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC BY-NC-ND 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work",
    "url": "https://hsd-fmsb.org/index.php/hra/article/view/5940",
    "length": 33979,
    "type": "html",
    "id": 3010,
    "source": "MedicinalPlants"
  },
  {
    "id": 4000,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 0)",
    "text": "P H A R M A C O P É E D ' A F R I Q U E D E L ' O U E S T O r g a n i s a t i o n O u e s t A f r i c a i n e d e l a S a n t é Copyright 2013, Organisation Ouest-Africaine de la Santé (OOAS). Tous droits réservés. ISBN Aucune partie de cette publication ne peut être reproduite, stockée dans un système documentaire ou transmise sous quelle que forme ou moyens électronique, mécanique, photocopie, enregistrement ou autre sans l'autorisation préalable de l'Organisation Ouest Africaine de la Santé. Conçu, imprimé et relié par KS PRINTCRAFT GH. LTD. P. O. BOX 1074 KNUST JUNCTION KUMASI, GHANA Tel: 233-277412577",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 613,
    "source": "PDF_chunked"
  },
  {
    "id": 4001,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1)",
    "text": "OOAS Page i LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP CONTENU CONTENU................................................................................................................. ........I AVANT-PROPOS..............................................................................................................III PRÉFACE..................................................................................................................... ...V INTRODUCTION .............................................................................................................VII REMERCIEMENTS............................................................................................. .............XI ACACIA NILOTICA...........................................................................................................1 ACACIA SENEGAL............................................................................................................6 ADONSONIA DIGITATA....................................................................................................9 AGERATUM CONYZOIDES..............................................................................................14 ALCHORNEA CORDIFOLIA..............................................................................................18 ALLIUM SATIVUM...........................................................................................................23 ALOE SCHWEINFURTHI..................................................................................................29 ALOE VERA...................................................................................................................32 ALSTONIA BOONEI........................................................................................................36 ARGEMONE MEXICANA..................................................................................................40",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 1934,
    "source": "PDF_chunked"
  },
  {
    "id": 4002,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 2)",
    "text": "ALOE VERA...................................................................................................................32 ALSTONIA BOONEI........................................................................................................36 ARGEMONE MEXICANA..................................................................................................40 AZADIRACHTA INDICA...................................................................................................44 BALANITES AEGYPTIACA..............................................................................................51 BRIDELIA FERRUGINEA..................................................................................................56 CARICA PAPAYA...........................................................................................................62 CINCHONA PUBESCENS................................................................................................69 CRYPTOLEPIS SANGUINOLENTA ....................................................................................72 CYMBOPOGON CITRATUS..............................................................................................76 EUPHORBIA HIRTA........................................................................................................81 HALLEA STIPULOSA......................................................................................................86 HARRISONIA ABYSSINICA..............................................................................................89 HIBISCUS SABDARIFFA.................................................................................................93 HYMENOCARDIA ACIDA .................................................................................................97 KHAYA SENEGALENSIS ...............................................................................................101 LAWSONIA INERMIS.....................................................................................................105",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 2030,
    "source": "PDF_chunked"
  },
  {
    "id": 4003,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 3)",
    "text": "HYMENOCARDIA ACIDA .................................................................................................97 KHAYA SENEGALENSIS ...............................................................................................101 LAWSONIA INERMIS.....................................................................................................105 LIPPIA MULTIFLORA.....................................................................................................109 MITRAGYNA INERMIS...................................................................................................113 MOMORDICA CHARANTIA.............................................................................................116 MORINDA LUCIDA........................................................................................................121 MORINGA OLEIFERA....................................................................................................125 OCIMUM BASILICUM.....................................................................................................131 OCIMUM GRATISSIMUM................................................................................................135",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 1196,
    "source": "PDF_chunked"
  },
  {
    "id": 4004,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 4)",
    "text": "OOAS Page ii LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP PHYLLANTHUS NIRURI.................................................................................................140 PHYTOLACCA DODECANDRA.......................................................................................145 PTEROCARPUS ERINACEUS.........................................................................................150 RAUWOLFIA VOMITORIA...............................................................................................153 SARCOCEPHALUS LATIFOLIUS.....................................................................................157 SCLEROCARYA BIRREA...............................................................................................161 SCOPARIA DULCIS.......................................................................................................167 SECURIDACA LONGEPEDUNCULATA.............................................................................171 SENNA ALATA .............................................................................................................177 SENNA ALEXANDRINA..................................................................................................182 SENNA OCCIDENTALIS.................................................................................................185 SENNA PODOCARPA....................................................................................................191 SOLANUM TORVUM......................................................................................................195 SORGHUM BICOLOR....................................................................................................199 SPATHODEA CAMPANULATA .......................................................................................203",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 1837,
    "source": "PDF_chunked"
  },
  {
    "id": 4005,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 5)",
    "text": "SOLANUM TORVUM......................................................................................................195 SORGHUM BICOLOR....................................................................................................199 SPATHODEA CAMPANULATA .......................................................................................203 SPERMACOCE VERTICILLATA.......................................................................................207 SPONDIAS MOMBIN......................................................................................................210 TETRAPLEURA TETRAPTERA........................................................................................215 TINOSPORA BAKIS.......................................................................................................219 VERNONIA AMYGDALINA .............................................................................................222 VERNONIA COLORATA .................................................................................................227 ZANTHOXYLUM XANTHOXYLOIDES ...............................................................................231 ZINGIBER OFFICINALE..................................................................................................236 INDEX DES NOMS SCIENTIFIQUES DE PLANTES.............................................................242 INDEX DES NOMS COMMUNS ........................................................................................246 INDEX DES MALADIES...................................................................................................249 ANNEXE......................................................................................................................251",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 1757,
    "source": "PDF_chunked"
  },
  {
    "id": 4006,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 6)",
    "text": "OOAS Page iii LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP AVANT -PROPOS Le recours aux plantes médicinales pour le traitement des maladies, remonte à l'antiquité. Fruit de la combinaison de l'instinct, de l'observation, du goût et de l'expérience, les hommes et les femmes de l'antiquité, traitaient la maladie, à l'aide de plantes, de produits d'origine animale et minérale qui ne faisaient pas partie de leur régime alimentaire habituel. L'homme de l'antiquité a appris par l'expérience à faire la distinction entre les parties de plantes présentant des effets bénéfiques et celles qui étaient soit dangereuses ou inefficaces. Il a également appris quelles combinaisons ou procédés donnaient les résultats les plus optimaux. C'est cette connaissance des remèdes dérivés des plantes qui s'est développé avec le temps et est passée de bouche à oreille, de génération en génération.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 905,
    "source": "PDF_chunked"
  },
  {
    "id": 4007,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 7)",
    "text": "des plantes qui s'est développé avec le temps et est passée de bouche à oreille, de génération en génération. Au cours du temps, chaque communautétribu a méthodiquement réuni l'information sur les plantes médicinales et élaboré des pharmacopées des plantes bi en définies. L'essentiel de la pharmacopée de la médecine conventionnelle, bien plus tard au 20ème siècle, a été élaborée à partir des traditions des plantes médicinales des populations indigènes et même qu'à ce jour, un grand nombre de médicaments communément utilisés ont pour origine les plantes. Les plantes médicinales constituent dès lors une ressource vitale susceptible d'être mobilisée pour son intérêt tant sanitaire que socio- économique. Toutefois, n'eut été, le coût exorbitant des médicaments modernes, l'insuffisance des budgets nationaux alloués à la santé et l'inadéquation des infrastructures sanitaires qui ont obligé plus d'un gouvernement africain a reconsidérer les avantages",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4008,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 8)",
    "text": "infrastructures sanitaires qui ont obligé plus d'un gouvernement africain a reconsidérer les avantages des systèmes de soins de santé traditionnels, le secteur aurait été amplement relégué aux calendes grecques. Il est intéressant de constater, avec le regain d'intérêt dont la phytothérapie fait l'objet, une préoccupation grandissante relative à sa qualité, innocuité et efficacité au regard de la mauvaise qualité des prépar ations, de l'importante charge microbienne caractéristique des plantes récoltées directement de la nature, des dosages qui ne sont pas normalisés et l'évidence scientifique limitée. En 1978, l'Assemblée Mondiale de la Santé, a adopté la Résolution AMS 31.33 sur les plantes médicinales, demandant à l'OMS de coordonner les efforts des Etats Membres en vue de l'adoption de Bonnes Pratiques de Fabrication ainsi que du développement et de l'application de méthodes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 891,
    "source": "PDF_chunked"
  },
  {
    "id": 4009,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 9)",
    "text": "médicinales, demandant à l'OMS de coordonner les efforts des Etats Membres en vue de l'adoption de Bonnes Pratiques de Fabrication ainsi que du développement et de l'application de méthodes scientifiques, de normes et spécifications internationales relatives à la preuve d'innocuité et d'efficacité de produits de plantes médicinales, et tout particulièrement, les médica ments galéniques. La Résolution AMS 41.19 sur la Médecine Traditionnelle et les plantes médicinales adoptée en 1988 a mis l'accent sur la nécessite d'une coordination et d'une coopération internationale en vue de jeter les bases de la conservation des plantes médicinales au profit des générations futures. Ces deux résolutions ont inscrit l'utilisation et la conservation rationnelles et durables des plantes médicinales au cœur des politiques de santé publique. Des préoccupations ont également été soulevées en rapport avec l'exploitation non réglementée des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4010,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 10)",
    "text": "au cœur des politiques de santé publique. Des préoccupations ont également été soulevées en rapport avec l'exploitation non réglementée des bio ressources du continent Africain, la dégradation de l'environnement, la déforestation, les feux de brousse incontrôlés et les mauvaises pratiques agricoles ayant pour conséquences la disparition d'espèces rares ou en danger de plantes médicinales. Malheureusement, pour un grand nombre de pays de la Région Afrique de l' OMS, la législation nécessaire à une production locale durable, la conservation et la protection des espèces de plantes médicinales, est limitée et là où elle existe, elle n'est pas appliquée. Pour sa part, l'OMS a fourni quelques outils et directives que les états pourraient adapter à leurs situations particulières en vue de développer et d'utiliser leurs systèmes de médecine indigènes. Sont particulièrement pertinents à cet égard les Directives de l'OMS sur les Bonnes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4011,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 11)",
    "text": "indigènes. Sont particulièrement pertinents à cet égard les Directives de l'OMS sur les Bonnes Pratiques Agricoles et de Récoltes ainsi que celles relatives à la conservation des plantes médicinales et les Monographies des plantes médicinales de l'OMS. Certains pays de la Région ont depuis lors, utilisé ces outils, adopté des politiques nationales sur la conservation des plantes médic inales ou cultivé de nouvelles variétés de plantes médicinales et compilé des inventaires de l'information scientifique sur les plantes médicinales.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 536,
    "source": "PDF_chunked"
  },
  {
    "id": 4012,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 12)",
    "text": "OOAS Page iv LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP Assurer la sauvegarde des plantes médicinales de la Région Afrique tout en assurant la promotion de l'uti lisation des médicaments à base de plantes pour le traitement de pathologies, requiert une stratégie efficace, durable et coordonnée. C'est dans ce contexte que je valide la présente pharmacopée élaborée par l'Organisation Ouest africaine de la Santé, ins titution spécialisée de la Communauté Economique des Etats de l'Afrique de l'Ouest (CEDEAO) qui résume la base scientifique de quelques plantes médicinales communes aux états -membres et qui indique par ailleurs les critères permettant d'en assurer l'identité, la pureté et la qualité. J'ose espérer que la Pharmacopée des Plantes Médicinales de la CEDEAO bénéficiera de la part des Etats Membres, d'une grande adhésion, contribuant ainsi à améliorer l'accès à des soins de santé de qualité pour les populations de la sous- région.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 974,
    "source": "PDF_chunked"
  },
  {
    "id": 4013,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 13)",
    "text": "Etats Membres, d'une grande adhésion, contribuant ainsi à améliorer l'accès à des soins de santé de qualité pour les populations de la sous- région. Dr Luis Gomes Sambo Directeur Régional de l'OMS pour l'Afrique Brazzaville-Congo",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 229,
    "source": "PDF_chunked"
  },
  {
    "id": 4014,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 14)",
    "text": "OOAS Page v LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP PR ÉFACE L'importance de la médicine traditionnelle en matière de prestation de soins de santé primaire a été reconnue par la Conférence Internationale sur les SSP tenue à Alma Ata, URSS, en septembre 1978. Par la Déclaration d'Alma Ata, il est lancé un appel pour la santé pour tous d'ici à l'an 2000). Cette conférence a été suivie en 1988 par celle de Thaïlande au cours de laquelle la Déclaration sauvons les plantes qui sauvent des vies, connue sous le nom de Déclaration de Chiang Mai a été faite. Pour des raisons qui relèvent à la fois de l'économie et des préférences culturelles, beaucoup d'Africains ont recours à la médecine traditionnelle pour leurs besoins de santé, recours qui est souvent fait de manière simultanée avec les soins médicaux conventionnels. Toutefois il reste encore",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 877,
    "source": "PDF_chunked"
  },
  {
    "id": 4015,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 15)",
    "text": "souvent fait de manière simultanée avec les soins médicaux conventionnels. Toutefois il reste encore pour un certain nombre de pays qui n'ont pas admis, du moins officiellement, la place de la médecine traditionnelle dans l'offre de soins de santé. Cette résistance résulte pour l'essentiel de la distinction philosophique observée entre d'une part la médecine conventionnelle basée sur les résultats d'expérimentations et qui considère la maladie comme la resultante de l'action d'agents pathologiques et d'autre part la médecine traditionnelle qui conçoit que la maladie puisse avoir des causes surnaturelles et survenir suite au déséquilibre entre le corps, l'esprit et l'âme. A ce titre, le Plan Stratégique 2009- 2013 d e l'Organisation Ouest -africaine de la Santé (OOAS) a consacré parmi ses activités -clefs, la promotion de la recherche en médecine traditionnelle ainsi que la production et la conservation locale des plantes médicinales ;la rédaction d'une pharmacopée",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 978,
    "source": "PDF_chunked"
  },
  {
    "id": 4016,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 16)",
    "text": "la production et la conservation locale des plantes médicinales ;la rédaction d'une pharmacopée nationale et sous-régionale en étant une sous-activité. Dans cet objectif, des données sur les plantes médicinales de l'Afrique de l'Ouest ont fait l'objet d'une compilation et d'une revue lors d'un forum organisé par l'OOAS à Ouagadougou en novembre 2008. Dans le même temps, un Comité d'Experts de six membres a été mis sur pied en vue de former le noyau chargé de la rédaction de la 1 ère édition de la Pharmacopée des Plantes de l'Afrique de l'Ouest. Outre le professeur Marian Ewurama Addy (Ghana), qui en ass urait la Présidence ledit Comité était également composé du Pr. Jean- Baptiste Nikiema (Burkina Faso); du Dr. Pepas Vicente Natak (Guinée Bissau); du Pr.Mamadou Aliou Baldé (Guinée Conakry); du Pr. Tony Elujoba (Nigéria) et du Pr. Emmanuel Bassène (Sénégal) . Le comité s'est vu confier un mandat de deux ans à titre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4017,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 17)",
    "text": "Natak (Guinée Bissau); du Pr.Mamadou Aliou Baldé (Guinée Conakry); du Pr. Tony Elujoba (Nigéria) et du Pr. Emmanuel Bassène (Sénégal) . Le comité s'est vu confier un mandat de deux ans à titre d'organe consultatif chargé de faire toutes recommandations appropriées en vue de l'élaboration de la pharmacopée, au profit du programme de Médecine Traditionnelle de l'OOAS. La première rencontre du Comité s'est tenue à Accra en mars 2009, rencontre au cours de laquelle le canevas de présentation des monographies de la pharmacopée a été révisé et une liste de 57 plantes médicinales communes à tous les pays membres de la CEDEAO (Communauté Economi que des Etats de l'Afrique de l'Ouest) arrêtée sur la base de critères convenus. Lesdits critères étaient : les plantes médicinales communément utilisées dans l'espace CEDEAO ; la répartition géographique ; la disponibilité des données pertinentes ; les pa thologies prioritaires (paludisme, hypertension, diabète,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 960,
    "source": "PDF_chunked"
  },
  {
    "id": 4018,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 18)",
    "text": "disponibilité des données pertinentes ; les pa thologies prioritaires (paludisme, hypertension, diabète, VIHSIDA, tuberculose, drépanocytose) et disponibilité d'études scientifiques. Une feuille de route du projet a par ailleurs été examinée et il a été recommandé que pour accélérer la production de la pharmacopée, le Professionnel en charge du Programme de Médecine Traditionnelle de l'OOAS le Dr Busia, assure la compilation d'un projet de toutes les monographies réalisées conformément au canevas révisé, à partir de l'ensemble des ressources disponibl es (bases de données sur les plantes, livres, revues, pharmacopées notamment). Les projets de monographies devraient alors être renvoyés aux experts concernés pour finalisation. Suite à des consultations avec certains acteurs-clefs, quatre experts supplémentaires, en la personne du Pr Rokia Sanogo (Mali), du Pr Olobayo Kunle (Nigéria), du Dr Pierre Agbani et du Dr Kofi Annan (Ghana) ont été co- optés",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 4019,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 19)",
    "text": "certains acteurs-clefs, quatre experts supplémentaires, en la personne du Pr Rokia Sanogo (Mali), du Pr Olobayo Kunle (Nigéria), du Dr Pierre Agbani et du Dr Kofi Annan (Ghana) ont été co- optés comme membres du Comité des Experts. Le Comité des Experts a effectué la revue des projets de monographies et proposé une méthodologie pour combler toutes lacunes identifiées à l'occasion d'une réunion de suivi tenue à Bamako- Mali, au mois de juin 2009, conformément à la recommandation de sa première rencontre. Par la suite, le Comité a procédé à la révision de la première mouture de toutes les monographies et fait des propositions quant à la suite du travail à accomplir, à Cotonou- Bénin en novembre 2009. Il a été",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 716,
    "source": "PDF_chunked"
  },
  {
    "id": 4020,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 20)",
    "text": "OOAS Page vi LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP convenu à cette étape que les experts devaient redoubler d'efforts afin que le projet puisse être achevé dans les délais. En application de la feuille de route convenue, la seconde mouture des monographies a été examinée au cours d'une réunion de suivi tenue à Accra- Ghana au mois de juillet 2010. En rappel d'une recommandation selon laquelle des études de toxicité ainsi que les données d'innocuité doivent figurer sur toutes les monographies, les participants ont été informés sur les laboratoires identifiés aux fins des études requises. Il s'agit du National Institute for Pharmaceutical Research and Development à Abuja- Nigéria, du Département de Médecine Traditionnelle de l'Institut National de Recherche en Santé Publique à Bamako- Mali et du Noguchi Memorial Institute for Medical Research,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 883,
    "source": "PDF_chunked"
  },
  {
    "id": 4021,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 21)",
    "text": "Development à Abuja- Nigéria, du Département de Médecine Traditionnelle de l'Institut National de Recherche en Santé Publique à Bamako- Mali et du Noguchi Memorial Institute for Medical Research, à Accra -Ghana. Pour des raisons logistiques toutefois, ce sont l'Institut malien avec le Pr Rokia Sanogo comme enquêtrice principale et l'Unité de Toxicologie du Département de pharmacologie, de la Faculté de la Pharmacie et Sciences Pharmaceutiques de l'Université Kwame Nkrumah des Sciences et Technologie de Kumasi -Ghana sous la houlette du Pr Charles Ansah et du Dr Kofi Annan, Chef du Département de Phytothérapie de la même Faculté, qui ont effectué tous les tests de toxicité, de pureté et d'identité de toutes les monographies. Novembre 2010 marquant la fin du mandat de deux années du Comité des Experts, une réunion a été convoquée en marge du Congrès Scientifique Annuel des Praticiens de la Médecine",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 909,
    "source": "PDF_chunked"
  },
  {
    "id": 4022,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 22)",
    "text": "Novembre 2010 marquant la fin du mandat de deux années du Comité des Experts, une réunion a été convoquée en marge du Congrès Scientifique Annuel des Praticiens de la Médecine Traditionnelle et Conventionnelle tenu à Lagos -Nigéria, en vue de faire le point des progrès réalisés depuis la dernière rencontre en juillet 2010. Le Comité a à l'occasion fait les recommandations appropriées qui ont in fine abouti à la reconduction du Comité des Experts avec le Pr Tony Elujoba comme nouveau président. Le nouveau Comité devait par après parachever le travail sur les monographies au cours de deux forums tenus successivement au mois de juin et octobre 2011 à Dakar-Sénégal et Lomé- Togo. Ces rencontres devaient être suivies par une réunion d'un groupe de travail de redaction, tenue cette fois à Bobo Dioulasso, en février 2012. Le nouveau Président du Comité des Experts, le Pr Tony Elujoba et la Dr Kofi Annan se sont alors portés volontaires pour finaliser le travail de rédaction.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 982,
    "source": "PDF_chunked"
  },
  {
    "id": 4023,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 23)",
    "text": "Comité des Experts, le Pr Tony Elujoba et la Dr Kofi Annan se sont alors portés volontaires pour finaliser le travail de rédaction. De tout ce qui précède, il apparaît clairement que l'élaboration de ce document aura été marquée par un formidable élan de dévouement, par une capacité de résilience hors du commun, et enfin un sens aigu du don de soi au service d'une envie acharnée d'une meilleure pratique de la Médecine traditionnelle dans notre sous-région. Je voudrais dès lors exprimer au nom de notre Organisation et à l'endroit de tous ceux qui auront, de près ou de loin contribuer au succès de cette entreprise, toute ma gratitude. Nous sommes tout particulièrement reconnaissants à tous les experts qui en dépit de leurs calendriers surchargés, ont consenti des sacrifices incommensurables afin que l'œuvre des monographies puisse voir le jour. Qu'il me soit permis de remercier PROMETRA International pour l'appui technique combien",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4024,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 24)",
    "text": "consenti des sacrifices incommensurables afin que l'œuvre des monographies puisse voir le jour. Qu'il me soit permis de remercier PROMETRA International pour l'appui technique combien inestimable apporté au travers de son représentant, M. Charles Katty. Les remerciements particuliers de l'OOAS vont à L'Organisation Mondiale de la Santé, à travers son Bureau Régional pour l'Afrique pour l'assistance technique exceptionnelle dont elle aura bénéficié sous la forme de la participation de sa Conseillère Régionale en Médecine Traditionnelle, le Dr Ossy MJ Kasilo, à la plupart des réunions tenues dans le cadre de la mise en œuvre du présent projet. Je forme le voeu ardent que l'esprit de collaboration qui aura présidé à l'él aboration de cette pharmacopée continue à prévaloir jusqu'à l'institutionnalisation totale de la Médecine Traditionnelle dans l'espace CEDEAO. Dr Placido Cardoso Directeur Général Organisation Ouest Africaine de la Santé",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4025,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 25)",
    "text": "OOAS Page vii LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP INTRODUCTION Selon les estimati ons de l'organisation Mondiale de la Santé (OMS) environ 80 des populations des pays en développement, ont recours à la médecine traditionnelle et en particulier à la phytothérapie pour leur besoins en soins de santé. Sur certains continents tels que l'A frique et l'Asie, les herbes sont même utilisées comme première ligne de traitement pour les pathologies telles que le paludisme, le diabète, l'hypertension, la drépanocytose, les dermatoses et tout récemment, les infections opportunistes du VIHSIDA. En f ait plus de 120 produits pharmaceutiques couramment utilisés aujourd'hui sont dérivés des plantes, la plupart d'entre eux provenant des régions tropicales du monde, y compris l'Afrique. Le marché mondial des médicaments à base de plantes est en expansion continue, avec une valeur",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 905,
    "source": "PDF_chunked"
  },
  {
    "id": 4026,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 26)",
    "text": "du monde, y compris l'Afrique. Le marché mondial des médicaments à base de plantes est en expansion continue, avec une valeur globale annuelle estimée à environ 800 million de dollars américains. Par exemple, entre 2003- 2004, les recettes annuelles ont atteint 5 milliards de dollars américains en Europe de l'ouest, pendant que les ventes atteignaient un total de 14 milliards en 2005 en Chine. Au Brésil, les mêmes recettes étaient de 160 millions en 2007. En conséquence du regain d'intérêt dont la médicine traditionnelle a fait l'objet dans la seconde moitié du 20eme siècle, l'initiative Sante pour tous d'ici à l'an 2000 de l'OMS, a reconnu que les programmes adoptes dans l'un quelconque des pays en développement, n'auraient aucun impact si ceux-ci ne prennent pas en considération le développement et l'intégration de la médecine traditionnelle dans leurs programmes de soins de santé primaire.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 905,
    "source": "PDF_chunked"
  },
  {
    "id": 4027,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 27)",
    "text": "ceux-ci ne prennent pas en considération le développement et l'intégration de la médecine traditionnelle dans leurs programmes de soins de santé primaire. Au travers de ce programme, l'OMS a reconnu la situation particulière des pays moins industrialises en matière de médecine traditionnelle et de soins de santé de manière générale. C'est cette reconnaissance qui a conduit à la tenue de la conférence OMSUNICEF de Alma Ata, URSS, tenue en 1978, au cours de laquelle les participants ont résolu et ont expressément demande aux états - membres de : i. initier des programmes globaux en vue de l'identification, de l'évaluation, la culture et la conservation des plantes médicinales utilisées en médicine traditionnelle; ii. assurer le contrôle de qualité des médicaments produits à partir de plantes médicinales en utilisant des techniques modernes et en appliquant les normes appropriées et les bonnes pratiques de fabrication.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4028,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 28)",
    "text": "utilisant des techniques modernes et en appliquant les normes appropriées et les bonnes pratiques de fabrication. Conformément à cet engagement, les Chefs d'Etats et de Gouvernements de l'Organisation de l'Unité Africaine d'alors, actuelle Union Africaine ont déclaré la période 2000- 2010, Décennie de la Médecine Traditionnelle Africaine. Cette déclaration fut suivie plus tard en 2001, de la Déclaration d'Abuja demandant aux Etats-Membres d'accorder la priorité à la recherche sur les médicaments traditionnels utilise pour la prise en charge du VIH -SIDA, du paludisme, de la tuberculose et d'autres maladies infectieuses. Le Sommet de l'Union Africaine a pris à son compte à Maputo en 2003 la proposition de l'OMS d'instituer une Journée de la Médecine Traditionnelle Africaine dans les Etats -membres le 31 aout chaque année, à titre de stratégie pour promouvoir la médecine traditionnelle dans les systèmes de santé.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 4029,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 29)",
    "text": "aout chaque année, à titre de stratégie pour promouvoir la médecine traditionnelle dans les systèmes de santé. A la suite de ces déclarations, en 2007, le Comité Régional pour l'Afrique de l'OMS, a déclaré la recherche et le développement en matière de médecine traditionnelle, comme priorité à l'occasion de la 5eme Journée de la Médecine Traditionnelle. En 2008, la Déclaration de Ouagadougou sur les Soins de Santé Primaire et les systèmes de Sante en Afrique, a réitéré la Déclaration d'Alma Ata de 1978, en demandant aux pays de mett re en place des mécanismes durables de renforcement de la disponibilité, dans des conditions de couts et d'accessibilité améliorées, des médicaments essentiels ainsi que les approches sous directive communautaire et les médicaments traditionnels Africains. Au cours de la même année, des représentants des états -membres de l'OMS, se sont rencontres à",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 890,
    "source": "PDF_chunked"
  },
  {
    "id": 4030,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 30)",
    "text": "ainsi que les approches sous directive communautaire et les médicaments traditionnels Africains. Au cours de la même année, des représentants des états -membres de l'OMS, se sont rencontres à Beijing, en Chine pour adopter une autre déclaration demandant aux états d'élaborer des politiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 290,
    "source": "PDF_chunked"
  },
  {
    "id": 4031,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 31)",
    "text": "OOAS Page viii LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP en matière de médecine traditionnelle et de promouvoir l'éducation, la recherche et le dé veloppement dans le domaine. Pour l'Afrique en particulier, ces initiatives marquent sans aucun doute des étapes majeures dans les efforts déployés en vue de la prise en compte et de l'institutionnalisation de la médecine tradit ionnelle dans les systèmes nationaux de sante. L'Afrique présente une riche diversité de plantes, dont un grand nombre ont servi pendant des millénaires, de sources de médicaments. A titre d'exemples parmi ces plantes médicinales commercialement exploitables, l'on peut noter entre autres : Rauwolfia vomitoria, source majeure l'agent tranquillisant et antihypertenseur qu'est la réserpine ; Zingiber officinale : utilise pour ses propriétés carminatives et anti -inflammatoires ; Catharanthus roseus : source des agents anti -",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4032,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 32)",
    "text": "propriétés carminatives et anti -inflammatoires ; Catharanthus roseus : source des agents anti - cancérigènes tels que la vinblastine, la vincristine et le phytolacca dodecandra, utilise comme molluscicide pour lutter contre la schistosomiase. Entre autres exemples notables, nous avons le Pausinystalia yohimbedu Cameroun, Nigeria et Rwan da, qui produit l'alcaloïde yohimbine ayant des effets stimulants et aphrodisiaques ; Harpagophytum procumbens, produit comme médicament brut dans certains pays de l'Afrique australe pour ses propriétés antirhumatismales ; Ricinus communis a partir duquel est produit le laxatif connu sous le nom d'huile de ricin ; Agave sisalana, riche en hecogenine, employée pour la synthèse partielle de médicaments stéroïdiens tels que les corticostéroïdes et autres contraceptifs oraux ; Cinchona succirubra qui produit la quinine, agent antipaludique essentiel ainsi que l'herbe anti -hypertensive qu'es t Hibiscus sabdariffa, exportée du",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 969,
    "source": "PDF_chunked"
  },
  {
    "id": 4033,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 33)",
    "text": "antipaludique essentiel ainsi que l'herbe anti -hypertensive qu'es t Hibiscus sabdariffa, exportée du Soudan et de l'Egypte et cultivée a l'origine pour la production de la fibre Libérienne de sa tige. Il faut reconnaitre cependant que l'inf ormation sur l'intérêt thérapeutique des plantes médicinales du continent n'a fait l'objet d'une documentation ni systématique ni complète. Par ailleurs aucune de ces plantes n'a été ni rigoureusement évaluée ni correctement standardise. Dans une tentative de pallier ces inconvénients, des appels ont été lances pour une collaboration meilleure et soutenue entre praticiens de la médicine traditionnelle et ceux de la médecine conventionnelle tout comme les chercheurs d'ailleurs en vue de la validation de l'information sur l'utilisation judicieuse des remèdes à base de plantes. Plusieurs états du continent ont réagi positivement à ces appels par le lancement de programmes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4034,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 34)",
    "text": "base de plantes. Plusieurs états du continent ont réagi positivement à ces appels par le lancement de programmes visant la promotion du secteur. A travers le continent un certain nombre de ministères en charge des questions de santé encouragent le recours aux plantes médicinales locales, et ont mis en place en conséquence des directions chargées de la mise en œuvre d'une telle politique. A titre d'exemple, dans certains pays du continent Africain, les t radipraticiens de santé ont été associes a des campagnes de sensibilisation des autres initiatives de promotion sanitaire, notamment dans les domaines de l'hygiène et de la sécurité, de l'utilisation des condoms et de la diffusion des connaissances. En outre la recherche en matière de produits naturels ainsi que des programmes de développement ont été inities en vue de l'exploitation des avantages thérapeutiques des plantes médicinales utilisées",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 907,
    "source": "PDF_chunked"
  },
  {
    "id": 4035,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 35)",
    "text": "ont été inities en vue de l'exploitation des avantages thérapeutiques des plantes médicinales utilisées dans le traitement des pathologies telles que le paludisme, le VIHSIDA, la drépanocytose, l'hypertension, la malnutrition et le diabète. Entre autres exemples, nous avons le Centre de Recherche des Phytomedicaments, créé depuis 1975 au Ghana, le Centre de Recherche sur la Pharmacopée et la Médecine Traditionnelle au Rwanda en 1982, le Département de Médecine Traditionnelle de l'Institut National de Sante Publique au Mali, en 1968, l'organisation du village Chemist au sein du Département de Pharmacognosie de l'Université Obafemi Awolowo a Ile-Ife, au Nigeria ainsi que l'Institut de Médecine Traditionnelle de l'Ecole Muhimbili des Sciences de la Sante de l'Université de Dar-es-Salaam, Tanzanie, en 1974. Parallèlement à ces évènements, des appels sont faits en direction des décideurs pour leur soutien",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 913,
    "source": "PDF_chunked"
  },
  {
    "id": 4036,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 36)",
    "text": "l'Ecole Muhimbili des Sciences de la Sante de l'Université de Dar-es-Salaam, Tanzanie, en 1974. Parallèlement à ces évènements, des appels sont faits en direction des décideurs pour leur soutien en faveur de la création de pharmacopées établissant les normes modernes d'évaluation de la qualite,de l'innocuité et de l'efficacité des plantes médicinales, tout en présentant l'information pour une identification correcte, une description générale et les caractérist iques morphologiques dans le souci de sauvegarder la santé publique.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 533,
    "source": "PDF_chunked"
  },
  {
    "id": 4037,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 37)",
    "text": "OOAS Page ix LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP En fait le développement et la préservation d'une assurance qualité au profit des plantes médicinales remontent jusqu'au 14eme siècle ou des pharmaciens et botanistes Italiens, préoccupés par le danger potentiel d'une erreur d'étiquetage et d'adultération ont mis au point ce qui est aujourd'hui considéré comme la première pharmacopée modern. La première du genre dans le monde anglo- saxon, Pharmacopoeia Londoninsis, a été publiée en 1618 e n Angleterre et pendant les 18eme et 19 eme siècles, plusieurs pays Européens, la Russie, l'Espagne, la Suède et l'Allemagne notamment, ont créé des pharmacopées nationales. La première pharmacopée des Etats -Unis d'Amérique fut publiée en 1778, pour les besoins de l'Armée des Etats-Unis. Plus récemment cependant plusieurs tentatives ont été menées visant à élaborer des monographies",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 910,
    "source": "PDF_chunked"
  },
  {
    "id": 4038,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 38)",
    "text": "publiée en 1778, pour les besoins de l'Armée des Etats-Unis. Plus récemment cependant plusieurs tentatives ont été menées visant à élaborer des monographies permettant de définir des critères d'identité et de qualité tout en fournissant l'information thérapeutique. Par exemple la C ommission E en Allemagne, publie depuis 1984 des monographies thérapeutiques et La Coopérative Scientifique Européenne pour la Phytothérapie, font de même depuis 1991. L'Organisation Mondiale de la Sante a elle aussi publie deux volumes de monographies des plantes les plus couramment utilises à travers le monde. Le besoin d'un document récapitulatif et a jour de la connaissance scientifique sur les plantes médicinales les plus communément utilisées, ne s'est jamais fait ressentir autant qu'aujourd'hui, à un moment où l'intérêt du public pour les plantes médicinales s'est accru considérablement.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 884,
    "source": "PDF_chunked"
  },
  {
    "id": 4039,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 39)",
    "text": "médicinales les plus communément utilisées, ne s'est jamais fait ressentir autant qu'aujourd'hui, à un moment où l'intérêt du public pour les plantes médicinales s'est accru considérablement. L'initiative de l'élaboration d'une Pharmacopée des Plantes Médicinales par l'OOAS, qui est née dans un premier temps des Déclarations ci -dessus rappelées, arrive à titre de réponse à l'inexistence de pharmacopées nationales. A ce jour seuls le Ghana et le Nigeria disposent de pharmacopées nationales. La décision a été prise dès le départ de la conception de la Pharmacopée des Plantes médicinales, que celle- ci vi serait essentiellement la sante et la sécurité du patient. Ainsi tous les efforts nécessaires ont été accomplis pour rendre disponible l'information requise sur la toxicité, l'identité et la pureté, les caractéristiques macroscopiques et microscopiques, les empreintes Chromatographiques sur Couche Mince (TLC) ainsi que l'utilisation ethno- médicale et les effets",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 975,
    "source": "PDF_chunked"
  },
  {
    "id": 4040,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 40)",
    "text": "la pureté, les caractéristiques macroscopiques et microscopiques, les empreintes Chromatographiques sur Couche Mince (TLC) ainsi que l'utilisation ethno- médicale et les effets biologiques et pharmacologiques. La Pharmacopée des Plantes médicinales de la CEDEAO, servira aux tradi -praticiens de santé, aux consommateurs, aux experts en médicine traditionnelle, aux responsables de programmes, médecins, pharmaciens, chercheurs, étudiants, décideurs en matière de politiques de santé, partenaires au développement et organisations non- gouvernementales impliquées dans le développement de la médecine traditionnelle. Compilée par des experts venus des Etats -membres de la CEDEAO, la Pharmacopée des Plantes Médicinales de l'Afrique de l'Ouest comprend 55 monographies des plantes médicinales communes à l'ensemble des 15 états formant la CEDEAO, chacune d'entre elles étant présentée selon le canevas ci-dessous énoncé :",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 921,
    "source": "PDF_chunked"
  },
  {
    "id": 4041,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 41)",
    "text": "l'ensemble des 15 états formant la CEDEAO, chacune d'entre elles étant présentée selon le canevas ci-dessous énoncé : Noms : nom botanique avec l'auteur; famille; synonymes; noms communs; noms vernaculaires (pas plus de trois par pays). Pour toutes les monographies, le nom botanique est choisi pour le titre. Toutefois, la tâche qui devait se révéler la plus délicate, fut celle de trouver les trois noms vernaculaires les plus communs pour l'ensemble des pays, ce qui a eu pour conséquence, de plusieurs des monographies soient présentées sans la liste complète des noms vernaculaires. Information générale (résumé) : description de la plante; utilisations ethno- médicales; données scientifiques, cliniques et d'innocuité. Description de la plante: plantes entières ou parties, surtout celles prés entant des propriétés médicinales; parties fraiches ou séchées si des parties séchées sont utilisés; photographies (bonne",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 4042,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 42)",
    "text": "Description de la plante: plantes entières ou parties, surtout celles prés entant des propriétés médicinales; parties fraiches ou séchées si des parties séchées sont utilisés; photographies (bonne qualité, haute résolution); numéro d'herbier; habitat et répartition géographique; définition de la substance médicinale (partie de la plante présentant un intérêt)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 361,
    "source": "PDF_chunked"
  },
  {
    "id": 4043,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 43)",
    "text": "OOAS Page x LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP Composes chimiques: composes actifs et non actifs, mais les structures chimiques sont réserves aux composes connus pour leur contribution à l'activité de la plante. Activités biologiques et pharmacologiques : données expérim entales; données cliniques (le cas échéant) Données d'innocuité : toxicité aigüe; toxicité chronique et sub- chronique (le cas échéant); contre- indications; effets secondaires. Indications thérapeutiques : prétentions confirmées Actions thérapeutiques : sur la base de données biologiques et pharmacologiques Tests d'identité et de pureté : taux d'humidité; teneurs en cendres; valeurs extractives; empreintes chromatographiques; macroscopie et microscopie (qualitative et quantitative) -échantillons entiers et sous forme de poudres Dosages : obtenus de textes aussi reconnus que la Pharmacopée des Etats -Unis qui exprime la dose",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4044,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 44)",
    "text": "sous forme de poudres Dosages : obtenus de textes aussi reconnus que la Pharmacopée des Etats -Unis qui exprime la dose des infusions et décoctions en termes de ratio poidsvolume de 120 (c'est -à-dire 1 portion d'herbe séchée pour 20 portions d'eau). Ai nsi la dose thérapeutique traditionnelle pour les infusionsdécoctions est de 30g d'herbe séchée dans 600 ml d'eau, 60- 200 ml trois fois par jour, tandis que les concentrations de teintures sont elles exprimées en termes de ratio poidsvolume (p:v). En règle générale, bon nombre de praticiens de la phytothérapie, préfèrent prescrire sous forme de doses de 15 (c'est -adire 1kg d'herbe dans 5 litres de solvant) ou même des teintures encore plus diluées avec des formulations prescrites entre 2,5 -5 ml, tro is fois par jour). Ainsi donc, à l'exception de quelques rares cas, 15 en teintures, c'est ce qui est recommandé dans l'ensemble du texte.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 900,
    "source": "PDF_chunked"
  },
  {
    "id": 4045,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 45)",
    "text": "de quelques rares cas, 15 en teintures, c'est ce qui est recommandé dans l'ensemble du texte. Conditions de stockage : selon des informations obtenues d'autres texts. Références : revues scientifiques; livres; rapports techniques; publications institutionnelles; thèses; information émanant des bonnes pratiques en Médecine Traditionnelle. La Pharmacopée Ouest -africaine des Plantes Médicinales, est un document de référence non seulement pour la sous -région mais également pour le continent Africain dans son ensemble. Il est à espérer que les autorités nationales de santé lui confèrent un statut juridiquement exécutoire dans la sous-région. Dr Kofi Busia Chargé de programme, Médecine Traditionnelle Ouest Africaine de la Santé Organisation 01 BP 153, Bobo Dioulasso 01, Burkina Faso kbusiawahooas.orgkofi_busiahotmail.com",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 828,
    "source": "PDF_chunked"
  },
  {
    "id": 4046,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 46)",
    "text": "OOAS Page xi LA PHARMACOPÉE DES PLANTES MÉDICINALES DE L'AFRIQUE DE L'OUEST WAHP REMERCIEMENTS La médecine traditionnelle reste encore le premier recours des populations surtout rurales en quête de soins de santé. C'est pourquoi l'Organisation ouest Africaine de la santé dès sa création a fait de son développement un programme prioritaire. Ainsi, dans le cadre son plan stratégique l'OOAS s'est fixé comme objecti f de contribuer à institutionnaliser de manière effective la médecine traditionnelle. Et un des axes prioritaires de ce programme est d'assurer la sauvegarde des plantes médicinales tout en assurant la promotion de l'utilisation des médicaments à base de plantes pour le traitement de pathologies. La présente pharmacopée en constitue un résultat majeur. Au nom du Directeur Général de l'Organisation Ouest Africaine de la Santé, il nous revient d'exprimer nos sincères remerciements et de façon singulière aux experts qui ont très vite adhéré à l'idée du",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 971,
    "source": "PDF_chunked"
  },
  {
    "id": 4047,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 47)",
    "text": "nos sincères remerciements et de façon singulière aux experts qui ont très vite adhéré à l'idée du projet et dont les précieuses contributions et le soutien sans faille ont permis l'élaboration de ce document historique. Il s'agit de : Pr. Marian Ewurama Addy (Ghana), Pr. Jean- Baptiste Nikiema (Burkina Faso) ; Dr Pepas Vicente Natak (Guinée Bissau) ; Pr. Mamadou Aliou Balde (Guinée Conakry) ; Pr. Tony Elujoba (Nigéria) ; Pr. Emmanuel Bassene (Sénégal) ; Pr. Rokia Sanogo (Mali) ; Pr. Olobayo Kunle (Nigéria) ; Pr. Charles Ansah (Ghana) ; Dr Pierre Agbani (Bénin) ; Pr. (Mme) Edith Ajaiyeoba (Nigéria) ; Dr Kofi Annan (Ghana) ; Charles Katy (Sénégal) ; Dr Ossy M.J. Kasilo (OMSAFRO) ; Dr Ehoule Kroa (Côte d'Ivoire) ; Dr Koffi Koudouvo (Togo) et Dr Rokhaya Ndiaye Kande (Sénégal). Ensuite, notre haute appréciation s'a dresse particulièrement au Dr Kofi Annan pour nous avoir mis à disposition toutes les empreintes chromatographiques et les superbes photos de toutes les plantes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 983,
    "source": "PDF_chunked"
  },
  {
    "id": 4048,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 48)",
    "text": "disposition toutes les empreintes chromatographiques et les superbes photos de toutes les plantes contenues dans cette pharmacopée ; au Pr. Tony Elujoba, pour ses efforts inlassables dans la finalisation du projet, au Dr Roch A. Houngnihin et au Pr. Drissa Diallo pour avoir effectué le travail final d'édition de la version française. Ce travail a aussi bénéficié énormément de l'apport de nombreux autres experts et personnel d'appui dont les coordonnées figurent dans l'annexe que nous tenons à remercier pour leur inestimable contribution à différents stades du projet. Enfin, nous exprimons notre profonde gratitude à l'OMSAFRO et à PROMETRA International pour leur appui technique. Dr Johanna AUSTIN BENJAMIN Directrice Département des Soins de Santé Primaires",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 766,
    "source": "PDF_chunked"
  },
  {
    "id": 4049,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 49)",
    "text": "OOAS Page 1 Acacia nilotica WAHP Nom botanique Acacia nolitica (L.) Willd. ex Del var. Nolitica Acacia nilotica var. adansonii Guill et Perr Famille Mimosaceae Synonymes Mimosa scorpioides L., Mimosa arabica Lam., Acacia arabica Willd., Acacia adansonii Guill. Perott. Noms communs Anglais: Egyptian mimosa Français: Gonakier; Acacia nilotique, Acacia du Nil. Noms vernaculaires Burkina Faso: Moore- Peg-nenga, Dioula- Baganayiri;Bogonan, Fulfulde-Gaoudi;Gawdi Ghana: Akan Odanwoma Mali: Bambara Bagana, Malinke Bagana, Dogons Barin Nigéria: Hausa Bagawura Niger: Hausa Bagaroua, Djerma Baani Sénégal: Wolof Gonaki, Serer Nep Nep; Pular Gaudi Description de la plante Arbre épineuxatteignant 20 m de haut, avec un tronc droit et cylindrique en forme de fût, d'environ 60 cm de diamètre, et de couronne dense; son écorce est brun- foncé ou noir.Son écorce est profondément fissurée ou craquelée",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 893,
    "source": "PDF_chunked"
  },
  {
    "id": 4050,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 50)",
    "text": "tronc droit et cylindrique en forme de fût, d'environ 60 cm de diamètre, et de couronne dense; son écorce est brun- foncé ou noir.Son écorce est profondément fissurée ou craquelée avec des entailles gris -roses, exsudant une résine rouge ; les tiges sont vert -olives à brunâtres, tomenteux à glabre; épines fixées par paires à la base de la feuille droite et mince quand elle est longue, parfois suspendues quand elle est courte, grise pâle à blanc, de 0,5 à 8 ( - 15) cm de long; les feuilles sont suppléantes, bipennées, bleutées de 4 -10 cm de long, 3- 6 pinnules et 10- 25 paires ( -30) de pavillons de folioles glabres plus ou moins pubescentes, oblongues de 1,5- 7 mm de long; le pétiole porte souvent 1 (2) glandes avant la première paire de pinnules et d'autres glandes à la base de chaque paire de pinnules ou seulement la paire de pennes mesure 3- 6 ( -8) cm de long; l'inflorescence en faisceau est de (1) 2- 4 pédicellée de glomérules. Il y a un ensemble",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 967,
    "source": "PDF_chunked"
  },
  {
    "id": 4051,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 51)",
    "text": "paire de pinnules ou seulement la paire de pennes mesure 3- 6 ( -8) cm de long; l'inflorescence en faisceau est de (1) 2- 4 pédicellée de glomérules. Il y a un ensemble jaune lumineux à la base d'une feuille qui mesure 1,2-1,5 cm de diamètre; les fruits plats ou cylindriques sont de 1,5- 2,2 cm de diamètre et 10-15 cmde long , jaunes au bruns ou gris quand ils sont mûrs. Ils contiennent généralement 4-10 graines brunes plus ou moins plates et rondes de 6,5 à 9 mm de diamètre. Numéro du spécimen de l'herbier Ghana: 132 (GC) Mali: 498 (DMT) Togo: TOGO04821 Habitat et répartition géographique A. nilotica est très répandue dans les régions de savane du Nord.Son aire de répartition s'étend du Mali au Soudan et en Egypte. Il néc essite un environnement bien éclairé pour sa croissance. Le gel brut affecte les petites plantules etles grands arbres. Il est résistant à la sécheresse et pousse mieux sur des sols alluviaux bruts, plats",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4052,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 52)",
    "text": "environnement bien éclairé pour sa croissance. Le gel brut affecte les petites plantules etles grands arbres. Il est résistant à la sécheresse et pousse mieux sur des sols alluviaux bruts, plats ou légèrement ondulés et dans les zones de ravins. Il est considéré comme une mauvaise herbe nuisible en Afrique du Sud. Partie utilisée de la plante Fruit Autres parties utilisées Feuille, écorce de la tige, écorce de la racine, rameau feuillé, rameau feuillé fleuri. Caracéristiques botaniques Fruits frais ou séchés de Acacia nolitica (L.) Willd. ex Del var. nolitica (Mimosaceae) Utilisations ethnomédicales A. nilotica est utilisé dans de nombreuses cultures pour traiter la bronchite, les douleurs thoraciques, le rhume, la diarrhée, la dysenterie, la fièvre, les hémorragies, la lèpre, les troubles oculaires, la pneumonie, les maux de gorge (Chhabra et Uiso, 1991; Watt 1962), la syphilis (Kambizi et Afolayan 2001; Watt 1962); la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4053,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 53)",
    "text": "la fièvre, les hémorragies, la lèpre, les troubles oculaires, la pneumonie, les maux de gorge (Chhabra et Uiso, 1991; Watt 1962), la syphilis (Kambizi et Afolayan 2001; Watt 1962); la candidose buccale, les infections fongiques de la peau (Lev et Amar, 2002; Srinivasan et al .,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 278,
    "source": "PDF_chunked"
  },
  {
    "id": 4054,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 54)",
    "text": "OOAS Page 2 Acacia nilotica WAHP 2001); le paludisme et la rage de dents (Jain et al., 2005; Kubmarawa et al., 2007). La décoction de l'écorce est utilisée pour traiter les complications pré, intra et post-partum (Kaingu et al., 2011) et la décoction chaude de l'écorce de racine est utilisée pour les complications gastro- intestinales et la babésiose (Nanyingi et al., 2008). Les fruits sont utilisés contre la gale (Lev et Amar, 2000) Activités biologiques et pharmacologiques Chuabal et al., (2003) ont rapporté des activ ités anti-inflammatoires et antihelminthiques de la plante. Les tanins contenus dans les extraits ont montré des effets algicides et molluscicides contre les escargots Bulinus truncatus et Biomphalaria pfeifferi d'eau douce (Ayoub et Yankov, 1985) et les extraits aqueux ont montré des propriétés antibactériennes in vitro (Abd El Nabi et al., 1992). Des études in vivo ont montré que les extraits méthanoliques de l'écorce de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4055,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 55)",
    "text": "des propriétés antibactériennes in vitro (Abd El Nabi et al., 1992). Des études in vivo ont montré que les extraits méthanoliques de l'écorce de la tige, du fruit et de la feuille assurent une protection complète contre la diarrhée provoquée par l'huile de ricin, tel qu'un médicament anti - diarrhéique, lopéramide (Agunu et al., 2005). Ces extraits (0,5 à 3,0 mg ml) ont montré un effet dose-dépendante anti -diarrhéique sur le jéjunum isolé de lapin avec une relaxation initiale, qui a été rapidement suivie par la contraction du jéjunum à 3,0 mg ml (Agunu et al., 2005). D'autres études ont également montré que différents extraits de la plante ont des effets antifongiques à large spectre et des effets antibactériens (Hamsa et al., 2006; Abd El Nabi et al., 1992; Srinivasan et al., 2001; Ahmad et al., 1998). Différents extraits de l'écorce des racines et des fruits se sont avérés avoir une activité antifongique particulière contre les levures et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4056,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 56)",
    "text": "1998). Différents extraits de l'écorce des racines et des fruits se sont avérés avoir une activité antifongique particulière contre les levures et Candida albicans (Gupta et Bilgrami, 1970; Sinha et Anjana, 1984; Almagboul et al., 1988; Runyoro et al., 2006). Le Niloticane, un diterpène isolé de l'écorce a montré une activité antibactérienne contre les bactéries Gram -positives Bacillus subtilis et Staphylococcus aureus (Eldeen et al., 2010). Sultana et al. (2007) ont également montré que les extraits de l'écorce ont une capacité antioxydante in vitro, tandis que Shah et al. (1997) ont trouvé que l'extrait alcoolique possède un effet d'agrégation plaquettaire antagoniste d'une manière dose- dépendante. Les extraits méthanoliques des gousses ont montré leur efficacité contre le VIH -PR (Bessong et Obi, 2006) et des parties de la plantes fraîches sont réputées actives contre l'hépatite C (Hussein et al., 2000). L'activité antipaludique de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4057,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 57)",
    "text": "montré leur efficacité contre le VIH -PR (Bessong et Obi, 2006) et des parties de la plantes fraîches sont réputées actives contre l'hépatite C (Hussein et al., 2000). L'activité antipaludique de l'extrait d'acétate d'éthyle contre différentes souches chloroquino résistantes et sensibles du Plasmodium falciparuma été rapporté (El -Tahir et al., 1999). L'éther phénolique et polyphénolique riches, l'acétate d'éthyle et les fractions d'acétone de l'écorce ont montré des effets antimutagènes et cytotoxiques dans le test d'Ames (Kaur et al., 2005). Données cliniques Dansune enquêtedel'effet antimicrobien d'un bain de bouche contenant un extrait d' Acacia nilotica sur la formation de plaque supra- gingivale et gingivite, comparée à la formulation de contrôle de bain de bouche ( contrôle positif contenait 0,2 de gluconate de chlorhexidine; le contrôle négatif était un placebo) sur 30 bénévoles , le groupe qui a utilisé la formule à base de plante",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 4058,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 58)",
    "text": "de bain de bouche ( contrôle positif contenait 0,2 de gluconate de chlorhexidine; le contrôle négatif était un placebo) sur 30 bénévoles , le groupe qui a utilisé la formule à base de plante était exposé àmoins de plaques et d' indices gingivaux par rapport au placebo; cependant la formule à base de plantes avec des valeurs plus élevées que celles du gluconate de chlorhexidine. L'inhibition microbienne est inférieure au gluconate de chlorhexidine, mais significativement plus élevée que le placebo. Cela a montré une activité antimicrobienne de l'extraitdans lemaintien de la santé bucco- dentaire (El-Menoufy et al., 2010). Constituants chimiques Tanins (( -) Esters galloyle épigallocatéchine), alcaloïdes, saponines, protéines (Kumaresan et al., 1984; Ramana et al., 2000; Sawe et al., 1998; Mlambo et al., 2008). Test d'identité et de purété Teneur en humidité: 5,56 Cendre totale: 6,57 Substancesextractibles par l'eau: 47,69",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4059,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 59)",
    "text": "OOAS Page 3 Acacia nilotica WAHP Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0.25 mm) G60F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0.5 ml) et d'acideacétique glacial (10 ml ), 85 ml deméthanol et 5 ml d'acidesulfurique concentré, puis chauffé à 100- 110C pendant 5-10mn Présence de cinq taches distinctes avec valeurs R f de 0,84 (rose), 0,68 (rose), 0,45 (violet), 0,26 (rose) et 0,10 (rose). Chromatogramme Macroscopie L'ecorce est dure, brun- foncée ou noire, profondément fissurée longitudinalement et transversalement, la surface intérieure brun- rougeâtre, longitudinalement striée et fibreuse; se casse difficilement et présente une fracture fibreuse; avecun goût astringent. Microscopie La coupe transversale de l'écorce mature montre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4060,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 60)",
    "text": "rougeâtre, longitudinalement striée et fibreuse; se casse difficilement et présente une fracture fibreuse; avecun goût astringent. Microscopie La coupe transversale de l'écorce mature montre 15-25 couches à paroi mince,légèrement aplaties et essentiellement rectangulaires, des cellules de liège de couleur brune, quelques lenticelles formées par la rupture des cellules de liège; lescellules corticales secondaires ovales ou allongées, beaucoupde cellules tannifères, variables dans la forme et la taille présentent des grands groupes; le phloème secondaire est constitué de tubes criblés, de cellules d'accompagnement, fibres, fibres de cristaux et fibres de parenchyme du phloème dans de nombreux groupes à parois épaisses ;les tissus du phloème sont remplis de contenu rougeâtre ou brun; les fibres de cristaux à paroi épaisse, allongés, divisés par des cloisons trans versales en segments, contiennent chacun un cristal prismatique d'oxalate de calcium, des rayons",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 969,
    "source": "PDF_chunked"
  },
  {
    "id": 4061,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 61)",
    "text": "ou brun; les fibres de cristaux à paroi épaisse, allongés, divisés par des cloisons trans versales en segments, contiennent chacun un cristal prismatique d'oxalate de calcium, des rayons médullaires unis àmulti-sériés presque droits; des cellules de rayons allongées à polygonale, de 20- 24 cellules hautes et 2- 5 séries ;des cristaux d'oxalate d e calcium sont dispersés parmi les cellules de pierre du parenchyme sécondaire du cortex et du phloème (Abid et al., 2005). Matériel végétal en poudre La poudre d'écorce de tronc de couleur brun rougeâtre, sous le microscope présente de nombreux cristaux d'oxalate de calcium, cellules de pierre, à la fois avec unlarge ou étroit lumen, des stries et des fibres de cristal. Actions thérapeutiques Molluscicide, antiplasmodiale, antibactérien, antiviral, antidiarrhéique, antifongique, anti - agrégation plaquettaire, antihypertenseur, anti - inflammatoire, antihelminthique, antioxydant et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4062,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 62)",
    "text": "Molluscicide, antiplasmodiale, antibactérien, antiviral, antidiarrhéique, antifongique, anti - agrégation plaquettaire, antihypertenseur, anti - inflammatoire, antihelminthique, antioxydant et immunomodulateur (Eldeen et al., 2010;. Sultana et al., 2007; Bessong et O bi, 2006; Hamsa et al., 2006; Runyoro et al ., 2006; Agunu et al., 2005; Chuabal et al., 2003; Kambizi et Afolayan, 2001; Srinivasan et al., 2001; Hussein et al., 2000). Indications thérapeutiques Infections, toux, inflammations, diarrhée et douleurs. Données de sécurité Pendant 24 heures, la DL 50 de l'extrait aqueux du fruit ( p.o) chez la souris était supérieure à 2000 mgkg. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'administration par voie orale de l'extrait à 500-2000 mgkg à des souris mâles et femelles pendant 14 jours. Précautions d'emploi Aucun n'a été signalé. Cependant, l'utilisation prolongée de plantes riches en tanin doit être",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 967,
    "source": "PDF_chunked"
  },
  {
    "id": 4063,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 63)",
    "text": "500-2000 mgkg à des souris mâles et femelles pendant 14 jours. Précautions d'emploi Aucun n'a été signalé. Cependant, l'utilisation prolongée de plantes riches en tanin doit être évitée car les tanins sont connus pour précipiter les protéines et agissent sur l'absorption du Fe. Effets indésirables Aucun n'a été signalée Contre-indications Aucune n'a été signalée Dosage et forme galénique Décoction, onguent, cataplasme Conservation A conserver dans un endroit frais et sec.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 476,
    "source": "PDF_chunked"
  },
  {
    "id": 4064,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 64)",
    "text": "OOAS Page 4 Acacia nilotica WAHP Références Abd El Nabi, O.M., Reisinger, E.C., Reinthaler, F.F., Still, F. et al. (1992). Antimicrobial activity of Acacia nilotica (L.) Willd. ex Del. var. nilotica (Mimosaceae). Journal of Ethnopharmacology 37:77-79. Abid, M., Mushtaq, A., Asma, J., Muhammad, Z., Saima, N. (2005). Pharmacognostic studies of some indigenous medicinal plants of Pakistan. Ethnobotanical Leaflets 9: 1-6. Agunu, A., Yusuf, S., Andrew, G.O., Zezi, A.U., Abdurahman, E.M. (2005). Evaluation of five medicinal plants used in diarrhoea treatment in Nigeria. Journal of Ethnopharmacology 101:27 30. Ahmad, I., Mehmood, Z., Mohammad, F. (1998). Screening of some Indian medicinal plants for their antimicrobial properties. Journal of Ethnopharmacology 62:183193. Almagboul, A.Z., Bashir, A.K., Karim, A., Salih, M., Farouk, A., Khalid, S.A. (1988). Antimicrobial activity of certain Sudanese plants used in",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 917,
    "source": "PDF_chunked"
  },
  {
    "id": 4065,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 65)",
    "text": "Ethnopharmacology 62:183193. Almagboul, A.Z., Bashir, A.K., Karim, A., Salih, M., Farouk, A., Khalid, S.A. (1988). Antimicrobial activity of certain Sudanese plants used in folkloric medicine. Screening for antifungal activity (VI). Fitoterapia 59:393396. Ayoub, H.S.M., Yankov, L. K. (1985). Potential molluscicides from some tannin-containing plants growing in the Sudan. Fitoterapia 6:371-373. Bessong, P.O., Obi, C.L. (2006). Ethnopharmacology of HIV in South Africa - A mini review. African Journal of Biotechnology 5:1693-1699. Chhabra, S.C., Uiso, F.C., (1991). Antibacterial activity of some Tanzanian plants used in traditional medicine. Fitoterapia 62:499503. Chuabal, R., Mujumdar, A., Puranik, V., Deshpande, V., Deshpande, N. (2003). Isolation and X -ray study of an anti -inflammatory active androstene steroid from Acacia nilotica. Planta Medica 69:287288. Eldeen, I.M.S., Van Heerden, F.R., Van Staden,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 918,
    "source": "PDF_chunked"
  },
  {
    "id": 4066,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 66)",
    "text": "and X -ray study of an anti -inflammatory active androstene steroid from Acacia nilotica. Planta Medica 69:287288. Eldeen, I.M.S., Van Heerden, F.R., Van Staden, J. (2010). In vitro biological activities of niloticane, a new bioactive cassane diterpene from the bark of Acacia nilotica subsp. Kraussiana. Journal of Ethnopharmacology 128:55556. El-Menoufy, H.S., Maha, G.. Amr, N.M.A, Nayra, M. (2010). Clinical and Antimicrobial efficacy of Acacia Nilotica mouth rinse preparation in inhibiting the development of plaque and gingivitis (A comparative study). Journal of Egyptian Dental Association 56(1):57-62. EI-Tahir, A., Satti, G.M.H., Khalid, S.A. (1999). Antiplamodial activity of selected Sudanese medicinal plants with emphasis on Acacia nilotica. Journal of Phytotherapy 13:474-47. Gupta, S.C., Bilgrami, R.S. (1970). Inhi bitory effect of some plant decoctions on the production and activity of cellulolytic (GX) enzyme of three",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4067,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 67)",
    "text": "nilotica. Journal of Phytotherapy 13:474-47. Gupta, S.C., Bilgrami, R.S. (1970). Inhi bitory effect of some plant decoctions on the production and activity of cellulolytic (GX) enzyme of three pathogenic fungi. Proceedings of the National Academy of Science India Sert B 40:68. Hamza, O.J.M., van den Bout -van den Beukel, C.J.P., Matee, M. I.N., Moshi, M.J. et al. (2006). Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections Journal of Ethnopharmacology 108:124-132. Hussein, G., Miyashiro, H., Nakamura, N., Hattori, M., Kakiuchi, N., Shimotohno, K. (2000). Inhibitory effect of sudanese medicinal plant extracts on hepatitis C virus protease. Phytotherapy Research 14:510 - 516. Jain, A., Katewa, S.S., Galav, P.K., Sharma, P. (2005). Medicinal plant diversity of Sitamata wildlife sanctuary, Rajasthan, India. Journal of Ethnopharmacology 102:143-157. Kaingu, C.K., Oduma, J.A., Kanui, T.I. (2011).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 4068,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 68)",
    "text": "(2005). Medicinal plant diversity of Sitamata wildlife sanctuary, Rajasthan, India. Journal of Ethnopharmacology 102:143-157. Kaingu, C.K., Oduma, J.A., Kanui, T.I. (2011). Practices of Traditional Birth Attendants in Machakos District, Kenya. Journal of Ethnopharmacology 137(1):495-502. Kambizi, L., Afolayan, A.J. (2001) . An ethnobotanical study of plants used for the treatment of sexually transmitted diseases (njovhera) in Guruve District, Zimbabwe. Journal of Ethnopharmacology 77: 59. Kaur, K., Michael, H., Arora, S., Härknen, P., Kumar, S. (2005). In vitro bioactivity-guided fractionation and characterization of polyphenolic inhibitory fractions from Acacia nilotica (L.) Willd. ex Del. Journal of Ethnopharmacology 99:353 360. Kubmarawa, D., Ajoku, G.A., Enwerem, N.M., Okorie, D.A., (2007). Preliminary phytochemical and antimicrobial screening of 50 medicinal plants from Nigeria. African Journal of. Biotechnology. 6(14):1690-1696.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4069,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 69)",
    "text": "OOAS Page 5 Acacia nilotica WAHP Kumaresan, A., Mshella, T.A., Aliu, Y.O. (1984). Biochemical evaluation of bagawura seeds for use as livestock feed. Animal Feed Science a nd Technology 11:45-48. Lev, E., Amar, Z. (2000). Ethnopharmacological survey of traditional drugs sold in Israel at the end of the 20th century. Journal of Ethnopharmacology 72:191205. Lev, E., Amar, Z. (2002). Ethnopharmacological survey of traditional drugs sold in the Kingdom of Jordan. Journal of Ethnopharmacology 82:131 145. Mlambo, V., Mould, F.L, Sikosana, J.L.N., Smith, T. et al ., (2008). Chemical composition and in vitro fermentation of tannin-rich tree fruits. Animal Feed Science and Technology, 140; 402417. Nanyingi, O.M., Mbaria, M.J., Lanyasunya, L.A., Wagate, G.C. et al . (2008). Ethnopharmacological survey of Samburu district, Kenya. Journal of Ethnobiology and Ethnomedicine 4:14. Ramana, D.B.V., Singh, S., Solankia, K.R., Negi,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4070,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 70)",
    "text": "Wagate, G.C. et al . (2008). Ethnopharmacological survey of Samburu district, Kenya. Journal of Ethnobiology and Ethnomedicine 4:14. Ramana, D.B.V., Singh, S., Solankia, K.R., Negi, A.S. (2000). Nutritive evaluation of some nitrogen and non- nitrogen-fixing multipurpose tree species. Animal Feed Science and Technology 88:103-111. Runyoro, D.K.B., Ngassapa, O.D., Matee, M.I.N., Joseph, C.C., Moshi, M.J. (2006). Medicinal plants used by Tanz anian traditional healers in the management of Candida infections. Journal of Ethnopharmacology 106:158165. Sawe, J.J., Tuitoek, J.K., Ottaro, J.M. (1998). Evaluation of common tree leaves or pods as supplements for goats on range area of Kenya. Small Ruminant Research 28:3137. Shah, B.H., Safdar, B., Virani, S.S., Nawaz, Z. et al. (1997). The Antiplatelet Aggregatory Activity of Acacia nilotica is due to Blockade of Calcium Influx through Membrane Calcium Channels.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 914,
    "source": "PDF_chunked"
  },
  {
    "id": 4071,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 71)",
    "text": "Shah, B.H., Safdar, B., Virani, S.S., Nawaz, Z. et al. (1997). The Antiplatelet Aggregatory Activity of Acacia nilotica is due to Blockade of Calcium Influx through Membrane Calcium Channels. General Pharmacology 29(2):251-255. Sinha, K.K., Anjana, S. (1984). Evaluation of plant barks against aflatoxin production and growth of Aspergillus parasiticus . National Academy of Science Letters (India) 7:299300. Srinivasan, D., Nathan, S., Suresh, T., Lakshmana Per umalsamy, P. (2001). Antimicrobial activity of certain Indian medicinal plants used in folkloric medicine. Journal of Ethnopharmacology 74:217-220. Sultana, B., Anwar, F., Przybylski, R. (2007). Antioxidant activity of phenolic components present in barks of Azadirachta indica, Terminalia arjuna, Acacia nilotica and Eugenia jambolana Lam. trees. Food Chemistry 104:11061114. Watt, J.M. (1962.) Leguminosae. In: J.M. Watt and M.G. Breyer-Brandwijk (Eds.), The Medicinal",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4072,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 72)",
    "text": "arjuna, Acacia nilotica and Eugenia jambolana Lam. trees. Food Chemistry 104:11061114. Watt, J.M. (1962.) Leguminosae. In: J.M. Watt and M.G. Breyer-Brandwijk (Eds.), The Medicinal and Poisonous Plants of Southern and Eastern Africa. Livingstone Ltd., Edinburgh 546.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 266,
    "source": "PDF_chunked"
  },
  {
    "id": 4073,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 73)",
    "text": "OOAS Page 6 Acacia senegal WAHP Nom botanique Acacia senegal (L.) Willd Famille Mimosaceae Synonyme Acacia verek Guill et Perr; Mimosa senegal L. Noms communs Anglais: Gum Arabic tree Français: Gommier, Gommier blanc, Acacia du sénégal. Noms vernaculaires Burkina Faso:Mooré Gon-peélga, Dioula Patuku, Fulfuldé Patuki;debehi;délbi. Cote d'Ivoire: Baule Kundo Ghana: Sisaala Sofia, Hausa Akovia, Akoura Mali: Bambara Patukill, Arabic Askab, Noms Patuki Nigéria: Hausa Dakwara Niger: Hausa Akkora Sénégal: Wolof Verek, Serer- Ndongargavod Description de la plante C'est un arbuste épineux de 6 à 7 m de haut, avec un tronc droit,gris fissuré, et parfois avec des rameaux près de la base; les feuilles sont ovales, bipennées avec 2- 6 paires de pennes et 6-15 paires de folioles; l'arbuste a uneinflorescence axillairede fleurs blanches parfumées; les gousses sont des plaques membraneuses de 11 cm par 2 cm, avec 7 ou 8",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 917,
    "source": "PDF_chunked"
  },
  {
    "id": 4074,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 74)",
    "text": "6-15 paires de folioles; l'arbuste a uneinflorescence axillairede fleurs blanches parfumées; les gousses sont des plaques membraneuses de 11 cm par 2 cm, avec 7 ou 8 graines beiges,circulaire et aplaties. Numéro du specimen de l'herbier Mali: 1796 (DMT) Habitat et repartition géographique Acacia senegal se trouve dans les zones désertiques africaines du Sénégal jusqu'à la Mer Rouge. Au Sénégal, il pousse surles sols légers et sahéliens. On le retrouve communément sur les côtes sableuses des îles du Saloum et de la Casamance au Sénégal oriental, ainsi que dans le parc du Niokolo-Koba (Fortin et al., 2000). Parties utilisées de la plante Gomme Autres parties utilisées Écorce de tronc Caractéristiques botaniques La gomme arabique est constituée d'exsudat gommeux, séché d'Acacia senegal (L.) Willd (Mimosaceae). Utilisations ethnomédicales Chezles Maures et les bergers Touareg, la plante est destinée à la consommation. Ceux -ci",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4075,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 75)",
    "text": "gommeux, séché d'Acacia senegal (L.) Willd (Mimosaceae). Utilisations ethnomédicales Chezles Maures et les bergers Touareg, la plante est destinée à la consommation. Ceux -ci l'utilisent pour la préparation d'un régime alimentaire de lait, sucre, millet et dattes (Fortin et al., 2000). Diverses préparations de la plante sont prescrites pour les douleurs thoraciques, la migraine, la dysentérie, la diarrhée, les douleurs abdominales et les coliques. Il est également utilisé en médecine vétérinaire (Tabuti et al, 2003; Kerharo et Adam, 1974). L'exsudat de gomme est utilisé pour le traitement de la dysenterie, les inflammations des muqueuses et en externe comme pansement pour les brûlures, les plaies de mamelons et les nodules lépreux (Parveen et al , 2007; Watt et Breyer -Brandwijk, 1962). La décoction des fleurs et de la gomme est utilisée pour traiter la conjonctivite, la dermatite, les saignements et les plaies (Jain et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4076,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 76)",
    "text": "(Parveen et al , 2007; Watt et Breyer -Brandwijk, 1962). La décoction des fleurs et de la gomme est utilisée pour traiter la conjonctivite, la dermatite, les saignements et les plaies (Jain et al., 2005) et les feuilles sont pressentiesé loigner les mauvais esprits (Tabuti et al., 2003). Activités biologiques et pharmacologiques Dans la littérature, il y a très peu d'informations sur les activités biologiques de la plante car elle a été principalement étudiée pour la valeur commerciale des gommes qu'el le produit. Elles sont utilisées comme épaississant et émulsifiant dans la production alimentaire. Marwah et al. (2007) ont démontré l'activité antioxydante de ces extraits. Données cliniques L'administration de lagomme d'acacia à des patients hypercholestérolémiques pendant 4 à 12 semaines n'a eu aucuneffet sur les niveaux de lipides plasmatiques ( Jensen et al, 1993; Haskellet al, 1992). A une concentration de 0,5, le mélange dela gomme d'acacia inhibe les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 970,
    "source": "PDF_chunked"
  },
  {
    "id": 4077,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 77)",
    "text": "semaines n'a eu aucuneffet sur les niveaux de lipides plasmatiques ( Jensen et al, 1993; Haskellet al, 1992). A une concentration de 0,5, le mélange dela gomme d'acacia inhibe les enzymes protéases bactériennes , suggérant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 222,
    "source": "PDF_chunked"
  },
  {
    "id": 4078,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 78)",
    "text": "OOAS Page 7 Acacia senegal WAHP ainsi que l'acacia peut être utilisé pour limiter le développement de la maladie parodontale. En outre, mâcher une gomme d'acacia pendant 7 jours, comparé à une gomme sans sucre, a montré une réduction des indices gingivales et la formation de plaques ; la diffé rence totale des indices était significative (P 0,05) chez ceux qui suggèrent que la gomme d'acacia inhibe principalement le dépôt précoce de plaques (Gazi, 1991). Constituants chimiques Mélange composé de glycoprotéines et de polysaccharides (acide arabique) et leurs sels de calcium, magnésium et potassium; les tanins (Kerharo et Adam, 1974). Test d'identité et de pureté Teneur en humidité: 16,23 Cendre totale: 9,46 Substances extractibles par l'eau: 53,40 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4079,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 79)",
    "text": "Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC) chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d 'acideacétique glacial (10 ml ), 85 ml de méthanol et 5ml d'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de six tâches distinctes avec valeurs R f de 0,94 (jaune), 071 (rose), 0,48 (rose), 0.30 (violet), 0,25 (violet) et 0,22 (jaune). Macroscopie La gomme arabique apparaît sous forme de larmes arrondies ou ovales, avec une taille qui varie, généralement entre 0,5 à 2 cm de diamètre, blanchâtres ou blanc -jaunâtre, opaque, en raison de la présence de nombreuses petites Chromatogramme fissures sur la surface; elle se divise facilement en de nombreux petits fragments anguleux avec une surface en verre transparente, brillante,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4080,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 80)",
    "text": "Chromatogramme fissures sur la surface; elle se divise facilement en de nombreux petits fragments anguleux avec une surface en verre transparente, brillante, pratiquement inodore, insipide et mucilagineuse (Pharmacopée africaine, 1985). Macroscopie La gomme arabique apparaît sous forme de larmes arrondies ou ovales, avec une taille qui varie, généralement entre 0,5 à 2 cm de diamètre, blanchâtres ou blanc -jaunâtre, opaque, en raison de la présence de nombreuses petites fissures sur la surface; elle se divise faci lement en de nombreux petits fragments anguleux avec une surface en verre transparente, brillante, pratiquement inodore, insipide et mucilagineuse (Pharmacopée africaine, 1985). Microscopie Sous le microscope, la gomme arabique est blanche avec des partic ules angulaires; aucune présence de grains d'amidon, de particules de tissu végétal et de parois cellulaires mucilagineuses (contrairement à la gomme adragante). Matériel végétal en poudre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 964,
    "source": "PDF_chunked"
  },
  {
    "id": 4081,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 81)",
    "text": "présence de grains d'amidon, de particules de tissu végétal et de parois cellulaires mucilagineuses (contrairement à la gomme adragante). Matériel végétal en poudre La gomme arabique est un extrait de matériel gommeux, acellulaire, dépourvu de toute organisation cellulaire. Actions thérapeutiques Expectorant, émollient topique, anti - inflammatoire, membrane protectrice de muqueuse, antihémorragique, vulnéraire (Parveen et al., 2007; Jain et al., 2005; Fortin et al.,2000). Indications thérapeutiques Diarrhée, dysenterie, toux, inflammation des muqueuses, brûlures.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 570,
    "source": "PDF_chunked"
  },
  {
    "id": 4082,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 82)",
    "text": "OOAS Page 8 Acacia senegal WAHP Données de sécurité En 24 heures, la DL 50 de l'extrait aqueux de la gomme ( p.o) chez la souris a été au- delà de 2000 mgkg. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'administration par voie orale de l'extrait à 500- 2000 mgkg à des souris mâles et femelles, pendant 14 jours. Précautions d'emploi Tout comme la formulation d'un excipient pharmaceutique, la gomme arabique doit être utilisée en proportion correcte dans les crèmes, les émulsions et les suspensions. Effets indésirables Des réactions allergiques aux formes de gomme et depoudre d'acacia ont été rapportées et des problèmes respiratoires et lésions cutanées ont été signalés. L'utilisation abusive peut provoquer des lésions rénales et hépatiques (Leung et Foster, 1980). Contre-indications En cas de diarrhée, l'utilisation par voie orale doit être médicalement supervisée. Dosage et forme galénique",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 4083,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 83)",
    "text": "des lésions rénales et hépatiques (Leung et Foster, 1980). Contre-indications En cas de diarrhée, l'utilisation par voie orale doit être médicalement supervisée. Dosage et forme galénique Formulation composée d'infusion, suspensions, crème, émulsions et emmolients externes ou topique. La gomme arabique est prise comme un thé : 20 g par litre d'eau bouillante (Fortin et al . 2000). Conservation A conserver dans un endroit frais et sec. Références Fortin, D., Lô, M., Maynart, G. (2000). Plantes medicinales du sahel. Dakar, Enda- Editions, 2 ème Ed., 2000, 280p. Gazi, M.I. (1991).The finding of antiplaque features in Acacia arabica type of chewing gum. Journal of Clinical Periodontology 18:75-77. Haskell, W. L., Spiller, G.A., Jensen, C.D., Ellis, B.K., Gates, J.E. (1992). Role of water -soluble dietary fiber in the management of elevated plasma cholesterol in healthy subjects. American Journal of Cardiology 69:433-439.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4084,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 84)",
    "text": "B.K., Gates, J.E. (1992). Role of water -soluble dietary fiber in the management of elevated plasma cholesterol in healthy subjects. American Journal of Cardiology 69:433-439. Jain, A., Katewa, S.S., Galav, P.K., Sha rma, P. (2005). Medicinal plant diversity of Sitamata wildlife sanctuary, Rajasthan, India. Journal of Ethnopharmacology 102:143157. Jensen, C.D., Spiller, G.A., Gates , J.E., Miller, A.F., Whittam, J.H. (1993). The effect of acacia gum and a water -soluble dietary fiber mixture on blood lipids in humans. Journal of American College of Nutr ition 12:147-154. Kerharo, J., Adam, J.G. (1974). La pharmacopée Sénégalaise traditionnelle, Plantes médicinales et toxiquesVIGOT, PARIS, 1974, p. 241-245. Leung, A.Y., Foster, S. (1980). Encyclopedia of Common Natural Ingredients Used in Food, Drugs, and Cosmetics . New York, NY: J. Wiley and Sons. Marwah, R.G., Fatope, M.O., Al Mahrooqi, R., Varma, G.B. et al. (2007). Antioxidant capacity of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 4085,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 85)",
    "text": "Common Natural Ingredients Used in Food, Drugs, and Cosmetics . New York, NY: J. Wiley and Sons. Marwah, R.G., Fatope, M.O., Al Mahrooqi, R., Varma, G.B. et al. (2007). Antioxidant capacity of some edible and wound h ealing plants in Oman. Food Chemistry 101:465470. Parveen, P., Upadhyay, B., Roy, S., Kumar, A. (2007). Traditional uses of medicinal plants among the rural communities of Churu district in the Thar Desert, India. Journal of Ethnopharmacology 113:387399. Tabuti, J.R.S., Lye, K.A., Dhillion, S.S. (2003). Traditional herbal drugs of Bulamogi, Uganda: plants, use and administration. Journal of Ethnopharmacology 88:1944.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 637,
    "source": "PDF_chunked"
  },
  {
    "id": 4086,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 86)",
    "text": "OOAS Page 9 Adonsonia digitata WAHP Adansonia digitata L. Famille Bombacaceae Synonyme Adansonia sphaerocarpa A. Chev. Noms communs Anglais: Baobab Français: Baobab Noms vernaculaires Burkina Faso: Mooré Twèga, Dioula Sira, Fulfuldé bolbe;bouki Ghana: Akan - Odadeē Mali: Bambara - Zira, Manlinké- Sito, Dogon - Oro Niger: Hausa Kouka, Djerma Kogna Nigéria: Yoruba Ose Sénégal: Wolof Gui, Gouïe; Serer Bàk, Diola Bu Bak, Hausa Kuka Sierra leone: Fula Sule, Kono Sela, Madingo - Sida Togo: Moba Tokala, Ewe Adidotsi, Nawdem Todi Description de la plante A. digitata est un arbre caractéristique de 15- 20 m de longavec un tronc très large et épais, d'environ 2 m de diamètre, dur, spongieux, avec de grandes branches tortueuses, généralement étalées et tordues (Malgras, 1992); l'écorce est brun-grisâtre et normalement lisse, mais peut souvent être diversement plié et cousu à partir",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 883,
    "source": "PDF_chunked"
  },
  {
    "id": 4087,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 87)",
    "text": "de grandes branches tortueuses, généralement étalées et tordues (Malgras, 1992); l'écorce est brun-grisâtre et normalement lisse, mais peut souvent être diversement plié et cousu à partir des années de croissance; les feuilles sont alternes, digitées, à bord entier ou denticulé, et composé de six à sept folioles obovales ou ovales, acuminées, aiguës, légèrement pubescentes sur la surface; les fleurs sont grandes et blanches, solitaires, pendantes (10-20 cm), avec des tiges très longues qui s'élèvent jusqu'à 80 cm (Malgras, 1992; Kerharo et Adam, 1974) ;les fleurs sont équipées de deux bractéoles qui fleurissent la nuit; les fruits sont des capsules appelées \"pain de singe\" ; ils sont oblongues, ovoïdes ou arrondis, boisés et poilus, avec 8- 15 cm de large et suspendue au sommetd'une longue tige (Malgras, 1992); le fruit est épicarpe et verdâtre; A maturité, il contient de nombreuses graines noires dures dans une pulpe farineuse blanche.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4088,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 88)",
    "text": "sommetd'une longue tige (Malgras, 1992); le fruit est épicarpe et verdâtre; A maturité, il contient de nombreuses graines noires dures dans une pulpe farineuse blanche. Numéro du specimen de l'herbier Ghana: A2083 (Ghana Hebarium) Mali: 2358 (DMT) Togo: TOGO02476 Togo: TOGO02476 Habitat et repartition géographqiue A. digitata pousse communément dans les forêts épineuses des savanes africaines, caractérisées par de faibles altitudes et précipitations annuelles limitées telles que cellesdes zones soudano- sahélienne (600 à 900 mm de précipitations annuelles). Il se trouve dans les régions chaudes boisées et sèches en Stoney, sur les sols bien drainés, les zones sans gel qui reçoivent des précipitations faibles. Cependant, il s'adapte à n'importe quel sol (Le Flamboyant, 1993). A. digitata est résistant au feu, aux termites et à la sécheresse. Il préfère une nappe phréatique élevée et est très sensible à l'engorgement et au",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4089,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 89)",
    "text": "n'importe quel sol (Le Flamboyant, 1993). A. digitata est résistant au feu, aux termites et à la sécheresse. Il préfère une nappe phréatique élevée et est très sensible à l'engorgement et au gel. C'est une espèce protégée, souvent plantée et associée aux travaux humains (Giffard, 1974). Parties utilisées de la plante Feuilles, Pulpe du fruit Autres parties utilisés Écorce de la tige et racine Caractéristiques botaniques Le Baobab se compose de la feuille ou la pulpe séchée du fruit blanc d'Adansonia digitata L. (Bombacaceae). Utilisations ethnomédicales A. digitata est utilisé pour traiter les infections parasitaires, la diarrhée et les douleurs abdominales (Diehl et al. 2004). La décoction de l'écorce de la racine ou de la tige est utilisée comme désinfectant des plaies chroniques. Le jus de l'écorce de tige fraîche est appliqué sur les petits furoncles .La poudre mélangée à de l'huile de graines de Lannea microcarpa est appliquée",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4090,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 90)",
    "text": "comme désinfectant des plaies chroniques. Le jus de l'écorce de tige fraîche est appliqué sur les petits furoncles .La poudre mélangée à de l'huile de graines de Lannea microcarpa est appliquée sur les gros furoncles (Inngjerdingen et al., 2004). La décoction de l'écorce de tige est administrée par voie orale pour traiter les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 327,
    "source": "PDF_chunked"
  },
  {
    "id": 4091,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 91)",
    "text": "OOAS Page 10 Adonsonia digitata WAHP maladies infectieuses telles que les maladies sexuellement transmissibles (Magas souba et al., 2007). A. digitata est utilisé pour le traitement de la fièvre, la diarrhée, l'hémoptysie, le hoquet et les troubles des voies urinaires et digestives (Ribeiro et al, 2010;. Van Wyk, 2008). Les feuilles séchées sont conservées pendant 1- 2 ans dans un récipient fermé, pilées et tendues et la gomme qui en résulte est utilisée comme un remède pour la carie dentaire. Certains guérisseurs recommandent l'ajout d'une coquille d'escargot séchée avant de piler les feuilles. La décoction de feuille est également utilisée par voie orale pour le traitement du paludisme (Nguta et al, 2010a; 2010b). Dans certaines régions d'Afrique, de l'Inde, de Sri Lanka et de l'Ouest des Indes, les malades du paludisme sont conseillés de prendre un moût contenant l'écorce séchée de baobab pour traiter la fièvre qui résulte de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4092,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 92)",
    "text": "de l'Inde, de Sri Lanka et de l'Ouest des Indes, les malades du paludisme sont conseillés de prendre un moût contenant l'écorce séchée de baobab pour traiter la fièvre qui résulte de la maladie. L'écorce de la plante est utilisée pour traiter la tuberculose, la toux chronique, la bronchite et la débilité (Luo et al , 2011; Ribeiro et al, 2010). Activités biologiques et pharmacologiques Les extraits aqueux de méthanol et d'acétonitrile de la fleur ont montré une activité antifongique contre Microsporum canis , Trichophyton rubrum et Epidermophyton floccosum (Locher et al., 1995). Deeni et Sadiq (2002) ont rapporté des activités antibactériennes et antifongiques in vitro de l'extrait méthanolique de la feuille. L'extrait de feuille a également présenté des activités anthelminthiques (Diehl et al., 2004), les feuilles, la pulpe du fruit et les graines d' A. digitata ont montré une activité antivirale contre le virus de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4093,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 93)",
    "text": "anthelminthiques (Diehl et al., 2004), les feuilles, la pulpe du fruit et les graines d' A. digitata ont montré une activité antivirale contre le virus de la grippe, del'herpès simplex, celui du virus respiratoire syncytial (Vimalanathan et Hudson, 2009) et de la poliomyélite. La plante a des propriétés analgésique, anti -inflammatoire et antipyrétique. Ramadan et al. (1993) on constaté que la pulpe du fruit de baobab a les mêmes propriétés anti -inflammatoires quecelles de la phénylbutazone chez le rat. La poudre issue de la feuille est un anti -asthmatique (Sallet et al., 1946). L'administration intraveineuse de l'extrait de feuille chez des animaux a provoqué une chute de la pression carotidienne et une fréquence respiratoire accrue avec une amplitude croissante. Plusieurs études ont rapporté les capacités antioxydantes de la pulpe du fruit de baobab, en raison de sa haute teneur en vitamine C (Lamien- Meda et al., 2008;. Blomhoff",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4094,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 94)",
    "text": "croissante. Plusieurs études ont rapporté les capacités antioxydantes de la pulpe du fruit de baobab, en raison de sa haute teneur en vitamine C (Lamien- Meda et al., 2008;. Blomhoff et al., 2010;. Brady, 2011). En plus d'avoir des propriétés analgésiques, il a été montré également que la pulpe du fruit baisse la température corporelle élevée, sans affecter la température normale du corps (Ramadan et al ., 1993). Al -Qarawi et al. (2003) ont également signalé que la pulpe du fruit possèdeà la fois des propriétés hépatoprotectiveset hépatorestoratives chez les rats albinos Wistar mâles. Données cliniques Dans une étude clinique portant sur 160 enfants âgés de 8 mois, l'efficacité de la solution locale composée de la pulpe du fruit séché de baobab avec de l'eau et du sucre, a été comparée à la solution standard que l'OMS utilisée pour traiter les enfants atteints de diarrhée aiguë. Il a été observé que, bien que la solution de l'OMS soit",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4095,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 95)",
    "text": "avec de l'eau et du sucre, a été comparée à la solution standard que l'OMS utilisée pour traiter les enfants atteints de diarrhée aiguë. Il a été observé que, bien que la solution de l'OMS soit supérieure au mélange de baobab, il n'y avait aucune différence statistique entre les deux solutions en termes de durée de la diarrhée et de gain de poids. En outre, on a trouvé que la solution tradition nelle locale est une excellente source nutritive, plus économique que la solution de l'OMS et est aussi disponible pour les communautés pauvres (Tal-Dia et al., 1997). Constituants chimiques Vitamine A, B et C; minéraux (calcium, phosphore); mucilage; protéine; cellulose; tanins, anthraquinones, saponines, pectines, stérols et triterpènes; acides aminés (sauf cystine et tryptophane); acides organiques (acide citrique, acide tartrique, acide malique, acide stéarique, acide linoléique, acide oléique, acide palmitique) (Gaiwe, 1989; Kerharo et Adam, 1974;. Toury et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 966,
    "source": "PDF_chunked"
  },
  {
    "id": 4096,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 96)",
    "text": "tryptophane); acides organiques (acide citrique, acide tartrique, acide malique, acide stéarique, acide linoléique, acide oléique, acide palmitique) (Gaiwe, 1989; Kerharo et Adam, 1974;. Toury et al 1957). Test d'identité et de purété Teneur en humidité: 12-13 Cendre totale: 7-9 Substance extractible par l'eau: 5,2 Substance extractible par l'éthanol (70): 20,0 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60F254, et phase mobile : éther de pétrole (40-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 549,
    "source": "PDF_chunked"
  },
  {
    "id": 4097,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 97)",
    "text": "OOAS Page 11 Adonsonia digitata WAHP 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de quatre tâches distinctes avec valeurs R f de 0,68 (rose), 0,48 (violet), 0,42 (rose) et de 0,28 (rose). Chromatogramme Macroscopie Feuilles alternes, digitées à bord entier ou denticulé, et composées de six à sept folioles, obovales ou ovales, acuminées, aiguës, légèrement pubescentes sur la surface (Malgras, 1992; Kerharo et Adam, 1974); les fruit s sont des capsules oblongues, ovoïdes ou arrondis, ligneux et pubescents, de 8- 15 cm de large ; l'épicarpe du fruits est verdâtre; avec de nombreuses graines noires, dures dans une pulpe farineuse blanche. La pulpe blanche, molle enfermée dans une coque dureest la principale source de nourriture et de médicaments",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4098,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 98)",
    "text": "graines noires, dures dans une pulpe farineuse blanche. La pulpe blanche, molle enfermée dans une coque dureest la principale source de nourriture et de médicaments Microscopie La coque du fruit est composée de nombreuses cellules de pierre lignifiées, des vaisseaux d'élémentsfortement dénoyautées et des fibres sclerenchymateuses lignifiées; la pulpe est presqu'entièrement constituée de grandes cellules parenchymateuses polygonales ou irrégulières non aoûtés avec un bec contenant de nombreux gros grains d'amidon, simples ou composés, angulaires ou sphériques avec des striatrions et hiles distinctes les semenc es, avecdes téguments brunâtres durs sont composés de cellules de pierre et de nombreux petits vaisseaux; le noyau blanc est constitué de cellules parenchymateuses molles, cellules à huileet de nombreuses fibres non aoûtées à parois dénoyautées; de nombreux grains d'aleurone sont présents dans une cellule (Ghani et Agbejule, 1986).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4099,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 99)",
    "text": "huileet de nombreuses fibres non aoûtées à parois dénoyautées; de nombreux grains d'aleurone sont présents dans une cellule (Ghani et Agbejule, 1986). Matériel végétal en poudre Vaisseaux de xylème avec des murs dénoyautées, nombreuses cellules de pierre lignifiées de rouge avec de l'acide chlorhydrique, du phloroglucinol et d es fibres lignifiées sclérenchymateuses, également beaucoup de grains d'amidon de grande taille qui se colorent en bleu-foncé avec une solution d'iode; les grains d'aleurone sont nombreux. Actions thérapeutiques Antiasthmatique (Sallet et al. 1946), antibactérienne et antifongique (Deeni et Sadiq, 2002), hypotenseur, anti -histaminique, diaphorétique, antihémorragique, anti -sudorifique (Malgras, 1992), antihelminthique et larvicide (Diehl et al., 2004), antipaludique (Nguta et al ., 2010b), analgésique, anti -inflammatoire et antipyrétique (Ribeiro et al., 2010). Indications Therapeutiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4100,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 100)",
    "text": "(Diehl et al., 2004), antipaludique (Nguta et al ., 2010b), analgésique, anti -inflammatoire et antipyrétique (Ribeiro et al., 2010). Indications Therapeutiques Asthme, constipation, inflammation, douleur, fièvre, diarrhée, hémorragies, paludisme. Données de sécurité En 24 heures, la DL 50 de l'extrait aqueux de la gomme ( p.o) chez la souris a été au- delà de 2000 mgkg. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'administration orale de l'extrait à 500-2000 mgkg à des souris mâles et femelles pendant 14 jours. Précautions d'emploi La pression artérielle doit être surveillée chez les patients hypertendus. Effets indésirables A fortes doses, il peut causer une hypotension. Contre-indications En cas de diarrhée, son utilisation doit être surveillée. Dosage et formegalénique Décoction Conservation A conserver dans un endroit frais et sec. Références",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 909,
    "source": "PDF_chunked"
  },
  {
    "id": 4101,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 101)",
    "text": "Contre-indications En cas de diarrhée, son utilisation doit être surveillée. Dosage et formegalénique Décoction Conservation A conserver dans un endroit frais et sec. Références Al-Qarawi, A.A., AL -Damegh, M.A., El -Mougy, S.A. (2003). Hepatoprotective influence of Adansonia digitata Pulp. Journal of Herbs, Spices and Medicinal Plants 10:1-6.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 345,
    "source": "PDF_chunked"
  },
  {
    "id": 4102,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 102)",
    "text": "OOAS Page 12 Adonsonia digitata WAHP Blomhoff, R., Car isen, M., Halvorsen, B., Holte, K., Bohn, S. et al. (2010). The total antioxidant content of more than 3100 foods, beverages, spices, herbs and supplements used worldwide. Nutrition Journal 9:3. Deeni, Y.Y., Sadiq, N.M. (2002). Antimicrobial properties and phytochemical constituents of the leaves of African mistletoe ( Tapinanthus dodoneifolius (DC) Danser) (Loranthaceae): an ethnomedicinal plant of Hausaland, Northern Nigeria. Journal of Ethnopharmacology 83:235- 240. Diehl, M.S., Kamanzi Atindehou, K., Téré, H., Betschart, B. (2004). Prospect for anthelminthic plants in the Ivory Coast using ethnobotanical criteria. Journal of Ethnopharmacology 95:277 284. Gaiwe, R., Nkulinkiye- Nfura, T., Bassenne, E., Olschwan, G., Ba, D. et al . (1989). Calcium et mucilage dans les feuilles de Adansonia digitata (Baobab). Pharmaceutical Biology 27(2):101-104. Ghani, A. and Agbejule, A.O. (1986). A",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 4103,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 103)",
    "text": "E., Olschwan, G., Ba, D. et al . (1989). Calcium et mucilage dans les feuilles de Adansonia digitata (Baobab). Pharmaceutical Biology 27(2):101-104. Ghani, A. and Agbejule, A.O. (1986). A pharmacognostical study of the fruit of Adansonia digitata L. In the S tate of Medicinal Plants Research in Nigeria. Proceedings of a workshop. Edited by Sofowora. Abayomi. Univ ersity of Ibadan Press. Nigeria. Giffard, P.L. (1974). L'arbre dans le paysage sénégalais, sylviculture en zone tropicale sèche. Centre technique for estier tropical, Dakar. p.127- 128. Inngjerdingen, K., Nergård, C.S., Diallo, D., Mounkoro, P.P., Paulsen, B.S. (2004). An ethnopharmacological survey of plants used for wound healing in Dogonland, Mali, West Africa. Journal of Ethnopharmacology 92:233244. Kerharo, J., Adam, J.G. (1974). La pharmacopée Sénégalaise traditionnelle, plantes médicinales et toxiques. Vigot, Paris, p. 241-245. Lamien-Meda, A., Lamien, C.E., Compaore,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4104,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 104)",
    "text": "Kerharo, J., Adam, J.G. (1974). La pharmacopée Sénégalaise traditionnelle, plantes médicinales et toxiques. Vigot, Paris, p. 241-245. Lamien-Meda, A., Lamien, C.E., Compaore, M.M.Y., Meda, R.N.T., Kiendrebeogo, M. et al . (2008). Polyphenol content and antioxidant activity of fourteen wild edible fruits from Burkina Faso. Molecules 13:581-594. Le Flamboyant Bulletin de liaison des membres du Réseau Arbres Tropicaux (1993). 27:12-13. Locher, C.P., Burch, M.T., Mower, H.F., Berestecky, J., Davis, H., et al . (1995). Antimicrobial activity and anticomplement activity of extracts obtained from selected Hawaiian medicinal plants. Journal of Ethnopharmacology 49:23-32. Luo, X., Pires, D., Aínsa, J.A., Gracia, B., Mulhovo, S., et al ., (2011). Antimycobacter ial evaluation and preliminary phytochemical investigation of selected medicinal plants traditionally used in Mozambique. Journal of Ethnopharmacology 137(1):114-120.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4105,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 105)",
    "text": "evaluation and preliminary phytochemical investigation of selected medicinal plants traditionally used in Mozambique. Journal of Ethnopharmacology 137(1):114-120. Magassouba, F.B., Diallo, A., Kouyaté, M., Mara, F, Mara, O. et al . (2007). Ethnobotanic al survey and antibacterial activity of some plants used in Guinean traditional medicine. Journal of Ethnopharmacology 114:4453. Malgras, D. (1992). Arbres et Arbustes guérisseurs des savanes africaines. Edition Karthala et ACCT, Paris, p. 346. Nguta, J.M, Mbaria, J.M., Gakuya, D.W., Gathumbi, P.K., Kiama, S.G., ( 2010a). Antimalarial herbal remedies of Msambweni, Kenya. Journal of Ethnopharmacology 128:424 432. Nguta, J.M. , Mbaria, J.M., Gakuya, D.W., Gathumbi, P.K., Kiama, S.G., 2010b. Traditional antimalarial phytotherapy remedies used by the South Coast community, Kenya. Journal of Ethnopharmacology 131:256267. Ramadan, A., Harraz, F.M., El -Mougy, S.A.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4106,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 106)",
    "text": "antimalarial phytotherapy remedies used by the South Coast community, Kenya. Journal of Ethnopharmacology 131:256267. Ramadan, A., Harraz, F.M., El -Mougy, S.A. (1993). Anti -inflammatory, analgesic and antipyretic effects of the fruit pulp of Adansonia digitata, Fitoterapia 65:418-422. Ribeiro, A., Romeiras, M.M., Tavares, J., Faria, M.T. (2010). Ethnobotanical survey in Canhane village, district of Massingir, Mozambique: medicinal plants and traditional knowledge. Journal of Ethnobiology and Ethnomedicine 6:33. Sallet, A., Vincent, D., Sero, M. (1946). De l'emploi thérapeutique du Baobab. In Press Médicale, 4:353. Tal-Dia, A., Toure, K., Sarr, O., Sarr, M., Cisse, M.F. et al . (1997). A baobab solution for the prevention and treatment of acute dehydrati on in infantile diarrhea. Dakar Medicine 42:68-73.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 816,
    "source": "PDF_chunked"
  },
  {
    "id": 4107,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 107)",
    "text": "OOAS Page 13 Adonsonia digitata WAHP Toury, J., Lunven, P., Giorgi, R., Jacquesson, M. (1957). Extrait tiré dans le baobab, arbre providence de l'Afrique. Anale de la nutrition et de l'alimentation, In Ministere De L'economie Rurale-Direction Des Eaux Et Forêts, Leçon N 3, p. 1-4. Van Wyk, B.E. (2008). A broad review of commercially important southern African medicinal plants, Journal of Ethnopharmacology , 119:342355.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 422,
    "source": "PDF_chunked"
  },
  {
    "id": 4108,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 108)",
    "text": "OOAS Page 14 Ageratum conyzoides WAHP Nom botanique Ageratum conyzoides L. Famille Asteraceae Synonyme Ageratum latifolium Car., A. cordifolium Roxb,A. album Stend., A. odoratum Vilm., A. hirsutum Lam., A. obtusifolium Lam. Noms communs Bouc australien contre les mauvaises herbes, bouc contre les mauvaises herbes, Ageratum mexicain Noms vernaculaires Burkina Faso: Dioula Chou kolan, Fulfuld é Kikalapurél;kisalapuré Cote d'Ivoire : Baule Kondre, Dan Dussuo, Gagu Maingue Gambia: Fula Pulaar Chikara Pre, Manding Mandinka Hatayajambo Ghana: Akyem Adwowakuro, Asante Guakuro, Fante Efumomoe Guinée- Bissau: Crioulo Balquiama, Fula Laboel, Mandinka Boro Guinée: Fula Pulaar Kumba-Dongul Libéria: Basa Omalu-Ana, Mano Dah Vo Nigéria: Yuroba Imi esu, Edo Ebegho, Igbo Ngwa Sénégal: Diola Ekerkeda, Manding Bambara Nun Gu, Wolof Gobu. Sierra Leone : Kono Yandigbene Yani, K rio",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 874,
    "source": "PDF_chunked"
  },
  {
    "id": 4109,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 109)",
    "text": "Nigéria: Yuroba Imi esu, Edo Ebegho, Igbo Ngwa Sénégal: Diola Ekerkeda, Manding Bambara Nun Gu, Wolof Gobu. Sierra Leone : Kono Yandigbene Yani, K rio Wet-Ed-Lif, Susu Dyalonke-Khampu-Na. Description de la plante C'est une plante herbacée annuelle, dressée, ramifiée, légèrement hispide qui s'élève jusqu'à 1 m de haut; les feuilles sont opposées, disposées en alternances; ovales, avec des setose- pubères sur les nervures dela surface inférieure, le bord crénelé, la pétiole mince, les capitules bleu- violetes ou blanchâtres, petites, abondantes, en cymes terminales. Numéro du specimen de l'herbier Ghana: A1847 (Herbier du Ghana) Nigéria: FHI108305 (Institut de Recherche Forestière sur l'Herbier, Ibadan) Togo: TOGO00775 Habitation et repartition géographique A. conyzoides pousse abondamment dans le Nord du Ghana, du Mali et du Cameroun. On le retrouve habituellement dans les endroits humides ou pendant la saison des pluies dans",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4110,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 110)",
    "text": "A. conyzoides pousse abondamment dans le Nord du Ghana, du Mali et du Cameroun. On le retrouve habituellement dans les endroits humides ou pendant la saison des pluies dans les villages abandonnés et les zones herbeuses y compris sur les routes (Dokosi, 1998; GHP, 1992). Parties utilisées de la plante Feuilles fraîches ou sèches. Autres parties utilisées Racine; plante entière Caractéristiques botaniques Ageratum se compose de feuilles fraîches ou séchées d'Ageratum conyzoides L. (Asteraceae). Utilisations ethnomédicales A. conyzoides est utilisé dans diverses régions d'Afrique, d'Asie et d'Amérique du Sud pour traiter une grande variété de maladies, de même que la maladie mentale, les maux de tête, les coliques, l'ulcère de la peau, les coupures et plaies, les brûlures et la dyspnée. Il est utilisé comme purgatif, fébrifuge, anti -artralgique et antipyrétique. Au Nigeria, la décoction de la plante est utilisée en externepour traiter la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4111,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 111)",
    "text": "plaies, les brûlures et la dyspnée. Il est utilisé comme purgatif, fébrifuge, anti -artralgique et antipyrétique. Au Nigeria, la décoction de la plante est utilisée en externepour traiter la diarrhée et les douleurs intestinales ; il est incorporé dans des savons traditionnels préparés à partir de cendres de plantes telles que le cacao (Theobroma cacao) et le palmier à huile ( Elaeis guinensis). Au Kenya, il est utilisé comme un anti-asthmatique, antispasmodique et hémostatique, tandis que dans lamédecine populaire brésilienne, les thés d' A. conyzoides sont pr is comme un anti -inflammatoire, un analgésique, un anti -diarrhéique. Au Vietnam, il est utilisé pour les problèmes gynécologiques. D'autres utilisations traditionnelles le prennent comme anti-démangeaison, antitussif, vermifuge, anti-rhumatismal et anti -caries. La plante est très couramment utilisée comme désinfectant et haemostatique pour les plaies (Haensel et al.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4112,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 112)",
    "text": "comme anti-démangeaison, antitussif, vermifuge, anti-rhumatismal et anti -caries. La plante est très couramment utilisée comme désinfectant et haemostatique pour les plaies (Haensel et al., 1994). L'application de la sève des feuilles sur",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 238,
    "source": "PDF_chunked"
  },
  {
    "id": 4113,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 113)",
    "text": "OOAS Page 15 Ageratum conyzoides WAHP les mains des joueurs de cartes est censée leurs porter chance (Durodola, 1977). Activités biologiques et pharmacologiques Dans diverses études expérimentales, l' A. conyzoides a donné des résultats encourageants anti-inflammatoire, analgésiques, antibactériens et des propriétés curativessurles plaies. L'extrait brut de la racine et les parties aér iennes ont démontré une activité de blocage neuromusculaire sur le diaphragme du nerf phrénique d'un rat isolé.Les extraits d' A. conyzoides ont montré les chaînes de calcium bloquant activité, semblable à celle du verapramil (Achola et Munenge, 1997). Les extraits aqueux de feuille ont une action analgésique très efficace chez le rat (Bioka et al., 1993) et les extraits d'éther et de chloroforme ont montré une activité in vitro contre Staphylococcus aureus (Durodola, 1977). Yamamoto et al . (1991) n'ont trou vé aucunes propriétés anti -inflammatoires et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4114,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 114)",
    "text": "d'éther et de chloroforme ont montré une activité in vitro contre Staphylococcus aureus (Durodola, 1977). Yamamoto et al . (1991) n'ont trou vé aucunes propriétés anti -inflammatoires et analgésiques in vivo . Mais l'extrait a présenté une activité histaminique in vitro partielle de type agoniste. L'extrait méthanolique de la plante entière a montré des propriétés antibactériennes (S. aureus , Bacillus subtilis , Escherichia coli et Pseudomonas aeruginosa ) (Almagboul et al ., 1985). Les études animales ont démontré des effets curatifs de la plante sur les blessures et, son extrait alcoolique a entrainé une baisse dose-dépendante induite par la radiat ion in vivo de la mortalité. Un savon local contenant des extraits d' A- conyzoides avec d'autres plantes médicinales comme l'Aloès, n'a montré aucun effet significatif antibactérien et antifongique sur les organismes d'essai (Moody et al., 2004). Données cliniques L'extrait de la feuille a été employé dans le",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 971,
    "source": "PDF_chunked"
  },
  {
    "id": 4115,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 115)",
    "text": "effet significatif antibactérien et antifongique sur les organismes d'essai (Moody et al., 2004). Données cliniques L'extrait de la feuille a été employé dans le traitement de la douleur chronique chez les patients atteints d'ostéoarthrite. Au Brésil, un extrait de jus de la plante entière a été donné aux patients présentant l 'arthrite; il a été ainsi rapporté une baisse de la douleur à 66 et 24 d'amélioration de la mobilité après une semaine de traitement sans effets secondaires (Marqueset al.,1988). Constituants chimiques Huile volatile (eugénol); chromènes; triterpénoïdes, y compris stérols; flavonoïdes et composés phénoliques (conyzorigun, 5- méthoxynobilétine, quercétine, glycosides kaempférol); alcaloïdes; benzofuranes et tanins (Okunade, 2002; GHP, 1992; Gill, 1978). Test d'identité et de purété Teneur en humidité: pas plus de 9,6 Cendre totale: 18,68 O O O OCH3 H3CO H3CO OCH3 O OCH3 O HO HO O OH OH O HO O Kaempferol Eugenol ChromeneConyzorygun",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 966,
    "source": "PDF_chunked"
  },
  {
    "id": 4116,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 116)",
    "text": "Test d'identité et de purété Teneur en humidité: pas plus de 9,6 Cendre totale: 18,68 O O O OCH3 H3CO H3CO OCH3 O OCH3 O HO HO O OH OH O HO O Kaempferol Eugenol ChromeneConyzorygun Substances extractibles par l'eau: 17,5 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv, la révélation est réalisée par la pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de neuf tâches distinctes avec valeurs R f de 0,89 (rose), 0,81 (gris), 0,74 (marron), 0,42 (rose), 0,35 (rose), 0,26 (rose), 0,22 (cendres), 0,19 (violet) et 0,09 (violet ). Chromatogramme Macroscopie Feuille simple de 4- 7 cm de long sur 2- 5 cm de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 909,
    "source": "PDF_chunked"
  },
  {
    "id": 4117,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 117)",
    "text": "(gris), 0,74 (marron), 0,42 (rose), 0,35 (rose), 0,26 (rose), 0,22 (cendres), 0,19 (violet) et 0,09 (violet ). Chromatogramme Macroscopie Feuille simple de 4- 7 cm de long sur 2- 5 cm de large, mince, pétiolée de 1 -3 cm de long; forme ovale largement cunéiforme à la base; marge crénelée; sommet aigu; nervation réticulée;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 323,
    "source": "PDF_chunked"
  },
  {
    "id": 4118,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 118)",
    "text": "OOAS Page 16 Ageratum conyzoides WAHP hispide, couleur verte; forte odeur piquante avec un goût amer. Microscopie Nombreux vêtements depoils tordus sur la surface supérieure, éparpillés sur la surface inférieure, des poilsglandulaires sur la face supérieure; présence de stomates anisocytiques; de cellules d'huile visible.La section transversale montre une structure dorsoventrale; des cellules épidermiques avec une cuticule verruqueuse; l es cellules du mésophylle sont interrompues dans la région de la nervure médiane par un tissu de collenchyme à la fois au- dessus et en- dessous du faisceau vasculaire. Le xylème est lignifié; les gouttelettes d'huile (jaunes) sontprésentes dans le mésophylle spongieux. Matériel végétal en poudre Couleur verdâtre; odeur piquante; les fragments de lamelle montrent des poils, des cellules d'huil, des stomates, des veines et veinules anisocytiquesavec des éléments de xylème lignifiés. Actions thérapeutiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 4119,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 119)",
    "text": "de lamelle montrent des poils, des cellules d'huil, des stomates, des veines et veinules anisocytiquesavec des éléments de xylème lignifiés. Actions thérapeutiques Analgésique; antibactérien; anticoagulant; antihelminthique; émétique; anti -inflammatoire; antipaludique; antioxydant; antirhumatismal; dépuratif, fébrifuge; hémostatique; insecticide; purgatif; radio- protection; stimulant et vulnéraire (Ganesh et al., 2003; Okunade, 2002; Sampson et al ., 2000; Durodola, 1977; GHP, 1992; Almagboul et al., 1985). Indications thérapeutiques Amibiase; prolapsus rectal; arthrite; béribéri; catarrhe; céphalées, conjonctivite; rhume; convulsions; \"craw -craw\", diabète, diarrhée; dysenterie; dyspepsie, dyspnée; enteralgia; épistaxis, fièvre, flatulence, troubles menstruels (tension pré- menstruelle, amenorrhée); infertilité féminine primaire et secondaire; menace d'avortement, infections des voies urinaires; plaies (GHP, 1992; Abena et al, 1993; Mshana et al., 2000).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 971,
    "source": "PDF_chunked"
  },
  {
    "id": 4120,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 120)",
    "text": "féminine primaire et secondaire; menace d'avortement, infections des voies urinaires; plaies (GHP, 1992; Abena et al, 1993; Mshana et al., 2000). Données de sécurité Sur une période de 24 heures, la DL 50 de l'extrait aqueux de feuilles de la plante ( p.o) était 2000 mgkg chez la souris. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'administration par voie orale de l'extrait à 500 - 2000 mgkg à des souris mâles et femelles, pendant 14 jours. Des doses plus élevées ( 125 mgkg) ont causé la mortalité des rats; et à des doses de 50- 100 mgkg, des symptômes tels que l'ataxie, la sédation et la ptose légère, ont été observées (Ganesh et al , 2003). Précautions d'emploi Devrait être employé avec soin chez les enfants et les femmes enceintes. Effets indésirables Bien que les études animales aient montré que la plante est sûre, Trigo et al., (1988) ont trouvé plusieurs alcaloïdes, dont 1,2-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4121,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 121)",
    "text": "et les femmes enceintes. Effets indésirables Bien que les études animales aient montré que la plante est sûre, Trigo et al., (1988) ont trouvé plusieurs alcaloïdes, dont 1,2- desifropirrolizidinique et licopsamine, ce qui peut induire une hépatotoxicité. Contre-indications Diabète Dosage et formegalénique Infusion: 20- 30 g de feuilles sèches par litre d'eau; prendre 3- 4 tasses à thé par jour. Décoction: jus de feuilles fraîches meurtries; 30- 50 g par litre d'eau; prendre 3- 4 tasses à thé par jour. Teinture: 1:5 30 d'éthanol frais, prendre 2- 5 ml deux fois par jour. Capsule: 1-2 g deux fois par jour. Conservation A conserver dans un endroit frais et sec dans des récipents fermés, à l'abri de la lumière Références Abena, A.A., Kintsangoula- Mbaya, G.S., Diantama, J., Bioka, D. (1993). Analgesic effects of a raw extract of Ageratum conyzoides in the rat. Encephale. 19(4): 329-32. Achola, K.J., Munenge, R.W. (1997). Activity of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4122,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 122)",
    "text": "Diantama, J., Bioka, D. (1993). Analgesic effects of a raw extract of Ageratum conyzoides in the rat. Encephale. 19(4): 329-32. Achola, K.J., Munenge, R.W. (1997). Activity of Ageratum conyzoides on isolated Rat Phrenic Nerve-Diaphragm and Blood Pressure on Anaesthetised Rats. Pharmaceutical Biology 35(1):31-37. Almagboul, A.Z, Farroq, A.A., Tyagi, B.R. (1985). Antimicrobial activity of certain Sudanese plants used in folkloric medicine: Screening for antibacterial activity, part II. Fitoterapia, 56:103- 109. Bioka, D., Banyikwa, F.F., Choudhuri, M.A. (1993). Analgesic effects of a crude extract of Ageratum conyzoides in the rat. Acta Horticulturae, 332:171-176. Dokosi, O.B. (1998). Herbs of Ghana. Ghana University Press: Ghana; 276-279.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 747,
    "source": "PDF_chunked"
  },
  {
    "id": 4123,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 123)",
    "text": "OOAS Page 17 Ageratum conyzoides WAHP Durodola, J.I. (1977). Antibacterial property of crude extracts from a herbal wound healing remedy-Ageratum conyzoides, L. Planta Medica 32(4):388-390. Ganesh, C.J., Annie, S., Shaival, K.R., Prasad, M.B. (2003). Evaluation of the radioprotective effect of Ageratum conyzoides Linn. extract in mice exposed to different doses of gamma radiation. Journal of Pharmacy and Pharmacology 55(8): 1151. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana. Gill, S. (1978). Flavonoid compounds of the Ageratum conyzoides L. herb. Acta Poloniae Pharmaceutica 35(2):241-243. Haensel, R., Keller, K., Rimpler, H., Schnei der, G. (1994). Hagers Handbuch der Pharm.Praxis 5.Auflage Springer Heidelberg, New York Band 4: 135-37. Marques, N., Costalat, L.T., Fernandes, S.R.M., Napoli, M.D.M., Samara, A.M. (1988). Revista Brasileira de Rhematologie 28:109. Moody, J.O., Adebiyi, O.A., Adeniyi, B.A. (2004).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4124,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 124)",
    "text": "4: 135-37. Marques, N., Costalat, L.T., Fernandes, S.R.M., Napoli, M.D.M., Samara, A.M. (1988). Revista Brasileira de Rhematologie 28:109. Moody, J.O., Adebiyi, O.A., Adeniyi, B.A. (2004). Do Aloe vera and Ageratum conyzoides enhance the antimicrobial activity of traditional medicinal soft soaps. Journal of Ethnopharmacology 92(1): 57-60. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organi sation of African UnityScientific, technical and research committee. Okunade, A.L. (2002). Ageratum conyzoides L. (Asteraceae). Fitoterapia 73(1):1-16. Sampson, J.H., Phillipson, J.D., Bowery, N.G., O'Neill, M.J., et al., (2000). Ethnomedicinally selected plants as sources of potential analgesic compounds: indication of in vitro biological",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 899,
    "source": "PDF_chunked"
  },
  {
    "id": 4125,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 125)",
    "text": "Sampson, J.H., Phillipson, J.D., Bowery, N.G., O'Neill, M.J., et al., (2000). Ethnomedicinally selected plants as sources of potential analgesic compounds: indication of in vitro biological activity in receptor binding assays. Phytotherapy Research 14(1):24-29. Trigo, J.R., Campos, S., Pereira, A.M. (1988). Presença de alcalóides pirrolizidinicos em Ageratum conyzoides L. p. 13. In: Simposio de Plantas Medicinais do Brasil, Sao Paulo. (Resumos). Yamamoto, L.A., Soldera, J.C., Emim, J.A., et al., (1991). Pharmacological screening of Ageratum conyzoides L. (Mentrasto). Memórias do Instituto Oswaldo Cruz, 86(2):145-147.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 624,
    "source": "PDF_chunked"
  },
  {
    "id": 4126,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 126)",
    "text": "OOAS Page 18 Alchornea cordifolia WAHP Nom botanique Alchornea cordifolia (Schmach Thonn) Müell Famille Euphorbiaceae Synonyme Alchornea cordata Benth., Schousboea cordifolia Schum. Et Thonn Noms communs Anglais: Christmas bush French: Arbre de djeman, Alchornéa cordiforme Noms vernaculaires Burkina Faso: Dioula kho sira;ko yira, Fulfuldé - Lahédi Cote d'I voire: Baoulé Agni, Akyé N'dzin, Malinké Koyira Ghana: Akan Ogyamma, Fante Egyamma, Ga Adangbe- Gboo Mali: Bambara Kô gira, Malinké Kogira, Peulh Holâta, Bulora Nigéria: Hausa- Bambami, Igbo Ububo, Yoruba Ewe Ipa, Esinyin Sénégal: Wolof- Lah, Diola- Purger yéné, Serer - Ardana, Yira Sierra Leone: Madingo Yisai, Mende Njekoi, Susu Bolontha Togo: Ewé Avovlo, Ouatchi Avovlo Description de la plante A. Cordifolia est un petit arbre ou arbuste de plusieurs tiges, atteignant 5- 8 m de haut; la tige est armée d'épines émoussées; de feuilles à",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 900,
    "source": "PDF_chunked"
  },
  {
    "id": 4127,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 127)",
    "text": "Description de la plante A. Cordifolia est un petit arbre ou arbuste de plusieurs tiges, atteignant 5- 8 m de haut; la tige est armée d'épines émoussées; de feuilles à long pétiole; largement ovales, cordées à la base, un apex courtement acuminé, entier ou légèrement denté, une stellaire pubère ou légèrement glabrescenteen dessous, des glandes dans les aisselles des nervures basales; des fleurs blanches verdâtre fixées sur des pointes pendantes ou grappes de style longet permanent sur le fruit ; les fruits sontbicellulair es, petits, avec une stellaire pubescente. Numéro du spécimen de l'herbier Ghana: GC 42071(Collections du Ghana) Mali: 00660 (DMT) Nigéria: FHI 108437 Togo:TOGO03023 Habitation et repartition géographique A. Cordifolia est largement distribué dans tous les pays d'Afrique de l'Ouest et à travers l'Afrique tropicale, dans les forêts secondaires, généralement à proximité des eaux, des endroits humides ou marécageux.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4128,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 128)",
    "text": "les pays d'Afrique de l'Ouest et à travers l'Afrique tropicale, dans les forêts secondaires, généralement à proximité des eaux, des endroits humides ou marécageux. Parties utilisées de la plante Feuille Autres parties utilisées Écorce de tige, racine et fruit. Caractéristiques botaniques Alchornea se compose de la feuille fraîche ou séchée d'Alchornea cordifolia (Schmach Thonn) Müell (Euphorbiaceae). Utilisations ethnomédicales A. cordifolia est couramment utilisé dans la pharmacopéeafricaine, en co mbinaison avec d'autres plantes; toutes les parties de la plante sont utilisées. Les feuilles sont utilisées dans de nombreux pays africains pour le traitement des affections microbiennes, les inflammatoires et maladies liées au stress (Neuwinger, 2000). La décoction de feuille se prend pour le mal de ventre en Côte d'Ivoire et au Burkina Faso, alors qu'une combinaison de l'écorce de tige et de l'écorce de Symphonia lobuliffera est utilisée",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4129,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 129)",
    "text": "décoction de feuille se prend pour le mal de ventre en Côte d'Ivoire et au Burkina Faso, alors qu'une combinaison de l'écorce de tige et de l'écorce de Symphonia lobuliffera est utilisée comme apéritif (Kerharo et Bouquet, 1950). Les racines sont utilisées contre la lèpre (Abbiw, 1990) et la poudre de feuilles a des propriétés de cicatrisation contre les blessures et l'ulcère (propriétés Kerharo et Bouquet, 1950). Au Mali et en Côte d'Ivoire, la plante est utilisée pour traiter le paludisme (Mustofa et al. 2000). Activités biologiques et pharmacologiques L'extrait de feuille a démontré des activités antimicrobiennes contre Escherichia coli , Citrobacta diversus , Salmonella enteritidis , Shigella flexneri et Staphylococcus aureus (Tona et al., 1998). L'activ ité antimicrobienne de l'écorce de tige a été également démontrée contre Staphylococcus aureus , Bacillus subtilis , Escherichia coli et Klebsiella pneumoniae (Ebi,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4130,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 130)",
    "text": "OOAS Page 19 Alchornea cordifolia WAHP 2000). 50 de l'extrait éthanolique de la feuille a montré une activité antibactérienne in vivo contre Staphylococcus aureus . L'administration intrapéritonéale d'un extrait de 25 à 200 mgkg, a significativement augmenté le temps de survie des souris infectées (Igbeneghu et al., 2007). Les extraits aqueux étaient actifs contre toutes les 21 souches bactériennes testées etont montré les niveaux les plus élévés de l'activité antibactérienne du CMI contre Staphylococcus aureus résistant à la méthicilline dans la gamme de 1.6 à 3.1 mg ml (Pesewu et al., 2008).Barry et al. (2002) ont également montré les propriétés antifongiques de la plante sur le Microsporon canis et Trichophyton mentagrophytes . L'extrait de la plante a affiché une activité antitripanosomiale ( Trypanosoma congolense et Trypanosoma brucei) à 200 μ g ml (Agbe et al . 1987) et l'extrai t éthanolique des feuilles a",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4131,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 131)",
    "text": "de la plante a affiché une activité antitripanosomiale ( Trypanosoma congolense et Trypanosoma brucei) à 200 μ g ml (Agbe et al . 1987) et l'extrai t éthanolique des feuilles a montré une activité inhibitrice contre la souche K1 du Plasmodium falciparum avec une valeur IC50 de 4,19 μgml (Togola, 2002). L'acide ellagique, isolé à partir du même extrait, a montré une activité modérée contre le P. falc iparum, avec des valeurs CI 50 entre 0,2 et 0,5 μmol (Banzouzi et al ., 2002). 80 de l'extrait méthanolique a présenté une activité antiplasmodiale prononcée contre la souche ghanéenne de P. falciparum avec des valeurs de CI 50 allant de 0.5 à 3.0 μgml (Mes ia et al., 2008).Plusieurs extraits préparés à partir de l'écorce de racine ont affiché une activité antiamibienne avec un CI 50 inférieure à 100 μgml (Tona et al., 1998). La plante posséde également une activité anti -inflammatoire in vivo (Okoye et al.2011;. Mavar -Manga et al., 2008;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4132,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 132)",
    "text": "antiamibienne avec un CI 50 inférieure à 100 μgml (Tona et al., 1998). La plante posséde également une activité anti -inflammatoire in vivo (Okoye et al.2011;. Mavar -Manga et al., 2008; Osadebe et Okoye, 2003), et un effet dose- dépendante antidiarrhéique sur les souris (Agbor et al, 2004.). Olaleye et al ., (2006) ont rapporté une activité hépatoprotectrice in vivo de l'extrait hydro-alcoolique de la feuille. La plante a également eu un moyen de protection contre le stress oxydatif (Olaleye et Rocha, 2007); les polyphénols issus de l'extrait d'acétate d'éthyle ont montré des activités de protection antioxydant et anti -élastate (Kouakou- Siransy et al., 2010). Umukoro et Aladeokin (2010) ont prouvé que la prise orale de l'extrait de feuille à 100-400 kgkg a eu des propriétés in vivo anti - stressanti-fatigue. L'extrait méthanolique de la feuille à 500 mgkg et 1000 mgkg a des propriétés anti -ulcéreuses (Nguelefac k et al .,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4133,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 133)",
    "text": "100-400 kgkg a eu des propriétés in vivo anti - stressanti-fatigue. L'extrait méthanolique de la feuille à 500 mgkg et 1000 mgkg a des propriétés anti -ulcéreuses (Nguelefac k et al ., 2005). Ayisi et Nyadedzor (2003) ont rapporté une activité antivirale significative sur les processus de réproduction du VIH -1. Des modifications histologiques du pancréas ont été observées après l'administration de l'extrait éthanolique de la f euille chez les rats rendus diabétiques par administration d'alloxane (Eliakim-Ikechukwu et Obr, 2009). La plante peut être efficace pour augmenter le recul élastique de la paroi aortique et, peut donc réduire la pression artérielle (Eliakim -Ikechukwu et O br, 2009). La fraction riche en flavonoïdes des extraits ont démontré un effet immunostimulant (Nworu et al ., 2010a et Nworu et al., 2010b). Données cliniques Aucune information disponible Constituants chimiques Alcaloïdes (ex: alchornine et alcaloïdes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4134,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 134)",
    "text": "2010a et Nworu et al., 2010b). Données cliniques Aucune information disponible Constituants chimiques Alcaloïdes (ex: alchornine et alcaloïdes connexes); tanins, flavonoïde et proanthocyanidine (Bennet, 1950; Paris, 1958; Pruja, 1987; Ogundipe et al ., 2001;. Ayisi et Nyadedzor, 2003;. Kouakou- Siransy et al., 2010) , cadinol, caryophyllène, linalool et (E) -α- bergamotène (Okoye et al. 2011). Test d'identité et de pureté Teneur en humidité: pas plus de 4,8 Cendre totale: 5,6 Substances extractibles par l'eau: pas moins de 22,8 Substances extractibles par l'éthanol (70): pas moins de 22,03 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 914,
    "source": "PDF_chunked"
  },
  {
    "id": 4135,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 135)",
    "text": "phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de quatre tâches distinctes avec valeursR f de 0,82 (marron), 0,54 (bleu), 0.47 (rose) et 0,40 (rose).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 388,
    "source": "PDF_chunked"
  },
  {
    "id": 4136,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 136)",
    "text": "OOAS Page 20 Alchornea cordifolia WAHP Chromatogramme Macroscopie Feuille simple, alterne, pétiolée de 10- 28 cm de long sur 6- 16 cm de large, de forme ovale, à base cordée, apex acuminé, bord entier denté de couleur verte, pétiole rouge pourpe, inodore; avecun goût un peu amer fade. Microscopie La vue d'ensemble montre des typesde poilsavec ramifications unicellulaires et poils de revêtement unicellulaires; des cellules épidermiques verruqueuses, des stomates anisocytiques sur la surface inférieure. La section transversale présente une disposition de feuilles dorso- ventrales; une couche de palissade bicellulaire avec de nombreux cristaux d'oxalate de calcium rosette ;les cellules mésophylles abondent dans le tissu collenchyme dans la région de la nervure médiane à la fois dans lasurface supérieure et inférieure, le mésophylle spongieux avec des cristaux de rosette; un faisceau vasculaire bicollatéral, délimitée par un bouclier en forme de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4137,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 137)",
    "text": "médiane à la fois dans lasurface supérieure et inférieure, le mésophylle spongieux avec des cristaux de rosette; un faisceau vasculaire bicollatéral, délimitée par un bouclier en forme de fibres péricycliques lignifiées; des éléments lignifiés de xylème. Matériel végétal en poudre Couleur vert, inodore, goût légèrement amer avec de nombreux vaisseaux de xylème et de fibres lignifiés et réticulés; des poils devêtements unicellulaires et étoilés avec des bases lignifiées; des stomates anisocytiques, des cristaux prismatiques et rosettes d'oxalate de calcium; des veines a vec des gaines et des cristaux prismatiques. Actions thérapeutiques Antipaludique, antidiarrhéique, febrifuge, anti - inflammatoire, antimicrobien, analgésique, vulnéraire, antitussive, anti -infectieux, antispasmodique. Indications thérapeutiques Paludisme, troubles gastro- intestinaux, dysménorrhée, fièvre, fractures, douleurs rhumatismales, stomatites, toux et blessures.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4138,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 138)",
    "text": "antispasmodique. Indications thérapeutiques Paludisme, troubles gastro- intestinaux, dysménorrhée, fièvre, fractures, douleurs rhumatismales, stomatites, toux et blessures. Données de sécurité Sur une période de 24 jours, la DL 50 de l'extrait aqueux (p.o) des feuilles de la plante est 2000 mgkg chez la souris. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'administration orale d'extrait de 500-2000 mgkg ( p.o) à des souris mâles et femelles pendant 14 jours. L'extrait a été bien toléré par les animaux; aucun décès n'a été observé à des doses orales de 500- 4000 mgkg (Umukoro et Aladeokin, 2010). Des résultats négatifs ont été obtenus dans le test de mutation bactérienne inverse in vitro, suggérant ainsi qu'il est potentiellement certain de l'utiliser à des doses élevées (Hong et Lyu, 2011), avec peu ou aucune tendance à provoquer une mutation dans les cellules de mammifères. Précautions d'emploi",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4139,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 139)",
    "text": "est potentiellement certain de l'utiliser à des doses élevées (Hong et Lyu, 2011), avec peu ou aucune tendance à provoquer une mutation dans les cellules de mammifères. Précautions d'emploi Grossesse, hypotension Effets indésirables Aucune information disponible Contre-indications Dysfonctionnements du foie Dosage et forme galénique Décoction: 30- 50 g de feuilles séchées par litre d'eau; 3-4 tasses de thé par jour Infusion: 20- 30 g de feuilles séchées par litre d'eau; 3-4 tasses de thé par jour Teinture: 1:5, éthanol à 45; 5 ml trois fois par jour Conservation Conserver dans un endroit frais et sec. Références Abbiw D. K. (1990). Useful plants of Ghana, Royal botanique garden, Kew edition, 126-247. Agbor, G. A., Léopold, T., Ngogang, Y. J. (2004). the antidiarrhoeal activity of Alchornea cordifoli a leaf extract. Phytotherapy Research 18:873-876. Agbe, S.A.O., Oguntimein, B. (1987). Anti- Trypanocidal activity of Alchornea cordifolia,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4140,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 140)",
    "text": "the antidiarrhoeal activity of Alchornea cordifoli a leaf extract. Phytotherapy Research 18:873-876. Agbe, S.A.O., Oguntimein, B. (1987). Anti- Trypanocidal activity of Alchornea cordifolia, Phytotherapy research 1:151-153. Ayisi, N. K., Nyadedzor, C. (2003). Comparative in vitro effects of AZT and extrac ts of Ocimum gratissimum, Ficus polita, Clausena anisata,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 364,
    "source": "PDF_chunked"
  },
  {
    "id": 4141,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 141)",
    "text": "OOAS Page 21 Alchornea cordifolia WAHP Alchornea cordifolia, and Elaeophorbia drupifera against HIV -1 and HIV -2 infections. Antiviral Research 58:25-33. Banzouzi, J.T., Prado, R., Menan, H., Valentin, A., Roumestan, C. et al. (2002). In vitro antiplasmodial activity of extracts of Alchornea cordifolia and identification of an active constituent: ellagic acid. Journal of Ethnopharmacology 81:399-401. Barry, M.S., Oulalé, K., Camara, N., Vuetinck, A.J. et al . (2002). E valuation de l activité antifongique de plantes à usage populaire en Guinée , Poster lors du syposium international sur la chimie et la pharmacologie des plantes utilisées en médecine traditionelle en Afrique, 6- 8 Mars Bamako Mali. Bennet, H. (1950). Alchornea cordifolia leaves and bark from Nigeria. Colonial plant annual Products 1:132-134. Ebi, G. C. ( 2000). Antimicrobial activities of Alchornea cordifolia. Fitoterapia 72:69-72. Eliakim-Ikechukwu, C.F., Obri, A.I. (2009).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4142,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 142)",
    "text": "Products 1:132-134. Ebi, G. C. ( 2000). Antimicrobial activities of Alchornea cordifolia. Fitoterapia 72:69-72. Eliakim-Ikechukwu, C.F., Obri, A.I. (2009). Histological changes in the pancreas following administration of ethanolic extract of Alchornea cordifolia leaf in alloxan- induced diabetic Wistar rats. Nigerian Journal of Physiological Science 24(2):153-155. Hong, C.E ., Lyu, S.Y . (2011). Genotoxicity detection of five medicinal plants in Nigeria. Journal of Toxicological Science 36(1):87-93. Igbeneghu, O. A., Iwalewa, E. O., Lamikanra, A. (2007). A study of the in vivo activity of the leaf extract of Alchornea cordif olia against multiply antibiotic resistant S. aureus isolate in mice. Phytotherapy Research 21: 67-71. Kerharo, J., Bouquet, A. (1950). Plantes médicinales et toxiques de la Côte d Ivoire, Haute Volta, Edition Vigot, 67. Kouakou-Siransy, G ., Sahpaz, S ., Nguessan, G.I., Datté, J.Y. et al. (2010). Effects of Alchornea",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4143,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 143)",
    "text": "médicinales et toxiques de la Côte d Ivoire, Haute Volta, Edition Vigot, 67. Kouakou-Siransy, G ., Sahpaz, S ., Nguessan, G.I., Datté, J.Y. et al. (2010). Effects of Alchornea cordifolia on elastase and superoxide anion produced by human neutrophils. Pharmaceutical Biology 48(2):128-33. Mavar-Manga, H., Haddad, M., Pieters, L., Baccelli, C. et al. (2008). Anti -inflammatory compounds from leaves and root bark of Alchornea cordifolia (Schumach. Thonn.) Müll. Arg. Journal of Ethnopharmacology 115(1):25-29. Mesia, G.K., Tona, G.L., NANGA, T.H., Cimanga, R.K., Apers, S. et al . (2008). Antiprotozoal and cytotoxic screening of 45 plant extracts from Democratic Republic of Congo. Journal of Ethnopharmacology 115(3):409-415. Mustofa Alexis, V., Francoise, B., Yves, P., Koné- Bamba, D., Mallié, M. (2000). Antiplasmodial activity of plant extract used in west african traditional medicine. J ournal of Ethnopharmacology 73:145-151.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4144,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 144)",
    "text": "Bamba, D., Mallié, M. (2000). Antiplasmodial activity of plant extract used in west african traditional medicine. J ournal of Ethnopharmacology 73:145-151. Neuwinger, H.D. (2000). African Traditional Medicine. A dictionary of plant use and applications. Medpharm Scientific publishers Stuttgart. Germany. Nguelefack, T. B., Watcho, P., Sylvie, L. W., Kamany, A. (2005). Effects of the methanolic leaf extract of Alchornea cordifolia on different gastric ulcer models in rats. Cameroon Journal of Experimental Biology 1:54-56. Nworu, C.S., Esimone, C.O., Tenbusch, M., Nabi, G., et al. (2010). Adjuvant Properties of AcF1, an immunostimulant fraction of Alchornea cordifolia extract. Immunological Investigations 39(2):132- 158. Nworu, C.S., Temchura, V., Okoye, .F.B, Akah, P.A. et al . (2010). Activation of murine lymphocytes and modulation of macrophage functions by fractions of Alchornea cordifolia (Euphorbiaceae) leaf extract.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4145,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 145)",
    "text": "P.A. et al . (2010). Activation of murine lymphocytes and modulation of macrophage functions by fractions of Alchornea cordifolia (Euphorbiaceae) leaf extract. Immunopharmacology and Immunotoxicology 32(1):28-36. Ogundipe, O.O., Moody, J.O., Hougton, P. (2001). Occurrence of flavonol sulfates in Alchornea laxiflora. Pharmaceutical Biology 2(6): 421-423. Okoye, F.B ., Osadebe, P.O ., Nworu, C.S ., Okoye, N.N . et al . (2011). Topical anti - inflammatory constituents of lipophilic leaf fractions of Alchornea floribunda and Alchornea cordifolia. Natural Products Research Jun 27. Olaleye, M. T., Adegboye, O.O., Akindahunsi, A. (2006). Alchornea cordifolia extract protects wistar albino rat against acetaminophen- induced liver damage. African Journal of Biotechnology 5:2439-2445.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 785,
    "source": "PDF_chunked"
  },
  {
    "id": 4146,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 146)",
    "text": "OOAS Page 22 Alchornea cordifolia WAHP Olaleye, M.T., Rocha, J.B. (2007). Commonly used tropical medicinal plants exhibit distinct in vitro antioxidant activities against hepatotoxins in rat liver. Experimental Toxicology and Pathology 58(6):433-438. Osadebe, P.O., Okoye, F.B.C. (2003). Anti - inflammatory effects of crude methanolic extract and fractions of Alchornea cordifolia leaves. Journal of Ethnopharmacology 89:19-24. Paris, R., Mignon, H. (1958). Sur quelques Méliaceae réputés fébrifuges. Bulletin Societe Pharmacologie 46:104-108. Pesewu, G.A., Cutler, R.R., Humber, D.P. (2008). Antibacterial activity of plants used in traditional medicines of Ghana with particular reference to MRSA. Journal Ethnopharmacology 116(1):102- 111. Pruja, S. (1987). Contribution à l étude phytochimique de Alchornea cordifolia mémoire de DEA INP Toulouse.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 851,
    "source": "PDF_chunked"
  },
  {
    "id": 4147,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 147)",
    "text": "111. Pruja, S. (1987). Contribution à l étude phytochimique de Alchornea cordifolia mémoire de DEA INP Toulouse. Tona, L., Kambu, K., Ngimbi, N., Cimanga, K. Vlietinck, A. J. (1998). Antiamoebic and phytochemical screening of somme Congolese medicinal plants. Journal of Ethnopharmacology 61:57-65. Togola, A. (2002). Etude de la phytochimie et de l activité antipaludique de Alchornea cordifolia (Euphorbiaceae) These de pharmacie, Faculté de Médecine de Pharmacie et d Odonto- Stomatologie, Université de Bamako, 105p. Umukoro, S., Aladeokin, A.C. (2010). Evaluation of the anti -stress and anticonvulsant activities of leaf extract of Alchornea cordifolia in mic e. Journal of Ethnopharmacology 127(3):768-770.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 713,
    "source": "PDF_chunked"
  },
  {
    "id": 4148,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 148)",
    "text": "OOAS Page 23 Allium sativum WAHP Nom botanique Allium sativum L. Famille Lilliaceae Synonyme Porvium sativum Relib. Noms communs Anglais:Garlic Français:Ail commun Noms vernaculaires Burkina Faso : Moor é Gando;Layi, Dioula Laii, Fulfuldé Toumé Ghana: Twi Gyene Kankan, Ga Adangbe Aya, Hausa Tafarmuwa Mali: Bambara Tumé, Tamachek Teskart Nigéria: Hausa Tafárnúúwáá, Igbo Oy Ayón, Ayún, Yoruba Àlubósa, Ayúu Sénégal: Wolof Laji, Manding Bambara Layi Togo: Ewe Ayo, Nima Ayo, Ouatchi - Ayo Description de la plante Une herbe dressée, robuste et pérenne à bulbe de60 cm de hauteur, avec un bulbe central, couvert d'écailles à l'aisselle. Le bulbe se compose d'un certain nombre de caïeux ou gousses enfermées dans une peau semblable à du papier. Les feuilles sont longues, plates et lisses avec une lame de feuille à forme cylindrique, creuse, linéaire, plate et solide à sommet aigu (apex acuminé); une inflorescence",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 915,
    "source": "PDF_chunked"
  },
  {
    "id": 4149,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 149)",
    "text": "du papier. Les feuilles sont longues, plates et lisses avec une lame de feuille à forme cylindrique, creuse, linéaire, plate et solide à sommet aigu (apex acuminé); une inflorescence sphérique avec des fleurs colorées blanches ou rose-violacées sur des pédoncules grêles (Burkill, 1995; Gill, 1992). Numéro du specimen de l'herbier Nigeria: FHI 107900 (Institut de Recherche Forestière sur l'Herbier, Ibadan) Habitat et répartition géographique A. sativum est originaire de l'Asie Centrale, mais cultivé maintenant dans de nombreuses parties du monde, notamment en Europe, en Afrique du Nord, en Asie, en Amérique du Nord et en Afrique de l'Ouest (GHP 2007; Burkill 1995; Adjanahoun et al, 1991). Parties utilisées de la plante Bulbe Autres parties utilisées L'huile du bulbe (ESCOP, 1999). Caractéristiques botaniques L'ail se compose du bulbe entièr d' Allium sativum L. (Lilliaceae). Utilisations ethnomédicales",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 914,
    "source": "PDF_chunked"
  },
  {
    "id": 4150,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 150)",
    "text": "Autres parties utilisées L'huile du bulbe (ESCOP, 1999). Caractéristiques botaniques L'ail se compose du bulbe entièr d' Allium sativum L. (Lilliaceae). Utilisations ethnomédicales L'ail est un anti-cholestérol, un anti-hypertenseur, un anticoagulant, un anti -diarrhéique, un anti - dysentérique, un stimulant immunitaire, un stomachique, un sudorifique, un expectorant, un vermifuge, un anti -irritant, un diurétique, un antibiotique à large spectre. Il est utilisé en externe pour l'arthrite, les cors, les verrues, l es névralgies (Elujoba et Olawode, 2004; Gill, 1992;Adjanahoun et al., 1991), la fièvre, la toux, les flatulences, l'ulcère, la raucité de la voix, la bronchite et autres problèmes respiratoires, les maladies de la peau, les brûlures, l'otite et l'amygdalite, les rhumatismes, la tuberculose, la typhoïde, l'artériosclérose, le diabète, l'hyperlipidémie et la prévention de l'athérosclérose (en fonction de l'âge) des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4151,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 151)",
    "text": "l'amygdalite, les rhumatismes, la tuberculose, la typhoïde, l'artériosclérose, le diabète, l'hyperlipidémie et la prévention de l'athérosclérose (en fonction de l'âge) des changements vasculaires (OMS, 1999). Activités biologiques et pharmacologiques Plusieurs études scientifiques ont montré que l'ail a des propriétés antihyperlipidémiantes, antihypertensives et anticoagulantes (Auer et al., 1990; Broche et al., 1990; Barrie et al., 1987). De nombreuses actions thérapeutiques de l'ail sont attribuées à l'allicine et à ses métabolites. Par exemple l'allicine et son dérivé sulfurique ont la propriétéd'inhibé in vitro la prolifération de la leucémie maligne de plusieurs cellules humaines non atteintes.Des études in vitro ont montré que l'ajoène possède des propriétés anti - thrombotiques et antimicrobiennes en réduisant le taux de cholestérol; l'ajoène présente des effets inhibiteurs sur l'activation des plaquettes (Apitz-Castro et al., 1986.), leurs liaisons à la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 975,
    "source": "PDF_chunked"
  },
  {
    "id": 4152,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 152)",
    "text": "thrombotiques et antimicrobiennes en réduisant le taux de cholestérol; l'ajoène présente des effets inhibiteurs sur l'activation des plaquettes (Apitz-Castro et al., 1986.), leurs liaisons à la paroi du vaisseau sanguin endommagé (Apitz -",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 238,
    "source": "PDF_chunked"
  },
  {
    "id": 4153,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 153)",
    "text": "OOAS Page 24 Allium sativum WAHP Castro et al., 1994) et à la formation de thrombus (Apitz-Castro et al., 1992). Il prévient également la perte de plaquettes sanguines, empêche la circulation de la lipoxygénase et l'activité de la tyrosine phosphatase dans les plaquettes humaines (Srivastava et Tygi, 1993) de même que la réduction de la biosynthèse du cholestérol (Gebhardt et al., 1994). Les composés de disulfure et de trisulfure de diallyle possèdent des propriétés d'agrégation plaquettaire et de formation antithromboxane (Bordia et al., 1998). Des extrai ts aqueux et organiques de l'ail ont inhibé in vivo l'agrégation plaquettaire (Mohamed et Woodward, 1986). Les extraits d'ail réduisent l'accumulation de cholestérol dans les vaisseaux sanguins et le développement de plaques artériosclérotiques dans la paroi artérielle de lapins nourris en cholestérol (Koscielny et al., 1999; Effendy et al ., 1997). Les extraits ont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4154,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 154)",
    "text": "sanguins et le développement de plaques artériosclérotiques dans la paroi artérielle de lapins nourris en cholestérol (Koscielny et al., 1999; Effendy et al ., 1997). Les extraits ont également montré des effets antihypertenseurs, une activité anticoagulante accrue, une diminution de la viscosité du sang et l'amélioration de la fonction cardio- vasculaire (Kendler, 1987). L'huile d'ail produit inversion marquée de changements métaboliques liés à l'infarctus du myocarde induit par l'isoprotérénol (Saravanan et Prakash, 2004). Les extraits d'ail ont montré des propriétés larvicid es contre les larves d'anophèles et de culicinés et, une forte activité inhibitrice contre une série de bactéries pathogènes et champignons (Benkeblia 2004). Ajoène présente des activités antimycosiques, antimicrobiennes et antivirales. D'autres tests in vitro et in vivo ont également montré que l'ail a des effets antifongiques à large spectre (Davies",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4155,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 155)",
    "text": "antimicrobiennes et antivirales. D'autres tests in vitro et in vivo ont également montré que l'ail a des effets antifongiques à large spectre (Davies et Perrie, 2003) et présente une activité synergique avec l'amphotéricine B qui inhibe la croissance fongique (Tansley et Appleton, 1975). De vastes recherches scientifiques ont montré que divers produits commerciaux faits à base d'ail possèdent des activités antivirales contre une série de virus, y compris l'herpès simplex de types 1 et 2, la grippe A et les virus de type B, le cytomégalovirus humain, le virus de la stomatite vésiculeuse, le rhinovirus, le virus de l'immunodéficience humaine (VIH), la pneumonie virale et le rotavirus. Il a été démontré que l'allicinea une activité antibactérienne (Cavallito et Bailey, 1944). De nombreuses études épidémiologiques, cliniques et de laboratoire ont démontré le rôle de l'ail dans la prévention du cancer (Bianchini et Vainio, 2001; Dorant et al.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4156,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 156)",
    "text": "et Bailey, 1944). De nombreuses études épidémiologiques, cliniques et de laboratoire ont démontré le rôle de l'ail dans la prévention du cancer (Bianchini et Vainio, 2001; Dorant et al., 1996). Les constituants chimiques de la poudre et de l'huile d'ail possèdent un puissant effet antibactérien sur Helicob acter pylori , qui peut expliquer son effet supposé protecteur contre le cancer gastrique. Les propriétés chimio- préventives de la plante ont été attribuées à des composés organo- sulfuriques qui modulent l'activité de plusieurs enzymes du métabolisme, en activant ou détoxifiant les agents cancérigènes et en inhibant la formation de plusieurs additifs d'ADN dans les tissus cibles (Bianchini et Vainio, 2001). Il a été démontré que le disulfure de diallyle possédait une puissante activité chimio -préventif cont re les cancers du côlon, du poumon et de la peau. Données cliniques Les préparations de la poudre d'ail ont montré un",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4157,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 157)",
    "text": "activité chimio -préventif cont re les cancers du côlon, du poumon et de la peau. Données cliniques Les préparations de la poudre d'ail ont montré un potentiel de réduction des lipides, mais aussi la dimunition du taux d'activateur tissulaire du plasminogène et d'hématocrite; augmenté de 4,2 le diamètre moyen des artérioles et de 5,9 les veinules par rapport aux contrôles; augmenté de même le débit érythrocytaire capillaire et la diminution du taux de viscosité et de fibrinogène du plasma, causée par la réduction des concentrations de lipides sériques et l'activité sensiblement accrue de l'activitéur tissulaire du plasmogène par rapport au placébo; l'agrégation plaquettaire induite par l'adénosine diphosphate et le collagène a été significativement inhibée entre 2 à 4 heures après l'ingestion d'ail et, est restée inférieure pendant 7 à 14 jours après le traitement ; une diminution de la proportion des agrégats de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4158,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 158)",
    "text": "significativement inhibée entre 2 à 4 heures après l'ingestion d'ail et, est restée inférieure pendant 7 à 14 jours après le traitement ; une diminution de la proportion des agrégats de circulation plaquettaire et l'agrégation spontanée de plaquettes par rapport au groupe placebo et diminué également la glycém ie moyenne (OMS, 1999). Plusieurs rapports cliniques et des méta- analyses ont révélé les effets anti -cholestérol de l'ail cru et de suppléments d'ail. Il a été montré que l'ail peut diminuer les lipoprotéines de faible densité et augmenter les niveaux de lipoprotéines de haute densité (Ernst, 1987; Chang et Johnson, 1980). L'application topique de l'ajoène a produitune réponse clinique significative chez les patients atteints d'un carcinome basocellulaire de la peau. L'ail présente un pouvoir stimulant de c ellules effectrices immunisées, comprenantles cellules T et celles de morts naturelles (Bianchini et Vainio, 2001). Constituants chimiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 4159,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 159)",
    "text": "présente un pouvoir stimulant de c ellules effectrices immunisées, comprenantles cellules T et celles de morts naturelles (Bianchini et Vainio, 2001). Constituants chimiques L'huile volatile est composée principalement de soufre contenant des substances telles que le sulfure de diallyle, l 'alliine, l'allicine et l'alliinase (Gill, 1992),les vitamines A, B, C, D et E, l'ajoène (Chevallier, 1996), les oléorésines, les acides aminés; les minéraux (germanium, calcium, cuivre, fer, potassium, magnésium, sélénium, zinc); la saponine; les glycosid es cyanogènes; les thioglycosides et les flavonoïdes (GHP, 1992); les oléorésines, les acides aminés, les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 653,
    "source": "PDF_chunked"
  },
  {
    "id": 4160,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 160)",
    "text": "OOAS Page 25 Allium sativum WAHP vitamines A, B, C et D ( Newall et al ., 1996;. Leung et Foster, 1996; GHP, 1992). Tests d'identité et de purété Teneur en humidité: pas plus de 7,0 Cendre totale: pas plus de 5,0 Cendre insoluble dans l'acide: pas plus de 1,0 Substances extractibles par l'eau: pas moins de 5,00 Substances extractibles par l'éthanol (70): pas moins de 4,00 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence d'un tâche violette distincte avec valeur Rf 0,75 Chromatogramme Macroscopie Le bulbe d'ail frais ou séché soigneusement se",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4161,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 161)",
    "text": "pendant 5-10 mn. Présence d'un tâche violette distincte avec valeur Rf 0,75 Chromatogramme Macroscopie Le bulbe d'ail frais ou séché soigneusement se compose du bulbe principal entouré de plusieurs bulbes secondaires ou caïeux. Il ya plusieurs couches extérieures de feuilles de protection qui ont tendance à entourer la gaine interne. La gaine intérieure entoure les gousses qui sont généralement de forme asymét rique, sauf celles du centre. Plus de 20 caïeux fermés avec de nombreuses racines courtes sont étroitement intégrés; un bulbe composé de sous -globuleux de 4-6 cm de large; 8-15 bulbilles, entouré de 1-2 écailles membraneuses blanchâtres sèches et attachées à unebase circulaire aplatie; les bulbilles individuelles se cassent facilement après le retrait des enveloppes extérieures; connu pour sa forte odeur persistante, âcre, piquante, aromatique, désagréable et caractéristique des alliacées, et le goût fort. A la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4162,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 162)",
    "text": "après le retrait des enveloppes extérieures; connu pour sa forte odeur persistante, âcre, piquante, aromatique, désagréable et caractéristique des alliacées, et le goût fort. A la lumière, la couleur est brun-violacé, chamois pâle au gris. Microscopie Les deux parties supérieures et inférieures des cellules épidermiques apparaissent comme une couche dans chaque cas. L'épiderme extérieure ou supérieure est dépourvu de la chloro phylle, mais contient des sclérites lignifiées qui sont allongées et opposées, également de longues fibres mesurant jusqu'à 500 μ de longueur sur 3 μ de largeur, les cellules des écailles sèches contiennent des cristaux rhomboïdes d'oxalate de calcium. Les cellules supérieures de l'épiderme aproximité de la couche d'écailles sèches constituent la seule couche de cellules cuboïques rectangulaire, suivie par plusieurs couches de grandes cellules parenchymateuses. Les faisceaux vasculaires (xylème et phloème)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4163,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 163)",
    "text": "sèches constituent la seule couche de cellules cuboïques rectangulaire, suivie par plusieurs couches de grandes cellules parenchymateuses. Les faisceaux vasculaires (xylème et phloème) sont présentssous formede vaisseaux lignifiés spirauxet annulaires. L'épiderme inferieur a des cellules, plus petites que celles de l'épiderme supérieur. L'écaille membraneuse externese compose de la masse au sol de cellules parenchymateuses contenant des cristaux prismatiques et de l'amidon, traversés par des éléments vasculaires; deux revêtements d'écailles de différentesbulbilles: celui de l'extérieur se compose de cellules parenchymateuses à parois verticales avec peu de fibres et l'autre intérieure es t entièrement constituée de prosenchyme. La section transversale du bulbe décalaminé montre un corps extérieur avec un épiderme comprenant des sclérites isodiamétriques lignifiées, au sein du cuticule, duparenchyme cortical avec quelques grains d'amidon qui montrent des croix",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 973,
    "source": "PDF_chunked"
  },
  {
    "id": 4164,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 164)",
    "text": "corps extérieur avec un épiderme comprenant des sclérites isodiamétriques lignifiées, au sein du cuticule, duparenchyme cortical avec quelques grains d'amidon qui montrent des croix de Malte à la lumière polarisée, les cellules à huile essentielles dont le contenu jaunâtreest disséminé parmi le parenchyme du bas ; les faisceaux vasculaires collatéraux sont constitués de vaisseaux lignifiés annulaires et spiraux légèrement épaissiset des fibres de phloème non aoûté avec des cellules de parenchyme dispersées dans le tissu au dessus tandis qu'un corps intérieur se compose d'un corps fusiforme avec la disposition de tissu tel que celui de l'extérieur, avec un épider me dans lequel le tissu",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 694,
    "source": "PDF_chunked"
  },
  {
    "id": 4165,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 165)",
    "text": "OOAS Page 26 Allium sativum WAHP corticale est avec des cellules d'essence et des faisceaux vasculaires; un organe en forme d'embryon qui est fusiforme avec les deux extrémités repliées, remplissent le noyau central du bulbille avec une disposition de tissus comme le corps externe (GHP, 1992). Matériel végétal en poudre Les sclérites de couches épidermiques de feuilles de revêtement ou de protection; les cellules épidermiques des gousses intérieures ou bulbilles se retrouvent avec lescellules de cuticule sur la surface inférieure, qui sont de taille plus petite que les cellules supérieures de l'épiderme; les copeaux ou les fragments d'éléments vasculaires lignifiés, en spirale et annulaire, peu de stomates et des cristaux d'oxalate de calcium. La couleur pâle au blanc - grisâtre ou violacé, l'odeur et le goût particulier des alliacés est aromatique et piquant. Actions thérapeutiques Antihypertenseur, antidiabétique, anti -",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4166,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 166)",
    "text": "grisâtre ou violacé, l'odeur et le goût particulier des alliacés est aromatique et piquant. Actions thérapeutiques Antihypertenseur, antidiabétique, anti - thrombotique, antifongique, antioxydant, anti - cancérigènes, antibactérien, anti -asthmatique, immunomodulateur; digestif, anti -inflammatoire; antipyrétique, antiscorbutique, antitussif, expectorant, myorelaxant GIT lisse, antibactérien, anticoagulant, carminative, diaphorétique, antihyperhomocysteinemique, antihyperlipidémiant, stomachique (GHP, 1992; Abdullah et al., 1989; Barrie et al., 1987; Joshi et al., 1987; Chadha, 1985; Watt et Breyer - Brandwijk, 1962). Indications thérapeutiques L'athérosclérose, la constipation, le diabète, la diarrhée, la dysenterie; l'otite, la goutte, les maux de tête, hyper tension, la lèpre, les rhumatismes, les morsures de serpent, les symptômes de l'infections des voies respiratoires (par exemple le rhume, la fièvre, la toux, la bronchite, la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4167,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 167)",
    "text": "de tête, hyper tension, la lèpre, les rhumatismes, les morsures de serpent, les symptômes de l'infections des voies respiratoires (par exemple le rhume, la fièvre, la toux, la bronchite, la congestion du sinus), la tuberculose (Watt et Breyer- Brandwijk, 1962). Données de sécurité La DL 50 de l'extrait aqueux du bulbe centrale (p.o) chez la souris sur une période de 24 heures a été au-delà de 2000 mgkg. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'administration orale de l'extrait de 500-2000 mgkg à des souris mâles et femelles pendant 14 jours. Précautions d'emploi L'ail doit être pris avec des aliments (Corzo- Martinez et al., 2007) parce que des doses excessives, en particulier à jeûn peuvent provoquer des maux d'estom ac, des flatulences, des brûlures d'estomac, des nausées, des diarrhées et des changements dans la flore intestinale qui peuvent augmenter le risque de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4168,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 168)",
    "text": "provoquer des maux d'estom ac, des flatulences, des brûlures d'estomac, des nausées, des diarrhées et des changements dans la flore intestinale qui peuvent augmenter le risque de saignement post -opératoire (Benkeblia, 2004). L'utilisation concomitante avec des anticoagulants ou des médicaments qui empêchent des agrégations anti -plaquettaires (ex : aspirine) peut prolonger le saignement ou le temps de coagulation (Gill, 1992). Effets indésirables L'ail peut aussi provoquer une mauvaise haleine et des odeurs corporelles; la dermatite allergique, des brûlures, des cloques et l'effet d'asthme (Jellin et al., 2003; Brinker, 2001; Sunter, 1991; OMS, 1999). Contre-indications Les enfants de moins de 12 ans (peut provoquer des coliques chez les bébés), l'hémophilie, les maladies rénales, les maladies du foie, le cancer de la prostate, le lupus érythémateux systémique; il devrait être évitée chez les patients ayant une peau malade ou endommagé",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4169,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 169)",
    "text": "maladies rénales, les maladies du foie, le cancer de la prostate, le lupus érythémateux systémique; il devrait être évitée chez les patients ayant une peau malade ou endommagé (Jellin et al., 2003;.. Barnes et al., 2002; Brinker, 2001; Sunter, 1991; Ernst, 1987; Boon et Smith, 1999). Dosages et formegalénique Bulbe intact, décoction, teinture, comprimés, capsules. De façon générale, le bulbe frais et l'huile de bulbe peuvent être donnés à 2- 5 mg par jour (un bulbe, 1- 2 fois par jour) alors que la poudre donnée au quotidien es t de 400-1200 mg par jour, la teinture 1:5 dans 60 d'éthanol est donnée à 5 ml trois fois par jour Conservation A conserver dans un endroit frais et sec, à l'abri de la lumière et de d'humidité dans un récipient bien fermé. Références Abdullah, T.H., K irkpatrick, D.V., Carter, J. (1989). Enhancement of Natural Killer Cell Activity in AIDS with Garlic. Deutsch Zeishrift fur Onkologie 21: 52-53.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4170,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 170)",
    "text": "bien fermé. Références Abdullah, T.H., K irkpatrick, D.V., Carter, J. (1989). Enhancement of Natural Killer Cell Activity in AIDS with Garlic. Deutsch Zeishrift fur Onkologie 21: 52-53. Adjanohoun, E, et al., (1991). Contribution to ethnobotanical and floristic studies in western Nigeria. publis hed by the Scientific, Technical and Research Commission of the Organisation of African Unity (OAUSTRC), Lagos. Apitz-Castro, R., Badimon, J.J., Badimon, L. (1994). A garlic derivative, ajoene, inhibits platelet deposition on severely damaged vessel",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 546,
    "source": "PDF_chunked"
  },
  {
    "id": 4171,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 171)",
    "text": "OOAS Page 27 Allium sativum WAHP wall in an in vitro porcine experimental model. Thrombosis Research 75: 243. Apitz-Castro, R., Badimon, J.J., Badimon, L. (1992). Effect of ajoene, the major antiplatelet compound from garlic, on platelet thrombus formation. Thrombosis Research 68:145. Apitz-Castro, R., Escalante, J., Vagase, R., Jain, M.K. (1986). Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin. Thrombosis Research 42: 303. Auer, W., Eiber, A., Hertkorn, E. et al., (1990). Hypertension and hyperlipidaemia: garlic helps in mild cases. British Journal of Clinical Practice 44 (suppl. 69): 3-6. Barnes, J., Anderson, L.A., Phillipson, J.D. (2002). Herbal Medicines: A guide for healthcare professionals. 2nd ed. London (UK): Pharmaceutical Press. Barrie, S.A., Wright, J.V., Pizzorono, J.E. (1987). Effects of garlic oil on platelet aggregation, serum",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 4172,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 172)",
    "text": "professionals. 2nd ed. London (UK): Pharmaceutical Press. Barrie, S.A., Wright, J.V., Pizzorono, J.E. (1987). Effects of garlic oil on platelet aggregation, serum lipids and blood pressure in humans. Journal of Orthomolecular Medicine 2:1521. Benkeblia, N. (2004). Antimicrobial activity of essential oil extracts of various onions ( Allium cepa) and garlic ( Allium sativum ). Lebensm. - Wiss.u.-Technology 37: 263-268. Bianchini, F., Vainio, H. (2001). Allium vegetables and organosulfur compounds: do they help prevent cancer? Environmental Healt h Perspectives 109 (9):893. Boon, H., Smith, M. (1999). The Botanical Pharmacy: The Pharmacology of 47 Common Herbs. Quarry Press Inc.: Kingston (Ontario). Bordia, A., Verma, S.K., Srivastava, K.C. (1998). Effect of garlic ( Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 58(4): 257-263.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 4173,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 173)",
    "text": "blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 58(4): 257-263. Brinker, F. (2001). Herb Contraindications and Drug Interactions. 3rd edition. Sandy (OR): Eclectic Medical Publications. Broche, T., Platt, D., Dorner, H. (1990). The effect of a garlic preparation on the composition of plasma lipoproteins and erythrocyte membranes in geriatric subjects. British Journal of Clinical Practice 44 (suppl. 69):12-19. Burkill, H. M. (1995). The Useful Plants of West Tropical Africa. Vol. 1, 2 nd Edition, Families A D, Royal Botanic Gardens, Kew. London. Cavallito, C.J., Bailey, J.H. (1944.) Allicin, the antibacterial principles of Allium sativum I. Isolation, physical proper ties and antibacterial action. Journal of the American Chemical Society 66:1950-1951. Chadha, Y.R. (1985). The Wealth of India. Vol. 1: A. New Delhi: Publications and Information",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4174,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 174)",
    "text": "action. Journal of the American Chemical Society 66:1950-1951. Chadha, Y.R. (1985). The Wealth of India. Vol. 1: A. New Delhi: Publications and Information Directorate, Council of Scientific and Industrial Research. Chang, M.L.W., Johnson, M.A. (1980). Effect of garlic on lipid metabolism and lipid synthesis in rats. The Journal of Nutrition 110:931-936. Chevallier, A. (1996). The Encyclopedia of Medicinal Plants. Printed by New Interlitho, Milan, Italy. Corzo-Martínez, M., Corzo, N., Villamiel, M. (2007). Biological properties of onions and garlic. Trends in Food Science and Technology 18: 609- 625. Davis, S.R., Perrie, R. (2003). The in-vitro susceptibility of Cryptococcus neoformans to allitridium. In Program and Abstracts of the 15th Congress of ISHAM (abstract 113). San Antonio, TX, USA. Dorant, E., Van den Brandt, P.A., Goldbohm, R.A., Sturmans, F. (1996). Consumption of onions and a reduced risk of stomach carcinoma. Gastroenterology 110:12.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 962,
    "source": "PDF_chunked"
  },
  {
    "id": 4175,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 175)",
    "text": "TX, USA. Dorant, E., Van den Brandt, P.A., Goldbohm, R.A., Sturmans, F. (1996). Consumption of onions and a reduced risk of stomach carcinoma. Gastroenterology 110:12. Effendy, J.L., Simmons, D.L., Ca mpbell, G.R., Campbell, J.H. (1997). The effect of aged garlic extract Kyolic'', on the development of experimental atherosclerosis. Atherosclerosis 132:37-42. Elujoba, A.A., Olawode, E.O. (2004). Technical Report of the commissioned chromatographic fingerprint analysis on Allium sativum bulb to World Health Organization, Nigeria.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 533,
    "source": "PDF_chunked"
  },
  {
    "id": 4176,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 176)",
    "text": "OOAS Page 28 Allium sativum WAHP Ernst, E. (1987) Cardiovascular effects of garlic (Allium sativum ): a review. Pharmatherapeutica; 5:83-89. ESCOP. European Scientific Co -operative of Phytotherapy (1999). Monographs on the Medicinal Uses of Plant Drugs. United Kingdom. Ghana Herbal Pharmac opoeia (1992). The Advent Press, Accra, Ghana. Ghana Herbal Pharmacopoeia (2007). Accra, Ghana. Gebhardt, R., Beck, H., Wagner, K.G. (1994). Inhibition of cholesterol bi osynthesis by allicin and ajoene in rat hepatocytes and HepG2 cells. Biochimica et Biophysica Acta 1213:57. Gill, L. S. (1992). Ethnomedical Uses of Plants in Nigeria. Printed and Published by University of Benin Press. Benin-City, Nigeria. Jellin, J.M., Batz, F., Hitchens, K., editors (2003). Pharmacist's LetterPrescriber's Letter Natural Medicines Comprehensive Database. Stockton (CA): Therapeutic Research Faculty. Joshi, D.J., Dikshit, R. K., Mansuri, S.M. (1987).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4177,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 177)",
    "text": "Pharmacist's LetterPrescriber's Letter Natural Medicines Comprehensive Database. Stockton (CA): Therapeutic Research Faculty. Joshi, D.J., Dikshit, R. K., Mansuri, S.M. (1987). Gastrointestinal Actions of Garlic O il. Phytotherapy Research 1(3):140-141. Kendler, B.S. (1987). Garlic ( Allium sativum) and Onion ( Allium cepa): A Review of Their Relationship to Cardiovascular disease. Preventive Medicine 16:670-685. Koscielny, J., Klüßendorf, D., Latza, R., Schmitt, R. et al., (1999). The antiatherosclerotic effect of Allium sativum. Atherosclerosis 144:237-249. Leung, A.Y., Foster, S. (1996). Encyclopedia of Common Natural Ingredients Used in Foods, Drugs and Cosmetics, 2nd edition. New York: John Wiley and Sons. Mohammad, S.F., Woodward, S.C. (1986). Characterisation of a potent inhibitor of platelet aggregation and release reaction isolated from Allium sativum (garlic). Thrombosis Research 44:793-806.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 914,
    "source": "PDF_chunked"
  },
  {
    "id": 4178,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 178)",
    "text": "Characterisation of a potent inhibitor of platelet aggregation and release reaction isolated from Allium sativum (garlic). Thrombosis Research 44:793-806. Newall, C. A., Anderson, A.L et al. (1996). Herbal medicines: a guide for health - care professionals. London, Pharmaceutical Press. Saravanan, G., Prakash, J. (2004). Effect of garlic ( Allium sativum) on lipid peroxidation in experimental myocardial infarction in rats. Journal of Ethnopharmacology 94:155-158. Sendl, A. (1995). Allium sativum and Allium ursinum Part 1 Chemistry, analysis, history and botany. Phytomedicine 4:323-339. Srivastava, K.C., Tyagi, O.C. (1993). Effects of a garlic-derived principle (ajoene) on aggregation and arachidonic acid meta bolism in human blood platelets. Prostaglandins Leukotrienes Essential Fatty Acids 49:587. Sunter, W.H. (1991). Warfarin and garlic. Pharmaceutical Journal 246:722. Tansley, M.R., Appleton, J.A. (1975). Inhibition of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4179,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 179)",
    "text": "Fatty Acids 49:587. Sunter, W.H. (1991). Warfarin and garlic. Pharmaceutical Journal 246:722. Tansley, M.R., Appleton, J.A. (1975). Inhibition of fungal growth by garlic extract. Myc ologia 67:409-413. Watt, J.M., Breyer -Brandwijl, M.G. (1962). The Medicinal and Poisonous Plants of Southern and Eastern Africa. E. and S. Livingstone Ltd: Edinburgh and London. WHO (1999).Monographs on Selected Medicinal Plants. World Health Organization, Geneva , Switzerland.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 462,
    "source": "PDF_chunked"
  },
  {
    "id": 4180,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 180)",
    "text": "OOAS Page 29 Aloe schweinfurthi WAHP Nom botanique Aloe schweinfurthii Baker Famille Lilliaceae Synonyme Aloe barteri Bak; Aloe barteri var. lutea Chev; Aloe trivialis Chev Noms communs Aloès géant Ouest Africain, la palme affectionnée par l'éléphant Noms vernaculaires Ghana: Akan Sereberebe, Brong Nsesareso Abrobe Nigéria: Fula Fulfulde Balli Nyibi, Yuroba Eti eerin anago, Hausa Hantsar Sénégal: Bambara Layi. Togo: Ewe Adi adi Description de la plante Une herbe succulente et vivace, acaule(sanst ige) ou avec une tige courte couchée ; les feuilles en rosettes ou seules sont recourbés au sommet; elles sont de couleur vert -grisâtre avec des tâches blanchâtres sur les deux surfaces, lancéolées, longues et promues à sommet aigu, avec environ 60- 80 cm de long sur 6- 8 cm de large à la base ; la marge blanchâtre dentée est dirigée vers l'extérieurdes parties inférieures ; les dents sont insérées sur 1 cm d'intervalle, virant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4181,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 181)",
    "text": "large à la base ; la marge blanchâtre dentée est dirigée vers l'extérieurdes parties inférieures ; les dents sont insérées sur 1 cm d'intervalle, virant au rouge à maturité; la tige est de 20- 40 cm de long ; les bractées sont petites, mesurant 4-7 mm et lancéolées; les panicules sont des grappes cylindriques avec une inflorescence peu ramifiée; 8-10 rameaux de panicules et de pédoncule. Les grappes ou racèmessontsimples mais peu ramifiées, constituées de filaments jaunes, d'anthères oranges; de bourgeons verts et dressés, d'étamines roses (Odeleye, 2004; Burkill, 1995). Numéro du specimen de l'herbier Nigéria: FHI 106875 Togo: TOGO11618 Habitat et répartition géographique Plante herbacée vivace avec une rosette de feuilles charnues; elle pousse dans les endroits herbeux ou savane humide et est distribuée du Sénégal au Nigéria et s'étend à travers l'Afrique Centrale en Zambie et au Malawi. C'est une plante de collines rocheuses qu'on rencontre au",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 960,
    "source": "PDF_chunked"
  },
  {
    "id": 4182,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 182)",
    "text": "herbeux ou savane humide et est distribuée du Sénégal au Nigéria et s'étend à travers l'Afrique Centrale en Zambie et au Malawi. C'est une plante de collines rocheuses qu'on rencontre au Ghana, au Niger, du Nigeria à l'Ouest du Cameroun, au Soudan et dans le bassin du Congo. La plante est cultivée surtout pour ses propriétés médicinales et ses utilisations ethnomédicales (Odeleye, 2004; Burkill, 1995). Parties utilisées de la plante Feuilles entières, jus jaune ou gel trans parent incolore Caractéristiques botaniques L'Aloe géant Ouest Africain se compose de la feuille entière, du jus ou du gel d' Aloe schweinfurthii Baker (Lilliaceae). Utilisations ethnomédicales La plante est cultivée en particulier pour le traitement d'affections telles que les troubles intestinaux et urogénitaux. Il est appliqué de façon externe sur les plaies, les blessures et les brûlures. La sève est ajoutée à l'eau potable et donner aux volailles pour, dit -on, les protéger",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 962,
    "source": "PDF_chunked"
  },
  {
    "id": 4183,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 183)",
    "text": "intestinaux et urogénitaux. Il est appliqué de façon externe sur les plaies, les blessures et les brûlures. La sève est ajoutée à l'eau potable et donner aux volailles pour, dit -on, les protéger contre le choléra aviaire. Les fleurs comestibles sont parfois utilisés comme ingrédients dans les soupes (Odeleye, 2004; Burkill, 1995; Hutchinson et Dalziel, 1958). Activités biologiques et pharmacologiques Les actions biologiquespharmacologiques de cette plante ne sont pas visi blement inscrite dans la littérature. Toutefois, le jus jaune possède des propriétés laxatives, tandis que le gel blanc guéri des brûlures et des plaies fraîches comparables à l'Aloe vera (Odeleye et al, 2008). Données cliniques Aucune information disponible Constituants chimiques Il y a deux parties distinctes d' A. schweinfurthii contenant des constituants chimiques complètement différentes, qui n'ont pas été étudiés. L'exsudat jaune se compose",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4184,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 184)",
    "text": "OOAS Page 30 Aloe schweinfurthi WAHP principalement de composés phénoliques, qui comprennent les dérivés de l'anthracène purgative, par exemple l'aloïne, tandis que la composition chimique des constituants internes du parenchyme incolore n'a pas été étudiée (Odeleye, 2004). Tests d'identité et de purété Teneur en humidité: pas plus de 93 Cendre totale: pas plus de 12 Cendre insoluble dans l'acide: pas plus de 2 Cendre soluble dans l'eau: pas moins de 2,50 Substances extractibles par l'eau: pas moins de 36,00. Substances extractibles par l'éthanol (70): pas moins de 24,00 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice (0,25 mm) G60F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4185,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 185)",
    "text": "60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de quatre tâches distinctes avec valeurs R f de 0,77 (brun), 0,68 (rose), 0,45 (rose) et 0,25 (rose). Macroscopie C'est une plante herbacée vivace à feuilles charnues d'environ 60 cm de long sur 7,8 cm de large, avec bords dentés. Une plante de drageonnage. La feuille est charnue, vert grisâtre avec la surface foliaire tachetée de blanc, virant au rouge en saison sèche. Les pédoncules sont Chromatogramme de 60-80 cm de long.Les bourgeons sont dressés ; les fleurs pendantes, vertes dans le bourgeon, deviennent jaunes et d'autres oranges. Microscopie Les couches de cellules et les stomates anomocytiquesranunculeux sont assez nombreuses sur la face supérieure, mais moins",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4186,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 186)",
    "text": "bourgeon, deviennent jaunes et d'autres oranges. Microscopie Les couches de cellules et les stomates anomocytiquesranunculeux sont assez nombreuses sur la face supérieure, mais moins et dispersées sur la face inférieure; les parois anticlinales droites ou légèrement ondulées sont petites et allongées sur les deux faces (supérieure et inférieure). Les cellules épidermiques inférieures mesurent 55,2 à 131,3 μ de long sur 48,3 à 69,0 μ de large, alors que les cellules de la surface supérieure mesurent 69,0 à 144,9 μ sur 48,3 à 75,9 μ. Les cristaux d'oxalate de calcium et les poils sont absents, et les surfaces épidermiques sont glabres.La coupe transversale montre l'absence d'oxalate de calcium et de raphides. A la frontière des zones corticales centrales et externes, il y a des faisceaux fibrovasculaires, disposées parallèlement à l'épiderme, à une distance de l'intérieur du mésophylle sous la forme d'une ellipse. Le xylème et le phloème sont à paroi",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 962,
    "source": "PDF_chunked"
  },
  {
    "id": 4187,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 187)",
    "text": "faisceaux fibrovasculaires, disposées parallèlement à l'épiderme, à une distance de l'intérieur du mésophylle sous la forme d'une ellipse. Le xylème et le phloème sont à paroi mince et en forme de spirale. Les fibres sont absentes dans la section longitudinale (Odeleye, 2004). Matériel végétal en poudre Stomates anomocytiquesranunculeux : de nombreux stomates sont présents dans certains grands fragments de l'épiderme supérieur, des fragments moins riches en stomates proviennent de la surface inférieure; les cellules à parois anticlinales, droites ou légèrement ondulées épidermiques, petites et allongées; aucunpoils ou cristaux d'oxalate de calcium; les éléments des faisceaux vasculaires sont en spirale.; les taches de poudre de feuilles trouvées sur la surface lorsque frottées les unes contre les autres, sont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 820,
    "source": "PDF_chunked"
  },
  {
    "id": 4188,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 188)",
    "text": "OOAS Page 31 Aloe schweinfurthi WAHP de couleur chocolat brun ou verdâtre -brun. L'odeur caractéristique est nauséabonde avec un goût aigre et amer (Odeleye, 2004). Actions thérapeutiques Laxatif purgatif, antimicrobien et cicatrisant. Indications thérapeutiques Constipation, plaies, brûlures, ulcère, herpès (OMS, 1990) Données de sécurité Sur une période de 24 heures, la DL 50 de l'extrait aqueux des feuilles de la plante ( p.o) chez la souris a été au- delà de 2000 mgkg. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'admi nistration orale de l'extrait à 500- 2000 mgkg à des souris mâles et femelles pendant 14 jours. Précautions d'emploi Ne pas le prendre à jeûn. Effets indésirables Diarrhée Contre-indications L'aloe géant Ouest Africain ne doit pas être utilisé chez les patients qui ont une obstruction intestinale ou une sténose, une atonie, une déshydratation sévère avec une déplétion",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4189,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 189)",
    "text": "L'aloe géant Ouest Africain ne doit pas être utilisé chez les patients qui ont une obstruction intestinale ou une sténose, une atonie, une déshydratation sévère avec une déplétion électrolytique ou de la constipation chronique, les maladies intestinales inflammatoires, la colite ulcéreuse, le syndrome du côlon irrit able, chez les enfants de moins de 10 ans. Il ne doit pas être également utilisé pendant la grossesse ou l'allaitement. Dosage et forme galénique Décoction Conservation A conserver dans un endroit frais et sec, à l'abri de l'humidité et de la lumière. Références Burkill, H.M (1995). The Useful Plants of West Tropical Africa Vol. 3 Family J-L Kew: Royal Botanic Garden. pp. 492-493. Hutchinson, J., Dalziel, J.M. (1958). Flora of West Tropical Africa 2 nd Edition, Revised by Keay R. W. J London: Crown Age nts for Overseas Governments and Administration. p. 476. Odeleye, O.M. (2004). Comparative",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 916,
    "source": "PDF_chunked"
  },
  {
    "id": 4190,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 190)",
    "text": "West Tropical Africa 2 nd Edition, Revised by Keay R. W. J London: Crown Age nts for Overseas Governments and Administration. p. 476. Odeleye, O.M. (2004). Comparative Pharmacognostical studies on Aloe schwenfurthii Baker and Aloe vera (Linn.) Burm. F. M. Sc (Pharmacognosy) Thesis , Obafemi Awolowo University, Nigeria. WHO Monogr aphs on Selected Plants (1990). Vol. 1 Geneva: World Health Organization, p 33- 49.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 415,
    "source": "PDF_chunked"
  },
  {
    "id": 4191,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 191)",
    "text": "OOAS Page 32 Aloe vera WAHP Nom botanique Aloe vera Linn. Famille Lilliaceae Synonyme Aloe barbadensis Mill Nom commun Curacao aloe, Aloés vulgaire Noms vernaculaires Burkina Faso: Kirma Magno Gu Dondialé, Manding Sinzé Toro, Bambara Sogobahu Cote d'Ivoire: Manding Sinzé Toro, Maninka Bamalagba, Senufo Dyimini Nimbéléké. Ghana: Akan Sereberebe, Brong Nsesareso Abrobe Nigéria: Fula Fulfulde Balli Nyibi Balli Nyiwa, Gwari Omvi, Hausa Zaabuwaa, Yoruba-eti eerin oyinbo Sénégal: Fula Sogoba Hu, Bambara Sogoba Bu, Maninka Kadio Kandio. Togo: Ewe Adi Adi Gbe, Basari Dissawede, Kabye Sulefadium Description de la plante Une rosette acaule de feuilles charnues atteignant 3 0-40 cm de haut ; les feuilles sont succulentes, et s'élevent au centre de la plante. Elles peuvent varier de 0,8 à 60 cm de long ; les feuilles épaisses et charnues peuvent conserver une grande quantité d'eau pendant la saison",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 899,
    "source": "PDF_chunked"
  },
  {
    "id": 4192,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 192)",
    "text": "succulentes, et s'élevent au centre de la plante. Elles peuvent varier de 0,8 à 60 cm de long ; les feuilles épaisses et charnues peuvent conserver une grande quantité d'eau pendant la saison pluvieuse et peuvent donc survivre tout au long de la sécheresse.Les feuilles inférieures sonten rosette et s'étalent ou se posentà la surface du sol avec un périanthe rose ou rouge et un gonflement prononcé à la base, brusquement rétrécie au- dessus de l'ovaire avec une partie plus étroite au-dessus de la base et un élargissement à la gorge; l'influorescence est simple ou ramifiée, soit terminale ou latérale, avec généralement des fleurs de nuances orange ou rouge, mais parfois jaune ou même blanche, atteignant 45- 120 cm de long à maturité et une base de 7,5 cm ou un plus grand diamètre ; les fruits (si disponibles) ne dépassent pas 2,5 cm de long (Burkill, 1995; Hutchinson et Dalziel, 1958; Renolds, 1966; Young, 1950). Numéro du spécimen de l'herbier Nigeria: FHI 106026",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 975,
    "source": "PDF_chunked"
  },
  {
    "id": 4193,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 193)",
    "text": "fruits (si disponibles) ne dépassent pas 2,5 cm de long (Burkill, 1995; Hutchinson et Dalziel, 1958; Renolds, 1966; Young, 1950). Numéro du spécimen de l'herbier Nigeria: FHI 106026 Habitatet répartition géographique L'aloe est une plante herbacée vivace, originaire d'Afrique, Australe et Orientale. Il a été par la suite introduit en Afrique du Nord, dans la péninsule arabique, en Chine, au Gibraltar, dans les pays méditerranée et aux Antilles . Dans l'Aruba, au Bonaire, en Maiti, en Inde, en Afrique du Sud, aux États -Unis d'Amérique et au Venézuéla, elle est cultivée à but commercial. L'aloe a été importédans certains pays d'Afrique y compris dans la région Ouest Africaine où elle est couramment cultivée dans des pots et massifs de fleurs à la convenance des populations locales (OMS, 1991). Parties utilisées de la plante Feuille entière , jus jaune ou gel transparent et incolore. Caractéristiques botaniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 4194,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 194)",
    "text": "massifs de fleurs à la convenance des populations locales (OMS, 1991). Parties utilisées de la plante Feuille entière , jus jaune ou gel transparent et incolore. Caractéristiques botaniques Curaçao aloe se compose de la feuille entière, du jus ou du gel transparent de l'Aloe vera Linn. (Lilliaceae) Utilisation Ethnomedicale L'Aloes vera est utilisée en médecine traditionnelle pour traiter la dermatite, l'inflammation de la peau provoquée par les rayons du soleil , la douleur kys tique, l'ulcère gastro-duodénal, le rhume, la tuberculose, la gonorrhée, l'asthme, la dysentérie, les maux de tête, les infections fongiques et le diabète (Sample et al , 2001;. OMS, 1991; Ali et al ., 1990). Activités biologiques et pharmacologiques Les en quêtes biologiques et chimique sont confirmé la présence de propriétés antibactérienne et anti -inflammatoire de l 'aloès Vera dans la cicatrisation ( Davis, 1994; Udupa et al., 1994). L'Aloe- émodine est responsable des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 962,
    "source": "PDF_chunked"
  },
  {
    "id": 4195,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 195)",
    "text": "confirmé la présence de propriétés antibactérienne et anti -inflammatoire de l 'aloès Vera dans la cicatrisation ( Davis, 1994; Udupa et al., 1994). L'Aloe- émodine est responsable des propriétés antivirale et antifongique d e la plante (Von Zyl et Viljoen, 2001).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 264,
    "source": "PDF_chunked"
  },
  {
    "id": 4196,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 196)",
    "text": "OOAS Page 33 Aloe vera WAHP Données cliniques L'effet laxatif de l'aloès est principalement dû aux glycosides dihydroxyanthracène 1- 8, aloïne A et B (anciennement appelé barbaloïne). Après administration orale, les aloines A et B, qui ne sont pas absorbées dans l'intestin supérieur, sont hydrolysées dans le côlon par les bactéries intestinales, puis réduites à des métabolites actifs (le principal métabolite actif est aloé- émodine-9- anthrone), agissant comme un stimulant et un irritant pour les v oies gastro- intestinales. L'effet laxatif de l'aloès n'est généralement pas observé avant 6 heures après administration par voie orale, et parfois pas avant 24 heures ou au déla (OMS, 1999). Constituants chimiques Les composés phénoliques comprennent les anthraquinones et chromones, les protéines, les glucides (Davis, 1994; Udupa et al., 1994 ; Bruce, 1967;. Lorenzett et al, 1964;. Von Zyl et Viljoen, 2001) Tests d'identité et de pureté",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4197,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 197)",
    "text": "anthraquinones et chromones, les protéines, les glucides (Davis, 1994; Udupa et al., 1994 ; Bruce, 1967;. Lorenzett et al, 1964;. Von Zyl et Viljoen, 2001) Tests d'identité et de pureté Teneur en humidité: pas plus de 12 Cendre totale: pas plus de 11,00 Cendre insoluble dans l'acide: pas plus de 2 Cendre insoluble dans l'eau: pas moins de 3 Substances extractibles par l'eau: pas moins de 38,00 Substances extractibles par l'éthanol (70): pas moins de 25,00 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60 oC) chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5ml d'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Presence de trois tâches distinctes avec valeurs R",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4198,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 198)",
    "text": "(0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5ml d'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Presence de trois tâches distinctes avec valeurs R f de 0.58 (rose), 0.39 (rose) and 0.21 (rose). Chromatogramme Macroscopie Herbe vivace succulente, presque sessiles, marge épineuse avec paroi mince; feuilles de 30- 50 cm de long sur 10 cm de large à la base, tachetées, de couleur petits pois lorsqu'elles sont jeunes, avec des tâches blanchâtres de forme allongée ; il y a la présence de feuilles plates ou légèrement concaves sur la surface supérieure de couleur vert grisâtre; de même que des feuilles munies de dents, qui sont plus encombrées sur la partie inférieure vers le bas et plus espacés au dessous de la pointe; les bractées sont très petites; les fleurs sont jaunes vives à orange foncées, tubulaires de 25- 35 cm de long, disposées en pic lâche élancé ; les étamines sont souvent projetées au- delà du tube",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 4199,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 199)",
    "text": "bractées sont très petites; les fleurs sont jaunes vives à orange foncées, tubulaires de 25- 35 cm de long, disposées en pic lâche élancé ; les étamines sont souvent projetées au- delà du tube du périanthe aculescent ou presque.Aucentre de la rosette de la feuille, se pose une grappe de30- 40 cm de long (Odeleye, 2004; Pharmacopée africaine, 1985). Microscopie L'épiderme des cellules polygonales et tabulaires sont couvertes d'une épaisse cuticule striée, de stomates anomocytiquesranunculaceuses; les faisceaux fibrovasculaires sont disposés parallèlement à l'épiderme, à une courte distance de l'intérieur du mésophylle sous la forme d'une ellipse; les faisceaux vasculaires sont accompagnés d'un très grand tubulaire allongé et descellules péricycliques à parois minces, contenant des exsudats jaunes; la section tranversale montre des cellules palissadiques et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 867,
    "source": "PDF_chunked"
  },
  {
    "id": 4200,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 200)",
    "text": "OOAS Page 34 Aloe vera WAHP des cristaux d'oxalate de calcium ; les cellules palissadiques sont de petites formes, rondes ou cycliques. Il y a présence de faisceaux de xylème et de phloème (Odeleye, 2004). Matériel végétal en poudre La poudre d'Aloès est de couleur jaune verdâtre à brun jaunâtre; ses taches sont trouvées sur la surface quand on la frotte l'une contre l'autre; il a un goût caractéristique aigre, nauséabonde et amer. Au micr oscope, ilprésente des fragments avec de nombreux cristaux aciculaires d'oxalate de calcium, noyés dans une matrice amorphe (Odeleye, 2004; Pharmacopée Africaine, 1985). Actions thérapeutiques Cathartique, anti -inflammatoire, anti -cancéreux, antiviral, an tiprotozoaire, antiparasitaire, insecticide, analgésique, vulnéraire. Indications thérapeutiques Brûlures, dermatite, douleur kystique, ulcère gastro-duodénal, rhume, tuberculose, gonorrhée, asthme, dysenterie, maux de tête, diabète et infections fongiques.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4201,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 201)",
    "text": "Indications thérapeutiques Brûlures, dermatite, douleur kystique, ulcère gastro-duodénal, rhume, tuberculose, gonorrhée, asthme, dysenterie, maux de tête, diabète et infections fongiques. Données de sécurité Dans une évaluation de toxicité aiguë de 24 heures, la DL 50 de l'extrait aqueux des feuilles de la plante ( p.o) chez la souris était supérieure à 2000 mgkg. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'administration par voie orale de l'extrait à 500- 2000 mgkg aux souris mâles et femelles, pendant 14 jours. Précautions d'emploi L'utilisation excessive ou prolongée peut provoquer la néphrite, la gastrite, les vomissements et la diarrhée entachée de sang et de mucus. Effets indésirables Gastrite, vomissements et diarrhée Contre-indications L'Aloe ne doit pas être utilisé chez les patients qui ont l'obstruction intestinale ou la sténose, l'atonie, la déshydratation sévère avec déplét ion",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4202,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 202)",
    "text": "Contre-indications L'Aloe ne doit pas être utilisé chez les patients qui ont l'obstruction intestinale ou la sténose, l'atonie, la déshydratation sévère avec déplét ion électrolytique ou constipation chronique, les maladies intestinales inflammatoires, la colite ulcéreuse, le syndrome du côlon irritable, chez les enfants de moins de 10 ans. Il ne doit pas également être utilisé pendant la grossesse ou l'allaitement. Dosage et formegalénique Jus séché: 50-200 mg par voie orale pour les adultes Décoction: deux cuillerées à soupe par jour avant les repas Conservation A conserver dans un endroit frais et sec, à l'abri de l'humidité et de la lumière. Références African Pharmacopoeia (1985). Vol. 1, First Edition, Lagos, Nigeria: The Organisation of African Unity's Scientific Technical and Research Commission. Ali, I. A., Shalably, N.M., Elgamal, M.H., Mousa, A. (1990). Antifungal effects of different plant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 914,
    "source": "PDF_chunked"
  },
  {
    "id": 4203,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 203)",
    "text": "African Unity's Scientific Technical and Research Commission. Ali, I. A., Shalably, N.M., Elgamal, M.H., Mousa, A. (1990). Antifungal effects of different plant extracts and their major components of selected Aloe species. Phytotherapy Research 13:401- 402. Bruce, W.G.G. (1967). Investigation of antibacterial activity in Aloe. South African Medical journal 41:984. Burkill, A.I.M. (1995). The Useful Plants of West Tropical Af rica Vol. 3 Family J -L Kew: Royal Botanic Garden, pp. 492-493. Davis, R.M. (1994). Anti-inflammatory and wound healing of growth substances in Aloe vera. Journal of American Paediatric. Medicine Association 84:77-81. Hutchinson, J., Dalziel, J.M. (1958). Floral of West Tropical Africa Vol 1, Part 2 London: Crown Agents for Overseas Governments and Administration. pp 476. Lorenzett, I.J. et al.,. (1964). Bacteriostatic property of Aloe vera. Journal of Pharmaceutical Society 53:1287-1290. Odeleye, O.M. ( 2004). Comparative",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4204,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 204)",
    "text": "Administration. pp 476. Lorenzett, I.J. et al.,. (1964). Bacteriostatic property of Aloe vera. Journal of Pharmaceutical Society 53:1287-1290. Odeleye, O.M. ( 2004). Comparative Pharmacognostical studies on Aloe schweinfurthii Baker and Aloe vera (Linn.) Burm. F. M. Sc (Pharmacognosy) Thesis , Obafemi Awolowo University, Ile-Ife, Nigeria. Reynolds, G.W. (1966). The Aloes of tropical Africa and Madagascar Swaziland: The Trustee Aloe Book found in Mbabane. Sample, S.J., Ryke, S.M, Reynolds, G.D., Flowe, R.L. (2001). In vitro Antiviral activity of the anthraquinous chrysophic acid against Polovirus. Antiviral Research 49:169-148.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 634,
    "source": "PDF_chunked"
  },
  {
    "id": 4205,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 205)",
    "text": "OOAS Page 35 Aloe vera WAHP Udupa, S.L., udupa, A.L., Kurkami , D.R. (1994). Anti-inflammatory and wound healing properties of Aloe vera. Fitoterapia 65:141-145. Von Zyl, R.L., Viljoen, A.M. (2001). In vitro activities of Aloe extract against Plasmodium falciparum. South African Journal of Bot any 68:106-110. WHO Monographs on selected medicinal plants (1991). Vol.1. Geneva: World Health Organization Geneva, Switzerland. Young, H.W (1950). Textbook of Pharmacognosy 6 th edition, Philadelphia: Blakiston. OOAS Page 36 Aloe vera WAHP",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 536,
    "source": "PDF_chunked"
  },
  {
    "id": 4206,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 206)",
    "text": "OOAS Page 37 Alstonia boonei WAHP Nom Botanique Alstonia boonei De Willd. Famille Apocynaceae Synonyme Alstonia congolensis Engl. Noms communs Texture enbois; Tabouret de bois Noms vernaculaires Burkina Faso: Fulfuldé Moyatabél Cote d 'Ivoire: Abe Onguie Honguie, Baule Emien Miei, Kulango Senuro Ghana: Twi - Onyame Dua, Ga Adangbe Sinu, Nzema Nyamenlebaka Guinée: Fula Pulaar Leguere, Kissi Tiendo, Loma Zolo Guinée-Bissau: Fula Pulaar Bantera-Foro, Manding MandinkaBantam-Foro (D'o) Libéria: Dan Yung, Kru Guere (Krahn) Gona- Tu Nigéria: Edo Ukhu, Engenni Uguwa, Igbo Egbu, Yoruba-ahun Sénéegal: Banyun Ti Keung, Diola Bain, Fula Pulaar Ataforo. Sierra Leone: Mende Kalo Wulo Togo: Ewe Nyami dua, Ouatchi tonton, Mina - siaketekre Description de la plante Un arbre à feuilles caduques atteignant 35 m de haut avec un contreforts profond et cannelé haut",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 855,
    "source": "PDF_chunked"
  },
  {
    "id": 4207,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 207)",
    "text": "Togo: Ewe Nyami dua, Ouatchi tonton, Mina - siaketekre Description de la plante Un arbre à feuilles caduques atteignant 35 m de haut avec un contreforts profond et cannelé haut et étroit; tacheté de blanc et brun clair; le latex est abondant et blanc ; les feuilles sont en verticilles au niveau des nœuds, oblancéolées, avec apex arrondi etnervures acuminées etlatérales proéminentes, presque perpendiculaire à la nervure médiane ; les fleurs sont blanches à cymes terminales laxistes; les fruits jumelésjusqu'à 16 cm de long ont des follicules minces et des graines de soie brune à chaque extrémité. Numéro du specimen de l'herbier Ghana: GC 45909 Togo: TOGO02006 Habitat et répartition géographique C'est un arbre à feuilles caduques qui pousse à environ 35 m des zones forestières du Ghana et de toute l'Afrique tropicale. Parties utilisées de la plante Ecorce de la tige Autres parties utilisées Feuilles Caractéristiques botaniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4208,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 208)",
    "text": "de toute l'Afrique tropicale. Parties utilisées de la plante Ecorce de la tige Autres parties utilisées Feuilles Caractéristiques botaniques Alstonia se compose del'écorce fraîche ou séchée du tronc d' Alstonia boonei Willd De (Apocyanaceae). Utilisations médicales L'Alstonia boonei est largement utilis é enAfrique de l'Ouest et Centrale pour le traitement du paludisme, de la fièvre, des helminthes intestinaux, du rhumatisme et de l'hypertension (Abel et Busia, 2005; Betti, 2004; Sofowora, 1993). L'écorce du tronc est couramment utilisée pour traiter le paludisme (Idowu et al., 2010; Titanji et al ., 2008). Une infusion de l'écorce est utilisée comme sérum antivenimeux en cas de morsures de serpents; il est également utilisé dans le traitement de la miction douloureuse et des affections rhumatismales (Asuzu et d'Anaga, 1991). L'infusion de l'écorce de racine et de tige est considérée comme un remède pour l'asthme.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4209,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 209)",
    "text": "dans le traitement de la miction douloureuse et des affections rhumatismales (Asuzu et d'Anaga, 1991). L'infusion de l'écorce de racine et de tige est considérée comme un remède pour l'asthme. Un liquide fabriqué à partir de l'écorce de tige et des feuilles se boit pour traiter l'impuissance. Au Ghana, il est donné pour les maux de dents et aux femmes après accouchement pour aider à expulser le placenta. En Côte d'Ivoire et au Burkina Faso, il est appliqué localement pour réduire l'œdème et nettoyer les plaies purulentes et les fractures ouvertes. Au Nigéria, il est utilisé pour les ulcèr es et, au Cameroun et au Libéria comme remède contre les morsures de serpent et le poison de flèche. Activités biologique et pharmacologique L'écorce du tronc de A. boonei a été signalée posséder des activités anti -inflammatoires, analgésiques et antipyrétiques (Olajide et al., 2000). Il a montré une activité schizonticide du",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 4210,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 210)",
    "text": "OOAS Page 38 Alstonia boonei WAHP sang sur le chimiosuppression obtenudurant les quatre premiers jours du test d'infection précoce. Uneactivité significative (p 0,05) a également été enregistrée au cours de l'infect ion établie ; ce qui est comparable à la drogue standard (chloroquine, 5 mgkgjour) dans l'enquête réalisée par Iyiola et al . (2011). L'extrait aqueux de la plante a eu un effet in vivo de contraction à la fois sur l'iléon de cobayeet sur la bande d'estomac de rat; l'effet était plus prononcé sur la bande d'estomac de rat que sur l'iléon de cobaye (Taiwo et Makinde, 1996). Les extraits de l'écorce du troncont montré (Taiwo et al., 1998), des effets de fixation du complément, anti - arthritiques et analgési ques in vitro chez l'animal. Les extraits méthanoliques de l'écorce du troncont inhibél'œdème de la patte induite par la carragénine, granulome provoqué par une boulette de coton et inhibé la perméabilité",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4211,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 211)",
    "text": "l'animal. Les extraits méthanoliques de l'écorce du troncont inhibél'œdème de la patte induite par la carragénine, granulome provoqué par une boulette de coton et inhibé la perméabilité vasculaire causée par l'acide acétique (Olajide et al., 2000). L'extrait alcoolique a démontré une protection contre l'œdème de la patte arrière du rat causé par le blanc d'œuf (Osadebe, 2002). Les extraits d' A. boonei ont des effets antihelminthiques potentiels par leur capacité à inhiberla glutathion S -transférases des nématodes parasites (Fakae et al ., 2000). Les propriétés insecticides des extraits aqueux de la feuille et de l'écorce de tige ont été démontrées contre la pyrale rose Sesamia calamistis Hampson (Lepidoptera: Noctuidae), ravageur important du maïs; les extraits de feuilles et de l'écorce de tige ont causé à la fois d'une manière dose-dépendante, labaisse significative du poids des larves (Oigiangbe et al, 2007). Les propriétés",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4212,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 212)",
    "text": "l'écorce de tige ont causé à la fois d'une manière dose-dépendante, labaisse significative du poids des larves (Oigiangbe et al, 2007). Les propriétés antioxydantes d'A. boonei ont été rapportées par Akinmoladun et al. (2007). Taiwo et al., (1998) ont également étudié l'activité de l'écorce de tige sur le complément humain et les leucocytes polynucléaires. Il a été rapporté une néphrotoxicité provoquée par l'extrait sur le cobaye et un effet de reproduction de l'ext rait méthanolique chez les rats mâles. L'extrait a aussi montré de manière significative la baisse du taux de cholestérol et de lipoprotéine à p 0,05, chez des animaux recevant une dose de 50 mg à 200mgkg poids (Oze et al , 2007; 2008;. Raji et al., 2005). Odeku et al. (2008) ont réalisée des essais de formulation sur l'écorce du tronc en utilisant une forme solide de dosage. Données cliniques Aucune information disponible Constituants chimiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 920,
    "source": "PDF_chunked"
  },
  {
    "id": 4213,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 213)",
    "text": "des essais de formulation sur l'écorce du tronc en utilisant une forme solide de dosage. Données cliniques Aucune information disponible Constituants chimiques Alcaloïdes (échitamine, échitamidine, alstonine, alstonidine); triterpénoïdes (lupéol, acide ursolique, β -amyrine); tanins; iridoïdes (boonein, loganine); minéraux (calcium, phosphore, fer, sodium, potassium et magnésium); acide ascorbique (Ojewole, 1984; Iwu, 1993). Tests d'identité et de pureté Teneur en humidité: (écorce de la tige) 12,3; (feuille) 8,7 Cendre totale: (écorce de la tige) de 8,0; (feuille) 8,3 Substances extractiblespar l'eau: pas moins de 4,20 Substances extractibles par l'éthanol (70): 8,20 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice (0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv, la révélation est réalisée par pulvérisation du mélange",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4214,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 214)",
    "text": "stationnaire : gel de silice (0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv, la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acideacétique glacial (10 ml), 85 ml de méthanol et 5 ml d'acidesulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de quatre taches roses distinctes avec valeurs Rf de 0,96, 0,65, 0,47 et 0,38. Macroscopie L'écorce est vert grisâtre et lenticellée sur la surface extérieure avec une lumière jaunecrème sur la surface intérieure; une cassure courte et fibreuse; une odeur particulière et un goût amer.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 616,
    "source": "PDF_chunked"
  },
  {
    "id": 4215,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 215)",
    "text": "OOAS Page 39 Alstonia boonei WAHP Chromatogramme Microscopie La coupe transversale de l'écorce montre descellules de liègesur leslignesradiales tangentiellement allongées, une seule couche de cellules de cambium avec des éléments bruns rougeâtres; le cortex est constitué de la masse basale de cellules parenchymateuses avec des groupes isolés de sclérites lignifiées et de fibr es péricycliques lignifiées; les cristaux prismatiques d'oxalate de calcium sont présents dans le cortex, de même que les cellules en latex; unfaisceaude cylindre vasculaire est entrecoupé par des rayons médullaires et desfibres lignifiés dans la région du phloème. Matériel végétal en poudre Couleur jaune-chamois; goût amer; fragments de liège, prismes d'oxalate de calcium, fibres lignifiés et sclérites. Actions thérapeutiques Antipyrétique, anti-inflammatoire, analgésique, antirhumatismale, antipaludique, antimicrobienne, insecticide (Olajide et al., 2000;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4216,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 216)",
    "text": "lignifiés et sclérites. Actions thérapeutiques Antipyrétique, anti-inflammatoire, analgésique, antirhumatismale, antipaludique, antimicrobienne, insecticide (Olajide et al., 2000; GHP,1992 ; Oigiangbe, 2007). Indications thérapeutiques Polyarthrite, rhumatoïde, paludisme, rougeole, furoncles, blessures, hypertension artérielle, cataracte, rétention du placenta, anémie (Mshana et al, 2000;Taiwo et al, 1998; GHP, 1992). Données de sécurité La DL 50 des extraits aqueux des feuilles ( p.o) chez la souris était 2000 mgkg en 24 heures. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'administration orale de l'extrait à 500- 2000 mgkg per. os. à des souris mâles et femelles pendant 14 jours. La plante est relativement sans danger, bien que la toxicité sur le foie, les reins et la rate ait été observée avec les triterpénoïdes dans les expériences en laboratoire. Précautions d'emploi",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4217,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 217)",
    "text": "danger, bien que la toxicité sur le foie, les reins et la rate ait été observée avec les triterpénoïdes dans les expériences en laboratoire. Précautions d'emploi Médicaments contenant des alcaloïdes bruts; ils doivent donc être pris avec précaution. Effets indésirables L'utilisation excessive ou prolongée peut entrainer le syndrome de Steven Johnson. Contre-indications Grossesse et allaitement, dysfonctionnements du foie. Dosage et forme galénique Décoction: 30-50 g par litre d'eau; boire 3-4 tasses par jour. Teinture: 1:5 dans de l'éthanol à 45; prendre 5 ml trois fois par jour. Conservation Conserver dans un endroit sombre, frais et sec. Références Abel, C., Busia, K. (2005). An exploratory ethnobotanical study of the practice of Herbal Medicine by the Akan People of Ghana. Alternative Medicine Review, p 42. Akinmoladun, A.C., Ibukun, E. O., Afor, E., Akinrinlola, B.L. (2007). Chemical constituents",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 913,
    "source": "PDF_chunked"
  },
  {
    "id": 4218,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 218)",
    "text": "Medicine by the Akan People of Ghana. Alternative Medicine Review, p 42. Akinmoladun, A.C., Ibukun, E. O., Afor, E., Akinrinlola, B.L. (2007). Chemical constituents and antioxidant activity of Alstonia boonei . African Journal of Biotechnology. 8(10):1197- 1201. Asuzu, I.U., Anaga, A.O. (1991). Pharmacological screening of the aqueous extract of Alstonia boonei stem bark. Fitoterapi a 63:411-417. Betti, J.L. (2004). An ethnobotanical study of medicinal plants among Pigmies in Dja biosphere Reserve, Cameroon. Afican Study Monographs 25(1):1-27. Fakae, B.B., Campbell, A.M., Barrett, J., Scott, I.M. et al., (2000). Inhibition of glutat hione S - transferases (GSTs) from parasitic nematodes by extracts from traditional Nigerian medicinal plants. Phytotherapy Research 14(8):630-634. Ghana Herbal Pharmac opoeia (1992). The Advent Press, Accra, Ghana.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 856,
    "source": "PDF_chunked"
  },
  {
    "id": 4219,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 219)",
    "text": "OOAS Page 40 Alstonia boonei WAHP Idowu, O.A., Soniran, O.T., Ajana, O., Aw orinde, D.O. (2010). Ethnobotanical survey of antimalarial plants used in Ogun State, Southwest Nigeria. African Journal of Pharmacy and Pharmacology 4:055-060. Iwu, M.M. (1993). In: Handbook of African Medicinal Plants. CRC Press, Boca Raton, FL. pp 116-118. Iyiola, O.A., Tijani, A.Y., Lateef, K.M. (2011). Antimalarial activity of the stem bark of Alstonia boonei in Mice. Asian Journal of Biological Science 4:235-243. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, Technical and Research Committee. Odeku, O.A., Adegoke, O.A., Majekodunmi, S.O. (2008). Formulation of the extract of the stem bark of Alstonia boonei as tablet dosage form.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 4220,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 220)",
    "text": "Committee. Odeku, O.A., Adegoke, O.A., Majekodunmi, S.O. (2008). Formulation of the extract of the stem bark of Alstonia boonei as tablet dosage form. Tropical Journal of Pharmaceutical Research 7:987-994. Oigiangbe, O.N., Igbinosa, I.O., Tamo, M. (2007). Insecticidal activity of the medicinal plant, Alstonia boonei De W ild, against Sesamia calamistis Hampson. Journal of Zhejiang University -Science B. 8 (10): 752755. Olajide, O.O., Awe, S.O., Makinde, M., Ekhelar, A.I., Olusola, A. et al. (2000). Studies on the anti - inflammatory, antipyretic and analgesic properties of Alstonia boonei stem bark. Journal of Ethnopharmacology 71:179-186. Ojewole, J.A.O. (1984). Studies on the pharmacology of echitamine, an alkaloid from the stem bark of Alstonia boonei L. (Apocynaceae). International Journal of Crude Drug Research 22:121-143. Osadebe, P.O. (2002). Anti -inflammatory properties of the root bark of Alstonia boonei.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4221,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 221)",
    "text": "International Journal of Crude Drug Research 22:121-143. Osadebe, P.O. (2002). Anti -inflammatory properties of the root bark of Alstonia boonei. Nigerian J.ournal of Natural Products and Medicine 6:39-41. Oze, G., Harrisson, N., Okey, O., Ukoha A. (2008). Changes in Lipid and Haematological profile of aqueous extract of Alstonia boonei in rats. The Internet Journal of Hematology 4(1). Oze, G., Nwanjo, H., Onyeze, G. (2007). Nephrotoxicity caused by the extract of Alstonia boonei (De Wild) Stem bark in Guinea pigs. Internet. Journal of Nutrition and Wellness 3:2-2. Raji, Y., Salman, T.M., Akinsomisoye, O.S. (2005). Reproductive functions in male rats treated with methanolic extracts of Alstonia boonei stem bark. African Journal of Biomedical Research 8:105-111. Sofowora, A. (1993). Medicinal plants and traditional medicine in Africa. Spectrum Book Ltd., Ibadan, Nigeria. p289. Taiwo, O.B., Kroes, B.H., Beukelman, C.J.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4222,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 222)",
    "text": "Research 8:105-111. Sofowora, A. (1993). Medicinal plants and traditional medicine in Africa. Spectrum Book Ltd., Ibadan, Nigeria. p289. Taiwo, O.B., Kroes, B.H., Beukelman, C.J., Horsten, S.T., et al. (1998). Activity of stem bark of Alstonia boonei de wild on human complement and polymorph nuclear leucocyt es. Journal of Ethnopharmacology 17:13-15. Taiwo, O.B., Makinde, J.M. (1996). Contractile activity of Alstonia boonei stem bark extract on isolated rat stomach strip and guinea pig ileum. Indian Journal of Pharmacology 28(2):110-112. Taiwo, O.B., Van Den Berg, A.J.J., Kores, B.H. et al. (1998). Activity of the stem bark extract of Alstonia boonei de wild (Apocynaceae) on human complement and polymorphonuclear leukocytes. Indian Journal of Pharmacology 30(3):169-174. Titanji, V.P.K., Zofou, D., Ngemeny a, M.N. (2008). The antimalarial potential of medicinal plants used for the treatment of malaria in Cameroonian folk medicine. African Journal of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 962,
    "source": "PDF_chunked"
  },
  {
    "id": 4223,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 223)",
    "text": "Titanji, V.P.K., Zofou, D., Ngemeny a, M.N. (2008). The antimalarial potential of medicinal plants used for the treatment of malaria in Cameroonian folk medicine. African Journal of Traditional, Complimentary and Alternative Medicine 5:302-321.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 244,
    "source": "PDF_chunked"
  },
  {
    "id": 4224,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 224)",
    "text": "OOAS Page 41 Argemone mexicana WAHP Nom botanique Argemone mexicana L. Famille Papaveraceae Synonyme Argemone ochroleuca doux Noms communs Mexican poppy, Prickly poppy, Mexican prickly, yellow poppy, yellow thistle (Anglais). Pavot épineux, Pavot du Mexique, Tâche de l'œil, Chardon du pays (Français). Noms vernaculaires Ghana: Akan- Akusiribie, Twi- Kokosakyi aduro Mali: Bambara- Bozobo, Dogon- Aignètawa, Sonkeriai, Senoufo- Naka - taba Sénégal: Wolof- Garabu-mag, Diola- Fambora, Serer- Dahatu Fa N'Gol Togo: Adja- Houétchègnon Description de la plante mexicana est une plante annuelle herbacée, dressée et ramifiée, atteignant 1 m de haut, avec une base boisé; sesfeuilles alternes et sessiles, lancéolées glabres avec unbord lobé et dentelé sont terminées par des pointes piquantes, des côtes alternes, des épines sur la face inférieure du limbe; les fleurs sont terminales et peuvent atteindre 2,5 à 5 cm de diamètre avec des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4225,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 225)",
    "text": "sont terminées par des pointes piquantes, des côtes alternes, des épines sur la face inférieure du limbe; les fleurs sont terminales et peuvent atteindre 2,5 à 5 cm de diamètre avec des sépales vertes et des pétales jaune- vifs; les fruits sont des capsules ovoïdes, rectangulaires avec de nombreuses épines dressées ou étalées; le latex est jaune, tan dis que la graine est brun- foncée, ronde et claire. Numéro du spécimen de l'herbier Mali: DMT - 0873 Nigeria: FHI 62256 Habitat et répartition géographique Argemone mexicana est originaire du Mexique, mais se trouve maintenant dans de nombreux pays tropicaux des deux hémisphères. La plante est très répandue dans toute l'Afrique et se produit de façon irrégulière dans la zone soudano-sahélienne de l'Afrique de l'Ouest hemispheres. Parties utilisées de la plante Partie aérienne sans graines ; feuilles Autres parties utilisées Racine Caractéristiques botaniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 918,
    "source": "PDF_chunked"
  },
  {
    "id": 4226,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 226)",
    "text": "hemispheres. Parties utilisées de la plante Partie aérienne sans graines ; feuilles Autres parties utilisées Racine Caractéristiques botaniques Argémone se compose des parties aériennes fraîches ou séchées d' Argemone mexicana L. (Papaveraceae). Utilisations ethnomédicales Les feuilles sont traditionnellement utilisées pourles douleurs entériques, les douleurs musculaires, la gonorrhée, la constipation, la jaunisse etdysfonctionnement du foie, le paludisme simple, la toux, les maux de dents, la douleur oculaire, l'écoulement urétral, les troubles hépato- biliaires, les fièvres bilieuses, l'hématurie et l'eczéma. Le jus est utilisé comme sédatif, antiémétique, et dans le traitement des infections auriculaires et des maladies oculaires. Les graines infusées et la partie aérienne sont utilisées comme diurétique, purgatif et sudorifique. L'hui le est utilisée dans la constipation, l'insomnie, les infections de la peau et les plaies.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4227,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 227)",
    "text": "utilisées comme diurétique, purgatif et sudorifique. L'hui le est utilisée dans la constipation, l'insomnie, les infections de la peau et les plaies. Activités biologiques et pharmacologiques La plante entière a des propriétés hypotenseur, narcotique, diaphorétique et diurétique. Les feuilles et les tiges ont éga lement des effets antibactérien, antiviral, spasmodique et stimulant. L'extrait de ses capsules est un hypnotique et un antitussif, etle latex possède des propriétés anticoagulantes. L'extrait méthanoliquea montré une activité antiplasmodiale comparableà c elle de Artemisia annua (Sangaré, 2003; Diallo et al, 2006; Adjobimey et al., 2004). Les extraits aqueux et méthanoliques des feuilles et des graines ont montré une activité antibactérienne contre Staphylococcus aureus, Bacillus subtilis, Escherichia coli et Pseudomonas aeruginosa (Bhattacharjee et al., 2006). L'extrait de la plante a démontré une activité anti -VIH prometteur sur",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4228,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 228)",
    "text": "contre Staphylococcus aureus, Bacillus subtilis, Escherichia coli et Pseudomonas aeruginosa (Bhattacharjee et al., 2006). L'extrait de la plante a démontré une activité anti -VIH prometteur sur les lignées cellulaires humaines et les cellules T",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 244,
    "source": "PDF_chunked"
  },
  {
    "id": 4229,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 229)",
    "text": "OOAS Page 42 Argemone mexicana WAHP CD4 CEM-GFP infectées par le VIH 1NL4.3. Les extraits bruts (hexane, acétate d'éthyle, acétone et méthanol) des feuilles, ont montré une activité antiappétante dose-dépendante qui pourrait être exploitée pour la lutte contre les moustiques (Elango et al. 2011). Données cliniques Une étude clinique observationnelle a confirmé l'utilisation ethnomédicale de la décoction de la plante dans le traitement du paludisme simple chez les patients âgés de plus de 5 ans, avec 89 de réponse clinique adéquate (Sidibé, 2006 ; Willcox et al, 2007). Dans un essai randomisé et contrôlé, la décoction de la plante a démontré une efficacité clinique dans le traitement du paludisme simple, qui se comparebien avec une combinaison thérapeutique à base d'artémisinine. Dans les deux cas, la progression vers un paludisme grave, est restée inférieure à 5 (Dakuo, 2008). Il serait donc possible d'utiliser la décoction",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4230,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 230)",
    "text": "thérapeutique à base d'artémisinine. Dans les deux cas, la progression vers un paludisme grave, est restée inférieure à 5 (Dakuo, 2008). Il serait donc possible d'utiliser la décoction comme traitement de première ligne en tant que complément au traitement standard dans les zones de forte transmission du paludisme (Graz et al., 2010). Constituants chimiques Tanins, benzoquinones, coumarines, mucilage, stérols, triterpènes et alcaloïdes (berbérine; dihydrosanguinarine, benzophénanthridines allocryptopine, protopine , dihydrochelerithrine et chélérythrine); acides gras (alcool cérylique, bêta sistostérol), acides organiques (acide tartrique, acide succinique, acide citrique et acide malique), acides combinés et acides aminés libres, monosaccharides (glucose et fructose), minéraux et vitamine C; flavonoïdes (rutine et quercétine) (Singh et al., 2012;. Rahman et Ilyas, 1961). Tests d'identité et de purêté Teneur en humidité: 6,53 Cendre totale: 17,33",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 960,
    "source": "PDF_chunked"
  },
  {
    "id": 4231,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 231)",
    "text": "minéraux et vitamine C; flavonoïdes (rutine et quercétine) (Singh et al., 2012;. Rahman et Ilyas, 1961). Tests d'identité et de purêté Teneur en humidité: 6,53 Cendre totale: 17,33 Substances extractibles par l'eau: pas moins de 20,00 Substances extractibles par l'éthanol (70): pas moins de 19,40 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de quatre tâches distinctes avec valeurs Rf de 0,83 (cendres), 0,50 (rose), 0,41 (rose) et 0,23 (violet). Chromatogramme Macroscopie Poudre verte, insipide, rugueus eau toucher avec une odeur caractéristique de tabac.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4232,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 232)",
    "text": "(rose), 0,41 (rose) et 0,23 (violet). Chromatogramme Macroscopie Poudre verte, insipide, rugueus eau toucher avec une odeur caractéristique de tabac. Microscopie Groupes de fibres avec cristaux d'oxalate de calcium, des vaisseauxspiralés, nombreux cristaux d'oxalate de calcium, quelques fragments d'épiderme. Matériel végétal en poudre Des cellules du parenchyme de l'épiderme des feuilles, des fibres transportant des crystaux d'oxalate de calcium comme identifiées conformément à l'analyse générale ; des fragments microscopiques de cellules d'épiderme, , des fibres de xlylèm e, des vaisseaux spiralés et de nombreux cristaux d'oxalate de calcium isolés. Actions thérapeutiques Hypotensif, narcotique, diaphorétique, diurétique, antibactérien, antiviral, laxatif, anti -inflammatoire,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 788,
    "source": "PDF_chunked"
  },
  {
    "id": 4233,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 233)",
    "text": "OOAS Page 43 Argemone mexicana WAHP vulnéraire, antitussif, anticoagulant, antiplasmodiale, antiappétant et répulsif (Sangaré, 2003 ; Diallo et al. 2006;.. Adjobimey et al, 2004, Bhattacharjee et al ,. 2006; Elango etal., 2011). Indications thérapeutiques Paludisme simple, dracunculose. Donnée de sécurité Sur une période de 24 heures, la DL 50 de l'extrait aqueux des parties aériennes de la plante sans les graines ( p.o.) a été au- delà de 2000 mg kg,chez la souris. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'administration par voie oral e de l'extrait de 500 - 2000 mg kg à des souris mâles et femelles pendant 14 jours. Une étude précédente au Mali a montré qu'une DL 50 de la décoction administrée par voie orale à des souris pendant 72 heures était 3,205 g kg. Dans quelques études de t oxicité sub -chronique, l'administration répétée de 300 mg kg d'extrait",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4234,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 234)",
    "text": "décoction administrée par voie orale à des souris pendant 72 heures était 3,205 g kg. Dans quelques études de t oxicité sub -chronique, l'administration répétée de 300 mg kg d'extrait aqueux ( p.o) pendant 30 jours, n'a pas eu d'incidence sur les paramètres biochimiques du sang, du foie et des reins, chez les rats (Sanogo et al., 2008). Le latex et les graines sont toxiques et peuvent donc provoquer des hémorragies intestinales et la mort. Précautions d'emploi Ne pas l'utiliser plus d'une semaine. Effets indésirables Vomissement, diarrhée, jambes enflées, éruption cutanée, essoufflement et dans les cas extrêmes, glaucome, et arrêt cardiaque. Contre-indications Enfants et femmes enceintes Dosage et forme galénique Décoction Poudre de la feuille: 30 g dans 500 ml d'eau pendant 30 min. Prise deux fois par jour. Conservation A conserver dans un endroit frais et sec, à l'abri de la lumière. Références",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 909,
    "source": "PDF_chunked"
  },
  {
    "id": 4235,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 235)",
    "text": "Décoction Poudre de la feuille: 30 g dans 500 ml d'eau pendant 30 min. Prise deux fois par jour. Conservation A conserver dans un endroit frais et sec, à l'abri de la lumière. Références Adjobimey, T., Edayé, I., Lagnika, L., Gbenou, J. et al. (2004). Activités antiplasmodiales in vitro de quelques plantes antipaludiques de la pharmacopée béninoise, Comptes Rendus Chimie 7:10231027. Bhattacharjee, I., Chatterjee, S.K., Chatterjee, S., Chandra, G . (2006). Antibacterial potentiality of Argemone mexicana solvent extracts against some pathogenic bacteria. Memorias do Instituto Oswaldo Cruz 101(6):645-648. Dakuo, F. (2008). Etude comparative du traitement du paludisme simple présomptif à domicile par A.mexicana et les combinaisons thérapeutiques à base d'artéminisinine dans le village de Missidougou Région de Sikasso. Thèse de médecine Bamako, 94P. Diallo, D., Graz, B., Falquet, J., Traoré, A.K. et. al. (2006). Malaria treatment in remote areas of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4236,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 236)",
    "text": "village de Missidougou Région de Sikasso. Thèse de médecine Bamako, 94P. Diallo, D., Graz, B., Falquet, J., Traoré, A.K. et. al. (2006). Malaria treatment in remote areas of Mali: use of modern and traditional medicines, patient outcome. Transaction of the Royal Society of Tropical Medicine and Hygiene 100:515-520. Elango, G ., Rahuman, A.A ., Kamaraj, C ., Bagavan, A ., Zahir, A.A . (2011). Screening for feeding deterrent activity of herbal extracts against the larvae of malaria vector Anopheles subpictus Grassi. Parasitology Research 108(3):513-519. Graz, B., Willcox, M.L., Diakite, C., Falquet, J. et al. (2010). Argemone mexicana decoction versus artesunate-amodiaquine for the management of malaria in Mali: policy and public -health implications. Transactions of Royal Society of Tropical Medicine and Hygiene. 104(1):33-41. Rahman, W ., Ilyas, M . (1961). Flavone glycosides from the flowers of Argemone mexicona L. (Papaveraceae). Comptes Rendus",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 960,
    "source": "PDF_chunked"
  },
  {
    "id": 4237,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 237)",
    "text": "Tropical Medicine and Hygiene. 104(1):33-41. Rahman, W ., Ilyas, M . (1961). Flavone glycosides from the flowers of Argemone mexicona L. (Papaveraceae). Comptes Rendus Hebdomadaires des Seances de l Academie des Sciences 27:252. Sangaré, D. (2003). Etude de la prise en charge du paludisme par les thérapeut s traditionnels dans les aires de santé de Kendié (Bandiagara) et de Finkolo AC (Sikasso), Thèse de Pharmacie, FMPOS, Université du Mali. Sanogo, R., Maiga, A., Djimdé, A., Doumbia, L., Guirou, C. et al. (2008). Etude de la toxicité sub- chronique du décocté de Argemone Mexicana. Médecine et Pharmacopée Traditionnelles 15:26 31. Sidibé, O. (2006). Etude de Argemone mexicana dans le traitement traditionnel du Paludisme non comliqué dans le village de Missidougou Région",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 780,
    "source": "PDF_chunked"
  },
  {
    "id": 4238,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 238)",
    "text": "OOAS Page 44 Argemone mexicana WAHP de Sikasso, Mali. Thèse de Pharmaci e, FMPOS, Université de Bamako. Singh, S ., Pandey, V.B ., Singh, T.D . (2012). Alkaloids and flavonoids of Argemone mexicana. Natural Product Research ; 26:16-21. Willcox, M.L., Graz, B., Falquet, J., Sidibé, O. et al. (2007). Argemone mexicana decoction for treatement of uncomplicated falciparum malaria, Transaction of the Royal Society of Tropical Medicine and Hygiene 101:1190-1198.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 460,
    "source": "PDF_chunked"
  },
  {
    "id": 4239,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 239)",
    "text": "OOAS Page 45 Azadirachta indica WAHP Nom botanique Azadirachta indica A. Juss Famille Meliaceae Synonyme Melia azadirachta Linn., Melia indica (A. Juss) Brandis Noms communs Neem, Lilas indienne; Arbre margosa; Nim Noms vernaculaires Burkina Faso: Mooré Niim, Dioula Nîmyiri, Fula Fulfuldé Tirotiya;Goodji Cote d'Ivoire: Akye Djé Ndédzakoè , Ando' Tchitchèndé Gambia: Manding Mandinka Yirinding Kunango Ghana: Twi Dua Gyane, Ewe Liliti, Hausa Dongo Yaro Mali: Ba mbara - Mali yirini, Senoufo Gnimitigue, Dyula Goo-gay Niger: Hausa - Dogon Yaro, Songhai Méli, Djerma - Milleize. Nigéria: Hausa Dogonyaro, Kanuri Gányá Nîm, Yoruba Dongoyaro Sénégal: Manding Mandinka Tubabo toboro, Soce-tubabo, Wolof Dim dim i buki Togo: Ewe Sabuleti, Mina Kiniti, Adja Sablagbe Description de la plante A. indica est un arbre atteignant 25 m de haut, droit, plein, avec une écorce rayée et fissurée;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 882,
    "source": "PDF_chunked"
  },
  {
    "id": 4240,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 240)",
    "text": "Togo: Ewe Sabuleti, Mina Kiniti, Adja Sablagbe Description de la plante A. indica est un arbre atteignant 25 m de haut, droit, plein, avec une écorce rayée et fissurée; les feuilles sont alternes paripennées avec environ 5- 8 paires de folioles asymétriques à la base, long bout acuminé; ovale- lancéolées, grossièrement denteléesau bord ; il a une inflorescence de panicules axillaires, beaucoup fleurie avec denombreuses fleurs blanches et pédicellées, ainsi que des pédicelles d'environ 1,5 m m de long ; lessépales sont ovales - orbiculaires avec environ 1 mm de long, des pétales blanches,oblancéolées, de 5 à 6 mm de long, il y a des anthères dansl'apex de lobe; le fruit ellipsoïde, ovoïdeavec une seule graine glabre qui est jaune à maturité. La plante peut vivre jusqu'à environ 200 ans (Trewari, 1992). Numéro du specimen de l'herbier Nigeria: FHI 107439 Togo: TOGO04647 Habitat et répartition géographique",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 916,
    "source": "PDF_chunked"
  },
  {
    "id": 4241,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 241)",
    "text": "vivre jusqu'à environ 200 ans (Trewari, 1992). Numéro du specimen de l'herbier Nigeria: FHI 107439 Togo: TOGO04647 Habitat et répartition géographique Arbre tropical à feuilles persistantes; originaire de l'Inde et de la Birmanie; il pousse en Asie du sud et en Afrique de l'Ouest; on le trouve couramment dans les zones côtières et dans leNord de la savaneau Ghana, mais à la fois plus croissant et cultivé dans les parties nord et sud du Nigéria. Il est à présentdans les Caraïbes et en Amérique centrale (Trewari, 1992; GHP, 1992). La plante grandit facilement, même sans irrigation dans les zones arides, semi arides et dans les sols pauvres sablonneux ou caillouteux où le jardinage et la culture sont normalement impossibles. Parties utilisées de la plante Feuilles Autres parties utilisées Écorce du tronc et graines Caractérisques botaniques Le neem est composé de la feuille fraîche ou séchée d'Azadirachta indica A.Juss. (Meliaceae).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4242,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 242)",
    "text": "Feuilles Autres parties utilisées Écorce du tronc et graines Caractérisques botaniques Le neem est composé de la feuille fraîche ou séchée d'Azadirachta indica A.Juss. (Meliaceae). Utilisations ethnomédicales A. Indica est utilisé dans la m édecine ancienne pour le traitement du paludisme, la toux, la nausée, les vomissements, la fièvre, la jaunisse, la gonorrhée, l'infestation par les vers intestinaux, les troubles de la peau, les furoncles, l'ulcère, l'eczéma et la lèpre. Activités biologiques et pharmacologiques Plusieurs études pharmacologiques ont été réalisées pour valider les propriétés médicinales d'A. indica. Il a été démontré que certains composés du neem posséderaient un effet d'inhibition dose- dépendante sur le comportement alimentaire normal (Mitchell et al., 1997). Les feuilles et l'écorce de tige d' A. indica sont utilisés comme agents antipaludiques et leur",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 886,
    "source": "PDF_chunked"
  },
  {
    "id": 4243,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 243)",
    "text": "OOAS Page 46 Azadirachta indica WAHP efficacité a été confirmée par plusieurs études de laboratoire (Aladesanmi et al , 1988;. Ekanem 1978). Les propriétés ant ipaludiques ont été diversement attribuées à un nimbolide (Rochanankij et al., 1985) et un autre limonoïde, gédunine (Khalid et Duddeck, 1989). Iwu et al . (1986) ont suggéré que l'extrait de neem exerce une action antipaludique en provoquant une perturbation par la réaction de l'oxydoréduction en imposant un stress oxydant très fort sur les parasites du paludisme. Dans une autre étude, la boule formée de déchets de bois imbibés dans de l'huile de neem diluée à 5 d'acétone et placée dans des réservoirs d'eau de stockage a contrôlé l'élevage de Anopheles stephensi et Aedes aegypti pendant 45 jours (Nagpal et al ., 1995).Les composantes de l'huile, particulièrement l'azadirachtine ont un potentiel pesticide (Koul et al, 1990;. Schmutterer et al , 1990; Tanzubil et al, 1990). Les Limonoïdes du",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 4244,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 244)",
    "text": "1995).Les composantes de l'huile, particulièrement l'azadirachtine ont un potentiel pesticide (Koul et al, 1990;. Schmutterer et al , 1990; Tanzubil et al, 1990). Les Limonoïdes du Neem ont une activité larvicide, pulicide, adulticide et antioviposition, et peuvent donc être bénéfiques dans les programmes de lutte contre les moustiques (Nathan et al ., 2005). Les propriétés anti -inflammatoires de la plante ont également été démontrées dans différentes études. La fraction aqueuse de l'extrait alcoolique des feuilles a montré une activité anti - inflammatoire sur le granulome provoqué par unouate de coton in vivo (Chattopadhway, 1998);, des propriétés antioxydante, hépatoprotective (Bhanwra et al ., 2000), anti - ulcèreuse (Dorababu et al., 2004); ainsi que des propriétés chronotrope négative et inotrope négative hypoglycémique (Khosla et al ., 2000). L'extrait de feuilles a montré une activité cardioprotectrice équipotente sur la nécrose",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 4245,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 245)",
    "text": "propriétés chronotrope négative et inotrope négative hypoglycémique (Khosla et al ., 2000). L'extrait de feuilles a montré une activité cardioprotectrice équipotente sur la nécrose myocardique induite par l'isoprénaline comparée à la vitamine E, chez les animaux de laboratoire (Peer et al., 2007). La prise orale dedosesde 10- 200mgkg d'extrait des feuilles de neem produit des effets anxiolytiques comparables à celle induite par le diazépam ( Jaiswal et al.,1994). Un effet hypotenseur dose- dépendant de l'extrait hydroalcoolique de feuilles a été rapporté (Chattopadhyay, 1997;.Khanna et al .,1995). L'administration orale de l'extrait de feuilles réduit la glycémie chez les animaux normaux et chez ceux rendus diabétiques par administration de la stréptozocine, avec un effet hypoglycémiant comparable au glibenclamide (Khosla et al., 2000). L'extrait de feuilles a bloqué les effets de l'adrénaline sur le métabolisme du glucose et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4246,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 246)",
    "text": "de la stréptozocine, avec un effet hypoglycémiant comparable au glibenclamide (Khosla et al., 2000). L'extrait de feuilles a bloqué les effets de l'adrénaline sur le métabolisme du glucose et réduit l'utilisation périphérique du glucose chez des rats diabétiques et normaux (Chattopadhyay, 1996). Une étude des effets de l' A. indica sur les lésions par réperfusion et l'hypoperfusion cérébrale à long terme basée sur les propr iétés antioxydante, anti -inflammatoire et anxiolytique de la plante a montré que l'administration de 500 mgkgjour pendant 15 jours réduit significativement l'hypoperfus fonctionnelle induite par les perturbations telles que les troubles d'anxiété, l'appr entissage et la perte de mémoire (Yanpallewar, 2005). Les extraits de Neem ont montré une activité anti -ulcèreuse gastrique dose- dépendante chez les rats stressés. Les extraits ont causé une diminution du dommage des muqueuses gastriques induit",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4247,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 247)",
    "text": "Neem ont montré une activité anti -ulcèreuse gastrique dose- dépendante chez les rats stressés. Les extraits ont causé une diminution du dommage des muqueuses gastriques induit par l'éthanol; une augmentation de la quantité du mucus gastrique adhérent chez les animaux stressés et les extraits ont également démontré un potentiel anti -histaminique significatif (Garg et al., 1993). Bandyopadhyay et al., (2002) ont étudié les propriétés gastro- protectrices de l'extrait de l'écorce de la tige d' A. indica et lui ont attribué la capacité d'inhiber la sécrétion d'acide par l'intermédiaire d'un blocage de H K- ATPase, aussi bien que l'inhibition des dommages oxydants des muqueuses gastriques en bloquant la peroxydation de lipide et en nettoyant les radicaux hydroxyles endogènes. L'extrait aqueux des feuilles s'est avéré efficace pour baisser les niveaux élevés du taux d'enzymes hépatiques sériques et la nécrose hépatique induite par le paracétamol ( Bhanwra et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 968,
    "source": "PDF_chunked"
  },
  {
    "id": 4248,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 248)",
    "text": "L'extrait aqueux des feuilles s'est avéré efficace pour baisser les niveaux élevés du taux d'enzymes hépatiques sériques et la nécrose hépatique induite par le paracétamol ( Bhanwra et al., 2000). Khanna et al., (1995) ont observé des propriétés analgésiques et sédatives in vivo dans les extraits d' A. indica . L'extrait hydro- alcoolique de feuilles a provoqué un effet hypotenseur dose- dépendante (Chattopadhway, 1997) et l'administration orale de faibles doses (10- 200 mgkg) a également montré l'effet anxiolytique comparable à celle induite par le diazépam (Jaiswal et al., 1994). L'administration orale de l'extrait méthanolique a une activité antibactérienne significative contre le Vibrio- cholerae résistant aux combinaisons thérapeutiques chez la souris (Thakurta et al., 2007). L'extrait éthanolique de feuille a démontré une action anti -dermatophytique ou antifongique beaucoup plus forte comparée à l'action in vitro",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4249,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 249)",
    "text": "2007). L'extrait éthanolique de feuille a démontré une action anti -dermatophytique ou antifongique beaucoup plus forte comparée à l'action in vitro de l'extrait aqueux (Venugopal et Venugopal, 1994), tandis que une pâte de feuille, d'écorce et l'huile de la plante montraient des activités molluscicides, dépendantes de la dose et du temps (Singh et al., 1996). Les extraits éthanoliques de la graine ont revélé des effets anthelmintiques (Hordegen et al., 2006). Des études in vitro ont montré que la formulation à base de plantes, le praneem contenant des extraits purifiés de neem est efficace contre le VIH et les agents pathogènes des maladies sexuellement transmissibles , et possédait aussi une activité contraceptive (Joshi et al., 2005). Les effets de stimulation du système immunitaire des extraits de feuilles ont été démontrés in vivo. Les extraits ont renforcé des titres d'anticorps par",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 901,
    "source": "PDF_chunked"
  },
  {
    "id": 4250,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 250)",
    "text": "OOAS Page 47 Azadirachta indica WAHP l'immunisation d'antigène typh oïde H. et ont induit l'hypersensibilité retardée après l'administration de tuberculine et de DNCB aux animaux. Il a été démontré que l'extrait ethanolique du neempourrait causer la mort des cellules cancéreuses de la prostate en induisant l'apoptose (Kumar et al., 2006). Haque et Baral (2006) ont également prouvé que le prétraitement des souris avec la préparation de feuille de neem cause l'inhibition prophylactique de la croissance du carcinome d'Ehrlich murin et du mélanome B16. Les extraits méthanoliques de la feuille ont également stimulé la reproductions in vitro de cellules souches (Gonzalez -Garza, 2007). Données cliniques L'application topique d'une crème d' A. indica sur des parties du corps exposées au taux de 2,0 gpersonne bénéficie d'une pr otection contre les moustiques Aedes, Culex et Anophèles (Dua et al., 1995). Dans les tests sur l'homme, les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4251,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 251)",
    "text": "des parties du corps exposées au taux de 2,0 gpersonne bénéficie d'une pr otection contre les moustiques Aedes, Culex et Anophèles (Dua et al., 1995). Dans les tests sur l'homme, les extraits ont stimulé l'immunité humorale en augmentant les niveaux d'anticorps et l'immunité médiée par les cellules en augmentant le nombre total de lymphocytes et les cellules T en 21 jours (Ansari et al ., 1997). Dans une étude sur une période de 6 semaines, menée sur des hommes âgés de 20- 30 ans, les gels dentaires contenant l'extrait de neem se sont avérés avoir la capacité de réduire l'indice de plaque et le nombre de bactéries que dans le groupe de contrôle (Pai et al., 2004 ). Constituants chimiques Alcaloïdes, tanins, coumarine, stigmastérol, flavonoïdes ou polyphénols, saponines et sucre, Vit. C. composés triterpènes meliacae limonoïde: azadirachtine, nimbolide, gédunine, salanin, autres meliacins; diterpènes; caroténoïdes, sucres réducteurs et huile fixes ont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 964,
    "source": "PDF_chunked"
  },
  {
    "id": 4252,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 252)",
    "text": "Vit. C. composés triterpènes meliacae limonoïde: azadirachtine, nimbolide, gédunine, salanin, autres meliacins; diterpènes; caroténoïdes, sucres réducteurs et huile fixes ont présents. Tests d'identité et de pureté Teneur en humidité: pas plus de 30. Cendretotale: pas plus de 11,6 Cendre insolubledans l'acide-: Pas plus de 1,2 cendres solubles dans l eau: pas moins de 1,8 Substances extractibles par l'eau: Pas moins de 16 Substances extractibles par l'alcool (70): Pas moins de 22 Ratio de palissade: 4.5 - 06.20 à 07.08 (présent uniquement sur la surface supérieure) Indice stomatique: 5,0 à 12,8 (surface inférieure) Nombre de stomates: 300-333 à 500 Nombre de Veine-îlot: 2,5 à 3,0 Nombre deveinules de terminaison: 26,0 à 28,0 (Elujoba et Olawode, 2004) Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4253,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 253)",
    "text": "Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de trois tâches distinctes avec valeurs deR f de 0,45 (gris foncé), 0,33 (rose) et 0,29 (vert). Chromatogramme Macroscopie Les feuilles composées sont paripennées et alternativesdans leur disposition ; sur chaque feuille, il peut y avoir jusqu'à 5- 8 paires de folioles attachées au rachis par un petit pétiole ; les rameaux sont ovales -lancéolés à falciformes lancéolées dans la forme, asymétriques à la base, avec un sommet long acuminé, grossièrement dentelés sur les bords, parfois",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 918,
    "source": "PDF_chunked"
  },
  {
    "id": 4254,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 254)",
    "text": "les rameaux sont ovales -lancéolés à falciformes lancéolées dans la forme, asymétriques à la base, avec un sommet long acuminé, grossièrement dentelés sur les bords, parfois lobés, avec un sommet acuminé et vert brillant (surface supérieure) jusqu'à environ 11 cm de long sur 3cm de large, glabres, avec une nervure médiane entière; les fruits sont ellipsoïdes, drupacés avec 1-graine, jaunes, glabrede 1,2 à 2 cm de long; son goût est légèrement amer avec",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 456,
    "source": "PDF_chunked"
  },
  {
    "id": 4255,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 255)",
    "text": "OOAS Page 48 Azadirachta indica WAHP une odeur alliacée(Pharmacopée africaine, 1985). Microscopie Une vue d'ensemble montre des stomates anomocytiquesprésents sur l'épiderme inférieure des poils unicellulaires occasionnels. La section transversale montre des épidermes à cuticules lisses,des parois cellulaires anticlinales presque droites, des cristaux en rosette dans le mésophylle; le collenchyme interrompt le mésophylle à la fois sur les surfaces supérieure et inférieure de la région de la nervure médiane; les faisceaux vasculaires sont fortement courbés, et garantis; les vaisseaux de xylème sont lignifiés; la section transversale de la nervure de la feuille présente une structure bicollatérale, caractérisée par de masses sous -épidermiques de collenchyme sur les deux surfaces ; le xylème prend la forme d'un arc fortement incurvée, tandis que les deux surfaces ont des cuticules lisses, des cellules épidermiques à parois",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4256,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 256)",
    "text": "de collenchyme sur les deux surfaces ; le xylème prend la forme d'un arc fortement incurvée, tandis que les deux surfaces ont des cuticules lisses, des cellules épidermiques à parois pratiquement droites, particulièrement ceux de l'épiderme supérieur; les stomates anomocytiques sont présents sur l'épiderme inférieur tout en étant absents sur l'épiderme supérieur; la feuille ne contient pas d'amidon ou de cristaux d'oxalate de calcium (Ekejiuba, 1984). Matériel végétal en poudre Cellules épidermiques à parois droites, lamelle de pièces montrant des stomates anomocytiques, des cellules collenchymateuses, des vaisseaux de xylème, des pièces de lamelle montrant des stomates anomocytiques; des parois droitesde cellules épidermiques; des éléments vasculaires lignifiés présents dans les veines et veinules, des cristaux enrosette, une absence de granules d'amidon; avec un goût légèrement amer; une couleur brun- verdâtre et une odeur alliacée.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4257,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 257)",
    "text": "veines et veinules, des cristaux enrosette, une absence de granules d'amidon; avec un goût légèrement amer; une couleur brun- verdâtre et une odeur alliacée. Actions thérapeutiques Antiémétique, antiappétissant (insecticide), antifongique, anti -inflammatoire, antipaludéen, antiseptique (en savons médicamenteux), antiprurigineux; antipyrétique, antiviral (systémique), anxiolytique, dépuratif, emménagogue, vermifuge, galactogogue, hypoglycémique, stimulant immunitaire (GHP, 1992). Indications thérapeutiques Troubles sanguins, furoncles, constipation, dermatite, diabètes sucrés, diarrhée, dysenterie, eczéma, fièvre, hépatite, hyperacidité, hypertension, helminthiases intestinales, jaunisse, lumbago, paludisme, pharyngite, prurit; psoriasis, teigne, gale, ulcère; blessures (Dennis, 2002; Mshana et al, 2000; GHP, 1992). Données de sécurité Les études (300- 3000 mgkg) chez le rat ont montré que la DL 50 de l'extrait aqueux de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4258,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 258)",
    "text": "(Dennis, 2002; Mshana et al, 2000; GHP, 1992). Données de sécurité Les études (300- 3000 mgkg) chez le rat ont montré que la DL 50 de l'extrait aqueux de la feuille d'Azardirachta indica (p.o) était supérieur à 3000 mgkg et il n'y avait aucune manifestation de signes cliniques de toxicité au cours de la période de l'étude de toxicité aiguë. Dans une étude subaiguë de 14 jours, des changements du rapport organepoids corporel (doses 100 mgkg) et certains paramètres hématologiques à une dose de 3000 mgkg ont été observés. L'administration de l'extrait aqueux à des rats (doses 100 mg) a entraîné une augmentation des niveaux de trans aminases hépatiques (ALT, AST et GGT, ALP) et la réduction de l'albumine sérique. Les paramètres de la fonction rénale ont été également touchés. Précautions d'emploi Etre prudent dans l'administration de l'extrait aqueux chez les maladesdu foie et et du rein. Les extraits de Neem nedevraient pas être prisà",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4259,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 259)",
    "text": "été également touchés. Précautions d'emploi Etre prudent dans l'administration de l'extrait aqueux chez les maladesdu foie et et du rein. Les extraits de Neem nedevraient pas être prisà fortes dosessur une longue période; les limonoïdes montrent une très faible toxicité, en particulier dans l'administration par voie orale. Les effets toxiques de la feuille de neem ont été observés sur des animaux de pâturage. Effets indésirables Aucun effet n'a été signalé et aucun prévu, si elle est prise à des doses thérapeutiques. Contre-indications Maladie rénale connueetou hépatique, hypoglycémie, personnes âgées et enfants, grossesse et allaitement. Dosage et forme galénique Décoction: 30 g de feuilles séchées dans 900 ml d'eau ; laisser bouillir jusqu'à réduction à 600 ml; prendre 1 tasse de thé trois fois par jour Teinture : 1:5 dans de l'alcool de 45, 5 ml trois fois par jour Extrait liquide 1:2 dans l'alcool de 45, 2,5 ml trois fois par jour",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4260,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 260)",
    "text": "prendre 1 tasse de thé trois fois par jour Teinture : 1:5 dans de l'alcool de 45, 5 ml trois fois par jour Extrait liquide 1:2 dans l'alcool de 45, 2,5 ml trois fois par jour Conservation A conserver dans un endroit frais et sec. Références African Pharmacopoeia Vol. 1(1985). Ed. 1, published by the Organisation of African Unity's Scientific Technical Research Commiss ion, Lagos. Nigeria pp 30-31.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 400,
    "source": "PDF_chunked"
  },
  {
    "id": 4261,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 261)",
    "text": "OOAS Page 49 Azadirachta indica WAHP Aladesanmi, A.J., Awe, S.O., Adesanya, S.A., Bray, D.H. (1988). Antimalarial activity of some Nigerian medicinal plants. In: Adesina, S.K. (Ed) Drug Production from natural products. Proceedings of the 7 th International Symposium of DRPU. Medex Publications, Lagos, Nigeria. Ansari, K.U., Kasturi, N., Tewarson, S.L., Singh, S., Pandey, R.C. (1997). An experimental and clinical evaluation of immuno- modulating potential of Azadirachta indica (Neem) extract. Indian Journal of Cli nical Pharmacology and Therapeutics. 8:82-84. Bandyopadhyay, U., Biswas, K., Chatterjee, R., Bandyopadhyay, D. et al ., (2002). Gastroprotective effect of Neem ( Azadirachta indica) bark extract: possible involvement of H K-ATPase inhibition and scavengi ng of hydroxyl radical. Life Science 71: 2845-2865. Bhanwra, S., Singh, J., Khosla, P. (2000). Indian Effect of Azadirachta indica. (Neem) leaf",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 918,
    "source": "PDF_chunked"
  },
  {
    "id": 4262,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 262)",
    "text": "H K-ATPase inhibition and scavengi ng of hydroxyl radical. Life Science 71: 2845-2865. Bhanwra, S., Singh, J., Khosla, P. (2000). Indian Effect of Azadirachta indica. (Neem) leaf aqueous extract on paracetamol -induced liver damage in rats. Journal of Physiology and Pharmacology 44(1):64-68. Chattopadhyay, R.R. (1998). Possible biochemical mode of anti -inflammatory action of Azadirachta indica A. Juss in rats. Indian Journal Experimental Biology 36:418-420. Chattopadhyay, R.R. (1996). Possible mechanism of antihyperglycaemic effect of Azadirachta indica leaf extract. Part IV. General Pharmacology 27:431-434. Chattopadhyay, R.R. (1997). Effect of Azadirachta indica hydroalcoholic leaf extract on the cardiovascular system. General Pharmacology 28:449-451. Dennis, F. (2002) (Ed). Manual for the propagation of medicinal plants in Ghana. Darwin Initiative for the Survival of Species. Dua, V.K., Nagpal, B.N. and Sharma, V.P.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4263,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 263)",
    "text": "Dennis, F. (2002) (Ed). Manual for the propagation of medicinal plants in Ghana. Darwin Initiative for the Survival of Species. Dua, V.K., Nagpal, B.N. and Sharma, V.P. (1995). Repellent action of neem cream against mosquitoes. Indian Journal of Malariology 32:47- 53. Dorababu, M., Prabha, T., Priyambada, S., Agrawal, V.K. et al., (2004). Effect of Bacopa monniera and Azadirachta indica on gastric ulceration and healing in experiment NIDDM rats. Indian Journal of Experimental Biology 42:389- 393. Ekanem, J. (1978). Dongo Yaro. Does it work? Nigerian Medical Journal 8(1):8. Ekejiuba, E.C. (1984). Establishment of some Pharmacopoeial Standards for Sel ected Nigerian Medicinal Plants. M. Phil. (Pharmacognosy) Thesis, University of Ife (now Obafemi Awolowo University), Ile-Ife. Nigeria. Elujoba, A.A., Olawode, E.O. (2004). Technical report of the commissioned chromatographic fingerprint analysis on Azadirachta indica leaf.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4264,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 264)",
    "text": "University), Ile-Ife. Nigeria. Elujoba, A.A., Olawode, E.O. (2004). Technical report of the commissioned chromatographic fingerprint analysis on Azadirachta indica leaf. Submitted to the World Health Organization, Nigeria. Garg, G.P., Nigam, S.K., Ogle, C.W. (1993). The gastric antiulcer effects of the leaves of the neem tree. Planta Medica 59(3):215-217. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana. González-Garza, M.T., Codinach, M., Alcaraz, C., Moreno- Cuevas, J. et al., (2007). Effect of Azadirachta indica leaf methanol extracts on stem cell reproduction. Fitoterapia 78:235-237. Haque, E., Baral, R. (2006). Neem ( Azadirachta indica) leaf preparation induces prophylactic growth inhibition of murine Ehrlich carcinoma in Swiss and C57BL6 mice by activation of NK cells and NK -T cells. Immunobiology 211:721- 731. Hördegen, P., Cabaret, J., Hertzberg, H., Langhans, W. et al., (2006). In vitro screening of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4265,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 265)",
    "text": "Swiss and C57BL6 mice by activation of NK cells and NK -T cells. Immunobiology 211:721- 731. Hördegen, P., Cabaret, J., Hertzberg, H., Langhans, W. et al., (2006). In vitro screening of six anthelmintic plant products against larval Haemonchus contortus with a modified methyl - thiazolyl-tetrazolium reduction assay. Journal of Ethnopharmacology 108:85-89. Iwu, M.M., Obidoa, O., Anazodo, M. (1986). The antimalarial activity of Azadirachta indica - mode of action. Pharmacy World 3(3):16-20. Jaiswal, A.K., Bhattacharya, S.K., Acharya, S.B. (1994). Anxi olytic activity of Azadirachta indica leaf extract in rats. Indian Journal of Experimental Biology 32: 489-491. Joshi, S.N., Katti, U., Godbole, S., Bharucha, K. et al., (2005). Phase I safety study of Praneem polyherbal vaginal tablet use among HIV -",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 807,
    "source": "PDF_chunked"
  },
  {
    "id": 4266,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 266)",
    "text": "OOAS Page 50 Azadirachta indica WAHP uninfected women in Pune, India. Transactions of the Royal Society of Tropical Medicine and Hygiene 99:769-774. Khalid, S.A., Duddeck, H. (1989). Isolation and Characterisation of an antimalarial agent of the neem tree Azadirachta indica. Journal of Natural Products , 52(5):922-927. Khanna, N., Goswani, M., Sen, P., Ray, A. (1995). Antinociceptive action of Azadirachta indica. Indian Journal of Experimental Biology 33:848-850. Khosla, P., Bhanwra, S., Singh, J., Seth, S. et al., (2000). A study of hypoglycaem ic effects of Azadirachta indica (Neem) in normal and alloxan diabetic rabbits. Indian Journal of Physiology and Pharmacology 44(1):69-74. Koul, O., Isman, M. B., Kethar, C. M. (1990). Properties and Uses of Neem, Azadirachta indica. Canadian Journal of Botany 68:1-11. Kumar, S., Suresh, P.K., Vijayababu, M.R., Arunkumar, A. et al., (2006). Anticancer effects of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 916,
    "source": "PDF_chunked"
  },
  {
    "id": 4267,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 267)",
    "text": "Properties and Uses of Neem, Azadirachta indica. Canadian Journal of Botany 68:1-11. Kumar, S., Suresh, P.K., Vijayababu, M.R., Arunkumar, A. et al., (2006). Anticancer effects of ethanolic neem leaf extract on prostate cancer cell line (PC -3). Journal of Ethnopharmacology 105: 246-250. Mitchell, M.J., Smith, S.L., Johns on, S., Morgan, E.D. (1997). Effects of the neem tree compounds azadirachtin, salannin, nimbin, and 6- desacetylnimbin on ecdysone 20- monooxygenase activity. Archives of Insect Biochemistry and Physiology 35(1-2):199-209. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Nagpal, B.N., Srivastana, A., Sharma, V.P. (1995). Control of mosquito breeding using wood",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 4268,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 268)",
    "text": "African UnityScientific, technical and research committee. Nagpal, B.N., Srivastana, A., Sharma, V.P. (1995). Control of mosquito breeding using wood scrapings treated with neem oil. Indian Journal of Malariology 32: 64-69. Nathan, S.S., Kalaivani, K., Murugan, K. (2005). Effects of neem limonoids on the malaria vector Anopheles stephensi Liston (Diptera: Culicidae). Acta Tropica 96:47 Pai, M.R., Acharya, L.D., Udupa, N. (2004). Evaluation of antiplaque activity of Azadirachta indica leaf extract gel -a 6 -week clinical study. Journal of Ethnopharmacology 90: 99-103. Peer, P.A., Trivedi, P.C., Nigade, P.B., Ghaisas, M.M. et al., (2007). Cardioprotective effect of Azadirachta indica A. Juss. on isoprenaline induced myocardial infarction in rats. International Journal of Cardiology; doi Ray, A., Banerjee, B.D., Sen, P. (1996). Modulation of humoral and cell-mediated immune responses by Azadirachta indica (Neem) in",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4269,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 269)",
    "text": "International Journal of Cardiology; doi Ray, A., Banerjee, B.D., Sen, P. (1996). Modulation of humoral and cell-mediated immune responses by Azadirachta indica (Neem) in mice. Indian Journal of Experimental Biology 34:698-701. Rochanankij, S., Tebttearanonth, Y., Yenjai, C., Yuthavong, Y. (1985). Journal of Tropical Medicine and S.E. Asian Public Health 16:66. Schmutterer, H. (1990) Properties and Potential of Natural Pesticides from the Neem Tree, Azadirachta indica. Ann. Rev. Entomol. 35:271- 97. Singh, K., Singh, A., Singh, D.K. (1996). Molluscicidal activity of neem ( Azadirachta indica A. Juss). Journal of Ethnopharmacology 52: 35- 40. Thakurta, P., Bhowmik, P., Mukherjee, S., Hajra, T.K. et al., (2007). Antibacterial, antisecretory and antihemorrhagic activity of Azadirachta indica used to treat cholera and diarrhoea in India. Journal of Ethnopharmacology 111:607- 612. Tanzubil, P. B., McCaffery, A. R. (1990). Effects",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4270,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 270)",
    "text": "and antihemorrhagic activity of Azadirachta indica used to treat cholera and diarrhoea in India. Journal of Ethnopharmacology 111:607- 612. Tanzubil, P. B., McCaffery, A. R. (1990). Effects of Azadirachtin on Reproduction in the African Armyworm (Spodoptera exempta). Entomologia Experimentalis et Applicata 57:115-121. Trewari, D. N. (1992). Monograph on Neem (Azadirachta indica A. Juss), 279. Int. Book Distributors: Dehra Dun, India. Venugopal, P.V., Venugopal, T.V. (1994). Antidermatophytic activity of neem ( Azadirachta indica) leaves in vitro . Indian Journal of Pharmacology 26:141-143. Yanpallewar, S., Raib, S., Kumar, M., Chauhan, S. et al., (2005). Neuroprotective effect of Azadirachta indica on cerebral post -ischemic",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 734,
    "source": "PDF_chunked"
  },
  {
    "id": 4271,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 271)",
    "text": "OOAS Page 51 Azadirachta indica WAHP reperfusion and hypoperfusion in rats. Life Sciences 76:1325-1338.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 103,
    "source": "PDF_chunked"
  },
  {
    "id": 4272,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 272)",
    "text": "OOAS Page 52 Balanites aegyptiaca WAHP NomBotanique Balanites aegyptiaca (L.) Del. Famille Zygophyllaceae Synonyme Ximenia aegyptiaca L., Agialida senegalensis van Tiegh., Agialida barteri van Tiegh., Balanites ziziphoides mildbr Schlechter Noms communs Soap berry tree, Thorn tree (anglais); Datte du désert (Français) Noms vernaculaires Burkina Faso : Mooré kyéguelga, Dioula Zèkènè, Fulfulde Tannê;yoléteki Ghana: Dagaare Gongo Mali: Bambara Zèkènè; Dogon Mono, Noms Tale Sénégal: Wolof Sump; Serer Model, lol; Arabe Hadjlidj Togo: Gourmantche Konkonlangpag; Moba Okopakbo Description de la plante Arbre épineux, à feuilles caduques, allant jusqu'à 8 mètres de haut, avecramificationimportante et complexe; le tronc est bien défini, droit ou légèrement tortueux avec une écorce brun- grisâtre, crevassée longitudinalement; les branches d'épines droites de 2- 7 cm sont nombreuses; les jeunes branches secondaires",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 915,
    "source": "PDF_chunked"
  },
  {
    "id": 4273,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 273)",
    "text": "légèrement tortueux avec une écorce brun- grisâtre, crevassée longitudinalement; les branches d'épines droites de 2- 7 cm sont nombreuses; les jeunes branches secondaires sont vertes, pubescentes et aussi épineuses; l'inflorescence est indéterminée et comporte 5 à 12 fleurs disposées sur un pédoncule pubescente de longueur variable; le fruit est une drupe charnue de 1 à 2,5 cm de long, de forme ovale-oblongue, avec une surface soyeuse- pubescente et une couleur blanche- verdâtre, à l'intérieur de laquelle il n'y a qu'une seule graine; il fleurit de Mars à Mai et fructifie de Juillet à Octobre. Numéro du specimen de l'herbier Mali: 2015 Togo:TOGO09436 Habitat et répartition géographique Le palmier dattier du désert se situe principalement en Afrique tropicale, particulièrement au Sahara central et occidental, ainsi qu'en Asie extrême- Oriental. Il est arrivé de la Méditerranée via l'Egypte et pousse bien sur les sols sablonneux et sur tous les types de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 4274,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 274)",
    "text": "particulièrement au Sahara central et occidental, ainsi qu'en Asie extrême- Oriental. Il est arrivé de la Méditerranée via l'Egypte et pousse bien sur les sols sablonneux et sur tous les types de géomorphologie: dépressions, fonds des vallées, plaines, et même montagnes. Parties utilisées de la plante Fruit Autres parties utilisées Ecorce du tronc Caractéristiques botaniques Les balanites se composent des fruits de Balanites aegyptiaca (L.) Del (Zygophyllaceae). Utilisations ethnomédicales Dans le Sahel, les feuilles et les fruits sont utilisés comme denrées alimentaires pendant la saison sèche et pendant les périodes de vaches maigres. Les feuilles sont séchées et transformées en poudre pour être utilisées dans la préparation de la sauce (Cook et al , 1998; Lockett et al, 2000). De son amande est extraite l'huile de table (Kamel et Koskinen, 1995). L'extrait de fruit est ajouté à la bouillie et mangé par les mères allaitantes pour stimuler la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4275,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 275)",
    "text": "Lockett et al, 2000). De son amande est extraite l'huile de table (Kamel et Koskinen, 1995). L'extrait de fruit est ajouté à la bouillie et mangé par les mères allaitantes pour stimuler la production de lait, et les noix utilisées pour traiter la douleur et le malaise liésà la motilité et aux ballonnements intestinaux excessifs( Lockett et al., 2000). B. aegyptiaca est l'une des espèces fourragères les plus appétentes pour les animaux domestiques de pâturage (Toutain, 1980; Savadogo, 2004). L'écorce de racine est écrasée, ajoutée à l'eau, imbibée et bu pour son effet purgatif (Koch et al., 2005). Les graines sont utilisées pour traiter les cancers et l'hydrocèle (Abubakar et al., 2007). La tige et les écorces de racines sont réduites en poudre et mélangées à d'autres espèces, puis bouillies avec de l'eau pour être utilisées contre la candidose buccale (Runyoro et al., 2006a). L'écorce du tronc est macérée dans de l'eau chaude, et l'extrait qui en",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 960,
    "source": "PDF_chunked"
  },
  {
    "id": 4276,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 276)",
    "text": "d'autres espèces, puis bouillies avec de l'eau pour être utilisées contre la candidose buccale (Runyoro et al., 2006a). L'écorce du tronc est macérée dans de l'eau chaude, et l'extrait qui en résulte est consommé pour l'asthme, la toux sèche et les infections des voies respiratoires (Maregesi et al., 2007). Certaines préparations",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 331,
    "source": "PDF_chunked"
  },
  {
    "id": 4277,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 277)",
    "text": "OOAS Page 53 Balanites aegyptiaca WAHP médicinales sont fabriquées avec des huiles essentielles extraites desparties de B. aegyptiaca (Said et al., 2002). Les feuilles de la plante et les jeunes branches sont macérées et appliquées à l'état frais comme cataplasme sur les plaies (Said et al., 2002). La racinede la plante en poudre est dissoute dans de l'eau, et ensuite utilisée en bain pour traiter la rougeole. Il est également pris comme thé contre les fibromes utérins (Tabuti et al., 2003), ou transformé en pâte et appliqué aux saignements des gencives ou inséré dans la cavité de la dent douloureuse trois fois par jour jusqu'à guerrison (Tapsoba et Deschamps, 2005). Activités biologiques et pharmacologiques La plante entière est utilisée comme antiparasitique, antihelminthique, antipyrétique, poison du poisson, abortif et molluscicide (Iwu, 1993). Une dose de 20 mgkg de l'extrait aqueux du mésocarpe de fruit a été aussi bien efficace",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4278,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 278)",
    "text": "antiparasitique, antihelminthique, antipyrétique, poison du poisson, abortif et molluscicide (Iwu, 1993). Une dose de 20 mgkg de l'extrait aqueux du mésocarpe de fruit a été aussi bien efficace en tant que antihelminthique sur le ver Fasciola gigantica qu'une dose d'albendazole de 9gkg (Koko et al., 2000) et 200 mgkg du même extrait sur les souris infectées par le Schistosoma mansoni (Koko et al ., 2005). L'extrait du mésocarpe de fruit a également montré une activité antidiabétique significative sur les souris rendues diabétiques par la streptozotocine. L'effet a été attribué à des saponines stéroïdiens (Kamel et al., 1991).Le mélange de saponines isolés de graines, de balanitines 6 et 7, a une activité anti-cancéreuse sur les cellules humaines (Gnoula et al., 2008). Les feuilles fraîches, les écorces s échées et les racines se sont avéréés actives contre Bacillus subtilis, Penicillium crustosum, Saccharomyces cerevisiae,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4279,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 279)",
    "text": "(Gnoula et al., 2008). Les feuilles fraîches, les écorces s échées et les racines se sont avéréés actives contre Bacillus subtilis, Penicillium crustosum, Saccharomyces cerevisiae, Epilachna varivestis, Biomphalaria glabrata et Lymnaea natalensis (Taniguchi et al, 1978;Liu et Nakanishi, 1982) et la fraction de sapo nine du mésocarpe de la plante a une activité faible contre Aedes aegypti, Aspergillus niger et Candida albicans (Saeed et al., 1995). Le fruit et l'écorce de racine ont des fortes activités sur Candida albicans (Nanyingi et al , 2008;. Runyoro, et al , 2006b; Saeed et al , 1995). L'extrait de fruits a également des propriétés immunomodulatrices in vitro (Koko et al., 2008). Données cliniques Aucune information disponible Constituants chimiques La plante contient des protéines, des glucides (Nour et al , 1986), des saponines (balanitine- 3, 6-methyldiosgénine, balanitoside (Kamel, 1998; Hosny et al., 1992), glycosides de prégnane",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4280,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 280)",
    "text": "La plante contient des protéines, des glucides (Nour et al , 1986), des saponines (balanitine- 3, 6-methyldiosgénine, balanitoside (Kamel, 1998; Hosny et al., 1992), glycosides de prégnane (Kamel et Koskinen, 1995). Tests d'identité et de pureté Teneur en humidité: pas plus de 8,45 Cendre totale: 12,21 Substances extractibles par l'eau: pas plus de 16,30 Substances extractibles par l'éthanol (70): pas moins de 14,89 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acideacétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendan t 5-10 mn. Présence de trois taches distinctes avec valeurs Rf de 0,40 (cendres), 0,31 (rose) et 0. 027 (rose).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4281,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 281)",
    "text": "sulfurique concentré, puis chauffé à100- 110C pendan t 5-10 mn. Présence de trois taches distinctes avec valeurs Rf de 0,40 (cendres), 0,31 (rose) et 0. 027 (rose). Macroscopie On observe des parties plates ou creusées de l'écorce de tige; une écorce externe de couleur gris-jaunâtre avec des fissures verticales, lenticellées; une écorce intérieure avec des striations verticales fines; un cuir épais; une cassure courte; une odeur particulière; un goût amer (GHP, 2007).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 472,
    "source": "PDF_chunked"
  },
  {
    "id": 4282,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 282)",
    "text": "OOAS Page 54 Balanites aegyptiaca WAHP Chromatogramme Microscopie Les vues en coupe (coupes transversales et longitudinales) montrent une paroi mince de liège lignifiée: des cellules ; les cellules extérieures montrent des exfoliations; trois couches minces de cellules cambiales séparent la couche de liège du cortex; le cortex se compose de groupes isolés de nombreux scl érites à parois lignifiées épaissies et une petitelumière, deux types de cellules scléréides -isodiamétriques et des cellules étirées; de grands cristaux en rosette se produisent dans le parenchyme cortical ; le tissu du phloème se compose de parenchyme et delarges rayons médullaires avec des cristaux prismatiques d'oxalate de calcium, des fibres lignifiés de phloème qui se produisent dans des groupes isolés de parenchyme de phloème (GHP , 2007). Matériel végétal en poudre Il est caractérisé par une couleur chamoise; une odeur sternutatoire, un goût amer; de nombreux",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4283,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 283)",
    "text": "groupes isolés de parenchyme de phloème (GHP , 2007). Matériel végétal en poudre Il est caractérisé par une couleur chamoise; une odeur sternutatoire, un goût amer; de nombreux sclérides isodiamétriques et étirés, lignifiés, longs fibres à la fois lignifiés et non lignifiés, peu de cellules de liège, des macles et cristaux prismatiques d'oxalate de calcium, des grains d'amidon (GHP, 2007). Actions thérapeutiques Antidiabétique (Kamel et al., 1991), antihelminthique (Koko et al 2000; Koko et al , 2005), anticancéreux (Gnoula et al., 2008); antipyrétique, molluscicide (Iwu, 1993), antibactérien (Taniguchi et al., 1978; Li u et Nakanishi, 1982), antifongique (Saeed et al , 1995; Speroni et al, 2004); anti -inflammatoire, antimicrobien (Speroni et al., 2004; Runyoro et al, 2006b; Nanying et al , 2008) et immunmodulatrice (Koko et al., 2008). Indications thérapeutiques Constipation, diabète, schistosomiase. Données de sécurité",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4284,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 284)",
    "text": "al, 2006b; Nanying et al , 2008) et immunmodulatrice (Koko et al., 2008). Indications thérapeutiques Constipation, diabète, schistosomiase. Données de sécurité Les études chez le rat (300- 3000 mg kg) ont montré que la DL 50 de l'extrait aqueux de l'écorce de tige était 3000 mgkg. Mais une augmentation de l'AST et une diminution de l'ALT ont été détectées chez l e rat. Cependant, cecine peut pas indiquer nécessairement l'hépatotoxicité pendant que l'augmentation des AST est associée à des dommages d'autres tissus dans le corps en dehors du foie. Aucun effet indésirableserieux sur le foie et les fonctions rénales n'aété observé dans les sections HE. On a observé l'augmentation du nombre de globules blancs à des doses 100 mgkg et de la SMI à des doses 3000 mgkg. L'utilisation de l'extrait aqueux de l'écorce de tige de la plante dans la dose recommandée peut ê tre sans problème de sécurité grave. Précautions d'emploi",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4285,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 285)",
    "text": "des doses 3000 mgkg. L'utilisation de l'extrait aqueux de l'écorce de tige de la plante dans la dose recommandée peut ê tre sans problème de sécurité grave. Précautions d'emploi Faire un suivi régulier de la glycémie. Effets indésirables Il peut provoquer une hypoglycémie. Contre-indications Hypoglycémie Dosage et forme galénique Décoction: 30-50 g par litre d'eau; prendre 3-5 tasses à thé par jour Teinture: 1:5 dans de l'éthanol à 50; 5 ml trois fois par jour Conservation A conserver dans un endroit frais et sec. Références Abubakar, M.S., Musa, A.M., Ahmede, A., Hussaini, I.M. (2007). The perception and practice of traditional medicine in the treatment of cancers and inflammations by the Hausa and Fulani tribes of Northern Nigeria Journal of Ethnopharmacology 111:625629. Cook, J. A., Vanderjagt, D.J., Pastuszyn, A., Mounkaïla, G. et al . (1998). Nutrient content of two indigenous Plant foods of the werstern Sahel:",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4286,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 286)",
    "text": "Ethnopharmacology 111:625629. Cook, J. A., Vanderjagt, D.J., Pastuszyn, A., Mounkaïla, G. et al . (1998). Nutrient content of two indigenous Plant foods of the werstern Sahel: Balanites aegyptiaca and Maerua crassifolia. Journal of Food Composition and Analysis 11:221-230. Ghana Herbal Pharmacopoeia (2007). STEPRI, Accra, Ghana. Gnoula, C., Mégalizzi, V., De Nève, N., Sauvage, S., Ribaucour, F. et al. (2008). Balanitin-6 and -7: diosgenyl saponins isolated from Balanites",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 475,
    "source": "PDF_chunked"
  },
  {
    "id": 4287,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 287)",
    "text": "OOAS Page 55 Balanites aegyptiaca WAHP aegyptiaca Del. display significant anti- tumor activity in vitro and in vivo . International Journal of Oncology 32(1):5-15. Hosny, M ., Khalifa, T ., Caliş, I ., Wright, A.D ., Sticher, O . (1992). Balanitoside, a furostanol glycoside, and 6- methyldiosgenin from Balanites aegyptiaca. Phytochemistry, 31(10):3565-3569. Iwu, M.M., (1993). Handbook of African Medicinal Plants. CRC Press, Boca Raton, Florida, USA. Kamel, M.S . (1998). A Furostanol saponin from fruits of Balanites aegyptiaca. Phytochemistry 148(4):755-757. Kamel, M.S ., Koskinen, A . (1995). Pregnane glycosides from fruits of Balanites aegyptiaca. Phytochemistry 40(6):1773-1775. Kamel, M.S ., Ohtani, K ., Kurokawa, T ., Assaf, M.H., el-Shanawany, M.A . et al. (1991). Studies on Balanites aegyptiaca fruits, an antidiabetic Egyptian folk medicine. Chemical and Pharmaceutical Bulletin (Tokyo), 39(5):1229-33.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 920,
    "source": "PDF_chunked"
  },
  {
    "id": 4288,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 288)",
    "text": "M.H., el-Shanawany, M.A . et al. (1991). Studies on Balanites aegyptiaca fruits, an antidiabetic Egyptian folk medicine. Chemical and Pharmaceutical Bulletin (Tokyo), 39(5):1229-33. Koch, A., Tamez, P., Pezzuto, J., Soejarto, D. (2005). Evaluation of plants used for antimalarial treatment by the Maasai of Kenya. Journal of Ethnopharmacology 101:9599. Koko, W.S., Abdalla, H.S., Galal, M., Khalid, H.S. (2005). Evaluation of oral ther apy on Mansonial Schistosomiasis using single dose of Balanites aegyptiaca fruits and praziquantel Fitoterapia, 76(1):30-34. Koko, W.S ., Galal, M ., Khalid, H.S .(2000). Fasciolicidal efficacy of Albizia anthelmintica and Balanites aegyptiaca compared with albendazole. Journal of Ethnopharmacology 71(1-2):247-252. Koko, W.S., Ahmed Mesaik, M., Yousaf, S., Galal, M., Choudhary, M.I. (2008). In vitro immunomodulating properties of selected Sudanese medicinal plants. Journal of Ethnopharmacology 118:2634.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4289,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 289)",
    "text": "Galal, M., Choudhary, M.I. (2008). In vitro immunomodulating properties of selected Sudanese medicinal plants. Journal of Ethnopharmacology 118:2634. Liu, W., Nakanishi, K., (1982). The structures of balanitins, potent molluscicides isolated from Balanites aegyptiaca. Tetrahedron 38:513519. Lockett, C.T., Calvert, C.C. and Grivetti, L.E. (2000). Energy and micronutrient composition of dietary and medicinal wild plants consumed during drought. Study of rural Fulani, Northeastern Nigeria. International Journal of Food Science and Nutrition 51:195-208. Maregesi, S.M., Ngassapa, O.D., Pieters, L., Vlietinck, A.J. (2007). Ethnopharmacological survey of the Bunda district, Tanzania: Plants used to treat infectious diseases. Journal of Ethnopharmacology 113:457470. Nanyingi, O.M., Mbaria, M.J., Lanyasunya, L.A., Wagate, G.C., Koros, B.K., et al . (2008). Ethnpharmacological survey of Samburu district, Kenya. Journal of Ethnobiology and",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4290,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 290)",
    "text": "Nanyingi, O.M., Mbaria, M.J., Lanyasunya, L.A., Wagate, G.C., Koros, B.K., et al . (2008). Ethnpharmacological survey of Samburu district, Kenya. Journal of Ethnobiology and Ethnomedicine 4:14. Nour, A.A.A.M., Ahmed, A.H.R., Abdel -Gayoum, A.G.A.A. ( 1986). chemical study of Balanites aegyptiaca L. (Lalob) fruits grown in Sudan. Journal of Science of Food and Agriculture 36 :12541258. Runyoro, D.K.B., Ngassapa, O.D., Matee, M.I.N., Joseph C.C., Moshi, M.J. (2006a). Medicinal plants used by Tanzanian traditional healers in the management of Candida infections. Journal of Ethnopharmacology 106:158165. Runyoro, D.K.B., Matee, M.I.N., Ngassapa, O.D., Joseph, C.C., Mbwambo, Z.H. (2006b). Screening of Tanzanian medicinal plants for anti - Candida activity. BMC Complementary and Alternative Medicine 6: 11. Said, O., Khalil, K., Fulder, S., Azaizeh, H. (2002). Ethnopharmacological survey of medicinal herbs in Israel, the Golan Heights and",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4291,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 291)",
    "text": "Alternative Medicine 6: 11. Said, O., Khalil, K., Fulder, S., Azaizeh, H. (2002). Ethnopharmacological survey of medicinal herbs in Israel, the Golan Heights and the West Bank region. Journal of Ethnopharmacology 83: 251-265. Savadogo, S. (2004). Contribution au suivi écologique des ressources fourragères dans la zone de chasse de Pama Nord et le ranch de gibier de Singou. Mémoire d'ingénieur, Université Polytechnique de Bobo- Dioulasso, Institut du Développement Rural, Burkina Faso. 89 p. Saeed, A., Ibrahim, N., Bashand, Y.S., El - Gengaihi, S. (1995). Saponins of Balanites aegyptiaca Del fruits and biological evaluation. Bulletin of Faculty of Pharmacy, Cairo Univer sity 33:105-109. Speroni, E., Cervellati, R., Innocenti, G., Costa, S., Guerra, M., Acqua, S., Govoni, P. (2004). Anti-inflammatory, anti -nociceptive and antioxidant activities of Balanites aegyptiaca (L.)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 883,
    "source": "PDF_chunked"
  },
  {
    "id": 4292,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 292)",
    "text": "OOAS Page 56 Balanites aegyptiaca WAHP Delile. Journal of Ethnopharmacology 98:117 125. Tabuti, J.R.S., Lye, K.A., Dhillion, S.S. (2003). Traditional herbal drugs of Bulamogi, Uganda: plants, use and administration. Journal of Ethnopharmacology 88:1944. Taniguchi, M., Chapya, A., Kubo, I., Nakanishi, K. (1978). Screening of East African plants for antimicrobial activity. Chemical and Pharmaceutical Bulletin 26:29102913. Tapsoba, H., Deschamps, J.P. (2006). Use of medicinal plants for the treatment of oral diseases in Burkina Faso. Journal of Ethnopharmacology 104:6878. Toutain, B. (1980). Le rôle des ligneux pour l'élevage dans les régions soudaniennes de l'Afrique de l'Ouest. In (H N Le Houérou, Editeur.), Colloque international sur les fourrages ligneux en Afrique, état des connaissances. Addis-Abeba, Ethiopie, 8- 12 avril, CIPEA, pp. 105-110.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 857,
    "source": "PDF_chunked"
  },
  {
    "id": 4293,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 293)",
    "text": "OOAS Page 57 Bridelia ferruginea WAHP Nom Botanique Bridelia ferruginea Benth Famille Euphorbiaceae Synonyme Bridelia micrantha var. ferruginea (Benth) Müll Noms communs Bridelia Noms vernaculaires Benin: Baatonun- Bemebenku, Gbe Fo Honsukokué , Yoruba Nago Hira Burkina Faso : Mooré Ambriaka, Dioula sagoui;sagwann baboni, Fulfuldékojuteki;daafi Cote d'Ivoire: Manding Maninka Saba Sagba, Senufo Dyimini Nakurugo Ghana: Tw Opam fufuo, Ga Adamgbe Flatsho, Hausa Kisni Guinea: Fula Pulaar Dafi, Manding Maninka Baboni, Maninka Sagba Mali: Bambara Saguan, Noms Daafi, Senoufo Gnirin-o-tigue Nigéria: Yoruba Ira odan, Eepo ira; Ibo Oha, Hausa Kisni Sierra L eone: Susu Tholinyi, Kissi Sindio, Hono Bembeh Togo: Ewe Akamati, Bassar N'tchintchi, Lamba Kolu Description de la plante C'est un petit arbre ou un arbuste non-laticifère d' environ 4- 15 m de hauteur et jusqu'à 1,5 m de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 876,
    "source": "PDF_chunked"
  },
  {
    "id": 4294,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 294)",
    "text": "Togo: Ewe Akamati, Bassar N'tchintchi, Lamba Kolu Description de la plante C'est un petit arbre ou un arbuste non-laticifère d' environ 4- 15 m de hauteur et jusqu'à 1,5 m de circonférence avec des ramifications faibles, portant souvent des épines et pouv ant être réduit à la couleur pourpre ; les feuilles peuvent être de petite ou moyenne taille, simples, pétiolées à stipules, ovales -lancéolées, tomenteuses, caduques, alternes ou parfois sous -alternes, en spirales ; le limbe est largement elliptique, à bor d entier avec unapex acuminé ou aigu (GHP, 1992); des cuticules oblongues ou ovales, irrégulières plus ou moins dentées, avec un épiderme supérieur pubescent d' environ 3,8 à 10,0 cm de long sur 2,5-6,4 cm de large avec des bords légèrement ondulés, peu et brusquement acuminés ; la tige est généralement de 1- 2,5 cm de long, robuste et densément poilu; ses veines sont pennatinervées, sous la forme d'un réseau",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4295,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 295)",
    "text": "bords légèrement ondulés, peu et brusquement acuminés ; la tige est généralement de 1- 2,5 cm de long, robuste et densément poilu; ses veines sont pennatinervées, sous la forme d'un réseau dense et bien en évidence, parfois légèrement poilues, et de temps en temps avec des poils qui obscurcissent la face inférieure de la feuille; l'inflorescence a de nombreuses fleurs en glomérules avec des axillaires très denses ; les fleurs mâles sont vert-jaunâtres avec un pédicelle de 1,5-2 mm de long; les fleurs femellessont subsessiles avec 2 ou 3 fronts de styles courts, ayant 0,6 cm de diamètre; les sépales jaune- verdâtres ont des pétales très petites et étroites; chaque grappe de fleurs se compose généralement de sexe masculin et féminin; avec un parfum agréable; ses fruits sont en forme de drupe, uniloculaires, oblongues ou parfois subglobuleux avec unpéricarpe vert, rouge et bleu- noir à maturité, des fruits parfois obovoïdes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4296,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 296)",
    "text": "un parfum agréable; ses fruits sont en forme de drupe, uniloculaires, oblongues ou parfois subglobuleux avec unpéricarpe vert, rouge et bleu- noir à maturité, des fruits parfois obovoïdes de 0,8 cm de long, le plus souvent ellipsoïde mesurant 0,6 cm de long. Il est très persistant sur es branches; l'ecorce de tige est grise foncée craquée, rugueuse, souvent écailleuse à barre oblique mince et rouge; les branches sont longues, parfois épineuses, minces, équipées de courtes épines acérées, des rameaux rouillés et pubescents; habituellement couverts de poil s courts, souvent de couleur rouille (Adjanahoun et al, 1991; Okunji, 1987). Numéro du specimen de l'herbier Ghana: GC 7714 Nigeria: FHI 107453 Togo: TOGO03072 Habitat et répartition géographique Il se reproduit généralement dans la savane de la Guinée et les plaines côtières de l'Afrique, notamment au Burkina Faso, en Côte d'Ivoire, au Ghana, au Nigéria et au Togo ainsi qu'en Asie et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4297,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 297)",
    "text": "Il se reproduit généralement dans la savane de la Guinée et les plaines côtières de l'Afrique, notamment au Burkina Faso, en Côte d'Ivoire, au Ghana, au Nigéria et au Togo ainsi qu'en Asie et en Australie (GHP, 1992). Parties utilisées de la plante Feuilleetécorce de tronc Autrespartiesutilisées Écorcede la racine",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 315,
    "source": "PDF_chunked"
  },
  {
    "id": 4298,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 298)",
    "text": "OOAS Page 58 Bridelia ferruginea WAHP Caractéristiques botaniques Bridelia se compose de la feuille ou de l'écorce de tige de Bridelia ferruginea Benth. (Euphorbiaceae). Utilisations ethnomédicales Infections bactériennes, diabète, arthrite, contusions, furoncles, dislocation, brûlur es, maladies pédiatriques (en particulier fièvre issue du paludisme), dysentérie, muguet (mycosique stomatite) chez les enfants, antidote pour les morsures de serpent, gonorrhée, helminthiases, paludisme, trypanosomiases, infections sexuellement transmissi bles, inflammation (Okpekon et al, 2004; Olajide et al, 2003; Irobi et al, 1994;Narayan, 1994; Iwu 1993; Hentchoya, 1991; Oliver-Bever 1960; Dalziel, 1937). Activités Biologiques et pharmacologiques Un extrait brut de la plante et la rutine pure, réduisent la glycémie à jeûn (FBS) des lapins blancs de la Nouvelle- Zélande jusqu'à 20 dans les 30 minutes suivant l'administration, atteignant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4299,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 299)",
    "text": "Un extrait brut de la plante et la rutine pure, réduisent la glycémie à jeûn (FBS) des lapins blancs de la Nouvelle- Zélande jusqu'à 20 dans les 30 minutes suivant l'administration, atteignant 35 dans un délai d'une heure et demie, et reste à ce niveau pour un maximum de 3 heures (Addae-Mensah et Munenge, 1989). Il a été observé que les extraits étaient plus éfficaces que la dose normale d'un médicament antidiabétique, la glibenclamide, (0,13 mgkg), mais ont été moins éfficaces que l'insuline. Cependant, l'extrait contenant la rutine a démontré une activité s tatistiquement similaire à celle de l'insuline, en se montrant capable d'inhiber artificiellement l'hyperglycémie aiguë induite. Une administration quotidienne du décocté de feuilles de la plante a entraîné une réduction significative de la glycémie (Iwu, 1986; Githens, 1949). Les extraits de feuilles ont montré des effets hypoglycémiants, mais ont été moins éfficaces sur le diabète causé par",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 4300,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 300)",
    "text": "réduction significative de la glycémie (Iwu, 1986; Githens, 1949). Les extraits de feuilles ont montré des effets hypoglycémiants, mais ont été moins éfficaces sur le diabète causé par l'alloxane (Githens, 1949; Iwu, 1980, 1986). Des extraits aqueux et éthanolique de la plante ont démontré des activi tés antifalciformantes (Mpiana et al, 2007). Les extraits de la plante ont montré une activité cytotoxique et cytostatique (Rashid et al., 2000). Les extraits de B. ferruginea ont montré des activités antimicrobienne, anti -VIH et antispasmodique (Cimanga et al, 1999; Akinpelu et Olorunmola, 2000; Muanza et al, 1995; Onoruvwe et al, 2001). Le biflavanol et les dérivés de l'acide quinique ont été reconnus pour inhiber le système complémentaire (Cimanga et al, 1999; Stryer, 1995). Les flavonoïdes quercétine, quercitrine et rutine ont également été repérés pour avoir des effets antiviraux contre la coxsackie, l' Herpès simplex, la rougeole, le virus parainfluenza et le",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 976,
    "source": "PDF_chunked"
  },
  {
    "id": 4301,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 301)",
    "text": "rutine ont également été repérés pour avoir des effets antiviraux contre la coxsackie, l' Herpès simplex, la rougeole, le virus parainfluenza et le virus de la polio (Addae -Mensah, 1992). Les flavonoïdes de B. ferruginea ont empêché l'oxydation de la xanthine et l'activité inhibitrice de balayage de superoxyde à des concentrations in vitro très faibles (micromolaire) (Cimanga et al , 2001; Gabor, 1986). Les extraits de feuilles d'acétate d'éthyle, d'hexane et de méthanol ont tous été reconnus éfficace contre Bacillus subtilis, Escherichia coli, Pseudomonas frutescens, Staphylococcus aureus et Streptococcus faecalis (Talla et al., 2002) tandis que les extraits aqueux et éthanoliques de l'écorce en poudre ont été reconnus avoir une activité ant ifongique contre Candida albicans , et une activité antibactérienne contre Escherichia coli, Klebsiella sp., Proteus vulgaris, P. mirabilis S. aureus, S. epidermidis, S. lactis et S.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4302,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 302)",
    "text": "activité ant ifongique contre Candida albicans , et une activité antibactérienne contre Escherichia coli, Klebsiella sp., Proteus vulgaris, P. mirabilis S. aureus, S. epidermidis, S. lactis et S. pyogenes (Irobi et al., 1994).L'extrait aqueux de l'écorce de tige a causé une inhibition significative del'œdème de la patte de rat provoqué par la carragénine, mais l'activité a diminué dans l'oedème de la patte de la souris. L'extrait a aussi supprimé la formation granulomateuse du tissu, particulièrement sur l'inflammation c hronique (Olajide et al., 1999). Les extraits aqueux de l'écorce de tige ont montré une activité anti-inflammatoire médiée par la régulation négative de TNFα (Olajide, et al, 2003). Six plantes médicinales africaines, y compris l'Azadiractha indica, B. ferruginea, Commiphora mol mol, Garcinia kola et Curcuma longaont démontré un effet antithrombotique in vivo (Olumayokun, 1999). L'effet de l'extrait de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4303,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 303)",
    "text": "compris l'Azadiractha indica, B. ferruginea, Commiphora mol mol, Garcinia kola et Curcuma longaont démontré un effet antithrombotique in vivo (Olumayokun, 1999). L'effet de l'extrait de plante sur le lipopolysaccharide (LPS) induit par un choc septique et la perméabilité vasculaire sur la partie dorsale de la peau des souris a montré que le pré- traitement avec environ 10- 80 mgkg de l'extrait inhibe le syndrome de choc septique chez des souris d'une manière dose- dépendante, une dose de 80 mgkg s est avérée aussi éfficace que 100 mgkg du médicament pentoxifylline. La même gamme de dosage de l'extrait (10-80 mgkg) a également réduit la fuite de LPS provoquée par le colorant sur la peau des souris. Les extraits éthanoliques de l'écorce de feuilles et de tige ont montré une activité neuromusculaire (Onoruvwe et al , 2001; 1994). D autres extraits de la plante ont montré une activité cytotoxique et cytostatique (Rashid et al., 2000). Données cliniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 962,
    "source": "PDF_chunked"
  },
  {
    "id": 4304,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 304)",
    "text": "neuromusculaire (Onoruvwe et al , 2001; 1994). D autres extraits de la plante ont montré une activité cytotoxique et cytostatique (Rashid et al., 2000). Données cliniques L'administration d'une décoction de feuilles à un patient féminin diabétique de 49 ans, a faittomberletaux de sucre dans le sangà jeûn de 242 mgdl à environ 120 mgdl après 12 semaines. Ce chiffre a demeuré à ce niveau pendant huit semaines (Addae- Mensah, 1992). Pendant l'administration immédiate de B.ferruginea à une femme hypertendue de 45 ans, qui avait été diagnostiqué du diabète à un",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 562,
    "source": "PDF_chunked"
  },
  {
    "id": 4305,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 305)",
    "text": "OOAS Page 59 Bridelia ferruginea WAHP examen de routine le niveau de sucre dans le sang à jeûn a été réduit de 370 mgdl à 250 mgdl après une semaine et, a continué à baisser jusqu'à ce qu'il se normalise après onze semaines. Aucun médicament n'a été prescrit pour son hyper tension, mais sa pression artérielle est passée de 18090à 14090 au cours de la période de traitement (Addae- Mensah, 1992; Ampofo, 1977). Des extraits aqueux de feuilles ont été en mesure de normaliser les niveaux de glycémie à jeûn et aidé à éliminer la glycosurie des patients atteints de diabète de la maturité (Iwu, 1993). Constituants chimiques Flavonoïdes (bridélilactone et bridélilactoside, apigénine et kaempférol, gallocatéchine- (4-O-7- épigallocatéchine, quercétine- 3 ,3- méthyléther, acide 3,5- dicaffeoylquinique, quercétine 3,7,3,4- tetramethylether, quercétine 3- O-glucoside, rutine, myricitrine, myricétine -3-O-β-glucoside, ferrugin); biflavanol (gallocatéchine- 4-O-7-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 963,
    "source": "PDF_chunked"
  },
  {
    "id": 4306,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 306)",
    "text": "acide 3,5- dicaffeoylquinique, quercétine 3,7,3,4- tetramethylether, quercétine 3- O-glucoside, rutine, myricitrine, myricétine -3-O-β-glucoside, ferrugin); biflavanol (gallocatéchine- 4-O-7- épigallocatéchine); triterpènes, stéroïdes, tanins, saponines, triterpénoïdes, lignanes; phénols et tanins (Cimanga et al, 2001 ; Rashid et al, 2000; Addae-Mensah et Achenbach, 1985; Irobi et al , 1994;. GHP, 1992; de-Bruyne et al, 1998;. Oliver- Bever, 1960). Tests identitéet de purété Teneur en humidité (la Pharmacopée Africaine, 1985): pas plus de 25 Cendre totale: pas plus de 14,6 Cendre insoluble dans l'acide : pas plus de 1,8 Cendre solubles dans l'eau: pas moins de 1,3 Substancesextractibles par l'eau: Pas moins de 31,4 substances extractibles par l'éthanol (70): pas moins de 31,4 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4307,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 307)",
    "text": "moins de 31,4 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de quatre points caractéristiques avec des valeurs Rf de 0,92 (violette), 0,81 (rose), 0,65 (rose) et 0,37 (violet). Chromatogramme Macroscopie Feuilles: simples, alternes; courtement pétiolées, à marge entière, de 3,8- 10 cm de long sur 2,5- 6,4 cm de large, avec un apex courtement acuminé ou aigu; une base symétrique; une texture glabre papyracée; de fortes nervures centrales sur sa face inférieure, modérées sur sa face supérieure traversées par des faisceaux vasculaires et formées par un arc de faisceaux",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 960,
    "source": "PDF_chunked"
  },
  {
    "id": 4308,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 308)",
    "text": "texture glabre papyracée; de fortes nervures centrales sur sa face inférieure, modérées sur sa face supérieure traversées par des faisceaux vasculaires et formées par un arc de faisceaux vasculaires collatéraux de couleur verte; avec une odeur faiblem ent aromatique et un goût neutre ou légèrement insipide ou sucré. Écorce de la tige: gris foncé, écailleuse, intérieur rougeâtre; apparaissant de facon caractéristique sur les marchés de plantes médicinales découpés en petits morcaux courts Microscopie Feuille: vue dorsoventrale présentant d'abondants fragments avec des celules lamelaires, l'épiderme supérieur sans stomates, une cuticule mince; une couche de palissade unique et des cellules minces; l'épiderme inférieur est recouvert de cuticule lisse asse z épaisse et se compose de cellules semblables à ceux de l'épiderme supérieur; les poils multicellulaires, poils de couverturenon glandulaires, quelques stomates paracytiques,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4309,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 309)",
    "text": "épaisse et se compose de cellules semblables à ceux de l'épiderme supérieur; les poils multicellulaires, poils de couverturenon glandulaires, quelques stomates paracytiques, entourés de 2- 3 cellules subsidiaires; une mésophylle parenchymateuse, des faisc eaux vasculaires avec un phloème constituéd'élements souples, une paroi mince, des vaisseaux de xylème , avec des groupes de cellules de parenchyme entre les deux; des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 423,
    "source": "PDF_chunked"
  },
  {
    "id": 4310,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 310)",
    "text": "OOAS Page 60 Bridelia ferruginea WAHP idioblastes de cristaux d'oxalate de calcium microsphénoïdale, abondant dans le mésophyl le et quelques autres dispersés dans le parenchyme et le phloème; la nervure médiane de l'épiderme supérieur se compose de cellules polygonales à parois verticales et une cuticule épaisse. Écorce de la tige: la section transversale montre des régions côti ère et intercostale remplies de cellules sclérenchymateuses et parsemées de différents cristaux d'oxalate de calcium. L'écorce entoure des cellules parenchymateuses qui contiennent également des cristaux d'oxalate de calcium. Les parois anticlinales des c ellules parenchymateuses sont pour la plupart droites, parfois onduléesavec de grandes quantités de tanins. La section radiale tangentielle montre des rayons de tissus diffusés hétérogènes et multisériés. Les rayons médullaires contiennent de l'oxalate de calcium de rayon0, 15 à 0,07 sur une largeur de 0,085 à 0,02 mm.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4311,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 311)",
    "text": "rayons de tissus diffusés hétérogènes et multisériés. Les rayons médullaires contiennent de l'oxalate de calcium de rayon0, 15 à 0,07 sur une largeur de 0,085 à 0,02 mm. Matériel végétal en poudre Feuille: verdâtre; inodore, goût fade, fragments de lamina montrant des poils sur des veines et veinules; de nombreux grains d'amidon simples, des fibres lignifiée s, des vaisseaux, des fragments de veines et veinules Abondants fragments de cellules lamilaire vue de surface, cellules àfines parois sinueuses anticlinales de l'épiderme supérieur, légèrement inférieur avec des parois épaisses, des cellules épidermiques avec des fragments de poils, quelques stomates paracytiques et polygonales dispersés, des cellules à parois droites de l'épiderme supérieur; une nervure médiane à cuticule épaisse. Ecorce de tige: Vaisseaux canelésintervasculairesqui sont alternés et largeset grands, quelques -uns mesurant 9,8 μ à 33,6μ. Les fibres sont de tailles",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4312,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 312)",
    "text": "une nervure médiane à cuticule épaisse. Ecorce de tige: Vaisseaux canelésintervasculairesqui sont alternés et largeset grands, quelques -uns mesurant 9,8 μ à 33,6μ. Les fibres sont de tailles différentes mesurant 21 μ à 50 μ. Certaines fibres contiennent des cristaux prismatiques d'oxalate de calcium. Actions thérapeutiques Antidiabétique, antihypertenseur, antivirale, anti - VIH, antibactérien, antifongique, anti - inflammatoire, antispasmodique; antipyrétique et analgésique, anthelminthique; anti -tumorale; diurétique. Indications thérapeutiques Arthrite, diabète sucré, diarrhée, troubles gastro- intestinaux et génito- urinaire (par exemple la syphilis); glossite, goutte, maux de tête, helminthiases; mugu et buccal (bain de bouche); oligo-urie; virus de la poliomyélite; douleurs rhumatismales (Mshana, 2000; Addae- Mensah, 1992; GHP , 1992; Ayensu, 1978). Donnée de sécurité La DL 50 de l'extrait aqueux des feuilles était",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4313,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 313)",
    "text": "oligo-urie; virus de la poliomyélite; douleurs rhumatismales (Mshana, 2000; Addae- Mensah, 1992; GHP , 1992; Ayensu, 1978). Donnée de sécurité La DL 50 de l'extrait aqueux des feuilles était 3000 mg kg chez le rat. Dans les études de toxicité aiguë (300- 3000 mgkg), aucun changement significatif dans le ratio poids - corporel ou organe poids -corporel n'a été observé chez les rats, aucun signe clinique de toxicité n'a été observé dans l'étude aiguë. A la dose la plus élevée (3000 mgkg) une augmentation significative de la GGT et de créatinine sérique a été relevée. Précautions d'emploi Il faut être prudent dans l'administration de l'extrait a queux chez les patients souffrant d'insuffisance hépatique, ainsi quede la fonction rénale. Effets indésirables Une dose élevée peut provoquer une hypoglycémie. Contre-indications Malades souffrantd'insuffisance rénale etou hépatique, hypoglycémie, pers onnes âgées et enfants. Dosage et forme galénique",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4314,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 314)",
    "text": "hypoglycémie. Contre-indications Malades souffrantd'insuffisance rénale etou hépatique, hypoglycémie, pers onnes âgées et enfants. Dosage et forme galénique Infusion: 20 g de feuilles séchées par litre d'eau; infuser pendant 15 minutes et prendre 3- 4 tasses par jour Décoction: faire bouillir 30 g de feuilles séchées dans un litre d'eau pendant 15 minutes; boi re 3-5 tasses par jour Teinture: 1:5 dans de l'éthanol 30; 5 ml trois fois par jour. Conservation A conserver dans un endroit frais et sec. Références Addae-Mensah, I., Munenge, R.W. (1989). Quercetin-3-neohesperidose (rutin) and other flavonoids as the active hypoglycaemic agents in Bridelia ferruginea. Fitoterapia IX(4): 359-362. Addae-Mensah, I. (1992). Towards a Rational Scientific Basis for Herbal Medicine: A Phytochemist's Two-Decade Contribution. Accra: Ghana Universities Press, 22-27. Addae-Mensah, I., Achenbach, H. (1985). Terpenoids and flavonoids of Bridelia ferruginea.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4315,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 315)",
    "text": "Phytochemist's Two-Decade Contribution. Accra: Ghana Universities Press, 22-27. Addae-Mensah, I., Achenbach, H. (1985). Terpenoids and flavonoids of Bridelia ferruginea. Phytochemistry 24(8):1817-1819.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 201,
    "source": "PDF_chunked"
  },
  {
    "id": 4316,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 316)",
    "text": "OOAS Page 61 Bridelia ferruginea WAHP Adjanohoun, E. et al., (1991). Contribution to ethnobotanical and floristic studies in Western Nigeria. Published by the Scientific, Technical and Research Commission of the Organization of African Unity, Lagos, Nigeria. Akinpelu, D.A., Olorunmola, F.O. (2000). Antimicrobial Activity of Bridelia ferruginea fruit. Fitoterapia; 71:75-76. Ampofo, O. (1977). Some clinical observations on the treatment of selected diseases by herbal preparations. Paper presented at the International Conference on Medicinal Plant Research, University of Ife, Nigeria. Ayensu, E.S. (1978). Medicinal Plants of West Africa. Michigan: Reference Publication Inc., p. 121-122. Cimanga, K., Ying L., de Bruyne T., Apers S., Cos P., et al . (2001). Radical scavenging and xanthine oxidase inhibitory activity of phenolic compounds from Bridelia ferruginea stem bark. Journal of Pharmacy and Pharmacology 53:5:757-761.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4317,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 317)",
    "text": "xanthine oxidase inhibitory activity of phenolic compounds from Bridelia ferruginea stem bark. Journal of Pharmacy and Pharmacology 53:5:757-761. Cimanga, K., Ying, L., de Bruyne, T., Apers, S., Pieters, L. et al . (1999). Complement -inhibiting Constituents of Bridelia ferruginea Stem Bark. Planta Medica 65:213-217. Dalziel, J. M. (1937). The useful plants of West Tropical Africa. Published by Crown Agents for Overseas Governments and Administrations, London. De-Bruyne,T., Cimanga, K., Pieters, L., Claeys, M. et al., (1998). Gallocatechin-(4-0-7)- epigallocatechin, a new biflavonoid isolated from Bridelia ferruginea. Natural Products Letters 11:47-52. Gabor, M. (1986). Anti -inflammatory and anti - allergic properties of flavonoids. Prog Clinical and Biological Research 213:471-480. Ghana Herbal Pharmacopoeia (1992). Bridelia Leaf. The Advent Press, Ghana, 25-27. Githens, T.S. (1949). Drug Plants of Africa.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 921,
    "source": "PDF_chunked"
  },
  {
    "id": 4318,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 318)",
    "text": "Biological Research 213:471-480. Ghana Herbal Pharmacopoeia (1992). Bridelia Leaf. The Advent Press, Ghana, 25-27. Githens, T.S. (1949). Drug Plants of Africa. Pennsylvania: University of Pennsylvania Press. Hentchoya, H.J. (1991). Contribution a l'etude de plantes medecinales du Cameroun; Raport sur la prospection et la selection de quelques plantes devant faire l'objet d'une etude chimique. Irobi, O.N., Moo- Young, M., Anderson, W.A., Daramola, S.O. (1994). Antimicrobial activity of bark extracts of Bridelia ferruginea (Euphorbiaceae). Journal of Ethnopharmacology 43(3):185-190. Iwu, M.M. (1993). Handbook of African Medicinal Plants. Florida: CRC Press, Iwu, M.M. (1986). African Ethnomedicine. Enugu, Nigeria: USP Press. Iwu, M.M. (1980). Antidiabetic Properties of Bridelia ferruginea leaves. Planta Medica 39:247. Mpiana, P.T., Tshibangu, D.S.T., Shetonde, O.M., Ngbolua, K.N. (2007). In vitro antidrepanocytary actvity (anti-sickle cell anemia)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4319,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 319)",
    "text": "Bridelia ferruginea leaves. Planta Medica 39:247. Mpiana, P.T., Tshibangu, D.S.T., Shetonde, O.M., Ngbolua, K.N. (2007). In vitro antidrepanocytary actvity (anti-sickle cell anemia) of some congolesse plants. Phytomedicine 14:192-195. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Muanza, D.N., Euler, K.L., Williams, L., Newman, D.J. (1995). Screening for anti -HIV activities of nine medicinal plants from Zaire. Int ernational Journal of Pharmacognosy 33:98-106. Narayan, P.M. (1994). An ethnobotanical survey of herbal drugs of Kashi district, Nepal. Fitoterapia LXV 1:7-13. Okpekon, T., Yolou, S., Gleye, C., Roblot, F. et al. (2004). Antiparasitic activities of medic inal plants used in Ivory Coast. Journal of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 4320,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 320)",
    "text": "Fitoterapia LXV 1:7-13. Okpekon, T., Yolou, S., Gleye, C., Roblot, F. et al. (2004). Antiparasitic activities of medic inal plants used in Ivory Coast. Journal of Ethnopharmacology 90:91-97. Okunji, O.C. (1987). Molluscicidal and antifungal properties of some Nigerian medicinal plants. Ph.D. (Pharmacognosy) Thesis University of Nigeria Nsukka, Nigeria. Olajide, O.A., Ma kinde, J.M., Awe, S.O. (1999). Effects of the aqueous extract of Bridelia ferruginea stem bark on carrageenan- induced oedema and granuloma formation in rats and mice. Journal of Ethnopharmacology 66:113-117. Olajide, O.A., Okpako, D.T., Makinde, J.M. (2003). Anti -inflammatory properties of Bridelia",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 674,
    "source": "PDF_chunked"
  },
  {
    "id": 4321,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 321)",
    "text": "OOAS Page 62 Bridelia ferruginea WAHP ferruginea stem bark. Inhibition of lipopolysaccaride-induced septic shock and vascular permeability. Journal of Ethnopharmacology 88(2-3): 221-214. Olajide, O.A., Makinde, J.M., Okpako, D.T., Awe, S.O. (2000). Studies on the anti -inflammatory and related pharmacological properties of the aqueous extract of Bridelia ferruginea stem bark. Journal of Ethnopharmacology 71:153-160. Oliver-Bever, B. (1960). Medicinal Plants of Nigeria. Nigerian College of Arts, Science and Technology, p. 20. Olumayokun, A.O. (1999). Investigation of the effects of selected medicinal plants on experimental thrombosis. Phytotherapy Research 13(3):231232. Onoruvwe, O., Olayinka, A.O., Lot, T.Y., Udoh, F.V. (2001). Effects of stem bark and leaf extracts of Bridelia ferruginea on rat bladder smooth muscle. Fitoterapia, 72(3): 230-235.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 858,
    "source": "PDF_chunked"
  },
  {
    "id": 4322,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 322)",
    "text": "extracts of Bridelia ferruginea on rat bladder smooth muscle. Fitoterapia, 72(3): 230-235. Onoruvwe, O., Olayinka, A.O., Lot, T.Y. and Udoh, F.V. (1994). Effects of stem bark and leaf extracts of Bridelia ferruginea on skeletal muscle. Phytotherapy Research 8: 38-41. Rashid, M.A., Gustafson, K.R., Cardellina, J.H., Boyd, M.R. (2000). A new podophyllotoxin derivative from Bridelia ferruginea. Natural Product Letters 14(4): 285-292. Stryer, L. (1995). Biochemistr y. New York: W.H. Freeman and Company, 376-377. Talla, E., Djamend, D., Djouldé, D.R., Tatsadjeu, L .et al., (2002). Antimicrobial activity of Bridelia ferruginea leaves extracts. Fitoterapia 73:343- 345.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 670,
    "source": "PDF_chunked"
  },
  {
    "id": 4323,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 323)",
    "text": "OOAS Page 63 Carica papaya WAHP Nom commun Carica papaya L. Famille Caricaceae Synonyme Carica hermaphrodita Blanco; Carica mamaya Vellon Noms communs Pawpaw; melon tree, mummy apple, Papaya (Anglais),Papayer (Français) Noms vernaculaires Burkina Faso: Bissa Nassara-krou, Mossi P apaï, MooreBudebalod;bogfiré,Fulfuldé- Mãndjé Cote d'Ivoire: Abbey Oloko, Akye - M'bomou, baoule Oflè Gambia: Mandinka Papiya, Fulla Budi baga, Wollof Papakayo Ghana: Akan Brofre, Ga- Dangbe Akpakpa, Ewe Adiba Mali: Bambara Mandje, Dogons Ane sara kambe, Senoufo Manli Nigéria: H ausa Gwanda, gwadda, Yoruba Igi-Ibepè; Ibo ogede ojo. Togo: Ewe Adibati, Mina Adubati, Akasselem Brofude Sénégal: Wolof Papayo, Peuhl papaya, papayo, Diola bum papa Sierra leone : Mandigo Sida, Mende Fakali, Hono Sela Description de la plante Un arbreà faible bois ,droit,généralementnon ramifiéatteignant5-6m de haut avec des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 887,
    "source": "PDF_chunked"
  },
  {
    "id": 4324,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 324)",
    "text": "Sierra leone : Mandigo Sida, Mende Fakali, Hono Sela Description de la plante Un arbreà faible bois ,droit,généralementnon ramifiéatteignant5-6m de haut avec des cicatrices foliaires rémarquable surun tronccreux; les feuilles sont grandes , palmées, atteignant parfois un mètre de diamètre et groupées au sommet du tronc , munies d'une longue pétiole, creuse et robuste, avec des cymes d'inflorescences axillaires ; des fleurs unisexuées dioïques blanches ou verdâtres , occasionnellement hermaphrodites ; la présence de fleurs mâle et femelle unisexuées sur les différentes plantes ; les fleurs mâles sont gamopétales et glandes, tandis queles femelles sont larges, polypétales, sous-sessiles; ses fruits sont de forme oblongue ou oblongue- ovale jusqu'à 30 cm long sur 7-11cm de large avec un mésocarpe charnu, de couleur jaune ou or quand il est mûr et vert quand il est non mûr. Nuléro du spécimen de l'herbier Côte d'Ivoire: 5634, 6244 (Herbier du Centre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4325,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 325)",
    "text": "mésocarpe charnu, de couleur jaune ou or quand il est mûr et vert quand il est non mûr. Nuléro du spécimen de l'herbier Côte d'Ivoire: 5634, 6244 (Herbier du Centre National de Floristique) Ghana: GC 801 Nigeria: FHI 107430 Togo: TOGO0340 Habitat et répartition géographique Originaire d'Amérique tropicale et cultivé dans de nombreuses autres régions tropicales, il est cultivémoins couramment dans le Sahel (probablement en raison de la pénurie d'eau). La plante estcultivée dans les jardins et fermes. Parties utilisées de la plante Feuille, fruit ou racine Autres parties utilisées Graine Caractéristiques botaniques La papaye est composée des feuilles, fruits ou racines de Carica papaya L. (Caricaceae). Utilisations ethnomédicales La plante est utilisée pour divers besoins (Pharmacopée Africaine, 1 985; Ake Asse, 2001). L'infusion des feuilles fraîches ou séchées est utilisée pour traiter les maladies fébriles. La",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 4326,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 326)",
    "text": "La plante est utilisée pour divers besoins (Pharmacopée Africaine, 1 985; Ake Asse, 2001). L'infusion des feuilles fraîches ou séchées est utilisée pour traiter les maladies fébriles. La décoction de feuilles est utilisée pour traiter l'hernie, le paludisme, la douleur urogénitale, la gonorrhée et le cancer. Les vapeurs pro venant des feuilles sont également utilisés pour traiter l'asthme. La racine enpâte est dissoute dans l'eau chaude et utilisé comme un lavement pour traiter les douleurs abdominales. Elle est également mélangéeà l'huile de palme et appliquée comme cataplas me pour traiter les panaris. La racine est macérée dans l'eau froide et utilisée comme rince- bouche dans les cas de caries dentaires. Les racines macérées sont également utilisées par voie orale contre l'urétrite (miction douloureuse), la typhoïde, la fièv re, et comme laxatif. Les racines peuvent également",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 892,
    "source": "PDF_chunked"
  },
  {
    "id": 4327,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 327)",
    "text": "OOAS Page 64 Carica papaya WAHP être macérées dans du vin de palme ou décoctées et bu pour traiter la dysenterie et la blénnorragie. Les racines et les feuilles sont utilisées comme diurétiques. La décoction de fruits non mûrs est un re mède contre la jaunisse, l'anémie falciforme et l'hépatite. Le fruit mûr écrasé est appliquée comme crèmepour traiter les furoncles, et l'infusion de la poudre de graines séchées est priseà jeûn comme vermifuge. Activités biologiques et pharmacologiques De nombreuses études scientifiques ont été menées afin de valider les actions pharmacologiques les plus connues de la plante, incluant les actions antimicrobiennes (amœbicide, bactériostatique); stomachique, vermifuge;galactogogue; oxytoxique;digestive; hémostatique; cicatrisante etcarminative (BPH 1992; Pampelune- Roger, 1998). Les extraits d'alcool et de butanol des feuilles séchées ont montré une activité spasmolytique sur l'iléon isolé",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4328,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 328)",
    "text": "hémostatique; cicatrisante etcarminative (BPH 1992; Pampelune- Roger, 1998). Les extraits d'alcool et de butanol des feuilles séchées ont montré une activité spasmolytique sur l'iléon isolé du cobaye (Kambu et al., 1990). L'extrait éthanolique de la feuille sèche administré par voie intrapéritonéale à des rats a montré des effets analgésique, anticonvulsivant, relaxant musculaire, chronotrope positif et tranquillisant (Gupta et al., 1990). A faible dose, le carpaine réduit les contractions cardiaques et baisse ai nsi la tension artérielle, mais à des doses élevées, il produit une vasoconstriction (Oliver -Bever, 1960).L'alcaloïde des feuilles, le carpaine a montré des propriétés diurétique et amibicide. l'extrait hydro- alcoolique de la racine a montré une activité in vitro contre Neisseria gonorrhoeae (Caceres, 1992; Caceres et al., 1995). Les fractions purifiées protéiques obtenues séparément de l'endocarpe frais, de l'épicarpe,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4329,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 329)",
    "text": "une activité in vitro contre Neisseria gonorrhoeae (Caceres, 1992; Caceres et al., 1995). Les fractions purifiées protéiques obtenues séparément de l'endocarpe frais, de l'épicarpe, des graines, des fruits et des feuilles fraîches ont montré une activité in vitro contre Bacillus cereus, Escherichia coli , Pseudomonas aeruginosa,Staphylococcus aureus Shigella flexneri, Proteus vulgaris et Salmonella typhimurium (Argueta, 1994; Emeruwa, 1982 ), tandis que l'extrait méthanolique pur du fruitamontré une action anti -inflammatoire (Yasukawa et al., 1993). Osato et al. (1993) ont également signalé les propriétés bactériostatiques in vitro du jus de la pulpe non mûre et des graines du fruit contre Bacillus subtilis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, P roteus vulgaris, Pseudomonas aeruginosa, Salmonella typhi et Staphylococcus aureus. Les Extraits des mêmes parties ont également montré une activité",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4330,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 330)",
    "text": "Klebsiella pneumoniae, P roteus vulgaris, Pseudomonas aeruginosa, Salmonella typhi et Staphylococcus aureus. Les Extraits des mêmes parties ont également montré une activité antioxydante comparable à celle du miso de la pâte de soja, de riz et de la levure boulangère (Osato et al., 1993). 95 d'extrait éthanolique de la racine a montré une activité antibactérienne in vitro contre Escherichia coli et Staphylococcus aureus (George et Pandali, 1949); l'extrait aqueux a eu un effet in vitroanti -candida (Gundidza, 1986). Le latex des différentes parties de la plante a démontré qu'il possède une activité antifongique in vitro contre le Candida albicans (Giordani et al 1996; Giordani et al, 1991). Chen et al (1981) ont constaté que le latex du fruit vert est un moyen de protection contre l es ulcères d'estomac en réduisant la sécrétion d'acide histamine induite chez les rats (Chen et al., 1981).Le jus laiteux des fruits non mûrs contient",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4331,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 331)",
    "text": "est un moyen de protection contre l es ulcères d'estomac en réduisant la sécrétion d'acide histamine induite chez les rats (Chen et al., 1981).Le jus laiteux des fruits non mûrs contient l'enzyme protéolytique \"papaïne\", composé de papaïne et chymopapaïne (Oliver -Bever, 1960). Les propriétés attendrissantes de la papaïne, le plus souvent combinée avec de l'alcali (par exemple borax ou carbonate de potassium), ont été utilisées dans le traitement des furoncles, des cors, des tubercules cutanées, de l'eczéma, des tâches de rousseur, des sinus, des verrues et des tumeurs. Il a la capacité de coaguler le lait et de digérer le tissu fibreux de la chair à la foissur l'acide et l'alcali et a été utilisé pour traiter les ulcères et comme agent anti -inflammatoire pour réduire l'enflure, la fièvre et les adhérences après chirurgie. Son dérivée, la chymopapaïne est parfois utilisée par voie intraveineuse en chirurgie orthopédique pour dissoudre le noyau du disque",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 968,
    "source": "PDF_chunked"
  },
  {
    "id": 4332,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 332)",
    "text": "chirurgie. Son dérivée, la chymopapaïne est parfois utilisée par voie intraveineuse en chirurgie orthopédique pour dissoudre le noyau du disque intervertébral en cas d'hernie des nerfs lombaires ou des nerfs coincés (Pampelune- Roger,1998;http:www.biopark.orgperupapaya. html). Données cliniques Des essais ont montré que l'application quotidienne de la pâte sur les brûlures infectées est efficace dans les brûlures et la prévention des plaies infectées provenant de brûlures (Starley et al., 1999). L'application topique du fruit non mûr a favorisé la desquamation, la granulation, la cicatrisation et la réduction des odeurs dans les ulcères chroniques de la peau, en étant plus efficace que d'autres applications topiques (Hewitt et al., 2000). Contituants chimiques Phényl-propanoïdes (acide caféique), alcaloïdes (carpaine 9 dihydrocarpaine I et II, pseudo- carpaïne, cotinine, myosmine, nicotine, choline, pyridine, carpasamine); glucoside c yanogène",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4333,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 333)",
    "text": "Phényl-propanoïdes (acide caféique), alcaloïdes (carpaine 9 dihydrocarpaine I et II, pseudo- carpaïne, cotinine, myosmine, nicotine, choline, pyridine, carpasamine); glucoside c yanogène (Nahrstedt, 1987); alcaloïdes: carpaine, nicotine; xylitol et saponines; caroténoïdes ( β-carotène, ε- carotène, cryptoxanthine), lycopène, annins; acide α-linolénique, benzénoides, benzaldéhyde, glucosinolates benzyle, salicylate de méthyle, composés soufrés, benzyle isothiocyanate; protéines: papaïne, chimopapaine A, ω- protéase, vitamines A, C et E2; minéraux: potassium, principalement calcium, fer, phosphore; stérols ( β-sitostérol;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 627,
    "source": "PDF_chunked"
  },
  {
    "id": 4334,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 334)",
    "text": "OOAS Page 65 Carica papaya WAHP dehydroavenostérol, compestérol, cholestérol, stigmastérol), acide gras (palmitique, stéarique, oléique, linoléique); phosphatides; pectine, acide citrique (Silvaraj et Pal, 1982; Tang, 1971; Hegnauer, 1973; Duc, 1992; Duc, 1986; Kambu et al., 1990;. Moneret et al, 1985;. Kermanshai et al, 2001; Hashem et al, 1980;. Pickersgill, 1990; Duc et Atchley, 1986; Idstein et al, 1985;. Argueta et al, 1994; Kerharo et Adam, 1974). Tests d'identité et de pureté Teneur en humidité: 83 (immature) Cendre totale: pas plus de 43,2 (immature) Cendre insoluble dans l'acide: pas plus de 3,7 (immature) Cendresoluble dans l'eau : pas moins de 33,2 (immature) Substances extractibles par l'eau: pas moins de 6,3 (immature) Substances extractibles par l'éthanol à 70: pas moins de 2,2 (immature) (Pharmacopée Africaine, 1985; Odukoya et Elujoba, 2004) Empreintes chromatographiques Extrait chloroformique",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 4335,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 335)",
    "text": "Substances extractibles par l'éthanol à 70: pas moins de 2,2 (immature) (Pharmacopée Africaine, 1985; Odukoya et Elujoba, 2004) Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de cinq taches distinctes avec valeurs Rf de 0,92 (rose), 0,80, 0,60, 0,55 et 0,40 (vert). Chromatogramme Macroscopie Le fruit est une baie d'environ 15- 22 cm de long sur 7- 11 cm de large, oblongues à oblongues - ovales dans la forme, de couleur vert -foncée quand il est non mûr. Il contient du latex dans le péricarpe, devenant jaune -orange à maturité et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 4336,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 336)",
    "text": "sur 7- 11 cm de large, oblongues à oblongues - ovales dans la forme, de couleur vert -foncée quand il est non mûr. Il contient du latex dans le péricarpe, devenant jaune -orange à maturité et disparaissant à maturité ; de nombreuses graines grisâtres non mures, noir quand elles sont mûres, avec une placentation pariétale; l'épicarpe est coriace avec un mésocarpe charnu de couleur orange à maturité et vert quand il est non mûr. L'endocarpe est inconnu (Pharmacopée Africaine, 1985). Microscopie L'épiderme du péricarpe se compose de cellules polygonales isodiamétriques avec des parois droites anticlinales, des stomates rares de type ranunculaceuse, sans po ils; le mésocarpeest formé de plusieurs couches de cellules parenchymateuses à paroi mince.La couche la plus externe est plus ou moins allongée et tangentiellement avec des petites cellules; la couche intérieure est constituée de grandes cellules parenchymateuses rondes ou ovales; les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4337,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 337)",
    "text": "plus externe est plus ou moins allongée et tangentiellement avec des petites cellules; la couche intérieure est constituée de grandes cellules parenchymateuses rondes ou ovales; les torons vasculaires sont formés d'étroites navires spirales non lignifiées, et une partie de phloème; le mésocarpe montre de nombreuxvaisseaux laticifères anastomosés, contenant une substance colorée jaune avec de l'iode et pe ude granules d'amidon; les cristaux d'oxalate de calcium sont absents; la section transversale montre une couche externe membraneuse avec des grains d'amidon, délimitéespar desprojections étoilées qui forment la texture qui présente elle- même quatre couches distinctes: un tissu sclerenchymateux externe formé de projections et des vaisseaux en latex sont présents dans ce tissu; une région de cellules lactifères produite à côté de cette couche,est suivie sur le côté intérieur par une couche compacte de liège en forme de tissu; l'endosperme comprend des cellules de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 977,
    "source": "PDF_chunked"
  },
  {
    "id": 4338,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 338)",
    "text": "OOAS Page 66 Carica papaya WAHP parenchyme avec des globoïdes corporelles (Pharmacopée Africaine, 1985). Matériel végétal en poudre Cellules polygonales isodiamétriques de l'épiderme, cellules parenchymateuses à paroi mince arrondies ou ovales du mésocarpe; fragments de vaisseaux spiralés, avec quelques grains d'amidon et stomates. Actions thérapeutiques Antibactériene, antifongique, vermifuge, diurétique, anti -ulcéreux, analgésique, anti - inflammatoire, vulnéraire, amibicide et anticonvulsivante. (Caceres, 1992; Caceres et al, 1995; Emeruwa, 1982; George et Pandali, 1949; Argueta, 1994; Osato et al , 1993;. Gundidza, 1986; Giordani et al , 1991; Kambu et al , 1990; Gupta et al, 1990;. Oliver -Bever, 1960; Yasukawa et al, 1993;. Chen et al, 1981;. Starley, 1999; Grandvaux, 1986; Phillipson et O'Neill, 1987). Indications thérapeutiques Colite, constipation chronique, dysenterie, hypertension, mal de dent, pharyngite, rétention",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4339,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 339)",
    "text": "1999; Grandvaux, 1986; Phillipson et O'Neill, 1987). Indications thérapeutiques Colite, constipation chronique, dysenterie, hypertension, mal de dent, pharyngite, rétention urinaire, ulcère de la peau, ver de Guinée, jaunisse, syndro me du côlon irritable, ascaridiase, helminthiases intestinales (oxyures, ténia), pharyngite, dystocie, dracunculose, empoisonnement du kérosène, fièvre, blessures, amibiase (Mshana et al, 2000;. GHP, 1992). Données de sécurité Pendant une surveillance de 24 heures après traitement avec une dose unique de 300 à 3000 mgkg, les études animales chez les rats mâles (p.o) ont montré que la DL 50 de l'extrait aqueux des feuilles était 3000 mgkg. Il n'y avait pas de signes de toxicité clinique. L'administrati on répétée pendant 14 jours n'a pas eu d'incidence sur le sang et ses éléments cellulaires. La fonction hépatique et rénale était également normale. Sur la base de cette étude, il n'ya pas",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4340,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 340)",
    "text": "répétée pendant 14 jours n'a pas eu d'incidence sur le sang et ses éléments cellulaires. La fonction hépatique et rénale était également normale. Sur la base de cette étude, il n'ya pas de problème de sécurité dans l'utilisation de l'extrait aqueux de C arica papaya. L'extrait éthanolique du fruit vert admnistré par voie intrapéritonéale à des souris a donné une DL 50 de 325,2 mgkg (Nahrstedt, 1987). L'administration intraveineuse de la chymopapaïne a donnéune DL 50 de 79 mgkg chez la souris, 120 mgg che z les rats, 15 mgkg chez le lapin et 16,7 mgkg chez le chien. Après l'injection de chymopapaïne donnée pour le traitement des hernies discales, le choc anaphylactique a été observée sur 1 des patients (Moneret Vautrin et al., 1985). L'administration or ale de 10mlkg de l'extrait aqueux de la racine (10 g à macérer dans 500 ml d'eau) à des souris pendant 14 jours n'a montré aucun signe évident de toxicité (Sripanidkulchai",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4341,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 341)",
    "text": "L'administration or ale de 10mlkg de l'extrait aqueux de la racine (10 g à macérer dans 500 ml d'eau) à des souris pendant 14 jours n'a montré aucun signe évident de toxicité (Sripanidkulchai et al, 2001). Une préparation du fruit appliquée pendant cinq jours consécutifs sur le dos (2 g50 cm 2) du lapin ne provoque pas d'irritation cutanée (Garcia-Gonzalez et al., 2001), mais l'extrait aqueux dela graine produit une stérilité irréversible sur les rats mâles albinos en raison de la motilité des spermatozoïdes qui ont diminué (Charles, 1988). Précautions d'emploi La papaïne peut provoquer un avortement en début de grossesse et peut avoir la capacité de dissoudre une protéine responsable de l'adhérence de l'œuf fécondé dans la muqueuse de l'utérus (Adebiyi et al. 2002). Effets indésirables A doses elévées, l'extrait de la plante peut provoquer l'irréversibilité de la tocolyse utérine probablement dû à un effet toxique de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4342,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 342)",
    "text": "de l'utérus (Adebiyi et al. 2002). Effets indésirables A doses elévées, l'extrait de la plante peut provoquer l'irréversibilité de la tocolyse utérine probablement dû à un effet toxique de l'isothiocyanate de benzyle dans le myomètre (Adebiyi et al., 2003). La plante est bien toléré chez les enfant s (Starley et al., 1999). Cependant, des réactions anaphylactiques à la papaïne ont été rapportés (Duke, 1985). Les symptômes cliniques d'allergie à la papaïne ont été rapportés chez certains patients (De Clerck et al., 2007). L'hépatotoxicité de l'extrait de méthanol de la graine a été rapporté (Udoh et Udoh, 2005; Adebiyi et Adaikan, 2005). Le latex contenant de la papaïne a été signalé pour induire les douleurs thoraciques, la gastrite, la rhinite, le jaunissement de la paume des mains, les irritations de la peau et les cloques, le choc anaphylactique et l'asthme sévère (Blanco et al, 1998, Blumenthal et al 1998; Badin et al, 1978). Contre-indications",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 962,
    "source": "PDF_chunked"
  },
  {
    "id": 4343,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 343)",
    "text": "les irritations de la peau et les cloques, le choc anaphylactique et l'asthme sévère (Blanco et al, 1998, Blumenthal et al 1998; Badin et al, 1978). Contre-indications Grossesse et allaitement; hypotension, médicaments aniticoagulants comme la coumadine, le warfarine, le miradon et l'anisindione (Shaw, 1997; Shulman, 1997) Dosage et forme galénique Décoction: 30 g de feuilles séchées dans 900 ml d'eau à ébullition jusqu'à réduction à 600 ml, 1 cuillère à café trois fois par jour. Infusion: 30 g de feuilles séchées dans 60 0 ml d'eau, 1 cuillère à café trois fois par jour Teinture: teinture à 1:5 dans l'alcool de 50 5 fois ml par jour Latex:10-20 g mélangé avec du miel et de l'eau chaude après chaque repas; le latex frais de fruits verts, avec une dose de 4 à 8 g (1 à 2 cuillères à soupe pour les enfants) et de 8 à 16 g (2 à 4 cuillères à soupe pour les adultes), dilué",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 880,
    "source": "PDF_chunked"
  },
  {
    "id": 4344,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 344)",
    "text": "OOAS Page 67 Carica papaya WAHP dans un peu d'eau, ou mélangé avec 3 ou 4 cuillèreés à soupe de miel. Conservation A conserver dans un endroit frais et sec. Références Adebiyi, A., Adaikan, P.G. (2005). Modulation of jejunal contractions by extract of Carica papaya L. seeds. Phytotherapy Research 19:628632. Adebiyi, A., Adaikan, P.G., Prasad, R.N.V. (2003). Tocolytic and toxic activity of papaya seed extract on isolated rat uterus. Life S ciences 74: 581592. Adebiyi, A., Adaikan, P.G., Prasad, R.N. (2002). Papaya ( Carica papaya) consumption is unsafe in pregnancy: fact or fable? Scientific evaluation of a common belief in some parts of Asia using a rat model. British Journal of Nutrition 88(2):199- 203. African Pharmacopoeia Vol. 1 (1985). 2 nd edition, Lagos, published by Organization of African Unity's Scientific, Technical and Research Commission, Lagos, Nigeria, pp3-4. Ake Assi, L., (2001- 2002). Flore de la Côte",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4345,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 345)",
    "text": "nd edition, Lagos, published by Organization of African Unity's Scientific, Technical and Research Commission, Lagos, Nigeria, pp3-4. Ake Assi, L., (2001- 2002). Flore de la Côte d'Ivoire: catalogue sys tématique, biogéographie et écologie. Mémoire de botanique systématique. Conservatoire et Jardin Botanique de Genève, 2 volumes. Argueta, A., Cano, L., Rodarte, M.E. (1994). Atlas de las plantas de la medicina tradicional mexicana. Tomo II. México D.F., México: Instituto Nacional Indigenista. P 1117-1119. Badin, R., Cassaign, R., Christie, R.B. (1978). Papain in pharmaceutical enzymes.Gand, Belgium: Ed.D. RUyssen A. Lauwers. Blanco, C., Ortega, N., Castillo, R., Alvarez, M. et al (1998). Carica papaya pollen allergy. Annals of Allergy Asthma and Immunology 81(2):171-175. Blumenthal, M., Busse, W.R., Goldberg, A., Gruenwald, J. et al . (1998). The Complete German Commission E Monographs, 1st ed. American Botanical Council, Austin, TX.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4346,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 346)",
    "text": "Blumenthal, M., Busse, W.R., Goldberg, A., Gruenwald, J. et al . (1998). The Complete German Commission E Monographs, 1st ed. American Botanical Council, Austin, TX. Caceres, A., Menende, Z.H., Mendez, E., Cohobon, E., Samayoa, B.E. et al . (1995). Antigonorrhoeal activity of plants used in Guatemala for the treatment of sexually transmitted diseases. Journal of Ethnopharmacology 48(2):85-88. Caceres, A. (1992). Antigonorrhoeal activity of plants used in Guatemala for the treatment of sexually transmitted diseases. Informe TRAMIL. Facultad de farmacia, Universidad de San Carlos, Guatemala. Charles, C. (1988). TRAMIL survey. Movement for Cultural Awareness MCA, Roseau, Dominica. Chen, C.F., Chen, S.M., Chow, S.Y., Han, P.W. (1981). Protective effects of Carica papaya L. on the exogenous gastric ulcer in rats. American Journal of Chinese Medicine 9(3):205-212. De Clerck, L.S., Ebo, D.G., Bridts, C.H., Stevens,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 921,
    "source": "PDF_chunked"
  },
  {
    "id": 4347,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 347)",
    "text": "(1981). Protective effects of Carica papaya L. on the exogenous gastric ulcer in rats. American Journal of Chinese Medicine 9(3):205-212. De Clerck, L.S., Ebo, D.G., Bridts, C.H., Stevens, W.J. (2007). Anglo- edema and Oral Allergy Syndrome Due to the Consumption of Carica Papaya. Journal of Allergy and Clinical Immunology 111(2):S103. Duke, J.A. (1992). Handbook of phytochemical constituents of GRAS herbs and other economic plants.Boca Raton, USA: CRC Press. Duke, J .A., Atchley, A.A. (1986). Handbook of proximate analysis tables of higher plants. Boca Raton, USA: C R C Press. p36. Duke, J.A. (1985). Handbook of medicinal herbs. Boca Raton, USA: CRC Press. Emeruwa, A.C. (1982). Antibacterial substances from Carica papaya fruit extract. Journal of Natural Products 45(2):123-127. Garcia-Gonzalez, M., Coto, M.T., Gonzalez, C.S., Pazos, L, (2001). Repeated dose dermal irritability of the grated fresh fruit of Carica",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4348,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 348)",
    "text": "Natural Products 45(2):123-127. Garcia-Gonzalez, M., Coto, M.T., Gonzalez, C.S., Pazos, L, (2001). Repeated dose dermal irritability of the grated fresh fruit of Carica papaya. (Irritabilidad dérmica del fruto fresco rallado de Carica papaya dosis repetida). Informe Tramil. Laboratorio de Ensayos Biológicos LEBI, Escuela de Medicina Universidad de Costa Rica, San Pedro, Costa Rica. George, M., Pandalai, K.M. (1949). Investigations on plant antibiotics. Part IV. Further sear ch for antibiotic substances in Indian medicinal plants. Indian Journal of Medical Research 37:169-181. Ghana Herbal Pharmacopoeia (1992), 120- 122. The Advent Press: Accra, Ghana.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 659,
    "source": "PDF_chunked"
  },
  {
    "id": 4349,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 349)",
    "text": "OOAS Page 68 Carica papaya WAHP Gimletted, J.D. (1939). A dictionary of Malayan medicine. New York, USA: O xford University Press. Giordani, R., Cardenas, M.L., Moulin- Traffort, J., Regli, P. (1996). Fungicidal activity of latex sap from Carica papaya and antifungal effect of D - ()-glucosamine on Candida albicans growth. Mycoses 39(3-4):103-10. Giordani, R., Siepaio, M., Moulin- Traffort, J., Regli, P. (1991). Antifungal action of Carica papaya latex: isolation of fungal cell wall hydrolysing enzymes. Mycoses 34:469-477. Grandvaux, J. (1986). Carica papaya, plante médicinale d'actualité. Thèse pharmacie n 686, Paris XI, France. Gundidza, M. (1986). Screening of extracts from Zimbabwean higher plants II: ntifungal properties. Fitoterapia 57(2):111-113. Gupta, A., Wambebe, C.O., Parsons, D.C. (1990). Central and cardiovascular effects of the alcoholic extract of the leaves of Carica papaya. International Journal of Crude Drug Research",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4350,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 350)",
    "text": "Gupta, A., Wambebe, C.O., Parsons, D.C. (1990). Central and cardiovascular effects of the alcoholic extract of the leaves of Carica papaya. International Journal of Crude Drug Research 28(4):257-266. Hashem, F.M., Haggag M.Y., Galal, A.M.S. (1980). A phytochemical study of Carica papaya L. growing in Egypt. Egyptian Journal of Pharmaceutical Sciences 21 (34):199-214. Hegnauer, R. (1973). Chemotaxonomie der Pflanzen. Basel. Schweiz: Birkhauser Verlag.6:882. Hewitt, H., Whittle, S., Lopez, S., Bailey, E., et al. (2000). Topical use of papaya in chronic skin ulcer therapy in Jamaica. West Indian Medical Journal 49(1): 32-33. Idsteins, H., Bauer, C., Schreier, P. (1985). Volatile acids in tropical fruits: cherimoya (Annona cherimolia Mills.), guava (Psidium guajava L.), mango (Mangifera indica L. var. alphonso), papaya ( Carica papaya L.). Z Lebensm Unters Forsch 180(5):394-397. Kambu, K., Tona, l., Kaba, S., Cimanga, K.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4351,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 351)",
    "text": "guajava L.), mango (Mangifera indica L. var. alphonso), papaya ( Carica papaya L.). Z Lebensm Unters Forsch 180(5):394-397. Kambu, K., Tona, l., Kaba, S., Cimanga, K., Mukala, N. (1990). Antispasmodic activity of extracts proceeding of plant antidiarrheic traditional preparations used in Kinshasa, Zaire Annals of Pharmacy 48(4):200-208. Kerharo, O.J., Adam, J. (1974). La Pharmacopée sénégalaise traditionnelle. Paris, France: Ed. Vigot Frères. Kermanshai, R., McCarry, B.E., Rosenfeld, J., Summers, P.S., Weretilnyk, E.A. et al . (2001) . Benzyl isothiocyanate is the chief or sole anthelmintic in papaya seed extrac ts: Phytochemistry 57(3):427-35. Moneret Vautrin, D.A., Benoist, M., Laxenaire, M.C., Croizier, A., Gueant, J.L. (1985). Allergy to chymopapain: value of predictive tests before chemonucleolysis. Annals French Anesth Reanim 4(3):313-3 15. Mshana, N.R., Abbiw, D.K., Addae -Mensah, I., Ahiyi, M.R.A. et al (2000). Traditional medicine",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 4352,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 352)",
    "text": "chemonucleolysis. Annals French Anesth Reanim 4(3):313-3 15. Mshana, N.R., Abbiw, D.K., Addae -Mensah, I., Ahiyi, M.R.A. et al (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Nahrstedt, A. (1987). Recent developments in chemistry, distribution and biology the cyanogenic glycosides. In: Hostettmann, K., Lea, P.J. (Eds). Biologically active natural products. Oxford, USA: Oxford Science Publications, p167- 184, 213-234. Odukoya, O .O, Elujoba, A.A (2004). Technical Report of the commissioned the physical constant determination for Carica papaya fruit to World Health Organization, Nigeria. Oliver-Bever, B. (1960). Medicinal Plants in Nigeria. The Nigerian College of Arts, Science and Technology, 52. Osato, J.A., Santiago, L.A., Remo, G.M, Cuadra, M.S., Mori, A. (1993). Antimicrobial and",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4353,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 353)",
    "text": "Nigeria. The Nigerian College of Arts, Science and Technology, 52. Osato, J.A., Santiago, L.A., Remo, G.M, Cuadra, M.S., Mori, A. (1993). Antimicrobial and antioxidant activities of unripe papaya. Life Science 53(17):1383-1389. Pamplona-Roger, G.D. (1998). Papaya Tree- Digestive and Vermifuge. Encyclopaedia of Medicinal Plants: Education and Health Library 1, 435. Artes Graficas Toledo: Spain. Phillipson, J., O'neill, M. (1987). Antimalarial and amoebicidal natural products. In: Hostettmann K, Lea Pj, (Eds). Biologically active natural products. Oxford, USA: Oxford Science Publications. P 49- 64.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 603,
    "source": "PDF_chunked"
  },
  {
    "id": 4354,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 354)",
    "text": "OOAS Page 69 Carica papaya WAHP Pickersgill, R., Sumner, I., Goodenoug, H.P. (1990). Preliminary crystallographic data for protease omega. European Journal of Biochemistry 190(2):443-444. Shaw, D., Leon, C., Kolev, S. et al . (1997). Traditional remedies and food supplements: a 5- year toxicological study. Drug Saf 17(5):342-356. Shulman, A. (1997). Toxicological problems of traditional remedies and food supplements. International Journal of Alternative Complimentary Medicine 1997:9-10. Silvaraj, Y., Pal, D.K. (1982). Changes in the chemical composition of papaya (Thailand variety) during growth and development. Journal of Food Science and Technology 19:257-259. Sripanidkulchai, B., Wongpanich, V., Laupattarakasem, P., Suwansaksri, J. et al (2001). Diuretic effects of selected Thai indigenous medicinal plants in rats. Journal of Ethnopharmacology 75:185190.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 869,
    "source": "PDF_chunked"
  },
  {
    "id": 4355,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 355)",
    "text": "(2001). Diuretic effects of selected Thai indigenous medicinal plants in rats. Journal of Ethnopharmacology 75:185190. Starley, I.F., Mohammed, P., Schneider, G., Bickler, S.W. (1999). The treatment of pediatric burns using topical papaya. Burns, 25 (7):636- 639. Tang, C.S. (1971). Benzyl isothiocyanate of papaya fruit. Phytochemistry 10:117. Udoh, F.V., Udoh, P.B. (2005). Hepatotoxicity of the methanol extract of Carica papaya (Paw- Paw) seeds in Wistar rats. Pharmaceutical Biology 43:349352. Yasukawa, K., Yamaguchi, A., Arita Jsakurai, S., Ikeda, A. (1993). Inhibitory effect of edible plant extracts on 12- O-tetradecanoylphorbol-13- acetate-induced ear oedema in mice. Phytotherapy Research 7(2):185-189.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 714,
    "source": "PDF_chunked"
  },
  {
    "id": 4356,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 356)",
    "text": "OOAS Page 70 Cinchona pubescens WAHP Nom botanique Cinchona pubescens V ahl. Famille Rubiaceae Synonyme Cinchona succirubra Pavon ex Klotzsch Noms communs Anglais: quinine Français: quinquina rouge Noms vernaculaires Nigéria: Yoruba-Kinin Description de la plante C'est un grand arbuste ou un petit arbre à feuillage persistant, grandissant jusqu'à 15- 20 m de haut; les feuilles sont opposées, lancéolées et arrondies à 10-40 cm de long ; l'arbre produit des fleurs blanches, roses et jaunes ou en panicules terminales; le fruit est une petite capsule contenant de nombreuses graines. Habitat et repartition géographique Le genre Cinchona pubescens est originaire des forêts tropicales des Andes du Sud Ouest de l'Amérique, mais largement cultivé aujourd'hui dans les régions tropicales humides d'Afrique et de Madagascar (à une altitude comprise entre 600-3300 m) pour sa valeur marchande et particulièrement en raison de son constituant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4357,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 357)",
    "text": "dans les régions tropicales humides d'Afrique et de Madagascar (à une altitude comprise entre 600-3300 m) pour sa valeur marchande et particulièrement en raison de son constituant antipaludique et de la quinine (Pharmacopée Pfricaine, 1985). Parties utilisées de la plante Écorce séchée du tronc Caractéristiques botaniques Cinchona se compose de l'écorce séchée du tronc de Cinchona pubescens Vahl. (Rubiaceae) Utilisation médicale Le \"Cinchona\" est née de la comtesse de Chinchon, épouse d'un vice- roi du Pérou, qui avait été guérie d'un type de fièvre palustre avec l'écorce de l'arbre de quinquina en 1638. Le nom quinquina vient de \"kina- kina\", qui signifie écorce écorce au Pérou. La quinine, obtenu à partir de l'écorce, a d'abord été proposée à la vente en Angleterre en 1658 et rendue officielle dans la Pharmacopée britannique en 1677. L'écorce de quinquina a été incluse dans de nombreuses formulations en Europe, telles que",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4358,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 358)",
    "text": "vente en Angleterre en 1658 et rendue officielle dans la Pharmacopée britannique en 1677. L'écorce de quinquina a été incluse dans de nombreuses formulations en Europe, telles que la \"poudre comtesse\", et la \"poudre des Jésuites\". Outre le paludisme, l'écorce a été également utilisée pour traiter la fièvre, l'indigestion, les maladies de la bouche et de la gorge, ainsi que le cancer. De petites doses de l'extrait de l'écorce de quinquina ont des propriétés astringentes, toniques et amères. À doses élevées, les extraits produisent une action antipaludique et antipyréti que. La quinine est cytotoxique et anti -protozoaire, en particulier contre l'agent causal du paludisme. Il agit principalement sur les formes érythrocytaires asexuées (schizonticide). À des doses élevées, la quinine provoque des troubles sensoriels (acouphènes, vertiges, diplopie) et la libération d'ocytocine (risque d'avortement). La quinidine est un composé anti -arythmique, diminuant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 4359,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 359)",
    "text": "la quinine provoque des troubles sensoriels (acouphènes, vertiges, diplopie) et la libération d'ocytocine (risque d'avortement). La quinidine est un composé anti -arythmique, diminuant l'excitabilité du cœur en réduisant la perméabilité de l'ion de potassium.Les extraits bruts et les fractions d'écorce de la plante sont actives contre la souche 3D7 de la chloroquine sensibles au P. falciparumin vitro (IC 50 10 μg ml), mais ne sont pas actifs in vivo sur P. berghei (Ce'u de Madureira et al., 2002). La plante est tonique, amère, apéritive et est un stimulant digestif. Un des polysaccharides de l'écorce est cytotoxique. À des doses élevées, il provoque une thrombocytopénie (Jäger et al 2007; Buddenhagen et al , 2004). L'extrait de dichlorométhaneméthanol (1:1) a montré une activité cytotoxique contre les cellules cancéreuses du sein (Kaileh et al., 2007). La décoction de l'écorce est administrée par voie orale comme antipyrétique et comme stimulant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4360,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 360)",
    "text": "activité cytotoxique contre les cellules cancéreuses du sein (Kaileh et al., 2007). La décoction de l'écorce est administrée par voie orale comme antipyrétique et comme stimulant d'appétit dans le traitement du paludisme (Hanlidou et al., 2004). Les feuilles sont utilisées contre la fièvre, les maux de tête et les infections respiratoires (Kaileh et al., 2007). Activités biologiques et pharmacologiques De petites doses de l'extrait d'écorce de quinquina a propriétés astringentes, toniques et amer. À des doses élevées, les extraits de produire une action antipaludique et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 576,
    "source": "PDF_chunked"
  },
  {
    "id": 4361,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 361)",
    "text": "OOAS Page 71 Cinchona pubescens WAHP antipyrétique. La quinine est cytotoxique et donc anti-protozoaire, en particul ier contre l'agent causal du paludisme. Il agit principalement sur les formes érythrocytaires asexuées (schizonticide). À des doses élevées, la quinine provoque des troubles sensoriels (acouphènes, vertiges, diplopie) et la libération d'ocytocine (risque d'avortement). La quinidine est un composé anti -arythmique, ce qui diminue l'excitabilité du cœur en réduisant sa perméabilité à l'ion potassium. Des extraits bruts et les fractions de l'écorce de la plante est active contre la souche 3D7 sensibles à la chl oroquine de P. falciparum in vitro (CI50 10 pg ml), mais n'est pas active sur P. berghei in vivo (voir Ce'u de Madureira et al., 2002). La plante est tonique, amer, apéritif et stimulant digestif. L'un des polysaccharides à partir de l'écorce est cytotoxique. À fortes doses, elle provoque une thrombopénie (Jäger et al 2007;. Buddenhagen",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 969,
    "source": "PDF_chunked"
  },
  {
    "id": 4362,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 362)",
    "text": "amer, apéritif et stimulant digestif. L'un des polysaccharides à partir de l'écorce est cytotoxique. À fortes doses, elle provoque une thrombopénie (Jäger et al 2007;. Buddenhagen et al, 2004.). Le dichlorométhane méthanol (1:1) extrait a montré une activité cytotoxique contre les cellules cancéreuses du sein (Kaileh et al., 2007). La décoction d'écorce est administrée par voie orale comme antipyrétique et comme stimulant de l'appétit pour le traitement du paludisme (Hanlidou et al., 2004). Les feuilles sont utilisées contre la fièvre, des maux de tête et des infections respiratoires (Kaileh et al., 2007). Données cliniques Des études cliniques ont montré qu'une dose effective d'extrait naturelle de l'écorce de quinquina provoque la même activité antipaludique qu'une dose efficace du médicament synthétisé de la quinine. Une étude en 1998 a renseigné les effets bénéfiques de l'écorce naturelle de quinine contre lescrampes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4363,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 363)",
    "text": "antipaludique qu'une dose efficace du médicament synthétisé de la quinine. Une étude en 1998 a renseigné les effets bénéfiques de l'écorce naturelle de quinine contre lescrampes de jambes, avec l'acouphènequi est le seul effet secondaire documentée. En 2002, une étude à double aveugle etdu placebo a été menée sur 98 personnes souffrant de crampes nocturnes de jambes. Elles ont pris 400 mg de quinine par jour pendant 2 semaines. Les résultats ont montré que la quinine administrée à cette dose a effectivement réduit la fréquence, l'intensité, et la douleur des crampes dans les jambes sans avoir des effets sec ondaires pertinentes (http:www.rain-tree.com). Constituants chimiques Quinine, quininidine, cinchonine et cinchonidine (Pharmacopée Africaine, 1985); aricine, acide caféique, cinchophyllamine, acide cinchotannique, cinchotine, conquinamine, cuscamidine, cuscamine, cusconidine, cusconine, épicatéchine, javanine, paricine,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4364,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 364)",
    "text": "caféique, cinchophyllamine, acide cinchotannique, cinchotine, conquinamine, cuscamidine, cuscamine, cusconidine, cusconine, épicatéchine, javanine, paricine, proanthocyanidines, quinacimine, quinamine, acide quinique, quinicine, acide quinovique, et quinovine et sucirubine (www.rain -Tree.com: Tropical plant Data Base sept 2009). Test d'identité et de purété Teneur en humidité: pas plus de 8.35 Cendre totale: 9.42 Substances extractibles par l'eau: pas moins de 3.45 Substances extractibles par l'éthanol (70): pas moins de 12.35 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4365,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 365)",
    "text": "réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de cinq taches distinctes avec valeurs R f de 0,82 (rose), 0,75 (rose), 0,68 (rose), 0,48 (rose) et 0,21 (rose). Macroscopie L'écorce est brunâtre et donne une vapeur rouge foncée lorsqu'elle est chauffée àsec. Elle a un goût amer. Microscopie On observe des microcristaux d'oxalate de calcium parfois dans l'idioblaste; de grandes fibres lignifiées, jaunâtres quand elles ne sont pas tâchetées de façon remarquable et n'ont pas de stries; il y a de même la présence de cellules à parois mince de liège dont le contenu est brun.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 732,
    "source": "PDF_chunked"
  },
  {
    "id": 4366,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 366)",
    "text": "OOAS Page 72 Cinchona pubescens WAHP Chromatogramme Matériel végétal en poudre L'écorce en poudre contient de petits grains d'amidon; des cristaux d'oxal ate de calcium microcristallines dispersés; de grandes fibres isolées avec des trous et des stries. Des sclérites très occasionnelles, des cellules à parois minces de liègeabondantes avec un contenu brun. Actions thérapeutiques Antipaludique, antipyrétique, astringent, tonique, fébrifuge amer, antiarythmique, apéritif. Indications thérapeutiques Paludisme, fièvre, connu comme tonique amer stomachique, sécrétions digestives insuffisantes (Jäger et al., 2007). Données de sécurité Des études aiguës de 24 heures chez la souris (voie orale) ont montré que laDL 50 de l'extrait aqueux de l'écorce de tige était 2000 mgkg. Les études de toxicité aiguë n'ont pas montré de signes cliniques de toxicité après traitement des souris mâle et femelle (500 à 2000 mgkg; voie orale) pendant 14 jours.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4367,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 367)",
    "text": "Les études de toxicité aiguë n'ont pas montré de signes cliniques de toxicité après traitement des souris mâle et femelle (500 à 2000 mgkg; voie orale) pendant 14 jours. Précautions d'emploi L'alcaloïde contenu dans les drogues brutes doit être administré avec prudence. Effets indésirables La surconsommation provoque un\"quinisme\" (des acouphènes, avec ou sans stupeur, des vertiges, une perte auditive temporaire), jusqu'à un coma mortel. Contre-indications Grossesse et patients hypersensibles aux alcaloïdes du quinquina. Dosage et forme galénique Extractum Cinchonae Fluidum (extrait fluide de quinquina) Extractum Cinchonae siccum Composite Tinctura Cinchonae (teinture composéede quinquina) Les doses appropriées de quinquina dépendront de plusieurs facteurs tels que l'âge de l'utilisateur, sa santé, et plusieurs autres conditions. Conservation A conserver dans un endroit frais et sec, à l'abri de la lumière Références",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4368,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 368)",
    "text": "de plusieurs facteurs tels que l'âge de l'utilisateur, sa santé, et plusieurs autres conditions. Conservation A conserver dans un endroit frais et sec, à l'abri de la lumière Références Buddenhagen, C.E., Rentería, J.L., Gardener, M., Wilkinson ,S.R., Soria, M. et al . (2004). The control of a highly invasive tree Cinchona pubescens in Galapagos . dans Weed Technology 18:1194-1202. Do Ce u de Madureira, M., Martins, A.P. Gomes, M., Paiva, J., et al. (2002). Antimalarial activity of medicinal plants used in traditional medicine in S. Tome and Prı ncipe islands. Journal of Ethnopharmacology 81:23-29. Hanlidou, E., Karousou, R., Kleftoyanni, V., Kokkini, S. (2004). The herbal market of Thessaloniki (N Greece) and its relation to the ethnobotanical tradition. Journal of Ethnopharmacology 91, 281299. Jäger, H., Tye, A., Kowarik, I. (2007). Tree invasion in naturally treeless environments: impacts of quinine (Cinchona pubescens) trees",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4369,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 369)",
    "text": "Ethnopharmacology 91, 281299. Jäger, H., Tye, A., Kowarik, I. (2007). Tree invasion in naturally treeless environments: impacts of quinine (Cinchona pubescens) trees on native vegetat ion of Galapagos . dans Biological conservation, vol., p. 297-307. Kaileh, M., Berghe, W.V., Boone, E., Essawi, T., Haegeman, G. (2007). Screening of indigenous Palestinian medicinal plants for potential anti - inflammatory and cytotoxic activity. Journal of Ethnopharmacology 113:510516. Pharmacopée Africaine (1985). Organisation de l'Unité Africaine, Commission Scientifique Technique et de la Recherche (CSTROUA). 1ère édition, vol. 1.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 623,
    "source": "PDF_chunked"
  },
  {
    "id": 4370,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 370)",
    "text": "OOAS Page 73 Cryptolepis sanguinolenta WAHP Nom botanique Cryptolepis sanguinolenta (Lindl.) Schlt Famille PeriplocaceaeAsclepiadaceae Synonyme Pergularia sanguinolenta Lindl.; C. triangularis N.E. Br. Noms communs Quinine du Ghana; racine jaune-colorant Noms vernaculaires Cote d'Ivoire: Anyi Alui Okle Ghana: Twi Nibima, Ewe Kadze, Hausa Gangaman Guinée Bissau: Banyan Konit, Diola Fu Lemok, Vulgar Balanta Butnacimbore Guinée: Fula Pulaar Delboi, Manding Bambara Uiduloia, Maninka Nombon Nigéria: Hausa Gangamaa, Igbo (Ogwashi) Kpolokoto Sénégal: Balanta Butnasimbor, Diola Flup Ahayte Buka Ka, Bambara Vidukokoy Sierra Leone: Koranko Firabantikpa, Mende Kpokoyangole Togo: Ewe Kedze, Ouatchi Anotsidzen, Mina Kadzen. Description de la plante C'est un arbustemince volubile oudebrouillage avec des feuilleselliptiques, oblongues - elliptiques,à apex aigu courtement acuminé et a",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 881,
    "source": "PDF_chunked"
  },
  {
    "id": 4371,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 371)",
    "text": "Kadzen. Description de la plante C'est un arbustemince volubile oudebrouillage avec des feuilleselliptiques, oblongues - elliptiques,à apex aigu courtement acuminé et a base symétrique , pétiolée, jusqu'à 7cm de long sur 3 cm de large, glabre; son inflorescence en cyme est latérale sur les pousses de branches ; quelque peu fleuries ,avec un tube de corolle jusqu'à 5 millimètres de long, jaune; paire de fruits de follicules linéaires ; les graines ont de longs poils soyeux. La plante sèchée à un parfum agréable et un eracine avec un goût amer. Numéro du specimen de l'herbier Ghana: GC 47510 Togo: TOGO02215 Habitat et répartition géographique Originaire d'Afrique et retrouvé dans des endroits tels qu'en Afrique -Centrale, Orientale et de l'Ouest (Tona et al , 1998; Silva et al, 1996; Oliver-Bever, 1986). Il pousse communément dans les espaces ouverts éparpillés, généralement parmi les clairières de forêts (Luo et al, 1998; GHP, 1992).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4372,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 372)",
    "text": "Oliver-Bever, 1986). Il pousse communément dans les espaces ouverts éparpillés, généralement parmi les clairières de forêts (Luo et al, 1998; GHP, 1992). Parties utilisées de la plante Racine Autres parties utilisées Feuilles et tiges Caractéristiques botaniques La quinine du Ghana est composée de racine fraîche ou séchée de Cryptolepis sanguinole nta (Lindl.) Schlt (Periplocaceae) Utilisations ethnomédicales L'extrait aqueux de cryptolepis est utilisé par les tradipraticiens de santépeuls de Guinée- Bissau pour traiter la jaunisse et l'hépatite (Oliver -Bever, 1986). Au Zaïre et dans la circonscript ion de la Casamance au Sénégal, les infusions de racines sont utilisées dans le traitement de troubles intestinaux et de l'ulcère (Silva et al , 1996; Kerharo et Adam, 1974). Au Ghana, les décoctés de poudre de racines séchées dans l'eau de la plante, sont utilisées dans le traitement de diverses formes d'infections, de la fièvre, du",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4373,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 373)",
    "text": "Kerharo et Adam, 1974). Au Ghana, les décoctés de poudre de racines séchées dans l'eau de la plante, sont utilisées dans le traitement de diverses formes d'infections, de la fièvre, du paludisme, des infections urinaires et des infections des voies respiratoires supérieures, du rhumatisme et des maladies vénériennes. Une décoction aqueuse de l'écorce de la r acine est utilisée dans la médecine traditionnelle congolaise pour le traitement de l'amibiase (Boye, 1989). Activités biologiques et pharmacologiques Des recherches scientifiques ont démontré un large éventail d'actions phytopharmacologiques du C. sanguinolenta, conformément à son usage traditionnel. La racine a été diversement utiliséeen tant que médicament antipaludique, antihypertenseur, anti -inflammatoire, agent antimicrobien et anti -hyperglycémique. Le C. sanguinolenta a montré une activité contre l'infection à campylobactérie et V. cholerae (Sawer, 1995). Les extraits de la plante se sont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 4374,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 374)",
    "text": "antimicrobien et anti -hyperglycémique. Le C. sanguinolenta a montré une activité contre l'infection à campylobactérie et V. cholerae (Sawer, 1995). Les extraits de la plante se sont averés être efficaces contre Entamoeba",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 221,
    "source": "PDF_chunked"
  },
  {
    "id": 4375,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 375)",
    "text": "OOAS Page 74 Cryptolepis sanguinolenta WAHP histolyticain vitro (Tona et al., 1998). La cryptolépine a montré une activité plus forte que les antibiotiques, le co- trimazole et le sulfaméthoxazole, mais tout aussi efficace que l'ampicilline (Paulo et al., 1994b). Le composé a également démontré des effets anti -hypertenseur et antipyrétique chez les chiens (Raymond- Hamet, 1938). La plante a démontré une activité antimicrobienne (schistosomes) et antifongique (Iwu, 1993). Les extraits aqueux ont été révélés moins efficaces que les extraits éthanoliques dans certaines études anti -paludéennes et antibactériennes (Cimanga et al , 1997; Boye, 1989). L'extrait éthanolique aqueux de l'écorce de racine a montré un antibactérien puissant, un anticomplément et des activités antivirales modérées, mais aucun effet antifongique n'a pu être détectée (Cimanga et al., 1996). D'autres études ont montré que l'extrait de C. sanguinolenta a des effets anti -inflammatoires et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 971,
    "source": "PDF_chunked"
  },
  {
    "id": 4376,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 376)",
    "text": "modérées, mais aucun effet antifongique n'a pu être détectée (Cimanga et al., 1996). D'autres études ont montré que l'extrait de C. sanguinolenta a des effets anti -inflammatoires et anti-hyperglycémiques (Bierer, et al, 1998; Bamgbose et Noamesi, 1981). Les infusions de racines sont utilisées au Zaïre et au Sénégal dans le traitement des troubles de l'estomac et de l'intestin (Sofowora, 1982; Kerharo et Adam, 1974). Une décoction aqueuse de l'écorce de racine est utilisée au Congo pour le traitement de l'amibiase (Tona, et al., 1998). Données cliniques Des essais cliniques menés au Ghana sur l'efficacité anti-paludéen de l'herbe ont donné des résultats encourageants (Boye, 1989; Boye et Ampofo, 1990). Constituants chimiques Cryptolépine, quindoline, dérivé phénolique de cryptolépine et deux autres alcaloïdes non caractérisés (Addy, 2003; Bierer et al, 1998;.Paulo et al , 1995;. Dwuma- Badu et al , 1978;.. Gellert et al., 1951).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4377,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 377)",
    "text": "cryptolépine et deux autres alcaloïdes non caractérisés (Addy, 2003; Bierer et al, 1998;.Paulo et al , 1995;. Dwuma- Badu et al , 1978;.. Gellert et al., 1951). Tests d'identité et de purété Teneur en humidité: pas plus de 9.2 Cendre totale: 8.9 Substances extractibles par l'eau: pas moins de 20.2 Substances extractibles par l'éthanol (70): pas moins de 11.9 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de trois taches distinctes avec valeurs R f de 0,92 (jaune), 0,72 (rose) et 0,45 (rose) Chromatogramme Macroscopie Racine tortueuse, avec peu ou pas de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4378,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 378)",
    "text": "pendant 5-10 mn. Présence de trois taches distinctes avec valeurs R f de 0,92 (jaune), 0,72 (rose) et 0,45 (rose) Chromatogramme Macroscopie Racine tortueuse, avec peu ou pas de ramification de radicelles; surface extérieure brun- jaunâtre, longitudinalement striée, des fissures occasionnelles ou exfoliatiantes; des fractures lisses sur la surface transversale jaune avec une odeur faible et un goût amer. Microscopie La coupe transversale montre 5-8 dispositions de cellules de liège à parois minces avec une couleur brun- jaunâtre; un cortex secondaire d'environ deux tiers de diamètre de racine, des cellules polygonales à parois mi nces du parenchyme jusqu'à 1.0 μm de diamètre avec des grains d'amidon simples et composés de 0.05-0.18 μm; le parenchyme du phloème et les tubes criblés sont séparés du cortex à partir du bois, le bois se compose de vaisseaux épais",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 870,
    "source": "PDF_chunked"
  },
  {
    "id": 4379,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 379)",
    "text": "OOAS Page 75 Cryptolepis sanguinolenta WAHP lignifiés, de fibres et de trachéides, de vaisseaux de 0.23 à 1.27 μm de diamètre et de fibres de 0,05 à 0,27 μm de diamètre. Matériel végétal en poudre Couleur jaune; goût amer; cellules de liège; parenchyme avec grains d'amidonabondants; éléments de xylème lignifiés de vaisseaux et de fibres abondants. Actions thérapeutiques Antibactérien; anti -inflammatoire; antipaludique (souches sensibles et résistantes à la chloroquine); antipyrétique; antiviral; hypoglycémiant; hypotenseur (Addy, 2003; GHP, 1992; Iwu, 1993; Silva, 1996; Brierer, 1998). Indications thérapeutiques Coliques abdominales; amibiase, diarrhée, fièvre, hypertension, infections microbiennes, paludisme, rhumatisme, maux d'estomac, infections des voies respiratoires et urinaires (Candida) et maladies vénériennes (Mshana et al, 2000; Iwu 1993; Boye et Ampofo, 1990; Wright et al, 1996; Boakye-Yiadom, 1979). Données de sécurité",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4380,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 380)",
    "text": "(Candida) et maladies vénériennes (Mshana et al, 2000; Iwu 1993; Boye et Ampofo, 1990; Wright et al, 1996; Boakye-Yiadom, 1979). Données de sécurité Dans les études animales chez le rat, la DL 50 était 3000 mgkg et le traitement n'a pas provoqué de changements dans le ratio organepoids c orporel. L'extrait aqueux a provoqué une augmentation dose-dépendante de la durée de sommeil chez le rat pentobarbital dans les deux études de toxicité subaiguë de 24 heures et de 14 jours (Ansah et al ., 2008). En outre, l'extrait aqueux a provoqué une dim inution de l'activité spontanée chez la souris lorsqu'on utilisesa cage d'activité (Ansah et al., 2008). Une augmentation du nombre de plaquettes et de neutrophiles polynucléaires a été observée, mais il n'y avait pas d'effets indésirables graves sur le foie ou le rein. L'activité anxiogène de l'extrait aqueux a été démontrée chez la souris (Ansah et al., 2008). L'extrait aqueux est cytotoxique pour",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4381,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 381)",
    "text": "foie ou le rein. L'activité anxiogène de l'extrait aqueux a été démontrée chez la souris (Ansah et al., 2008). L'extrait aqueux est cytotoxique pour les cellules mammelles in vitro . L'activité cytotoxique de l'importante cryptolépine alcaloïde est considérée comme étant due à l'interaction avec l'ADN (Bonjean et al., 1988) et la liaison à la topoisomérase II (Bonjean et al ., 1988). L'extrait aqueux affecte la reproduction et le développement du fœtus chez la souris grâce à l'inhibition de la croissance intra- utérine, la diminution de la fertilité féminine et masculine. Précautions d'emploi Ne pas administrer l'extrait acqueux pendant la grossesse. Des précautions doivent être prises lors de la conduite ou l'utilisation de machines. Effets indésirables Les résultats des études animales suggèrent que l'extrait aqueux peut entraîner une sédation, une faible numération des spermatozoïdes et éventuellement un avortement spontané en cas",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4382,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 382)",
    "text": "Les résultats des études animales suggèrent que l'extrait aqueux peut entraîner une sédation, une faible numération des spermatozoïdes et éventuellement un avortement spontané en cas de surdosage, mais cela n'a pas été démontré chez l'homme. Contre-indications Grossesse, faible numération de spermatozoïdes, ulcération gastrique. Dosage et forme galénique Infusion: 2,5 g sachet de l'écorces de racines trempées dans 150 ml (1 tasse) d'eau bouillante; laisser infuser pendant 5- 10 minutes (Boye, 2002) Décoction: 40 g par litre d'eau, 3- 5 tasses de café tous les jours Teinture: 1:5 dans de l'alcool 45, 5 ml trois fois par jour Conservation A conserver dans un endroit frais et sec. Références Addy, M. (2003). Cryptolepis: An African Traditional Medicine that Provides Hope for Malaria Victims. HerbalGram 60:54-59, 67. Ansah, C., Zhu, H., Gooderham, N.J. (2008). The mechanism of cryptolepine- induced cell death.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4383,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 383)",
    "text": "Traditional Medicine that Provides Hope for Malaria Victims. HerbalGram 60:54-59, 67. Ansah, C., Zhu, H., Gooderham, N.J. (2008). The mechanism of cryptolepine- induced cell death. Journal of Pharmacology Toxicology, 3: 291-301. Bamgbose, S.O.A, Noamesi, B.K. (1981). Studies on cryptolepine II: Inhibition of carrageenan-induced oedema by cryptolepine. Planta Medica, 41:392 396. Boakye-Yiadom, K. (1979). Antimicrobial properties of some West African medicinal plants. II. Antimicrobial activity of aqueous extracts of Cryptolepis sanguino lenta (Lindl.) Schlechter. Quart Journal of crude Drug Researcg, 17:78-80. Bonjean, K., DePauw -Gillet, M.C., Defresne, M.P. et al., (1988). The DNA intercalating alkaloid cryptolepine interacts with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry 37:5136-46. Boye, G.L. (1989). Studies on antimalarial action of Cryptolepis sanguinolenta extract.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4384,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 384)",
    "text": "inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry 37:5136-46. Boye, G.L. (1989). Studies on antimalarial action of Cryptolepis sanguinolenta extract. Proceedings of the International Symposium on East-West Medicine; Seoul, Korea, 243-51. Boye, G.L., Ampofo, O. (1990). Medicinal Plants in Ghana. In: Wagner and Farnsworth NR, editors. Economic and Medicinal Plants",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 383,
    "source": "PDF_chunked"
  },
  {
    "id": 4385,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 385)",
    "text": "OOAS Page 76 Cryptolepis sanguinolenta WAHP Research. Vol. 4. Plants and Traditional Medicine. London: Academic Press; 32-33. Bierer, D.E., Fort, D.M., Mendez, C.D. et al., (1998). Ethnobotanical -directed discovery of the antihyperglycaemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities. Journal of Medicinal Chemistry, 41: 894-901. Cimanga, K., De Bruyne, T., Pieters, L., Vlietinc k, A.J. (1997). In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta . Journal of Natural Products 60:688-691. Cimanga, K., De Bruyne, T., Lasure, A., Van Poel, B. et al., (1996). In vitro biological activities of alkaloids from Cryptolepis sanguinolenta . Planta Medica 62(1):22-27. Dwuma-Badu, D., Ayim, J.S.K., Fiagbe, N.Y.I., Knapp, P.E. et al., (1978). Constituents of West African medicinal plants XX: Quindoline from",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4386,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 386)",
    "text": "Planta Medica 62(1):22-27. Dwuma-Badu, D., Ayim, J.S.K., Fiagbe, N.Y.I., Knapp, P.E. et al., (1978). Constituents of West African medicinal plants XX: Quindoline from Cryptolepis sanguinolent a. Journal of Pharmaceutical Science 67:4339-434. Gellert, E., Raymond-Hamet, Schlittler, E. (1951). Die Konstitution des Alkaloids Cryptolepin. (The structure of the alkaloid cryptolepine) Helvetica Chimica Acta; 34: 642-51. Ghana Herbal Pharmacopoeia ( 1992). The Advent Press: Accra, Ghana. Iwu, M. (1993). Handbook of African medicinal plants. CRC Press, Boca Raton, FL. Kerharo, J., Adam, J.G. (1974). La pharmacopee Senegalaise traditionnelle. Plantes medicinal et toxiques. Paris: Vigot et Freres; 632-633. Luo, J., Fort, D.M., Carlson, T.J., et al., (1998). Cryptolepis sanguinolenta : an ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycaemic agent. Diabetic Medicine; 15:367-74.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4387,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 387)",
    "text": "Cryptolepis sanguinolenta : an ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycaemic agent. Diabetic Medicine; 15:367-74. Mshana, N.R., Abbiw, D. K., Addae -Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al. (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Oliver-Bever, B.E.P. (1986). Medicinal Plants in Tropical West Africa. Cambridge: Cambridge University Press; pgs 18, 41, 131, 205. Paulo, A., Gomes, E.T., Houghton, P.J. (1995). New alkaloids from Cryptolepis sanguinolenta. Journal of Natural Productcs 58:1485-1491. Paulo, A., Pimentel, M., Viegas, S., et al. (1994a) Cryptolepis sanguinolenta activity against diarrhoeal bacteria. Journal of Ethnopharmacology 44:73-77. Paulo, A., Duarte, A., Gomes, E.T. (1994b). In",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4388,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 388)",
    "text": "Cryptolepis sanguinolenta activity against diarrhoeal bacteria. Journal of Ethnopharmacology 44:73-77. Paulo, A., Duarte, A., Gomes, E.T. (1994b). In vitro antibacterial screening of Cryptolepis sanguinolenta alkaloids. Journal of Ethnopharmacology 44:127-130. Raymond-Hamet, C.R. (1938). Hypotensive and vasodilator effects of cryptolepine. Comptes rendus de l'Académie des sciences 207: 1016- 1018. Sawer, I.K., Berry, M.I., Brown, M .W., Ford, J.L. (1995). The effect of cryptolepine on the morphology and survival of Escherichia coli , Candida albicans and Saccharomyces cerevisiae. Journal of Applied Bacteriology 79:314-321. Silva, O., Duarte, A., Cabrita, J., Pimentel, M., et al., (1996). Antimicrobial activity of Guinea- Bissau traditional remedies. Journal of Ethnopharmacology 50:55-59. Sofowora, A. (1982). Medicinal Plants and Traditional Medicine in Africa. John Wiley and Sons. Chichester; 221-223.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 914,
    "source": "PDF_chunked"
  },
  {
    "id": 4389,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 389)",
    "text": "Bissau traditional remedies. Journal of Ethnopharmacology 50:55-59. Sofowora, A. (1982). Medicinal Plants and Traditional Medicine in Africa. John Wiley and Sons. Chichester; 221-223. Tona, L., Kambu, K., Ngimbi, N. , et al., (1998). Antiamoebic and phytochemical screening of some Congolese medicinal plants. Journal of Ethnopharmacology 61(1): 57-65. Wright, C.W., Phillipson, J.D., Awe, S.O., Kirby, G.C., et al., (1996). Antimalarial activity of cryptolepine and some other anhydronium bases. Phytotherapy Research 10:361-363.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 530,
    "source": "PDF_chunked"
  },
  {
    "id": 4390,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 390)",
    "text": "OOAS Page 77 Cymbopogon citratus WAHP Nom botanique Cymbopogon citratus (DC.) Stapf. Famille Poaceae Synonyme Andropogon citratus DC Noms communs Herbe de fièvre; Citronnelles (F). Noms vernaculaires Burkina Faso : Dioula Bin boulou;citroneli, Fulfuldé Wuluundé Gambie: Manding Mandinka Kanyang Yallo Ghana: Fante Ti-Ahaban, Ga-Adangbe Ti-Ba, Ewe Tighe. Guinée: Konyagi I-Dεl Tεgag Guinée-Bissau: Crioulo Belgata, Mali: Bambara Bin boulou, SenoufoCafi- gna Nigéria: Ibibio Myoyaka Makara, Igbo (Owerri) Achara Ehi, Yoruba Kooko Oba. Sierra Leone : Bulom(Kim) Pei-Poto, Kono Pu-Lumbi, Mendu Pu-Lumbe. Sénégal: Bambara cè kala Togo: Ewe Tsigbe, Ouatchi Gbehoin, Mina Fifaglass Description de la plante C'est une herbe vivace, corpulante, aromatique atteignant de 2 m de haut ou plus. Elle est rarement fleurie, robuste avec des feuilles vert - claires odorantes et aromatiques, se dressantsur",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 890,
    "source": "PDF_chunked"
  },
  {
    "id": 4391,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 391)",
    "text": "C'est une herbe vivace, corpulante, aromatique atteignant de 2 m de haut ou plus. Elle est rarement fleurie, robuste avec des feuilles vert - claires odorantes et aromatiques, se dressantsur les racines adventives; les glumes inférieures de l'épillet sessile sont étroitement lancéolées, presque plates, profondément concaves, avec un fond de dépression arrondie et sans ailes au sommet. Les limbes de feuilles sont linéaires à filiformes, se rétrécissant à la base; les feuilles sont odorantes, liées par un ruban adhésif de 70 cm de long sur 5-15 mm de large aux extrémités; les marges scrabeuses et des nervures proéminentes sont en dessous; l'inflorescence est en panicules (Burkill, 1985). Numéro du specimen de l'herbier Nigeria: FHI 107437 Togo: TOGO10749 Habitat et repartition géographique Elle est originaire de l'Asie tropicale et cultivée dans les maisons comme une herbe médicinale; de même, elle est utilisée comme plante",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4392,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 392)",
    "text": "Togo: TOGO10749 Habitat et repartition géographique Elle est originaire de l'Asie tropicale et cultivée dans les maisons comme une herbe médicinale; de même, elle est utilisée comme plante ornementale en horticulture dans les composés, en bordure des routes, sur les berges et les flancs des collines pour enrayer l'érosion. Parties utilisées de la plante Feuilles fraîches ou séchées Autres parties utilisées Fleur Caractéristiques botaniques La citronnelle est une feuille fraîche ou séchée de Cymbopogon citratus L. (Poaceae) Utilisations ethnomédicales C. citratus est utilisé comme un médicament antipaludique, diurétique, tonique, stomachique, emménagogue fébrifuge, antiseptique, anxiolytique, hypnotique, anticonvulsivant, hypotenseur, anticatarrhale et antiheumatique dans la médecine traditionnelle africaine (Pharmacopée Africaine, 1985; Burkill, 1985; Kerharo et Adam, 1974; Oliver, 1959). Il est indiqué pour la toux, le lumbago, l'entorses, la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4393,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 393)",
    "text": "dans la médecine traditionnelle africaine (Pharmacopée Africaine, 1985; Burkill, 1985; Kerharo et Adam, 1974; Oliver, 1959). Il est indiqué pour la toux, le lumbago, l'entorses, la teigne, le pied d'athlète, le paludisme, la fièvre, la jaunisse, les infections de la gorge et des voies respiratoires, les pertubations modérées avec douleur sévère, l'hypertension, le diabète sucré, l'obésité, les troubles nerveux et gastr o- intestinales (Adeneye et Agbaje, 2007; Blanco et al, 2007; Tchoumbougnang et al, 2005; Onabanjo et al , 1993; Gill, 1992; Carlini et al , 1986). Activités biologiques et pharmacologiques Une crème faite avec la plante a été efficace contre la teigne et des isolats cliniques in vitrode quatre dermatophytes (Wannissorn et al , 1996; Lima et al, 1993). Dans un essai de deux jours sur une peau d'un oiseau d'expérience, les formulations d'onguent et de crème contenant l'huile de citronnelle ont montré des actio ns",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4394,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 394)",
    "text": "Lima et al, 1993). Dans un essai de deux jours sur une peau d'un oiseau d'expérience, les formulations d'onguent et de crème contenant l'huile de citronnelle ont montré des actio ns répulsives de moustiques comparable à celle d'un produit répulsif commercial de moustique",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 271,
    "source": "PDF_chunked"
  },
  {
    "id": 4395,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 395)",
    "text": "OOAS Page 78 Cymbopogon citratus WAHP (Oyedele et al., 2002). L'huile essentielle possède également une activité antibactérienne (Wannissorn et al., 2005). Les composants géranial et néral ont individ uellement montré une action antibactérienne à large spectre, mais le myrcène seule n'a montré aucune activité antibactérienne observable (Onawunmi et al., 1984). L'huile essentielle a également possédé une action antinociceptive tandis que l'administration par voie orale et intrapéritonéale de l'huile a augmenté le temps de réaction des stimuli thermiques et empêchant fortement les contorsions causées par l'acide acétique chez les souris. La naloxone, un antagoniste des opioïdes a empêché l'action antinocic eptive centrale de l'huile (Viana et al., 2000). Les extraits de plante se sont également avérés avoir des effets analgésiques topiques (Lorenzetti et al ., 1991). Des études in vivo ont montré que l'huile essentielle possède des propriétés anxiolytique,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 968,
    "source": "PDF_chunked"
  },
  {
    "id": 4396,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 396)",
    "text": "se sont également avérés avoir des effets analgésiques topiques (Lorenzetti et al ., 1991). Des études in vivo ont montré que l'huile essentielle possède des propriétés anxiolytique, sédative et anticonvulsivante (Blanco et al., 2007) ainsi que des effets antimicrobien et anti - oxydant (Saccheti et al., 2005) et un effet inhibiteur sur le début d'une phase de diéthylnitrosamine induite par l'hépatocarcinogenèse chez le rat (Puatanachokchai et al ., 2002). Les extraits de feuilles de C. citratus ont montré des effets antidiabétiques in vivo . Une prise orale quotidienne à jeûn de 125 à 500 mgkg de l'extrait aqueux des feuilles fraîches de la plante réduit la glycémie et les paramètres lipi diques normaux, des rats mâles Wistar pendant 42 jours. L'extrait a elévé le niveau du cholestérol HDL de plasma, mais le niveau de triglycéride de plasma est resté inchangé (Adeneye et Agbaje, 2007). Les extraits de la plante ont montré la vasorelaxat ion endothélium -",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 969,
    "source": "PDF_chunked"
  },
  {
    "id": 4397,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 397)",
    "text": "HDL de plasma, mais le niveau de triglycéride de plasma est resté inchangé (Adeneye et Agbaje, 2007). Les extraits de la plante ont montré la vasorelaxat ion endothélium - dépendante sur la préparation isolée, perfusée de l'artère mésentérique (Carbajal et al , 1989.) et l'extrait de feuilles d'éthanol a également été signalé avoir des propriétés anti -mutagène et anti-cancérigène (Suaeyun et al , 1997; Vinitketkurmnuen et al., 1994). Données cliniques Dans une étude préliminaire, l'infusion de la citronnelle a démontré des effets bénéfiques dans le traitement de la candidose buccale chez les patients vivant avec le VIHSIDA. Des essais cliniques suboptimauxet sous -optimaux humainsont également été menés sur la citronnelle pour évaluer ses effets sur l'hyperlipidémie et l'anxiété. Une étude s'est penchée sur des capsules d'huile de citronnelle pour réduire le cholestérol chez les patients hypercholestérolémiques et n'a constaté aucun",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4398,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 398)",
    "text": "l'hyperlipidémie et l'anxiété. Une étude s'est penchée sur des capsules d'huile de citronnelle pour réduire le cholestérol chez les patients hypercholestérolémiques et n'a constaté aucun avantage notable. Une autre étude réalisée par Leite et al . (1986) a également montré que Lemongras n'a aucun effet dans le traitement de l'anxiété. Constituants chimiques Constituants volatils du pétrole (par exemple cymbopogone, cymbopogonol, citral, géraniol, citronellal, camphène et connexes monoterpènes, triterpènes et sesquiterpènes); alcaloïdes, saponines, flavonoïdes, tanins et sucres simples (Onabanjo et al, 1993; GHP, 1992; Hanson et al ., 1976) Tests d'identité et de purété Teneureneau:( Pharmacopée Africaine ,1986): pas plus de 68 Cendretotale: pas plus de 8,1 Cendrenon soluble dans l 'acide: pas plus de 0,9 Cendresoluble dans l'eau: moins de 2,5 Valeur soluble extractibledans l 'eau: moins de 7,0 Valeur soluble extractible dans l 'alcool (70):",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4399,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 399)",
    "text": "Cendrenon soluble dans l 'acide: pas plus de 0,9 Cendresoluble dans l'eau: moins de 2,5 Valeur soluble extractibledans l 'eau: moins de 7,0 Valeur soluble extractible dans l 'alcool (70): moins de 9,2 Indice stomatique: 30,8 Tenueur en huile volatile: moins de 0,75 (Elujoba et Odeleye, 2005; Odukoya et al , 1987). Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de quatre taches distinctes avec valeurs R f de 0,90 (violet), 0.74 (violet), de 0,62 (violet) et 0,47 (violet). Macroscopie Une graminée vivace, rarement annuelle,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 916,
    "source": "PDF_chunked"
  },
  {
    "id": 4400,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 400)",
    "text": "pendant 5-10 mn. Présence de quatre taches distinctes avec valeurs R f de 0,90 (violet), 0.74 (violet), de 0,62 (violet) et 0,47 (violet). Macroscopie Une graminée vivace, rarement annuelle, herbeodorante, avec des feuilles aromatiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 235,
    "source": "PDF_chunked"
  },
  {
    "id": 4401,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 401)",
    "text": "OOAS Page 79 Cymbopogon citratus WAHP Chromatogramme (citron), très parfumées, formant des touffes compactes, pouvant atteindre environ 1- 2 m de haut; les feuilles sont portées par un chaume, droit, et une gaine de lame entourant la base de la prochaine feuille supérieur sur le chaume ; la gaine est tubulaire et fendue sur le côté opposé à la lamelle; les feuilles sont non- auriculées et habituellement vert -vives, pubescentes, longues et étroites avec des veines normalement parallèles; la lamelle de feuilles linéaires, larges a une nervation parallèle; la marge des feuilles est pubescente, entière avec un apex atténué, se rétrécissant à la base, jusqu'à 60 cm de long ou plus sur 15 cm de large; le limbe defeuille linéaires ou larges ont une nervation paral lèle; les gaines foliaires inférieures ont une floraison onduléeparticulière; la plante est rarement fleurie avec unefloraison de 1,5 à 1,75 m de long et de nombreuses ramifications; les chaumes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 963,
    "source": "PDF_chunked"
  },
  {
    "id": 4402,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 402)",
    "text": "les gaines foliaires inférieures ont une floraison onduléeparticulière; la plante est rarement fleurie avec unefloraison de 1,5 à 1,75 m de long et de nombreuses ramifications; les chaumes rhizomateuses ont 15- 250 cm de haut, herbacées et non ramifi ées en haut; les nœuds de chaume sont des nœuds glabres et chaume solide; les pousses sont aromatiques (Folorunso et al, 2005; Odukoya, 1984; Kerharo et. Adams, 1974). Microscopie On observe les caractéristiques microscopiques typiques d'une herbeespèces monocotylédone; les cellules épidermiques de la surface supérieure se composent de cellules parenchymateuses tabulaires, de forme irrégulière tandis que l'épiderme inférieur est constitué de cellules similaires contenant des cristaux prismatiques d'oxalate de calcium; des stomates en forme de dôme se trouvent sur la surface inférieure, tandis que la section longitudinale montre des cellulesle long des parois, contenant des cristaux d'oxalate de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4403,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 403)",
    "text": "stomates en forme de dôme se trouvent sur la surface inférieure, tandis que la section longitudinale montre des cellulesle long des parois, contenant des cristaux d'oxalate de calcium; des poils tecteurs multicellulaires, de types couvr ant; les éléments vasculaires d'épaississement annulaire et réticulés regorgent des zones côtières remarquables et intercostales dans la surface abaxiale. Des poils piquantes sont présentes sur la zone côtière, mésurant 2,75-3,75 μ de long avec des aiguillons intercostaux de longueur 1μ; des stomates paracytiques et solitaire ou entre piquants intercostaux ou microhairs; les stomates sont de 1,75-2 μ de long sur 1,5-1,75 μ de large, soit 1 ou 2 rangées parallèles qui se produisent dans la zone intercostale; les microhairs de type panicoïdeprésents sur les zones côtière et intercostale avec 2- 2,5 μ de long sur 0,5- 0,75 μ de large lorsque unisériées; quelques microhairs bisériés présents; de longues cellules similaires",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 4404,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 404)",
    "text": "panicoïdeprésents sur les zones côtière et intercostale avec 2- 2,5 μ de long sur 0,5- 0,75 μ de large lorsque unisériées; quelques microhairs bisériés présents; de longues cellules similaires dans la forme costal et intercostal de 5,5-7,5 μ de long, et ondulées; cellules courtes présentes sur la zone intercostal de 0,5- 0,75 μ de long contenant des tanins légers jaunâtres;sur la surface adaxiale, les zones de costales et intercostales sont visibles; dans la section transversale, la limbe de feuilles est adaxiallement plate avec une nervure centrale visible; la feuille est amphistomatiques tandis que les faisceaux vasculaires sont disposés de façon linéaire et bicollatérale à travers la lame; le sclérenchyme, les osteosclérides ou macrosclérides entourent les faisceaux vasculaires; le métaxylème mesure 1,25- 2,25 μ de large sur 2,25-3 μ de long; le mésophylle n'est pas différencié dans la palissade ou dans le type spongieux, mais est constitué de cellules",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 969,
    "source": "PDF_chunked"
  },
  {
    "id": 4405,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 405)",
    "text": "vasculaires; le métaxylème mesure 1,25- 2,25 μ de large sur 2,25-3 μ de long; le mésophylle n'est pas différencié dans la palissade ou dans le type spongieux, mais est constitué de cellules polygonales; les régions costales sont présentes dans la section longitudinale tangentielle de la feuille; la région côtière est serrées entre les vaisseauxet les tubes criblés; les stomates anomocytiques linéaires situés dans 1 ou 2 rangées se produisent dans les régions intercostales; quelques poils (microhair) non- glandulaires unisériés, de 2,5- 3 μ de long sur l'épiderme se trouvent dans les régions intercostales ; les piquants sont présents sur les deux surfaces abaxiale et adaxiale, avec 3,25-5,7 μ de large sur 3,25- 8,25 u de long; les fragments de vaisseaux sont occasionnellement de forme annulaires avec des perforations simples; les cellules du parenchyme sont de forme rectangulaire; les parois d'extrémité sont généralement perpendiculaires,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 4406,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 406)",
    "text": "annulaires avec des perforations simples; les cellules du parenchyme sont de forme rectangulaire; les parois d'extrémité sont généralement perpendiculaires, occasionnelement obliques et de 5 à 7,5 μ de long; les parois anticlinales sont droites; les druses, les tanins et les grains d'amidon sont présents dans les cellules du parenchyme des régions côtières. Ils sont à la fois intercostales et costales, (Odukoya, 1984). Matériel végétal en poudre Des fibres lignifiées apparaissent avec une lumière persistante, di munuant aux extrémités;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 541,
    "source": "PDF_chunked"
  },
  {
    "id": 4407,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 407)",
    "text": "OOAS Page 80 Cymbopogon citratus WAHP les cellules du parenchyme sont plus ou moins allongées, les stomates anomocytiques sont disposées linéairement entre les cellules du parenchyme; les cristaux polyhydriques d'oxalate de calcium; les aiguillons de 3,25 à 8,25 μ de longueur, des fragments des tissus de faisceau vasculaire (xylème et phloème), de l'épaississement annulaire et réticulée, et non lignifiées ont des bordures de navires dénoyautées, non-glandulaires, couvrant les poils et beaucoup de globules d'huile dans le champ de vision de la lumière. Ils sont de couleur verte avec une odeur aromatique (comme celui du citron) et ungoût caractéristique (Folorunso et al., 2005). Actions thérapeutiques Analgésique, antiasthmatique (prophylactique), anticatarrhale, antidiarrhéique, antibactérien, anti-diabétique, antifongique, antirhumatisme, carminative, diurétique, fébrifuge, vasodilatateur, antinociceptif, sédative, anxiolytique, insectifuge",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4408,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 408)",
    "text": "anti-diabétique, antifongique, antirhumatisme, carminative, diurétique, fébrifuge, vasodilatateur, antinociceptif, sédative, anxiolytique, insectifuge (huile de citronnelle); sudorifique (Dokosi, 1998; Ayittey-Smith, 1989). Indications thérapeutiques Asthme, catarrhe, choléra, adjuvant cosmétique, diarrhée, fièvre, rhumatismes, teigne. Données de sécurité La DL 50 de l'extrait aqueux des feuilles chez le rat (p.o) était 3000 mgkg. Aucun signe de toxicité n'a été observé c hez les rats femelles utilisés pour l'étude ; de mêmequ'aucun effet sur le système sanguin, rénal ou hépatique. Dans la présente étude, l'extrait aqueux des feuilles amontré une sécurité sûre. Précautions d'emploi L'huile volatile (huile de Cymbopogon) obtenue par distillation de la vapeur des feuilles fraîches une fois utilisée comme agent aromatisant ou comme préparation antimicrobienne, doit être réglementé pour éviter tout risque de toxicité excessive. Effets indésirables",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4409,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 409)",
    "text": "une fois utilisée comme agent aromatisant ou comme préparation antimicrobienne, doit être réglementé pour éviter tout risque de toxicité excessive. Effets indésirables Des études expérimentales n'ont montré aucun effet indésirable. Contre-indication Grossesse et allaitement Dosage et forme galénique Décoction: 30 g d'herbe séchée dans 900 ml d'eau et laisser mijoter jusqu'à réduction à 600 ml; 1 tasse à thé trois fois par jour. Infusion: 30 g d'herbe séchée dans 600 ml d'eau, 1 tasse à thé trois fois par jour. Teinture: 1:5 dans de l'éthanol45; 5 ml trois fois par jour. Conservation A conserver dans des récipients bien fermés, dans un endroit frais et sec, à l'abri de la lumière. Référence Adeneye, A.A., Agbaje, E.O. (2007). Hypoglycemic and hypolipidemic effects of fresh leaf aqueous extract of Cymbopogon citratus Stapf. in rats. Journal of Ethnopharmacology 112:440-444. African Pharmacopoeia Vol. 1. (1985). 1Ed.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4410,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 410)",
    "text": "leaf aqueous extract of Cymbopogon citratus Stapf. in rats. Journal of Ethnopharmacology 112:440-444. African Pharmacopoeia Vol. 1. (1985). 1Ed. Organisation of African Uni ty's Scientific, Technical and Research Commission, Lagos. Nigeria. Ayittey-Smith, E. (1989). Prospects and scope of plant medicine in health care. Accra: Ghana Universities Press. Blanco, M.M., Costa, C.A.R.A., Freire, A.O., Santos Jr, J.G. et al ., (20 07). Neurobehavioral effect of essential oil of Cymbopogon citratus in mice. Phytomedicine, 4: 007. Burkill, H. M. (1985). The Useful Plants of West Tropical Africa. 2 nd Edition. Vol. 1. Royal Botanic Gardens, Kew. London. Carbajal, D., Casaco, A., Arr uzazabala, L., Gonzalez, R. et al ., (1989). Pharmacological study of Cybopogon citratus leaves. Journal of Ethnopharmacology 25:103-107. Carlini, E.A., Contar, J.P., Silva -Filho, A.R., Da Silveira-Filho, N.G. et al ., (1986). Pharmacology",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 4411,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 411)",
    "text": "study of Cybopogon citratus leaves. Journal of Ethnopharmacology 25:103-107. Carlini, E.A., Contar, J.P., Silva -Filho, A.R., Da Silveira-Filho, N.G. et al ., (1986). Pharmacology of lemongrass ( Cymbopogon citratus Stapf.) I: Effect of teas prepared from the leaves on laboratory Animals. Journal of Ethnopharmacology 17:37-64. Dokosi, O.B. (1998). Herbs of Ghana, Ghana University Press: Ghana, 564-565. Elujoba, A. A , Olawode, E. O. (2005). Techni cal Report of the commissioned chromatographic fingerprint analysis on Cymbopogon citratus to World Health Organization, Nigeria. Folorunso, A. E., Omobuwajo, O. R., Elujoba, A. A. (2005). Technical Report of commissioned macro- and micro- morphology of Cymbopogon citratus leaf submitted to World Health Organization, Nigeria.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 779,
    "source": "PDF_chunked"
  },
  {
    "id": 4412,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 412)",
    "text": "OOAS Page 81 Cymbopogon citratus WAHP Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana. Gill L, S. (1992). Ethnomedical Uses of Plants in Nigeria. Printed and Published by University of Benin Press. Benin-City, Nigeria. Hanson, S.W., Crawford, M., Koker, M.E.S., Menezes, F.A. (1976). Cymbopogonol, a new triterpenoid from Cymbopogon citratus . Phytochemistry 15:1074-1075. Kerharo, J., Adams, J.G. (1974). La Pharmacopea Senegalaise Medicine Traditional. Vigot, Paris p. 645. Leite, J.R., Seabra, M.L., Maluf, E., Assolant, K., Suchecki, D., Tufik, S. et al (1986). Pharmacology of lemongrass ( Cymbopogon citratus Stapf).Assessment of eventual toxic, hypnotic and anxiolytic effects on humans. Journal of Ethnopharmacology 17:7583. Lima, E.O., Gompertz, O.F., Giesbrecht, A.M., Paulo, M.Q. (1993). In vitro antifungal activity of essential oils obtained from officinal plants against dermatophytes. Mycoses 36(9):333336.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4413,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 413)",
    "text": "Lima, E.O., Gompertz, O.F., Giesbrecht, A.M., Paulo, M.Q. (1993). In vitro antifungal activity of essential oils obtained from officinal plants against dermatophytes. Mycoses 36(9):333336. Lorenzetti, B.B., Souza, G.E.P., Sarti, S.J. et al., (1991). Myrcene mimics the peripheral analgesic activity of lemon grass tea. Journal of Ethnopharmacology 34:43-48. Odukoya, A., Elujoba A.A., Sofowora, A. (1987). Establishment of some pharmacopoeial standards for Nigerian medicinal plants VI: Cymbopogon citratus (DC.) Stapf. Nigerian Journal of Pharmaceutical Science 3(2):39-42. Odukoya, O.A. (1984). Establishment of Pharmacopoeia standards for two Nigeria medicinal plants. M.Phil. (Pharmacognosy) Thesis. University of Ife (now Obafemi Awolow o University), Ile Ife, Nigeria. Oliver, B. (1959). Nigerian Medicinal Plants. The Nigerian College of Science and Technology, Ibadan. Nigeria (1959) pp. 60-63. Onabanjo, A.O., Agbaje, E.O., Odusote, O.O.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4414,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 414)",
    "text": "Oliver, B. (1959). Nigerian Medicinal Plants. The Nigerian College of Science and Technology, Ibadan. Nigeria (1959) pp. 60-63. Onabanjo, A.O., Agbaje, E.O., Odusote, O.O. (1993). Effects of Aqueous Extracts of Cymbopogon citratus in Malaria. Journal of Protozoological Research 3:4045. Onawunmi, G.O., Yisak, W.A., Ogunlana, E.O. (1984). Antibacterial constituents in the essential oil of Cymbopogon citratus (DC) Stapf. Journal of Ethnopharmacology 12:274-286. Oyedele, A .O., Gbolade, A.A., Sosan, M.B., Adewoyin, F.B. et al ., (2002). Formulation of an effective mosquito- repellent topical product from Lemongrass oil. Phytomedicine 9: 259262. Puatanachokchai, R., Kishida, H., Denda, A., Murata, N. et al ., (2002). Inhibitory effects of lemon grass ( Cymbopogon citratus , Stapf) extract on the early phase of hepatocarcinogenesis after initiation with diethylnitrosamine in male Fischer 344 rats. Cancer Letters 183:915.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4415,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 415)",
    "text": "lemon grass ( Cymbopogon citratus , Stapf) extract on the early phase of hepatocarcinogenesis after initiation with diethylnitrosamine in male Fischer 344 rats. Cancer Letters 183:915. Sacchetti, G., Maietti, S., Muzzoli, M., Scaglianti, M. et al., (2005). Comparative evaluation of 11 essential oils of different origin as functional antioxidants, antiradicals and antimicrobials in foods. Food Chemistry 91:62-632. Tchoumbougnang F, Zollo PH, Dagne E, Mekonnen Y (2005). In vivo antimalarial acti vity of essential oils from Cymbopogon citratus and Ocinum gratissimum on mice infected with Plasmodium berghei. Planta Medica 71:2023. Suaeyun, R., Kinouchi, T., Arimochi, H., Vinitketkumnuen, U . et al ., (1997). Inhibitory effects of lemon grass ( Cymbopogon citratus Stapf) on formation of azoxymethane- induced DNA adducts and aberrant crypt foci in the rat colon. Carcinogenesis 18:949955. Viana, G.S.B., Vale, T.G., Pinho, R.S.N., Matos,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4416,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 416)",
    "text": "Stapf) on formation of azoxymethane- induced DNA adducts and aberrant crypt foci in the rat colon. Carcinogenesis 18:949955. Viana, G.S.B., Vale, T.G., Pinho, R.S.N., Matos, F.J.A. (2000). Antinociceptive effect of the essential oil from Cy mbopogon citratus in mice. Journal of Ethnopharmacology 70:323327. Vinitketkumnuen, U., Puatanachokchai, R., Kongtawelert, P., Lertprasertsuke, N. (1994). Antimutagenicity of lemon grass ( Cymbopogon citratus Stapf) to various known mutagens in salmonella mutation assay. Mutation Research 341:71-75. Wannissorn, B., Jarikasem, S., Siriwangchai, T., Thubthimthe, S. (2005). Antibacterial properties of essential oils from Thai medicinal plants. Fitoterapia 76: 233-236. Wannissorn, B., Jarikasen, S., Soontorntoanasart, T. (1996). Antifungal activity of lemon grass oils and lemon grass oil cream. Physiotherapy Research 10:551-554.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 873,
    "source": "PDF_chunked"
  },
  {
    "id": 4417,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 417)",
    "text": "OOAS Page 82 Euphorbia hirta WAHP Nom botanique Euphorbia hirta L. Famille Euphorbiaceae Synonyme Euphorbia pilulifera L., E. capitata Lam., Chamaesyce hirta (L) Millsp Noms communs Euphorbe hérissée;petit euphorbe (French) Noms vernaculaires Burkina Faso: Bisa - Gazingere Binne, Fulafulde - Dabbirteeki, Haoussa - Nonone Kuchia Côte d'Ivoire: Baoulé- Adododo, Gagou - Tao Moa, Krou Bété- Blableg-Ware Ghana: Akan - Kakaweadwe, Ewe- Notsigbe, Nzema - Aakuba Guinée-Bissau: Fula Pulaar Taquelpolhe Libéria: Mano- To A Gbondo Mali: Dogon- Peleguere Djimi, Bambara Dabadabileni Nigéria: Yoruba -Emile, irawo'le, Fula Fulfulde - Endamyel, Hausa -Noonon Kurciyaa Sénégal: Badyara - Makoreselu, Diola Flup -Ku Tim, Fula Pulaar- En Engil Sierra Leone: Limba -Fuŋkele, Loko -Bumbuŋgo, Mende- Bεlεji Togo: Ewe - Anonsikan, Akasselem- Melandjebe, Ouatchi - Nostika Description de la plante La plante est herbacée, érigée ou prostrée",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 4418,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 418)",
    "text": "Sierra Leone: Limba -Fuŋkele, Loko -Bumbuŋgo, Mende- Bεlεji Togo: Ewe - Anonsikan, Akasselem- Melandjebe, Ouatchi - Nostika Description de la plante La plante est herbacée, érigée ou prostrée atteignant 20-40 cm de haut, pubescente, mince, se développant souvent près des sols; elle a des tiges annuelles, dont certains sont pérennes; Elle est couverte de poils hérissés jaunâtres, surtout dans les parties les plus jeunes. Les parties les plus anciennes ont des taches rougeâtre- violettes. Les feuilles sont toutes strictement opposées, et en général, nettement inégales à la base; obliquement ovales à lancéolées, arrondies d'un côté, de forme oblongue- obovale, de 2 à 5 cm de long sur 2 cm de large; minutieusement dentées ou serratulés à sommet aigu avec la présence de stipules; une inflorescence asymétrique avec des touffes axillaires compactes et des glomérules terminaux. Les fleurs sont petites et jaunâtres, mâles ou",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4419,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 419)",
    "text": "présence de stipules; une inflorescence asymétrique avec des touffes axillaires compactes et des glomérules terminaux. Les fleurs sont petites et jaunâtres, mâles ou bisexuées avec une ovaire et une capsule velue, involucre, avec des grappes denses et pédonculées assez lon gues. Les petites fruits d'environ 1 mm de diamètre, sont des capsules jaunâtres et velues s'ouvrant en trois lobes ; chaque carpelle lointainement carénée avec une graine rougeâtre à quatre côtés transversalement plissés (NHP, 2008; seule GHP, 1992). Numéro du specimen de l'herbier Ghana: GC 47751 Nigeria: FHI 107438 Togo: TOGO03188 Habitat et répartition géographique E. hirta est une mauvaise herbe commune aux villes et villages à proximité des drains, des routes et des lieux incultes; originaire de l'Inde et de la plupart des pays tropicaux. Parties utilisées de la plante Feuilles fraîches ou séchées ou parties aériennes Autres parties utilisées Plante entière",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4420,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 420)",
    "text": "de la plupart des pays tropicaux. Parties utilisées de la plante Feuilles fraîches ou séchées ou parties aériennes Autres parties utilisées Plante entière Caractéristiques botaniques Herbe de l'asthme australienne se compose de feuilles fraîches ou séchées de Euphorbia hirta L. (Euphorbiaceae). Utilisations ethnomédicales Elle est utilisée dans le traitement de la fièvre,la piqûre de scorpion, de la toux, de l'asthme,bronchique paroxystique, de la dysenterie amibienne, le rhume des foins et des infestations de vers (NHP, 2008). En Chine, la plante est utilisée pour traiter le pied l'athlète, la dysenterie, et autres affections cutanées.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 644,
    "source": "PDF_chunked"
  },
  {
    "id": 4421,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 421)",
    "text": "OOAS Page 83 Euphorbia hirta WAHP Activités biologiques et pharmacologiques Les extraits aqueux de la plante ont fortement réduit la libération de prostaglandines I2, E2 et D2. Les extraits ont aussi empêché l'aggrégation plaquettaire et diminué la formation de l'œdème de la patte rat induite par la carragénine (Hiermann et Bucar, 1994). Les extraits aqueux et éthanolique des feuilles ont montré un effet diurétique semblable à celui de l'acétazolamide; les extraits ont produiten fonction du temps une augmentation de la production d'urine (Johnson et al, 1999.). L'extrait aqueux de feuilles a causé une diminution de la motilité gastro- intestinale chez des rats normaux et réduit l'effet de la diarrhée induite par l'huile de ricin chez les souris (Hore et al., 2006).La décocté lyophilisé de la plante a eu une activité antidiarrhéique sur la diarrhée induite par l'huile de ricin, l'acide arachidonique et la prostaglandine E2 (Galvez et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4422,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 422)",
    "text": "la plante a eu une activité antidiarrhéique sur la diarrhée induite par l'huile de ricin, l'acide arachidonique et la prostaglandine E2 (Galvez et al., 1993). Les extraits éthanoliques ont été jugés agents antibactériens non- cytotoxiques et efficaces Vijaya et al ., 1995). Les extraits éthanoliques des parties aériennes ont montré une activité antimicrobienn e à large spectre, en particulier contre Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa et Staphylococcus aureus (Sudhakar et al ., 2006). La plante s'est avérée efficace in vitro, in vivo et cliniquement, contre Entamoeba, l'agent causal de la dysenterie amibienne (Evans, 2002). La préparation de la plante entière de E. hirta est vendue au Mali pour le traitement de ce mal (Keita, 1994). Les extraits aqueux et en série des extraits purifiés de latex ont une puissante activité molluscicide (Singh et al., 2004). Les doses d'extraits à léthanol et au dichlorométhane",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4423,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 423)",
    "text": "(Keita, 1994). Les extraits aqueux et en série des extraits purifiés de latex ont une puissante activité molluscicide (Singh et al., 2004). Les doses d'extraits à léthanol et au dichlorométhane de la plante entière administrées par voie orale à 100-400 mgkg par jour ont produit une importante chimiosuppression de la parasitémie chez les souris infectées par P. berghei berghei (Baslas et Agarwal, 1980) et une forte activité antiplasmodiale (IC 50 3gml) (Tona et al., 2004). La plante s'est avérée posséder des effets sédatifs, anxiolytiques, analgésiques centraux, antipyrétiques et antiphlogistiques (Singh et al ., 2004). Données cliniques Un essai clinique au Sénégal a montré que E. hirta est efficace pour traiter la dysenterie amibienne (Ridet et Chartol, 1964). Constituants chimiques Diterpènes (esters de phorbol); triterpènes (y compris les phytostérols, c.-à- dire β-sitostérol, β- amyrine, stigmastérol, campestérol); flavonoïdes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4424,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 424)",
    "text": "Constituants chimiques Diterpènes (esters de phorbol); triterpènes (y compris les phytostérols, c.-à- dire β-sitostérol, β- amyrine, stigmastérol, campestérol); flavonoïdes (quercitrine, quercitol, myriscitrine); tanins hydrolysables (euphorbins A -E), acides aromatiques (acides shikimique et connexes); alcaloïdes, coumarines, anthocyanes et saponines (GHP, 1992). Tests d'identité et de pureté Teneur en humidité: séché à l'air une poudre grossière ne perd pas plus de 25 à 105oC. Cendre totale: pas plus de 13,6 Cendre insoluble dans l'acide: pas plus de 3,0 Cendre soluble dans l'eau: pas moins de 3,0 Valeur substances extractibles par l'eau: pas moins de 17,0 Valeursubstances extracibles par l'éthanol (70) : pas moins de 11,5 Ratio de palisade: 3,3 à 4,38 -5,50 Indice stomatique: 8,3 à 22,6 (surface supérieure); de 18,8 à 25,0 (surface inférieure) Nombre de stomates: 100 à 250 -400 (surface supérieure), 300-317-400 (surface inférieure)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4425,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 425)",
    "text": "Indice stomatique: 8,3 à 22,6 (surface supérieure); de 18,8 à 25,0 (surface inférieure) Nombre de stomates: 100 à 250 -400 (surface supérieure), 300-317-400 (surface inférieure) Nombre de veine-îlot: 2,0 à 3,5 Nombre de veinules de terminaison: 11,0 à 14,5 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acideacétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de deux taches distinctes avec valeurs R f de 0,59 (rose) et 0,31 (violet).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 767,
    "source": "PDF_chunked"
  },
  {
    "id": 4426,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 426)",
    "text": "OOAS Page 84 Euphorbia hirta WAHP Chromatogramme Macroscopie La tige est cylindrique, velue et souvent rougeâtre ou blanche avec un jus laiteux; les feuilles simples sont disposées de manière opposée. Elles sont oblongues lancéolées mesurant 2-4 cm de long sur 0,3-1,5 cm de large, courtement pétiolées, minutieusement dentées avec un sommet aigu et une base asymétrique, et une marge approx imativement dentées ou dentelées; le sommet aigu, la base asymétrique et vélue de couleur verte sont sur les deux faces ; la poudre de couleur pourpe ou violet - foncée a un goût fade et aucune odeur ; les fleurs sont à l'aisselle des feuilles comme desgrappes rondes denses ou des cymes terminales à sommet acuminé ; le fruit est triloculaire et plissés avec desgrains des quatre côtés (GHP, 1992). Microscopie La surface d'ensemble montre des poils tecteurs pluriicellulaires unisériés sur les deux côtés de l a feuille, avec des cellules écrasées et des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4427,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 427)",
    "text": "côtés (GHP, 1992). Microscopie La surface d'ensemble montre des poils tecteurs pluriicellulaires unisériés sur les deux côtés de l a feuille, avec des cellules écrasées et des cicatrices présentes; la section transversale de la feuille présente une structure biface avec deux surfaces épidermiques ayant une cuticule lisse, l'épiderme supérieur se compose de parois anticlinales presque droites , tandis que que la partie inférieure de l'épiderme est ondulée, les stomates de type anomocytiques sont présents sur les deux faces, plus abondants sur la surface inférieure; la région nervure manque de tissus collenchymateux; mais avec une seule c ouche de palissade; les cellules de latex et les canaux se produisent autour des faisceaux vasculaires de veines y compris sur la nervure médiane, les navires de xylème lignifiés et des grains d'amidon dans le mésophylle; une couche du parenchyme modifiée entoure immédiatement chaque faisceau vasculaire comme une",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4428,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 428)",
    "text": "navires de xylème lignifiés et des grains d'amidon dans le mésophylle; une couche du parenchyme modifiée entoure immédiatement chaque faisceau vasculaire comme une caractéristique particulière de la feuille; des poils sont dispersés sur toute la feuille, unisériée de 3- 6 cellulaires, légèrement incurvés, avec des parois minces verruqueuses, d'environ 243,3 à 695 microns de longueur; les idioblastes diffèrent sensiblement des cellules ordinaires dans la forme, la taille et le contenu (GHP, 1992). Matériel végétal en poudre De couleur verte; l'amidon se produit en grandes quantités; les gouttelettes isolées de latex sont aussi présentes dans les cellules avecde longs poils tecteurs pluriicellulaires; des éléments lignifiés de faisceaux vasculaires (vaisseaux de xylème), des fibres non lignifiées. Les caractéristiques d'identification comprennent des stomates anomocytiquesanisocytiques; unicellulaires, verruqueuses, certains poils",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4429,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 429)",
    "text": "xylème), des fibres non lignifiées. Les caractéristiques d'identification comprennent des stomates anomocytiquesanisocytiques; unicellulaires, verruqueuses, certains poils unisériés dans les fragments; les cellules épidermiques avec des parois anticlinales ondulées et droits, des fragments d'éléments vasculaires. Actions thérapeutiques Antiasthmatique; anthelminthique; anti - inflammatoire; antimicrobien; antipyrétique; bronchodilatateur; antispasmodique (voies respiratoires) (Ayitey -Smith, 1989); anxiolytique ; galactogogue; pectorale; sédatif (GHP, 1992; Lanhers et al., 1990; 1991). Indications thérapeutiques Amibiase, asthme, bronchites; catarrhe, constipation, toux, diarrhée, dracunculose; euneresis; coliques, dysenterie, maladies génito- urinaires; gonorrhée ; rhume des foins; impuissance (légère); occlusion intestinale; menace d'avortement; spasme laryngé respiratoire supérieure; troubles de la vision ; vomissements (Singh et al, 2004;. Tona et al ,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 970,
    "source": "PDF_chunked"
  },
  {
    "id": 4430,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 430)",
    "text": "impuissance (légère); occlusion intestinale; menace d'avortement; spasme laryngé respiratoire supérieure; troubles de la vision ; vomissements (Singh et al, 2004;. Tona et al , 1999a;GHP, 1992). Données de sécurité La DL 50 de l'extrait aqueux des feuilles chez le rat était 3000 mgkg. Il n'y a pas eude changements significatifs dans les ratiospoids organepoids corporel et la valeur hématologique. L'augmentation du taux d'AST et d'ALT a été observée dans des études de courte durée (300- 3000 mgkg) chez le rat, sans effets négatifs significatifs sur la fonction rénale. Précautions d'emploi Etre prudent dans l'administration de l'extrait aqueux chez les patients ayant une fonction",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 686,
    "source": "PDF_chunked"
  },
  {
    "id": 4431,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 431)",
    "text": "OOAS Page 85 Euphorbia hirta WAHP hépatique et un effet de cancérogène non confirmée, dû à la teneur en esters de phorbol. Effets indésirables Nausées, vomissements et réactions allergiques Contre-indications Grossesse et allaitement, bronchodilatateurs, patients hépatobiliaires connus, personnes âgées et enfants. Dosages et forme galénique Infusion: 20-30 g de plante séchée par litre d'eau; boire 3-4 tasses par jour. Décoction: 30-50 g de feuilles séchées; boire 3- 4 tasses par jour. Extrait liquide (BPC 1949): 1:1 dans de l'alcool de 45; 0,12-0,3ml trois fois par jour. Teinture (BPC 1923): 1:5 dans de l'alcool 60, prendre 0,6-2 ml trois fois par jour. Conservation A conserver dans un endroit frais et sec, à l'abri de la lumière. Références Ayitey-Smith, E. (1989). Prospects and Scope of Plant Medicine in Health Care, 12- 13. Ghana Universities Press: Accra, Ghana. Baslas, R., Agarwal, R. (1980). Chemical",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4432,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 432)",
    "text": "Références Ayitey-Smith, E. (1989). Prospects and Scope of Plant Medicine in Health Care, 12- 13. Ghana Universities Press: Accra, Ghana. Baslas, R., Agarwal, R. (1980). Chemical examination of E. hirta. In International Research Congress On Natural Products As Medici nal Agents, Strasbourg. France. Book of abstracts II Michler, E and Reinhard, E. (eds) p. 25. British Pharmaceutical Codex (1949). British Pharmaceutical Codex (1923). Evans, W.C. (2002). Tr ease and Evans Pharmacognosy, 15 th ed., 492. Saunders: London, UK. Galvez, J., Zarzuelo, A., Crespo, M.E., Lorente, M.D., et al., (1993). Antidiarrhoeic activity of Euphorbia hirta extract and isolation of an active flavonoid constituent. Planta Medica 59(4):333- 336. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana. Hiermann, A., Bucar, F. (1994). Influence of some traditional medicinal plants of Senegal on prostaglandin biosynthesis. Journal of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4433,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 433)",
    "text": "Advent Press: Accra, Ghana. Hiermann, A., Bucar, F. (1994). Influence of some traditional medicinal plants of Senegal on prostaglandin biosynthesis. Journal of Ethnopharmacology 42:111-116. Hore, S.K., Ahuja, V., Mehta, G., Kumar, P. et al. (2006). Effect of aqueous Euphorbia hirta leaf extract on gastrointestinal motility. Fitoterapia 77:35-38. Johnson, P.B., Abdurahman, E.M., Tiam, E.A., Abdu-Aguye, I. et al. (1999). Euphorbia hirta leaf extracts increase urine output and electrolytes in rats. Journal of Ethnopharmacology 65(1):63-69. Keita, A. (1994). Activities of the traditional medicine department in Mali. International workshop by the GIFTS of Health, Mbarara, Uganda. December 6-9. Lanhers, M.C., Fleurentin, J., Dorfman, P., et al. (1991). Analgesic, antipyretic and anti - inflammatory properties of Euphorbia hirta L. Planta Medica 57:225-231. Lanhers, M.C., Fleurentin, J., Cabalion, P., et al. (1990). Behaviour effects of Euphorbia hirta L.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 963,
    "source": "PDF_chunked"
  },
  {
    "id": 4434,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 434)",
    "text": "inflammatory properties of Euphorbia hirta L. Planta Medica 57:225-231. Lanhers, M.C., Fleurentin, J., Cabalion, P., et al. (1990). Behaviour effects of Euphorbia hirta L., sedative and anxiolytic properties. Journal of Ethnopharmacology 29:189-198. Nigeria Herbal Pharmacopoeia (2008). The Federal Secretariat Complex, Abuja, Nigeria. Ridet, J., Chartol, A. (1964). The Antidysenteric Properties of Euphorbia hirta. Med. Trop. 24:119- 143. Singh, S.K., Yadav, R.P., Singh, D., Singh, A. (2004). Toxic effect of two common Euphorbiales lattices on the freshwater snail Lymnaea acuminate. Environmental Toxicology and Pharmacology 15:8793. Sudhakar, M., Rao, C.V., Rao, P.M., Raju, D .B. et al., (2006). Antimicrobial activity of Caesalpinia pulcherrima, Euphorbia hirta and Asystasia gangeticum. Fitoterapia 77:378380. Tona, L., Cimanga, R.K., Mesia, K., Musuamba, C.T., De Bruyne, T. et al., (2004). In vitro activity",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 918,
    "source": "PDF_chunked"
  },
  {
    "id": 4435,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 435)",
    "text": "pulcherrima, Euphorbia hirta and Asystasia gangeticum. Fitoterapia 77:378380. Tona, L., Cimanga, R.K., Mesia, K., Musuamba, C.T., De Bruyne, T. et al., (2004). In vitro activity of extracts and fr actions from seven medicinal plants used in the Democratic Republic of Congo, Journal of Ethnopharmacology, 93:27-32. Tona, L., Kambu, K., Mesia, K., Cimanga, K., Apers, S et al., (1999a.). Biological activities of traditional preparations form some medic inal plants used as antidiarrhoeal in Kinshasa, Congo. Phytomedicine 6:59-66.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 530,
    "source": "PDF_chunked"
  },
  {
    "id": 4436,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 436)",
    "text": "OOAS Page 86 Euphorbia hirta WAHP Vijaya, K., Ananthan, S., Nalini, R. (1995). Antibacterial effect of theaflavin, polyphenon 60 (Camellia sinensis ) and Euphorbia hirta on Shigella spp. - a cell culture study. Journal of Ethnopharmacology, 49:115-118.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 252,
    "source": "PDF_chunked"
  },
  {
    "id": 4437,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 437)",
    "text": "OOAS Page 87 Hallea stipulosa WAHP Nom botanique Hallea stipulosa (DC.) Leroy Famille Rubiaceae Synonymes Fleroya stipumosa (DC) Y.F. Deng, Mitragyna stipulosa (DC.) Kuntze, Nauclea stipulosa DC., Nauclea macrophylla Perr. Lepr. ex DC., Nauclea bracteosa Welw., Mitragyna chevalieri K.Krause Noms communs Anglais : African linden, Abura Français : Tilleul d'Afrique, Bahia Noms vernaculaires Ghana : Subaha Akan - Akoa, Nzema - Baya Guinée-Conakry : Pular Maninka Kouranko, Föfè Pöpö-Soussou, Kissi - Pawe Libéria : Kru - Boh Sénégal : Joola - Bubagala Description de la plante C'est un arbre qui pousse jusqu'à 15- 20 m de hauteur avecun tronc cylindrique sans basede 1 m de diamètre. Il a une écorce très épaisse, écailleuseet unecouronne dense avec pl usieurs touffes ; les feuilles sont simples, opposées, légèrement coriaces, elliptiques, largesmesurant 10 à 50 cm de long avec un système de racine pivotante ; Il a une inflorescence de type cyme",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 4438,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 438)",
    "text": "touffes ; les feuilles sont simples, opposées, légèrement coriaces, elliptiques, largesmesurant 10 à 50 cm de long avec un système de racine pivotante ; Il a une inflorescence de type cyme composée de nombreuses petites fleurs globulaires avec des calices blancs serrés, des petites capsules sphériques de fruits. Numéro du spécimen de l'herbier Ghana: GC 7625 Habitat et répartition géographique Ce sont des espèces qui dans les zones inondées périodiquement, les savanes et près des étangs temporaires. Ils existent en Afrique tropicale (Guinée, Mauritanie, Sénégal, Cameroun, Tchad, Soudan). Parties utilisées de la plante Feuilles et écorce du tronc. Caractéristiques botaniques Hallea se compose de l'écorce de tige ou feuilles de Hallea stipulosa (DC.) Leroy (Rubiaceae) Utilisations ethnomédicales En Côte d'Ivoire, l'écorce est prescrite pour le traitement de la gonorrhée (Bouquet et Debray, 1974). En Guinée, la décocté de l'écorce de tige",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4439,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 439)",
    "text": "Utilisations ethnomédicales En Côte d'Ivoire, l'écorce est prescrite pour le traitement de la gonorrhée (Bouquet et Debray, 1974). En Guinée, la décocté de l'écorce de tige est utilisée comme diurétique, antiseptique et anti-infectieux ; l'infusé est utilisé dans le traitement de l'infertilité féminine et les feuilles comme un antiseptique topique pour les blessures (Magassouba et coll., 2007). Au Ghana, le décocté de l'écorce de tige séchée, administrée par voie orale, est très efficace contre le ver de Guinée (Cromley, 1990). Le décocté est utilisé pour traiter le paludisme chez les adultes (Kohler et al., 2002), tandis que l'écorce est utilisée pour le traitement des infections génitales, urinaires et les infections par les vers (Adjahonoun et al., 1974 ; Womé, 1985). Activités biologiques et pharmacologiques L'activité antipaludique de la fraction lipophile de l'écorce de tige, des racines et des feuilles a été démontrée sur la souche de Plasmodium",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 966,
    "source": "PDF_chunked"
  },
  {
    "id": 4440,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 440)",
    "text": "Activités biologiques et pharmacologiques L'activité antipaludique de la fraction lipophile de l'écorce de tige, des racines et des feuilles a été démontrée sur la souche de Plasmodium falciparum avec respectivement IC 50 de 36,1 μ ml, 48,7 μ ml et 20,4- 32,6 μ ml. Cependant, une autre étude a signalé que les fractions lipophiles de l'écorce de tige ou de racine sont inactives avecun CI50 50,0 μg ml (Kohler et al., 2002). Les 40 de solution aqueuse d'extra its d'écorce de tige ont montré une activité antibactérienne contre le Vibrio cholera (Akinsinde et Kwamboka, 1995). Données cliniques Aucune information disponible Constituants chimiques Plusieurs triterpènes ont été isolés de la plante, y compris les α- amyrine, acide quinovique--3 -O-β- D-quinovopyranoside-27-O-β-D-glucopyranosyle; acide quinovique, acide ursolique, quinovine C glycoside, acide- 3-O-acétyle-βursolique ; acide quinovique-3-O-β-D-glucopyranoside; acide",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4441,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 441)",
    "text": "D-quinovopyranoside-27-O-β-D-glucopyranosyle; acide quinovique, acide ursolique, quinovine C glycoside, acide- 3-O-acétyle-βursolique ; acide quinovique-3-O-β-D-glucopyranoside; acide oléanolique; zygophyloside B, zygophyl oside D,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 231,
    "source": "PDF_chunked"
  },
  {
    "id": 4442,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 442)",
    "text": "OOAS Page 88 Hallea stipulosa WAHP daucostérole (Fatima et al., 2002 ; Tapondju et al., 2002). Tests d'identité et de pureté Teneur en eau : 8,85 (écorce de tige) 8.36 (feuilles) Cendre totale: 4,80 (écorce de tige) 6,00 (feuilles) Valeur substances extractibles par l'eau: 9.40 (écorce de tige) 9.01 (feuilles) Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de quatre taches distinctes avec R fde 0,60 (Rose), 0,30 (Rose), 0,25 (Rose) et 0,20 (violet). Chromatogramme Macroscopie La macroscopie de la plante présente des feuilles",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4443,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 443)",
    "text": "distinctes avec R fde 0,60 (Rose), 0,30 (Rose), 0,25 (Rose) et 0,20 (violet). Chromatogramme Macroscopie La macroscopie de la plante présente des feuilles vertes, lorsqu'elles sont fraîches, simples avec un long pétiole ; un limbe de 15- 45 cm de long sur 8 à 15 cm de large avec forme elliptique; une marge entière ; un sommet obtus, une feuille à base cunéiformeou ronde, une nervation réticulée, glabre mais pubescent sur les en dessous des nervures, une texture charnue avec une nervure centrale importante. Microscopie La f ace épidermique adaxiale a des parois droites anticlinales avec de nombreux globules d'huile et des sclérites ; aucune présence destomates et poilsde poils; la surface abaxiale a de nombreux sclérites et des stomates qui sont de types diacytique et paracytique (donc la feuille est hypostomatique) ; la section transversale de la feuille est dorsiventrale avec 2 couches de cellules épidermiques disposées de façon",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4444,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 444)",
    "text": "de types diacytique et paracytique (donc la feuille est hypostomatique) ; la section transversale de la feuille est dorsiventrale avec 2 couches de cellules épidermiques disposées de façon compacte sur la face ventrale, recouverte par une cuticule mince; l'épiderme supérieur est suivi d'une seule couche de tissus de palissade ; le mésophylle spongieux est grossièrement organisé avec de nombreux espaces intercellulaires ; la nervure principale a uneprotubérance concave importante portant des poils pluricellulaires de 3 -7 cellules de long, avec destêtes coniques; des faisceaux vasculaires en forme de dôme avec un xylème de 3- 4 cellules. Des oxalates de calcium (c'est -à-dire des raphides) sont présents sur la face adaxiale et dans la région du cortex. Matériel végétal en poudre Cellules parenchymateuses de l'épiderme ; plusieursglobules d'huile flottantes, cellules en pierre ou sclérites, stomates de types diacytiques ou paracytiques, quelques cellules de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 969,
    "source": "PDF_chunked"
  },
  {
    "id": 4445,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 445)",
    "text": "Cellules parenchymateuses de l'épiderme ; plusieursglobules d'huile flottantes, cellules en pierre ou sclérites, stomates de types diacytiques ou paracytiques, quelques cellules de parenchymes palissadiques;les poils sont de type couvrant, avec des têtes pluricellul aires et coniques, des vaisseaux du xylème et des cristaux d'oxalate de calcium. Actions thérapeutiques Antipaludéen, antibactérien. Indications thérapeutiques Paludisme, choléra, anémie, blessure. Données de sécurité Vingt-quatre heures d'études approf ondies de toxicité chez les souris ( p.o) ont montré que, la DL 50 de l'extrait aqueux des feuilles de la plante est 2000 mgkg. Des études moins approfondies ne montrent pas de signes cliniques de toxicité après traitement des souris mâles et femelles (500 à 2000 mgkg p.o)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 794,
    "source": "PDF_chunked"
  },
  {
    "id": 4446,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 446)",
    "text": "OOAS Page 89 Hallea stipulosa WAHP pendant 14 jours. L'administration subchronique de l'extrait aqueux d'un mélange contenant la plante n'a pas affecté la prise de poids ou le poids moyen des organes au fil du temps chez les rats. On a noté, par ailleurs, des variations importantes des données biochimiques, hématologiques, ainsi que celles relatives à l'analyse d'urine par rapport aux rats témoins. Il n'y a, contrario, pas de modifications dans la morphologie des tissus du foie, des reins, des poumons et du cœur à des dos es de 28, 280 et 560 mgkg jour (Martey et al.., 2010). Précautions d'emploi Ne pas dépasser les doses recommandées. Effets indésirables De fortes doses peuvent occasionner des troubles gastro-intestinales. Contre-indications Grossesse et allaitement. Dosage et forme galénique Décoction : 30 g de matériel végétal séché dans 900 ml d'eau ; faire bouillir jusqu'à réduction de l'eau à 600 ml ; prendre deux cuillérées à soupe",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4447,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 447)",
    "text": "Dosage et forme galénique Décoction : 30 g de matériel végétal séché dans 900 ml d'eau ; faire bouillir jusqu'à réduction de l'eau à 600 ml ; prendre deux cuillérées à soupe trois fois par jour. Conservation A conserver dans un endroit frais et sec. Références Adjanohoun, E., Ahyi, M.R.A., Ake Assi, L. et al. (1974). Contribution aux études ethnobotaniques et floristiques en République populaire du Congo. Agence de coopération culturelle et technique, (A.C.C.T.), Paris, 605 p., (1988) A partir de la banque de données Pharmel 2 (réf. HP 10). Akinsinde, K.A., Olukoya, D.K. (1995). Vibriocida activities of some local herbs. Journal of Diarrhoeal Diseases Research 13 (2):127-129. Bouquet, A., Debray, M. (1974). Plantes médicinales de la Côte d'Ivoire.Travaux et Documents de l'ORSTOM., Paris, n 32, 232 p. Comley, J.C.W. (1990). New macrofilaricidal leads from plants?; Tropical Medical Parasitology 41(1):1-9. Fatima, N., Tapondjou, L.A., Lontsi, D.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4448,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 448)",
    "text": "Comley, J.C.W. (1990). New macrofilaricidal leads from plants?; Tropical Medical Parasitology 41(1):1-9. Fatima, N., Tapondjou, L.A., Lontsi, D., Sondengam, B.L. et al. (2002). Quinovic acid glycosides from Mitragyna stipulosa- first examples of natural inhibitors of snake venom Phosphodiesterase i. Natural Product Letters 16(6):389-393. Kohler, I., Jenett Siems, K., Kraft, C., Siems, K. et al . (2002). Herbal remedies traditionally used against malaria i n Ghana: bioassay -guided fractionation of Microglossa pyridolia (Asteraceae) Z Naturforsch ser C 57C (1112):1022-1027. Magassouba, F.B., Diallo, A., Kouyaté, M., Mara, F., et al ., (2007). Ethnobotanical survey and antibacterial activity of some plants used in Guinean traditional medicine. Journal of Ethnopharmacology 114:44-53. Martey, O.N., Armah, G., Okine, L.K. (2010). Absence of organ specific toxicity in rats treated with tonica, an aqueos herbal haematinic",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4449,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 449)",
    "text": "Ethnopharmacology 114:44-53. Martey, O.N., Armah, G., Okine, L.K. (2010). Absence of organ specific toxicity in rats treated with tonica, an aqueos herbal haematinic preparation. African Journal of Traditional, Complementary and Alternative Medicine, 7(3): 231-240. Tapondjou, L.A., Lontsi, D., Sondengam, B.L., Choudhary, M.I . et al . (2002). Structure- activity relationship of triterpenoids isolated from Mitragyna stipulosa on cytotoxicity; Archives of Pharmaceutical Research 25(3): 270-274. Wome, B. (1985). Recherches ethnopharmacognosiques sur les plantes médicinales utilisées en médecine traditionnelle à Kisangani (Haut -Zaïre).Thèse de doctorat, Université libre de Bruxelles, Fac. Sc., 561 p.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 706,
    "source": "PDF_chunked"
  },
  {
    "id": 4450,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 450)",
    "text": "OOAS Page 90 Harrisonia abyssinica WAHP Nom botanique Harrisonia abyssinica Oliv. Famille Simaroubaceae Synonymes Harrisonia occidentalis Engl., Zanthoxylum guineense Stapf. Noms communs Baingou (français) Noms vernaculaires Ghana : Asante-Fintinko, Guinée-Conakry : Kpèlè - Zhinwuon Nyegolo Côte D'Ivoire : Agni- Baingou Nigéria : Haoussa - Arujere Sierra Leone : Kissi -Mama Kundu Togo: Ewe- Xedja, Mina- Hedjan, Adja-Xedjatsi Description de la plante Arbuste très ramifié, parfois grimpant, pouvant atteindre 8 m de haut; écorce brun- clair ou gris avec des branches longues et souples; les feuilles alternes de composées imparipennées, compris entre 2 à 7 paires de folioles vont jusqu'à 25 cm de long avec des inflorescences axillaires ou panicules terminales érigées, glabres ou poilus, de 2 à 14 cm de long; les fleurs sont bisexuées, régulières, de 4 à 6 lobes, glabres avec un fruit déprimé, globuleux, une baie rouge,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4451,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 451)",
    "text": "ou panicules terminales érigées, glabres ou poilus, de 2 à 14 cm de long; les fleurs sont bisexuées, régulières, de 4 à 6 lobes, glabres avec un fruit déprimé, globuleux, une baie rouge, à maturité noir avec 4 à 8 lobes. Numéro du spécimen del'herbier Ghana: GC 47015 Togo : TOGO08458 Habitat et répartition géographique Il est présent dans les forêts sempervirentes sèches ou xérophytiques (dans la savane). On le trouve souvent dans les régions côtières. Parties utilisées de la plante Feuilles ou écorce du tronc Autres parties utilisées Écorce de la racine Caractéristiques botaniques Harrisonia se compose de la feuille ou de l'écorce de la tige de Harrisonia abyssinica Oliv. (Simaroubaceae) Utilisations ethnomédicales La poudre de l'écorce de la racine et la décocté ou l'infusé de la racine sont utilisés contre les maladies vénériennes, la fièvre, le paludisme, la diarrhée, les vers intestinaux, les maladies",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4452,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 452)",
    "text": "ou l'infusé de la racine sont utilisés contre les maladies vénériennes, la fièvre, le paludisme, la diarrhée, les vers intestinaux, les maladies urinaires, la gonorrhée, les douleurs dentaire et d'estomac. Les feuilles avec des graines d'Aframomum melegueta, du kaolin et du sel sont efficaces contre les pertes vaginales. Les racines sont mâchées avec la graine de palme et utilisées comme aphrodisiaque (Balde, 1990), tandis que la décoction de racine est utilisée contre le paludisme, la gonococcie, la tuberculose et la schistosomiase. La décoction des jeunes racines est efficace contre l'insomnie, les étourdissements, les nausées, les vomissements, l'orchite et la tuberculose. Le décocté est également susceptible de provoquer l'avortement (Kirira et al., 2006 ; Hassanali et al., 1987). Activités biologiques et pharmacologiques De nombreuses études ont démontré l'activité antiplasmodiale de la plante contre les souches",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4453,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 453)",
    "text": "1987). Activités biologiques et pharmacologiques De nombreuses études ont démontré l'activité antiplasmodiale de la plante contre les souches de Plasmodium falciparum (Tahir et al. , 1999). Les extraits méthanoliques de feuilles et d'écorce de tige ont démontré respectivement des propriétés antiplasmodiales avec un IC 50 de 50- 60 μml et 4,7 gml. Les extraits aqueux et chloroformique des racines se sont révélés inactifs contre les souches de Plasmodium (Spencer et al., 1947). L'extrait méthanolique des feuilles s'est révélé actif contre l e Mycobacterium phlei (Anani et coll., 2002), tandis que les extraits chloroformique et éthanolique de la racine ont également montré une activité contre le Mycobacterium fortuitum avec un MIC supérieur à 1 mgml (Balde et al., 1995). L'extrait de la feuil le s'est révélé actif contre le Bacillus subtilis, le Staphylococcus aureus , mais inactif contre la bactérie E. coli, le Klebsiella",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4454,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 454)",
    "text": "de la feuil le s'est révélé actif contre le Bacillus subtilis, le Staphylococcus aureus , mais inactif contre la bactérie E. coli, le Klebsiella pneumoniae et le Pseudomonas aeruginosa (Anani et al., 2002); par ailleurs, l'extrait méthanolique de l'écorce de la racine a démontré",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 279,
    "source": "PDF_chunked"
  },
  {
    "id": 4455,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 455)",
    "text": "OOAS Page 91 Harrisonia abyssinica WAHP une activité contre Helicobacter pylori avec un MIC de 250 μml (Fabry et coll., 1996). Les extraits de la plante ont été étudiés sur d'autres ravageurs et vecteurs; l'extrait éthanolique de l'écorce de tige a été inactif chez la souris infectées expérimentalement avec Schistosoma mansoni (Balde et al., 1989), bien que les extraits non polaires aient démontré une toxicité élevée contre le Biomphalaria glabrata. L'extrait méthanolique de l'écorce de la racine (0,03 ) a montré une activité contre le Candida albicans (Sawhney et al., 1978) tandis que l'extrait méthanolique de la feuillea été inactif contre la même espèce et autres souches fongiques (Anani et al., 2000). L'extrait méthanolique d'un échantillon de feuille obtenu au Togo a été actif contre l' herpès simplex (250 μ ml), le virus de Sindbis (500 μml) et le poliovirus (500 gml) (Hudson et al., 2000). Des extraits aqueux,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4456,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 456)",
    "text": "échantillon de feuille obtenu au Togo a été actif contre l' herpès simplex (250 μ ml), le virus de Sindbis (500 μml) et le poliovirus (500 gml) (Hudson et al., 2000). Des extraits aqueux, éthanolique et chloroformique de l'écorce de la racine ont montré uneactivité modérée ou marquée contre H herpes simpl ex de type 1, le Coxsackie B2 et le virus de la forêt de Semliki (Balde et al., 1995). Cependant, les extraits se sont révélés inactifs contre le poliovirus et le virus vésiculaire stimatitis. Données cliniques Aucune information disponible Constituants chimiques Stéroïdestriterpènes : sitostérol, stigmastérol, campestérol, poriferastérol, stigmasténone, stigmastatrienone, sitosténone, friedélanone, méthylcholesténone, cycloabyssinone (Balde et al., 2000), limonoïdes: obacunone; harrisonine; acétoxyharrisonine; diacétoxyharrisonine; pédonine; atalantolide; dehydroriciopsine (Okorie, 1982 ; Liu et al., 1982; Rajab et al.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4457,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 457)",
    "text": "al., 2000), limonoïdes: obacunone; harrisonine; acétoxyharrisonine; diacétoxyharrisonine; pédonine; atalantolide; dehydroriciopsine (Okorie, 1982 ; Liu et al., 1982; Rajab et al., 1997, 1999; Chabbra et al., 1984 ; Nakanishi, 1982 ; Hassanali, 1987; Rajab et al ., 1999 ; Rugutt et al ., 2001; Balde et al ., 1987, 1988), quassinoide: perforaquassine A (Rajab et al ., 1999), chromones: alloptaeroxylline; alloptaeroxylline méthyl ; hydroxyméthyl alloptaeroxylline; peucenine (Okorie, 1982 ; Balde et al., 1987), terpénoïde (polykétides prénylés): oumarone ; bissaone ; aissat one ; dalandaone (Balde et al., 2001), acides gras, anthocanidines, polysaccharides, polyuronides (Balde, 1990), anthocyanidines, saponines, huiles essentielles (Chhabra et al., 1984). Tests d'identité et de pureté Teneur en eau : 8,35 (écorce de la tige) Cendretotale: 9,42 (écorce de la tige) Valeur substance extractible par l'eau: pas moins de 10,96 (écorce de la tige)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4458,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 458)",
    "text": "Teneur en eau : 8,35 (écorce de la tige) Cendretotale: 9,42 (écorce de la tige) Valeur substance extractible par l'eau: pas moins de 10,96 (écorce de la tige) Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, pu is chauffé à100- 110C pendant 5-10 mn. Présence de quatre taches distinctes avec un Rfde 0,92 (Rose), 0,69 (violet), 0,47 (violet) et 0,34 (violet). Chromatogramme Macroscopie La macroscopie présente des feuilles vertes à l'état frais, composées et peu pétiolées ; un limbe de long de 3 à 5 cm sur 1 à 2 cm de large ; de forme oblancéolée à elliptique; une marge entière",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 915,
    "source": "PDF_chunked"
  },
  {
    "id": 4459,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 459)",
    "text": "La macroscopie présente des feuilles vertes à l'état frais, composées et peu pétiolées ; un limbe de long de 3 à 5 cm sur 1 à 2 cm de large ; de forme oblancéolée à elliptique; une marge entière ; le sommet est rond ou légèrement acuminé ;la base foliaire est modérée ;la nervation est réticulée ;lasurface foliaire est glabre au- dessus mais pubescente en dessous, la texture est fine et sèche comme du papier avec une nervure centrale saillante. Microscopie Les cellules épidermiques ont des parois anticlinales ondulantes sur la face adaxiale et sont directement ondulées sur la face inférieure ;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 599,
    "source": "PDF_chunked"
  },
  {
    "id": 4460,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 460)",
    "text": "OOAS Page 92 Harrisonia abyssinica WAHP les cellules sont striées ; les deux surfaces ont de nombreux globules d'huile ;les poils unicellulaires sont courts avec aussi bien des poils pluricellulaires de base que stellaires ; certaines des cellules sur la surface abaxiale sont lignifi ées ; avec des feuilles dorsiventrales dans la section transversale, un épiderme unique sur les deux surfaces avec une cuticule épaisse ; les cellules épidermiques sont de forme cuboïde- rectangulaire et sont disposées de manière compacte ; l'épiderme infér ieur est également constitué d'une couche unique avec une cuticule mince et de nombreux stomates ; la feuille est donc hypostomatique ; le mésophylle est différencié en palissades et parenchyme lacuneux avec 2 couches de parenchyme palissadique contigus à l'épiderme supérieur ; les tissus spongieux sont isodiamétriques avec 3 ou 4 cellules épaisseset faiblement connectés ; la nervure centrale montre une protubérance étroite",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 970,
    "source": "PDF_chunked"
  },
  {
    "id": 4461,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 461)",
    "text": "palissadique contigus à l'épiderme supérieur ; les tissus spongieux sont isodiamétriques avec 3 ou 4 cellules épaisseset faiblement connectés ; la nervure centrale montre une protubérance étroite sur la face ventrale et 2 couches d'épiderme ; la protubérance sur la face dorsale est large ; des poils pluricellulaires de 3 ou 4 cellules sont présents sur les protubérances ; les faisceaux vasculaires sont centralement placés avec 4- 6 xylèmesmonocellulaires formant un arc convexe pour le phloème. Matériel végétal en poudre Des cellules parenchymateuses épidermiques ondulées, des poils courts monocellulaires et stellaires, des vaisseaux de xylème et quelques cellules palissadiques ont été entregistrés Actions thérapeutiques Antipaludéen, antibactérien, antifongique, antiviral (Anani et al., 2002; Hudson et al., 2000; Fabry et al., 1998; Balde et al., 1995; Balde et al., 1990 ; Sawhney et al., 1978). Indications thérapeutiques Paludisme, infections",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4462,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 462)",
    "text": "antiviral (Anani et al., 2002; Hudson et al., 2000; Fabry et al., 1998; Balde et al., 1995; Balde et al., 1990 ; Sawhney et al., 1978). Indications thérapeutiques Paludisme, infections Données de sécurité La DL 50 de l'extrait aqueux de l'écorce ( p.o) de la tige chez la s ouris a été 2000 mgkg en 24 heures; aucun signe clinique de toxicité n'a été observé après le traitement des souris mâles et femelles (500 à 2000 mgkg p.o) pendant 14 jours. Précautions d'emploi Ne pas dépasser les doses prescrites. Effets indésirables Aucune information disponible. Contre-indications Aucune information disponible. Dosage et forme galénique Décoction: 30 g de matériel végétal séché dans 900 ml d'eau ; faire bouillir jusqu'à réduction de la quantité d'eau à 600 ml; prendre deux cuillérées à soupe trois fois par jour. Conservation A conserver dans un endroit frais et sec,à l'abri de la lumière. Références Anani, K., Hudson, J.B., Desouza, C., Akpagana,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4463,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 463)",
    "text": "cuillérées à soupe trois fois par jour. Conservation A conserver dans un endroit frais et sec,à l'abri de la lumière. Références Anani, K., Hudson, J.B., Desouza, C., Akpagana, K., Tower, G.H.N. et al . (2002). Investigation of medicinal plants of Togo for ant iviral and antimicrobial activities. Pharmaceutical Biology 38:40-45. Balde, A.M., Vanhaelen, M., Ottinge, R. (1987). A chromone from the root -bark of Harrisonia abyssinica. Phytochemistry 26(8):2415-2416. Balde, A.M., Vanhaelen, M., Daloze, D. (1988). 5-Dehydrooriciopsin, A Ring- D cleaved tetranortriterpenoid from Harrisonia abyssinica. Phytochemistry 27(3):942-943. Balde, A.M., Van Marck, E.A., Kestens, L., Gigase, P.L., Vlietinck, A.J. (1989). Schistosomicidal Effect of Pavetta owariensis and Harrisonia abyssinica In Mice Infected With Schistosoma mansoni ; Planta Medica 55(1):41- 43. Balde, M.A. (1990). in Biological and Phytochemical Investigations on three plants",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4464,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 464)",
    "text": "and Harrisonia abyssinica In Mice Infected With Schistosoma mansoni ; Planta Medica 55(1):41- 43. Balde, M.A. (1990). in Biological and Phytochemical Investigations on three plants widely used in Guinean traditional medicine. Doctoral Thesis Pharmaceutical Sciences. University of Antwerp, Belgium. Balde, A.M., Pieters, L., De Bruyne, T., Geerts, S. et al . (1995). Biological investigations on Harrisonia abyssinica. Phytomedicine 4:299-302. Balde, A.M., Apers, S., De Bruyne, T., Van Den Heuvel, H. et al. (2000). Steroids from Harrisonia abyssinica.; Planta Medica 66:67-69. Balde, A.M., Apers, S., Claeys, M., Pieters, L., Vlietinck, A.J. (2001). Cycloabyssinone, a new cycloterpene from Harrisonia abyssinica. Fitoterapia 72:438-440. Chabbra, S.C., Uiso, F.C., Mshiu, E .N. (1984). Phytochemical screening of Tanzanian medicinal plants. I. Journal of Ethnopharmacology 11(2):157-179. Fabry, W., Okemo, P.O., Ansorg, R. (1998).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4465,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 465)",
    "text": "Phytochemical screening of Tanzanian medicinal plants. I. Journal of Ethnopharmacology 11(2):157-179. Fabry, W., Okemo, P.O., Ansorg, R. (1998). Antibacterial Activity of East African medicinal",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 193,
    "source": "PDF_chunked"
  },
  {
    "id": 4466,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 466)",
    "text": "OOAS Page 93 Harrisonia abyssinica WAHP plants. Journal of Ethnopharmacology 60(1):79- 84. Fabry, W., Okemo, P., Ansorg, R. (1996). Activity of East African medicinal plants against Helicobacter pylori . Chemotherapy (Basel) 42(5):315-317. Hassanali, A., Bentley, M.D., Slawin, A.M.Z., Williams, D.J. et al . (1987). Pedonin, a spiro tetranortriterpenoid insect antifeedant from Harrisonia abyssinica. Phytochemistry 26(2) 573- 575. Hudson, J.B., Anani, K., Lee, M.K., De Souza, C. et al . (2000). Further investigations on the antiviral activities of medicinal plants of Togo. Pharmaceutical Biology 38(1):46-50. Kirira, P.G., Rukunga, G.M., Wanyonyi, A.W., Muregi, F.M. et al. (2006). Anti-plasmodial activity and toxicity of extracts of plants used in traditional malaria therapy in Meru and Kilifi Districts of Kenya. Journal of Ethnopharmacology 106(3):403-407. Liu, H.W., Kubo, I., Nakanishi, K. (1982). A Southern Army -Worm antifeedant, 12- Beta-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4467,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 467)",
    "text": "Districts of Kenya. Journal of Ethnopharmacology 106(3):403-407. Liu, H.W., Kubo, I., Nakanishi, K. (1982). A Southern Army -Worm antifeedant, 12- Beta- acetoxyharrisonin from an African shrub Harrisonia abyssinica. Heterocycles 17: 67-71. Nakanishi, K. (1982). Recent studies on bioactive compounds from plants. Journal of Natural Products 45(1):15-26. Okorie, D.A. (1982). Chromones and Limonoids from Harrisonia abyssinica. Phytochemistry 21: 2424-2426. Rajab, M.S., Rugutt, J.K., Fronczek, F.R., Fischer, N.H. (1997). Structural revis ion of Harrisonin and 12- Beta-Acetoxyharrisonin, two limonoids from Harrisonia abyssinica. Journal of Natural Products 60(8):822-825. Rajab, M.S., Fronczek, F.R., Mulholland, D.A., Rugutt, J.K. (1999). 11- Beta, 12- Beta- Diacetoxyharrisonin, a tetranortrit erpenoid from Harrisonia abyssinica . Phytochemistry 52(1): 127-133. Rugutt, J.K., Rugutt, K.J., Berner, D.K. (2001).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 915,
    "source": "PDF_chunked"
  },
  {
    "id": 4468,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 468)",
    "text": "Diacetoxyharrisonin, a tetranortrit erpenoid from Harrisonia abyssinica . Phytochemistry 52(1): 127-133. Rugutt, J.K., Rugutt, K.J., Berner, D.K. (2001). Limonoids from Nigerian Harrisonia Abyssinica and their stimulatory activity against Striga hermonthica Seeds. Journal of Natural Product s 64 (11):1434-1438. Sawhney, A.N., Khan, M.R., Ndaalio, G., Nkunya, M.H.H., Wevers, H. (1978). Studies on the rationale of African Traditional Medicine. Part III. Preliminary Screening of medicinal plants for antifungal activity. Pakistani Journal of Sc ience and Industry Research 21:193-196. Spencer, C.F., Koniuszy, F.R., Rogers, E.F., Shavel, J.R.J. et al . (1947). Survey of plants for antimalarial activity. Lloydia 10:145-174. Tahir, A.E. Satti, G.M.H., Khalid, S.A (1999). Antiplasmodial activity of selected Sudanese medicinal plants with emphasis on Maytenus senegalensis (Lam.) Exell. Journal of Ethnopharmacology 64(3):227-233.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4469,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 469)",
    "text": "OOAS Page 94 Hibiscus sabdariffa WAHP Nom botanique Hibiscus sabdariffaL. Famille Malvaceae Synonymes Hibiscus digitatus Cav.; Hibiscus gossypiifolius; Mill., Hibiscus sanguineus Griff.; Sabdariffa rubra Kostel Noms communs Anglais : Red Sorrel, Karkade, Roselle, thé Hibiscus, Soudan, Zobo Français : Oiselle de Guinée, thé rose d'Abyssinie (français) Noms vernaculaires Burkina Faso : Bobo Yoro, Fulfuldé Follere; pôllê, Dioula Dah wiléni, Mooré bito ou wegderé Gambie: Fula Pulaar Foleray, Manding Mandinka Dawaso, Wolof Bissab Ghana: Dagbani Dibemre, Hausa Yakuwa, Konkomba Tingyanbam Guinée: Basari Yamen, Fula Pulaar Folere Ba Di, Konyagi Yavetyan Guinée-Bissau: Balanta Mbatu, Crioulo Baguiche, Manding Mandinka - Cutcha Mali: Dogon Handjibane, Bambara Dah Bileni, Senoufo Tangnire Niger: Dende Jisima, Songhai Jisima Nigéria: Fula Fulfulde Dorongu, Hausa Abin Kan, Yoruba Amukan, isapa",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 893,
    "source": "PDF_chunked"
  },
  {
    "id": 4470,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 470)",
    "text": "Mali: Dogon Handjibane, Bambara Dah Bileni, Senoufo Tangnire Niger: Dende Jisima, Songhai Jisima Nigéria: Fula Fulfulde Dorongu, Hausa Abin Kan, Yoruba Amukan, isapa Sénégal: Vulgar Bassap, Tukulor Folerebadi, Bambara Da Kumu Sierra Leone : Bulom Satoε, Koranko Dagbami, Krio Sakpa Togo: Ewe Anyegba, Mina Gnatu, Kabye Gnotu Description de la plante Originaire d'Afrique de l'ouest, c'est une plante tropicale, annuelle, de 150- 210 cm de hauteur, formant un large bouquet de branches à partir de la base; elle a des feuilles lobées, rougeâtres. Les tiges également rougeâtres, presque ou tout à fait glabres. La partie comestible la plus importante est le sépale ou calice charnue, rouge intense, avec un goût acide qui est récolté avant de se transformer en matière ligneuse. Le calice est la partie qui reste après la floraison. Les feuilles sont ovales et simples. Les tiges ont 7.2-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 887,
    "source": "PDF_chunked"
  },
  {
    "id": 4471,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 471)",
    "text": "de se transformer en matière ligneuse. Le calice est la partie qui reste après la floraison. Les feuilles sont ovales et simples. Les tiges ont 7.2- 9,6 cm de diamètre.Les feuilles sont constituées de 3 lobes qui mesurent 2,4 cm ou plus, généralement larges et crénelées -dentelées ou dentelées. Les fleurs sont axillaires, solitaires et presque sessiles. La corolle estjaune et deux fois plus longue que son épai sseur. Les fruitssont ovoïdes, pubescentsde 1,2 à 1,8 cm de long (GHP, 2007). Numéro du spécimen de l'herbier Ghana: GC 53222 Nigéria : FHI 86659 Togo : 04434 Habitat et répartition géographique La plante provient du Soudan, Egypte et Asie du sud-est. El le pousse bien dans les zones de savane du Nigéria, où elle constitue désormais une boisson populaire appelée \"zobo\" où elle est communément consommée comme telle. Parties utilisées de la plante Calice et calyculus Autres partie utilisées Aucune Caractéristiques botaniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4472,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 472)",
    "text": "communément consommée comme telle. Parties utilisées de la plante Calice et calyculus Autres partie utilisées Aucune Caractéristiques botaniques L'hibiscus est le calice et le calyculus séchés de Hibiscus sabdariffa L. (Malvaceae) Utilisations ethnomédicales Le calice séché de cette plante possède une grande valeur commerciale en raison de son utilisation comme colorant végét al pour les aliments et les médicaments, mais principalement en raison de son utilisation comme boisson et, récemment, pour ses propriétés antihypertensives (Haji -Farabi et Haji - Tarkhani, 1999). La plante est une boisson tropicale couramment utilisée en médecine traditionnelle pour le traitement de l'hypertension, de la pyrexie, des inflammations, des troubles hépatiques, des problèmes rénaux et urinaires et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 793,
    "source": "PDF_chunked"
  },
  {
    "id": 4473,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 473)",
    "text": "OOAS Page 95 Hibiscus sabdariffa WAHP de l'obésité (Liu et al ., 2006). Ses feuilles sont couramment utilisées comme diurétique, sédatif et réfrigérant, et ses fruits comme un anti - scorbutique. Les calices sont souvent préparés comme une boisson et utilisés comme diurétique léger, antiseptique colorectal et intestinal, léger laxatif et comme sécours dans les pathologies ducœur et des nerfs, pour baisser la pression sanguine et traiter les artères calcifiées (Ajay et coll., 2007; Onyenekwe et al., 1999). Activités biologiques et pharmacologiques Il estplus probablement un spasmolytique et, peut protéger contre l'angine de poitrine. Il peut être utilisé pour faciliter la prise de poids. Des études ont confirmé son utilisation ethnomédicale comme un antihypertenseur (Carvajal -Zarrabal et al., 2005; Hansawasdi et al ., 2001). Les extraits aqueux du calice de H. sabdariffa chez des rats anesthésiés ont provoqué de façon dose",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4474,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 474)",
    "text": "comme un antihypertenseur (Carvajal -Zarrabal et al., 2005; Hansawasdi et al ., 2001). Les extraits aqueux du calice de H. sabdariffa chez des rats anesthésiés ont provoqué de façon dose dépendante une diminutionde la pression artérielle moyenne (Hirupanich et al., 2006). Le sectionnement des nerfs vagaux droits et gauches n'a pas exercé un effet significatif dans la chute de la pression moyenne artérielle. Le blocus cholinergique de 0,2 mg- 1 kg d'atropine, le blocus histaminergique de 1 mg - 1kg de cimétidine et 15 mg- 1 kgde prométhazine ont significativement atténué la réponse hypotensive (Hirupanich et al., 2006). Les extraits de fleurs séchées possèdent une act ivité antioxydante et protègent les rats hépatocytes de t -BHP induite par la cytotoxicité et la génotoxicité (Christian et al., 2006; Falade et al., 2005). Une lectine, réagissant avec les globules rouges polyagglutinables T, Tn et Th présents dans un",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4475,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 475)",
    "text": "par la cytotoxicité et la génotoxicité (Christian et al., 2006; Falade et al., 2005). Une lectine, réagissant avec les globules rouges polyagglutinables T, Tn et Th présents dans un extrait de la graine de la plante s'est révélée être un ajout utile à ceux disponibles pour distinguer la polyagglutinabilité des différents types de globules rouges. L'application topique de l'acide protocatéchuique isolé de la plante (5, 10 ou 20 mmol) qui a été lancée avec du benzo αpyrène (BαP, 5 minutes avant le traitement de TPA (15 nmol) deux fois par semaine, à des souris, pendant 20 semaines, a significativement inhibé l'incidence des tumeurs, alors que toutes les souris du groupe ayant subi le traitement TPA ont développé des tumeurs. Les mêmes doses de l'APC ont également réduit la formation de peroxyde d'hydrogène dans la peau des souris. Ces résultats indiquent que l'APC possède un potentiel chimio-préventif (Herrera-Arellano et al., 2004). Données cliniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 963,
    "source": "PDF_chunked"
  },
  {
    "id": 4476,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 476)",
    "text": "peroxyde d'hydrogène dans la peau des souris. Ces résultats indiquent que l'APC possède un potentiel chimio-préventif (Herrera-Arellano et al., 2004). Données cliniques L'urine de 36 sujets sains, après la consommation du jus de la fleur, a montré une diminution de la créatinine, de l'acide urique, du citrate, du tartrate, du calcium, du sodium, du potassium et du phosphate mais pas de l'oxalate (Carvajal-Zarrabal et al ., 2005). Cela pourrait aider au traitement et à la prévention des calculs rénaux. Constituants chimiques Tanin (catéchines), pigmentation (cyanidine et delphinidine), fer, calcium, zinc ; aluminium, chrome, cuivre, fer, acide d'hibiscus, acide protocatéchique, acides hétérogènes polysaccharides, composés phénoliques, flavonoïdes, β-carotène, riboflavine, thiamine, niacine et ascorbique, acides malique et hibiscique. Tests d'identité et de pureté Teneur en humidité : pas plus de 12 à 105C. Cendre total: pas plus de 10",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4477,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 477)",
    "text": "niacine et ascorbique, acides malique et hibiscique. Tests d'identité et de pureté Teneur en humidité : pas plus de 12 à 105C. Cendre total: pas plus de 10 Cendre insoluble dans l'acide: pas plus de 1,5 Valeur substancle extractible par l'eau: pas moins de 40 pH du décocté: 3.20 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de deux t aches distinctes avec Rf de 0,37 (violet) et 0,08 (violet). Chromatogramme",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 799,
    "source": "PDF_chunked"
  },
  {
    "id": 4478,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 478)",
    "text": "OOAS Page 96 Hibiscus sabdariffa WAHP Macroscopie Le calice est de couleur rouge- vin, gamosépalé, actinomorphe avec estivation valvaire. Le calice est coriace. Microscopie Les cellules épidermiques sont minces et polygonales ; les cellules du parenchyme sont polygonales avec 1,5- 16 μ de diamètre, à parois droites anticlinales; les faisceaux vasculaires sont collatéraux et disposés linéairement; les vaisseaux du xylème sont annulaires; les géodes exubérantes sont visibles; les chromoplastes apparaissent sous la forme de taches noires .Les tanins sont jaunes -clairs; des cristaux de géodes apparaissent également dans les cellules parenchymateuses; les cristaux monohydriques et trihydriques sont rarement présents (PSN, 2008). Matériel végétal en poudre Il est composé de cellules parenchy mateuses de l'épiderme, principalement d'éléments vasculaires d'épaississement annulaire; la suspension aqueuse du matériel en poudre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4479,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 479)",
    "text": "Il est composé de cellules parenchy mateuses de l'épiderme, principalement d'éléments vasculaires d'épaississement annulaire; la suspension aqueuse du matériel en poudre donne une coloration bleue à la solution de chlorure ferrique. Actions thérapeutiques Antiseptique, aphrodisiaque, astringent, résolutif, cholagogue, digestif, diurétique, stomachique, léger laxatif, sédatif, antihypertenseur, antitussif et uricosurique (Perry, 1980). Indications thérapeutiques Troubles gastro- intestinaux, hypercholestérolémie, calculs rénaux, dommages hépatiques, ivresse (Hirunpanich et al ., 2006; Morton, 1987). Données de sécurité La DL 50 des extraits aqueux de feuilles (p.o) chez la souris a été 2000 mgkg en 24 heures; aucun signe clinique de toxicité n'a été observé après le traitement des souris mâl es et femelles (500 à 2000 mgkg p.o) pendant 14 jours. Précautions d'emploi Une consommation prolongée chez l'homme",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 917,
    "source": "PDF_chunked"
  },
  {
    "id": 4480,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 480)",
    "text": "après le traitement des souris mâl es et femelles (500 à 2000 mgkg p.o) pendant 14 jours. Précautions d'emploi Une consommation prolongée chez l'homme pourrait produire un dommage du foie (Alarcon- Aguilar, 2007). Bien que la consommation moyenne de 150 180 mgkgjour semble sans danger, l es extraits doivent toutefois être prises avec prudence (Alarcon-Aguilar et coll., 2007). Effets indésirables L'utilisation excessive peut causer des perturbations gastro- intestinales chez quelques patients. Contre-indications Patients présentant une affection hépatique;grossesse et lactation. Dosage et forme galénique Décoction \"Zobo\" est une boisson populaire des communautés traditionnelles d'Afrique de l'ouest avec aucun régime posologique spécifique. Conservation A conserver dans un endroit frais et sec, à l'abri de la lumière et de l'humidité. Références Alarcon-Aguilar, F.J., Zamilpa, A., Perez -Garcia,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 906,
    "source": "PDF_chunked"
  },
  {
    "id": 4481,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 481)",
    "text": "Conservation A conserver dans un endroit frais et sec, à l'abri de la lumière et de l'humidité. Références Alarcon-Aguilar, F.J., Zamilpa, A., Perez -Garcia, M.D., Almanza-Perez, J.C. et al., (2007). Effect of Hibiscus sabdariffa on obesity in MSG mice. Journal of Ethnopharmacology 114: 66-71. Ajay, M., Chai, H.J., Mustafa, A.M., Gilani, A.H., Mustafa, M.R. (2007). Mechanisms of the anti - hypertensive effect of Hibiscus sabdariffa L. calyces. Journal of Ethnopharmacology 109:388- 393. Carvajal-Zarrabal, O., Waliszewski, S.M., Barradas-Dermitz, D.M., Orta -Flores, Z., Hayward-Jones, P.M. et al., (2005). The consumption of Hibiscus sabdariffa dried calyx ethanolic extract reduced lipid profile in rats. Plant Foods for Human Nutrition 60:153-159. Christian, K.R., Nair, M.G., Jackson, J.C. (2006). Antioxidant and cyclooxygenase inhibitory activity of sorrel ( Hibiscus sabdariffa). Journal of Food Composition and Analysis 19:778-783.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4482,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 482)",
    "text": "Christian, K.R., Nair, M.G., Jackson, J.C. (2006). Antioxidant and cyclooxygenase inhibitory activity of sorrel ( Hibiscus sabdariffa). Journal of Food Composition and Analysis 19:778-783. Falade, O.S., Otemuyiwa, I.O., Oladipo, A., Oyedapo, O.O. et al., (2005). The chemical composition and membrane stability activity of some herbs used in local therapy for anemia. Journal of Ethnopharmacology 102:15-22. Ghana Herbal Pharmacopoeia (2007). Quali type limited, Accra, Ghana. Haji-Faraji, M., Haji -Tarkhani, A. (1999). The effect of sour tea ( Hibiscus sabdariffa) on essential hypertension. Journal of Ethnopharmacology 65:231236. Hansawasdi, C., Kawabata, J., Kasai, T. (2001). Hibiscus acid as an inhibitor of starch digestion in the Caco- 2 cell model system. Bioscience, Biotechnology and Biochemistry 65:2087-2089.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 822,
    "source": "PDF_chunked"
  },
  {
    "id": 4483,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 483)",
    "text": "OOAS Page 97 Hibiscus sabdariffa WAHP Herrera-Arellano, Flores -Romero, A.S., Ch!avez - Soto, M.A., Tortoriello, J. (2004). Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial. Phyt omedicine 11:375 382. Hirunpanich, V., Utaipat, A., Morales, N.P., Bunyapraphatsara, N., Sato, H. (2005). Antioxidant effects of aqueous extracts from dried calyx of Hibiscus sabdariffa Linn. (Roselle) in vitro using rat low -density lipoprotein (LDL). Biological and Pharmaceutical Bulletin 28:481- 484. Hirunpanich, V., Utaipat, A., Morales, N.P., Bunyapraphatsara, N., Sato, H et al., (2006). Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of Hibiscus sabdariffa L. in hypercholesterolemic rats. Journal of Ethnopharmacology 103:252-260.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 881,
    "source": "PDF_chunked"
  },
  {
    "id": 4484,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 484)",
    "text": "sabdariffa L. in hypercholesterolemic rats. Journal of Ethnopharmacology 103:252-260. Liu, J.Y., Chen, C.C., Wang, W.H., Hsu, J.D., Yang, M.Y. et al.,(2006). The protective effects of Hibiscus sabdariffa extract on CCl 4-induced liver fibrosis in rats. Food and Chemical Toxicology, 44. Morton, J.F. (1987). Roselle, Hibiscus sabdariffa L. In: Morton, J.F. (Ed.). Fruits of Warm Climates. Miami, Fl. USA, pp. 281-286. Nigerian Herbal Pharmacopoeia (2008). The Federal Secretariat Complex, Abuja, Nigeria. Onyenekwe, P.C., Ajani, E.O., Ameh, D.A., Gamaniel, K.S. (1999). Antihypertensive effect of roselle ( Hibiscus sabdariffa) calyx infusion in spontaneously hypertensive rats and a comparison of its toxicity with that in Wistar rats. Cell Biochemistry and Function 17:199206. Perry, L.M. (1980). Medicinal Plants of East and Southeast Asia. Attributed Properties and",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 869,
    "source": "PDF_chunked"
  },
  {
    "id": 4485,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 485)",
    "text": "comparison of its toxicity with that in Wistar rats. Cell Biochemistry and Function 17:199206. Perry, L.M. (1980). Medicinal Plants of East and Southeast Asia. Attributed Properties and Uses.MIT Press, Cambridge. MA, 334360.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 224,
    "source": "PDF_chunked"
  },
  {
    "id": 4486,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 486)",
    "text": "OOAS Page 98 Hymenocardia acida WAHP Nom botanique Hymenocardia acida Tul. Famille Hymenocardiaceae Synonymes Hymenocardia mollis Pax. Noms communs Cœurs-volants (français), Heart-fruit (en anglais) Noms vernaculaires Burkina Faso : Dioula Grengeni; komoni; tanyaro, Fulfuldé samatahi;gnohi;péléti Ghana: Akan Duakokowa, Brong Sabrakyi Mali: Bambara Grègnéni, Malinké Diegbè, Pular Pellitoro Sénégal: Wolof Enkélèn Description de la plante Le nom générique Hymenocardia est dérivé des mots grecs \"hymen\" membrane et \"kardia\" cœur, en référence aux fruits en forme de cœur qui ont une membrane transparente (hymen). Le nom spécifique acida décrit le goût aigre de ses fruits (Burkill, 1994). H. acida est unpetit arbre ou arbuste de savane d'environ 9 m de haut; les rameaux deviennent brun rouille comme les pelures d'écorce; le tronc est court, souvent aplati et habituellement sinueux; les branches",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 900,
    "source": "PDF_chunked"
  },
  {
    "id": 4487,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 487)",
    "text": "arbuste de savane d'environ 9 m de haut; les rameaux deviennent brun rouille comme les pelures d'écorce; le tronc est court, souvent aplati et habituellement sinueux; les branches forment une couronne assez volumineuse, un peu arrondie ; l'écorce est lisse ou floconneuse, rose-brune lorsqu'elle est fraiche mais devient plus tard brune- pâle ou grise; les feuilles sont épaisses, coriaces, elliptiques -oblongues jusqu'à 8,75 cm de long sur 3,75 cm de large, habituellement pubescentes lorsqu'elles sont jeunes avec un tapis dense de poils et des glandes dorées en dessous; le sommet obtus arrondis, avec une base obtuse; pétiole mince, jusqu'à 1,8 cm de long; fleurs unisexuées, fleurs mâles jaune- rougeâtre disposées en grappes d'épis jusqu'à 6,5 cm de long; calice rouge, en forme de godet, anthères blanc -crème, fleurs femelles vertes, placées à l'aisselle des branches latérales feuillues et portant un stigmate saillant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4488,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 488)",
    "text": "forme de godet, anthères blanc -crème, fleurs femelles vertes, placées à l'aisselle des branches latérales feuillues et portant un stigmate saillant de couleur pourpre qui s'étale à environ 1,25 cm; fruit comprimé, obcordé et brun rougeâtre de 2,5 cm de long sur 2,5- 3,75 cm de large, en paires le long d'un bord; chacun a une aile mince, pâle et brune de forme presque carrée avec graines aplaties, brun, brillant. Numéro du spécimen de l'herbier Ghana: GC 45069 Habitat et répartition géographique La plante se trouve dans les savanes soudanaises et guinéennes, sur les terres plus ou moins sablonneuses, limoneuses ou argileuses. Elle estégalement présente dans les savanes et les forêts décidues, souvent sur les dunes au bord des lacs. Elle se rencontre en Afrique tropicale, du Sénégal au Cameroun. Parties utilisées de la plante Feuille Autres parties utilisées Écorce du tronc, écorce de la racine Caractéristiques botaniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4489,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 489)",
    "text": "Afrique tropicale, du Sénégal au Cameroun. Parties utilisées de la plante Feuille Autres parties utilisées Écorce du tronc, écorce de la racine Caractéristiques botaniques Hymenocardia est composédes feuilles fraîches ou séchées d' Hymenocardia acida Tul. Hymenocardiaceae Utilisations ethnomédicales La décoction de feuilles est utilisée pour traiter le paludisme (Vonthron- Senecheau et al., 2003), les ulcères de la peau et le diabète (Igoli et Gray, 2008). La décoction des racines est utilisée comme rince- bouche contre les caries et la mauvaise haleine (Kerharo et Adam, 1974); Il est hypotenseur et antipyrétique, antipaludique (Bernard, 2001) et également utilisé pour traiter les crises de drépanocytose (Mpiana et coll., 2007), la stomatite, la diarrhée, la dysenterie, les ulcères gastriques, les coliques et les menstrues douloureuses (Ukwe, 1997). Lorsqu'elle est mélangé avec du miel, la décoction de feuilles",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 4490,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 490)",
    "text": "2007), la stomatite, la diarrhée, la dysenterie, les ulcères gastriques, les coliques et les menstrues douloureuses (Ukwe, 1997). Lorsqu'elle est mélangé avec du miel, la décoction de feuilles est utilisée pour traiter les troubles digestifs (Ukwe, 1997). Le mélange d'infusion d'écorce et de feuilles est utilisé contre les troubles respiratoires, l'hypertension artérielle, l'épilepsie et l'aliénation mentale (Basilevskaia, 1969 ; Diallo, 2002).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 448,
    "source": "PDF_chunked"
  },
  {
    "id": 4491,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 491)",
    "text": "OOAS Page 99 Hymenocardia acida WAHP Activités biologiques et pharmacologiques Les extraits de la plante ont montré une activité antimicrobienne contre Staphylococcus aureus et Bacillus cereus . L'extrait a été inactif contre les bactéries Gram -négatives et les champignons. L'extrait aqueux possède des propriétés anti - inflammatoires et anticomplément. Il interfère sur les voies classiques et alternatives du système complémentaire avec des MICs de 13.32 et 60.34 mgml (Balde et coll., 1996). Mpiana et al., (2007) ont montré que la pl ante a une activité importante antifalciforme. L'effet diurétique observé de l'extrait aqueux était comparable au furosémide. Les extraits hydroalcooliques ont révélé des propriétés antioxydantes (3038 66 μmol TEg) semblables à l'acide chlorogénique (3165 186 micromol TEg) et, supérieure à l'extrait éthanolique de romarin (591 20 μmol TEg) (Duval et Baldi, 2010). Les extraits aqueux",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4492,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 492)",
    "text": "μmol TEg) semblables à l'acide chlorogénique (3165 186 micromol TEg) et, supérieure à l'extrait éthanolique de romarin (591 20 μmol TEg) (Duval et Baldi, 2010). Les extraits aqueux possèdent un effet vasorelaxant dû en partie à une action directe sur l'appareil contractile et aussi par la stimulat ion de l'endothélium vasculaire (Duval et Balde, 2010), tandis que l'extrait dichlorométhane des rameaux feuillus a montré une importante activité antitrypanosomalemodérée in vitro contre le Plasmodium falciparum. L'extrait brut de la racine a montré une activité anthelminthique importante contre le parasite intestinal Haemonchus contortus. L'extrait éthanolique de racine montre une activité antibactérienne in vitro contre Klebsiella pneumoniae, Staphylococcus aureus , Streptococcus mutans et Salmonella enterica , ainsi que des activités anti -inflammatoires et spasmolytiques in vivo, chez des souris et rats. Données cliniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4493,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 493)",
    "text": "Streptococcus mutans et Salmonella enterica , ainsi que des activités anti -inflammatoires et spasmolytiques in vivo, chez des souris et rats. Données cliniques Des études cliniques ont confirmé des effets antihypertenseurs des extraits et amélioré les formes posologiques (sachets de thé, microsphères de capsules) Duval et Baldé, 2010. Constituants chimiques Stérols, proanthocyanidines, coumarines, flavonoïdes, triterpénoïdes (acide betulinique et cycloarténol) (Diallo, 2004), alcaloïde (hymenocardine peptide) (Pai et al., 1968), Tests d'identité et de pureté Teneur en eau : 9,90 Cendre total: 4,25 Valeur substances extractiblespar l'eau : 8,17 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 920,
    "source": "PDF_chunked"
  },
  {
    "id": 4494,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 494)",
    "text": "stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10 mn. Présence de quatre taches roses distinctes avec R f de 0,65, 0,34, 0,31 et 0,21. Chromatogramme Macroscopie La macroscopie présente des feuilles vertes lorsqu'elles sont fraîches, simples et peu pétiolées avec un limbe de 4- 8 cm de long sur 1,5 à 4 cm de large ; de forme elliptique et oblongue; une marge entière ; un sommet obtus. La base de la feuille est ronde avec une nervation réticulée, une surface de feuilles glabres ; les jeunes feuilles sont pubescentes à la base ; la texture est charnue avec une nervure centrale saillante. Microscopie La surface épidermique adaxiale des feuilles est",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4495,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 495)",
    "text": "glabres ; les jeunes feuilles sont pubescentes à la base ; la texture est charnue avec une nervure centrale saillante. Microscopie La surface épidermique adaxiale des feuilles est droite avec des cellules polygonales, fortement lignifiées et sans stomates, des stries visibles, unicellulaires ; des poils non glandu laires sur les bords de la face,une surface abaxiale avecdes parois anticlinales droites ondulées etrondes, des poils glandulaires pluricellulaires, parfois peltées ; isobilatérale; une épiderme à couche unique avec des cellules hypodermiques ; la forme des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 573,
    "source": "PDF_chunked"
  },
  {
    "id": 4496,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 496)",
    "text": "OOAS Page 100 Hymenocardia acida WAHP cellules est polygonale et le mésophylle est indifférenciée ; la section transversale passant par le milieu de la nervure principale montre des protubérances sur les faces ventrales et dorsales ; unecuticule épaisse dans les rainures et des faisceaux vasculaires sont dans cinq grappes au centre ;des vaisseaux du xylème entourent le phloème. Matériel végétal en poudre Les cellules parenchymateuses de parois polygonales droites, unicellulaires, couvrent les poils et les vaisseaux du xylème. Actions thérapeutiques Antihypertenseur, antipaludique, antimicrobien, anti-inflammatoire, antifalciforme, diurétique, antioxydant, vasorelaxant. Indications thérapeutiques Hypertension artérielle, paludisme, diabète, impuissance, diarrhée, dysenterie, ulcères gastriques, coliques, menstruations douloureuses, drépanocytose, trypanosomiase (Sara et al ., 2004; Ukwe, 1997; Mpiana et coll.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 4497,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 497)",
    "text": "impuissance, diarrhée, dysenterie, ulcères gastriques, coliques, menstruations douloureuses, drépanocytose, trypanosomiase (Sara et al ., 2004; Ukwe, 1997; Mpiana et coll., 2007; Igoli et Gray, 2008; Vonthron- Senecheau et al., 2003; Igoli et al., 2005). Données de sécurité Dans une étude approfondiede 24 heures, la DL 50 des extraits aqueux de la feuille ( p.o) chez la souris 2000 mgkg; aucun signe clinique de toxicité n'a été observé après le traitement des souris mâles et femelles (500 à 2000 mgkg, p.o) pendant 14 jours. Précautions d'emploi Ne pas dépasser les doses recommandées. Effets indésirables Aucune information disponible. Contre-indications Patients avec hypotension orthostatique. Dosage et forme galénique Décoction (environ 30 minutes) de feuilles (environ 90 g dans 500 ml d'eau), prendre 1 tasse (environ 75 ml) 3 fois par jour (per-os). Conservation A conserver dans un endroit frais et sec. Références",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4498,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 498)",
    "text": "(environ 90 g dans 500 ml d'eau), prendre 1 tasse (environ 75 ml) 3 fois par jour (per-os). Conservation A conserver dans un endroit frais et sec. Références Baldé, A.M., Huang, Y., Liu, Z., Pieters, L., Oularé, K. et al . (1996). Antimicrobial and anticomplement activities of eleven guinean plants. Congrès de Metz. Basilevskaia, (1969). Plantes Médicinales de Guinée ; Imprimerie Nat ionale Patrice Lumumba, Conakry; 271 p. Conakry, République de Guinée. Bernard, B. (2001). Dictionnaire des plantes médicinales du monde ; Réalité et Croyance; Edition Estem ; 275 p. Burkill, H.M. (1994). Useful plants of West Tropical Africa. Vol. 2. Families E -I. Royal Botanical Gardens, Kew. Diallo, M.S.T. (2004). Investigations ethnobotanique et phytochimique de Hymenocardia acida et Lantana camara . Thèse de DEA de Phytothérapie et Plantes Médicinales, Département Pharmacie, Faculté de Médecine- Pharmacie-Odontostomatologie, Université de Conakry.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4499,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 499)",
    "text": "Hymenocardia acida et Lantana camara . Thèse de DEA de Phytothérapie et Plantes Médicinales, Département Pharmacie, Faculté de Médecine- Pharmacie-Odontostomatologie, Université de Conakry. Diallo, M.S.T. (2002). Contribution à l'étude phytochimique de Hymenocardia acida Tull. 57 p thèse de fin d' étude supérieure en Pharmacie; Faculté de Médecine Pharmacie- Odonto Stomatologie, Université de Conakry. Duval, O., Balde, A.M. (2010). Evaluations des activités vasodilatatrices et antioxydantes de plantes employees dans le traitement de l'hypertension artér ielle en médecine traditionnelle guinéenne. Première Journée Thématique de la CIDPHARMEF. Valorisation des pharmacopées et médecines traditionnelles dans la lutte contre l'hypertension artérielle,le diabète et le paludisme dans l'espace CIDPHARMEF: Acquis et Défis. Ouagadougou (Burkina Faso), 9 février (communication orale). Igoli, O.J., Gray, I.A. (2008). Friedelanone and",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4500,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 500)",
    "text": "diabète et le paludisme dans l'espace CIDPHARMEF: Acquis et Défis. Ouagadougou (Burkina Faso), 9 février (communication orale). Igoli, O.J., Gray, I.A. (2008). Friedelanone and other triterpenoids from Hymenocardia acida. International Journal of Physical Sciences 3(6) - 156-158. Igoli, O.J., Ogaji, O.G., Tor-Anyin, T.A., Igoli, N.P. (2005). Traditional medicine practice amongst the Igede people of Nigeria, part II ; African Journal of Traditional Medicine 2: 34-152. Kerharo, J., Adam, J.G. (1974). Pharmacopée Phytomedicine sénégalaise traditionnelle des plantes médicinales et toxiques ; Edition Vigot et frères. Mpiana, P., Tshibangu, D., Shetonde, O., Ngbolua, K. (2007). In vitro antidrepanocytary actvity (anti -sickle cell anemia) of some Congolese plants ; 14( 2):192-195.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 785,
    "source": "PDF_chunked"
  },
  {
    "id": 4501,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 501)",
    "text": "OOAS Page 101 Hymenocardia acida WAHP Pai, M., Marchand, J., Ratle, G., François- Jarreau, J. (1968). L'Hymenocardine, alcaloides de l 'Hymenocardia acida Tull ; Bulletin de la Société Chimique de France, n 7. Sara, H., Frederic, O., Reto, B., Victor, A., Joëlle, Q.L. (2004). In vitro antitrypanosomal activity of ethnopharmacologically selected Benines plants ; Journal of ethnopharmacology 91:37-42. Ukwe, C.V. (1997). Antiulcer activity of aqueous stembark extract of Hymenocardia acida Tul (Euphorbiaceae). International Journal of Pharmacognosy 35(5) 354-357. Vonthron-Senecheau, C., Weniger, B., Ouattara, M., Bi, F.T. et al . (2003). In vitro antiplasmodial activity and cytotoxicity of ethnobotanically selected Ivorian plants; Journal of Ethnopharmacology 87:221-225.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 777,
    "source": "PDF_chunked"
  },
  {
    "id": 4502,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 502)",
    "text": "OOAS Page 102 Khaya senegalensis WAHP Nom botanique Khaya senegalensis A. Juss. Famille Meliaceae Synonymes Swietenia senegalensis Lam. Noms communs Dry zone mahogany, mahogany, African cedar (anglais); Cailcedrat du Sénégal, Acajou du Sénégal (Français) Noms vernaculaires Burkina Faso : Mooré kuka, Dioula Djala, Fulfuldé kayi;kayl Cote d'Ivoire: Malinké Jala Ghana: Twi Kuntunkuri, Fante Okum, Ewé - Logo Mali: Bambara Jala, Dogon Pell, Peulh Kaille Nigéria: Yoruba Oganwo, Hausa Madaci, Ibo Ono onu Sénégal: Serer - N'garin, Wolo f Hay, Diola Bu ririt Togo: Ewé Mahougen, Ouachi Mahougani Description de la plante C'est un arbre pouvant atteindre 40 m de haut avec une circonférence de 4 m, ramifié en 2 ou 3 branches principales d'environ 8 m, donnant une large couronne étalée, composée de feuilles pennées, de 6- 8 paires de folioles, elliptiques - lancéolées, opposées, glabres, les fleurs sont de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 905,
    "source": "PDF_chunked"
  },
  {
    "id": 4503,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 503)",
    "text": "branches principales d'environ 8 m, donnant une large couronne étalée, composée de feuilles pennées, de 6- 8 paires de folioles, elliptiques - lancéolées, opposées, glabres, les fleurs sont de couleur crème avec une inflorescence de panicules bien visibles (Adegbola, 1986). Numéro du spécimen de l'herbier Ghana : UIH 13757 Mali : 0731 DMT Nigéria : 107447 FHI Habitat et répartition géographique Largement répandu dans les forêts de la savane d'Afrique. Parties utilisées de la plante Écorce du tronc Autres parties utilisées Écorce, feuille, racine Caractéristiques botaniques L'acajou se compose de l'écorce de tige fraîche ou séchée de Khaya senegalensis A. Juss (Meliaceae). Utilisation ethnomédicale L'écorce de la tige, amère, est utilisée comme remède contre la fièvre. Ainsi, le décocté ou l'écorce fraîche macérée dans de l'eau froide ou l'écorce séchée, pulvérisée et mélangée avec du sel est prise à petites doses tous les deux jours.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4504,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 504)",
    "text": "remède contre la fièvre. Ainsi, le décocté ou l'écorce fraîche macérée dans de l'eau froide ou l'écorce séchée, pulvérisée et mélangée avec du sel est prise à petites doses tous les deux jours. L'écorce est utilisée comme stomachique et tonique amer, dépuratif, vermifuge et taeniacide dans le traitement de la syphilis. L'écorce et les graines écrasées sont utilisées comme emménagogue. L'infusé froid de l'écorce est administré aux chevaux comme tonique pour stimuler leur appétit et aux bovins souffrant de la douve du foie( ou distomatose hépatique) . L'écorce pulvérisée et séchée est utilisée comme un pansement des ulcères sur le dos des chameaux et chevaux (Adesogan et al ., 1967; Androulakis et al., 2006). Activités biologiques et pharmacologiques Un limonoïde des extraits aqueux de l'écorce de tige et de feuilles indique une activit é antifalciforme forte (automne et al ., 1999). L'application locale de pommades à base",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4505,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 505)",
    "text": "Un limonoïde des extraits aqueux de l'écorce de tige et de feuilles indique une activit é antifalciforme forte (automne et al ., 1999). L'application locale de pommades à base d'extraits hydro- alcooliques de l'écorce à des animaux de laboratoire a montré que la plante a une activité anti -inflammatoire. Un extrait de l'écorce a également montré des effets antiprolifératifs et pro- apoptotiques sur des lignées de cellules cancéreuses (Androulakis et al., 2006). Des extraits se sont révélés plus puissants contre Culex annulirostris. L'hexane et l'éthanol ont été les meilleurs solvants pour l'extraction des huiles essentielles (Shaalan et al., 2006). Les constituants anthelminthiques de l'extrait d'écorce ont démontré une activité in vitro et in vivo contre les nématodes gastro-intestinaux de moutons (Ademola et al., 2009). Koko et coll. (2008) ont s ignalé les propriétés immunomodulatrices in vitro des extraits",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 4506,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 506)",
    "text": "OOAS Page 103 Khaya senegalensis WAHP éthanoliques d'écorce et de feuilles. Les extraits alcooliques à une dose de 2 gkg ont causé la dépression, la sédation et la réduction de l'activité locomotrice chez la souris; ces extraits ont également protégé 70 des souris contre les convulsions induites par la leptazol. Les limonoïdes 3 α, 7 α-dideacetylkhivorin, isolés de l'extrait méthanolique, ont montré une croissance importante des activités inhibitrices contre les cellules MCF-7, SiHa et Caco-2 avec des valeurs d'IC 50 de l'ordre de 0,07- 0,14 μ (Zhang et al ., 2007). L'administration orale de l'extrait d'écorce de tige éthanolique (2 mgkg) chez les rats, a augmenté significativement les activités de la phosphatase alcaline du foie, de l'alanine aminotransférase et de l'aspartate aminotransférase par référenceà des témoins. Les résultats indiquent que l'extrait éthanolique de l'écorce de tige a la capacité d'induire la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4507,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 507)",
    "text": "aminotransférase et de l'aspartate aminotransférase par référenceà des témoins. Les résultats indiquent que l'extrait éthanolique de l'écorce de tige a la capacité d'induire la synthèse des enzymes hépatiques (Yakubu et al., 2005). Données cliniques Aucune information disponible Constituants chimiques Limonoïdes (méthyl angolensate, khayalenoides A et B);, 2, 6-dihydroxybenzoquinone ; capstérol ; stigmastérol et β-sitostérol; scopolétine ; scoparone et aeculetin (Yuan et al., 2009; Zhang et al., 2009). Tests d'identité et de pureté Teneur en humidité: pas plus de 5,10 Cendre totale: 20,07 Cendre insoluble dans l'acide: pas plus de 1 . Cendre soluble dans l'eau: pas moins de 0,6 . Valeur substances extractibles par l'eau: pas moins de 16,69 . Valeur substances extractibles par l'éthanol (70 ): pas moins de 15,75 . Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 4508,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 508)",
    "text": "moins de 16,69 . Valeur substances extractibles par l'éthanol (70 ): pas moins de 15,75 . Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60F254, et phase mobile : éther de pétr ole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de trois taches distinctes avec Rf de 0,68 (Rose), 0,45 (Rose) et 0,32 (Rose). Chromatogramme Macroscopie L'écorce de tige se présente habituellement sous forme de copeaux ou de parties de bois en forme de courbe, jusqu'à 2 cm d'épaisseur; la surfac e extérieure est rugueuse, brun- rougeâtre avec des taches grises et blanches; la surface intérieure est brune, finement striée longitudinalement; avec une cassure, fibreuse",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4509,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 509)",
    "text": "extérieure est rugueuse, brun- rougeâtre avec des taches grises et blanches; la surface intérieure est brune, finement striée longitudinalement; avec une cassure, fibreuse dans la partie intérieure et granulaire dans la partie externe. Microscopie On observe des cellules de liège avec des scléréides lignifiées en groupes dans la couche de liège, radialement allongées avec des cavités étroites. Les couches de cellules de cork sont immédiatement remplis de prismes d'oxalate de calcium à côté dela racine du parenchyme, du phloème et des rayons vasculaires; les plaques de tamis sont à parois épaisses ; des cristaux d'oxalate de calcium sont dispersés dans tout le parenchyme ; les fibres du phloèmemesurent 151-4111430 μ de long sur 14-20-35 μ de large; les pr ismes d'oxalate de calcium mesurent respectivement, 11- 46 x 7 -35 x 7- 18 μ de long, de large et de haut; les macles d'oxalate de calcium mesurent 140539 μ de diamètre; les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4510,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 510)",
    "text": "OOAS Page 104 Khaya senegalensis WAHP cellules pierreuses, 275 52 x 52- 119 μ; les rayons médullaires sont plus large ou c omposés de 2 cellules, avec des cellules à parois minces rectangulaires délimitées par des groupes de fibres de phloème alternant avec le parenchyme. Matériel végétal en poudre La poudre de l'écorce est brun- rougeâtre, caractérisée par des fibres de phlo ème courbées ou droites, des prismes et des macles d'oxalate de calcium et des grains de pierre isolés ;; des cellules de liègeet des tissus de parenchyme. Actions thérapeutiques Antifalciforme, antioxydant, anti -inflammatoires, antiproliférative, antipal udique, antimicrobien, anthelminthiques. Indications thérapeutiques Anémie, arthrite, furoncles, varicelle, convulsions, fatiguepériodique, fièvre, fatigue générale, hémorroïdes, maux de tête, bouton de chaleur; helminthiases intestinales, manque d'appéti t, paludisme, maladies sexuellement",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4511,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 511)",
    "text": "fatiguepériodique, fièvre, fatigue générale, hémorroïdes, maux de tête, bouton de chaleur; helminthiases intestinales, manque d'appéti t, paludisme, maladies sexuellement transmissibles, ulcère, vers intestinaux (Mshana et al., 2000; Dennis, 2002; GHP, 1992). Données de sécurité Dans une étude de toxicité aiguë de 24 heures, la DL 50 des substances aqueuses de d'écorce de tige (p.o) chez la souris a été 2000 mgkg. Des études de toxicicté subaigüe n'ont montré aucun signe clinique de toxicité après traitement des souris mâles et femelles (500 à 2000 mgkg; p.o) pendant 14 jours. L'administration orale quotidienne d'extrait aqueux de l'éc orce de tige à des doses de 10, 20 et 40 mgkg, pendant 28 jours, à des rats, a révélé que la plante peut être potentiellement toxique (Abubakar et al ., 2010). Prolongée (28 jours), l'administration orale des extraits aqueux d'écorce de tige à 100- 2000 mgkg à des poussins de quatre- semaines était",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4512,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 512)",
    "text": "potentiellement toxique (Abubakar et al ., 2010). Prolongée (28 jours), l'administration orale des extraits aqueux d'écorce de tige à 100- 2000 mgkg à des poussins de quatre- semaines était relativement sûre (Nwosu et al ., 2011). L'administration à long terme de l'extrait éthanolique a eu un effet plus néfaste sur les reins (Adebayo etal., 2003). Précautions d'emploi Il est susceptible d'interférer avec le métabolisme de certains médicaments dans le foie en raison de ses propriétés de détoxification hépatique et antihépatoxique. L'extrait éthanolique de Khaya senegalensis a exercé un effet plus néfaste sur les reins, lorsqu'il est administré sans int érruption sur une période prolongée comparativement à une période courte. Cela aura un impact négatif sur le fonctionnement des reins (Adebayo et al., 2003). Effets indésirables Insuffisance respiratoire, myodegénération, perturbation de la structure mitochondriale. Contre-indications",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4513,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 513)",
    "text": "sur le fonctionnement des reins (Adebayo et al., 2003). Effets indésirables Insuffisance respiratoire, myodegénération, perturbation de la structure mitochondriale. Contre-indications Des doses élevées peuvent provoquer des faiblesses au niveau des membres, unediminution de l'activité locomotrice et une grave hypothermie, ainsi qu'un potentiel abortif. Dosage et forme galénique Décoction : 30 g de graines moulues grillées dans 900 ml d'eau; laisser bouillir jusqu'à réduction de l'eau à 600 ml ; prendre 1 tasse trois fois par jour Teinture : 1:5 à 50 d'alcool, 5 ml trois fois par jour. Conservation A conserver dans un endroit frais et sec. Références Abubakar, M.G., Lawal, A., Usman, M.R. (2010). Hepatotoxicity studies of sub- chronic administration of aqueous stem bark of Khaya senegalensis in albino rats. Bayero Journal of Pure and Applied Sciences 3(1):2628. Adebayo, J.O ., Yakubu, M.T ., Egwim, E.C .,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 917,
    "source": "PDF_chunked"
  },
  {
    "id": 4514,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 514)",
    "text": "administration of aqueous stem bark of Khaya senegalensis in albino rats. Bayero Journal of Pure and Applied Sciences 3(1):2628. Adebayo, J.O ., Yakubu, M.T ., Egwim, E.C ., Owoyele, V.B ., Enaibe, B.U . (2003). Effect of ethanolic extract of Khaya senegalensis on some biochemical parameters of rat kidney. Journal of Ethnopharmacology 88(1):69-72. Adegbola, O.R. (1986). Establishment of Pharmacopoeial Standards for Khaya senegalensis A. Juss. and Piper guineense Schum. and Thonn. M.Phil. (Pharmacognosy) Thesis University of Ife (now Obafemi Awolowo University), Ile-Ife Nigeria. Adesogan, E.K., Adesida, G.A., Taylor, D.A.H. (1967). Extractives from Khaya senegalensis. Chemical Communications 16:790-791. Androulakis, X.M., Muga, S.J., Chen, F., Koita, Y. et al. (2006). Chemopreventive effects of Khaya senegalensis bark extract on human colorectal cancer. Anticancer Research 26(3B):2397-405. Dennis, F. (Ed) (2002). Manual for the",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4515,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 515)",
    "text": "et al. (2006). Chemopreventive effects of Khaya senegalensis bark extract on human colorectal cancer. Anticancer Research 26(3B):2397-405. Dennis, F. (Ed) (2002). Manual for the propagation of medicinal plants in Ghana. Darwin Intiative for the Survival of Species. Fall, A.B., Vanhaelen-Fastré, R., Vanhaelen, M., Lo, I ., Toppet, M . (1999). In vitro antisickling activity of a rearranged limonoid isolated from",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 413,
    "source": "PDF_chunked"
  },
  {
    "id": 4516,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 516)",
    "text": "OOAS Page 105 Khaya senegalensis WAHP Khaya. senegalensis . Planta Medica 65(3):209- 12. Ghana Herbal Pharmacopoeia (1992). The Advent Press, Accra, Ghana. Koko, W.S., Mesaik, M.A., Yousaf, S., Galal, M., Choudhary, M.I . (2008). In vitro immunomodulating properties of selected Sudanese medicinal plants. Journal of Ethnopharmacology 118(1):26-34. Mshana, N. R., Abbiw, D.K., Addae -Mensah, I., Ahiyi, M.R.A. et al (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Nwosu, C.O., Yahayah, K., Igbokwe, I.O. (2011). Toxicity and Anticoccidial Efficacy of Some Plants Used in the Traditional Treatment of Avian Coccidiosis in Semi -arid Northeastern Nigeria. Research Journal of Parasitology 6(1):1830. Shaalan, E.A ., Canyon, D.V ., Younes, M.W ., Abdel-Wahab, H., Mansour, A.H. (2006). Efficacy",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4517,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 517)",
    "text": "Coccidiosis in Semi -arid Northeastern Nigeria. Research Journal of Parasitology 6(1):1830. Shaalan, E.A ., Canyon, D.V ., Younes, M.W ., Abdel-Wahab, H., Mansour, A.H. (2006). Efficacy of eight larvicidal botanical extracts from Khaya senegalensis and Daucus carota against Culex annulirostris. Journal of American Mosquito Control Association 22(3):433-436. Yakubu, M.T., Adebayo,, O.J., Egwim, E.C., Owoyele, V.B. (2005). Increased liver alkaline phosphatase and aminotransferase activities following administration of ethanolic extract of Khaya senegalensis stem bark to rats. Biochmistry 17(1):27-32. Yuan, T ., Yang, S.P ., Zhang, C.R ., Zhang, S ., Yue, J.M. (2009). Two limonoids, khayalenoids A and B with an unprecedented 8- oxa- tricyclo4.3.2.0(2,7)undecane motif, from Khaya senegalensis. Organic Letters 11(3):617-20. Zhang, H ., Tan, J ., Vanderveer, D ., Wang, X .,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 880,
    "source": "PDF_chunked"
  },
  {
    "id": 4518,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 518)",
    "text": "and B with an unprecedented 8- oxa- tricyclo4.3.2.0(2,7)undecane motif, from Khaya senegalensis. Organic Letters 11(3):617-20. Zhang, H ., Tan, J ., Vanderveer, D ., Wang, X ., Wargovich, M.J ., Chen, F . (2009). Khayanolides from African mahogany Khaya senegalensis (Meliaceae): A revision. Phytochemistry. 70(2):294-9. Zhang, H ., Wang, X ., Chen, F ., Androulakis, X.M., Wargovich, M.J. (2007). Anticancer activity of limonoid from Khaya senegalensis . Phytotherapy Research 21(8):731-734. .",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 494,
    "source": "PDF_chunked"
  },
  {
    "id": 4519,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 519)",
    "text": "OOAS Page 106 Lawsonia inermis WAHP Nom botanique Lawsonia inermis l. Famille Lythraceae Synonymes Lawsonia alba Lam. Noms communs Henna, Egyptian privet (anglais) ; Crin (français) Noms vernaculaires Burkina Faso : Moor é Lalé, Dioula Djabi, Fulfuldé Djabe;Lêlla Ghana: Dagbani Z abella, Hausa Lalle Mali: Bambara Dabé, Maninka- Dyabi, Pular Dyabè, Sérère Fuden Nigéria: Yoruba Laali Sénégal: Soussou Laali, Wolof Fuden, Malinké Djabi Description de la plante Arbuste de 2 à 9 m de haut, fortement ramifiées avec des branches minces ; écorce lisse, blanche et fibreuse ; les feuilles sont simples, opposées et entières, glabres, sessiles subsessiles et pennatinervé; inflorescence : une panicule terminale, pyramidale, de 10 à 25 cm de long ; des fleurs très odorantes, bisexuées, blanches et glabres ; desboule de fruits capsuloide de 8 mm de diamètre, glabres, indéhiscents et clair-brun à maturité.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 902,
    "source": "PDF_chunked"
  },
  {
    "id": 4520,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 520)",
    "text": "long ; des fleurs très odorantes, bisexuées, blanches et glabres ; desboule de fruits capsuloide de 8 mm de diamètre, glabres, indéhiscents et clair-brun à maturité. Numéro du spécimen de l'herbier Ghana: GC 577 Habitat et répartition géographique La plante est largement distribuée de l'Iran au Pakistan et à l'ouest de l'Inde. On le rencontre également dans lesrégions méditerranéennes, tropicales, subtropicales et sahéliennes de l'Afrique (Aweke et al ., 2005). EIle est cultivée principalement dans les jardins potagers et près des maisons, de préférence dans les sols sableux. Parties utilisées de la plante Feuille Autres parties utilisées Écorce du tronc, racine, fleur. Caractéristiques botaniques Hena est composé de feuilles de Lawsonia inermis l. (Lythraceae) Utilisation ethnomédicale La plante est un emménagogue et un abortif. Les feuilles infusées sont utilisées contre la trypanosomiase (Aweke et al., 2005) et le",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4521,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 521)",
    "text": "inermis l. (Lythraceae) Utilisation ethnomédicale La plante est un emménagogue et un abortif. Les feuilles infusées sont utilisées contre la trypanosomiase (Aweke et al., 2005) et le décocté de feuilles est utilisé pour traiter le paludisme (Loua, 2004). Activités biologiques et pharmacologiques Les extraits de henné ont montré une activité molluscicide contre Lymnaea acuminata et Indoplanorbis exustus (Singh et Singh, 2001; Okpekon et al ., 2004). Un extrait de feuilles a montré des effets antitumoraux et tuberculostatiques in vivo . L'extrait a montré un large spectre fongitoxique de divers dermatophytes, qui a été attribué au lawsone. Des préparations à base de plante ont montré une activité antifertilité. Lawsonia possède une activité antimicrobienne in vitro contre un large spectre de souches bactériennes (comme Shigella sonnei) et contre C. albicans (Habbal et al., 2005). L'extrait éthanolique de la plante a des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4522,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 522)",
    "text": "activité antimicrobienne in vitro contre un large spectre de souches bactériennes (comme Shigella sonnei) et contre C. albicans (Habbal et al., 2005). L'extrait éthanolique de la plante a des effets curatifs importants et une activité inhibitrice sur la glycation des protéines (Sultana et al., 2008). Des extraits foliaires éthanoliques, aqueux et méthanoliques ont montré une activité inhibitrice modeste de la transcriptase inverse (Suthienkul et al., 1993). L'activité tuberculostatique de la plante a été démontrée in vitro et in vivo (Sharma, 1990), tandis que l'extrait de l'écorce de tige a montré des propriétés fongistatiques et fongicides (Singh et Pandey, 1989 ; Tripathi et al., 1978). L'activité hypoglycémique in vitro de l'extrait méthanolique a été démontrée par Arayne et al. (2007) et Mikhaeil et al. (2004) ont montré que les propriétés antioxydantes de l'extrait étaient comparables à celle de l'acide ascorbique.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4523,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 523)",
    "text": "a été démontrée par Arayne et al. (2007) et Mikhaeil et al. (2004) ont montré que les propriétés antioxydantes de l'extrait étaient comparables à celle de l'acide ascorbique. Plusieurs autres propriétés ont été attribuées au composé de lawsone et aux constituants tels que",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 272,
    "source": "PDF_chunked"
  },
  {
    "id": 4524,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 524)",
    "text": "OOAS Page 107 Lawsonia inermis WAHP les flavonoïdes (lutéoline, acacetine), l'acide gallique, les hydrates de carbone (Aweke et al., 2005). Ces propriétés incluent des activités antipyrétique, anti -inflammatoire et analgésique (Ali et al., 1995). Données cliniques Aucune information disponible Constituants chimiques Quinones (lawsone et 2-hydroxy-1, 4 - naphtoquinone, lawsoniaside, 1, 4- naphtoquinone, isoplumbagine); xanthones (laxanthones); flavonoïdes (lutéoline, lutéoline- glycosides, acacetine, apigénine- glycosides); tanins; coumarines (lacoumarine, scopolétine, esculétine, fraxetine) ; dérivés du naphtalène (1, 2-dihydroxy-4-glucosylnapthalène, diglucosyloxy - 1,4-2-hydroxynaphthalène 1, 3- dihydroxynaphtalène, 4 -glucosyloxy-1, 2- dihydroxynapthalène); stérols ( β-sitostérol, stigmastérol, daucostérol); triterpènes pentacycliques (hennadiol, lupéol, acide betulinique bétuline); huiles essentielles. Tests d'identité et de pureté",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4525,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 525)",
    "text": "stigmastérol, daucostérol); triterpènes pentacycliques (hennadiol, lupéol, acide betulinique bétuline); huiles essentielles. Tests d'identité et de pureté Teneur en humidité : pas plus de 7,3 Cendre totale : 8,32 Valeur soluble extractible par l'eau : pas moins de 11.20 Valeur soluble extractible par l'alcool (70 ): pas moins de 9.52 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation es t réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de cinq tachesdistinctes avec R f de 0,68 (Rose), 0,61 (brun- rougeâtre), 0,45 (Rose), 0,35 (Rose) et 0,20 (Rose). Chromatogramme Macroscopie",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 915,
    "source": "PDF_chunked"
  },
  {
    "id": 4526,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 526)",
    "text": "pendant 5-10 mn. Présence de cinq tachesdistinctes avec R f de 0,68 (Rose), 0,61 (brun- rougeâtre), 0,45 (Rose), 0,35 (Rose) et 0,20 (Rose). Chromatogramme Macroscopie Feuilles coriaces, glabres, vert -brun, oblongues ou largement lancéolée, base symétrique, marge entière et aigüe à acuminé, 2- 3 cm de long sur 1- 2 cm de large, peu pétiolées ;le pétiole est concavo-convexe; les nervures pernnativées et réticulées; les nervures latérales quittent la nervure centrale à un angle de 60 par rapport aux feuilles. Microscopie On observe des feuilles isobilatérales avec 2 ou 3 rangées de cellules palissadiques adhérant à l'épiderme supérieur et 1 ou 2 lignes adhérant à l'épiderme inférieur avec un étroit et lacuneux mésophylle contenant des idioblastes avec des groupes de cristaux d'oxalate de calcium; l'épiderme supérieur est constitué de cellules polygonales de diamètre similaires, avec des parois droites anticlinales, quelques stomates",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4527,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 527)",
    "text": "groupes de cristaux d'oxalate de calcium; l'épiderme supérieur est constitué de cellules polygonales de diamètre similaires, avec des parois droites anticlinales, quelques stomates anomocytiques recouverts d'une cuticule striée, de cellules de l'épiderme supérieur. Mais les stomates sont plus fréquentes et les parois anticlinales l égèrement sinueuses. Dans la région de la nervure centrale, le cordon vasculaire est entouré d'un arc de fibres péricycliques, cordonsde faisceaux vasculaires bicollatéraux. Des bandes de collenchyme sub- épidermiques sont présentes.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 567,
    "source": "PDF_chunked"
  },
  {
    "id": 4528,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 528)",
    "text": "OOAS Page 108 Lawsonia inermis WAHP Matériel végétal en poudre Il est de couleur vert -foncé avec une faible odeur et un goût astringent, légèrement amer; présentant des fragments de cellules épidermiques supérieures et inférieures recouvertes d'une cuticule striée et de stomates anomocytiques, groupes de cristaux d'oxalate de calcium, plusieurs cellules pallissadiques, vaisseaux spiraux, annelés et réticulés;des fragments de fibres péricycliques lignifiées avec des murs épais, une cavité étroite et des pics aigus. Actions thérapeutiques Antipaludéen, trypanocidal, molluscicide, tuberculostatique, fongitoxique, antitumorale, antimicrobien, antipyrétique, anti -inflammatoire, analgésique, curatif (Singh et Singh, 2001; Okpekon et al., 2004; Loua, 2004; Aweke et al., 2005; Habbal et al., 2005; Ali et al., 1995). Indications thérapeutiques Paludisme, tuberculose, infections bactériennes et fongiques. Données de sécurité La DL",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4529,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 529)",
    "text": "2005; Habbal et al., 2005; Ali et al., 1995). Indications thérapeutiques Paludisme, tuberculose, infections bactériennes et fongiques. Données de sécurité La DL 50 de l'extrait aqueux de feuilles s'est révélé 3000 mgkg chez le rat. Lors des études de toxicité subaiguë de l'administration répétée (300-3000 mgkg p.o) pendant 14 jours, aucun effet indésirable grave n'a été observé sur le sang et ses éléments cellulaires, le poids corporel ou les ratios organespoids corporel. Il n'y n'avait aucun effet de l'extrait aqueux sur la fonction rénale et l'eff et sur la fonction hépatique a été considéré comme insigifiant. Une allergie de contact (peau) au henné pur a été signalée (Polat et al., 2009). La cytotoxicité du henné et du lawsone a été démontrée (Sauriasari et al.,), 2007. L'utilisation de henné peut avoir des effets secondaires tels que l'anémie hémolytique, en cas de carence en glucose- 6-phosphate déshydrogénase (Kok et al., 2004). Une dose",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4530,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 530)",
    "text": "2007. L'utilisation de henné peut avoir des effets secondaires tels que l'anémie hémolytique, en cas de carence en glucose- 6-phosphate déshydrogénase (Kok et al., 2004). Une dose quotidienne de 3, 30 ou 300 mg d'extrait de la plante produit 40- 60 d'avortement chez les rats; l'infertilité qui en résulte est permanente (Munshi et al., 1977). Précautions d'emploi Il est recommandé de surveiller la fonction hépatique pendant la durée du traitement. Effets indésirables Légère augmentation des transaminases hépatiques. Contre-indications Maladie du foie. Dosage et forme galénique Infusion : 30 g de feuilles séchées dans 600 ml d'eau; 3-4 tasses par jour Teinture : 1:5 à 45 d'alcool; 5 ml trois fois par jour Conservation A conserver dans un endroit frais et sec Références Ali, B.H., Bashir, A.K., Tanira, M.O. (1995). Anti- inflammatory, antipyretic, and analgesic effects of Lawsonia inermis L. (henna) in rats. Pharmacology 51(6):356-63.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4531,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 531)",
    "text": "Références Ali, B.H., Bashir, A.K., Tanira, M.O. (1995). Anti- inflammatory, antipyretic, and analgesic effects of Lawsonia inermis L. (henna) in rats. Pharmacology 51(6):356-63. Arayne, M.S., Sultana, N., Mirza, A.Z., Zuberi, M.H., Siddiqui, F.A. (2007). In vitro hypoglycemiant acti vity of methanolic ex tract of some indigenous plants ; Pakistani Journal of Pharmaceutical Science 20(4):268-73. Aweke, Getachew, Tapapul, Suzanne, (2005). Lawsonia inermis L. Internet Fiche de Protabase. Jansen, P.C.M. Cardon, D. (Editeurs). PROTA (P lant Resources of Tropical Africa Ressources végétales de l'Afrique tropicale), Wageningen, Pays Bas. http:database.prota.orgrecherche.htm. Visité le 24 juin. Habbal, O.A., Al -Jabri, A.A., El -Hag, A.H., Al - Mahrooqi, Z.H. et al . (2005). In-vitro antimicrobial activity of Lawsonia inermis Linn (henna). A pilot study on the Omani henna. Saudi Medical Journal 26(1):69-72.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 913,
    "source": "PDF_chunked"
  },
  {
    "id": 4532,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 532)",
    "text": "Mahrooqi, Z.H. et al . (2005). In-vitro antimicrobial activity of Lawsonia inermis Linn (henna). A pilot study on the Omani henna. Saudi Medical Journal 26(1):69-72. Kök, A.N., Ertekin, M.V., Ertekin, V., Avci, B. (2004). Henna ( Lawsonia inermis L.) induced haemolytic anaemia in siblings. International Journal of Clinical Practice 58(5):530-532. Loua, J. (2004). Investigations thérapeutiques et phytochimique de Lawsonia inermis L. utilisé en médecine traditionnelle guinéenne dans le traitement du paludisme ; thèse de Phytothérapie et Plantes Méd icinales, Département de Pharmacie, Faculté de médecine- Pharmacie- Odontostomatologie, Université de Conakry, Guinée. Mikhaeil, B.R., Badria, F.A., Maatooq, G.T., Amer, M.M. (2004). Antioxydant and immunomodulatory constituents of henna leaves. Zeitschrift für Naturforschung C. 59(7-8):468-476. Munshi, S.R., Shetye, T.A., Nair, R.K. (1977). Antifertility activity of three indigenous plant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4533,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 533)",
    "text": "Zeitschrift für Naturforschung C. 59(7-8):468-476. Munshi, S.R., Shetye, T.A., Nair, R.K. (1977). Antifertility activity of three indigenous plant preparations. Planta MedIca 31(1):73-75.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 187,
    "source": "PDF_chunked"
  },
  {
    "id": 4534,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 534)",
    "text": "OOAS Page 109 Lawsonia inermis WAHP Okpekon, T., Yolou, S., Gleye, C., Roblot, F., Loiseau, P. et al. (2004). Antiparasitic activities of medicinal plants used in Ivory Coast. Journal of Ethnopharmacology 90(1):91-97. Polat, M., Dikilitaş, M., Oztaş, P., Alli, N. (2009). Allergic contact dermatitis to pure henna; Dermatoogyl Online Journal 15(1):15. Sauriasari, R., Wang, D.H., Takemura, Y., Tsutsui, K., Masuoka, N. et al ., (2007). Cytotoxicity of lawsone and cytoprotective activity of antioxydants in catalase mutant Escherichia coli; Toxicology 235:103-111. Singh, A., Singh, D.K. (2001). Molluscicidal activity of Lawsonia inermis and its binary and tertiary combinations with other plant derived molluscicides. Indian Journal of Experimental Biology 39(3):263-268. Sharma, V.K. (1990). Tuberculostatic activity of henna ( Lawsonia inermis L.). Tubercle. 71(4):293-295.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 877,
    "source": "PDF_chunked"
  },
  {
    "id": 4535,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 535)",
    "text": "Sharma, V.K. (1990). Tuberculostatic activity of henna ( Lawsonia inermis L.). Tubercle. 71(4):293-295. Singh, V.K., Pandey, D.K. (1989). Fungitoxic studies on bark extract of Lawsonia inermis against ringworm fungi; Hindustan Antibiotic Bulletin 31(1-2):32-35. Sultana, N., Choudhary, M.I., Khan, A. (2008). Protein glycation inhibitory activities of Lawsonia inermis and its active principles; Journal of Enzyme Inhibition and Medicinal Chemistry 24(1):257-261. Suthienkul, O., Miyazaki, O., Chulasiri, M., Kositanont, U., Oishi, K. (1993). Retroviral reverse transcri ptase inhibitory activity in Thai herbs and spices : screening with Moloney murine leukemia viral enzyme. Southeast Asian Journal of Tropical Medicine and Public Health. 24(4):751-755. Tripathi, R.D., Srivastava, H.S., Dixitm, S.N. (1978). A fungitoxic principle from the leaves of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 852,
    "source": "PDF_chunked"
  },
  {
    "id": 4536,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 536)",
    "text": "Journal of Tropical Medicine and Public Health. 24(4):751-755. Tripathi, R.D., Srivastava, H.S., Dixitm, S.N. (1978). A fungitoxic principle from the leaves of Lawsonia inermis L. Experientia 34(1):51-52.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 204,
    "source": "PDF_chunked"
  },
  {
    "id": 4537,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 537)",
    "text": "OOAS Page 110 Lippia multiflora WAHP Nom botanique Lippia multiflora mold Famille Verbenaceae Synonymes Lippia adoensis Hochst.; Lippia grandifolia Hochst. ex Walp. Noms communs Thé de bosquet ; thé de Gambie ; Herbe guérisseuse ; TI-arbre Noms vernaculaires Burkina Faso: Mooré Kwilg-wisaoré, Dioula Kangaliba, Fulfuldé Légal café Cote d 'Ivoire: Anyi Amaniena, Kalango Akankoino, Maninka Sonugba Suba Gambie: Fular Usumbolomo, Mandika Killiba (Sisilinghyamo), Wolof Mbormbor Ghana: Akan Sre-Nunum, Ga Naasuruu, Ewe Afudoti (Afu) Guinée: Fula Pulaar Bahe, Susu Diohuli Mali: Fula Pulaar Bahe-Bahe, Manding Bambara Gane Ba Nigéria: Fula Fulfulde Dirisi, Yoruba Efinrin- Gogara Fefe Sénégal: Balanta Brege, Serer Mbalat, Diola Busag Sierra Leone: Temne A-Kimbo Togo: Tem Fasau Klouto Avudati, Ewe Nyone Description de la plante Arbuste robuste, ligneux, aromatique et pérenne",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 874,
    "source": "PDF_chunked"
  },
  {
    "id": 4538,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 538)",
    "text": "Busag Sierra Leone: Temne A-Kimbo Togo: Tem Fasau Klouto Avudati, Ewe Nyone Description de la plante Arbuste robuste, ligneux, aromatique et pérenne avec tige striée, feuilles peu pubescentes, simples, oblong ues lancéolées, texture épaisse, marge pectinée, nervures latérales de 7- 8 paires, de couleur bleu- vert ; les fleurs sont blanchâtres, odorantes avec une inflorescence ramifiée. Numéro du spécimen de l'herbier Ghana: GC 47812 Togo : TOGO09207 Habitat et répartition géographique Il est présent en Guinée et dans la savane côtière ; également en Afrique Occidentale tropicale. Parties utilisées de la plante Feuille Autres parties utilisées Plante entière; racine Utilisations ethnomédicales LeLippia est u ne plante populaire qui a une longue histoire d'utilisation dans la médecine traditionnelle africaine et d'autres parties du monde, en tant que thé aromatique Les feuilles sont utilisées comme une boisson chaude et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4539,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 539)",
    "text": "longue histoire d'utilisation dans la médecine traditionnelle africaine et d'autres parties du monde, en tant que thé aromatique Les feuilles sont utilisées comme une boisson chaude et comme une infusion de thé pour les fièvres, les troubles gastro- intestinaux, entérite, toux et rhume. Les collectivités rurales dans certaines parties d'Afrique de l'Ouest prennent le thé Lippia après une dure journée de travail pour se détendre et améliorer le sommeil, tandis que dans les zones urbaines, le thé est consommé le matin pour soulager le stress. Au Ghana et au Nigeria, une infusion des feuilles est utilisée pour le traitement des infections microbiennes et du paludisme (Kerharo et Adam, 1974; Kunle et al., 2003 ; Ajaiyeoba et al ., 2004). Le thé est également utilisé traditionnellement comme un antihypertenseur et un laxatif. Une boisson à base de feuilles bouillies et de noix palmistesest utilisée pour expulser le placenta après",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4540,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 540)",
    "text": "également utilisé traditionnellement comme un antihypertenseur et un laxatif. Une boisson à base de feuilles bouillies et de noix palmistesest utilisée pour expulser le placenta après l'accouchement (Burkill, 1997; Irvine, 1961). Au Mali, la poudre de feuilles est utilisée dans la préparation d'un remède contre le paludisme (Diallo et al., 2004). Activités biologiques et pharmacologiques Les extraits de feuilles de la plante ont des effets hypotenseurs considérables (Pham et coll., 1988). L. multifloraa démontré des propriétés tranquillisantes et analgésiques comparables au diazépam (Abena et al ., 1998). L'huile a également montré des effets de relaxants musculaires ; il déprime la contractilité cardiaque (Mwangi et al., 1992; Mwangi, 1990). Les extraits d'hexane et de dichlorométhane ontmontré l'activité antimicrobienne avec la fraction d'hexane possédant la plus grande activité, attribuable au carvacrol, un agent",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4541,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 541)",
    "text": "OOAS Page 111 Lippia multiflora WAHP antimicrobienisolé de ces extraits (Kunle et al ., 2003). L'huile essentielle a une activité antibiotique contre les larves de moustiques et s'est révélée plus active que DEET comme insectifuge lors des tests sur le charançon du maïs (Sitophilus zeamais) (Mwangi et al., 1991). L'huile de Lippia adémontré une activité antifongique remarquable contre Colletotrichum coffeanum, l'agent pathogène de la maladie descérises de caféier (Mwangi et al. , 1991; Addae-Mensah, 1992). L'huile essentielle a également montré un effet analgésique significatif et dose- dépendante sur les contorsions induit es par l'acide acétique chez la souris; seulement une dose de 8 mlkg d'huile essentielle a annulé l'hyperexia induite par la levure de bière et aucun effet sur la formation du granulome n'a été observé. Données cliniques Aucune information disponible Constituants chimiques Huile volatile: (linalol, camphre, alpha terpinéol,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4542,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 542)",
    "text": "granulome n'a été observé. Données cliniques Aucune information disponible Constituants chimiques Huile volatile: (linalol, camphre, alpha terpinéol, thymol et autres monoterpènes); flavonoïdes; saponine (glycoside) (Pelissier, 1994; GHP, 1992). Tests d'identité et de pureté Teneur en humidité: pas plus de 7,9 Cendre totale: 17,8 Cendre insoluble dans l'acide: 27,9 : Valeur substances extractibles par l'eau : pas moins de 1,58 Valeur substances extractibles par l'éthanol (70 ): pas moins de 5,02 Empreintes chromatographiques Extrait chloroformique L'analyse par chrom atographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 911,
    "source": "PDF_chunked"
  },
  {
    "id": 4543,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 543)",
    "text": "réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de cinq taches distinctes avec R fde 0,66 (violet), 0,51 (violet), 0,42 (Rose), 0,38 (Rose) et 0,29 (Rose). Chromatogramme Macroscopie On observe des feuilles largement oblongues - lancéolées de 5- 12 cm de long sur 2- 4 cm de large. La marge est dentelée, avec un sommet accuminé, une base asymétrique, une nervation réticulée, une texture grossière; elles sont de couleur vert-olive, avec une odeur aromati que et un goût piquant. Microscopie Les deux surfaces sont recouvertes de plusieurs revêtements et poils glandulaires, plus abondants sur la surface inférieure, des revêtements depoils unicellulaires unisériés, minces et glanduleuses; des stomates paracytiques sur les deux surfaces; un épiderme strié; la section transversale montre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4544,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 544)",
    "text": "unicellulaires unisériés, minces et glanduleuses; des stomates paracytiques sur les deux surfaces; un épiderme strié; la section transversale montre des parois cellulaires épidermiques anticlinales droits; le mésophylle abonde dans les tissus de collenchyme dans la région de la nervure médiane; faisceaux vasculaires bicollat éraux et xylème lignifiée. Matériel végétal en poudre Il est de couleur verte avec une odeur aromatique ; le matériel végétal en poudre a de nombreux poils de vêtements, glanduleuse ; des stomates paracytiques sur la face inférieure etdes éléments vascul aires lignifiés dans les veines et veinules.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 626,
    "source": "PDF_chunked"
  },
  {
    "id": 4545,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 545)",
    "text": "OOAS Page 112 Lippia multiflora WAHP Actions thérapeutiques Adjuvant pour les cosmétiques (huile), antihypertenseur, antipaludique, antimicrobien, diurétique, laxatif, désinfectant de bouche (localement), relaxant musculaire, sudorifique (Pelissier, 1994; GHP, 1992). Indications thérapeutiques Hypertension artérielle, conjonctivite, adjuvant cosmétique, dysménorrhée, fièvre, gastro- entérite,; insomnie, insuffisance de la lactation; paludisme, nausée, maladies vénériennes, rétention du placenta, xérostomie (Mshana et al., 2000; GHP, 1992; Addae-Mensah, 1992). Données de sécurité La DL 50 de l'extrait aqueux ( p.o) s'est avéré être 3000 mgkg chez le rat. On a observé une diminution significative des organes cibles: foie, rein et cœur, à des doses 100 mgkg et les poumons 1 000 mgkg, une augmentation du MCV, MCH, LYM, mais une diminution du CCMH et des neutrophiles. À une dose de 3000 mgkg, il y a augmentation du ALP, GGT, bilirubine",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4546,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 546)",
    "text": "poumons 1 000 mgkg, une augmentation du MCV, MCH, LYM, mais une diminution du CCMH et des neutrophiles. À une dose de 3000 mgkg, il y a augmentation du ALP, GGT, bilirubine directe, urée et créatinine, suggérant un effet néfaste sur les reins et le foie à des doses élevées chez les rats. Précautions d'utilisation Des précautions doivent être prises dans l'administration de l'extrait aqueux chez les patients présentant une altération des fonctions hépatique et rénale, surtout à doses élevées. Effets indésirables Sédatif ; purgatif ; à des doses élevées possible augmentation de transaminases hépatiques, de créatinine et de l'urée. Contre-indications Hypotension, personnes âgées, grossesse et allaitement et médicaments antihypertenseurs. Dosage et forme galénique Perfusion;tTeinture; spray Infusion: 30 g de feuilles séchées dans 600 ml d'eau ; 3-4 tasses par jour Teinture: 1:5 à 45 d'alcool ; 5 ml trois fois par jour Conservation",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4547,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 547)",
    "text": "Perfusion;tTeinture; spray Infusion: 30 g de feuilles séchées dans 600 ml d'eau ; 3-4 tasses par jour Teinture: 1:5 à 45 d'alcool ; 5 ml trois fois par jour Conservation A conserver dans un endroit frais et sec dans des récipients couverts Références Abena, A.A., Ngondzo- Kombeti, G.R., Bioka, D. (1998). Psychopharmacologic properties of Lippia multiflora . Article in French. Encephale, 24(5): 449-454. Addae-Mensah, I. (1992). Towards a Rational scientific Basis for Herbal Medicine: A phytochemist's Two- decade Contribution. An Inaugural Lecture delivered at the University of Ghana, Legon, 45. Ghana Universities Press: Accra. Ajaiyeoba, E.O., Falade, C.O., Fawole, O.I., Akinboye, D. et al ., (2004). Efficacy of herbal remedies used by herbalists in Oyo State Nigeria for treatment of Plasmodium falciparum infections--a survey and an observation. African J Med Sci., 33(2):115-119. Burkill, H.M. (1997). Useful plants of West",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4548,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 548)",
    "text": "for treatment of Plasmodium falciparum infections--a survey and an observation. African J Med Sci., 33(2):115-119. Burkill, H.M. (1997). Useful plants of West tropical Africa Volume 1, Botanical Gardens Kew. Diallo, D., Maiga, A., Diakité, C., Willcox, M. (2004). Malarial 5: development of an antimalarial phytomedicine in Mali. In Traditional Herbal Medicines for Modern times: Traditional medicinal plants and Malaria edited by Merlin Willcox, Gerard Bodeker and Philippe Rasoanaivo, CRC PRESS, London. pp 117-130. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana. Irvine, F. R. (1961). Woody Plants of Ghana. Oxford University Press. Kerharo, J., Adam, J.G., (1974). La Pharmacopée Sénégalaise Tr aditionnelle: Plantes médicinales et toxiques, Editions Vigot frères Paris. Kunle, O., Okogun, J., Egamana, E., Emojevwe, E., Shok, M. (2003). Antimicrobial activity of various extracts and carvacrol from Lippia",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4549,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 549)",
    "text": "frères Paris. Kunle, O., Okogun, J., Egamana, E., Emojevwe, E., Shok, M. (2003). Antimicrobial activity of various extracts and carvacrol from Lippia multiflora leaf extract. Phytomedicine 10( 1): 59- 61. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScie ntific, technical and research committee. Mwangi, J.W., Addae- Mensah, I., Muriuki, G., Munavu, R. et al., (1992). Essential oils of Lippia species in Kenya IV. Maize weevil ( Sitophilus",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 635,
    "source": "PDF_chunked"
  },
  {
    "id": 4550,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 550)",
    "text": "OOAS Page 113 Lippia multiflora WAHP zeamais) repellency and larvicidal activity. Internatinoal Journal of Crude Drug Research 30:9-17. Mwangi, J.W. (1990). Pharmacological and biological studies of Kenyan Lippia species with special reference to their essential oil content. PhD Thesis, University of Nairobi, Kenya. Pelissier, Y., Marion, C., Casadebaig, J., Milhau, M., Kone, D., et al ., (1994). A Chemical, Bacteriological, Toxicological and Clinical Study of the Essential Oil of Lippia multiflora Mold. (Verbenaceae) Journal of Essential Oil Research 6:623-630. Pham Huu Chanh, Yao, K., Pham Huu Chanh, A. (1988). Comparative hypotensive effects of compounds extracted from Lippia multiflora leaves. Planta Medica 54:294-296.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 732,
    "source": "PDF_chunked"
  },
  {
    "id": 4551,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 551)",
    "text": "OOAS Page 114 Mitragyna inermis WAHP 2012 Nom botanique Mitragyna inermis (Willd.) O. Kuntze Famille Rubiaceae Synonymes Uncaria i nermis (Willd)., Mitragyna africana (Willd.) KORTH, Nauclea africana (Willd.). Noms communs False abura (en anglais) Noms vernaculaires Burkina Faso :Mooré Yiilga, Dioula Djum, Fulfildé kwali;koli;kadiolé Ghana: Dagare Ila, Akan Kukyamfie Nigéria: Igbo Akpatenyi Sénégal: Arabic Agbal Togo: Ewe Lenkati, Mina Elikpati, Moba Yelowum Description de la plante Un arbre jusqu'à 16 m de haut élevé, souvent densément ramifié dès la base, composée alors de 4-5 m de haut nombreuse, tige dressée, avec arrondi, à cime ouverte. Ec Lisse à rugueuse, grise à brun pâle, brun clair, tranche fibreuse. Tiges pubescent, brun pâle. Stipules caduques, foliacées, lancéolées -oblongues, 1,5 à 2 cm de long, rougeâtre. Fe Opposées, glabres ou plus ou moins pubesc entes en dessous sur les nerfs",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 908,
    "source": "PDF_chunked"
  },
  {
    "id": 4552,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 552)",
    "text": "Tiges pubescent, brun pâle. Stipules caduques, foliacées, lancéolées -oblongues, 1,5 à 2 cm de long, rougeâtre. Fe Opposées, glabres ou plus ou moins pubesc entes en dessous sur les nerfs (feuilles adultes) ou finement pubescentes (jeunes feuilles), elliptiques ou obovales, 6- 9 ( - 14) cm de long et 3,5 à 5 ( -8) cm, pointu ou courtement acuminé à l'apex, cunéiforme, arrondie ou subcordée à la base. Les jeunes feuilles sont souvent teintées de rouge. Pétiole de 0,6 à 1 cm de long. Nerv Pennée, à environ 3 nerfs 1-2 mm de la base de la lame, et 6- 9 paires de nervures secondaires saillantes peine bordant la lame. Nervilles plus ou moins visible. Inflorescence solita ire, compacte, tête globuleuse, avec un 3- 9 cm de long pédoncule glabre, un terminal ou à la base d'une feuille, composées d'un grand nombre de fleurs odorantes, de 2- 2,5 cm de diamètre. Fleurs sessiles, blanches ou crème, avec glabre tubulaire calice, 5 -lobées, glabres, corolle en",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 960,
    "source": "PDF_chunked"
  },
  {
    "id": 4553,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 553)",
    "text": "composées d'un grand nombre de fleurs odorantes, de 2- 2,5 cm de diamètre. Fleurs sessiles, blanches ou crème, avec glabre tubulaire calice, 5 -lobées, glabres, corolle en tube, et un style en forme de goupillon, qui dépassait de 3- 5 mm. Infructescence sphérique, brun noirâtre tournant, 1.2- 1.8cm de diamètre, persistant longtemps sur l'arbre. Fruits, une petite capsule oblongue, d'environ 5 mm de l ong, surmontée d'une couronne de forme cornée, déhiscente en deux moieties pour révéler un grand nombre de graines. Numéro du spécimen de l'herbier Ghana : VBS482 Togo : TOGO07354 Utilisations ethnomédicales Maladie du foie, troubles digestifs et intestinaux, paludisme, hypertension (Adjanohoun et coll., 1985 Phillipson et Wright, 1991), abortif, vermifuge, antiémétique, débilité, analgésique et antalgique. Activités biologiques et pharmacologiques Les alcaloïdes totaux extraits des feuilles de Guiera senegalensis et ceux de M. inermis ont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4554,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 554)",
    "text": "antalgique. Activités biologiques et pharmacologiques Les alcaloïdes totaux extraits des feuilles de Guiera senegalensis et ceux de M. inermis ont montré un effet synergique antipaludique. L'activité antipaludique de la plante et l'absence de génotoxicité ont été démontrées in vitro et in vivo (Monjanel-Mouterde et al ., 2006). Les extraits de la plante inhibent la croissance du Plasmodium falciparum (Mustafa et al., 2000). Les extraits aqueux produisent une augmentation ex vivo , proportionnelle au niveau de concentration de la réponse contractile cardiaque et du débit coronarien. Mais ils n'ont, Clinical data No information available Chemical constituents Indole alkaloids (rhynchophylline, rotundifoline, speciophylline and uncarine); tripterpenoid saponins (inermiside I and inermiside II) Cheng et al., 2002; Shellard and Sarpong, 1969, 1970; Shellard et al., 1971. Tests d'identitéet de purité Teneur en humidité: pas plus 8.9",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4555,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 555)",
    "text": "OOAS Page 115 Mitragyna inermis WAHP 2012 Cendre totale: 12.02 Valeur substances extractibles par l'eau : pas moins de 7,35 Valeur substances extractibles par l'éthanoll (70 ): pas moins de 10.30 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de six taches distinctes avec R f de 0,98 (Rose), 0,76 (Rose), 0,69 (Rose), 0,53 (jaune), 0, 46 (Rose) et 0,22 (Rose). Chromatogramme Macroscopie L'écorce est grisâtre avec une surface assez douce.L'écorce intérieure est pâle ou brun- foncée et fibreuse. Elle a un goût et une odeur particulière. Microscopie",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4556,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 556)",
    "text": "Macroscopie L'écorce est grisâtre avec une surface assez douce.L'écorce intérieure est pâle ou brun- foncée et fibreuse. Elle a un goût et une odeur particulière. Microscopie Les feuilles ont des parois droites de cellules épidermiques avec de nombreuses cellules anisocytique. De nombreux vêtements de poils unicellulaires et pluricellulaires. L'écorce a de nombreux vaisseaux et des fibres corticales dénoyautées. Actions thérapeutiques Antipaludéen, antispasmodiq ue, cardiotonique, anticholestérémique Indications thérapeutiques Paludisme, diarrhée, dysménorrhée, maladie cardiaque. Données de sécurité La DL 50 de l'extrait aqueux ( p.o) s'est avérée être 3000 mg kg chez le rat. Dans les études de toxicité subaig uë (300- 3000 mgkgp.o) de 14 jours, aucune variation significative du poids corporel n'a été observée, mais, en revanche, une diminution du poids du foie à des doses (1000 mgkg a été notée. La numération de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4557,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 557)",
    "text": "jours, aucune variation significative du poids corporel n'a été observée, mais, en revanche, une diminution du poids du foie à des doses (1000 mgkg a été notée. La numération de globules blancs a augmenté avec le traitement, mais aucun effet indésirable sur la fonction hépatique n'a été observé. Il y avait une augmentation significative des taux de créatinine sérique, à des doses 1000 mgkg de l'extrait aqueux. Précautions d'emploi Des précautions doivent être observées da ns l'administration de l'extrait aqueux aux patients qui ont une fonction rénale altérée et en cas de pathologie cardiaque, surtout à doses élevées. Effets indésirables Augmentation possibleà des doses élevéesde la créatinine sérique. Contre-indications Maladie rénale Dosage et forme galénique Docoction: feuille de 30 g par litre d'eau, faire bouillir pendant 10 à 15 minutes, prendre une tasse pleine trois fois par jour. Teinture: 1-5 à 45 d'éthanol; 5 ml trois fois par",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 4558,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 558)",
    "text": "Docoction: feuille de 30 g par litre d'eau, faire bouillir pendant 10 à 15 minutes, prendre une tasse pleine trois fois par jour. Teinture: 1-5 à 45 d'éthanol; 5 ml trois fois par jour Conservation A conserver dans un endroit frais et sec, loin de la lumière.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 259,
    "source": "PDF_chunked"
  },
  {
    "id": 4559,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 559)",
    "text": "OOAS Page 116 Mitragyna inermis WAHP 2012 Références Adjanohoun, F.J., Ake, A., Floret, J.J., Guinko, S. et al ., (1985). Contribution aux etudes ethnohotaniques et floristiques du Mali Médecine Traditionnelle et Pharmacopée. ACCT, Paris. Cheng, Z. H., Yu, B.Y., Yang, X.W. (2002). 27- Nor triterpenoid glycosides from Mitragyna inermis. Phytochemistry 61:379-382. Monjanel-Mouterde, S., Traoré, F., Gasquet, M, Dodero, F., et al., (2006). Lack of toxicity of hydroethanolic extract from Mitragyna inermis (Willd.) O. Kuntze by gavage in the rat. Journal of Ethnopharmacology 103, 319-326. Mustafa, V.A., Benoit -Vical, F., Pelissier, Y., Kone-Bamba, D. et al. (2000). Antiplasmodial activity of plant extracts used in West Africa traditional medicine. Journal of Ethnopharmacology 73, 145-151. Ouédraogo, S., Ranaivo, H.R., Ndiaye, M., Kaboré, Z.I. et al ., (2004). Cardiovascular properties of aqueous extract from Mitragyna",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4560,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 560)",
    "text": "Ethnopharmacology 73, 145-151. Ouédraogo, S., Ranaivo, H.R., Ndiaye, M., Kaboré, Z.I. et al ., (2004). Cardiovascular properties of aqueous extract from Mitragyna inermis (wild). Journal of Ethnopharmacology 93:345-350. Phillipson, J.D., Wright, C.W. ( 1991). Can Ethnopharmacology contribute to the development of antimalarial agents? Journal of Ethnopharmacology 32:155-165. Shellard, E.J., Sarpong, K. (1969). The alkaloids of the leaves of Mitragyna inermis (Willd.) O. Kuntze. Journal of Pharmacy and Pharmacology 21(suppl):113-117. Shellard, E.J., Sarpong, K. (1970). The alkaloids pattern in the leaves, stem -bark and root -bark of Mitragyna species from Ghana. Journal of Pharmacy and Pharmacology, 22 (Suppl.):34-39. Shellard, E.J ., Phillipson, J.D., Sarpong, K. (1971). Rhynchophylline and isorhynchophylline N-oxides from species of Mitragyna. Phytochemistry 10:2505-2511.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 885,
    "source": "PDF_chunked"
  },
  {
    "id": 4561,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 561)",
    "text": "Shellard, E.J ., Phillipson, J.D., Sarpong, K. (1971). Rhynchophylline and isorhynchophylline N-oxides from species of Mitragyna. Phytochemistry 10:2505-2511. Sy, G.Y., Sarr, A., Diéye, A.M., Faye, B. (2004). Myorelaxant and antispasmodic effects of the aqueous extract of Mitragyna inermis barks on Wistar rat ileum. Fitoterapia 75: 447-450. Touré, H., Balansard, G., Pauli, A.M., Scotto, A.M. (1996). Pharmacological investigation of alkaloids from leaves of Mitragyna inermis (Rubiaccae). Journa l of Ethnopharmacology 54:59-62.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 531,
    "source": "PDF_chunked"
  },
  {
    "id": 4562,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 562)",
    "text": "OOAS Page 117 Momordica charantia WAHP Nom botanique Momordica charantia l. Famille Cucurbitaceae Synonymes Momordica thollonii Cogn. Noms communs Anglais: Balsam pear, African cucumber, Cundeamor, Bitter apple, Bitter melon, Carilla plant, Wild cucumber, Bitter cucumber , Français: Poire de balsame, Concombre Africain, Margose, merveilles de la liane Noms vernaculaires Bénin: Fon Goun Nyèsinkèn, Yorouba Edjini, Dendi Atakluma Burkina Faso: Fulfildé Njalam fetuhi Côte d'Ivoire : Adioukrou Sing Biep, Guéré- N'guéné Boué Ghana: Akan Nyanya, Ewe Kakle, Hausa Daddagu Nigéria: Yoruba Ejinrin Togo: Ewe Agnagnran, Adja Adounka, Mina Guêssikan Description de la plante C'est une herbacée grimpante, porteuse de vrille, atteignant 5 mètres; la feuille est numérique et lobées, alternes, pétiolées avecun long pédoncule et pourvue de vrilles co- pétiolaires simples et d'un limbe fin ;il est généralement",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 902,
    "source": "PDF_chunked"
  },
  {
    "id": 4563,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 563)",
    "text": "atteignant 5 mètres; la feuille est numérique et lobées, alternes, pétiolées avecun long pédoncule et pourvue de vrilles co- pétiolaires simples et d'un limbe fin ;il est généralement pentagonale, divisé en cinq lobes principaux, de 2 à 6 cm de long sur 10 à 25 mm de large avec un dessus arrondi; 2 à 5 ner vures secondaires par lobe; la feuille a unebase profondément cordée avec 3 veines; poils doux et lisses des deux côtés, mince par le haut, plus long et plus dense sur les nervures en dessous; les fleurs sont de couleur jaune avec 3 cm de large, 5 lobes obtus dans le coin supérieur, avec trois crêtes longitudinales, des fleurs mâles de 4 à 7 cm de long, pourvues d'un pédoncule axillaire, des bractées foliacées et cordées légèrement au- dessus de la base, des fleurs femelles au sommet de l'ovaire, une pédoncu le de 3 ou 4 cm recouverts d'épines denses; des fruits en forme de baies avec un extérieur verruqueux distinct et une forme oblongue, creuse en coupe",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 971,
    "source": "PDF_chunked"
  },
  {
    "id": 4564,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 564)",
    "text": "sommet de l'ovaire, une pédoncu le de 3 ou 4 cm recouverts d'épines denses; des fruits en forme de baies avec un extérieur verruqueux distinct et une forme oblongue, creuse en coupe transversale, avec une couche relativement mince de chair entourant une cavité centrale de grains, remplie de grosses graines plates et de la moelle; les graines et la moelle semblent blanches lorsque les fruits sont verts; orange- vif à maturité de 3 à 6 cm de long sur 2 ou 3 cm de large avec épines molles; lorsque le fruit murit, la chair devient plus fer me, plus amer et excessivement désagréable à manger. Numéro du spécimende l'herbier Ghana: GC 47907 Togo : TOGO02802 Habitat et répartition géographique C'est une espèce pantropicale, largement cultivée en Asie, en Afrique et dans les Caraïbes pour ses fruits comestibles ; elle est originaire de l'Inde, mais répandue dans les régions tropicales ; se rencontrent principalement dans les zones",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4565,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 565)",
    "text": "pour ses fruits comestibles ; elle est originaire de l'Inde, mais répandue dans les régions tropicales ; se rencontrent principalement dans les zones au climat plus ou moins humide ; se présente comme une mauvaise herbe le long des routes et à la périphérie des vill es, entre les haies, les buissons ou les arbustes et les cultures abandonnées ; parfois cultivées dans les maisons (GHP, 1992). Parties utiliées de la plante Feuilles et fruits Autres parties utilisées Plante entière, racine Caractéristiques botaniques Le Concombre africain se compose des feuilles fraîches ou séchées ou des fruits de Momordica charantia l. (Curcurbitaceae) Utilisations ethnomedicales M. charantia est une plante médicinale populaire largement utilisée en médecine traditionnelle dans tous les pays tropicaux humides et subhumides, où elle pousse spontanément. Chez les Yoruba du Nigéria, la décoction est utilisée pour traiter le paludisme, et au Sénégal, les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4566,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 566)",
    "text": "dans tous les pays tropicaux humides et subhumides, où elle pousse spontanément. Chez les Yoruba du Nigéria, la décoction est utilisée pour traiter le paludisme, et au Sénégal, les feuilles sont indiquées pour le traitement de la fièvre, tandis que les fruits et l es feuilles sont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 281,
    "source": "PDF_chunked"
  },
  {
    "id": 4567,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 567)",
    "text": "OOAS Page 118 Momordica charantia WAHP utilisées contre les états de démangeaison de la peau telles que la gale (Paulino de Albuquerque et al., 2007). Le décocté ou cataplasme des feuilles est utilisée pour traiter les aphtes buccaux, les blessures gangrénées et les ulcères gastriques (Agyare et al., 2009), alors que la plante entière est utilisée pour traiter le paludisme, les maux de ventre, l'acidité de l'estomac, la fièvre, la diarrhée, les parasites intestinaux et les affections rénales (Luziatelli et al., 2010). Fruits, pousses tendres et racines tendres sont utilisées pour le traitement du diabète, de la purification du sang et pour les morsures de serpent. D'autres utilisent également les feuilles pour traiter la rage, les pectoraux et les douleurs rhumatismales (Pradhan et Badola, 2008). Activités biologiques et pharmacologiques L'ingestion orale de différentes doses de fruits, de jus ou poudre par des sujets souffrant de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4568,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 568)",
    "text": "(Pradhan et Badola, 2008). Activités biologiques et pharmacologiques L'ingestion orale de différentes doses de fruits, de jus ou poudre par des sujets souffrant de diabète sucré apparaissant dans la vieillesse (diabète de type2) réduit significativement le taux de glucose sanguin etou améliore la tolérance au glucose (Welihinda et al., 1986). La décoction de fruits a montré une activité hypoglycémique chez les lapins normaux. Charantin semble être en partie responsable de l'effet hypoglycémique. Le p-insuline isol ée de graines et de fruits de la plante a également montré une activité hypoglycémique (Ng et al ., 1986; Welihinda et al., 1986; Best et al., 1924). L'extrait alcoolique de la pulpe a une activité antidiabétique (Sarkar et coll., 1996). Un groupe de protéi nes inactivant le ribosome ( α - et β-momorcharine, momordine et cucurbitacine B) a été signalés comme possédant une activité cytotoxique (GHP, 1992).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4569,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 569)",
    "text": "et coll., 1996). Un groupe de protéi nes inactivant le ribosome ( α - et β-momorcharine, momordine et cucurbitacine B) a été signalés comme possédant une activité cytotoxique (GHP, 1992). L'extrait aqueux brut de la plante a démontré sa capacité d'inhiber la guanylate cyclase d'enzyme, qui sem ble être liée à la pathogénie et la réplication du psoriasis, de la leucémie et du cancer. Cet extrait aqueux brut a éliminé des cellules de leucémie humaine en fonction des doses administrées, tandis que les lymphocytes humains normaux soumis aux mêmes doses n'étaient pas affectés (GHP, 1992). Le composé momordine a démontré une activité cytotoxique in vivo contre le lymphome de Hodgkin, tandis que plusieurs autres études in vivo ont montré l'activité cytostatique et antitumorale de la plante entière. Les extraits aqueux inhibent la croissance du cancer de la prostate chez le rat et l'apparition de tumeurs mammaires chez la souris (GHP, 1992). Les protéines α - et β-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 971,
    "source": "PDF_chunked"
  },
  {
    "id": 4570,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 570)",
    "text": "entière. Les extraits aqueux inhibent la croissance du cancer de la prostate chez le rat et l'apparition de tumeurs mammaires chez la souris (GHP, 1992). Les protéines α - et β- momorcharine ont révélé une activité inhibitrice in vitro du virus du VIH. La protéine anti - immunovirus humaine du Momordica (MAP30) a été reconnue pour activer les cellules tueuses naturelles et donc interférer avec la réplication du virus VIH. Elle augmente aussi la production de l'interféron-gamma, une substance naturelle qui combat tous les t ypes de virus du corps. Des extraits de la plante ont également démontré une activité antivirale contre le virus de l' herpès simplex de type 1 et des effets antihelminthiques et anti -inflammatoires (Lans et al ., 2007; Beloin et al., 2005). Des extraits mét hanolique ont une activité anti -ulcèreuse (Alam et al ., 2009). Les feuilles de M. charantia ont été identifiées comme possédant des propriétés antibactériennes contre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4571,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 571)",
    "text": "activité anti -ulcèreuse (Alam et al ., 2009). Les feuilles de M. charantia ont été identifiées comme possédant des propriétés antibactériennes contre E. coli et Staphylococcus aureus (Georges et Pandelai, 1949), tandis que des effets antiparasites in vitro de l'extrait méthanolique de la plante entière ont été rapportés (Mesia et al ., 2008). L'extrait alcoolique du fruit a montré une activité spermicide (un extrait par l'éthanol a induit une réduction du poids des testicules et de la produc tion de spermatozoïdes chez les gerbilles et les chiens), tandis que la racine a des effets abortifs chez les femelles (Jamwall et Anand, 1964). Les graines ont démontré la capacité de provoquer l'avortement chez les rats et les souris; les fruits et les f euilles ont révélé un effet antifertilité in vivo chez les animaux femelles. Plusieurs composants du fruit comme le charantin et le sitostérol ont montré des effets stimulants sur l'utérus (Yeung, 1996).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4572,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 572)",
    "text": "effet antifertilité in vivo chez les animaux femelles. Plusieurs composants du fruit comme le charantin et le sitostérol ont montré des effets stimulants sur l'utérus (Yeung, 1996). Données cliniques Un essai de quatre semaines, randomisé, à double insu, a révélé que la plante a un léger effet hypoglycémique et qu'elle réduit de façon significative la glycémie chez les patients atteints de diabète de type 2, et qui ont pris 2000 mg par jour. On a observé, toutefois, qu'elle était moins efficace que le médicament antidiabète metformine (Fuangchan et al., 2011). Constituants chimiques Une étude de quatre semaines, randomisées, en double-anonymat qui a comparél'apport de 2 g jour de melon amer, avec 1 gjour de médicament de metformine c ontre le diabète normal a constaté que la drogue a eu un effet modeste hypoglycémiant chez les patients diabétiques de type 2. Il a été, cependant, noté qu'il était moins efficace que la metformine",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4573,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 573)",
    "text": "normal a constaté que la drogue a eu un effet modeste hypoglycémiant chez les patients diabétiques de type 2. Il a été, cependant, noté qu'il était moins efficace que la metformine antidiabétique (Fuangchan et al., 2011). Test d'identité et de pureté Teneur en humidité: pas plus de 7,7 Cendretotale: 16.73 Valeur substances extractibles par l'eau : pas moins de 22,6 Valeur substances extractibles par l'éthanol (70 ): pas moins de 20,7",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 437,
    "source": "PDF_chunked"
  },
  {
    "id": 4574,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 574)",
    "text": "OOAS Page 119 Momordica charantia WAHP Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice (0,25 mm) G60F254, et phase mobile: éther de pétrole( 40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de sept taches distinctes avec R fde 0,90 (violet), 0,82 (brun), 0,79 (bleu), 0,72 (jaune), 0,63 (jaune), 0,36 (violet) et 0,33 (violet). Chromatogramme Macroscopie On observe une herbe grimpante avec vrilles tordues en spirale à nœuds avec feuilles simples, pétiolées, alternes ou verticillées, profondément lobées, avec des marges ondulées; tige rainurée ; des fleurs mâl es et femelles (hermaphrodites); bractées foliacées; des fruits ellipsoïdes, de 5- 7",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4575,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 575)",
    "text": "lobées, avec des marges ondulées; tige rainurée ; des fleurs mâl es et femelles (hermaphrodites); bractées foliacées; des fruits ellipsoïdes, de 5- 7 cm de long, verruqueux, striés, verts tournant orange-clair à maturité, se fractionnantpour révéler plusieurs graines aplaties rouges intense. Microscopie Les deux faces de la feuille arborent de nombreux poils, également sur les veines et veinules, des poilsà la fois non- glandulaires, pluricellulaires unisériés et de type glandulaires ; parois de cellules épidermiques ondulées ; stomates anomocytiques avec 4 ou 5 cellules subsidiaires; une coupe transversale de la feuille montre une structure dorsiventrale; des poils non glandulaires géants avec des cellules affaissées sontprésents sur la surface supérieure tandis que quelques-uns d'eux se présentent sur les nervures de la face inférieure; des cellules palissadiques contiguës aux cellules de collenchyme dans la région de la nervure",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4576,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 576)",
    "text": "quelques-uns d'eux se présentent sur les nervures de la face inférieure; des cellules palissadiques contiguës aux cellules de collenchyme dans la région de la nervure centrale, des mésophylles lacuneux composés de grandes cellules parenchymateuses et contenant des cristaux d'oxalate de calcium de type rosette; les éléments du xylème vasculaire sont lignifiées; la tige est pubescente; la coupe transversale montre une couche épidermique externe; une couche parenchymateuse forme le cortex; un sclérenchymelignifié encercle les tissus vasculaires avec une moelle centrale pourvue de cellules parenchymateuses, dont certaines ont des cristaux d'oxalate calcique enrosette. Matériel végétal en poudre Couleur brun- verdâtre; odeur caractéristique; goût amer; poils glandulaires avec des têtes pluricellulaires, nombreuxpoil s non glandulaires, unisériés et affaissés; vaisseaux lignifiées dexylème avec également des éléments",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 4577,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 577)",
    "text": "goût amer; poils glandulaires avec des têtes pluricellulaires, nombreuxpoil s non glandulaires, unisériés et affaissés; vaisseaux lignifiées dexylème avec également des éléments vasculaires au niveau de la nervure principale et des fragments de la tige; des fragments de limbe montrent des variétés de cellules épidermiques et des s tomates anomocytiques; présence de grains d'amidon. Actions thérapeutiques Antimicrobien, antidiabétique, anti -diarrhéique, antifertilité, antihelminthique, anti -inflammatoire, antinéoplasique, antioxydant, antitumorale, anti - ulcère, antiviraux, astringen t, fébrifuge, vulnéraire. Indications thérapeutiques Diabète, plaies, ulcères, herpès, infections parasitaires, hypertension artérielle ; douleurs abdominales, brûlures, cancer du sein, contraception, dermatite, fièvre, VIHSIDA, maladies infectieuses (ex: dysenterie, gonorrhée, varicelle), paludisme, rougeole, otite, débilité sénile, éruptions cutanées (ex: pian), panaris",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 967,
    "source": "PDF_chunked"
  },
  {
    "id": 4578,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 578)",
    "text": "contraception, dermatite, fièvre, VIHSIDA, maladies infectieuses (ex: dysenterie, gonorrhée, varicelle), paludisme, rougeole, otite, débilité sénile, éruptions cutanées (ex: pian), panaris (Mshana et al., 2000, GHP, 1992; Dennis, 2002).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 236,
    "source": "PDF_chunked"
  },
  {
    "id": 4579,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 579)",
    "text": "OOAS Page 120 Momordica charantia WAHP Données sécuritaires Dans une étude de toxicité aiguë de 24 heures, la DL50 des extraits aqueux de feuilles ( p.o) chez la souris a été 3000 mgkg. Les études de toxicité subaigüe ne montrent pas de signes cliniques de toxicité après traitement des souris mâles et femelles (500 à 1000 mgkg; p. o) pendant 14 jours, en dehors de l'hypoglycém ie. Lors d'études de toxicité subchronique, l'administration répétée de 100, 200 et 1000 mgkg d'extrait aqueux de feuilles pendant 14 jours a provoqué une hypoglycémie. Les arilles rouges des graines sont dangereux pour les enfants. Deux cas d'empoisonnement secondaire à l'ingestion de l'infusé de feuilles fraîches ont été signalés. Ils ont entraîné un état épileptique qui a nécessité des hospitalisations. La toxicité des extraits des deux fruits (éthanol et jus de fruits non mûrs) a été évaluée chez des r ats normaux et diabétiques. Les deux extraits ont diminué les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 4580,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 580)",
    "text": "nécessité des hospitalisations. La toxicité des extraits des deux fruits (éthanol et jus de fruits non mûrs) a été évaluée chez des r ats normaux et diabétiques. Les deux extraits ont diminué les taux de glucose sanguin dans les deux types de rat. Chez des rats normaux, les deux extraits n'ont eu aucun effet significatif sur les taux sanguins d'urée, de créatinine, d'ALT, d'AST et d'AP, alors que chez les rats diabétiques, les deux extraits ont provoqué une importante chute des niveaux d'urée sérique, de créatinine, d'ALT, d'AST, d'AP, du taux de cholestérol et de triglycérides. Ces extraits ont démontré uneactivité antidiabétique, des pr opriétés hépatique et hypolipidémique (El Sattar El Batran et coll., 2006). Précautions d'emploi Un contrôle de la glycémie estindispensable en cas d'administration de feuilles aqueuses et d'extraits de l'écorce; éviter l'administration concomitante avec d'autres médicaments antidiabétiques sauf sous surveillance médicale.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 971,
    "source": "PDF_chunked"
  },
  {
    "id": 4581,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 581)",
    "text": "cas d'administration de feuilles aqueuses et d'extraits de l'écorce; éviter l'administration concomitante avec d'autres médicaments antidiabétiques sauf sous surveillance médicale. Effets indésirables L'avortement et des effets antifertilité ont été observés chez les animaux femelles, ainsi que la réduction du taux de fertilité masculine, mais il n'y a aucun effet sur la production de sperme, du coma hypoglycémique et des convulsions ; Contre-indications Personnesayant un déficit génétique érythrocytaire de glucose 6- phosphate déshydrogénase; grossesse. Dosage et forme galénique Décoction: 30 g de parties aériennes de la plante séchées dans 900 ml d'eau; laisser mijoter jusqu'à ce que la quantité d'eau soit réduite à 600 ml; prendre 1 tasse trois fois par jour. Infusion: 30 g de parties aériennes séchées dans 600 ml d'eau; prendre 1 tasse trois fois par jour Teinture: 1:5 à 45 d'éthanol; 5 ml trois fois par jour",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4582,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 582)",
    "text": "Infusion: 30 g de parties aériennes séchées dans 600 ml d'eau; prendre 1 tasse trois fois par jour Teinture: 1:5 à 45 d'éthanol; 5 ml trois fois par jour Capsules: 1-2 g de feuilles en poudre, 1 capsule deux fois par jour Conservation A conserver dans un endroit frais et sec. Références Agyare, C., Asase, A., Lechtenberg, M., Niehues, M. et al. (2009). An ethnopharmacological survey and in vitro confirmation of ethnopharmacological use of medicinal plants used for wound healing in Bosomtwi-Atwima-Kwanwoma area, Ghana. Journal of Ethnopharmacology 125:393403. Alam, S., Asad, M., Asdaq, S.M.B., Prasad, V .S. (2009). Antiulcer activity of methanolic extract of Momordica charantia L. in rats. Journal of Ethnopharmacology 123:464469. Beloin, N., Gbeassor, M., Akpagana, K., Hudson, J. et al . (2005). Ethnomedicinal uses of Momordica charantia (Cucurbitaceae) in Togo and relation to its phytochemistry and biological",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 4583,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 583)",
    "text": "Beloin, N., Gbeassor, M., Akpagana, K., Hudson, J. et al . (2005). Ethnomedicinal uses of Momordica charantia (Cucurbitaceae) in Togo and relation to its phytochemistry and biological activity. Journal of Ethnopharmacology 96:4955. Best, C.H., Smith, R.G., Scott, D.A. (1924). An insulin-like material in various tissues of the normal and diabetic animal. American Journal of Physiology 68:161-182. Dennis, F. (Ed) (2002). Manual for the propagation of medicinal plants in Ghana. Darwin Initiative for the Survival of Species. Derrida, M. What is Bitter Melon (Momordica charantia): What is Bitter Melon used for today? htpp:www.mdidea.comproductsherbextractbitt ermelondata.html El Sattar El Batran, S.A., El -Gengaihi, S.E., El Shabrawy, O.A. (2006). Some toxicological studies of Momordica charantia L. on albino rats in normal and alloxan diabetic rats. Journal of Ethnopharmacology 108:236242. Fuangchan, A., Sonthisombat, P., Seubnukarn,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4584,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 584)",
    "text": "studies of Momordica charantia L. on albino rats in normal and alloxan diabetic rats. Journal of Ethnopharmacology 108:236242. Fuangchan, A., Sonthisombat, P., Seubnukarn, T., Chanouan, R. et al ., (2011). Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. Journal of Ethnopharmacology 134:422428. Ghana Herbal Pharmacopoeia (1992), 95- 98, The Advent Press: Accra, Ghana.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 426,
    "source": "PDF_chunked"
  },
  {
    "id": 4585,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 585)",
    "text": "OOAS Page 121 Momordica charantia WAHP Georges, M., Pandelai, K.M. (1949). Investigation on plant antibiotics IV. Further search for antibiotic substances in Indian Medicinal plants. Indian Journal of Medical Research 37, 169- 181. cited by Oliver-Bever, 1986. Jamwall, K.S., Anand, N.K. (1964). Preliminary screening of some reputed abortifacient indigenous plants. Indian Journal of Medical Research. cited by Oliver-Bever, 1986. Khanna, P., Nag, T.N., Jain, S.C., Mohan, S. (1974). Extraction of insulin from a plant source. 3rd International Congress on Plant Tissue Cell Cultures, 21-26th July, Leicester, UK. Lans, C., ( 2007). Comparison of plants used for skin and stomach problems in Trinidad and Tobago with Asian ethnomedicine. J ournal of Ethnobiology and Ethnomedicine 3:3. Luziatelli, G., Sørensen, M., Theilade, I., Mølgaard P. (2010). Asháninka medicinal plants: a case study from the native community of Bajo",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4586,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 586)",
    "text": "Ethnobiology and Ethnomedicine 3:3. Luziatelli, G., Sørensen, M., Theilade, I., Mølgaard P. (2010). Asháninka medicinal plants: a case study from the native community of Bajo Quimiriki, Junín, Peru. Journal of Ethnobiology and Ethnomedicine 6: 21. Mesia, G.K., Tona, T.H., Nanga, T.H., Cimanga, R.K. et al . (2008). Antiprotozoal and cytotoxic screening of 45 plant extracts from Democratic Republic of Congo. Journal of Ethnopharmacology 115:409415. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al ., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Ng, T.B., Wong, C.M., Li, W.W., Yeung, H.W. (1986). Insulin- like molecules in Momordica charantia seeds. Journal of Ethnopharmacology 15:107-117. Olaniyi A. A., Marquis V. O. (1975).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 920,
    "source": "PDF_chunked"
  },
  {
    "id": 4587,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 587)",
    "text": "Ng, T.B., Wong, C.M., Li, W.W., Yeung, H.W. (1986). Insulin- like molecules in Momordica charantia seeds. Journal of Ethnopharmacology 15:107-117. Olaniyi A. A., Marquis V. O. (1975). Phytochemical and preliminary Pharmacological investigation of an alkaloi d obtained from Momordica foetida, Journal of Pharmacy, 6: 117- 119. Paulino de Albuquerque, U., Monteiro, J.M., Ramos, M.A., Cavalcanti de Amorim, E.L. (2007). Medicinal and magic plants from a public market in northeastern Brazil. Journal of Ethnopharmacology 110:7691. Pradhan, B.K., Badola, H.K. (2008). Ethnomedicinal plant use by Lepcha tribe of Dzongu valley, bordering Khangchendzonga Biosphere Reserve, in North Sikkim, India. Journal of Ethnobiology and Ethnomedicine 4, 22. Sarkar, S., Pranava, M. , Marita, R. (1996). Demonstration of the hypoglycaemic action of Momordica charantia in a validated animal model of diabetes. Pharmacology Research 33:1-4.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 4588,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 588)",
    "text": "22. Sarkar, S., Pranava, M. , Marita, R. (1996). Demonstration of the hypoglycaemic action of Momordica charantia in a validated animal model of diabetes. Pharmacology Research 33:1-4. Welihinda, J., Karunanayake, E.H., Sheriff, M.H., Jayasinghe, K.S. (1986). Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. Journal of Ethnopharmacology 17(3):277-82. Yeung, H.W. (1996). A highly efficient procedure for purifying the ribosome- inactivating proteins alpha- and beta- momorcharins from Momordica charantia seeds, N -terminal sequence comparison and establishment of their N - glycosidase activity. Life Science 59:901-909.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 656,
    "source": "PDF_chunked"
  },
  {
    "id": 4589,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 589)",
    "text": "OOAS Page 122 Morinda lucida WAHP Nom botanique Morinda lucida .Benth. Famille Rubiaceae Synonymes Morinda citrifolia L. Nomscommuns Brimstone tree (anglais) Arbre à soufre, oruwo (Francais) Noms vernaculaires Burkina Faso: Dioula Mangana Ghana: Akan Bronyadua Konkroma Nigéria: Igbo Nuke, Yoruba Oruwo Sierra Leone: Mende Hojologbo Togo: Ewé Dzadzaklan, Ouatchi Dadaklan, Adja Tsikémachou Description de la plante M. lucida est un arbuste à feuillage persistant ou un arbre de petite ou moyenne taille de 18- 25 mètres de haut, avec le tronc et les branches souvent tortueux ou noueux; l'écorce lisse est grossièrement écailleuse, grise à brune, souvent avec des couches distinctes pourpre. Les feuilles sont opposées, simples et entières; stipulées, ovales ou triangulaires, le pétiole long de 1- 7 mm jusqu'à 1,5 cm ; le limbe est elliptique, 6- 18 cm X 2-9 cm, avec une base arrondie ou cunéiforme,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 902,
    "source": "PDF_chunked"
  },
  {
    "id": 4590,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 590)",
    "text": "ovales ou triangulaires, le pétiole long de 1- 7 mm jusqu'à 1,5 cm ; le limbe est elliptique, 6- 18 cm X 2-9 cm, avec une base arrondie ou cunéiforme, un sommet aigu ouacuminé, brillant au- dessus et parfois finement pubescent à l'état jeune. Il a une inflorescence en tête pédonculée de 4 à 7 mm de diamètre, 1- 3 sur les nœuds face à une seule feuille ; un pédoncule allant jusqu'à 8 cm de long portant à la base une glande pétiolée en forme de coupe. Les fleurs sont bisexuées, régulières, avec 5- mères, hétérostylées, odorantes; un calice en forme de coupe, d'environ 2 mm de long, persistant; une corolle en forme de plateau, d'environ 1,5 cm long, blanc ou jaune- vert, des lobes ovale- lancéolées, jusqu'à 5 mm 2,5 mm; un style d'ovaire inférieur de 2 cellules de 8- 11 mm de long avec 2 lobes de stigmatede 4 à 7 mm de long et 5 étamines. Les fruits sont des nombreuses drupes, rassemblées dans un syncarpe succulent presque g lobuleux de 1 à 2,5 cm de diamètre,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 971,
    "source": "PDF_chunked"
  },
  {
    "id": 4591,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 591)",
    "text": "2 lobes de stigmatede 4 à 7 mm de long et 5 étamines. Les fruits sont des nombreuses drupes, rassemblées dans un syncarpe succulent presque g lobuleux de 1 à 2,5 cm de diamètre, doux et noirs à maturité; un pyrène comprimé ovoïde, de 6,5 mm 4 mm maximum, rouge, brun-foncé, très dur, 1 graine. Graine ellipsoïde, d'environ 3,5 mm 2 mm 0,5 mm, jaunâtre, molle. Numéro du specimen de l'herbier Ghana: 1189 Togo: TOGO07498 Habitat et répartition géographique Morinda lucida se rencontre du Sénégal au Soudan, au sud de l'Angola et en Zambie. Il est parfois planté autour des villages et pousse dans les prairies, les flancs exposés, les forêts l es plus profondes, souvent sur des termitières, parfois dans les zones qui sont régulièrement inondés, du niveau de la mer jusqu'à 1300 m d'altitude. Parties utilisées de la plante Feuilles, racines et écorce du tronc. Caractéristiques botaniques L'arbre à citrons se compose de la feuille, de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4592,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 592)",
    "text": "Parties utilisées de la plante Feuilles, racines et écorce du tronc. Caractéristiques botaniques L'arbre à citrons se compose de la feuille, de la racine ou de l'écorce de la tige de Morinda lucida Benth. (Rubiaceae) Utilisations ethnomédicales En Afrique de l'Ouest, M. lucida est une plante importante dans la médecine traditionnelle. Les décoctions et les infusions ou les cataplasmes de racines, de l'écorce et des feuilles sont des remèdes reconnus pour le traitement de différents types de fièvre (y compris la fièvre jaune), le paludisme, la trypanosomiase et les poussées de fièvre pendant le travail. La p lante est également utilisée dans les cas de diabète, d'hypertension, accident vasculaire cérébral, dysenterie, douleurs abdominales, ulcères, lèpre et gonorrhée. Au Nigéria, M. lucida est l'un des quatre remèdes traditionnels les plus couramment utilisés contre la fièvre. En Côte d'Ivoire, une décoction de l'écorce est utilisée",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4593,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 593)",
    "text": "et gonorrhée. Au Nigéria, M. lucida est l'un des quatre remèdes traditionnels les plus couramment utilisés contre la fièvre. En Côte d'Ivoire, une décoction de l'écorce est utilisée contre la jaunisse ;en République Démocratique du Congo, elle est associée à l'écorce de racine en poudre comme un cataplasme pour traiter les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 324,
    "source": "PDF_chunked"
  },
  {
    "id": 4594,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 594)",
    "text": "OOAS Page 123 Morinda lucida WAHP démangeaisons et la teigne. Les fruits sont utilisés dans le traitement de l'asthme (Chin, 2002) et au Nigéria, les feuilles sont utilisées pour traiter le diabète (Gbolade, 2009; www.prota.org). Les feuilles, l'écorce du tronc et les racines sont utilisées dans le traitement du paludisme (Asase et Oppong- Mensah, 2009; Adebayo et Kretti, 2011), tandis que l'infusion ou la décoction des feuilles et l'écorce du tronc, sont utilisées par voie orale dans le traitement du cancer (Ashida et al., 2010). La décoction de l'écorce du tronc est également utilisée dans le traitement des hémorroïdes et de l'ulcère gastrique (Agyare et al., 2009). Activités biologiques et pharmacologiques Il a été rapporté l'effet purgatif d'un extrait méthanolique des feuilles de la plante. Le traitement par voie orale (12, 5-100 mgkg) a provoqué une augmentation marquée du nombre de selles humides chez les rats et potentialisée la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4595,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 595)",
    "text": "méthanolique des feuilles de la plante. Le traitement par voie orale (12, 5-100 mgkg) a provoqué une augmentation marquée du nombre de selles humides chez les rats et potentialisée la diarrhée provoquée par l'huile de ricin chez la souris (Olajide et al ., 1999). L'extrait méthanolique sec des feuilles a stimulé la vidange gastr ique chez le rat et la motilité intestinale chez la souris. L'extrait n'a induit ni une ulcération gastrique ni la protection contre l'ulcère induite par l'acide acétylsalicylique chez les rats. (Olajide et al., 1998). L'extrait de l'écorce de racine a montré une activité mutagène avec une faible cytotoxicité (Sowemimo et al ., 2007). Des extraits des feuilles ont eu un effet inhibiteur significatif in vitro , selon la dose, sur la croissance du Plasmodium falciparum (do Ceu de Madureira, 2002; Tona et al ., 1999). L'extrait brut des feuilles et de l'écorce du tronc avait également eu un effet antiplasmodial avec respectivement une CI",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 973,
    "source": "PDF_chunked"
  },
  {
    "id": 4596,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 596)",
    "text": "de Madureira, 2002; Tona et al ., 1999). L'extrait brut des feuilles et de l'écorce du tronc avait également eu un effet antiplasmodial avec respectivement une CI 50 de 3.900 et 5 700 μgml, tandis que le composé l'acide ursolique isolé de la plante, présentait une activité antiplasmodiale avec une CI50 de 3.100 μgml (Adebayo et Kretti, 2011). Des extraits des feuilles et de l'écorce des tiges ont montré des propriétés cytotoxiques significatives mais non sélectives (Ashidi et al., 2010). Les acides anthraquinones et triterpénoïdes de la pla nte ont montré des activités antileishmaniales et antipaludiques in vitro (Sittie et al., 1999). Données cliniques Aucune information disponible Constituants chimiques Anthraquinones (Durodola, 1974, Koumaglo et al., 1992 ; Sittie et al ., 1999); acide urs olique et autres acides triterpéniques (Cimanga et al., 2006; Adebayo et Kretti, 2011). Test d'identité et de pureté Teneur en eau: 6,35 (feuilles), 6,13 (écorce",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 4597,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 597)",
    "text": "autres acides triterpéniques (Cimanga et al., 2006; Adebayo et Kretti, 2011). Test d'identité et de pureté Teneur en eau: 6,35 (feuilles), 6,13 (écorce de tige) Cendre totale: feuilles: 8,39 (feuilles), 5,54 (écorce de tige) Cendre sulf atée: 12.33 (feuilles), 6,64 (écorce de tige) Valeur ssubstances extractibles par l'eau: pas moins de 17,65 (feuilles), 20.89 (écorce de tige) Valeur substances extractibles par l'éthanol (70 ): pas moins de 15,78 (écorce de la tige) Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de trois taches roses",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4598,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 598)",
    "text": "anisaldéhyde (0,5 ml) et d 'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de trois taches roses distinctes avec Rf de 0,79 et 0,71 0,61. Chromatogramme",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 246,
    "source": "PDF_chunked"
  },
  {
    "id": 4599,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 599)",
    "text": "OOAS Page 124 Morinda lucida WAHP Macroscopie L'écorce externe est lisse et que presque écailleuse, gris -brun; l'écorce interne est brun- clair à jaunâtre. Elle a une odeur aromatique et un goût amer. Microscopie Présence de cellules du collenchyme à parois épaisses en dessous de l'épiderme supér ieur et au-dessus de l'épiderme inférieur; des cristaux aciculaires dans les cellules du parenchyme cortical; un faisceau vasculaire est en forme d'arc; des cellules épidermiques à parois droits avec de nombreux stomates isocytiques; poils tecteurs unicellulaires. Matériel végétal en poudre Présence de cristaux d'oxalate de calcium aciculaires ainsi que des raphides avec quelques cristaux prismatiques. Une abondance de pierre despuits; de nombreuses cellules de liège et des vaisseaux dénoyautées. Actions thérapeutiques Antipaludéen, antipyrétique, antileishmanial, antidiabétique, pesticide, antitrypanosomale et antihelminthique (Okpekon et al., 2004).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4600,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 600)",
    "text": "Actions thérapeutiques Antipaludéen, antipyrétique, antileishmanial, antidiabétique, pesticide, antitrypanosomale et antihelminthique (Okpekon et al., 2004). Indications thérapeutiques Paludisme, fièvre, jaunisse, diabète et trypanosomiase, helminthiasis (Okpekon et al., 2004). Données de sécurité La DL 50 de l'extrait aqueux (p.o) s'est avérée être 3000 mgkg chez le rat. Des études de toxicité subaiguës (300- 3000 mgkg p.o) sur l'administration répétée pendant 14 jours, n'a pas montré d'effet significatif sur le poids corporel. Une diminution du poids relatif du foie, des poumons et de la rate a été observée chez des rats traités, avec des niveaux décroissants du taux d'hémoglobine (CCMH), mais avec une augmentation du VGM et des plaquettes; les niveaux d'ALP et de GGT ont accrus avec une diminution de l'albumine sérique. Une augmentation de la créatininémie a été observée à la dose de 3000 mgkg. Précautions d'emploi",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4601,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 601)",
    "text": "niveaux d'ALP et de GGT ont accrus avec une diminution de l'albumine sérique. Une augmentation de la créatininémie a été observée à la dose de 3000 mgkg. Précautions d'emploi Une prudence devait être observée dans l'administration de l'extrait aqueux, notamment chez les patients souffrant de déficiences des fonctions rénales et hépatiques. Effets indésirables A des doses élevée, augmentation possiblede la créatinine sérique. Contre-indications Maladies rénales et hépatiques. Dosage et formegalénique Décoction : 30 g de matériel végétal dans 900 ml d'eau ; laisser bouillir jusqu'à ce que réduction de l'eau à 600 ml ; 1 tasse trois fois par jour. Références Adebayo, J.O., Krettli, A.U. (2011). Potential antimalarials from Nigerian plants: A review. Journal of Ethnopharmacology 133:289302. Agyare, C., Asase, A., Lechtenberg, M., Niehues, M., Deters, A., Hensel, A. (2009). An ethnopharmacological survey and in vitro",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4602,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 602)",
    "text": "Journal of Ethnopharmacology 133:289302. Agyare, C., Asase, A., Lechtenberg, M., Niehues, M., Deters, A., Hensel, A. (2009). An ethnopharmacological survey and in vitro confirmation of ethnopharmacological use of medicinal plants used for wound healing in Bosomtwi-Atwima-Kwanwoma area, Ghana. Journal of Ethnopharmacology 125:393403. Asase, A., Akwetey, G.A., Achel, D.G. (2010). Ethnopharmacological use of herbal remedies for the treatment of malaria in the Dangme West District of Ghana. Journal of Ethnopharmacology 129:367376. Asase, A., Oppong- Mensah, G. (2009). Traditional antimalarial phytotherapy remedies in herbal markets in southern Ghana. Journal of Ethnopharmacology 126:492499. Ashidi, J.S., Houghton, P.J., Hylands P.J., Efferth, T., (2010). Ethnobotanical survey and cytotoxicity testing of plants of South- western Nigeria used to treat cancer, with isolation of cytotoxic constituents from Cajanus cajan Millsp.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4603,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 603)",
    "text": "Efferth, T., (2010). Ethnobotanical survey and cytotoxicity testing of plants of South- western Nigeria used to treat cancer, with isolation of cytotoxic constituents from Cajanus cajan Millsp. Leaves. Journal of Ethnopharmacology 128:501 512. Chin, W.Y. (2002). A Guide to Medicinal Plants. Singapore Science Centre, Singapore. Cimanga, R.K., Tona, G.L., Mesia, G.K., Kambu, O.K., Bakana, D.P. et al ., (2006). Bioassay - guided isolation of antimalarial triterpenoid acids from the leaves of Morinda lucida. Pharmaceutical Biology 44:677681. Do Ceu de Madureira, M., Paula Martin, A., Gomes, M., Paiva, J., Proenca da Cuhna, A., do Rosario, V. (2002). Antimalarial activity of medicinal plants used in traditional medicine in S. Tome and Principe islands. Journal of Ethnopharmacology 81:23-29.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 796,
    "source": "PDF_chunked"
  },
  {
    "id": 4604,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 604)",
    "text": "OOAS Page 125 Morinda lucida WAHP Durodola, J.I. (1974). Antineoplastic property of a crystalline compound extracted from Morinda lucida. Planta Medica 26:208211. Gbolade, A.A. ( 2009). Inventory of antidiabetic plants in selected districts of Lagos State, Nigeria. Journal of Ethnopharmacology 121:135 139. Koumaglo, K., Gbeassor, M., Nikabu, O., De Souza, C., Werner, W. (1992). Effects of three compounds extracted from Morinda lucida. Planta Medica. 58:533534. Olajide, O.A., Awe, S.O., Makinde, J.M. (1999). Purgative effect of the methanol extract of Morinda lucida. Fitoterapia 70:1-4. Olajide, O.A., Awe, S.O., Makinde, J.M. (1998) . The Effects of Morinda lucida Benth (Rubiaceae) Extract on the Gastrointestinal. Tract of Rodents. Phytotherapy Research 12: 439441. Okpekon, T., Yolou, S., Gleye, C., Roblot, F., Loiseau, P. et al. (2004). Antiparasitic activities of medicinal plants used in Ivory Coast . Journal of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4605,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 605)",
    "text": "Phytotherapy Research 12: 439441. Okpekon, T., Yolou, S., Gleye, C., Roblot, F., Loiseau, P. et al. (2004). Antiparasitic activities of medicinal plants used in Ivory Coast . Journal of Ethnopharmacology 90:9197. Sittie, A.A., Lemmich, B., Olsen, C.E., Hviid, I., Kharazmi, A. et al . (1999). Structure Activity studies: in vitro antileishmanial and antimalarial activites of anthraquinones from Morinda lucida. Planta Medica 65:259261. Sowemimo, A.A., Fakoya, F.A., Awopetu, I., Adesanya, S.A. (2007). Toxicity and mutagenic activity of some selected Nigerian plants. Journal of Ethnopharmacology 113:427432. Tona, L., Ngimbi, N.P., Tsakala, M., Mesia, K., Cimanga, K. et al ., (1999). Antiplasmodial activity of 20 crude extracts from nine African medicinale plants in Kinshasa Congo. Journal of Ethnopharmacology 68:193-302. Tona, L., Cimanga, R.K., Mesia, K., Musuamba,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 873,
    "source": "PDF_chunked"
  },
  {
    "id": 4606,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 606)",
    "text": "activity of 20 crude extracts from nine African medicinale plants in Kinshasa Congo. Journal of Ethnopharmacology 68:193-302. Tona, L., Cimanga, R.K., Mesia, K., Musuamba, C.T., De Bruyne, T. et al . (2004). In vitro antiplasmodial activity of extracts and fractions from seven medicinal plants used in the Democratic Republic of Congo. Journal of Ethnopharmacology 93:2732.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 374,
    "source": "PDF_chunked"
  },
  {
    "id": 4607,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 607)",
    "text": "OOAS Page 126 Moringa oleifera WAHP Nom botanique Moringa oleifera Lam. Famille Moringaceae Synonymes Moringa pterygosperma Gaern. (I), Moringa aptera Noms communs Arbre de raifort ; Arbre à baguette ; Arbre d'huile de Ben ; Arbre miracle ; arbre clarifi cateur ; arbre de Kelor ; Meilleure amie de la mère. Noms vernaculaires Burkina Faso : Moore Arzan Ti iga, Dioula ArdjinaYiri, Fulfuldé Gilgandja Ghana: Dagari Zangala, Ewe Babatsi, Hausa Zingaridende Mali: Bambara Nevrede, Mandigue Nebedayo Nigéria: Yuroba Ewe Igbale, Hausa Danga Senegal: Wolof Nebeday Togo: Ewe Yovovigbe, Ouatchi Kpotsi, Lamba Spe Description de la plante C'est un arbre tropical vivace, de petite ou moyenne taille allant jusqu'à 12 m de haut à maturité, avec des branches retombantes ; une tige fragile avec une écorce liégeuse ;couramment cultivée dans certains pays africains comme barrière vivante ; il a tendance à",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 896,
    "source": "PDF_chunked"
  },
  {
    "id": 4608,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 608)",
    "text": "maturité, avec des branches retombantes ; une tige fragile avec une écorce liégeuse ;couramment cultivée dans certains pays africains comme barrière vivante ; il a tendance à avoir des racines profondes et généralement une couronne en forme de parapluie et une tige unique souvent; texture d'écorce legère ; une arborescence développant une base à caudex avec l'âge ; feuilles coriaces, vert -foncé sur la face supérieure, vert-pâle, presque mauve sur la face inférieure ; composées, tripennées (ou sub- pennées, imparipennées).Chaque feuille a jusqu'à neuf folioles avec une grande variété de tailles, 0,7-5,3 cm de long et sur 0,3 à 3,6cm de large,folioles pétiolées (0,1 à 0,4 cm de long), marge entière, obtuses, sommets arrondis ou émarginé avec une nervation réticulée, opposées sur les axes primaires, secondaires et tertiaires, les formes des folioles vont d'elliptiques, ovales à obovées, folioles terminales, obovale et plus larges que les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4609,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 609)",
    "text": "opposées sur les axes primaires, secondaires et tertiaires, les formes des folioles vont d'elliptiques, ovales à obovées, folioles terminales, obovale et plus larges que les latérales de forme elliptique ou ovoïde, folioles très pâles quand elle est jeune, bases de folioles symétriques, aiguës, arrondies ou obtuses. Les folioles séchées sont duveteuses et à texture de papier et de couleur brunâtre à vert -jaunâtre; Inflorescences axillaires, plus courtes que les feuilles; les fleurs sont de couleur crème ou blanc avec 2,5 cm de diamètre; des étamines jaunes, apparaissent en panicules durant les périodes de stress; les fruits ou gousses pendantes, sont verts et succulents quand ils sont jeunes et bruns à maturité; triangulaires, effilés aux deux extrémités , de 30 à 120 cm de long, 1,8 cm de large, fractionnement sur la longueur en 3 parties lorsqu'il est sec; chaque gousse contient environ 20 graines brun foncé avec 3 ailes de papier.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4610,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 610)",
    "text": "long, 1,8 cm de large, fractionnement sur la longueur en 3 parties lorsqu'il est sec; chaque gousse contient environ 20 graines brun foncé avec 3 ailes de papier. Habitat et répartition géographique M. oleifera semble être originaire ds régions du sous-Himalaya au Nord de l'Inde. Cependant, elle pousse dans de nombreuses régions des savanestropicales, se diffuse probablement grâce à une culture intensive à des fins diverses. Selon Muluvi et al. (1999). Moringa a été introduit en Afrique à partir de l'Inde à la fin du XX ème siècle. Dans la sous -région Ouest - Africaine, M. oleifera semble être plus importante dans les régions relativement plus arides. On le trouve au Ghana, surtout dans les régions du Nord du Mali, dans les zones septentrio nnales plus arides du Nigeria et dans de nombreux autres endroits où il est connu pour être comestibles. Moringa est acclimatéeau Malawi, Niger, Sénégal et en Tanzanie. En Inde, les jeunes gousses ou pilons sont mises en",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 972,
    "source": "PDF_chunked"
  },
  {
    "id": 4611,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 611)",
    "text": "autres endroits où il est connu pour être comestibles. Moringa est acclimatéeau Malawi, Niger, Sénégal et en Tanzanie. En Inde, les jeunes gousses ou pilons sont mises en conserve et exportées partout dans le monde. Moringa est adaptée à des conditions arides sableuses et bien que résistante à la sécheresse, il est intolérant à l'engorgement des sols. Il peut pousser dans les périodes de chaleur exceptionnelle sous les tropiques humides, dans des conditions d'aridité désséchante ou dans des sols indigents. Cependant, le Moringa pousse mieux dans un sol sableux sec et produit beaucoup moins de feuillage lorsqu'il est en permanence sous stress",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 649,
    "source": "PDF_chunked"
  },
  {
    "id": 4612,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 612)",
    "text": "OOAS Page 127 Moringa oleifera WAHP hydrique. Il peut être cultivé comme une plante annuelle ou à effet de serre dans les zones tempérées. La plante est reconnue pour tolérer des précipitations annuelles de 4,8- 40,3 dm, température ambiante de 26 à 40 OC et des pH de 4,5 à 8,5. Elle pousse bien du niveau de la mer jusqu'à une altitude de 1000 m. Dans des climats tropicaux et subtropicaux , elle fructifie librement et de manière continue. Moringa est reconnupour sa tolérance aux attaques bactériennes, mycobactériennes et fongiques, même si elle a ses propres agents pathogènes spécifiques. L'élagage intense encourage les pousses latérales et l'augmentation de la production de feuilles, maintient la plante à une hauteur pratique pour la récolte et fournit un moyen d'obtenir des rendements très élevés de matériel végétal. Parties utilisées de la plante Feuille Autres parties utilisées Fleurs, fruits, racines, graines Caractéristiques botaniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4613,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 613)",
    "text": "matériel végétal. Parties utilisées de la plante Feuille Autres parties utilisées Fleurs, fruits, racines, graines Caractéristiques botaniques Moringa se compose des feuilles fraîches ou séchées de Moringa oleifera Lam (Moringaceae). Utilisations ethnomédicales La plante est cultivée pour ses feuilles, ses frui ts, ses racines et ses graines pour diversemplois, aussi bien alimentaires que médicamenteuses. Presque toutes les parties de la plante sont utiles comme nourriture. Toutefois, les feuilles et les gousses sont plus utilisées comme sources de nourriture ou de compléments. Les jeunes feuilles de M. oleifera sont comestibles et font partie de l'alimentation traditionnelle dans de nombreux pays où l'arbre pousse et sont consommées préparées ou ajoutées à la nourriture sous forme de poudre de feuilles séchées. Les graines sont mangées comme arachides et l'huile extraite de celles -ci est comestible. Les racines épaissies sont utilisées",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 4614,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 614)",
    "text": "nourriture sous forme de poudre de feuilles séchées. Les graines sont mangées comme arachides et l'huile extraite de celles -ci est comestible. Les racines épaissies sont utilisées comme substitut du raifort. Une utilisation plus notable de la poudre de feuilles de Moringa est utile pour le traitement et la pr évention de la malnutrition, surtout chez les enfants. Dans une unité de soins pédiatriques d'un hôpital au Sénégal, les cas signalés de malnutrition infantile ont enregistré une chute de près de 600, en 1997, et moins de 50 en l'an 2000. Le dossier des ut ilisations médicinales de M. oleifera dans les anecdotes populaires est abondant. Des parties de plantes autres que les feuilles sont responsables de la plupart des utilisations médicinales de la plante, surtout les racines et les graines. Toutefois, les f euilles ont aussi des usages médicinaux qui relèvent de la tradition. Les fleurs, les feuilles et les racines de la plante",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4615,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 615)",
    "text": "les graines. Toutefois, les f euilles ont aussi des usages médicinaux qui relèvent de la tradition. Les fleurs, les feuilles et les racines de la plante sont utilisées pour le traitement des tumeurs. Les feuilles en cataplasme, sontappliquéessur les plaies ou frottées sur les tempes comme traitement pour les maux de tête. Le cataplasme de feuilles est également utilisé pour réduire les gonflements glandulaires. Les feuilles sont utilisées comme purgatif, pour favoriser la digestion et dans la médecine traditionnelle comme agent hypochol estérolémiant chez les personnes obèses. Le jus extrait à partir des feuilles est appliqué directement à l'oeil pour le traitement de la conjonctivite. Il est aussi chauffé et appliqué dans les zones touchées pour soulager la douleur causée par l'entorse. Les feuilles sont utilisées dans une préparation et prise pour le traitement de l'hypertension artérielle. En Inde, la plante est utilisée comme un abortif (Nath et al., 1992).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 975,
    "source": "PDF_chunked"
  },
  {
    "id": 4616,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 616)",
    "text": "feuilles sont utilisées dans une préparation et prise pour le traitement de l'hypertension artérielle. En Inde, la plante est utilisée comme un abortif (Nath et al., 1992). Activités biologiques et pharmacologiques Les glycosides isothiocyanate de la plante et les thiocarbamates niaziminin A et niaziminin B ont montré une activité hypotensive (Faizi et al ., 1994). L'administration intraveineuse (1- 10 mgkg) de tous les composés (niazinine A, niazinine, niazimicine B et niaziminine A B) produit des ef fets hypotenseurs et bradycardisants chez des rats Wistar anesthésiés. Le prétraitement des animaux avec de l'atropine (1 mgkg) a complètement supprimé les effets hypotenseurs et bradycardisants de l'acétylcholine (ACh), tandis que les réactions cardiovasculaires des composés isolés sont demeurées inchangées, éliminant l'implication possible de l'activation des récepteurs muscariniques. Tous les composés (50- 150 pgmL) ont produit des effets inotropiques et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 968,
    "source": "PDF_chunked"
  },
  {
    "id": 4617,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 617)",
    "text": "demeurées inchangées, éliminant l'implication possible de l'activation des récepteurs muscariniques. Tous les composés (50- 150 pgmL) ont produit des effets inotropiques et chronotropes négatifs sur les oreillettes isolées de cobaye. Les contractions spontanées de l'utérus du rat ont été également inhibées par tous les composés (Gilani et al., 1992 et 1994). Il a été démontré que les glucosinolates de la plante ont une activité antibiotique, tandis que les composés thiocarbamates et l'isothiocyanates inhibent l'activation du virus Epstein Barr induit par le promoteur de tumeur teleocidin B-4 dans les cellules Raji (Murakami et al., 1998). Le jus de feuilles et l'écorce de tige ont inhibé Staphylococcus aureus mais pas Escherichia coli. 50 d'extraitéthanolique de la partie aérienne de M. oleifera a montré une activité anticancéreuse contre le carcinome épidermoïde humain du rhinopharynx en culture de tissus et de la leucémie lymphocytaire P388",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 4618,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 618)",
    "text": "partie aérienne de M. oleifera a montré une activité anticancéreuse contre le carcinome épidermoïde humain du rhinopharynx en culture de tissus et de la leucémie lymphocytaire P388 chez la souris. L'extrait brut de M. oleifera a démontré avoir un effet hypocholestérolémiant . Ghasi et al . (2000) ont montré que",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 312,
    "source": "PDF_chunked"
  },
  {
    "id": 4619,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 619)",
    "text": "OOAS Page 128 Moringa oleifera WAHP l'administration d'un extrait brut de feuilles avec une diète riche en matière grasseréduit le taux de cholestérol sérique, du foie et des reins, chez les ra ts. L'extrait de feuilles de M. oleifera peut servir à réglementer l'hyperthyroïdie puisqu'il a été reconnu pour inhiber la conversion périphérique de la thyroxine (T4) en triiodotyronine (T3) chez les rats femelles (Tahiliani et Kar, 2000). Cependant, cet effet était absent chez les rats mâles. Dans une étude, pour évaluer le potentiel anti -reproductif de la plante, l'extrait de feuilles de M. oleifera s'est avéré 100 abortif à une dose équivalente à 175 mgKg de produit sec (Nath et al ., 1992) de départ . Les saponines sont présentes, mais contrairement à leurs homologues dans les autres plantes, les saponines dans M. oleifera ne montrent pas de propriétés hémolytiques. Des extraits méthanoliques de feuilles ont montré des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4620,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 620)",
    "text": "contrairement à leurs homologues dans les autres plantes, les saponines dans M. oleifera ne montrent pas de propriétés hémolytiques. Des extraits méthanoliques de feuilles ont montré des effets antiulcérogènes et hépatoprotecteurs chez les rats (Pal et al ., 1995); l'extrait aqueux de la feuille a également montré des effets anti - ulcéreux (Pal et al., 1995) indiquant que les composés anti -ulcéreux sont largement distribués dans la plante. Une étude japonaise de 2007 a montré que la consommation de Moringa améliore in vivole diabète (Hurtel, 2008) et une étude similaire en Thaïlande dans la même année a révélé que Moringa contient des antioxydants qui provoquent une diminution des taux de cholestérol sanguin accompagnée d'une diminution significative de la formation de plaques d'athérome (Hurtel, 2008). Une étude par Jaiswal et al. (2009) a montré que les extraits aqueuxde feuilles possédaient des propriétés antidiabétiques et hypoglycémiques.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4621,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 621)",
    "text": "plaques d'athérome (Hurtel, 2008). Une étude par Jaiswal et al. (2009) a montré que les extraits aqueuxde feuilles possédaient des propriétés antidiabétiques et hypoglycémiques. On a observé également une réduction significative de la glycosurie et de la protéinurie. Diverses études ont démontré la valeur nutritionnelle des feuilles de Moringa (Ching et Mohamed, 2001; Girija et al. 1982). Dans uneétudesur certaines plantes sauvages d'importance utilisées lors de la sécheresse, Lockett et al. (2000) ont conclu que Moringa est une bonne source de protéines, de graisses, de calcium, de fer, de cuivre et de zinc. Les feuilles sont une bonne source de méthionine d'acides aminés contenant du soufre et de la cystéine, qui sont souvent faibles en protéines végétales. Cependant, la composition en acides aminés des protéines se compare avantageusement avec les normes de l'Organisation Mondiale de la Santé concernant les acides aminés essentiels",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4622,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 622)",
    "text": "Cependant, la composition en acides aminés des protéines se compare avantageusement avec les normes de l'Organisation Mondiale de la Santé concernant les acides aminés essentiels (Freiberger et al., 1998). M. oleifera a la teneur la plus élevée de zinc de tous les légumes à feuilles non conventionnelles étudiés, quoique la dose journalière moyenne des différents micro- nutriments étaient plus faibles que les apports journaliers recommandés, sauf pour le magnésium (Barminas et al ., 1998). Les feuilles de la plante contiennent également des quantités importantes de sélénium et de phosphore (Freiberger et al., 1998). Les feuilles contiennent des quantités élevées de provitamine A, sous la forme de caroténoïdes, notamment du β - carotène et des quantités élevées de vitamine C. Nambiar et Seshadri (2001) ont trouvé que par rapport aux paramètres de la croissance, les feuilles fraîches de M. oleifera, ainsi que la poudre de feuilles, étaient meilleures à la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 966,
    "source": "PDF_chunked"
  },
  {
    "id": 4623,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 623)",
    "text": "Nambiar et Seshadri (2001) ont trouvé que par rapport aux paramètres de la croissance, les feuilles fraîches de M. oleifera, ainsi que la poudre de feuilles, étaient meilleures à la synthèse de la vitamine A. Données cliniques L'administration de 3 g de poudre fine d'amandes de graines séchées à vingt patients souffrant d'asthme léger ou modéré, pendant 3 semaines a entraîné une augmentation significative du taux d'hémoglobine et une réduction de la vitess e de sédimentation des érythrocytes chez la majorité des patients. On a observé également une amélioration significative des scoresde symptômes et la gravité des crises asthmatiques (Agrawal et Mehta, 2008). Constituants chimiques Substances à action oest rogène (y compris le β- sitostérol); pectinesterase; pterygospermin; alcaloïdes (moringine et moringinine); Hétérosides acétylés (ex: niaziminine A, niaziminin b niazirin, niazirinin), (Faizi et al. , 1995; Murakami et al ., 1998); glycosides",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4624,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 624)",
    "text": "alcaloïdes (moringine et moringinine); Hétérosides acétylés (ex: niaziminine A, niaziminin b niazirin, niazirinin), (Faizi et al. , 1995; Murakami et al ., 1998); glycosides contenant des is othiocyanates (Faizi et al., 1994); (4- (4'-O-acetyl-α-L-rhamnosyloxy) benzyle isothiocyanate) (Evans, 1996); Β- carotène, sucres réducteurs; tanins et flavonoïdes glycosides cardiaques. Tests d'identité et de pureté Teneur en eau: pas plus de 10 Cendretotale: pas plus de 10 Cendre insoluble dans l'acide : pas plus de 1,5 Valeur substances extractibles par l'eau : pas moins de 7 Valeur substances extractibles par l'éthanol (70 ): pas moins de 3 Ratio de palissade : 6,2- 7,50 Nombre deveine-îlot: 12.00-14.00. Nombre de veinule de terminaison : 14 h 00 - 17 h 00 Nombre de stomates : surface inférieure de 5.20 9,80Index stomatique : surface inférieure de 6,60 12.00 Empreintes chromatographiques Extrait chloroformique",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 914,
    "source": "PDF_chunked"
  },
  {
    "id": 4625,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 625)",
    "text": "h 00 Nombre de stomates : surface inférieure de 5.20 9,80Index stomatique : surface inférieure de 6,60 12.00 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60F254, et phase mobile: éther de pétrole (40-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 294,
    "source": "PDF_chunked"
  },
  {
    "id": 4626,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 626)",
    "text": "OOAS Page 129 Moringa oleifera WAHP 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de quatre taches distinctes avec Rf avec 0,98 (Rose), 0,81 (Rose), 0,59 (gris) et 0,35 (gris-foncé). Chromatogramme Macroscopie Les feuilles de M. oleifera sont composés, tripinnée et imparipennées, mesurant entre 30- 60 cm de long et 10 à 20 cm de large; les feuilles sont opposées sur les axes primaire, secondaire et tertiaire. Chaque feuille ajusqu'à neuf (9) folioles. Les folioles terminales sont obovales et plus grandes que les latérales de forme elliptique ou ovale. Les bases de folioles sont symétriques, aiguë, arrondies ou obtuses, pétiolées (0,1- 0,4 cm de long), avec marges entières, obtuses, arrondies ousommeté marginé et une nervation",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4627,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 627)",
    "text": "ou ovale. Les bases de folioles sont symétriques, aiguë, arrondies ou obtuses, pétiolées (0,1- 0,4 cm de long), avec marges entières, obtuses, arrondies ousommeté marginé et une nervation réticulée. Les folioles fraîche sont une texture coriace, vert-foncé sur la face supérieure et vert - clair sur la surface inférieure, les feuilles séchées ont une texture foliacée et unecouleur brunâtre à vert-jaunâtre. Microscopie L'épiderme supérieur est com posé de cellules à parois cireuses. Mais celles des veines semblent être à parois droite; la cuticule est mince et lisse; les stomates sont rares; les cellules palissadiques sous -jacentes sont très bien enveloppées; les cellules de l'épiderme inférieur sont aussi à parois cireuses; de nombreux stomates, aussi bien anomocytiques qu'anisocytiques, sont surtout présents sur la face inférieure des folioles ; les deux surfaces portent des poils tecteurs unisériés typiquement longs, minces et à parois minces souv ent",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 967,
    "source": "PDF_chunked"
  },
  {
    "id": 4628,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 628)",
    "text": "qu'anisocytiques, sont surtout présents sur la face inférieure des folioles ; les deux surfaces portent des poils tecteurs unisériés typiquement longs, minces et à parois minces souv ent courbés ; la coupe transversale de la foliole de M. oleifera révèle un arrangement dorsi -ventrale, avec une palissade à double couche qui fusionne dans le collenchyme de la région de la nervure centrale. L'arrangement de tissu dans la région de la nerv ure centrale montre un épiderme supérieur attenant à la région étroite du collenchyme sous laquelle est localisée une région du parenchyme; les cellules du tissu du parenchyme sont de très petite taille et très compactes. La partie centrale de la nervure principale est occupée par un tissu vasculairede forme recourbée, légèrement lignifié, entouré d'une zone de parenchyme très compacte portant des grains d'amidon attenant au collenchyme et contigüeà l'épiderme inférieur ; dans la région du parenchyme, au- dessus et au-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 4629,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 629)",
    "text": "d'une zone de parenchyme très compacte portant des grains d'amidon attenant au collenchyme et contigüeà l'épiderme inférieur ; dans la région du parenchyme, au- dessus et au- dessous de la région du tissu vasculaire sont localisés des idioblastes irrégulièrement distribuées contenant des cristaux d'oxalate de calcium de type multicylindrique; l'épiderme supérieur comme inférieur de la nervure médiane portedes poils unicellulaires minces mais longs et courbés; la section transversale du pétiole montre la même disposition de tissusquecelle observée au niveau de la nervure centrale, sauf qu'il n'y a ici aucun tissu palissadique. Matériel végétal en poudre Lapoudre de fol ioles de M. oleifera fluide révèle de nombreux poils unisériés unicellulaires, entiers comme brisés, dont certaines sont de forme courbés; près de la base, des stomates de type anomocytique sont présents. Des fragments de limbe; en vue sectionnelle, font apparaître",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4630,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 630)",
    "text": "entiers comme brisés, dont certaines sont de forme courbés; près de la base, des stomates de type anomocytique sont présents. Des fragments de limbe; en vue sectionnelle, font apparaître des cellules épidermiques avec une couche",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 228,
    "source": "PDF_chunked"
  },
  {
    "id": 4631,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 631)",
    "text": "OOAS Page 130 Moringa oleifera WAHP unique de cellules palissadiques. Des fragments brisés de veines avec les vaisseaux de xylème réticulés et dénoyautés sont présents. Il y a des cristaux prismatiques et des grappes abondantes d'oxalate de calcium dispersés dans la poudre et grains d'amidon. Actions thérapeutiques Antiparasitaire, antimicrobien, antiviral, adjuvant, anticholestérémique. Indications thérapeutiques Hypertension, diabète, le paludisme, l'asthme, malnutrition, taux de cholestérol élevé. Données de sécurité La DL 50 de l'extrait aqueux ( p.o) s'est avéré être 3000 mgkg chez le rat. Aucune variation significative du poids corporel, mais une réduction du poids relatif du foie à la dose de 3000 mgkg a été observée; le profil hématologique n'était pas significativement affecté. L'ALP et la GGT augmentent significativement à toutes les doses de l'extrait aqueux supérieures à 100 mgkg. La créatinine sérique s'est élevée à 3 000 mgkg.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4632,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 632)",
    "text": "affecté. L'ALP et la GGT augmentent significativement à toutes les doses de l'extrait aqueux supérieures à 100 mgkg. La créatinine sérique s'est élevée à 3 000 mgkg. Précautions d'emploi Une précaution doit êtr e observée dans l'administration de l'extrait aqueux chez les patients qui ont des fonctions rénales et hépatiques altérées. Effets indésirables Augmentation possible de créatinine sérique à fortes doses avec l'ALP et la GGT élevées. Contre-indications Maladies rénales et hépatiques Dosage et formes galénique Aucun dosage précis lorsque la feuille est consommée comme un légume feuillu soit cru ou bouilli. Conservation A conserver dans un endroit frais et sec. Références Barminas, J.T., Ch arles, M., Emm anuel, D. (1998). Mineral composition of non- conventional leafy vegetables. Plant Foods and Human Nutrition 53:29-36. Ching, L.S., Mohamed, S. (2001). Alpha- tocopherol content in 62 edible tropical plants.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4633,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 633)",
    "text": "leafy vegetables. Plant Foods and Human Nutrition 53:29-36. Ching, L.S., Mohamed, S. (2001). Alpha- tocopherol content in 62 edible tropical plants. Journal of Agriculture and Food Chemistry 49: 3101-3105. Evans, W.C. (1996). Trease and Evans' Pharmacognosy (14 th Edition). WB Saunders Co. Ltd. London. pp 336. Faizi, S., Siddiqui, B.S., Saleem, R., Siddiqui, S., Aftab, K., Giliani, A.H. (1994). Isolation and structure elucidation of new nitrile and mustard oil glycosides from Moringa oleifera and their effect on blood pressure. Journal of natural Products 57:1256-1261. Faizi, S., Siddiqui, B.S., Saleem, R., Siddiqui, S., Aftab, K. Giliani, A.H. (1995). Fully acetylated carbamate and hypotensive t hiocarbamate glycosides from Moringa oleifera. Phytochemistry 38:957-963. Freiberger, C.E., Vanderjagt, D.J., Pastuszyn, A., Glew, R.S., Mounkaila, G. et al. (1998). Nutrient content of the edible leaves of seven wild plants",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4634,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 634)",
    "text": "Phytochemistry 38:957-963. Freiberger, C.E., Vanderjagt, D.J., Pastuszyn, A., Glew, R.S., Mounkaila, G. et al. (1998). Nutrient content of the edible leaves of seven wild plants from Niger. Plant Foods and Human Nutrition 53:57-69. Ghasi, S., N wobodo, E. Ofili, J.O. (2000). Hypocholesterolemic effects of crude extract of leaf of Moringa oleifera Lam in high -fat diet fed wistar rats. Journal of Ethnopharmacology 69:21- 25. Girija, V., Shar ada, D., Pushpamma, P. (1982). Bioavailability of thiamine, riboflavin and niacin from commonly consumed green leafy vegetables in the rural areas of Andhra Pradesh in India. International Journal of Vitamin and Nutrition Research 52:9-13. Lockett, C.T., Calvert, C.C., Gri vetti, L.E. (2000). Energy and micronutrient composition of dietary and medicinal wild plants consumed during drought. Study of rural Fulani, northeastern Nigeria. Internationa Journal of Food Science and Nutrition, 51:195-208.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4635,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 635)",
    "text": "and medicinal wild plants consumed during drought. Study of rural Fulani, northeastern Nigeria. Internationa Journal of Food Science and Nutrition, 51:195-208. Muluvi, G.M., Sprent, J.I., Soranzo, N., Provan, J., Odee, D. et al . (1999). Amplified fragment length polymorphism (AFLP) analysis of genetic variation in Moringa oleifera Lam. Molecular Ecology, 8:463-470. Murakami, A., Kitazono, Y., Jiwajinda, S., Koshimizu, K., Ohigashi, H. (1 998). Niaziminin, a thiocarbamate from the leaves of Moringa oleifera, holds a strict structural requirement for inhibition of tumor -promoter-induced Epstein- Barr virus activation. Planta Medica 64:319-323.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 651,
    "source": "PDF_chunked"
  },
  {
    "id": 4636,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 636)",
    "text": "OOAS Page 131 Moringa oleifera WAHP Nambiar, V.S., Seshadri, S. (2001). Bioavailability trials of beta -carotene from fresh and dehydrated drumstick leaves ( Moringa oleifera) in a rat model. Plant Foods and Human Nutrition 56:83-95. Nath, D., Sethi, N., Singh, R.K., Jain, A.K. (1992). Commonly used Indian arbortifacient plants with special reference to their teratologic effects in rats. Journal of Ethnopharmacology 36: 147-154. Pankaja, N., Prakash, J. (1994). Availability of calcium from kilkeerai ( Amaranthus tricolor ) and drumstick ( Moringa oleifera) greens in weanling rats. Nahrung 38:199-203. Tahiliani, P., Kar, A. (2000). Role of Moringa oleifera leaf extract in the regulation of thyroid hormone status in adult male and female rats Pharmacology Research 41:319-323.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 784,
    "source": "PDF_chunked"
  },
  {
    "id": 4637,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 637)",
    "text": "OOAS Page 132 Ocimum basilicum WAHP Nom botanique Ocimum basilicum L. Famille Lamiaceae Synonymes Ocimum lanceolatum Schum Tonn, Ocimum dicotomum Hochst ex Benth., Ocimum americanum L., Ocimum. menthaefolium A. Chev., Ocimum album, Ocimum anisatum, Ocimum barrelieri, Ocimum medium, Plectranthus barrelieri Noms communs Anglais: Sweet Basil Français: Basilic, basilic aux sauces, basilic commun, basilic romain, Framboisin (Antilles), Herbe Royale, Savetiers d'amélioration, Des Pistou. Noms vernaculaires Burkina Faso : Moor é Yulin-gnuuga, Dioula chou kolan, Fulfuldé Ngunguné;gugumã Cote d'Ivoire: Baule Emia Ghana: Akan Nunum, Ga Sulu, Ewe Dzevetu Mali: Bambara Chou Kolan Nigéria: Yoruba efinrin wewe Sierra Leone: Kono Peinga Togo: Akasalem Kunyonyo Description de la plante C'est une petite plante annuelle aromatique, sous-arbrisseau ou arbuste avec des tiges ramifiées quadrangulaires, qui formentt des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 911,
    "source": "PDF_chunked"
  },
  {
    "id": 4638,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 638)",
    "text": "Togo: Akasalem Kunyonyo Description de la plante C'est une petite plante annuelle aromatique, sous-arbrisseau ou arbuste avec des tiges ramifiées quadrangulaires, qui formentt des boules compactes de couleur vert clair. Les feuilles sont dentées, clairement pédicellées, minces, elliptiques, ovales ou oblongues, cunéiformes à la base, acuminées au sommet de 2 à 4 cm de long; l'inflorescence verticillées s'élève jusqu'à 20 cm avec un pédicelle très court, incurvé de lâches racèmes terminaux de pétales de fleurs blanches, de pétales blanches mesurant 4 ou 5 mm, des lobes de calice orbiculaires à plus de 6 mm de diamètre, un limbe de forme ovoïde à campanulée, un calice à 2 lèvres; la lèvre supérieure à 3 dents, une dent médiane circulaire à obovale, une marge ailée, décurrentes, des dents latérales plus courtes; la lèvre inférieure à 2 dents, des dents plus étroitesà sommet acuminé à épineux, parfois approximatif, un tube de corolle légèrement plus",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4639,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 639)",
    "text": "décurrentes, des dents latérales plus courtes; la lèvre inférieure à 2 dents, des dents plus étroitesà sommet acuminé à épineux, parfois approximatif, un tube de corolle légèrement plus courte que le calice ou rarement protubérant, dilatée, campanulée obliquement au niveau de la gorge; limbe à 2 lèvres, presque (3 ou 4) lobées; une lèvre inférieure un peu allongées ou non, une marge entière, plateou légèrement concave, 4 étaminessaillantes, déclinées sur la lèvre inférieure de la corolle; les 2 antérieures sont plus long; des filaments libres ou 2 connées antérieurs à la base; des anthères réniformes - ovoïdes, 1- de style locellé, plus long que les étamines, 2-fentes au sommet; lobes subégaux, subulés ou plats; nucules ovoïdes. Numéro du spécimen de l'herbier Ghana : GC52343 Habitat et répartition géographique La plante préfère la lumière (sandy) et les sols bien drainés de milieu (loameux) ; préfère les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 918,
    "source": "PDF_chunked"
  },
  {
    "id": 4640,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 640)",
    "text": "Numéro du spécimen de l'herbier Ghana : GC52343 Habitat et répartition géographique La plante préfère la lumière (sandy) et les sols bien drainés de milieu (loameux) ; préfère les sols acides, neutres et basiques (alcalins). Il ne peut pas croître dans l'ombre ; exige un sol humide, préférablement sur lits cultivées. Parties utilisées de la plante Feuille Autres parties utilisées Fleur Caractéristiques botaniques Sweet basil est composé des feuilles fraîches ou séchées de Ocimum basilicum L (Lamiaceae) Utilisations ethnomédicales Sweet basil a été utilisé pendant des milliers d'années comme herbe culinaire et médicinale. Il agit principalement sur les systèmes digestifs et nerveux, soulage les flatulences, les crampes d'estomac, les coliques et les indigestions. Les feuilles et les sommités fleuries sont antispasmodiques, aromati ques, carminatives, digestif, galactogogue, stomachique et tonique (Singh etal., 2011). Elle est prise en interne dans",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 960,
    "source": "PDF_chunked"
  },
  {
    "id": 4641,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 641)",
    "text": "OOAS Page 133 Ocimum basilicum WAHP le traitement de maladies fébriles (notamment rhume et grippe), de l'indigestion, des nausées et des crampes d'estomac, des gastro- entérites, des migraines, des insomnies, de la dépression et de la fatigue. En externe, il est utilisé pour traiter l'acné, la perte de l'odorat, les piqûres d'insectes, les morsures de serpents et les infections de la peau. Les feuilles peuvent être récoltées tout au long de la saison de croissance et utilisées fraîches ou séchées (Njorege, 2006). La graine mucilagineuse est considérée comme une perfusion dans le traitement de la gonococcie, de la dysenterie et de la diarrhée chronique. Il est reconnu pour élim iner le film et l'opacité des yeux. La racine est utilisée dans le traitement des affections intestinales chez les enfants. Les extraits de la plante sont bactéricides et antiparasitaires. En Inde, le basilic est utilisé pour les affections dentaires en",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4642,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 642)",
    "text": "traitement des affections intestinales chez les enfants. Les extraits de la plante sont bactéricides et antiparasitaires. En Inde, le basilic est utilisé pour les affections dentaires en raison de ses effets antimicrobiens proposés (Patel et venkatakrishna, 1988). L'huile essentielle est utilisée en aromathérapie. Activités biologiques et pharmacologiques Dans une étude de laboratoire, O. basilicum a montré une activité antibactérienne prometteuse contre le Salmonella spp., Escherichaicoli, Campylobacter jejunii et Clostridium perferingens (Wannissorn et al ., 2005). L'huile essentielle obtenue à partir des parties aériennes est également efficace contre les isolats cliniques multirésistants prélevésde Enterococcus, Staphylococcus et Pseudomonas (Opalchenova et al., 2003). Une étude par Niture et al., (2006) a montré que O. basilicum a un potentiel anticancéreux. Les extraits de la plante ont causé une augmentation des niveaux",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4643,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 643)",
    "text": "et al., 2003). Une étude par Niture et al., (2006) a montré que O. basilicum a un potentiel anticancéreux. Les extraits de la plante ont causé une augmentation des niveaux deméthylguanine-O-6-ADN-méthyltransférase (MGMT) ainsi qu'une augmentation de l'expression de glutathion S -transférase-pi-, quoique dans une moindre mesure que le MGMT. L'huile de basilic doux, a été reconnue 12,7 fois moins puissante que l'agent anticancéreux fluoro- uracile dans les lignées cellulaires de cancer (leucémie P388) (Manasroi et al., 2006). O. basilicum a montré des effets inhibiteurs contre le VIH -1 induite par la cytopathogenicité dans les cellules MT -4 (Yamasaki et al ., 1998). Les composants actifs dans l'ex trait des échantillons ont été reconnus pour êtredes substances polaires solubles dans l'eau. En outre, ces extraits aqueux inhibent la formation de cellules géantes en co- culture de cellules de la mue- 4 avec ou sans infection par",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4644,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 644)",
    "text": "pour êtredes substances polaires solubles dans l'eau. En outre, ces extraits aqueux inhibent la formation de cellules géantes en co- culture de cellules de la mue- 4 avec ou sans infection par le VIH -1 et ont montré une activité inhibitrice contre la transcriptase inverse du VIH -1. Dans une deuxième étude de laboratoire, Chiang et al. (2005) ont conclu que les extraits aqueux et éthanoliques bruts deO. basilicum et des composants tels que l'apigénine, le linalol et l'acide ursolique présentent une activité antivirale in vitro à large spectre. Cependant, aucune activité n'a été notée pour la carvone, cinéole, bêta-caryophyllène, farnésol, fenchone, géraniol, ß-myrcène ou α-thuyone. L'acide rosmarinique présent dans la plante inhibe les processus inflammatoires liés au complément (Renzuli et al., 2004) et, est également capable de réduire la production d'espèces radicalaires de l'oxygène, des protéines et l'inhibition de la synthèse ADN",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4645,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 645)",
    "text": "inflammatoires liés au complément (Renzuli et al., 2004) et, est également capable de réduire la production d'espèces radicalaires de l'oxygène, des protéines et l'inhibition de la synthèse ADN et de l'apoptose in vitro . L'effet répulsif de moustiques de la plante a également été rapporté (Erler et coll., 2006). Sur la based'une étude in vitro des spermatozoïdes humains, basilic est censé posséder des puissantes actions spermicides (Buch et coll., 1988). Données cliniques Dans une ét ude sur des patients atteints de bronchite chronique, l'exposition aux huiles essentielles de basilic a causé la réduction des taux plasmatiques de diéniques conjugués et de cétones et d'activation de la catalase dans les globules rouges caractéristiques des effets antioxydants (Siurin, 1997). O. basilicum a été étudié chez l'humain pour l'acné vulgaire, bien qu'un mécanisme d'action ne soit pas clarifié (Balambal et al., 2005). Constituants chimiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4646,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 646)",
    "text": "antioxydants (Siurin, 1997). O. basilicum a été étudié chez l'humain pour l'acné vulgaire, bien qu'un mécanisme d'action ne soit pas clarifié (Balambal et al., 2005). Constituants chimiques Huiles essentielles (linalol, epi -α-cadinol, α- bergamotene, γ-cadinène, eugénol, chavicol, linalol, anéthole, estragole, limonène, cuminaldehyde, contient des dérivés d'acides α- terpinéol et cinamic) (Abdulah et al., 2008; Politeo, 2007). Tests d'identité et de pureté Teneur en eau: pas plus de 9,9 Cendre totale:11.14 Valeur substances extractibles par l'eau : pas moins de 14,50 Valeur substances extractibles par l'éthanol (70 ): pas moins de 8,94 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie C CM avec phase stationnaire : gel de silice ( 0,25 mm) G60F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 915,
    "source": "PDF_chunked"
  },
  {
    "id": 4647,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 647)",
    "text": "stationnaire : gel de silice ( 0,25 mm) G60F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de cinq taches distinctes avec R f de 0,91 (Rose), 0,80 (gris), 0,73 (gris), 0,45 (Rose) et 0,20 (Rose).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 444,
    "source": "PDF_chunked"
  },
  {
    "id": 4648,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 648)",
    "text": "OOAS Page 134 Ocimum basilicum WAHP Chromatogramme Macroscopie Verdâtre à odeur aromatique et de saveur amère; feuilles simples, peu pétiolées; limbe de 3-5 cm de long sur 1,5 à 2 cm de large ; forme ovale à obovale ; la marge est faiblement dentée ; le sommet est acuminé, la base foliaire estcunéiforme et la nervation réticulée. La surface de la feuille est glabre, texture papier avec une nervure centrale déprimée. Microscopie Les bandes épidermiques ont révélé une topographie de la surface qui montre des parois anticlinales ondulées,des poils non glandulaires, unicellulaires et multicellula ires; de nombreuses gouttelettes d'huile; des stomates, principalement à la face inférieure paracytique, sclérites abondantes sur la face adaxiale ; une coupe transversale de la nervure a montré une légère dépression sur la face dorsale et une légère protu bérance sur la face ventrale avec des cellules, de forme ovoïde- globuleuse ; des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4649,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 649)",
    "text": "coupe transversale de la nervure a montré une légère dépression sur la face dorsale et une légère protu bérance sur la face ventrale avec des cellules, de forme ovoïde- globuleuse ; des faisceaux vasculaires montrent une légère forme concave avec un xylème de 2 ou 3 cellules. Matériel végétal en poudre Les cellules parenchymateuses ondulées de l'épiderme, poils tecteurs non glandulaires, , unicellulaires et pluricellulaires ; des stomates paracytiques, de nombreux sclérites, des vaisseaux du xylème. Actions thérapeutiques Antiasthmatique, anticonvulsivant, insectifuge, antibactérien, répulsif, antiflatulence. Indications thérapeutiques Catarrhe chronique, asthme, convulsions, coliques, indigestion. Données de sécurité L'extrait aqueux avait une DL 50 3000 mgkg (p.o.) chez les rats mâles. Aucun signe de toxicité aigue n'a été observé après administration d'une dose unique allant de 300 à 3000mgkg suivie par un monitoring de plus de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4650,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 650)",
    "text": "50 3000 mgkg (p.o.) chez les rats mâles. Aucun signe de toxicité aigue n'a été observé après administration d'une dose unique allant de 300 à 3000mgkg suivie par un monitoring de plus de 24h. Les changements du poids corporel des animaux traités étaient comparable à ceux des animaux témoins. Le profil hématologique était normal.Une élevation de l'AST aété o bservée mais pas pour l'ALT. ALP a montré une légère coissance à une dose 1000mgkg suggerant un eventuel effet secondaire de l'extrait aqueux sur le système hépatobiliaire. Il n'y avait aucune évidence de perturbation de la fonction rénale. Précautions d'emploi Une prudence devrait être observée chez les patients qui ont une hypoglycémie et une maladie du foie. L'huile de basilic contient de l'estragole, un agent potentiellement cancérogène et mutagène. Il ne doit pas être pris pendant la grossesse ou administré à des nourrissons et à des enfants Effets indésirables",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4651,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 651)",
    "text": "l'estragole, un agent potentiellement cancérogène et mutagène. Il ne doit pas être pris pendant la grossesse ou administré à des nourrissons et à des enfants Effets indésirables Hypoglycémie et insuffisance hépatique possible. Contre-indications Maladie de foie et grossesse.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 275,
    "source": "PDF_chunked"
  },
  {
    "id": 4652,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 652)",
    "text": "OOAS Page 135 Ocimum basilicum WAHP Dosage et forme galénique Décoction: 30 g du matériel végétal dans 900 ml d'eau; laisser m ijoter jusqu'à ce réduction à 600 ml; prendre 1 cuillerée à soupe deux fois par jour. Conservation A conserver dans un endroit frais et sec. Références Balambal, R., Thiruvengadam, K.V., Kameswarant, L., Janaki, V.R., Thambiah, A.S. (1985). Ocimum basili cum in acne vulgaris --a controlled comparison with a standard regime. Journal of Association of Physicians India 33(8):507-508. Buch, J.G., Dikshit, R.K., Mansuri, S.M. (1988). Effect of certain volatile oils on ejaculated human spermatozoa. Indian Journal of Medical Research 87(4):361-363. Manosroi, J., Dhumtanom, P., Manosroi, A. (2006). Anti -proliferative activity of essential oil extracted from Thai medicinal plants on KB and P388 cell lines. Cancer Letters 235(1):114-120. Niture, S.K., Rao, U.S., Srivenugopal, K.S. (2006). Chemopreventative strategies targeting",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 4653,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 653)",
    "text": "extracted from Thai medicinal plants on KB and P388 cell lines. Cancer Letters 235(1):114-120. Niture, S.K., Rao, U.S., Srivenugopal, K.S. (2006). Chemopreventative strategies targeting the MGMT repair protein: augmented expression in human lymphocytes and tumor cells by ethanolic and aqueous extracts of several Indian medicinal plants. International Journal of Oncology 29(5):1269-1278. Njorege, G.N., Bussman, R.W. (2006). Traditional management of ear, nose and thorat (ENT) diseases in central Kenya. Journal of Ethnobotany and Ethnomedicine 2(1): 54. Opalchenova, G., Obreshkova, D. (2003). Comparative studies on the acti vity of basil --an essential oil from Ocimum basilicum L. --against multidrug resistant clinical isolates of the genera Staphylococcus, Enterococcus and Pseudomonas by using different test methods. Journal of Microbiology Methods 54(1):105-110. Patel, V.K., Venkatakrishna- Bhatt, H. (1988).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 921,
    "source": "PDF_chunked"
  },
  {
    "id": 4654,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 654)",
    "text": "Staphylococcus, Enterococcus and Pseudomonas by using different test methods. Journal of Microbiology Methods 54(1):105-110. Patel, V.K., Venkatakrishna- Bhatt, H. (1988). Folklore therapeutic indigenous plants in periodontal disorders in India (review, experimental and clinical approach). Internationa Journal of Clinical Pharmacolo gy, Therapeutics and Toxicology 26(4):176-184. Politeo, O., Jukic, M. , Milos, M. (2007). Chemical composition and antioxidant capacity of free volatile aglycones from basil ( Ocimum basilicum L.) compared with its essential oil. Food Chemistry 101(1): 379385. Renzulli, C., Galvano, F., Pierdomenico, L., Speroni, E ., Guerra, M.C. (2004). Effects of rosmarinic acid against aflatoxin B1 and ochratoxin-A-induced cell damage in a human hepatoma cell line (Hep G2). Journal of Applied Toxicology 24(4):289-296. Singh, V., Kumar, V., Suvagiy, V. (2011). A review on ethnom edical uses of Ocimum",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4655,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 655)",
    "text": "hepatoma cell line (Hep G2). Journal of Applied Toxicology 24(4):289-296. Singh, V., Kumar, V., Suvagiy, V. (2011). A review on ethnom edical uses of Ocimum sanctum (Tulsi). International Research Journal of Pharmacy 2(10):1-3. Siurin, S.A. (1997). Effects of essential oil on lipid peroxidation and lipid metabolism in patients with chronic bronchitis. Klin Med (Mosk) 75(10):43-45. Wannissorn, B., Jarikasem, S., Siriwangcha i, T., Thubthimthed, S. (2005). Antibacterial properties of essential oils from Thai medicinal plants. Fitoterapia 76(2):233-236. Yamasaki, K., Nakano, M., Kawahata, T., Mori, H., Otake, T. et al . (1998). Anti -HIV-1 activity of herbs in Labiatae. Biological and Pharmaceutical Bulletin 21(8):829-833.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 729,
    "source": "PDF_chunked"
  },
  {
    "id": 4656,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 656)",
    "text": "OOAS Page 136 Ocimum gratissimum WAHP Nom botanique Ocimum gratissimum L. Famille Lamiaceae Synonymes Ocimum viride Willd, Ocimum guineense Schum et Thonn. Noms communs Thé rouge, plante de moustiques, f euille de fièvre, plante de fièvre de la Sierra Leone Noms vernaculaires Cote d'Ivoire : Anyi Samane, Baule Aloamagneree, Fulfulde Cunfere Ghana: Adangme Gbekona, Akan Onunum , Ga Sru Sulu Suru Guinée Bissau: Crioulo Doreda Guinée: Manding Maninka Su-Guen-Fira Nigéria: Edo Aramogho, Hausa Dai Dooyaata Gidaa, Igbo Ncho-Anwu Nchuagwunta, Yoruba-efinrin nla Sénégal: C rioulo Doreda, Fula Kunfere, Maninka Sukuru Baba, Susu' Barikiri Togo: Ewe Dzogbeti, Akaselem Ditsunonon Description de la plante La plante est un arbuste dressé qui pousse à une hauteur de 1,8 m ; les tiges sont presque glabres avec des feuilles qui ont plutôt un long pétiole, lancéolées à oblongues-lancéolées,ovale",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 890,
    "source": "PDF_chunked"
  },
  {
    "id": 4657,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 657)",
    "text": "La plante est un arbuste dressé qui pousse à une hauteur de 1,8 m ; les tiges sont presque glabres avec des feuilles qui ont plutôt un long pétiole, lancéolées à oblongues-lancéolées,ovale ou obovale, base cunéiforme ou asymétrique, sommet cunéiforme ou acuminé, marge dentelée, dentées ou faiblement dentelées, jusqu'à 12 cm de long, 4 cm de large ; les fleurs sont de couleur blanc -crème ou jaunâtres, pédicelle puberuleux, calice à deux lèvres, lèvres inférieures ovales, lèvres supérieures oblongues à deux dents; survenant en racèmes paniculées habituellement de 15 cm de long, de couleur verte au stade de bourgeon mais devenant brunes quand sèches (Trease et Evans, 1972). Numéro du spécimen de l'herbier Ghana : GC52056 Nigeria : FHI 107436 Togo : TOGO04218 Habitat et répartition géographique Il est largement répandu dans les régions tropicales, y compris en Afrique et se trouvent principalement dans les jardins, les vieilles",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4658,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 658)",
    "text": "Togo : TOGO04218 Habitat et répartition géographique Il est largement répandu dans les régions tropicales, y compris en Afrique et se trouvent principalement dans les jardins, les vieilles fermes près des villages. Il est également cultivé dans différentes régions d'Afrique de l'Ouest. On le trouve dans beaucoup de régions du Nigéria, au nord et au sud. Parties utilisées de la plante Feuille Autres parties utilisées Fleur Caractéristiques botaniques L'herbe à thé se compose des feuilles fraîches ou séchées de Ocimum gratissimum L. (Lamiaceae) Utilisations ethnomedicales O. gratissimum est réputé dans la médecine traditionnelle africaine pour son utilisation dans le traitement des voies respiratoires supérieures (toux, pneumonie, etc.) et des troubles digestifs (diarrhée, dysenterie, etc.), des pathologies de la peau, fièvre, maux de tête et conjonctivite (Onajobi, 1986 ; Oliver -Bever, 1960). Il est utilisé comme un anticonvulsivant et un agent",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4659,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 659)",
    "text": "(diarrhée, dysenterie, etc.), des pathologies de la peau, fièvre, maux de tête et conjonctivite (Onajobi, 1986 ; Oliver -Bever, 1960). Il est utilisé comme un anticonvulsivant et un agent antibactérien dans le traitement du paludisme et de la variole (Irvine, 1961). Les feuilles sont utilisées pour traiter les saignements du nez et de l'étourdissement. Elles sont croquées ou bouillies avec du sel et utilisées comme fébrifuge et diaphorétique. Le liquide obtenu en frottant la feuille avec un peu d'eau est utilisé comme goutte ophtalmique pour les affections ophtalmiques comme la conjonctivite. L'infusé de feuille est mélangé avec du poivre pour traiter la dysenterie (Dalziel, 1936). L'huile de feuilles est utilisée pour prévenir les piqûres de m oustiques et comme un répulsif pour les autres insectes. Les feuilles sont également utilisées pour traiter la constipation, la ménorragie et les coliques abdominales. La plante entière est utilisée pour",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4660,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 660)",
    "text": "et comme un répulsif pour les autres insectes. Les feuilles sont également utilisées pour traiter la constipation, la ménorragie et les coliques abdominales. La plante entière est utilisée pour les rhumatismes et la racine, pour les mosures de serpent (Adjanohoun et coll., 1991).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 280,
    "source": "PDF_chunked"
  },
  {
    "id": 4661,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 661)",
    "text": "OOAS Page 137 Ocimum gratissimum WAHP Activités biologiques et pharmacologiques Nakamura et al. (1999) ont montré que l'huile essentielle et les extraits purifiés de la plante ont une activité antibactérienne in vitro ; l'effet antimicrobien a été attribuée à l'eugénol aux monoterpenoides et au thymol contenus dans les huiles volatiles (Oliver -Bever, 1960 ; Sainsbury et Sofowora, 1971). L'huile essentielle présentait, en fonction de la dose, une activité antimicrobienne significative contre Staphylococcus aur eus, Shigella flexineri, Salmonella enteritidis , Escherichia coli , Klebsiella spp et Proteus mirabilis (Nakamura et al., 1999). Le composé responsable de l'activité antimicrobienne a été identifié comme l'eugénol (Nakamura et al ., 1999). Dans une étude connexe, Bitsindou et Ouamba (1997) ont constaté que l'huile volatile de O. gratissimum avait une activité plus élevée que l'huile volatile de Ocimum bacilicum et qu'elle était plus",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 4662,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 662)",
    "text": "connexe, Bitsindou et Ouamba (1997) ont constaté que l'huile volatile de O. gratissimum avait une activité plus élevée que l'huile volatile de Ocimum bacilicum et qu'elle était plus puissante que les agents antimicrobiens de référence (tétracycline, oxacillin e, clotrimazole, céfotaxime, mécillinam, clinamycine, clotrimazole, kétoconazole et nystatine) contre S. aureus, Stretococcus faecalis , E.coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus vulgaris, Aspergillus fumigatus , Trichophyton mentagrophytes etCandida albicans . L'huile inhibe 80 des souches dermatophite testées (Lima et al., 1993) et a également montré une activité contre Trichophyton rubrum et Trichophyton mentagrophytes . Des effets antibactériens remarquables, supérieurs à ceux des produits antiseptiques commerciaux utilisés comme témoins positifs, ont été démontrés à 2 . Les extraits foliaires ont montré des effets antiviraux (anti -VIH-1) prometteurs (Ayisi et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4663,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 663)",
    "text": "des produits antiseptiques commerciaux utilisés comme témoins positifs, ont été démontrés à 2 . Les extraits foliaires ont montré des effets antiviraux (anti -VIH-1) prometteurs (Ayisi et Nyadedzor, 2003). Des extraits d' O. gratissimum ont également montré des eff ets antihelminthiques prometteurs de par leur capacité d'inhiber les glutathions S-transférases des nématodes parasitiques (Fakae et al ., 2000). L'huile essentielle réversible et en fonction de la concentration a montré des effets relaxants sur le muscle li sse intestinal (Madère et al ., 2002). Les extraits méthanoliques de feuilles ont démontré un effet hypoglycémique significatif in vivo (Aguiy et al., 2000), tandis que des extraits aqueux et méthanoliques des feuilles ont permis la coagulation du sang (Edemeka et Ogwu, 2000). L'huile de Ocimum était plus efficace dans les bases hydrophiles que dans des bases lipophiles dans certains onguents (Orafidiya et al., 2001). Desfractions aqueuses et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 971,
    "source": "PDF_chunked"
  },
  {
    "id": 4664,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 664)",
    "text": "2000). L'huile de Ocimum était plus efficace dans les bases hydrophiles que dans des bases lipophiles dans certains onguents (Orafidiya et al., 2001). Desfractions aqueuses et butanoliques del'extrait brut de feuille ont induit l'anticoagulation du sang à 10- 12 mgml (Elujoba et al., 2001). Une étudedu décocté de feuilles contre des espèces multirésistantes Shigellaisolées de patients, atteints de dysenterie bacillaire, a inhibé les isolats à 3000 mgml (Iwalokun et al., 2001 ; Ilori et al., 1996). Données cliniques Aucune information disponible Constituants chimiques Huile volatile (ex : thymol, eugénol, alpha et βpinène, camphène, terpinène, limonène et méthyle eugénol, camphre, caryophylline); triterpènes; sucres réducteurs (GHP, 1992; Onajobi, 1986; Sainsbury et Sofowora, 1971; Sofowora, 1970 ; El Said et al., 1969). Tests d'identité et de pureté Teneur en eau: poudre, lorsque séchés à 105C ne perd pas plus de 50 ;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4665,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 665)",
    "text": "Onajobi, 1986; Sainsbury et Sofowora, 1971; Sofowora, 1970 ; El Said et al., 1969). Tests d'identité et de pureté Teneur en eau: poudre, lorsque séchés à 105C ne perd pas plus de 50 ; 45 lorsque séchés à l'air libre Cendre totale : 15,5 Cendre insoluble dans l'acide : 3,4 Cendre soluble dans l'eau : 4,0 Valeur subtances extractibles par l'eau : pas moins de 15,0 Valeur sustances extractibles par l'éthanol (70 ): pas moins de 10,0 Ratio palissadique: 4,25-5.89-7,5 Index de stomates: 12,5-28,7 (surface supérieure); 18.2-28.5 (surface inférieure) Nombre de stomates: 100-184-300 (face supérieure) ; 300-317-400 (face inférieure) Nombre de veine-îlots: 3,5-4,0 Nombre deveinule de terminaison: 10.0-14,5 (Elujoba et Olawode, 2004) Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4666,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 666)",
    "text": "Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 316,
    "source": "PDF_chunked"
  },
  {
    "id": 4667,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 667)",
    "text": "OOAS Page 138 Ocimum gratissimum WAHP (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100 -110C pendant 5-10 mn. Présence de quatre taches distinctes avec Rf de 0,76 (Rose), 0,65 (violet) et 021 (violet). Chromatogramme Macroscopie Les feuilles sont simples, disposées de manière decussée; longuememt pétiolées, lancéolées, oblongues-lancéolées ou ovales à obovées; sommet aigu ou acuminé ou aigu aux deux extrémités; base cunéiforme ou asymétrique; nervure centrale saillante sur la surface dorsale; nervation réticulée relativement glabre, à marge dentée ou faiblement dentée peuvantaller jusqu'à 12 cm de long sur6 cm de large, nettement glandulaires -ponctuées en dessous ; elles ont des racèmes ressemblant à des épis, strictes et solitaires à plusieurs dans une panicule allant jusqu'à 15 cm de long; odeur ressemblant à celle du thym, aromatique, piquante mais caractéristique; goût âcre,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4668,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 668)",
    "text": "strictes et solitaires à plusieurs dans une panicule allant jusqu'à 15 cm de long; odeur ressemblant à celle du thym, aromatique, piquante mais caractéristique; goût âcre, aromatique, épicée ou mentholée, couleur verte (Ekejiuba, 1984). Microscopie Coupe transversale dorsiventrale, couche palissadique unique; le mésophylle rempli d'amidon, jouxte le collenchyme dans la région de la nervure médiane. La nervure et la structure bifaciale transversale, les masses sub- épidermiques caractéristiques du collenchyme sont surr les deux surfaces; le mésophylle lacuneux contient des gouttelettes d'huile, un faisceau vasculairebicollatéral, entouré de fibres péricycliques lignifiées; les stomatesdiacytiquessont sur les deux surfaces, plus fréquentes sur l'épiderme inférieur; la glande de la surface est parsemée (ponctuée); les poils sont nombreux chezles jeunes feuilles; ils sont pluricellulaires , non globuleuses, coniques et abondants sur la nervure médiane et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 964,
    "source": "PDF_chunked"
  },
  {
    "id": 4669,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 669)",
    "text": "glande de la surface est parsemée (ponctuée); les poils sont nombreux chezles jeunes feuilles; ils sont pluricellulaires , non globuleuses, coniques et abondants sur la nervure médiane et les nervures latérales, ils sont , pluricellulaires unisériés situés sur les veines et veinules surla face inférieure; 3 à 8 cellules longues, légèrement courbées à parois fines, glanduleuses d'environ 243- 521 μ de long avec des poils identiques se trouvent sur la tige (Ekejiuba, 1984). Matériel végétal en poudre Des fonctionnalités d'identification comprennent les parois de cellules épidermiques ondulées; des éléments lignifiées de veines et de veinules; des grains d'amidon ; des gouttelettes d'huile; des poilspluricellulaires non globulaires, unisériés, verruqueux, et relativement courbés; certains sontmunis de cellules affaissées de petits groupes de cellules parenchymateuses épidermiques fragmentées,de tissu de collenchyme etde stomates diacytiques;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4670,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 670)",
    "text": "certains sontmunis de cellules affaissées de petits groupes de cellules parenchymateuses épidermiques fragmentées,de tissu de collenchyme etde stomates diacytiques; présence d'éléments de vaisseauxdexylème fragmentés et de gouttelettes d'huile de couleur verte avec un goût aromatique, épicé. Actions thérapeutiques Antibactérien, antiseptique, antispasmodique (huile essentielle), antitussif, diaphorétique, fébrifuge, laxatif, ophtalmique, stomachique. Indications thérapeutiques Diarrhée, coliques, infections bactériennes, catarrhe, conjonctivite, dysenterie, fièvre, maux de tête, rhumatismes, sinusite, m aladies de la peau, troubles des voies respiratoires supérieures (toux, pneumonie, etc.) et vomissement (GHP, 1992 ; Onajobi, 1986). Données de sécurité Les études animales chez les rats mâles ont montré que la DL 50 de l'extrait aqueux (p.o) est 3000 mgkg. Aucun signe de toxicité n'a été observé dans le traitement des animaux après",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4671,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 671)",
    "text": "Les études animales chez les rats mâles ont montré que la DL 50 de l'extrait aqueux (p.o) est 3000 mgkg. Aucun signe de toxicité n'a été observé dans le traitement des animaux après une dose unique (300- 3000 mgkg), suivie de surveillance, sur une période de 24 heures. Les modifications du poids corporel étaient comparables à celles des animaux traités à l'excipient. Le profil hématologique était normal. Une élévation de l'AST a été observée mais pas celle de l'ALT. L'ALP a également montré une légère augmentation, à des doses 1 000 mgkg, ce qui suggère que l'extrait aqueux a un effet néfaste sur le sy stème hépatobiliaire. Aucune preuve de perturbation de la fonction rénale n'a été observée. Précautions d'emploi Une prudence devrait être observée chez les patients qui ont une hypoglycémie et une maladie du foie. Ne doit pas être utilisé dans la constipation chronique; son utilisation en cas de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 907,
    "source": "PDF_chunked"
  },
  {
    "id": 4672,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 672)",
    "text": "OOAS Page 139 Ocimum gratissimum WAHP saignement doit être médicalement supervisée; une surdose ou une utilisation prolongée peut entraîner une constipation chronique et une inertie colique. Sa prise peut de même irriter les muqueuses lorsque utilisé à l'extérieur et à fortes doses; la grossesse et l'allaitement. Effets indésirables Possible dysfonctionnement hépatique et hypoglycémie. Contre-indications Maladie du foie. Dosage et forme galénique Décoction: 30 g feuilles dans 900 ml d'eau; laisser e n ébullition jusqu'à réduction de l'eau à 600 ml; prendre 1 tasse trois fois par jour Infusion: 30 g d'herbe séché dans 600 ml d'eau; 1 tasse à thé trois fois par jour. Teinture: 1:5 à 50 d'éthanol de 5 ml trois fois par jour. Huiles essentielles: 2-3 gouttes trois fois par jour. Conservation Il doit être conservé dans des récipients bien fermés, dans un endroit frais, sec et sombre, loin de la lumière et de l'humidité. Références",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4673,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 673)",
    "text": "Conservation Il doit être conservé dans des récipients bien fermés, dans un endroit frais, sec et sombre, loin de la lumière et de l'humidité. Références Adjanohoun, E. et al., (1991). Contribution to Ethnobotanical and Florist ic studies in Western Nigeria Lagos, Nigeria: The Organization of African Unity's Scientific Technical and Research Commission, pp293-294. Aguiy,i J.C., Obi, C.I., Gang, S.S., Igweh A.C. (2000). Hypoglycaemic activity of Ocimum gratissimum in rats. Fitoterapia 71(4):444-446. Ayisi, N.K., Nyadedzor, C. (2003). Comparative in vitro effects of AZT and extracts of Ocimum gratissimum, Ficus polita , Clausena anisata, Alchornea cordifolia, and Elaeophorbia drupifera against HIV -1 and HIV -2 infections. Antivira l Research 58(1):25-33. Dalziel, J.M. (1936). The Useful Plants of West Tropical Africa London: Crown Agents for the Overseas Governments and Administrations. Edemeka, D.B.U., Ogwu, A.S. (2000). Blood",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4674,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 674)",
    "text": "Dalziel, J.M. (1936). The Useful Plants of West Tropical Africa London: Crown Agents for the Overseas Governments and Administrations. Edemeka, D.B.U., Ogwu, A.S. (2000). Blood Coagulation Activities of the Leaf Extracts of Ocimum gratissimum Plant in Man. Journal of Herbs, Spices and Medicinal Plants 7(4):914. Ekejiuba, E.C. (1984). Establishment of some Pharmacopoeial Standards for Selected Nigerian Medicinal Plants. M.Phil. (Pharmacognosy) Thesis, University of Ife, Ile-Ife, Nigeria. El- Said, F., Sofowora, E. A., Malcom, S.A, Hofer, A. (1969). An investigation into the efficacy of Ocimum gratissimum as used in Nigerian native medicine. Planta Medica 17(2):195-200. Elujoba A.A, Olawode, E.O. (2004). Technical Report of the C ommissioned Chromatographic fingerprint analysis on Ocimum gratissimum Leaf. Submitted to the World Health Organization, Nigeria. Elujoba A. A., Durosinmi M.A., Oyedeji A.O., Oduola, T. (2001). Studies on the possible",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4675,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 675)",
    "text": "fingerprint analysis on Ocimum gratissimum Leaf. Submitted to the World Health Organization, Nigeria. Elujoba A. A., Durosinmi M.A., Oyedeji A.O., Oduola, T. (2001). Studies on the possible coagulant properties of Ocimum grati ssimum. Nigerian Journal of Health Sciences 1(1):14-17. Elujoba, A.A., Oladele, A.T. (2006). Technical Report of the Commissioned Herbarium Sample Preparation for Ocimum gratissimum Leaf. Submitted to the World Health Organisation, Nigeria. Fakae, B.B., Campbell, A.M., Barrett, J., Scott, I.M. et al., (2000). Inhibition of glutathione S - transferases (GSTs) from parasitic nematodes by extracts from traditional Nigerian medicinal plants. Phytotherapy Research 14(8):630-634. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana. Iwalokun, B.A., Gbenle, G.O., Adewole, T.A., Akinsinde, K.A. (2001). Shigellocidal properties of Three Nigerian Medicinal Plants: O. gratissimum, Terminalia avicennoides and",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4676,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 676)",
    "text": "Iwalokun, B.A., Gbenle, G.O., Adewole, T.A., Akinsinde, K.A. (2001). Shigellocidal properties of Three Nigerian Medicinal Plants: O. gratissimum, Terminalia avicennoides and Mormodica balsamina . Journal of Health Population and Nutrition, 19(4):331-335. Ilori, M., Sheteolu, A.O., Omonibgehin, E.A., Adeneye, A.A. (1996). Antidiarrhoeal activities of O. gratissimum (Lamiaceae). Journal of Diarrhoeal Disentery Research 14:283-285. Irvine, F.R. (1961). Woody Plants of Ghana with Special Reference to their Uses London: Oxford University Press, pp 40-520. Lima, E.O., Gompertz, O.F., Giesbrecht, A.M., Paulo, M.Q. (1993). In vitro antifungal activity of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 654,
    "source": "PDF_chunked"
  },
  {
    "id": 4677,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 677)",
    "text": "OOAS Page 140 Ocimum gratissimum WAHP essential oils obtained from officinal plants against dermatophytes. Mycoses 36:333-336. Madeira, S.V., Matos, F.J., Leal -Cardoso, J.H., Criddle, D.N. (2002). Relaxant effects of the essential oil of Ocimum gratissimum on isolated ileum of the guinea pig. Journal of Ethnopharmacology 81(1):1-4. Nakamura, C.V., Ueda-Nakamura, T., Bando, E., Melo, A.F.N., et al., (1999). Antibacterial activity of Ocimum gratissimum essential oil. Mem Inst Oswaldo Cruz, Rio de Janeiro, 94(5); 675-678. Ndounga, M., Ouamba, J.M. (1997). Antibacterial and antifungal activities of essential oils of O . gratissimum and O. bacilicum from Congo. Fitoterapia 68(2):190-191. Oliver-Bever, B. (1960). Medicinal Plants in Nigeria. Lectures delivered in 1959 in the Pharmacy Department of the Nigerian College of Arts, Science and Technology. Nigerian College of Art and Technology, Nigeria. Onajobi, F.D. (1986). Smooth muscle contracting",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4678,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 678)",
    "text": "Pharmacy Department of the Nigerian College of Arts, Science and Technology. Nigerian College of Art and Technology, Nigeria. Onajobi, F.D. (1986). Smooth muscle contracting lipid-soluble principles in chromatographic fractions of Ocimum gratissimum. Journal of Ethnopharmacology,18:3-11. Orafidiya, O.L., Oyedele, A.O., Shi ttu, A.O., Elujoba, A.A. (2001). The formulation of an effective topical antibacterial product containing Ocimum gratissimum leaf essential oil. International Journal of Pharmaceutics 224:177- 183. Sainsbury, M., Sofowora, E.A. (1971). Essential oil from the leaves and inflorescence of Ocimum gratissimum. Phytochemistry 10:3309. Sofowora, E.A. (1970). A study of the variations in essential oils of cultivated Ocimum gratissimum. Planta Medica 18(2):173. Trease, G.E., Evans, W.C. (1972). Pharmacognosy 13th edition, London: Bailliere Tindall. WHO publication (1998). Quality Control",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 910,
    "source": "PDF_chunked"
  },
  {
    "id": 4679,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 679)",
    "text": "gratissimum. Planta Medica 18(2):173. Trease, G.E., Evans, W.C. (1972). Pharmacognosy 13th edition, London: Bailliere Tindall. WHO publication (1998). Quality Control Methods for Plant Materials. Geneva: The World Health Organization (WHO), pp 34-37. .",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 252,
    "source": "PDF_chunked"
  },
  {
    "id": 4680,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 680)",
    "text": "OOAS Page 141 Phyllanthus niruri WAHP Nom botanique Phyllanthus niruri var genuinus Mull Arg Famille Euphorbiaceae Synonymes Phyllanthus carolinianus Blanco; P. asperulatus Hutch; Phyllanthus filiformis Parmex Baillon; Nymphanthus niruri Lour; Diasperus niruri (L) Kuntze. Sous -espèce Phyllanthus fraternus togoensis BruneI Roux Noms communs Casseur de pierre, graines -porte-moi, séné créole, séné de canne de pois, mauvaise herbe à quinine, mauvaise herbe d'ouragan, mauvaise herbe du vent de gale. Noms vernaculaires Burkina Faso : Mooré Tinguin garga, Fulfuldé Lébèl Cote d 'Ivoire: Baules Ugniassi, Kru Guere Tienwe, Kulango Lumbodiataka. Ghana: Twi Bowomma guwakyi, Ga Dangme Mbatoatshi, Nzema Nwamenle Guinée Bissau: Fula Pulaar Bubunguel Guinée: Kissi Fundelo Un'do, Koranko Kode, Toma Sakade Nigéria: Edo Orosorsor, Igbo Ososo, Igbo (Ibuzo) Awueli Sierra Leone: Mende Eroboe",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 884,
    "source": "PDF_chunked"
  },
  {
    "id": 4681,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 681)",
    "text": "Guinée: Kissi Fundelo Un'do, Koranko Kode, Toma Sakade Nigéria: Edo Orosorsor, Igbo Ososo, Igbo (Ibuzo) Awueli Sierra Leone: Mende Eroboe Description de la plante C'est une planteannuelle glabre de 30- 50 cm de haut avec une tige rainurée; légèrement ailée; avec des feuilles simples, alternes et distiques, elliptiques-oblongues, arrondies aux deux extrémités; de 6- 14 mm de long sur 25- 5,5 mm de large; de couleur vert -pâle avec fleurs unisexuées, solitaires avec six sépales; les fleurs mâles sont aux aisselles inférieures et les femelles dans les aisselles supérieures avec des disques profondément dentelés et de styles très courts ; les capsules de fruits sont d'environ 2 mm de diamètre. Numéro du spécimen de l'herbier Togo : TOGO03567 Habitat et répartition géographique La plante se produit souvent dans les jardins, les décharges d'ordures et sur les routes. Parties utilisées de la plante Feuille Autres parties utilisées",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4682,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 682)",
    "text": "La plante se produit souvent dans les jardins, les décharges d'ordures et sur les routes. Parties utilisées de la plante Feuille Autres parties utilisées Parties aériennes Caractèristiques botaniques Phyllanthus est constitué de feuilles de Phyllanthus nirurivar genuinus Mull Arg (Euphorbiaceae). Utilisations ethnomédicales Son nom espagnol chanca piedra, qui signifie \"briseur de pierre\" ou \"Eclat de pierre\", décrit son utilisation populaire entre les amazoniens pour éliminer les calculs biliaires et rénaux. Il est également utilisé contre l'hépatite, le rhume, la grippe, la fièvre, la tuberculose, le paludisme, le diabète, l'hypertension et les patholgies du foie, entre autres. En Asie, dans les régions méditerranéennes et dans la plupart des régions d'Afrique, la plante est bouillie et consommée comme du thé. L'infusé des parties aériennes séchées, administré par voie orale est utilisé comme diurétique, antipyrétique et antipaludique",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4683,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 683)",
    "text": "d'Afrique, la plante est bouillie et consommée comme du thé. L'infusé des parties aériennes séchées, administré par voie orale est utilisé comme diurétique, antipyrétique et antipaludique (Weninger et al ., 1986 ; Kitisin, 1952). L'infusé de la plante entière fraîche est également administré par voie orale pour traiter la gonorrhée et autres troubles génito- urinaires (Sahu, 1984 ; Khan et al., 1978). Un décocté de la plante séchée est utilisécontre la toux chez les nouveau-nés (Velazco, 1980) et la racine fraîche est un remède contre la jaunisse. L'extrait aqueux des feuilles et des racines est pris par voie orale contre le diabète et comme diurétique. L'infusé de jeunes pousses est administréen cas de dysenterie, tandis que les feuilles sont couramment utilisées pour traiter la fièvre. Il peut également être utilisé pour augmenter l'appétit, soulager les inflammations et comme un remède de l'anorexie (Asprey et Thornton, 1955). En",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4684,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 684)",
    "text": "couramment utilisées pour traiter la fièvre. Il peut également être utilisé pour augmenter l'appétit, soulager les inflammations et comme un remède de l'anorexie (Asprey et Thornton, 1955). En Inde, le fruit est utilisé à l'extérieur contre la teigne, la gale et les ulcères tuberculeux.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 287,
    "source": "PDF_chunked"
  },
  {
    "id": 4685,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 685)",
    "text": "OOAS Page 142 Phyllanthus niruri WAHP L'infusé de la plante séchée est administré par voie orale contre le diabète et l'asthme en médecine ayurvédique (Sircar, 1984; Chauhan et al., 1977; Jain et Sharma, 1967). Dans les îles Fidji, la plante entière en poudre séchée, mélangée avec du beurre est administrée par voie orale contre la jaunisse. Le jus de feuilles fraîches est utilisé à l'extérieur pour les coupures et contusions, mais pour les maladies de l'œil, le jus est mélangé à l'huile de ricin et appliqué à l'œil. L'infusé de la racine verte est prise par voie orale pour traiter les menstruations lourdes (Singh, 1986). Activités biologiques et pharmacologiques Phyllanthus niruri a été l'objet de recherches phytochimiques approfondiespendant plus de quatre décennies. Des études animales et humaines à l'aide d'un infusé simple ont montré la capacité de la plante à promouvoir l'élimination des calculs rénaux (Santos, 1990). Un extrait de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4686,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 686)",
    "text": "quatre décennies. Des études animales et humaines à l'aide d'un infusé simple ont montré la capacité de la plante à promouvoir l'élimination des calculs rénaux (Santos, 1990). Un extrait de la plante a montré un puissant effet inhibiteur sur laformation in vitro de l'oxalate de calcium (Campos et al ., 1999) ; il a également inhibé la croissance des calculs matriciels dans des vessies de rats ensemencés avec du calcium et des satellites réduits en comparaison avec les rats témoins (Freitas et al ., 2002). La plante a été également reconnuecomme un stimulant de la sécrétion d'acides biliaires et pour sa capacité à réduire les taux de cholestérol sanguin (Khanna, et al., 2002). Les extraits hydroalcooliques de la plante ont montré des effets analgésiques chez les souris (Santos, et al., 1995) et dans d'autres modèles de douleur neurogène testés (Santos et al ., 2000). Le geraniin contenu dans la plante est sept fois plus puissant comme analgésique que l'aspirine ou",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 977,
    "source": "PDF_chunked"
  },
  {
    "id": 4687,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 687)",
    "text": "al., 1995) et dans d'autres modèles de douleur neurogène testés (Santos et al ., 2000). Le geraniin contenu dans la plante est sept fois plus puissant comme analgésique que l'aspirine ou l'acétaminophène (Miguel et al., 1996); ses effets antiulcérogènes et gastroprotecteurs ont également été démontrés(Hung et al., 1995). Des fractions d'extrait de P. fraternus contenant de l'alkamide ont montré une activité antiplasmodiale in vitro modérée (Sittie et al., 1998) tandis que la fraction méthanolique a des propriétés hépatoprotectrices avérées(Ahmed et al., 2002). Deux autres études in vivo ont également signalé l'activité hypoglycémiantede la plante (Hukeri et al ., 1986; Ramakishnan et al., 1982). L'extrait aqueux de P. niruri augmente la durée de vie des souris atteint de cancer du foie (Rajeshkumar et al ., 2000) et,a montré une activité inhibitrice de la trans criptase inverse du VIH-1 (Ogata et coll., 1992). Données cliniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4688,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 688)",
    "text": "foie (Rajeshkumar et al ., 2000) et,a montré une activité inhibitrice de la trans criptase inverse du VIH-1 (Ogata et coll., 1992). Données cliniques L'administration d'extraits de P. niruri à des enfants atteints d'hépatite aiguë a restauré la fonction hépatique dans les cinq jours (Thabrew et coll., 1996) et l'ingestion d'herbe en pou dre par les adultes atteints d'une hépatite chronique a montré des effets antihepatotoxiques (Wang et al., 1994). Les capsules de poudre foliaire ont causée significativement la réduction de la pression systolique sanguine, l'augmentation du volume d'urine et l'excrétion d'urine et du sodium sérique ainsi qu'une réduction des taux de glucose sanguin (Srividya et al ., 1995) dans un test sur des humains. Constituants chimiques Alcaloïdes (sécurinine et alcaloïdes apparentés), lignanes (ex: phyllanthin et hyp ophyllanthin), tanins, flavonoïdes (quercétine, rutine),salicylate de méthyle, acide carboxylique, saponines.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 4689,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 689)",
    "text": "lignanes (ex: phyllanthin et hyp ophyllanthin), tanins, flavonoïdes (quercétine, rutine),salicylate de méthyle, acide carboxylique, saponines. Tests d'identité et de pureté Teneur en eau: pas plus de 7.3 Cendre totale: 12.3 Valeur substances extractibles par l'eau :not less than 19.0 Valeur substances extractibles par l'éthanol (70): pas mois de 15.4 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 777,
    "source": "PDF_chunked"
  },
  {
    "id": 4690,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 690)",
    "text": "OOAS Page 143 Phyllanthus niruri WAHP Chromatogramme Macroscopie Plante herbacée à tige cylindrique; feuilles simples stipulées; alternes; rouge affleurant ou pourpre à la base de la branche; feuilles Microscopie La vue d'ensembe montre des parois de cellules épidermiques ondulées, anticlinales, papill euses, glanduleuses; anisocytiques (surface supérieure), une face inférieure paracytiques et des stomates anisocytiques (surface inférieure); une rangée de rosette de cristaux à chaque côté de la nervure médiane,; des poils accrochés sur les marges de la f euille; la coupe transversale montre une disposition dorsoventrale ; un épiderme inférieur notammentpapilleux; lapallissade d'une cellule épaisse. Plus de la moitié de l'épaisseur du limbe est discontinue dans la région de la nervure médiane; la région de la nervure centrale est occupée par un parenchyme cuboïde avec des mâcles de cristaux dans les cellules inférieures; un faisceau",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4691,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 691)",
    "text": "dans la région de la nervure médiane; la région de la nervure centrale est occupée par un parenchyme cuboïde avec des mâcles de cristaux dans les cellules inférieures; un faisceau vasculaire collatéral, des vaisseaux de xylème lignifiés et des grains d'amidon dans le mésophylle. Matériel végétal en poudre Couleur verte; odeur caractéristique; goût amer, astringent; fragments de limbe avec des mâcles de cristaux, des fibres et des vaisseaux; grains de pollen ovoïdes avec une exine lisse; des grains d'amidon. Actions thérapeutiques Antilithique, antiviral, antiprotozoaire, hypoglycémique, analgésique, anti - inflammatoire, antimutagène, antispasmodique, antibactérien, carminatif, cholérétique, diurétique, fébrifuge, hypotenseur, laxatif, stomachique, tonique, vermifuge, digestif, antihepatotoxique (Ahmed et a l., 2002; Sittie et al., 1998; GHP, 1992). Indications thérapeutiques Diabète; problème hépatique causé par l'alcool;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4692,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 692)",
    "text": "stomachique, tonique, vermifuge, digestif, antihepatotoxique (Ahmed et a l., 2002; Sittie et al., 1998; GHP, 1992). Indications thérapeutiques Diabète; problème hépatique causé par l'alcool; ictère, paludisme; calculs rénaux; calculs biliaires; hypertension artérielle; cancer du foie; hépatite; anémie ; taux de cholestérol élev é; ulcère ; dysenterie ; coliques ; vaginite ; tumeurs ; grippe ; cystite ; prostatite ; maladies vénériennes ; infections des voies urinaires; accident vasculaire cérébral; douleurs abdominales; diarrhée; dystocie; soins prénataux; hyperglycémie; septicém ie; piqûres de serpent; infection virale (Mshana et al., 2000; GHP, 1992). Données de sécurité Des études chez l'animal ont montré que la DL 50 de l'extrait aqueux de feuilles ( p.o) chez des rats femelles a été 3000 mgkg. Les études de toxicité aiguë (3 00-3000 mgkg, administration d'une dose de 24 heures et répétée pendant 14 jours) ne montrent pas de signes cliniques de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 962,
    "source": "PDF_chunked"
  },
  {
    "id": 4693,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 693)",
    "text": "femelles a été 3000 mgkg. Les études de toxicité aiguë (3 00-3000 mgkg, administration d'une dose de 24 heures et répétée pendant 14 jours) ne montrent pas de signes cliniques de toxicité. Les changements du poids corporel et celui relatif d'organes d'animaux traités n'étaient pas significativement différents de ceux des rats témoins. Il n'y a pas d'effets négatifs sur le sang et les cellules du sang, le foie ou les reins. Précautions d'emploi Les niveaux de sucre et la pression sanguine sont à surveiller en cas de traitement à long terme. Effets indésirables Retirer immédiatement le médicament, le cas échéant, en cas d'hypotension ;abortif à fortes doses. Effets antifertilité réversibles in vivo (Rao et Alice, 2001). Contre-indications Susceptible de potentialiser l'insuline et les antidiabétiques, probablement en raison de la geraniin (Ueno et al., 1988).Troubles cardiaques etou de médicaments pour le coeur, hypoglycémie, hypotension.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4694,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 694)",
    "text": "antidiabétiques, probablement en raison de la geraniin (Ueno et al., 1988).Troubles cardiaques etou de médicaments pour le coeur, hypoglycémie, hypotension. Dosage et forme galénique Décoction ; perfusion ; teinture ; extrait liquide Décoction: 30 g de feuilles vertes séchées dans 900 ml d'eau; laisser bouillir jusqu'à réduction de la quantité d'eau à 600 ml ; prendre 1- 3 tasses par jour Infusion : 30 g de feuilles sèche dans 600 ml d'eau; prendre 1-3 tasses par jour Teinture-1:5 à 50 d'éthanol, de 5 ml trois fois par jour Extraits fluidesextraits-eau-glycérine: 1:1 à 50 d'alcool; 2-6ml, 2 ou 3 fois par jour",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 616,
    "source": "PDF_chunked"
  },
  {
    "id": 4695,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 695)",
    "text": "OOAS Page 144 Phyllanthus niruri WAHP Conservation A conserver dans un endroit frais et sec. Références Ahmed, B., Al-Howiriny, T.A., Mathew, R. (2002). Antihepatotoxic activity of Phyllanthus fraternus . Pharmazie 57(12):855-856. Asprey, G.F., Thornton, P. (1955). Medicinal Plants of Jamaica.III, West Indian Medical Journal 4:69-82. Campos, A.H. et al., (1999). Phyllanthus niruri inhibits calcium oxalate endocytosis by renal tubular cells: its role in urol ithiasis. Nephron 81(4): 393-397. Chauhan, J. S., Sultan, M., Srivastava, S.K. (1977). Two new Glycoflavones from the roots of Phyllanthus niruri . Planta medica 32:217-222. Freitas, A.M., et al., (2002). The effect of Phyllanthus niruri on urinary inhib itors of calcium oxalate crystallization and other factors associated with renal stone formation. B.J.U. Int., 89(9):829-834. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 909,
    "source": "PDF_chunked"
  },
  {
    "id": 4696,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 696)",
    "text": "oxalate crystallization and other factors associated with renal stone formation. B.J.U. Int., 89(9):829-834. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana. Hukeri, V.I. et al., (1988). Hypoglycaemic activity of flavonoids of Phyllanthus niruri in rats. Fitoterapia, 59(1):68-70. Hung, C.R. et al., (1995). Prophylactic effects of sucralfate and geraniin on ethanol -induced gastric mucosal damage in rats. Chinese Journa of Physiology 38(4):211-217. Jain, S.R., Sharma, S. N. (1967). Hypoglycaemic Drugs of Indian Indigenous Origin, Planta Medica 15(4):439-442. Khanna, A.K., et al., (2002). Lipid lowering activity of Phyllanthus niruri in hyperglycaemic rats. Journal of Ethnopharmacology 82(1):19-22. Khan, M.R., Ndaalio, G. , Nkunya, M.H.H, Wevers, H. (1978). Studies on the rationale of African traditional medicine Part II. Preliminary screening of medicinal plants for antigonococci activity, Pak., J. SCI. IND. RES. 27(516):189-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 4697,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 697)",
    "text": "Wevers, H. (1978). Studies on the rationale of African traditional medicine Part II. Preliminary screening of medicinal plants for antigonococci activity, Pak., J. SCI. IND. RES. 27(516):189- 192. Kitisin, T. (1952). Pharmacological studi es III Phyllanthus niruri . Siriraj Hospital Gaz 4:641- 649. Miguel, O.G., et al., (1996). Chemical and preliminary analgesic evaluation of geraniin and furosin isolated from Phyllanthus sellowianus . Planta Medica 62(2): 146-149. Mshana, N.R., Abbiw, D.K. , Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Ogata et al., (1992). HIV-1 reverse transcriptase inhibitor from Phyllanthus niruri . AIDS Res Hum Retroviruses 8(11):1937-1944. Rajeshkumar, N.V. et al., (2000). Phyllanthus",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4698,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 698)",
    "text": "committee. Ogata et al., (1992). HIV-1 reverse transcriptase inhibitor from Phyllanthus niruri . AIDS Res Hum Retroviruses 8(11):1937-1944. Rajeshkumar, N.V. et al., (2000). Phyllanthus amarus extract administration increases the lifespan of rats with hepatocell ular carcinoma. Journal of Ethnopharmacology. 73(1-2):215-219. Ramakrishnan, P.N. et al., (1982). Oral hypoglycaemic effect of Phyllanthus niruri (Linn) leaves. Indian Journal of Pharmaceutical Sciences. 44(1):10-12. Rao, M.V., Alice, K.M. (2001). Contraceptive effects of phyllanthus amarus in female mice. Phytotherapy Research 15(3):265-267. Sahu, T. R. (1984). Less known uses of weeds as medicinal plants. Ancient Science of Life. ,3 (4): 245-249. Santos, D.R. (1990). Cha de quebra- pedra (Phyllanthus niruri ) na litiase urinariaem humanos e ratos. Thesis, Escola Paulista de Medicina (Sao Paulo, Brazil). Santos, A.R. et al., (1995). Analysis of the",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 920,
    "source": "PDF_chunked"
  },
  {
    "id": 4699,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 699)",
    "text": "(Phyllanthus niruri ) na litiase urinariaem humanos e ratos. Thesis, Escola Paulista de Medicina (Sao Paulo, Brazil). Santos, A.R. et al., (1995). Analysis of the mechanisms underlying the antinociceptive effect of the extracts of plants from the genus Phyllanthus. G eneral Pharmacology 26(7):1499- 1506. Santos, A.R. et al., (2000). Antinociceptive properties of extracts of new species of plants of the genus Phyllanthus (Euphorbiaceae). Journal of Ethnopharmacology 72(12): 229-238.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 486,
    "source": "PDF_chunked"
  },
  {
    "id": 4700,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 700)",
    "text": "OOAS Page 145 Phyllanthus niruri WAHP Singh, Y.N. (1986). Traditional medicine in Fiji. Some herbal folk cures used by Fiji Indians. Journal of ethnopharmacology 15(1):57-88. Sircar, N.N. (1984). Pharmacotherapeutics of Dasemani Drugs. Ancient Science of Life. 3 (3): 132-135. Sittie, A.A., Lemmich, E., Olsen, C.E., Hviid, L . et al., (1998). Alkamides from Phyllanthus fraternus. Planta Medica 64(2): 192-193. Srividya, N. et al., (1995). Diuretic, hypotensive and hypoglycaemic effect of Phyllanthus amarus . Journal of Indian Experimental Biology 33(11):861-864. Thabrew, M.R. et al.,(1996). Phytogenic agents in the therapy of liver disease. Phytotherapy Research 10(6):461-467. Ueno, H. et al., (1988). Chemical and pharmaceutical studies on medicinal plants in Paraguay. Geraniin, an angiotens in-converting enzyme inhibitor from paraparai mi', Phyllanthus",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 863,
    "source": "PDF_chunked"
  },
  {
    "id": 4701,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 701)",
    "text": "Ueno, H. et al., (1988). Chemical and pharmaceutical studies on medicinal plants in Paraguay. Geraniin, an angiotens in-converting enzyme inhibitor from paraparai mi', Phyllanthus niruri. Journal of Natural Products 51(2):357-359. Wang, M.X. et al., (1994). Observations of the efficacy of Phyllanthus spp. In treating patients with chronic hepatitis. B., 19(12): 750-752. Weninger ,B., Rouzier, R.M., Henrys, D.D., Henrys, J.H., Anthon, R. (1986). Popular medicine of Plateau of Haiti. 2 Ethnopharmacological inventory. Journal of ethnopharmacology 17(1):13-30.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 562,
    "source": "PDF_chunked"
  },
  {
    "id": 4702,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 702)",
    "text": "OOAS Page 146 Phytolacca dodecandra WAHP Nom botanique Phytolacca dodecandra l'Hér. Famille Phytolaccaceae Synonymes Phytolacca abyssinica Hoffin; Pircunia abyssinica Moq. Noms communs Endod, soap berry, African soap berry (Anglais).Phytolaque, Endod (Français ). Fitolaca Noms vernaculaires Ghana: Akan Ahoro Nigeria: Igbo Ogwashi Okomofo Uburuku Aweli, Yoruba Ososo Description de la plante C'est un arbuste dioïque grimpant,enchevêtré, semi-succulent ou parfois une liane avec tiges jusqu'à 10- 20 m de long, avec une racine pivotante; un tronc qui sélève parfois jusqu'à 35 cm de diamètre; les tiges sont généralement glabres; les feuilles sont alternes, simples et entières; sans stipules; un pétiole de 1 à 4 cm de long; un limbe ovoïde grossièrement elliptique de 3 cm 1.5 9.5 cm, avec une base arrondie, légèrement décurrentes sur le pétiole, un sommet aigü arrondi, mucroné, glabre peu poilu;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 901,
    "source": "PDF_chunked"
  },
  {
    "id": 4703,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 703)",
    "text": "long; un limbe ovoïde grossièrement elliptique de 3 cm 1.5 9.5 cm, avec une base arrondie, légèrement décurrentes sur le pétiole, un sommet aigü arrondi, mucroné, glabre peu poilu; une inflorescence axillaire ou terminale de 5 -30 cm de long. Les nombreuses fleurs avec axe velu; bractées jusqu'à 2,5 mm long, peu velues, fonctionnellement unisexuées, de 5- mères sontdoux-parfumée; un pédicelle de 2 à 8 mm de long; les fleurs mâles ont des sépales étroitement oblongues, d'environ 2,5 mm de long, recourbées, blanchâtres à vert -jaunâtre, pétales absentes, 10- 20 étamines en 2 verticilles, libres, filaments de 3 à 7 mm de long, ovaire généralement rudimentaire; les fleurs femelles avec des sépales oblongues à ovales, d'environ 2,5 mm de long, recourbées, accrescentes dans les fruits avec tournant jaune à rouge, pétales absents, 8- 12 étamines, rudimentaires, ovaire supérieur composé de 4- 5 carpelles ovoïdes de styles libresde 1 à 2 mm de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4704,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 704)",
    "text": "accrescentes dans les fruits avec tournant jaune à rouge, pétales absents, 8- 12 étamines, rudimentaires, ovaire supérieur composé de 4- 5 carpelles ovoïdes de styles libresde 1 à 2 mm de long, courbés, stigmates linéaires; le fruit est composé de 4 ou 5 baies d'une graine, soudées à la base, jusqu'à 15 mm de diamètre, charnue; les résidues sont du style pointu tournés vers l'extérieur au niveau du sommet, orange ou pourpre rouge à maturité. Les graines sont en forme de reins, aplaties latéralement avec 2- 4 mm de long et de couleur noir- brillant. Numéro du spécimen de l'herbier Ghana: GC 52816 Nigeria : FHI 109009 Habitat et répartition géographique P. dodecandra est originaire d'Afrique subsaharienne et de Madagascar. Il a été introduit en Asie et en Amérique tropicale. On le trouve dans la forêt, à la lisière des forêts, dans la forêt riveraine, les fourrés, les bosquets plus humides, le long des clôtures deterres cultivées",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4705,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 705)",
    "text": "trouve dans la forêt, à la lisière des forêts, dans la forêt riveraine, les fourrés, les bosquets plus humides, le long des clôtures deterres cultivées et autour des maisons, sur les pentes des montagnes et en plein champ, à 1500 3000 m d'altitude. Il pousse mieux sous la lumière provenant du soleil surdes sols faiblement acides et humides, qui contiennent des concentrati ons élevées de matières organiques. Il pousse également dans les zones avec une pluviométrie annuelle d'environ 1400 mm et une saison sèche distincte. De même que dans les régions où l'évapotranspiration est élevée, surtout à basse altitude (au- dessous de 1500 m), l'ombre partielle devrait être disponible pour que les plantes ne brûlent et ne se flétrissent. L'ombre complète réduit considérablement à la fois la production de fruits et les concentrations de saponine. Parties utilisées de la plante Fruits Autres parties utilisées Racine, feuilles, graines Caractéristiques botaniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 963,
    "source": "PDF_chunked"
  },
  {
    "id": 4706,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 706)",
    "text": "production de fruits et les concentrations de saponine. Parties utilisées de la plante Fruits Autres parties utilisées Racine, feuilles, graines Caractéristiques botaniques Endod se compose du fruit de Phytolacca dodecandra l'Hér (Phytolaccaceae).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 247,
    "source": "PDF_chunked"
  },
  {
    "id": 4707,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 707)",
    "text": "OOAS Page 147 Phytolacca dodecandra WAHP Utilisations ethnomédicales Phytolacca dodecandra (plantations) est originaire d'Ethiopie, d'Afrique centrale et orientale. En Éthiopie, où il est connu comme un savon traditionnel, les baies de plantes toxiques sont couramment utilisées pour se laver et se débarrasser des poux et controler ou empoisonner les escargots d'eau douce (Pankhurst, 1965). Il est également utilisé pour éliminer les parasites intestinaux, pour l'avortement et contre les pellicules, la gonorrhée, les sangsues, les vers intestinaux, l'anthrax, la rage, la teigne, les démangeaisons de la peau et autres maladies de la peau (Watt et Breyer-Brandwijk, 1962, Esser et al ., 2003). En Afrique centrale, orientale et à Madagascar, un extrait de racines, de feuilles, des fruits et graines est utilisé comme purgatif, laxatif, diurétique ou émétique. Ces parties de la plante sont utilisées pour traiter un large spectrum de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4708,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 708)",
    "text": "un extrait de racines, de feuilles, des fruits et graines est utilisé comme purgatif, laxatif, diurétique ou émétique. Ces parties de la plante sont utilisées pour traiter un large spectrum de maladies, y compris les infestations de ver, les oedèmes, la diarrhée, les douleurs abdominales, les blessures, la gale, l'eczéma, le psoriasis, la lèpre, les furoncles et le vitiligo. Une infusion de fruits ou la décoction de racines est beaucoup prise pour traiter les maladies vénériennes, la bilharziose, la rage, la malaria, le mal de gorge et autres problèmes respiratoires, les douleurs rhumatismales et l'ictère. En Ethiopie et au Zimbabwe, les fruits verts riches en saponi nes molluscicides, sont très utilisés pour contrôler les escargots transmettant la bilharzioses. La sève des feuilles est cicatrisante et hémostatique et provoque une sensation de brûlure de la peau. Une infusion de fruits ou de racines est prise par voie orale et les jeunes feuilles et les tiges sont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 978,
    "source": "PDF_chunked"
  },
  {
    "id": 4709,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 709)",
    "text": "provoque une sensation de brûlure de la peau. Une infusion de fruits ou de racines est prise par voie orale et les jeunes feuilles et les tiges sont mâchées pour provoquer l'avortement. En Afrique de l'est, les feuilles au sol sont appliquées à des tumeurs; la décoction de racine est aussi absorbée pour provoquer des vomissements comme traitement des gland es élargies. En Tanzanie, les feuilles ou l'écorce de racines macérées sont utilisées pour traiter l'épilepsie. A Madagascar, une décoction des parties aériennes est appliquée pour traiter les hémorroïdes. En Afrique orientale et australe, la plante entière est considérée comme toxique, et il est dit avoir causé la mort accidentelle de personnes mangeant les feuilles comme un légume. La plante n'est généralement pas utilisée comme bois de chauffe, la fumée étant présumée réduire la capacité sexuelle masculine. Activités biologiques et pharmacologiques Kloos et McCullough (1984) rapporte que plus de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 964,
    "source": "PDF_chunked"
  },
  {
    "id": 4710,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 710)",
    "text": "utilisée comme bois de chauffe, la fumée étant présumée réduire la capacité sexuelle masculine. Activités biologiques et pharmacologiques Kloos et McCullough (1984) rapporte que plus de 1000 plantes ont été testées pour leurs activités molluscicides et les baies non- mûres de P. dodecandra ont été reconnues pour être les plus puissantes. Les cercaires schistosomes et autres larves de trématodes sont très vulérables à l'endod (Spielman et lemme, 1973 ; Fleming, 1975). L'endoda été utilisée dans le contrôle de la population de Biomphalaria pfeifferi et la transmission de la schistosomiase en Éthiopi e (Abebe et al. , 2005), mais dans le contrôle du Schistosoma mansoni, on a constaté que, après une période de quatre ans d'intervention, la réduction au niveau de la prévalence et l'intensité du plathélminthe était limitée. Le potentiel antifongique de la plante contre 33 souches médicale menteuses importantes de levures etdermatophytes a été étudié par",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 4711,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 711)",
    "text": "l'intensité du plathélminthe était limitée. Le potentiel antifongique de la plante contre 33 souches médicale menteuses importantes de levures etdermatophytes a été étudié par Woldeamanuel et al., (2005). La CMI de l'extrait aqueux varie entre 312.5- 19,5 mgl. Aucune activité n'a été observée contre les levures, mais l'activité la rvicide sur la faune et la flore des cours d'eau a été notée dans une étude de toxicité comparative portant sur l'endod et autres composés. Les larves de moustiques sont particulièrement sensibles à l'effet létal des endods avec une susceptibilité confirmée de larves de la mouche noire ( Simulium spp .), qui provoque l'onchocercose et des larves de la mouche de maison, Musca domestica. On pense que les escargots et les moustiques transmettant le paludisme peuvent se reproduire dans le même type d'environnement, donc le contrôle des escargots avec des endods peut avoir l'avantage de réduire des multitudes de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4712,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 712)",
    "text": "le paludisme peuvent se reproduire dans le même type d'environnement, donc le contrôle des escargots avec des endods peut avoir l'avantage de réduire des multitudes de moustiques. Karunamoorthi et al ., (2008) ont également démontré le potentiel toxique de l'extrait brut de baies de P. dodecandra contre des macroinvertébrés aquatiques Baetidae (éphémères) et Hydropsychidae (phryganes). L'endoda été reconnu dans des études de laboratoire pour causer de fortes contractions utérines (Stolzenberg et al. , 1976), conformément à son utilisation comme un abortif dans les sociétés t raditionnelles en Ethiopie et autres parties de l'Afrique. L'njection intra- utérine de petites quantités d'extrait d'endod chez des souris enceintes a causé un avortement apparemment stérile et inoffensif. En plus de la prévention de la grossesse, il peut être utile comme une pilule du lendemain (Stolzenberg et Parkhurst, 1974). Données cliniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4713,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 713)",
    "text": "apparemment stérile et inoffensif. En plus de la prévention de la grossesse, il peut être utile comme une pilule du lendemain (Stolzenberg et Parkhurst, 1974). Données cliniques L'extrait de butanol d'endod a démontré être un agent biologique extrêmement efficace contre le sperme humain, ce qui explique son utilisation comme agent de contr ôle des naissances à partir d'une mousse vaginale produite localement (Parkhurst et Stolzenberg, 1975).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 445,
    "source": "PDF_chunked"
  },
  {
    "id": 4714,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 714)",
    "text": "OOAS Page 148 Phytolacca dodecandra WAHP Constituants chimiques Saponines (glycosides triterpéniques, les aglycones de glycosides sont composées principalement d'acide oléanolique, de bayogenin, d'acide hydroxyoleanolique - 2 et de hédérogenine), phytostérols, lipides (acide palmitique, acide oléique, acide stéarique), sucres, amidons, lpectines et gencives (Parkhurst et al., 1973 ; Lemme et al., 1972). Tests d'identité et de pureté Teneur en eau: pas plus de 12,3 Cendre totale: 16,4 Valeur substances extractibles par l'eau : pas moins de 18,9 Valeur substances extractibles par l'éthanol (70 ): pas moins de 16,2 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4715,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 715)",
    "text": "phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de quatre taches caractéristiques R fs (violet), de 0,74 0,72 (vert), 0,54 (violet) et 0,23 (Rose). Macroscopie La feuille est verdâtre avec une odeur caractéristique; simple, courtement pétiolées; limbe de 3- 6 cm de long sur 1,5- 2 cm de large, de forme ovées à obovées; la marge est faiblement dentées; le sommet est acuminé; la Chromatogramme feuille a une base cunéiforme et nervation réticulée; la surface foliaire est glabre, ressemblant à une texture de papier avec une nervure médiane déprimée. Microscopie Présence de cellules épidermiques à parois ondulées, de poils tecteurs unicellulaires et pluricellulaires, de stomates, principalement",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4716,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 716)",
    "text": "nervure médiane déprimée. Microscopie Présence de cellules épidermiques à parois ondulées, de poils tecteurs unicellulaires et pluricellulaires, de stomates, principalement d'abondantes sclérites anisocytique sur la surface adaxiale; la section transversale de la nervure médiane a montré une légère creux sur la face dorsale et une légère protubérance sur la face ventrale avec des cellules en forme d'ovoïde-globuleux; les faisceaux vasculaires montrent une forme légère concave avec 2- 3 xylèmes unicellulaires. Matériel végétal en poudre Cellules parenchymateuses ondulées de l'épiderme ; poils tecteurs non- glandulaires unicellulaires et pluriccellulaires; des stomates anisocytiques, d'abondantes sclérites et des vaisseaux de xylème. Indications thérapeutiques Démangeaisons, teigne, gonococcie, vers intestinaux, anthrax et rage, oedème, douleur abdominale, eczéma, psoriasis, lèpre, furoncle. Actions thérapeutiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4717,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 717)",
    "text": "Indications thérapeutiques Démangeaisons, teigne, gonococcie, vers intestinaux, anthrax et rage, oedème, douleur abdominale, eczéma, psoriasis, lèpre, furoncle. Actions thérapeutiques Laxatif, anthelm inthique, émétique, sudorifiques, diurétique, anti -infectieux, analgésique, molluscicide, haemostatique. Données de sécurité A l'instar des autres molluscicides, les têtards et les petits poissons sont touchés par P. dodecandra à des concentrations mollus cicides. Les oiseaux qui se nourrissent de baies, de plantes sauvages semblent intacts, comme le",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 554,
    "source": "PDF_chunked"
  },
  {
    "id": 4718,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 718)",
    "text": "OOAS Page 149 Phytolacca dodecandra WAHP font les punaises d'eau dans les cours d'eau traitées (Lemme et Yau, 1975). Des études préliminaires sur la toxicité du P. dodecandra chez une variété d'espèces animales et végétales ainsi que des tests pour les propriétés cancérigènes ont été entreprises (Lemme, 1970; Lemme et Ames, 1975). Un mouton gavé avec l'extrait d'eau à une dose de 1 gkg de poids corporel est mort dans les 96 heures, alors qu'une dose de 200 mgkg de poids corporel n'a eu aucun effet apparent sur les reins et les tests de fonction hépatique effectués sur une période de 4 jours. L'administration par voie orale à des chiens d'une dose de 100 à 200 mgkg de poids corporel a causé des vomiss ements en quelques minutes. Une injection intraveineuse à la dose de 50 mgkg de poids corporel a été mortelle en moins de 24 heures, mais 8 mgml de sang ne montrent aucun changement significatif. La toxicité aiguë des deux molluscicides extraits de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4719,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 719)",
    "text": "50 mgkg de poids corporel a été mortelle en moins de 24 heures, mais 8 mgml de sang ne montrent aucun changement significatif. La toxicité aiguë des deux molluscicides extraits de P. dodecandra et niclosamide, a été déterminée. Endod-S a montré en24h uneCL 50 de 2,57 et 5,37 mgL respectivement pour Biomphalaria glabrata (albinos) et Biomphalaria pfeifferi . En 24h, Niclosamide produit une CL 50 de 0,063 mgL et 0.049 mgL respectivement pour Biomphalaria glabrata (albinos) et Biomphalaria pfeifferi. La CL 50 de 4h de Schistosoma mansoni cercaire est de 2,92 mgL pour les endod- S et 0,0008 mgL pour la niclosamide. La CL 50 de24h pour le Tilapia nilotica est de 1,82 mgL pour l'endod-S et 0, 21 mgL pour la niclosamide. La toxicité aiguë pour les rats et les souris a été évaluée en donnant 0, 1000 et 2500 mgkg de poids corporel d'endod dans l'eau distillée à des concentrations de 50 mgml et de 250 mgml par gavage, après que les animaux aient été suivis",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 960,
    "source": "PDF_chunked"
  },
  {
    "id": 4720,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 720)",
    "text": "évaluée en donnant 0, 1000 et 2500 mgkg de poids corporel d'endod dans l'eau distillée à des concentrations de 50 mgml et de 250 mgml par gavage, après que les animaux aient été suivis pendant 3 jours. Les valeurs de DL 50 ont été déterminées chez les rats et les souris des deux sexes. Chez les rats, la DL 50 était 1000 mgkg pour les mâles et 920 mgkg pour les femelles, alors que chez la souris la DL 50 est de 1600 mgkg pour les mâles et 3280 mgkg pour les femelles. Les symptômes toxiques évoqués chez les rats et les souris étaient une salivation excessive, une somnolence etdes poils rudes. Précautions d'emploi La plante peut être toxique, alors l'utiliser avec précaution. Effets indésirables Peut causer la diarrhée. Contre-indications Grossesse et allaitement. Dosage et forme galénique Décoction: 30 g de végétaux séchés dans 900 ml d'eau; laisser bouillir jusqu'à réduction de la quantité de l'eau à 600 ml; prendre 1- 3 cuillerées",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4721,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 721)",
    "text": "Dosage et forme galénique Décoction: 30 g de végétaux séchés dans 900 ml d'eau; laisser bouillir jusqu'à réduction de la quantité de l'eau à 600 ml; prendre 1- 3 cuillerées à soupe par jour. Conservation A conserver dans un endroit frais et sec. Références Abebe, F., Erko, B., Gemetchu, T., Gundersen, S.G. (2005). Control of Biomphalaria pfeifferi population and schistosomiasis transmission in Ethiopia using the soap berry endod ( Phytolacca dodecandra), with special emphasis on application methods. Transaction of the Royal Society of Tropical Medicine and Hygiene 99(10):787794. Esser, K.B., Semagn, K., Wolde Yohannes, L. (2003). Medicinal use and social status of the soap berry endod ( Phytolacca dodecandra) in Ethiopia. Journal of Ethnopharmacology 85(2 3): 269277. Flemings, M.B. (1975). Effects of Endod on preidiracular glands on the larvae of mosquitoes. Unpublished report, C.W. Post College, Long",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 914,
    "source": "PDF_chunked"
  },
  {
    "id": 4722,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 722)",
    "text": "269277. Flemings, M.B. (1975). Effects of Endod on preidiracular glands on the larvae of mosquitoes. Unpublished report, C.W. Post College, Long Island University, New York, no. 5, pp 198-202. Karunamoorthi, K., Bishaw, D., Mulat, T. (2008). Laboratory evaluation of Ethopian Medicinal plant, Phytolacca dodecandra extract for its toxic effectiveness against aquatic macro- invertebrates. European Review for Medical and Pharmacological Sciences, 12: 381-380. Kloos, H., McCullough, F.S. (1984). Plant Molluscicides. In: Lemma A., Heyneman,D. Silangwa S.M. (Eds.) Phytolacca dodecandra (Endod) Dublin, Ireland, Tycooly International Publishing Ltd. Lemma, A. (1970) . A laboratory and field evaluation of the molluscicidal properties of Phytolacca dodecandra. Bulletin WHO 42, 597- 617. Lemma, A., Ames, B.N. (1975). Screening for mutagenic activity of some molluscicides. Transactions of the ROYAL Society of Tropical Medicine and Hygiene , 69, 167-168.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4723,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 723)",
    "text": "617. Lemma, A., Ames, B.N. (1975). Screening for mutagenic activity of some molluscicides. Transactions of the ROYAL Society of Tropical Medicine and Hygiene , 69, 167-168. Lemma, A., Brody, G., Newell, G.W., Parkhurst R.M.,Skinner, W.A. (1972). Endod ( Phytolacca dodecandra), a natural product molluscicide:",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 309,
    "source": "PDF_chunked"
  },
  {
    "id": 4724,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 724)",
    "text": "OOAS Page 150 Phytolacca dodecandra WAHP increased potency with butanol extraction. The Journal of Parasitology 1972; 58: 104-107. Pankhurst, R. (1965). A historical examination of traditional Ethiopian medicine and surgery. Ethiopian Medical Journal, 3: 157-172. Parkhurst, R.M., Stolzenberg, S.J. (1975). Saponin-containing spermicidal composition, U.S. Patent Office, No. 3,886,372. Parkhurst, R.M., Thomas, D.W., Skinner, W.A., Cary, L.W. (1973). Molluscicidal saponins of Phytolacca dodecandra: oleanoglycotoxin- A. Phytochemistry 12: 1437-1442. Spielman, A., Lem ma, A. (1973). Endod extract, a plant derived molluscicidal toxicity for maoquitoes. American. Journal Tropical Medicine and Hygiene, 22: 802-804. Stolzenberg, S.J., Parkhurst, R.M., Reist, E.J. (1976).Blastocidal and co ntraceptive actions of extracts of Endod ( Phytolacca dodecandra). Contraception. 14:39-51.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 881,
    "source": "PDF_chunked"
  },
  {
    "id": 4725,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 725)",
    "text": "Stolzenberg, S.J., Parkhurst, R.M., Reist, E.J. (1976).Blastocidal and co ntraceptive actions of extracts of Endod ( Phytolacca dodecandra). Contraception. 14:39-51. Stolzenberg, S.J., Parkhurst, R.M. (1974). Spermicidal action of compounds from Phytolacca dodecandra. Contraception, 10, 135- 143. Watt, J., Breyer -Brandwijk, M.C. (1962). The medicinal and poisonous plants of Southern and Eastern Africa, 2 nd Ed. Livingstone, E.S. Publishers, Edinburgh. Wodeamanuel, Y., Abate, G. (2005). In vitro activity of Phytolacca dodecandra (endod) against dermatophytes. Ethopian Medical Journal 43(1): 31-34.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 604,
    "source": "PDF_chunked"
  },
  {
    "id": 4726,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 726)",
    "text": "OOAS Page 151 Pterocarpus erinaceus WAHP Nom botanique Pterocarpus erinaceus Poir. Famille Légumineuses Papilionacées Synonyme Pterocarpus echinatus DC. Noms communs Anglais: African rosewood, Senegal rosewood, African barwood, African teak, African kino tree. Français: Santal rouge d'Afrique, Vène, ven, palissandre du Sénégal, Portugais: Pau sangue. Noms vernaculaires Burkina Faso : Mooré Noèèga ou Nohinga, Dioula Gôni;gweni;mbeny, Fulfuldé Bani ;banu ;bané ;bari Guinée: Maninka- Gbene Gbin, Pular Barybani Banigue, Kissi Koilo Kouelo Mali: Bambara Mguèni Nigéria: Hausa Dorowan Kurmi, Igbo Aze Egu, Yuroba Apepe Sénégal: Sérère Ban, Wolof Vèn, Malinké N'gbéhun Description de la plante Petit arbre de couronne ouverte et arrondie atteignant 15 à 20 m de haut avec un fût rectiligne, cylindrique dépourvu de branches qui va jusqu'à une hauteur de 10 m avec des nervures de lumière contreforts; il a une écorce",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 915,
    "source": "PDF_chunked"
  },
  {
    "id": 4727,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 727)",
    "text": "atteignant 15 à 20 m de haut avec un fût rectiligne, cylindrique dépourvu de branches qui va jusqu'à une hauteur de 10 m avec des nervures de lumière contreforts; il a une écorce brun-grisâtre à noirâtre, fissurée et écailleuse; ses feuilles sont alternes, composées imparipennées avec 5- 11 folioles avec une inflorescence axillaire ou terminale, paniculée et densément couverte de poils bruns avec des fleurs bisexuées, à pédicelle velu. Les fruits circulaires sont légumineux, aplatis et indéhiscents. Numéro du spécimen de l'herbier Ghana: A 4689 Togo: TOGO06455 Habitat et répartition géographique P. erinaceus est natif de la région sahélienne de l'Afrique de l'Ouest, et pousse aussi bien sur tous les types de sols, que la latérite. L'arbre pousse également sur les plaines Africaines ensoleillées et chaudes, pendant les longues saisons sèches et les fréquents incendies. On peut également le trouver dans les forêts du",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4728,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 728)",
    "text": "pousse également sur les plaines Africaines ensoleillées et chaudes, pendant les longues saisons sèches et les fréquents incendies. On peut également le trouver dans les forêts du parc national de la Comoé en Côte d' Ivoire qui est géographiquement près du Sahel, mais avec un système d'humidité plus élevée. Parties utilisées de la plante Feuille et écorce de la tige Autres parties utilisées Racines Caractéristiques botaniques Le bois rose africain est composé de la feuille ou l'écorce de tige de Pterocarpus erinaceus Poir (Papilionaceae). Utilisation ethnomédicale La plante est utilisée dans le traitement des fièvres et des plaies. La feuille infusée est utilisée pour traiter la diarrhée, la dysenterie et les vers intestinaux (Karou et al ., 2003) et la décoction ou l'infusion de l'écorce de tige et des racines est efficace contre les infections bronchiques, les maux de dents, la dysenterie, les menstrues douloureuses, l'anémie, la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4729,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 729)",
    "text": "décoction ou l'infusion de l'écorce de tige et des racines est efficace contre les infections bronchiques, les maux de dents, la dysenterie, les menstrues douloureuses, l'anémie, la gonorrhée, l'hémorragie post -partum, le ténia, la lèpre, les tumeurs et les ulcères (Karou et al ., 2003). La décoction des feuilles a des propriétés aphrodisiaques. La plante est utilisée comme insectifuge et pour le traitement de la syphilis (Karou et al ., 2003), l'insomnie et les infections fongiques de la peau (Olowokudejo et al., 2008). Activités biologiques et pharmacologiques Les extraits aqueux et méthanolique de l'écorce ont montré des propriétés antibactériennes et antifongiques in vitro contre les espèces pathogènes de plusieurs Staphylococcus, Streptococcus, Mycobacterium smegmatis et Mycobacterium tuberculosis (Nuhu et al., 2000). Les extraits de feuilles ont montré une activité antiplasmodiale in vitro contre le Plasmodium",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4730,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 730)",
    "text": "Streptococcus, Mycobacterium smegmatis et Mycobacterium tuberculosis (Nuhu et al., 2000). Les extraits de feuilles ont montré une activité antiplasmodiale in vitro contre le Plasmodium falciparum (Karou et al., 2003). Bizimana et al . (2006) ont rapporté l'activité trypanocide de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 283,
    "source": "PDF_chunked"
  },
  {
    "id": 4731,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 731)",
    "text": "OOAS Page 152 Pterocarpus erinaceus WAHP plante contre diff érentes espèces de trypanosomes, tandis que Duvall (2008) a démontré une activité antigonadotrope de la plante chez les rats femelles. Il a été également rapporté que des extraits de la plante possèdent une activité antioxydante (Karou et al., 2005). Données cliniques Aucune information disponible Constituants chimiques Homoptérocarpine, ptérocarpine, angolensine, Acide acetyloléanolique, afromosine pseudobaptigenine, alcaloïdes, tanins, Saponines et flavonoïdes (Nuhu et al., 2000; Bevan et al., 1966; Akisanya et al., 1959). 000; Bevan et al., 1966; Akisanya et al., 1959). Tests d'identité et de pureté Teneur en humidité: pas plus de 9,21 Cendre totale: 13,70 Valeur substances extractibles par l'eau: pas moins de 14,30 Valeur substances extractibles par l'éthanol (70): pas moins de 15,70 Empreintes chromatographiques Extrait chloroformique",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 911,
    "source": "PDF_chunked"
  },
  {
    "id": 4732,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 732)",
    "text": "Valeur substances extractibles par l'eau: pas moins de 14,30 Valeur substances extractibles par l'éthanol (70): pas moins de 15,70 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60 F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10 mn. Présence de quatre taches distinctes avec R f de 0,89 (rose), 0,62 et 0,48 (violet). Chromatogramme Macroscopie Feuilles fraiches et de couleur verte, composées d'un long pétiole; limbe de 6- 11 cm de long sur 4-6 cm de large; oblongues à elliptiques dans la forme; marge entière; apex à base acuminée ; feuilles rondes et pubescentes avec nervation réticulée, texture charnue avec une nervure",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4733,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 733)",
    "text": "4-6 cm de large; oblongues à elliptiques dans la forme; marge entière; apex à base acuminée ; feuilles rondes et pubescentes avec nervation réticulée, texture charnue avec une nervure médiane proéminente. Microscopie Les cellules épidermiques ont des parois anticlinales droites ondulées sur la surface adaxiale et sur l'abaxiale droite; Présence de stomates sur la surface abaxiale de types anomocytiques et paracytiques; la section transversale de la feuille est isobilatérale, avec l'épiderme simple posé sur les deux surfaces avec une cuticule épaisse de mésophylle indifférencié avec de nombreux espaces aériens; les poils pluricellulaires avec des têtes glandulaires sont présents sur les deux surfaces, plus visibles sur la surface ventrale; la section transversale passant par la région de nervure centrale montre des protubérances sur les deux côtés ventraux et dorsaux formant ainsi une forme ovoïde; les faisceaux vasculaires ont la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4734,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 734)",
    "text": "transversale passant par la région de nervure centrale montre des protubérances sur les deux côtés ventraux et dorsaux formant ainsi une forme ovoïde; les faisceaux vasculaires ont la forme d'un éventail; les xylèmes (5- 7 loculaire) situés au- dessus du phloème, placés au centre de la région liminales sont des cellules de pierre. Matériel végétal en poudre Présence de cellules parenchymateuses de l'épiderme, parois anticlinales droites, stomates",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 450,
    "source": "PDF_chunked"
  },
  {
    "id": 4735,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 735)",
    "text": "OOAS Page 153 Pterocarpus erinaceus WAHP anomocytiques et paracytiques, poils glandulaires pluricellulaires, vaisseaux de xylème. Actions thérapeutiques Antipaludique (Karou et al., 2003), antibactérien et antifongique (Nuhu et al ., 2000), antioxydant (Karou et al., 2005), trypanocide (Bizimana et al., 2006), antigonadotrope (Duvall, 2008). Indications thérapeutiques Paludisme, dysenterie, diarrhée, fièvre, insomnie. Données de sécurité Les études animales ont montré que la DL 50 de l'extrait aqueux des feuilles ( p.o.) chez les rats mâles est 3000 mgkg. Il n'y avait aucun signes cliniques de toxicité pendant la période de traitement (300-3000 mg kg). Les changements du poids corporel et relatif des organes des animaux traités étaient comparables à ceux véhiculés par les animaux traités. Le sang et les cellules sanguines, le foie ou les reins n'ont pas été affectées par le traitement. Il y avait aucune",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 916,
    "source": "PDF_chunked"
  },
  {
    "id": 4736,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 736)",
    "text": "animaux traités étaient comparables à ceux véhiculés par les animaux traités. Le sang et les cellules sanguines, le foie ou les reins n'ont pas été affectées par le traitement. Il y avait aucune difficulté liée à la sécurité des résultats de cette étude. Précautions d'emploi Aucune information disponible Effets indésirables Aucune information disponible Contre-indications Aucune information disponible Dosage et forme galénique 300 g de matériel végétal bouilli avec 900 ml d'eau jusqu'à réduction à 600 ml; prendre 2 cuillerées à soupe deux fois par jour. Conservation A conserver dans un endroit frais et sec. Références Akisanya, A., Bevan, C.W.L., Hirst, J. (1959). West African timbers. II. Heartwood constituents of the genus Pt erocarpus. Journal of the Chemical Society 2679-2681. Bevan, C.W.L., Ekong, D.E.U., Obasi, M.E., Powell, J.W. (1966). West African timbers. XIII. Extracts from the heartwood of Amphimas",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 4737,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 737)",
    "text": "Chemical Society 2679-2681. Bevan, C.W.L., Ekong, D.E.U., Obasi, M.E., Powell, J.W. (1966). West African timbers. XIII. Extracts from the heartwood of Amphimas pterocarpoides and Pterocarpus erinaceus . Journal of the Chemical Soc iety Section C: Organic (5):509-510. Bizimana, N., Uwe, T., Karl -Hans, Z., Drissa, D., Coulibaly, D. et al . (2006). Evaluation of medicinal plants from Mali for their in vitro and in vivo trypanocidal activity. Journal of Ethnopharmacology 103(3):350-356. Duvall, C.S. (2008). Pterocarpus erinaceus Poir. Internet Fiche de Protabase. Louppe, D., Oteng-Amoako, A.A., Brink, M. (Editeurs). PROTA (Plant Resources of Tropical Africa Ressources végétales de l'Afrique tropicale), Wageningen, Pays Bas. Karou, D., Mamoudou, H., Dicko, S.S., Jacques, S.,Traore, A.S. (2003). Antimalarial activity of Sida acuta Burm. f. (Malvaceae) and Pterocarpus erinaceus Poir. (Fabaceae). Journal of Ethnopharmacology 89:291294.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4738,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 738)",
    "text": "S.,Traore, A.S. (2003). Antimalarial activity of Sida acuta Burm. f. (Malvaceae) and Pterocarpus erinaceus Poir. (Fabaceae). Journal of Ethnopharmacology 89:291294. Karou, D., Dicko, M.H., Simpore, J., Traore, A .S. (2005). Antioxidant and antibacterial activities of polyphenols from ethnomedicinal plants of Burkina Faso. African Journal of Biotechnology 4(8):823-828. Nuhu, A. M., Mshelia, M.S., Yakubu, Y. (2000). Antimicrobial screening of the bark extract of Pterocarpus erinaceus tree. Journal of Chemical Society of Nigeria 25:85-87. Olowokudejo, J.D., Kadiri, A.B., Travih, V.A. (2008). An Ethnobotanical Survey of Herbal Markets and Medicinal Plants in Lagos State of Nigeria. Ethnobotanical Leaflets 12: 851-865.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 723,
    "source": "PDF_chunked"
  },
  {
    "id": 4739,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 739)",
    "text": "OOAS Page 154 Rauwolfia vomitoria WAHP Noms botaniques Rauwolfia vomitoria Azfel. Familles Apocynaceae Synonymes Rauvolfia senegambiae A DC; Hylacium owariense P. Beauv Noms communs Swizzlestick, Rauwolfia africain (Englais) Noms vernaculaires Burkina Faso : Dioula Kolidjohkhi, Fulfuldé Moyatjalal;Ligéré Ghana: Akan Kakapenpen; Ewe Dodemak Powoe; Hausa Wada Mali: Bambara Kolijoi Nigéria: Yoruba Asofeiyeje Togo: Ewe Ou Adja, Dodemakpowoe; Akposso Ilonotchi, Oklubètè; Sénégal: Diola Gi Upa Description de la plante C'est un arbuste ou petit arbre de 15 m de haut, avec ramification dichotomique; les feuilles sont verticillées par groupes de 4 ou 5, variables, de forme ovale, elliptiques ou oblongues, avec un sommet acuminé, une base cunéiforme, glabre et des nervures l atérales de 10- 16 paires; l'inflorescence est terminale avec des corymbes fleuris, des petites fleurs blanches, un nœud de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 899,
    "source": "PDF_chunked"
  },
  {
    "id": 4740,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 740)",
    "text": "sommet acuminé, une base cunéiforme, glabre et des nervures l atérales de 10- 16 paires; l'inflorescence est terminale avec des corymbes fleuris, des petites fleurs blanches, un nœud de 3-4 niveau et de nombreux fruits verts qui deviennent rouges à maturité (GHP, 2007). Numéro du spécimen de l'herbier Ghana: A2492 Mali: 898 DMT TOGO: TOGO02112 Habitation et répartition géographique La plante se développe naturellement dans les forêts galeries, mais surtout dans les recrus forestières où les périodes de jachère se prolongent. R. vomitoria est originaire du Cameroun, République Démocratique du Congo, Ghana, Libéria, Nigeria, Sénégal, Soudan et Ouganda, mais est maintenant cultivée dans de nombreux pays tropicaux et subtropicaux. Parties utilisées de la plante Racines Autres parties utilisées Ecorce de la tige Caractéristiques botaniques Le Rauwolfia Africain se compose des racines fraîches ou séchées de Rauvolfia vomitoria",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4741,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 741)",
    "text": "Racines Autres parties utilisées Ecorce de la tige Caractéristiques botaniques Le Rauwolfia Africain se compose des racines fraîches ou séchées de Rauvolfia vomitoria Azfel. (Apocyanaceae) Utilisations ethnomedicales Dans la médecine traditionnelle africaine, la décoction des feuilles ou des racines est administré par voie orale pour traiter la maladie mentale (Iwu, 1993; Costa- Campos et al., 2004). La feuille macérée est utilisée pour le traitement de l'hypertension et de la fièvre, et la décoction est utilisée contre la gonorrhée, les rhumatismes, le ret ard de croissance, les troubles hépatiques et les maladies de la peau (Mesia et al ., 2008). La décoction de racine est utilisée pour traiter les hémorroïdes (Agyare et al. 2009). Activités biologique et pharmacologie Tous les alcaloïdes de R. vomitoria, e t les alcaloïdes simples ont une action sympatholytique et sont donc utilisés dans le traitement de l'hypertension (Oliver-Bever, 1960).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4742,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 742)",
    "text": "Tous les alcaloïdes de R. vomitoria, e t les alcaloïdes simples ont une action sympatholytique et sont donc utilisés dans le traitement de l'hypertension (Oliver-Bever, 1960). La réserpine et la rescinnamine sont considérés comme principaux agents hypotenseur de la plante, dépresseur du système nerveux central, sédatif qui ont des actions vasodilatatrices et antihépatotoxiques. Bien que la réserpine ait un effet sédatif et tranquillisant, il n'est pas hypnotique. La Barre (1973) a insinué que la réserpine a sans doute un antimétabolite de sérotonine et de catécholamines, car il provoque l'appauvrissement de la sérotonine au niveau des terminaisons nerveuses. Il est employé comme un agent hypotenseur telle que la rescinnamine et la reserpiline dans le traitement de l'hypertension artérielle et com me tranquillisant dans la gestion de l'anxiété et des psychoses (Oliver-Bever, 1986; La Barre, 1973), tandis que l'ajmaline a des actions coronaires et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4743,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 743)",
    "text": "OOAS Page 155 Rauwolfia vomitoria WAHP vasodilatatrices périphériques et, est donc utilisé dans le traitement de l'angine et de la maladie de Raynaud (Fattorusso et Riter, 1967). De faibles doses d'extrait aqueux de la racine de l'écorce ont causée la tachypnée, alors que les doses élevées ont entraîné une augmentation bradypnée et la mort par arrêt respiratoire et cardiaque.. Une préparation de réserpine sans l'alcaloïde de l'écorce de racine a un puissant effet hypotenseur chez les chats et les rats (Oliver-Bever, 1960). L'extrait éthanolique de l'écorce de racine a montré une importante activité antiplasmodiale avec une IC 50 de 2,5 1,0 μg ml sur les cellules souches de Plasmodium falciparum in vitro résistantes à la chloroquine (Zihiri et al. 2005). Le R. vomitoria a considérablement réduit jusqu'à 30, l'accumulation de lipides chez les rats diabétiques (Campbell et al., 2006.); les extr aits aqueux et éthanoliques des racines sont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4744,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 744)",
    "text": "considérablement réduit jusqu'à 30, l'accumulation de lipides chez les rats diabétiques (Campbell et al., 2006.); les extr aits aqueux et éthanoliques des racines sont efficaces contre plusieurs souches sensibles et résistantes de bactéries qui ont un pourcentage d'inhibition de 16 à 100 (Pesewu et al., 2008). Données cliniques Aucune information disponible Constituants chimiques Les alcaloïdes (réserpine, rescinnamine, serpentine, reserpoxidine, séredine, ajmaline, alstonine, iso -ajmaline, isoreserpiline, raumatorine, rauvomitine, reserpiline, serpagine, vomalidine, yohimbine, tetraphylline) et des flavonoïdes (pharmacopée africaine, 1985; Iwu et 1982, Paris, 1943 ; Amer et Cour, 1980; Iwu et Cour, 1982). Tests d'identité et de pureté Teneur en humidité: pas plus de 12,0 Cendre totale: 11,89 Valeur substances extractibles par l'eau: pas moins de 21,9 Valeur substances extractibles par l'éthanol (70): pas moins de 19,7",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4745,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 745)",
    "text": "Cendre totale: 11,89 Valeur substances extractibles par l'eau: pas moins de 21,9 Valeur substances extractibles par l'éthanol (70): pas moins de 19,7 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60 F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10 mn. Présence de trois taches distinctes avec R f de 0.69 (rose), 0.50 (rose) et 0.22 (bleue). Chromatogramme Macroscopie Racines subcylindriques, légèrement coniques et parfois ramifiée, allant jusqu'à 30 cm de long, 15 cm de circonférence et rarement jusqu'à 9 cm de diamètre. La sur face extérieure brun- grisâtre est profondément fissurée de manière longitudinale",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4746,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 746)",
    "text": "cm de circonférence et rarement jusqu'à 9 cm de diamètre. La sur face extérieure brun- grisâtre est profondément fissurée de manière longitudinale ou lisse obtenu par frottement avec quelques sections obliques de la radicelle; le suber, s'il est présent, casse en esquille dans le bois fin, poreux, chamois ou jaune. Microscopie Couche stratifiée constituée de celllules subérisées nivellées ayant chacun 3à 4 sites en direction radiale alternée avec des zones de cellules ligneuses avec de 1à 120 sites de 55 μ. Environ 5 à 16 couches de parenchymes constitués de , sclérit es d'environ 12 à 18 μ de large ou de longueur isolement ou en petits groups contenant quelques fois de petits prismes de cristaux d'oxalate de calcium.; phloeme avec des cellules secrétrices éparpillées à contenus",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 789,
    "source": "PDF_chunked"
  },
  {
    "id": 4747,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 747)",
    "text": "OOAS Page 156 Rauwolfia vomitoria WAHP granulaires et des groupes isolés de sc lérites,. Plus de bandes sont des sclérites discontinues dans le phloème en alternance avec des tissus externes, transpercés, effondrés, tandis que la zone intérieure est traversée par des éléments clairement définis, avec de nombreux vaisseaux de xylème d'environ 36 à 180 μ de diamètre, seuls ou en couples, subcylindriques avec des petites ponctuations aréolées, des éléments de vaisseaux d'environ 75 à 1200 μ de long, de nombreuses fibres d'environ 200 à 1500 μ de long sur 32 μ de large, avec une fente en forme de creux obliques avec des rayons médullaires larges, trois cellules hétérogènes, des groupes de sclérites isolées ; les grains d'amidon présents dans tous les tissus du parenchyme sont ronds et mesurent 1- 10 à 20μ de diamètre. Il y a également quelques grains regroupés par 2 ou 4; une section transversale présentent une écorce de liège mince avec des cellules",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 960,
    "source": "PDF_chunked"
  },
  {
    "id": 4748,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 748)",
    "text": "sont ronds et mesurent 1- 10 à 20μ de diamètre. Il y a également quelques grains regroupés par 2 ou 4; une section transversale présentent une écorce de liège mince avec des cellules stratifiées, comprimées, subérisées, alternent avec des cellules plus grandes lignifiées; une couche mince de cambium de liège présente un cortex secondaire constitué de cellules de parenchyme ( 20-40 μm x 20 -28 μm) avec de nombreux grains d'amidon; un parenchyme est interrompu par des sclérites lignifiées, seuls ou en groupes, de diamètre isodiamétriques de 20- 25 μm avec un lumen étroit; le phlo ème a des éléments de tamis ainsi qu'un parenchyme de cristaux prismatiques; un phloème est intercalé de cellules de rayons médullaires, des cellules de 1- 3 larges, qui contiennent des grains d'amidon; de xylème lignifié, constitué de vaisseaux (environ 20- 80 μm de diamètre), de trachéides et de parenchyme. Matériel végétal en poudre Présence de cellules parenchymateuses;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 4749,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 749)",
    "text": "d'amidon; de xylème lignifié, constitué de vaisseaux (environ 20- 80 μm de diamètre), de trachéides et de parenchyme. Matériel végétal en poudre Présence de cellules parenchymateuses; sclérites lignifiées, nombreux vaisseaux de xylème, dénoyautés, nombreux fibres de xylème, des cellules lignifiées de rayons médullaires, grains d'amidon à l'intérieur des cellules parenchymateuses, cellules de liège, petits prismes de cristaux d'oxalate de calcium, cellules sécrétrices dispersées. Actions thérapeutiques Antiplasmodiale, antidiabétique; antibactérien; hypotenseur, sédatif (Pe sewu et al ., 2008; Campbell et al., 2006; Zihiri et al., 2005). Indications thérapeutiques Troubles psychiatriques (psychoses), hypertension, bradycardie, insomnie, arythmie; angine, schizophrénie, dermatoses parasitaires (ex : poux de la tête), constipat ion, lumbago, maladies infectieuses; pian, paludisme, morsures de serpents, diabète, plaies (Mshana",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4750,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 750)",
    "text": "angine, schizophrénie, dermatoses parasitaires (ex : poux de la tête), constipat ion, lumbago, maladies infectieuses; pian, paludisme, morsures de serpents, diabète, plaies (Mshana et al., 2000; GHP, 2007; Oliver-Bever, 1960). Données de sécurité La DL 50 de l'extrait aqueux de l'écorce de la tige (p.o) a été jugée 3000 mgkg chez les rats. Dans les études aiguës (300- 3000 mgkg), la défécation, la miction et la salivation, qui sont des signes clairs de stimulation cholinergique, ont été observées dans les études aigües, en 24 heures. Dans une étude de 14 jours, une augmentation signi ficative du poids corporel et une diminution conséquente de l'organepoids corporel du foie, des reins et du cœur s'est seulement produite à une dose élevée de 3000 mgkg. Le taux de créatinine sérique a augmenté à 3000 mgkg. Aucun effet nocif n'a été obs ervé sur le sang et ses éléments cellulaires ou le foie. Précautions d'emploi La dose recommandée ne doit pas être",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4751,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 751)",
    "text": "à 3000 mgkg. Aucun effet nocif n'a été obs ervé sur le sang et ses éléments cellulaires ou le foie. Précautions d'emploi La dose recommandée ne doit pas être dépassée, car cela pourrait provoquer des symptômes cholinergiques et des lésions rénales. Effets indésirables Hypotension, hypoglycémie, bradycardie, diarrhée, congestion nasale, troubles intestinaux. Contre-indications Hypotension, insuffisance cardiaque, diarrhée. Dosage et forme galénique Décoction: 30 g de racines hachées, coupées et séchées et du rhizome dans 900 ml d'eau; laisser m ijoter jusqu'à réduction à 600 ml; prendre 1-3 tasses quotidiennes (GHP, 2007) Teinture: 1- 5 dans 50 d'alcool, 5 ml trois fois par jour Conservation A conserver dans un endroit frais et sec, loin de la lumière Références Agyare, C., Asase, A., Lechtenberg, M., Niehues, M., Deters, A., Hensel, A. (2009). An ethnopharmacological survey and in vitro confirmation of ethnopharmacological use of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4752,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 752)",
    "text": "Références Agyare, C., Asase, A., Lechtenberg, M., Niehues, M., Deters, A., Hensel, A. (2009). An ethnopharmacological survey and in vitro confirmation of ethnopharmacological use of medicinal plants used for wound healing in Bosomtwi-Atwima-Kwanwoma area, Ghana. Journal of Ethnopharmacology 125:393403. Amer, M.M. and Court, W.E. (1980). Leaf alkaloids of Rauwolfia vomitoria. Phytochemistry 19:1833-1836.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 407,
    "source": "PDF_chunked"
  },
  {
    "id": 4753,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 753)",
    "text": "OOAS Page 157 Rauwolfia vomitoria WAHP Campbell, J.I.A., Mortensen, A., Mølgaard, P. (2006). Tissue lipid lowering-effect of a traditional Nigerian anti -diabetic infusion of Rauwolfi a vomitoria foilage and Citrus aurantium fruit. Journal of Ethnopharmacology 104:379386. Costa-Campos, L., Iwu, M., Elisabetsky E., (2004). Lack of pro- convulsant activity of the antipsychotic alkaloid alstonine. Journal of Ethnopharmacology 93:307310. Fattorusso, V. and Ritter, O. (1967). Dictionnaire de Pharmacologié Clinique. Mason, Paris, cited by Oliver-Bever, 1986. Ghana Herbal Pharmacopoeia (2007). 208- 212, The Advent Press: Accra, Ghana. Hage, S., Kienlen- Campard, P., Octave, J.N., Quetin-Leclercq, J. (2010). In vitro screening on _-amyloid peptide production of plants used in traditional medicine for cognitive disorders. Journal of Ethnopharmacology 131:58559. Iwu, M.M. (1993). Handbook of African Medicinal",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 912,
    "source": "PDF_chunked"
  },
  {
    "id": 4754,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 754)",
    "text": "_-amyloid peptide production of plants used in traditional medicine for cognitive disorders. Journal of Ethnopharmacology 131:58559. Iwu, M.M. (1993). Handbook of African Medicinal Plants. Boca Raton, F L, CRC Press Inc., pp. 219220. Iwu, M.M. and Court, W.E. (1982). Stem bark alkaloids of Rauwolfia vomitoria. Planta Medica 45, 105-111. La Barre, J. (1973). Hypotensive effects of the completely dereserpinised extract of Rauwolfia vomitoria. Arzneimittel-forschung 23:600-605. Mesia, G.K., Tona, T.H., Nanga, T.H., Cimanga, R.K., Apers, S. et al. (2008). Antiprotozoal and cytotoxic screening of 45 plant extracts from Democratic Republic of Congo. Journal of Ethnopharmacology 115:409-415. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al ., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 920,
    "source": "PDF_chunked"
  },
  {
    "id": 4755,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 755)",
    "text": "Ahiyi, M.R.A., Ekper, J.A., et al ., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, techni cal and research committee. Oliver-Bever, B (1986). Medicinal plants in tropical West Africa. Cambridge University Press, London. Oliver-Bever, B. (1960). Medicinal Plants in Nigeria. The Nigerian College of Arts, Science and Technology, 52. Paris, R. (1943). Sur une Apocynacee africaine, le Rauwolfia vomitoria. Annals of Pharmacy France 1:138-142. Pesewu, G.A., Cutler, R.R., David, P. Humber, D.P. (2008). Antibacterial activity of plants used in traditional medicines of Ghana with particular reference to MRSA. Journal of Ethnopharmacology 116 :102111. Pharmacopée Africaine (1985) . Organisation de l'Unité Africaine, Commission Scientifique Technique et de la Recherche (CSTROUA). 1ère édition, vol. 1.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 4756,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 756)",
    "text": "Ethnopharmacology 116 :102111. Pharmacopée Africaine (1985) . Organisation de l'Unité Africaine, Commission Scientifique Technique et de la Recherche (CSTROUA). 1ère édition, vol. 1. Zirihi, G.N., Mambu, L., Guédé- Guina, F., Bodo, B., Grellier, P. (2005). In vitro antiplasmodial activity and cytotoxicity of 33 West African plants used for treatment of malaria. Journal of Ethnopharmacology 98:281285.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 403,
    "source": "PDF_chunked"
  },
  {
    "id": 4757,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 757)",
    "text": "OOAS Page 158 Sarcocephalus latifolius WAHP Nom botanique Sarcocephalus latifolius (J.E Sm.) Bruce Magpar Famille Rubiaceae Synonymes Sarcocephalus esculentus Afzel.ex Sabine; Sarcocephalus sambucinus K. Schum.; Nauclea latifolia Sm,Nauclea esculenta (Afzel. ex Sabine) Merrile; Sarcocephalus sassandrae A. Chev.; Sarcocephalus russeggeri Kotschy ex Schweinf Noms communs Pêche africaine ; Pêche de Guinée ; Figues du pays ; Pêche Nègre Noms vernaculaires Burkina Faso : Dagaari Anguma, Fulfulde Bakulehi, Grusi Dianlo Cote d Ivoire: Adyukru Edik, Akye Esubo Monleuh Sibo, Anyi Balimbe Sibo Tere Gambie: Fula Dundake, Mandinka Bakaba, Ba-Tio, Wolof Koba Nandok Ghana: Adangme Akabi, Akan Awintin, Dagbani Galungun Guinée Bissau: Balanta Cunhe Tetugole, Bioyogo Canhame, Crioulo Diunk Mali: Dogon Ayugu, Manding Bambara Bari Nigéria: Edo Aragbaihi, Hausa Igiyaa Tafaashiyaa, Igbo Mbiliinu, Yoruba Egbesi",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 902,
    "source": "PDF_chunked"
  },
  {
    "id": 4758,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 758)",
    "text": "Bioyogo Canhame, Crioulo Diunk Mali: Dogon Ayugu, Manding Bambara Bari Nigéria: Edo Aragbaihi, Hausa Igiyaa Tafaashiyaa, Igbo Mbiliinu, Yoruba Egbesi Sénégal: Vulgar Dundake, Balanta Batio Feas, Diola Flup Bundufe Sierra Leone : Bulom Gbilgbil-Le, Fula Dunduke, Gola Yumbuyamba Togo: Bassari Degangande, Ewe Alo Kubasa Kaio, Konkomba Bunangim Description de la plante C'est un arbuste étoufant ou petit arbre à feuilles persistantes qui pousse dans les savanes boisées jusqu'à à 9 m de haut avec un tronc tortueux qui peut atteindre jusqu' à 30 cm de diamètre ; il a une écorce rugue use, des feuilles elliptiques ou ovales arrondies, base cunéiforme, arrondie ou subcordate, de 10- 20 cm long sur 6- 12 cm de large, glabres, peu obovées, sommetbrusquement acuminées, surface supérieure foncée, pétiole rouge, stipules courtes, larges, ovales et plus persistantes ;fleuris (mars -juin, août, décembre- janvier), un",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 914,
    "source": "PDF_chunked"
  },
  {
    "id": 4759,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 759)",
    "text": "sommetbrusquement acuminées, surface supérieure foncée, pétiole rouge, stipules courtes, larges, ovales et plus persistantes ;fleuris (mars -juin, août, décembre- janvier), un pédicelle de 1-2 cm de long ; les capitules blancs s'élèvent jusqu'à 5 cm de diamètre, avec une odeur douce et parfumée, recherchés par les abeilles. Ils deviennent grands et charnus, avec un fruit rouge, charnu. Les fruits sont relativement peu profonds-et dénoyautés jusqu'à 9 cm de diamètre; en saison de fructification (mai-juin, septembre- octobre), la pâte comestible devient suavement acide avec de nombreuses graines incorporés. Numéro du spécimen de lherbier Ghana : GC43845 Togo : TOGO07535 Habitat et répartition géographique Dans la savane de Guinée et également dans les savanes de prairies. Parties utilisées de la plante Racine Autres parties utilisées Fruits, feuilles et écorce du tronc. Caracteristiques botaniques Sarcocephalus se compose de fragments de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4760,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 760)",
    "text": "Parties utilisées de la plante Racine Autres parties utilisées Fruits, feuilles et écorce du tronc. Caracteristiques botaniques Sarcocephalus se compose de fragments de racines de Sarcocephalus latifolius (J.E Sm.) Bruce Magpar (Rubiaceae) séchéset découpés transversalement et hachés. Utilisations ethnomedicales Les extraits d'écorce, de racines et de feuilles sont utilisés par les peuples d'Afrique de l'Ouest, Centrale et Orientale pour diverses affections dont les plaies, gonorrhée, troubles d'estomac, toux et fièvre. La plante est utilisée dans la médecine populaire nigériane dans le traitement des hémorroïdes et de la dysentérie. Un infusé de l'écorce a été largement utilisé comme tonique et fébrifuge, d'où l'appellation de \"Quinine africaine\" (Oliver -Bever, 1986). La racine en poudre et l'écorce ont été utilisées pour traiter les plaies et gonorrhée au Soudan, Ghana, Côte- d'Ivoire et Nigéria (Irvine, 1961).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4761,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 761)",
    "text": "\"Quinine africaine\" (Oliver -Bever, 1986). La racine en poudre et l'écorce ont été utilisées pour traiter les plaies et gonorrhée au Soudan, Ghana, Côte- d'Ivoire et Nigéria (Irvine, 1961). Aussi, un décocté de l'écorce de racine est -il",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 237,
    "source": "PDF_chunked"
  },
  {
    "id": 4762,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 762)",
    "text": "OOAS Page 159 Sarcocephalus latifolius WAHP couramment employé dans le traitement des troubles de l'estomac, de la fièvre, la toux et le paludisme (Irvine, 1961). La plante a également été utilisée comme un composant de poison de flèche dans le nord du Nigéria et de la Côte d'Ivoire. Activités biologiques et pharmacologiques Les extraits aqueux chauds de l'écorce de racine et de tige ont démontré une activité antiplasmodialein vitro contre le Plasmodium falciparum (Gbeasor, et al., 1989), tandis que les extraits méthanolique et éthanolique des fruits séchés, de la tige et de l'écorce de racine ont été reconnus comme possédant des propriétés antibactériennes et spasmolytiques (Ogunlana, 1975). L'extrait d'écorce de racine,en fonction de la dose, a causé une diminution significative de l'activité motrice spontanée et du comportement exploratoire chez des animaux de laboratoire. L'extrait a également prolongé le temps de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4763,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 763)",
    "text": "la dose, a causé une diminution significative de l'activité motrice spontanée et du comportement exploratoire chez des animaux de laboratoire. L'extrait a également prolongé le temps de sommeil pentobarbital et atténué l'intensité de la stéréotypie induite par l'apomorphine, mais n'a eu aucun effet sur la coordination motrice (Amos et al., 2005). L'extrait de racine a montré des activités antibactériennes et antifongiques à large spectre (Iwu, 1993 ; Deeni et Hussain, 1991) et l'extrait aqueux d'écorce de tronc a démontré une activité antiparasitaire (espèces variées de nématodes) chez le mouton. L'administration de l'extrait àdes moutons infestés par des vers a entraîné une amélioration des niveaux d'hémoglobine et de leucocytose (Onyeyili et al ., 2001). Les extraits des feuilles ont démontré des activités hépatoprotectrices et hypoglycémiques chez le rat (Akpanabiatu et al., 2005, Gidado et al ., 2005), tandis que l'extrait de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4764,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 764)",
    "text": "ont démontré des activités hépatoprotectrices et hypoglycémiques chez le rat (Akpanabiatu et al., 2005, Gidado et al ., 2005), tandis que l'extrait de racine a montré des effets antihepatotoxiques et inhibé la multiplication de Trypanosoma brucei en infection (Madubunyi, 1995). Données cliniques Aucune information disponible Constituants chimiques Tanins, phénols, saponines, terpènes, stéroïdes, sucres réducteurs' alcaloïd es glycoalcaloïdes et indoloquinolizidine (ex: naucletine, nauclefidine, etc.), hydrates de carbone, résines, principes amers. Tests d'identité et de pureté Teneur en en eau: 8,3 Cendre totale: 12,9 Valeur substances extractibles par l'eau: pas moins de 11,0 Valeur subtances extractibles par l'eau l'éthanol (70 ): pas moins de 6.88 Tests for identity and purity Moisture Content: 8.30 Total Ash: 12.90 Water-soluble extractive: not less than 11.00 Alcohol-soluble (70) extractive: not less than 6.88.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4765,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 765)",
    "text": "Tests for identity and purity Moisture Content: 8.30 Total Ash: 12.90 Water-soluble extractive: not less than 11.00 Alcohol-soluble (70) extractive: not less than 6.88. Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par p ulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de quatre taches distinctes avec R f de 0,47 (Rose), 0,37 (Rose), 0,19 (Rose) et 0,14 (brun-pâle). Chromatogramme Macroscopie Racine cylindrique ou brisée, matériaux légérs et moyens, surface extérieure lenticellée, écorce grisâtre-brune, bois jaune (rosé lorsque découpé frais), odeur agréable, goût amer. Microscopie",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4766,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 766)",
    "text": "Racine cylindrique ou brisée, matériaux légérs et moyens, surface extérieure lenticellée, écorce grisâtre-brune, bois jaune (rosé lorsque découpé frais), odeur agréable, goût amer. Microscopie L'écorce de la racine se compose de plusieurs couches parfois exfoliée, légèrement lignifiées, grossièrement stratifiés, des cellules de liège polygonale à parois fines; région corticale",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 379,
    "source": "PDF_chunked"
  },
  {
    "id": 4767,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 767)",
    "text": "OOAS Page 160 Sarcocephalus latifolius WAHP composée de nombreuses couches de cellules parenchymateuses oblongues et parfois sphériques; gouttelettes d'huile abondantes, cellules sécrétrices dispersées dans le cortex, de nombreuses cellules sclérenchymateuses lignifiées isolées mais habituellement en forme d'agrégats; les sclérites ont un flux lumineux réduit et sont distribués plus vers les tissus du phloème, formant un anneau un peu décousu autour d'elle ; le tissu de phloème se compose d'un réseau fin d'arrangement radial de rayons médullaires séparant les faisceaux de fibres lignifiées du phloème, parenchyme isodiamétrique avec des grains d'amidon qui abondent dans tous les tissus de l'écorce sauf dans les cellules de liège; des cristaux de rosette sont présents dans le parenchyme du phloème; le xylème, composée de grands vaisseaux dispersés dans le bois; certains imprégnés de matières jaunes; le bois est lignifié et se",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4768,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 768)",
    "text": "sont présents dans le parenchyme du phloème; le xylème, composée de grands vaisseaux dispersés dans le bois; certains imprégnés de matières jaunes; le bois est lignifié et se compose d'éléments de gros vaisseaux, trachéides, des fibres de bois et des cellules de parenchyme avec plusieurs grains d'amidon. Matériel végétal en poudre Brun-jaunâtre, odeur agréable, goût amer, cellules de liège lignifiées à parois minces, cellules parenchymateuses et sclerenchymateuses corticales, individuellement et en petits groupes, rayons médullaires, vaisseaux de xylème et de phloème, sclérites (certaines avec un grand flux lumineux) ; f ibres (certaines lignifiées), parenchyme, grains d'amidon, cristaux d'oxalate de calcium faiblement distribués, cellules de rosette sécrétrices de gouttelettes d'huile présentes dans la drogue en poudre. Actions thérapeutiques Antibactérien, antipaludique, antipyrétique, cytotoxique, diurétique, fébrifuge, stomachique, tonique.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4769,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 769)",
    "text": "dans la drogue en poudre. Actions thérapeutiques Antibactérien, antipaludique, antipyrétique, cytotoxique, diurétique, fébrifuge, stomachique, tonique. Indications thérapeutiques Douleurs abdominales, hémorroïdes, dysenterie, arthrite, caries dentaires, diarrhée, fièvre, hépatite infectieuse, paludisme, oligourie, bouche septique , mal de dents (Mshana et al ., 2000; GHP, 1992; Oliver-Bever, 1960). Données de sécurité L'extrait aqueux avait une DL 50 2000 mgkg (p.o.) chez les rats et les souris; aucune activité toxique significative n'a été observée au niveau des organes ou du sys tème, durant les 28 jours de l'étude de la DL 50 de l'extrait aqueux de l'écorce de tronc ( p.o) s'est avéré être 3000 mgkg chez le rat; Il n'y avait aucune preuve de toxicité pour les animaux dans l'étude de toxicité subaiguë de 14 jours (300- 3000 mgkg) et aucune anomalie au niveau du foie et des enzymes hépatiques AST, ALP et ALT chez les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4770,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 770)",
    "text": "toxicité pour les animaux dans l'étude de toxicité subaiguë de 14 jours (300- 3000 mgkg) et aucune anomalie au niveau du foie et des enzymes hépatiques AST, ALP et ALT chez les rats. Il n'y avait aucun effet sur la bilirubine conjuguée et totale qui résulte souvent d'un ictère ou d'une maladie du foie; aucun effet sur la créatinine ou l'urée qui sont des indicateurs sensibles de la fonction rénale et aucun effet sur les triglycérides, le cholestérol et le glucose. Globalement, l'extrait de plante n'affecte pas négativement le système hématopoïétique. L'extrait fait apparaitre certaines proprié tés psychoactives chez les rongeurs (50- 200 mgkg p.o.) prolongeant la durée et le raccourcissement de l'apparition du sommeil induit par le pentobarbital chez les rats, en fonction de la dose. Il a (50- 200 mgkg p.o. ) également significativement (p 0,05) réduit le SMA chez la souris. La réduction était liée à la dose et au temps. Précautions d'emploi",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4771,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 771)",
    "text": "dose. Il a (50- 200 mgkg p.o. ) également significativement (p 0,05) réduit le SMA chez la souris. La réduction était liée à la dose et au temps. Précautions d'emploi Ne pas dépasser les doses recommandées. Effets indésirables Peut retarder l'accouchement. Contre-indications Inertie utérine, rétention urinaire, consti pation, grossesse. Dosage et forme galénique Préparation locale: 250 g macérés dans environ 600 ml de \"gin\" (boisson alcoolisée locale) ou de l'eau chaude; 100 ml pris par voie orale deux ou trois fois par jour selon la sévérité de l'état fébrile. Teinture: 1:5 à 50 d'éthanol, de 5 ml trois fois par jour. Conservation A conserver dans un endroit frais et sec. Références Akpanabiatu, M.I., Umoh, I.B., Eyong, E.U., Udoh, F.V. (2005). Influence of Nauclea latifolia Leaf Extracts on Some Hepatic Enzymes of Rats Fed on Coconut Oil and Non- Coconut Oil Meals. Pharmaceutical Biology (Formerly International",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4772,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 772)",
    "text": "Udoh, F.V. (2005). Influence of Nauclea latifolia Leaf Extracts on Some Hepatic Enzymes of Rats Fed on Coconut Oil and Non- Coconut Oil Meals. Pharmaceutical Biology (Formerly International Journal of Pharmacognosy 43(2):153-157. Amos, S., Abbah, J., Chindo, B., Edmond, I., Binda, L. et al., (2005). Neuropharmacological effects of the aqueous extract of Nauclea latifolia root bark in rats and mice. Journal of Ethnopharmacology 97(1): 53-57. Deeni, Y., Hussain, H. (1991). Screening for",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 489,
    "source": "PDF_chunked"
  },
  {
    "id": 4773,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 773)",
    "text": "OOAS Page 161 Sarcocephalus latifolius WAHP antimicrobial activity and for alkaloids of Nauclea latifolia. Journal of Ethnopharmacology 35:91 96. Gidado, A., Ameh, D.A., Atawodi, S.E. (2005). Effect of Nauclea latifolia leaves aqueous extracts on blood glucose levels of normal and alloxan-induced diabetic rats. African Journal of Biotechnology 4(1):91-93. Gbeassor, M., Tona, L., Kossou, Y., Amegbo, K., De souza, C. et al. (1989). Antimalarial effects of eight African medicinal plants. Journal of Ethnophamacology 25:115-118. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana. Hotellier, F., Delaveau, P., Poussett, J.I. (1981). Naucleofoline, a new alkaloid from Nauclea latifolia SM (Rubiacea). C.R. Seances Acad. Sci. Ser. 2 293(8):577-578. Irvine, E.R. (1961). Woody Plants of Ghana.Oxford University Press, London. Pp 963- 965. Iwu, M.M. (1993). A handbook of African medicinal plants. CRC Press, Boca Raton, FL, USA.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4774,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 774)",
    "text": "Irvine, E.R. (1961). Woody Plants of Ghana.Oxford University Press, London. Pp 963- 965. Iwu, M.M. (1993). A handbook of African medicinal plants. CRC Press, Boca Raton, FL, USA. Madubunyi, I. (1995). Anti -hepatotoxic and Trypanocidal Activities of the ethanolic root extract of Nauclea latifolia root bark. Journal of Herbs Spices and Medicinal Plants, 3(2): 23-53. Mshana, N.R., Abbiw, D.K., Addae -Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Ogunlana, E.O., Ramstad, E. (1975). Investigation into the antibacterial activities of local plants. Planta Medica 27:354. Oliver-Bever, B. (1986). Medicinal plants in Tropical West Africa. Cambridge University Press, London.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 878,
    "source": "PDF_chunked"
  },
  {
    "id": 4775,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 775)",
    "text": "Investigation into the antibacterial activities of local plants. Planta Medica 27:354. Oliver-Bever, B. (1986). Medicinal plants in Tropical West Africa. Cambridge University Press, London. Oliver-Bever, B. (1960). Medicinal Plants in Nigeria. Lectures delivered in 1959 in the Pharmacy Department of the Nigerian College of Arts, Science and Technology. Nigerian College of Art and Technology: Nigeria. Onyeyili, P.A., Nwosu C.O., Amin, J.D., Jibike, J.I. (2001). Anthelmintic activity of crude aqueous extract of Nauclea latifolia stem bark against ovine nem atodes. Fitoterapia 72(1):12- 21.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 594,
    "source": "PDF_chunked"
  },
  {
    "id": 4776,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 776)",
    "text": "OOAS Page 162 Sclerocarya birrea WAHP Nom botanique Sclerocarya birrea (A. Rich) Hochst. Famille Anacardiaceae Synonyme Sclerocarya caffra Sond, Poupartia caffra (Sond.), Poupartia birrea (A.Rich.), Spondias birrea Noms communs (Anglais) Marula, Cider tree; Prunier d'Afrique, Sclérocarya à bière, prunier jaune (en français). Noms vernaculaires Burkina Faso : Mooré Nobέga;Noabga, Dioula N'gouna;kunan;kuntan, Fulfuldé Hedi Cote d'Ivoire: Malinké N'guma Ghana: Dagbani M umuga, Mole Noagba Mali: Bambara N'gunan Kutan Dao, Dogon Bi, Peulh: He Di, Kedέ, Έri, Hέdέhi Niger: HaussaDania, Zarma Diney, Béribéri Koma Sénégal: Wolof Bir Ber, Basari Ngudy Description de la plante S. birrea est un arbre à feuilles de taille moyenne, à tige unique, terrestre, dressé, caduque, pérenne d'environ 10- 15 m de hauteur (van Wyk et al., 1997). L'écorce de la tige est",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 856,
    "source": "PDF_chunked"
  },
  {
    "id": 4777,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 777)",
    "text": "S. birrea est un arbre à feuilles de taille moyenne, à tige unique, terrestre, dressé, caduque, pérenne d'environ 10- 15 m de hauteur (van Wyk et al., 1997). L'écorce de la tige est rugueuse, avec un aspect gris -tacheté en raison du gris contrastant qu'elle a et son motif brun pâle. Les feuilles sont composées, caduques, imparipennées, de 7 à 10 paires de folioles ovales, ellipt iques et glabres, les folioles sont vertes à la surface supéieure et plus claires sur la face inférieure.,; Elles sont habituellement dentelées seulement quand elle sont jeunes, sinon entières. Les fleurs sont petites, dioïques, de couleur verdâtre, en épis plus courts de 2 cm de long à la charge sur les petites grappes allongées à l'extrémité des branches et apparaissent généralement avant les feuilles, le fruit est une drupe verte sur l'arbre, tombant à l'automne et devenant jaune clair au sol; il a trois graines contenues dans le noyau dur. La",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4778,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 778)",
    "text": "apparaissent généralement avant les feuilles, le fruit est une drupe verte sur l'arbre, tombant à l'automne et devenant jaune clair au sol; il a trois graines contenues dans le noyau dur. La pulpe charnue est très nutritive; les arbres femelles de S. birrea soutiennent les fruits pierreux comme une prune d'environ 30 mm de diamètre) (Thovhogi, 2009; van Wyk et al ., 2000; Ojewole, 2003). Numéro du spécimen d'herbier Ghana: GC 35847 Mali: 0071 DMT Habitat et répartition géographique Originaire de l'Afrique tropicale, le Sclerocarya birrea est très répandue au Nord du Kwazulu- Natal dans la zone soudano- sahélienne de l'Ethiopie (Afrique du Sud), dans le sud de la Gambie, à l'ouest du Nigeria et du Cameroun en Afrique centrale, et à l'Est du Kenya et du Soudan (Thovhogi, 2009; Belemtougri et al., 2007). La plante pousse naturellement dans divers types de bois, sur un sol sableux ou une terre occasionnellement sableuse. Parties utilisées de la plante",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 4779,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 779)",
    "text": "2007). La plante pousse naturellement dans divers types de bois, sur un sol sableux ou une terre occasionnellement sableuse. Parties utilisées de la plante Feuille, écorce de la tige Autres parties utilisées Racines et fruits Caractéristiques botaniques Le Sclerocarya se compose de feuilles ou d'écorce de la tige fraîche ou séchée de Sclerocarya birrea (A. Rich) Hochst. (Anacardiaceae). Utilisations ethnomédicales Les feuilles de Sclerocarya birrea sont utilisées pour traiter l'ictère et l'écorce est combinée avec les feuilles de Cymbopogon gigantus pour traiter l'ascite. La plante est efficace dans le traitement de la rougeole. Une boisson faite à partir des feuilles est utilisée pour traiter la gonorrhée et les racines et l'écorce comme laxatifs. La macération de l'écorce du tronc est utilisée dans le traitement de la douleur abdominale, des nausées, des vomissements, de la syphilis, la dysenterie, le rhumatisme et a un effet",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4780,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 780)",
    "text": "macération de l'écorce du tronc est utilisée dans le traitement de la douleur abdominale, des nausées, des vomissements, de la syphilis, la dysenterie, le rhumatisme et a un effet prophylactique contre le paludisme. L'écorce du tronc, en combinaison avec Momordica balsamina est indiquée pour les morsures de serpent ou piqûre de scorpion. L'écorce est un",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 355,
    "source": "PDF_chunked"
  },
  {
    "id": 4781,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 781)",
    "text": "OOAS Page 163 Sclerocarya birrea WAHP remède efficace pour traiter les hémorroïdes. Les pellets fabriqués à partir de l'écorce sont utilisés pour les névralgies de la carie dentaire (Adjanohoun et al., 1980). Au Ghana, les feuilles sont utilisées pour traiter les morsures de serpent, et le prurit (filaire); l'écorce de la tige, la racine et les fruits sont utilisées pour traiter respectivement la pharyngite, la splénomégalie et le goitre, (Mshana et al ., 2000.). Extérieurement, la pâte de l'écorce est ajoutée au beurre de karité et appliqué sur le front pour traiter la migraine et la blépharite. Le jus de fruits est efficace dans le traitement des infections de l'oreille, de la constipation, de l'hypertension, de l'anorexie, et du scorbut. Les graines sont recommandées par certains thérapeutes pour asthénie (Kerharo et Adams, 1974). Activités biologiques et pharmacologiques La plante dispose de propriétés antidiabétiques,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4782,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 782)",
    "text": "recommandées par certains thérapeutes pour asthénie (Kerharo et Adams, 1974). Activités biologiques et pharmacologiques La plante dispose de propriétés antidiabétiques, analgésiques, antiplasmodiale, anti - inflammatoires, antidiarrhéiques, antimicrobiennes, antihypertenseur, anticonvulsivant, gas troprotecteur et antioxydant (Ojewole et al. 2010;Makom et al ., 2010; Fotio et al. 2010; Keita, 2005; Ojewole, 2002; Van de Venter et al., 2008; Gondwe et al., 2008;Dimo et al., 2007; Coulibaly, 1988; Haidara, 1999; Laurens, 1976; Gueye et al., 1973). Selon Gueye (1973), l'administration orale et intrapéritonéale de l'extrait aqueux des feuilles a un effet sur la glycémie et une action périphérique sur la captation du glucose chez les rats. L'extrait éthanolique de l'écorce de tronc réduit la pression artérielle et a un effet protecteur sur les reins et le cœur pendant le diabète (Gondwe et al., 2008). Les extraits méthanoliques et aqueux",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4783,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 783)",
    "text": "éthanolique de l'écorce de tronc réduit la pression artérielle et a un effet protecteur sur les reins et le cœur pendant le diabète (Gondwe et al., 2008). Les extraits méthanoliques et aqueux de l'écorce de tronc administrés par voie orale à une dose de 500 mgkg ont montré une action anti-inflammatoire encourageante sur l'œdème de la patte du rat (Ojewole, 2002) et une dose de 300 mgkg d'extrait méthanolique de l'écorce de tronc a montré une inhibition maximale à la fois sur l'inflammation aiguë et chronique chez le rat (Fotio et al ., 2009). L 'extrait aqueux de l 'écorce de tige a des propriétés hypotensives et vasorelaxante (Ojewole, 2006). Les extraits aqueux, éthanolique et chloroformique ont un effet antagonique significatif sur la libération de calcium induite par la caféine du réticulum sarcoplasmique (Belemtougri et al. 2001). L'activité antidiarrhéique des tanins et des procyanidines du décocté lyophilisé de l'écorce",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4784,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 784)",
    "text": "calcium induite par la caféine du réticulum sarcoplasmique (Belemtougri et al. 2001). L'activité antidiarrhéique des tanins et des procyanidines du décocté lyophilisé de l'écorce de tronc a été démontrée (Galvez et al ., 1991). L'extrait acétonique de l'écorce de la tige et des feuilles ont démontré des propriétés antibactériennes contre Staphylococcus aureus , Pseudomonas aeruginosa, Escherichia coli , Enterococcus faecalis et Mycobacterium tuberculosis (Green et al., 2010; Eloff, 2001). Les extraits acétoniques et aqueux de l'écorce de tronc ont montré une forte activité antibactérienne contre les souches de Helicobacter pylori - résistantes au métronidazole à la clarithromycine (Njume et al., 2011B; Njume et al., 2011 a.). La valeur nutritive des noix de Sclerocarya birrea a également été démontrée chez les enfants (Glew et al., 2004). Données cliniques Les propriétés antidiabétiques des feuilles macérées et décoctées ont été confirmés par",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 4785,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 785)",
    "text": "démontrée chez les enfants (Glew et al., 2004). Données cliniques Les propriétés antidiabétiques des feuilles macérées et décoctées ont été confirmés par des études cliniques (Gueye, 1973). Les essais cliniques ont montré l'efficacité de la décoction des feuilles chez des patients diabétiques de type 2 (Sanogo, 2007). Constituants chimiques Tanins (Ester galloyl épicatéchine- 3-), alcaloïdes, saponines, flavonoïdes, terpènes, coumarines, triterpénoïdes, phytostérols, glucides, huiles, protéines, fibres, acide ascorbique et minéraux (Ojewole et al ., 2010 ; Glew et al., 2004 ; Bracca et al., 2003; Haidara, 1999; Smith et al., 1996; Galvez et al., 1992; Eromosele et al., 1991;. Dao, 1988; Laurens, 1976; Kerharo et Adams, 1974). Tests d'identité et de pureté Teneur en humidité: 7.80 (feuilles) 7.80 (écorce de la tige) Centre totale: 9.30 (feuilles) 6.41 (écorce de la tige) Cendre sulfatée: 16.11 (feuilles) 9.54 (écorce de la tige)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4786,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 786)",
    "text": "Teneur en humidité: 7.80 (feuilles) 7.80 (écorce de la tige) Centre totale: 9.30 (feuilles) 6.41 (écorce de la tige) Cendre sulfatée: 16.11 (feuilles) 9.54 (écorce de la tige) Valeur substances extractibles par l'eau: pas moins de 31.30 (feuilles) 27.30 (écorce de la tige)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 273,
    "source": "PDF_chunked"
  },
  {
    "id": 4787,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 787)",
    "text": "OOAS Page 164 Sclerocarya birrea WAHP Valeur substances extractibles par l'éthanoll (70): pas moins de 21 (feuilles) Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60 F254, et phase mobile : éther de pétrole (40-60oC) chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml), 85 ml de méthanol et 5 ml d'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10 mn. Présence de quatre taches distinctes avec R f de 0,88 (rose), 0,48 (rose), 0,32 (rose) et 0,10 (rose). Chromatogramme Macroscopie Les feuilles sont im paripennées, opposées, avec desfolioles un peu elliptiques, arrondies ou dentées au bord; les veines de remplacement sont de chaque côté du pétiole et le bord du limbe incurvé est asymétrique avec un pétiole très court. Microscopie",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4788,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 788)",
    "text": "dentées au bord; les veines de remplacement sont de chaque côté du pétiole et le bord du limbe incurvé est asymétrique avec un pétiole très court. Microscopie Présence d'une coupe tr ansversale dorsoventrale, une couche palissadique unique; un mésophylle rempli d'amidon, heurte sur le collenchyme dans la région de la nervure centrale, des caractéristiques sous -épidermiques de masses de collenchyme sur les deux surfaces, un faisceau vas culaire bicollatéral, entouré par des fibres péricycliques lignifiés; des stomates isocytiques sur les deux surfaces, de nombreux poils pluricellulaires dans les jeunes feuilles, abondantes sur la nervure centrale et les veines. Matériel végétal en poudre Abondants cristaux d'oxalate de calcium, fragments d'épiderme, grains d'amidon, nombreux fragments de tissus, stomates sur le fragment épidermes, quelques fragments de tissus de xylème, nombreux fragments de fibres sclérenchyme. Actions thérapeutiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4789,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 789)",
    "text": "nombreux fragments de tissus, stomates sur le fragment épidermes, quelques fragments de tissus de xylème, nombreux fragments de fibres sclérenchyme. Actions thérapeutiques Antidiabétique (Gueye, 1973, Laurens, 1976, Coulibaly, 1988; Haidara, 1999; Ojewole, 2003); vasorelaxants et hypotenseur (Ojewole, 2006;. Belemtougri et al ., 2001); antidiarrhéiques et antibactériens (Eloff, 2001); analgésiques, anti - inflammatoire, antimicrobien, antiplasmodiale, anticonvulsivant et antioxydant (Ojewole, 2003, Van de Venter et al ., 2008, Dimo et al ., 2007;.. Ojewole, 2002; Ojewole et al ., 2010;.. Fotio et al., 2010), anti -mycobacterium tuberculosis (Green et al., 2010) anti -Helicobacter pylor i (Njume et al., 2011B, Njuma et al., 2011a). Indications thérapeutiques Diabète sucré ou diabète de type 2. Données de sécurité L'étude de toxicité aiguë de 24 heures a montré que la DL 50 des extraits aqueux de l'écorce de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 4790,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 790)",
    "text": "Indications thérapeutiques Diabète sucré ou diabète de type 2. Données de sécurité L'étude de toxicité aiguë de 24 heures a montré que la DL 50 des extraits aqueux de l'écorce de la tige ( p.o) chez la souris e st 2000 mgkg. Les études subaigües n'ont montré aucun signe clinique de toxicité après traitement pendant 14 jours de la souris mâle et femelle (500 à 2000 mgkg; p.o). Dans les études de toxicité sub- chronique, l'administration répétée de l'extrait aqueux des feuilles pendant 45 jours n'a pas affecté les paramètres biochimiques du sang, le foie et la fonction rénale. Le poids relatif du foie, la rate et les reins n'ont pas été affectés; les caractéristiques histologiques étaient normales. L'administration répétée de l'extrait aqueux de l'écorce pendant 45 et 90 jours n'a pas causé d'importants changements dans le poids corporel et relatif des organes cibles (foie, rate et rein). L'extrait aqueux n'a pas causé une anémie, mais",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4791,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 791)",
    "text": "l'écorce pendant 45 et 90 jours n'a pas causé d'importants changements dans le poids corporel et relatif des organes cibles (foie, rate et rein). L'extrait aqueux n'a pas causé une anémie, mais provoqué une hypoglycémie. D es transaminases hépatiques ont été en particulier affectées à une dose élevée de 1000 mgkg; les caractéristiques histologiques étaient normales. La créatinine est restée normale, avec une légère augmentation des niveaux d'acide urique par rapport au grou pe témoin. Précautions d'emploi L'extrait aqueux de la plante peut provoquer l'hypoglycémie et augmenter les paramètres hépatiques et rénaux. Surveiller régulièrement les paramètres biochimiques de glycémie du foie et des reins lors d'une utilisation prol ongée. Ne pas le combiner avec d'autres médicaments hypoglycémiants, sauf sous la supervision de spécialistes.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 845,
    "source": "PDF_chunked"
  },
  {
    "id": 4792,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 792)",
    "text": "OOAS Page 165 Sclerocarya birrea WAHP Effets indésirables Maladies du rein et du foie Contre-indications Hypoglycémie Dosage et forme galénique Poudre, décoction, teinture Préparation: mettre 60g de feuilles séchées dans un litre d'eau, faire bouillir pendant 15 minutes et filtrer. Mode d'administration : par voie orale sous la forme de décoction. Dosage selon la glycémie: jusqu'à 2 g l: 60 g en 3 doses, au-delà de 2 gl: 100g en 3 doses et le traitement dure 7 jours. Le traitement d'entretien est effectué avec une dose de 40 g en 2 doses. Décoction: mettre 30 g de graines broyées dans 900 ml d'eau et laisser mijoter jusqu'à 600 ml de réduction, et boire un verre d'eau trois fois par jour. Teinture: 1:5 dans 50 d'alcool, 5 ml trois fois par jour Conservation A conserver dans un récipient bien fermé, dans un endroit frais et sec, à l'abri de la lumière. Références Adjanohoum, E., Ahyi, A.M., Aké Assi, L., Dan",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 920,
    "source": "PDF_chunked"
  },
  {
    "id": 4793,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 793)",
    "text": "par jour Conservation A conserver dans un récipient bien fermé, dans un endroit frais et sec, à l'abri de la lumière. Références Adjanohoum, E., Ahyi, A.M., Aké Assi, L., Dan Dicko, L., Daouda, H. et al . (1980). Médecine traditionnelle et pharmacopée. Contribution aux études ethnobotaniques et floristiques au Niger, Edition ACCT., Paris, 251 p. Belemtougri, R.G ., Constantin, B ., Cognard, C ., Raymond, G ., Sawadogo, L. (2001). Effects of Sclerocarya birrea (A. rich) hochst (anacardiaceae) leaf extracts on calcium signalling in cultured rat skeletal muscle cells. Journal of Ethnopharmacology 76(3):247-252. Braca, A., Politi, M., Sanogo, R. , Sanou, H, Morelli, I. et al . (2003). The Chemical Composition and Antioxidant Activity of Phenolic Compounds from Wild and Cultivated Sclerocarya birrea (Anacardiaceae) Leaves. Journal of Agricultural and Food Chemistry (51):66898-6695. Coulibaly, B. (1988). Contribution à l'étude des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4794,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 794)",
    "text": "Compounds from Wild and Cultivated Sclerocarya birrea (Anacardiaceae) Leaves. Journal of Agricultural and Food Chemistry (51):66898-6695. Coulibaly, B. (1988). Contribution à l'étude des remèdes traditionnels utilisés dans le traitem ent du diabète au Mali, Thèse de pharmacie, Bamako (Mali), N88, 113 p. Dao, A. (1988). Etudes botaniques et phytochimiques de Sclerocarya birrea (A. Rich). Hochst. (Anacardiaceae), Thèse de pharmacie, Bamako (Mali), N38, 69 p. Dimo, T., Rakotonirina, S.V., Tan, P.V., Azay, J., Dongo, E . et al . (2007). Effect of Sclerocarya birrea (Anacardiaceae) stem bark met hylene chloridemethanol extract on streptozotocin- diabetic rats. Journal of Ethnopharmacology 110(3):434-438. Eloff, J.N. (2001). Antibacterial activity of Marula (Sclerocarya bir rea (A. Rich.) Hochst. subsp. caffra (Sond.) Kokwaro) (Anacardiacae) bark and leaves. Journal of Ethnopharmacology 76(3): 305308. Eromosele, I.C., Eromosele, C.O., Kuzhkuzha,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 4795,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 795)",
    "text": "(Sclerocarya bir rea (A. Rich.) Hochst. subsp. caffra (Sond.) Kokwaro) (Anacardiacae) bark and leaves. Journal of Ethnopharmacology 76(3): 305308. Eromosele, I.C., Eromosele, C.O., Kuzhkuzha, D.M. (1991). Evaluation of mineral elements and ascorbic acid contents in fruit s of some wild plants. Plant Foods and Human Nutrition 41(2):151-154. Fernandes, R., Fernandes, A. (1966). Anacardiaceae. In: Exell, A.W., Fernandes, A. Wild, H. (Editors). Flora Zambesiaca. Volume 2, part 2. Crown Agents for Oversea Governments and Adm inistrations, London, United Kingdom. pp. 550615. Fotio, A.L., Dimo, T., Nguelefack, T.B., Dzeufiet, P.D., Ngo Lemba, E . et al . (2009). Acute and chronic anti -inflammatory properties of the stem bark aqueous and methanol extracts of Sclerocarya birrea (Anacardiaceae). Inflammopharmacology 17(4):229-237. Fotio, A.L., Olleros, M.L., Vesin, D ., Tauzin, S ., Bisig, R . et al . (2010). In vitro inhibition of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4796,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 796)",
    "text": "Sclerocarya birrea (Anacardiaceae). Inflammopharmacology 17(4):229-237. Fotio, A.L., Olleros, M.L., Vesin, D ., Tauzin, S ., Bisig, R . et al . (2010). In vitro inhibition of lipopolysaccharide and Mycobacterium bovis bacillus Calmette Guérin- induced inflammatory cytokines and in vivo protection from D - galactosamineLPS -mediated liver injury by the medicinal plant Sclerocarya birrea. International Journal of Immunopathology and Pharmacology 23(1):61-72. Galvez, J., Zarzuelo, A.M.E., Utrilla, M.P., Jimenez, J., Spiessens, C. et al . (1991). Antidiarrhoic activity of Sclerocarya birrea bark Extract and it's active tannin constituent in Rats. Research phytotherapy 5:276-278. Galvez, J., Zarzuelo, A., Busson, R., Cobbaert, C., De Witte, P. (1992). (-)-Epicatechin-3-galloyl",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 782,
    "source": "PDF_chunked"
  },
  {
    "id": 4797,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 797)",
    "text": "OOAS Page 166 Sclerocarya birrea WAHP ester: a secretagogue compound from the bark of Sclerocarya birrea. Planta Medica 58(2):174- 175. Glew, R.S., VanderJagt, D.J., Huang, Y.S., Chuang, L.T., Bosse, R. et al . (2004). Nutrtional analysis of the edible pit of Sclerocarya birrea (A. Rich). Hochst. In the Republic of Niger (daniya, Haussa). Journal of Food Composition and Analysis 17:99-111. Gondwe, M, Kamadyaapa, D.R ., Tufts, M ., Chuturgoon, A.A ., Musabayane, C.T . (2008). Sclerocarya birrea (A. Rich.) Hochst. Anacardiaceae stem -bark ethanolic extract (SBE) modulates blood glucose, glomerular filtration rate (GFR) and mean arterial blood pressure (MAP) of STZ -induced diabetic rats. Phytomedicine 15(9):699-709. Green, E., Samie, A., Obi, C.L. , Bessong, P.O ., Ndip, R.N . (2010). Inhibitory properties of selected South African medicinal plants against Mycobacterium tuberculosis. Journal of Ethnopharmacology 130(1):151-157.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4798,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 798)",
    "text": "Ndip, R.N . (2010). Inhibitory properties of selected South African medicinal plants against Mycobacterium tuberculosis. Journal of Ethnopharmacology 130(1):151-157. Gueye, M. (1973). Contribution à l'ét ude pharmacodynamique d'une plante antidiabétique (Sclerocarya birrea (A. Rich). Hochst., Thèse doctorat sciences pharmaceutiques. Dakar. Sénégal. Haidara, T. (1999). Etude botanique, phytochimique et pharmacologique de trios plantes de la pharmacopée mal ienne indiquées dans le traitement du diabète, Thèse Pharmacie, FMPOS, Université de Bamako, Mali. Kerharo, J., Adams, J.G. (1974). La pharmacopée sénégalaise traditionnelle plantes médicinales et toxiques, Edition Vigot et frères, Paris, 1011 p. Laurens, A. (1976). Sur des Anacardiacées africaines et malgaches, Poupartia birrea , Pourpartia caffra et Anacardium occidentale (Etude particulière des polyphénols des feuilles), Thèse doctorat, Pharm. (Etat), Paris.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4799,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 799)",
    "text": "africaines et malgaches, Poupartia birrea , Pourpartia caffra et Anacardium occidentale (Etude particulière des polyphénols des feuilles), Thèse doctorat, Pharm. (Etat), Paris. Makom N,I.G ., Frigerio, F ., Casimir, M., Ngueguim, T.F ., Dongo, E . et al. (2010). Sclerocarya birrea (Anacardiaceae) stem -bark extract corrects glycaemia in diabetic rats and acts on beta- cells by enhancing glucose- stimulated insulin secretion. Journal of Endocrinology 205(1):79-86. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al ., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Njume, C ., Afolayan, A.J ., Ndip, R.N . (2011a). Preliminary Phytochemical Screening and In Vitro Anti-Helicobacter pylori Activity of Acetone and Aqueous Extracts of the Stem Bark of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4800,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 800)",
    "text": "Njume, C ., Afolayan, A.J ., Ndip, R.N . (2011a). Preliminary Phytochemical Screening and In Vitro Anti-Helicobacter pylori Activity of Acetone and Aqueous Extracts of the Stem Bark of Sclerocarya birrea (Anacardiaceae). Archives of Medical Research 42(3):252-257. Njume, C., Afolayan, A.J., Green, E., Ndip, R.N. (2011). Volatile compounds in the stem bark of Sclerocarya birrea (Anacardiaceae) possess antimicrobial activity against drug- resistant strains of Helicobacter pylori. , 38(4): 319-324. Ojewole, J.A.O. (2002). Eva luation of the anti - inflammatory properties of Sclerocarya birrea (A. Rich). Hochst. (family: Anacardiaceae) stem -bark extracts in rats. Journal of Ethnopharmacology 85:217-220. Ojewole, J.A. (2003). Hypoglycemic effect of Sclerocarya birrea (A. Rich.) H ochst. Anacardiaceae stem -bark aqueous extract in rats. Phytomedicine, 10(8):675-681. Ojewole, J.A . (2006). Vasorelaxant and hypotensive effects of Sclerocarya birrea (A",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4801,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 801)",
    "text": "Anacardiaceae stem -bark aqueous extract in rats. Phytomedicine, 10(8):675-681. Ojewole, J.A . (2006). Vasorelaxant and hypotensive effects of Sclerocarya birrea (A Rich) Hochst (Anacardiaceae) stem bark aqueous extract in rats. Cardiovascular Journal of South Africa 17(3):117-123. Ojewole, J.A ., Mawoza, T ., Chiwororo, W.D ., Owira, P.M. (2010). Sclerocarya birrea (A. Rich) Hochst. 'Marula' (Anacardiaceae): a review of its phytochemistry, pharmacology and toxicology and its ethnomedicinal uses. Phytotherapy Research 24(5):633-639. Sanogo, S. (2007). Etude de la phytochimie et de l'effet hypoglycémiant de trois plantes utilisées dans la pharmacopée traditionnelle au Mali, Thèse Pharmacie, FMPOS, Université de Bamako, Mali. Smith, G.C ., Clegg, M.S ., Keen, C.L. , Grivetti, L.E. (1996). Mineral values of selected plant foods common to southern Burkina Faso and to Niamey, Niger, West Africa. International Journal",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4802,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 802)",
    "text": "Smith, G.C ., Clegg, M.S ., Keen, C.L. , Grivetti, L.E. (1996). Mineral values of selected plant foods common to southern Burkina Faso and to Niamey, Niger, West Africa. International Journal of Food Science and Nutrition 47(1):41-53.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 234,
    "source": "PDF_chunked"
  },
  {
    "id": 4803,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 803)",
    "text": "OOAS Page 167 Sclerocarya birrea WAHP Van de Venter, M., Roux, S., Bungu, L.C., Louw, J., Crouch, N.R . et al . (2008). Antidiabetic screening and scoring of 11 plants traditionally used in South Africa. Journal of Ethnopharmacology 119(1):81-86.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 246,
    "source": "PDF_chunked"
  },
  {
    "id": 4804,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 804)",
    "text": "OOAS Page 168 Scoparia dulcis WAHP Nom botanique Scoparia dulcis L. Famille Scrophulariaceae Synonyme Scoparia ternata Forssk; Capraria dulcis (L) Kuntze; Gratiola micrantha Franch Sav. Noms communs Anglais: Sweet broom; bitter broom; broom weed; licorice weed Noms vernaculaires Burkina Faso : Mooré koostiiga, Dioula N'timintiminin Ghana: Twi Onyame ko metiri; Fante Oguan nkyene, Ga Shuoblo Mali: Bamabara Ntimitimini, Bruturut Sénégal: Balanta Brutulut Sierra Leone: Bulom Tjunkae Description de la plante Une plante arbustive dressée de 20- 70 cm de haut avec des tiges glabres, des feuilles opposées ou verticillées, étroitement lancéolées, crénelées dans la moitié supérieure, rétrécies, entière dans la moitié inférieure et glabre. Les fleurs sont en grappes minces au niveau supérieur des aisselles des feuilles avec quatre pétales, blanches ou bleuâtres et un fond velu; le fruit est une capsule globuleuse.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 917,
    "source": "PDF_chunked"
  },
  {
    "id": 4805,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 805)",
    "text": "fleurs sont en grappes minces au niveau supérieur des aisselles des feuilles avec quatre pétales, blanches ou bleuâtres et un fond velu; le fruit est une capsule globuleuse. Numéro du spécimen de l'herbier Mali: DMT 941 Nigeria: FHI 65355 Togo: TOGO08437 Habitat et répartition géographique C'est une mauvaise herbe similaire à celle qu'on retrouve dans les décharges d'ordures, dans les villages et aux abords des chemins et routes, ainsi que dans les endroits marécageux. Il est largement distribué dans de nombreux pays tropicaux. Parties utilisées de la plante Feuilles Autres parties utilisées Rameaux, écorce, racine Caractéristiques botaniques Le balai doux se compose de la feuille fraîche ou séchée de Scoparia dulcis L. (Scrophularaceae). Utilisations ethnomédicales S. dulcis est utilisé pour traiter le diabète, l'hypertension, les troubles abdominaux, la douleur, la fièvre, l'inflammation, la bronchite, les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 921,
    "source": "PDF_chunked"
  },
  {
    "id": 4806,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 806)",
    "text": "Utilisations ethnomédicales S. dulcis est utilisé pour traiter le diabète, l'hypertension, les troubles abdominaux, la douleur, la fièvre, l'inflammation, la bronchite, les hémorroïdes et l'hépatose (Hayashi, 2000; Satyanarayana 1969; Freire et al., 1993; Hayashi et al., 1993; Chow et al.,1974). La plante est utilisée contre les brûlures, l'herpès, les boutons, la dysenterie et la perte des cheveux (Luziatelli et al., 2010), les feuilles pour les problèmes dermatologiques (Rodrigues, 2006) et les troubles de la prostate (Lans, 2007b). La plante entière est utilisée dans les rituels magico- religieux (Paulino de Albuquerque et al., 2007). Activités biologiques et pharmacologiques S. dulcis a des propriétés antivirale, antitumorale, antiulcérogène, anti -inflammatoire, antidiabétique, diurétique, anti -microbienne et antioxydante. Un extrait méthanolique des feuilles a montré des eff ets anti -cancéreux (Nishino et al ., 1993). Plusieurs études portant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 964,
    "source": "PDF_chunked"
  },
  {
    "id": 4807,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 807)",
    "text": "antidiabétique, diurétique, anti -microbienne et antioxydante. Un extrait méthanolique des feuilles a montré des eff ets anti -cancéreux (Nishino et al ., 1993). Plusieurs études portant sur des composés isolés obtenus à partir de la plante ont montré qu'ils possèdent un potentiel anti-tumoral (Ahsan et al., 2003; Fulda et al., 2000; Nishino et al., 1993). Des études in vi tro et in vivo ont montré que l'acide scopadulcique B et C ont la capacité d'inhiber la prolifération cellulaire, la réplication de Herpes simplex 1, la sécrétion d'acide gastrique et la PTH stimulée par la résorption osseuse. Alors que l'acide scopadulcique B promeut des activités antitumorales, scopadulcique C qui potentialisent des effets antiviraux et inhibent l'acide α scoparique A -glucuronidase (Hayashi, 2000; Hayashi et al., 1992; Hayashi et al., 1988). Le scoparinol a démontré des activités in vivo de potentialisation analgésique, anti -inflammatoire,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4808,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 808)",
    "text": "scoparique A -glucuronidase (Hayashi, 2000; Hayashi et al., 1992; Hayashi et al., 1988). Le scoparinol a démontré des activités in vivo de potentialisation analgésique, anti -inflammatoire, diurétique et barbituriques (Ahmed et al., 2001).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 239,
    "source": "PDF_chunked"
  },
  {
    "id": 4809,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 809)",
    "text": "OOAS Page 169 Scoparia dulcis WAHP Freire et al., (1991, 1993, 1996) ont rapporté des propriétés analgésiques, anti -inflammatoires et sympathomimétique de la plante. L'acide scopaducilique B, le scopadol scopadulciol et le diacétyle (. Hayashi et al., 1987) ont montré un effet protecteur gastrique réversible inhibant l'activité H K-ATPase (Asano et al., 1990; Hayashi et al., 1990b; Hayashi et al., 1991a; Mesía -Vela et al., 2007). Les ext raits aqueux de la plante ont montré des effets antidiabétiques chez les rats (Pari et al., 2005; Latha et al., 2004; Pari et Venkateswaran, 2002) et l'activité antioxydante in vitro (Ratnasooriya et al. , 2005). D'autres études ont également montré des propriétés antioxydantes et antimicrobiennes in vitro (champignons et bactéries) de la plante (Pari et al ., 2004;Garcia et al., 2010). Les fractions de chloroformeméthanol de la plante ont montré une activité antimicrobienne contre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4810,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 810)",
    "text": "vitro (champignons et bactéries) de la plante (Pari et al ., 2004;Garcia et al., 2010). Les fractions de chloroformeméthanol de la plante ont montré une activité antimicrobienne contre plusieurs bactéries pathog ènes de l'homme et des souches de champignons (ex : Salmonella typhii, Staphylococcus aureus, Escherichia coli, Candida albicans, Aspergillus niger , etc.) (Latha et al., 2006; Lans, 2007a). Les feuilles ont une activité antiplasmodiale (Ruiz et al., 2011). L'extrait aqueux lyophilisé des parties aériennes de la plante a inhibé l'histamine ou la stimulation de béthanéchol de la sécrétion d'acide gastrique stimulée chez des souris avec la même force et avec la purification de la bioactivité- guidée de l'extrait donné à une fraction riche en flavonoïdes avec une activité spécifique 4- 8 fois plus élevés que l'extrait aqueux (Meséıa- Vela et al ., 2007;. Igoli et al., 2005). Données cliniques L'administration orale d'une dose quotidienne de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4811,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 811)",
    "text": "avec une activité spécifique 4- 8 fois plus élevés que l'extrait aqueux (Meséıa- Vela et al ., 2007;. Igoli et al., 2005). Données cliniques L'administration orale d'une dose quotidienne de 15-20 mg à des patients diabétiques, a produit une réduction de la glycosurie et de l'hyperglycémie, la cicatrisation des plaies et influencé l'augmentation de l'activité hématopoïétique (Nath et al ., 1945 à:. Dokosi, 1998). Constituants chimiques Diterpènoïdes (acide scopadulci que A, B, et C; acide scoparique A et scopaduline); triterpénoïdes (friedeline, glutinol, α- amyrine, acide bétulinique, acide ifflaionique et acide dulcioique); scopadiol, scopadulciol; amelline; coumarines, saponines, tanins, acides aminés, flavonoïdes (hydroxytricetine- 8-glucoronide-7, apigénine); alcaloïdes (6- méthoxy benzoxazolinone), oléor ésines; réducteurs de sucres (Akendengue et al., 2005; Hayashi 2000; Mahato et al., 1981; Freire, 1993; Nath, 1945). Tests d'identité et de pureté",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 967,
    "source": "PDF_chunked"
  },
  {
    "id": 4812,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 812)",
    "text": "benzoxazolinone), oléor ésines; réducteurs de sucres (Akendengue et al., 2005; Hayashi 2000; Mahato et al., 1981; Freire, 1993; Nath, 1945). Tests d'identité et de pureté Teneur en humidité: Pas plus de 9.5 Cendre totale: 11.22 Valeur substancesextractibles par l'eau: Pas moins de 15.06 Valeur substances extractibles par l'éthanol (70) : Pas moins de 18.29 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60 F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10 mn. Présence de trois taches distinctes avec R f de 0.85 (rose), 0,59 (marron) et 0,42 (rose). Chromatogramme",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 889,
    "source": "PDF_chunked"
  },
  {
    "id": 4813,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 813)",
    "text": "OOAS Page 170 Scoparia dulcis WAHP Macroscopie Feuilles simples, pétiolées, opposée et verticillées; forme elliptiques ou étroitement lancéolées; marges dentelées; 2,5- 5,0 cm de long, 1,5 cm de large; sommet aigu; base symétrique; nervation pennée; texture papyracée, couleur verte; odeur particulière; goût légèrement amer . Microscopie Les deux faces supérieure et inférieure montrent des cuticules striés; des parois supérieures de cellules épidermiques sont ondulées et les parties inférieures plus ondulées; des stomates anisocytiques sont sur les deux faces, plus abondante sur la surface inférieure; les poils glandulaires sont sur la surface inférieure; la section transversale montre des épidermes vallonnés, papilleuses; les feuilles sont de type biface. La couche de palissade est interrompue dans la région de la nervure médiane par des cellules collenchymes; la nervure médiane est proéminente sur la surface inférieure; le faisceau",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4814,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 814)",
    "text": "biface. La couche de palissade est interrompue dans la région de la nervure médiane par des cellules collenchymes; la nervure médiane est proéminente sur la surface inférieure; le faisceau vasculaire est garanti ; les vaisseaux de xylème en spirale sont lignifiés avec des corps refringents (oléorésine) présents dans toutes les cellules; les cristaux prismatiques d'oxalate de calcium sont présents dans de nombreux tissus. Matériel végétal en poudre Couleur Verte; odeur spécifique; goût légèrement amer; cellules épidermiques parenchymateuses, fragments de limbe montrant des stomates anisocytiques; poils glandulaires, veines avec éléments de faisceaux vasculaires lignifiés, spirales; prismes d'oxalate de calcium; présence d'huile; présence de grains d'amidon. Actions thérapeutiques Antiasthmatique, fébrifuge, antidiabétique, anticancéreux, analgésiques, antihypertenseur, antioxydant, antimicrobien, antispasmodique (Mshana et al. 2000; GHP 1992).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 4815,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 815)",
    "text": "Actions thérapeutiques Antiasthmatique, fébrifuge, antidiabétique, anticancéreux, analgésiques, antihypertenseur, antioxydant, antimicrobien, antispasmodique (Mshana et al. 2000; GHP 1992). Indications thérapeutiques Diabète, hypertension légère, troubles menstruels (douleur, crampe, syndrome prémenstruel), infections des voies respiratoires bactériennes et virales (maux de gorge et ulcérations de la bouche), douleur (arthrite, migraine, maux de tête, maux d'estomac, douleurs musculaires), maladies vénériennes et infections des voies urinaire, varices, helminthiases intestinales, toux, asthme (Mshana et al., 2000; GHP, 1992). Données de sécurité Les études animales (100 -3000 mgkg) chez le rat ont montré que la DL 50 de l'extrait aqueux des feuilles de Scoporia dulcis (p.o) était au -delà de 3000 mgkg et qu'il n'y avait pas de manifestation de signes cliniques de toxicité au cours de la période de l'étude de toxicité aiguë. Il",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4816,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 816)",
    "text": "feuilles de Scoporia dulcis (p.o) était au -delà de 3000 mgkg et qu'il n'y avait pas de manifestation de signes cliniques de toxicité au cours de la période de l'étude de toxicité aiguë. Il n'y avait aucun changement dans le ratio organepoids corporel ou dans les paramètres hématologiques à l'intervalle posologique testé durant l'étude subaigüe de 14 jours. L'administration de l'extrait aqueux à des rats (doses 100 mgkg) a entraîné des niveaux accrus de transaminases hépatiques (ALT, AST, GGT, ALP) et de bilirubine indirecte. Les empreintes de la fonction rénale n'ont pas changé. Ces résultats suggèrent des dommages possibles du système hépatobiliaire. Précautions d'emploi Etre prudent dans l'administration de l'extrait aqueux pour la maladie du foie. Effets indésirables Aucuns effets indésirables connus s'il est utilisé à des doses thérapeutiques, bien que dans une étude, un extrait éthanolique a inhibé la fixation",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4817,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 817)",
    "text": "Effets indésirables Aucuns effets indésirables connus s'il est utilisé à des doses thérapeutiques, bien que dans une étude, un extrait éthanolique a inhibé la fixation du radioligand à la dopamine et à la sérotonine et, l'extrait aqueux donné par voie intra- gastrique aux rats a potentialisé les effets des barbituriques. Contre-indications Maladies hépatiques connues, patients âgés et enfants, grossesse, antidépresseurs ou barbituriques; hypoglycémie. Dosage et forme galénique Infusion décoction: 30 g dans 600 ml d'eau, prendre 1 verre à eau deux fois par jour Teinture: 1:5 dans 60 d'éthanol, 5 ml trois fois par jour Capsules: 2-3 g deux fois par jour Conservation A conserver dans un endroit frais et sec, loin de la lumière. Références Ahmed, M. et al. (2001). Analgesic, diuretic, and anti-inflammatory principle from Scoparia dulcis. Pharmazie 56(8):657-660. Ahsan, M. et al. (2003). Cytotoxic diterpenes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 916,
    "source": "PDF_chunked"
  },
  {
    "id": 4818,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 818)",
    "text": "Références Ahmed, M. et al. (2001). Analgesic, diuretic, and anti-inflammatory principle from Scoparia dulcis. Pharmazie 56(8):657-660. Ahsan, M. et al. (2003). Cytotoxic diterpenes from Scoparia dulcis. Journal of Natural Products 66(7):985-961. Akendengue, B., Lemamy, G.J., Bourobou, H.B., Laurens, A. (2005). Bioactive natural compounds from medico-magic plants of Bantu area. Studies in Natural Product Chemistry 32(12):803-820.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 433,
    "source": "PDF_chunked"
  },
  {
    "id": 4819,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 819)",
    "text": "OOAS Page 171 Scoparia dulcis WAHP Asano, S., Mizutani, M., Hayashi, T., Morita , N. et al (1990). Reversible inhibitions of gastric H,K-ATPase by scopadulcic acid B and diacetyl scopadol. New biochemical tools of H ,K- ATPase. Journal of Biological Chemistry 265: 2216722173. Chow, S.Y., Chen, S.M., Yang, C.M., Hsu, H. (1974). Pharmacological studies on China herbs. (I) Hypotensive effect of 30 Chinese herbs. Journal of Formosan Medical Association 73:729-739. Dokosi, O.B. (1998) .Herbs of Ghana, 400- 402. Ghana University Press: Ghana. Freire, S.M.F., Emim, A.J.S., Lapa, A.J., Souccar, C. et al. (1993). Analgesic and anti - inflammatory properties of Scoparia dulcis L. extract and glutinol in rodents. Phytotherapy Research 7:408-414. Freire, S.M., Torres, L.M., Roque, N.F., Souccar, C. et al. (1991). Analgesic activity of a triter pene isolated from Scoparia dulcis L. (Vassourinha). Memorias Intituto Oswaldo Cruz 86:149-151.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4820,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 820)",
    "text": "C. et al. (1991). Analgesic activity of a triter pene isolated from Scoparia dulcis L. (Vassourinha). Memorias Intituto Oswaldo Cruz 86:149-151. Freire, S.M., Torres, L.M., Souccar, C., Lapa, A.J. (1996). Sympathomimetic effects of Scoparia dulcis L. and catecholamines isolated from plant extracts. Jour nal of Pharmacy and Pharmacology 48:624-628. Fulda, S. et al . (2000). Betulinic acid induces apotopsis through a direct effect on mitochondria in neuroecto-dermal tumours. Medical Pediatrics and Oncology 35(6):616-618. Garcia, D., Domingues, M.V., Rodri gues, E., (2010). Ethnopharmacological survey among migrants living in the Southeast Atlantic Forest of Diadema, São Paulo, Brazil. Journal of Ethnobiology and Ethnomedicine 6:29. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana, 135-137. Hayashi, T. (2000). Biologically active diterpenoids from Scoparia dulcis (scrophulariaceae). Studies in Natural Product Chemistry 21(2):689-727.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 4821,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 821)",
    "text": "Advent Press: Accra, Ghana, 135-137. Hayashi, T. (2000). Biologically active diterpenoids from Scoparia dulcis (scrophulariaceae). Studies in Natural Product Chemistry 21(2):689-727. Hayashi, T., Okamura, K., Tamada, Y., Iida, A. et al (1993). A new chemotype of Scoparia dulcis. Phytochemistry 33:349-352. Hayashi, T, Kawasaki, M., Okamura, K., Tamada, Y. et al (1992). Scoparic acid A, a beta- glucuronidase inhibitor from Scoparia dulcis . Journal of Natural Products 55:1748-1755. Hayashi, K., Hayashi, T., Morita, N., (1992). Cytotoxic and Antiturnour Activity of Scopadulcic Acid from Scoparia dulcis L. Phytotherapy Research 6:6-9. Hayashi, T., Okamura, K., Kakemi, M., Asano, S. et al (1990b). Scopadulcic acid B, a new tetracyclic diterpenoid from Scoparia dulcis L. Its structure, H,K() -adenosine triphosphatase inhibitory activity and pharmacokinetic behavior in rats. Chemical Pharmaceutical Bulletin (Tokyo) 38:2740-2745.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4822,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 822)",
    "text": "structure, H,K() -adenosine triphosphatase inhibitory activity and pharmacokinetic behavior in rats. Chemical Pharmaceutical Bulletin (Tokyo) 38:2740-2745. Hayashi T, Asano S, Mizutani M, Takeguchi N et al (1991a). Scopadulciol, an inhibitor of gastric H , K -ATPase from Scoparia dulcis, and its structure-activity relationships. Journal of Natural Products 54, 802809. Hayashi, T. et al . (1988). In vitro and in vivo antiviral activity of scopadulcic acid B from Scoparia dulcis , Scrophulariaceae, against Herpes simplex virus type 1. Antiviral Research 9(6):345-354. Hayashi, T., Kishi, M., Kawasaki, M., Arisawa, M. et al (1987). Scopadulcic acid A and acid- B, new diterpenoids with novel skeleton, from a paraguayan crude drug Typycha kuratu (Scoparia dulcis). Tetrahedron Letters 28:3693. Igoli, J.O., Ogaji, O.G., Tor -Anyiin, T.A., Igoli, N.P. (2005). Traditional medicine practice amongst the Igede people of Nigeria. Part II.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4823,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 823)",
    "text": "(Scoparia dulcis). Tetrahedron Letters 28:3693. Igoli, J.O., Ogaji, O.G., Tor -Anyiin, T.A., Igoli, N.P. (2005). Traditional medicine practice amongst the Igede people of Nigeria. Part II. African Journal of Traditional Complementary and Alternative Medicine 2:134152. Lans, C. (2007a). Comparison of plants used for skin and stomach problems in Trinidad and Tobago with Asian ethnomedicine. Journal of Ethnobiology and Ethnomedicine 3:3. Lans, C., (2007b). Ethnomedicines used in Trinidad and Tobago for reproductive problems. Journal of Ethnobiology and Ethnomedicine 3:13. Latha, M., Ramkumar, K.M., Pari, L., Damodaran, P.N., et al . (2006). Phytochemical and antimicrobial study of an antidiabetic plant: Scoparia dulcis L. Journal of Medicinal Food 9: 391-394",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 765,
    "source": "PDF_chunked"
  },
  {
    "id": 4824,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 824)",
    "text": "OOAS Page 172 Scoparia dulcis WAHP Latha, M., Pari, L., Sitasawad, S., Bhonde, R. (2004). Insulin-secretagogue activity and cytoprotective role of the traditional antidiabetic plant Scoparia dulcis (Sweet Broomweed). Life Sciences 75:2003-2014. Luziatelli, G., Sørensen, M., Theilade, I., Mølgaard, P. (2010). Asháninka medicinal plants: a case study from the native community of Bajo Quimiriki, Junín, Peru. Journal of Ethnobiology and Ethnomedicine 6:21. Mahato, S.B., Das, M.C., Sahu, N.P. (1981). Triterpenoids of Scoparia dulcis . Phytochemistry 20:171-173. Meséia-Vela, S., Bielavsky, M., Torres, L.M.B., Freire, S.M., Lima- Landman, M. et al . (2007). In vivo inhibition of gastric acid secretion by the aqueous extract of Scoparia dulcis L. in rodents. Journal of Ethnopharmacology 111:403408. Mshana, N.R., Abbiw, D.K., Addae-Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al ., (2000). Traditional medicine and pharmacopoeia.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4825,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 825)",
    "text": "Journal of Ethnopharmacology 111:403408. Mshana, N.R., Abbiw, D.K., Addae-Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al ., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Nath, M.C. (1945). The new antidiabetic principle (amellin) occurring in nature. I. Studies on some of its biochemical properties. Chemical Abstracts 39:3361-3362. Nishino, H., Hayashi, T., Arisawa, M., Satomi, Y., Iwashima, A., (1993). Antitumorpromoting activity of scopadulcic acid B, isolated from the medicinal plant Scoparia dulcis L. Oncology 50:100-103. Pari, L. et al ., (2005). Antidiabetic effect of Scoparia dulcis : effect on lipid peroxidation inn streptozotocin diabetes. Gann P hysiology and Biophysics 24(1):13-26. Pari, L. et al. (2004). Protective role of Scoparia",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 909,
    "source": "PDF_chunked"
  },
  {
    "id": 4826,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 826)",
    "text": "Scoparia dulcis : effect on lipid peroxidation inn streptozotocin diabetes. Gann P hysiology and Biophysics 24(1):13-26. Pari, L. et al. (2004). Protective role of Scoparia dulcis plant extract on brain antioxidant status and lipid peroxidation in STZ diabetic male Wistar rats. BMC Complementary and Alternative Medicine 4:16. Pari, L., Venkateswaran, S. (2002). Hypoglycaemic Activity of Scoparia dulcis L. Extract in Alloxan Induced Hyperglycaemic Rats. Phytotherapy Research 16:662664. Paulino de Albuquerque, U., Monteiro, J.M., Ramos, M.A., Cavalcanti de Amorim, E.L., (2007). Medicinal and magic plants from a public market in northeastern Brazil. Journal of Ethnopharmacology 110:7691. Ratnasooriya, W.D., Jayakody, J.R., Premakumara, G.A., Ediriweera, E.R. (2005). Antioxidant activity of water extract of Scoparia dulcis. Fitoterapia 76:220-222. Rodrigues, E. (2006). Plants and Animals Utilized as Medicines in the Jaú National Park",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4827,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 827)",
    "text": "Antioxidant activity of water extract of Scoparia dulcis. Fitoterapia 76:220-222. Rodrigues, E. (2006). Plants and Animals Utilized as Medicines in the Jaú National Park (JNP), Brazilian Amazon. Phytotherapy Research 20:378391. Ruiz, L., Ruiz, L., Maco, M., Cobos, M., Gutierrez-Choquevilca, A -L., Roumv, V. (2011). Plants used by native Amazonian groups from the Nanay River (Peru) for the treatment of malaria. Journal of Ethnopharmacology 133:917921. Satyanarayana, K. (1969). Chemical examination of Scoparia dulcis (L): Part I. Journal of Indian Chemical Society 46:765-766.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 580,
    "source": "PDF_chunked"
  },
  {
    "id": 4828,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 828)",
    "text": "OOAS Page 173 Securidaca longepedunculata WAHP Nom botanique Securidaca longepedunculata Fres. Famille Polygalaceae Synonyme Securidaca spinosa Sim. Lophostylis pollida klotzsch Noms communs Anglais: Violet tree Français: Arbuste à Serpent Noms vernaculaires Burkina Faso : Mooré Palgu ;Pélga, Bissa Hensasi, Dioula Djoro;Djoto, Fulfuldé Alali Cote d'I voire: Lobi Samuele, Gagou: Dioro, Malinké Diulo, Ndjuru Gambie: Malinké Juto Djuto, Wolof Fuf, Fula Alali Ghana: Akan Ofodo Kyrito Guinée Conakry: Malinké Diodo, Fula Diantu Mali: Bambara Djoro Dioro, Peulh Iguili, Dogon Toroe Niger: Hausa Warnagunguna, Fula Adali, Djerma Hasukore Nigéria: Hausa Sanya, Fula: Adali, Adehi, Yoruba Ipeta Sénégal: Diola Fu Daray, Serer Kuf Kuf, Wolof Fuf Togo: Ouatchi Etritou, Mina Metritu, Ewé Kpeta Sierra Leone: Malinké Juto, Jodoo Description de la plante",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 846,
    "source": "PDF_chunked"
  },
  {
    "id": 4829,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 829)",
    "text": "Yoruba Ipeta Sénégal: Diola Fu Daray, Serer Kuf Kuf, Wolof Fuf Togo: Ouatchi Etritou, Mina Metritu, Ewé Kpeta Sierra Leone: Malinké Juto, Jodoo Description de la plante S. longipedunculata est un arbuste à semi - feuilles ou un petit arbre qui pousse jusqu' à 12 m de haut, avec un fût souvent aplati ou légèrement cannel é au niveau du tronc; très ramifiée, à cime ouverte, couronne à vu d'œil plutôt éparse; jeunes branches tombantes et pubescentes; l'écorce est lisse, épaisse et jaune clair et couvre une fibre de bois jaune; la racine est très épaisse avec une odeur caract éristique de salicylate de méthyle; les feuilles sont alternes, entières, simples, oblongues - elliptiques, de 5 à 6 cm de long sur 13- 20 mm de large avec des poils très fins quand elle est jeune mais les perd à maturité; elle a un sommet arrondi, une base étroite effilée; un pétiole mince; les fleurs pourpres papilionacées sont d'environ 10 mm de long, très parfumées et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 4830,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 830)",
    "text": "jeune mais les perd à maturité; elle a un sommet arrondi, une base étroite effilée; un pétiole mince; les fleurs pourpres papilionacées sont d'environ 10 mm de long, très parfumées et fixées par de longues tiges minces en racèmes axillaires terminaux; le fruit est une samare de 4 à 5 cm de long, plus ou moins une noix ronde, un peu veinée fortement, parfois lisse, unique, oblongue, assez courbée avec une aile membraneuse allant jusqu'à 4 cm de long. Numéro du spécimen d'Herbier Ghana: 2799 Mali: 0058 DMT Togo:TOGO06917 Habitat et répartition géographique S. longiped unculata se produit dans un large éventail de végétation, de semi -aride à la forêt dense maquis, y compris dans les nombreuses zones boisées, les habitats de brousse et les forêts-galeries. Elle est largement distribuée dans les régions soudano- sahélienne, soudanienne et soudano -guinéenne d'Afrique dont l'Angola, le Bénin, le Botswana, le Burundi,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4831,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 831)",
    "text": "forêts-galeries. Elle est largement distribuée dans les régions soudano- sahélienne, soudanienne et soudano -guinéenne d'Afrique dont l'Angola, le Bénin, le Botswana, le Burundi, le Cameroun, le Tchad, la Côte d'Ivoire, la République Démocratique du Congo, l'Érythrée, l'Éthiopie, la Gambie, le Ghana, la Guinée , le Kenya, le Malawi, le Mal i, le Mozambique, la Namibie, le Niger, le Nigéria, le Rwanda, le Sénégal, le Sierra Leone, l' Afrique du Sud, le Soudan, la Tanzanie, l'Ouganda, la Zambie, le Zimbabwe. Parties utilisées de la plante Feuille et écorce de la racine Autres parties utilisées Ecorce du tronc Caractéristiques botaniques L'Arbre Violet se compose de l'écorce de la racine ou de feuille de Securidaca longepedunculata Fres. (Polygalaceae) (Polygalaceae) Utilisations ethnomédicales La racine fraîche est réduite en pulpe et vigoureusement frottée sur une morsure de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 886,
    "source": "PDF_chunked"
  },
  {
    "id": 4832,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 832)",
    "text": "OOAS Page 174 Securidaca longepedunculata WAHP serpent. La décocté de la pulpe ou des feuilles de racine en combinaison avec d'autres plantes est utilisé pour provoquer le vomissement et la purgation après intoxication (Kerharo et Adam, 1974). La décocté des feuilles écrasées est appliquée sur les plaies et les furoncles pour évacuer le pus. La mousse obtenue à partir de la racine est mélangée avec de l'eau pour traiter la gonorrhée, tandis que le décocté de racines fraîches est utilisé pour traiter la bronchite, les douleurs abdominales et la lèpre. Des infusions d'écorce de racine et de tige sont recommandées comme antidote contre l'empoisonnement; une poudre faite à partir de la racine est prisée pour les maux de tête. En Ethiopie, la fumée de la racine est inhalée sous forme d'encens médicinale pour traiter les flatulences. La poudre d'écorce est utilisée pour soigner les blessures et la pâte d'écorce pilée avec du sulfate de cuivre est appliquée aux",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 968,
    "source": "PDF_chunked"
  },
  {
    "id": 4833,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 833)",
    "text": "forme d'encens médicinale pour traiter les flatulences. La poudre d'écorce est utilisée pour soigner les blessures et la pâte d'écorce pilée avec du sulfate de cuivre est appliquée aux boursouflures causées par le ver de Guinée afin de favoriser son expulsion. La pâte d'écorce de racine en poudre est utilisée pour la polyarthrite rhumatoïde, le rhumatisme chronique, les ecchymoses ou l'enflure. En Afrique de l'Ouest, la plante est utilisée pour le traitement des convulsions infantiles et combiné avec Boophane disticha à des fins psychotropes. La plante est connue dans de nombreux pays africains comme un abortif (Oliver-Bever, 1986). Activités biologiques et pharmacologiques Les propriétés antivenimeuses et anti - inflammatoires de la plante ont été démontrées dans plusieurs études scientifiques (Koné, 1989; Coulibaly née Diop, 1986; Metou, et al ., 1989). L'extrait chloroformique de la racine a montré une activité antibactérienne contre les bactéries",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 964,
    "source": "PDF_chunked"
  },
  {
    "id": 4834,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 834)",
    "text": "dans plusieurs études scientifiques (Koné, 1989; Coulibaly née Diop, 1986; Metou, et al ., 1989). L'extrait chloroformique de la racine a montré une activité antibactérienne contre les bactéries à Gram -positive et Gram -négative et les isolats cliniques de Klebsiella pneumoniae (Pallant et Steenkamp, 2008), tandis que l'extrait aqueux a été trouvé complètement inactif (Almagboul et al., 1985). Les extraits acétonique et hexanique ont montré une activité anti -mycobacterium tuberculosis avec une MIC de plus de 100 μml (Green et al ., 2010), tandis que l'extrait hexanique a montré une activité significative contre le Mycobacterium bovis BCG et le Mycobacterium tuberculosis H37Ra avec une MIC minimum de 15.6 à 62.5 μgmL (Luo et al., 2011). L'extrait de dichlorométhane des racines à une dose de 150 mg kg réduit significativement la parasitémie chez les souris infectées expérimentalement avec le Trypanosoma brucei brucei (Aderbauer et al.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4835,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 835)",
    "text": "à une dose de 150 mg kg réduit significativement la parasitémie chez les souris infectées expérimentalement avec le Trypanosoma brucei brucei (Aderbauer et al., 2008). Les activités trypanocides et cytotoxiques de la plante ont également été démontrées par Nibret et al., (2009). L'extrait au dichlorométhane a montré une activité trypanocide avec une CI 50 inférieure à 20 μgml. Akinmoladun et al. (2010) ont également démontré l'activité antioxydante de la plante. L'administration orale d'un décocté de racine produit un effet sédatif, anxiolytique et anticonvulsivant d'une manière dose-dépendante (Adeyemi et al., 2010; Oliver -Bever, 1986). Le composé de sécurinine a montré une activité in vitro antipaludique sur le Plasmodium falciparum (Weenen et al. 1990) et les acides dérivés de la quinine isolés des racines ont des activités in vitro anti-VIH (Mahmood et al ., 1993). La plante a également une activité contre le virus de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4836,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 836)",
    "text": "(Weenen et al. 1990) et les acides dérivés de la quinine isolés des racines ont des activités in vitro anti-VIH (Mahmood et al ., 1993). La plante a également une activité contre le virus de la poliomyélite à une concentration comprise entre 10 et 50 mg ml (Beuscher et al., 1994). Les extraits de racines ont des propriétés protéolytiques, analgésiques, anti - inflammatoires, ant ioxydantes et hypoglycémiantes (Muanda, et al ., 2010;. Ojewole, 2008; Bah, 2006). Données cliniques Aucune information disponible Constituants Chimiques Saponines, tanins, anthraquinones; alcaloïdes; terpènes; salicylate de méthyle; stérols, sucres, acides caféique, acide sinapique, (Odebiyi, 1978; Kamwendo et al., 1985;. Kerharo et Adam, 1974; Declaude, 1971; Lenz, 1913; Mahmood et al., 1993;. Costa et al., 1992, Scandola et al., 1994; Mitaine-Offer et al., 2010; Muanda, et al., 2010). Tests d'identité et de pureté Teneur en humidité: pas plus de 4,59 Cendre totale: 2,33",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 4837,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 837)",
    "text": "1993;. Costa et al., 1992, Scandola et al., 1994; Mitaine-Offer et al., 2010; Muanda, et al., 2010). Tests d'identité et de pureté Teneur en humidité: pas plus de 4,59 Cendre totale: 2,33 Valeur substances extractibles par l'eau: pas moins de 19,29",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 248,
    "source": "PDF_chunked"
  },
  {
    "id": 4838,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 838)",
    "text": "OOAS Page 175 Securidaca longepedunculata WAHP Valeur substances extractibles par l'éthanol (70): 15,40 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60 F254, et phase mobile: éther de pétrole (40-60oC) chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml) , 85 ml de méthanol et 5 ml d'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10. Présence de deux taches distinctes pourpres avec Rf de 0,92 et 0,35. Chromatogramme Macroscopie La racine de S . longepedunculata est tortueuse, rugueuse, jaune- claire, très épaisse avec une odeur particulière; feuilles fraîches et couleur verte, simple et peu pétiolées; limbe de 2- 5 cm de long sur 2- 3 cm de large; oblongues - lancéolées dans la forme; marge entière; ronde au sommet, la base de la feuille est cunéiforme",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4839,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 839)",
    "text": "verte, simple et peu pétiolées; limbe de 2- 5 cm de long sur 2- 3 cm de large; oblongues - lancéolées dans la forme; marge entière; ronde au sommet, la base de la feuille est cunéiforme et la nervation est réticulée, la surface foliaire est glabre, mais pubescente en dessous, texture papyracée avec une nervure médiane déprimée. Microscopie La feuille est isobilatérale; les cellules épidermiques sur la surface adaxial e possèdent des parois droites anticlinales et ondulés sur la surface abaxiale; les stomates et les poils sont absents sur la surface adaxiale, mais de nombreux stomates anomocytiques, paracytiques et des poils glandulaires sont présents sur la surface abaxiale; de nombreux sphaerocrystals sont sur cette surface; cellules épidermiques rectangulaires avec une couche de cuticule cireuse; cellules striées; mésophylle indifférencié avec des cellules de parenchyme fortement lignifiées; la région de nervure médiane montre une protubérance convexe avec",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 972,
    "source": "PDF_chunked"
  },
  {
    "id": 4840,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 840)",
    "text": "cuticule cireuse; cellules striées; mésophylle indifférencié avec des cellules de parenchyme fortement lignifiées; la région de nervure médiane montre une protubérance convexe avec des cellules en forme d'ovoïde- globuleux; des faisceaux vasculaires sont disposés en forme d'éventail avec 6- 8 xylèmes annulés; la cellule de la gaine renferme à la fois le phloème et le xylème; les poils sont absents. Matériel végétal en poudre Feuille de couleur verdâtre, odeur particulière, cellules épidermiques, parenchymateuses avec parois anticlinales droites. Certaines sont ondulées et vallonnées avec de nombreux stomates de types anomocytique et paracytique, des poils glandulaires et tissus en xylème. Actions thérapeutiques Anti-inflammatoire (Coulibaly Nee Diop, 1986, Metou, et al., 1989.), Antibactérien (Almagboul et al., 1985.); Antipaludique (Weenen et al., 1990.), Antiviral (Beuscher et al., 1994;. Mahmood et al ., 1993); analgésique et hypoglycémiante",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4841,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 841)",
    "text": "Metou, et al., 1989.), Antibactérien (Almagboul et al., 1985.); Antipaludique (Weenen et al., 1990.), Antiviral (Beuscher et al., 1994;. Mahmood et al ., 1993); analgésique et hypoglycémiante (Ojewole, 2008); antiparasitaire (Nibret et al ., 2010);. antioxydant (Akinmoladun et al ., 2010). Anticonvulsivant, sédatif et anxiolytique (Muanda et al., 2010), anti -Mycobacterium tuberculosis (Green et al., 2010, Luo et al., 2011). Indications thérapeutiques Douleurs, vers -intestionaux, rhumatisme, psoriasis, eczéma et maladies immuno- suppressives, lèpre, plaie. Données de sécurité Dans une étude de toxicité aiguë de 24 heures, la DL 50 de l'extrait aqueux de racine (p.o) chez la souris a été 2000 mgkg. Les sous -études de toxicité aiguë n'ont pas montré de signes cliniques de toxicité après traitement des souris mâles et femelles (500 à 2000 mgkg; p.o) pendant 14 jours. La prise orale de l'extrait aqueux de racine pendant 28 jours, a entraîné",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4842,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 842)",
    "text": "cliniques de toxicité après traitement des souris mâles et femelles (500 à 2000 mgkg; p.o) pendant 14 jours. La prise orale de l'extrait aqueux de racine pendant 28 jours, a entraîné une toxicité en diminuant le système antioxydant chez les animaux traités (Ajiboye et al. 2010). La dose létale minimale chez les rats de l'extrait éthanolique brut de l'écorce de tige a été de 50 mgkg en 24 heures (Sandberg et Cronlund, 1982). Certaines saponines actives de la racine sont très toxiques lorsqu'on administre la DL 50 de 500 mgkg par voie orale et 50 mg kg par voie parentérale chez la souris (Tubery, 1969). La DL 50 de saponines brutes, abondantes dans l'extrait de racine fraiches a été de 0.875kg par administration orale. L'ingestion de la racine par la voie orale provoque une irritation du tube digestif, qui peut être mortelle entrainant ainsi la mort après 19 heures. Les humains ont une réaction beaucoup plus sensible avec une DL 50",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4843,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 843)",
    "text": "la voie orale provoque une irritation du tube digestif, qui peut être mortelle entrainant ainsi la mort après 19 heures. Les humains ont une réaction beaucoup plus sensible avec une DL 50 170 mgKg par voie orale (Scandola et al., 1994.). Les feuilles sont moins toxiques que la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 277,
    "source": "PDF_chunked"
  },
  {
    "id": 4844,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 844)",
    "text": "OOAS Page 176 Securidaca longepedunculata WAHP tige et la racine; la DL 50 de l'extrait aqueux lyophilisé macéré par voie orale est de 5gkg ou 53,76 gkg (Scandola et al., 1994.). La sécurinine a une toxicité très élevée. Les doses de 0,1- 0,2 mgkg à 5- 30 mgkg peut causer la mort par arrêt respiratoire (Chang Hui-yun, 1974). Précautions d'emploi Ne pas dépasser les doses prescrites; la racine a démontré une très faible marge de sécurité. Lauto-médication n'est pas à encourager. Effets indésirables Mauvaise odeur et et mauvais goût; la racine peut provoquer des nausées et des vomissements. Contre-indications Pathologies liées à la grossesse, foie et cœur. Dosage et forme galénique Décoction, poudres Capsules de sénégénate de magnésium: 130 mg, 2-10 capsules par jour Conservation A conserver dans un endroit frais et sec. Références Aderbauer, B ., Clausen, P.H ., Kershaw, O ., Melzig, M.F . (2008). In vitro and in vivo",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4845,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 845)",
    "text": "mg, 2-10 capsules par jour Conservation A conserver dans un endroit frais et sec. Références Aderbauer, B ., Clausen, P.H ., Kershaw, O ., Melzig, M.F . (2008). In vitro and in vivo trypanocidal effect of lipophilic extracts of medicinal plants from Mali and Burkina Faso. Journal of Ethnopharmacology 119(2):225-231. Adeyemi, O.O ., Akindele, A.J ., Yemitan, O.K ., Aigbe, F.R ., Fagbo, F.I . (2010). Anticonvulsant, anxiolytic and sedative activities of the aqueous root extract of Securidaca longepedunculata Fresen. Journal of Ethnopharmacology 130(2):191-195. Ajiboye, T.O., Salau, A.K., Yakubu, M.T., Oladiji, A.T. (2010). Aqueous extract of Securidaca longepedunculata root induce redox imbalance in male rat liver and kidney. Human Experimental Toxicology 29(8):679-688. Akinmoladun, A.C ., Obuotor, E.M., Farombi, E.O. (2010). Evaluation of antioxidant and free radical scavenging capacities of some Nigerian",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 917,
    "source": "PDF_chunked"
  },
  {
    "id": 4846,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 846)",
    "text": "Toxicology 29(8):679-688. Akinmoladun, A.C ., Obuotor, E.M., Farombi, E.O. (2010). Evaluation of antioxidant and free radical scavenging capacities of some Nigerian indigenous medicinal plants. Journal of Medicinal Food 13(2):444-451. Almagboul, A.Z., Farouk, A., Bashir, A.K., Karim, A., Sa lah, M. (1985). Antibacterial activity of Sudanese plants used in folkloric Medicine III. Fitoterapia 56:195-200. Bah, S., Paulsen, B.S., Diallo, D., Johansen, H.T.(2006). Characterization of cysteine proteases in Malian medicinal plants. Journal of Ethnopharmacology 107(2):89-198. Beuscher, N., Bodinet, C., Neumann Haefelim, D., Marstom, A., Hostettmann, K. (1994). Antiviral activity of African medicinal plants. Journal Ethnopharmacology 42:101-109. Chang, Hui -yun, (1974). Toxicity of securinine and comparaison with strychnine. Chinese Medical Journal 4:65. Costa, C., Bortazzo, A., Allegri, G., Curcuroto, D., Traloli, P. (1992). Indole alkaloids from the",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 4847,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 847)",
    "text": "and comparaison with strychnine. Chinese Medical Journal 4:65. Costa, C., Bortazzo, A., Allegri, G., Curcuroto, D., Traloli, P. (1992). Indole alkaloids from the roots on an African plant, Securidaca longepeduncalata. Isolation by column chromatography and prel iminary structural characterization by mass spectrometry. Journal of heterocycle Chemestry. P:16411647. Coulibaly née Diop (1986). Contribution à l'étude de Securidaca longepedunculata Fres. Thèse de Doctorat en Pharmacie Dakar, n 47, 105 p. Declaude, C. (1971). Etude comparative des saponines extraits de deux Polygaleae africaines, le Securidica longpedunculata Fres et de P olygala aciculans . Bulletin societe Royale des sciences. Liège (397405). Green, E., Samie, A., Obi, C.L. , Bessong, P.O ., Ndip, R.N . (2010). Inhibitory properties of selected South African medicinal plants against Mycobacterium tuberculosis. Journal of Ethnopharmacology 130(1):151-157.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4848,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 848)",
    "text": "Ndip, R.N . (2010). Inhibitory properties of selected South African medicinal plants against Mycobacterium tuberculosis. Journal of Ethnopharmacology 130(1):151-157. Kamwendo, W.Y., Chiotha, S.S., Msonthi, J .D. (1985). Screening of plants used traditionally in schistosomiasis in Malawi. Fitorapia 56:229232. Kerharo, J., Adams, J.G. (1974). La pharmacopée sénégalaise traditionnelle plantes médicinales et toxiques, Edition Vigot et frères, Paris, 633666. Koné, P.P. (1980) . Etudes botaniques, électrophysicologiques et pharmacologiques du venin de Nga migrocollis et d'une substance antivénéneuse de la pharmacopée traditionnelle africaine (Extrait de Securidaca longepedunculata). Thèse de Doctorat d'Etat en",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 713,
    "source": "PDF_chunked"
  },
  {
    "id": 4849,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 849)",
    "text": "OOAS Page 177 Securidaca longepedunculata WAHP Sciences, Université Nationale de Côte d'Ivoire, 171 p. Lenz, W. (1913). un tersuchungen der wurzelrin de Von Securidaca longepedunculata. Arbeiten aus dem Pharmazeutischen Institut der Universitiit Berlin 10, Luo, X ., Pires, D ., Aínsa, J.A ., Gracia, B ., Mulhovo, S . et al . (2011). Antimycobacterial evaluation and preliminary phytochemical investigation of selected medicinal plants traditionally used in Mozambique. Journal of Ethnopharmacology, 137(1), 114120. Mahmood, N., Moore, P.S., De Tommasi, N., De Simone, F., Colman, S. et al. (1993). Inhibition of HIV infection by caffeoylquinic acid derivates. Antiviral Chemistry and Chemotherapy. 4:235 - 240. Metou, G., Faye, B., Richard temple, A., Lo, I. (1989). Plantes de la Pharmacopée Sénégalaise. Activité anti-inflammatoire chez le rat des écorces de racine de Securidaca longepedunculata fres (Polygalaceae). Bulletin de laison : Médecine",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 4850,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 850)",
    "text": "(1989). Plantes de la Pharmacopée Sénégalaise. Activité anti-inflammatoire chez le rat des écorces de racine de Securidaca longepedunculata fres (Polygalaceae). Bulletin de laison : Médecine Traditionnelle et Pharmacopée 3, n 1. Mitaine-Offer, A.C ., Pénez, N ., Miyamoto, T ., Delaude, C., Mirjolet, J.F. et al. (2010), Duchamp O, Lacaille-Dubois MA . Acylated tri terpene saponins from the roots of Securidaca longepedunculata. Phytochemistry 71(1):90-94. Muanda, F.N ., Dicko, A ., Soulimani, R . (2010). Assessment of polyphenolic compounds, in vitro antioxidant and anti -inflammation properties of Securidaca longepedunculata root barks. Comptes Rendus de Biologie 333(9):663-669. Nibret, E., Ashour, M.L., Rubanza, C..D, Wink, M. (2009). Screening of some Tanzanian medicinal plants for their trypanocidal and cytotoxic activities. Phytotherapy Research 177 180. Nibret, E ., Ashour, M.L., Rubanza, C..D , Wink, M. (2010). Screening of some Tanzanian",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 4851,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 851)",
    "text": "medicinal plants for their trypanocidal and cytotoxic activities. Phytotherapy Research 177 180. Nibret, E ., Ashour, M.L., Rubanza, C..D , Wink, M. (2010). Screening of some Tanzanian medicinal plants for their trypanocidal and cytotoxic activities. Phytotherapy Research 24(6):945-947. Odebiyi, O.O. (1978). Preliminary phytochemical and antimicrobial examination of leaves of Securidaca longepedunculata. Nigerian Journal of Pharmaceutics 9:29-30. Ojewole, J.A. (2008). Analgesic, anti - inflammatory and hypoglyc aemic effects of Securidaca longepedunculata (Fresen.) Polygalaceae root -bark aqueous extract. Inflammopharmacology 16(4):174-181. Oliver-Bever, B . (1986) . Medicinal plants in tropical West Africa, Cambridge University Press. Cambridge. Pallant, C , Steenkamp, V . (2008). In vitro bioactivity of Venda medicinal plants used in the treatment of respiratory conditions. Human and Experimental Toxicology. 27(11):859-866.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4852,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 852)",
    "text": "Pallant, C , Steenkamp, V . (2008). In vitro bioactivity of Venda medicinal plants used in the treatment of respiratory conditions. Human and Experimental Toxicology. 27(11):859-866. Sandberg, F., Gronlund, A. (1982). An ethnopharmacological inventory of medicinal and toxic plants from Equatorial Africa. Journal of Ethnopharmacology 5:187204. Scandola, M., Games, D.E., Costa, C., Allegri, G., Bertazzo, A. et al. (1994). Structural study of alkaloids from Securidaca longepedunculata roots. Isolation and characterization by supercritical fluid chromatography mass spectrometry. Journal Heterocyclic Chemistry 31:219-224. Tubery, P. (1969). Alcoholic extract of Securidaca longepedunculata used against Psoriasis. Fr Demande 6665 (1,3 1969) ; Chemical Abstract 75:52792. Tubery, P. (1974). Anti -inflammatory triterpenic alcohol acids. Chemical Abstract 82:103132. Weenen, H., Nkunya, M.H.H., Bray, D.H., Mwasumbi, L.B., Kinabo, L.S. et al . (1990).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4853,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 853)",
    "text": "Tubery, P. (1974). Anti -inflammatory triterpenic alcohol acids. Chemical Abstract 82:103132. Weenen, H., Nkunya, M.H.H., Bray, D.H., Mwasumbi, L.B., Kinabo, L.S. et al . (1990). Antimalarial c ompounds containing an α, β- unsaturated carbonyl moiety from Tanzania medicinal plants. Planta Medica 56:371-373.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 308,
    "source": "PDF_chunked"
  },
  {
    "id": 4854,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 854)",
    "text": "OOAS Page 178 Senna alata WAHP Nom botanique Senna alata(L) Roxb. Famille Légumineuse-Ceasalpiniacées Synonyme Cassia alata L., Hepetica alata Ref., Cassia bracteata L.; Cassia herpetica Jacq. Noms communs Arbuste teigne, plante craw -craw, roi de la forêt, chandelier cassia; teigne séné; guajava; teigne de brousse; les sept chandeliers d'or; chandeliers de l'empereur; bougie végétale de l'impératrice; Bougie de Noël; chandelier séné; bougie de brousse, fleur de St Christophe. Noms vernaculaires Ghana: Twi Osempe, Ga Adangbe Bayisa, Ewe Agbobladzoe Nigérian: Yoruba Asunwon oyinbo, Hausa Majamfari, Ibo Ogalu Niger: Hausa Sanga Sanga Togo: Ewe - Zangarati, Ouatchi Zanguerati, Adja Zangalati Description de la plante C'est un arbuste à faible bois, très décoratif avec une apparence inhabituelle et intéressante, d'environ 3 m de hauteur ou plus avec des feuilles composées pennées constituées de 8- 14",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 908,
    "source": "PDF_chunked"
  },
  {
    "id": 4855,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 855)",
    "text": "C'est un arbuste à faible bois, très décoratif avec une apparence inhabituelle et intéressante, d'environ 3 m de hauteur ou plus avec des feuilles composées pennées constituées de 8- 14 paires de folioles oblongues à obovales (5-16 cm de long sur 3-8 cm de large) qui sont arrondies à l'extrémité; le rachis est étroit ailé avec une arête reliant les rameaux; le pétiole et le rachi vont jusqu'à 60 cm de long (Hutchinson et Dalziel, 1958), les plantes fleurissent de Février à Octobre jusqu'à Novembre; les fleursdanslescymesterminauxde lacrête, produisantdes fleurs jaune- or corpulentes, denses, dressées et larges, des grappes spiciformes avec des étamines fertiles, des fruits avec quatre grandes ailes crénelées au milieu, droites avec des ailes le long des côtés, contiennent 30-40 graines par fruit, mesurent 15- 25 cm de long et environ 1,8 cm de large, vertes si non mures et noires à maturité (Adjanohoun et al., 1991). Numéro du spécimen de l'herbier",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 962,
    "source": "PDF_chunked"
  },
  {
    "id": 4856,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 856)",
    "text": "contiennent 30-40 graines par fruit, mesurent 15- 25 cm de long et environ 1,8 cm de large, vertes si non mures et noires à maturité (Adjanohoun et al., 1991). Numéro du spécimen de l'herbier Nigeria: FHI 107441 Togo: TOGO00121 Habitat et répartition géographique Originaire de l'Amérique, mais maintenant largement distribuées dans les régions tropicales, y compris l'Afrique de l'Ouest du Sénégal au Nigeria (Irvine, 1961), c'est une plante commune dans les vil lages, sur les terrains vagues, dans les clairières et les maisons; cultivée ou spontanée. Au Nigeria, il peut être trouvé dans la forêt tropicale et la savane, à la fois dans les parties sud et nord du pays (Elujoba et Ogunti, 1993). Parties utilisées de la plante Rameaux sechés Autres parties utilisées Fleur; racine; graine; écorce Caractéristiques botaniques L'Alata feuille est constituée dejeunes rameaux frais ou sèchés de Senna alata L. Roxb. (Leguminosae-Ceasalpinioideae).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4857,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 857)",
    "text": "Fleur; racine; graine; écorce Caractéristiques botaniques L'Alata feuille est constituée dejeunes rameaux frais ou sèchés de Senna alata L. Roxb. (Leguminosae-Ceasalpinioideae). Utilisations ethnomédicales Les feuilles sont utilisées pour la dermatite, l'eczéma, la teigne, les helminthiases intestinales, la téniase, la constipation, la gonorrhée, la bronchite, l'asthme, le retard dans le travail et comme un abortif (Oliver -Bever, 1986; Hauptman et Lacerda, 1950). Activités biologiques et pharmacologiques Plusieurs rapports de laboratoire ont apporté un soutien à certaines anciennes revendicationsd'herbes. Les glycosides anthranoïdes provoquent la purgation en stimulant le péristaltisme dans le gros intestin et diminuent l'absorption d'eau. Les extraits de diverses parties de la plante ont donné des résultats encourageants des propriétés antimicrobiennes et analgésiques (Palanichamy et Nagarajan, 1991) et des activités laxatives",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4858,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 858)",
    "text": "diverses parties de la plante ont donné des résultats encourageants des propriétés antimicrobiennes et analgésiques (Palanichamy et Nagarajan, 1991) et des activités laxatives (Ogunti et Elujoba, 1993; Nickell, 1959). Les extraits alcooliques de la feuille et de la fleur de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 274,
    "source": "PDF_chunked"
  },
  {
    "id": 4859,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 859)",
    "text": "OOAS Page 179 Senna alata WAHP S. alata ont montré une activité antimicrobienne non spécifiques surles bactéries gram -positives (Benjamin et Lamikanra, 1981). Dans une étude réalisée par Crockett en 1992, les extraits ont été signalés être efficaces dans le traitement des infections opportunistes du SIDA. Les extraits éthanoliques ont montré une forte activité antimicrobienne contre diverses espèces de champignons dermatophytes, avecune faible activité contre les champignons non- dermatophytes; les espèces bactériennes et de levure ont montré une résistance in vitro de l'extrait (Ibrahim, 1995). L'extrait éthanolique des feuilles a montré des valeurs basses de la CMI de 12,5 à 25,0 mgml contre Trichophyton rubrum et Basidiobolus haptosporus (Lemli, 1976). L'extrait de feuilles a également montré une activité analgésique maximalein vivo par rapport au kaempférol 3- O-sophorosides et la morphine (Palanichamy et Nagarajan, 1990).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4860,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 860)",
    "text": "1976). L'extrait de feuilles a également montré une activité analgésique maximalein vivo par rapport au kaempférol 3- O-sophorosides et la morphine (Palanichamy et Nagarajan, 1990). L'huile extraite de la feuille a eu des ef fets inhibiteurs sur les bactéries Gram -positives et Gram-négatives, y compris Pseudomonas sp., Staphylococcus aureus et Escherichia coli (Okafor et al., 2001). Données cliniques Dans un essai multicentrique randomisé, les infusions de feuilles administrées au coucher se sont avérées avoir une action purgative plus énergique que le placebo. Un petit pourcentage des participants (16- 25) ont été signalés avoir subi des effets secondaires minimes, c'est -à- dire, nausée, dyspepsie, douleurs abdominales et diarrhée (Thamlikitkul et al., 1990). Une étude clinique de 10 ans a trouvé que l'extrait de feuilles est un agent antifongique efficace pour le traitement du pityriasis versicolor (Damodaran et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 4861,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 861)",
    "text": "clinique de 10 ans a trouvé que l'extrait de feuilles est un agent antifongique efficace pour le traitement du pityriasis versicolor (Damodaran et Venkataraman, 1994). Oladele et al (2010, 2012) font état d'une étude clinique observationnelle avec des savons à base de plantes de Senna alata pour la gestion des infections superficieles de la peau comprenant principalement du Taenia vesicolor et T. corporis comme agents pathogènes parmi les prisonniers. Il a considérablement dégagé les lésions sur 94 des patients en 4 semaines,. Dans une étude connexe au même groupe de recherche, 3 de Senna alata incorporé dans le savon à base de plantes, a donné un meilleur résultat que les deux autres savons à base d'herbe (Ola dele et al., 2012). Constituants chimiques Anthraquinones: aloé- émodine, glycoside rhéine et aloé- émodine glycoside, sennosides, rein, acide chrysophanique; tanins et mucilage (Elujoba et al , 1989; Rai et Adbullahi, 1978;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4862,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 862)",
    "text": "Anthraquinones: aloé- émodine, glycoside rhéine et aloé- émodine glycoside, sennosides, rein, acide chrysophanique; tanins et mucilage (Elujoba et al , 1989; Rai et Adbullahi, 1978; Ogunti et al, 1991; GHP, 1992; Gupta, 1991). Tests d'identité et de pureté Teneur en humidité: la poudre grossière ne perd pas plus de 12 après dessiccation à 100 C Cendres totales: pas plus de 10,0 Cendres insolubles dans l'acide: pas plus de 1,6 Cendres sulfatées: pas plus de 15,0 Cendres solubles dans l'eau: pas moins de 5,0 Substancesextractibles par l'eau (poudre grossière): pas moins de 20,0 Substances extractibles par l'éthanol (70) (poudre grossière): pas moins de 17,0 Indice stomatique: 10 - 14,25 à 18,3 (surface supérieure), de 18,5 à 21,85 - 25 (surface inférieure) Nombre de stomates: 275 à 296 -320 (surface supérieure), 405 - 472 - 515 (surface inférieure) Ratio depalissade: 8,25 - 9,53 à 10,50 Nombre de veine-îlot: 13 - 15,8 à 20,0",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4863,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 863)",
    "text": "inférieure) Nombre de stomates: 275 à 296 -320 (surface supérieure), 405 - 472 - 515 (surface inférieure) Ratio depalissade: 8,25 - 9,53 à 10,50 Nombre de veine-îlot: 13 - 15,8 à 20,0 Nombre deveinules de terminaison: 17,5 - 19 à 21,5 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de six taches distinctes avec valeurs R f de 0,96 (rose), 0, 93 (rose), 0,71 (rose), 0,53 (rose), 0,47 (marron) et 0,38 (rose).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 796,
    "source": "PDF_chunked"
  },
  {
    "id": 4864,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 864)",
    "text": "OOAS Page 180 Senna alata WAHP Chromatogramme Macroscopie Feuilles composées et paripennées, varient de 30-60 cm de longavec 8- 14 paires de folioles attachées au rachis; rameaux vert -grisâtres, minces et semblables au papier, oblongues - obovales à lancéolées, asymétriques à la base, 50-150 cm de long et 40 à 90 mm de large, à sommet mucroné, base plat ou rond, marge entière, pétiole court de 1- 3 mm de long, nervures pennées, plus distinctes sur la face inférieure avec d es nervures latérales laissant la nervure médiane à un angle d'environ 60; deux surfaces couvertes de poils; texture papyracée, couleur verdâtre à l'état frais, surface inférieure vert-grisâtre, pétiole brun- jaunâtre; goût légèrement amer, mucilagineuse et feuilles courbées lorsque séchées légèrement avec une couleur vert-grisâtre (Elujoba et Ogunti, 1993). Microscopie La couche épidermique se compose de cellules polygonales couvertes par une cuticule mince,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4865,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 865)",
    "text": "couleur vert-grisâtre (Elujoba et Ogunti, 1993). Microscopie La couche épidermique se compose de cellules polygonales couvertes par une cuticule mince, verruqueuse et vallonnée ;des stomates paracytiques; les cellules épidermiques et des stomates sont moins ondulées sur la surface supérieure et couvertes depoils avec bouts pointus, parois épaisses et verruqueuses, coniques et parfois apprimés à l'épiderme, présents sur les deux surfaces unicellulair es avec la base entourée par des cellules épidermiques radialementallongées ;les grappes d'oxalate de calcium sont réparties dans tout le tissu tandis qu'on rétrouve des prismes dans les cellules épidermiques ; la section transversale présente une disposi tion de feuilles dorsoventrales, avec une cuticule épaisse, papilleuse sur la surface inférieure et lescellules épidermiques cuboïdes; les paroisverruqueuses épaisses sont muniesd'une couche unitaire de cellules palissadiques discontinues, sous",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4866,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 866)",
    "text": "papilleuse sur la surface inférieure et lescellules épidermiques cuboïdes; les paroisverruqueuses épaisses sont muniesd'une couche unitaire de cellules palissadiques discontinues, sous l'épiderme supérieure avec presque droites parois anticlinales; interrompu dans la région de la nervure par des cellules de mésophylle spongieux; la nervure médiane projetée sur la surface inférieure est traversée par un brin vasculaire formé par un arc de faisceaux vasculaires garantis, un endoderme dans deux demi-cercles enfermant le faisceau vasculaire collatéral ;un toron entier entouré par une péricycle sclerenchymateuse suivie du cortexse compose de 3- 5 rangées de cellules de parenchyme et des rangées de 2- 3 ce llules collenchymes; les vaisseaux du xylème et de l'endoderme (fibreuse) sont lignifiés tandis que l'épiderme et les cellules du mésophylle contiennent du mucilage, qui contient à sont tour des substances ergastiques rondes et jaunâtres (Elujoba et Ogunti, 1993).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 974,
    "source": "PDF_chunked"
  },
  {
    "id": 4867,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 867)",
    "text": "l'épiderme et les cellules du mésophylle contiennent du mucilage, qui contient à sont tour des substances ergastiques rondes et jaunâtres (Elujoba et Ogunti, 1993). Matériel végétal en poudre Il est composé de fragments de cellules épidermiques qui sont de forme polygonale avec des stomates paracytiques, des fragments munis d'une cicatrice et des cellules épidermiques rayonnantes à l'extérieur, un tissu de xylème réticulé, annulaire (lignifié), des vaisseaux spiraux ; trachés; peu de fibres de phloème non lignifiées; uneparoi verruqueuse caractéristique couverte de trichomes unicellulaires et unisériés, apprimés, desfragments de vases dénoyautées et des groupes de fibres qui ont des prismes de cristaux d'oxalate de calcium pouvant également être isolés et se produit commedes gaines sur les nervures; il y a de même la présence degrains d'amidon, de 26- 42 cm, 49-120 cm de long, de couleur verte avec un goût am er caractéristique. Actions thérapeutiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 4868,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 868)",
    "text": "les nervures; il y a de même la présence degrains d'amidon, de 26- 42 cm, 49-120 cm de long, de couleur verte avec un goût am er caractéristique. Actions thérapeutiques Laxatif, antibactérien, antifongique, antiviral Indications thérapeutiques Ascite, constipation, craw -craw, dermatoses, démangeaisons, dystocie, eczéma, gonorrhée, lèpre, mycose, parturition, teigne, bardeaux, ulcère, tatouage (Mshana et al, 2000;. Assane, 1993; GHP, 1992 ; NHP, 2008). Données de sécurité Dans les études animales utilisant des rats femelles, la DL 50 était 3000 mgkg et le traitement (300- 3000 mgkg) n'a pas provoqué de changements dans le poids corporel ou dans le rapport organepoids corporel. Dans les études aiguës (300- 3000 mgkg), la diarrhée a été signalée chez le groupe qui a reçu 3000 mgkg. Il n'y avait pas de changements significatifs dans l'hématologie, le foie ou la fonction rénale. L'extrait aqueux de la feuille est considéré comme fiable.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4869,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 869)",
    "text": "OOAS Page 181 Senna alata WAHP Précautions d'emploi Des doses élevées peuvent affecter l'absorption d'autres médicaments provoqués par la reduction du temps de transit intestinal. L'utiliser chez les mères qui allaitent, les enfants de moins de 10 ans et pendant plus de 2 semaines, exigeune surveillance médicale. Comme avec toutes les herbes contenant du glycoside- anthranoïde, l'utilisation sur une longue durée peut provoquer la pigmentation de la muqueuse intestinale, ainsi q ue des nausées et des vomissements à fortes doses. Effets indésirables Diarrhée Contre-indications Grossesse et l'allaitement; saignement rectal, appendicite, occlusion intestinale et sténose; des doses élevées peuvent provoquer lapalpitation, la colique, les douleurs abdominales, la diarrhée, la perte d'électrolytes et la déshydratation, les troubles inflammatoires de l'intestin; des douleurs abdominalesidiopathiques; les hémorroïdes, la colite et l'ulcère.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4870,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 870)",
    "text": "la perte d'électrolytes et la déshydratation, les troubles inflammatoires de l'intestin; des douleurs abdominalesidiopathiques; les hémorroïdes, la colite et l'ulcère. Dosage et forme galénique Teinture, infusion (thé), décoction. Infusion: (chaude ou froide): des gousses ou des feuilles séchées doivent être trempées dans de l'eau chaude pendant 6 -12 heures; mettre1 cuillèrée à café dans environ 150 ml d'eau; filtrer après 10 minutes, prendre une tasse le matin etou avant d'aller au lit. Laxatif: 3- 4 g comme infusion chaude au moment du coucher. Conservation A conserver dans un endroit frais et sec. Références Adjanohoun, E. et al., (1991). Contribution to Ethnobotanical and Floristic studies in Western Nigeria Lagos, Nigeria: Organization of African Unity's Scientific Technical and Research Commission. Assane, M., (1993). Choleretic effects of Cassia alata Linn. in the rat. Dakar Medical.; 38(1):73- 77.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4871,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 871)",
    "text": "Unity's Scientific Technical and Research Commission. Assane, M., (1993). Choleretic effects of Cassia alata Linn. in the rat. Dakar Medical.; 38(1):73- 77. Benjamin, T.V., Lamikanra, A. (1981). Quarterly Journal of Crude Drug research 19: 93-96. Crockett, C.O. (1992). Cassia alata and the preclinical search for therapeutic agents for the treatment of opportunistic infections in AIDS patients. Cell and Molecular Biology 38(5):505- 511. Damodaran, S., Venkataraman, S. (1994). A study on the therapeutic efficacy of Cassia alata, Linn. leaf extract against Pityriasis versicolor. Journal of Ethnopharmacology 42(1):19-23. Elujoba, A. A., Ogunti, E.O. (1993). Pharmacopoeial and biological standardization of Cassia alata and Cassia podocarpa with reference to Senna. Glimpses in Plant Research XI, 469-479. Elujoba, A.A., Ajulo, O.O., Iweibo, G.O. (1989). Chemical and Biological analyses of Nigerian Cassia species for laxative activity. Journal of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4872,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 872)",
    "text": "XI, 469-479. Elujoba, A.A., Ajulo, O.O., Iweibo, G.O. (1989). Chemical and Biological analyses of Nigerian Cassia species for laxative activity. Journal of Pharmaceutical and Biomedic al Analysis 7(12):1453 1457. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana. Gupta, D. (1991).Flavonoid glycosides from Cassia alata. Phytochemistry 30(8): 2761-2763. Hauptman, H., Lacerda, V.L. (1950). Journal of American Chemical Society 72: 1492. Ibrahim, D. (1995). Antimicrobial activity of Cassia alata from Malaysia. Journal of Ethnopharmacology.; 45(3):151-156. Irvine, F.R (1961). Woody plants of Ghana London: Oxford University Press. Irvine, F.R. (1903). Plants of the Gol d Coast London: Oxford University Press. P 521-525. Lemli, J.A. (1976). Pharmacology 14(Suppl.1):6272. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al., (2000). Traditional medicine and pharmacopoeia.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4873,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 873)",
    "text": "Lemli, J.A. (1976). Pharmacology 14(Suppl.1):6272. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al., (2000). Traditional medicine and pharmacopoeia. Contribution to the r evision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. NHP (2008). Nigerian herbal pharmacopoeia. The Federal Ministry of Health, Abuja. Nigeria Nickell L.G. (1959). Economi c Botany 13:281- 318. Ogunti, E.O., Elujoba, A.A. (1993). Laxative activity of Cassia alata. Fitoterapia 64 (5):437 439.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 576,
    "source": "PDF_chunked"
  },
  {
    "id": 4874,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 874)",
    "text": "OOAS Page 182 Senna alata WAHP Ogunti, E.O., Aladesanmi, J.A., Adesanya, S.A, (1991). Antibacterial activity of Cassia alata. Fitoterapia 62:537. Okafor, J.I., Eze, E.A., Njoku, O.U. (2001). Nigerian Journal of Natural Products and Medicine 5: 59-60. Oladele, A. T., Dairo, B. A., Elujoba, A. A. and Oyelami, A. O. (2010). Management of superfacial fungal infections with Senna alata (alata) soap: A preliminary report . Afri. J. Pharm. Pharmacol. 4 (3): 98-103 Oladele, A. T., Elujoba, A. A. and Oyelami, A. O. (2012). Clinical studies of three herbal soaps in the management of superfacial fungal infections. Res. J. Medicinal Plant 6 (1): 56-64 Oliver-Bever, B. (1986). Medicinal Plants in Tropical West Africa London: Cambridge University Press, p.124-327. Palanichamy, S., Nagarajan, S.J. (1990). Analgesic activity of Cassia alata leaf extract and kaempferol-3-O-sophoroside. Journal of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 892,
    "source": "PDF_chunked"
  },
  {
    "id": 4875,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 875)",
    "text": "Palanichamy, S., Nagarajan, S.J. (1990). Analgesic activity of Cassia alata leaf extract and kaempferol-3-O-sophoroside. Journal of Ethnopharmacology 29(1):73-78. Palanichamy, S. (1990). Antifungal activity of Cassia alata leaf extract. Journal of Ethnopharmacology 29(3):337-340. Rai, P.P., Abdullahi, N. (1978). Occurrence of anthraquinone in Cassia species. Nigerian Journal of Pharmacy 9:160165. Thamlikitkul, V., Bunyapraphatsara, N., Dechatiwongse, T., Theerapong, S., et al. (1990). Randomized controlled trial of Cassia alata Linn. for constipation. Journal of Medical Association of Thailand 73(4):217-22 .",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 615,
    "source": "PDF_chunked"
  },
  {
    "id": 4876,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 876)",
    "text": "OOAS Page 183 Senna alexandrina WAHP Nom botanique Senna alexandrina Mill Famille Legumineuses-Ceasalpiniacées Synonymes Cassia senna L.; Cassia acutifolia Del; Cassia angustifolia Valil.; Cassia elongata Lam.; Cassia lantiva Brisch; Cassia lanceolata Collad Noms communs Séné d'Alexandrie (Cassia acutifolia Del.);Séné de Tinnevelly (Cassia angustifolia Valil.) Noms vernaculaires Mali: Tamachek Aghe-Agher, Egerger Niger: Arabic Senna Jebeli, Senna Makha Nigéria: Arabic Shuwa Senna Jebeli, Hausa Filáskon Máká Description de la plante Un petit arbuste av ec une pile droite de 1 à 1,5 m de haut, composé de feuilles paripennées d'environ 10 cm de longueur, 3- 7 paires de folioles d'environ 12- 24 cm de long sur 7- 12 mm de large, étroit, de couelur vert -pâle à vert - jaunâtre ; les fleurs sont zygomorphes avec des pétales jaunes, les fruits sont elliptiques, aplatis avec une gousse déhiscente de 4- 7 cm de long",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 920,
    "source": "PDF_chunked"
  },
  {
    "id": 4877,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 877)",
    "text": "de large, étroit, de couelur vert -pâle à vert - jaunâtre ; les fleurs sont zygomorphes avec des pétales jaunes, les fruits sont elliptiques, aplatis avec une gousse déhiscente de 4- 7 cm de long sur 2 cm de large. Il contient 6- 10 graines par gousse (OMS, 1999; Pharmacopée Africaine, 1985; Wallis, 1967). Habitat et répartition géographique La plant e est largement répandue dans les territoires du Haut -Nil, d'Alexandrie, du Soudan et d'autres zones semi-désertiques d'Afrique. Parties utilisées de la plante Feuille Autres parties utilisées Fruit Caractéristiques botaniques Le séné d'Alexandrie est c onstitué des rameaux ou des fruits secs de Senna alexandrina Mill (Leguminosae-Ceasalpinioideae). Utilisations ethnomédicales Il est utilisé dans l'évacuationde l'intestin, la constipation, la maladie du foie, la jaunisse, l'anémie, la splénomégalie et la typhoïde. Activités biologiques et pharmacologiques Les effets laxatifs du séné sont dues à la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4878,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 878)",
    "text": "constipation, la maladie du foie, la jaunisse, l'anémie, la splénomégalie et la typhoïde. Activités biologiques et pharmacologiques Les effets laxatifs du séné sont dues à la présence de sennosides A et B, qui influent la motilité du côlon et améliorent le transit propulsif du colon. Le sené provoque la contraction péristaltique, en augmentant sensiblement le taux de défécation, le poids des matières fécales et la fluidité des selles (Fleming, 2000). Données cliniques Les sennosides améliorent la selle des patients souffrant du syndrome du côlon sévère, irritable. Ils n'ont pas bouleversé le schéma habituel du nombre de défécation et ont ramollinettement les selles. En outre, les sennosides augmentent de manière significative le taux du transit du côlon et augmentent le péristaltisme du côlon, entraînant une augmentation à la foi s du poids fécal et de la masse bactérienne sèche. Les sennosides sont mal absorbés dans l'appareil",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4879,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 879)",
    "text": "et augmentent le péristaltisme du côlon, entraînant une augmentation à la foi s du poids fécal et de la masse bactérienne sèche. Les sennosides sont mal absorbés dans l'appareil supérieur gastro-intestinal (OMS, 1999). Constituants chimiques Les glycosides hydroxyanthracènes, particulièrement les sennosides A, B, C et D, l'aloé-émodine, rhéine- 8-glucosides, le mucilage et les flavonoïdes (la Pharmacopée Africaine, 1985; Wallis, 1967), Sennocides A, B, C (Okafor et al, 2001). Tests d'identité et de pureté Teneur en humidité: pas plus de 10 (feuilles), 12 (fruits) Cendres totales: pas plus de 12 (feuilles); 6 (fruits) Cendres insoluble dans l'acide: pas plus de 2 (feuilles); 2 (fruits) Substances extractible par l'eau: pas moins de 3 (feuilles), 25 (fruits) Indice stomatique: 10-12.5-15 Nombre de stomates: 11.04 à 12.02 -13 Nombre veine-îlot: 20-25-30",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 862,
    "source": "PDF_chunked"
  },
  {
    "id": 4880,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 880)",
    "text": "OOAS Page 184 Senna alexandrina WAHP Ratio de palissade: 4.5 à 9.5-18 (épiderme supérieur) de 3,5 à 7,0 - 14,5 (inférieure de l'épiderme) Matière organique étrangère: pas plus de 1,0 (feuilles); 1,0 (fruits). Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acét ique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de six taches distinctes avec valeurs R f de 0,94 (rose), 0,89 (marron), 0,76 (vert), 0,62 (violet), 0,48 (violet) et 0,32 (brun jaunâtre). Chromatogramme Macroscopie Les folioles sont lancéolées à ovales -lancéolées de 2,5 cm de long sur 0,5 à 1,6 cm de large, de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 908,
    "source": "PDF_chunked"
  },
  {
    "id": 4881,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 881)",
    "text": "0,32 (brun jaunâtre). Chromatogramme Macroscopie Les folioles sont lancéolées à ovales -lancéolées de 2,5 cm de long sur 0,5 à 1,6 cm de large, de couleur grisâtre,vert -pâle ou vert -jaunâtre; texture mince et fragile ; dans le commerce, les feuilles semblent plus ou moins brisées, asymétriquesdans la forme, et inégales à la base ;elles sont recouvertes sur les deux faces de poils blanchâtres bien visibles à proximité des veines ; le sommet est aigu et mucroné avec un pétiole d'environ 1 mm de long; une veine plus visible sur l'épiderme inférieur, un rayon (si présent) mince, de 7 à 10 cm de long, 4 à 6 paires de folioles avec une odeur légère, un goût mucilagineux avec une caractéristique d'amertume (OMS, 1999; BPC, 1959). Les fruits sont des gousses légumineuses entières, latéralement comprimées, presque plats et largement oblongues, gousses fines, vert - jaunâtres à bru- jaunâtres, d'environ 3- 6 cm de long sur 2,5 cm de large, un apex rond avec de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 966,
    "source": "PDF_chunked"
  },
  {
    "id": 4882,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 882)",
    "text": "latéralement comprimées, presque plats et largement oblongues, gousses fines, vert - jaunâtres à bru- jaunâtres, d'environ 3- 6 cm de long sur 2,5 cm de large, un apex rond avec de légers points saillants, comportant environ 5- 7 loges contenant des graines dures, obovales - cunéiformes, de 5- 6 mm de long sur 3- 4 mm de large; ayant un péricarpe sec et membraneux avec un embryon grand et droit, vert avec des cotylédons plats, entourés d'un endosperme rare de couleur grise. Matériel végétal en poudre La poudre de feuilles est de couleur vert -clair à vert-jaune avec des fragments de cellules épidermiques polygonales, des stomates paracytiques, unicellulaires, coniques, verruqueuses, couvrant les poilsqui sont isolés ou attachés à des fragments de cellul es épidermiques, des fragments de faisceaux vasculaires avec des gaines de cristaux prismatiques d'oxalate de calcium, des grappes de cristaux d'oxalate de calcium, des fragments",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4883,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 883)",
    "text": "épidermiques, des fragments de faisceaux vasculaires avec des gaines de cristaux prismatiques d'oxalate de calcium, des grappes de cristaux d'oxalate de calcium, des fragments isolés ou à l'intérieur des cellules du parenchyme. La poudre du fruit contie nt des fragments de cellules d'épicarpe contenant des stomates de type anomocytique ou paracytique unicellulaires, coniques et des poils verruqueuses, qui sont isolés ou fixés sur des cellules, aux fibres de l'endocarpe polygonales et descellules mucilagineuses de l'endosperme. Actions thérapeutiques Laxatif, antibactérien, antifongique Indications thérapeutiques Constipation, maladie du foie, jaunisse, anémie, splénomégalie et typhoïde",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 694,
    "source": "PDF_chunked"
  },
  {
    "id": 4884,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 884)",
    "text": "OOAS Page 185 Senna alexandrina WAHP Données de sécurité Dans les études animales utilisant des rats femelles, la DL 50 était 3000 mgkg et le traitement (300- 3000 mgkg) n'a pas provoqué de changements dans le ratio organepoidscorporel. Dans les études aiguës (300-3000 mgkg), la diarrhée a été observée dans le groupe ayant reçu 3000 mgkg. Il n'y a pas eu de changements significatifs dans l'hématologie, le foie ou la fonction rénale. L'extrait aqueux des feuilles est considéré comme sûr. Précautions d'emploi Pas de précautions particulières. Cependant des doses élevées peuvent affecter l'absorption d'autres médicaments en raison de la réduction du temps du transit intestinal. Sauf sur avis médical, il ne devrait pas être utilisé pendant plus de 14 jours ou pour les enfants âgés de moins de 10 ans (British Pharmacopée, 1988; Godding, 1998). Effets indésirables Des doses élevées peuvent entraîner la préhension excessive, une gêne abdominale, la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4885,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 885)",
    "text": "moins de 10 ans (British Pharmacopée, 1988; Godding, 1998). Effets indésirables Des doses élevées peuvent entraîner la préhension excessive, une gêne abdominale, la diarrhée, la déplétion électrolytique, et la perte de poids; des doses plus élevées ou l'utilisation chronique peut endommager le foie, le rein et affecter la spermatogenèse (Adefemi et al, 1988.). L'usage prolongé peut causer une décoloration de l'urine. Contre-indications Grossesse, occlusion intestinalesténose, appendicite, diurétique, corticothérapie ou digoxine; hypermotilité des intestins. Dosage et forme galénique Comme laxatif: 0,5 à 2.0 g en tant que thé chaud au moment du coucher, et comme purgatif: 2-4 g en tant thé chaud au moment du coucher Conservation A conserver dans un récipient bien fermé, à l'abri de la lumière et l'humidité Références Adefemi, O. A., Elujoba, A. A. and Odesanmi, W. O. (1988). Evaluation of Cassia podocarpa with",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 4886,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 886)",
    "text": "A conserver dans un récipient bien fermé, à l'abri de la lumière et l'humidité Références Adefemi, O. A., Elujoba, A. A. and Odesanmi, W. O. (1988). Evaluation of Cassia podocarpa with reference to Senna. W. Afri. J. Pharmacol. Drug Res. 8 (1): 41-47 African Pharmacopoeia Volume 1 (1985). First Edition, published by Organization of African Unity's Scientific Technical and Research Commission (OAUSTRC), Lagos, Nigeria. British Pharmaceutical Codex (1959). Published by the Pharmaceutical Society of Great Britain and printed by the Pharmaceutical Press, London. British Pharmacopoeia (1988). Published by Her Majesty's Stationary office and printed by the Pharmaceutical press, London. Flemming, T.E. (2000). Physicians' Desk References for herbal medicines 2 nd Edition. Medical Economics Company. Godding, E. W. (1998). Laxatives and the special roles of Senna. Pharmacology 36(1):230-236. Okafor J.I, Eze E.A., Njoku O. U. (2001).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4887,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 887)",
    "text": "nd Edition. Medical Economics Company. Godding, E. W. (1998). Laxatives and the special roles of Senna. Pharmacology 36(1):230-236. Okafor J.I, Eze E.A., Njoku O. U. (2001). Nigerian Journal of Natural Products and Medicine 5 59-60. Wallis, T. E. (1967). Textbook of Pharmacognosy 5 th Edition published by J and A Churchill Ltd, London. World Health Organization (1999). WHO Monographs on selected medicinal plants. Vol 1, published by WHO, Geneva.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 449,
    "source": "PDF_chunked"
  },
  {
    "id": 4888,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 888)",
    "text": "OOAS Page 186 Senna occidentalis WAHP Nom botanique Senna occidentalis (L.) Link Famille Leguminosae-Ceasalpinioideae Synonyme Cassia occidentalis L.; Cassia caroliniana Walter; Cassia foetida Persoon; Ditremexa occidentalis (L) Britt Rose Noms communs Coffee senna, Mogdad coffee, stinkweed (Anglais); Herbe puante (Français); Fedegosa (Portuguais) Noms vernaculaires Buirkina Faso : Moo ré Kinkéliba, Dioula M'balan m'balan;mbala fin, Fulfuldé Tasbati Cote d 'Ivoire: Baoulé Aloukou Sere Sere, Malinké Badjaa; Akyé M'bechilè Gambie: Mandinka Kassala, Fulla Tiga Sowru, Wollof Hobi Ghana: Akan Mmofraborodee, Ga Dangme Gbekebii Arnadaa, Ewe Dzongbale Mali: Bambara N'Balan Balanfing, Noms Tasbati, Malinké Kassé Niger: Djerma Sanga Sanga, Hausa Raydoré Nigéria: Yoruba Rere Sénégal: Serer Ben Fènè; Bénékèné, Wolof Bantamaré, Diola Bufata Sierra Leone : Kisi Dilankido, Shebro",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 877,
    "source": "PDF_chunked"
  },
  {
    "id": 4889,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 889)",
    "text": "Niger: Djerma Sanga Sanga, Hausa Raydoré Nigéria: Yoruba Rere Sénégal: Serer Ben Fènè; Bénékèné, Wolof Bantamaré, Diola Bufata Sierra Leone : Kisi Dilankido, Shebro Sabibosueleh, Temne E- Bambaforke Togo: Ewé Bessissan, Ouatchi Avakofè; Adja Laloui Description de la plante Herbe glabre ou sous arbuste; annuelle ou jusqu'à 3 ans de durée; feuilles composée spennées,avec 4- 5 paires de folioles dont la paire terminale est la plus grande; les folioles sontlargement lancéolées ou ovales, de 3,5- 10 cm de long sur3- 4 cm de large ; le sommet est pointu, une glande près de la base du rachis des feuilles ; les fleurs sont jaunes avec une gousse linéaire defruits, un peu aplatie , brusquement à bec. Numéro du specimen de l'herbier Ghana: GC45900 Mali: 1525 (DMT) Habitat et répartition géographique C'est une mauvaise herbe commune qui se retrouve sur les terrains vagues dans les villages",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 891,
    "source": "PDF_chunked"
  },
  {
    "id": 4890,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 890)",
    "text": "Ghana: GC45900 Mali: 1525 (DMT) Habitat et répartition géographique C'est une mauvaise herbe commune qui se retrouve sur les terrains vagues dans les villages et les villes et le long des routes pantropicales. Parties utilisées de la plante Feuille Autres parties utilisées Graineset racines Caractéristiques botaniques Le café séné se compose de la feuille séchée de Senna occidentalis (L.) Link (Leguminosae- Ceasalpinioideae). Utilisations ethnomédicales S. oc cidentalisest employé dans beaucoup de régions d'Afrique pour traiter toute une variété de maux tels que les abcès, les contusions, les cataractes, la constipation, les infections oculaires, les maux de tête, la jaunisse, les infections rénales, la lèpre, le paludisme, les douleurs du rein, les troubles menstruels, le rhumatisme, la teigne, la gale, les maux de gorge, l'ulcère d'estomac, les maux d'estomac, la syphilis, le tétanos, les vers, les fièvres, la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4891,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 891)",
    "text": "douleurs du rein, les troubles menstruels, le rhumatisme, la teigne, la gale, les maux de gorge, l'ulcère d'estomac, les maux d'estomac, la syphilis, le tétanos, les vers, les fièvres, la tuberculose, l'anémie, les troubles du foie, la fatigue générale, l'asthme, les bronchites, les maladies vénériennes (Chukwujekwu et al, 2005;. Tona et al, 2004; Samy et Ignacimuthu, 2000; Kuo et al , 1996;. Saraf et al , 1994;. Soukup, 1970; Rutter, 1990; Coimbra, 1994; Ayensu, 1981; Altschul, 1983; Ronquillo, 1988; Robineau, 1989; Standley Steyermark, 1946; Kabiruddin, 1951; Kirthikar et al 1969). Au Mali, les feuilles sont utilisées pour traiter l'oedème et la décoction est faite pour le paludisme, la fièvre issue de la grossesse, la fièvre jaune, les maux de tête et la conjonctivite. Les graines sont brassées dans une boisson ressemblant à du café pour soigner l'asthme, l'hypertension, le paludisme, les fièvres et les maux d'estomac.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 4892,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 892)",
    "text": "OOAS Page 187 Senna occidentalis WAHP Activités biologiques et pharmacologiques L'effet laxatif des différentes parties de la plante de Senna a été signalé depuis longtempsdans les années 1950 (Grote et Woods, 1951). Plusieurs études scientifiques ont montré que S. occidentalis a des propriétés antibiotique, anti - inflammatoire, vermifuge, abortive, cholagogue, cicatrisante, diurétique, laxative et tonique (Ake, 1983; Morton, 1981; Robineau 1989; Chukwujekwu et al. 2006). Les parties aériennes de la plante (feuilles, fruits et feuilles) ont des propriétés purgatives (Watt et Breyer -Brandwijk, 1962). Les extrai ts de la feuille ont montré une activité antibactérienne à large spectre contre B. subtilis et S. aureus (Samy et Ignacimuthu, 2000) et les extraits au benzène et à l'éther des feuilles, des racines et des graines ont également été actifs contre les bactér ies Gram - positives et Gram -négatives (Ikram et al., 1978).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4893,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 893)",
    "text": "2000) et les extraits au benzène et à l'éther des feuilles, des racines et des graines ont également été actifs contre les bactér ies Gram - positives et Gram -négatives (Ikram et al., 1978). Il a montré une activité antibactérienne contre Salmonella typhi (Perez et Anesini, 1994;. Evans et al 2002). Une étude menée par Tona et al. (1999) a également montré que les extraits éthanoliques et au dichlorométhane des feuilles possédaient un effet anti -parasitaire in vitro , tandis que les extraits éthanolique, dichlorométhane et aqueux de l'écorce de racine lyophilisés produisent les chemosuppressions de la parasitémie d'une manière dose- dépendante; l'extrait éthanolique lipophilisé était plus actif (Tona et al, 1999; Tona et al, 2001;. Tona et al, 2004.). Toutefois, Gasquet et al. (1993), ont rapporté de légers effets antipaludiques. Une autre étude réalisée par Caceres et al. (199lc) a constaté que la décoction de feuilles était active",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4894,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 894)",
    "text": "2004.). Toutefois, Gasquet et al. (1993), ont rapporté de légers effets antipaludiques. Une autre étude réalisée par Caceres et al. (199lc) a constaté que la décoction de feuilles était active contreE. flocossum, M. gypseum, T. mentagrophytes et T. rubrum. Des études In vivo et in vitro ont montré que les extraits aqueux de la plante possèdent uneactivité anti -mutagènes contre la mutagénicité induite par le benzo α pyrène et cyclophosphamide (Sharma et al . 1999; Sharma et al ., 2000a;. Sharma et al., 2001). L'administration des extraits de la plante a induit un renforcement de l immunité des animaux exposés au cyclophosphamide (Bin- Hafeez et al.2001). Les ét udes in vivo ont également montré que la poudre de la plante a une activité anti -inflammatoire, ainsi qu'une capacité à stabiliser la membrane érythrocytaire humaine contre la lyse induite par l'hypotonicité (Sadique et al 1987). L'extrait de feuille produ it",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4895,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 895)",
    "text": "capacité à stabiliser la membrane érythrocytaire humaine contre la lyse induite par l'hypotonicité (Sadique et al 1987). L'extrait de feuille produ it une hépatoprotection significative (Jafri, et al. 1999) tandis que son extrait aqueux provoque une activité anti -hyperglycémique importante chez les rats diabétiques induit par l'alloxane (Verma et al ., 2010). L'extrait aqueux de la plante entière, a également eu plus de potentiel que les extraits hydro-alcoolique et alcoolique contre desvariétés de celluleshumainesdecancerà 100,30,et10μgml. L'extrait hydro- alcoolique a démontré un potentiel contre Bacillus subtilis (Bhagat et Saxena, 2010), tandis que la fraction d'acétate d'éthyle de l'extrait méthanolique des feuilles montre un potentiel antioxydant elévée de la plante (El -Hashash et al., 2011). Les extraits aqueux et hydro- alcoolique du C. occidentalis ont induit une inhibition complète de l'éclosion des œufs à une concentration inférieure ou égale",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 969,
    "source": "PDF_chunked"
  },
  {
    "id": 4896,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 896)",
    "text": "plante (El -Hashash et al., 2011). Les extraits aqueux et hydro- alcoolique du C. occidentalis ont induit une inhibition complète de l'éclosion des œufs à une concentration inférieure ou égale à 1mgml. L'extrait aqueux a également induit une inhibition de 96,36 du développement larvaire, mais les extraits hydro- alcooliques de la plante (9) ont eu un mauvais effet inhibiteur (Eguale et al., 2011). Données cliniques L'efficacité de S. occidentalis comme stimulant pour la repigmentation de la peau dans le vitiligo a été démontrée dans des études précliniques et cliniques (Babitha et al., 2011). Constituants chimiques Anthraquinoniques (par exemple les sennosides, le chrysophanol, le physcion, le helminthosporine, l'émodine), les huiles grasses, les flavonoïdes ((jacein 7- rhamnoside, mattencinol 7- rhamnoside, matteucinol 7- rhamnoside, jaceidin- 7-rhamnoside, cassiaoccidentalins A, B et C), les xa nthones (cassiollin); le gallactomannan, les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 4897,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 897)",
    "text": "mattencinol 7- rhamnoside, matteucinol 7- rhamnoside, jaceidin- 7-rhamnoside, cassiaoccidentalins A, B et C), les xa nthones (cassiollin); le gallactomannan, les polysaccharides et les tanins) (Chukwujekwu et al., 2006; Chauhan et al., 2001; Purwar et al., 2003; Hatano et al., 1999; Ikram et al., 1978; Glasby, 1991; Rai et Shok, 1983; Gupta et al., 2005).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 357,
    "source": "PDF_chunked"
  },
  {
    "id": 4898,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 898)",
    "text": "OOAS Page 188 Senna occidentalis WAHP Tests d''identité et de pureté Teneur en humidité: 8,84 Cendre totale: 11,54 Substances extractibles par l'eau: pas moins de 21,64 Substances extractibles par l'éthanol (70): pas moins de 21,17 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn.Présence de huit taches distinctes avec valeurs R f de 0,71 (rose), 0,64 (rose), 0,55 (gris-foncé), 0,35 (rose), 0,29 (rose), 0,21 (marron), 0,19 (violet) et 0,09 (vert). Chromatogramme Macroscopie La graine séchée est aplatie, peu obovale avec une extrémité (raphé) pointue; une texture lisse,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 4899,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 899)",
    "text": "0,21 (marron), 0,19 (violet) et 0,09 (vert). Chromatogramme Macroscopie La graine séchée est aplatie, peu obovale avec une extrémité (raphé) pointue; une texture lisse, dure, brune avec des feuilles de couleur verte avec une odeur caractéristique et un léger goût amer. Microscopie La texture comprend une couche extérieure cuticulariseé entourant une couche vascularisée circonscrite; l'intérieur est une monocouche de cellules orientées radialement isodiamétriques; suivie d'un tissu sclerenchymateux tangentiellement allongé à l'intérieur; une couche hyaline sépare le tégument de l'endosperme. Les feuilles ont des cellules épidermiques àparois droites avec de nombreux stomates paracytiques sur les deux surfaces. Peu de poils de revêtement unicellulaires éparpillés. Matériel végétal en poudre Les graines grillées, de couleur brun- foncée ont une odeur aromatique ressemblant à celle du café; les tissus sont sclerenchymateux; les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4900,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 900)",
    "text": "Matériel végétal en poudre Les graines grillées, de couleur brun- foncée ont une odeur aromatique ressemblant à celle du café; les tissus sont sclerenchymateux; les fibres inlignifiées,courtes, ; le tissu est compact comme du liège; dessclérites; des cellules parenchymateusesavec de l'huile degrains d'amidon. La poudre de feuilles àparois droites est composée de cellules épidermiques, quelques poils unicellulaires et des grains d'amidon éparpillés. Actions thérapeutiques Antianémique, antimicrobien, désintoxiquant, anti-hypertenseur, antihelminthique, antihépatite, antipaludique. Indications thérapeutiques Douleurs abdominales, anémie, infections bactériennes et fongiques, cirrhose, désintoxication, l'hypertension, vers intestinaux, troubles hépatiques (ictère, hépatite, blessureschutte, etc), paludisme, parasites de la peau (Mshana et al, 2000; GHP, 1992). Données de sécurité La DL 50 de l'extrait aqueux des feuilles (p.o) chez",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4901,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 901)",
    "text": "blessureschutte, etc), paludisme, parasites de la peau (Mshana et al, 2000; GHP, 1992). Données de sécurité La DL 50 de l'extrait aqueux des feuilles (p.o) chez la souris sur une période de 24 heures était 2000 mgkg. Les études de toxicité aiguë n'ont pas montré de signes cliniques de toxicité après traitement des souris mâle et femelle (500 à 2000 mgkg; po) pendant 14 jours. Dans une étude de toxicité sub- chronique, l'administration répétée de l'extrait aqueux peut provoquer une hypoglycémie et un dysfonctionnement du foie et du rein chez les rats. La toxicité des fèves fraîches ou séchées a été démontrée dans plusieurs études animales. La DL 50 est de 1 gkg pour les souris et les rats. La toxicité est attribuée à des alcaloïdes, différents anthraquinones et à leurs dérivés, mais les toxines spécifiques n'ont pas été identifiées. Le spectre et l'histopathologie clinique l empoisonnement par S. occidentalis chez les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4902,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 902)",
    "text": "anthraquinones et à leurs dérivés, mais les toxines spécifiques n'ont pas été identifiées. Le spectre et l'histopathologie clinique l empoisonnement par S. occidentalis chez les enfants ressemblent à ceux dela toxicité chez l'animal, affectant principalement le foi e, le muscle squeletique et les tissus du cerveau. Le taux de létalité en cas d'intoxication aiguë sévère est de 75- 80 chez les enfants (Vashishtha et al., 2009). L'ingestion de fortes doses de feuilles peut exposer des personnes au risque d'hépatotoxicité (Vanderperren et al 2005;. Borrelli et al, 2005;. Nuhu et Aliyu, 2008). Les études de toxicité aiguë menées chez les rats ont révélé que les extraits hydroalcooliques de la tige et des feuilles ont été bien toléré, la DL 50 était supérieure à 5 gkg. L'administration sub- aiguë orale pendant la grossesse chez les rats femelles Wistar n'a montré statistiquement",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 885,
    "source": "PDF_chunked"
  },
  {
    "id": 4903,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 903)",
    "text": "OOAS Page 189 Senna occidentalis WAHP aucune différence significative entre le rat témoin et les groupes traités en termes deprogénitureliaison; le fœtus, le placenta et le poids de l'o vaire, le nombre d'implantation et de sites de résorption, le nombre de corps jaunes dans les ovaires et le taux de perte de la pré- et post-implantation (Aragão, et al., 2009). Le traitement subaigü avec les extraits hydroalcooliques de tige et de feuille n'a pas modifié le gain de poids corporel, la consommation en nourriture et eau et les profils hématologiques et biochimiques; aucun changement dans les caractéristiques macroscopiques et microscopiques des organesn'ont été observées chez les rats (Silva et al., 2011). Effets indésirables L'ingestion àlong terme de petites quantités et uneseuledose élevée de la semence ont causée le myodégénération, l'insuffisance respiratoire, la perturbation de la structure mitochondriale et la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4904,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 904)",
    "text": "L'ingestion àlong terme de petites quantités et uneseuledose élevée de la semence ont causée le myodégénération, l'insuffisance respiratoire, la perturbation de la structure mitochondriale et la mort des lapins (O'Hara et Pierce, 1974). Des doses élevées peuvent interférer avec le métabolisme de certains médicaments dans le foie. Précautions d'emploi L'extrait aqueux de la plante peut provoquer une hypoglycémie et une augmentation de lafonction hépatique et rénale. La glycémie et les paramètres biochimiques du foie et du rein doivent être régulièrement surveillés en cas d'utilisation sur une longue durée. Contre-indications Grossesse, hypotension, antihypertenseurs Dosage et forme galénique Décoction: 10 g de feuilles séchées en poudre dans 500 ml d'eau; 1 tasse de thé deux fois par jour. Teinture: 1:5 dans de l'éthanol à 50; 5 ml trois fois par jour Conservation A conserver dans unrécipientbien fermé, dans un",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 4905,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 905)",
    "text": "dans 500 ml d'eau; 1 tasse de thé deux fois par jour. Teinture: 1:5 dans de l'éthanol à 50; 5 ml trois fois par jour Conservation A conserver dans unrécipientbien fermé, dans un endroit frais et sec, à l'abri de la lumière. Références Ake, A.L. (1983). Some medicinal properties of Cassia occidentalis , Caesalpinaceae, in the lower Ivory Coast. Bothalia 14:617- 620 (in French). Altschul, S. (1983). Drugs and Foods from Lirrle- Known Planis. Harvard University Press, Cambridge MA 116-120. Aragão, T.P ., Lyra, M.M. , Silva, M.G ., Andrade, B.A. et al . (2009). Toxicological reproductive study of Cassia occidentalis L. in female Wistar rats. Journal of Ethnopharmacology 123(1):163- 166. Ayensu, E.S. (1 981). Medicinal Plants of the West Indies. Reference Publications, Algonac 282. Babitha, S., Shin, J.H., Nguyen, D.H., Park, S.J. et al . (2011). A stimulatory effect of Cassia occidentalis on melanoblast differentiation and",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4906,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 906)",
    "text": "282. Babitha, S., Shin, J.H., Nguyen, D.H., Park, S.J. et al . (2011). A stimulatory effect of Cassia occidentalis on melanoblast differentiation and migration. Archives of Dermatology Research. 303(3):211-216. Bhagat, M., Saxena, A.K . (2010). Evaluation of Cassia occidentalis for in vitro cytotoxicity against human cancer cell lines and antibacterial activity. Indian Journal of Pharmacology 42(4):234-237. Bin-Hafeez, B., Ahmad, I., Haque, R., Raisuddin, S. (2001). Protective effect of Cassia occidentalis L. on cyclophosphamide- induced suppression of humoral immunity in mice. Journal of Ethnopharmacology 75:13-18. Borrelli, F., Capasso, R., Av iello, G., Di Carlo, G. et al. (2005). Senna and the formation of aberrant crypt foci and tumors in rats treated with azoxymethane. Phytomedicine 2(6-7):501-505. Cáceres, A., Lopez, B.R., Giron, M.A., Logemann, H. (1991). Plants used in Guatemala for the treatment of dermatophytic infections. I.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4907,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 907)",
    "text": "azoxymethane. Phytomedicine 2(6-7):501-505. Cáceres, A., Lopez, B.R., Giron, M.A., Logemann, H. (1991). Plants used in Guatemala for the treatment of dermatophytic infections. I. Screening for antifungal activity of 44 plant extracts. Journal of Eihnopharmacology 31: 263- 276. Chauhan, D., Chauhan, J.S., Siddiqu,i I.R., Singh, J. (2001). Two new anthroquinone glycosides from leaves of Cassia occidentalis . Indian Journal of Chemistry Section B -Organic Chemistry including Medicinal Chemistry 40:860- 863. Chukwujekwu, J.C., Coombes, P.H., Mulholland, D.A., van Staden, J. (2006). Emodin, an antibacterial anthraquinone from the roots of Cassia oc cidentalis. South African Journal of Botany 72, 295-297. Chukwujekwu, J.C., van Staden, J., Smith, P. (2005). Antibacterial, anti -inflammatory and antimalarial activities of some Nigerian medicinal",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 850,
    "source": "PDF_chunked"
  },
  {
    "id": 4908,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 908)",
    "text": "OOAS Page 190 Senna occidentalis WAHP plants. South African Journal of Botany 71: 316- 325. Coimbra, R. (1994). Manual de Fitoterapia, 2nd edn. Editora Cejup, Belem, Brazil. Eguale, T ., Tadesse, D ., Giday, M . (2011). In vitro anthelmintic activity of crude extracts of five medicinal plants against e gg-hatching and larval development of Haemonchus contortus . Journal of Ethnopharmacology. 137(1):108-13. El-Hashash, M.M., Abdel-Gawad, M.M ., El- Sayed, M.M ., Sabry, W.A . et al. (2010). Antioxidant properties of methanolic extracts of the leaves of seven Egyptian Cassia species. Acta Pharmaceutica 60(3):361-367. Evans, C.E., Banso, A., Samuel, O.A. (2002). Efficacy of some nupe medicinal plants against Salmonella typhi : an in vitro study. Journal of Ethnopharmacology 80(1):21-24. Gasquet, M., Delmas, F., Timon- David, P., Keita, A., et al. (1993). EvaIuation of in vitro and in vivo effects of a traditional antimalarial 'Malarial 5'.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4909,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 909)",
    "text": "Ethnopharmacology 80(1):21-24. Gasquet, M., Delmas, F., Timon- David, P., Keita, A., et al. (1993). EvaIuation of in vitro and in vivo effects of a traditional antimalarial 'Malarial 5'. Fitoterapia 64:423-426. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana, 111-113. Glasby, J.S. (1991). Dictionary of Plants Containing Secondary Metabolites. Taylor Francis, London 488. Grote, I.W., Woods, M. (1951). The laxative activity in mice of the various parts of the senna plant. Journal of American Pharmaceutical Association 40(1):52-53. Gupta, S., Pradeep, S., Soni, P.L. (2005). Chemical modification of Cassia occidentalis seed gum: carbamoylethylation. Carbohydrate Polymers 59:501506. Hatano, T., Mizuta, S., Ito, H., Yoshida, T. (1999). C -Glycosidic flavonoids from Cassia occidentalis. Phytochemistry 52:1379-1383. Ikram, M., Hussain, S.F. (1978). Compendium of Medicinal Plants. Pakistan Council of Scientific",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4910,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 910)",
    "text": "(1999). C -Glycosidic flavonoids from Cassia occidentalis. Phytochemistry 52:1379-1383. Ikram, M., Hussain, S.F. (1978). Compendium of Medicinal Plants. Pakistan Council of Scientific and Industrial Research, Peshawar 77-78. Jafri, M.A ., Subhani, M.J., Javed, K., Singh, S. (1999). Hepatoprotective activity of leaves of Cassia occidentalis against paracetamol and ethyl alcohol intoxication in rats. Journal of Ethnopharmacology 66:355-361. Kabiruddin, M. (1951). Makhzanul Advia Shaikh Mohd. Bashir, Lucknow, 454-455. Kirthikar, K.R, Basu, B.D., An, I.C.S. (1969). Indian Medicinal Plants, 2 nd ed. Periodical Experts, New Delhi 1, 623. Kuo, S.C., Chen, S.C., La, C.F., Teng, C.M. et al . (1996). Studies on the anti -inflammatory and antiplatelet activities of constituents isolated from the roots and stem of Cassia occidentalis L. Chinese Pharmaceutical Journal 48:291302. Morton, J.F. (1987). Fruits of Warm Climates.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 4911,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 911)",
    "text": "antiplatelet activities of constituents isolated from the roots and stem of Cassia occidentalis L. Chinese Pharmaceutical Journal 48:291302. Morton, J.F. (1987). Fruits of Warm Climates. Published by the author, Coral Gables FL 204- 209. Mshana, N.R., Abbiw, D.K. , Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al ., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Nuhu, A.A., Aliyu, R. (2008). Effects of Cassia occidentalis aqueous leaf extract on biochemical markers of tissue damage in rat.Tropical Journal of Pharmaceutical Research 7(4):1137-1142. O'Hara, P.J., Pierce, K.R. (1974). Toxic cardiomyopathy caused by Cassia occidentalis II. Biochemical studies in poisoned rabbits. Vetenary Pathology 11:110-124. Perez, C., Anesini, C. (1994). In vitro",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 915,
    "source": "PDF_chunked"
  },
  {
    "id": 4912,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 912)",
    "text": "cardiomyopathy caused by Cassia occidentalis II. Biochemical studies in poisoned rabbits. Vetenary Pathology 11:110-124. Perez, C., Anesini, C. (1994). In vitro antibacterial activity of Argentine folk medicinal plants against Salmonella typhi . Journal of Ethnopharmacology 44(1):41-46. Purwar, C., Rai, R., Srivastava, N., Singh, J. (2003). New flavonoid glycosides from Cassia occidentalis. Indian Journal of Chemistry Section B-Organic Chemistry Including Medicinal Chemistry 42:434-436. Rai, P.P., Shok, M. (1983). Anthraquinone glycosides from plant parts of Cassia occidentalis. Indian Journal of Pharmaceutical Science 45(2):87-88.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 639,
    "source": "PDF_chunked"
  },
  {
    "id": 4913,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 913)",
    "text": "OOAS Page 191 Senna occidentalis WAHP Robineau, L. (1989). Hacia una Farmacopea Caribeia. Enda- Caribe y Universidad National Autonoma de Honduras, Santo Domingo 474. Ronquillo, F.A. , Melgar, M.F., Carrillo, J.E., Martinez, A.B. (1989). Especies Vegetales de Use Actual y Potential en Alimentacion y Medicina de Ias Zonas Semiaridas del Nororiente de Guatemala. Cuadernos de Investigacidn No. 7- 88. USAC-DIGI, Guatemala, 249. Rutter, R.A . (1990). Catalogo de Plantas Utiles de la Amazonia Peruana. Instituto Linguistico de Verano, Yarinacocha, Peru. Sadique, J., Chandra, V., Thenmozhi, V., Elango, V. (1987). Biochemical modes of action of Cassia occidentalis and Cardiospermum halicacabum in inflammation. Journal of Ethnopharmacology 19:201-212. Samy, R.P., Ignacimuthu, S. (2000). Antibacterial activity of some folklore medicinal plants used by tribals in Western Ghats of India. Journal of Ethnopharmacology 69:63-71.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4914,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 914)",
    "text": "Samy, R.P., Ignacimuthu, S. (2000). Antibacterial activity of some folklore medicinal plants used by tribals in Western Ghats of India. Journal of Ethnopharmacology 69:63-71. Sharma, N., Trikha, P. , Athar, M., Raisuddin, S. (1999). Protective effect of Cassia occidentalis extract on chemical -induced chromosomal aberrations in mice. Drug and Chemical Toxicology 22:643-653. Sharma, N., Trikha, P., Athar, M., Raisuddin, S. (2000a). In vitro inhibition of carcinogen-induced mutagenicity by Cassia occidentalis and Emblica officinalis. Drug and Chemical Toxicology 23: 477-484. Sharma, N., Trikha, P., Athar, M., Raisuddin, S. (2001). Protective effect of Cassia occidentalis extract on chemical -induced chr omosomal aberrations in mice. Annals of Tropical Medicine and Parasitology 95(1):47-57. Silva, M.G ., Aragão, T.P ., Vasconcelos, C.F ., Ferreira, P.A ., Andrade, B.A . (2011). Acute and subacute toxicity of Cassia occidentalis L. stem",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 4915,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 915)",
    "text": "and Parasitology 95(1):47-57. Silva, M.G ., Aragão, T.P ., Vasconcelos, C.F ., Ferreira, P.A ., Andrade, B.A . (2011). Acute and subacute toxicity of Cassia occidentalis L. stem and leaf in Wistar rats. 136(2):341-346. Soukup, J. (1970). Vocabulary of the Common Names of the Peruvian Flora and Catalog of the Genera. Editorial Salesiano, Lima 436. Standley, P.C., Steyermark, J.A. (1946). Flora of Guatemala. Fieldiana; Botany 24(5):116- 122, 246-266, 478-489. Tona, L., Cimanga, R.K., Mesia, K., Musuamba, C.T. et al (2004). In vitro antiplasmodial activity of extracts and fractions from seven medicinal plants used in the Democratic Republic of Congo. Journal of Ethnopharmacology 93:27-32. Tona, L., Mesia, K., Ngimbi, N. P., Chrimwami, B. et al . (2001). In vivo antimalarial activity of Cassia occidentalis , Morinda morindoides and Phyllanthus niruri . Annals of Tropical Medicine and Parasitology 95(1): 47-57.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 4916,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 916)",
    "text": "et al . (2001). In vivo antimalarial activity of Cassia occidentalis , Morinda morindoides and Phyllanthus niruri . Annals of Tropical Medicine and Parasitology 95(1): 47-57. Tona, L., Ngimbi, N.P., Tsakala, M., Mesia, K. et al (1999). Antimalarial activity of 20 crude extracts from nine African medicinal plants used in Kinshasa, Congo. Journal of Ethnopharmacology 68:193-203. Vanderperren, B., Rizzo, M., Angenot, L., Haufroid, V., Jadoul, M. et al. (2005). Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Annals of Pharmacotherapy 39(7-8)1353-1357. Vashishtha, V.M., John, T.J., Kuma,r A. (2009). Clinical and pathological features of acute toxicity due to Cassia occidentalis in vertebrates. Indian Journal of Medical Research 130(1):23- 30. Verma, L., Khatri, A ., Kaushik, B ., Patil, U.K ., Pawar, R.S . ( 2010). Antidiabetic activity of Cassia occidentalis (L) in normal and alloxan-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4917,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 917)",
    "text": "30. Verma, L., Khatri, A ., Kaushik, B ., Patil, U.K ., Pawar, R.S . ( 2010). Antidiabetic activity of Cassia occidentalis (L) in normal and alloxan- induced diabetic rats. Indian Journal of Pharmacology :42(4):224-228. Watt, J.M., Breyer -Brandwijk, M.G. (1962). The medicinal and poisonous plants of Southern and Eastern Africa. 2nd edn. Livingstone: London.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 360,
    "source": "PDF_chunked"
  },
  {
    "id": 4918,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 918)",
    "text": "OOAS Page 192 Senna podocarpa WAHP Nom botanique Senna podocarpa(Guill. Perr.) Lock Famille Legumineusea-Caesalpiniacées Synonyme Cassia podocarpa Guill. et Perr Noms communs Feuille de Podocarpa Noms vernaculaires Cote d'Ivoire : Baule Niaaka Niabaka, Kru Guere Siogelebe, Sioguele Belebel Kweni Gambie: Manding Mandinka Kanayiro Ghana: Akan Sreso Simpe, Ga Nyonbele, Wasa Nsuduru Guinée: Basari Mbokwe, Fula Pulaar Yeleuk, Konyagi Mpman Guinée Bissau: Manding Mandink Adjam, Djam-Cafae, Pepel - Beuroque Libéria: Mano - Ba La Bli Nigéria: Igbo Gaalu, Igbo (Agulu) Ogaala, Yoruba asunwon anago, peiebe. Sénégal: Balanta Banban, Diola Bunan Bunangabo, Fula - Bendiagkafara Sierra-Leone: Kono Wawa, Loko Balaga, Temne E-Ai-Ani Description de la plante Arbuste glabre,atteignant 5 m de haut, feuilles composées paripennées, parfois imparipennées; de pétiole et rachis jusqu'à 30 cm de long; des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 892,
    "source": "PDF_chunked"
  },
  {
    "id": 4919,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 919)",
    "text": "Temne E-Ai-Ani Description de la plante Arbuste glabre,atteignant 5 m de haut, feuilles composées paripennées, parfois imparipennées; de pétiole et rachis jusqu'à 30 cm de long; des paires de 4- 5folioles, elliptiques avec des extrémités rétrécies de 6- 12 cm de long sur 3- 6 cm de large; les fleursqui surviennent entre Octobre et Décembre sont jaune- claires; une inflorescence avec unegrappe terminale spiciformedense et droite; les fruits sont des goussesnon ailées, droites, plates, nouées présentes au centre, brun- noires à maturité, brillantes, plats à bec et légèrement courbées avec des crêtes transversal es de 10- 12 cm de long et environ 1,5 cm de large; les gousses sont indéhiscentes avec une fructification entre Novembre et Janvier; les graines sont de 14- 16 par gousse et de couleur brun- foncée à noire, lisses, dures et de forme oblongues, avec un bout pointu (Irvine, 1961). Numéro du spécimen de l'herbier Nigeria: FHI 107435",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4920,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 920)",
    "text": "par gousse et de couleur brun- foncée à noire, lisses, dures et de forme oblongues, avec un bout pointu (Irvine, 1961). Numéro du spécimen de l'herbier Nigeria: FHI 107435 Habitation et repartition géographique Il se reproduit dans la savane en Guinée et dans les clairières secondaires, parfois cultivée dans les maisons; on le retrouve également dans les friches. La plante est distribuée du Sénégal au Nigéria, mais cependant limitée aux zones de la forêt tropicale du Nigéria à savoir: Bénin, Ile- Ife, Olokemeji, Ibadan, Lagos et Nsukka. Il ne se retrouvegénéralement pas dans le Nord et les hautes parties de l'Estdu Nigéria (Dalziel, 1936). Parties utilisées de la plante Feuilles fraîches et séchées Autres parties utilisées Racine Caractéristiques botaniques La feuille de Podocarpa est constituée des feuilles de Senna podocarpa (Guill. et Perr.) Lock (Legumineuse-Caesalpiniacées). Utilisations ethnomédicales",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 920,
    "source": "PDF_chunked"
  },
  {
    "id": 4921,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 921)",
    "text": "Racine Caractéristiques botaniques La feuille de Podocarpa est constituée des feuilles de Senna podocarpa (Guill. et Perr.) Lock (Legumineuse-Caesalpiniacées). Utilisations ethnomédicales Il est utilisé dans la tradition comme purgatif, stimulant de l'accouchement, anti -gonococcique, expulseur du ver de Guinée, emménagogue et ecbolique (Anton et Haag-Berriere, 1980). Activités biologiques et pharmacologiques La feuille de Podocarpa contient 0,65 d'anthraquinones libreset 1 d'anthraquinones combinées (Rai et Abdullahi, 1978). Il produit une importante activité laxative à 500 mgkg chez le rat avec un Senna -biologique équivalent à 0,8 ou un pourcentage de 80 de Senna- activité. Il est exempt de variation géographique ou saisonnière de l'effet laxatif, mais les jeunes feuilles produisent une plus grande activité laxative que les vieilles (Elujoba et al, 1989). L'infusion aqueuse et l'extrait méthanolique de S.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 921,
    "source": "PDF_chunked"
  },
  {
    "id": 4922,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 922)",
    "text": "ou saisonnière de l'effet laxatif, mais les jeunes feuilles produisent une plus grande activité laxative que les vieilles (Elujoba et al, 1989). L'infusion aqueuse et l'extrait méthanolique de S. podocarpa ont montré à la fois un effetlaxatif in vitro (Akomolafe et al., 2004). Une suspension de la poudre des feuilles produitdes matières fécales humides chez la souris (Larbi et Lewis,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 386,
    "source": "PDF_chunked"
  },
  {
    "id": 4923,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 923)",
    "text": "OOAS Page 193 Senna podocarpa WAHP 1976). Les feuilles de S. podocarpa ont été formulées en comprimés et utilisées comme un substitut du Senna officiel au Ghana et au Nigeria (Sofowora, 2002). Données Cliniques Aucune information disponible Constituants chimiques Glycosides anthracène; glycosides anthraquinoniquesO-et-C-; anthraquinones libres (Emodine). Tests d'identité et de pureté Teneur en eau: pas plus de 12 lorsque la poudre brute est séchée à 100 C pendant4 heures. Cendre totale: pas plus de 10,0 Cendre insoluble dans l'acide : pas plus de 15,0 Cendre sulfatée: pas plus de 16,0 Cendre soluble dans l eau : pas moins de 3,5 Substances extractibles par l'eau: pas moins de 17,0 Substances extractibles par l'éthanoll (70): pas moins de 15,0 Indice stomatique: 2,6 - 4.5 à 9.1 (surface supérieure), 12,5 - 20 - 28,5 (surface inférieure) Nombre de stomates: 24 - 46 - 72 (surface supérieure), 306 - 480 - 708 (surface inférieure)",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4924,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 924)",
    "text": "Indice stomatique: 2,6 - 4.5 à 9.1 (surface supérieure), 12,5 - 20 - 28,5 (surface inférieure) Nombre de stomates: 24 - 46 - 72 (surface supérieure), 306 - 480 - 708 (surface inférieure) Ratio depalissade: 4 - 5 à 6,5 Nombrede veine-îlot: 18 - 20 à 25,5 Nombre de veinules de terminaison: 17-19.5- 24.5 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm)G60F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de sept tâches distinctes avec valeurs R f de 0,92 (brun rougeâtre), 0,88 (vert jaunâtre), 0,76 (r ose), 0,63 (rose), 0,52 (rose), 0,46 (jaune) et 0,22 (violet). Chromatogramme Macroscopie",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 4925,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 925)",
    "text": "distinctes avec valeurs R f de 0,92 (brun rougeâtre), 0,88 (vert jaunâtre), 0,76 (r ose), 0,63 (rose), 0,52 (rose), 0,46 (jaune) et 0,22 (violet). Chromatogramme Macroscopie Les feuilles composées sont paripennées avec environ 25 cm de long sur 9 cm de large, la taille augmente progressivement à partir de la base du sommet du rachis; l e pétiole est court et vigoureux; le sommet est pointu ou émarginé, avec 4 à 5 paires de folioles mesurant 4cm à 14,5 cm de longueuret 2,5 cmà 9,5 cm de large.La largeur maximale se trouve au centre. Les folioles sont vert -jaunâtres et pâles, elliptiques à ovales -lancéolées, asymétriques à la base; la bordureest entière et les deux surfaces sont couvertes de poils avec une inervation pennée, prohéminente sur la surface inférieure. Les veines latérales quittent la nervure centrale à un angle d'environ 45 et s'anastomosent pour former une crête près de la bordure; la texture est papyracée avec une",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4926,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 926)",
    "text": "inférieure. Les veines latérales quittent la nervure centrale à un angle d'environ 45 et s'anastomosent pour former une crête près de la bordure; la texture est papyracée avec une odeur légère, un goût caractéristique, mucilagineux, astringent et légèrement amer (Elujoba et Ogunti, 1993). Microscope La vue d'ensemble montre despoils de revêtements verruqueux sur les cellules épidermiques à parois ondulées sur les deux surfaces. La plus petite surface inférieure est ondulée ; l'épiderme de la feuille se compose de cellules polygonales avec des parois anticlinales légèrement ondulées couver tes d'une cuticule mince montrant des stomates parasitaires sur les deux surfaces, mais plus abondants sur la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 705,
    "source": "PDF_chunked"
  },
  {
    "id": 4927,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 927)",
    "text": "OOAS Page 194 Senna podocarpa WAHP surface inférieure, de même que des cicatrices; les mesures des cellules épider miques sont de 35 - 85 μ de long sur 50 -60 de large pour la surface supérieure et de 60- 90 μ de long sur 40- 70 μ de large pour la surface inférieure; les poils protection unicellulaires sont de forme conique, avec des parois verruqueuses qui sont souvent plaquées contre la surface épidermique; ils mesurent 320 μ de long sur 87 μ de large vers le milieu; les grappes de cristaux d'oxalate de calcium sont enfermés dans des cellules du parenchyme (Elujoba et Ogunti, 1993); la section transversale qui montr e une structure bifaciale contenant deux couches palissadiques discontinues, interrompues par les cellules du mésophylle spongieux dans la région de la nervure médiane en dessous du tissu collenchymateux dans le lamina différencie la feuille de S. podocarpa de celle de Senna alata (une espèce connexe) qui a une seule couche",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 4928,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 928)",
    "text": "nervure médiane en dessous du tissu collenchymateux dans le lamina différencie la feuille de S. podocarpa de celle de Senna alata (une espèce connexe) qui a une seule couche de palissade discontinue dans la région de la lamina sous l'épiderme supérieur; le mésophylle est différenciée en tissu palissadique et spongieux; une cuticule mince limite les deux surfaces; la nervure centrale est projetée sur la face abaxiale et est traversée par une mèche vascularisé formé par un arc de faisceaux vasculaires collatéraux; la mèche entière est entouré par un péricycle sclerenchymateux, suivi vers l'extérieur par le c ortex, composé de 4 à 6 dispositions de cellules de parenchyme et ensuite par 3- 5 dispositions de cellules de collenchyme; le xylème est lignifié; le mésophylle spongieux contient de l'amidon, de l'oxalate de calcium, des cristaux prismatiques et de l'épiderme mucilagineux. Matériel végétal en poudre Il se compose de poils tecteurs unicellulaires; de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 967,
    "source": "PDF_chunked"
  },
  {
    "id": 4929,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 929)",
    "text": "spongieux contient de l'amidon, de l'oxalate de calcium, des cristaux prismatiques et de l'épiderme mucilagineux. Matériel végétal en poudre Il se compose de poils tecteurs unicellulaires; de cellules épidermiques entières et fragmentées; de stomates paracytiques; les macles de cristaux d'oxalate de calcium et les cellules palissadiques ont des tr aits caractéristiques avec des fragments de limbe; les éléments de vascularisation sont identifiables par des éléments vasculaires lignifiés présents dans les veines et les veinules; de couleur vert -foncée à jaune pâle ou à brun- foncée, avec une odeur caractéristique et une saveur astringente et légèrement amère. Actions thérapeutiques Purgatif, stimulant de travail, anti-gonococcique, propulseur du ver de Guinée, emménagogue. Indications thérapeutiques Laxatif, plaie et angine, paludisme, oligurie et ulcère de la peau (Mshana et al., 2000; GHP, 1992). Données de sécurité",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4930,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 930)",
    "text": "propulseur du ver de Guinée, emménagogue. Indications thérapeutiques Laxatif, plaie et angine, paludisme, oligurie et ulcère de la peau (Mshana et al., 2000; GHP, 1992). Données de sécurité Dans les études animales utilisant des rats femelles, la DL 50 était 3000 mgkg et le traitement (300- 3000 mgkg) n'a pas provoqué de changements dans le poids corporel ou dans le ratio organepoids corporel. Dans les études aiguës (300- 3000 mgkg), la diarrhée a été observée dans le groupe ayant reçu 3000 mgkg. Il n'y avait pas de changements significatifs de l'hématologie, du foie ou de la fonction rénale. L'extrait aqueux des feuilles est considéré comme sûr. Précautions d'emploi L'utilisation prolongée peut causer la diarrhée, des coliques abdominales, la déshydratation, la faiblesse musculaire, la perte de poids et endommager le plexus myentérique. L'utiliser au delà de deux semaines ou chez des enfants âgés de moins de 10 ans nécessite une",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 4931,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 931)",
    "text": "faiblesse musculaire, la perte de poids et endommager le plexus myentérique. L'utiliser au delà de deux semaines ou chez des enfants âgés de moins de 10 ans nécessite une surveillance médicale comme pour le Senna alexandrina. Effets indésirables Des doses élevées peuvent causer la diarrhée et conduire à la perte du fluide et de l'électrolyte comme pour le Senna alexandrina. Adefemi et al. (1988) ont rapporté que des doses élevées peuvent provoquer un excès de préhension, une gêne abdominale, la diarrhée,la déplétion électrolytique, et la perte de poids; des doses plus élevées ou une utilisation chronique peut endommager le foie, le rein et affecter la spermatogenèse. Contre-indications Grossesse et allaitement, occlusion intestinalesténose, appendicite, ainsi que les contre-indications du Senna alexandrina. Dosage et formegalénique Décoction: 30 g feuilles séchées dans 900 ml d'eau et laisser mijoter jusqu'à réduction à 600",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4932,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 932)",
    "text": "contre-indications du Senna alexandrina. Dosage et formegalénique Décoction: 30 g feuilles séchées dans 900 ml d'eau et laisser mijoter jusqu'à réduction à 600 ml; prendre 1-3 tasses tous les jours Infusion: 30 g de feuilles séchées dans 600 ml d'eau; 1-3 tasses tous les jours Teinture-1:5 dans de l'éthanol 50, 5 ml trois fois par jour Conservation A conserver dans un récipient bien fermé, dans un endroit frais et sec, à l'abri de la lumière et de l'humidité. Références Adefemi, O. A., Elujoba, A. A. and Odesanmi, W. O. (1988). Evaluation of Cassia podocarpa with reference to Senna. W. Afri. J. Pharmacol. Drug Res. 8 (1): 41-47.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 636,
    "source": "PDF_chunked"
  },
  {
    "id": 4933,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 933)",
    "text": "OOAS Page 195 Senna podocarpa WAHP Akomolafe, R.O., Adeoshun, I.O., Ayoka, A.O., Elujoba, A.A., Iwalewa, E.O. (2004). An in vitro study of the effects of Cassia podocarpa fruit on the intestinal motility of rats. Phytomedicine 11(2- 3):249-254. Anton, R., Haag-Berriere, M. (1980). The therapeutic uses of natural authraquinones other than laxative actions. Pharmacology suppliments 20:104-112. Dalziel J.M. (1936). Useful Plants of West Tropical Africa London: Crown Agents for Overseas Governments and Administration. Elujoba, A.A., Ogunti, E. O. (1993) . Pharmacopoeial and Biological standardization of Cassia alata and Cassia podocarpa with reference to Senna. Glimpses in Medicinal Plant Research xi: 469-479. Elujoba A. A. et al., (1989). Chemical and Biological analyses of Nigerian Cassia species for laxative activity. Journal of Pharmaceutical and Biomedical Analysis 7: 1453-1457. Ghana Herbal Pharmacopoeia (1992). The",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 4934,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 934)",
    "text": "Biological analyses of Nigerian Cassia species for laxative activity. Journal of Pharmaceutical and Biomedical Analysis 7: 1453-1457. Ghana Herbal Pharmacopoeia (1992). The Advent Press: Accra, Ghana. Irvine, F.R. (1961). Woody Plants of Ghana with special reference to their uses London: Oxford University Press. Larbi, S.O., Lewis, R.A. (1976). Biological assay of Cassia podocarpa: a plant related to senna. West African Journal of Pharmacol ogy and Drug Research 3(2):149-52. Mshana, N.R., Abbiw, D.K., Addae -Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. Rai, P.P., Abdullahi, N. J. (1978). Occurrence of anthraquinones in Nigerian Cassia species. Journal of Pharmacy 9:160-165.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 888,
    "source": "PDF_chunked"
  },
  {
    "id": 4935,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 935)",
    "text": "African UnityScientific, technical and research committee. Rai, P.P., Abdullahi, N. J. (1978). Occurrence of anthraquinones in Nigerian Cassia species. Journal of Pharmacy 9:160-165. Sofowora, A. (2002). Plants in African traditional medicine-an overview. In: Tease and Evan Pharmacognosy, 15 th edn., 492. Saunders: London.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 324,
    "source": "PDF_chunked"
  },
  {
    "id": 4936,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 936)",
    "text": "OOAS Page 196 Solanum torvum WAHP NomBotanique Solanum torvum Sw. Famille Solanaceae Synonymes Solanum mayanum Lundell ;Solanum ferrugineum Jacq.; Solanum mannii Wright Nomscommuns Solanum Noms vernaculaires Ghana: Akan- Kwao Nsuswaa Cote d'Ivoire: Kyama- Guiguisuron Nigéria: Edo- Omgbabelara, Yoruba- asimonwu Sierra Leone: Kono- Kōlau Description de la plante Arbuste dressé, atteignant 3,55 m de hauteur; tige de couleur vert -pâle, étoilée, tormentose, armé d'épines plates éparses; feuilles alternes, ovales à oblongues, lobées pennées, de 7-19 cm de long, de 5-18 cm de large, poils étoilés sur les deux faces; pétiole de 1- 4 cm de long, également armés d'épines de 1- 3 cm; inflorescence latérale, racémeuse généralement extra-axillaire, souvent dichotomique; avec beaucoup de fleurs, , blanches, d'environ 1 cm de long, tube de corolle courte, branchesde 5 lobes, 4 étamines, filaments courts, anthères",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 912,
    "source": "PDF_chunked"
  },
  {
    "id": 4937,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 937)",
    "text": "extra-axillaire, souvent dichotomique; avec beaucoup de fleurs, , blanches, d'environ 1 cm de long, tube de corolle courte, branchesde 5 lobes, 4 étamines, filaments courts, anthères réunies en cône, ovaire 2- loculaire; fruit rond, 1- 15 mm de diamètre, vert si immature, orange pâle à maturité. Numéro du spécimen de l'herbier Ghana: GC 37723 Habitat et répartition géographique S. torvum provient de l'Europe centrale et de l'Amérique du Sud, où on le trouve au Mexique, au Brésil et au Pérou ; il est largement répandu dans les Caraïbes. C'est présentement une mauvaise herbe pantropicale en Afrique occidentale et centrale, une culture potagère, qui se produit probablement aussi bien dans d'autres régions d'Afrique. S. torvum s'établit sur des terrains ouverts, les sols perturbés, le long des routes, dans les pâturages broussailleux, sur les terres agricoles récemment abandonnées, sur les berges des rivières et sur les terres incultes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4938,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 938)",
    "text": "terrains ouverts, les sols perturbés, le long des routes, dans les pâturages broussailleux, sur les terres agricoles récemment abandonnées, sur les berges des rivières et sur les terres incultes où il pousse souvent commeune mauvaise herbe difficile à contrôler. Au Cameroun, c'est une ancienne espèce particulière des terres en jachère. Il est connu comme mauvaise herbe nuisible dans le sud- est des États -Unis. On le trouve normalement près des zones humides ou dans les zones à fortes précipitations, principalement dans les régions de plaine, mais tolérant des périodes sèches (www.prota.org). Il pousse bien en plein soleil, à la lumière ou à l'ombre, mais obtient des résultats médiocres sous les forêts à canopée fermée. Parties utilisées de la plante Fruit Autres parties utilisées Feuilles, tige et racine Caractéristiques botaniques Solanum se compose de fruits frais de Solanum torvum SW. (Solanaceae) Utilisations ethnomédicales",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4939,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 939)",
    "text": "Fruit Autres parties utilisées Feuilles, tige et racine Caractéristiques botaniques Solanum se compose de fruits frais de Solanum torvum SW. (Solanaceae) Utilisations ethnomédicales Les fruits, les fleurs et les tiges de Solanum possèdent des propriétés carminatives, anthelminthiques et amères. La racine est expectorante et utilisée dans le traitement de la douleur de la poitrine issue de la toux, l'asthme et la bronchite. Les feuilles sont appliquées en externe comme un agent de soulagement de la douleur. Différentes parties de la plante sont utilisées dans le monde entier comme un antidote contre le poison et pour le traitement de la fièvre, des plaies, des maux de dents, de l'ulcération gastrique, des maladies de la peau, des troubles de la reproduction, de la fièvre et de l'hypertension artérielle (Noumi et al. , 1999; Noumi et Dibakto, 2000; Noumi, 2004; Ndebia et al., 2007; Muthu et al., 2006; Kala, 2005). Dans",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 4940,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 940)",
    "text": "des troubles de la reproduction, de la fièvre et de l'hypertension artérielle (Noumi et al. , 1999; Noumi et Dibakto, 2000; Noumi, 2004; Ndebia et al., 2007; Muthu et al., 2006; Kala, 2005). Dans le traitement de l'infertilité féminine, 3 à 4 g de fruits sont macérés dans du vin de palme et administré oralement (Telefo et al., 2011). Les fruits sont préparés avec les feuilles et une tasse de la décoction est bue pour traiter le paludisme (Asase et al.. 2010). Les feuilles sont utilisées en",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 494,
    "source": "PDF_chunked"
  },
  {
    "id": 4941,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 941)",
    "text": "OOAS Page 197 Solanum torvum WAHP Amérique centrale, en Inde, et au Gabon pour soigner les coupures, les blessures et le diabète. En Sierra Leone, le décocté du fruit est administré aux enfants souffrant de la toux, alors qu'au Sénégal la plante est utilisée pour traiter les maux de gorge et le mal de ventre. Aux Philippines, les racines de S. torvum sont utilisées pour les maux d'estomac, tandis que la décoction est bue contre l'indigestion, la douleur gastrique au niveau du nombril, le rhumatisme, l'engourdissement, la contusion, les douleurs musculaires lombaires et l'aménorrhée. Le décocté est utilisé dans certains domaines pour réduire l'hémorragie du post-partum. Activités Biologiqueset pharmacologiques Le Torvanol isoflavonoïde A et le stéroïdien glycoside torvoside H isolés, tirés des fruits ont montré une activité antivirale contre le virus de l'herpès simplex de type 1 (www.prota.org). La solasodine glycoalcaloïde présente dans les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 4942,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 942)",
    "text": "glycoside torvoside H isolés, tirés des fruits ont montré une activité antivirale contre le virus de l'herpès simplex de type 1 (www.prota.org). La solasodine glycoalcaloïde présente dans les feuilles et les fruit s, est utilisée en Inde comme contraceptifs oraux dans la production d'hormones sexuelles stéroïdiennes (www.prota.org). L'extrait méthanolique des fruits a montré un large spectre d'activités antimicrobiennes. Les études sur l'effet de la poudre de feuilles séchées en Inde n'ont montré aucun changement significatif en ce qui concerne le profil lipidique, du glucose, des acides aminés, le niveau total d'acide uronique et la non- insulino-dépendancedes patients diabétiques ( www.prota.org). L'extrait éthanolique a montré de puissants effets d'agrégation plaquettaire, et l'extrait aqueux des feuilles a montré à la fois une propriété analgésique et anti -inflammatoire. L'extrait méthanolique réduit la pression artéri elle, les",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 947,
    "source": "PDF_chunked"
  },
  {
    "id": 4943,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 943)",
    "text": "d'agrégation plaquettaire, et l'extrait aqueux des feuilles a montré à la fois une propriété analgésique et anti -inflammatoire. L'extrait méthanolique réduit la pression artéri elle, les changements de réactivité vasculaire aux catécholamines et inverseles altérations métaboliques induites par le fructose. Le S. torvum a eu une activité inhibitrice catalytique et antioxydante (Kusirisin, et al ., 2009). Dans une étude in vitro contre des souches pathogènes de l'homme, les extraits aqueux et éthanolique se sont avérés efficaces contre les souches bactériennes avec une inhibition comparable à celle des antibiotiques commerciales. Des extraits méthanoliques de racines ont affiché des effets antibactériens et antifongiques encourageants sur tous les organismes d'essai. L'extrait méthanolique à la dose de 750 mgkg a produit une inhibition significative des ulcérations gastriques induites par HCléthanol, l'indométacine par laligature du pyloreou par le",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 4944,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 944)",
    "text": "L'extrait méthanolique à la dose de 750 mgkg a produit une inhibition significative des ulcérations gastriques induites par HCléthanol, l'indométacine par laligature du pyloreou par le stress. Toutes les fractions de l'extrait méthanolique ont inhibé de manière significative la formation d'ulcère. Les extraits de fruits présentent des effets hypertendus in vitro et in vivo (Nguelefack, et al. 2009). Données cliniques Aucune information disponible Constituants chimiques Isoflavonoïde (torvanol A), glycoside stéroïdien (torvoside H), néochlorogénine 6- O-β-D- quinovopyranoside, neochlorogenin- 6-O-β-D- xylopyranosyle-(13)-β-D-quinovopyranoside, neochlorogénine- 6-O-α-L-rhamnopyrannosyl-(1 3) -β-D-quinovopyranoside, solagenin- 6-O-β- D-quinovopyranoside, solagenin- 6-O-α-L- rhamnopyrannosyl-(13)-β-D- quinovopyranoside, isoquercétine, rutine, kaempférol, quercétine, alcaloïdes (solasodine, soagenin), tanins (Kusirisin, et al ., 200 9; Yuan-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 4945,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 945)",
    "text": "rhamnopyrannosyl-(13)-β-D- quinovopyranoside, isoquercétine, rutine, kaempférol, quercétine, alcaloïdes (solasodine, soagenin), tanins (Kusirisin, et al ., 200 9; Yuan- Yuan et al ., 2011; Pérez -Amador et al ., 2007; Arthan et al., 2006) Tests d'identité et de pureté Teneur en eau: pas moins de 16,8 Cendre totale: 13,24 Valeur substances extractiblespar l'eau: pas moins de 24,6 Valeur substances extractibles par l'éthanol 70: pas moins de 13.9 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60F254,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 595,
    "source": "PDF_chunked"
  },
  {
    "id": 4946,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 946)",
    "text": "OOAS Page 198 Solanum torvum WAHP et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la r évélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de cinq points caractéristiques avec Rf 0,96 (rose), 0,80 (rose), 0,67 (gris), 0,60 (rose) et 0,44 (vert). Chromatogramme Macroscopie Le fruit est une baie avec un calice persistant; de forme globoïde, diamètre 1,0- 1,5 cm; péricarpe charnu mais dure, , de couleur vert -pâle à maturé devenant, jaunâtre quand elle est mure avec une ; odeur caractéristique et un goût douceâtre, avec un arrière- goût légèrement amer. Microscopie La section transversale du fruit montre une couche cuticulaire externe, légèrement striée soutenant les poils glandulai res; le péricarpe est différencié dans l'épicarpe, le mésocarpe et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 4947,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 947)",
    "text": "La section transversale du fruit montre une couche cuticulaire externe, légèrement striée soutenant les poils glandulai res; le péricarpe est différencié dans l'épicarpe, le mésocarpe et l'endocarpe; l'épicarpe est composé de 2- 3 couches de cellules rondes; le mésocarpe se compose de grandes cellules rondes ou ovales serrées ; les cellules de l'épicarpe et du mésocarpe cont iennent des cristaux prismatiques ;l'endocarpe se compose de grandes cellules parenchymateuses contenant microcristaux (idioblastes) ou de miniscules cristaux prismatiques; de nombreuses petites graines remplissent les deux loges. Matériel végétal en poudre Nombreuses gouttelettes d'huile; petits vaisseaux spiralés et minuscules cristaux d'oxalate de calcium en prismes ; grains d'amidon sphériques, de diamètre 2- 11 μm, nombreux groupes de sclérites lignifiés à parois sinueuses particulières, certains avec des parois cellulaires légèrement épaissies et grandes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 4948,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 948)",
    "text": "d'amidon sphériques, de diamètre 2- 11 μm, nombreux groupes de sclérites lignifiés à parois sinueuses particulières, certains avec des parois cellulaires légèrement épaissies et grandes lumen, et d'autres sans épaississement. Actions thérapeutiques Antipyrétique, antirhumatismal, anti - inflammatoire, anti -infectieux, anti -contusion, analgésique, carminative, vermifuge, amer, expectorant. Indications thérapeutiques Toux persistante, asthme, bronchite, maux de gorge, empoisonnements, fièvre, coupures et plaies, maux de dents, ulcère gastrique, maladies de la peau, troubles de la reproduction, hypertension artérielle, paludisme, diabète, indigestion, douleurs gastriques au niveau du nombril, rhumat isme, engourdissement , aménorrhée, hémorragie post-partum. Données de sécurité La DL 50 de l'extrait aqueux des feuilles ( p.o) a été jugée 3000 mgkg chez le rat. Il n'y avait aucun signe de toxicité en dessous de 3000",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 4949,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 949)",
    "text": "Données de sécurité La DL 50 de l'extrait aqueux des feuilles ( p.o) a été jugée 3000 mgkg chez le rat. Il n'y avait aucun signe de toxicité en dessous de 3000 mgkg. A 3000 mgkg, on a observé une perte de poids importante, une diminution relative du poids du foie, des reins, des poumons et du cœur. L'augmentation du nombre de plaquettes, globules blancs, une diminution du nombre d'hématies et HB a été observé à 3000 mgkg. Les fonctions du foie et du rein ont également été affectées à 3000 mgkg comme démontré respectivement par l'ALP accrue, les bilirubines et le sérum decréatinine. Précautions d'emploi Aucune recommandation sur l a base de l'étude de toxicité aiguë chez le rat. Toutefois, on rapporte que les fruits non mûrs sont toxiques. Effets indésirables Des doses élevées peuvent affecter la fonction du foie et du rein. Contre-indications Aucune information disponible. Dosage et forme galénique Décoction amère, poudre, jus.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4950,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 950)",
    "text": "Des doses élevées peuvent affecter la fonction du foie et du rein. Contre-indications Aucune information disponible. Dosage et forme galénique Décoction amère, poudre, jus. Décoction de 15 à 30 g de racines séchés, transformés en sirop ou suspension alcoolique. Conservation A conserver dans un endroit frais et sec. Références Arthan, D ., Kittakoop, P ., Esen, A ., Svasti, J . (2006). Furostanol glycoside 26- O-beta-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 420,
    "source": "PDF_chunked"
  },
  {
    "id": 4951,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 951)",
    "text": "OOAS Page 199 Solanum torvum WAHP glucosidase from the leaves of Solanum torvum. Phytochemistry 67(1):27-33. Asase, A., Akweteya, G.A., Achelb, D.G. (2010). Ethnopharmacological use of herbal remedies for the treatment of malaria in the Dangme West District of Ghana. Journal of Ethnopharmacology 129:367376. Kala, C. P. (2005) . Ethnomedicinal botany of the Apatani in the Eastern Himalayan region of India. Journal of Ethnobiology and Ethnomedicine 1:11. Kusirisin, W., Jaikang, C., Chaiyasut, C., Narongchai, P. (2009). Effect of Polyphenolic Compounds from Solanum torvum on Plasma Lipid Peroxidati on, Superoxide anion and Cytochrome P450 2E1 in Human Liver Microsomes. Medicinal Chemistry 5:583-588. Muthu, C., Ayyanar, M., Raja, N., Ignacimuthu, S. (2006). Medicinal plants used by traditional healers in Kancheepuram District of Tamil Nadu, India. Journal of Ethnobiology and Ethnomedicine 2:43. Ndebia, E.J., Kamga, R., Nchunga- Anye, N.B.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4952,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 952)",
    "text": "healers in Kancheepuram District of Tamil Nadu, India. Journal of Ethnobiology and Ethnomedicine 2:43. Ndebia, E.J., Kamga, R., Nchunga- Anye, N.B. (2007). Analgesic and anti -inflammatory properties of aqueous extract from leaves of Solanum torvum (Solanaceae). African Journal of Traditional, Complementary and Alternative Medicine 4:240244. Nguelefack, T.B., Feumebo, C.B., Ateufack, G., Watcho, P., Tatsimo, S. et al . (2008). Anti - ulcerogenic properties of the aqueous and methanol extracts from the leaves of Solanum torvum Swartz (Solanaceae) in rats. Journal of Ethnopharmacology 119:135140. Nguelefack, T.B., Mekhfi, H., Dongmo, A.B., Dimo, T., Watcho, P. et al. (2009). Hypertensive effects of oral administration of the aqueous extract of Solanum torvum fruits in treated rats: Evidence from i n vivo and in vitro studies. Journal of Ethnopharmacology 124(3):592-599. Noumi, E., Houngue, F., Lontsi, D. (1999).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 4953,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 953)",
    "text": "extract of Solanum torvum fruits in treated rats: Evidence from i n vivo and in vitro studies. Journal of Ethnopharmacology 124(3):592-599. Noumi, E., Houngue, F., Lontsi, D. (1999). Traditional medicines in prymary health care: plants used for the treatment of hypertension in Bafia Cameroon. Fitoterapia 70(2):134139. Noumi, E., Dibakto, T.W. (2000). Medicinal plants used for peptic ulcer in the Bangangte region, western Cameroon. Fitoterapia 71:406- 412. Noumi, E. (2004). Animal and plant poisons and their antidotes in Eseka and Mbalmayo regions, Centre Province, Cam eroon. Journal of Ethnopharmacology 93:231241. Pérez-Amador, M.C., Muñoz, O.V., García, C.J.M., González, E.A.R. (2007). Alkaloids in Solanum torvum Sw (Solanaceae). International Journal of Experimental Botany 76:39- 45. ISSN 0031-9457. Telefo, P.B., L ienou, L.L., Yemele, M.D., Lemfack, M.C., Mouokeu, C. et al . (2011). Ethnopharmacological survey of plants used for",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4954,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 954)",
    "text": "Journal of Experimental Botany 76:39- 45. ISSN 0031-9457. Telefo, P.B., L ienou, L.L., Yemele, M.D., Lemfack, M.C., Mouokeu, C. et al . (2011). Ethnopharmacological survey of plants used for the treatment of female infertility in Baham, Cameroon. Journal of Ethnopharmacology 136:178187. Yuan-Yuan, L.U., Jian -Guang, L.U.O., Lin g-Yi, K.O.N.G. (2011). Chemical Constituents from Solanum torvum. Chinese Journal of Natural Medicines 9(1):3032.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 443,
    "source": "PDF_chunked"
  },
  {
    "id": 4955,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 955)",
    "text": "OOAS Page 200 Sorghum bicolor WAHP Nom botanique Sorghum bicolor (L.) Moench Famille Poaceae Synonyme Sorghum aethiopicum (Hack.) Rupr. Ex, Sorghum arundinaceum (Desv.) Stapf, Sorghum lanceolatum Stapf, Sorghum verticilliflorum (Steud.) Stapf., Sorghum virgatum (Hack.) Stapf Noms communs Grand mil, mais de Guinée, sorgho doux. Noms vernaculaires Burkina Faso : Mooré Baninga ou kazieega, Dioula Gnô wilé, Fulfuldé Bayéri;ghaouri Ghana: Dagare Kazu Kpulekpule, Dagbani Chi, Akan Atoko Mali: Bambara Kenegue, Dogon Eme, Senoufos Kale Gue Nigéria: Hausa Chi Nduka, Kanuri Mbio, Yoruba Oka baba Togo: Ewe Adako, Mina Ada, Ouatchi Adadzen Description de la plante Il s'agit d'une canne comme l'herbe, qui s'élève jusqu'à 6 m de haut avec de grandes grappes de grains ramifiés. Les grains sont de petites taille d'environ 3- 4 mm de diamètre; la couleur varie du jaune- pâle au brun- rougeâtre à brun- foncé",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 903,
    "source": "PDF_chunked"
  },
  {
    "id": 4956,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 956)",
    "text": "jusqu'à 6 m de haut avec de grandes grappes de grains ramifiés. Les grains sont de petites taille d'environ 3- 4 mm de diamètre; la couleur varie du jaune- pâle au brun- rougeâtre à brun- foncé selon le cultivar. La plupart des cultivars sont annuelles, quelques -uns sont des plantes vivaces. Cultivés, la plupart des sorghos sont sans rhizomes. Les nœuds de chaumes sont soit glabres ou peu tomenteuses, avec une inflorescence contractée. Numéro du spécimen de l'herbier Ghana: EAC 123 Togo: TOGO11487 Habitat et répartition géographique S. bicolor est une culture africaine qui est largement distribuée à travers le monde. Les différents cultivars se trouvent dans différentes régions en fonction du climat. Il est adapté à un large éventail de conditions écologiques. Il est surtout une plante des régions chaudes et sèches et survit aussi bien au climat froid que dans les habitats gorgés d'eau. Parties utilisées de la plante Feuilles",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4957,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 957)",
    "text": "surtout une plante des régions chaudes et sèches et survit aussi bien au climat froid que dans les habitats gorgés d'eau. Parties utilisées de la plante Feuilles Autres parties utilisées Tigeet graine Caractéristiques botaniques Le maïs de Guinée se compose de la feuille sèche de Sorghum bicolor (L.) Moench (Poaceae). Utilisations ethnomédicales Le sorgho s'est avéré être un antiabortive, cyanogénétique, adoucissant, diurétique, émollient, intoxicant et poison; et c'est un remède populaire pour le canc er, l'épilepsie et le mal de ventre (Duke et Wain, 1981). Alors que sa racine est utilisée contre le paludisme, la graine est indiquée pour la diarrhée et les douleurs du sein, la tige pour les enflures tuberculeuses au Zimbabwe. En Inde, la plante est considérée comme anthelminthique et insecticide, et en Afrique du Sud, en combinaison avec Erigeron canadense L ., il est utilisé pour l'eczéma. En Chine, les graines sont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4958,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 958)",
    "text": "est considérée comme anthelminthique et insecticide, et en Afrique du Sud, en combinaison avec Erigeron canadense L ., il est utilisé pour l'eczéma. En Chine, les graines sont utilisées dans la fabrication d'alcool ;la coque dela graine est braisée au sucre roux, ajoutée à un peu d'eau et appliquée sur la poitrine des patients atteint de rougeole. Les graines sont considérées comme bénéfiques dans les flux (Perry, 1980). La décoction de feuilles est utilisée pour traiter la rougeole (Morton (1981), tandis qu'un mél ange de la poudre de graines et le calebassier ( Cresentia) représente un traitement pour les affections pulmonaires. Au Venezuela, les graines sont grillées et rendues en poudre pour être utilisées contre la diarrhée; au Brésil, le décocté des graines est utilisé pour la bronchite, la toux et les autres douleurs de la poitrine. Les graines préparées avec de l'huile chaude sont appliquées sur le dos des patients",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4959,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 959)",
    "text": "la bronchite, la toux et les autres douleurs de la poitrine. Les graines préparées avec de l'huile chaude sont appliquées sur le dos des patients atteints de congestion pulmonaire. Grieve (1984), recommande qu'une décoction d'environ",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 233,
    "source": "PDF_chunked"
  },
  {
    "id": 4960,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 960)",
    "text": "OOAS Page 201 Sorghum bicolor WAHP 50 g de graines soit bouillie dans environ un litre à 12 litre d'eau pour le traitement des troubles rénaux et urinaires. Activités biologiques et pharmacologiques Des doses de 200, 400 et 800 mgkg de poids corporel des extraits aqueux de l'écorce de la tige de S. bicolor ont montré des propriétés antianémiques dans la déficience en fer des rats sevrés (Oladiji et al, 2007). L'activité antioxydante in vitro des extraits méthanoliques a été démontrée (Hegde et Chandra, 2005). Un peptide isolé de la plante a fortement inhibé d'une manière dose- dépendante la reproduction de Herpès simplex virus de type 1 (HSV -1). Le peptide a eu également un effet prophylactique in vitro contre l'infection du HSV -1 (Filho et al.,2008). Le décocté de la plante a montré une activité de membrane stabilisante in vitro et peut donc contribuer à stabiliser les globules rouges provenant d'un traumatisme dû au stress (Falade",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 4961,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 961)",
    "text": "al.,2008). Le décocté de la plante a montré une activité de membrane stabilisante in vitro et peut donc contribuer à stabiliser les globules rouges provenant d'un traumatisme dû au stress (Falade et al. 2005). Cho et al. (2000) ont observé que les rats qui se nourrissaient avec le sorgho entier, le millet commun ou sarrasin, ont causé une augmentation de l'excrétion fécale des acides biliaires et du cholestérol HDL sans changement du taux total de cholestérol. Toutefois, il a été constaté que la forte teneur en tanin, non- tanin du sorgho et du son de blé, a augmenté le cholestérol total du sérum sanguin chez les rats. Lee et Pan (2003) ont également montré que les résidus alimentaires de distillerie du tanin-sorgho ont une activité antioxydante par leur capacité à inhiber l'oxydation d'hémoglobine-catalysée d'acide linoléique et, améliorent considérablement le sang- éclairci et l'intégrité de la membrane érythrocytaire des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 4962,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 962)",
    "text": "leur capacité à inhiber l'oxydation d'hémoglobine-catalysée d'acide linoléique et, améliorent considérablement le sang- éclairci et l'intégrité de la membrane érythrocytaire des cellules sanguines de poissons, pendant l'hiver. Il ya eu plusieurs rapports sur la diminution du surplus du poids des animaux nourris avec du tanin de sorgho (Cousins et al., 1981; Lizardo et al.,1995; Al -Mamary et al. , 2001; Muriu et al. , 2002). Des études in vitro ont également révélé les propriétés anti -cancérigènes du sorgho. Grimmer et al. (1992) ont démontré l'anti - mutagène des extraits de polyphénols de sorgho. Données cliniques Aucune information disponible Constituants chimiques Alcaloïdes (hordenine), saponines, phytates, phénols, tanins, acide cyanhydrique, quinone, sorgoléone, dihydrosorgoléone, fibres, protéines, glucides; acides gras insaturés et non- saturés (Mehmood et al. , 2008; Oladiji et al. , 2007; Hegde et Chandra, 2005; Morton, 1981; Barbosa",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4963,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 963)",
    "text": "sorgoléone, dihydrosorgoléone, fibres, protéines, glucides; acides gras insaturés et non- saturés (Mehmood et al. , 2008; Oladiji et al. , 2007; Hegde et Chandra, 2005; Morton, 1981; Barbosa et al., 2001). Tests d'identité et de pureté Teneur en eau: pas plus de 7,20 Cendre totale: 9,33 Valeur substances extractibles par l'eau: pas moins de 11,33 Valeur substances extractibles par l'éthanol (70): pas moins de 9,21 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25mm) G60F254, et phase m obile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de deux taches distinctes avec R f de 0,28 (orange) et 0,18 (jaune). Chromatogramme",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4964,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 964)",
    "text": "OOAS Page 202 Sorghum bicolor WAHP Macroscopie Feuilles larges et épaisses semblables à celles du maïs, mais plus courtes et plus larges; limbes glabres et cireuses. Les marges se c hevauchent juste au-dessus de l'épiderme inférieur. Microscopie Les cellules épidermiques ondulées de types graminées entre coupées ont de nombreux stomates isocytiques sur les deux surfaces, ainsi que la présence de quelques longs poils tecteurs unicell ulaires. La nervure médiane a montré la présence de cellules à parois épaisses du collenchyme au dessous de l'épiderme supérieur avec de nombreux faisceaux vasculaires rayés. Matériel végétal en poudre Cristaux aciculaires d'oxalate de calcium avec des cellules épidermiques onduleuses entrecoupées de nombreux stomates. Il ya peu de poils unicellulaires isolés et des cellules de pierre. Les cellules lignifiées sont présentes. Actions thérapeutiques Antioxydant, antianémique, antiviral , anti-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 4965,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 965)",
    "text": "de poils unicellulaires isolés et des cellules de pierre. Les cellules lignifiées sont présentes. Actions thérapeutiques Antioxydant, antianémique, antiviral , anti- cholestérolémique, anticancéreux, anti -obésité, anti-coagulant. Indications thérapeutiques Anémie, infections virales, bronchite, toux, affections rénales et urinaires. Données de sécurité La DL 50 de l'extrait aqueux des parties aériennes (p.o) a été jugée 3000 mgkg chez le rat ; il n'y a eu aucune preuve d'augmentation du poids des organes, mais la diminution de poids relatif des organes a été observé à une dose maximale testée (3000 mgkg). Les fonctions hépatiques et rénales n'ont pas été affectées par le traitement, mais des niveaux élevés de bilirubine ont été observés dans l'étude subaiguë de 14 jours. Précautions d'emploi Etre prudent chez les nourrissons. Effets indésirables Une dose élevée peut entraîner des troubles respiratoires. Contre-indications",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 4966,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 966)",
    "text": "Précautions d'emploi Etre prudent chez les nourrissons. Effets indésirables Une dose élevée peut entraîner des troubles respiratoires. Contre-indications Les patients qui ont des difficultés respiratoires. Dosage et forme galénique Infusion: environ 25 g par jour; Extrait liquide: environ 25 ml par jour; Teinture: 1:5, alcool à 90 ; 0,3 -1,2 ml à 25 ml max par semaine. Conservation Conserver dans un endroit frais et sec. Références Al-Mamary, M., Al -habori, M., Al -Aghbari, A., Al - Obeidi, A. (2001). In vivo effects of dietary sorghum tannins on rabbit digestive enzymes and mineral absorption. Nutrition Research 21: 1393-1401. Barbosa, L.C.D.A., Demuner, M.L.F .A.J., Pereira, A.A.D.S.C. (2001). Preparation and Phytotoxicity of sorgoleone analogues. Química Nova 24 (6). Cho, S.H., Choi, Y., Ha, T.Y. (2000). In vitro and in vivo effects of proso millet, buckwheat and sorghum on cholesterol metabolism. FASEB Journal 14 (4):A249.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 4967,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 967)",
    "text": "Nova 24 (6). Cho, S.H., Choi, Y., Ha, T.Y. (2000). In vitro and in vivo effects of proso millet, buckwheat and sorghum on cholesterol metabolism. FASEB Journal 14 (4):A249. Cousins, B.W., Tanksley, T.D., Knabe, D.A., Zebrowska, T. (1981). Nutrient digestibility and performance of pigs fed sorghums varying in tannin concentration. Journal of Animal Science 53:1524-1529. Duke, J.A., wain, K.K. (1981).The medic al plants of the world. Computer index with more than 85000 entries, Vol 3. Falade, O.S., Otemuyiwa, I.O., Oladipo, A., Oyedapo, O.O. et al . (2005). The chemical composition and membrane stability activity of some herbs used in local therapy for anemia. Journal of Ethnopharmacology 102:15-22. Filho, I.C., Cortez, D.A.G., Ueda -Nakamura, T., Nakamura, C.V. et al . (2008). Antiviral activity and mode of action of a peptide isolated from Sorghum bicolor. Phytomedicine 15:202-208. Grieve, M. (1984).A Modern Herbal, Penguin. ISBN 0-14-046-440-9.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 4968,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 968)",
    "text": "and mode of action of a peptide isolated from Sorghum bicolor. Phytomedicine 15:202-208. Grieve, M. (1984).A Modern Herbal, Penguin. ISBN 0-14-046-440-9. Grimmer, H.R., Parbhoo, V., McGarth, R.M. (1992). Antimutagenicity of polyphenol -rich fractions from Sorghum bicolor grain. Journal of Agricultural and Food Chemistry 59:251-256. Hegde, P.S., Chandra, T.S. (2005). ESR spectroscopic study reveals higher free radical quenching potential in kodo millet ( Paspalum scrobiculatum) compared to other millets. Food Chemistry 92:177-182.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 535,
    "source": "PDF_chunked"
  },
  {
    "id": 4969,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 969)",
    "text": "OOAS Page 203 Sorghum bicolor WAHP Lee, S.M., Pan, B.S. (2003). Effects of dietary sorghum distillery residue on hematological characteristics of cultured grey mullet (Mugil cephalus) an animal model for prescreening antioxidant and blood thinning activities. Journal of Food Biochemistry 27:1-18. Lizardo, R., Peiniau, J., Aumaitre, A. (1995). Effect of sorghum on performance, digestibility of dietary-components and activities of pancreatic and intestinal enzymes in the weaned piglet. Animal Feed Science and Technology 56:67-82. Mehmood, S., Orhan, I., Ahsan, Z., Aslan, S. et al. (2008). Fatty acid composition of seed oil of different Sorghum bicolor varieties, Food Chemistry (2008), doi: 0.1016j.foodchem.2008.01.014. Morton, J.F. (1981). Atlas of medicinal plants of middle America: Bahamas to Yucatan. CC Thomas, springfield, II. Muriu, J.I., N joka-Njiru, E.N., Tuitoek, J.K.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 888,
    "source": "PDF_chunked"
  },
  {
    "id": 4970,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 970)",
    "text": "middle America: Bahamas to Yucatan. CC Thomas, springfield, II. Muriu, J.I., N joka-Njiru, E.N., Tuitoek, J.K., Nanua, J.N. (2002). Evaluation of sorghum (Sorghum bicolor ) as replacement for maize in the diet of growing rabbits ( Oryctolagus cuniculus). Asian -Australian Journal of Animal Science 15:565-569. Oladiji, A.T., Jacob, T.O ., Yakubu, M.T. (2007). Anti-anaemic potentials of aqueous extract of Sorghum bicolor (L.) moench stem bark in rats. Journal of Ethnopharmacology 111:651-656. Perry, C.M. (1980). Medicinal plants of East and Southeast Asia. MIT Press, Cambridge MA. Watt, J.M., Breyer -Brandwij, K. (1962). The medicinaland poisonous plants of southern and eastern Africa. 2 nd Ed. ES livingstone Ltd., Edinburgh, London.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 741,
    "source": "PDF_chunked"
  },
  {
    "id": 4971,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 971)",
    "text": "OOAS Page 204 Spathodea campanulata WAHP Nom botanique Spathodea campanulata P. Beauv. Famille Bignoniaceae Synonyme Spathodea tulipifera (Thom.) G. Don., S. danckelmaniana Büttn, S. nilotica Seeman, Bignonia tulipifera Thom. Noms communs Anglais: African tulip tree, Flame tree, Fountain tree, Uganda flame, Nile flame, Nandi flame Français : Tulipier africain, Arbre flamme, Bâton de sorcier Noms vernaculaires Burkina Faso: Fulfuldé Djapelede;kafavano Ghana: Akan Akuakuoninsuo Nigéria: Bokyi Kenshie Sénégal: Balanta Blalo Togo: Ewe Adatsigo, Fon Dudu, Ouatchi Adassigolo Description de la plante C'est un arbre dioïque d'environ 35 m de haut, qui est souvent sous forme de buisson de savane, avec des racines superficielles; cannelées mesurant environ 60 cm de diamètre, avec une écorce grise, brun- pâle et lisse, devenant gris -foncée à maturité, rugueuse et écailleuse avec base cylindrique; les feuilles sont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 917,
    "source": "PDF_chunked"
  },
  {
    "id": 4972,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 972)",
    "text": "cannelées mesurant environ 60 cm de diamètre, avec une écorce grise, brun- pâle et lisse, devenant gris -foncée à maturité, rugueuse et écailleuse avec base cylindrique; les feuilles sont opposées ou en verticilles de 3, imparipennées. Les stipules sont absentes; il a une inflorescence en grappe terminale et des fleurs bisexuées; les fruits sont étroitement ellipsoïdes, mesurent 15 à 27 cm de long et sont déhiscents par 2 valves. Numéro du spécimen de l'herbier Ghana: GC 1012 Togo: TOGO02454 Habitatet répartition géographique S. campanulata est une plante de taille moyenne, spontanée qui pousse communément dans plusieurs pays africains comme le Ghana, le Niger ia, le Gabon, le Cameroun, la Guinée, l'Angola, le Congo, le Soudan, l'Ouganda et le Sénégal. Elle se développe dans les forêts à feuilles caduques, dans les régions boisées, à la lisière des forêts en savane et, est souvent cultivé comme arbre de rue (Ofori -Kwakye et al.,2009).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4973,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 973)",
    "text": "feuilles caduques, dans les régions boisées, à la lisière des forêts en savane et, est souvent cultivé comme arbre de rue (Ofori -Kwakye et al.,2009). Parties utilisées de la plante Ecorce du tronc Autres parties utilisées Feuille Caractéristiques botaniques La Tulipe africaine se compose de l'écorce de tronc fraîche ou séchée de S. campanulata Beauv P. (Bignoniaceae) Utilisations ethnomédicales Les différentes parties de S. campanulata sont utilisés dans la médecine traditionnelle africaine pour le traitement d'une variété de maladies, y compris la dysenterie, la gastrite, les ulcères, les douleurs pelviennes chez les femm es, les maux de tête, l'œdème, la dermatite, le ver de Guinée. L'écorce du tronc est appliqué comme pâte pour soigner les blessures (Mensah et al. , 2003). La feuille macérée est utilisée contre l'urétrite et est un antidote contre le poison. La décoction d e l'écorce est utilisée pour des problèmes rénaux,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4974,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 974)",
    "text": "feuille macérée est utilisée contre l'urétrite et est un antidote contre le poison. La décoction d e l'écorce est utilisée pour des problèmes rénaux, les inflammations et les plaintes de la peau (Irvin, 1961); l'écorce de tronc est utilisée comme lavement dans le diabète (Niyonzima, 1997). L'écorce du tronc macérée est un remède pour les maladies infect ieuses, y compris les infections sexuellement transmissibles (Magassouba et al., 2007). Au Ghana, la plante est utilisée pour le traitement de la dyspepsie, l'ulcère gastro- duodénal, l'arthrite, la fracture, le mal de dents, les maux d'estomac et l'ulcère d'estomac (Agbovie et al, 2002). Activités biologiques et pharmacologiques Un fractionnement bioactivité- guidée a conduit à l'isolement des polysaccharides qui ont montré une forte activité hypoglycémiante et reproductible (Niyonzima et al., 1999; Niyonzima, 1997). L'extrait au méthanol de l'écorce de la tige a montré des effets antimicrobiens, antifongique,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 974,
    "source": "PDF_chunked"
  },
  {
    "id": 4975,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 975)",
    "text": "une forte activité hypoglycémiante et reproductible (Niyonzima et al., 1999; Niyonzima, 1997). L'extrait au méthanol de l'écorce de la tige a montré des effets antimicrobiens, antifongique, antioxydants in vitro (Trichophyton sp), (Mensah",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 238,
    "source": "PDF_chunked"
  },
  {
    "id": 4976,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 976)",
    "text": "OOAS Page 205 Spathodea campanulata WAHP et al., 2003; 2006) et des propriétés cicatrisantes in vivo (Sy et al., 2005). Les cérébrosides ont inhibé de manière significative la croissance de nombreuses bactéries gram -positives et gram - négatives (Mboso et al., 2008). La plante est connue pour être active contre Pseudomonas solanecearum (Amusan et al ., 1994). L'activité antipaludique de l'extrait d e l'écorce de la tige a été rapportée sur des souris infectées par Plasmodium berghei (Makinde et al. , 1988). L'extrait de feuille a démontré qu'il possède des effets analgésiques. Ofori -Kwakye et al. (2009) signalent l'activité antimicrobienne des extrait s de l'écorce de la tige contre quatre souches de bactéries et une levure de Candida albicans. S. campanulata, et Hoslundia opposita et Pycnanthus angolensis, couramment utilisée par les praticiens de la médecine traditionnelle au Ghana pour la cicatrisati on en cas d'ulcère de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 4977,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 977)",
    "text": "campanulata, et Hoslundia opposita et Pycnanthus angolensis, couramment utilisée par les praticiens de la médecine traditionnelle au Ghana pour la cicatrisati on en cas d'ulcère de l'estomac, démontrant ainsi une forte activité anti-adhésive contre Helicobacter pylori (Agyare et al., 2009). Données cliniques Aucune information disponible Constituants chimiques Acide férulique, acide vanillique; verminoside (6- O-caféoyle-catalpol: glycoside iridoïde), atranorine, spathoside, (nouvelle cérébroside), acide spathodéa; triterpènes: 3ß, 19α ,24- trihydroxyolean-12-ène-28-oïque), acide oléanolique, 3β -acétoxy-oléanolique, des acides β-sistostérol-3-O-β des d- glucopyranoside; quercétine, l'acide caféique, acide siaresinolique, 3β-acétoxy-oléanolique, acide β -sistostérol-3-O- β-D-glucopyranoside, β -sistostérol, spathodol (stérol d'hydroxyle); cyanidine- 3-O-rutinoside , pélargonidine-3-O-rutinoside; acide pomolique, les est ers d'acide p- hydroxybenzoïque et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 968,
    "source": "PDF_chunked"
  },
  {
    "id": 4978,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 978)",
    "text": "β-D-glucopyranoside, β -sistostérol, spathodol (stérol d'hydroxyle); cyanidine- 3-O-rutinoside , pélargonidine-3-O-rutinoside; acide pomolique, les est ers d'acide p- hydroxybenzoïque et phényléthanol; octacosanol et triacontanol (Gorman et al, 2004; Niyonzima, 1997; Mbosso et al, 2008; Silvère et al, 1990). Tests d'identité et de pureté Teneur eneau: pas plus de9.09 Centre totale: 6.95 Valeur substances extractibles par l'eau: pas moins de 24.63. Valeur substances extractibles par l'éthanol (70): pas moins de 17.89 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, pui s chauffé à 100- 110C",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4979,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 979)",
    "text": "réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, pui s chauffé à 100- 110C pendant 5-10 mn. Présence de six taches distinctes avec R f de 0.66 (rose), 0.52 (rose), 0.47 (rose), 0.32 (bleue), 0.25 (bleue) et 0.13 (bleue). Chromatogramme Macroscopie La feuille est composée d'un long pétiole; d'un limbe de 10-15 cm de long sur 6- 8 cm de large; elliptiques à forme oblongue; avec marge entière etsommet acuminé. La base de la feuille est légèrement cunéiforme, avec une nervation réticulée, une surface foliaire glabre. La texture est semblable au papier avec une nervure proéminente. Microscopie Les bandes épidermiques sur les deux surfaces possèdent des murs anticlinaux ondulés à vallonné et de nombreux globules d'huile;",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 830,
    "source": "PDF_chunked"
  },
  {
    "id": 4980,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 980)",
    "text": "OOAS Page 206 Spathodea campanulata WAHP différents types de poils sont présents sur les deux surfaces; de nombreux poils non- glandulaires unicellulaires, ainsi que des poils glandulaires pluricellulaires sur la surface adaxiale; des poils non- glandulaires pluricellulaires courts sur l'abaxiale; des stomates anisocytiques sur les deux surfaces (c'est-à-dire la feuille est amphistomatiques), mais nombreux sur la surface abaxiale; la section transversale de la feuille est isobilatérale, les cellules épidermiques ont la forme d'un parallélépipède rectangulaire. Le mésophylle est indifférencié ;les cellules spongieuses sont décousues; la r égion de la nervure médiane a une saillie convexe supérieure sur la surface dorsale; les faisceaux internes portent des vaisseaux de xylème spirale lignifiés; les poils pluricellulaires ont des cellules de bases renflées présentes sur les protubérances de la nervure médiane, 7 faisceaux vasculaires collatérales",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 4981,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 981)",
    "text": "vaisseaux de xylème spirale lignifiés; les poils pluricellulaires ont des cellules de bases renflées présentes sur les protubérances de la nervure médiane, 7 faisceaux vasculaires collatérales sont agencés avec le phloème, disposés en alternance à la base de 3- 5 xylèmes alvéoles; la moelle centrale porte de grandes cellules collenchymateuses. Matériel végétal en poudre Cellules parenchym ateuses avec de nombreuses gouttelettes d'huile, différents types de poils, dont de nombreux non- glandulaires unicellulaires, des polis non- glandulaires pluricellulaires ainsi que des poils glandulaires pluricellulaires, des poils non- glandulaires pluricellulaires courts; des stomates anisocytiques, des cellules épidermiques, des vaisseaux de xylème en spirale lignifiés. Actions thérapeutiques Anti-inflammatoire, anti -VIH (Niyonzima et al ., 1999.), antidiabétique (Niyonzima, 1997), antipaludéen (Makinde et al., 1988), antioxydant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 4982,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 982)",
    "text": "Actions thérapeutiques Anti-inflammatoire, anti -VIH (Niyonzima et al ., 1999.), antidiabétique (Niyonzima, 1997), antipaludéen (Makinde et al., 1988), antioxydant et antimicrobien vulnéraire (Ofori -Kwakye et al. , 2009; Mensah et al., 2003; 2006). Indications thérapeutiques Inflammation, VIH, diabète, paludisme, infections bactériennes, plaies. Données de sécurité La DL 50 de l'extrait aqueux de l'écorce de la tige (p.o) a été jugée 3000 mg kg chez le rat.Dans les études subaiguës (300- 3000 mg kg), aucun changement significatif dans le poids corporel ou le poids relatif des organes n'a été observé. Le nombre total de globules blancs sang uins a augmenté mais le nombre de neutrophiles a été réduit à la plus forte dose testée (3000 mg kg). A 3000 mg kg, il y a augmentation des protéines totales, de globuline, GGT et créatinine. Précautionsd'emploi Aucunes précautions spéciales requises dans la dose recommandée d'extrait aqueux.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 4983,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 983)",
    "text": "totales, de globuline, GGT et créatinine. Précautionsd'emploi Aucunes précautions spéciales requises dans la dose recommandée d'extrait aqueux. Effets indésirables Aucuns effets indésirables graves signalés. Contre-indications Aucune Dosage et forme galénique Infusion: environ 25 g par jour Teinture: 1:5 alcool à 90 de 0,3-1,2 ml à 25 ml max par semaine. Conservation A conserver dans un endroit frais et sec. Références Agbovie, T., Amponsah, K., Crentsil, O.R., Dennis, F., Odamtten, G.T. et al . (2002). Conservation and sustainable use of medicinal plants in Ghana - Ethnobotanical Survey. Agyare, C. , Asase, A., Lechtenberg, M., Niehues, M., Deters, A., Hensel, A. (2009). An ethnopharmacological survey and in vitro confirmation of ethnopharmacological use of medicinal plants used for wound healing in Bosomtwi-Atwima-Kwanwoma area, Ghana. Journal of Ethnopharmacology 125(3):393-403. Akoègninou, A., van der Burg, W.J., van der",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 4984,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 984)",
    "text": "medicinal plants used for wound healing in Bosomtwi-Atwima-Kwanwoma area, Ghana. Journal of Ethnopharmacology 125(3):393-403. Akoègninou, A., van der Burg, W.J., van der Maesen, L.J.G. (2006). Flore Analytique du Bénin. Backhuys Publishhers, p. 428. Amusan, O.O.G., Bhembe, F.N., Mkhatshwa, F.T., Thwala, E.Z. (1994). Antibacterial activity of Annona senegalensisi , Andrache ovalis and Spathodea campanulata against Pseudomonas solsnecearum. UNISWA Journal of Agriculture 3:6266. Gorman, R., Schreiber, L., Kolodziej, H. (2004). Cuticular wax profiles of leaves of some traditionally used African Bignoniaceae. Zeitschrift für Naturforschung: C . 59(9- 10):631- 635. Irvin, F.R. (1961). in Wood plants of Ghana ; London : Oxford University Press, pp739-740. Lisowski, S. (2009). Flore (Angiospermes) de la République de Guinée ; première partie (texte). Scripta Botanica Belgica, 41, 517p. Magassouba, F.B., Diallo A., M. Kouyaté, F.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 934,
    "source": "PDF_chunked"
  },
  {
    "id": 4985,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 985)",
    "text": "Lisowski, S. (2009). Flore (Angiospermes) de la République de Guinée ; première partie (texte). Scripta Botanica Belgica, 41, 517p. Magassouba, F.B., Diallo A., M. Kouyaté, F. Mara, O. et al . (2007). Ethnobotanical survey and antibacterial activity of some plants used in",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 272,
    "source": "PDF_chunked"
  },
  {
    "id": 4986,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 986)",
    "text": "OOAS Page 207 Spathodea campanulata WAHP Guinean traditional medicine. Journal of Ethnopharmacology 114(1):44-53. Makinde, J.M., Amusan, O.O., Adesogan, E.K. (1988). The antimalarial activity of Spathodea campanulata stem bark extract on Plasmodium berghei berghei in mice. Planta Medica 54(2):122-125. Meléndez, P.A., Capriles, V.A. (2006). Antibacterial properties of tropi cal plants from Puerto Rico. Phytomedicine 13(4):272. Mensah, A.Y., Houghton, P.J., Dickson, R.A., Fleischer, T.C., Heinrich, M., Bremner, P. (2006). In vitro evaluation of effects of two Ghanaian plants relevant to wound healing. Phytotherapy Research 20(11):941-944. Mensah A Y, Houghton P J, Fleischer T C, Adu C, Agyare C, Ameade A E. (2003). Antimicrobial and antioxidant properties of two Ghanaian plants used traditionally for wound healing. Journal of Pharmacy and Pharmacology 55(Supplement):S-4. Mme, B. (1969). Plantes Médicinales de Guinée.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 4987,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 987)",
    "text": "and antioxidant properties of two Ghanaian plants used traditionally for wound healing. Journal of Pharmacy and Pharmacology 55(Supplement):S-4. Mme, B. (1969). Plantes Médicinales de Guinée. Conakry, République de Guinée Mbosso, E.J., Ngouela, S., Nguedia, J.C., Penlap, V., Rohmer, M., Tsamo, E. (2008). Spathoside, a cerebroside and other antibacterial constituents of the stem bark of Spathodea campanulata. Natural Product Research 22(4):296-304. Niyonzima, G. (1997). Contribution to the study of the antidiabetic activit y of an African medicinal plant: Spathodea camapanulata P. Beauv. (Bignoniaceae). Thesis, University of Antwerp (Belgium). Niyonzima, G., Laekeman, G., Witvrouw, M., Van Poel, B., Pieters, L. et al. (1999). Hypoglycemic, anticomplement and anti -HIV activities of Spathodea campanulata stem bark. Phytomedicine 6(1):45-49. Ofori-Kwakye, K., Kwapong, A.A. , Adu F. (2009).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 899,
    "source": "PDF_chunked"
  },
  {
    "id": 4988,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 988)",
    "text": "anticomplement and anti -HIV activities of Spathodea campanulata stem bark. Phytomedicine 6(1):45-49. Ofori-Kwakye, K., Kwapong, A.A. , Adu F. (2009). Antimicrobial Activity of Extracts and Topical Products of the Stem Bark of Spathodea Campanulata for Wound Healing. African Journal of Traditional, Complementary and Alternative Medicine 6(2): 168174. Silvere, N., Barthelemy, N., Etienne, T., Beibam, L., Sondengam, J.D.C. (1990). Spathodic acid: A triterpene acid from the stem bark of Spathodea campanulata. Phytochemistry 29(12): 3959- 3961. Sy, G.Y., Nongonierma, R.B., Ngewou, P.W., Mengata, D.E., Dieye, A.M. et al . (2005). Healing activity of methanolic extract of the barks of Spathodea campanulata Beauv (Bignoniaceae) in rat experimental burn model. Dakar Medical 50(2): 77-81.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 790,
    "source": "PDF_chunked"
  },
  {
    "id": 4989,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 989)",
    "text": "OOAS Page 208 Spermacoce verticillata WAHP Nom botanique Spermacoce verticillataL. Famille Rubiaceae Synonyme Borreria verticillata(L) G.F.W Mey, Spermacoce globosa Schum. Thonn Noms communs Buttonweeds, African borreria (Englais); Borreria verte, Borrerie verticillé (Français) Noms vernaculaires Burkina Faso: Fulfuldé Gurdudal Mali: Bambara Missini Koumbere, Peuhl Samtarde Nigéria: Yoruba Irawo-Ile Sénégal: Wolof Ndatukan, Bu Gôr; Serer Murah, Faduala, Diola Karibun, Eribun Description de la plante Arbuste touffu, atteignant 1 mètre de haut, ramifié, légèrement argileux, tiges glabres avec des gaines stipulaires qui sont lisses ou rugueuses; les feuilles sont glabres, oblancéolées de 7 mm à 4 cm avec des nervures latérales, pas très proéminentes; avec une infloressence, sphérique, compacte, terminale et axillaire de 10 à 15 mm de diamètre, généralement avec deux bractées foliacées",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 894,
    "source": "PDF_chunked"
  },
  {
    "id": 4990,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 990)",
    "text": "latérales, pas très proéminentes; avec une infloressence, sphérique, compacte, terminale et axillaire de 10 à 15 mm de diamètre, généralement avec deux bractées foliacées d'environ 1 cm de long, courbé vers le bas,avec de petites fleurs blanches ; le fruit est une drupe, sèche et déhiscente. Numéro du specimen de l'herbier Ghana: GC 53415 Mali: 2515 (DMT) Habitat et répartition géographique Il s'agit d'une plante tropicale qui est largement distribuée dans toute la région soudano- guinéenne et une partie du Sahel, en particulier le long de la côte ouest -africaine et de l'Amérique du Sud, ainsi queMadagascar. Partiesutiliséesde la plante Feuille, racine, parties aériennes. Caractéristiques botaniques Le Borreria africain se compose des parties aériennes fraiches ou sèches de Spermacoce verticillata L.(Rubiaceae). Utilisations ethnomédicales Le Borreria verticillata est traditionnellement utilisé pour traiter la lèpre, les furoncles, la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 4991,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 991)",
    "text": "verticillata L.(Rubiaceae). Utilisations ethnomédicales Le Borreria verticillata est traditionnellement utilisé pour traiter la lèpre, les furoncles, la blanches, l'impuissance, et les hémorroïdes (Paulino de Albuquerque et al., 2007). La plante est utilisée pour traiter l'inflammation (Gazzaneo et al., 2005) et comme insecticide (Rohrig et al., 2008). La décoction de l'écorce est administrée par voie orale pour traiter les maladies infectieuses, y compris les infections sexuellement transmissibles (Magassouba et al., 2007). Biological biologique et pharmacologique Les alcaloïdes isolés de B. verticillata possèdent des propriétés antibactériennes (Pieters et Vlietinck, 2005). L'alcaloïde borreverine a montré une activité antimicrobienne in vitro . La concentration inhibitrice minimale a été inférieure à 50 μ gml pour le cocci à gram -positif (en particulier Staphylococcus aureus), 6 mgml pour Vibrio cholerae, et supérieure à 200 μ gml pour",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 4992,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 992)",
    "text": "concentration inhibitrice minimale a été inférieure à 50 μ gml pour le cocci à gram -positif (en particulier Staphylococcus aureus), 6 mgml pour Vibrio cholerae, et supérieure à 200 μ gml pour plusieurs souches à Gram négatif (Maynart et al., 1980 ). L'extrait méthanolique de racine est actif contre les souches multirésistantes du Pseudomonas aeruginosa (De Sa Peixoto Neto et al., 2002). Données cliniques Aucune information disponible Constituants chimiques Il est constitué d'huile essentielle (hydrocarbures sesquiterpénique, lactones sesquiterpénique, composés phénoliques et acides polycarboxyliques aromatiques); azulène alcaloïdes (borrérine et borrévérine) (Pharmacopée Africaine, 1985); iridoïdes et iridosides (daphylloside 1, asperuloside 2, férétoside 3, méthyledésacétylaspérulosidate 4, aspéruloside, férétoside, daphyloside et acide asperulosidique 7) (Sainty et al 1981).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 890,
    "source": "PDF_chunked"
  },
  {
    "id": 4993,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 993)",
    "text": "OOAS Page 209 Spermacoce verticillata WAHP Tests d'identité et de pureté Teneur en humidité: pas plus de 7,12 Cendres totales: 4,06 Substances extractibles par l'eau: pas plus de 10,48 Substancesextractibles par l'éthanol (70): 11,06 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Présence de six taches distinctes avec valeurs Rf de 0,89 (rose), 0,79 (pourpre), 0,45 (rose), 0,38 (rose), 0,27 (rose) et 0,18 (pourpre). Chromatogramme Macroscopie La feuille est oblancéolée dans la forme avec une texture douce, une surface glabre et verte",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 917,
    "source": "PDF_chunked"
  },
  {
    "id": 4994,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 994)",
    "text": "(pourpre), 0,45 (rose), 0,38 (rose), 0,27 (rose) et 0,18 (pourpre). Chromatogramme Macroscopie La feuille est oblancéolée dans la forme avec une texture douce, une surface glabre et verte quand elle est fraîche. Elle mesure 10- 50 mm de long sur 3 à 10 mm de large. La marge est entière avec un apex acuminé aigu, tandis que la nervation est pennée- réticulée. La tige est obscurée à l'angle. L'odeur est légère et la couleur est brunâtre une fois sèche, avec un goût particulier. Microscopie La feuille a des cell ules épidermiques supérieures presque droites mesurant 31.9- 116.0 μmà 17.4- 52.2 μm; les cellules épidermiques inférieures sont légèrement ondulées, ou nettement ondulées, mesurant 38.2-133.4μm de long sur 20.3-63.8 μm de large. Les cristaux d'oxalate de calcium et les poilssont absents tandis que les stomates de type rubiacés sont présents sur les deux surfaces avec une plus grande quantité sur la surface",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 4995,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 995)",
    "text": "Les cristaux d'oxalate de calcium et les poilssont absents tandis que les stomates de type rubiacés sont présents sur les deux surfaces avec une plus grande quantité sur la surface inférieure. Le mésophylle est constitué d'une rangée de cellules palissadiques sur l'épiderme supérieur seulement. Les fonctions spéciales comprennent denombreux petits globules d'huile de forme sphérique tout au long du mésophylle. Matériel végétal en poudre Couleur brunâtre avec une légère odeur caractéristique et, contenant des fragments de bois de tige et de racine, mais aussi des fragments de lame de feuilles avec des stomates rubiacés, un reste de faisceaux vasculaires, des cellules de parenchyme, tandis que les cristaux d'oxalate de calcium et les poilssont absents. La Borreria en poudre est conforme aux exigences de la teneur en alcaloïdes indolestotaux, des profils d'identification, des cendres et des valeurs extractibles. Actions thérapeutiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 4996,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 996)",
    "text": "Borreria en poudre est conforme aux exigences de la teneur en alcaloïdes indolestotaux, des profils d'identification, des cendres et des valeurs extractibles. Actions thérapeutiques Antibactérien, antibiotique, antiseptique, antischistosomiase, anti -inflammatoire, insecticide, anti -eczéma (Gazzaneo et al, 2005; Rohrig et al, 2008; Pieters et Vlietinck, 2005) Indications thérapeutiques Infections intestinales, constipation, schistosomiase, inflammations, lèpre, furoncles, plaies, infections cutanées, eczéma. Données de sécurité Les études de toxicité aiguë de 24 heures chez la souris (voie orale) ont montré que, la DL 50 de l'extrait aqueux des parties aériennes de la plante est 2000 mgkg. Dans les études de toxicité subaiguë, aucun signe clinique de toxicité n'a été observé après l'administration",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 809,
    "source": "PDF_chunked"
  },
  {
    "id": 4997,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 997)",
    "text": "OOAS Page 210 Spermacoce verticillata WAHP orale de l'extrait (500- 2000 mgkg; p.o) à des souris mâles et femelles pendant 14 jours. Précautionsd'emploi La prise orale de produits à base de plante contenant des alcaloïdes doit être faite avec modération. Effets indésirables Un surdosage peut provoquer des troubles gastro-intestinaux. Contre-indications Peau réactive et allergique Dosage et forme galénique En interne: thé, huile essentielle, capsules, Extérieurement: généralement comme une application topique de la peau; lotions, teintures, onguents, pâtes. Conservation A conserver dans un endroit frais et sec. Références De Sá Peixoto Neto, P.A ., Vladimilsa Silva, M ., Corrente Campos, N.V ., Porfírio, Z ., Caetano, L.C. (2002). Antibacterial activity of Borreria verticillata roots. Fitoterapia 73(6):529-531. Gazzaneo, L.R.S., Paiva de Lucena, R.F., Paulino de Albuquerque, U. (2005). Knowledge",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 907,
    "source": "PDF_chunked"
  },
  {
    "id": 4998,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 998)",
    "text": "L.C. (2002). Antibacterial activity of Borreria verticillata roots. Fitoterapia 73(6):529-531. Gazzaneo, L.R.S., Paiva de Lucena, R.F., Paulino de Albuquerque, U. (2005). Knowledge and use of medicinal plants by local specialists in a region of Atlantic Forest in the state of Pernambuco (Northeaster n Brazil). Journal of Ethnobiology and Ethnomedicine 1:9. Magassouba, F.B., Diallo, A., Kouyaté, M., Mara, F., Mara, O. et al (2007). Ethnobotanical survey and antibacterial activity of some plants used in Guinean traditional medicine. Journal of Ethnopharmacology 114:4453. Maynart, G., Pousset, J.L., Mboup, S., Denis, F. (1980). Antibacterial effect of borreverine, an alkaloid isolated from Borreria verticillata (Rubiaceae). Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales; 174(5):925-928. Paulino de Albuquerque, U., Monteiro, J.M., Ramos, M.A., Cavalcanti de Amorim, E.L. (2007). Medicinal and magic plants from a public",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 4999,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 999)",
    "text": "la Societe de Biologie et de ses Filiales; 174(5):925-928. Paulino de Albuquerque, U., Monteiro, J.M., Ramos, M.A., Cavalcanti de Amorim, E.L. (2007). Medicinal and magic plants from a public market in northeastern Brazil. Journal of Ethnopharmacology 110:7691. Pharmacopée Africaine Organisation de l'Unité Africaine (1985) Commission Scientifique Technique et de la Recherche (CSTROUA). 1ère édition, vol. 1. Pieters, L., Vlietinck, A.J., (2005). Bioguided isolation of pharmacologically active plant components, still a valuable strategy for the finding of new lead compounds? Journal of Ethnopharmacology 100:5760. Rohrig, E., Sivinski, J., Wharton, R. (2008). Comparison of Parasitic Hymenopter captured in malaise traps baited with two flowering plants, Lobularia maritime (Brassicales: Brassicaceae) and Spermacoce verticillata (Gentianales: Rubiaceae). Florida Entomological Society 91:621-627. Sainty D., Bailleul, F., Delaveau, P., Jacquemin,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 5000,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1000)",
    "text": "and Spermacoce verticillata (Gentianales: Rubiaceae). Florida Entomological Society 91:621-627. Sainty D., Bailleul, F., Delaveau, P., Jacquemin, H. (1981). Iridoids of Borreria verticillata. Planta Medica 42(7):260-264.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 220,
    "source": "PDF_chunked"
  },
  {
    "id": 5001,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1001)",
    "text": "OOAS Page 211 Spondias mombin WAHP NomBotanique Spondias mombin L. Famille Anacardiaceae Synonyme Spondias aurantiaca Schum Thonn, Spondias brasiliensis Mart, Spondias lucida Salisd., Spondias lutea T, Spondias myrobalanus L, Spondias oghibee G. Don, Spondias pseudomyrobalanus L. Tuss, Mauria juglandifolia Benth, Myrobalanus lutea Maef Noms communs Anglais: Hog plum Français: Mombin, Prune mombin ou Prune Myrobolan. Noms vernaculaires Burkina Faso: Dioula Mingo; Minkon, Fulfuldé Talé;tali Cote d'Ivoire: Abe Ngba Ghana: Twi Atoaa Mali: Barbara Minko Mingo N inkom, Peul Talé tali, Dogon Enye Vevey Nigéria: Yoruba Agliko Sénégal: Wolof Sob ninkôm, Serer Yoga, Diola Bu lila Bu lilu Togo: Ewe Akoukonti, Adja Kukon, Adele Inyanya Description de la plante Un arbre qui pousse de 15 à 25 m de haut avec une écorce claire, striée, fissurée, rugueuse et épaisse; une écorce généralement couverte de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 898,
    "source": "PDF_chunked"
  },
  {
    "id": 5002,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1002)",
    "text": "Inyanya Description de la plante Un arbre qui pousse de 15 à 25 m de haut avec une écorce claire, striée, fissurée, rugueuse et épaisse; une écorce généralement couverte de grosses épines et résine se dégagent de ses blessures;un fût épaissi à la base, atteignant 0,75 m de diamètre environ; des branches évasées à feuillage complet et équilibré, feuilles composées, imparipennées, mesurant 50 cm de long avec 5- 8 paires de folioles de 7 cm de long et 3,5 cm de large, inégales à base courtement acuminées, une nervure courte au bord du limbe unissant les nervures latérales. des petites fleurs blanches, parfumées avec de grands panicules terminales apparaissent au cours de la défoliation de la saison sèche; les inflorescences sont disposées en panicules terminales, pyramidales, de 20 à 40 cm de long, couvert principalement de poils courts; le fruit est une prune astringente douce; la chaire plus ou moins acide et agréable, a des drupes ovoïdes de 2,5 à",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 5003,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1003)",
    "text": "pyramidales, de 20 à 40 cm de long, couvert principalement de poils courts; le fruit est une prune astringente douce; la chaire plus ou moins acide et agréable, a des drupes ovoïdes de 2,5 à 4 cm de long et 2 sur 2,5 cm de large. Numéro du spécimen de l'herbier Mali: 0279 DMT Togo: TOGO 01851 Habitat et répartition géographique La plante est originaire d'Amérique tropicale, y compris les Antilles, mais a été naturalisée dans certaines Régions d'Afrique, en Inde et en Indonésie. Elle est rarement cultivée. Elle pousse bien dans les climats chauds et sur une grande variété de sols: les sols sableux sur du gravier peu profond ou dans un sol argileux lourd. Parties utilisées de la plante Ecorce du tronc et feuille Autres parties utilisées Racine, fleur etfruit Caractéristiquesbotaniques L'hog prunese compose de l'écorce de la tige et des feuilles de Spondias mombin L. (Anacardiaceae). Utilisations ethnomédicales",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 921,
    "source": "PDF_chunked"
  },
  {
    "id": 5004,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1004)",
    "text": "Racine, fleur etfruit Caractéristiquesbotaniques L'hog prunese compose de l'écorce de la tige et des feuilles de Spondias mombin L. (Anacardiaceae). Utilisations ethnomédicales Au Mali, la plante est utilisée pour traiter la carie dentaire, et utilisée également comme un diurétique, l axatif, purgatif et fébrifuge (Adjanohoun et al., 1979.). Les extraits de feuilles ont de puissantes propriétés antimicrobiennes et antifongiques. Le jus obtenu par l'extraction des feuilles fraîches est couramment utilisé au Sénégal pour le traitement des maladies oculaires, alors que la feuille ou le décocté des bourgeons racinaires est prescrit",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 635,
    "source": "PDF_chunked"
  },
  {
    "id": 5005,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1005)",
    "text": "OOAS Page 212 Spondias mombin WAHP pour la diarrhée et la dysenterie où il est à consommer pendant les coliques (Kerharo et Adam, 1974). La décoction des feuilles ajoutée à du sel a des propriétés diurétiques et laxatives (Adjanohoun et al, 1979). La décoction de feuilles est également un remède pour les caries, les abcès dentaires, les coliques, les maladies oculaires et divers maux de dents (Boullard, 2001). L'infusé de l'écorce est utilisé comme anthelminthique et rince- bouche pour les maux de dents; le décocté de l'écorce est utilisé en cas de toux accompagnée de graves symptômes inflammatoires, et vomissements. L'écorce séchée est utilisée comme un spray sur les plaies fraîches de la circoncision et l'écorce du tronc est utilisé comme un thé pour les femmes enceintes (Boullard, 2001). Activités biologiques et pharmacologiques L'extrait de feuilles de S. mombin présente des effets antibactériens à large spectre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 5006,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1006)",
    "text": "enceintes (Boullard, 2001). Activités biologiques et pharmacologiques L'extrait de feuilles de S. mombin présente des effets antibactériens à large spectre comparables à ceux de l'ampicilline et de la gentamicine (Abo et al., 1999). Les extrait à l'eau froide, l'eau chaude et à l'éthanol de la plante n'ont pas inhibé les streptocoques cariogènes isolés chez des patients souffrant de carie dentaire (Amadi et al ., 2007). L'esters de caféoyle et les ellagitanins présents dans la plante ont montré une activité antivirale prononcée contre les virus de Coxsackie et Herpès simplex (Corthout et al., 1991; 1992). Une série de 6 acides -alkenylsalicyliques isolés à partir de l'extrait éthanolique des feuilles et des tiges de S. mombin ont révélé avoir un effet prononcé antibactérien contre Bacillus cereus , Streptococcus pyogenes , et Mycobacterium fortuitum et un effet molluscicide contre Biophalaria glabrata , escargot, hôte intermédiaire dans le cycle de vie du",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 969,
    "source": "PDF_chunked"
  },
  {
    "id": 5007,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1007)",
    "text": "Streptococcus pyogenes , et Mycobacterium fortuitum et un effet molluscicide contre Biophalaria glabrata , escargot, hôte intermédiaire dans le cycle de vie du schistosome (Corthout et al ., 1994). Un gel phytothérapique comprenant un extrait hydroalcoolique de S. mombin avec le chitosane a démontré une activité antivirale contre Herpès simplex. L'administration orale d'une dose unique de pectines obtenues à partir de la plante a causé une diminution significative de la glycémie chez les rats rendus diabétiques par l'alloxane (El Fiki, 2000). Les extraits aqueux, méthanolique et éthanolique possèdent des effets anxiolytiques modulés par la transmission GABAergique, ainsi que des effets sédatifs et antidopaminergique (Ayoka et al ., 2005; 2006). Les extraits aqueux de feuilles, de l'écorce de tronc et de l'écorce de racine ont démontré une activité anthelminthique (Ademola et al., 2005; Gbolade et Adeyemi, 2008). Les extraits de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 5008,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1008)",
    "text": "Les extraits aqueux de feuilles, de l'écorce de tronc et de l'écorce de racine ont démontré une activité anthelminthique (Ademola et al., 2005; Gbolade et Adeyemi, 2008). Les extraits de la plante ont montré une activité antiplasmodiale sur les souches standards de Plasmodium falciparum chloroquino-résistantes (Diallo et al., 2007). Données cliniques Aucune information disponible Constituants chimiques Tanins, palmitique, linoléique, oléique, stéarique, les acides linoléiques, des flavonoïdes (quercétine, quercitrine, rutine, et 7- O- glucosides); saponine, sucres, alcaloïdes, tanins condensés (proanthocyanines) (Moronkola et al., 2003; Apori et a l., 1998;El Fiki, 200 0; Edeoga et Eriata, 2001). Tests d'identité et de pureté Teneur en eau: pas plus de 6,65 Cendre totale: 20,00 Cendre sulfatée: 16,88 Valeur substances extractibles par l'eau: pas moins de 11,87 Valeur substances extractibles par l'éthanol (70): pas moins de 11,01",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 5009,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1009)",
    "text": "Cendre totale: 20,00 Cendre sulfatée: 16,88 Valeur substances extractibles par l'eau: pas moins de 11,87 Valeur substances extractibles par l'éthanol (70): pas moins de 11,01 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de cinq taches distinctes avec R f de 0,95 (brun), 0,91 (brun), 0,50 (vert), 0,38 (rose) et 0,27 (pourpre).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 719,
    "source": "PDF_chunked"
  },
  {
    "id": 5010,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1010)",
    "text": "OOAS Page 213 Spondias mombin WAHP Chromatogramme Macroscopie On observe une couleur verte avec une odeur douce et un goût amer; feuilles composées, courtement pétiolées; un limbe de 5- 10 cm de long, 2-5 cm de large; marge faiblement dent ée en scie; oblongues ou oblongues -lancéolées à sommet obtus ou largement acuminées. La base de la feuille est oblique avec une nervation réticulée, feuille à surface glabre et à texture charnue et une nervure médiane proéminente. Microscopie La surface épidermique adaxiale présente des parois anticlinales droites et de nombreuse tête de poils; des poils simples avec des têtes coniques; la surface abaxiale a des parois légèrement ondulées et de longs poils pluricellulaires qui sont parfois ramifiés; des stomates anisocytiques présents; la section transversale de la feuille dorsiventrale compacte dispose de cellules épidermiques. Une seule couche sur les deux faces latérales sont",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 928,
    "source": "PDF_chunked"
  },
  {
    "id": 5011,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1011)",
    "text": "stomates anisocytiques présents; la section transversale de la feuille dorsiventrale compacte dispose de cellules épidermiques. Une seule couche sur les deux faces latérales sont couvertes d'une cuticule mince; le mésophylle est différencié dans la palissade et le parenchyme spongieux; l'épiderme supérieur est suivi de 1- 2 couches de parenchyme palissadique, de parenchyme spongieux de 3- 4 couches de cellules avec un groupe de cellules sclérenchymateuse au milieu; la nervure centrale est comme une saillie ov oïde sur les deux côtés ventrales et dorsales et porte des poils courts simples, le faisceau vasculaire centripète à l'exemple du xylème (3- 5 lobé) entoure le phloème ;des cristaux d'oxalate de calcium sont dispersés sur le faisceau vasculaire. Matériel végétal en poudre Les cellules épidermiques ont des parois parenchymateuses droites anticlinales, des poils simples avec des têtes coniques pluricellulaires, parfois ramifiée; stomates anisocytiques,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 969,
    "source": "PDF_chunked"
  },
  {
    "id": 5012,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1012)",
    "text": "Les cellules épidermiques ont des parois parenchymateuses droites anticlinales, des poils simples avec des têtes coniques pluricellulaires, parfois ramifiée; stomates anisocytiques, quelques parenchymes palissadiques; des cellules sclérenc hymateuses, des fragments de vaisseaux des faisceaux vasculaires; des cristaux d'oxalate de calcium dispersés. Actions thérapeutiques Large spectre antiseptique et antibactérien, abortif, anthelminthique, anti -cancérigènes, anticonvulsivant, anti -dopaminergique, antifongique, antioxydant, antispasmodique, antiviral, anxiolytique, cytotoxique, relaxant musculaire, hémostatique, sédatif, stimulant utérin, nervin. Indications thérapeutiques Vers et parasites intestinaux , troubles menstruels (douleur,crampes et irrégularité), infections vaginales et infection à levures. Données de sécurité La DL 50 de l'extrait aqueux d'écorce de tronc (p.o) chez la souris était 2000 mgkg en 24",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 5013,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1013)",
    "text": "infections vaginales et infection à levures. Données de sécurité La DL 50 de l'extrait aqueux d'écorce de tronc (p.o) chez la souris était 2000 mgkg en 24 heures. Aucun signe clinique de toxicité n'a été observé après le traitement des souris mâles et femelles (500 à 2000 mgkg; p.o) pendant 14 jours. Dans une étude de toxicité sub- chronique, l'administration répétée de l'extrait aqueux de l'écorce de la tige (p.o) à 100, 200 et 1000 mgkg pendant 45 jours n'a pas causé de changement significatif dans le poids corporel ou le poids relatif des organes cibles (foie, rate et rein). L'extrait aqueux n'a pas affecté le taux d'hémoglobine (pas d'anémie). Cependant, l'extrait a causé une certaine hypoglycémie aux doses testées. Les transaminas es hépatiques ont été en particulier affectées avec une dose élevée à 1000 mgkg, bien que cette augmentation ne corresponde pas à des modifications histologiques; les caractéristiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 5014,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1014)",
    "text": "ont été en particulier affectées avec une dose élevée à 1000 mgkg, bien que cette augmentation ne corresponde pas à des modifications histologiques; les caractéristiques histologiques étaient normales. La créatinine est restée normale, mais les niveaux d'acide urique ont augmenté à la dose de 1000 mgkg par rapport au groupe témoin. Les extraits aqueux, méthanolique et éthanolique des feuilles administrées oralement jusqu'à une dose de 5 gkg ne sont pas toxiques pour les souris. Lors de l'injection intrapéritonéale, les valeurs de la DL 50 souris ou les rats ont été calculées pour être respectivement (480- 620 mgkg) pour l'extrait éthanolique, (1080- 1100 mgkg) pour l'extrait méthanolique et (1360- 1420 mgkg) pour l'extrait aqueux (Ayoka et al. , 2005). L'extrait hydroéthanolique desfeuilles de S. mombin est non-toxique et a une importante activité anticonceptionnelle (Uchendu et Isek, 2008) Précautions d'emploi",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 5015,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1015)",
    "text": "hydroéthanolique desfeuilles de S. mombin est non-toxique et a une importante activité anticonceptionnelle (Uchendu et Isek, 2008) Précautions d'emploi Ne doit pas être utilisé à fortes doses; surveiller régulièrement les paramètres biochimiques glycémiques, hépatiques et rénaux sur une",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 287,
    "source": "PDF_chunked"
  },
  {
    "id": 5016,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1016)",
    "text": "OOAS Page 214 Spondias mombin WAHP utilisation prolongée à faibles doses; éviter l'utilisation concomitante d'autres médicaments hypoglycémiants, sauf sous supervision d'experts. Effets indésirables Le fruit est très acide et rend les dents et la langue fortement aigres. Contre-indications Infections de la dent et pendant la grossesse. Dosage et forme galénique Infusion: environ 25 g par jour Teinture: 1:5 d'alcool à 90 de 0,3-1,2 ml, 25 ml max par semaine Conservation Conserver dans un endroit frais et sec. Références Abo, K. A., Ogunleye, V.O., Ashidi, J.S. (1999). Antimicrobial potential of Spondias mombin, Croton zambesicus and Zygotritonia crocea. Phytotherapy Research 13(6):494-497. Ademola, I.O ., Fagbemi, B.O ., Idowu, S.O.(2005). Anthelmintic activity of extracts of Spondias mombin against gastrointestinal nematodes of sheep: studies in vitro and in vivo. Tropical Animal Health and Production 37(3):223-235.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 5017,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1017)",
    "text": "Spondias mombin against gastrointestinal nematodes of sheep: studies in vitro and in vivo. Tropical Animal Health and Production 37(3):223-235. Adjanohoun, E.J., Ake Assit, L., Floret, J.J., Guinko, S., Koumaré M. et al. (1979). Médecine traditionnelle (MT) et pharmacopée, contribution aux études ethnobotaniques et floristiques au Mali. ACCT. Paris; 27, 33 p. Amadi, E. S., Oyeka, A ., Onyeagba, R.A ., Okoli, I., Ugbogu, O.C . (2007). Studies on the antimicrobial effects of Spondias mombin and Baphia nittida on dental caries organism. Pakistani Journal of Biological Sci ence 10(3):393-397. Apori, S.O., Castro, F.B., Shand, W.J., Orskov, E.R. (1998). Chemical composition, in sacco degradation and in vitro gas production of some Ghanaian browse plants. Animal Feed Science and Technology 76(1-2):129-138. Ayoka, A.O ., Akomolafe, R.O ., Iwalewa, E.O ., Akanmu, M.A ., Ukponmwan, O.E . (2006). Sedative, antiepi leptic and antipsychotic effects",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 5018,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1018)",
    "text": "and Technology 76(1-2):129-138. Ayoka, A.O ., Akomolafe, R.O ., Iwalewa, E.O ., Akanmu, M.A ., Ukponmwan, O.E . (2006). Sedative, antiepi leptic and antipsychotic effects of Spondias mombin L. (Anacardiaceae) in mice and rats. Journal of Ethnopharmacology 103(2):166-175. Ayoka, A.O., Akomolafe, R.O., Iwalewa E.O., Ukponmwan, O. E. (2005). Studies on the anxiolytic effect of Spondias mombin L. (Anacardiaceae) extracts. African Journal of Traditional, Complimentary and Alternative Medicine 2(2):153165. Boullard, B. (2001). Dictionnaire des plantes médicinales du monde. Réalités et croyances. 25, 113, 249, 357, 374, 532 p. Corthout, J., Pieters, L., Claeys, M., Geerts, S., Vanden Berghe, D., Vlietinck, A. (1994). Antibacterial and molluscicidal phenolic acids from Spondias mombin. Planta Medica 60(5): 460-463. Corthout, J., Pieters, L., Claeys, M., Vanden Berghe, D., Vlietinck, A. (1992). Plant antiviral",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 914,
    "source": "PDF_chunked"
  },
  {
    "id": 5019,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1019)",
    "text": "from Spondias mombin. Planta Medica 60(5): 460-463. Corthout, J., Pieters, L., Claeys, M., Vanden Berghe, D., Vlietinck, A. (1992). Plant antiviral agents 9. Antiviral caffeoyl esters from Spondias mombin. Phytochemistry 31(6):1979-1981. Corthout, J., Pieters, L.A., Claeys, M., Vanden Berghe, D.A., Vli etinck, A.J. (1991). Plant antiviral agents. Part 8. Antiviral ellagitannins from Spondias mombin. Phytochemistry, 30(4): 1129-1130. Diallo, D ., Diakité, C., Mounkoro, P.P., Sangaré, D., Graz, B . et al . (2007). Knowledge of traditional healers on malaria in Kendie (Bandiagara) and Finkolo (Sikasso) in Mali. Mali Medical 22(4):1-8. Edeoga, H.O., Eriata, D.O. (2001). Alkaloid, tannin and saponin contents of some Nigerian medicinal plants. Journal of Medicinal and Aromatic Plant Sciences 23(3):344-349. El Fiki, N.M. (2000). Chemical composition and biological activity of Spondias lutea L. cultivated",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 910,
    "source": "PDF_chunked"
  },
  {
    "id": 5020,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1020)",
    "text": "medicinal plants. Journal of Medicinal and Aromatic Plant Sciences 23(3):344-349. El Fiki, N.M. (2000). Chemical composition and biological activity of Spondias lutea L. cultivated in Egypt Journal of Pharmaceutical Sciences 25:206-221. Gbolade, A.A ., Adeyemi, A.A. (2008) . Anthelmintic activities of three medicinal plants from Nigeria. Fitoterapia 79(3):223-225. Kerharo, J., Adam, J.G. (1974). Pharmacopée sénégalaise traditionnelle: Plantes medecinales et toxiques. Edit. Vigot Frères, Paris, 133, 583, 696, 750, 779 et 780 p.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 532,
    "source": "PDF_chunked"
  },
  {
    "id": 5021,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1021)",
    "text": "OOAS Page 215 Spondias mombin WAHP Moronkola, D., Kasali, A.A., Olusegun, E. (2003). Constituents of Spondias mombin L. and the comparison between its fruit and leaf essential oils. Journal of Essential Oil-Bearing Plants 6(3): 148-152. Uchendu, C.N ., Isek, T . (2008). Antifertility activity of aqueous ethanolic leaf extract of Spondias mombin (Anacardiaceae) in rats. African Health Science 8(3):163-167. .",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 410,
    "source": "PDF_chunked"
  },
  {
    "id": 5022,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1022)",
    "text": "OOAS Page 216 Tetrapleura tetraptera WAHP Nom botanique Tetrapleura tetraptera (Schum Thonn.) Famille Mimosaceae Synonyme Adenanthera tetraptera Schum.Thonn., Tetrapleura thornningii Benth Noms communs Tetrapleura pod Noms vernaculaires Ghana: Akan Prekese Nigeria: Yuroba Aridan, Hausa Kalangun daji, Igbo Shosho Description de la plante Arbre forestier à feuille de taille moyenne, d'environ 20 m de haut et 3 m de circonférence, avec un feuillage identique à celle de la fougère. Les feuilles sont de couleur vert -foncé, généralement dépourvu de contreforts, avec couronne mince, feuilles c omposées, bipennées, d'environ 5- 10 paires de folioles alternes: oblongue-elliptiques, sub- sessiles, pubescentes au niveau de la face inférieure; l'écorce est lisse, grisâtre, très mince, avec une entaille rougeâtre et une odeur forte, des brindilles prati quement glabres à poils minuscules et feuillage jeune",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 907,
    "source": "PDF_chunked"
  },
  {
    "id": 5023,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1023)",
    "text": "grisâtre, très mince, avec une entaille rougeâtre et une odeur forte, des brindilles prati quement glabres à poils minuscules et feuillage jeune avec tige commune de 15- 30 cm de long, légèrement canalisées sur la surface supérieure . Les feuilles sont de 6- 12 cm de largeur sur chaque côté de l'axe. Les folioles sont glabres avec des tiges minces d'environ 0,25 cm de long. Les nervures latérales sont indistinctes et fonctionnent à grand angle de la nervure médiane proéminente; il a une inflorescence en épi axillaire ; les fleurs sont de couleur crème ou rose, virant à l'orange, serrées les unes contre les autres en grappes spiciformes de 5- 20 cm de long, le plus souvent par paires à l'aisselle des feuilles supérieures. Les fleurs sont individuelles avec des tiges grêles d'environ 20 étamines courtes avec des fruits qui sont des gousses à côtés ailés, de 15-25 cm de long et environ 5 cm de diamètre persistants, suspendus à l'extrémité",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 5024,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1024)",
    "text": "avec des tiges grêles d'environ 20 étamines courtes avec des fruits qui sont des gousses à côtés ailés, de 15-25 cm de long et environ 5 cm de diamètre persistants, suspendus à l'extrémité des branches sur des tiges robustes Ces fruits sont sombres, brun- rougeâtre ou pourpre brun- foncé à noir à maturité, mais verdâtre lorsque imatures, glabres et luisantes, généralement courbée et d'environ 15 cm de long . Deux des ailes sont durs, ligneux et les deux autres sont remplis d'une pâte molle; d'une graine dure, noire, plate- ovale, d'environ 0,75 cm de long, intégré dans le corps de la nacelle, qui ne se fend pas, noir mais lumineux avec une robe- verte à l'intérieur de laquelle est contenue de l'huile (Burkill, 1995; Adjanahoun et al., 1991). Numéro du spécimen de l'herbier Ghana: GC 1274 Nigeria: FHI107427 Togo: TOGO04983 Habitat et répartition géographique T. tetraptera est commune dans la ceinture de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 918,
    "source": "PDF_chunked"
  },
  {
    "id": 5025,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1025)",
    "text": "Numéro du spécimen de l'herbier Ghana: GC 1274 Nigeria: FHI107427 Togo: TOGO04983 Habitat et répartition géographique T. tetraptera est commune dans la ceinture de la lisière forestière tropicale ouest -africaine, en particulier dans la forêt secondaire. L'espèce se retrouve dans toute la zone de forêt, dans le sud de la savane boisée, en particulier au Bénin, Burkina Faso, Cambodge, Cameroun, Tchad, Côte d'Ivoire, Gambie, Ghana, Guinée, Libéria, Mali, Mauritanie, Niger, Nigéria, Sénégal, Sierra Leone, le Togo et l'Ouganda (Burkill, 1995). Parties utilisées de la plante Fruit Autres parties utilisées Ecorce du tronc Caractéristiquesbotaniques Tetrapleura pod se compose des fruits secs de Tetrapleura tetraptera (Schum Thonn) Taub. (Mimosaceae). Utilisations ethno-médicales La plante est réputée être efficace dans la gestion des convulsions, de l'œdème de la lèpre, des douleurs rhumatismales, de l'asthme, de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 5026,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1026)",
    "text": "(Mimosaceae). Utilisations ethno-médicales La plante est réputée être efficace dans la gestion des convulsions, de l'œdème de la lèpre, des douleurs rhumatismales, de l'asthme, de la stérilité féminine et de l'inflammation. Le décocté de l'écorce est utilisé pour la toux, la bronchite, les règles douloureuses et l'arthrite, alors que le décocté de la racine est utilisé contre la jaunisse. L'extrait aqueux de coques est utilisé comme anticonvulsivant, tandis que sa pâte est utilisée",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 486,
    "source": "PDF_chunked"
  },
  {
    "id": 5027,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1027)",
    "text": "OOAS Page 217 Tetrapleura tetraptera WAHP pour traiter les rhumatismes. L'odeur intense sur la torréfaction est prétendue avoir des propriétés répulsives surles insectes et les serpents (Gill, 1992). Dans certaines parties de l'Afrique de l'ouest, le fruit sert d'épice ou comme sources multivitaminées. Dans les régions orientales du Nigeria, les fruits sont utilisés pour préparer des soupes pour nourrices, dès le premier jour de leur accouchement, afin d'éviter la contraction du post-partum. Activités biologiques et pharmacologiques Les saponines de T. tetraptera sont les plus puissants naturels parmi les molluscicides (Maillard et al. , 1989; Adewunmi et al. , 1982). Les extraits méthanoliques de la feuil le, des rameaux feuillus,, de l'écorce de tronc, de l'écorce de racine et des fruits possèdent une activité molluscicide (Adewunmi et al., 1999; Ngazzapa et al., 1989) contre une variété d'escargots d'eau douce, y compris Bulinus",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 5028,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1028)",
    "text": "l'écorce de racine et des fruits possèdent une activité molluscicide (Adewunmi et al., 1999; Ngazzapa et al., 1989) contre une variété d'escargots d'eau douce, y compris Bulinus globosus, Lymnaea natalensis, L. columelle, et Physa waterlotti (Adewunmi et Marquis, 1981; Adewunmi et al. , 1982; Adewunmi et al. , 1989). L'extrait aqueux de la plante est également efficace contre Bulinus globosus (Adewunmi et Marquis, 1987). L'application de l'extrait aqueux sur un site d'escargot infesté a réduit la population d'escargots sur le terrain et gardé les sites de transmission exempts de production de cercaires de schistosomes pendant environ 28 jours (Adewunmi, 1984; Adewunmi et Furu, 1989). Des études ont montré qu e la plantation de T. tetraptera le long des cours d'eau a le potentiel de contrôler localement la schistosomiase (Adewunmi, 1991). La saponine aridanine triterpénoïde est reconnue pour être responsable de l'activité molluscicide du fruit",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 5029,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1029)",
    "text": "potentiel de contrôler localement la schistosomiase (Adewunmi, 1991). La saponine aridanine triterpénoïde est reconnue pour être responsable de l'activité molluscicide du fruit (Adesina et Reisc h, 1985; Mailard et al., 1989). L'extrait de T. tetraptera affiche une activité anti - ulcère (Noamesi et al. , 1992), anticonvulsivante (Akah et Nwambie, 1993) et des propriétés d'émulsification (Olaifa et al., 1993). Les extraits alcooliques et aqueux ont inhibé la croissance de Staphylococcus aureus (Salako et al., 1990) et les extraits éthanolique et de saponines d'écorce de tronc ont montré un effet inhibiteur sur l'hormone lutéinisante libéré par les cellules hypophysaires (El Izzi et al., 1990), indiquant sa puissance comme agent contraceptif. Lacoque du fruit, la pulpe du fruit et les semences ont été reconnues pour contenir des quantités variables de nutriments comme les protéines, les lipides et les minéraux (Essien et al., 1994). Données cliniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 963,
    "source": "PDF_chunked"
  },
  {
    "id": 5030,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1030)",
    "text": "reconnues pour contenir des quantités variables de nutriments comme les protéines, les lipides et les minéraux (Essien et al., 1994). Données cliniques Aucune information disponible Constituants chimiques Les dérivés de l'acide aminopropionique; terpénoïdes (aridanin), alcaloïdes (mimosine), saponines, flavonoïdes, acide cinnamique, acide caféique, tanins, terpènes, huiles fixes, hydrate de carbone, et triglycoside (Adewunmi, 1999; Adesina et Reisch, 1985; Mailard et al . , 1989; Ngazzapa et al., 1989). Tests d'identité et de pureté Teneur en eau: pas plus de 6,65 Cendre totale: 20 Cendres soluble dans l'acide: pas plus de 7,51 Valeur substances extractibles par l'eau: pas moins de 10,30 Valeur substances extractibles par l'éthanol (70): pas moins de 13,60 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM ave phase stationnaire : gel de silice ( 0,25mm) G60F254 , et phase mobile: éther de pétrole (40- 60",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 5031,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1031)",
    "text": "Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM ave phase stationnaire : gel de silice ( 0,25mm) G60F254 , et phase mobile: éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldehyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à100- 110C pendant 5-10 mn. Macroscopie Fruits sombre brun avec surface rugueuse brillante; forme tétraédrique, 18- 24 cm de long, 5-6 cm de large; coriaces épicarpe avec mésocarpe et l'endocarpe charnue (Folorunso et al., 2005).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 627,
    "source": "PDF_chunked"
  },
  {
    "id": 5032,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1032)",
    "text": "OOAS Page 218 Tetrapleura tetraptera WAHP Chromatogramme Microscopie La section transversale montre un épicarpe avec des cellules épidermiques unisériées qui sont polygonale, angulaires et des lamelles de collenchymes; épaissies, lignifiées, des cellules sclerenchymateuses, macroscléréides et ostéoscléréides bien épaissi es et lignifiées; des chromoplastes et chloroplastes en dessous de l'épicarpe, des fibres de mésocarpe bien allongées, substances ergastiques présentes; un endocarpe rempli de cellules parenchymateuses polygonales et macroscléréides; la coupe longitudinale montre l'épiderme; l'épicarpe est rempli de macroscléréides et osteoscléréides, lamelles de collenchymes et angulaire; parenchyme, polygonale avec des cristaux en grains de sable, des grains d'amidon et de cristaux du genre des cactacées; faisceaux collatéraux vasculaires et cellules parenchymateuses polygonales dans l'endocarpe (Folorunso et autres, 2005).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 5033,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1033)",
    "text": "cristaux du genre des cactacées; faisceaux collatéraux vasculaires et cellules parenchymateuses polygonales dans l'endocarpe (Folorunso et autres, 2005). Matériel végétaleen poudre La poudre est constituée de cellules du parenchyme, allongées àparois extrêmes largeset obliques ;les cellules tangentiel les et les fibresdu collenchyme allongées sont présentes; les ostéoscléroses, les substances ergastiques, les cristaux trieèdriques d'oxalate de calcium, les tanins et des cristaux en grains de sable sont abondants (Folorunso et al., 2005). Actions thérapeutiques Molluscicide, antihypertenseurs, anti -ulcéreux anticonvulsivant, anti -diabétique et anti - oxydantes. Indications thérapeutiques Convulsions, de l'hypertension, le diabète, l'ulcère; schistosomiase. Données de sécurité La DL50 de l'extrait aqueux de feuilles (po) a été trouvé pour être 3000 mg kg chez le rat. Dans les études de toxicité subaiguë (300- 3000 mg",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 5034,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1034)",
    "text": "Données de sécurité La DL50 de l'extrait aqueux de feuilles (po) a été trouvé pour être 3000 mg kg chez le rat. Dans les études de toxicité subaiguë (300- 3000 mg kg), aucun changement significatif n'a été observé dans le poids corporel des animaux au cours de la période de traitement. Il y avait réduction significative du poids relatif du foie et des poumons des animaux traités. Nombre WBC et RBC et le contenu HB a également augmenté. Aucun effet indésirable significatif n'a été observé sur le foie et les reins. Précautions d'emploi Aucunes précautions spéciales requises dans la dose recommandée de l'extrait aqueux. Effets indésirables Des doses élevées peuvent causer des nausées et des vomissements. Contre-indications Patients sensibles à son odeur particulière. Dosage et forme galénique Infusion: environ 25 g par jour Décoction: 300 g du fruit écrasé et bouilli avec 900 ml jusqu'à réduction à 600 ml; prendre deux",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 5035,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1035)",
    "text": "Dosage et forme galénique Infusion: environ 25 g par jour Décoction: 300 g du fruit écrasé et bouilli avec 900 ml jusqu'à réduction à 600 ml; prendre deux (2) cuillerées à soupe deux fois par jour Teinture: 1:5, alcool à 90 de 0,3- 1,2 ml, à 25 ml max par semaine Conservation A conserver dans un endroit frais et sec, protégé de l'humidité et la lumière. Références Adesina, S. K., Reisch, J. (1985). A triterpenoid glycoside from Tetrapleura tetraptera fruit. Phytochemistry 24:3003-3006. Adewunmi, C.O. (1984). Water extract of Tetrapleura tetraptera: An effective molluscicide for the control of Schistosomiasis and fascioliasis in Nigeria. Journal of Animal Product Research 4(1):7384. Adewunmi C. O. (1999). Medicinal Plants, Parasites and Snails in Health. Inaugural Lecture, Series 132, Obafemi Awolowo University, Ile-Ife, Nigeria. Adewunmi, C.O. Furu, P. (1989). Evaluation of aridanin, a glycoside, and Aridan, an aqueous",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 932,
    "source": "PDF_chunked"
  },
  {
    "id": 5036,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1036)",
    "text": "Lecture, Series 132, Obafemi Awolowo University, Ile-Ife, Nigeria. Adewunmi, C.O. Furu, P. (1989). Evaluation of aridanin, a glycoside, and Aridan, an aqueous extract of Tetrapleura tetraptera fruit, on Schistosoma mansoni and S. bovis . Journal of Ethnopharmacology 27: 277-283.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 279,
    "source": "PDF_chunked"
  },
  {
    "id": 5037,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1037)",
    "text": "OOAS Page 219 Tetrapleura tetraptera WAHP Adewunmi, C.O., Marquis, V.O. (1981). Laboratory evaluation of the molluscicidal properties of aridan, an extract from Tetrapleura tetraptera (Mimosaceae) on Bulinus globosus. Journal of Parasitology 67:713716. Adewunmi, C.O., Furu, P., Masen, H. (1 989). Evaluation of the effects of low concentrations of aridanin isolated from Tetrapleura tetraptera Taub. (Mimosaceae) on the growth and egg production of Biomphalaria glabrat and Lymnaea columella. Phytotherapy Research 3:8184. Adewunmi, C.O., Adesin a, S.K., Marquis, V.O. (1982). On the Laboratory and Field Evaluation of the Molluscicidal Properties of Tetrapleura tetraptera. Bulletin of Animal Health and Production in Africa 30:89-94. Adewunmi, C.O. (1991). Plant molluscicides Potential of Aridan, Tetrapleura tetraptera for schistosomiasis control in Nigeria. The Science of Total Environment 102: 21-33. Adjanohoun, E. et al (1991). Contribution to",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 5038,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1038)",
    "text": "Potential of Aridan, Tetrapleura tetraptera for schistosomiasis control in Nigeria. The Science of Total Environment 102: 21-33. Adjanohoun, E. et al (1991). Contribution to Ethnobotanical and floristic studies in Western Nigeria Published by the Organization of African Unity's Scientific, Technical and Research Commission, Lagos, Nigeria. Aka, P.A., Nwabie, A.I. (1993). Use of T. tetraptera as anti-convulsant. Fototerapia 64:42. Burkill, H.M. (1995). The Useful Plants of West Tropical Africa Vol. 3, 2 nd Edition Families J L, Royal Botanic Gardens, Kew. London. Essien, E .U., Izunwane, B.C., Aremu, C. Y., Eka, O. U. (1994). Significance for humans of the nutrient contents of the dry fruit of Tetrapleura tetraptera. Plant Food Human Nutrition 45 (1): 47-51. Folorunso, A.E., Elujoba A.A., Omobuwajo, O.R. (2005). Technical Report of commissioned macroscopical evaluation of the fruit pod of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 900,
    "source": "PDF_chunked"
  },
  {
    "id": 5039,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1039)",
    "text": "tetraptera. Plant Food Human Nutrition 45 (1): 47-51. Folorunso, A.E., Elujoba A.A., Omobuwajo, O.R. (2005). Technical Report of commissioned macroscopical evaluation of the fruit pod of Tetrapleura tetraptera pod. S ubmitted to the World Health Organization, Nigeria. Gill, L. S. (1992). Ethnomedical Uses of Plants in Nigeria published by University of Benin Press, Benin City, Nigeria. Maillard, M., Adewumi, C. O., Hostettman, K. (1989). New triterpenoid N -acetylglycosides with molluscicidal activity from Tetrapleura tetraptera Taub. Helv. Chim. Acta 72:668-673. Ngazzapa O. D. et al. (1989). Bulletin of chemical Society 31:91-96. Noamesi, B.K., Mensah, J.F., Dagne, E., Bogale, M. (1992). Effect of Tetrapluera tetraptera: seventh symposium on medicinal plants, spices and other natural products: Abstract No Wp -20, Manila. Salako, Q., Akpau, U.E., Ette, E.I., Essien, E.E., Ipeaiyeda, O. (1990). Fitoterapia 61: 169-171.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 5040,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1040)",
    "text": "OOAS Page 220 Tinospora bakis WAHP Nom botanique Tinospora bakis (A. Rich) Miers Famille Menispermaceae Synonyme Cocculus bakis A. Rich Noms communs Tinospora Noms vernaculaires Burkina Faso : Mooré Bésindé, Fulfuldé Bakañi;bakañé Ghana: Kusasi Ba Ila Nigéria: Igbo Aga Oyi Sénégal: WolofBakis, Sérère-Péis,PeuhlAbolo Description de la plante C'est une herbacée tortillant ou une plante vivace arbustive atteignant 10-15 m de haut; les tiges sont grimpantes, glabres et garnies de très grandes lenticelles blanches, avec racines tubéreuses; la sève est translucide; les feuilles simples et alternes, largement ovées; àbase cordée; sommet peu acuminé; pétiole de 2 à 8 cm de long; fleurs jaunes verdâtres, disposées en grappes axillaires mesurant 3 à 10 cm de long; fleurs mâles de petite taille, avec 9 cm de long sur 4 à 5 mm de large, arrondi à trois sépales supportés sur des pédoncules de 3 à 5",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 898,
    "source": "PDF_chunked"
  },
  {
    "id": 5041,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1041)",
    "text": "en grappes axillaires mesurant 3 à 10 cm de long; fleurs mâles de petite taille, avec 9 cm de long sur 4 à 5 mm de large, arrondi à trois sépales supportés sur des pédoncules de 3 à 5 mm; les fruit s sont de petites baies verdâtres; ovales, de 1 cm de long avec un léger renflement à la base, apicule au sommet et pédicelles de 8 à 10 mm. Numéro de spécimen d'herbier Mali: 1787 DMT Togo: TOGO04726 Habitat et répartition géographique La plante est éparpillée sur les rives des cours d'eau dans certaines parties de l'Afrique sub- saharienne, et l'on la rencontre fréquemment au Sénégal, au Mali, en Mauritanie, au Niger, dans le nord du Nigeria, dans l'est du Soudan, en Ethiopie et en Angola. Parties utilisées de la plante Racinerhizome Autres parties utilisées Aucune Caractéristiques botaniques Le Tinospora se compose de la racinerhizome de Tinospora bakis (A. Rich) Miers (Menispermaceae). Utilisations ethnomédicales",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 5042,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1042)",
    "text": "Aucune Caractéristiques botaniques Le Tinospora se compose de la racinerhizome de Tinospora bakis (A. Rich) Miers (Menispermaceae). Utilisations ethnomédicales La plante est utilisée par voie orale pour le traitement de la jaunisse, la fièvre, le paludisme grave, les troubles menstruels, la schistosomiase, la dermatite et une mauvaise vision (Oyen, 2008; Kerharo et Adam, 1974). Activités biologiques et pharmacologiques Les extraits de la racine ont montré une activité cholérétique importante et une activité de protection contre la toxicité du tétrachlorure de carbone aiguë et subaiguë chez le rat (Fall et al., 2010; Thioune et al., 2002; Kamssouloum et al., 1988). Diallo et al., (1997) ont démontré l'effet hépatoprotecteur in vitro des extraits de racines; les extraits de racine ont augmenté la sécrétion de la bile à des faibles doses, mais ont causé une toxicité à des doses élevées. Les extraits aqueux et les alcaloïdes totaux, y compris le",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 5043,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1043)",
    "text": "les extraits de racine ont augmenté la sécrétion de la bile à des faibles doses, mais ont causé une toxicité à des doses élevées. Les extraits aqueux et les alcaloïdes totaux, y compris le palmatine, ont montré une activité antipyrétique in vivo (Zafinindra et al. 2003) et une activité modérée contre une souche résistante à la chloroquine du Plasmodium falciparum (Ouattara et al ., 2006). Les extraits de racines ont également montré une acti vité immunmodulatoire in vitro (Koko et al., 2008). Données cliniques Aucune information disponible Constituants chimiques Alcaloïdes (palmatine, ancolie), ( Oyen, 2008), glycosides stéroïdiens, saponines, tanins, coumarines, anthocyanes, caroténoïdes, ac ides gras, polysaccharides et sucres réducteurs.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 750,
    "source": "PDF_chunked"
  },
  {
    "id": 5044,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1044)",
    "text": "OOAS Page 221 Tinospora bakis WAHP Tests d'identité et de pureté Teneur en eau: 9,59 Cendre totale: 4,76 Cendre sulfatée: 6,66 Valeur subtances extractibles par l'eau: 18,87 à 24,55 Valeur subtances extractibles par l'éthanol (70) d'extraction: pas moins de 20,10 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25mm) G60F254, et phase mobile: éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d 'acide sulfurique concentré, puis chauffé à 100- 110C pendant 5-10 mn. Présence de trois taches distinctes avec R f de 0,48 (violet), 0,35 (violet) et 0,24 (bleu-noir). Chromatogramme Macroscopie Les racines sont tubéreuses et les feuilles ont un goût amer et une odeur particulière. Microscopie",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 913,
    "source": "PDF_chunked"
  },
  {
    "id": 5045,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1045)",
    "text": "f de 0,48 (violet), 0,35 (violet) et 0,24 (bleu-noir). Chromatogramme Macroscopie Les racines sont tubéreuses et les feuilles ont un goût amer et une odeur particulière. Microscopie Présence de nombreux grains d'amidon de taille variable, plus ou moins arrondis ; mi crocristaux absents ou très rares; présence d'amidon, poils épidermiques présents sur les deux faces de la feuille. Matériel végétal en poudre Poudre de racines séchées très fine, couleur ivoire; goût amer; nombreux grains d'amidon; poils tecteurs intégrés dans les cellules épidermiques à parois ondulées. Nombreuses cellules de parenchyme, présence de vaisseaux réticulés non lignifiés. Actions thérapeutiques Anti-ictère, hépatoprotecteur, antipyrétique, antipaludique. Indications thérapeutiques Jaunisse, paludisme, hépatite, fièvre Données de sécurité La DL 50 de l'extrait aqueux du rhizome ( p.o) chez la souris était 2000 mgkg en 24 heures. Aucun",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 5046,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1046)",
    "text": "Indications thérapeutiques Jaunisse, paludisme, hépatite, fièvre Données de sécurité La DL 50 de l'extrait aqueux du rhizome ( p.o) chez la souris était 2000 mgkg en 24 heures. Aucun signe clinique de toxicité n'a été observé après le traitement des souris mâles et femelles (500 à 2000 mgkg; p.o) pendant 14 jours. Les tests de toxicité sur les alcaloïdes totaux ont montré qu'une dose de 5 mgkg administrées par voie orale n'était pas toxique pour les cobayes, alors qu'une dose de 100 mgkg a causé la mort en 20 minutes sans convulsion (Oyen, 2008). Précautions d'emploi Ne pas dépasser les doses prescrites à cause des effets toxiques. Effets indésirables La racine peut provoquer des effets toxiques tels que les vomissements et une dépression de l'appareil respiratoire. Contre-indications Grossesse Dosage et formegalénique Décoction: 200 g du matériel végétal en poudre, bouilli avec 1000 ml d'eau jusqu'à réduction de la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 5047,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1047)",
    "text": "l'appareil respiratoire. Contre-indications Grossesse Dosage et formegalénique Décoction: 200 g du matériel végétal en poudre, bouilli avec 1000 ml d'eau jusqu'à réduction de la quantité à 600 ml; prendre deux (2) cuillerées à soupe deux fois par jour. Conservation A conserver dans un endroit frais et sec, à l'abri de la lumière.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 331,
    "source": "PDF_chunked"
  },
  {
    "id": 5048,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1048)",
    "text": "OOAS Page 222 Tinospora bakis WAHP Références Diallo, S.A ., Niang, N.M., Ndiaye, A.K ., Dieng, C., Faye, B. (1997). Effet hépatoprotecteur d'une plante de la pharmacopée Sénégalaise: Tinospora bakis (Menispermaceae) en utilisant le modèle in vitro. Dakar Medical 42(1):15-18. Fall, A.D., Lapo, R.A., Barry, A.Y., Diatta, W., Diatta, K. et al . (2010). Activite choleretique de l'extrait aqueux des racines de Tinospora bakis (a. Rich) Miers chez le rat : recherche des fractions actives. Dakar Médical. Kamssouloum, T.M.A., Faye, B., Bas sene, E., Afoutou, J.M. (1988). Contribution à l'étude de l'action hépatoprotectrice de Tinospora bakis (Miers) (Menispermaceae ). Afrique Médicale XXVII (266):401-406. Kerharo, J., Adam (1974). La pharmac opée sénégalaise traditionnelle; plantes médicinales et toxiques.- Ed. Vigot Frères, Paris VIe, 1011p. Koko, W.S., Ahmed, M., Yousaf S., Galal, M., Iqbal Choudhary, M. (2008). In vitro",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 5049,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1049)",
    "text": "sénégalaise traditionnelle; plantes médicinales et toxiques.- Ed. Vigot Frères, Paris VIe, 1011p. Koko, W.S., Ahmed, M., Yousaf S., Galal, M., Iqbal Choudhary, M. (2008). In vitro immunomodulating properties of selected Sudanese medicinal plants. Journal of Ethnopharmacology 118:2634. Ouattara Y., Sanon, S. Traoré, Y., Mahiou, V., AzasN. And Sawadogo L. (2006). Antimalarial activity of Swartzia madagascariensi s Dev. (Legumineuseae), Combretum glutinosum Guill Perr (Combretaceae) and Tinospora bakis, (Menispermaceae), Burkina Faso medicinal plants. African Journal of Traditional, Complementary and alternative Medicine 3(1): 7581. Oyen, L.P.A. (2008). Tinospora bakis (A.Rich.) Miers. In: Schmelzer, G.H. Gurib- Fakim, A. (Editeurs). Prota 11(1): Medicinal plantsPlantes médicinales 1. CD -Rom. PROTA, Wageningen, Pays Bas. Thioune, O ., Sene, C.T ., Ngom, S ., Diop, A.B .,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 881,
    "source": "PDF_chunked"
  },
  {
    "id": 5050,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1050)",
    "text": "(Editeurs). Prota 11(1): Medicinal plantsPlantes médicinales 1. CD -Rom. PROTA, Wageningen, Pays Bas. Thioune, O ., Sene, C.T ., Ngom, S ., Diop, A.B ., Bassene, E., Faye, B., Lo, I. (2002). Preparation of a syrup with Bakis roots ( Tinospora bakis) and evaluation of its choleretic activity in rats. Dakar Medical 47(1):60-63. Zafinindra, L.R ., Diatta, W ., Dieye, A.M ., Nongonierma, R ., Faye, B., Bassene, E. (2003). Antipyretic effect of aqueous extract and alcaloid of Tinospora bakis (Miers) in rabbits. Dakar Medical 48(1):29-33.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 538,
    "source": "PDF_chunked"
  },
  {
    "id": 5051,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1051)",
    "text": "OOAS Page 223 Vernonia amygdalina WAHP Nom botanique Vernonia amygdalina Del Famille Asteraceae Synonyme Vernonia senegalensis A Chev. Noms communs Feuille amère Noms vernaculaires Benin: Tem Aloma Ghana: Adangme Agba, Akan Bowin, Guanga Gonja Saŋka Guinée: Fula Pulaar Bantara Burure, Manding Maninka Kossa Fina. Nigéria: Hausa Chusar Doki, Igbo Olugbu, Yoruba Ewuro Jije. Sierra Leone : Krio Bita-Lif, Mende Nje Nyani, Temne A-Bita-Lif Togo: Ewe AVenya, Tem Tusima Description de la plante C'est un arbuste ou petit arbre, de 2- 5 m de haut avec des branches striées, pubescentes , devenant glabres à maturité; les feuilles sont alternes, obovales -lancéolées, entières ou finement dentées, pubescentes à la base avec des fleurons au sommet mesurant 6 mm de diamètre, de même que de nombreuses panicules corymbes, des pappus blancs et un parfum agréable. Numéro du spécimen de l'herbier Ghana: GC 52083",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 904,
    "source": "PDF_chunked"
  },
  {
    "id": 5052,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1052)",
    "text": "des fleurons au sommet mesurant 6 mm de diamètre, de même que de nombreuses panicules corymbes, des pappus blancs et un parfum agréable. Numéro du spécimen de l'herbier Ghana: GC 52083 Nigeria: FH108988 Habitat et répartition géographique On le trouve sous les tropiques, le long des clôtures des maisons et dans les villages, comme plantes médicinales et plante de pot. Il se développe dans un style commun aux zones écologiques d'Afrique et est sensible à la sécheresse (Bonsi et al. 1995). Parties utilisées de la plante Feuilles Autres parties utilisées Rameaux jeune tige, racine Caractéristiques botaniques La feuille fraîche ou séchée de Vernonia amygdalina Del (Asteraceae) est amère. Utilisations ethnomédicales La plante est utilisée dans plusieurs pays pour le traitement de la schistosomiase, de la dysenterie amibienne, des douleurs abdominales, de la fièvre résultant du paludisme, la toux et comme",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 912,
    "source": "PDF_chunked"
  },
  {
    "id": 5053,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1053)",
    "text": "La plante est utilisée dans plusieurs pays pour le traitement de la schistosomiase, de la dysenterie amibienne, des douleurs abdominales, de la fièvre résultant du paludisme, la toux et comme laxatif (Huffman et al.,1996; Dalziel, 1937). Le V. amygdalina est communément appelée feuille amère en raison de son goût amer. Activités biologiques et pharmacologiques Les extraits des feuilles et des écorces de racines ont montré une activité antipaludique et antiplasmodiale contre souches de Plasmodium berghei sensibles aux médicaments de chez la souris (T ona et al., 2004; Abosi et Raseroka, 2003). Certains sesquiterpènes et constituants stéroïdiens présentent une activité antiplasmodiale in vitro (Phillipson et al., 1993); Les lactones sesquiterpènes, les vernolides et vernodalols ont démontré une activité bactéricide et antifongique significative (Erasto et al., 2006). Les extraits de feuilles contenant de la lutéoléine",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 5054,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1054)",
    "text": "vernodalols ont démontré une activité bactéricide et antifongique significative (Erasto et al., 2006). Les extraits de feuilles contenant de la lutéoléine ont montré les propriétés antioxydantes in vitro (Igile et al ., 1994) et les extraits éthanoliques des racines assurent une protection contre la létalité induite par le pentylénététrazole. Les extraits ont également des effets antipyrétique et analgésique (Okokon et Onah, 2004). Divers extraits de V. amygdalina ont démontré qu'ils possèdent des propriétés antibactérienne et antileishmanienne, antimutagène, antioxydante et anti-cancereuse (Erasto et al ., 2007;Izevbige, 2003; Iwalokun et al ., 2003;. Akinpelu 1999; Obaseiki-Ebor et al., 1993;. Tadesse et al ., 1993). Le composé d'élamanolide a des propriétés répulsives sur les insectes (Ganjian, 1983). Des extraits de feuilles de la plante ont montré une activité inhibitrice contre le Trichomonas vaginalis (Hakizamungu et al.,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 942,
    "source": "PDF_chunked"
  },
  {
    "id": 5055,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1055)",
    "text": "propriétés répulsives sur les insectes (Ganjian, 1983). Des extraits de feuilles de la plante ont montré une activité inhibitrice contre le Trichomonas vaginalis (Hakizamungu et al., 1992). Le vernodaline et le vernolide ont des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 228,
    "source": "PDF_chunked"
  },
  {
    "id": 5056,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1056)",
    "text": "OOAS Page 224 Vernonia amygdalina WAHP propriétés antitumorales contre les cellules leucémiques (Jisaka et al., 1993), tandis que leurs extraits bruts empêchent la croissance des cellules cancéreuses de la prostate (Izevbigie, 2003). Les extraits aqueux de feuilles contenant des peptides et édotides empêchent la croissance des cellules cancéreuses du sein (Atanaskova et al., 2002; Mandlekar et Kong, 2001). L'extrait chloroformique riche en sesquiterpénone a montré une activité cytotoxique dans les cellules nasopharynx carcinome de l'homme (Kupchan et al ., 1969). L'extrait aqueux a provoqué une augmentation de la production d'acide et entraîné la contraction de l'iléon de cobaye (Owu et al., 2008). Les extraits aqueux des feuilles de la plante réduisent la glycémie chez les lapins normoglycémiques et chez ceux rendus diabétiques par l'alloxane (Akah et Okafor, 1992) de même chez les rats et souris rendus diabétiques par la STZ (NIPRD Rapport",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 955,
    "source": "PDF_chunked"
  },
  {
    "id": 5057,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1057)",
    "text": "normoglycémiques et chez ceux rendus diabétiques par l'alloxane (Akah et Okafor, 1992) de même chez les rats et souris rendus diabétiques par la STZ (NIPRD Rapport technique, 2006). Un extrait méthanolique des feuilles de V. amygdalina a montré un effet carthatique chez la souris au repas test du charbon de bois (Awe et al., 1999). Données cliniques Aucune information disponible Constituants chimiques Lactones sesquiterpènes (vernolépine vernolide et vernodalol), tannins, flavonoïdes (lutéoléines), saponines (vernoniosides), alcaloïdes, calcium, aminoacides, vitamine C (Masaba, 2000; Saye d et al., 1982). Tests d'identité et de propriété Teneur en humidité: 8,30 Centre totale: 12,5 Valeur substances extractibles par l'eau: pas moins de 20,50 Valeur substances extractibles par l'éthanol (70): pas moins de 17,01 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 5058,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1058)",
    "text": "moins de 20,50 Valeur substances extractibles par l'éthanol (70): pas moins de 17,01 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60 F254, et phase mobile : éther de pétrole (40- 60oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10 mn. Présence de quatre taches distinctes avec valeurs de R f 0.68 (brun brillant), 0.40 (rose), 0.28 (violet) et 0.24 (violet). Chromatogramme Macroscopie Feuille simple pétiolée de forme elliptique avec sommet acuminé; une base symétrique atteignant 17 cm de long sur 8 cm de large; à marge de scie irrégulière dentée; la nervation est réticulée avec une texture fine similaire au papier (sec); elle est de couleur verte avec une odeur",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 5059,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1059)",
    "text": "marge de scie irrégulière dentée; la nervation est réticulée avec une texture fine similaire au papier (sec); elle est de couleur verte avec une odeur spécifique et un goût amer (GHP, 2007). Microscopie La vue d'ensemble montrent des cellules épidermiques à parois presque droites sur les deux surfaces; la surface supérieure a quel ques stomates anomocytiques, quelques poils, pluriicellulaires unisériées, glandulaires à têtes ovales, des poils tecteurs coniques; des poilsglandulaires bicellulaires sessiles, une surface inférieure avec de nombreux stomates anomocytiques et certains stomates anisocytiques avec des cellules épidermiques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 640,
    "source": "PDF_chunked"
  },
  {
    "id": 5060,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1060)",
    "text": "OOAS Page 225 Vernonia amygdalina WAHP plus petites, une cuticule striée, de nombreux poils pluricellulaires, glandulaires unisériées; la section transversale présente une disposition dorsoventrale de cellules épidermiques avec une ligne droite de parois anticlinales rayées sur les deux surfaces et contenant du mucilage; une seule couche des cellules palissadiques a été interrompue dans la région de la nervure centrale par les cellules collenchymateuses; le mésophylle spongieux occupe le r este de l'espace de la lamina saine et les faisceaux vasculaires présents dans les veines et veinules; les cristaux en rosette et les grains d'amidon isolés se trouvent dans les cellules du mésophylle spongieux; les faisceaux vasculaires sont collatéraux avec des tissus lignifiés du xylème (BPH, 2007) . Matériel végétal en poudre Il est de couleur verte avec une odeur spécifique et un goût amer; des fragments de limbe qui montrent des stomates anomocytique et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 958,
    "source": "PDF_chunked"
  },
  {
    "id": 5061,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1061)",
    "text": "xylème (BPH, 2007) . Matériel végétal en poudre Il est de couleur verte avec une odeur spécifique et un goût amer; des fragments de limbe qui montrent des stomates anomocytique et anisocytique; des cellules parenchymateuses de palissade, une cuticule striée; unisériée, bicellulaire, multicellulaire, des poils tecteurs glandulaires, de nombreux fragments de poils; des cristaux en rosette; des grains d'amidon; des fragments de veinules avec des éléments lignifiées de xylème. Actions thérapeutiques Analgésique; antibactérien; anticancéreux; antidiabétique; antifongique; antihelminthique; anti-inflammatoire; antipaludique; antioxydant; antipyrétique; antitumorale; diurétique. Indications thérapeutiques Douleur abdominale; asthme, troubles cutanées bactériennes et fongiques, constipation, diabète, fièvre, maux de tête, helminthiases, paludisme, oligurie; prurit; psoriasis; teigne; infections des voies respiratoires (BPH, 2007;Mshana et al., 2000).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 5062,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1062)",
    "text": "fièvre, maux de tête, helminthiases, paludisme, oligurie; prurit; psoriasis; teigne; infections des voies respiratoires (BPH, 2007;Mshana et al., 2000). Données de sécurité La LD50 de l'extrait aqueux de feuille (p.o) s'est avéré 3000 mgkg chez les rats. On a observé la toxicité aiguë sous forme de défécation, salivation, urination (signes cholinergiques) après administration d'une dose unique de l'extrait. La réduction du poids relatif du foie, du rein, des poumons et du cœur ont été enregistrés à des doses 1000 mgkg. On a observé une augmentation du WBC, RBC, MCV et des plaquettes. Les fonctions hépatique et rénale étaient affectées à 3000 mgkg, comme en témoigne les niveaux élevées de créatinine, d'ALPE, de GGT, d'urée et de sérum. Les sous- études de toxicités aiguës (administration par voie orale quotidienne de 750,1500, 3000 mgkg pendant 28 jours) et l'évaluation sous-chronique de toxicité (administration par voie orale",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 5063,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1063)",
    "text": "études de toxicités aiguës (administration par voie orale quotidienne de 750,1500, 3000 mgkg pendant 28 jours) et l'évaluation sous-chronique de toxicité (administration par voie orale quotidienne de 750,1500, 3000 mgkg pendant 90 jours) ont plus loin confirmé que la sécurité de la plante depuis les organestissus (foie, cerveau, rein, cœur, rate, intestin, estomac, testicules et poumons) n'ont pas été compromises particulièrement aux doses modérées. L'examen histopathologique de quelques organestissus (cerveau, poumon, intestin, testicules) a montré seulement une pathologie mineure à 1500 et 300 mgkg. De tels changements étaient également présents dans certains des animaux témoins . Une certaine observation suggestive de lésion hépatocellulaire comme indiqué par l'élévation d 'activité enzymatique d'ALT et d'AST n'a pas été concluante (rapport technique de NIPRD, 2006). Précautions d'emploi Prendre soin du rein et des maladies du foie.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 5064,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1064)",
    "text": "enzymatique d'ALT et d'AST n'a pas été concluante (rapport technique de NIPRD, 2006). Précautions d'emploi Prendre soin du rein et des maladies du foie. Effets indésirables La venonine a une activité cardiaque et toxique sur les souris et les chiens (Abbiw 1990). Contre-indications Grossesse et allaitement, ulcère gastrique; néphrite, insuffisance rénale et hépatique. Dosage et forme galénique Décoction: faire bouillir 40 g de feuilles séchées par litre d'eau pendant 15 minutes; boire 4 verrethé trois fois par jour Teinture: 1:5 dans 30 d'éthanol, prendre 5 ml trois fois par jour Conservation A conserver dans un endroit frais et sec. Références Abbiw, K. (1990). Useful plants of Ghana: West African uses of wild and cultivated plants. Intermediate Technology Publications, London. Abosi, A.O. , Raseroka, B.H. (2003). In vivo antimalarial activity of Vernonia amygdalina. British Journal of Biomedical Scieice 60(2): 89- 91.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 5065,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1065)",
    "text": "Intermediate Technology Publications, London. Abosi, A.O. , Raseroka, B.H. (2003). In vivo antimalarial activity of Vernonia amygdalina. British Journal of Biomedical Scieice 60(2): 89- 91. Akah, P.A, Okafor, C.L (1992). Blood sugar Lowering Effect of Vernonia amygdalina Del. In an experimental rabbit model. Phytotherapy Research 6:171-173.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 342,
    "source": "PDF_chunked"
  },
  {
    "id": 5066,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1066)",
    "text": "OOAS Page 226 Vernonia amygdalina WAHP Akinpelu, D.A. (1999). Antimicrobial activity of Vernonia amygdalina leaves. Fitoterapia 70:432- 434. Atanaskova, N., Keshamouni, V.G., Krieger, J.S., Schwartz, J.A., Miller, F., et al . (2002). MAP kinasesoestrogen receptor cross -talk enhances oestrogen-mediated signalling and tumour growth but does not confer tamoxifen resistance. Oncogene 21:4000-4008. Awe, S.O., Makinde, J.M., Olajide, O.A. (1999). Cathartic effect of the leaf extract of Vernonia amygdalina. Fitoterapia 70:161-165. Bonsi, M.L.K., Osuji, P.O., Tuah, A.K., Umunna, N.N. (1995). Vernonia amygdalina as a supplement to teff str aw (Eragrostis tef.) fed to Ethiopian Menz sheep. Agroforestry Systems 31(3): 229-241. Dalziel, J.M. (1937). The Useful Plants of West Tropical Africa. London: Crown Agents for the Colonies, 421-422. Erasto, P., Grierson, D.S., Afolayan, A.J. (2007). Evaluation of antioxidant activity and the fatty",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 939,
    "source": "PDF_chunked"
  },
  {
    "id": 5067,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1067)",
    "text": "Tropical Africa. London: Crown Agents for the Colonies, 421-422. Erasto, P., Grierson, D.S., Afolayan, A.J. (2007). Evaluation of antioxidant activity and the fatty acid profile of the leaves of Vernonia amygdalina growing in South Africa. Food Chemistry 104:636642. Erasto, P., Grierson, D.S., Afolayan, A.J. (2006). Bioactive sesquiterpene lactones from the leaves of Vernonia amygdalina. Journal of Ethnopharmacology 106:117120. Ganjian, I., Kubo, I., and Fludzinsky, P. (1983). Insect antifeedant elamnolide lactone from Vernonia amygdalina. Phytochem. 22, 2525- 2526, cited by Jain and Tripathi, 1993. Ghana Herbal Pharmac opoeia (2007),30- 34.QualiType limited: Accra, Ghana. Hakizamungu, E., Van Puyvelde, I., Wery, M. (1992). Screening of Rwandese Medicinal plants for anti -trichomonas activity. Journal of Ethnopharmacology 36: 143-146. Huffman, M.A., Koshimizu, K., Ohigashi, H. (1996). Ethnobotany and zoopharmacognosy of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 933,
    "source": "PDF_chunked"
  },
  {
    "id": 5068,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1068)",
    "text": "for anti -trichomonas activity. Journal of Ethnopharmacology 36: 143-146. Huffman, M.A., Koshimizu, K., Ohigashi, H. (1996). Ethnobotany and zoopharmacognosy of Vernonia amygdalina, a medicinal plant used by humans and chimpanzees. In: Compositae: Biology and Utilization, Caligari, P.D.S. Hind, D.J.N. (eds), 2, 351-360. Igile, G.O., Oleszek, W., Jurzysta, M., Bu rda, S. et al., (1994). Flavonoids from Vernonia amygdalina and their antioxidant activities. Journal of Agriculture and Food Chemistry 42:2445-2448. Iwalokun, B.A., Bamiro, S.B. , Durojaiye, O.O. (2003). An Antimicrobial Evaluation of Vernonia amygdalina (Compositae) Against Gram -positive and Gram-negative Bacteria from Lagos, Nigeria. West African Journal of Pharmacology and Drug Research 19:9-15. Izevbige, E.B. (2003). Discovery of water soluble anticancer agents (Edotides) from a vegetable found in Benin city, Nigeria. Experimental Biology and Medicine, 228: 293-298.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 5069,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1069)",
    "text": "Izevbige, E.B. (2003). Discovery of water soluble anticancer agents (Edotides) from a vegetable found in Benin city, Nigeria. Experimental Biology and Medicine, 228: 293-298. Jisaka, M. Takagaki, T., Nozaki, H., Tada, T. et al., (1993). Steroid glycosides from Vernonia amygdalina. a possible chimpazee medicinal plant. Phytochemistry 34: 409-413. Kupchan, S.M. , Hemingway, R.J., Karim, A., Werner, D. (1969). Tumour inhibitors. XLVII. Vernodalin and vernomygdin, two new cytotoxic sesquiterpene lactones from Vernonia amygdalina del. Journal of Organic Chemistry 34:3908 - 3911. Mandlekar, S., Kong, A.N. (2001). Me chanisms for tamoxifen. Apoptosis 6:469-477. Masaba SC (2000). The antimalarial activity of Vernonia amygdalina Del (Compositae). Transactions of the Royal Society of Tropical Medicine and Hygiene 94:694-695. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al ., (2000). Traditional medicine and pharmacopoeia.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 5070,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1070)",
    "text": "Medicine and Hygiene 94:694-695. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A., Ekper, J.A., et al ., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics Studies of Ghana. Organisation of African UnityScientific, technical and research committee. NIPRD (2006). T echnical report on the antidiabetic activity of Vernonia amygdalina. Obaseiki-Ebor, E.E., Odukoya, K., Telikepalli, H., Mitscher, L.A. (1993). Antimutagenic activity of extracts of leaves of four common edible vegetable plants in Nigeria (West Africa). Mutation Research 302:109-117.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 618,
    "source": "PDF_chunked"
  },
  {
    "id": 5071,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1071)",
    "text": "OOAS Page 227 Vernonia amygdalina WAHP Okokon, J.E., Onaah, M.I. (2004). Pharmacological Studies on Root Extract of Vernonia amygdalina. Nigerian Journal of Natural Products and Medicine l8:59-61. Owu, D.U., Ben, E.E., Antai, A.B., Ekpe, E.A. et al., (2008). Stimulation of gastric acid secretion and intestinal motility by Vernonia amygdalina extract. Fitoterapia 79:97100. Phillipson, J.D., Wright, C.W., Kirby, G.C., Warhust, D.C. (1993). Phytochemistry of some plants used in traditional medicine for the treatment of protozoal diseases. Abstracts, International Symposium of the Phytochemical Society of Europe; University of Lausanne, Switzerland. Sayed, M.D., Zaki, A.Y., El -Marzabai, M.M, Doss, S.L. (1982). Medicinal Plants, Phytochemistry 21: 944. Tadesse, A, Gebre- Hiwot, A., Asres, K. et al., (1993). The in vitro activity of Vernonia",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 848,
    "source": "PDF_chunked"
  },
  {
    "id": 5072,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1072)",
    "text": "Doss, S.L. (1982). Medicinal Plants, Phytochemistry 21: 944. Tadesse, A, Gebre- Hiwot, A., Asres, K. et al., (1993). The in vitro activity of Vernonia amygdalina on Leishmania aethiopica. Ethiopian Medical Journal 31(3):183-189. Tona, L., Cimanga, R.K., Mesia, K., Musuamba, C.T. et al., (2004). In vitro antiplasmodial activity of extracts and fractions from seven medicinal plants used in the Democratic Republic of Congo. Journal of Ethnopharmacology 93:27-32.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 463,
    "source": "PDF_chunked"
  },
  {
    "id": 5073,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1073)",
    "text": "OOAS Page 228 Vernonia colorata WAHP Nom botanique Vernonia colorata (Wild) Deake Famille Asteraceae Synonyme Vernonia senegalensis (Pers.) Less., Epatorium colotatum Willd Noms communs Feuilles amères Noms vernaculaires Burkina Faso : Mooré koa-safandé, Dioula Khô safouné, Fulfuldé Ndumburkhat, Mossi Kosa Safandé, Bambara Ko Safna Cote d'Ivoire: Agni Baoulé Abovi Abowi Aovi, Akyé Todzo, Malinké Kosafna Mali: Bambara Ko-Safina, Malinké Ko-Safina Nigéria: Hausa Shiwaka, Yoruba Ewuro, Edo Owiro Sénégal: Wolof Ndumburghat Zidor, Diola Ka Sipa, Serer Mam Mbumkarkap Togo: Ewé Aloma, Ouatchi Alo, Adja Alotsi Description de la plante Vernonia colorata est un arbuste très ramifié ou petit arbre atteignant 3- 5 m de haut avec des feuilles pubescentes, ovales -elliptiques de 8- 15 cm de long sur 5- 10 de large avec des bords nettement ondulés, une surface supérieure très",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 873,
    "source": "PDF_chunked"
  },
  {
    "id": 5074,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1074)",
    "text": "petit arbre atteignant 3- 5 m de haut avec des feuilles pubescentes, ovales -elliptiques de 8- 15 cm de long sur 5- 10 de large avec des bords nettement ondulés, une surface supérieure très velue et une face inférieure couverte de poils laineux denses; le pétiole long de15- 30 mm de est pubescent; les inflorescences ont aplaties les panicules, composée de petites capitules de 5 à 15 cm de long; les fleurs blanches ou bleutées sont tubulaires de 8- 10 mm; les fruits sont des akènes glabres, avec un pappus brun- rougeâtre de 3 mm de long (Aké Assi et Guinko, 1986). Numéro du spécimen de l'herbier Ghana: GC 35269 Mali: 0074 DMT Togo: TOGO01207 Habitat et répartition géographique La plante se développe aussi bien dans la savane que dans les forêts tropicales, particulièrement dans les endroits de croissance secondaire et humides. Elle est fréquente dans la plupart des pays d'Afrique de l'Ouest, d'Afrique Centrale, d'Afrique du Sud et des pays tropicaux.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 963,
    "source": "PDF_chunked"
  },
  {
    "id": 5075,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1075)",
    "text": "secondaire et humides. Elle est fréquente dans la plupart des pays d'Afrique de l'Ouest, d'Afrique Centrale, d'Afrique du Sud et des pays tropicaux. Parties utilisées de la plante Feuilles Autres parties utilisées Tige , Racines Caractéristiques botaniques Vernonia colorata est composé de la feuille fraîche ou séchée de Vernonia colorata (Wild) Deake (Asteraceae). Utilisations ethnomédicales Vernonia colorata est l'une des légumes feuilles comestibles les plus consommées de toutes les espèces du genre Vernonia trouvés en Afrique Occidentale et au Cameroun. Ses feuilles de goût sucré et amer sont vendus frais ou secs et utilisées comme ingrédient commun de soupe. V. colorata a longtemps été utilisée en médecine traditionnelle pour le traitement de la toux, de la fièvre, de l'hépatite, de la gastrite, du diabète, des coliques, des rhumatismes, de la dysenterie, de la colite ulcéreuse, des maladies vénériennes, de la diarrhée, des furoncles et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 954,
    "source": "PDF_chunked"
  },
  {
    "id": 5076,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1076)",
    "text": "fièvre, de l'hépatite, de la gastrite, du diabète, des coliques, des rhumatismes, de la dysenterie, de la colite ulcéreuse, des maladies vénériennes, de la diarrhée, des furoncles et éruptions cutanées (Hutchings et al., 1996). Les infusions ou décoctions de feuilles sont utilisées pour l'otite, la fièvre et comme rince- bouche pour l'amygdalite. L'extrait de feuilles fraîches est appliquée sur les plaies (Kerharo et Adam, 1974; Ake Assi et Guinko, 1986; Oliver -Bever, 1996; Adjanohoun et al., 1985). Activités biologiques et pharmacologiques Plusieurs études ont démontré les activités antipaludiques des extraits de V. colorata (Benoit et al., 1996; 2000; Menan et al., 2006 et Kaou et al., 2008). Une étude menée par Kraft et al. (2003) a prouvé que les extraits lipophiles des parties aériennes, les lactones sesquiterpéniques de la plante, ainsi que les phénylpropanoïdes isolés et les terpénoïdes possèdent une puissante activité",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 5077,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1077)",
    "text": "parties aériennes, les lactones sesquiterpéniques de la plante, ainsi que les phénylpropanoïdes isolés et les terpénoïdes possèdent une puissante activité antiplasmodiale. Ses lactones sesquiterpéniques",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 202,
    "source": "PDF_chunked"
  },
  {
    "id": 5078,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1078)",
    "text": "OOAS Page 229 Vernonia colorata WAHP possèdent également des propriétés anthelminthique, amibicide, antischistosomiase, plasmodicidal, leishmanicide et des propriétés relaxantes in vitro et in vivo sur les muscles (Campos et al., 2003; Gasquet, et al., 1985;. Toubiana et Gaudemer, 1967; Kupchan et al ., 1969; Asaka et al., 1977 ; Ohigashi et al., 1994). Les extraits au dichlorométhane, acétonique et éthanolique ont présenté une activité encourageante anti-toxoplasme. Les extraits des feuilles de la plante possèdent une puissante activité antibactérienne contre différentes souches de bactéries (Kelmanson et al ., 2000); la vernodaline isolé des feuilles a une activité antibactérienne significative contre Staphylococcus aureus (. Reid et al ., 2001), tandis que les extraits aqueux, méthanolique et d'acétate d'éthyle étaient actifs contre Pseudomonas aeruginosa (Jonathan et al., 2000). Stafford et al. (2005) ont constaté que les extraits aqueux, éthanolique et",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 971,
    "source": "PDF_chunked"
  },
  {
    "id": 5079,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1079)",
    "text": "d'acétate d'éthyle étaient actifs contre Pseudomonas aeruginosa (Jonathan et al., 2000). Stafford et al. (2005) ont constaté que les extraits aqueux, éthanolique et hexaniqueextemporané du matériel végétal âgé de plus de quatre- vingt dix (90) Jours et de plus d'une (1) année , ont une activité antibactérienne . Différents extraits des feuilles possèdent également des effets hypoglycémique et antidiabétique chez les rats normoglycémique et ceux rendus diabétiques par administration d'alloxane (Sy et al, 2004; 2005, 2006). Données cliniques Aucune information disponible Constituants chimiques Acides aminés, vitamine C, caroténoïdes, fer, huile essentielle, lactones sesquiterpéniques (vernolide, hydroxyvernolide,19- hydroxyglaucolide A, dérivés de la vernodaline) (Ejoh de al., 2005a ; Ejoh et al., 2005b; Senatore et al., 2004.; Rabe et al., 2002;Toubiana et Gaudemer, 1967; Gasquet et al., 1985; Toubiana et Gaudemer, 1967; Kupchan et al., 1969; Asaka",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 961,
    "source": "PDF_chunked"
  },
  {
    "id": 5080,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1080)",
    "text": "(Ejoh de al., 2005a ; Ejoh et al., 2005b; Senatore et al., 2004.; Rabe et al., 2002;Toubiana et Gaudemer, 1967; Gasquet et al., 1985; Toubiana et Gaudemer, 1967; Kupchan et al., 1969; Asaka et al., 1977). Tests d'identité et de pureté Teneur en humidité: pas plus de 4,81 Cendre totale: 7,12 Valeur substances extractibles par l'eau: pas moins de 25,12 Valeur substances extractibles par l'éthanol (70) : pas moins de 22,50 Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire: gel de silice ( 0,25 mm) G60 F254, et phase mobile: éther de pétrole(40-60 oC) chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10 mn. Présence de quatr e taches distinctes avec valeurs R f de 0,67 (brun jaunâtre), 0,48 (rose),",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 5081,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1081)",
    "text": "méthanol et 5 ml d'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10 mn. Présence de quatr e taches distinctes avec valeurs R f de 0,67 (brun jaunâtre), 0,48 (rose), 0,35 (rose) et 0,12 (marron). Chromatogramme Macroscopie Feuille simple et pétiolée de forme elliptique à sommet acuminé; base symétrique; marge dentée irrégulière en scie; nervation réticulée; texture pubescente de couleur verte avec une odeur caractéristique et un goût amer. Microscopie La vue d'ensemble montrent des cellules épidermiques à parois presque droites sur les deux surfaces; la surface supérieure a quelques stomates anomocytiques , quelques poils pluricellulaires unisériées, glandulaires à têtes ovales, des poils tecteurs coniques; des poils glandulaires bicellulaires sessiles; une surface inférieure avec de nombreux stomates",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 827,
    "source": "PDF_chunked"
  },
  {
    "id": 5082,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1082)",
    "text": "OOAS Page 230 Vernonia colorata WAHP anomocytiques et certains stomates anisocytiques avec des cellules d'épidermes plus petites; une cuticule striée; nombreux poils pluricellulaires, glandulaires unisériés ;la section transversale montre une disposition dorsoventrale; les cellules épidermiques avec une ligne droite de parois anti clinales rayent les deux surfaces et contiennent du mucilage; une seule couche de cellules palissadiques a été interrompu dans la région de la nervure centrale par les cellules collenchymateuses; le mésophylle spongieux occupe le reste de l'espace de la lamina sauf pour les faisceaux vasculaires dans les veines et veinules. Matériel végétal en poudre On observe une poudre verte et amère, des fragments de lame montrant des stomates anomocytique et anisocytique, des cellules épidermiques parenchymateuses; des poils pluuricellulaires et glandulaires à têtes ovales, des poils tecteurs unicellulaires, coniques ; du",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 5083,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1083)",
    "text": "anomocytique et anisocytique, des cellules épidermiques parenchymateuses; des poils pluuricellulaires et glandulaires à têtes ovales, des poils tecteurs unicellulaires, coniques ; du mucilage ; des cellules palissadiques ; des faisceaux vasculaires et des tissus de xylème. Actions thérapeutiques Antipaludiques, entérite, anthelm inthique antidiabétique, cicatrisant, antischistosomiase, hémostatique, apéritif et tonique digestif. Indications thérapeutiques Paludisme, dysenterie amibienne, diabète, infections bactériennes Données de sécurité En 24 heures, la DL 50 des extraits aque ux de feuilles et d'écorce ( p.o) chez la souris a été 2000 mgkg. Aucun signe clinique de toxicité n'a été observé après le traitement des souris mâles et femelles (500 à 2000 mgkg; p.o) pendant 14 jours. Précautions d'emploi L'ingestion excessive peut provoquer la diarrhée Effets indésirables Aucun n'a été signalé Contre-indications",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 5084,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1084)",
    "text": "et femelles (500 à 2000 mgkg; p.o) pendant 14 jours. Précautions d'emploi L'ingestion excessive peut provoquer la diarrhée Effets indésirables Aucun n'a été signalé Contre-indications Grossesse et allaitement; ulcère gastrique, néphrite Dosage et forme galénique Décoction: faire bouillir 40g de feuilles séchées dans un litre d'eau pendant 15 minutes; boire 4 tasses à thé trois fois par jour. Conservation A conserver dans un endroit sec et frais. Références Adjanohoun, E. J., Ake Assi, L., Floret, J.J., Giunko, S., Koumare, M. et al., (1985). Contribution aux E ö tudes Ethnobotaniques et Floristiques au Mali; ACCT: Paris, 1985. Ake Assi, L., Guinko, S. (1986). Plants Used in Traditional Medicine in West Africa; Editions Roche: Basel. Asaka, Y., Kubota, T., Kulkarni, A.B. (1977). Studies on a bitter principle from Vernonia anthelmintica . Phytochemistry 16:1838-1839. Bamba, D., Balansard, G., Maillard, C., Gayte -",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 5085,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1085)",
    "text": "Asaka, Y., Kubota, T., Kulkarni, A.B. (1977). Studies on a bitter principle from Vernonia anthelmintica . Phytochemistry 16:1838-1839. Bamba, D., Balansard, G., Maillard, C., Gayte - Sorbier, A. (1984). Study of amino acids from Vernonia colorata (Wild) Drake leaves. Plantes Medicinales et Phytotherapie 18(3):154-159. Benoit, F., Valentin, A., Pelissier, Y., Diafou ka, F., Marion, C. et al . (1996). In vitro antimalarial activity of vegetal extracts used in West African traditional medicine. American Journal of Tropical Medicine and Hygiene 54:6771. Benoit, F, Santillana-Hayat, M., Kone-Bamba, D., Mallie, M., Deroui n, F. (2000). Anti-Toxoplasma activity of vegetal extracts used in West African traditional medicine. Parasite (Paris, France) 7(1):3-7. Campos, M., Oropeza, M., Héctor, P., Fernández, J. (2003). Relaxation of Uterine and Aortic Smooth Muscle by Glaucolid es D and E from Vernonia liatroides. Biological and",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 5086,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1086)",
    "text": "7(1):3-7. Campos, M., Oropeza, M., Héctor, P., Fernández, J. (2003). Relaxation of Uterine and Aortic Smooth Muscle by Glaucolid es D and E from Vernonia liatroides. Biological and Pharmaceutical Bulletin 26(1):112-115. Ejoh, A.R., Tanya, A.N., Djuikwo, N.V., Mbofung, C.M. (2005a). Effect of processing and preservation methods on vitamin c and total carotenoid levels of some V ernonia (bitter leaf) species African Journal of Food and Nutritional Sciences 5(2):1-11. Ejoh, R.A., Tanya, A.N., Djuikwo, V.N., Mbofung, C.M. (2005b). Effect of processing and preservation on the iron and vitamin A (total carotenoid) levels of some species of Vernonia. Sciences des Aliments 25(3):185-192. Gasquet, M. Bamba, D., Babadjamian, A., Balansard, G., Timon- David, P. (1985). Amoebicidal and anthelmintic activity of vernolide and hydroxyvernolide isolated from Vernonia",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 863,
    "source": "PDF_chunked"
  },
  {
    "id": 5087,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1087)",
    "text": "OOAS Page 231 Vernonia colorata WAHP colorata (Willd.) Drake leaves. European Journal of Medicinal Chemistry 20(2):111-115. Hutchings, A., Haxton Scott, A., Lewis, G., Cunningham, A. (1996). Zulu Medicinal PlantsAn Inventory. University of Natal Press, Pietermaritzburg. Jonathan, E., Kelmanson, A.K.J., Johannes, S. (2000). Zulu medicinal plants with antbacterial activity. Journal of Ethnopharmacology 69(3):241-246. Kaou, A.M. , Mahiou-Leddet, V ., Hutter, S ., Aïnouddine, S ., Hassani, S . et al . (2008). Antimalarial activity of crude extracts from nine African medicinal plants. Journal of Ethnopharmacology 116(1):74-83. Kelmanson, J.E., Ja ger, A.K., van Staden, J. (2000). Zulu medicinal plants with antibacterial activity. Journal of Ethnopharmacology 69:241- 246. Kerharo, J., Adam, J.G. (1974). La Pharmacope e Senegalaise Traditionnelle: Plantes Me dicinales et Toxiques ; Editions Vigot Freres: Paris.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 917,
    "source": "PDF_chunked"
  },
  {
    "id": 5088,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1088)",
    "text": "246. Kerharo, J., Adam, J.G. (1974). La Pharmacope e Senegalaise Traditionnelle: Plantes Me dicinales et Toxiques ; Editions Vigot Freres: Paris. Kraft, C., Jenett-Siems, K., Siems, K., Jakupovic, J., Mavi, S. et al . (2003). Herbal remedies traditionally used against malaria. In vitro antiplasmodial evaluation of medicinal plants from Zimbabwe. Phytotherapy Research 17(2):123-128. Kupchan, S.M., Hemingway, R.J., Karim, A., Werner, D. (1969).Tumor Inhibitors. XLVII. Vernodalin and vernomygdin, two new cytotoxic sesquiterpene lactones from Vernonia amygdalina. Journal of Organic Chemistry 34:3908-3911. Menan, H., Banzouzi, J.T., Hocquette, A., Pelissier, Y., Blache, Y. et al . (2006). Antiplasmodial activity and cytotoxicity of plants used in West African traditional medicine for the treatment of malaria. Journal of Ethnopharmacology 105:131136. Oliver-Bever, B. (1986). Medicinal Plants in Tropical West Africa. Cambridge University",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 5089,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1089)",
    "text": "treatment of malaria. Journal of Ethnopharmacology 105:131136. Oliver-Bever, B. (1986). Medicinal Plants in Tropical West Africa. Cambridge University Press, Cambridge, UK. Rabe, T., Mullholland, D., van Staden J. (2002). Isolation and identif ication of antibacterial compounds from Vernonia colorata leaves Journal of Ethnopharmacology 80:91-94. Reid, K., Jäger, A.K., van Staden, J. (2001). Isolation of anti -bacterial vernodalin from traditionally used Vernonia colorata . South African Journal of Botany 67:72-74. Senatore, F., Formisano, C., Sanogo, R. (2004). Essential oil from aerial parts of Vernonia colorata drake and Vernonia nigritiana Oliver et Hiern. (Asteraceae) growing wild in Mali Journal of Essential Oil-Bearing Plants 7(3):267-274. Stafford, G.I., Jager, A.K., van Staden, J. (2005). Effect of storage on the chemical composition and biological activity of several popular South African medicinal plants Journal of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 5090,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1090)",
    "text": "Stafford, G.I., Jager, A.K., van Staden, J. (2005). Effect of storage on the chemical composition and biological activity of several popular South African medicinal plants Journal of Ethnopharmacology 97(1):107-115. Sy, G.Y., Nongonierma, R.B., Sarr, M., Cisse, A., Faye, B . (2004). Antidiabetic activity of the leaves of Vemonia colorata (Wilid.) Drake (Composees) in alloxan- induced diabetic rats. Dakar Medical 49(1):36-39. Sy, G.Y., Cisse, A., Nongonierma, R.B., Sarr, M. et al . (2005) Hypoglycaemic and antidiabetic activity of acetonic extract of Vernonia colorata leaves in normoglycaemic and alloxan- induced diabetic rats . Journal of Ethnopharmacology 98(1-2):171-175. Sy, G.Y, Nongonierma, R.B., Cisse, A., Dieye, A.M, Wele, A. et al . (2006). Mechanisms of action of acetonic and hexanic extracts of leaves of Vernonia colorata (Willd.) Drake (Composeae) on blod glucose regulation. Dakar medical 51(1):42-46.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 5091,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1091)",
    "text": "action of acetonic and hexanic extracts of leaves of Vernonia colorata (Willd.) Drake (Composeae) on blod glucose regulation. Dakar medical 51(1):42-46. Toubiana, R., Gaudemer, A. (1967). Structure du vernolide, nouvel ester sesquiterpenique isole de Vernonia colorata. Tetrahedron Letters 14:333- 1336.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 303,
    "source": "PDF_chunked"
  },
  {
    "id": 5092,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1092)",
    "text": "OOAS Page 232 Zanthoxylum xanthoxyloides WAHP Nom botanique Zanthoxylum xanthoxyloides (Lam.) Waterm. Famille Rutaceae Synonyme Fagara senegalensis (DC.) A. Chev.; Zanthoxylum polygamum Schum.; Zanthoxylum senegalense DC. Fagara xanthoxyloides Lam Noms communs Candle wood; Zanthoxylum; Fagara Noms vernaculaires Burkina Faso: Mooré Rapeoko, Dioula Woo Benin: Gbe Gen - Eti, Vhe Heti, Yoruba Nago Ata Gambie: Fula Pulaar Barkele, Manding Mandinka Owo, Wolof Dengidek Ghana: Adangme Haatso, Akan Okanto, Ewe Ake Guinée: Fula Pulaar Barkele, Manding Maninka Huo Guinée-Bissau: Balanta Mantcha, Bidyogo Aranhe, Crioluo Bitonco Cote d'Ivoire: Baul Akuwe, Kru Bete Guessi, Klango Hango Mali: Manding Bambara Huo, Khasonke Wuho, Maninka Uo Nigéria: Hausa Fasa Kuwari, Igbo Uko, Yoruba orin ata. Sénégal: Balanta Macu, Diola Bu Santi, Manding Bambara Goro Ngua",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 853,
    "source": "PDF_chunked"
  },
  {
    "id": 5093,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1093)",
    "text": "Mali: Manding Bambara Huo, Khasonke Wuho, Maninka Uo Nigéria: Hausa Fasa Kuwari, Igbo Uko, Yoruba orin ata. Sénégal: Balanta Macu, Diola Bu Santi, Manding Bambara Goro Ngua Togo: Bassari Jarejare, Gbe Fon Che Description de la plante Petits arbres dioïques à tronc de 6 à 12 cm qu'on retrouve la plupart du temps sous les étages; ses branches sont épineuses ; ses rameaux et ses feuilles sont des rachis armés de panicules pointues et recourbées; sa feuille est imparipennée avec 3- 5 paires de folioles brillantes aromatiques, 3-10 cm de long sur 1,5 à 3,5 cm de large avec des nervures épineuses moyennes sur les bords elliptiques à ovales, oblongues à oblongues-lancéolées dans la forme et elliptiques ou légèrement obovales, arrondi ou échancré, ou sommetsommet très peu acuminé; il est larg ement cunéiforme; vert foncé, brillant, glabres, plutôt coriace avec une nervure centrale importante et des nervures latérales plutôt",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 929,
    "source": "PDF_chunked"
  },
  {
    "id": 5094,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1094)",
    "text": "échancré, ou sommetsommet très peu acuminé; il est larg ement cunéiforme; vert foncé, brillant, glabres, plutôt coriace avec une nervure centrale importante et des nervures latérales plutôt faibles et irrégulieres, en boucle près de la marge, reliés par un réseau ouvert de veines indistinctes; les pédoncules de folioles sont robustes, avec 0.2- 10.5 cm de long; les fleurs sont petites, nombreuses et blanche-verdâtre; les axillaires sont étroites , les panicules terminaux qui mesurent 5-25 cm de long ont des branches pointues, courtes; glabres et généralement sans épines. Ses fleurs sont individuelles mesurant environ 0,2 cm de long; les fruits sont glabres, bruns, d'environ 0,6 cm de diamètre, se divisant en deux pour montrer des graines bleues brillantes à l'intérieur qui ont un goût épicé; les capsules sphériques, ellipsoïdales ont une seule graine noire, ovoïde, sous-globulaire et brillante ; tous les organes",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 925,
    "source": "PDF_chunked"
  },
  {
    "id": 5095,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1095)",
    "text": "graines bleues brillantes à l'intérieur qui ont un goût épicé; les capsules sphériques, ellipsoïdales ont une seule graine noire, ovoïde, sous-globulaire et brillante ; tous les organes contiennent de l'huile essentielle, avec un goût de cannelle, fortement épicé (NHP, 2008). Numéro du spécimen de l'herbier Nigeria: FHI 107452 Togo: TOGO08061 Habitat et répartition géographique Elle est abondante dans les prairies côtières, forêt dense et la savane en Guinée. Elle se développe dans la plupart des pays ouest - africains. Ex. Ghana, Gambie, Togo, Nigéria, Sénégal et Côte d'Ivoire. Parties utilisées de la plante Racines Autres parties utilisées Feuilles et écorce de tige Caractéristiques botaniques Le Fagara est composé de la racine de Zanthoxylum xanthoxyloides (Lam.) Waterm. ou Zanthoxylum gillettii (De Willd.) Waterm. (Rutaceae). Utilisation ethnomédicale Le Fagara est utilisé dans de nombreux pays",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 911,
    "source": "PDF_chunked"
  },
  {
    "id": 5096,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1096)",
    "text": "Zanthoxylum xanthoxyloides (Lam.) Waterm. ou Zanthoxylum gillettii (De Willd.) Waterm. (Rutaceae). Utilisation ethnomédicale Le Fagara est utilisé dans de nombreux pays africains dans le traitement de l'entérite, la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 215,
    "source": "PDF_chunked"
  },
  {
    "id": 5097,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1097)",
    "text": "OOAS Page 233 Zanthoxylum xanthoxyloides WAHP dysenterie, la diarrhée, le ver de Guinée, l'urétrite, la toux, la fièvre, le rhume, l'engelure; le mal de dent, la morsure de serpent et l 'anémie falciforme. Il est utilisé comme curdent dans la plupart des pays ouest -africain (GHP, 2007; Dean et Schechter, 1978; Elujoba et Sofowora, 1977). Activités Biologique et pharmacologique Le Z. xanthoxyloides a des propriétés antifongiques, antibact ériennes, falciformiante et antileucémique. Les extraits aqueux, hydro- éthanolique de l'écorce de racine et de tige ont des effets antifongiques in vitro dose-dépendant (Ngane et al., 2000); son huile essentielle possède également une activité antibactérienne et antifongique (Tatsadjieu, 2003; Ngassoum et al., 2003). La fraction d'éther de l'extrait aqueux de racine a montré une activité antifalciformiante (Osoba et al ., 1989), en normalisant le HbA falciforme, le HBS et les crénelées de cellules",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 946,
    "source": "PDF_chunked"
  },
  {
    "id": 5098,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1098)",
    "text": "de racine a montré une activité antifalciformiante (Osoba et al ., 1989), en normalisant le HbA falciforme, le HBS et les crénelées de cellules globules rouges HbA in vitro (Sofowora, 2002). Les cellules traitées avec l'extrait de cellules falciformes ont pris une forme ronde (Rubriques et al., 1979). D'autres études ont montré que l'extrait est non- toxique sur les animaux sains (Isaacs-Sodoye et al., 1975). Le composé de fagaronine est antileucémique (Messner et al ., 1972) et les chlorures de nitidine et de fagaronine ont un myéloblaste aviaire et des effets inhibiteurs inverses de transcriptase (Addae-Mensah et al., 1992). Données cliniques Lorsqu'on administre 1,0 g par ml d'extrait aqueux de racine à des pa tients dont la douleur maximale est inférieure ou égale à 30mois, l'on observe lors du contrôle de l'extrait chez ces patients qui ont une douleur supérieure à 25 à 30 mois, une baisse de la douleur à un niveau zéro",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 5099,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1099)",
    "text": "maximale est inférieure ou égale à 30mois, l'on observe lors du contrôle de l'extrait chez ces patients qui ont une douleur supérieure à 25 à 30 mois, une baisse de la douleur à un niveau zéro lors du passage de l'extrait de Fagara (Isaacs et al.-Sodeye., 1975, Isaac-Sodeye, 1979). Constituants chimiques Alcaloïdes (berbérine, skimmianine, fagaramide, chélerythrine, canthine-6-1, fagaridine, fagaronine et alcaloïdes relatifs); acide p- hydroxybenzoïque, 2 hydroxymethylbenzoïque dérivés d'acide benzoïque (acide et acide vanillique); huile essentielle, tannin; flavonoïde; saponine; huile essentielle (α-pinène, transport- β-ocimène, citronellol, sabinène, myrcène, limonène et acétate de cytronellyl, α- phellandrène) (Tatsadjieu et al., 2003). Tests d'identité et de propriété Teneur en humidité: pas plus de 7.00 Cendre totale: pas plus de 5.01 Cendre insoluble dans l'acide: pas plus de 3.50 Centre soluble dans l'eau: pas moins de 0.25",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 5100,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1100)",
    "text": "Teneur en humidité: pas plus de 7.00 Cendre totale: pas plus de 5.01 Cendre insoluble dans l'acide: pas plus de 3.50 Centre soluble dans l'eau: pas moins de 0.25 Valeur substances extractibles par l'eau: pas moins de 10.00 (Poudre BP moyennement grossière) Valeur substances extractibles par l'éthanol (70): pas moins 10 (Poudre BP moyennement grossière) Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60 F254, et phase mobile: éther de pétrole (40-60oC) chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10 mn. Présence de quatre taches distinctes avec valeurs Rf de 0,99 (rose), 0,91 (rose), 0,64 (rose) et 0,46 (rose). Chromatogramme",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 905,
    "source": "PDF_chunked"
  },
  {
    "id": 5101,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1101)",
    "text": "OOAS Page 234 Zanthoxylum xanthoxyloides WAHP Macroscopie Racine cylindrique et tortueuse de 0,6 à 1,8 à 2,8 cm de long avec des radicelles attachés, mesurant environ 5 mm de diamètre ; la racine est dure, moins esquilleuse et une cassure fibreuse avec de l'amidon présent, de couleur foncée-chocolat et des plaques circulaires jaunâtres avec des tissus fins; la texture est très rugueuse avec un goût épicé, aromatique et amère (Olatunji, 1983). Microscopie La racine se compose de deux cellules de liège lignifiées et non lignifiées à paroi mince, rectangulaire à carrée, formant des bandes alternées; les fibres péricycliques sont présentes; les sclérites dans le phloème sont disposés dans des bandes continues de 1- 3; le parenchyme du phloème contient des grains d'amidon avec quelques fibres le phloème, des fibres de xylème et la présence de deux éléments de vaisseaux; la section transversale montre des cellules de liège suberiseés",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 5102,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1102)",
    "text": "d'amidon avec quelques fibres le phloème, des fibres de xylème et la présence de deux éléments de vaisseaux; la section transversale montre des cellules de liège suberiseés (certaines lignifiées) avec un contenu jaune- brun, d'environ 6- 7 couches épaisses, exfoliantes à certains endroits; la gamme de cellules parenchymateuses du cortex contient un grand nombre de grains d'amidon, des cellules d'huile et des cristaux prismatiques d'oxalate de calcium; une endoderme composée de cellules parenchymateuses contient de grandes quantités de grains d'amidon délimitées par le cortex du tissu vasculaire composé de phloème, qui est plafonné par des fibres péricycliques lignifiés, des rayons de cellules médullaires de 1- 2 sériés et de nombreux grains d'amidon; le bois est composé de navires lignifiés, de trachéi des dénoyautées du xylème et du parenchyme (Pharmacopée Africaine, 1985; Hutchinson et Dalziel, 1958). Matériel végétal en poudre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 943,
    "source": "PDF_chunked"
  },
  {
    "id": 5103,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1103)",
    "text": "est composé de navires lignifiés, de trachéi des dénoyautées du xylème et du parenchyme (Pharmacopée Africaine, 1985; Hutchinson et Dalziel, 1958). Matériel végétal en poudre Couleur jaune- pâle avec goût aromatique; présences de tissus de liège, nombreux grains d'amidon dans les cellules parenchymateuses, cristaux prismatiques d'oxalate de calcium et de fibres lignifiées ; certaines parties de cellules de liège ont des formes rectangulaires ou carrées, et présentent des fragments péricycliques de phloème et de fibres de xylème à éléments; la poudre montre des cristaux d'oxalate de calcium et des grains d'amidon donnant une réaction noire-bleuâtre à la solution iodée. Actions thérapeutiques Altérative; analgésique; anticancéreux; antihypertenseur; antipyrétique; antirhumatismaux ; antifalciformiante; antispasmodique; antimicrobien à large spectre; stimulant circulatoire; diaphorétique; emménagogue; sialogogue; diurétique,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 5104,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1104)",
    "text": "antirhumatismaux ; antifalciformiante; antispasmodique; antimicrobien à large spectre; stimulant circulatoire; diaphorétique; emménagogue; sialogogue; diurétique, antiseptique urinaire; astringent; laxatif (GHP, 2007). Indications thérapeutiques Hypertension artérielle; rhumatismes chroniques; fièvres; fibrosite; impuissance; faibles douleurs abdominales (post-partum), œdème, insuffisance circulatoire périphérique (par exemple la claudication intermittente et le syndrome de Raynaud); conjonctivite purulente, anémie falciforme; variole, syph ilis de la gorge; maux de dents; coqueluche et blessures (Mshana et al., 2000.). Données de sécurité La DL 50 de l'extrait aqueux de l'écorce de tige (p.o) a été jugée 3000 mgkg chez le rat. Dans les études subaiguës, aucun signe clinique de toxicité s' est avérée sur l'administration répétée de 300- 3000 mgkg pendant 14 jours. On a observé aucun changement significatif dans le",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 927,
    "source": "PDF_chunked"
  },
  {
    "id": 5105,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1105)",
    "text": "les études subaiguës, aucun signe clinique de toxicité s' est avérée sur l'administration répétée de 300- 3000 mgkg pendant 14 jours. On a observé aucun changement significatif dans le poids corporel ou le poids relatif des organes, soit une augmentation enregistrée de la numération leucocytaire, LYM, NEUT et MCV ; des niveaux accrus de transaminases hépatiques (ASAT, ALP, ALT et de GGT) ont été observés à la dose la plus élevée (3000 mgkg) testée, tandis que les niveaux d'albumine réduite de l'urée sérique ont augmenté de 3000 mgkg. D'autres études toxicologiques ont également montré que l'extrait n'a pas eu d'effets toxiques sur l'embryon du canard et du poulet ainsi que chez la souris. Il n'a pas été pas observé de caractéristiques tératogènes sur les embryons entiers; dans les études de toxicité aiguë par voie orale jusqu'à 50 gkg, aucun décès n'a été enregistré. La DL 50 par voie intrapéritonéale était de 20 g kg; par voie intraveineuse, elle était de",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 970,
    "source": "PDF_chunked"
  },
  {
    "id": 5106,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1106)",
    "text": "voie orale jusqu'à 50 gkg, aucun décès n'a été enregistré. La DL 50 par voie intrapéritonéale était de 20 g kg; par voie intraveineuse, elle était de 8 gkg, tandis que la DL 100 par cette dernière voie était de 14 gkg. Les études de toxicité chronique n'ont montré aucun changement pathologique (Isaacs -Sodeye et al., 1975). Il a été conclu que la toxicité de l'extrait aqueux de racine était pratiquement inexistante chez les animaux examinés et pendant la durée d'observation (Isaac-Sodeye, 1979) Précautions d'emploi Prendre des précautions en tenant compte des maladies rénales et hépatiques. Effets indésirables Des doses élevées peuvent provoquer des perturbations gastro- intestinales chez certains patients.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 716,
    "source": "PDF_chunked"
  },
  {
    "id": 5107,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1107)",
    "text": "OOAS Page 235 Zanthoxylum xanthoxyloides WAHP Contre-indications Dysfonctionnements rénaux et hépatiques Dosage et forme galénique Décoction: mettre 1-2 cuillèrees à café d'écorce dans 150 ml d'eau et laisser mijoter pendant 10- 15 minutes; boire 1-3 verre à thé par jour. Extrait liquide: 1:1 dans 45 d'éthanol; 1-3ml trois fois par jour Teinture: 1:5 dans l'éthanol 45, 2-5ml trois fois par jour. Conservation A conserver dans un endroit frais et sec. Références Addae-Mensah, I. (1992). Towards a Rational Scientific Basis for Herbal Medicine: A phytochemist's Two- decade Contribution. An Inaugural Lecture delivered at the University of Ghana, Legon, 45. Ghana Universities Press: Accra. Adesanya, S. A., Sofowora, A. (1983). Biological Standardization of Zanthoxylum roots for antisickling activity Planta. Medica 48:27-33. African Pharmacopoeia (1985). Vol. 1, First edition, published by Organization of African",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 5108,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1108)",
    "text": "Standardization of Zanthoxylum roots for antisickling activity Planta. Medica 48:27-33. African Pharmacopoeia (1985). Vol. 1, First edition, published by Organization of African Unity's Scientific, Technical and Research Commission, Lagos. Dean, J., Schechter, A.N. (1978). Sickle cell anaemia. Molecular and cellular basis of therapeutic approaches. New England Journal of Medicine 299:863-870. Elujoba, A. A., Sofowora, E. A. (1977). Detection and estimation of total acid in the antisickling fraction of Fagara species. Planta Medica 32(1):54-59. Ghana Herbal Pharmacopoeia (2007). 92- 96.Quali Type limited: Accra, Ghana. Headings, V., Abu, S., Castro, O. (1979). Characteristics of the antisickling activity of Fagara zanthoxyloides extract. In: Proceedings of the First International Conference on Sickle Cell Disease. Howard University Center for Sickle Cell Disease, Washington DC 163-167. Hutchinson, J., Dalziel, J.M. (1958). Flora of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 5109,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1109)",
    "text": "of the First International Conference on Sickle Cell Disease. Howard University Center for Sickle Cell Disease, Washington DC 163-167. Hutchinson, J., Dalziel, J.M. (1958). Flora of Tropical West Africa. Vol 1, Part II. Crown Agents for Overseas Governments and Administration, London (1958). Isaacs-Sodeye, W.A (1979). Preliminary clinical evaluation of crude extr act of Fagara zanthoxyloides. Proceedings of a symposium on Fagara and red blood cell, Faculty of Pharmacy, University of Ife. 1979. University of Ife Press, Nigeria Isaacs-Sodeye, W.A., Sofowora, E.A., Anderson, C.O., Marquis, V.O. et al., (1975). Extract of Fagara zanthoxyloides root in sickle cell anaemia: Toxicology and preliminary clinical trials. Acta Haematologica 53:158-164. Messner, W.M., Tin Wa, M., Fong, H.M.S., Bevelle, C. et al., (1972). Fagaronine, a new tumour inhibitor isolated from Fagar a zanthoxyloides Lam (Rutaceae). Journal of Pharmaceutical Science. 6:1958.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 5110,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1110)",
    "text": "Bevelle, C. et al., (1972). Fagaronine, a new tumour inhibitor isolated from Fagar a zanthoxyloides Lam (Rutaceae). Journal of Pharmaceutical Science. 6:1958. Mshana, N.R., Abbiw, D.K., Addae- Mensah, I., Ahiyi, M.R.A. et al., (2000). Traditional medicine and pharmacopoeia. Contribution to the revision of Ethnobotanical and Floristics S tudies of Ghana. Ngane, A.G., Biyiti, L., Zollo, P.H.A., Bouchet, P.H. (2000). Evaluation of antifungal activity of extracts of two Cameroonian Rutaceae: Zanthoxylum leprieurii Guill. et Perr. and Zanthoxylum xanthoxyloides Waterm. Journal of Ethnopharmacology 70: 335342. Ngassoum, M.B., Essia- Ngang, J.J., Tatsadjieu, L.N., Jirovetz, L. et al., (2003). Antimicrobial study of essential oils of Ocimum gratissimum leaves and Zanthoxylum xanthoxyloides fruits from Cameroon. Fitoterapia 74(3):284-287. NHP, ( 2006). Nigerian Herbal Pharmacopeia, First edition, Abuja, federal ministry of health, p181-185.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 5111,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1111)",
    "text": "leaves and Zanthoxylum xanthoxyloides fruits from Cameroon. Fitoterapia 74(3):284-287. NHP, ( 2006). Nigerian Herbal Pharmacopeia, First edition, Abuja, federal ministry of health, p181-185. Olatunji, O.A. (1983). The Biology of Zanthoxylum Linn. (Rutaceae) in Nigeria. Proceedings of the fifth international symposium on medicinal plants . Published by the Drug Research and Production Unit, University of Ife (Obafemi Awolowo lUniversity), Ile -Ife, Nigeria. Pp. 56-59. Osoba, O.A., Adesanya, S.A., Durosimi, M.A. (1989). Effect of Zanthoxylum xanthoxyloides and some substituted benzoic acids on glucos e- 6-phosphate and 6- phosphogluconate dehydrogenases in Hbss red blood cells. Journal of Ethnopharmacolology 27(1-2):177-183.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 732,
    "source": "PDF_chunked"
  },
  {
    "id": 5112,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1112)",
    "text": "OOAS Page 236 Zanthoxylum xanthoxyloides WAHP Sofowora, A. (2002). Plants in African Traditional Medicine-an overview. In: Trease and Evans Pharmacognosy, 15 th edn. Saunders: L ondon, 492-493. Tatsadjieu, L.N., Nganga, J.J.E., Ngassoum, M.B., Etoa, F.X. (2003). Antibacterial and antifungal activity of Xylopia aethiopica, Monodora myristica , Zanthoxylum xanthoxyloides and Zanthoxylum leprieurii from Cameroon. Fitoterapia 74:469-472.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 437,
    "source": "PDF_chunked"
  },
  {
    "id": 5113,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1113)",
    "text": "OOAS Page 237 Zingiber officinale WAHP Nom botanique Zingiber officinale Roscoe Famille Zingiberaceae Synonyme Amomum zingiber L. Zingiber blancoi Massk., Zingiber majus Rumph Noms communs Gingembre Noms vernaculaires Burkina Faso : Mooré Gnamaku, Dioula Dougouma niamako, Fulfuldé Gnamakou Bobo Dugumo nyamugu Ghana: Adangbe Odzahwi, Akan Akakador Tsintsimir, Dagbani - Sakarra Tschibilli Guinée: Fula Pulaar Niamaku, Limba - A-Mbir, Manding Maninka - Niamaku Susu Guinée-Bissau: Crioulo - Gengipe Libéria: Mano - Ge Su Nigéria: Arabic Shuwa Sakanjabir, Birom Syataa, Yoruba Atale. Sénégal: Bedik Nyamaku, Manding Bambara Dugukoro Ni Amaku, Wolof Dinjar. Sierra Leone : Bulom Wischa, Bulom Lone, Yalunka Nyakhamuna Togo: Anyi Anufo Kaka'dolo, Bassari Afu, Kabere Wessuguae. Description de la plante Le gingembre est un rhizome , une plante vivace de deux genres avec des tiges dressées de 1-",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 892,
    "source": "PDF_chunked"
  },
  {
    "id": 5114,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1114)",
    "text": "Togo: Anyi Anufo Kaka'dolo, Bassari Afu, Kabere Wessuguae. Description de la plante Le gingembre est un rhizome , une plante vivace de deux genres avec des tiges dressées de 1- 1,5 m de hauteur avec des feuilles lancéolées, alternes, lisses, engainantes qui meurent chaque année; l'une est de couleur pâle- verdâtre (tiges stériles) et, l'autre d'environ 20 cm ou moins de hauteur (les tiges fertiles portent des bractées de rechange) avec des fleurs courtes, stables et vert -jaunâtre, se terminant en longue courbe épineuse; chaque fleur présente un calice tubulaire supérieur, une corolle jaune- orangé avec trois lobes et 3 ovaires loculaires inférieures avec pointe touffue; le fruit est une capsule de petites graines argilites; le rhizome tubérisé et ramifié se propage et se multiplie dans le sous-sol (OMS, 1999; Gill, 1992). Numéro du spécimen de l'herbier Ghana: GC45906 Nigeria: FHI 107440 Habitat et répartition géographique",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 5115,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1115)",
    "text": "dans le sous-sol (OMS, 1999; Gill, 1992). Numéro du spécimen de l'herbier Ghana: GC45906 Nigeria: FHI 107440 Habitat et répartition géographique C'est une plante tropicale, particulièrement abondante en Indo- Malaisie; les grands producteurs mondiaux sont Fidji, l'Inde, la Jamaïque, le Nigéria, la Sierra Leone et la Chine; elle est commercialement cultivée dans presque tous les pays tropicaux et subtropicaux du monde. Parties utilisées de la plante Rhizome Autres parties utilisées Aucun Caractéristiques botaniques Ginger se compose du rhizome de de Zingiber officinale Roscoe (Zingiberaceae) Utilisations ethnomédicales Le gingembre est utilisé dans le traitement d'un grand nombre de maladies, y compri s le prolapsus rectal, les maux de dents, la raucité de la voix, la toux, le rhume, la grippe, les nausées et les vomissements liés à la grossesse, l'asthme, la fièvre, les coliques, la",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 895,
    "source": "PDF_chunked"
  },
  {
    "id": 5116,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1116)",
    "text": "prolapsus rectal, les maux de dents, la raucité de la voix, la toux, le rhume, la grippe, les nausées et les vomissements liés à la grossesse, l'asthme, la fièvre, les coliques, la dysménorrhée, la diarrhée, l'arthrite, l'hépatite, la dyspepsie (Samy , 2005; Millst et Bone, 2001; Adjanahoun et al., 1985; BHP, 1983). Activités biologiques et pharmacologiques Le gingembre a diverses propriétés phytopharmacologiques. Il a des actions stimulantes sur les systèmes nerveux central, circulatoire, et gastro- intestinal; Il augmente le péristaltisme et favorise la sécrétion de bile. les études in vitro ont prouvé que nombreux constituants du gingembre ont des propriétés anti-inflammatoires (Grzanna et al , 2005; Srivastava et Mustafa, 1989) ; les extraits de gingembre possèdent des effets inhibiteurs in vitro d'agrégation plaquettaire et de synthèses de thromboxane (Kiuchi et al ., 1992; Srivastava, 1986). Des études in vitro ont démontré que le",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 5117,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1117)",
    "text": "OOAS Page 238 Zingiber officinale WAHP gingembre présente des effets anti - inflammatoires par l'inhibition du métabolisme des acides arachidoniques à la fois par cyclo- oxygénases et voies de lipoxygénase (Backon, 1986). La simple dose orale de 33 mgkg d'huile de gingembre a supprimé de manière significative, l'auxiliaire chronique de l'arthrite grave chez les rats (Sharma et al ., 1994). L'extrait seul et en combinaison avec la vitamine E a partiellement amélioré la néphrotoxicité causée par la cisplatine (Ajith et al., 2007b). L'extrait éthanolique de la plante a également montré une activité antihyperlipidémique in vitro (Bhandari et al., 1998), alors que l'huile volatile a influencé à la fois la médiation cellulaire et la réponse immunitaire non spécifique de la prolifération des lymphocytes T ( Zhou et al., 2006). Le gingembre s'est également avéré avoir des propriétés anticancéreuses in vitro et in vivo",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 923,
    "source": "PDF_chunked"
  },
  {
    "id": 5118,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1118)",
    "text": "réponse immunitaire non spécifique de la prolifération des lymphocytes T ( Zhou et al., 2006). Le gingembre s'est également avéré avoir des propriétés anticancéreuses in vitro et in vivo (Bode et al., 2001; Katiyar et al. 1996; Koshimizu et al . 1988) ; le composé 6-gingérol a montré qu'elle peut empêcher l'adhérence cellulaire, l'invasion et la motilité des lignes cellulaires du cancer de sein chez l'humain (Lee et al., 1998). Données cliniques Dans une étude à petite échelle, la prise quotidienne de 15 g de rhizome frais de gingembre ou 40 g cuit de rhizome par 18 volontaires sains pendant deux semaines n'a pas diminué l'activité de cyclooxyg énase plaquettaire (Janssen et al., 1996). L'administration d'une dose unique de 2 g de rhizome séché ou un placebo à 8 volontaires sains n'a produit aucune différence dans le temps de saignement, de la numération plaquettaire, et du fonctionnement des plaquettes. Une randomisée, contrôlée contre",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 950,
    "source": "PDF_chunked"
  },
  {
    "id": 5119,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1119)",
    "text": "sains n'a produit aucune différence dans le temps de saignement, de la numération plaquettaire, et du fonctionnement des plaquettes. Une randomisée, contrôlée contre une étude croisée de placebo d'extraits de gingembre et d'ibuprofène ou de placebo d'individus souffrant d'arthrose de la hanche ou du genou, n'a trouvé aucune amélioration significative des symptômes à la fois pour le gingembre et les groupes d'ibuprofène avant un croisement sans aucune différence entre le gingembre et le placebo à la fin de l'étude (Bliddal et al ., 2000). Dans une autre étude randomisée en double aveugle, contrôlée contre le placebo, le pré- traitement des bénévoles ayant des antécédents de vomissement avec le gingembre, l'on a constaté une protection significative contre les nausées (Lien et al ., 2003).. D'autres études en double aveugle ont également montré l'efficacité du gingembre contre la cinétose ; un test clinique à double anonymat, contrôlé par le placebo, faisant",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 970,
    "source": "PDF_chunked"
  },
  {
    "id": 5120,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1120)",
    "text": "2003).. D'autres études en double aveugle ont également montré l'efficacité du gingembre contre la cinétose ; un test clinique à double anonymat, contrôlé par le placebo, faisant participer 26 femmes à leur premier trimestre de grossesse qui ont pris une cuillerée à soupe de sirop de gingembre contenant 1 g de gingembre quatre fois par jour, a montré que s i dans le groupe de gingembre des 8 femmes, le vomissement journalier cessait d'ici le sixième jour, alors que seulement 2 dans le groupe du placebo ont rapporté l'arrêt des vomissements. En outre, alors que 77 de celles qui prenaient le sirop de gingembre ont rapporté une diminution significative des nausées, 20 dans le groupe de placebo ont rapporté une amélioration. Dans une autre étude dans laquelle 70 femmes enceintes ont reçu 250 mg de poudre de gingembre fraîchement préparée ou un placebo, une réduction significative des nausées et du nombre de vomissements a été observée",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 5121,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1121)",
    "text": "70 femmes enceintes ont reçu 250 mg de poudre de gingembre fraîchement préparée ou un placebo, une réduction significative des nausées et du nombre de vomissements a été observée (Vutyavanich et al., 2001). Dans deux études en double aveugle effectuées sur des femmes après une chirurgie gynécologique capitale, des nausées ont été observée dans le groupe de placebo pendant toute la durée de l'étude. Seulement 28 des nausées ont été observées dans le groupe de gingembre et 30 dans le groupe de métoclopramide (Bone et al. , 1990). Dans un essai randomisé, à double aveugle, impliquant 27 femmes de chaque lot, qui avaient été admis à l'hôpital pour le traitement de la forme la plus sévère de hyperémèse grave, l'administration quotidienne d'une capsule de 250 mg de gingembre quatre fois par jour a entraîné une réduction significative des symptômes de vomissements incoercibles (Murphy, 1998). Une réduction significative des nausées et des vomissements a été observée",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 973,
    "source": "PDF_chunked"
  },
  {
    "id": 5122,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1122)",
    "text": "entraîné une réduction significative des symptômes de vomissements incoercibles (Murphy, 1998). Une réduction significative des nausées et des vomissements a été observée dans le groupe de gingembre, comparativement au placebo et au métoclopramide (Phillips et al., 1993). Dans un autre essai à double anonymat des nausées induites par la chimiothérapie dans laquelle 41 patients atteints de leucémie ont reçu le gingembre ou le placebo après l'administration de compazine (Pace, 1987), un plus grand bénéfice symptomatique a été observée dans le groupe de gingembre par rapport à celui du placebo. La consommation de gingembre a amélioré la douleur et les symptômes de troubles rhumatismaux (Srivastava et Mustafa, 1992). Le gingembre a été présenté comme remède efficace pour réduire la nausée postopératoire et les vomissements. Constituants chimiques Huile volatile (oléo -résine): monoterpènes 8- phellandrène, () -camphène, cinéole, le citral,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 949,
    "source": "PDF_chunked"
  },
  {
    "id": 5123,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1123)",
    "text": "efficace pour réduire la nausée postopératoire et les vomissements. Constituants chimiques Huile volatile (oléo -résine): monoterpènes 8- phellandrène, () -camphène, cinéole, le citral, bornéol; sesquiterpènes (zingibérène, bisabolène); gingérols ; vitamine du groupe B; (niacine, ribloflavine, thiamine); vitamine C; sucres réducteurs, acide phosphatidique; lécithine; acide folique; mucilage (GHP, 1992; Seukawa et al., 1984).",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 428,
    "source": "PDF_chunked"
  },
  {
    "id": 5124,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1124)",
    "text": "OOAS Page 239 Zingiber officinale WAHP Tests d'identité et de pureté Teneur en humidité: pas plus de 72,8 (frais), 5,2 (mastiqué à sec) Cendre totale: pas plus de 3,7 (mastiqué à sec), de 5,3 (séché à 60C) Cendre insoluble dans l'acide: pas plus de 4,3 (mastiqué à sec), de 2,8 (séché à 60C) Cendre soluble dans l'eau: pas moins de 1,0 (mastiquer à sec), 2,5 (séché à 60C) Valeur substances extractibles par l'eau: pas moins de 5,0 (mastiqué à sec), de 2,0 (séché à 60C) Valeur substances extractibles par l'éthanol (70): pas moins de 4,5 (mastiqué à sec), 3,0 (séché à 60C). Empreintes chromatographiques Extrait chloroformique L'analyse par chromatographie CCM avec phase stationnaire : gel de silice ( 0,25 mm) G60 F254, et phase mobile : éther de pétrole (40- 60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d'acide",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 5125,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1125)",
    "text": "60 oC)chloroforme 2:8 vv , la révélation est réalisée par pulvérisation du mélange anisaldéhyde (0,5 ml) et d'acide acétique glacial (10 ml ), 85 ml de méthanol et 5 ml d'acide sulfurique concentré, puis chauffé à 100-110C pendant 5-10 mn. Présence de cinq taches distinctes avec valeurs Rf de 0,89 (pourpre), de 0,80 (pourpre), de 0,56 (pourpre), de 0,46 (pourpre) et de 0,14 (pourpre) . Chromatogramme Macroscopie Latéralement-aplatis, ramifiés, incurvés (ou mis au rebut), les rhizomes connus sous le nom \"races\" ou \"mains\" sont des branches courtes, obovales, obliques appelé \"mains\" résultant de la surface supérieure des rhizomes. Chaque branche a une cicatrice déprimée à l'sommet; des rhizomes entiers sont de 5- 10 cm de long sur 1,5 à 3 à 4 cm de large et 1,0 à 1,5 cm d'épaisseur; la surface extérieure des rhizomes incurvés montre une couche externe, pâle à brun-foncé avec un liège visible ; la crête longitudinale est étroite et transversale avec une",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 964,
    "source": "PDF_chunked"
  },
  {
    "id": 5126,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1126)",
    "text": "d'épaisseur; la surface extérieure des rhizomes incurvés montre une couche externe, pâle à brun-foncé avec un liège visible ; la crête longitudinale est étroite et transversale avec une fracture raccourcie et féculente, ainsi qu'une projection de fibres; A l'aide d'une loupe, la surface transversale lisse montre de nombreuses cellules oléorésine jaune et des cellules à résine coupées, des faisceaux vasculaires dispersés et des endodermes séparant le cortex étroit et la stèle large. Il a une odeur agréable, aromatique et caractéristique; un goût accentué et agréablement piquant et aromatique (OMS, 1999; BP, 1980). Microscopie Le tissu moulu entier se compos e de paroi mince, de parenchyme cellulosique, de cellules polygonales arrondies d'environ 50 à 100 μ de diamètre, contenant de nombreuses granules d'amidon, mesurant chacune 50 μ de long sur 25 μ de larges et 7 μ d'épaisseur, de granulés d'amidon aplaties, ovales sub- rectangulaire,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 5127,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1127)",
    "text": "diamètre, contenant de nombreuses granules d'amidon, mesurant chacune 50 μ de long sur 25 μ de larges et 7 μ d'épaisseur, de granulés d'amidon aplaties, ovales sub- rectangulaire, transversalement striée, se trouvant dans les grains simples, perpendiculaire à long axe, avec chacun une protubérance terminale dans laquelle est situé le hile; des cellules contenant des masses oléorésines jaunes sont dispersés parmi les cellules d'amidon de palier qui sont des cellules suberisées, nombreuses dans le tissu moulu; des cellules pigmentaires ont un contenu sombre, brun- rougeâtre, se produisant dans le tissu du sol soit seuls ou en rangées axiales, associés aux fais ceaux vasculaires, qui sont fermés de manière collatérale avec un annulaire non-lignifié, spirale, réticulé avec épaississement scalariforme, souvent accompagnée de fibres à parois minces ayant une lumière entière et une lamelle moyenne lignifiée; les cri staux d'oxalate",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 5128,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1128)",
    "text": "non-lignifié, spirale, réticulé avec épaississement scalariforme, souvent accompagnée de fibres à parois minces ayant une lumière entière et une lamelle moyenne lignifiée; les cri staux d'oxalate de calcium et les sclérites sont absents, mais des quantités variables de cellules de liège, composées de cellules de parois minces sont présentes dans le gingembre à l'état pur (OMS, 1999 ; BP, 1980; Wallis, 1967). Les sections transversales du rhizome non pelées montrent la zone du tissu de liège comprenant la zone extérieure des cellules rectangulaires minces irrégulièrement disposées; la zone intérieure des cellules dans les lignes radiales et les grains d'amidon peuvent buter sur la région corticale; le cortex comporte des cellules parenchymateuses polygonales contenant d'abondants grains d'amidon simples , des cellules oléorésines avec un contenu jaunâtre; quelques paquets fibrovasculaires dispersées; une endoderme",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 5129,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1129)",
    "text": "OOAS Page 240 Zingiber officinale WAHP étroite comprenant des cellules allongées tangentiellement (environ deux cellules de large) avec des paquets fibrovasculaires radialement disposés entremêlés séparant le cortex d'un stèle beaucoup plus large, la masse au sol du stèle se compose de cellules parenchymateuses contenant beaucoup d'amidon, tel que le parenchyme cortical; les cellules nombreuses d'huile, les faisceaux fibrovasculaires comprennent des éléments de xylème légèrement lignifiés, des fibres de phloème disposés de façon collatérale et présente dans toutes les cellules de mucilage. Matériel végétal en poudre De nombreuses parois minces cellules du parenchyme du tissu broyé contenant des granules d'amidon abondantes, des fibres, des éléments de faisceaux vasculaires, non lignifiées, scalariformes, réticulées et un épaississement spirale, accompagnés par les cellules pigmentaires, oléo- résine dans des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 921,
    "source": "PDF_chunked"
  },
  {
    "id": 5130,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1130)",
    "text": "éléments de faisceaux vasculaires, non lignifiées, scalariformes, réticulées et un épaississement spirale, accompagnés par les cellules pigmentaires, oléo- résine dans des fragments ou des gouttelettes, la coloration par une solution d'iode; des fragments de cellules du liège, à paroi mince et polygonale, à partir des échantillons; unscrapped couleur jaunâtre à brun foncé, le goût est aromatique et le goût mordant est généralement agréable et aromatique (OMS, 1999; Wallis, 1967). Actions thérapeutiques Absorbant; analgésique, anti -émétique; anti - inflammatoire; antitussif; apéritif, c arminatif, cholagogue, sudorifique, fébrifuge, agent aromatisant; galactogogue; hypotenseur; stimulant circulatoire périphérique, doux anti - irritant, spasmolytique, sudorifique; apéritif (Suekawa et al, 1984.). Indications thérapeutiques Ballonnements, des furoncles; chilbains, toux, épuisement; flatulence, hémorroïdes, indigestion, douleurs articulaires, perte d'appétit, des",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 974,
    "source": "PDF_chunked"
  },
  {
    "id": 5131,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1131)",
    "text": "(Suekawa et al, 1984.). Indications thérapeutiques Ballonnements, des furoncles; chilbains, toux, épuisement; flatulence, hémorroïdes, indigestion, douleurs articulaires, perte d'appétit, des nausées et des vomissements; une mauvaise circulation (Dennis, 2002; GHP, 1992). Données de sécurité La DL 50 de l'extrait aqueux du rhizome (p.o) a été jugée 3000 mgkg chez des rats. Dans les études subaiguës (administration répétée de 300-3000 mgkg pendant 14 jours); aucun signe clinique de toxicité n'a été observé et aucun changement notable dans le poids corporel n'a été observ ée, mais une diminution relative du poids du foie, du rein, des poumons et du cœur s'est produite à l'application de 3000 mgkg. Le sang et ses éléments cellulaires ne sont pas affectés par le traitement et il n'y a eu aucun signe de dommages des systèmes hépatiques ou rénaux. Précautions d'emploi Aucune précaution spéciale requise pour la dose recommandée de l'extrait aqueux. Dans le",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 963,
    "source": "PDF_chunked"
  },
  {
    "id": 5132,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1132)",
    "text": "signe de dommages des systèmes hépatiques ou rénaux. Précautions d'emploi Aucune précaution spéciale requise pour la dose recommandée de l'extrait aqueux. Dans le traitement anticoagulant et celui de l'ulcère gastroduodénal, l'innocuité du gingembre n'a pas été formellement établie. Des doses excessives ne doivent pas être encouragées pour éviter des arythmies cardiaques et une dépression du SNC; il doit être utilisé avec prudence en présence de calculs biliaires et de conditions hémorragiques. il peut être utilisé pendant la grossesse, mais strictement sous contrôle médical. Effets indésirables Aucun rapport d'effets indésirables Contre-indications Aucune contre- indication avérée ( La prétendue contre-indication de nausées et de vomissements pendant la grossesse rapportés dans les monographies complètes de la Commission E. Allemande a été réfutée par Blumenthal, (2003). Dosage et forme galénique",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 910,
    "source": "PDF_chunked"
  },
  {
    "id": 5133,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1133)",
    "text": "vomissements pendant la grossesse rapportés dans les monographies complètes de la Commission E. Allemande a été réfutée par Blumenthal, (2003). Dosage et forme galénique Dans la plupart des cas, une dose spécifique de gingembre est de 1- 4 g par jour, en plusieurs doses Infusion: racine fraîche, infusée pen dant 5 minutes: 1 cuillère à café Décoction: mettre 1- 1,5 cuillerée à café de la poudre dans un verre d'eau Teinture: 1:2 dans de l'alcool de 75; 0,25- 5 ml trois fois par jour. Capsules: 1 ou 2 x 200mg Essence : Mettre 1-2 gouttes sur un morceau de sucre ou dans une cuillère à café de miel. Conservation A conserver dans un récipient bien fermé, dans un endroit frais, à l'abri de la lumière et de l'humidité. Références Adjanohoun, E. et al., (1985). Contribution to ethnobotanical and floristic studies in Western Nigeria. Published by Organization of African Unity's Scientific, Technical and Research Commission, Lagos, Nigeria.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 5134,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1134)",
    "text": "ethnobotanical and floristic studies in Western Nigeria. Published by Organization of African Unity's Scientific, Technical and Research Commission, Lagos, Nigeria. Ajith, T. A., Hema, U., Aswathy, M. S. (2007a). Zingiber officinale Roscoe prevents acetaminophen - induced acute hepatotoxicity by enhancing hepatic antioxidant status. Food and Chemical Toxicology, 45: 2267-2272.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 379,
    "source": "PDF_chunked"
  },
  {
    "id": 5135,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1135)",
    "text": "OOAS Page 241 Zingiber officinale WAHP Ajith, T.A., Nivitha, V., Usha, S. (2007b). Zingiber officinale Roscoe alone and in combination with α-tocopherol protect the kidney against cisplatin- induced acute renal failure. Food and Chemical Toxicology 45:921-927. Backon, J. (1986). Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry. Medical Hypotheses, 20:271- 278. Bhandari, U., Sharma, J.N., Zaf ar, R. (1998). The protective action of ethanolic ginger (Zingiber officinale) extract in cholesterol fed rabbits. Journal of Ethnopharmacology, 61:167 171. Bliddal, H., Rosetzsky, A., Schlichting, P. et al., (2000). A randomized, placebo controlled, cros s- over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage 8:9-12. Blumenthal, M. (2003). Ginger as an antiemetic during pregnancy. Alternative Therapy, Health and Medicine 9:19-21.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 931,
    "source": "PDF_chunked"
  },
  {
    "id": 5136,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1136)",
    "text": "osteoarthritis. Osteoarthritis Cartilage 8:9-12. Blumenthal, M. (2003). Ginger as an antiemetic during pregnancy. Alternative Therapy, Health and Medicine 9:19-21. Bode, A.M., Ma, W.Y., Surh, Y.J., Dong, Z . (2001). Inhibition of epidermal growth factor - induced cell transformation and activator protein 1 activation by 6 -gingerol. Cancer Research 61:850-853. Bone, M.E., Wilkinson, D.J., Young, J.R., et al., (1990). Ginger root --a new antiemetic.The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. Anaesthesia 45:669-671. British Pharmacopoeia Vol.1 (1980). Published by Her Majesty's Stationery Office and printed by the University Press, Cambridge. Chaiyakunapruk, N., Kitikannakorn, N., Nathisuwan, S., Leeprakobboon, K. et al., (2006). The efficacy of ginger for the prevention of postoperative nausea and vomiting: A meta- analysis. American Journal of Obstetrics and Gynecology 194:95- 99.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 948,
    "source": "PDF_chunked"
  },
  {
    "id": 5137,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1137)",
    "text": "(2006). The efficacy of ginger for the prevention of postoperative nausea and vomiting: A meta- analysis. American Journal of Obstetrics and Gynecology 194:95- 99. Dennis, F. (ed), W. (2002). Manual for the propagation and cultivation of medicinal plants for Ghana. Darwin Initiative for the Survival of Species. Gill, L. S. (1992). Ethnomedical Uses of Plants in Nigeria. Published by Uniben Press, Benin City, Nigeria. Ghana Herbal Pharmacopoeia (1992), 62- 64, The Advent Press: Accra, Ghana. Goyal, R.K., Kadnur, S.V. (2006). Beneficial effects of Zingiber officinale on goldthioglucose induced obesity. Fitoterapia 77:160-163. Grzanna, R., Lindmark, L., Frondoza, C.G. (2005). Ginger - a herbal medicinal product with broad anti -inflammatory actions. Journal of Medicinal Food 8(2):125-132. Guh, J.H., Ko, F.N., Jong, T.T., Teng, C.M. (1995). Antiplatelet effects of gingerol isolated from Zingiber officinale. Journal of Pharmacy and",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 5138,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1138)",
    "text": "Medicinal Food 8(2):125-132. Guh, J.H., Ko, F.N., Jong, T.T., Teng, C.M. (1995). Antiplatelet effects of gingerol isolated from Zingiber officinale. Journal of Pharmacy and Pharmacology 47:329-332. Haksar, A., Sharma, A., Chawla, R., Kumar, R. et al., (2006). Zingiber officinale exhibits behavioral radioprotection against radiation- induced CTA in a gender manner. Pharmacology, Biochemistry and Behavior 84:179-188. Janssen, P.L., Meyb oom, S., Van Staveren, W.A., et al ., (1996). Consumption of ginger (Zingiber officinale Roscoe) does not affect ex vivo platelet thromboxane production in humans. European Journal of Clinical Nutrition 50:772- 774. Katiyar, S.K., Agarwal, R., Mukhtar, H. ( 1996). Inhibition of tumor promotion in SENKAR mouse skin by ethanol extract of rhizome. Cancer Research 56:1023-1030. Kikuzaki, H., Kawasaki, Y., Nakatani, N. (1994). Structure of antioxidative compounds in ginger. In: Ho CT, Osawa T, Huang MT, Rosen RT, eds.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 5139,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1139)",
    "text": "Research 56:1023-1030. Kikuzaki, H., Kawasaki, Y., Nakatani, N. (1994). Structure of antioxidative compounds in ginger. In: Ho CT, Osawa T, Huang MT, Rosen RT, eds. Food phytochemicals for cancer prevention II, American Chemical Society, Washington, DC, 237243. Kiuchi, F., Iwakami, S., Shibuya. M. et al., (1992). Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chemic al and Pharmaceutical Bulletin 40:387-391. Koshimizu, K., Ohigashi, H., Tokuda, H., Kondo, A. et al., (1988). Screening of edible plants",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 550,
    "source": "PDF_chunked"
  },
  {
    "id": 5140,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1140)",
    "text": "OOAS Page 242 Zingiber officinale WAHP against possible antitumor promoting activity. Cancer Letters 39:247-257. Lee, E., Surh, Y.J. (1998). Induction of ap optosis in HL-60 cells by pungent vanilloids, 6 -gingerol, and 6-paradol. Cancer Letters 134:163-168. Lien, H.C., Sun, W.M., Chen, Y.H. et al., (2003). Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. American Journal of Physiology, Gastrointestine and Liver Physiology 284:G481- G489 Masuda, Y., Kikuzaki, H., Hisamoto, M., Nakatani, N. (2004). Antioxidant properties of gingerol related compounds from ginger. Biofactors 21:293296. Milt, S., Bone, K. ( 2001). Principles and Practice of Phytotherapy, Modern Herbal Medicine. Churchill Livingstone, London. pp. 394 to 403. Murphy, P.A. (1998). Alternative therapies for nausea and vomiting of pregnancy. Alternative Therapies 91(1):149-155. Pace, J.C. (1987). Oral ingestion of",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 937,
    "source": "PDF_chunked"
  },
  {
    "id": 5141,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1141)",
    "text": "Murphy, P.A. (1998). Alternative therapies for nausea and vomiting of pregnancy. Alternative Therapies 91(1):149-155. Pace, J.C. (1987). Oral ingestion of encapsulated ginger and reported self -care actions for the relief of chemotherapy associated nausea and vomiting. Diss Abstr Int.; 47:3297-B. Phillips, S., Ruggier, R., Hutchinson, S.E. (1993). Zingiber officinale (Ginger)--an antiemetic for day case surgery. Anaesthesia 48:715-717. Samy, R.P. (2005). Antimicrobial activity of some medicinal plants from India. Fitoterapia 76:697- 699. Suekawa, M., Ishige, A., Yuasa, K. et al., (1984). Pharmacological studies on ginger I. Pharmacological actions of pungent constituents, (6)-gingerol and (6) -shogaol. Journal of Pharmacobiodynamics 7:836-848. Sharma, S.S., Gupta, Y.K. (1998). Reversal of cisplatin-induced delay in gastric emptying in rats by ginger ( Zingiber officinale ). Journal of Ethnopharmacology 62: 49-55.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 926,
    "source": "PDF_chunked"
  },
  {
    "id": 5142,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1142)",
    "text": "Sharma, S.S., Gupta, Y.K. (1998). Reversal of cisplatin-induced delay in gastric emptying in rats by ginger ( Zingiber officinale ). Journal of Ethnopharmacology 62: 49-55. Sharma, S.S., Kochupillai, V., Gupta, S.K., Seth, S.D. et al., (1997). Antiemetic efficacy of ginger (Zingiber officinale) against cisplatin- induced emesis in dogs. Journal of Ethnopharmacology 57(2): 93-96. Sharma, J.N., Sri vastava, K.C., Gan, E.K. (1994). Suppressive effects of eugenol and ginger oil on arthritis rats. Pharmacology 49: 314-318. Srivastava, K.C., Mustafa, T. (1992). Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Medical Hypotheses 39:342-348. Srivastava, K.C. (1989). Effects of onion and ginger consumption on platelet thromboxane production in humans. Prostaglandins Leukotriene Essential Fatty Acids 35:183-185. Srivastava, K.C. (1986). Isolation and effects of some ginger components on platelet aggregation",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 5143,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1143)",
    "text": "production in humans. Prostaglandins Leukotriene Essential Fatty Acids 35:183-185. Srivastava, K.C. (1986). Isolation and effects of some ginger components on platelet aggregation and eicosanoid biosynthesis. Prostaglandins, Leukotrienes, and Medicine, 25, 187-198. Vishwakarma, S.L., Pa,l S.C., Kasture, V.S., Kasture, S.B. (2000.) Anxiolytic and antiemetic activity of Zingiber officinale. Phytotherapy Research, 16(7):621-626. Vutyavanich, T., Kraisarin, T., Ruangsri, R. (2001). Ginger for nausea and vomiting in pregnancy: randomized, double- masked, placebo-controlled trial. Obstetrics and Gynecolology, 97:577-582. Wallis, J.E. (1967). Textbook of Pharmac ognosy. 5 th edition, Churchill J.A. Ltd. Gloucester, London (1967). WHO monographs on selected medicinal plants (1999). Vol. 1, published by World Health Organization, Geneva. Zhou, H.l., Deng, Y.M., Xie, Q.M. (2006). The modulatory effects of the volatile oil of ginger on",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 938,
    "source": "PDF_chunked"
  },
  {
    "id": 5144,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1144)",
    "text": "(1999). Vol. 1, published by World Health Organization, Geneva. Zhou, H.l., Deng, Y.M., Xie, Q.M. (2006). The modulatory effects of the volatile oil of ginger on the cellular immune response in vitro and in vivo in mice. Journal of Ethnopharmacology 105:301- 305.",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 263,
    "source": "PDF_chunked"
  },
  {
    "id": 5145,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1145)",
    "text": "OOAS Page 243 Index des noms scientifiques de plantes WAHP A Acacia adansonii, 1 Acacia arabica, 1, 8 Acacia nilotica, 1 Acacia senegal, 6 Acacia verek, 6 Adansonia digitata, 9, 11, 12 Adansonia sphaerocarpa, 9 Adenanthera tetraptera, 215 Ageratum album, 14 Ageratum conyzoides, 14, 15, 16 Ageratum cordifolium, 14 Ageratum hirsutum, 14 Ageratum latifolium, 14 Ageratum obtusifolium, 14 Ageratum odoratum, 14 Agialida barteri, 51 Agialida senegalensis, 51 Alchornea cordata, 18 Alchornea cordifolia, 18, 20 Allium sativum, 23, 26, 27, 28 Aloe barbadensis, 32 Aloe barteri, 29 Aloe schweinfurthii, 29, 31 Aloe trivialis, 29 Aloe vera, 17, 32, 34 Alstonia boonei, 36, 38, 39 Alstonia congolensis, 36 Amomum zingiber, 236 Andropogon citratus, 76 Argemone mexicana, 40, 42 Argemone ochroleuca, 40 Azadirachta indica, 5, 44, 45, 46 B Balanites aegyptiaca, 51, 52, 53 Balanites ziziphoides, 51 Bignonia tulipifera, 203 Borreria verticillata, 207, 209",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 944,
    "source": "PDF_chunked"
  },
  {
    "id": 5146,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1146)",
    "text": "Argemone ochroleuca, 40 Azadirachta indica, 5, 44, 45, 46 B Balanites aegyptiaca, 51, 52, 53 Balanites ziziphoides, 51 Bignonia tulipifera, 203 Borreria verticillata, 207, 209 Bridelia ferruginea, 56, 57, 59 Bridelia micrantha, 56 C Capraria dulcis, 167 Carica hermaphrodita, 62 Carica mamaya, 62 Carica papaya, 62, 63 Cassia acutifolia, 182 Cassia alata, 177, 180 Cassia angustifolia, 182 Cassia bracteata, 177 Cassia caroliniana, 185 Cassia elongata, 182 Cassia foetida, 185 Cassia herpetica, 177 Cassia lanceolata, 182 Cassia lantiva, 182 Cassia occidentalis, 185, 188, 189 Cassia podocarpa, 191, 193, 194 Cassia senna, 182 Chamaesyce hirta, 81 Cinchona pubescens, 69, 71",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 674,
    "source": "PDF_chunked"
  },
  {
    "id": 5147,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1147)",
    "text": "OOAS Page 244 Index des noms scientifiques de plantes WAHP Cinchona succirubra, 69 Cocculus bakis, 219 Cryptolepis sanguinolenta, 72, 74 Cryptolepis triangularis, 72 Cymbopogon citratus, 76, 77, 79 D Diasperus niruri, 140 Ditremexa occidentalis, 185 E Epatorium colotatum, 227 Euphorbia capitata, 81 Euphorbia hirta, 81, 82, 84 Euphorbia pilulifera, 81 F Fagara senegalensis, 231 Fagara xanthoxyloides, 231 Fleroya stipumosa, 86 G Gratiola micrantha, 167 H Hallea stipulosa, 86, 88 Harrisonia abyssinica, 89, 91, 92 Harrisonia occidentalis, 89 Hepetica alata, 177 Hibiscus digitatus, 93 Hibiscus gossypiifolius, 93 Hibiscus sabdariffa, 93, 94, 95 Hibiscus sanguineus, 93 Hylacium owariense, 153 Hymenocardia acida, 97, 99 Hymenocardia mollis, 97 K Khaya senegalensis, 101, 103 L Lawsonia alba, 105 Lawsonia inermis, 105, 107 Lippia adoensis, 109 Lippia grandifolia, 109 Lippia multiflora, 109, 111 Lophostylis pollida, 172 M",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 5148,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1148)",
    "text": "K Khaya senegalensis, 101, 103 L Lawsonia alba, 105 Lawsonia inermis, 105, 107 Lippia adoensis, 109 Lippia grandifolia, 109 Lippia multiflora, 109, 111 Lophostylis pollida, 172 M Melia azadirachta, 44 Melia indica, 44 Mimosa arabica, 1 Mimosa scorpioides, 1 Mimosa senegal, 6 Mitragyna africana, 113 Mitragyna chevalieri, 86 Mitragyna inermis, 113, 115 Mitragyna stipulosa, 86, 88 Momordica charantia, 116, 119, 120 Momordica thollonii, 116 Morinda citrifolia, 121 Morinda lucida, 121, 123, 124 Moringa aptera, 125 Moringa oleifera, 125, 126, 129, 130 Moringa pterygosperma, 125 Myrobalanus lutea, 210",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 601,
    "source": "PDF_chunked"
  },
  {
    "id": 5149,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1149)",
    "text": "OOAS Page 245 Index des noms scientifiques de plantes WAHP N Nauclea africana, 113 Nauclea bracteosa, 86 Nauclea esculenta, 152 Nauclea latifolia, 157, 159, 160 Nauclea macrophylla, 86 Nauclea stipulosa, 86 Nymphanthus niruri, 140 O Ocimum album, 131 Ocimum americanum, 131 Ocimum anisatum, 131 Ocimum barrelieri, 131 Ocimum basilicum, 131, 132, 134 Ocimum dicotomum, 131 Ocimum gratissimum, 20, 135, 136, 138 Ocimum guineense, 135 Ocimum lanceolatum, 131 Ocimum medium, 131 Ocimum viride, 135 Ocimum menthaefolium, 131 P Pergularia sanguinolenta, 72 Phyllanthus asperulatus, 140 Phyllanthus carolinianus, 140 Phyllanthus filiformis, 140 Phyllanthus fraternus, 140, 143, 144 Phyllanthus niruri, 140, 141, 142, 143 Phytolacca abyssinica, 145 Phytolacca dodecandra, 145, 146, 148 Pircunia abyssinica, 145 Plectranthus barrelieri, 131 Porvium sativum, 23 Poupartia birrea, 161 Poupartia caffra, 161 Pterocarpus echinatus, 150",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 922,
    "source": "PDF_chunked"
  },
  {
    "id": 5150,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1150)",
    "text": "Phytolacca dodecandra, 145, 146, 148 Pircunia abyssinica, 145 Plectranthus barrelieri, 131 Porvium sativum, 23 Poupartia birrea, 161 Poupartia caffra, 161 Pterocarpus echinatus, 150 Pterocarpus erinaceus, 150, 152 R Rauvolfia senegambiae, 153 Rauwolfia vomitoria, 153, 155, 156 S Sabdariffa rubra, 93 Sarcocephalus esculentus, 157 Sarcocephalus latifolius, 157 Sarcocephalus russeggeri, 157 Sarcocephalus sambucinus, 157 Sarcocephalus sassandrae, 157 Schousboea cordifolia, 18 Sclerocarya birrea, 161, 162, 164 Sclerocarya caffra, 161 Scoparia dulcis, 167, 169, 170 Scoparia ternata, 167 Securidaca longepedunculata, 172, 175, 176 Securidaca spinosa, 172 Senna alata, 177, 178, 180 Senna alexandrina, 182, 184 Senna occidentalis, 185, 187, 188 Senna podocarpa, 191",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 764,
    "source": "PDF_chunked"
  },
  {
    "id": 5151,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1151)",
    "text": "OOAS Page 246 Index des noms scientifiques de plantes WAHP Solanum ferrugineum, 195 Solanum mannii, 195 Solanum mayanum, 195 Solanum torvum, 195, 197, 198 Sorghum aethiopicum, 199 Sorghum arundinaceum, 199 Sorghum bicolor, 199, 201, 202 Sorghum lanceolatum, 199 Sorghum verticilliflorum, 199 Sorghum virgatum, 199 Spathodea campanulata, 203, 204, 205 Spathodea danckelmaniana, 203 Spathodea nilotica, 203 Spathodea tulipifera, 203 Spermacoce globosa, 207 Spermacoce verticillata, 207, 209 Spondias aurantiaca, 210 Spondias birrea, 161 Spondias brasiliensis, 210 Spondias lucida, 210 Spondias lutea, 210, 213 Spondias mombin, 210, 213 Spondias myrobalanus, 210 Spondias oghibee, 210 Spondias pseudomyrobalanus, 210 Swietenia senegalensis, 101 T Tetrapleura tetraptera, 215, 216, 217 Tetrapleura thornningii, 215 Tinospora bakis, 219, 221 U Uncaria inermis, 113 V Vernonia amygdalina, 222, 223, 224 Vernonia colorata, 227, 229",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 924,
    "source": "PDF_chunked"
  },
  {
    "id": 5152,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1152)",
    "text": "T Tetrapleura tetraptera, 215, 216, 217 Tetrapleura thornningii, 215 Tinospora bakis, 219, 221 U Uncaria inermis, 113 V Vernonia amygdalina, 222, 223, 224 Vernonia colorata, 227, 229 Vernonia senegalensis, 222, 227 X Ximenia aegyptiaca, 51 Z Zanthoxylum guineense, 89 Zanthoxylum polygamum, 231 Zanthoxylum senegalense, 231 Zanthoxylum xanthoxyloides, 231, 232, 234 Zingiber blancoi, 236 Zingiber majus, 236 Zingiber officinale, 236, 239, 240",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 442,
    "source": "PDF_chunked"
  },
  {
    "id": 5153,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1153)",
    "text": "OOAS Page 247 Index des noms communs WAHP A Acacia du Nil, 1 Acacia du Sénégal, 6 Acacia nilotique, 1 Acajou du Sénégal, 102 Ageratum mexicain, 14 Ail commun, 23 Alchornéa cordiforme, 18 Aloès géant Ouest Africain, 29 Aloés vulgaire, 32 Arbre à baguette, 125 Arbre à soufre, 121 Arbre clarificateur, 125 Arbre d'huile de Ben, 125 Arbre de djeman, 18 Arbre de Kelor, 125 Arbre de raifort, 125 Arbre flamme, 203 Arbre margosa, 44 Arbre miracle, 125 Arbuste à Serpent, 172 Arbuste teigne, 177 B Bahia, 86 Baingou, 89 Baobab, 9 Basilic, 131 Basilic aux sauces, 131 Basilic commun, 131 Basilic romain, 131 Bâton de sorcier, 203 Borreria verte, 207 Borrerie verticillé, 207 Bouc australien contre les mauvaises herbes, 14 Bouc contre les mauvaises herbes, 14 Bougie de brousse, 177 Bougie de Noël, 177 Bridelia, 56 C Cailcedrat du Sénégal, 101 Casseur de pierre, 140 chandelier séné, 177 Chardon du pays, 40 Citronnelles, 76 Cœurs-volants, 97",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 5154,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1154)",
    "text": "Bougie de brousse, 177 Bougie de Noël, 177 Bridelia, 56 C Cailcedrat du Sénégal, 101 Casseur de pierre, 140 chandelier séné, 177 Chardon du pays, 40 Citronnelles, 76 Cœurs-volants, 97 Concombre Africain, 116 Crin, 105 Curacao aloe, 32, D Datte du désert, 51 Des Pistou., 131 E Endod, 145 Euphorbe hérissée, 81 F Fagara, 231 False abura, 113 Feuille amère, 222, 228",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 364,
    "source": "PDF_chunked"
  },
  {
    "id": 5155,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1155)",
    "text": "OOAS Page 248 Index des noms communs WAHP Feuille de Podocarpa, 191 Feuillede fièvre, 135 Figues du pays, 157 Fitolaca, 145 Framboisin, 131 G Gingembre, 236 Gommier, 6 Gommier blanc, 6 Gonakier, 1 Graines-porte-moi, 140 Grand mil, 199 H Herbe de fièvre, 76 Herbe guérisseuse, 109 Herbe puante, 185 Herbe Royale, 131 L la palme affectionnée par l'éléphant, 29 Lilas indienne, 44 M Mais de Guinée, 199 Margose, 116 Mauvaise herbe du vent de gale., 140 Mauvaise herbe à quinine, 140 Mauvaise herbe d'ouragan, 14O Meilleure amie de la mère, 125 Merveilles de la liane, 116 Mombin, 210 N Neem, 44, 45, 47, 48, 49 O Oiselle de Guinée, 93 P Palissandre du Sénégal, 150 Papayer, 62 Pavot du Mexique, 40 Pavot épineux, 40 Pêche africaine, 157 Pêche de Guinée, 157 Pêche Nègre, 157 Petit euphorbe, 81 Phytolaque, 145 plante craw-craw, 177 plante de fièvre de la Sierra Leone, 135 plante de moustiques, 135 Poire de balsame, 116 Prune mombin, 210",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 5156,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1156)",
    "text": "Pêche Nègre, 157 Petit euphorbe, 81 Phytolaque, 145 plante craw-craw, 177 plante de fièvre de la Sierra Leone, 135 plante de moustiques, 135 Poire de balsame, 116 Prune mombin, 210 Prune Myrobolan, 210 Prunier d'Afrique, 161 prunier jaune, 161 Q Quinine du Ghana, 72 Quinquina rouge, 69 R Racine jaune-colorant, 72 Rauwolfia Africain, 153 Roi de la forêt, 177",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 359,
    "source": "PDF_chunked"
  },
  {
    "id": 5157,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1157)",
    "text": "OOAS Page 249 Index des noms communs WAHP S Santal rouge d'Afrique, 150 Savetiers d'amélioration, 131 Sclérocarya à bière, 161 Séné créole, 140 Séné d'Alexandrie, 182 Séné de canne de pois, 140 Séné de Tinnevelly, 182 Solanum, 195 Sorgho doux, 199 T Tabouret de bois, 36 Tâche de l'œil, 40 Tetrapleura pod, 215 Texture enbois, 36 Thé de bosquet, 109 Thé de Gambie, 109 Thé rose d'Abyssinie, 93 Thé rouge, 135 TI-arbre, 109 Tilleul d'Afrique, 86 Tinospora, 219 Tulipier africain, 203 V Vène, 150",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 494,
    "source": "PDF_chunked"
  },
  {
    "id": 5158,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1158)",
    "text": "OOAS Page 250 Index des maladies WAHP A Accident Vasculaire Cérébral, 121,142 Aménorrhée, 16,197 Amibiase, 16, 65, 74, 83 Anémie, 38, 87, 103,142, 183, 187, 201 Angine, 155, 193 Arthrite, 16, 59, 159 Arythmie, 155 Ascaridiase, 16, 65 Asthme, 11, 34, 79, 83, 129, 133,169, 197, 224 Athérosclérose, 26 B Basdeaux, 179 Béribéri, 16 Bradycasdie, 155 Bronchite, 83, 197, 201 BrÛlures, 7, 31, 34, 118 C Cancer du foie, 142 Cataracte, 38 Catarrhe, 16, 79, 83, 133, 137 Céphalées, 16 Choléra, 79, 87 Coliques, 74, 83, 99, 133, 137, 142 Colite, 65 Conjonctivite, 16, 111, 137, 233 Constipation, 11, 26, 31, 47, 53, 65, 83, 155, 179, 183, 208, 224 Convulsions, 133, 217 D Dermatite, 34, 47, 118, 155, 179 Diabéte, 16, 26, 34, 47, 53, 59, 99, 118, 123,142, 155, 163, 169, 197, 205, 217, 224, 229 Diarrhée, 3, 7, 11, 16, 26, 47, 59, 74, 79, 83, 99, 114, 137, 142, 152, 159 Douleur, 3, 11, 20, 59, 118, 142, 147, 159, 169,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 909,
    "source": "PDF_chunked"
  },
  {
    "id": 5159,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1159)",
    "text": "155, 163, 169, 197, 205, 217, 224, 229 Diarrhée, 3, 7, 11, 16, 26, 47, 59, 74, 79, 83, 99, 114, 137, 142, 152, 159 Douleur, 3, 11, 20, 59, 118, 142, 147, 159, 169, 174, 187, 197, 224, 239 Dracunculose, 42, 65, 83 Dysenterie, 7, 16, 26, 34, 47, 65, 83, 99, 137, 142, 152, 159, 229 Dysménorrhée, 20, 111, 114 Dyspepsie, 16 Dyspnée, 16 E Eczéma, 47, 147, 174, 179 Épistaxis, 16 F Fiévre, 11, 16, 20, 47, 65, 71, 74, 79, 103, 111, 118, 123, 137, 152, 159, 197, 220, 224 G Gale, 47 Gonorrhée, 34, 83, 179 Goutte, 26, 59 H Helminthiases, 47, 59, 65, 103, 123, 169, 224 Hémorragies, 11, 103, 197 Hémorroides, 159, 239 Hépatite, 47, 142, 159, 220",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 638,
    "source": "PDF_chunked"
  },
  {
    "id": 5160,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1160)",
    "text": "OOAS Page 251 Index des maladies WAHP Herpés, 31, 118 Hypertension, 26, 38, 47, 65, 74, 99, 111, 118, 129, 142, 155, 169, 197, 217, 233 I Impuissance, 83, 99, 233 Infections, 3, 34, 74, 91, 107, 137, 201, 205, 208 Inflammation, 3, 7, 11, 205, 208 Insomnie, 111, 152, 155 Insuffisance dela lactation, 111 J Jaunisse, 47, 65, 123, 183, 220 L Lépre, 174, 179, 208 Lumbago, 47, 155 M Menstruations Douloureuses, 99 Mycose, 179 P Paludisme, 11, 20, 38, 42, 47, 71, 74, 87, 91, 99, 103, 107, 111, 114, 118, 123, 129, 142, 152, 155, 159, 193, 197, 205, 220, 224, 229 Pharyngite, 65 Plaies, 31, 118, 155, 174, 193, 197, 205, 208 Prolapsus rectal, 16 Prurit, 47, 224 Psoriasis, 47, 147, 174, 224 Psychoses, 155 R Rhumatisme, 26, 74, 79, 137, 174, 197, 233 Rhumatoide, 38 Rhume, 16, 34 Rougeole, 38, 118 S Schistosomiase, 53, 208, 217 Schizophrénie, 155 Splénomé galie, 183 Syphilis, 233 T",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 879,
    "source": "PDF_chunked"
  },
  {
    "id": 5161,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1161)",
    "text": "R Rhumatisme, 26, 74, 79, 137, 174, 197, 233 Rhumatoide, 38 Rhume, 16, 34 Rougeole, 38, 118 S Schistosomiase, 53, 208, 217 Schizophrénie, 155 Splénomé galie, 183 Syphilis, 233 T Teigne, 47, 79, 147, 179, 224 Toux, 3, 7, 83, 169, 201, 239 Trypanosomiase, 99, 123 Tuberculose, 26, 34, 107 U Ulcére, 31, 34, 47, 65, 99, 103, 118,142, 179, 193, 197, 217 V VIHSIDA, 118",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 364,
    "source": "PDF_chunked"
  },
  {
    "id": 5162,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1162)",
    "text": "OOAS Page 252 Annexe WAHP Comité d'experts (1) Prof Marian Ewurama Addy Chairperson Vice Chancellor Anglican University College of Technology, GHANA Tel : 23321511380233208135867 E-mail: ewuramaug.edu.gh aitcicyahoo.com Prof Mamadou Aliou Balde Chef du Département de Pharmacie à l'UGANC GUINEE CONAKRY Tél: 22460255882 Email: bmaliou2002yahoo.fr Prof Tony Elujoba Professor of Pharmacognosy, Department of Pharmacognosy, Faculty of Pharmacy Obafemi Awolowo University, Ile-Ife, NIGERIA Mobile phone: 2348034025633 E-mail: tonyeluyahoo.com aelujobaoauife.edu.ng Prof Olobayo Kunle Director, Pharmaceutical Technology and Raw Material Development, National Institute for Pharmaceutical Research and Development (NIPRD) Idu, Abuja, NIGERIA Tel: 2348033145095 E-mail: olobayokunleyahoo.co.uk kunleoohotmail.com Prof Emmanuel Bassene Laboratoire de Pharmacognosie et Botanique, Faculté de Médecine Pharmacie et Odontologie,",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 5163,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1163)",
    "text": "Tel: 2348033145095 E-mail: olobayokunleyahoo.co.uk kunleoohotmail.com Prof Emmanuel Bassene Laboratoire de Pharmacognosie et Botanique, Faculté de Médecine Pharmacie et Odontologie, UCAD, SENEGAL Tél : 221776438067221338245038 Email: aynenuthotmail.com aynenutucad.sn Prof Rokia Sanogo Maître de Conférences Agrégé du CAMES, FMPOS Département Médecine Traditionnelle de l'INRSP BP 1746 Bamako et Université de Bamako, MALI Tél:2232021462322366746534 22320242904 E-mail: rosanogoyahoo.fr aidemetafribonemali.net Prof Jean-Baptiste Nikiema Directeur Général des Pharmacies, des Médicaments et des Laboratoires Ministère de la Santé Ouagadougou, Burkina Faso Tél : 22650324622670259201 E-mail: jbnikiemayahoo.fr jb_nikiemauniv- ouaga.bf Dr Pepas Vicente Natak Direcçao de Serviços Farmacêuticos Sc Direcçao Geral Da Saùde Pùublica, GUINEE BISSAU Fax: 245 201 188 Email: minsapgov.hotmail.com pevnatakyahoo.com.br",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 909,
    "source": "PDF_chunked"
  },
  {
    "id": 5164,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1164)",
    "text": "Dr Pepas Vicente Natak Direcçao de Serviços Farmacêuticos Sc Direcçao Geral Da Saùde Pùublica, GUINEE BISSAU Fax: 245 201 188 Email: minsapgov.hotmail.com pevnatakyahoo.com.br Dr Pierre Agbani University of Abomey-Calavi, BENIN E-mail: pagbaniyahoo.fr Comité d'experts (2) Prof Tony Elujoba Chairperson Professor of Pharmacognosy, Department of Pharmacognosy, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, NIGERIA Mobile phone: 234 803 402 56 33 E-mail: tonyeluyahoo.com aelujobaoauife.edu.ng Prof Rokia Sanago Deputy Chairperson Maître de Conférences Agrégé du CAMES, FMPOS Département Médecine Traditionnelle de l'INRSP BP 1746 Bamako et Université de Bamako, MALI Tél:22320214623223667465342232024290 4 E-mail: rosanogoyahoo.fr aidemetafribonemali.net Prof (Mrs) Edith Ajaiyeoba Deputy Director, Distance Learning Centre, Dept of Pharmacognosy Faculty of Pharmacy University of Ibadan, Ibadan, NIGERIA",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 916,
    "source": "PDF_chunked"
  },
  {
    "id": 5165,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1165)",
    "text": "aidemetafribonemali.net Prof (Mrs) Edith Ajaiyeoba Deputy Director, Distance Learning Centre, Dept of Pharmacognosy Faculty of Pharmacy University of Ibadan, Ibadan, NIGERIA E-mail: edajaiyeyahoo.com Dr Kofi Annan Head of Department Department of Herbal Medicine Faculty of Pharmacy, College of Health Sciences Kwame Nkrumah University of Science and Technology, Kumasi-GHANA Tel: 233274243641 E-mail : annan.kofi82yahoo.com",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 424,
    "source": "PDF_chunked"
  },
  {
    "id": 5166,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1166)",
    "text": "OOAS Page 253 Annexe WAHP Dr Koffi Koudouvo Doctorat en Biologie de Développement Spécialité: Ethnobotanique et Pharmacologie des Substances Naturelles Ecole Doctorale: Sciences-Environnement-Santé Faculté des SciencesUniversité de Lomé- TOGO, BP 1515 Tel: 22822550942289055204 Email: kkoudouvogmail.com koudouvotg.refer.org Dr Djakalia Ouattara co Directeur Coordonnateur du Programme National de Promotion de la Médecine Traditionnelle; COTE d'IVOIRE Tél: 225 20 32 47 6805 68 86 23 Fax: 225 20 33 27 81 Email: xylopia2002yahoo.fr pnpmt_ciyahoo.fr Dr Rokhaya Ndiaye Kande Responsable du bureau de pharmacopée traditionnelle, Direction Pharmacie et des Laboratoires, Ministère de la Santé, SENEGAL Email : rokiandiayekandeyahoo.fr D'autres contributeurs et le personnel de soutien Prof Drissa Diallo Chef du Département Médecine Traditionnelle de l'INRSP BP 1746 Bamako-MALI Tél : 2232214326. Email: dri.dialloyahoo.fr",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 919,
    "source": "PDF_chunked"
  },
  {
    "id": 5167,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1167)",
    "text": "soutien Prof Drissa Diallo Chef du Département Médecine Traditionnelle de l'INRSP BP 1746 Bamako-MALI Tél : 2232214326. Email: dri.dialloyahoo.fr Prof Kone Bamba Dieneba UTR Sciences Pharmaceutiques et Biologiques BPV 34, Abidjan, BP 358 Codex 3-COTE D'IVOIRE Tel : 22522444246225470862 E-mail: konebambahotmail.com Prof Amedegnato Degnon Chef de Service de la Médecine Interne au CHU Tokoin-Lomé-TOGO Tél: 22822229282289172050 Email: degnonjmyahoo.fr Prof Lanre Moody Dean, Faculty of Pharmacy University of Ibadan, NIGERIA Tel. 2348034271740 E-mail: lanmoodyyahoo.com Mr Abu Sumaila Herbal Medicines Unit Food and Drugs Board-GHANA E-mail: asumailafdbghanagov.gh Tel: 233262689296 Dr Ehoule Kroa Directeur Coordonnateur du Programme National de Promotion de la Médecine Traditionnelle; COTE D'IVOIRE Tél.: 22520324768225 05 68 86 23 Fax : 22520332781 Email: ekroa2002yahoo.fr pnpmt_ciyahoo.fr Dr Roch A. Houngnihin",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 916,
    "source": "PDF_chunked"
  },
  {
    "id": 5168,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1168)",
    "text": "Traditionnelle; COTE D'IVOIRE Tél.: 22520324768225 05 68 86 23 Fax : 22520332781 Email: ekroa2002yahoo.fr pnpmt_ciyahoo.fr Dr Roch A. Houngnihin Coordonnateur National Programme National de la Pharmacopée et de la Médecine Traditionnelle Ministère de la Santé, 01 BP 882, Cotonou- BENIN Tél: 2299506133593708368 Fax: 22921334583 E-mail: roch_houngnihin2001yahoo.fr Dr Kadidja Djierro Directrice de la Médecine et Pharmacopée Traditionnelles BURKINA FASO Tel : 226 5032466076000011 E-mail: djierrokyahoo.fr Dr Bunmi Omoseyindemi Chairman, Lagos State Traditional Medicine Board Ministry of Health 7 King George V Road, Onikan, Lagos-NIGERIA Tel: 23480232063032348054257659 Email: bunmiomoseyinyahoo.com Dr Isaac Kingsley Amponsah Department of Pharmacognosy Faculty of Pharmacy, College of Health Sciences Kwame Nkrumah University of Science and Technology, Kumasi-GHANA Tel: 233243888337 E-mail : ik_amponsahyahoo.com",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 917,
    "source": "PDF_chunked"
  },
  {
    "id": 5169,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1169)",
    "text": "Department of Pharmacognosy Faculty of Pharmacy, College of Health Sciences Kwame Nkrumah University of Science and Technology, Kumasi-GHANA Tel: 233243888337 E-mail : ik_amponsahyahoo.com Mrs Rita Kusi Appiah Medical Herbalist St Luke Natural Health Clinic Tema-GHANA Tel: 233 244 97 70 29 E-mail: naa3calotropisyahoo.co.uk Mme Agnes Imby Eholly Directeur Coordonnateur du Programme National de la Promotion de la Médecine Traditionnelle-Cote d'Ivoire Tél. 225 20 32 47 6805 68 86 23 Fax : 225 20 33 27 81 E-mail: imby2003yahoo.fr Ms Diana Opare Tema-GHANA E-mail: dopare59yahoo.com",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 583,
    "source": "PDF_chunked"
  },
  {
    "id": 5170,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1170)",
    "text": "OOAS Page 254 Annexe WAHP Mrs Quincy Olasumbo Ayodele Quincy Herbal Slimmers 12 Crescent hsc 3 Kado, Abuja-Nigeria Tel:234 805 5008000 E-mail: quincyayoaol.com Les experts qui ont effectué des études de toxicité Prof Charles Ansah Leader Principal Investigator Toxicology Group Department of Pharmacology College of Health Sciences Kwame Nkrumah University of Science and Technology, Kumasi-GHANA E-mail: charlesansah88yahoo.com cansah.pharmknust.edu.gh Prof Rokia Sanago Maître de Conférences Agrégé du CAMES, FMPOS Département Médecine Traditionnelle de l'INRSP BP 1746 Bamako et Université de Bamako, MALI Tél: 223202146232236674653422320242904 E-mail: rosanogoyahoo.fr aidemetafribonemali.net Partenaires Mr Charles KATY Chargé de Programme et Coordinateur des recherches au Centre Expérimental des Médecines Traditionnelles de Fatick PROMETRA International",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 861,
    "source": "PDF_chunked"
  },
  {
    "id": 5171,
    "title": "2013_pharmacopee-des-plantes-medicinales-afrique-de-louest (chunk 1171)",
    "text": "Partenaires Mr Charles KATY Chargé de Programme et Coordinateur des recherches au Centre Expérimental des Médecines Traditionnelles de Fatick PROMETRA International Sicap Liberté II n1538 Dakar-Sénégal Tel: 22182496482218322850 Fax: 2215819621 E-mail : prometraprometra.org erickgrefer.sn Dr Ossy MJ Kasilo Regional Advisor, Traditional Medicine WHOAFRO P.B. 6 Brazzaville République du Congo Tel : 47-241-39268 Fax : 47-241-39511 Email : kasilooafro.who.int; okasiloyahoo.co.uk",
    "url": "data\\raw\\2013_pharmacopee-des-plantes-medicinales-afrique-de-louest.pdf",
    "length": 478,
    "source": "PDF_chunked"
  },
  {
    "id": 5172,
    "title": "African-Traditonal-Medicine_E (chunk 1172)",
    "text": "I ! 15th Meeting of the Inter-African Expert Committee on African Traditional Medicine and Medicinal Plants. Arusha, Tanzania: 15-17 January, 2002 2001-2010 : OAU Decade for African Traditional Medicine Paper: IDRC1 Support to Research on Medicinal Plants and Traditional Medicine in Africa by Dr. Francois Gasenqayire\" The International Development Research Centre (IDRC) is a public corporation created by the Parliament of Canada in 1970 to help developing countries use science and knowledge to find practical, long-term solutions to the social, economic, and environmental problems they face. Support is directed toward developing an indigenous research capacity to sustain policies and technologies developing countries need to build healthier, more equitable, and more prosperous societies. IDRC, Regional Office for Eastern and Southern Africa. P.O.Box 62084 Nairobi, Kenya. ____'.n __ .' , . \" ..",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 905,
    "source": "PDF_chunked"
  },
  {
    "id": 5173,
    "title": "African-Traditonal-Medicine_E (chunk 1173)",
    "text": "I. Introduction Most of the World population in developing countries continue to rely on traditional health systems and medicinal plants to meet their health care needs. In Sub-Saharan Africa, health provision is beyond the reach of most rural population. The incidence of tropical diseases and the HIVAIDS epidemic continues to rise as a result of weak health infrastructure and declining standards of living. In most cases traditional medicine is the only option available to the people. it is estimated that about 85 per cent of rural communities in Sub-Saharan Africa rely on traditional remedies, most of which are plant-based. In addition to their use in traditional medicine, medicinal plants are precious resources for the pharmaceutical, food and cosmetic industries. Yet their stock are diminishing due to the rapid loss of biodiversity as a result of environmental degradation factors such as demographic pressure, unsustainable utilization of resources, drought,",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 974,
    "source": "PDF_chunked"
  },
  {
    "id": 5174,
    "title": "African-Traditonal-Medicine_E (chunk 1174)",
    "text": "due to the rapid loss of biodiversity as a result of environmental degradation factors such as demographic pressure, unsustainable utilization of resources, drought, deforestation, and lack of adequate resource management. At the same time, there is a gradual loss of indigenous knowledge on medicinal plants and traditional medicine as a result of death of the older people who have traditionally been the custodians of this knowledge. II. Support to Research on Medicinal, Plants and Tradltlonal Medicine, in Africa The International Development Research Centre (IDRC) support for research on medicinal plants and traditional medicine is consistent with the recognition that biodiversity, or genetic variability, is vital to the health of the planet and its people, It secures our food supply, provides a source of medecine, and helps regulate our climate. The International Development Research Centre, through its Sustainable Use of",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 936,
    "source": "PDF_chunked"
  },
  {
    "id": 5175,
    "title": "African-Traditonal-Medicine_E (chunk 1175)",
    "text": "secures our food supply, provides a source of medecine, and helps regulate our climate. The International Development Research Centre, through its Sustainable Use of Biodiversity Program Initiative (SUB PI), supports medicinal-plant research that reflects its commitment to promoting the production and use of knowledge to attenuate poverty and improve living conditions in the developing countries. Accordingly, the Centre played a major role ir. the process that led to the Declaration on tile Decade for African Traditional Medicine (2001-2010) by the Summit of the African Union (Lusaka, July 2001), and hopes to participate in this event 11.1Sustainable Use of Biodiversity Programme Initiative (SUB PI) The SUB PI addresses two related concerns: the importance of biodiversity resources to human livelihoods, particularly to marginalized communities; and enhancing the role of these communities in the sustainable use of biodiversity 2",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 941,
    "source": "PDF_chunked"
  },
  {
    "id": 5176,
    "title": "African-Traditonal-Medicine_E (chunk 1176)",
    "text": ";' ! SUB PI's Objectives: To promote the use, maintenance, and enhancement of the knowledge, mnovation, and practices of Indigenous and local communities that conserve and sustainably use biodiversity; To support the development of policies and legislation that recognize the rights of Indigenous and local communities to genetic resources, as well as to the equitable sharing of benefits from the use of these resources; To develop gender-sensitive incentives, methods, livelihood options, and policies that facilitate community-based participation in biodiversity conservation and management strategies. 11.2In the area of medicinal plants Approach: IDRC supports research on medicinal plants through a multidisciplinary approach that integrates key issues in health, conservation, indigenous knowledge, and local economic development. IDRC supports research activities that are community-based but that can influence national and international policy objectives Research Focus",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 979,
    "source": "PDF_chunked"
  },
  {
    "id": 5177,
    "title": "African-Traditonal-Medicine_E (chunk 1177)",
    "text": "local economic development. IDRC supports research activities that are community-based but that can influence national and international policy objectives Research Focus Biodiversity conservation: documenting the uses of medicinal plants, their taxonomy and relative abundance, identifying those which may be endangered, and establishing community-based conservation strategies and practices; Improved access to health care: promoting collaboratior. between health care institutions and traditional medecine practitioners to undertake research leading to safe, effective, affordable, and culturally appropriate treatments and practices; Marketing and employment opportunities: identifying potentially marketable medicinal plants as a source of income and employment for local communities. The development of standardized production, quality control, and sustainable harvesting methods are emphasized; Use of indigenous knowledge: supporting collaborative and participatory",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 972,
    "source": "PDF_chunked"
  },
  {
    "id": 5178,
    "title": "African-Traditonal-Medicine_E (chunk 1178)",
    "text": "The development of standardized production, quality control, and sustainable harvesting methods are emphasized; Use of indigenous knowledge: supporting collaborative and participatory research between local communities and scientific institutions. Documentation and development of medicinal plants based on traditional knowledge must ensure that local communities have control of, access to, and benefits from research through intellectual property rights legislation, protocols and other .,.)",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 493,
    "source": "PDF_chunked"
  },
  {
    "id": 5179,
    "title": "African-Traditonal-Medicine_E (chunk 1179)",
    "text": "mechanisms; Networking: racilitating linkages and exchanges, within and between regions, that enhance local access to information and benefits from research and development opportunities. Improved access to information and communication technologies can amend inequalities in access to information on medicinal plants, and help to forster national, regional and international collaboration. 11.3Examples of current IORC-funded projects and activities in Africa IORC has supported projects and activities on medicinal plants and traditional medicine in Africa since 1974. Currently, IORC supports projects and activities in Africa that involve local communities and non governmental organizations, universities, national governments, and international bodies in research and development on medicinal plants and natural products. The following projects and activities are current examples of IORC-funded activities. Medicinal Plants and Biodiversity (Uganda)",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 956,
    "source": "PDF_chunked"
  },
  {
    "id": 5180,
    "title": "African-Traditonal-Medicine_E (chunk 1180)",
    "text": "plants and natural products. The following projects and activities are current examples of IORC-funded activities. Medicinal Plants and Biodiversity (Uganda) Like many other African countries, Uganda faces an acute shortage of drugs, most of which are imported from abroad. A large part of the population depends on medicinal plant products. However, the plants are facing depletion -- some are endangered, largely because of increased pressure on the land and destructive harvesting methods. Building on baseline information on medicinal plants, this project works with local communities, traditional healers, and health practitioners to investigate 15 rare and endangered species of medicinal plants. The aim is to understand local perceptions of these plants and their uses, and determine plant conservation issues in four regions of the country. Effective strategies will be developed to conserve, propagate, and use",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 920,
    "source": "PDF_chunked"
  },
  {
    "id": 5181,
    "title": "African-Traditonal-Medicine_E (chunk 1181)",
    "text": "these plants and their uses, and determine plant conservation issues in four regions of the country. Effective strategies will be developed to conserve, propagate, and use these plants in a sustainable way. At the same time, the project is helping traditional healers, ethnomedicine researchers, and health workers gain experience in non destructive methods of harvesting, and more effective preservation. They are also learning how to investigate the safety and efficacy of widely-used traditional remedies. iJrJi4rd Institutions: National Chemotherapeutics Research Laboratory and the Entebbe Botanical Gardens, and Makerere University Medicinal Plants in Traditional Health Practices (Ethiopia) Home to some 80 ethnic groups with distinct languages and dialects, Ethiopia has an extremely varied socioeconomic and cultural landscape. Even within a relatively small geographical area, farming and production systems, and the use of plants as a source",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 5182,
    "title": "African-Traditonal-Medicine_E (chunk 1182)",
    "text": "extremely varied socioeconomic and cultural landscape. Even within a relatively small geographical area, farming and production systems, and the use of plants as a source of medicine, can vary widely. This project seeks to acquire information and document the use of locally important medicinal plant genetic resources and traditional knowledge systems in selected Ethiopian communities. The project will also identify gender differences in traditional health knowledge and practice, and access to resources, and 4",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 514,
    "source": "PDF_chunked"
  },
  {
    "id": 5183,
    "title": "African-Traditonal-Medicine_E (chunk 1183)",
    "text": "assess community access to and use of modern health services. Potential areas of complementarity between traditional and modern health systems will be identified. Institutions: Biodiversity Institute, National Traditional HealerOrganisation, Addis Ababa University, and University of OxfordDevelopment Studies Centre. Cq-ROM Database on Malagasy Medicinal Plants Madagascar is endowed with rich and unique plant diversity: 13 000 species are found on an area of 590 000 square kilometres. Documenting, conserving, and using Malagasy biodiversity in a sustainable way are pressing priorities as the island is threatened with desertification. This project gather and compile all existing information and data on the use of Madagascar's medicinal plants to help develop a policy for their conservation and sustainable utilization. The compiled information will be disseminated on CD-ROM. Institution: Institut malgache de recherche appliquee (IMRA)",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 945,
    "source": "PDF_chunked"
  },
  {
    "id": 5184,
    "title": "African-Traditonal-Medicine_E (chunk 1184)",
    "text": "conservation and sustainable utilization. The compiled information will be disseminated on CD-ROM. Institution: Institut malgache de recherche appliquee (IMRA) Community Based Conservation of Medicinal Plants (Kenya) Kenya's biological resources are diverse, with an estimated 35,000 known species of - animals, plants and micro-organisms. These resources form the basic source of livelihood especially for the 80 of the country's rural population who relies directly or indirectly on biodiversity for its survival. Like most countries in Sub-Saharan Africa, health provision in Kenya is beyond the reach of most rural population. The incidence of tropical diseases c....ldthe HIVAIDS epidemic continues to rise as a result of weak health infrastructure and declining standards of living. In most cases traditional medicine is the only option available to the people. Moreover, biodiversity is being rapidly lost as result of environmental degradation factors such as demographic",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 979,
    "source": "PDF_chunked"
  },
  {
    "id": 5185,
    "title": "African-Traditonal-Medicine_E (chunk 1185)",
    "text": "medicine is the only option available to the people. Moreover, biodiversity is being rapidly lost as result of environmental degradation factors such as demographic pressure, unsustainable utilization of resources, drought, deforestation, and lack of adequate resource management. At the same time, there is a gradual loss of indigenous knowledge on medicinal plants and traditional medicine as a result of death of the older people who have traditionally been the custodians of this knowledge. Although Kenya was one of the first countries in the developing world to create a National Environment Secretariat (NES) in 1972 to address environmental policy formulation and implementation, and despite the recently developed National Biodiversity Strategy (1996), most of the research and conservation efforts undertaken at various levels are fragmented resulting often in duplication and inefficient utilization of limited resources and capacity. I I I I I I I I I I",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 5186,
    "title": "African-Traditonal-Medicine_E (chunk 1186)",
    "text": "at various levels are fragmented resulting often in duplication and inefficient utilization of limited resources and capacity. I I I I I I I I I I This project builds on preliminary surveys conducted within Luo-Suba and Kamba communities in respectively the Nyanza and Eastern provinces of Kenya and seeks to enhance capacity and capability at local community, institutional and national levels for the sustainable use and conservation of medicinal plants biodiversity and improvement of health and productivity of the people. To this end, the project is focussing on conducting ethnobotanical surveys to complement previous studies in the target I I I I I I I 5",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 662,
    "source": "PDF_chunked"
  },
  {
    "id": 5187,
    "title": "African-Traditonal-Medicine_E (chunk 1187)",
    "text": "regions, developing conservation strategies for identified threatened plant species, conducting toxicological assessment on selected plants in order to determine their levels of safety and to avoid possible health risks. In addition, the project further aims at addressing the national institutional capacity and capability for medicinal plants biodiversity use and conservation. Institutions: Maseno University; National Museums of Kenya and Kenya Forest Researcy Institute Medicinal Biodiversity (West Africa) In West Africa, a shortage of basic medications, lack of health services, high cost of drugs, and traditional practices, mean that most of the population - particularly in rural areas - resorts to traditional medicine, healers, and herborists. Unfortunately, this centuries-old traditional knowledge is being eroded. This project seeks to restore confidence in this accessible and culturally appropriate system of health care by",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 940,
    "source": "PDF_chunked"
  },
  {
    "id": 5188,
    "title": "African-Traditonal-Medicine_E (chunk 1188)",
    "text": "centuries-old traditional knowledge is being eroded. This project seeks to restore confidence in this accessible and culturally appropriate system of health care by increasing the knowledge and capacities of populations and developing sustainable methods of producing plant-based medicines in Mali, Guinea, and Togo. The project team is identifying medicinal plants with potential therapeutic properties against common ailments; evaluating biologically active components; and testing toxicity levels of selected plants. In addition, the project is examining threats to conservation and proposing conservation options. The researchers are working in collaboration with traditional healers, herbalists, students, researchers, and decision to create viable policy options for the sustainable development of medicinal plants. Institutions: Departement de rnedecine traditionnelle -INRSP (Mali), Universite de Lome (Togo), and Institut .Ie recherche et d'appui au devetoppernent communautaire -",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 989,
    "source": "PDF_chunked"
  },
  {
    "id": 5189,
    "title": "African-Traditonal-Medicine_E (chunk 1189)",
    "text": "Institutions: Departement de rnedecine traditionnelle -INRSP (Mali), Universite de Lome (Togo), and Institut .Ie recherche et d'appui au devetoppernent communautaire - IRADEC (Guinea). Sacred Forests (Ivory Coast) In the Ivory Coast, the sacred forests are steeped in village lore and lineages. For a long time, populations' cultural practices contributed to the forests' protection. Unfortunately, there is now pressure to change the status of these forests: forested land has decreased from 21 million hectares in 1957 to 2.8 million in 1995. Deforestation is increasing by 6.5 percent a year (approximately 300,000 hectares). This is affecting the cultural and spiritual heritage of the local communities and is causing a severe decline in biodiversity, particularly in uncultivated food crops and medicinal plants. The Sacred Forest project aims to develop strategies, based on the local populations' cultural",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 913,
    "source": "PDF_chunked"
  },
  {
    "id": 5190,
    "title": "African-Traditonal-Medicine_E (chunk 1190)",
    "text": "in biodiversity, particularly in uncultivated food crops and medicinal plants. The Sacred Forest project aims to develop strategies, based on the local populations' cultural practices, to preserve the forests and their biodiversity. It also recognizes medicinal plants' social and economic importance for stakeholders. Institution: Croix Verte de Cote d'ivoire. Economic Importance and Conservation of Medicinal Plants (Senegal) 6",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 430,
    "source": "PDF_chunked"
  },
  {
    "id": 5191,
    "title": "African-Traditonal-Medicine_E (chunk 1191)",
    "text": "Workshops and Conferences I I I I 1 I I I I I I I I I I I I I I I I I I I I II I I The project builds on the recommendations of several workshops and meetings held previously in Senegal on conservation of medicinal plants. In order to increase sustainability of activities dedicated to the conservation and valorization of medicinal plants, the project seeks first to document the socio-economic profiles of stakeholders, and main market characteristics of medicinal plants. It tries to improve understanding of various aspects of medicinal plants exploitation by communities and other stakeholders within the context of rural economy, which is becoming more and more important as a result of increasing poverty. The project' activities also aim to propose a legal framework, as well as a framework for exchange and dissemination of information, in collaboration with organized traditional healer associations. Institutions: UICN-Snegal, ENOA tiers Monde, and Universite Cheikh Anta Oiop de",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 990,
    "source": "PDF_chunked"
  },
  {
    "id": 5192,
    "title": "African-Traditonal-Medicine_E (chunk 1192)",
    "text": "information, in collaboration with organized traditional healer associations. Institutions: UICN-Snegal, ENOA tiers Monde, and Universite Cheikh Anta Oiop de DakarFaculte de Medecine et de Pharmacie IORC has organized andor supported the organization of workshops and conferences about medicinal plants and traditional medicine. These include: The \"First OAUSTRCOEPAKIP03 Workshop on Medicinal Plants and Herbal Medicine in Africa: Policy issues on Ownership, Access and Conservation,\" Nairobi, Kenya, April 1997; The \"Regional Workshop on Medicinal Plants and Traditional Medicines in Africa,\" Conakry, Guinea, November 1997, for Francophone participants including nongovernmental organization (NGO) representatives, researchers, and tradipractitioners; 7 The \"Regional Workshop on Medicinal Plants and Traditional Medicines in Africa,\" Cape Town, South Africa, April 1998, for English-speaking NGO representative s, researchers and tradipractitioners;",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 953,
    "source": "PDF_chunked"
  },
  {
    "id": 5193,
    "title": "African-Traditonal-Medicine_E (chunk 1193)",
    "text": "7 The \"Regional Workshop on Medicinal Plants and Traditional Medicines in Africa,\" Cape Town, South Africa, April 1998, for English-speaking NGO representative s, researchers and tradipractitioners; The \"International Conference on Medicinal Plants, Traditional Medicine and Local Communities: Challenges and Opportunities of the New Millennium,\" Nairobi, May 2000, in parallel to the 5th Conference of the Parties to the Biological Diversity Convention (COP V). The Conakry and Cape Town workshops and the Nairobi international conference were organized within the framework of the IORC-supported Medicinal Plants and Local 3 First OAUSTRCDEPAKIPO Workshop: OAlJ: Organization of African Unity STRC: Scientific. Technical and Research Commission, Nigeria DEPA: Development Partners (an NGO based in Kakamega, Kenya) KIPO: Kenya Industrial Property Office I I I I",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 863,
    "source": "PDF_chunked"
  },
  {
    "id": 5194,
    "title": "African-Traditonal-Medicine_E (chunk 1194)",
    "text": "Communities (Africa) project, implemented by Environment Liaison Centre International (ELCI, Nairobi). First National Workshop on Medicinal, Aromatic, and Other Underutilized Plant Species in Kenya: Towards the Promotion of Medicinal and Other Underutilized Plants in Kenya for Sustainable Socio-economic Development. Naivacha, 29tl1 October- 3rd November 2001. 11.4lORe Involvement in the 2001-2010 Decade for African Traditional Medicine The conference held in Nairobi in 2000 was hosted by a coalition of organizations, including ELCI and Global Initiative for Traditional Systems of Health, among others. Conference participants formally requested African governments and the Organisation of African Unity (OAU) to adopt a Decade devoted to the promotion and development of medicinal plants, traditional medicines, and pharmacopoeia in Africa, as a means of drawing public attention to both the rich heritage of African traditional medicine and the",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 5195,
    "title": "African-Traditonal-Medicine_E (chunk 1195)",
    "text": "of medicinal plants, traditional medicines, and pharmacopoeia in Africa, as a means of drawing public attention to both the rich heritage of African traditional medicine and the pressures it now faces. A formal recommendation was drafted to this end. As a follow up, a process coordinated at IDRC's Regional Office for East and Southern Africa in Nairobi involved most of African participants in the conference -- especially IDRC partners -- to sensitize African governments to this important issue. Contacts were also established with the OAU Secretariat. As a result, three governments requested the OAU Secretary General to put the Decade of Traditional Medicine on the agenda of the OAU Summit to be held in Lusaka, Zambia, in July 2001: first Uganda, followed by Madagascar and Ghana. The issue was put on the agenda of the 74th OAU Council of Ministers. IDRC facilitated the participation of projects leaders, Mr. Corn Alele",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 930,
    "source": "PDF_chunked"
  },
  {
    "id": 5196,
    "title": "African-Traditonal-Medicine_E (chunk 1196)",
    "text": "followed by Madagascar and Ghana. The issue was put on the agenda of the 74th OAU Council of Ministers. IDRC facilitated the participation of projects leaders, Mr. Corn Alele Amai of Uganda and Prof. Philippe Hasoanaivo of Madagascar, in the OAU meetings. And on the 11th of July 2001, the 2001-2010 Decade for African Traditional Medicine was launched by the Summit of the Organization of African Unity. Initiative Regional Collaborative Program of Research and Networking on Medicinal Biodiversity and Traditional Medicine (Africa) General Objective: This initiative seeks to build on existing activities, experiences and networks in the concerned area in Africa, To develop a programme of research and networking that will enable more coherent and effective collaboration among interested international, national and local 8",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 827,
    "source": "PDF_chunked"
  },
  {
    "id": 5197,
    "title": "African-Traditonal-Medicine_E (chunk 1197)",
    "text": "organizations currently working in Africa towards the sustainable, safe, and effective use of medicinal plants and herbal products. Specific-cbjectlves: To develop, in collaboration with the main stakeholders, a regional programme of research and specific activities to promote the development of medicinal plants and traditional medicine in Africa; To support the development and integration of information, research and experts networks (local: national, regional) dedicated to the sustainable, safe, and effective use of medicinal plants in Africa; To build capacity of relevant networks for research, exchange of information, and management of plant resources; To increase impact of the networks' activities on health, plants conservation, policy, and economic objectives. 9",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 778,
    "source": "PDF_chunked"
  },
  {
    "id": 5198,
    "title": "African-Traditonal-Medicine_E (chunk 1198)",
    "text": "References International Development Research Centre. IORC in a Changing World. Program Dir.ections 2002-2005. SUB. 2000. Sustainable Use of Biodiversity Initiative. Four Year Program Prospectus2000-2004 SUB PI. Medicinal plants Research Factsheet Series 1 of 5. IORC Support to Medicinal Plant Research. Program Overview. IORC. News Releases. Canada to participate in the Decade for African Traditional Medicine. 11July 2001. http:www.idrc.camediacommplants_e2.html 10 IORC. Research Projects Files. AFRICAN UNION UNION AFRICAINE African Union Common Repository http:archives.au.int Specialized Technical and representational Agencies AU STRC Archives 2002 IDRC support to research on medicinal plants and traditional medicine in Africa Gasenqayire, Francois Gasenqayire, Francois http:archives.au.inthandle1234567891846 Downloaded from African Union Common Repository",
    "url": "data\\raw\\African-Traditonal-Medicine_E.pdf",
    "length": 869,
    "source": "PDF_chunked"
  },
  {
    "id": 5199,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1199)",
    "text": "N2 T2 2025 Bulletin trimestriel d'information Appui stratégique au Gouvernement : actions, résultats et impacts Avril à Juin 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 129,
    "source": "PDF_chunked"
  },
  {
    "id": 5200,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1200)",
    "text": "Nous sommes ravis de vous retrouver pour ce deuxième numéro, qui marque une nouvelle étape dans notre engagement collectif. Après un premier numéro riche en partages et en retours positifs, nous orientons désormais notre regard vers l'avenir. La représentation de l'OMS au Burkina Faso, en collaboration avec le Gouvernement et les partenaires, a intensifié ses efforts pour faire progresser la couverture sanitaire universelle, répondre aux urgences sanitaires et renforcer les déterminants de santé. Ce bulletin met en lumière quelques activités menées résultats obtenus ce trimestre, illustrant l'impact concret de notre engagement collectif. À ce titre, nous saluons la bonne collaboration avec le ministère de la Santé, qui joue un rôle essentiel dans la mise en œuvre efficace des activités sur le terrain.Grâce à ce partenariat renforcé, les efforts se poursuivent pour améliorer l'accès aux soins, renforcer les systèmes de santé et promouvoir le bien-être des populations. Les",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 985,
    "source": "PDF_chunked"
  },
  {
    "id": 5201,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1201)",
    "text": "terrain.Grâce à ce partenariat renforcé, les efforts se poursuivent pour améliorer l'accès aux soins, renforcer les systèmes de santé et promouvoir le bien-être des populations. Les perspectives sont prometteuses, et ensemble, nous restons mobilisés pour faire progresser durablement la santé au Burkina Faso. Merci de continuer à nous lire, à nous accompagner et à soutenir ce bel élan collectif vers un avenir plus sain et plus solidaire. Chères lectrices, chers lecteurs, Bonne lecture à toutes et à tous Dr Seydou O. COULIBALY Représentant par intérim de l'OMS au Burkina Faso N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 591,
    "source": "PDF_chunked"
  },
  {
    "id": 5202,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1202)",
    "text": "Chez les participants, l'enthousiasme était perceptible. Pour Benjamin Sanou, assistant aux achats, cette immersion a été une opportunité précieuse pour explorer la plateforme et en maîtriser les fonctionnalités essentielles. Cet outil, à la fois intuitif et simple d'utilisation, représente un véritable levier d'efficacité dans mon travail quotidien. Sa mise en œuvre me permettrait de renforcer mon autonomie, d'améliorer la gestion de mes tâches et d'optimiser ma performance. Par ailleurs, il favoriserait une communication fluide avec mes collègues et, surtout, avec mon superviseur, assurant ainsi une meilleure coordination et un suivi plus rigoureux. , affirme-t-il. JUILLET 2025 Le personnel de l'OMS au Burkina Faso découvre un nouveau système de gestion pour une innovation renforcée Le personnel de l'OMS au Burkina Faso explore un nouveau système de gestion, ouvrant la voie à une innovation renforcée et à une optimisation des processus",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 951,
    "source": "PDF_chunked"
  },
  {
    "id": 5203,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1203)",
    "text": "Le personnel de l'OMS au Burkina Faso explore un nouveau système de gestion, ouvrant la voie à une innovation renforcée et à une optimisation des processus organisationnels. Les 21 et 22 mai 2025, tout le personnel, sans distinction de contrat, a pris part à une immersion interactive, explorant Workday, un module intégré au BMS conçu pour renforcer leur autonomie dans la gestion efficace du capital humain. Des sessions dynamiques sur Workday ont permis d'offrir une opportunité unique au personnel du bureau du Burkina Faso, d'expérimenter la plateforme. À travers un laboratoire interactif, ils ont pu tester différentes fonctionnalités et se familiariser avec cet outil conçu pour simplifier les processus internes. Madame Sabine Tindano, Chargée des ressources humaines, par ailleurs facilitatrice de cette immersion, a souligné que cette expérience était ouverte à tous et à toutes, indépendamment du type de contrat ou du profil, afin de garantir une",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 959,
    "source": "PDF_chunked"
  },
  {
    "id": 5204,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1204)",
    "text": "facilitatrice de cette immersion, a souligné que cette expérience était ouverte à tous et à toutes, indépendamment du type de contrat ou du profil, afin de garantir une prise en main fluide et efficace du système. L'objectif de ces sessions est d'assurer une transition sans stress vers cette nouvelle plateforme, démontrer sa facilité d'utilisation et mettre en avant ses avantages pour une gestion optimisée des ressources humaines , explique-t-elle. Une séance d'immersion des participants Une séance d'immersion des participants Ressourceshumaines N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 562,
    "source": "PDF_chunked"
  },
  {
    "id": 5205,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1205)",
    "text": "Le personnel de l'OMS au Burkina explore un nouveau système pour une transition fluide( suite) Au total, 88 membres du personnel ont pris part à cette immersion, conçue non seulement pour les familiariser avec la plateforme, mais aussi pour renforcer la fluidité de la communication et améliorer la coordination au sein des équipes. A l'instar des autres membres du personnel, le Représentant Pays de l'OMS au Burkina, Dr Coulibaly Seydou, a évalué positivement les sessions. Il estime qu'elles ont permis au personnel du bureau de se familiariser avec les fonctionnalités clés du système, toute chose qui facilitera ainsi son adoption progressive. L'apprentissage véritable ne réside pas seulement dans l'acquisition de connaissances, mais dans leur mise en pratique continue, permettant ainsi une appropriation durable. Dans une perspective d'apprentissage efficace et d'appropriation, il est essentiel de permettre aux utilisateurs de l'appliquer continuellement",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 5206,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1206)",
    "text": "une appropriation durable. Dans une perspective d'apprentissage efficace et d'appropriation, il est essentiel de permettre aux utilisateurs de l'appliquer continuellement car le savoir ne doit pas simplement être accumulé, mais doit activement être mis en œuvre pour renforcer son impact., a déclaré Dr Seydou Coulibaly. JUILLET 2025 N2 Le laboratoire a ainsi offert aux futurs utilisateurs l'opportunité de prendre en main le module ressources humaines (HCM) de BMS et de mieux comprendre son fonctionnement. Cette initiative s'inscrit dans une continuité logique après la formation sur le système de gestion du programme (SPM) qui avait déjà permis aux participants de se familiariser avec le volet gestion des programmes du système. Avec cette transition vers Workday, le bureau de l'OMS au Burkina Faso s'engage vers une gestion plus fluide, intuitive et efficace des ressources humaines, marquant ainsi une avancée stratégique pour ses opérations.",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 952,
    "source": "PDF_chunked"
  },
  {
    "id": 5207,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1207)",
    "text": "bureau de l'OMS au Burkina Faso s'engage vers une gestion plus fluide, intuitive et efficace des ressources humaines, marquant ainsi une avancée stratégique pour ses opérations. M.le réprésentant presentant lors de la séance d'immersion du BMS les participants apres les séances d'immersion avec leurs personnages Le personnel de l'OMS au Burkina Faso découvre un nouveau système de gestion pour une innovation renforcée Ressourceshumaines N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 450,
    "source": "PDF_chunked"
  },
  {
    "id": 5208,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1208)",
    "text": "Lutte contre le paludisme au Burkina Faso: campagne nationale de distribution gratuite de moustiquaire Paludisme Près de 33 milliards de francs CFA mobilisés . Grâce à l'engagement du gouvernement et de ses partenaires, plus de 15 millions de MILDA seront distribuées pour protéger plus de 30 millions de Burkinabè contre le paludisme. Le représentant de l'Organisation mondiale de la santé (OMS) au Burkina Faso, Dr Seydou Coulibaly , porte-parole des partenaires techniques et financiers, a salué cette initiative et réaffirmé l'engagement ferme des partenaires à accompagner le Burkina Faso dans son ambition d'éliminer le paludisme. Il a souligné que la distribution des MILDA, combinée à la chimioprévention saisonnière et à la vaccination, représente un outil essentiel dans la stratégie intégrée de lutte antipaludique. Le gouvernement burkinabè, avec l'appui de ses partenaires techniques et financiers, a procédé au lancement officiel de la campagne nationale",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 968,
    "source": "PDF_chunked"
  },
  {
    "id": 5209,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1209)",
    "text": "intégrée de lutte antipaludique. Le gouvernement burkinabè, avec l'appui de ses partenaires techniques et financiers, a procédé au lancement officiel de la campagne nationale de distribution universelle et gratuite de moustiquaires imprégnées d'insecticide à longue durée d'action (MILDA). Une initiative majeure dans la lutte contre le paludisme, qui demeure un problème de santé publique de premier plan au Burkina Faso. En 2024, plus de 10 millions de cas ont été recensés, causant la mort de plus de 3 000 personnes, dont une grande majorité d'enfants de moins de cinq ans. Le Premier ministre, Emmanuel OUEDRAOGO, patron de la cérémonie de lancement, a rappelé que \"cette campagne n'est pas une simple activité, mais un véritable combat pour la vie et pour l'avenir de notre pays.\" Le Burkina Faso fait partie des 11 pays les plus touchés par le paludisme dans le monde. La transmission est endémique sur tout le territoire, avec des zones à forte incidence, notamment",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 973,
    "source": "PDF_chunked"
  },
  {
    "id": 5210,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1210)",
    "text": "pays.\" Le Burkina Faso fait partie des 11 pays les plus touchés par le paludisme dans le monde. La transmission est endémique sur tout le territoire, avec des zones à forte incidence, notamment pendant la saison des pluies. Ce fardeau sanitaire mobilise depuis plusieurs années les efforts conjoints de l'État et de ses partenaires. Afin de briser le cycle de transmission, plus de 15 millions de MILDA seront distribuées à travers tout le pays. L'objectif est d'assurer une protection à chaque ménage, chaque individu. Pour y parvenir, le déploiement logistique est massif : 33 000 volontaires communautaires et 7 000 agents de santé seront mobilisés. Ces équipes auront pour mission de recenser les ménages, distribuer les moustiquaires, sensibiliser les familles à leur bon usage, identifier les gîtes larvaires et encourager leur destruction. Avec le debut de la saison pluvieuse, les autorités appellent les populations à faire bon usage des moustiquaires, et à participer activement",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 988,
    "source": "PDF_chunked"
  },
  {
    "id": 5211,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1211)",
    "text": "larvaires et encourager leur destruction. Avec le debut de la saison pluvieuse, les autorités appellent les populations à faire bon usage des moustiquaires, et à participer activement élimination du paludisme au Burkina Faso. Cette campagne de distribution gratuite s'inscrit dans une approche globale visant à réduire la morbidité et la mortalité liées au paludisme, particulièrement chez les populations les plus vulnérables. L'utilisation correcte et régulière des MILDA reste l'un des moyens les plus efficaces pour prévenir les piqûres de moustiques vecteurs du parasite. M. le Représentant de l'OMS délivrant le message au nom des partenaires techniques et financiersM. le premier Ministre en interview avec les journalistes après le lancement M. le premier Ministre remettant une moustiquaire à M. le ministre de la santé pour une bénéficiaire marquant le lancement officiel de la campagne N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 907,
    "source": "PDF_chunked"
  },
  {
    "id": 5212,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1212)",
    "text": "Participation de l'OMS à la journée internationale de lutte contre le paludisme Nwww.romade eallygreatsite.com helloreallygreatsite.com A l'occasion de la journée mondiale de lutte contre le paludisme tenue à Bobo Dioulasso le 25 avril sous le thème réinvestir, réimaginer et raviver nos efforts communs pour mettre fin au paludisme, l'OMS réaffirme son engagement et son soutien au ministère de la santé dans la lutte contre le paludisme lors d'un dialogue politique visant à renforcer les engagements gouvernementaux, notamment la déclaration de Yaoundé. En rappel, la Déclaration de Yaoundé qui a été signée en mars 2024 par les Ministres de la santé des 11 pays souscrivant à l'approche 'une charge élevée à un fort impact , réitère également l'engagement des dirigeants à mettre fin à la mortalité due au paludisme et à intensifier la lutte contre cette maladie afin d'en réduire l'incidence. Au cours de la célébration de la journée mondiale de lutte contre le paludisme, l'OM a",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 984,
    "source": "PDF_chunked"
  },
  {
    "id": 5213,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1213)",
    "text": "la mortalité due au paludisme et à intensifier la lutte contre cette maladie afin d'en réduire l'incidence. Au cours de la célébration de la journée mondiale de lutte contre le paludisme, l'OM a également soutenu le ministère de la santé dans plusieurs activités : l'animation d'un panel au LOC sur le paludisme,, le traitement des gites larvaires, un cross populaire afin de mobiliser la population sur la lutte contre le paludisme. Il a été également une occasion pour le lancement du bulettin sémestriel. Ce bulletin fait le point de la situation épidémiologique du paludisme durant le second semestre de l'année 2024 et permet d'avoir des données actualisées sur le paludisme et de prendre des décisions appropriées dans le cadre de l'élimination du paludisme au Burkina Faso d'ici 2030. Le lancement du Bulletin est l'une des activités de la célébration de la journée mondiale de lutte contre le paludisme Malgré des progrès significatifs, le paludisme",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 957,
    "source": "PDF_chunked"
  },
  {
    "id": 5214,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1214)",
    "text": "lancement du Bulletin est l'une des activités de la célébration de la journée mondiale de lutte contre le paludisme Malgré des progrès significatifs, le paludisme reste un problème de santé publique au Burkina Faso. Il constitue la première cause de consultation et de décès dans les formations sanitaires du pays. Dr Moyenga Laurent delegué par M. le Reprsentant Signant les engagements lancement du bullettin effectif avec M. e Sécretaire permanent et Dr Moyenga Laurent de l'OMS Dr Moyenga Laurent de l'OMS au cours d'un panel au Lycée Ouezziin Coulibaly de Bobo sur le paludisme Paludisme N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 603,
    "source": "PDF_chunked"
  },
  {
    "id": 5215,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1215)",
    "text": "OMS soutient la révision du guide national pour la planification familiale. L'édition 2024 de la SNPF a marqué un tournant important avec l'adoption d'une approche intégrée. Au-delà de la promotion de la planification familiale, elle a permis d'introduire plusieurs thématiques essentielles à la santé des femmes. Parmi celles-ci figurent la promotion de l'allaitement maternel, avec une insistance particulière sur la mise au sein dans l'heure qui suit la naissance et l'allaitement exclusif jusqu'à six mois ; le dépistage des lésions précancéreuses du col de l'utérus pour les femmes de 25 à 55 ans ; le dépistage du cancer du sein pour les femmes âgées de 15 à 55 ans ; la prévention des infections sexuellement transmissibles, dont le VIH ; ainsi que la lutte contre les hépatites virales B et C. Cette évolution thématique a permis de mieux couvrir les besoins de santé globale des femmes et d'améliorer l'efficience des interventions. Pour l'année 2025, les objectifs de la campagne sont",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 994,
    "source": "PDF_chunked"
  },
  {
    "id": 5216,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1216)",
    "text": "Cette évolution thématique a permis de mieux couvrir les besoins de santé globale des femmes et d'améliorer l'efficience des interventions. Pour l'année 2025, les objectifs de la campagne sont clairs. La planification familiale vise à atteindre 163 413 nouvelles utilisatrices de méthodes contraceptives parmi les femmes en âge de procréer, âgées de 19 à 49 ans, réparties dans les 13 régions du pays. Pour l'allaitement maternel, l'ambition est d'assurer que 100 des nouveau-nés soient mis au sein dans l'heure suivant leur naissance dans les maternités participantes. Pour le dépistage du cancer du col de l'utérus, la cible porte sur les femmes âgées de 25 à 55 ans, tandis que le dépistage du cancer du sein concernera celles de 15 à 55 ans. Quant aux services de prévention des ISTVIH et des hépatites virales, ils cibleront principalement les femmes en âge de procréer (15 à 49 ans), avec des objectifs définis à partir des résultats de l'année précédente, majorés de 5 .",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 977,
    "source": "PDF_chunked"
  },
  {
    "id": 5217,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1217)",
    "text": "virales, ils cibleront principalement les femmes en âge de procréer (15 à 49 ans), avec des objectifs définis à partir des résultats de l'année précédente, majorés de 5 . Dans le cadre de son engagement pour la réduction de la mortalité maternelle au Burkina Faso, l'Organisation mondiale de la Santé (OMS) apporte un appui technique au ministère de la Santé pour la révision du guide national de mise en œuvre de la Semaine Nationale de la Planification Familiale Plus (SNPF). Cette collaboration vise à adapter et renforcer un outil essentiel permettant de structurer l'organisation de cette campagne nationale, dont l'objectif est d'améliorer durablement l'accès des femmes, en particulier celles vivant dans des zones rurales ou marginalisées, aux services de santé sexuelle et reproductive. Depuis treize ans, la SNPF est une initiative phare dans la stratégie de santé publique du pays. Elle combine efficacement plaidoyer, prestations de soins renforcées et mobilisation",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 977,
    "source": "PDF_chunked"
  },
  {
    "id": 5218,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1218)",
    "text": "et reproductive. Depuis treize ans, la SNPF est une initiative phare dans la stratégie de santé publique du pays. Elle combine efficacement plaidoyer, prestations de soins renforcées et mobilisation communautaire. Pour garantir l'uniformité, la qualité et la cohérence de son déploiement, un guide national a été mis en place dès 2014. Il a fait l'objet de révisions en 2019 et 2023, intégrant les défis du terrain, notamment le contexte sécuritaire, les déplacements de populations et la politique nationale de gratuité des soins. La révision en cours se veut plus ambitieuse. Elle cherche à intégrer les nouvelles orientations adoptées en 2024 dans une logique d'amélioration continue des interventions et de réponse plus holistique aux besoins des femmes. Dr Bougma Mathieu modérant la séances plénière des travaux de groupes Vue d'ensemble de la salle Dr Sawadogo Ramatou de l'OMS donnant certaines précision ( appui technique) Couverture Maladie Universelle N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 973,
    "source": "PDF_chunked"
  },
  {
    "id": 5219,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1219)",
    "text": "OMS soutient la révision du guide national pour la planification familiale (suite) À travers cette révision du guide de mise en œuvre de la SNPF, l'OMS et le ministère de la Santé renforcent leur engagement à offrir des services de santé reproductive de qualité, accessibles à toutes les femmes, sans distinction. Ce travail commun vise à structurer durablement les prochaines éditions de la campagne, à améliorer les indicateurs de santé maternelle et à contribuer à la réduction de la mortalité maternelle et néonatale au Burkina Faso. Il s'inscrit pleinement dans la volonté de garantir à chaque femme un droit fondamental : celui de vivre une maternité sans danger et d'accéder, en tout lieu et en tout temps, à des soins essentiels et adaptés. Une attention particulière sera portée aux groupes spécifiques et vulnérables afin de garantir une couverture équitable de la population. Il s'agit notamment des femmes du secteur informel, des femmes au foyer, des",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 963,
    "source": "PDF_chunked"
  },
  {
    "id": 5220,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1220)",
    "text": "groupes spécifiques et vulnérables afin de garantir une couverture équitable de la population. Il s'agit notamment des femmes du secteur informel, des femmes au foyer, des jeunes non scolarisés, des élèves et étudiants, des personnes vivant avec un handicap, des populations en situation d'urgence humanitaire, des personnes en milieu carcéral, des professionnelles du sexe, des populations en conflit avec la loi, ainsi que du personnel militaire et paramilitaire en formation. L'inclusion de ces groupes dans la stratégie opérationnelle traduit la volonté des autorités sanitaires d'atteindre les populations souvent exclues des circuits classiques de soins. Dr Moyenga Isidore modérant la session plénière après les travaux de groupes Pour atteindre ces différents objectifs, trois principales modalités d'intervention seront mises en œuvre. La stratégie fixe se déroulera au sein des formations sanitaires, utilisant toutes les unités de services disponibles. La stratégie avancée",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 984,
    "source": "PDF_chunked"
  },
  {
    "id": 5221,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1221)",
    "text": "principales modalités d'intervention seront mises en œuvre. La stratégie fixe se déroulera au sein des formations sanitaires, utilisant toutes les unités de services disponibles. La stratégie avancée ciblera les zones situées entre cinq et dix kilomètres d'un centre de santé ainsi que les sites des personnes déplacées internes. Enfin, la stratégie mobile concernera les localités éloignées ou difficiles d'accès, situées à plus de dix kilomètres d'une formation sanitaire. Des équipes mobiles, dotées d'une logistique adaptée, seront mobilisées pour y assurer une offre de soins complète. Un participant donnant les détails de leur travail de groupe Couverture Maladie Universelle N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 693,
    "source": "PDF_chunked"
  },
  {
    "id": 5222,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1222)",
    "text": "Nwww.romade eallygreatsite.com helloreallygreatsite.com Renforcement de la santé maternelle : L'OMS Burkina Faso fait don de matériel médico-technique au ministère de la santé À l'occasion de la Journée internationale de la Sage- femme, commémorée chaque 05 Mai, l'Organisation Mondiale de la Santé Burkina Faso a procédé à une importante donation de matériel médico-technique à la Direction Générale de la Santé. Ce don s'inscrit dans le cadre des efforts visant à renforcer le système de santé, avec un accent particulier sur l'amélioration de la prise en charge des femmes enceintes et des nouveau-nés afin de réduire les décès évitables. Ce matériel médico-technique est destiné à optimiser la prise en charge des parturientes et des nouveau-nés en leur garantissant des soins plus sécurisés et accessibles. Pour les autorités ce matériel vient à point nommé et permettra de ...renforcer les structures de santé dans le but de réduire la mortalité maternelle et néonatale . Lors de la",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 988,
    "source": "PDF_chunked"
  },
  {
    "id": 5223,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1223)",
    "text": "Pour les autorités ce matériel vient à point nommé et permettra de ...renforcer les structures de santé dans le but de réduire la mortalité maternelle et néonatale . Lors de la cérémonie de remise, le Directeur Général de la Santé a exprimé sa profonde gratitude envers l'OMS pour son appui constant dans le renforcement du système de santé. Grâce à ce soutien, le Burkina Faso poursuit ses efforts pour améliorer la santé maternelle et infantile, contribuant ainsi à un système de santé plus efficace et mieux équipé pour répondre aux besoins des populations. Réception officielle du matériel par Monsieur le DGS en présence de la DSF , d'un membre l'association des sages femmes et de l'OMS Le Directeur général de la Santé, Dr Kouesyandé Joseph SOUBEIGA a officiellement reçu les équipements destinés à améliorer la qualité des soins dans les maternités. Parmi ces dispositifs figurent : Sonicaid X et appareils de cardiotocographie pour le suivi du bien-être",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 962,
    "source": "PDF_chunked"
  },
  {
    "id": 5224,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1224)",
    "text": "équipements destinés à améliorer la qualité des soins dans les maternités. Parmi ces dispositifs figurent : Sonicaid X et appareils de cardiotocographie pour le suivi du bien-être fœtal. Ventouses obstétricales facilitant les accouchements difficiles, des seringues d'AMIU pour la prise en charge des complications post- abortum, des fiches techniques, algorithme, des job aids pour l'utilisation harmonisé des prestataires sur le terrain qui vont pouvoir offrir des soins de qualité et les supports de communication sur la planification familiale, les auto-soins en santé maternelle visant à sensibiliser et informer les professionnels de santé et les patientes. Point du matériel fait à M. le Directeur Général de la Santé avant remise Quelque matériel entreposé Couverture Maladie Universelle N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 806,
    "source": "PDF_chunked"
  },
  {
    "id": 5225,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1225)",
    "text": "Burkina Faso : l'OMS accompagne le ministère de la Santé dans la promotion de l'auto-prise en charge en santé Nwww.romade eallygreatsite.com helloreallygreatsite.com Dans le cadre de son appui constant au renforcement du système de santé, l'Organisation mondiale de la Santé (OMS) au Burkina Faso soutient le ministère de la Santé, à travers la Direction de la Promotion et de l'Éducation pour la Santé (DPES), pour l'organisation de journées de sensibilisation et de plaidoyer autour de l'auto-prise en charge en santé, communément appelée self-care. Après l'élaboration du guide et d'orientation stratégique sur l'autosoins, fruit d'un appui technique et financier de l'OMS, le ministère engage une nouvelle étape : la sensibilisation des acteurs clés, dont les futurs professionnels de santé. Les premiers ateliers de sensibilisation se tiennent dans les villes de Ouagadougou et de Bobo- Dioulasso, et ciblent principalement les étudiants en formation dans les",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 964,
    "source": "PDF_chunked"
  },
  {
    "id": 5226,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1226)",
    "text": "santé. Les premiers ateliers de sensibilisation se tiennent dans les villes de Ouagadougou et de Bobo- Dioulasso, et ciblent principalement les étudiants en formation dans les écoles de santé publique, notamment les sages-femmes et infirmiers de l'École Nationale de Santé Publique (ENSP). La promotion des paquets de services d'auto-prise en charge permet d'améliorer l'accès aux services essentiels de santé, notamment dans les zones reculées, les contextes instables et les régions aux infrastructures sanitaires limitées , explique Dr Sawadogo Marthe, Représentante du Directeur de la DPES. Ces ateliers constituent une étape clé pour une appropriation effective du self-care par les futurs professionnels de santé, qui auront pour rôle de diffuser ces approches innovantes dans leurs lieux d'affectation, notamment en milieu rural ou périphérique. L'objectif de ces rencontres est clair : informer, former et mobiliser les futurs prestataires autour de l'auto-prise en",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 973,
    "source": "PDF_chunked"
  },
  {
    "id": 5227,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1227)",
    "text": "leurs lieux d'affectation, notamment en milieu rural ou périphérique. L'objectif de ces rencontres est clair : informer, former et mobiliser les futurs prestataires autour de l'auto-prise en charge en santé et bien-être, à travers la promotion du paquet de services self-care. Cette stratégie innovante vise à renforcer l'autonomie des individus dans la gestion de leur santé, tout en améliorant l'accès aux soins dans des contextes parfois contraints. Dr Sawadogo Marthe, Représentante de M. le Directeur de la DPES les Etudiants de l'ENSP prenant bonne notes de la session de sensibilisation sur l'auto soin Engageons-nous pour une santé plus accessible, inclusive et équitable pour tous, grâce à la promotion de l'auto-prise en charge ! Couverture Maladie Universelle N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 781,
    "source": "PDF_chunked"
  },
  {
    "id": 5228,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1228)",
    "text": "OMS et gynécologues unis pour réduire mortalité maternelle et néonatale Nwww.romade eallygreatsite.com helloreallygreatsite.com L'OMS apporte son soutien à la Société des gynécologues et obstétriciens du Burkina Faso (SOGOB) dans la lutte contre la mortalité maternelle et périnatale. Dans cette optique, elle a accompagné le 11ème congrès de la SOGOB, une tribune essentielle pour repenser les innovations et stratégies en faveur de la santé des mères et des nouveau-nés. Ce 11ème congrès réunit les experts autour du thème Mortalité maternelle et périnatale au Burkina Faso : Progrès vers les ODD dans un contexte de défis sécuritaires . Lors de la cérémonie d'ouverture, le président de la SOGOB, Pr Charlemagne Ouedraogo, a souligné l'importance des actions concertées visant à améliorer la santé maternelle et néonatale. Dr Lucien Robert Kargougou, Ministre de la Santé et parrain du congrès, a rappelé avec force que la mortalité",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 935,
    "source": "PDF_chunked"
  },
  {
    "id": 5229,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1229)",
    "text": "concertées visant à améliorer la santé maternelle et néonatale. Dr Lucien Robert Kargougou, Ministre de la Santé et parrain du congrès, a rappelé avec force que la mortalité maternelle et périnatale demeure l'un des drames les plus inacceptables de notre époque . L'OMS réaffirme son soutien indéfectible aux gynécologues et obstétriciens du Burkina Faso pour une santé maternelle et néonatale renforcée, garantissant un avenir plus sûr pour toutes les familles. Il a rappelé que, malgré les défis et l'adversité, la communauté scientifique demeure mobilisée, engagée à défendre les droits, la vie et la santé des femmes, des nouveau-nés et des familles. Le congrès représente un carrefour de savoir, d'expérience et d'innovations, permettant aux experts d'échanger sur les meilleures pratiques et les avancées en matière de santé maternelle et néonatale, selon les recommandations de l'OMS.",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 891,
    "source": "PDF_chunked"
  },
  {
    "id": 5230,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1230)",
    "text": "d'expérience et d'innovations, permettant aux experts d'échanger sur les meilleures pratiques et les avancées en matière de santé maternelle et néonatale, selon les recommandations de l'OMS. Pr Charlemagne Ouedraogo, président de la SOGOB en train de livrer son mot Pr Lankoandé Jean , président de la SOGOB en train de livrer son mot Presiduim de la cérémonie d'ouverture . De droite à gauche, Mme Zoungrana Blanche , predidente de l'Ossociation des sagesfemmes ; Dr Sawadogo Ramatou de l'OMS , Pr Charlemagne Ouedraogo , président de la SOGO et Dr Robert Kargougou,Ministre de la santé Le thème du congrès est un appel pressant à la responsabilité, à la solidarité et à l'action collective. Il encourage à évaluer le chemin parcouru et à renforcer les efforts pour atteindre les Objectifs de Développement Durable (ODD) d'ici 2030, en particulier ceux liés à la santé des mères et des enfants. Ce congrès est une opportunité unique pour analyser les stratégies en",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 965,
    "source": "PDF_chunked"
  },
  {
    "id": 5231,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1231)",
    "text": "les Objectifs de Développement Durable (ODD) d'ici 2030, en particulier ceux liés à la santé des mères et des enfants. Ce congrès est une opportunité unique pour analyser les stratégies en place, interroger les pratiques médicales et scientifiques, et mettre en lumière des solutions innovantes et éprouvées pour sauver des vies. Couverture Maladie Universelle N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 371,
    "source": "PDF_chunked"
  },
  {
    "id": 5232,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1232)",
    "text": "Nwww.romade eallygreatsite.com helloreallygreatsite.com Surveillance environnementale du poliovirus au Burkina Faso : l'OMS aux côtés du ministère de la Santé Dans le cadre de la lutte contre la poliomyélite, le Burkina Faso renforce son système de détection précoce grâce à la surveillance environnementale du poliovirus, une approche innovante mise en œuvre depuis mars 2016 par la Direction de la Prévention par les Vaccinations (DPV) du ministère de la Santé. Ce dispositif repose sur l'analyse régulière des eaux usées afin de détecter la présence éventuelle du virus de la poliomyélite, même en l'absence de cas humains. Il vient ainsi compléter la surveillance des paralysies flasques aiguës (PFA), qui demeure un indicateur clé de la circulation du poliovirus chez l'humain. Actuellement, dix sites sont couverts par ce système de surveillance : 6 sites dans la région du Centre, dans la capitale Ouagadougou, 4 sites dans les Hauts-Bassins, dans la ville de Bobo-Dioulasso.",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 982,
    "source": "PDF_chunked"
  },
  {
    "id": 5233,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1233)",
    "text": "couverts par ce système de surveillance : 6 sites dans la région du Centre, dans la capitale Ouagadougou, 4 sites dans les Hauts-Bassins, dans la ville de Bobo-Dioulasso. Ces deux zones ont été choisies en raison de leur densité de population et de leurs dynamiques de mobilité, qui constituent des facteurs de risque pour la transmission du poliovirus. L'Organisation mondiale de la Santé (OMS) accompagne activement cette initiative, en apportant un appui technique et financier au ministère de la Santé. La surveillance environnementale est une stratégie essentielle dans le processus mondial d'éradication de la poliomyélite, en particulier dans les pays à risque de résurgence. Elle permet de repérer de manière précoce une circulation silencieuse du virus et d'agir rapidement, même en l'absence de symptômes visibles dans la population. Grâce à ce système, les autorités sanitaires peuvent mieux anticiper les risques, cibler les interventions vaccinales et protéger durablement",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 985,
    "source": "PDF_chunked"
  },
  {
    "id": 5234,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1234)",
    "text": "en l'absence de symptômes visibles dans la population. Grâce à ce système, les autorités sanitaires peuvent mieux anticiper les risques, cibler les interventions vaccinales et protéger durablement les communautés contre cette maladie invalidante. Equipe OMS , DPV et mairie sur le terrain pour la collecte active Cet appui vise à renforcer les capacités nationales de surveillance, à garantir la qualité des prélèvements et des analyses en laboratoire, et à soutenir les mesures de riposte rapide en cas de détection du virus. Surveillance N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 550,
    "source": "PDF_chunked"
  },
  {
    "id": 5235,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1235)",
    "text": "Nwww.romade eallygreatsite.com helloreallygreatsite.com Urgences sanitaires L'OMS renforce son aide au Burkina Faso avec kits médicaux vitaux. Alors que le Burkina Faso continue de faire face à une crise sécuritaire et humanitaire, l'Organisation mondiale de la Santé (OMS) intensifie son appui aux populations les plus vulnérables. Dans les zones à défis sécuritaires, où l'accès aux soins est difficile , l'OMS vient de remettre un lot de kits d'urgence aux structures de santé en première ligne. Ce geste s'inscrit dans une stratégie d'intervention humanitaire renforcée. Selon le plan de réponse Humanitaire( HRP) plus de 2 millions de personnes auront besoin de soins médicaux urgents en 2025, en particulier dans les domaines de la santé primaire, des urgences obstétricales et de la santé mentale. Les besoins sont immenses, tandis que de nombreuses formations sanitaires fonctionnent à flux tendu, voire dans des conditions extrêmes. Les régions du Sahel, du Centre-Nord, de",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 982,
    "source": "PDF_chunked"
  },
  {
    "id": 5236,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1236)",
    "text": "besoins sont immenses, tandis que de nombreuses formations sanitaires fonctionnent à flux tendu, voire dans des conditions extrêmes. Les régions du Sahel, du Centre-Nord, de la boucle du Mouhoun et de l'Est, durement touchées par l'insécurité et les déplacements massifs de populations, ont été ciblées en priorité. Chaque kit remis contient des médicaments essentiels, du matériel de premiers secours, des fournitures de base et des équipements de protection pour les agents de santé. Ils permettront de garantir une prise en charge rapide et efficace des urgences médicales de 102 000 personnes, tout en contribuant à la continuité des services de santé essentiels. Au-delà d'un simple appui logistique, ce don incarne une volonté claire de r e nforcer la résilience du système de santé burkinabè, tout en apportant une réponse concrète à l'urgence humanitaire. En soutenant les acteurs de terrain, l'OMS œuvre à préserver la dignité et la vie des personnes déplacées, isolées ou",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 981,
    "source": "PDF_chunked"
  },
  {
    "id": 5237,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1237)",
    "text": "en apportant une réponse concrète à l'urgence humanitaire. En soutenant les acteurs de terrain, l'OMS œuvre à préserver la dignité et la vie des personnes déplacées, isolées ou privées d'accès aux soins. Dans un contexte où les défis sont immenses, ces kits représentent bien plus que du matériel :ils sont un acte de solidarité, un outil de survie et un levier de confiance pour les agents de santé qui se battent chaque jour au service des plus démunis. Des kits d'urgence expédiés par le cargo UNHAS à Dédougou Les deux images montrent le transport des kits vers les sites de prise en charge N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 605,
    "source": "PDF_chunked"
  },
  {
    "id": 5238,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1238)",
    "text": "Nwww.romade eallygreatsite.com helloreallygreatsite.com Urgences sanitaires Cette vaccination, déployée rapidement dans les zones ciblées, a permis de vacciner plus de 7 800 enfants âgés de 0 à 10 ans, contribuant ainsi à limiter la propagation du virus dans la communauté Agir tôt, sauver des vies : renforcer la surveillance basée sur les événements Ces formations se sont tenues dans les villes de Bobo-Dioulasso, Koudougou, Manga et Tenkodogo, dans le cadre de l'application du Règlement Sanitaire International (RSI) et de l'approche \"Une seule santé\" (One Health), qui reconnaît l'interdépendance entre la santé humaine, animale et environnementale. les sessions sont centrées sur la surveillance basée sur les événements (SBE), un système clé pour détecter rapidement les signaux inhabituels ou les événements de santé publique avant qu'ils ne se transforment en épidémie. Elles avaient pour objectifs de renforcer les capacités des acteurs multisectoriels impliqués",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 973,
    "source": "PDF_chunked"
  },
  {
    "id": 5239,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1239)",
    "text": "événements de santé publique avant qu'ils ne se transforment en épidémie. Elles avaient pour objectifs de renforcer les capacités des acteurs multisectoriels impliqués dans la surveillance et la gestion des risques sanitaires ; d'améliorer la détection, le signalement et la réponse aux événements sanitaires inhabituels et d'opérationnaliser le guide national de SBE, récemment validé par les autorités sanitaires. Présiduim d'ouverture des travaux avec les autorités régionales de la région des cascades N2 T2 2025 Dans un contexte mondial marqué par la recrudescence des maladies infectieuses émergentes et réémergentes dont plus de 75 sont d'origine animale (zoonoses) le Burkina Faso renforce son dispositif national de détection précoce et de réponse rapide face aux menaces sanitaires. Grâce au financement du Pandemic Fund, l'Organisation mondiale de la Santé (OMS) accompagne activement le gouvernement burkinabè dans la mise en œuvre d'une série de formations régionales de",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 983,
    "source": "PDF_chunked"
  },
  {
    "id": 5240,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1240)",
    "text": "Grâce au financement du Pandemic Fund, l'Organisation mondiale de la Santé (OMS) accompagne activement le gouvernement burkinabè dans la mise en œuvre d'une série de formations régionales de formateurs, ciblant les Directeurs régionaux de la Santé, de l'Environnement, des Eaux et Forêts, et de l'Élevage. Equipe de coordination de la vaccination du Round 0 contre la polio au niveau du CM de Kantchari Face à la détection d'une épidémie de poliovirus de variant type 2 (cPVDPV2) dans le district sanitaire de Diapaga, le Bureau de l'OMS au Burkina Faso a apporté un appui technique et logistique au ministère de la Santé pour organiser une vaccination de riposte. Riposte à l'épidémie de poliovirus variant de type 2 (cPVDPV2) dans le district sanitaire de Diapaga L'intervention s'inscrit dans le cadre des efforts déployés par le Burkina Faso, avec le soutien de ses partenaires, pour éradiquer la poliomyélite et renforcer la surveillance épidémiologique à travers une réponse",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 980,
    "source": "PDF_chunked"
  },
  {
    "id": 5241,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1241)",
    "text": "partenaires, pour éradiquer la poliomyélite et renforcer la surveillance épidémiologique à travers une réponse rapide et coordonnée Parmi les enfants vaccinés, 18 n'avaient jamais reçu de vaccin contre la poliomyélite auparavant (appelés enfants \"zéro dose\"), ce qui souligne l'importance de telles campagnes pour atteindre les populations les plus vulnérables et éloignées des services de santé. 141 formateurs issus des ministères de la Santé, de l'Environnement, de l'Agriculture et de l'Élevage ont été outillés pour renforcer le dispositif national de détection précoce et de réponse rapide aux menaces sanitaires.",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 619,
    "source": "PDF_chunked"
  },
  {
    "id": 5242,
    "title": "OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025 (chunk 1242)",
    "text": "Nwww.romade eallygreatsite.com helloreallygreatsite.com Echo de nos projets Echo Projet N2 T2 2025 Nwww.romade eallygreatsite.com helloreallygreatsite.com Echo de nos projets( suite) N2 T2 2025 Directeur de publication Dr Seydou COULIBALY Seydou Répresentant Résident par Intérim de l'OMS au Burkina Faso Comité de redaction : Dr Ramatou SAWADOGO Dr Clotaire Hien Mme SANON Edith M. TARPAGA Oumarou Dr Serge Marcial BATALIACK Dr Mwinmalo Ines Evelyne DA Dr Laurent MOYENGA Dr Minzah PEKELE Dr Seydou KABORE M. Inouffou ZONGO Dr Alain NGOYE Mme Sabine TINDANO M.Benjamin SANOU Coordination et conception: M. TARPAGA Oumarou Mme SANON Edith N2 T2 2025",
    "url": "data\\raw\\OMS_ Burkina_Faso_Bulletin_d'information.pdf T2 2025.pdf",
    "length": 649,
    "source": "PDF_chunked"
  }
]